[({'text': 'Patients must have adequate hematologic reserve with WBCe3000/mm3, absolute neutrophils e1500/mm3 and platelets e100,000/ mm3. Patients who are on Coumadin must have a platelet count of e150,000/ mm3', 'entities': [['54', '57', 'clinical_variable'], ['58', '66', 'lower_bound'], ['68', '88', 'clinical_variable'], ['90', '98', 'lower_bound'], ['103', '112', 'clinical_variable'], ['114', '126', 'lower_bound'], ['169', '183', 'clinical_variable'], ['188', '200', 'lower_bound']]}, 'NCT02438995'), ({'text': 'participants will be allowed to taper these drugs and will become eligible at least 4 weeks after the taper is completed', 'entities': [['85', '92', 'lower_bound']]}, 'NCT01742182'), ({'text': 'Have a diagnosis of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer for Parts F and H', 'entities': [['63', '67', 'clinical_variable'], ['78', '102', 'cancer']]}, 'NCT02057133'), ({'text': 'Diagnostic Imaging MRI and/or CT of the area to be treated within 8 weeks of any treatment. Baseline bone marrow biopsy and bone scan (with 99mTc-diphosphonate or MIBG scan (131I-MIBG or 123I-MIBG) from time of original diagnosis is required', 'entities': [['20', '23', 'treatment'], ['31', '33', 'treatment'], ['67', '74', 'upper_bound'], ['82', '91', 'treatment'], ['102', '120', 'treatment'], ['125', '134', 'treatment'], ['141', '160', 'treatment'], ['164', '173', 'treatment'], ['175', '184', 'treatment'], ['188', '197', 'treatment']]}, 'NCT02112617'), ({'text': 'women of childbearing', 'entities': [['1', '6', 'gender']]}, 'NCT02324608'), ({'text': 'All age groups, including adults', 'entities': [['5', '8', 'age']]}, 'NCT01720147'), ({'text': 'Sleep apnea', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT02709980'), ({'text': 'Current active treatment in another investigational study or participation in another investigational study in the 1 month prior to screening', 'entities': [['9', '25', 'treatment'], ['37', '58', 'treatment'], ['116', '129', 'upper_bound']]}, 'NCT02472834'), ({'text': 'Stroke, hip fracture, hip or knee replacement, or spinal surgery in the past 6 months', 'entities': [['1', '7', 'chronic_disease'], ['23', '46', 'treatment'], ['51', '65', 'treatment'], ['73', '86', 'upper_bound']]}, 'NCT02341235'), ({'text': 'Women who are suspected or known to be pregnant', 'entities': [['1', '6', 'gender'], ['40', '48', 'pregnancy']]}, 'NCT02832115'), ({'text': 'any invasive cancer in the last 5 years', 'entities': [['14', '20', 'cancer'], ['28', '40', 'upper_bound']]}, 'NCT01918644'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02053909'), ({'text': 'Pancreatic insufficiency', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT01851694'), ({'text': 'Failure of two trials of any SSRI or SNRI antidepressant medications', 'entities': [['30', '34', 'treatment'], ['38', '69', 'treatment']]}, 'NCT02473250'), ({'text': "has a history of another malignancy within 5 years before cycle 1, day 1 (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the IND office and supporter's medical monitor, is considered cured with minimal risk of recurrence)", 'entities': [['26', '36', 'cancer'], ['44', '51', 'upper_bound'], ['90', '136', 'cancer'], ['141', '172', 'cancer']]}, 'NCT03067571'), ({'text': 'Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption of drugs', 'entities': [['20', '49', 'chronic_disease']]}, 'NCT02124772'), ({'text': 'Previously untreated primary mediastinal diffuse large B-cell lymphoma, CD20 positive', 'entities': [['30', '71', 'cancer'], ['73', '86', 'cancer']]}, 'NCT01599559'), ({'text': 'Hospitalization for treatment of infection within 60 days of Day 0', 'entities': [['21', '30', 'treatment'], ['34', '43', 'chronic_disease'], ['51', '58', 'upper_bound']]}, 'NCT02347891'), ({'text': 'Patients who have received wide field radiotherapy d 28 days (defined as > 50% of volume of pelvis bones or equivalent) or limited field radiation for palliation < 14 days prior to study registration or those patients who have not recovered adequately from side effects of such therapy', 'entities': [['39', '51', 'treatment'], ['44', '51', 'treatment'], ['54', '61', 'upper_bound'], ['76', '79', 'lower_bound'], ['83', '105', 'clinical_variable'], ['138', '162', 'treatment'], ['165', '178', 'upper_bound']]}, 'NCT02048371'), ({'text': 'Patients receiving hematopoietic growth factor support, including erythropoietin (EPO), darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophagecolony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag or romiplostim) may continue to do so', 'entities': [['20', '55', 'treatment'], ['67', '87', 'treatment'], ['89', '100', 'treatment'], ['102', '147', 'treatment'], ['149', '205', 'treatment'], ['211', '231', 'treatment'], ['239', '250', 'treatment'], ['254', '265', 'treatment']]}, 'NCT02343042'), ({'text': 'Subject meets at least 2 of the 4 previously mentioned conditions classifying them as iron deficient', 'entities': [['24', '25', 'lower_bound'], ['33', '34', 'upper_bound']]}, 'NCT02404012'), ({'text': 'Plasma cell leukemia (> 2.0 X109/L circulating plasma cells by standard differential)', 'entities': [['1', '21', 'clinical_variable'], ['25', '35', 'lower_bound']]}, 'NCT02939183'), ({'text': 'Participants with an active autoimmune disorder requiring these therapies are also excluded', 'entities': [['29', '48', 'chronic_disease']]}, 'NCT02382549'), ({'text': 'Patients are anticipated to experience rapid deterioration in visual function and/or retinal structure as determined by an annual progression rate in at least one of the following parameters occurring in at least one eye (assessments recorded up to 2 years prior to the screening visit date may be considered to document evidence of rapid deterioration)', 'entities': [['160', '163', 'lower_bound'], ['250', '263', 'upper_bound']]}, 'NCT01367444'), ({'text': 'History of prior chemotherapy', 'entities': [['12', '30', 'treatment']]}, 'NCT02177292'), ({'text': 'Yale-Brown Obsessive Compulsive Scale total score e 16', 'entities': [['1', '50', 'clinical_variable'], ['53', '55', 'lower_bound']]}, 'NCT02355002'), ({'text': 'Systemic corticosteroids are permissible in the following circumstances', 'entities': [['1', '25', 'treatment']]}, 'NCT02309580'), ({'text': 'Total bilirubin =< 1.25 x upper limit of normal (ULN)', 'entities': [['1', '16', 'clinical_variable'], ['20', '54', 'upper_bound']]}, 'NCT02427841'), ({'text': 'Ropinirole (Requip)', 'entities': [['1', '20', 'treatment']]}, 'NCT02796391'), ({'text': 'Patients with uncontrolled intercurrent illnesses including, but not limited to an active infection requiring systemic therapy or a known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the trial', 'entities': [['28', '50', 'chronic_disease'], ['84', '100', 'chronic_disease'], ['111', '127', 'treatment'], ['139', '150', 'chronic_disease'], ['154', '181', 'chronic_disease']]}, 'NCT03162731'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02991651'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT03068780'), ({'text': 'Involved in standing program or must be able to tolerate at least 15 min upright', 'entities': [['67', '73', 'lower_bound']]}, 'NCT02943915'), ({'text': 'Anticoagulant usage such as heparin or Plavix', 'entities': [['1', '14', 'treatment'], ['29', '36', 'treatment'], ['40', '46', 'treatment']]}, 'NCT02661386'), ({'text': 'Evidence of active autoimmune disease requiring systemic treatment within preceding 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents', 'entities': [['20', '38', 'chronic_disease'], ['49', '67', 'treatment'], ['75', '93', 'upper_bound'], ['187', '204', 'treatment'], ['208', '232', 'treatment']]}, 'NCT02639065'), ({'text': 'ny increase in lymphadenopathy over best response that has persisted for more than 3 months', 'entities': [['16', '31', 'chronic_disease'], ['84', '92', 'lower_bound']]}, 'NCT01750567'), ({'text': 'Have previously participated in an investigational trial involving administration of any investigational agent', 'entities': [['6', '57', 'treatment'], ['90', '111', 'treatment']]}, 'NCT02016924'), ({'text': 'Subjects may have received any number of prior lines of therapy', 'entities': [['42', '64', 'treatment']]}, 'NCT02553642'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01464164'), ({'text': 'Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines', 'entities': [['25', '56', 'treatment']]}, 'NCT01604512'), ({'text': 'Have daily access to a smart phone, tablet, personal computer or other device capable of producing and transmitting videos over the internet', 'entities': [['6', '78', 'technology_access'], ['79', '141', 'technology_access']]}, 'NCT02371720'), ({'text': 'Documented evidence of PD after achieving at least SD for e 1 cycle during a previous MM regimen (i.e., relapsed MM)', 'entities': [['24', '26', 'chronic_disease'], ['52', '54', 'clinical_variable'], ['61', '68', 'lower_bound'], ['78', '97', 'treatment'], ['105', '116', 'cancer']]}, 'NCT02343042'), ({'text': 'recovery to the baseline count(in the absence of transfusion)Hgb >9.0g/dL', 'entities': [['62', '65', 'clinical_variable'], ['67', '74', 'lower_bound']]}, 'NCT02985554'), ({'text': 'Total bilirubin must be less than 1.5 times the upper limit of normal (ULN) unless the elevation is known to be due to Gilbert syndrome', 'entities': [['7', '16', 'clinical_variable'], ['35', '76', 'upper_bound'], ['120', '136', 'chronic_disease']]}, 'NCT02734771'), ({'text': 'Presence of esophagitis - Grade C or D (LA Classification)', 'entities': [['13', '24', 'chronic_disease']]}, 'NCT02429830'), ({'text': 'Known intolerance to infused protein products', 'entities': [['22', '46', 'allergy_name']]}, 'NCT02187848'), ({'text': 'Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for subjects with creatinine levels above institutional normal', 'entities': [['1', '11', 'clinical_variable'], ['50', '70', 'clinical_variable'], ['74', '92', 'lower_bound'], ['111', '128', 'clinical_variable']]}, 'NCT02857218'), ({'text': 'pregnant women admitted >24weeks and <30weeks gestational age', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender'], ['26', '33', 'lower_bound'], ['39', '46', 'upper_bound'], ['47', '58', 'clinical_variable'], ['59', '62', 'age']]}, 'NCT02221219'), ({'text': 'Subjects with known iron overload (genetic hemochromatosis)', 'entities': [['44', '59', 'chronic_disease']]}, 'NCT02359097'), ({'text': 'Hepatic: AST or ALT d 2.5 x ULN and bilirubin d 1.5 x ULN', 'entities': [['10', '13', 'clinical_variable'], ['17', '20', 'clinical_variable'], ['23', '32', 'upper_bound'], ['37', '46', 'clinical_variable'], ['49', '58', 'upper_bound']]}, 'NCT01505569'), ({'text': 'Must use acceptable form of birth control while on study', 'entities': [['6', '42', 'contraception_consent']]}, 'NCT02452008'), ({'text': 'HIV-infected men and women', 'entities': [['1', '13', 'chronic_disease'], ['14', '17', 'gender'], ['22', '27', 'gender']]}, 'NCT02573376'), ({'text': 'initial ZEST 1 study only included women', 'entities': [['36', '41', 'gender']]}, 'NCT02589600'), ({'text': 'Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast, adequately treated stage I or II cancer from which the patient is in complete remission', 'entities': [['34', '44', 'cancer'], ['71', '76', 'cancer'], ['80', '115', 'cancer'], ['119', '161', 'cancer'], ['182', '189', 'lower_bound'], ['193', '195', 'upper_bound'], ['196', '202', 'cancer'], ['232', '250', 'treatment']]}, 'NCT01894061'), ({'text': 'Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin)', 'entities': [['18', '29', 'treatment'], ['42', '57', 'treatment'], ['64', '77', 'treatment'], ['82', '92', 'treatment']]}, 'NCT02547818'), ({'text': 'e 10 years and < 70 years of age', 'entities': [['3', '11', 'lower_bound'], ['18', '26', 'upper_bound'], ['30', '33', 'age']]}, 'NCT00432094'), ({'text': 'Known contraindication to MRI (intracardiac pacer, defibrillator, certain intracranial aneurysm clips, intraocular or cochlear implants, claustrophobia, etc.)', 'entities': [['27', '30', 'treatment'], ['32', '50', 'treatment'], ['52', '65', 'treatment'], ['67', '102', 'treatment'], ['104', '115', 'treatment'], ['119', '136', 'treatment'], ['138', '152', 'chronic_disease']]}, 'NCT02388685'), ({'text': 'An inadequate response, loss of response, or intolerance to prior corticosteroid and/or immunosuppressant treatment', 'entities': [['61', '81', 'treatment'], ['89', '116', 'treatment']]}, 'NCT02171429'), ({'text': 'who are deemed eligible for transplant by their treating physician Disease status: CR or PR required', 'entities': [['29', '39', 'treatment']]}, 'NCT01908777'), ({'text': 'Treatment with cytotoxic chemotherapy within previous 28 days, or failure to recover from AEs due to cytotoxic chemotherapy administered more than 28 days previous (however, ongoing neuropathy is permitted)', 'entities': [['1', '10', 'treatment'], ['16', '38', 'treatment'], ['46', '62', 'upper_bound'], ['55', '62', 'lower_bound']]}, 'NCT02346526'), ({'text': 'Subjects of reproductive potential may not participate unless they have agreed to use an effective contraceptive method', 'entities': [['73', '120', 'contraception_consent']]}, 'NCT02128230'), ({'text': 'Hyperthyroidism', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02508311'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03176784'), ({'text': 'The effects of onalespib and AT7519M on the developing human fetus are unknown; for this reason, women of childbearing potential and male patients with partners of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry, for the duration of study participation, and for 2 months after completion of study; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; women of childbearing potential enrolling on study must have a negative pregnancy test within 72 hours of enrollment in order to be eligible; because there is an unknown but potential risk to nursing infants secondary to treatment of the mother with onalespib and AT7519M, breastfeeding should be discontinued while the mother is treated with onalespib and AT7519M', 'entities': [['16', '37', 'treatment'], ['98', '103', 'gender'], ['134', '147', 'gender'], ['193', '228', 'contraception_consent'], ['230', '238', 'contraception_consent'], ['242', '273', 'contraception_consent'], ['277', '287', 'contraception_consent'], ['360', '374', 'upper_bound'], ['405', '410', 'gender'], ['418', '426', 'pregnancy'], ['628', '646', 'pregnancy'], ['659', '667', 'upper_bound'], ['786', '836', 'treatment'], ['895', '929', 'treatment']]}, 'NCT02503709'), ({'text': 'Active central nervous system (CNS) malignant disease in subjects with a history of CNS malignancy', 'entities': [['8', '54', 'cancer'], ['85', '99', 'cancer']]}, 'NCT02454010'), ({'text': 'history of severe allergic reactions', 'entities': [['12', '37', 'chronic_disease']]}, 'NCT02776761'), ({'text': 'Participant has a history of thyroid cancer', 'entities': [['30', '44', 'cancer']]}, 'NCT02564978'), ({'text': 'Patients with a severe infection that on evaluation by the Principal Investigator precludes ablative chemotherapy or successful transplantation', 'entities': [['17', '33', 'chronic_disease'], ['93', '114', 'treatment'], ['129', '144', 'treatment']]}, 'NCT00368355'), ({'text': 'Known history of human immunodeficiency virus (HIV)', 'entities': [['18', '52', 'chronic_disease']]}, 'NCT02493530'), ({'text': 'Histologically proven cancer of the head and neck cancer', 'entities': [['23', '29', 'cancer'], ['37', '57', 'cancer']]}, 'NCT02480114'), ({'text': 'corticosteroids up to 20 mg of prednisone (or equivalent) is allowable throughout the study', 'entities': [['1', '16', 'treatment'], ['23', '28', 'upper_bound'], ['32', '42', 'treatment']]}, 'NCT01620216'), ({'text': 'symptomatic anemia', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02838797'), ({'text': 'aspartate aminotransferase (AST)', 'entities': [['1', '33', 'clinical_variable']]}, 'NCT02578641'), ({'text': 'Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x institutional upper limit of normal', 'entities': [['1', '33', 'clinical_variable'], ['35', '113', 'clinical_variable'], ['115', '157', 'clinical_variable'], ['162', '203', 'upper_bound']]}, 'NCT02520791'), ({'text': 'Hemoglobin >= 10 gm/dL', 'entities': [['1', '11', 'clinical_variable'], ['15', '23', 'lower_bound']]}, 'NCT01684397'), ({'text': 'Serum creatinine >1.5 x ULN', 'entities': [['1', '17', 'clinical_variable'], ['19', '28', 'lower_bound']]}, 'NCT02323126'), ({'text': 'Anemia (hemoglobin < 80g/L)', 'entities': [['1', '7', 'chronic_disease'], ['9', '19', 'clinical_variable'], ['22', '27', 'upper_bound']]}, 'NCT01895777'), ({'text': 'Lenalidomide is teratogenic with unknown potential for abortifacient effects', 'entities': [['1', '13', 'treatment'], ['17', '28', 'treatment']]}, 'NCT01572480'), ({'text': 'estimated Glomerular Filtration Rate < 60ml/min/1.73m2', 'entities': [['11', '37', 'clinical_variable'], ['40', '55', 'upper_bound']]}, 'NCT01530958'), ({'text': 'Patients must have received their last dose of other investigational or biological agent > 7 days prior to study entry', 'entities': [['73', '89', 'clinical_variable'], ['92', '104', 'upper_bound']]}, 'NCT01734512'), ({'text': 'Insufficient mobile leaflet available for grasping with the MitraClip device', 'entities': [['61', '77', 'treatment']]}, 'NCT01626079'), ({'text': 'hepatomegaly of greater than 2cm below the costochondral margin', 'entities': [['1', '13', 'clinical_variable'], ['30', '33', 'lower_bound']]}, 'NCT02105766'), ({'text': "Patients with related donors must have an adequate liver function as defined by a serum bilirubin <3.0, AST and ALT <3.0X upper limit of normal. Patients with unrelated donors must have an adequate liver function as defined by a serum bilirubin <1.8, AST and ALT < 2.5X upper limit of normal. Exceptions may be granted for patients with benign liver disorders such as Gilbert's disease", 'entities': [['83', '98', 'clinical_variable'], ['100', '103', 'upper_bound'], ['105', '108', 'clinical_variable'], ['113', '116', 'clinical_variable'], ['118', '144', 'upper_bound'], ['247', '250', 'upper_bound'], ['266', '292', 'upper_bound'], ['345', '360', 'chronic_disease'], ['369', '386', 'chronic_disease']]}, 'NCT01349101'), ({'text': 'ECOG performance status (100) of 0-3', 'entities': [['1', '24', 'clinical_variable'], ['27', '28', 'lower_bound'], ['36', '37', 'upper_bound']]}, 'NCT01059786'), ({'text': 'Creatinine =< institutional upper limit normal (ULN), CTCAE v 3.0 grade 0', 'entities': [['1', '11', 'clinical_variable'], ['15', '53', 'clinical_variable']]}, 'NCT00492778'), ({'text': 'Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment', 'entities': [['31', '51', 'chronic_disease'], ['59', '74', 'upper_bound']]}, 'NCT02101736'), ({'text': 'has a history of sickle cell disease [self-reported]', 'entities': [['18', '37', 'chronic_disease']]}, 'NCT02473354'), ({'text': 'non-pregnant female patients', 'entities': [['1', '13', 'pregnancy'], ['14', '29', 'gender']]}, 'NCT02501733'), ({'text': 'Severe COPD (use of supplemental oxygen, or have a one-second forced expiratory volume of less than 30% predicted)', 'entities': [['1', '12', 'chronic_disease'], ['101', '104', 'upper_bound']]}, 'NCT02966665'), ({'text': 'Must be free of systemic infection', 'entities': [['17', '35', 'chronic_disease']]}, 'NCT02549833'), ({'text': 'Have any other uncontrolled infection', 'entities': [['16', '38', 'chronic_disease']]}, 'NCT02143050'), ({'text': 'Patients with known CNS involvement with AML are eligible provided that they have been treated and CSF is clear for at least 2 weeks prior to enrollment into the study', 'entities': [['21', '45', 'cancer'], ['126', '139', 'lower_bound']]}, 'NCT01898793'), ({'text': 'Platelet e 100,000/mm3', 'entities': [['1', '9', 'clinical_variable'], ['12', '23', 'lower_bound']]}, 'NCT02360579'), ({'text': '=< 2.5 x institutional ULN (up to 5 times ULN in presence of liver metastases) (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)', 'entities': [['4', '27', 'upper_bound'], ['35', '46', 'upper_bound'], ['62', '78', 'cancer'], ['88', '101', 'upper_bound'], ['144', '157', 'upper_bound'], ['161', '170', 'treatment']]}, 'NCT02465060'), ({'text': 'Symptomatic arrhythmia not controlled by medication', 'entities': [['13', '23', 'chronic_disease']]}, 'NCT00788164'), ({'text': 'Myeloablative preparative regimen (for SAA any conditioning therapy allowed)', 'entities': [['1', '34', 'treatment'], ['40', '43', 'chronic_disease'], ['61', '68', 'treatment']]}, 'NCT02074631'), ({'text': 'Caregiver of a participating lung cancer survivor', 'entities': [['30', '41', 'cancer']]}, 'NCT02989974'), ({'text': 'Decompensated heart failure', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT02053246'), ({'text': 'normal kidney function (eGFR > 60 and normal urinalysis)', 'entities': [['25', '29', 'clinical_variable'], ['32', '34', 'lower_bound']]}, 'NCT02620449'), ({'text': 'DLCO < 80% of predicted or decrease in lung function (DLCO, DLCO/VA or FVC) of 10% or more over 12 months', 'entities': [['1', '5', 'clinical_variable'], ['8', '11', 'upper_bound'], ['61', '68', 'clinical_variable'], ['72', '75', 'clinical_variable'], ['80', '83', 'lower_bound'], ['97', '106', 'lower_bound']]}, 'NCT01445821'), ({'text': 'Molecular testing results from CLIA-certified laboratories (using tissue and/or blood) demonstrating BRAF V600 mutations a) For participants screened using a blood assay: obtain tissue-based testing result confirming study eligibility (within first 4 weeks after enrollment)', 'entities': [['244', '263', 'upper_bound']]}, 'NCT02091141'), ({'text': 'Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those > 7 years of age, when appropriate', 'entities': [['40', '43', 'age'], ['114', '121', 'lower_bound']]}, 'NCT02315612'), ({'text': 'Current statins use (statins lower ADMA levels), patients may stop and re-enroll after 2 weeks of stopping statins', 'entities': [['9', '16', 'treatment'], ['82', '95', 'upper_bound']]}, 'NCT02433977'), ({'text': 'Subjects who have chronic back pain attributed to lumbar facet joints arthropathy based on clinical evaluation (paraspinal tenderness and/or facet loading test in the absence of signs and symptoms suggestive of focal neurological deficits)', 'entities': [['58', '82', 'chronic_disease']]}, 'NCT02148003'), ({'text': "Substance abuse, medical, psychological, or social conditions that may interfere with the subject's participation in the study", 'entities': [['27', '40', 'chronic_disease']]}, 'NCT02466009'), ({'text': 'Absolute neutrophil count (ANC) >= 1,500 cells/mm^3', 'entities': [['1', '32', 'clinical_variable'], ['36', '52', 'lower_bound']]}, 'NCT02315196'), ({'text': 'Ongoing hemorrhage requiring blood product transfusion', 'entities': [['9', '19', 'chronic_disease']]}, 'NCT02901067'), ({'text': '4-10 weeks prior to surgery', 'entities': [['1', '2', 'lower_bound'], ['3', '11', 'upper_bound'], ['21', '28', 'treatment']]}, 'NCT02843945'), ({'text': 'Significant cardiac, renal or hepatic illness', 'entities': [['13', '20', 'chronic_disease'], ['22', '27', 'chronic_disease'], ['31', '46', 'chronic_disease']]}, 'NCT02417415'), ({'text': 'Toxic colitis', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT01978509'), ({'text': 'eGFR > 60 ml/min/1.73 m2', 'entities': [['1', '5', 'clinical_variable'], ['8', '25', 'lower_bound']]}, 'NCT01853163'), ({'text': 'Patients with adequate renal function', 'entities': [['24', '38', 'clinical_variable']]}, 'NCT02844738'), ({'text': 'Patients scheduled to undergo revision total knee arthroplasty for infectious reasons', 'entities': [['31', '63', 'treatment']]}, 'NCT01175044'), ({'text': 'Blood pressure at or above 160/100', 'entities': [['1', '15', 'clinical_variable'], ['28', '35', 'lower_bound']]}, 'NCT02600273'), ({'text': 'At least 22 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02343549'), ({'text': 'Female patients who are lactating or have a positive serum pregnancy test during the screening period', 'entities': [['1', '16', 'gender'], ['45', '69', 'pregnancy']]}, 'NCT02389517'), ({'text': 'patients with PTSD who are currently receiving individual or group therapy or patients who are currently taking antidepressant or anti-anxiety medication', 'entities': [['15', '19', 'chronic_disease'], ['48', '58', 'treatment'], ['62', '75', 'treatment'], ['113', '127', 'treatment'], ['131', '154', 'treatment']]}, 'NCT02856412'), ({'text': 'Subjects with type I diabetes melitis, hypothyroidism only requiring hormone replacement, resolved childhood asthma/atopy, patients with asthma requiring intermittent bronchodilator therapy, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger', 'entities': [['15', '38', 'chronic_disease'], ['40', '54', 'chronic_disease'], ['70', '89', 'treatment'], ['110', '116', 'chronic_disease'], ['117', '122', 'chronic_disease'], ['155', '190', 'treatment'], ['192', '206', 'chronic_disease'], ['216', '224', 'chronic_disease'], ['226', '235', 'chronic_disease'], ['240', '248', 'chronic_disease'], ['264', '282', 'treatment']]}, 'NCT02350764'), ({'text': 'patient is at least 21 years old', 'entities': [['21', '29', 'lower_bound']]}, 'NCT02332369'), ({'text': 'Substance use disorder during the 3 months prior to screening; except for Cannabis and Alcohol use Disorders', 'entities': [['1', '23', 'chronic_disease'], ['35', '49', 'upper_bound']]}, 'NCT02019940'), ({'text': 'Supine hypertension will be defined as SBPe150 mmHg', 'entities': [['1', '20', 'chronic_disease'], ['40', '43', 'clinical_variable'], ['44', '52', 'lower_bound']]}, 'NCT02417415'), ({'text': 'secondary to MDS treated at least by hypomethylating agent', 'entities': [['14', '17', 'cancer'], ['38', '59', 'treatment']]}, 'NCT02979366'), ({'text': 'Uncontrolled hypertension, defined as blood pressure persistently above 220 mmHg systolic or 120 mmHg diastolic, despite antihypertensive therapy', 'entities': [['1', '26', 'chronic_disease'], ['73', '81', 'lower_bound'], ['94', '102', 'lower_bound'], ['103', '112', 'clinical_variable'], ['122', '146', 'treatment']]}, 'NCT02232165'), ({'text': 'CBC/differential within 4 weeks prior to registration with adequate bone marrow function', 'entities': [['1', '4', 'treatment'], ['5', '17', 'treatment'], ['25', '38', 'upper_bound']]}, 'NCT01684904'), ({'text': 'Patients who are randomized to the control arm must not receive therapy based on prior molecular profiling', 'entities': [['65', '72', 'treatment']]}, 'NCT02152254'), ({'text': 'Tumors of low malignant potential', 'entities': [['1', '7', 'cancer']]}, 'NCT02672098'), ({'text': 'ECOG (Eastern Cooperative Oncology Group) performance status d1', 'entities': [['1', '61', 'clinical_variable'], ['63', '64', 'upper_bound']]}, 'NCT03186937'), ({'text': 'significant anemia', 'entities': [['13', '19', 'chronic_disease']]}, 'NCT01803451'), ({'text': 'Use of RT-CGM (continuous glucose monitor) within last 4 weeks', 'entities': [['8', '14', 'treatment'], ['27', '42', 'clinical_variable'], ['51', '63', 'upper_bound']]}, 'NCT01474889'), ({'text': 'Female patients must not be lactating or pregnant at screening', 'entities': [['1', '16', 'gender'], ['42', '50', 'pregnancy']]}, 'NCT02495168'), ({'text': 'No deleterious germline BRCA1 or BRCA2 mutation based on full sequencing and comprehensive rearrangement testing at an external reference laboratory', 'entities': [['25', '30', 'cancer'], ['34', '39', 'cancer']]}, 'NCT02401347'), ({'text': 'Younger than 21 years of age', 'entities': [['14', '22', 'upper_bound'], ['26', '29', 'age']]}, 'NCT03035773'), ({'text': 'idiopathic pulmonary fibrosis', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02843568'), ({'text': 'Any condition that, in the opinion of the study physician, makes it medically inappropriate or risky for the potential participant to enroll in the trial, including, but not limited to, contraindication to treatment with methylphenidate', 'entities': [['207', '216', 'treatment'], ['222', '237', 'treatment']]}, 'NCT02346201'), ({'text': 'Prior progesterone treatment', 'entities': [['1', '29', 'treatment']]}, 'NCT02397083'), ({'text': '24-item Hamilton Rating Scale for Depression (HRSD) score e 16', 'entities': [['1', '58', 'clinical_variable'], ['61', '63', 'lower_bound']]}, 'NCT01931202'), ({'text': 'Surgeries with general anesthesia alone or if combined with peripheral nerve blocks', 'entities': [['16', '34', 'treatment'], ['61', '84', 'treatment']]}, 'NCT02489019'), ({'text': 'Other unstable orthopaedic conditions that limit function', 'entities': [['7', '38', 'chronic_disease']]}, 'NCT02920866'), ({'text': 'Any gastrointestinal disease which would impair ability to swallow, retain, or absorb drug is not allowed', 'entities': [['5', '29', 'chronic_disease']]}, 'NCT01989546'), ({'text': 'History of allergy to midazolam or xylocaine', 'entities': [['23', '32', 'allergy_name'], ['36', '45', 'allergy_name']]}, 'NCT02356705'), ({'text': 'Symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history', 'entities': [['1', '26', 'chronic_disease'], ['41', '64', 'treatment']]}, 'NCT02411773'), ({'text': 'patients with B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma or post-transplant DLBCL are also eligible', 'entities': [['15', '30', 'cancer'], ['83', '112', 'cancer'], ['117', '133', 'cancer'], ['137', '158', 'cancer']]}, 'NCT01787409'), ({'text': 'Tumors with isocitrate dehydrogenase 1 (IDH1) or IDH2 mutations as determined by immunohistochemistry for the IDH1 R132H variant or by direct sequencing. IDH1/2-mutant gliomas have a markedly longer overall survival rate compared to those with IDH1/2-wildtype glioma (Parsons et al., 2008; Yan et al., 2009), indicating IDH1/2-mutant gliomas have a distinct natural history', 'entities': [['1', '7', 'cancer'], ['82', '102', 'treatment'], ['169', '176', 'cancer'], ['169', '175', 'cancer']]}, 'NCT02525692'), ({'text': 'Patients of childbearing or child-fathering potential must be willing use an effective method of contraception while being treated on this study and for 4 months after the last cell infusion', 'entities': [['63', '111', 'contraception_consent'], ['154', '162', 'upper_bound'], ['173', '191', 'treatment']]}, 'NCT01087294'), ({'text': 'Denies drinking any alcohol after learning about current pregnancy', 'entities': [['50', '67', 'pregnancy']]}, 'NCT02163434'), ({'text': 'BMI 25.0-35.0 kg/m2', 'entities': [['1', '4', 'bmi'], ['5', '9', 'lower_bound'], ['10', '20', 'upper_bound']]}, 'NCT02786251'), ({'text': 'Patients with an active infection or severe hematological, neurological, or other uncontrolled disease', 'entities': [['18', '34', 'chronic_disease'], ['45', '58', 'chronic_disease'], ['60', '72', 'chronic_disease'], ['83', '103', 'chronic_disease']]}, 'NCT02923011'), ({'text': 'Impairment of gastrointestinal function or gastrointestinal disease that may affect the absorption of cabozantinib. (e.g. ulcerative disease, malabsorption syndrome, or small bowel resection)', 'entities': [['1', '40', 'chronic_disease'], ['44', '68', 'chronic_disease'], ['103', '115', 'treatment'], ['123', '141', 'chronic_disease'], ['143', '165', 'chronic_disease'], ['170', '191', 'treatment']]}, 'NCT02101736'), ({'text': 'Chronic phase: None of the criteria for accelerated or blastic phase', 'entities': [['1', '14', 'cancer'], ['56', '69', 'cancer']]}, 'NCT02353728'), ({'text': 'Fasting serum cholesterol =< 300 mg/dL OR =< 7.75 mmol/L, AND fasting triglycerides =< 2.5 x ULN', 'entities': [['1', '26', 'clinical_variable'], ['30', '39', 'upper_bound'], ['46', '57', 'upper_bound'], ['63', '84', 'clinical_variable'], ['88', '97', 'upper_bound']]}, 'NCT02456857'), ({'text': 'e 18 years of age', 'entities': [['3', '11', 'lower_bound'], ['15', '18', 'age']]}, 'NCT02576301'), ({'text': 'Patients undergoing first catheter ablation for drug-refractory Persistent (PerAF) or long-standing persistent AF (LSPAF)', 'entities': [['27', '44', 'treatment']]}, 'NCT01672138'), ({'text': 'Positive core needle biopsy (ie, demonstrating invasive adenocarcinoma)', 'entities': [['10', '28', 'treatment'], ['57', '71', 'cancer']]}, 'NCT02515110'), ({'text': 'Clonal BMPCs 50%-60%', 'entities': [['1', '13', 'clinical_variable'], ['14', '17', 'lower_bound'], ['18', '21', 'upper_bound']]}, 'NCT01572480'), ({'text': 'We would not want to treat a young child experiencing chronic hypoglycemia', 'entities': [['63', '75', 'chronic_disease']]}, 'NCT00085982'), ({'text': 'Sesame oil allergy', 'entities': [['1', '11', 'allergy_name']]}, 'NCT02811510'), ({'text': 'Previous radiation exposure precluding radiation therapy', 'entities': [['40', '57', 'treatment']]}, 'NCT03076333'), ({'text': 'Concomitant administration of valproic acid', 'entities': [['31', '44', 'treatment']]}, 'NCT02036853'), ({'text': "Subject's aortic annulus is 19-27mm diameter as measured by CT conducted within 12 months prior to informed consent", 'entities': [['11', '25', 'clinical_variable'], ['29', '31', 'lower_bound'], ['32', '36', 'upper_bound'], ['37', '45', 'clinical_variable'], ['81', '96', 'upper_bound']]}, 'NCT02000115'), ({'text': 'Symptoms of orthostatic intolerance', 'entities': [['13', '36', 'chronic_disease']]}, 'NCT00409435'), ({'text': 'interruption of ART for more than 7 consecutive days since its initiation', 'entities': [['17', '20', 'treatment'], ['35', '36', 'lower_bound']]}, 'NCT02369406'), ({'text': 'BSA < 1.4 m²', 'entities': [['1', '4', 'clinical_variable'], ['7', '13', 'upper_bound']]}, 'NCT01187368'), ({'text': 'Receipt of an investigational agent or device within 30 days prior to enrollment or 5 half lives of the investigational drug (whichever is longer)', 'entities': [['15', '46', 'treatment'], ['54', '67', 'upper_bound'], ['105', '125', 'treatment']]}, 'NCT02108860'), ({'text': 'if clinically indicated additional imaging studies must be performed to rule out metastatic disease', 'entities': [['82', '100', 'chronic_disease']]}, 'NCT02201992'), ({'text': 'NYHA classes III, IV', 'entities': [['1', '13', 'clinical_variable'], ['14', '17', 'lower_bound'], ['19', '21', 'upper_bound']]}, 'NCT02169037'), ({'text': 'Organ, tissue or cell transplant prior to or after the primary solitary living donor liver transplant', 'entities': [['1', '6', 'treatment'], ['8', '14', 'treatment'], ['18', '33', 'treatment'], ['86', '102', 'treatment']]}, 'NCT02474199'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02176161'), ({'text': 'Death expected < 48h', 'entities': [['1', '15', 'clinical_variable'], ['18', '21', 'upper_bound']]}, 'NCT02851472'), ({'text': 'At least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02907918'), ({'text': 'Anticipated need to start new daily anti-inflammatory therapy such as NSAIDs (excluding aspirin for vascular prophylaxis), systemic corticosteroids, or anti-malarials, or plan to discontinue regular dosing with these drugs during study treatment', 'entities': [['37', '62', 'treatment'], ['71', '77', 'treatment'], ['124', '148', 'treatment'], ['153', '167', 'treatment'], ['237', '246', 'treatment']]}, 'NCT02572323'), ({'text': 'Patients who have had prior treatment with LY2606368 or other Chk inhibitors', 'entities': [['23', '77', 'treatment']]}, 'NCT02203513'), ({'text': 'Participant is human immunodeficiency virus negative (HIV-)', 'entities': [['16', '60', 'chronic_disease']]}, 'NCT02895945'), ({'text': 'active infection with hepatitis B or hepatitis C', 'entities': [['1', '17', 'chronic_disease'], ['23', '34', 'chronic_disease'], ['38', '49', 'chronic_disease']]}, 'NCT02807272'), ({'text': 'Female subjects must have a negative serum or urine pregnancy test within 72 hours prior to start of study medication', 'entities': [['1', '16', 'gender'], ['29', '62', 'pregnancy'], ['75', '89', 'upper_bound']]}, 'NCT02807272'), ({'text': 'Total bilirubin =< 1.5 x ULN', 'entities': [['1', '16', 'clinical_variable'], ['20', '29', 'upper_bound']]}, 'NCT02411656'), ({'text': 'No plans to move from the area over the 2-year period', 'entities': [['41', '47', 'lower_bound']]}, 'NCT03041415'), ({'text': 'Congenital heart disease, but only if the patient underwent surgical repair more than one year before enrolment', 'entities': [['1', '25', 'chronic_disease'], ['61', '76', 'treatment'], ['87', '95', 'lower_bound']]}, 'NCT02891850'), ({'text': 'Males', 'entities': [['1', '6', 'gender']]}, 'NCT02016924'), ({'text': 'previous head and neck cancer treated only by surgery, basal cell or squamous cell carcinoma of the skin which were treated with local resection only, or carcinoma in situ of the cervix', 'entities': [['24', '30', 'cancer'], ['47', '54', 'treatment'], ['56', '66', 'cancer'], ['70', '105', 'cancer'], ['155', '186', 'cancer']]}, 'NCT02296684'), ({'text': 'Donors who are not expected to meet the minimum target dose of marrow cells (1 x 108 total nucleated cells/kg recipient weight) for the initial marrow HCT or PBSC transplant (5.0 x 106 CD34/kg recipient weight)', 'entities': [['78', '110', 'lower_bound'], ['121', '127', 'clinical_variable'], ['137', '155', 'treatment'], ['159', '174', 'treatment'], ['176', '193', 'lower_bound']]}, 'NCT02100891'), ({'text': 'Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential', 'entities': [['1', '4', 'gender'], ['42', '63', 'contraception_consent']]}, 'NCT02269280'), ({'text': 'Myasthenia gravis', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02418195'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02423525'), ({'text': 'Active hepatitis B infection (defined as presence of Hep BsAg and/ or Hep B DNA)', 'entities': [['8', '19', 'chronic_disease'], ['20', '29', 'chronic_disease'], ['54', '62', 'chronic_disease'], ['54', '59', 'chronic_disease'], ['77', '80', 'clinical_variable']]}, 'NCT02541903'), ({'text': 'non-pregnant female volunteer', 'entities': [['1', '13', 'pregnancy'], ['14', '30', 'gender']]}, 'NCT01576575'), ({'text': 'Karnofsky e 70%', 'entities': [['1', '10', 'clinical_variable'], ['13', '16', 'lower_bound']]}, 'NCT00959140'), ({'text': 'non-melanoma skin cancer', 'entities': [['1', '25', 'cancer']]}, 'NCT02807272'), ({'text': 'Patients must have had at least 4 months of prior systemic chemotherapy', 'entities': [['33', '41', 'lower_bound'], ['45', '72', 'treatment']]}, 'NCT01972919'), ({'text': 'Registration to Step 0 must occur after stopping prior systemic anti-cancer therapy', 'entities': [['50', '84', 'treatment']]}, 'NCT02465060'), ({'text': 'prostate (adenocarcinoma)', 'entities': [['1', '26', 'cancer']]}, 'NCT00720785'), ({'text': 'Active disease (CDAI > 10)', 'entities': [['17', '21', 'clinical_variable'], ['24', '26', 'lower_bound']]}, 'NCT02030028'), ({'text': 'Previous therapy', 'entities': [['1', '17', 'treatment']]}, 'NCT02580981'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) Performance status 0,1, or 2', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['70', '71', 'upper_bound']]}, 'NCT02353728'), ({'text': 'Patient is anuric', 'entities': [['12', '18', 'chronic_disease']]}, 'NCT02476409'), ({'text': 'complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy', 'entities': [['23', '43', 'cancer'], ['47', '82', 'cancer'], ['87', '105', 'cancer'], ['110', '134', 'cancer'], ['141', '157', 'treatment']]}, 'NCT01366612'), ({'text': 'Subject has a history of hospitalization for acute illness in the previous 3 months', 'entities': [['26', '41', 'treatment'], ['46', '59', 'chronic_disease'], ['67', '84', 'upper_bound']]}, 'NCT02404012'), ({'text': 'prior treatment with sorafenib', 'entities': [['1', '31', 'treatment']]}, 'NCT02124772'), ({'text': 'No concurrent, active malignancy, other than nonmetastatic skin cancer or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma)', 'entities': [['23', '33', 'cancer'], ['46', '71', 'cancer'], ['87', '115', 'cancer'], ['137', '168', 'cancer']]}, 'NCT02307058'), ({'text': 'Women of child bearing age with the potential to become pregnant who do not have a clinically documented negative pregnancy test', 'entities': [['1', '6', 'gender'], ['24', '27', 'age'], ['50', '65', 'pregnancy'], ['106', '124', 'pregnancy']]}, 'NCT03129542'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01659203'), ({'text': 'Patients with history of hematologic malignancy', 'entities': [['26', '48', 'cancer']]}, 'NCT02706353'), ({'text': 'newly diagnosed constatipation', 'entities': [['17', '31', 'chronic_disease']]}, 'NCT02099591'), ({'text': 'Patients with a systemic or metabolic disorder leading to progressive bone deterioration', 'entities': [['17', '25', 'chronic_disease'], ['29', '47', 'chronic_disease']]}, 'NCT02501733'), ({'text': 'Known or active hepatitis B or C with abnormal liver function tests', 'entities': [['17', '33', 'chronic_disease'], ['39', '62', 'chronic_disease']]}, 'NCT02315196'), ({'text': 'Patients must have an ECOG Performance Status of 0-1', 'entities': [['23', '46', 'clinical_variable'], ['50', '51', 'lower_bound'], ['52', '53', 'upper_bound']]}, 'NCT02213497'), ({'text': 'synchronous breast carcinoma in ipsilateral breast', 'entities': [['1', '29', 'cancer'], ['33', '51', 'cancer']]}, 'NCT01766297'), ({'text': 'Available for the duration of the trial (6 months)', 'entities': [['42', '50', 'upper_bound']]}, 'NCT01940757'), ({'text': 'women', 'entities': [['1', '6', 'gender']]}, 'NCT02354703'), ({'text': 'bipolar I, bipolar II, unspecified bipolar and related disorders, Disruptive Mood Dysregulation Disorder (DMDD), cyclothymic disorder, other specified bipolar and related disorders, as well as mood disorder not otherwise specified (if diagnosed in the past as per DSM-IV)', 'entities': [['1', '8', 'chronic_disease'], ['1', '10', 'chronic_disease'], ['12', '22', 'chronic_disease'], ['56', '65', 'chronic_disease'], ['67', '112', 'chronic_disease'], ['114', '134', 'chronic_disease'], ['194', '207', 'chronic_disease']]}, 'NCT02515773'), ({'text': 'Congenital long QT syndrome', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT02393794'), ({'text': 'taken fish oil during the prior 3 months', 'entities': [['27', '41', 'upper_bound']]}, 'NCT02176902'), ({'text': 'Mixed donor chimerism (greater than 20%)', 'entities': [['1', '22', 'clinical_variable'], ['37', '40', 'lower_bound']]}, 'NCT02475707'), ({'text': '9-25 years old', 'entities': [['1', '2', 'lower_bound'], ['3', '11', 'upper_bound']]}, 'NCT02801136'), ({'text': 'Participation in another clinical study with an investigational drug within 30 days of Screening', 'entities': [['18', '69', 'treatment'], ['77', '84', 'upper_bound']]}, 'NCT02140554'), ({'text': 'Clinical indication for thiamine administration (alcoholism, known or highly suspected deficiency) or treatment with thiamine beyond the amount found in a standard multivitamin within the last 10 days', 'entities': [['25', '33', 'treatment'], ['189', '201', 'upper_bound']]}, 'NCT02974257'), ({'text': 'Thrombocytopenia', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02474927'), ({'text': 'Has a medical condition that precludes safe pursuit of gardening, i.e., severe orthopedic conditions, pending hip/knee replacement (within 6 mo.), paralysis, dementia, blindness, untreated stage 3 hypertension, or myocardial infarction, congestive heart failure, or conditions that required oxygen or hospitalization within 6 mo', 'entities': [['7', '24', 'chronic_disease'], ['80', '101', 'chronic_disease'], ['103', '131', 'treatment'], ['140', '145', 'upper_bound'], ['140', '144', 'upper_bound'], ['148', '157', 'chronic_disease'], ['159', '167', 'chronic_disease'], ['169', '178', 'chronic_disease'], ['190', '210', 'chronic_disease'], ['215', '236', 'chronic_disease'], ['238', '262', 'chronic_disease'], ['292', '298', 'treatment'], ['302', '317', 'treatment']]}, 'NCT02985411'), ({'text': 'patients < 18 months (< 547 days) of age with newly diagnosed INRG stage L2 neuroblastoma/ganglioneuroblastoma', 'entities': [['12', '21', 'upper_bound'], ['25', '33', 'upper_bound'], ['38', '41', 'age'], ['77', '90', 'cancer'], ['91', '111', 'cancer']]}, 'NCT02176967'), ({'text': 'Patients with cognitive disabilities or those lacking the mental capacity to understand and answer questionnaires', 'entities': [['15', '37', 'chronic_disease']]}, 'NCT02776475'), ({'text': 'Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications', 'entities': [['1', '14', 'treatment'], ['22', '29', 'upper_bound'], ['51', '63', 'treatment'], ['119', '127', 'upper_bound']]}, 'NCT01822522'), ({'text': 'atrial fibrillation with heart rate > 100 beats per minute (bpm)', 'entities': [['1', '20', 'chronic_disease'], ['26', '36', 'clinical_variable'], ['39', '65', 'lower_bound']]}, 'NCT02152254'), ({'text': 'No tylectomies so extensive that the cosmetic result is low or poor prior to radiotherapy', 'entities': [['4', '15', 'treatment'], ['78', '90', 'treatment']]}, 'NCT00909909'), ({'text': 'Significant organ system dysfunction (e.g., diabetes requiring medications, severe pulmonary, kidney or cardiovascular disease)', 'entities': [['45', '53', 'chronic_disease'], ['84', '93', 'chronic_disease'], ['95', '101', 'chronic_disease'], ['105', '127', 'chronic_disease']]}, 'NCT02706288'), ({'text': 'Surgical staging with retroperitoneal staging and lymphadenectomy', 'entities': [['1', '17', 'treatment'], ['23', '46', 'treatment'], ['51', '66', 'treatment']]}, 'NCT01992861'), ({'text': 'Bendamustine (Treanda)', 'entities': [['1', '23', 'treatment']]}, 'NCT02796391'), ({'text': 'Medical history of cancer or treatment for cancer in the last two years prior to Visit 1 (except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of uterine cervix, and prostatic cancer of low grade [T1 or T2] is exempted)', 'entities': [['20', '26', 'cancer'], ['30', '39', 'treatment'], ['58', '78', 'upper_bound'], ['120', '152', 'cancer'], ['154', '189', 'cancer'], ['195', '235', 'cancer']]}, 'NCT03165227'), ({'text': 'potassium > 5.0 meq/L at baseline', 'entities': [['1', '10', 'clinical_variable'], ['13', '22', 'lower_bound']]}, 'NCT02593110'), ({'text': 'atients with suspected sleep apnea, based on symptoms', 'entities': [['24', '35', 'chronic_disease']]}, 'NCT03133013'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status (PS) of d 1 (see APPENDIX 1)', 'entities': [['1', '66', 'clinical_variable'], ['72', '73', 'upper_bound']]}, 'NCT02533674'), ({'text': 'Subject has at least a score of 6 (severe) on 2 of the 3 BPRS positive symptoms (conceptual disorganization, hallucinatory behavior and unusual thought content) at all three Baseline Visits prior to undergoing surgery', 'entities': [['33', '34', 'lower_bound'], ['82', '108', 'chronic_disease'], ['110', '132', 'chronic_disease'], ['211', '218', 'treatment']]}, 'NCT02361554'), ({'text': 'Women who have a documented history of virologic failure while on non-nucleoside reverse transcriptase inhibitors (NNRTIs) but who had no resistance testing at the time of viral failure will be considered to have NNRTI-documented resistance', 'entities': [['1', '6', 'gender'], ['67', '123', 'treatment'], ['116', '121', 'treatment']]}, 'NCT02256631'), ({'text': 'Diagnosis of inflammatory breast carcinoma', 'entities': [['14', '43', 'cancer']]}, 'NCT02540330'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01919619'), ({'text': 'for 6 months prior to first dose of study drug', 'entities': [['5', '19', 'upper_bound'], ['37', '47', 'treatment']]}, 'NCT01532687'), ({'text': 'Patients with known hepatic insufficiency or severe hepatic disease', 'entities': [['21', '42', 'chronic_disease'], ['46', '68', 'chronic_disease']]}, 'NCT02994940'), ({'text': 'Ages 16 years old and up', 'entities': [['1', '5', 'age'], ['6', '14', 'lower_bound']]}, 'NCT03088709'), ({'text': 'Binge eating disorder', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02932748'), ({'text': 'Tanner stage I OR II breast development with no change in the past 6 months', 'entities': [['63', '76', 'upper_bound']]}, 'NCT01438034'), ({'text': 'severe visual impairment preventing use of a touch-tone telephone keypad', 'entities': [['1', '25', 'chronic_disease'], ['46', '73', 'technology_access']]}, 'NCT01530958'), ({'text': 'Histology-confirmed aggressive B-cell Non-Hodgkin lymphoma', 'entities': [['32', '59', 'cancer']]}, 'NCT02633111'), ({'text': 'Compliance with the run-in placebo treatment must be between 75% and 125%', 'entities': [['21', '45', 'treatment'], ['62', '65', 'lower_bound'], ['70', '74', 'upper_bound']]}, 'NCT02495168'), ({'text': 'Ineligible for surgical resection', 'entities': [['25', '34', 'treatment']]}, 'NCT02072356'), ({'text': 'Known HIV-positivity', 'entities': [['7', '10', 'chronic_disease']]}, 'NCT02124902'), ({'text': 'surgically sterile', 'entities': [['1', '19', 'treatment']]}, 'NCT02498951'), ({'text': 'History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin', 'entities': [['58', '74', 'allergy_name'], ['76', '87', 'allergy_name'], ['92', '103', 'allergy_name']]}, 'NCT01174121'), ({'text': 'Major surgery within four weeks before consent date', 'entities': [['1', '14', 'treatment'], ['22', '32', 'upper_bound']]}, 'NCT02419495'), ({'text': 'D816V KIT-positive systemic mastocytosis', 'entities': [['29', '40', 'treatment'], ['29', '41', 'chronic_disease']]}, 'NCT00044304'), ({'text': 'Males must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy', 'entities': [['1', '6', 'gender'], ['109', '118', 'treatment']]}, 'NCT03113695'), ({'text': 'No investigational agent(s) within the past 6 months', 'entities': [['4', '28', 'treatment'], ['40', '53', 'upper_bound']]}, 'NCT00788164'), ({'text': 'maternal tachycardia >100 bpm', 'entities': [['1', '21', 'clinical_variable'], ['23', '30', 'lower_bound']]}, 'NCT02469519'), ({'text': 'Be willing and able to undergo, at both 30-days and 6-months post-implant, a Multi-Slice Computed Tomography (MSCT) scan (or TEE, if medically or technically contraindicated for an MSCT) of the heart and cardiac structures', 'entities': [['41', '48', 'lower_bound'], ['53', '61', 'upper_bound'], ['62', '74', 'treatment'], ['78', '121', 'treatment'], ['111', '115', 'treatment'], ['126', '129', 'treatment']]}, 'NCT02000115'), ({'text': 'trying to become pregnant', 'entities': [['1', '26', 'pregnancy']]}, 'NCT02437773'), ({'text': 'Tumor is supratentorially located and measureable', 'entities': [['1', '6', 'cancer']]}, 'NCT02507232'), ({'text': 'Able to read and understand English', 'entities': [['1', '36', 'language_fluency']]}, 'NCT02341235'), ({'text': 'Moderate or severe mitral stenosis', 'entities': [['20', '35', 'chronic_disease']]}, 'NCT03088072'), ({'text': 'Patients must not have received prior treatment with inotuzumab ozogamicin', 'entities': [['33', '48', 'treatment'], ['54', '75', 'treatment']]}, 'NCT01925131'), ({'text': 'Most recent enzalutamide dose received is 160 mg once daily with no change in dose for at least 2 weeks prior to Screening', 'entities': [['13', '25', 'treatment'], ['97', '110', 'lower_bound']]}, 'NCT02215096'), ({'text': 'Hgb greater than or equal to 7.0 g/dL (can be transfused)', 'entities': [['1', '4', 'clinical_variable'], ['30', '38', 'lower_bound']]}, 'NCT02475707'), ({'text': 'Eastern Cooperative Oncology Group performance status of d 2', 'entities': [['1', '54', 'clinical_variable'], ['60', '61', 'upper_bound']]}, 'NCT02834403'), ({'text': 'Subjects must be planned to receive radiation therapy or to undergo prostatectomy', 'entities': [['37', '54', 'treatment'], ['69', '82', 'treatment']]}, 'NCT02997709'), ({'text': 'Head injury with loss of consciousness of > 5 minutes in the last 5 years', 'entities': [['1', '12', 'chronic_disease'], ['45', '54', 'lower_bound'], ['62', '74', 'upper_bound']]}, 'NCT03004807'), ({'text': 'Active untreated infection', 'entities': [['18', '27', 'chronic_disease']]}, 'NCT02978638'), ({'text': 'Patients with ABCB4, ABCB11, RALBP or CYP851 genotypes associated with mithramycin-mediated hepatotoxicity', 'entities': [['15', '20', 'treatment'], ['22', '28', 'treatment'], ['30', '35', 'treatment'], ['39', '45', 'treatment'], ['72', '107', 'treatment']]}, 'NCT01624090'), ({'text': 'pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02258438'), ({'text': 'either partner is planning to move outside the area in the next 8 months', 'entities': [['65', '73', 'upper_bound']]}, 'NCT03048838'), ({'text': 'Recent hospitalization or surgical procedure within 1 month prior to the study for any cause', 'entities': [['27', '45', 'treatment'], ['53', '66', 'upper_bound']]}, 'NCT02252081'), ({'text': 'Chronic, stable phase of recovery (>6 months from last post-concussive event)', 'entities': [['37', '45', 'lower_bound']]}, 'NCT02920788'), ({'text': 'Participants must have histologically confirmed diagnosis of locally advanced and/or metastatic triple negative breast cancer, ovarian cancer, bladder cancer, gastric cancer, or soft tissue sarcoma', 'entities': [['86', '126', 'cancer'], ['128', '142', 'cancer'], ['144', '158', 'cancer'], ['160', '174', 'cancer'], ['179', '198', 'cancer']]}, 'NCT02323191'), ({'text': 'GFR <90', 'entities': [['1', '4', 'clinical_variable'], ['6', '8', 'upper_bound']]}, 'NCT02169089'), ({'text': 'with concurrent gemcitabine, capecitabine, or infusional 5-fluorouracil', 'entities': [['17', '28', 'treatment'], ['30', '42', 'treatment'], ['47', '72', 'treatment']]}, 'NCT02843945'), ({'text': '18 - 80 years old', 'entities': [['1', '3', 'lower_bound'], ['6', '14', 'upper_bound']]}, 'NCT02252432'), ({'text': 'Patients with a currently active second malignancy', 'entities': [['41', '51', 'cancer']]}, 'NCT02585973'), ({'text': 'dementia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02346929'), ({'text': 'able to speak and read English sufficiently for completion of consent form and questionnaires', 'entities': [['1', '31', 'language_fluency']]}, 'NCT02796391'), ({'text': 'Patients who have been diagnosed or treated for another malignancy within 2 years before study enrollment', 'entities': [['57', '67', 'cancer'], ['75', '89', 'upper_bound']]}, 'NCT02481310'), ({'text': 'History or presence of clinically relevant cardiovascular abnormalities', 'entities': [['44', '72', 'chronic_disease']]}, 'NCT02541903'), ({'text': 'women', 'entities': [['1', '6', 'gender']]}, 'NCT02267772'), ({'text': 'metformin allergy', 'entities': [['1', '10', 'allergy_name']]}, 'NCT02519543'), ({'text': 'subjects with type 2 diabetes diagnosed during the past 2 years', 'entities': [['15', '30', 'chronic_disease'], ['52', '64', 'upper_bound']]}, 'NCT01107717'), ({'text': 'Life expectancy of at least 12 weeks', 'entities': [['1', '16', 'clinical_variable'], ['29', '37', 'lower_bound']]}, 'NCT02670044'), ({'text': 'Terminal Illness', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02971137'), ({'text': 'Sickle cell disease', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT01730794'), ({'text': 'Previously untreated non-M3 AML age >60 with no evidence of favorable karyotype defined by presence of t(8;21)(q22;q22) [AML1-ETO], inv16(p13;q22), or t(16;16)(p13;q22) [CBF²;MYH11] by cytogenetics, FISH, or RT-PCR', 'entities': [['22', '32', 'cancer'], ['33', '36', 'age'], ['38', '40', 'lower_bound'], ['104', '120', 'cancer'], ['133', '147', 'cancer'], ['152', '169', 'cancer']]}, 'NCT02583893'), ({'text': 'less than 23 hours of AHF care', 'entities': [['11', '19', 'upper_bound'], ['23', '31', 'clinical_variable']]}, 'NCT02519283'), ({'text': 'Known presence of significant congenital or acquired bleeding disorder unrelated to cancer', 'entities': [['54', '71', 'chronic_disease'], ['85', '91', 'cancer']]}, 'NCT02353728'), ({'text': 'Patients already enrolled in another investigational device or drug study (nor can enrolled patients be enrolled in other studies)', 'entities': [['38', '60', 'treatment'], ['64', '74', 'treatment']]}, 'NCT01812174'), ({'text': 'Non-English speaker', 'entities': [['1', '20', 'language_fluency']]}, 'NCT02781701'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status 0-1', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['64', '65', 'upper_bound']]}, 'NCT03162731'), ({'text': 'Histologically or cytologically confirmed advanced colorectal cancer', 'entities': [['52', '69', 'cancer']]}, 'NCT02484404'), ({'text': 'FEV1 is within acceptable limits', 'entities': [['1', '5', 'clinical_variable']]}, 'NCT01536522'), ({'text': 'Patients must have pathologically or cytologically proven transitional cell carcinoma of the urothelium', 'entities': [['59', '104', 'cancer']]}, 'NCT02459119'), ({'text': 'HAV may not be used for coronary artery repair', 'entities': [['25', '47', 'treatment']]}, 'NCT03005418'), ({'text': 'Use of ACE inhibitor currently or within the past 6 weeks', 'entities': [['8', '21', 'treatment'], ['46', '58', 'upper_bound']]}, 'NCT03135522'), ({'text': 'Major surgery less than 4 weeks before the start of the study', 'entities': [['1', '14', 'clinical_variable'], ['25', '32', 'upper_bound']]}, 'NCT02737475'), ({'text': 'greater than or equal to 18 years old', 'entities': [['26', '34', 'lower_bound']]}, 'NCT02404870'), ({'text': 'High risk: Stage cT1-T2 and Gleason 8-10 and prostate-specific antigen less than 150', 'entities': [['12', '17', 'clinical_variable'], ['18', '21', 'lower_bound'], ['22', '24', 'upper_bound'], ['29', '36', 'clinical_variable'], ['37', '38', 'lower_bound'], ['39', '41', 'upper_bound'], ['46', '71', 'clinical_variable'], ['82', '85', 'upper_bound']]}, 'NCT01508390'), ({'text': 'Histologically confirmed diffuse large cell or grade 3A/B follicular lymphoma', 'entities': [['26', '44', 'cancer'], ['48', '78', 'cancer']]}, 'NCT00670358'), ({'text': 'Subjects who have an allergy to miglustat or any of the components within the drug product', 'entities': [['33', '42', 'allergy_name']]}, 'NCT02030015'), ({'text': 'Temporal-mandibular joint disease', 'entities': [['1', '34', 'chronic_disease']]}, 'NCT02982772'), ({'text': 'Oral temperature < 100 degrees Fahrenheit', 'entities': [['1', '17', 'clinical_variable'], ['20', '42', 'upper_bound']]}, 'NCT02485639'), ({'text': 'Scheduled for living donor kidney transplant in the next 6 months', 'entities': [['28', '45', 'treatment'], ['53', '66', 'upper_bound']]}, 'NCT02593526'), ({'text': 'Subject consents to provide at least 10 unstained tumor slides for retrospective testing of HRAS gene tumor status', 'entities': [['38', '40', 'lower_bound'], ['51', '56', 'cancer'], ['93', '97', 'treatment']]}, 'NCT02383927'), ({'text': 'Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study drug or using an investigation device within 4 weeks of the first dose of treatment', 'entities': [['42', '55', 'treatment'], ['93', '114', 'treatment'], ['128', '138', 'treatment'], ['151', '171', 'treatment'], ['179', '186', 'upper_bound'], ['208', '217', 'treatment']]}, 'NCT02541565'), ({'text': 'Known or documented history of communicable disease, including AIDS, HIV, active Hepatitis', 'entities': [['64', '68', 'chronic_disease'], ['70', '73', 'chronic_disease'], ['82', '91', 'chronic_disease']]}, 'NCT02555280'), ({'text': 'Participant is judged by the investigator to have evidence of hemolysis', 'entities': [['63', '72', 'chronic_disease']]}, 'NCT02988960'), ({'text': "Subject has a connective tissue disease (e.g. Marfan's syndrome, medial degeneration)", 'entities': [['15', '40', 'chronic_disease'], ['47', '64', 'chronic_disease'], ['66', '85', 'chronic_disease']]}, 'NCT02365467'), ({'text': 'Males', 'entities': [['1', '6', 'gender']]}, 'NCT02914561'), ({'text': 'Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of TGR-1202', 'entities': [['11', '31', 'treatment'], ['39', '46', 'upper_bound'], ['50', '62', 'lower_bound'], ['86', '121', 'treatment']]}, 'NCT02493530'), ({'text': 'Anti-Convulsants: carbamazepine, Phenobarbital, Anti-Convulsant:phenytoin, Anti-Mycobacterial:rifabutin, PDE5 Inhibitors: sildenafil, vardenafil, tadalafil, HMG-CoA: Reductase Inhibitors: atorvastatin, rosuvastatin, Immuno-suppressants: cyclosporine,tacrolimus, sirolimus, Narcotic Analgesic: methadone, Oral Contraceptive:ethinyl estradiol, Macrolide Antibiotic:azithromycin, Inhaled/nasal steroid fluticasone, Antidepressant: trazodone', 'entities': [['1', '16', 'treatment'], ['1', '17', 'treatment'], ['19', '32', 'treatment'], ['34', '47', 'treatment'], ['65', '74', 'treatment'], ['76', '94', 'treatment'], ['95', '104', 'treatment'], ['106', '121', 'treatment'], ['123', '133', 'treatment'], ['135', '145', 'treatment'], ['147', '156', 'treatment'], ['158', '165', 'treatment'], ['167', '187', 'treatment'], ['189', '201', 'treatment'], ['203', '215', 'treatment'], ['217', '236', 'treatment'], ['238', '250', 'treatment'], ['251', '261', 'treatment'], ['263', '272', 'treatment'], ['274', '292', 'treatment'], ['294', '303', 'treatment'], ['305', '323', 'treatment'], ['324', '341', 'treatment'], ['343', '363', 'treatment'], ['364', '376', 'treatment'], ['378', '411', 'treatment'], ['413', '427', 'treatment'], ['429', '438', 'treatment']]}, 'NCT02207439'), ({'text': 'abnormal sensitivity to ionizing radiation', 'entities': [['25', '43', 'allergy_name']]}, 'NCT01868386'), ({'text': 'History of clinically significant stroke or other neurological disease of the central nervous system', 'entities': [['35', '41', 'chronic_disease'], ['51', '71', 'chronic_disease']]}, 'NCT02460783'), ({'text': 'Receiving any other anti-cancer agents or radiotherapy at the time of study entry', 'entities': [['21', '39', 'treatment'], ['43', '55', 'treatment']]}, 'NCT02311621'), ({'text': 'Subjects will be required to have dialysis treatment for >3 months with an average Kt/V 1.2, and be able to perform exercise safely', 'entities': [['35', '53', 'treatment'], ['59', '67', 'lower_bound']]}, 'NCT01990495'), ({'text': 'Known to be human immunodeficiency virus (HIV) seropositive', 'entities': [['13', '47', 'chronic_disease']]}, 'NCT02120222'), ({'text': 'Age and Performance Status, Arm B', 'entities': [['1', '4', 'age'], ['9', '27', 'clinical_variable']]}, 'NCT01505569'), ({'text': 'Willing to exercise for 12 months', 'entities': [['25', '34', 'upper_bound']]}, 'NCT02614365'), ({'text': 'Has had a prior monoclonal antibody d 28 days prior to study registration or who has not recovered (i.e., d Grade 1 or at baseline) from adverse events due to agents administered more than 28 days earlier', 'entities': [['39', '52', 'upper_bound'], ['39', '46', 'lower_bound'], ['109', '116', 'upper_bound']]}, 'NCT02365766'), ({'text': 'Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent', 'entities': [['1', '9', 'treatment'], ['11', '32', 'treatment'], ['44', '56', 'lower_bound'], ['76', '90', 'treatment']]}, 'NCT01614197'), ({'text': 'Prior vismodegib or other antagonists of the Hh pathway', 'entities': [['1', '17', 'treatment']]}, 'NCT01835626'), ({'text': "Clinical diagnosis of idiopathic Parkinson's disease (PD)", 'entities': [['34', '58', 'chronic_disease']]}, 'NCT02765282'), ({'text': 'Significant neurologic co morbidities such as cerebrovascular accidents with deficit or developmental delays which may impact learning and/or memor', 'entities': [['13', '38', 'chronic_disease'], ['47', '62', 'chronic_disease']]}, 'NCT01275716'), ({'text': 'Use of neuromuscular blocking agents within the 48 hours preceding testing', 'entities': [['8', '37', 'treatment'], ['49', '57', 'upper_bound']]}, 'NCT02332187'), ({'text': 'in children serum CR less than or equal to age-adjusted normal (age 12 to 15 maximum serum creatinine 1.2 mg/dl and age greater than 15 maximum serum creatinine 1.5 mg/dl)', 'entities': [['13', '21', 'clinical_variable'], ['44', '47', 'age'], ['69', '71', 'lower_bound'], ['86', '102', 'clinical_variable'], ['103', '112', 'upper_bound'], ['162', '171', 'upper_bound']]}, 'NCT00001337'), ({'text': 'Patient has been permanently discontinued from pasireotide study treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason', 'entities': [['48', '75', 'treatment']]}, 'NCT01794793'), ({'text': "History/physical examination with documentation of patient's weight within 30 days of registration", 'entities': [['76', '83', 'upper_bound']]}, 'NCT01684904'), ({'text': 'Diagnosis of multiple sclerosis according to the current McDonald Criteria', 'entities': [['14', '32', 'chronic_disease']]}, 'NCT01326715'), ({'text': 'Significant illness in the past 30 days requiring hospitalization', 'entities': [['28', '40', 'upper_bound']]}, 'NCT02507011'), ({'text': 'Current treated or untreated cancer', 'entities': [['9', '36', 'cancer']]}, 'NCT02404155'), ({'text': "Patients with a QT interval > 500 msec (using the Bazett's formula) within 28 days prior to registration", 'entities': [['17', '28', 'clinical_variable'], ['31', '39', 'lower_bound'], ['76', '89', 'upper_bound']]}, 'NCT02232516'), ({'text': 'Presence of fluorodeoxyglucose (FDG) avid metastatic lesions on positron emission tomography (PET)/CT scan (standardized uptake values [SUV]max > 5 of any single lesion)', 'entities': [['13', '37', 'treatment'], ['43', '61', 'cancer'], ['65', '107', 'treatment'], ['109', '144', 'clinical_variable'], ['147', '148', 'lower_bound']]}, 'NCT02143726'), ({'text': 'Adult males', 'entities': [['7', '12', 'gender']]}, 'NCT03001830'), ({'text': 'total bilirubin < 3 times ULN for age', 'entities': [['7', '16', 'clinical_variable'], ['19', '30', 'upper_bound'], ['35', '38', 'age']]}, 'NCT02932956'), ({'text': 'subjects who have an undetectable human immunodeficiency virus (HIV) viral load with CD (cluster of differentiation)4 >= 300 and are on highly active antiretroviral therapy (HAART) medication are allowed', 'entities': [['35', '69', 'chronic_disease'], ['86', '118', 'clinical_variable'], ['122', '125', 'lower_bound'], ['137', '192', 'treatment']]}, 'NCT03016871'), ({'text': 'B3: Neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) that are unresectable and medically significant', 'entities': [['5', '22', 'chronic_disease'], ['42', '80', 'chronic_disease']]}, 'NCT02124772'), ({'text': 'Receiving more than two inotropes', 'entities': [['21', '24', 'lower_bound'], ['25', '34', 'treatment']]}, 'NCT02645539'), ({'text': 'Have either progressed on, are intolerant to, or refused treatment with sorafenib or another approved TKI', 'entities': [['58', '67', 'treatment'], ['73', '82', 'treatment'], ['103', '106', 'treatment']]}, 'NCT02519348'), ({'text': "peripheral neuropathy and neurodegenerative disorders (i.e. Parkinson's disease or dementia)", 'entities': [['1', '22', 'chronic_disease'], ['27', '54', 'chronic_disease'], ['61', '80', 'chronic_disease'], ['84', '92', 'chronic_disease']]}, 'NCT02826681'), ({'text': 'Patients with other uncontrolled infections (see 2.3.2 for definitions)', 'entities': [['21', '44', 'chronic_disease']]}, 'NCT01945814'), ({'text': 'Target lesion must measure at least 15 mm in at least one dimension, and no more than 4 cm in any dimension', 'entities': [['37', '42', 'lower_bound'], ['55', '58', 'lower_bound'], ['87', '91', 'upper_bound']]}, 'NCT02514915'), ({'text': 'within 90 days prior to registration', 'entities': [['8', '21', 'upper_bound']]}, 'NCT01950351'), ({'text': 'At least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02891681'), ({'text': 'Previously untreated diffuse large B-cell lymphoma or grade 3B follicular lymphoma (of any stage)', 'entities': [['22', '51', 'cancer'], ['55', '83', 'cancer']]}, 'NCT02541565'), ({'text': 'who has at least one activity of daily living (ADL) deficits or a new or worsening cognitive or physical functioning problem', 'entities': [['18', '21', 'lower_bound']]}, 'NCT01600131'), ({'text': 'pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02823665'), ({'text': 'Available related donor who is mismatched at e 2 HLA alleles', 'entities': [['48', '49', 'lower_bound'], ['50', '61', 'clinical_variable']]}, 'NCT02566395'), ({'text': 'Eligible participants may have other co-morbid stable neuropsychiatric disorders, including depression and PTSD', 'entities': [['55', '81', 'chronic_disease'], ['93', '103', 'chronic_disease'], ['108', '112', 'chronic_disease']]}, 'NCT02920788'), ({'text': 'Visual Acuity d20/200 in the worst eye', 'entities': [['1', '14', 'clinical_variable'], ['16', '22', 'upper_bound']]}, 'NCT01367444'), ({'text': 'Delivery occurred at equal to or greater than 24 0/7 weeks gestational age', 'entities': [['47', '59', 'lower_bound'], ['60', '75', 'clinical_variable']]}, 'NCT03011567'), ({'text': 'Leukopenia (WBC <2.000/mm3) or lymhopenia (lymphocytes < 300/mm3)', 'entities': [['1', '11', 'cancer'], ['13', '16', 'clinical_variable'], ['18', '27', 'upper_bound'], ['32', '42', 'chronic_disease'], ['44', '55', 'clinical_variable'], ['58', '65', 'upper_bound']]}, 'NCT01781611'), ({'text': 'positive pregnancy test (if part of a clinical routine)', 'entities': [['10', '19', 'pregnancy']]}, 'NCT02687464'), ({'text': 'Have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation)', 'entities': [['19', '27', 'chronic_disease'], ['31', '49', 'chronic_disease'], ['51', '57', 'chronic_disease'], ['61', '85', 'chronic_disease']]}, 'NCT02041936'), ({'text': 'Glycosuria', 'entities': [['1', '11', 'chronic_disease']]}, 'NCT01200940'), ({'text': 'Age 18 or greater', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT02930018'), ({'text': 'medications stable for 8 weeks', 'entities': [['24', '31', 'upper_bound']]}, 'NCT02206945'), ({'text': 'Known history of testing positive for human immunodeficiency virus or known acquired immunodeficiency syndrome', 'entities': [['39', '67', 'chronic_disease'], ['77', '111', 'chronic_disease']]}, 'NCT02519322'), ({'text': 'other irregular heart rhythm', 'entities': [['7', '29', 'chronic_disease']]}, 'NCT03078504'), ({'text': 'Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial', 'entities': [['62', '73', 'allergy_name'], ['75', '93', 'allergy_name']]}, 'NCT03042689'), ({'text': 'PSA > 10ng/ml within the past 3 months may enter study', 'entities': [['1', '4', 'clinical_variable'], ['7', '14', 'lower_bound'], ['26', '39', 'upper_bound']]}, 'NCT01913106'), ({'text': 'Any of the following exclusionary criteria related to propranolol (diabetes, reactive airway/pulmonary disease, thyroid disease, bradyarrhythmias, unexplained syncope, narrow angle glaucoma, known hypersensitivity/adverse reaction to beta-blockers, potentially interacting drugs, underweight < 15 kg)', 'entities': [['55', '66', 'treatment'], ['68', '76', 'chronic_disease'], ['78', '111', 'chronic_disease'], ['113', '128', 'chronic_disease'], ['130', '146', 'chronic_disease'], ['160', '167', 'chronic_disease'], ['169', '190', 'chronic_disease'], ['235', '248', 'allergy_name'], ['281', '292', 'clinical_variable'], ['295', '300', 'upper_bound']]}, 'NCT02428205'), ({'text': 'Documented history of e1 symptomatic hyperammonemia event with ammonia e100 µmol/L', 'entities': [['24', '25', 'lower_bound'], ['26', '52', 'clinical_variable'], ['64', '71', 'clinical_variable'], ['73', '83', 'lower_bound']]}, 'NCT02991144'), ({'text': 'Known allergy to nitinol, polyester, or polyethylene', 'entities': [['18', '25', 'allergy_name'], ['27', '36', 'allergy_name'], ['41', '53', 'allergy_name']]}, 'NCT02806570'), ({'text': 'Intravenous use of rIX-FP within 14 days of subcutaneous administration of rIX-FP', 'entities': [['20', '26', 'treatment'], ['34', '41', 'upper_bound']]}, 'NCT02053792'), ({'text': 'curatively- treated basal cell carcinoma', 'entities': [['21', '41', 'cancer']]}, 'NCT03059355'), ({'text': 'Have food allergies related to the foods served in the study or are lactose intolerant', 'entities': [['6', '10', 'allergy_name'], ['69', '87', 'chronic_disease']]}, 'NCT02928874'), ({'text': 'Patients with MDS transformed to AML will be eligible even if they had not received prior therapy for AML', 'entities': [['15', '18', 'cancer'], ['34', '37', 'cancer'], ['85', '98', 'treatment']]}, 'NCT03150004'), ({'text': 'deep vein thrombosis', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT01954966'), ({'text': 'Patients receiving 2nd or greater line of therapy', 'entities': [['20', '23', 'lower_bound'], ['43', '50', 'treatment']]}, 'NCT02633111'), ({'text': 'All subjects must have recovered to grade <=1 from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment', 'entities': [['45', '46', 'upper_bound'], ['83', '101', 'treatment'], ['103', '116', 'treatment'], ['121', '133', 'treatment']]}, 'NCT02124772'), ({'text': 'Age 18 and older', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT02442635'), ({'text': 'Presence of an active, uncontrolled infection', 'entities': [['24', '46', 'chronic_disease']]}, 'NCT02114229'), ({'text': 'The procedure will be explained to subjects age 8 -17 years with formal consent being obtained from parents or legal guardian', 'entities': [['45', '48', 'age'], ['49', '50', 'lower_bound'], ['52', '60', 'upper_bound']]}, 'NCT01174108'), ({'text': 'Able to read and communicate in English', 'entities': [['1', '40', 'language_fluency']]}, 'NCT02531711'), ({'text': 'Claustrophobia (this would make lying in the scanner very uncomfortable)', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT01614990'), ({'text': 'Age e 10 year for Liposarcoma, Osteosarcoma, and Ewing sarcoma', 'entities': [['1', '4', 'age'], ['7', '14', 'lower_bound'], ['19', '30', 'cancer'], ['32', '44', 'cancer'], ['50', '63', 'cancer']]}, 'NCT02048371'), ({'text': 'Past medical history of: liver dysfunction (ie: cirrhosis), chronic alcohol abuse, gastrointestinal bleed or recent gastrointestinal bleed (within past 5 days), renal dysfunction or disease, seizures (or currently actively receiving treatment for seizures), inflammatory bowel disease (or currently actively receiving treatment for inflammatory bowel disease), hepatitis (or currently actively receiving treatment for hepatitis)', 'entities': [['26', '43', 'chronic_disease'], ['49', '58', 'chronic_disease'], ['84', '106', 'chronic_disease'], ['148', '159', 'upper_bound'], ['162', '190', 'chronic_disease'], ['192', '200', 'chronic_disease'], ['234', '243', 'treatment'], ['259', '285', 'chronic_disease'], ['362', '371', 'chronic_disease']]}, 'NCT03137498'), ({'text': 'Distant metastases', 'entities': [['1', '19', 'cancer']]}, 'NCT01688388'), ({'text': 'Patients must be <45 years of age', 'entities': [['19', '27', 'upper_bound'], ['31', '34', 'age']]}, 'NCT00258427'), ({'text': 'Acquired Immune Deficiency Syndrome (AIDS) based on CDC criteria', 'entities': [['1', '43', 'chronic_disease']]}, 'NCT02128100'), ({'text': 'Female patients need to be post-menopausal', 'entities': [['1', '16', 'gender']]}, 'NCT02129348'), ({'text': 'Severe pulmonary disease', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03108950'), ({'text': 'Ability to read and write in English', 'entities': [['1', '37', 'language_fluency']]}, 'NCT02989974'), ({'text': 'Patients must not have grade 2 or greater peripheral neuropathy', 'entities': [['24', '31', 'lower_bound'], ['43', '64', 'clinical_variable']]}, 'NCT01415752'), ({'text': 'Arm A dose level 4 (75 mg/m^2 cisplatin)', 'entities': [['31', '40', 'treatment']]}, 'NCT02535312'), ({'text': 'History of ITP, TTP or HUS', 'entities': [['12', '15', 'chronic_disease'], ['17', '20', 'chronic_disease'], ['24', '27', 'chronic_disease']]}, 'NCT02578901'), ({'text': 'Patients must be greater than 6-months post-stroke', 'entities': [['31', '39', 'lower_bound'], ['45', '51', 'chronic_disease']]}, 'NCT01686373'), ({'text': 'Current or history of hepatitis from any etiology, including history of active viral hepatitis A, B, or C', 'entities': [['23', '32', 'chronic_disease'], ['86', '106', 'chronic_disease']]}, 'NCT02574910'), ({'text': 'unstable cardiac conditions', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT03099070'), ({'text': 'Healthy men', 'entities': [['9', '12', 'gender']]}, 'NCT02607917'), ({'text': 'Clinical stage N0, M0', 'entities': [['10', '22', 'cancer']]}, 'NCT02470897'), ({'text': 'Undergoing diagnostic laparoscopy for unilateral non-palpable testis, who are found at laparoscopy to have an abdominal undescended testis, in whom a Fowler-Stephens Orchiopexy would be appropriate', 'entities': [['12', '34', 'treatment'], ['23', '34', 'treatment']]}, 'NCT02235623'), ({'text': 'History of cancer not in remission for the last 3 years except for basal cell carcinoma and squamous cell carcinoma', 'entities': [['12', '18', 'cancer'], ['44', '56', 'upper_bound'], ['68', '88', 'cancer'], ['93', '116', 'cancer']]}, 'NCT02261519'), ({'text': 'Evidence of squamous cell carcinoma', 'entities': [['13', '36', 'cancer']]}, 'NCT02582775'), ({'text': 'Patients must be medically fit enough to undergo surgery as determined by the treating medical and surgical oncology team', 'entities': [['50', '57', 'treatment']]}, 'NCT02519322'), ({'text': 'Known active herpetic infection', 'entities': [['7', '32', 'chronic_disease']]}, 'NCT02007239'), ({'text': 'Received treatment with an investigational drug within 30 days of screening', 'entities': [['10', '48', 'treatment'], ['56', '63', 'upper_bound']]}, 'NCT02035085'), ({'text': 'patients must agree to continue contraception for 30 days from the date of the last study drug administration', 'entities': [['15', '46', 'contraception_consent'], ['51', '58', 'upper_bound']]}, 'NCT02394535'), ({'text': 'Severe corneal diseases or prior corneal surgery', 'entities': [['8', '24', 'chronic_disease'], ['28', '49', 'treatment']]}, 'NCT02561104'), ({'text': 'Subjects of child-bearing potential must agree to use acceptable contraceptive methods during treatment and until the end of the study', 'entities': [['42', '87', 'contraception_consent'], ['95', '104', 'treatment']]}, 'NCT02310464'), ({'text': 'Subject has a known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment', 'entities': [['61', '75', 'allergy_name'], ['79', '93', 'allergy_name'], ['120', '133', 'treatment']]}, 'NCT02365467'), ({'text': 'Patients with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity', 'entities': [['15', '40', 'chronic_disease']]}, 'NCT02350764'), ({'text': 'Currently pregnant', 'entities': [['1', '19', 'pregnancy']]}, 'NCT03051516'), ({'text': 'Willing to limit the introduction of any new medications or treatment modalities for control of FM symptoms during the study', 'entities': [['46', '57', 'treatment'], ['61', '70', 'treatment'], ['97', '99', 'chronic_disease']]}, 'NCT02064296'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1', 'entities': [['1', '67', 'clinical_variable'], ['71', '72', 'lower_bound'], ['76', '77', 'upper_bound']]}, 'NCT02317991'), ({'text': 'Age at randomization: at least two months (at least 36 weeks gestational age for subjects less than two years of age) to 10 years of age (120 months)', 'entities': [['1', '4', 'age'], ['32', '42', 'lower_bound'], ['53', '61', 'lower_bound'], ['62', '77', 'age'], ['74', '77', 'age'], ['101', '110', 'upper_bound'], ['122', '130', 'upper_bound']]}, 'NCT01595529'), ({'text': 'Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor) or radiotherapy must have been completed at least 14 days prior to administration of T cells', 'entities': [['1', '13', 'treatment'], ['15', '31', 'treatment'], ['43', '68', 'treatment'], ['73', '85', 'treatment'], ['120', '133', 'lower_bound']]}, 'NCT02414269'), ({'text': 'Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune, psychological or other medical conditions', 'entities': [['59', '64', 'chronic_disease'], ['66', '71', 'chronic_disease'], ['73', '79', 'chronic_disease'], ['81', '85', 'chronic_disease'], ['87', '99', 'chronic_disease'], ['101', '107', 'chronic_disease'], ['109', '122', 'chronic_disease'], ['132', '150', 'chronic_disease']]}, 'NCT02451982'), ({'text': 'WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) apixaban plus 5 half-lives of study drug apixaban (2.5 days) plus 30 days (duration of ovulatory cycle) for a total of 32.5 days post-treatment completion', 'entities': [['121', '129', 'treatment']]}, 'NCT02366871'), ({'text': 'Having experienced a traumatic event within the past 10 years', 'entities': [['49', '62', 'upper_bound']]}, 'NCT02370173'), ({'text': 'The resting 12-lead electrocardiogram obtained during screening shows QTc (Fridericia correction) e470 ms or has a congenital prolonged QT syndrome', 'entities': [['13', '38', 'treatment'], ['71', '98', 'clinical_variable'], ['100', '106', 'lower_bound'], ['116', '148', 'chronic_disease']]}, 'NCT02743637'), ({'text': 'Concurrent use of MAO inhibitors, or use in the last two weeks', 'entities': [['19', '33', 'treatment'], ['49', '63', 'upper_bound']]}, 'NCT02879136'), ({'text': 'Infants with congenital toxoplasmosis Toxoplasma gondii confirmed prior to age 2.5 months', 'entities': [['14', '38', 'chronic_disease'], ['76', '79', 'age'], ['80', '90', 'upper_bound']]}, 'NCT00004317'), ({'text': 'for 14 days following the last dose of study drug', 'entities': [['5', '12', 'upper_bound']]}, 'NCT01532687'), ({'text': 'Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['14', '35', 'chronic_disease'], ['78', '94', 'chronic_disease'], ['108', '132', 'chronic_disease'], ['143', '158', 'chronic_disease'], ['168', '178', 'chronic_disease'], ['183', '202', 'chronic_disease']]}, 'NCT01928576'), ({'text': 'Newly diagnosed MCL: History of stroke or intracranial hemorrhage within 6 months prior to signing the consent', 'entities': [['17', '20', 'cancer'], ['33', '39', 'chronic_disease'], ['43', '66', 'chronic_disease'], ['74', '88', 'upper_bound']]}, 'NCT01880567'), ({'text': 'Psoriatic arthritis', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT03077243'), ({'text': 'Active infection is defined as a stool sample positive for Clostridium difficile toxin via EIA (enzyme immunoassay) and either symptoms (frequent loose stools)', 'entities': [['1', '17', 'chronic_disease'], ['60', '116', 'treatment'], ['147', '159', 'chronic_disease']]}, 'NCT02763033'), ({'text': 'Chemotherapy administered concurrently with primary radiation (e.g., weekly cisplatin)', 'entities': [['1', '13', 'treatment'], ['53', '62', 'treatment'], ['77', '86', 'treatment']]}, 'NCT03104699'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03102320'), ({'text': 'ISI cutoff score of 10 or higher', 'entities': [['1', '17', 'clinical_variable'], ['21', '23', 'lower_bound']]}, 'NCT03087799'), ({'text': 'Prior radiation therapy within 2 weeks prior to the first dose of the study regimen', 'entities': [['1', '24', 'treatment'], ['32', '45', 'upper_bound'], ['71', '84', 'treatment']]}, 'NCT02474173'), ({'text': 'The use of psychotropic medication for < 3 months', 'entities': [['12', '35', 'treatment'], ['42', '50', 'upper_bound']]}, 'NCT02707887'), ({'text': 'Diagnosed with PKU or other aminoacidopathy', 'entities': [['16', '19', 'chronic_disease'], ['29', '44', 'chronic_disease']]}, 'NCT01659749'), ({'text': 'hypovolemia', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT02339233'), ({'text': 'A serum creatinine based on age/gender', 'entities': [['3', '19', 'treatment'], ['29', '32', 'age']]}, 'NCT02323880'), ({'text': 'Central nervous system disease (cerebrovascular accidents, dementia, neurodegenerative disorders, epilepsy or history of head injury)', 'entities': [['1', '31', 'chronic_disease'], ['33', '58', 'chronic_disease'], ['60', '68', 'chronic_disease'], ['70', '97', 'chronic_disease'], ['99', '107', 'chronic_disease'], ['122', '133', 'chronic_disease']]}, 'NCT00739362'), ({'text': 'Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy', 'entities': [['22', '42', 'treatment'], ['50', '69', 'treatment'], ['71', '106', 'treatment']]}, 'NCT02488967'), ({'text': 'MRI (done within one year of the first visit) with significant abnormalities other than those associated with the neurological disorder causing chronic pain', 'entities': [['18', '26', 'upper_bound'], ['115', '136', 'chronic_disease']]}, 'NCT03029884'), ({'text': 'Allergy to contrast media that cannot be managed with standard care (e.g. steroids)', 'entities': [['12', '26', 'allergy_name'], ['55', '68', 'treatment'], ['75', '83', 'treatment']]}, 'NCT01648023'), ({'text': 'Active, clinically significant infection either grade > 2 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 or requiring the use of parenteral anti-microbial agents within 7 days before day 1 of study drug', 'entities': [['57', '58', 'lower_bound'], ['185', '217', 'treatment'], ['225', '231', 'upper_bound']]}, 'NCT02401347'), ({'text': 'Subjects must be co-enrolled in NIH protocol 08-HG-0059', 'entities': [['33', '56', 'treatment']]}, 'NCT01631617'), ({'text': 'History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins', 'entities': [['82', '90', 'allergy_name'], ['94', '114', 'allergy_name'], ['118', '133', 'allergy_name']]}, 'NCT02451423'), ({'text': 'GPC3 expression will be evaluated by standard immunohistochemistry (IHC). A tumor is considered GPC3 positive, when the staining is Grade 2 (>25% positive tumor cells) or above with an intensity score of 2 or above on a scale of 0 to 4', 'entities': [['47', '73', 'treatment'], ['77', '82', 'cancer'], ['139', '140', 'lower_bound'], ['143', '146', 'lower_bound'], ['147', '167', 'clinical_variable'], ['230', '231', 'lower_bound'], ['235', '236', 'upper_bound']]}, 'NCT02932956'), ({'text': 'Patients d 17 years of age', 'entities': [['12', '20', 'upper_bound'], ['24', '27', 'age']]}, 'NCT03113760'), ({'text': 'Birth weight < 1800 g (e.g., intrauterine growth restriction)', 'entities': [['1', '13', 'clinical_variable'], ['16', '22', 'upper_bound']]}, 'NCT02811263'), ({'text': 'Open biopsy is considered a major surgery', 'entities': [['1', '12', 'treatment'], ['29', '42', 'treatment']]}, 'NCT02369653'), ({'text': '18 years old or older', 'entities': [['1', '9', 'lower_bound']]}, 'NCT02338999'), ({'text': 'Seizure disorders must be well controlled on antiepileptic medication', 'entities': [['1', '18', 'chronic_disease'], ['46', '70', 'treatment']]}, 'NCT02502708'), ({'text': 'clinically diagnosed with knee OA using American College of Rheumatology (ACR) criteria', 'entities': [['27', '34', 'chronic_disease']]}, 'NCT02272218'), ({'text': 'Life expectancy > 3 months', 'entities': [['1', '16', 'clinical_variable'], ['19', '27', 'lower_bound']]}, 'NCT02452268'), ({'text': 'History of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol specified imaging sessions', 'entities': [['12', '26', 'treatment']]}, 'NCT02469129'), ({'text': 'Severe, unstable, or active inflammatory disease', 'entities': [['29', '49', 'chronic_disease']]}, 'NCT02252081'), ({'text': 'Patients with melanoma brain metastases are allowed', 'entities': [['15', '40', 'cancer']]}, 'NCT02910700'), ({'text': 'Teres minor dysfunction', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT01697865'), ({'text': 'Adjuvant systemic therapy before and after the protocol therapy per section 4.4.1', 'entities': [['1', '26', 'treatment'], ['19', '26', 'treatment']]}, 'NCT02893982'), ({'text': 'Subjects must own a Bluetooth capable modern smartphone capable of receiving and sending text messages and an active data plan', 'entities': [['15', '127', 'technology_access']]}, 'NCT03069716'), ({'text': 'Cannot lie comfortably flat on your back for up to 2 hours in the PET and MRI scanners (self-report)', 'entities': [['52', '59', 'upper_bound'], ['67', '70', 'treatment'], ['75', '87', 'treatment']]}, 'NCT02233868'), ({'text': 'Life-threatening illness', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT01505062'), ({'text': 'Documented surgical resection/debulking', 'entities': [['12', '30', 'treatment'], ['31', '40', 'treatment']]}, 'NCT02302235'), ({'text': 'ages 18-100 years', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '18', 'upper_bound']]}, 'NCT02219581'), ({'text': '> 18 years old', 'entities': [['3', '11', 'lower_bound']]}, 'NCT03073629'), ({'text': 'Use of any immunomodulatory agents within 30 days prior to study enrollment or planned use during the trial', 'entities': [['12', '35', 'treatment'], ['43', '56', 'upper_bound']]}, 'NCT02471430'), ({'text': 'unable to provide self-consent for participation (e.g., due to dementia)', 'entities': [['64', '72', 'chronic_disease']]}, 'NCT02830074'), ({'text': 'renal/electrolyte disorders and any other condition that the study screening physician considers would significantly impede participation in the study', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT03043963'), ({'text': 'No regular medication other than aspirin (other than oral hypoglycemic agents, hormonal contraceptives and medications taken only on an as-needed basis)', 'entities': [['12', '22', 'treatment'], ['34', '41', 'treatment'], ['54', '78', 'treatment'], ['80', '103', 'treatment'], ['108', '119', 'treatment']]}, 'NCT00862433'), ({'text': 'Sustained ventricular tachycardia', 'entities': [['11', '34', 'chronic_disease']]}, 'NCT02058095'), ({'text': 'Absolute lymphocyte count below the lower limit of normal (LLN)', 'entities': [['10', '26', 'clinical_variable']]}, 'NCT02956486'), ({'text': 'Disease free of other malignancies', 'entities': [['23', '35', 'cancer']]}, 'NCT02293109'), ({'text': 'Cohort 1 (reirradiation in patients with head and neck cancers with gross unresectable disease)', 'entities': [['42', '63', 'cancer']]}, 'NCT02474368'), ({'text': 'Left ventricular ejection fraction (LVEF) e 50% by transthoracic echocardiogram or multigated acquisition scan (MUGA)', 'entities': [['1', '42', 'clinical_variable'], ['45', '48', 'lower_bound'], ['52', '80', 'treatment'], ['84', '118', 'treatment']]}, 'NCT02907918'), ({'text': 'are enrolled in hospice and/or have a life expectancy of six months or less', 'entities': [['39', '54', 'clinical_variable'], ['58', '68', 'upper_bound']]}, 'NCT03046121'), ({'text': 'History of gastrointestinal surgery or disease', 'entities': [['12', '36', 'treatment']]}, 'NCT03181516'), ({'text': 'Stented lesion', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02316886'), ({'text': "At the Screen Visit, the subject's urine contains opiates, cocaine, amphetamines, barbiturates, or benzodiazepines that cannot be explained by appropriate use of prescribed medication", 'entities': [['51', '58', 'treatment'], ['60', '67', 'treatment'], ['69', '81', 'treatment'], ['83', '95', 'treatment'], ['100', '115', 'treatment'], ['174', '184', 'treatment']]}, 'NCT02354703'), ({'text': 'Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during this period', 'entities': [['1', '16', 'treatment'], ['31', '32', 'lower_bound'], ['47', '63', 'treatment'], ['71', '84', 'upper_bound']]}, 'NCT03034772'), ({'text': 'pregnancy or breast feeding', 'entities': [['1', '10', 'pregnancy']]}, 'NCT03106740'), ({'text': 'Relapsed/refractory MCL: Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drug', 'entities': [['1', '24', 'chronic_disease'], ['26', '44', 'treatment'], ['52', '59', 'upper_bound'], ['61', '73', 'treatment'], ['81', '88', 'upper_bound'], ['90', '123', 'treatment'], ['131', '138', 'upper_bound'], ['156', '172', 'treatment'], ['180', '188', 'upper_bound'], ['190', '207', 'treatment'], ['217', '239', 'treatment'], ['256', '269', 'treatment'], ['288', '329', 'treatment']]}, 'NCT01880567'), ({'text': 'GERD symptoms, in absence of PPI therapy (minimum 7 days)', 'entities': [['1', '5', 'chronic_disease'], ['30', '41', 'treatment'], ['51', '57', 'lower_bound']]}, 'NCT02429830'), ({'text': 'History or evidence of current clinically significant uncontrolled arrhythmias (exception: patients with controlled atrial fibrillation for > 30 days prior to randomization are eligible)', 'entities': [['68', '79', 'chronic_disease'], ['117', '136', 'chronic_disease'], ['143', '156', 'lower_bound']]}, 'NCT01989585'), ({'text': 'Thrombotic, embolic, venous or arterial events', 'entities': [['1', '47', 'chronic_disease']]}, 'NCT03042689'), ({'text': 'Diagnosis of schizophrenia, bipolar disorder, personality disorder or other Diagnostic and Statistical Manual of Mental Disorders (DSM-III) disorders that the investigator believes will interfere significantly with study compliance. Neurocognitive disorders affecting ability to consent will not be disqualifying as long as an appropriate guardian able to give consent has been appointed', 'entities': [['14', '27', 'chronic_disease'], ['29', '45', 'chronic_disease'], ['47', '67', 'chronic_disease'], ['234', '258', 'chronic_disease']]}, 'NCT03013543'), ({'text': 'absolute neutrophil count e1,000/mcL', 'entities': [['1', '26', 'clinical_variable'], ['28', '37', 'lower_bound']]}, 'NCT02985554'), ({'text': 'Forced expiratory volume in 1 second (FEV1) 40-90% predicted', 'entities': [['1', '44', 'clinical_variable'], ['45', '47', 'lower_bound'], ['48', '51', 'upper_bound']]}, 'NCT03140527'), ({'text': 'at risk of becoming pregnant', 'entities': [['21', '29', 'pregnancy']]}, 'NCT02087826'), ({'text': 'Women planning to become pregnant while on study through 1 week after receiving the last dose of study drug', 'entities': [['1', '6', 'gender'], ['7', '34', 'pregnancy'], ['58', '70', 'upper_bound'], ['98', '108', 'treatment']]}, 'NCT02520427'), ({'text': 'Patients that have an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease', 'entities': [['30', '48', 'chronic_disease'], ['59', '77', 'treatment'], ['89', '102', 'upper_bound']]}, 'NCT03162731'), ({'text': 'Type 1 diabetes or use of insulin pump', 'entities': [['1', '16', 'chronic_disease'], ['27', '39', 'treatment']]}, 'NCT02448498'), ({'text': 'Current use of organic nitrates', 'entities': [['16', '32', 'treatment']]}, 'NCT02819440'), ({'text': 'Severe liver disease or end-stage renal disease', 'entities': [['8', '21', 'chronic_disease'], ['25', '48', 'chronic_disease']]}, 'NCT01568918'), ({'text': 'Open-heart cardiac surgery', 'entities': [['1', '27', 'treatment']]}, 'NCT02361944'), ({'text': 'clinically significant severe renal insufficiency or severe hepatic disorders', 'entities': [['24', '50', 'chronic_disease'], ['54', '78', 'chronic_disease']]}, 'NCT03058783'), ({'text': 'moderate-severe COPD (FEV1<80% of normal values and/or FEV1/FVC < 0.70)', 'entities': [['1', '21', 'chronic_disease'], ['23', '27', 'clinical_variable'], ['28', '31', 'upper_bound'], ['56', '64', 'clinical_variable'], ['67', '71', 'upper_bound']]}, 'NCT02946268'), ({'text': 'Age 18-65', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT02418195'), ({'text': 'Hypertension', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02301663'), ({'text': 'ECOG performance status 0 or 1', 'entities': [['1', '24', 'clinical_variable'], ['25', '26', 'lower_bound'], ['30', '31', 'upper_bound']]}, 'NCT02080221'), ({'text': 'Pre-menopausal women as defined as four menstrual cycles within the last six months prior to pre-registration', 'entities': [['16', '21', 'gender'], ['69', '90', 'upper_bound']]}, 'NCT01905046'), ({'text': 'Thromboembolic events and/or bleeding disorders d 14 days (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study drug', 'entities': [['1', '15', 'chronic_disease'], ['30', '48', 'chronic_disease'], ['51', '58', 'upper_bound'], ['66', '92', 'chronic_disease'], ['96', '119', 'chronic_disease']]}, 'NCT02091999'), ({'text': 'Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment', 'entities': [['1', '10', 'chronic_disease'], ['21', '48', 'treatment'], ['66', '75', 'chronic_disease'], ['83', '97', 'upper_bound']]}, 'NCT02339922'), ({'text': 'Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C', 'entities': [['41', '75', 'chronic_disease'], ['77', '88', 'chronic_disease'], ['93', '104', 'chronic_disease']]}, 'NCT02501096'), ({'text': 'associated therapy with a strong cytochrome P-450 inhibitors', 'entities': [['34', '50', 'clinical_variable']]}, 'NCT02925923'), ({'text': 'family therapy', 'entities': [['1', '15', 'treatment']]}, 'NCT02567266'), ({'text': 'Liver dysfunction manifested by SGTP (ALT) > 5X Upper limit of normal (ULN) and/or Aspartate aminotransferase (AST) >5 X ULN and/or direct (conjugated) bilirubin > 2X ULN', 'entities': [['1', '18', 'chronic_disease'], ['33', '43', 'clinical_variable'], ['46', '48', 'lower_bound'], ['49', '76', 'clinical_variable'], ['72', '75', 'clinical_variable'], ['84', '116', 'clinical_variable'], ['118', '121', 'lower_bound'], ['133', '162', 'clinical_variable'], ['165', '167', 'lower_bound']]}, 'NCT02369653'), ({'text': 'Patients may have received re-irradiation but not to the index lesion within 4 weeks', 'entities': [['28', '42', 'treatment'], ['78', '85', 'upper_bound']]}, 'NCT01795313'), ({'text': "Subject has clinical evidence of infection that the Investigator deems significant to the completion of the procedure or that could compromise the subject's safety", 'entities': [['34', '43', 'chronic_disease']]}, 'NCT01313533'), ({'text': 'At least one tumor site that is at least 1 cm in the shortest transaxial diameter by computed tomography (CT) (Kinetic Studies Arm only; disease-free participants can be enrolled in the Dosimetry Studies Arm)', 'entities': [['10', '13', 'lower_bound'], ['14', '19', 'cancer'], ['42', '46', 'lower_bound'], ['86', '110', 'treatment']]}, 'NCT02469129'), ({'text': 'Clinical Dementia Rating (Global) = 0.5; Memory Box score must be at least 0.5', 'entities': [['1', '25', 'clinical_variable'], ['37', '40', 'lower_bound'], ['42', '58', 'clinical_variable']]}, 'NCT02547818'), ({'text': 'Glaucomatous visual field abnormality', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT02862938'), ({'text': 'Have an active systemic bacterial or fungal infection requiring antimicrobial therapy', 'entities': [['9', '54', 'chronic_disease'], ['65', '86', 'treatment']]}, 'NCT02222545'), ({'text': 'Participants <1 year of age will not be enrolled until >= 6 participants >= 1 year to < 18 years of age have received at least one cycle of therapy with suspension and until safety and pharmacokinetic assessment of these participants have been conducted', 'entities': [['25', '28', 'age'], ['59', '60', 'lower_bound'], ['89', '97', 'upper_bound'], ['128', '131', 'lower_bound'], ['141', '148', 'treatment'], ['186', '212', 'treatment']]}, 'NCT02639546'), ({'text': 'Current non-smokers with less than 15 pack year history', 'entities': [['36', '43', 'upper_bound']]}, 'NCT02421341'), ({'text': 'Patient qualifies for primary total knee arthroplasty based on physical exam and medical history', 'entities': [['37', '54', 'treatment']]}, 'NCT02255383'), ({'text': 'Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance score =< 3 (Karnofsky >= 30)', 'entities': [['23', '82', 'clinical_variable'], ['86', '87', 'upper_bound'], ['89', '98', 'clinical_variable'], ['102', '104', 'lower_bound']]}, 'NCT00293475'), ({'text': 'Preoperative diagnosis of either presumed first-time low or high grade glioma, or recurrent glioma, or metastasis, or meningioma', 'entities': [['61', '78', 'cancer'], ['72', '78', 'cancer'], ['104', '114', 'cancer'], ['119', '129', 'cancer']]}, 'NCT02191488'), ({'text': 'non-lactating females', 'entities': [['15', '22', 'gender']]}, 'NCT03077412'), ({'text': 'Known to be human immunodeficiency virus positive (HIV+)', 'entities': [['13', '57', 'chronic_disease']]}, 'NCT02458014'), ({'text': 'Unstable angina or transient ischemic attack', 'entities': [['1', '16', 'chronic_disease'], ['20', '45', 'chronic_disease']]}, 'NCT01620216'), ({'text': 'Calculated creatinine clearance >= 30 mL/min', 'entities': [['1', '32', 'clinical_variable'], ['36', '45', 'lower_bound']]}, 'NCT02542657'), ({'text': 'current BP < 160/90', 'entities': [['9', '11', 'clinical_variable'], ['14', '20', 'upper_bound']]}, 'NCT02589977'), ({'text': 'Previously untreated breast cancer determined by a core needle biopsy showing invasive ductal carcinoma or invasive lobular carcinoma', 'entities': [['22', '35', 'cancer'], ['52', '70', 'treatment'], ['88', '104', 'cancer'], ['117', '134', 'cancer']]}, 'NCT02352025'), ({'text': 'taking anti-cancer therapy for cancer other than ovarian (such as continuation of hormonal therapy for prostate or breast cancer diagnosed more than five years earlier)', 'entities': [['8', '27', 'treatment'], ['13', '19', 'cancer'], ['83', '99', 'treatment'], ['104', '112', 'cancer'], ['116', '129', 'cancer'], ['150', '160', 'lower_bound']]}, 'NCT02033616'), ({'text': 'Dyskeratosis Congenita', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02928991'), ({'text': 'Patients may be on corticosteroids if they are being given for disorders other than multiple myeloma (e.g., adrenal insufficiency, rheumatoid arthritis, etc.)', 'entities': [['20', '35', 'treatment'], ['85', '101', 'cancer'], ['109', '130', 'chronic_disease'], ['132', '152', 'chronic_disease']]}, 'NCT02253316'), ({'text': 'Pregnant women are excluded from this study because the effects of the study drugs on the developing fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender'], ['72', '82', 'treatment'], ['72', '83', 'treatment'], ['219', '228', 'treatment']]}, 'NCT01851369'), ({'text': 'Has not had menses at any time in the preceding 24 consecutive months', 'entities': [['49', '70', 'upper_bound']]}, 'NCT02595372'), ({'text': 'Patient used any medication that increases the risk of bleeding within 24 hours before the start of study treatment', 'entities': [['72', '80', 'upper_bound']]}, 'NCT02851407'), ({'text': 'Any condition that would prevent the subject from performing the research procedures (e.g. unstable coronary artery disease)', 'entities': [['101', '124', 'chronic_disease']]}, 'NCT01614990'), ({'text': 'Diabetes, hypertension, smoking, and hyperlipidemia, etc', 'entities': [['1', '9', 'chronic_disease'], ['11', '23', 'chronic_disease'], ['38', '52', 'chronic_disease']]}, 'NCT02741180'), ({'text': 'Participants also must not have a seizure disorder and must not be taking any medications that would affect cognition or behavior on the aggression task, including pain medication', 'entities': [['35', '51', 'chronic_disease']]}, 'NCT02882802'), ({'text': 'Acute illness or active systemic infection or sepsis', 'entities': [['1', '14', 'chronic_disease'], ['25', '43', 'chronic_disease'], ['47', '53', 'chronic_disease']]}, 'NCT01959425'), ({'text': 'Women of childbearing potential', 'entities': [['1', '6', 'gender']]}, 'NCT01670877'), ({'text': 'Newly diagnosed histologically confirmed invasive breast cancer', 'entities': [['51', '64', 'cancer']]}, 'NCT02204098'), ({'text': 'Other active malignancies besides NSCLC within 3 years prior to Screening', 'entities': [['14', '26', 'cancer'], ['35', '40', 'cancer'], ['48', '61', 'upper_bound']]}, 'NCT02588612'), ({'text': 'calculated utilizing the Cockcroft-Gault formula or 24-hour urine collection', 'entities': [['26', '49', 'clinical_variable']]}, 'NCT02004275'), ({'text': 'Immunomodulatory agent therapy within 7 days', 'entities': [['1', '31', 'treatment'], ['39', '45', 'upper_bound']]}, 'NCT03145181'), ({'text': 'Male pts cannot donate semen or sperm while taking pomalidomide and for 28 days after completing the study', 'entities': [['1', '5', 'gender'], ['52', '64', 'treatment'], ['73', '80', 'upper_bound']]}, 'NCT01464034'), ({'text': 'mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02796209'), ({'text': 'The duration of the current depressive episode must be at least 4 weeks and no longer than 3 years in length', 'entities': [['29', '47', 'chronic_disease'], ['65', '72', 'lower_bound'], ['92', '99', 'upper_bound']]}, 'NCT02640950'), ({'text': 'History of smoking greater than or equal to 10 cigarettes daily for the past year', 'entities': [['45', '47', 'lower_bound']]}, 'NCT01954966'), ({'text': 'Active central nervous system (CNS) disease in patient with history of CNS malignancy', 'entities': [['8', '44', 'chronic_disease'], ['72', '86', 'cancer']]}, 'NCT01619761'), ({'text': 'Creatinine =< 1.5 x ULN (within 1 week of study entry)', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'upper_bound'], ['33', '39', 'upper_bound']]}, 'NCT01822522'), ({'text': 'lactating females', 'entities': [['11', '18', 'gender']]}, 'NCT01841333'), ({'text': 'Hormonal-acting agents (including DES, aldosterone, and spironolactone but not including GnRH agonists or antagonists) are forbidden during the trial and must be stopped prior to enrollment. No washout period will be required for any of these agents', 'entities': [['1', '23', 'treatment'], ['35', '38', 'treatment'], ['40', '51', 'treatment'], ['57', '71', 'treatment'], ['90', '118', 'treatment']]}, 'NCT02555189'), ({'text': 'Patients with ovarian cancer or metastatic breast cancer and BRCA mutations must have received approved PARP inhibitor therapy', 'entities': [['15', '29', 'cancer'], ['33', '57', 'cancer'], ['62', '66', 'cancer'], ['105', '127', 'treatment']]}, 'NCT01827384'), ({'text': 'congestive heart failure', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03075761'), ({'text': 'Performance status: Karnofsky or Lansky <60%', 'entities': [['21', '30', 'clinical_variable'], ['34', '40', 'clinical_variable'], ['42', '45', 'upper_bound']]}, 'NCT02100891'), ({'text': 'Pregnant female patients', 'entities': [['1', '9', 'pregnancy'], ['10', '25', 'gender']]}, 'NCT01096368'), ({'text': 'Platelet Count, within reference range of lower limit of normal of 150,000 / uL and upper limit of normal of 400,000 / uL', 'entities': [['1', '15', 'clinical_variable'], ['68', '80', 'lower_bound'], ['110', '122', 'upper_bound']]}, 'NCT02485639'), ({'text': 'As there is potential for hepatic toxicity with nivolumab or nivolumab/ipilimumab combinations, drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab-containing regimen', 'entities': [['49', '58', 'treatment'], ['72', '95', 'treatment'], ['194', '222', 'treatment']]}, 'NCT02259621'), ({'text': 'clinically important autonomic disease', 'entities': [['22', '39', 'chronic_disease']]}, 'NCT02253316'), ({'text': 'within 12 months of their last adjuvant systemic treatment', 'entities': [['8', '17', 'upper_bound'], ['27', '59', 'treatment']]}, 'NCT02536794'), ({'text': 'age range of 8 - 21 years', 'entities': [['1', '4', 'age'], ['14', '15', 'lower_bound'], ['18', '26', 'upper_bound']]}, 'NCT03006718'), ({'text': 'be treatment naive to an EGFR monoclonal antibody', 'entities': [['4', '13', 'treatment'], ['26', '50', 'treatment']]}, 'NCT02496663'), ({'text': 'No evidence of hepatic insufficiency', 'entities': [['16', '37', 'chronic_disease']]}, 'NCT02033941'), ({'text': 'Self-identify as African American/Black', 'entities': [['18', '34', 'ethnicity']]}, 'NCT03148171'), ({'text': 'pre-existing untreated B12 deficiency', 'entities': [['24', '38', 'chronic_disease']]}, 'NCT02519543'), ({'text': 'Has history of calcium oxalate stones', 'entities': [['16', '38', 'chronic_disease']]}, 'NCT02516670'), ({'text': 'Medical provider willing to consider the result of the rapid turnaround test in decision to treat for gonorrhea/chlamydia', 'entities': [['103', '112', 'chronic_disease'], ['113', '122', 'chronic_disease']]}, 'NCT03098394'), ({'text': 'Serum total bilirubin d 2.0 mg/dL or >3.0 x ULN for subjects with hereditary benign hyperbilirubinemia', 'entities': [['13', '22', 'clinical_variable'], ['25', '34', 'upper_bound'], ['39', '48', 'lower_bound'], ['85', '103', 'treatment']]}, 'NCT03143985'), ({'text': 'Current urinary tract infection (UTI) (based on dipstick assessment) or recurrent culture-proven UTIs', 'entities': [['1', '38', 'chronic_disease'], ['98', '102', 'chronic_disease']]}, 'NCT02495389'), ({'text': 'Proximal non-aneurysmal aortic neck', 'entities': [['1', '36', 'chronic_disease']]}, 'NCT01726257'), ({'text': 'MRI contraindications per ACR guidelines, including patients with pacemakers, renal failure with eGFR<30 ml/min/1.73m2, and contrast allergy', 'entities': [['79', '92', 'chronic_disease'], ['98', '102', 'clinical_variable'], ['103', '119', 'upper_bound']]}, 'NCT03068442'), ({'text': 'History of psychosis', 'entities': [['12', '21', 'chronic_disease']]}, 'NCT02660528'), ({'text': 'Healthy pediatric siblings of a subject with Down syndrome', 'entities': [['46', '59', 'chronic_disease']]}, 'NCT02651493'), ({'text': 'Failure to obtain insurance/payment authorization for Zevalin, unless the subject agrees to cover the cost', 'entities': [['55', '62', 'treatment']]}, 'NCT01811368'), ({'text': 'Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 3 months after study treatment', 'entities': [['1', '5', 'gender'], ['10', '25', 'gender'], ['58', '107', 'contraception_consent'], ['175', '183', 'lower_bound'], ['196', '205', 'treatment']]}, 'NCT02512926'), ({'text': 'Clinically significant abnormalities on baseline laboratory tests (comprehensive metabolic panel, fasting lipid panel, Complete Blood Count (CBC) with differential, thyroid stimulating hormone)', 'entities': [['68', '97', 'treatment'], ['99', '118', 'treatment'], ['120', '164', 'treatment'], ['166', '193', 'treatment']]}, 'NCT02527564'), ({'text': 'Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 3 months after completing treatment', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['46', '81', 'contraception_consent'], ['83', '91', 'contraception_consent'], ['95', '126', 'contraception_consent'], ['128', '138', 'contraception_consent'], ['211', '225', 'upper_bound'], ['237', '246', 'treatment']]}, 'NCT02573493'), ({'text': 'Capable of undergoing leukapheresis', 'entities': [['23', '36', 'treatment']]}, 'NCT01660607'), ({'text': 'Leukopenia with WBC < 3.5', 'entities': [['1', '11', 'chronic_disease'], ['17', '20', 'clinical_variable'], ['23', '26', 'upper_bound']]}, 'NCT03095118'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01964404'), ({'text': 'greater than 20 acute care visits within the past year', 'entities': [['14', '16', 'lower_bound']]}, 'NCT02475993'), ({'text': 'Subject is on hemodialysis', 'entities': [['15', '27', 'treatment']]}, 'NCT02468778'), ({'text': 'cardiac: left ventricular ejection fraction >45% by echocardiogram (ECHO/MUGA)', 'entities': [['1', '8', 'chronic_disease'], ['10', '44', 'clinical_variable'], ['46', '49', 'lower_bound'], ['53', '79', 'treatment']]}, 'NCT01685411'), ({'text': "with early or childhood-onset SMD with at least one pathogenic mutant ABCA4 allele on each chromosome confirmed by direct sequencing and co-segregation analysis within the patient's family", 'entities': [['31', '34', 'chronic_disease'], ['49', '52', 'lower_bound']]}, 'NCT01367444'), ({'text': 'Platelet count < 50,000', 'entities': [['1', '15', 'clinical_variable'], ['18', '24', 'upper_bound']]}, 'NCT03008616'), ({'text': 'Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50%', 'entities': [['1', '22', 'treatment'], ['26', '61', 'treatment'], ['63', '80', 'clinical_variable'], ['87', '90', 'lower_bound']]}, 'NCT02094794'), ({'text': 'Fasting blood triglycerides greater than 500 mg/dL (5.6 mmol/L) at screening', 'entities': [['1', '28', 'clinical_variable'], ['42', '64', 'lower_bound']]}, 'NCT02993406'), ({'text': 'Use of systemic antibiotics within 1 month prior to Visit 1', 'entities': [['8', '28', 'treatment'], ['36', '49', 'upper_bound']]}, 'NCT02075671'), ({'text': 'Use of more than 80% FiO2 (fractional concentration of oxygen) or more than 15 cm H2O (water) of PEEP (positive end expiratory pressure)', 'entities': [['18', '21', 'lower_bound'], ['22', '63', 'clinical_variable'], ['77', '94', 'lower_bound'], ['98', '137', 'clinical_variable']]}, 'NCT02332187'), ({'text': 'current moderate-to-severe alcohol withdrawal requiring pharmacological treatment (see Section D.4.a. regarding alcohol detoxification)', 'entities': [['57', '82', 'treatment']]}, 'NCT03018704'), ({'text': 'No history of lung disease', 'entities': [['15', '27', 'chronic_disease']]}, 'NCT02995590'), ({'text': 'Patients who have previously received a galectin antagonist', 'entities': [['41', '60', 'treatment']]}, 'NCT02575404'), ({'text': 'Planned ongoing treatment with other drugs thought to potentially adversely interact with study drugs', 'entities': [['17', '43', 'treatment'], ['91', '102', 'treatment']]}, 'NCT02349867'), ({'text': 'Inability to undergo an MR of the abdomen/pelvis', 'entities': [['25', '27', 'treatment']]}, 'NCT01972919'), ({'text': 'breastfeeding women', 'entities': [['15', '20', 'gender']]}, 'NCT01942018'), ({'text': 'Taking herbal or homeopathic medications where the metabolism of the drug is not known', 'entities': [['8', '41', 'treatment']]}, 'NCT02118610'), ({'text': 'Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol', 'entities': [['27', '34', 'chronic_disease'], ['38', '59', 'chronic_disease']]}, 'NCT02452697'), ({'text': 'Left ventricular ejection fraction (LVEF) > 40%', 'entities': [['1', '42', 'clinical_variable'], ['45', '48', 'lower_bound']]}, 'NCT02293109'), ({'text': 'Ineligible for allogeneic stem cell transplant', 'entities': [['16', '47', 'treatment']]}, 'NCT02670044'), ({'text': "Any medical condition that, in the opinion of the Investigator, might interfere with the subject's participation in the study, poses any added risk for the subject, or confounds the assessment of the subject", 'entities': [['5', '22', 'chronic_disease']]}, 'NCT02347995'), ({'text': 'Subjects for whom sufficient cancer tissues are not available to meet the objectives of the study', 'entities': [['30', '44', 'cancer']]}, 'NCT02105545'), ({'text': 'Patients taking anti-thrombotic agents including clopidogrel, ticlopidine, coumadin, heparin, enoxaparin, and direct II or Xa inhibitors', 'entities': [['17', '39', 'treatment'], ['50', '61', 'treatment'], ['63', '74', 'treatment'], ['76', '84', 'treatment'], ['86', '93', 'treatment'], ['95', '105', 'treatment'], ['111', '120', 'treatment'], ['124', '137', 'treatment']]}, 'NCT02197351'), ({'text': 'Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 4 months after the last dose of investigational product', 'entities': [['9', '22', 'gender'], ['31', '100', 'contraception_consent'], ['177', '185', 'lower_bound']]}, 'NCT03148795'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02424968'), ({'text': 'Patients with documentation of well differentiated liposarcoma only (of the well differentiated/dedifferentiated liposarcoma family) are specifically excluded, owing to its characteristically slow growth', 'entities': [['52', '63', 'cancer']]}, 'NCT02048371'), ({'text': 'first-time ischemic left-hemispheric stroke or cerebrovascular accident', 'entities': [['12', '44', 'chronic_disease'], ['48', '72', 'chronic_disease']]}, 'NCT00903266'), ({'text': '24-item Hamilton Depression Rating Scale (HDRS) score of at least 21 on the first 17 items', 'entities': [['1', '54', 'clinical_variable'], ['67', '69', 'lower_bound']]}, 'NCT02046330'), ({'text': 'Participants must have histologically confirmed invasive breast cancer', 'entities': [['58', '71', 'cancer']]}, 'NCT02876302'), ({'text': 'has received daratumumab or other anti-CD38 therapies previously', 'entities': [['14', '25', 'treatment'], ['35', '54', 'treatment']]}, 'NCT03067571'), ({'text': 'Presence of at least one approximal caries lesion (scores RA1, RA2, RA3 according to the ICCMS radiographic scoring system) in one of the posterior teeth (premolars and molars) presented with full contact with the adjacent tooth', 'entities': [['22', '25', 'lower_bound']]}, 'NCT02591147'), ({'text': 'Total bilirubin =< 1.5 within 30 days prior to registration', 'entities': [['1', '16', 'clinical_variable'], ['20', '23', 'upper_bound'], ['31', '44', 'upper_bound']]}, 'NCT01993810'), ({'text': 'Moderate diffusion defect is defined as a DLCO corrected for hemoglobin down to 40 percent of predicted', 'entities': [['62', '72', 'clinical_variable'], ['81', '91', 'lower_bound']]}, 'NCT02186418'), ({'text': 'History of prolonged corticosteroid', 'entities': [['22', '36', 'treatment']]}, 'NCT01754298'), ({'text': 'Stable medication for IBS for at least 1 month', 'entities': [['23', '26', 'chronic_disease'], ['40', '47', 'lower_bound']]}, 'NCT03087799'), ({'text': 'Treatment entails significant risk for symptomatic mucositis likely to require opioid analgesia, as per the discretion of treating physician/NP', 'entities': [['1', '10', 'treatment'], ['40', '61', 'chronic_disease'], ['80', '96', 'treatment']]}, 'NCT02277548'), ({'text': 'Significant orthostatic hypotension (due to need for rapid chronotropic response to fall in blood pressure)', 'entities': [['13', '36', 'chronic_disease'], ['60', '72', 'treatment']]}, 'NCT00584649'), ({'text': 'symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['13', '37', 'chronic_disease'], ['48', '63', 'chronic_disease'], ['65', '83', 'chronic_disease'], ['88', '107', 'chronic_disease']]}, 'NCT01697293'), ({'text': 'Known or suspected immunodeficiency', 'entities': [['20', '36', 'chronic_disease']]}, 'NCT01940757'), ({'text': 'Blood pressure < 100/50 after run-in', 'entities': [['18', '24', 'upper_bound']]}, 'NCT02593110'), ({'text': 'menstrual cycles between 25 and 35 days in duration with no more than 5 days variability in cycle duration', 'entities': [['26', '28', 'lower_bound'], ['33', '40', 'upper_bound'], ['34', '40', 'lower_bound']]}, 'NCT01438073'), ({'text': 'Patients must be refractory to, or not a candidate for, established therapy known to provide clinical benefit for their malignancy', 'entities': [['69', '76', 'treatment'], ['121', '131', 'cancer']]}, 'NCT02863991'), ({'text': 'Presence of asthma', 'entities': [['13', '19', 'chronic_disease']]}, 'NCT02472834'), ({'text': 'All post-menarchal females must have a negative serum beta-human chorionic gonadotropin (beta HCG); sexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least 6 months after', 'entities': [['20', '27', 'gender'], ['40', '99', 'pregnancy'], ['157', '206', 'contraception_consent'], ['241', '255', 'lower_bound']]}, 'NCT02389309'), ({'text': 'Patients with a previous history of smoldering myeloma will be eligible if there is evidence of progressive disease requiring chemotherapy', 'entities': [['37', '55', 'cancer'], ['127', '139', 'treatment']]}, 'NCT00734877'), ({'text': 'FEV1 > 70% predicted on monitoring', 'entities': [['1', '5', 'clinical_variable'], ['8', '11', 'lower_bound']]}, 'NCT03089515'), ({'text': 'Overt cognitive difficulty demonstrated by not being clearly oriented to time or person or place (Arms 1-4)', 'entities': [['7', '27', 'chronic_disease'], ['99', '105', 'lower_bound'], ['106', '107', 'upper_bound']]}, 'NCT01365169'), ({'text': '(mild psychiatric illness may be included)', 'entities': [['2', '26', 'chronic_disease']]}, 'NCT03185208'), ({'text': 'Patients who are receiving any other investigational agents', 'entities': [['38', '60', 'treatment']]}, 'NCT02496663'), ({'text': 'Patients must be at least 4 weeks from last cytotoxic chemotherapy (including alkylating, anthracyclines, epipodophylatoxins, and platinum drugs), or immunomodulatory drugs (including lenalidomide or pomalidomide, or related derivatives) at time of treatment on this protocol', 'entities': [['27', '34', 'lower_bound'], ['45', '67', 'treatment'], ['79', '89', 'treatment'], ['91', '105', 'treatment'], ['107', '125', 'treatment'], ['131', '145', 'treatment'], ['151', '173', 'treatment'], ['185', '197', 'treatment'], ['201', '213', 'treatment'], ['250', '259', 'treatment']]}, 'NCT02078102'), ({'text': 'Selected primary teeth must have an anticipated exfoliation date greater than 12 months away', 'entities': [['79', '88', 'lower_bound']]}, 'NCT02601833'), ({'text': 'be 18 years or older', 'entities': [['4', '12', 'lower_bound']]}, 'NCT02709317'), ({'text': '21-75 years of age at the time of enrollment', 'entities': [['1', '3', 'lower_bound'], ['4', '12', 'upper_bound'], ['16', '19', 'age']]}, 'NCT00966979'), ({'text': 'The patient has cardiac conditions as follows: uncontrolled hypertension (blood pressure [BP] > 160/100) despite optimal therapy, uncontrolled angina, ventricular arrhythmias, congestive heart failure (New York Heart Association class II or above)', 'entities': [['61', '73', 'chronic_disease'], ['75', '94', 'clinical_variable'], ['97', '104', 'lower_bound'], ['114', '129', 'treatment'], ['144', '150', 'chronic_disease'], ['152', '175', 'chronic_disease'], ['177', '201', 'chronic_disease'], ['203', '229', 'clinical_variable'], ['230', '238', 'lower_bound']]}, 'NCT02152254'), ({'text': 'revious or concurrent malignancy', 'entities': [['12', '33', 'cancer']]}, 'NCT02366819'), ({'text': 'Patients with history of previous immunomodulatory therapy (not including lenalidomide or thalidomide)', 'entities': [['35', '59', 'treatment'], ['75', '87', 'treatment'], ['91', '102', 'treatment']]}, 'NCT02532231'), ({'text': 'ongoing or active infection', 'entities': [['12', '28', 'chronic_disease']]}, 'NCT02890979'), ({'text': 'Suppressive therapy for herpes simplex', 'entities': [['1', '20', 'treatment'], ['25', '39', 'chronic_disease']]}, 'NCT02270970'), ({'text': 'Known pre-existing interstitial lung disease', 'entities': [['20', '45', 'chronic_disease']]}, 'NCT02451553'), ({'text': 'Adequate cardiac function defined by radionucleotide angiogram or echocardiogram', 'entities': [['38', '63', 'treatment'], ['67', '81', 'treatment']]}, 'NCT01966367'), ({'text': 'Patients with known or suspected obstructive sleep apnea (OSA)', 'entities': [['34', '63', 'chronic_disease']]}, 'NCT02962557'), ({'text': 'Pregnant or nursing', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02501473'), ({'text': 'AST less than or equal to 5x upper limit of normal', 'entities': [['1', '4', 'clinical_variable'], ['27', '51', 'upper_bound']]}, 'NCT01953900'), ({'text': 'enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol', 'entities': [['1', '45', 'treatment'], ['67', '76', 'treatment']]}, 'NCT01849146'), ({'text': 'Patients with evidence of active septicemia, severe infection, gastrointestinal bleeding or severe gastrointestinal symptoms requiring medical or surgical therapy', 'entities': [['34', '44', 'chronic_disease'], ['53', '62', 'chronic_disease'], ['64', '89', 'chronic_disease'], ['100', '125', 'chronic_disease'], ['136', '163', 'treatment']]}, 'NCT01595061'), ({'text': 'Documented Alpha1-Proteinase Inhibitor (A1PI) genotype of Pi*Z/Z, Pi*Z/Null, Pi*Malton/Z, Pi*Null/Null, or other at-risk allelic combinations such as SZ (excluding MS and MZ) and an endogenous A1PI plasma levels of d11 ¼M', 'entities': [['12', '46', 'treatment'], ['183', '212', 'clinical_variable'], ['217', '222', 'upper_bound']]}, 'NCT02525861'), ({'text': 'pregnancy, breastfeeding, or plans to become pregnant within 6 months', 'entities': [['1', '10', 'pregnancy'], ['30', '54', 'pregnancy'], ['62', '70', 'upper_bound']]}, 'NCT02204956'), ({'text': 'Platelet count <100,000/mm3', 'entities': [['1', '15', 'clinical_variable'], ['17', '28', 'upper_bound']]}, 'NCT02498535'), ({'text': 'History of a different invasive malignancy within the past 3 years', 'entities': [['24', '43', 'cancer'], ['55', '67', 'upper_bound']]}, 'NCT01659203'), ({'text': 'severe recurrent autonomic dysreflexia', 'entities': [['18', '39', 'chronic_disease']]}, 'NCT03071393'), ({'text': 'Eye surgery (including cataract surgery) and or eye laser surgery within the past 6 months', 'entities': [['1', '12', 'treatment'], ['24', '40', 'treatment'], ['49', '66', 'treatment'], ['78', '91', 'upper_bound']]}, 'NCT02507687'), ({'text': 'women', 'entities': [['1', '6', 'gender']]}, 'NCT02875301'), ({'text': 'Liver iron evaluated by SQUID, MRI or liver biopsy within 12 months prior to enrollment in the study', 'entities': [['25', '30', 'treatment'], ['32', '35', 'treatment'], ['39', '51', 'treatment'], ['59', '74', 'upper_bound']]}, 'NCT02308904'), ({'text': 'Female subject must not be breastfeeding at Screening or during the study period, and for 60 days after the final study drug administration', 'entities': [['1', '15', 'gender'], ['91', '104', 'upper_bound']]}, 'NCT02236013'), ({'text': 'Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+)', 'entities': [['1', '27', 'chronic_disease'], ['29', '44', 'chronic_disease'], ['49', '69', 'chronic_disease'], ['108', '109', 'lower_bound'], ['110', '111', 'upper_bound']]}, 'NCT02000115'), ({'text': 'Males or females age greater than or equal to 18 years at the time of informed consent', 'entities': [['1', '6', 'gender'], ['10', '17', 'gender'], ['18', '21', 'age'], ['47', '55', 'lower_bound']]}, 'NCT02501096'), ({'text': 'Report being pregnant during the previous 6 months or planned pregnancy in the following 18 months', 'entities': [['14', '22', 'pregnancy'], ['34', '51', 'upper_bound'], ['55', '72', 'pregnancy'], ['90', '99', 'upper_bound']]}, 'NCT02932748'), ({'text': 'Advanced HCC with diagnosis confirmed pathologically or with noninvasive methods', 'entities': [['10', '13', 'cancer']]}, 'NCT02519348'), ({'text': 'Current or past history of psychosis, schizophrenia, bipolar disorder, delusional disorder or other psychotic disorder', 'entities': [['28', '37', 'chronic_disease'], ['39', '52', 'chronic_disease'], ['54', '70', 'chronic_disease'], ['72', '91', 'chronic_disease'], ['101', '119', 'chronic_disease']]}, 'NCT02165449'), ({'text': 'lupus', 'entities': [['1', '6', 'chronic_disease']]}, 'NCT03008616'), ({'text': 'Start or change dose of corticosteroids within 1 week of screening or a dose >20mg/day prednisone or equivalent', 'entities': [['17', '21', 'clinical_variable'], ['25', '40', 'treatment'], ['48', '54', 'upper_bound'], ['79', '87', 'lower_bound'], ['88', '98', 'treatment'], ['102', '112', 'treatment']]}, 'NCT03058679'), ({'text': 'Body mass index (BMI) over 30', 'entities': [['1', '22', 'bmi'], ['28', '30', 'lower_bound']]}, 'NCT02536846'), ({'text': 'Malignant disease other than that being treated in this study', 'entities': [['1', '10', 'cancer']]}, 'NCT01351103'), ({'text': 'Patients must consent to undergo biopsies of CSCC lesions (Groups 2 and 4 only)', 'entities': [['34', '42', 'treatment'], ['46', '58', 'cancer']]}, 'NCT02760498'), ({'text': 'Cancer-free and have not received any chemotherapy or radiation therapy for >/=12 months prior to enrolling on this study', 'entities': [['1', '7', 'cancer'], ['39', '51', 'treatment'], ['55', '72', 'treatment'], ['80', '95', 'lower_bound']]}, 'NCT00539162'), ({'text': 'history of traumatic brain injury associated with loss of consciousness of > 1 hour and/or intracranial/epidural/subdural bleeding', 'entities': [['12', '34', 'chronic_disease'], ['51', '72', 'clinical_variable'], ['78', '84', 'lower_bound'], ['92', '104', 'chronic_disease'], ['105', '113', 'chronic_disease'], ['114', '131', 'chronic_disease']]}, 'NCT02361554'), ({'text': 'Peripheral Nerve Injury', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT01809002'), ({'text': 'Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study', 'entities': [['23', '35', 'treatment'], ['39', '51', 'treatment'], ['59', '72', 'upper_bound']]}, 'NCT02101944'), ({'text': 'acute or chronic hepatic dysfunction as evidenced by clinically significant abnormalities in albumin, total protein, or prothrombin time, or evidence of hepatic injury with clinically important (> grade 1) changes in AST, ALT, ALP, bilirubin, or GGT values', 'entities': [['1', '37', 'chronic_disease'], ['94', '101', 'clinical_variable'], ['109', '116', 'clinical_variable'], ['121', '137', 'clinical_variable'], ['198', '205', 'lower_bound'], ['218', '221', 'clinical_variable'], ['223', '226', 'clinical_variable'], ['228', '231', 'clinical_variable'], ['233', '242', 'clinical_variable'], ['247', '250', 'clinical_variable']]}, 'NCT02680535'), ({'text': 'Current and/or former malignancy including basal cell carcinomas and squamous cell carcinomas', 'entities': [['44', '65', 'cancer'], ['70', '94', 'cancer']]}, 'NCT03068780'), ({'text': 'An EKG recorded at screening showing evidence of cardiac ischemia (ST depression depression of >/= 2 mm, measured from isoelectric line to the ST segment)', 'entities': [['50', '66', 'chronic_disease'], ['68', '81', 'clinical_variable'], ['100', '104', 'lower_bound'], ['120', '136', 'clinical_variable'], ['144', '154', 'clinical_variable']]}, 'NCT02512497'), ({'text': 'Subject agrees not to participate in another interventional study while on treatment', 'entities': [['76', '85', 'treatment']]}, 'NCT02236013'), ({'text': 'Use of 5-alpha reductase inhibitor within 42 days prior to cycle 1 day 1', 'entities': [['8', '35', 'treatment'], ['43', '56', 'upper_bound']]}, 'NCT03009981'), ({'text': 'A quit attempt in the past 30 days resulting in greater than 3 days of abstinence', 'entities': [['23', '35', 'upper_bound'], ['62', '68', 'lower_bound']]}, 'NCT02250664'), ({'text': 'treated basal cell carcinoma', 'entities': [['9', '29', 'cancer']]}, 'NCT02578641'), ({'text': 'Ileostomy, proctocolectomy or subtotal colectomy with ileorectal anastomosis', 'entities': [['1', '10', 'treatment'], ['12', '27', 'treatment'], ['31', '49', 'treatment'], ['55', '77', 'treatment']]}, 'NCT02200445'), ({'text': 'Patients with serious active infections', 'entities': [['30', '40', 'chronic_disease']]}, 'NCT02100891'), ({'text': 'Planned primary or adjuvant chemoradiation therapy', 'entities': [['20', '51', 'treatment']]}, 'NCT02480114'), ({'text': "Patients must have histologically or cytologically confirmed non-Hodgkin's lymphoma for which standard therapies do not exist or are no longer effective", 'entities': [['62', '84', 'cancer'], ['95', '113', 'treatment']]}, 'NCT01553071'), ({'text': 'infection', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT02641093'), ({'text': 'Intolerable or serious adverse reaction to ketamine during Phase II', 'entities': [['44', '52', 'treatment']]}, 'NCT02543983'), ({'text': 'Renal function', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02324439'), ({'text': 'Severe/uncontrolled concurrent illness/infection', 'entities': [['40', '49', 'chronic_disease']]}, 'NCT01554371'), ({'text': 'Liver disease', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT00606411'), ({'text': 'Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug', 'entities': [['1', '50', 'contraception_consent'], ['69', '84', 'treatment'], ['104', '111', 'upper_bound'], ['135', '145', 'treatment']]}, 'NCT02339922'), ({'text': 'Alcohol (more than 3 drinks per day)', 'entities': [['20', '21', 'lower_bound']]}, 'NCT00739362'), ({'text': 'Rapidly-progressing disease prior to HCT, defined as clinical or radiographic evidence of disease progression d 3 weeks prior to protocol registration despite previous achievement of stable or no disease (Appendix C & D)', 'entities': [['38', '41', 'treatment'], ['54', '78', 'treatment'], ['113', '126', 'upper_bound']]}, 'NCT02100891'), ({'text': 'Chronic opioid use', 'entities': [['1', '19', 'treatment']]}, 'NCT02473276'), ({'text': 'Patients with histologically documented solid tumors whose disease has progressed following at least one line of standard therapy or for which no standard therapy exists that has been shown to prolong survival', 'entities': [['41', '53', 'cancer'], ['102', '105', 'lower_bound'], ['114', '130', 'treatment']]}, 'NCT01827384'), ({'text': 'History of leptomeningeal disease', 'entities': [['12', '34', 'cancer']]}, 'NCT02091141'), ({'text': 'myocardial infarction within 6 months prior to screening', 'entities': [['1', '22', 'chronic_disease'], ['30', '44', 'upper_bound']]}, 'NCT02321501'), ({'text': 'Neonatal Adrenoleukodystrophy', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02171104'), ({'text': 'The participant has a history of lung or other organ transplant, is currently on a transplant list, or has undergone major lung surgery', 'entities': [['34', '38', 'treatment'], ['48', '64', 'treatment'], ['54', '64', 'treatment'], ['118', '136', 'treatment']]}, 'NCT02525861'), ({'text': 'Stroke', 'entities': [['1', '7', 'chronic_disease']]}, 'NCT00969332'), ({'text': 'Patients taking medication(s) (either daily or as needed) with the potential to affect the course of asthma or to interact with sympathomimetic amines', 'entities': [['17', '30', 'treatment'], ['102', '108', 'chronic_disease'], ['129', '151', 'treatment']]}, 'NCT02495168'), ({'text': 'The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms 14 days before Week 1 Day 1', 'entities': [['29', '84', 'clinical_variable'], ['87', '93', 'lower_bound'], ['94', '101', 'upper_bound']]}, 'NCT01639508'), ({'text': 'Active malignancy within 5 years with the exclusion of non-melanoma', 'entities': [['1', '18', 'cancer'], ['26', '33', 'upper_bound'], ['56', '68', 'cancer']]}, 'NCT02158793'), ({'text': 'Need for brainstem irradiation', 'entities': [['10', '31', 'treatment']]}, 'NCT02310399'), ({'text': 'Severe muscle damage defined as a global muscle damage score >5 on a 10cm VAS scale on the Muscle Damage Index (MDI)', 'entities': [['8', '21', 'clinical_variable'], ['63', '64', 'lower_bound'], ['75', '84', 'clinical_variable'], ['92', '117', 'clinical_variable']]}, 'NCT02043548'), ({'text': 'Histologically confirmed diagnosis of metastatic or locally advanced unresectable tumors', 'entities': [['39', '89', 'cancer']]}, 'NCT03149549'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02834403'), ({'text': 'surgery<4 weeks', 'entities': [['1', '8', 'treatment'], ['9', '16', 'upper_bound']]}, 'NCT02925923'), ({'text': 'Manual Ability Classification Scale Level II or III', 'entities': [['1', '52', 'clinical_variable']]}, 'NCT02923167'), ({'text': 'Acute illnesses such as acute pancreatitis in the last 8 weeks', 'entities': [['1', '16', 'chronic_disease'], ['25', '43', 'chronic_disease'], ['51', '63', 'upper_bound']]}, 'NCT01675154'), ({'text': 'Female and male smokers', 'entities': [['1', '7', 'gender'], ['3', '7', 'gender']]}, 'NCT01954966'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02148263'), ({'text': 'dependence on others for activities of daily living (i.e. a modified Rankin scale score of 4 or higher)', 'entities': [['61', '88', 'clinical_variable'], ['92', '93', 'lower_bound']]}, 'NCT02260258'), ({'text': 'patients with chronic diarrhea > 1 month without immune or inflammatory colitis is a PI decision on an individual patient basis', 'entities': [['15', '31', 'clinical_variable'], ['34', '41', 'lower_bound'], ['50', '56', 'chronic_disease'], ['60', '80', 'chronic_disease']]}, 'NCT02484404'), ({'text': 'Plan to be in the area for the next 3 months', 'entities': [['32', '45', 'upper_bound']]}, 'NCT02762604'), ({'text': 'Patients with active e grade 2 anorexia, nausea or vomiting, and/or signs of intestinal obstruction', 'entities': [['24', '31', 'lower_bound'], ['32', '40', 'chronic_disease']]}, 'NCT02574455'), ({'text': 'parent unable or not willing to receive text messages', 'entities': [['41', '54', 'technology_access']]}, 'NCT02343367'), ({'text': 'Regular menses, at least every 21-35 days', 'entities': [['32', '34', 'lower_bound'], ['35', '42', 'upper_bound']]}, 'NCT02606045'), ({'text': 'Less than six months post-injury', 'entities': [['11', '21', 'upper_bound']]}, 'NCT02329652'), ({'text': 'Cervical Posterior Fusion', 'entities': [['1', '26', 'treatment']]}, 'NCT01568918'), ({'text': 'Presence of chronic low back pain (CLBP)', 'entities': [['13', '41', 'chronic_disease']]}, 'NCT02460692'), ({'text': 'History of allergic reactions attributed to compounds of similar composition to agents used for kyphoplasty', 'entities': [['97', '108', 'treatment']]}, 'NCT02480036'), ({'text': 'Active pulmonary tuberculosis', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02640638'), ({'text': 'Histologically confirmed diagnose of a grade WHO grade III or IV glioma', 'entities': [['50', '72', 'cancer']]}, 'NCT01743950'), ({'text': 'Positive hepatitis A, B antigen or C or HIV test at screening', 'entities': [['10', '37', 'chronic_disease'], ['41', '44', 'chronic_disease']]}, 'NCT00713492'), ({'text': 'have known hypersensitivity to EPO or any of its components', 'entities': [['32', '35', 'allergy_name']]}, 'NCT02189889'), ({'text': 'Breast conservation contraindication such as inability to receive whole breast radiation therapy, inability to tolerate localization procedure, inability to lay flat or prone for radiation, and undesirable tumor to breast ratio', 'entities': [['67', '97', 'treatment'], ['207', '222', 'cancer']]}, 'NCT02522468'), ({'text': 'candidates for immediate breast reconstruction with tissue expanders', 'entities': [['26', '69', 'treatment']]}, 'NCT02395614'), ({'text': 'willing and able to use both nicotine patch and varenicline', 'entities': [['30', '44', 'treatment'], ['49', '60', 'treatment']]}, 'NCT03176784'), ({'text': 'FEV1 of at least 80% of predicted', 'entities': [['1', '5', 'clinical_variable'], ['18', '21', 'lower_bound']]}, 'NCT02857283'), ({'text': 'Prior radiation to the site of current primary disease, if re-treatment would lead to violation of known radiation dose tolerance limits for that site', 'entities': [['1', '16', 'treatment'], ['7', '16', 'treatment'], ['60', '72', 'treatment']]}, 'NCT02106988'), ({'text': 'Total sum of maximum diameters of each definite parenchymal hepatocellular carcinoma within the liver or maximum diameter of a single conglomerate HCC > 20 cm', 'entities': [['61', '85', 'cancer'], ['148', '151', 'clinical_variable'], ['154', '159', 'lower_bound']]}, 'NCT01730937'), ({'text': 'Patients must have recovered from major infections and/or surgical procedures', 'entities': [['35', '51', 'chronic_disease'], ['59', '78', 'treatment']]}, 'NCT02780401'), ({'text': 'While it would be advantageous to begin therapy on this second transplant regimen > 6 months following a prior myeloablative regimen or >2 months after a reduced intensity regimen, it is recognized that there are circumstances where this may not be practical', 'entities': [['41', '48', 'treatment'], ['57', '74', 'treatment'], ['85', '93', 'lower_bound'], ['138', '146', 'lower_bound']]}, 'NCT01666080'), ({'text': 'psychotic disorders not elsewhere classified', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02481245'), ({'text': 'Severe fetal growth restriction (EFW < 5%)', 'entities': [['1', '32', 'chronic_disease'], ['34', '37', 'clinical_variable'], ['40', '42', 'upper_bound']]}, 'NCT02983240'), ({'text': 'Active hepatitis B or hepatitis C with abnormal liver function tests', 'entities': [['8', '19', 'chronic_disease'], ['23', '34', 'chronic_disease']]}, 'NCT01494662'), ({'text': 'Unable to provide informed consent due to severe mental or physical illness, or substance intoxication at the time of interview', 'entities': [['43', '56', 'chronic_disease'], ['60', '76', 'chronic_disease']]}, 'NCT03175159'), ({'text': 'Histologically-confirmed metastatic or recurrent triple-negative breast cancer (defined as estrogen receptor d 5%, progesterone receptor d 5%, HER2-negative via immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH])', 'entities': [['50', '79', 'cancer'], ['92', '109', 'clinical_variable'], ['102', '215', 'treatment'], ['116', '137', 'clinical_variable'], ['144', '148', 'cancer'], ['162', '188', 'treatment']]}, 'NCT02401347'), ({'text': 'current or recent (within one week of surgery) systemic antibiotic use, intolerance to both clindamycin and cephalexin, discovery of a persistent cutaneous malignancy at the site of the defect following the reconstructive procedure and previous reconstruction at the site of the skin/soft-tissue defect', 'entities': [['27', '35', 'upper_bound'], ['39', '46', 'treatment'], ['48', '67', 'treatment'], ['93', '104', 'treatment'], ['109', '119', 'treatment'], ['147', '167', 'cancer'], ['208', '232', 'treatment']]}, 'NCT01912651'), ({'text': 'chloroma must be included as part of the treatment target', 'entities': [['1', '9', 'cancer'], ['42', '51', 'treatment']]}, 'NCT02122081'), ({'text': 'General performance status evaluated by ECOG 0-2 scale', 'entities': [['1', '45', 'clinical_variable'], ['46', '47', 'lower_bound'], ['48', '49', 'upper_bound']]}, 'NCT03002519'), ({'text': 'Proteinuria of > 5 g in 24 hours determined by a 24 hour urine collection or PCR > 4.5', 'entities': [['1', '12', 'treatment'], ['18', '21', 'lower_bound'], ['78', '81', 'clinical_variable'], ['84', '87', 'lower_bound']]}, 'NCT02252081'), ({'text': 'chronic (>3months) unilateral or bilateral common extensor tendon pain', 'entities': [['11', '18', 'lower_bound']]}, 'NCT03072381'), ({'text': 'The tumor must have been determined to be human epidermal growth factor receptor 2 (HER2)-negative', 'entities': [['5', '10', 'cancer'], ['43', '90', 'cancer']]}, 'NCT02488967'), ({'text': 'ECOG Performance Status d 1', 'entities': [['1', '24', 'clinical_variable'], ['27', '28', 'upper_bound']]}, 'NCT02585973'), ({'text': 'Methemoglobn >3%', 'entities': [['1', '13', 'clinical_variable'], ['15', '17', 'lower_bound']]}, 'NCT02498535'), ({'text': 'Patients who have undergone autologous stem cell transplantation within 3 months from study entry', 'entities': [['29', '65', 'treatment'], ['73', '81', 'upper_bound']]}, 'NCT02520791'), ({'text': 'glucocorticoids (other than topical usage)', 'entities': [['1', '16', 'treatment'], ['29', '42', 'treatment']]}, 'NCT02131467'), ({'text': 'Immune deficiency disease or known history of HIV, HBV, HCV', 'entities': [['1', '26', 'chronic_disease'], ['47', '50', 'chronic_disease'], ['52', '55', 'chronic_disease'], ['57', '60', 'chronic_disease']]}, 'NCT02301611'), ({'text': 'Patients must be >/= 18 years of age', 'entities': [['22', '30', 'lower_bound'], ['34', '37', 'age']]}, 'NCT02385110'), ({'text': 'Platelet count < 150,000/uL with ongoing full-dose anticoagulation therapy', 'entities': [['1', '15', 'clinical_variable'], ['19', '28', 'upper_bound'], ['52', '75', 'treatment']]}, 'NCT02278315'), ({'text': 'nursing women may not participate', 'entities': [['9', '14', 'gender']]}, 'NCT03004287'), ({'text': 'Donors with a history of coronary artery bypass grafting or angioplasty who are symptom free will receive a cardiology evaluation and be considered on a case-by-case basis', 'entities': [['26', '57', 'treatment'], ['61', '72', 'treatment']]}, 'NCT01087294'), ({'text': 'Prior chemotherapy to treat the metastatic disease', 'entities': [['7', '19', 'treatment'], ['33', '51', 'cancer']]}, 'NCT02905578'), ({'text': 'Previous malignancy', 'entities': [['10', '20', 'chronic_disease']]}, 'NCT02266745'), ({'text': 'Prior EGFR TKI therapy', 'entities': [['7', '23', 'treatment']]}, 'NCT01553942'), ({'text': 'Mutation in the GATA2 gene, or evidence of loss of expression of one allele of GATA2, by cDNA analysis performed by a CLIA certified laboratory, or the clinical syndrome of MonoMAC', 'entities': [['17', '22', 'clinical_variable'], ['70', '76', 'clinical_variable'], ['174', '181', 'chronic_disease']]}, 'NCT01861106'), ({'text': 'Patients must have serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =< 2.5 x IULN within 7 days prior to registration', 'entities': [['20', '66', 'clinical_variable'], ['71', '115', 'clinical_variable'], ['119', '129', 'upper_bound'], ['137', '149', 'upper_bound']]}, 'NCT01925131'), ({'text': '5 or more foci of demonstrable metastases on recent imaging modalities (CT, MR, FDG PET/CT)', 'entities': [['1', '2', 'lower_bound'], ['32', '42', 'cancer'], ['73', '75', 'treatment'], ['77', '79', 'treatment'], ['81', '84', 'treatment'], ['85', '91', 'treatment']]}, 'NCT02286843'), ({'text': 'Life expectancy of greater than 2 years', 'entities': [['1', '16', 'chronic_disease'], ['33', '40', 'lower_bound']]}, 'NCT01659203'), ({'text': 'Present with severe TBI, defined as GCS of 3 to 8', 'entities': [['21', '24', 'chronic_disease'], ['37', '40', 'clinical_variable'], ['44', '45', 'lower_bound'], ['49', '50', 'upper_bound']]}, 'NCT02407028'), ({'text': 'Fasting LDL cholesterol of <160 mg/dL', 'entities': [['1', '24', 'clinical_variable'], ['29', '38', 'upper_bound']]}, 'NCT02110069'), ({'text': 'Untreated symptomatic pelvic organ prolapse (POP) > POP-Q Stage II', 'entities': [['23', '50', 'clinical_variable'], ['53', '67', 'lower_bound']]}, 'NCT02495389'), ({'text': 'Lansky greater than or equal to 50', 'entities': [['1', '7', 'clinical_variable'], ['33', '35', 'lower_bound']]}, 'NCT03181126'), ({'text': 'Regularly (e5 days/week) take acetylsalicylic acid', 'entities': [['13', '24', 'lower_bound'], ['31', '51', 'treatment']]}, 'NCT02833207'), ({'text': 'Newly diagnosed clinical grade 2 or higher radiation pneumonitis according to CTCAE version 4.0 criteria', 'entities': [['26', '33', 'lower_bound'], ['44', '65', 'chronic_disease']]}, 'NCT02496585'), ({'text': 'History of allergy to mannitol', 'entities': [['23', '31', 'allergy_name']]}, 'NCT02389517'), ({'text': 'Outpatient undergoing standard-of-care 18FDG-PET at S. Mark Taper Foundation Imaging Center at CSMC', 'entities': [['40', '49', 'treatment']]}, 'NCT02249520'), ({'text': '1 month to < 6 months 0.4 0.4 6 months to < 1 year 0.5 0.5', 'entities': [['1', '8', 'clinical_variable'], ['14', '22', 'clinical_variable'], ['14', '30', 'upper_bound'], ['45', '59', 'upper_bound']]}, 'NCT02774421'), ({'text': 'Patients must have disease that is no longer considered responsive to available conventional modalities or treatments (failed any known standard curative or effective therapy for that disease)', 'entities': [['108', '118', 'treatment'], ['168', '175', 'treatment']]}, 'NCT01562626'), ({'text': 'Prior radiotherapy to the pelvic area', 'entities': [['1', '38', 'treatment']]}, 'NCT02040610'), ({'text': 'negative serum pregnancy (²-HCG) test', 'entities': [['1', '25', 'pregnancy']]}, 'NCT02302976'), ({'text': 'Has previously received a biologic agent targeting interleukin (IL)-12 or IL-23, including but not limited to ustekinumab or briakinumab (ABT-874)', 'entities': [['27', '80', 'treatment'], ['111', '122', 'treatment'], ['126', '147', 'treatment']]}, 'NCT02877134'), ({'text': 'more than one anti-hypertensive medication', 'entities': [['11', '14', 'lower_bound'], ['15', '43', 'treatment']]}, 'NCT03016351'), ({'text': 'Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization', 'entities': [['1', '39', 'chronic_disease'], ['59', '62', 'lower_bound'], ['106', '116', 'upper_bound']]}, 'NCT03138733'), ({'text': 'Physical evidence of right sided congestive heart failure and echocardiographic evidence of severe right ventricular dysfunction', 'entities': [['22', '58', 'chronic_disease'], ['100', '129', 'chronic_disease']]}, 'NCT03170349'), ({'text': 'Hypersensitivity to mithramycin', 'entities': [['21', '32', 'allergy_name']]}, 'NCT01624090'), ({'text': 'Disease or condition likely to cause death within 5 years', 'entities': [['51', '58', 'upper_bound']]}, 'NCT02570672'), ({'text': 'Patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapies', 'entities': [['34', '44', 'cancer'], ['154', '162', 'treatment'], ['166', '191', 'treatment']]}, 'NCT02400463'), ({'text': 'systolic blood pressure [SBP] equal to or more than 140 or diastolic blood pressure [DBP] equal to or more than 90', 'entities': [['1', '30', 'clinical_variable'], ['53', '56', 'lower_bound'], ['60', '90', 'clinical_variable'], ['113', '115', 'lower_bound']]}, 'NCT01712308'), ({'text': 'Patients must have a Karnofsky performance status e70% (or the equivalent ECOG level of 0-2) and an expected survival of e three months', 'entities': [['22', '50', 'clinical_variable'], ['52', '55', 'lower_bound'], ['53', '54', 'lower_bound'], ['75', '85', 'clinical_variable'], ['91', '92', 'upper_bound'], ['101', '118', 'clinical_variable'], ['124', '136', 'lower_bound']]}, 'NCT01811498'), ({'text': 'The following participants with relapsed DLBCL will be enrolled', 'entities': [['42', '47', 'cancer']]}, 'NCT02564744'), ({'text': 'Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody at screening', 'entities': [['19', '30', 'chronic_disease'], ['56', '79', 'chronic_disease'], ['90', '124', 'chronic_disease']]}, 'NCT02560766'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status =< 2', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'upper_bound']]}, 'NCT02397083'), ({'text': 'ECOG performance status <3', 'entities': [['1', '24', 'clinical_variable'], ['26', '27', 'upper_bound']]}, 'NCT03075826'), ({'text': 'Patients with uncontrolled intercurrent illness including, but not limited to psychiatric illness/social situations that would limit compliance with study requirements, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction in the past 6 months, invasive fungal infections, or active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis (i.e., quantifiable HBV-DNA and/or positive HbsAg, quantifiable HCV-RNA)', 'entities': [['79', '98', 'chronic_disease'], ['182', '206', 'chronic_disease'], ['208', '232', 'chronic_disease'], ['234', '252', 'chronic_disease'], ['254', '275', 'chronic_disease'], ['283', '296', 'upper_bound'], ['298', '324', 'chronic_disease'], ['329', '335', 'chronic_disease'], ['371', '387', 'chronic_disease'], ['389', '402', 'chronic_disease'], ['411', '420', 'chronic_disease'], ['422', '449', 'chronic_disease'], ['466', '483', 'chronic_disease']]}, 'NCT01827384'), ({'text': 'Confirmed diagnosis of CF', 'entities': [['24', '26', 'chronic_disease']]}, 'NCT02129803'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT01639508'), ({'text': 'Currently seeking treatment for alcohol use disorders', 'entities': [['19', '28', 'treatment'], ['33', '54', 'chronic_disease']]}, 'NCT00713492'), ({'text': 'Pregnancy (positive beta human chorionic gonadotropin [HCG] test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast-feeding', 'entities': [['1', '10', 'pregnancy'], ['71', '76', 'gender'], ['166', '188', 'treatment']]}, 'NCT01701986'), ({'text': 'CD4 plus CD45RA+ lymphocytes: absolute number less than or equal to 50 percent of the LLN OR T-cell receptor excision circles (TRECs)squared less than or equal to 5 percent of normal for age', 'entities': [['1', '4', 'clinical_variable'], ['10', '16', 'clinical_variable'], ['18', '29', 'clinical_variable'], ['69', '79', 'upper_bound'], ['87', '90', 'clinical_variable'], ['94', '134', 'clinical_variable'], ['164', '173', 'upper_bound'], ['188', '191', 'age']]}, 'NCT01306019'), ({'text': 'IQ > 80 (WASI full scale score)', 'entities': [['1', '3', 'clinical_variable'], ['6', '8', 'lower_bound']]}, 'NCT03037983'), ({'text': 'Patients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug (http://crediblemeds.org/)', 'entities': [['30', '39', 'treatment'], ['216', '226', 'treatment']]}, 'NCT02353728'), ({'text': 'Uncontrolled central nervous system (CNS) metastases', 'entities': [['14', '42', 'chronic_disease'], ['43', '53', 'cancer']]}, 'NCT02459119'), ({'text': 'No significant cardiac disease, including the following: unstable angina, New York Heart Association class II-IV congestive heart failure, myocardial infarction within six months prior to study enrollment', 'entities': [['16', '31', 'chronic_disease'], ['58', '73', 'chronic_disease'], ['75', '107', 'clinical_variable'], ['108', '110', 'lower_bound'], ['111', '113', 'upper_bound'], ['114', '138', 'chronic_disease'], ['140', '161', 'chronic_disease'], ['169', '185', 'treatment']]}, 'NCT02047474'), ({'text': 'Age > 18 years old', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT01918683'), ({'text': 'patients must not have had nitrosoureas or mitomycin C for 6 weeks prior to the initiation of study treatment', 'entities': [['28', '40', 'treatment'], ['44', '55', 'treatment'], ['60', '73', 'upper_bound'], ['95', '110', 'treatment']]}, 'NCT01434316'), ({'text': 'Uncontrolled autonomic dysreflexia', 'entities': [['14', '35', 'chronic_disease']]}, 'NCT02943915'), ({'text': 'Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy', 'entities': [['1', '35', 'chronic_disease'], ['57', '91', 'treatment']]}, 'NCT01827384'), ({'text': 'Patients in the asymptomatic CAD group', 'entities': [['17', '33', 'chronic_disease']]}, 'NCT02607748'), ({'text': 'Active drug addiction including alcohol, cocaine or intravenous drug use defined as occurring within the 6 months preceding diagnosis', 'entities': [['106', '114', 'upper_bound']]}, 'NCT02072148'), ({'text': 'history of diabetes mellitus', 'entities': [['12', '29', 'chronic_disease']]}, 'NCT03084146'), ({'text': 'Histologically confirmed locally advanced unresectable (Stage III) or Stage IV PDAC', 'entities': [['56', '84', 'cancer']]}, 'NCT02921022'), ({'text': 'Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject', 'entities': [['1', '34', 'contraception_consent']]}, 'NCT02339922'), ({'text': 'Have a known sensitivity to any of the constituents of the test product including sensitivities to sandalwood oil, fragrances or any member of the Compositae family of vascular plants (eg, sunflowers, daisies, dahlias, etc.)', 'entities': [['100', '114', 'allergy_name'], ['116', '126', 'allergy_name'], ['148', '184', 'allergy_name'], ['190', '200', 'allergy_name'], ['202', '209', 'allergy_name'], ['211', '218', 'allergy_name']]}, 'NCT03158974'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01553942'), ({'text': 'Person with Lidocaine sensitivity', 'entities': [['13', '22', 'allergy_name']]}, 'NCT02340650'), ({'text': 'prior ablation of a right atrial cardiac arrhythmia (i.e., typical right atrial flutter) is permitted', 'entities': [['1', '15', 'treatment'], ['21', '52', 'chronic_disease']]}, 'NCT03057548'), ({'text': 'Patients with idiopathic aplastic anemia and Fanconi anemia; (patients with aplastic anemia associated with paroxysmal nocturnal hemoglobinuria [PNH] or inherited marrow failure syndromes, except Fanconi anemia, will be allowed)', 'entities': [['15', '41', 'chronic_disease'], ['26', '41', 'chronic_disease'], ['46', '60', 'chronic_disease'], ['109', '150', 'chronic_disease'], ['154', '188', 'chronic_disease']]}, 'NCT00919503'), ({'text': '0 through 55 years of age', 'entities': [['1', '2', 'lower_bound'], ['11', '19', 'upper_bound'], ['23', '26', 'age']]}, 'NCT02171104'), ({'text': 'Evidence of developmental delay or evolving neurological disorders', 'entities': [['45', '67', 'chronic_disease']]}, 'NCT00186927'), ({'text': 'Hepatic impairment, severe renal impairment, lymphedema conditions such as Milroy disease, Meige lymphedema, Hennekam syndrome, Njolstad syndrome, Aagenaes syndrome, and Fabry disease, hypotension or at risk for hypotension, seizures or history of seizures', 'entities': [['1', '19', 'chronic_disease'], ['28', '44', 'chronic_disease'], ['46', '67', 'chronic_disease'], ['76', '90', 'chronic_disease'], ['92', '108', 'chronic_disease'], ['110', '127', 'chronic_disease'], ['129', '146', 'chronic_disease'], ['148', '165', 'chronic_disease'], ['171', '184', 'chronic_disease'], ['186', '197', 'chronic_disease'], ['226', '234', 'chronic_disease']]}, 'NCT02335242'), ({'text': 'The presence of alopecia of any grade and peripheral neuropathy d Grade 2 without pain', 'entities': [['17', '25', 'chronic_disease'], ['43', '64', 'chronic_disease'], ['67', '74', 'upper_bound']]}, 'NCT03143985'), ({'text': 'females', 'entities': [['1', '8', 'gender']]}, 'NCT01647321'), ({'text': 'Progression on standard therapy, not a candidate for further chemotherapy or patient declines other options', 'entities': [['16', '32', 'treatment'], ['62', '74', 'treatment']]}, 'NCT02466009'), ({'text': 'Individuals receiving ongoing therapy with any medication that is not to be taken with COBI or a component of the BR', 'entities': [['31', '38', 'treatment'], ['48', '58', 'treatment']]}, 'NCT02016924'), ({'text': '(LVAD) left ventricular assist device or heart transplantation expected within the next 3 months', 'entities': [['42', '63', 'treatment'], ['84', '97', 'upper_bound']]}, 'NCT02769611'), ({'text': 'For healthy controls only: no current or lifetime history of psychiatric disorders, and score of below 1 SD of mean on the SCS-R', 'entities': [['62', '83', 'chronic_disease'], ['104', '116', 'upper_bound'], ['124', '129', 'clinical_variable']]}, 'NCT02808702'), ({'text': 'Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)', 'entities': [['1', '13', 'treatment'], ['15', '25', 'treatment'], ['15', '26', 'treatment'], ['31', '40', 'treatment'], ['87', '100', 'lower_bound'], ['119', '131', 'treatment']]}, 'NCT02304458'), ({'text': 'Patients must have untreated or relapsed SCCS that is considered to be aggressive and locally advanced by the following criteria: tumors 2 cm or more, tumors invading deep tissues such as muscle, cartilage or bone; tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes; patients may have had prior surgical interventions or been treated with investigational agents with residual or recurrent disease', 'entities': [['131', '137', 'cancer'], ['138', '142', 'lower_bound']]}, 'NCT02324608'), ({'text': 'History of intracranial hemorrhage with prior hemorrhage stroke', 'entities': [['12', '35', 'chronic_disease'], ['47', '64', 'chronic_disease']]}, 'NCT02539160'), ({'text': 'cerebral palsy', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02430051'), ({'text': 'Time post injury greater than six months to assure neurological and emotional stability', 'entities': [['31', '41', 'lower_bound'], ['52', '64', 'chronic_disease']]}, 'NCT01923662'), ({'text': 'Subjects receiving androgen deprivation therapy (ADT)', 'entities': [['20', '54', 'treatment']]}, 'NCT03181867'), ({'text': 'AST (SGOT)/ALT (SGPT) d2.5 × upper limit of normal creatinine OR creatinine clearance e60 mL/min/1.73 m2 for patients with creatinine levels above normal', 'entities': [['1', '22', 'clinical_variable'], ['24', '51', 'upper_bound'], ['52', '62', 'clinical_variable'], ['66', '86', 'clinical_variable'], ['88', '105', 'lower_bound']]}, 'NCT02525692'), ({'text': 'prior therapy with single-agent rituximab is permitted', 'entities': [['1', '42', 'treatment']]}, 'NCT01754857'), ({'text': 'Participants who have undergone any recent phototesting, or phototherapy exposure, or those who are suspected of having a drug-induced photosensitivity', 'entities': [['44', '56', 'treatment'], ['61', '73', 'treatment']]}, 'NCT01516788'), ({'text': 'Idiopathic cytopenias of unclear significance (ICUS)', 'entities': [['1', '53', 'chronic_disease']]}, 'NCT02958462'), ({'text': 'All prior therapy must have been completed at least 21 days prior to enrollment (6 weeks for nitrosoureas or mitomycin C', 'entities': [['5', '18', 'treatment'], ['53', '60', 'lower_bound'], ['110', '121', 'treatment']]}, 'NCT01896999'), ({'text': 'Patients must have received at least one course of chemotherapy consisting of a platinum doublet and must have no acceptable standard treatment options', 'entities': [['38', '41', 'lower_bound'], ['52', '64', 'treatment'], ['135', '144', 'treatment']]}, 'NCT01737502'), ({'text': 'Topical, nasal, and inhaled steroids', 'entities': [['1', '8', 'treatment'], ['10', '15', 'treatment'], ['21', '37', 'treatment']]}, 'NCT02414269'), ({'text': 'Performance status: Karnofsky/Lansky score e 60%', 'entities': [['1', '19', 'clinical_variable'], ['21', '30', 'clinical_variable'], ['31', '43', 'clinical_variable'], ['46', '49', 'lower_bound']]}, 'NCT02167958'), ({'text': 'Tissue for diagnosis must be obtained by transrectal ultrasound biopsy', 'entities': [['42', '71', 'treatment']]}, 'NCT02339948'), ({'text': 'History of gout or hyperuricemia', 'entities': [['12', '16', 'chronic_disease'], ['20', '33', 'chronic_disease']]}, 'NCT01883258'), ({'text': 'Any patients with a known hypersensitivity to reslizumab or any of its excipients', 'entities': [['47', '57', 'treatment']]}, 'NCT02947945'), ({'text': 'Post-menarche females unwilling to use highly-efficacious contraception to prevent pregnancy', 'entities': [['15', '22', 'gender'], ['36', '72', 'contraception_consent'], ['84', '93', 'pregnancy']]}, 'NCT02484248'), ({'text': 'Significant interstitial lung disease', 'entities': [['13', '38', 'chronic_disease']]}, 'NCT03145298'), ({'text': 'Treatment with antihypertensive medications except beta-blockers', 'entities': [['16', '44', 'treatment']]}, 'NCT02845336'), ({'text': 'risk for needing at least 4 units of blood during/after surgery', 'entities': [['27', '43', 'lower_bound'], ['57', '64', 'treatment']]}, 'NCT02094118'), ({'text': 'Previous bariatric surgery or gastrointestinal surgery', 'entities': [['10', '27', 'treatment'], ['31', '55', 'treatment']]}, 'NCT02786251'), ({'text': 'Has consumed any foods/medications to which the recipient is allergic within the designated period of time', 'entities': [['18', '23', 'allergy_name'], ['24', '35', 'allergy_name']]}, 'NCT02134392'), ({'text': 'Strong inhibitors or strong inducers of CYP3A4/5', 'entities': [['1', '49', 'treatment']]}, 'NCT02321501'), ({'text': 'Patients who are receiving any other investigational agents', 'entities': [['38', '60', 'treatment']]}, 'NCT02111850'), ({'text': 'Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities', 'entities': [['18', '21', 'chronic_disease'], ['124', '133', 'treatment']]}, 'NCT01967823'), ({'text': 'Use of any medication from the prohibited concomitant therapies', 'entities': [['43', '64', 'treatment']]}, 'NCT03033498'), ({'text': 'Severe obesity (body mass index (BMI) z-score e3)', 'entities': [['1', '15', 'chronic_disease'], ['17', '46', 'clinical_variable'], ['48', '49', 'lower_bound']]}, 'NCT02562040'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02639546'), ({'text': 'Smoke >= 10 cig/day for the past year', 'entities': [['10', '20', 'lower_bound']]}, 'NCT02595749'), ({'text': 'subjects must have a 24-hour urine protein value < 1 g to be eligible', 'entities': [['22', '49', 'clinical_variable'], ['52', '55', 'upper_bound']]}, 'NCT01532687'), ({'text': 'Active autoimmune hemolytic anemia or thrombocytopenia', 'entities': [['8', '35', 'chronic_disease'], ['39', '55', 'chronic_disease']]}, 'NCT02514083'), ({'text': 'Women of childbearing potential who are or plan to become pregnant during the course of the trial', 'entities': [['1', '6', 'gender'], ['44', '67', 'pregnancy']]}, 'NCT03089281'), ({'text': 'Autologous HSCT within six weeks prior to start of AMG 330 treatment', 'entities': [['1', '16', 'treatment'], ['24', '39', 'upper_bound'], ['52', '69', 'treatment']]}, 'NCT02520427'), ({'text': 'Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA >/=10,000 copies/mL, or >/= 2,000 IU/mL)', 'entities': [['8', '19', 'chronic_disease'], ['44', '49', 'chronic_disease'], ['56', '63', 'chronic_disease'], ['65', '72', 'clinical_variable'], ['76', '92', 'lower_bound'], ['101', '112', 'lower_bound']]}, 'NCT02512497'), ({'text': "Patient's age 18 years or older", 'entities': [['11', '14', 'age'], ['15', '23', 'lower_bound']]}, 'NCT01815359'), ({'text': 'Bilirubin d 2 x the ULN', 'entities': [['1', '10', 'clinical_variable'], ['13', '24', 'upper_bound']]}, 'NCT03159702'), ({'text': 'cardiac shock', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT03062462'), ({'text': 'Pre-injury medications including blocking agents (alpha or beta) or other anti-arrhythmic drugs', 'entities': [['34', '65', 'treatment'], ['75', '96', 'treatment']]}, 'NCT01902810'), ({'text': 'Patients who do not read or understand English are eligible and may be consented according to institutional and federal regulations', 'entities': [['14', '47', 'language_fluency']]}, 'NCT02008656'), ({'text': 'Any condition that would contraindicate scanning (metal implants, claustrophobia or a breathing or movement disorder)', 'entities': [['67', '81', 'chronic_disease'], ['100', '117', 'chronic_disease']]}, 'NCT02165449'), ({'text': 'rior anti-cancer treatments such as chemotherapy, radiotherapy, hormonal, or immunotherapy (including anti-PD-1/PD-L1) are permitted', 'entities': [['37', '49', 'treatment'], ['51', '63', 'treatment'], ['65', '73', 'treatment'], ['78', '91', 'treatment'], ['103', '118', 'treatment']]}, 'NCT03110107'), ({'text': 'absolute neutrophil count (ANC) must be greater than or equal to 1000/mm3', 'entities': [['2', '32', 'clinical_variable'], ['66', '74', 'lower_bound']]}, 'NCT02236000'), ({'text': 'Current Gastrointestinal Bleeding or bowel ischemia', 'entities': [['9', '34', 'chronic_disease'], ['38', '52', 'chronic_disease']]}, 'NCT03129542'), ({'text': 'Bleeding disorder', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02254863'), ({'text': 'Patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption (e.g., inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease)', 'entities': [['15', '42', 'chronic_disease'], ['138', '153', 'treatment'], ['192', '217', 'treatment'], ['240', '262', 'chronic_disease'], ['268', '295', 'chronic_disease']]}, 'NCT01827384'), ({'text': 'Have uncontrolled hypertension defined as BP>140/90 mmHg on at least two consecutive visits in the past year (or BP>130/80 mmHg for those with diabetes or kidney disease) and Framingham Risk Scores (FRS) >20% (or at least one CVD risk factor including hyperlipidemia or diabetes)', 'entities': [['6', '31', 'chronic_disease'], ['43', '45', 'clinical_variable'], ['46', '57', 'lower_bound'], ['70', '73', 'lower_bound'], ['117', '128', 'lower_bound'], ['144', '152', 'chronic_disease'], ['156', '170', 'chronic_disease'], ['176', '204', 'clinical_variable'], ['206', '209', 'lower_bound'], ['223', '226', 'lower_bound'], ['227', '230', 'chronic_disease'], ['253', '267', 'chronic_disease']]}, 'NCT01643473'), ({'text': 'Unstable angina pectoris', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT01473628'), ({'text': 'First or second relapse of glioblastoma', 'entities': [['28', '40', 'cancer']]}, 'NCT01903330'), ({'text': 'Previously treated with HMA agent', 'entities': [['25', '34', 'treatment']]}, 'NCT02530463'), ({'text': 'LV dysfunction', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT00573027'), ({'text': 'untreated psychiatric disorder (e.g., major depression) found on structured interviews as these conditions have specific treatments and it would be inappropriate not to offer those treatments', 'entities': [['11', '31', 'chronic_disease'], ['39', '55', 'chronic_disease'], ['122', '132', 'treatment']]}, 'NCT03109210'), ({'text': 'No smartphone', 'entities': [['1', '14', 'technology_access']]}, 'NCT03186872'), ({'text': 'presence of an endometrial polyp or endometrial synechiae', 'entities': [['16', '33', 'chronic_disease'], ['37', '58', 'chronic_disease']]}, 'NCT02646930'), ({'text': 'Patients will provide at least 28-day baseline data in the form in the daily diary', 'entities': [['32', '38', 'lower_bound']]}, 'NCT03055767'), ({'text': 'No residual tumor (Grade 0, complete response, 0% tumor)', 'entities': [['4', '18', 'cancer'], ['13', '18', 'cancer']]}, 'NCT02639065'), ({'text': 'with an active known or suspected autoimmune disease', 'entities': [['35', '53', 'chronic_disease']]}, 'NCT03138512'), ({'text': 'Active ocular infection', 'entities': [['8', '24', 'chronic_disease']]}, 'NCT02148263'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02389023'), ({'text': 'Current treatment with immunosuppressant therapies', 'entities': [['24', '41', 'treatment']]}, 'NCT01505062'), ({'text': 'Normal glucose tolerance by OGTT confirmed within 7 weeks (no more than 52 days) of baseline (visit 0)', 'entities': [['51', '58', 'upper_bound'], ['73', '80', 'upper_bound']]}, 'NCT01773707'), ({'text': 'Other immunosuppressive medications such as methotrexate, cyclosporine, azathioprine or conditions such as common variable hypogammaglobulinemia', 'entities': [['7', '36', 'treatment'], ['45', '57', 'treatment'], ['59', '71', 'treatment'], ['73', '85', 'treatment'], ['124', '145', 'chronic_disease']]}, 'NCT02501473'), ({'text': 'ASA score 1-2', 'entities': [['1', '10', 'clinical_variable'], ['11', '12', 'lower_bound'], ['13', '14', 'upper_bound']]}, 'NCT00147056'), ({'text': 'History of any retinal and/or macular disease other than RP (e.g. retinal detachment) that in the opinion of the Investigator may have an impact on the safety of the subject, conduct of study procedures, or integrity of study data', 'entities': [['16', '23', 'chronic_disease'], ['31', '46', 'chronic_disease'], ['58', '60', 'chronic_disease']]}, 'NCT02464436'), ({'text': 'AST(SGOT)/ALT(SGPT) d 2.5 x ULN, alkaline phosphatase d 2.5 x ULN, unless bone metastasis is present in the absence of liver metastasis', 'entities': [['1', '4', 'clinical_variable'], ['5', '9', 'clinical_variable'], ['11', '14', 'clinical_variable'], ['15', '19', 'clinical_variable'], ['23', '32', 'upper_bound'], ['34', '54', 'clinical_variable'], ['75', '90', 'cancer'], ['120', '136', 'cancer']]}, 'NCT02369458'), ({'text': 'Impaired speed of information processing and working memory based on either the PASAT-3 or the SDMT (i.e. z <-1.5 controlling for age, education and sex)', 'entities': [['81', '88', 'treatment'], ['96', '100', 'treatment'], ['110', '114', 'upper_bound'], ['131', '134', 'age']]}, 'NCT02106052'), ({'text': 'LEEP for the treatment of cervical cancer in early stages', 'entities': [['1', '5', 'treatment'], ['27', '42', 'cancer']]}, 'NCT00900575'), ({'text': 'Active psychiatric disorder that would prevent eligibility for WLS or impede adherence to CLI, including clinically significant depression (hospitalization or suicidal ideation) in past 12 months', 'entities': [['1', '28', 'chronic_disease'], ['64', '67', 'treatment'], ['91', '94', 'chronic_disease'], ['106', '139', 'chronic_disease'], ['182', '196', 'upper_bound']]}, 'NCT02412540'), ({'text': 'Total Nucleated Cells (TNC) concentration of 30-42 x 106 cells/mL (pre-freeze)', 'entities': [['1', '42', 'clinical_variable'], ['46', '48', 'lower_bound'], ['49', '66', 'upper_bound']]}, 'NCT01883076'), ({'text': 'pregnancy or breastfeeding', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01695967'), ({'text': 'Hemoglobin >= 8.0 g/dL at baseline (may receive red blood cell [RBC] transfusions)', 'entities': [['1', '11', 'clinical_variable'], ['15', '23', 'lower_bound'], ['49', '82', 'treatment']]}, 'NCT02323880'), ({'text': 'History of seizure', 'entities': [['12', '19', 'chronic_disease']]}, 'NCT01964261'), ({'text': 'Significant neurologic disease that might affect cognition', 'entities': [['13', '31', 'chronic_disease']]}, 'NCT02462161'), ({'text': 'Patients who are receiving any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study. Concurrent treatment with bisphosphonates and denosumab is allowed for bony metastases but should be started before the first dose of neratinib', 'entities': [['32', '66', 'treatment'], ['87', '99', 'treatment'], ['101', '113', 'treatment'], ['118', '134', 'treatment'], ['162', '171', 'treatment'], ['177', '192', 'treatment'], ['197', '206', 'treatment'], ['227', '237', 'cancer'], ['285', '294', 'treatment']]}, 'NCT01494662'), ({'text': 'Eligible histologies include glioblastoma (GBM), anaplastic astrocytoma (AA) or gliosarcoma', 'entities': [['30', '48', 'cancer'], ['50', '77', 'cancer'], ['81', '92', 'cancer']]}, 'NCT01130077'), ({'text': 'recent diagnosis of cancer with a life-expectancy < 5 years', 'entities': [['21', '27', 'cancer'], ['35', '50', 'clinical_variable'], ['53', '60', 'upper_bound']]}, 'NCT02081404'), ({'text': 'low dose warfarin up to 2 mg po daily or use of subcutaneous low molecular weight heparin for thromboembolic prophylaxis', 'entities': [['10', '18', 'treatment'], ['25', '29', 'upper_bound'], ['83', '90', 'treatment'], ['95', '121', 'treatment']]}, 'NCT01261728'), ({'text': 'Suboptimal glucose control (A1C e 6.5%)', 'entities': [['29', '32', 'clinical_variable'], ['35', '39', 'lower_bound']]}, 'NCT01901055'), ({'text': 'Patients with a known allergy to Fluorodopa F 18 agent', 'entities': [['34', '55', 'allergy_name']]}, 'NCT02021604'), ({'text': 'Leukocyte count: no lower limit (within 2 weeks prior to enrollment) (participants may receive granulocyte colony stimulating factor [GCSF] and transfusions to meet these parameters)', 'entities': [['1', '16', 'clinical_variable'], ['41', '54', 'upper_bound'], ['97', '140', 'clinical_variable']]}, 'NCT02408861'), ({'text': 'Subjects have diagnosis of uncontrolled essential hypertension', 'entities': [['28', '63', 'chronic_disease']]}, 'NCT02293096'), ({'text': 'Isolated CNS 2 or 3 patients with < 0.1% MRD bone marrow involvement are not eligible', 'entities': [['14', '15', 'lower_bound'], ['19', '20', 'upper_bound'], ['21', '29', 'clinical_variable'], ['37', '41', 'upper_bound']]}, 'NCT01614197'), ({'text': 'Presence of a non-healing wound, non-healing ulcer, or bone fracture', 'entities': [['15', '32', 'chronic_disease'], ['34', '51', 'chronic_disease'], ['56', '69', 'chronic_disease']]}, 'NCT02048722'), ({'text': 'Documented LVEF of less than or equal to 45%', 'entities': [['12', '16', 'clinical_variable'], ['42', '45', 'upper_bound']]}, 'NCT01993719'), ({'text': 'HIV infection', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT03033888'), ({'text': 'other soft tissue or bony sarcomas', 'entities': [['27', '35', 'cancer']]}, 'NCT01449149'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT03071393'), ({'text': 'allergy to antibiotics contained in the ADM (Gentimicin, Cefoxitin, Lincomcin, polymixin B and Vancomycin) will not be included in the immediate implant combined with ADM group', 'entities': [['41', '44', 'allergy_name'], ['46', '56', 'allergy_name'], ['58', '67', 'allergy_name'], ['69', '78', 'allergy_name'], ['80', '91', 'allergy_name'], ['96', '106', 'allergy_name']]}, 'NCT02864862'), ({'text': 'childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication', 'entities': [['38', '71', 'pregnancy'], ['79', '93', 'upper_bound'], ['131', '141', 'treatment']]}, 'NCT02407171'), ({'text': 'immunotherapy', 'entities': [['1', '14', 'treatment']]}, 'NCT01676259'), ({'text': 'Is expected by the treating medical oncologist to continue on immunotherapy for at least three more months; imaging must show response, stable disease, or modest progression as determined by the treating medical oncologist; if there is modest progression, the patient must be clinically stable in terms of performance status and overall disease-related symptoms', 'entities': [['63', '76', 'treatment'], ['90', '107', 'lower_bound']]}, 'NCT03176173'), ({'text': 'history of bleeding diathesis', 'entities': [['12', '30', 'chronic_disease']]}, 'NCT01868386'), ({'text': 'HGB e 9 gm/dL', 'entities': [['1', '4', 'clinical_variable'], ['7', '14', 'lower_bound']]}, 'NCT01312857'), ({'text': 'allowable histologies for ovarian, fallopian, and peritoneal cancer include serous, clear cell, endometrioid, mucinous, transitional cell, undifferentiated, mixed, and carcinosarcoma', 'entities': [['27', '34', 'cancer'], ['36', '45', 'cancer'], ['51', '68', 'cancer'], ['77', '83', 'cancer'], ['85', '95', 'cancer'], ['97', '109', 'cancer'], ['111', '119', 'cancer'], ['121', '138', 'cancer'], ['140', '156', 'cancer'], ['158', '163', 'cancer'], ['169', '183', 'cancer']]}, 'NCT02020707'), ({'text': 'New York Heart Association (NYHA) class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemia', 'entities': [['1', '40', 'clinical_variable'], ['41', '43', 'lower_bound'], ['55', '68', 'chronic_disease'], ['70', '89', 'chronic_disease'], ['111', '134', 'chronic_disease'], ['159', '178', 'chronic_disease'], ['183', '203', 'treatment'], ['222', '230', 'chronic_disease']]}, 'NCT01959698'), ({'text': 'Eligible to undergo excisional surgery such as pleurectomy/decortication (P/DC) or any other mesothelioma surgery', 'entities': [['21', '39', 'treatment'], ['48', '80', 'treatment'], ['94', '114', 'treatment']]}, 'NCT02004028'), ({'text': 'Supratentorial mass effect with greater than 5 mm of midline shift or hydrocephalus. Infratentorial mass effect with fourth ventricle effacement or hydrocephalus', 'entities': [['1', '20', 'clinical_variable'], ['46', '50', 'lower_bound'], ['71', '84', 'chronic_disease'], ['118', '145', 'chronic_disease']]}, 'NCT02514915'), ({'text': 'White blood cell (WBC) count e 3,000/mm3 within 3 weeks prior to registration', 'entities': [['1', '29', 'clinical_variable'], ['32', '41', 'lower_bound'], ['49', '62', 'upper_bound']]}, 'NCT02264236'), ({'text': 'Creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal', 'entities': [['1', '21', 'clinical_variable'], ['25', '43', 'lower_bound']]}, 'NCT02520791'), ({'text': 'be a pregnant female (balance considerations)', 'entities': [['6', '14', 'pregnancy'], ['15', '21', 'gender']]}, 'NCT02748109'), ({'text': 'Subjects must agree not to become pregnant or to impregnate a female', 'entities': [['21', '43', 'pregnancy'], ['63', '69', 'gender']]}, 'NCT00967785'), ({'text': 'Hematocrit < 36% or hemoglobin < 12 g/dl', 'entities': [['1', '11', 'clinical_variable'], ['14', '17', 'upper_bound'], ['21', '31', 'clinical_variable'], ['34', '41', 'upper_bound']]}, 'NCT00930228'), ({'text': 'Patients who have not received standard chemotherapy, hormonal or targeted therapy for their underlying advanced/metastatic cancer', 'entities': [['32', '53', 'treatment'], ['55', '83', 'treatment'], ['105', '131', 'cancer']]}, 'NCT02310464'), ({'text': 'Participation in another concurrent treatment protocol', 'entities': [['26', '46', 'treatment']]}, 'NCT02762266'), ({'text': 'The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan', 'entities': [['35', '74', 'chronic_disease'], ['85', '88', 'treatment'], ['92', '125', 'treatment']]}, 'NCT02132598'), ({'text': 'Allergies to Lidocaine or Novocain', 'entities': [['14', '23', 'allergy_name'], ['27', '35', 'allergy_name']]}, 'NCT02540330'), ({'text': 'Chronic cytotoxic drug treatment', 'entities': [['9', '33', 'treatment']]}, 'NCT02551679'), ({'text': 'who have previously received any anti-PD-1/PD-L1 therapy, alone or in combination', 'entities': [['34', '57', 'treatment']]}, 'NCT03084640'), ({'text': 'Systolic heart failure defined as left ventricular ejection fraction d 45%', 'entities': [['1', '23', 'chronic_disease'], ['35', '69', 'clinical_variable'], ['72', '75', 'upper_bound']]}, 'NCT02584309'), ({'text': 'NSCLC with a targetable mutation in EGFR, ALK, ROS1 or BRAF', 'entities': [['1', '6', 'cancer'], ['37', '41', 'clinical_variable'], ['43', '46', 'clinical_variable'], ['48', '52', 'clinical_variable'], ['56', '60', 'clinical_variable']]}, 'NCT03037385'), ({'text': 'Women should not breast-feed a baby while on this study', 'entities': [['1', '6', 'gender']]}, 'NCT00715611'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03162978'), ({'text': 'Visual field loss', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT01407809'), ({'text': 'A total score of 2 or higher on the Gastroparesis Cardinal Symptoms Index (total score equals average of scores on the 3 subscales)', 'entities': [['18', '19', 'lower_bound'], ['37', '74', 'clinical_variable']]}, 'NCT02838797'), ({'text': 'FEV1 (Forced expiratory volume in 1 second)', 'entities': [['1', '44', 'clinical_variable']]}, 'NCT00959140'), ({'text': 'Prior autologous', 'entities': [['1', '17', 'treatment']]}, 'NCT02016781'), ({'text': 'Uncontrolled anxiety', 'entities': [['14', '21', 'chronic_disease']]}, 'NCT02946268'), ({'text': 'diagnosed connective tissue disorder, or congenital coagulation defects (patients on medical therapy with Coumadin or other blood thinning agents are eligible for participation)', 'entities': [['11', '37', 'chronic_disease'], ['42', '72', 'chronic_disease'], ['86', '115', 'treatment'], ['125', '146', 'treatment']]}, 'NCT01950351'), ({'text': 'History of two or more TCD studies with a velocity e 200 cm/sec by the non-imaging technique, or e185 cm/sec for the imaging technique or a indeterminate TCD', 'entities': [['12', '15', 'lower_bound'], ['24', '27', 'treatment'], ['24', '35', 'treatment'], ['43', '51', 'clinical_variable'], ['54', '64', 'lower_bound'], ['72', '93', 'treatment'], ['99', '109', 'lower_bound']]}, 'NCT01389024'), ({'text': 'history of a prior grade 3 or 4 immune-related adverse event (irAE) or any grade ocular irAE from prior immunotherapy', 'entities': [['14', '68', 'chronic_disease'], ['63', '67', 'chronic_disease'], ['99', '118', 'treatment']]}, 'NCT02419495'), ({'text': 'effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured', 'entities': [['21', '46', 'cancer'], ['48', '79', 'cancer'], ['81', '105', 'cancer'], ['129', '139', 'cancer'], ['157', '166', 'treatment'], ['181', '188', 'lower_bound']]}, 'NCT02423525'), ({'text': 'Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration', 'entities': [['1', '16', 'chronic_disease'], ['24', '48', 'chronic_disease'], ['59', '74', 'treatment'], ['86', '105', 'upper_bound']]}, 'NCT02542202'), ({'text': 'Known active central nervous system (CNS) involvement with AML at study entry', 'entities': [['60', '63', 'cancer']]}, 'NCT02670044'), ({'text': 'Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)', 'entities': [['22', '29', 'treatment'], ['32', '39', 'treatment'], ['42', '50', 'treatment']]}, 'NCT02358187'), ({'text': 'The participant has received radionuclide treatment within 6 weeks of the first dose of study treatment', 'entities': [['30', '52', 'treatment'], ['60', '67', 'upper_bound'], ['89', '104', 'treatment']]}, 'NCT01822522'), ({'text': 'Plan to discontinue care at the clinic within the next 3 months', 'entities': [['51', '64', 'upper_bound']]}, 'NCT01643473'), ({'text': 'No uncontrolled arrhythmias or New York Heart Association class III-IV heart failure', 'entities': [['17', '28', 'chronic_disease'], ['32', '64', 'clinical_variable'], ['65', '68', 'lower_bound'], ['69', '71', 'upper_bound'], ['72', '85', 'chronic_disease']]}, 'NCT03159702'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02953509'), ({'text': 'Any physical or mental impairment which would preclude participation in any of the examinations, such as inability to give verbal responses to eye charts', 'entities': [['5', '34', 'chronic_disease']]}, 'NCT02030990'), ({'text': 'Age 1 to 24 years', 'entities': [['1', '4', 'age'], ['5', '6', 'lower_bound'], ['10', '18', 'upper_bound']]}, 'NCT02374333'), ({'text': 'Recent hemoglobin A1c result between 6.5%-13%', 'entities': [['8', '22', 'clinical_variable'], ['38', '42', 'lower_bound'], ['43', '46', 'upper_bound']]}, 'NCT02448498'), ({'text': 'End stage medical illness (e.g. liver, kidney, pulmonary)', 'entities': [['1', '26', 'chronic_disease'], ['33', '38', 'chronic_disease'], ['40', '46', 'chronic_disease'], ['48', '57', 'chronic_disease']]}, 'NCT01973283'), ({'text': 'CT must be performed within 28 days of registration', 'entities': [['1', '3', 'clinical_variable'], ['29', '36', 'upper_bound']]}, 'NCT02143726'), ({'text': 'Participants with a history of treatment with an anti-PD-1, anti-PD-L1, anti-CTLA-4 or other investigational agents that target immune checkpoint inhibitors', 'entities': [['32', '59', 'treatment'], ['61', '71', 'treatment'], ['73', '84', 'treatment']]}, 'NCT02912572'), ({'text': 'Known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ', 'entities': [['18', '28', 'cancer'], ['68', '77', 'treatment'], ['100', '132', 'cancer'], ['134', '169', 'cancer'], ['173', '190', 'cancer']]}, 'NCT02332668'), ({'text': 'Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent', 'entities': [['1', '13', 'chronic_disease'], ['15', '25', 'chronic_disease'], ['43', '51', 'chronic_disease']]}, 'NCT01968109'), ({'text': 'An elevated serum gonadotropin level and estradiol level in the postmenopausal range (as locally defined) can be used to confirm menopausal status in a subject with <1 year of amenorrhea', 'entities': [['13', '37', 'clinical_variable'], ['42', '57', 'clinical_variable'], ['167', '173', 'upper_bound'], ['177', '187', 'chronic_disease']]}, 'NCT02188745'), ({'text': 'Subjects who are deemed suitable candidates for bilateral LASIK will be considered eligible for participation in this study', 'entities': [['49', '64', 'treatment']]}, 'NCT03122535'), ({'text': 'a life-threatening illness with life expectancy less than six months', 'entities': [['33', '48', 'clinical_variable'], ['59', '69', 'upper_bound']]}, 'NCT02593110'), ({'text': 'Inability to deliver target dose with CyberKnife due to normal tissue dose constraints', 'entities': [['39', '49', 'treatment']]}, 'NCT01890590'), ({'text': 'AST and ALT are each d5 × the ULN', 'entities': [['1', '12', 'clinical_variable'], ['23', '34', 'upper_bound']]}, 'NCT02266745'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02981173'), ({'text': 'Lipase < 1.5 X ULN (within 28 days of first study treatment)', 'entities': [['1', '7', 'clinical_variable'], ['10', '19', 'upper_bound'], ['28', '35', 'upper_bound'], ['51', '60', 'treatment']]}, 'NCT02519322'), ({'text': 'Subject is currently pregnant', 'entities': [['12', '30', 'pregnancy']]}, 'NCT02799095'), ({'text': 'Have history or findings of central or branch retinal artery or venous occlusion with significant vision loss or other retinal diseases that cause current visual impairment or would likely cause visual impairment over the time period of the study', 'entities': [['120', '136', 'chronic_disease']]}, 'NCT02857270'), ({'text': 'An additional cohort of 10 patients with BCLC stages A to C locally advanced or metastatic hepatocellular carcinoma (HCC) that is not surgically resectable will also be enrolled (See appendix for BCLC staging system)', 'entities': [['42', '46', 'cancer'], ['43', '44', 'upper_bound'], ['47', '55', 'lower_bound'], ['92', '122', 'cancer']]}, 'NCT02013492'), ({'text': 'Females who are pregnant or lactating', 'entities': [['1', '8', 'gender'], ['17', '25', 'pregnancy']]}, 'NCT03055377'), ({'text': 'Myocardial infarction within 6 months of starting study drug', 'entities': [['1', '22', 'chronic_disease'], ['30', '38', 'upper_bound']]}, 'NCT03113695'), ({'text': 'Women are post-menopausal and not taking hormone replacement therapy', 'entities': [['1', '6', 'gender'], ['42', '69', 'treatment']]}, 'NCT03179163'), ({'text': 'Subject has previously been dosed with Lu AF35700', 'entities': [['40', '50', 'treatment']]}, 'NCT03103646'), ({'text': 'Creatinine greater than 1.4mg/dL', 'entities': [['1', '11', 'clinical_variable'], ['25', '33', 'lower_bound']]}, 'NCT02981329'), ({'text': 'History of seizure disorder', 'entities': [['12', '19', 'chronic_disease']]}, 'NCT02480114'), ({'text': 'Symptomatic ascites or pleural effusion requiring medical intervention', 'entities': [['13', '20', 'chronic_disease'], ['24', '40', 'chronic_disease']]}, 'NCT02561988'), ({'text': 'within 90 days after discontinuation of dutasteride', 'entities': [['8', '21', 'upper_bound'], ['41', '52', 'treatment']]}, 'NCT02064036'), ({'text': 'Do not own or are not familiar with the use of a smartphone', 'entities': [['41', '60', 'technology_access']]}, 'NCT03134274'), ({'text': 'Pregnant and lactating women', 'entities': [['1', '9', 'pregnancy'], ['24', '29', 'gender']]}, 'NCT02826681'), ({'text': 'other immunocompromised conditions who may have infectious esophagitis', 'entities': [['7', '24', 'chronic_disease'], ['49', '71', 'chronic_disease']]}, 'NCT02081404'), ({'text': 'Diagnosis of a Sunderland Class 5 traumatic neuropathy (transection injury) of a digital nerve in the upper extremity', 'entities': [['35', '55', 'chronic_disease']]}, 'NCT02359825'), ({'text': 'Component of small-cell cancer or sarcomatoid cancer', 'entities': [['14', '31', 'cancer'], ['35', '53', 'cancer']]}, 'NCT02459119'), ({'text': "Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d' orange without erythema)", 'entities': [['1', '27', 'cancer'], ['158', '163', 'cancer']]}, 'NCT01953588'), ({'text': 'total bilirubin < = 1.5 X upper limit of normal', 'entities': [['1', '16', 'clinical_variable'], ['21', '48', 'upper_bound']]}, 'NCT01054196'), ({'text': 'Scores <5 ppm of expired carbon monoxide (CO) on the Smokelyzer', 'entities': [['9', '14', 'upper_bound'], ['18', '46', 'clinical_variable']]}, 'NCT02460900'), ({'text': 'Anti-CD20 monoclonal antibody therapy within the last 3 months, or absence of circulating B cells', 'entities': [['1', '38', 'treatment'], ['50', '63', 'upper_bound']]}, 'NCT02624258'), ({'text': 'Respiratory disease', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02487082'), ({'text': 'Relapsed/refractory MCL: Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty', 'entities': [['21', '24', 'cancer'], ['94', '101', 'treatment']]}, 'NCT01880567'), ({'text': 'Age range of 1.0-15.99 years, inclusive, at the time of enrollment', 'entities': [['1', '4', 'age'], ['14', '17', 'lower_bound'], ['18', '29', 'upper_bound']]}, 'NCT02042222'), ({'text': 'Current use of a positive airway pressure device (including continuous or bi-level positive airway pressure or adaptive servo-ventilation) or supplemental oxygen therapy', 'entities': [['18', '42', 'treatment'], ['18', '49', 'treatment'], ['112', '138', 'treatment'], ['143', '170', 'treatment']]}, 'NCT01807897'), ({'text': 'Patients with known active brain metastases', 'entities': [['28', '44', 'cancer']]}, 'NCT01811368'), ({'text': 'CTCL disease stage at study entry as follows, according to ISCL/EORTC (Olsen 2011)', 'entities': [['1', '5', 'cancer']]}, 'NCT01871727'), ({'text': 'has not undergone a hysterectomy or bilateral oophorectomy', 'entities': [['21', '33', 'treatment'], ['37', '59', 'treatment']]}, 'NCT02004275'), ({'text': 'Therapeutic antibodies, such as bevacizumab', 'entities': [['1', '23', 'treatment'], ['33', '44', 'treatment']]}, 'NCT02312245'), ({'text': 'preference will be given to patients with metastatic ovarian cancer, breast cancer, and malignant melanoma, as these malignancies have been shown to be sensitive to manipulation of the beta-adrenergic receptor', 'entities': [['43', '68', 'cancer'], ['70', '83', 'cancer'], ['89', '107', 'cancer'], ['118', '130', 'cancer']]}, 'NCT02013492'), ({'text': 'Asymptomatic, central nervous system metastases', 'entities': [['15', '48', 'cancer']]}, 'NCT01522768'), ({'text': 'N0 or N1 nodal disease as present on perioperative chest CT and/or PET CT', 'entities': [['7', '23', 'chronic_disease'], ['38', '60', 'treatment'], ['68', '74', 'treatment']]}, 'NCT02592551'), ({'text': 'age 2 years [12 kg] to 9 years inclusive; skeletal age <11 years', 'entities': [['1', '4', 'age'], ['5', '12', 'lower_bound'], ['24', '31', 'upper_bound'], ['57', '65', 'upper_bound']]}, 'NCT02574910'), ({'text': 'Participants must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2', 'entities': [['24', '84', 'clinical_variable'], ['85', '86', 'lower_bound'], ['87', '88', 'upper_bound']]}, 'NCT02437851'), ({'text': 'An upper limit of BMI was set to avoid rare outliers in BMI', 'entities': [['19', '22', 'bmi']]}, 'NCT02412540'), ({'text': 'Tumor deemed unresectable or metastatic', 'entities': [['1', '6', 'cancer']]}, 'NCT02048722'), ({'text': 'Thrombocytopenia, coagulopathy, or indication for ongoing anti-coagulation therapy', 'entities': [['1', '17', 'chronic_disease'], ['19', '31', 'chronic_disease'], ['59', '83', 'treatment']]}, 'NCT03118973'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01608438'), ({'text': 'female subjects of reproductive non childbearing potential', 'entities': [['1', '16', 'gender']]}, 'NCT02723994'), ({'text': 'Refractory / relapsed AML following e1 prior therapies (Arms 4a & 5a)', 'entities': [['1', '11', 'cancer'], ['14', '26', 'cancer'], ['38', '39', 'lower_bound'], ['40', '55', 'treatment']]}, 'NCT03066648'), ({'text': 'Histologically confirmed diagnosis of PTCL (using the most recent edition of the World Health Organization [WHO] Classification of Tumors of Hematopoietic and Lymphoid Tissues as guidance)', 'entities': [['39', '43', 'cancer']]}, 'NCT02232516'), ({'text': 'diabetic retinopathy', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02841540'), ({'text': 'Have a hemoglobin < 9.0 g/dL', 'entities': [['8', '18', 'clinical_variable'], ['21', '29', 'upper_bound']]}, 'NCT02682407'), ({'text': 'cutaneous toxicity', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02533674'), ({'text': 'Known to be HIV+', 'entities': [['13', '16', 'chronic_disease']]}, 'NCT02446093'), ({'text': 'Impetigo', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT00788164'), ({'text': 'Platelets >= 60,000 cells/mm^3', 'entities': [['1', '10', 'clinical_variable'], ['14', '31', 'lower_bound']]}, 'NCT01730937'), ({'text': 'Estimated creatinine clearance <15mL/min', 'entities': [['1', '31', 'clinical_variable'], ['33', '41', 'upper_bound']]}, 'NCT02400463'), ({'text': 'Vulnerable populations (e.g. pregnant, nursing, cognitively impaired, incarcerated)', 'entities': [['30', '38', 'pregnancy']]}, 'NCT02582905'), ({'text': 'Subjects with at least moderate PTSD with a CAPS-5 score e 25 at both Screening and Baseline visits', 'entities': [['33', '37', 'chronic_disease'], ['45', '57', 'clinical_variable'], ['60', '62', 'lower_bound']]}, 'NCT02479906'), ({'text': 'Adult male', 'entities': [['7', '11', 'gender']]}, 'NCT02265874'), ({'text': 'Able to make one initial appointment at the Army Medical Department Center and School at Fort Sam Houston, one treatment visit approximately 2-3 days after the initial visit, and then a final outcome visit approximately 5-7 days after 2nd visit', 'entities': [['112', '121', 'treatment'], ['142', '143', 'lower_bound'], ['144', '156', 'upper_bound'], ['221', '222', 'lower_bound'], ['223', '235', 'upper_bound']]}, 'NCT02415660'), ({'text': 'Non-tolerable > Grade 2 neuropathy', 'entities': [['1', '14', 'clinical_variable'], ['17', '24', 'lower_bound'], ['25', '35', 'chronic_disease']]}, 'NCT02383927'), ({'text': 'Target <1 cm from nerve plexus', 'entities': [['9', '13', 'upper_bound'], ['19', '31', 'clinical_variable']]}, 'NCT02076906'), ({'text': 'Other tobacco use besides cigarettes or little cigars (e.g., hookah, cigarillos, smokeless tobacco, chewing tobacco, pipes, cigars, etc.) on 10 or more days in the last month', 'entities': [['142', '144', 'lower_bound']]}, 'NCT02964182'), ({'text': 'Negative serum or urine pregnancy test', 'entities': [['1', '34', 'pregnancy']]}, 'NCT02159495'), ({'text': 'Significant renal dysfunction (CKD >stage 2)', 'entities': [['13', '30', 'chronic_disease'], ['32', '35', 'clinical_variable'], ['37', '44', 'lower_bound']]}, 'NCT02243631'), ({'text': "Seen previously in the clinics at Nova Southeastern University's The Eye Care Institute with a diagnosis for glaucoma suspect or optic nerve abnormalities", 'entities': [['110', '118', 'chronic_disease'], ['130', '155', 'chronic_disease']]}, 'NCT02157025'), ({'text': '> Grade 1 peripheral neuropathy within 14 days before enrollment', 'entities': [['3', '10', 'lower_bound'], ['11', '32', 'clinical_variable'], ['40', '54', 'upper_bound']]}, 'NCT02355535'), ({'text': 'known LIMA graft', 'entities': [['7', '17', 'treatment']]}, 'NCT02832115'), ({'text': 'Subjects with history of life-threatening toxicity related to prior immune therapy (e.g., anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures (e.g., hormone replacement after endocrinopathy)', 'entities': [['63', '237', 'treatment'], ['318', '337', 'treatment'], ['344', '358', 'chronic_disease']]}, 'NCT02519322'), ({'text': 'Platelet count >= 100,000/mm^3 (obtained =< 28 days prior to randomization)', 'entities': [['1', '15', 'clinical_variable'], ['19', '31', 'lower_bound'], ['45', '58', 'upper_bound']]}, 'NCT02393690'), ({'text': 'Patients must have fully recovered from acute treatment related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study', 'entities': [['47', '56', 'treatment'], ['83', '101', 'treatment'], ['103', '116', 'treatment'], ['120', '138', 'treatment']]}, 'NCT02457845'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'upper_bound'], ['68', '77', 'clinical_variable'], ['81', '84', 'lower_bound']]}, 'NCT02857218'), ({'text': 'No prior radiotherapy to e 25% of the bone marrow', 'entities': [['10', '22', 'treatment'], ['28', '31', 'lower_bound'], ['39', '50', 'clinical_variable']]}, 'NCT00670358'), ({'text': 'Adult males', 'entities': [['7', '12', 'gender']]}, 'NCT02272634'), ({'text': 'Hamilton Depression Rating Scale-24 (HRSD-24) score of 8-24', 'entities': [['1', '52', 'clinical_variable'], ['34', '36', 'upper_bound'], ['56', '57', 'lower_bound']]}, 'NCT02133898'), ({'text': 'post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy', 'entities': [['1', '29', 'chronic_disease'], ['111', '129', 'treatment']]}, 'NCT02255383'), ({'text': 'Diffusion capacity for carbon monoxide corrected (DLCOcorr) > 50% normal or a pediatric patient who is unable to perform pulmonary function tests (PFTs) but has adequate pulmonary function', 'entities': [['24', '60', 'clinical_variable'], ['63', '66', 'lower_bound'], ['122', '153', 'treatment']]}, 'NCT00719888'), ({'text': 'Plan for post operative radiation therapy', 'entities': [['10', '42', 'treatment']]}, 'NCT03144206'), ({'text': 'hypertension', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02245841'), ({'text': 'severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy', 'entities': [['1', '31', 'chronic_disease'], ['35', '53', 'chronic_disease'], ['72', '77', 'cancer'], ['89', '103', 'treatment']]}, 'NCT02439450'), ({'text': 'Age-adjusted normal serum creatinine', 'entities': [['1', '4', 'age'], ['21', '37', 'clinical_variable']]}, 'NCT02076906'), ({'text': 'Chemotherapy is not administered prior to, during, and for e 21 days after completion of radiotherapy (for patients receiving brachytherapy boost)', 'entities': [['1', '13', 'treatment'], ['62', '69', 'lower_bound'], ['90', '102', 'treatment'], ['127', '146', 'treatment']]}, 'NCT00909909'), ({'text': 'Prior treated malignancies in addition to breast cancer are acceptable', 'entities': [['15', '27', 'cancer'], ['43', '56', 'cancer']]}, 'NCT03158519'), ({'text': 'unstable angina, or unstable arrhythmia', 'entities': [['1', '16', 'chronic_disease'], ['21', '40', 'chronic_disease']]}, 'NCT01572480'), ({'text': 'documented clinically significant arrhythmias', 'entities': [['35', '46', 'chronic_disease']]}, 'NCT02343549'), ({'text': 'sclerotic GVHD', 'entities': [['11', '15', 'chronic_disease']]}, 'NCT02203903'), ({'text': 'Age > 18', 'entities': [['1', '4', 'age'], ['7', '9', 'lower_bound']]}, 'NCT03115398'), ({'text': 'Diagnosis of CKD with an eGFR d60 mL/min/1.73 m^2 at Screening and not expected to start dialysis within 6 months of Screeni', 'entities': [['14', '17', 'chronic_disease'], ['26', '30', 'clinical_variable'], ['32', '50', 'upper_bound'], ['90', '98', 'treatment'], ['106', '114', 'upper_bound']]}, 'NCT02648347'), ({'text': 'Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) e 2 x institutional upper limit of normal', 'entities': [['1', '82', 'clinical_variable'], ['85', '124', 'lower_bound']]}, 'NCT02181478'), ({'text': 'Oxygen saturation >= 90% by pulse oximetry', 'entities': [['1', '18', 'clinical_variable'], ['22', '25', 'lower_bound']]}, 'NCT01562626'), ({'text': 'An adequate clinical response following SOC antibiotic therapy, defined as (<3 unformed stools in 24 hours) for 2 or more consecutive days before randomization', 'entities': [['41', '63', 'treatment'], ['78', '79', 'upper_bound']]}, 'NCT03183128'), ({'text': 'Hepatic Function', 'entities': [['1', '17', 'treatment']]}, 'NCT01624090'), ({'text': 'Prehypertensive and Normotensive OEF/OIF/OND veterans without PTSD (controls)', 'entities': [['63', '67', 'chronic_disease']]}, 'NCT01627301'), ({'text': 'Other active malignancy =< 3 years prior to registration; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix', 'entities': [['14', '24', 'cancer'], ['28', '41', 'upper_bound'], ['71', '96', 'cancer'], ['100', '131', 'cancer']]}, 'NCT02312245'), ({'text': 'Post-meningitis ossification', 'entities': [['6', '29', 'chronic_disease']]}, 'NCT02310399'), ({'text': '23 to 32 +6 Gestational age', 'entities': [['1', '3', 'lower_bound'], ['7', '9', 'upper_bound'], ['13', '28', 'clinical_variable']]}, 'NCT03019367'), ({'text': 'have a limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled', 'entities': [['47', '53', 'upper_bound']]}, 'NCT02624258'), ({'text': 'Subjects with relapsed/refractory AML must have received either induction chemotherapy for AML or hypomethylating agents for hematologic disease before AML', 'entities': [['35', '38', 'cancer'], ['65', '87', 'treatment'], ['99', '121', 'treatment'], ['126', '145', 'chronic_disease']]}, 'NCT02587598'), ({'text': 'Sexual identification as female', 'entities': [['26', '32', 'gender']]}, 'NCT02951455'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02232165'), ({'text': '18 years of age or older', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT02106598'), ({'text': 'Severe visual impairment, defined as being unable to read large-print materials', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03137459'), ({'text': 'nursing females', 'entities': [['9', '16', 'gender']]}, 'NCT02111824'), ({'text': 'WBC e 4,000/µl', 'entities': [['1', '4', 'clinical_variable'], ['7', '15', 'lower_bound']]}, 'NCT02287558'), ({'text': 'Patients must have high-risk NB (MYCN-amplified stage 2/3/4/4S of any age and MYCN-nonamplified stage 4 in patients greater than 18 months of age', 'entities': [['34', '54', 'clinical_variable'], ['51', '54', 'age'], ['55', '56', 'lower_bound'], ['61', '63', 'upper_bound'], ['130', '139', 'lower_bound']]}, 'NCT03033303'), ({'text': 'History of post-ictal psychosis or post-ictal aggression', 'entities': [['12', '32', 'chronic_disease'], ['36', '57', 'chronic_disease']]}, 'NCT02531880'), ({'text': 'Significant risk for suicide or violence', 'entities': [['22', '29', 'chronic_disease']]}, 'NCT02316574'), ({'text': 'Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment', 'entities': [['16', '28', 'treatment'], ['30', '43', 'treatment'], ['48', '76', 'treatment'], ['81', '87', 'cancer'], ['88', '97', 'treatment']]}, 'NCT02519348'), ({'text': 'Age 18-64 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '16', 'upper_bound']]}, 'NCT02415660'), ({'text': 'Patients age 18- 89', 'entities': [['10', '13', 'age'], ['14', '16', 'lower_bound'], ['18', '20', 'upper_bound']]}, 'NCT02409810'), ({'text': 'Untreated infection at site of ulcer (i.e. cellulitis or osteomyelitis)', 'entities': [['11', '20', 'chronic_disease'], ['32', '37', 'chronic_disease'], ['44', '54', 'chronic_disease'], ['58', '71', 'chronic_disease']]}, 'NCT02313428'), ({'text': 'Major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK525762', 'entities': [['1', '14', 'treatment'], ['16', '28', 'treatment'], ['33', '46', 'treatment'], ['54', '61', 'upper_bound'], ['65', '74', 'treatment']]}, 'NCT01943851'), ({'text': 'Need for a chest wall resection', 'entities': [['12', '32', 'treatment']]}, 'NCT02063438'), ({'text': 'Patient must not have hypokalemia (value < institutional lower limit of normal)', 'entities': [['23', '34', 'chronic_disease']]}, 'NCT02465060'), ({'text': 'Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation', 'entities': [['14', '21', 'treatment'], ['23', '25', 'lower_bound'], ['29', '35', 'upper_bound'], ['46', '74', 'treatment']]}, 'NCT02213913'), ({'text': 'shortness of breath, orthopnea or edema', 'entities': [['1', '20', 'chronic_disease'], ['22', '31', 'chronic_disease'], ['35', '40', 'chronic_disease']]}, 'NCT02391987'), ({'text': 'Sex: Pink eye {adenoviral conjunctivitis (Ad-Cs)} occurs with equal prevalence in males and females, therefore we will recruit both genders', 'entities': [['6', '50', 'chronic_disease'], ['83', '100', 'gender']]}, 'NCT02472223'), ({'text': 'Absolute neutrophil count (ANC) >= 1500/mm^3', 'entities': [['1', '32', 'clinical_variable'], ['36', '45', 'lower_bound']]}, 'NCT02020707'), ({'text': 'Patient receiving oral or injected steroids', 'entities': [['19', '23', 'treatment'], ['27', '44', 'treatment']]}, 'NCT02252081'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT03112824'), ({'text': 'Anticipated surgery within 48 hours after insertion of the CVC', 'entities': [['13', '20', 'treatment'], ['28', '36', 'upper_bound']]}, 'NCT03003390'), ({'text': 'Research participant does not have uncontrolled seizure activity following surgery prior to starting the first T cell dose', 'entities': [['49', '56', 'chronic_disease'], ['76', '83', 'treatment']]}, 'NCT02208362'), ({'text': 'A diagnosis of UC made by standard clinical, radiological, endoscopic and histological criteria', 'entities': [['16', '18', 'chronic_disease']]}, 'NCT02200445'), ({'text': 'Sarcoma of lower extremity location', 'entities': [['1', '8', 'cancer']]}, 'NCT03144206'), ({'text': 'First episode of wheezing', 'entities': [['18', '26', 'chronic_disease']]}, 'NCT02436070'), ({'text': 'If acute osteomyelitis has been diagnosed, patient may be enrolled only after the infection has been controlled', 'entities': [['4', '23', 'chronic_disease'], ['83', '92', 'chronic_disease']]}, 'NCT02313428'), ({'text': 'Lack of English fluency', 'entities': [['9', '24', 'language_fluency']]}, 'NCT02841956'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['66', '67', 'upper_bound']]}, 'NCT01804465'), ({'text': 'Patients must have < Grade 2 pre-existing peripheral neuropathy (per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v 4.03)', 'entities': [['22', '29', 'upper_bound'], ['30', '64', 'treatment']]}, 'NCT02317991'), ({'text': 'Impaired wound healing or other extremity complications due to severe or uncontrolled diabetes mellitus in subjects whose Injectable Lesions are located in an extremity', 'entities': [['74', '104', 'chronic_disease']]}, 'NCT02557321'), ({'text': 'narcotics', 'entities': [['1', '10', 'treatment']]}, 'NCT02703220'), ({'text': 'patients e 16 years of age', 'entities': [['12', '20', 'lower_bound'], ['24', '27', 'age']]}, 'NCT02932280'), ({'text': 'Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 3.5 times the upper limit of normal within 14 days prior to starting therapy', 'entities': [['1', '37', 'clinical_variable'], ['38', '70', 'clinical_variable'], ['74', '109', 'upper_bound'], ['117', '130', 'upper_bound'], ['143', '150', 'treatment']]}, 'NCT01959698'), ({'text': 'Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease', 'entities': [['20', '44', 'cancer'], ['48', '63', 'cancer']]}, 'NCT02553941'), ({'text': 'Platelet count e100,000 platelets/mm3 Lab requirements (serum chemistry)', 'entities': [['1', '15', 'clinical_variable'], ['17', '24', 'lower_bound']]}, 'NCT02414269'), ({'text': 'Major hemorrhagic event within 28 days', 'entities': [['7', '24', 'chronic_disease'], ['32', '39', 'upper_bound']]}, 'NCT02576301'), ({'text': 'Clinically significant atrial and/or ventricular arrhythmias', 'entities': [['24', '61', 'chronic_disease']]}, 'NCT02133196'), ({'text': 'Autism/Schizophrenia', 'entities': [['1', '7', 'chronic_disease'], ['8', '21', 'chronic_disease']]}, 'NCT02926677'), ({'text': 'Results of tests must be within a range that would not preclude donating blood or undergoing leukapheresis', 'entities': [['94', '107', 'treatment']]}, 'NCT01430390'), ({'text': 'Patients who are receiving any other investigational agents concurrently', 'entities': [['38', '60', 'treatment']]}, 'NCT02584647'), ({'text': 'Patients must have adequate pulmonary function studies > 50% of predicted on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) > 50% of predicted', 'entities': [['20', '55', 'clinical_variable'], ['58', '61', 'lower_bound'], ['98', '102', 'clinical_variable'], ['104', '107', 'clinical_variable'], ['118', '143', 'clinical_variable']]}, 'NCT02128230'), ({'text': 'Histological confirmation of follicular lymphoma grades I, II diagnosed within 12 months (365 days) prior to registration', 'entities': [['30', '49', 'clinical_variable'], ['50', '58', 'lower_bound'], ['60', '62', 'upper_bound'], ['80', '106', 'upper_bound']]}, 'NCT02320292'), ({'text': 'UGI post-polypectomy induced ulcer with some SRH on endoscopy', 'entities': [['1', '21', 'treatment'], ['30', '35', 'chronic_disease'], ['53', '62', 'treatment']]}, 'NCT03065465'), ({'text': 'No prior history of multifocal adenocarcinoma in situ (ie, classic or pure bronchioloalveolar carcinoma)', 'entities': [['21', '54', 'cancer'], ['60', '104', 'cancer']]}, 'NCT02581787'), ({'text': 'Subject is male', 'entities': [['12', '16', 'gender']]}, 'NCT03169894'), ({'text': 'ANC e1000/µL', 'entities': [['1', '4', 'clinical_variable'], ['6', '13', 'lower_bound']]}, 'NCT02106650'), ({'text': 'Diabetes or current hypothyroidism', 'entities': [['1', '9', 'chronic_disease'], ['21', '35', 'chronic_disease']]}, 'NCT02531295'), ({'text': 'Patients < 18 years of age and >70 years of age', 'entities': [['12', '20', 'upper_bound'], ['24', '27', 'age'], ['33', '41', 'lower_bound']]}, 'NCT02202369'), ({'text': 'Healthy non-surgical patients with personal history of diabetes', 'entities': [['56', '64', 'chronic_disease']]}, 'NCT02823665'), ({'text': 'History of Guillain-Barre syndrome', 'entities': [['12', '35', 'chronic_disease']]}, 'NCT01967238'), ({'text': 'Chronic renal failure (hemodialysis or peritoneal dialysis)', 'entities': [['1', '22', 'chronic_disease'], ['24', '36', 'treatment'], ['40', '59', 'treatment']]}, 'NCT00673842'), ({'text': 'Adult patient (male or female) requiring emergency endotracheal intubation', 'entities': [['16', '30', 'gender'], ['52', '75', 'treatment']]}, 'NCT02643381'), ({'text': 'Known CNS lymphoma', 'entities': [['11', '19', 'cancer']]}, 'NCT02419560'), ({'text': 'Presence of clinically apparent or suspected metastasis to sites other than lymph nodes or peritoneal surfaces', 'entities': [['46', '56', 'cancer']]}, 'NCT01815359'), ({'text': 'Subjects with any implanted device that cannot be verified as MRI compliant', 'entities': [['63', '66', 'treatment']]}, 'NCT02995590'), ({'text': 'Serum albumin >= 2.8 g/dL (within 1 week of study entry)', 'entities': [['1', '14', 'clinical_variable'], ['18', '26', 'lower_bound'], ['35', '41', 'upper_bound']]}, 'NCT01822522'), ({'text': 'subjects who are on immune suppressive agents', 'entities': [['21', '46', 'treatment']]}, 'NCT02726347'), ({'text': 'Positive sentinel lymph node biopsy (ie, demonstrating invasive adenocarcinoma)', 'entities': [['65', '79', 'cancer']]}, 'NCT02515110'), ({'text': 'with congenital heart disease that has been palliated with a Fontan circulation', 'entities': [['6', '30', 'chronic_disease']]}, 'NCT02946892'), ({'text': 'Known bleeding disorders', 'entities': [['7', '25', 'chronic_disease']]}, 'NCT02514083'), ({'text': 'Creatinine =< 1.5 x ULN', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'upper_bound']]}, 'NCT02020707'), ({'text': 'History of HIV infection or known positive serology', 'entities': [['12', '15', 'chronic_disease'], ['44', '52', 'treatment']]}, 'NCT00357565'), ({'text': 'Patients with known hypersensitivity to the components of study drug or its analogs', 'entities': [['59', '69', 'allergy_name']]}, 'NCT01554371'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'lower_bound'], ['70', '71', 'upper_bound']]}, 'NCT02549937'), ({'text': 'Outborn infants who received enteral nutrition at the other institution prior to surgical repair', 'entities': [['82', '97', 'treatment']]}, 'NCT02860702'), ({'text': 'diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and DSM-5 criteria', 'entities': [['16', '41', 'chronic_disease']]}, 'NCT03133013'), ({'text': 'Platelets (plts) > 90,000', 'entities': [['1', '17', 'clinical_variable'], ['20', '26', 'lower_bound']]}, 'NCT01802346'), ({'text': 'History of malignancy with confirmed activating RAS mutation at any time', 'entities': [['12', '22', 'cancer']]}, 'NCT02257424'), ({'text': 'Receipt of drugs with laxative properties and herbal or natural remedies for constipation within 90 days of receiving MEDI4736 or MEDI + tremelimumab', 'entities': [['23', '31', 'treatment'], ['98', '105', 'upper_bound'], ['119', '127', 'treatment'], ['131', '150', 'treatment']]}, 'NCT02592551'), ({'text': 'Prior pelvic radiation therapy that would preclude radiation therapy if anal cancer develops', 'entities': [['1', '31', 'treatment'], ['14', '31', 'treatment'], ['73', '84', 'cancer']]}, 'NCT02437851'), ({'text': 'Subjects with any chronic disease', 'entities': [['19', '34', 'chronic_disease']]}, 'NCT02425566'), ({'text': 'Phase 2 (expansion) subjects must have either MDS or relapsed/refractory AML', 'entities': [['47', '50', 'chronic_disease'], ['54', '77', 'cancer']]}, 'NCT02576301'), ({'text': 'overweight or obese (BMI between the 85th and 99.9thth (<99th) percentile for age and gender', 'entities': [['1', '11', 'chronic_disease'], ['15', '20', 'chronic_disease'], ['22', '25', 'bmi'], ['38', '42', 'lower_bound'], ['47', '55', 'upper_bound'], ['58', '62', 'upper_bound'], ['79', '82', 'age']]}, 'NCT02343367'), ({'text': 'The primary language of the subjects must be English', 'entities': [['46', '53', 'language_fluency']]}, 'NCT02374918'), ({'text': 'Acute severe UC in the previous 12 months', 'entities': [['14', '16', 'chronic_disease'], ['24', '42', 'upper_bound']]}, 'NCT02922881'), ({'text': 'Patient has not had prior treatment with blinatumomab', 'entities': [['21', '36', 'treatment'], ['42', '54', 'treatment']]}, 'NCT02101853'), ({'text': 'Subjects who have had prior radiation to the region of the chest that would result in overlap of radiation therapy fields and determined by the treating physician to impede the treatment of the study malignancy', 'entities': [['23', '38', 'treatment'], ['98', '115', 'treatment'], ['178', '187', 'treatment'], ['201', '211', 'cancer']]}, 'NCT03141359'), ({'text': 'Uncontrolled cardiac angina or symptomatic congestive cardiac failure (NYHA Class III or IV)', 'entities': [['22', '28', 'chronic_disease'], ['44', '70', 'chronic_disease'], ['72', '76', 'clinical_variable'], ['77', '86', 'lower_bound'], ['90', '92', 'upper_bound']]}, 'NCT02200445'), ({'text': 'Not eligible for cytotoxic therapies', 'entities': [['18', '37', 'treatment']]}, 'NCT02670044'), ({'text': 'Have any other concurrent malignancies, except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin', 'entities': [['27', '39', 'cancer'], ['67', '84', 'cancer'], ['102', '139', 'cancer']]}, 'NCT02534922'), ({'text': "Has substance abuse or medical, psychological, or social conditions that, in the opinion of the Investigator, may interfere with the subject's participation in the clinical study or evaluation of the clinical study results", 'entities': [['24', '31', 'chronic_disease'], ['33', '46', 'chronic_disease'], ['51', '68', 'chronic_disease']]}, 'NCT03110354'), ({'text': 'Received antileukemic therapy within the last 3 weeks (with the exception of hydroxyurea or if the patient has definite refractory disease). Refractory patients who received therapy within the last 3 weeks may be eligible with prior approval of the Medical Monitor', 'entities': [['10', '30', 'treatment'], ['23', '30', 'treatment'], ['42', '54', 'upper_bound'], ['78', '89', 'treatment']]}, 'NCT02520011'), ({'text': 'Weight less than 110 lbs', 'entities': [['1', '7', 'clinical_variable'], ['18', '25', 'upper_bound']]}, 'NCT02389465'), ({'text': 'Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg/dl', 'entities': [['1', '16', 'clinical_variable'], ['39', '48', 'upper_bound'], ['74', '92', 'chronic_disease'], ['109', '124', 'clinical_variable'], ['135', '144', 'upper_bound']]}, 'NCT01993719'), ({'text': 'Total (T.) bilirubin, albumin, prothrombin time, and serum creatinine tests can be done within 14 days of study enrollment (only if not performed in the last 14 days)', 'entities': [['1', '21', 'treatment'], ['23', '30', 'treatment'], ['32', '48', 'treatment'], ['54', '70', 'treatment'], ['96', '103', 'upper_bound'], ['154', '166', 'upper_bound']]}, 'NCT03040726'), ({'text': 'Current therapy with ACE inhibitor,or Intolerance to ARB', 'entities': [['1', '35', 'treatment'], ['54', '57', 'treatment']]}, 'NCT02416102'), ({'text': 'Any patient or tumor/anatomical factors that may prevent brachytherapy apparatus from being properly and safely inserted and positioned and from radiation therapy being administered per ABS guidelines', 'entities': [['16', '21', 'cancer'], ['58', '71', 'treatment'], ['146', '163', 'treatment']]}, 'NCT00924027'), ({'text': 'Pulmonary function test (PFTs), including diffusion capacity within 8 weeks of registration', 'entities': [['1', '31', 'clinical_variable'], ['69', '76', 'upper_bound']]}, 'NCT01871454'), ({'text': 'Use of potent CYP3A4 inhibitors, such as ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice', 'entities': [['42', '54', 'treatment'], ['56', '66', 'treatment'], ['68', '82', 'treatment'], ['84', '93', 'treatment'], ['95', '107', 'treatment'], ['109', '119', 'treatment'], ['121', '131', 'treatment'], ['133', '142', 'treatment'], ['144', '154', 'treatment'], ['156', '169', 'treatment'], ['171', '185', 'treatment'], ['187', '199', 'treatment'], ['205', '215', 'treatment'], ['219', '235', 'treatment']]}, 'NCT02273362'), ({'text': 'psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT02857218'), ({'text': 'History of hypersensitivity reactions to murine protein-containing products', 'entities': [['42', '56', 'allergy_name']]}, 'NCT01953900'), ({'text': 'Patients > 10 years old', 'entities': [['12', '20', 'lower_bound']]}, 'NCT02076906'), ({'text': 'Evidence of leukemia recurrence after a nadir bone marrow biopsy demonstrates no evidence of residual leukemia', 'entities': [['13', '21', 'cancer'], ['41', '65', 'treatment'], ['94', '111', 'cancer']]}, 'NCT02583893'), ({'text': 'Non-selective monoamine oxidase (MAO)', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT02615873'), ({'text': 'Ages 18-40', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '11', 'upper_bound']]}, 'NCT02595749'), ({'text': 'Any age', 'entities': [['5', '8', 'age']]}, 'NCT02580981'), ({'text': 'Aged less than 18 years', 'entities': [['1', '5', 'age'], ['16', '24', 'upper_bound']]}, 'NCT02187848'), ({'text': 'Female patients and donors must not be pregnant or breastfeeding at the time of signing consent', 'entities': [['1', '16', 'gender'], ['28', '48', 'pregnancy']]}, 'NCT02143830'), ({'text': 'Patients with renal insufficiency (serum Cr > 1.5) due to the danger of nephrogenic systemic sclerosis with the administration of Gadolinium', 'entities': [['15', '34', 'chronic_disease'], ['36', '44', 'clinical_variable'], ['47', '50', 'lower_bound'], ['73', '103', 'chronic_disease'], ['131', '141', 'treatment']]}, 'NCT00948285'), ({'text': 'Major surgery within 4 weeks of first dose of study drug', 'entities': [['1', '14', 'treatment'], ['22', '29', 'upper_bound'], ['47', '57', 'treatment']]}, 'NCT02553941'), ({'text': 'LA diameter > 6 cm as measured by computerized tomography and confirmed by the imaging core laboratory', 'entities': [['1', '12', 'clinical_variable'], ['15', '19', 'lower_bound'], ['35', '58', 'treatment']]}, 'NCT02513797'), ({'text': 'Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)', 'entities': [['39', '73', 'chronic_disease'], ['83', '124', 'chronic_disease']]}, 'NCT02553642'), ({'text': 'Receiving prophylaxis for alcohol or drug withdrawal', 'entities': [['11', '22', 'treatment']]}, 'NCT02646787'), ({'text': 'multiple sclerosis', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT03016351'), ({'text': 'Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC', 'entities': [['27', '139', 'cancer']]}, 'NCT02927301'), ({'text': "cognitive impairment or inability to consent to treatment, as determined by the patient's oncologist", 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02712229'), ({'text': 'Alarm symptoms according to ROME III', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02079857'), ({'text': 'Current (last 28 days) treatment with naltrexone, acamprosate, disulfiram, topiramate or as these may also decrease alcohol use', 'entities': [['10', '22', 'upper_bound'], ['24', '49', 'treatment'], ['51', '62', 'treatment'], ['64', '74', 'treatment'], ['76', '86', 'treatment']]}, 'NCT02582905'), ({'text': "At the time of the biopsy and injections, the subject's BP should notbe significantly below the previously recorded stable pressure", 'entities': [['20', '41', 'treatment']]}, 'NCT02836574'), ({'text': 'emphysema', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT02588326'), ({'text': 'Adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists', 'entities': [['61', '65', 'allergy_name'], ['67', '74', 'allergy_name'], ['78', '95', 'allergy_name']]}, 'NCT01910818'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT02250534'), ({'text': 'Currently receiving a therapy not permitted during the study', 'entities': [['23', '30', 'treatment']]}, 'NCT02053792'), ({'text': 'Participants with PTCL (arm C) transplanted beyond 1st remission are also not eligible', 'entities': [['19', '65', 'treatment']]}, 'NCT02362997'), ({'text': 'Positive hepatitis A, B antigen, or C or HIV test at screening', 'entities': [['10', '38', 'chronic_disease'], ['42', '45', 'chronic_disease']]}, 'NCT00713492'), ({'text': 'They must have histologically or cytologically confirmed BC, CRC, GEC, melanoma, NSCLC, or RCC with liver metastases or HCC', 'entities': [['58', '60', 'cancer'], ['62', '65', 'cancer'], ['67', '70', 'cancer'], ['72', '80', 'cancer'], ['82', '87', 'cancer'], ['92', '95', 'cancer'], ['101', '117', 'cancer'], ['121', '124', 'cancer']]}, 'NCT02509507'), ({'text': 'ADHD Diagnosis', 'entities': [['1', '5', 'chronic_disease']]}, 'NCT02266784'), ({'text': 'Subjects with anuria (defined as urine output < 10mls/hr over 24 hours)', 'entities': [['15', '21', 'chronic_disease'], ['34', '46', 'clinical_variable'], ['49', '57', 'upper_bound'], ['63', '71', 'lower_bound']]}, 'NCT02578901'), ({'text': 'Patients with a history of metastatic cancer who are not currently NED', 'entities': [['28', '45', 'cancer']]}, 'NCT02979574'), ({'text': 'DVT', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT02875301'), ({'text': 'Acute medical illnesses precluding participation in the studies', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02430077'), ({'text': 'Male subjects must agree to practice contraception', 'entities': [['1', '14', 'gender'], ['20', '51', 'contraception_consent']]}, 'NCT02293109'), ({'text': 'Patients with intact vestibular function in at least one ear (non-study ear) as measured by vestibular evoked myogenic potential (VEMP)', 'entities': [['54', '57', 'lower_bound'], ['93', '136', 'treatment']]}, 'NCT02132130'), ({'text': 'Concomitant meniscus tear or cartilage injury that occurred at the same time as the as the ACL tear and which is considered a pain generator by the treating physician at the time intake into the study (i.e. a meniscus tear or cartilage lesion associated with an active BML)', 'entities': [['270', '273', 'cancer']]}, 'NCT01850758'), ({'text': 'Persisting toxicity related to prior therapy of NCI CTCAE grade >1 severity', 'entities': [['32', '45', 'treatment'], ['49', '64', 'clinical_variable'], ['66', '67', 'lower_bound']]}, 'NCT03104699'), ({'text': 'No previously reported thoracic radiotherapy', 'entities': [['24', '45', 'treatment']]}, 'NCT01871454'), ({'text': 'No change in treatment plan with growth hormone (GH) from randomisation to the end of the open-label period patients on growth hormone to stay on, patients off GH to stay off during this period. Adjustments in doses of growth hormone will be permitted)', 'entities': [['14', '23', 'treatment']]}, 'NCT02527200'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01726257'), ({'text': 'chronic myelogenous leukemia', 'entities': [['1', '29', 'chronic_disease']]}, 'NCT01366612'), ({'text': 'Use of previous hormonal therapy for up to 9 months is allowed for the treatment of prostate cancer as well as for prostate volume reduction', 'entities': [['8', '33', 'treatment'], ['44', '52', 'upper_bound'], ['72', '81', 'treatment'], ['85', '100', 'cancer']]}, 'NCT02353819'), ({'text': 'If calculated creatinine clearance is < 45 mL/min, a 24-hour urine collection for creatinine clearance may be performed', 'entities': [['15', '35', 'clinical_variable'], ['41', '50', 'upper_bound']]}, 'NCT01618357'), ({'text': 'Intravitreal injections (including but not limited to anti-vascular endothelial growth factors 60 days prior to the baseline', 'entities': [['1', '24', 'treatment'], ['55', '95', 'treatment'], ['96', '109', 'upper_bound']]}, 'NCT01280669'), ({'text': 'Completion of chest x-ray or CT, and CT, MRI or ultrasound of abdomen within 60 days of registration; these imaging tests must not show evidence of metastatic or locally-recurrent colon cancer', 'entities': [['15', '26', 'treatment'], ['30', '32', 'treatment'], ['42', '45', 'treatment'], ['49', '70', 'treatment'], ['78', '85', 'upper_bound'], ['149', '159', 'cancer'], ['181', '193', 'cancer']]}, 'NCT00819208'), ({'text': "History of severe personality disorder, where, based on the judgment of the investigators, the personality disorder will interfere with the patient's ability to complete the follow-up protocol, e.g. borderline personality disorder", 'entities': [['19', '39', 'chronic_disease'], ['200', '231', 'chronic_disease']]}, 'NCT02046330'), ({'text': 'Moderate hepatic impairment (Group 1): Child-Pugh Class B (7-9 points)', 'entities': [['1', '28', 'chronic_disease'], ['40', '58', 'clinical_variable'], ['60', '61', 'lower_bound'], ['62', '70', 'upper_bound']]}, 'NCT03048448'), ({'text': 'moderate (IQ 40-49) IDD', 'entities': [['11', '13', 'clinical_variable'], ['14', '16', 'lower_bound'], ['17', '19', 'upper_bound']]}, 'NCT02561754'), ({'text': "Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol", 'entities': [['24', '43', 'cancer'], ['132', '141', 'treatment']]}, 'NCT02389517'), ({'text': 'Serum albumin e 3.0 g/dL (30 g/L)', 'entities': [['1', '14', 'clinical_variable'], ['17', '34', 'lower_bound']]}, 'NCT02472834'), ({'text': 'Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty', 'entities': [['58', '66', 'treatment'], ['75', '86', 'allergy_name'], ['88', '93', 'allergy_name'], ['98', '120', 'allergy_name']]}, 'NCT02204098'), ({'text': 'Uncontrolled hyperthyroidism', 'entities': [['14', '29', 'chronic_disease']]}, 'NCT02903446'), ({'text': 'Prior malignancy, except for adequately treated basal cell or squamous cell carcinoma of the skin, or thyroid cancer', 'entities': [['7', '17', 'cancer'], ['49', '59', 'cancer'], ['63', '98', 'cancer'], ['103', '117', 'cancer']]}, 'NCT02524275'), ({'text': 'Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb prior to the study procedure with Rutherford Category 5 or 6', 'entities': [['24', '60', 'chronic_disease'], ['114', '133', 'clinical_variable'], ['134', '135', 'lower_bound'], ['139', '140', 'upper_bound']]}, 'NCT02758847'), ({'text': 'Subjects with previously treated brain metastasis who are free of central nervous system (CNS) symptoms', 'entities': [['34', '50', 'cancer']]}, 'NCT02393794'), ({'text': 'Women more than 50 years must be post-menopausal for at least 12 months following the end of all exogenous hormonal treatments OR', 'entities': [['1', '6', 'gender'], ['17', '25', 'lower_bound'], ['63', '72', 'lower_bound'], ['98', '127', 'treatment']]}, 'NCT02503722'), ({'text': 'Absence of pancreatic fluid collection (defined as those > 3cm in size located along the course of the main PD on cross-sectional imaging) at the time of study enrollment', 'entities': [['60', '63', 'lower_bound']]}, 'NCT03115918'), ({'text': 'Unable to perform knee strength testing due to reasons such as bilateral knee replacements', 'entities': [['64', '91', 'treatment']]}, 'NCT01842399'), ({'text': 'Human Papillomavirus (HPV)+ disease of the oropharynx', 'entities': [['1', '28', 'chronic_disease'], ['29', '54', 'chronic_disease']]}, 'NCT02641093'), ({'text': 'Current or planned psychotherapy', 'entities': [['20', '33', 'treatment']]}, 'NCT02332291'), ({'text': 'if they are untreated but asymptomatic and have had previous PD-1 treatment', 'entities': [['53', '76', 'treatment']]}, 'NCT02910700'), ({'text': 'A clinical diagnosis of SCID-X1 documented in the medical record', 'entities': [['25', '32', 'chronic_disease']]}, 'NCT01512888'), ({'text': 'HIV-positive patients are excluded', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT01928576'), ({'text': 'Age 18-65', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT03116230'), ({'text': 'history of previous atrial arrhythmia of any type', 'entities': [['21', '38', 'chronic_disease']]}, 'NCT02875405'), ({'text': 'Patients may be eligible upon resolution of the infection', 'entities': [['49', '58', 'chronic_disease']]}, 'NCT02446236'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['1', '34', 'chronic_disease'], ['66', '75', 'chronic_disease'], ['77', '113', 'chronic_disease'], ['115', '139', 'chronic_disease'], ['141', '159', 'chronic_disease'], ['164', '201', 'chronic_disease']]}, 'NCT03075826'), ({'text': 'Autoimmune or inflammatory disorder of any kind', 'entities': [['1', '11', 'chronic_disease'], ['15', '36', 'chronic_disease']]}, 'NCT02513485'), ({'text': 'Known hypersensitivity to edotreotide or everolimus', 'entities': [['27', '38', 'allergy_name'], ['42', '52', 'allergy_name']]}, 'NCT03049189'), ({'text': 'alter gastric pH (e.g. proton pump inhibitors)', 'entities': [['7', '17', 'clinical_variable'], ['24', '46', 'treatment']]}, 'NCT01200940'), ({'text': 'Gleason grade of 3+4 or 3+3', 'entities': [['1', '14', 'clinical_variable'], ['18', '21', 'upper_bound'], ['25', '28', 'lower_bound']]}, 'NCT00737893'), ({'text': 'Adult (e 18 years)', 'entities': [['10', '18', 'lower_bound']]}, 'NCT02934555'), ({'text': 'Flucytosine within 2 weeks prior to start of study treatment', 'entities': [['1', '12', 'treatment'], ['20', '33', 'upper_bound'], ['46', '61', 'treatment']]}, 'NCT02192359'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02479230'), ({'text': 'vitiligo and autoimmune alopecia (Arm B only)', 'entities': [['1', '9', 'chronic_disease'], ['14', '33', 'chronic_disease']]}, 'NCT01703949'), ({'text': 'Intraperitoneal ports may be placed during or at any time separate from surgical debulking', 'entities': [['73', '91', 'treatment']]}, 'NCT01061515'), ({'text': 'Total bilirubin < 3 mg/dL', 'entities': [['1', '16', 'clinical_variable'], ['19', '26', 'upper_bound']]}, 'NCT02508038'), ({'text': 'aged 18-90 years', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '17', 'upper_bound']]}, 'NCT02053909'), ({'text': 'Extrahepatic metastases', 'entities': [['1', '24', 'cancer']]}, 'NCT02762266'), ({'text': 'Total bilirubin < 2X normal', 'entities': [['1', '16', 'clinical_variable'], ['19', '28', 'upper_bound']]}, 'NCT01364363'), ({'text': 'Children less than 36 months (3 years) of age at time of definitive surgery (for histopathologic diagnosis) with or without metastatic disease', 'entities': [['20', '39', 'upper_bound'], ['43', '46', 'age'], ['69', '76', 'treatment'], ['125', '143', 'cancer']]}, 'NCT01505569'), ({'text': 'Histologic confirmation of PN tumor is not necessary in the presence of consistent clinical and radiographic findings, but should be considered if malignant degeneration of a PN is clinically suspected', 'entities': [['28', '36', 'cancer']]}, 'NCT02390752'), ({'text': 'There will be no selection on the basis of age, race, or gender', 'entities': [['44', '47', 'age']]}, 'NCT02674984'), ({'text': 'A history of delayed epithelial healing', 'entities': [['22', '40', 'treatment']]}, 'NCT01789333'), ({'text': 'Measurable metastatic disease', 'entities': [['12', '30', 'chronic_disease']]}, 'NCT02466009'), ({'text': 'female participants are advised to not become pregnant during study participation', 'entities': [['1', '20', 'gender'], ['47', '55', 'pregnancy']]}, 'NCT02437851'), ({'text': 'Any contraindication to suture, endovascular device, or other minimally invasive techniques including percutaneous, transseptal, and/or sub-xiphoid access', 'entities': [['25', '31', 'treatment'], ['33', '52', 'treatment'], ['73', '92', 'treatment'], ['103', '115', 'treatment'], ['117', '128', 'treatment'], ['137', '155', 'treatment']]}, 'NCT02513797'), ({'text': 'Have had known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for CNS involvement for at least one week prior to trial treatment; patients with primary brain tumors are not eligible; however, as patients are completing abiraterone therapy, they will be allowed to continue up to 10 mg/day of prednisone', 'entities': [['23', '62', 'cancer'], ['70', '94', 'cancer'], ['129', '145', 'cancer'], ['223', '230', 'treatment'], ['244', '260', 'lower_bound'], ['282', '297', 'treatment'], ['427', '435', 'treatment'], ['469', '483', 'lower_bound'], ['518', '538', 'cancer'], ['593', '612', 'treatment'], ['653', '662', 'upper_bound'], ['666', '676', 'treatment']]}, 'NCT02516670'), ({'text': 'Age e18 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02816736'), ({'text': 'Patients must have normal baseline cardiac function based upon echocardiogram or gated blood pool scan (multigated acquisition scan [MUGA]) with an ejection fraction >= 50%', 'entities': [['64', '78', 'treatment'], ['82', '103', 'treatment'], ['105', '139', 'treatment'], ['149', '166', 'clinical_variable'], ['170', '173', 'lower_bound']]}, 'NCT01959698'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status =<2', 'entities': [['1', '61', 'clinical_variable'], ['64', '65', 'upper_bound']]}, 'NCT02542202'), ({'text': 'Unrevascularized left main coronary artery stenosis >50%', 'entities': [['1', '52', 'clinical_variable'], ['54', '57', 'lower_bound']]}, 'NCT02516332'), ({'text': 'the tumor must be non-gene amplified by fluorescence in situ hybridization (FISH) performed upon the primary tumor', 'entities': [['5', '10', 'cancer'], ['41', '82', 'treatment'], ['102', '115', 'cancer']]}, 'NCT02536794'), ({'text': 'Patients must be adequately recovered from surgery at the time of randomization', 'entities': [['44', '51', 'treatment']]}, 'NCT02201992'), ({'text': 'antithrombin III deficiency', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT02366871'), ({'text': 'Patients acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator)', 'entities': [['31', '36', 'cancer'], ['37', '43', 'treatment'], ['87', '96', 'treatment'], ['118', '126', 'treatment']]}, 'NCT02452008'), ({'text': 'who have not yet had his/her eighty-fifth birthday', 'entities': [['30', '42', 'upper_bound']]}, 'NCT01169155'), ({'text': 'Subject is seeking surgical intervention for symptomatic POP, which is defined as experiencing symptoms of vaginal bulging or pelvic heaviness', 'entities': [['20', '41', 'treatment'], ['46', '61', 'chronic_disease']]}, 'NCT02021279'), ({'text': 'Age < 18', 'entities': [['1', '4', 'age'], ['7', '9', 'upper_bound']]}, 'NCT02441140'), ({'text': 'No changes in antidepressant medication(s) in the past one (1) month', 'entities': [['15', '43', 'treatment'], ['51', '69', 'upper_bound']]}, 'NCT02165449'), ({'text': 'Acute brain injury or elevated intracranial pressure (> 18 mmHg)', 'entities': [['1', '19', 'clinical_variable'], ['23', '53', 'clinical_variable'], ['57', '64', 'lower_bound']]}, 'NCT01730794'), ({'text': 'Prior exposure to gonadotoxic therapy', 'entities': [['19', '38', 'treatment']]}, 'NCT01421095'), ({'text': 'Unilobar HCC', 'entities': [['10', '13', 'cancer']]}, 'NCT02013778'), ({'text': 'Has a known hypersensitivity to bezlotoxumab', 'entities': [['33', '45', 'allergy_name']]}, 'NCT03182907'), ({'text': 'Contraindication for estrogen cream', 'entities': [['22', '36', 'allergy_name']]}, 'NCT01886794'), ({'text': 'confirmed sarcoma of the soft tissue or bone', 'entities': [['11', '18', 'cancer']]}, 'NCT01763970'), ({'text': "Medications that may alter oxycodone metabolism: St. John's wort, Dilantin, tegretol, corticosteroids, rifampin", 'entities': [['50', '65', 'treatment'], ['67', '75', 'treatment'], ['77', '85', 'treatment'], ['87', '102', 'treatment'], ['104', '112', 'treatment']]}, 'NCT02945293'), ({'text': 'diagnosis of breast cancer (initial or recurrence) within the last two years', 'entities': [['14', '27', 'cancer'], ['63', '77', 'upper_bound']]}, 'NCT02791646'), ({'text': 'participants with brain metastases previously treated with whole brain radiation or radiosurgery or participants with epidural disease previously treated with radiation or surgery who are asymptomatic and do not require steroid treatment for at least 4 weeks before starting study treatment are eligible', 'entities': [['19', '35', 'cancer'], ['60', '97', 'treatment'], ['72', '81', 'treatment'], ['90', '97', 'treatment'], ['119', '135', 'cancer'], ['221', '238', 'treatment'], ['252', '259', 'lower_bound'], ['276', '291', 'treatment']]}, 'NCT01822522'), ({'text': 'Glioblastoma or gliosarcoma disease with leptomeningeal spread', 'entities': [['1', '13', 'cancer'], ['17', '28', 'cancer'], ['42', '54', 'cancer']]}, 'NCT02340156'), ({'text': 'Presence of active 2nd malignancy requiring treatment', 'entities': [['24', '34', 'cancer'], ['45', '54', 'treatment']]}, 'NCT01059786'), ({'text': 'At least 12 month life expectancy', 'entities': [['10', '18', 'upper_bound'], ['19', '34', 'clinical_variable']]}, 'NCT01890590'), ({'text': 'Creatinine < (1.5 mg/dL) during screening evaluation (> 1.5 is allowed if epidermal growth factor receptor [EGFR] > 45 mL/min/1.73 m^2)', 'entities': [['1', '11', 'clinical_variable'], ['15', '18', 'lower_bound'], ['15', '24', 'upper_bound'], ['75', '114', 'clinical_variable'], ['117', '135', 'lower_bound']]}, 'NCT02881242'), ({'text': '50 - 75 years of age', 'entities': [['1', '3', 'lower_bound'], ['6', '14', 'upper_bound'], ['18', '21', 'age']]}, 'NCT02924194'), ({'text': 'Diagnosis of asthma requiring use of inhaled beta agonist >1 time per week', 'entities': [['14', '20', 'chronic_disease'], ['38', '58', 'treatment'], ['60', '75', 'lower_bound']]}, 'NCT02362308'), ({'text': 'Use of targeted therapy within two half-lives of registration', 'entities': [['8', '24', 'treatment'], ['32', '46', 'upper_bound']]}, 'NCT02048722'), ({'text': 'inflammatory arthritis', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT01754298'), ({'text': 'Patients with known acute hepatitis', 'entities': [['21', '36', 'chronic_disease']]}, 'NCT02672098'), ({'text': 'the patient must be recovered from the acute toxic effects of the treatment prior to start of study treatment', 'entities': [['67', '76', 'treatment'], ['95', '110', 'treatment']]}, 'NCT02112565'), ({'text': 'AML, ALL: Normal values for absolute neutrophil count (>1000/microL) and platelet count (>100,000/microL); Absence of extramedullary leukemia; Less than 5 percent blast cells present in the bone marrow', 'entities': [['1', '4', 'cancer'], ['6', '9', 'cancer'], ['29', '54', 'clinical_variable'], ['57', '68', 'lower_bound'], ['74', '88', 'clinical_variable'], ['91', '105', 'lower_bound'], ['134', '142', 'cancer'], ['154', '175', 'upper_bound']]}, 'NCT01795573'), ({'text': 'Untreated or symptomatic brain metastases requiring corticosteroid therapy (no corticosteroid use for this purpose in the preceding 4 weeks)', 'entities': [['26', '42', 'cancer'], ['53', '67', 'treatment'], ['53', '75', 'treatment'], ['133', '140', 'upper_bound']]}, 'NCT02451553'), ({'text': 'Hypernatremia as determined by serum sodium level > 150 meq/L', 'entities': [['32', '50', 'clinical_variable'], ['53', '62', 'lower_bound']]}, 'NCT02129348'), ({'text': 'Subjects that have had a myocardial infarction within the last 6 months', 'entities': [['26', '47', 'chronic_disease'], ['59', '72', 'upper_bound']]}, 'NCT02281409'), ({'text': 'Intention to change to peritoneal dialysis, or home HD in the next 6 months', 'entities': [['24', '43', 'treatment'], ['63', '76', 'upper_bound']]}, 'NCT02593526'), ({'text': 'Used any systemic steroids, immunosuppressant medications and anti-neoplastic treatment in the past 14 days', 'entities': [['10', '27', 'treatment'], ['29', '58', 'treatment'], ['63', '88', 'treatment'], ['96', '108', 'upper_bound']]}, 'NCT03153410'), ({'text': 'history of malignancy within 5 years prior to study entry', 'entities': [['12', '22', 'cancer'], ['30', '43', 'upper_bound']]}, 'NCT03006770'), ({'text': 'Infant with one or more superficial hemangiomas in the preproliferative phase or very early proliferative growth phase', 'entities': [['37', '48', 'cancer']]}, 'NCT01873131'), ({'text': 'Not sufficiently overweight or obese, BMI < 27 kg/m2', 'entities': [['32', '37', 'chronic_disease'], ['39', '42', 'bmi'], ['45', '53', 'upper_bound']]}, 'NCT02577549'), ({'text': 'Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device, such as a condom, diaphragm, or cervical/vault cap), for 16 weeks after the last dose of study drug', 'entities': [['1', '6', 'gender'], ['41', '46', 'gender'], ['102', '138', 'contraception_consent'], ['140', '150', 'contraception_consent'], ['152', '177', 'contraception_consent'], ['179', '197', 'contraception_consent'], ['201', '222', 'contraception_consent'], ['234', '240', 'contraception_consent'], ['242', '251', 'contraception_consent'], ['256', '274', 'contraception_consent'], ['281', '295', 'upper_bound'], ['313', '323', 'treatment']]}, 'NCT02392572'), ({'text': 'Subjects with active, known or suspected autoimmune disease', 'entities': [['42', '60', 'chronic_disease']]}, 'NCT02519322'), ({'text': 'At least one site of measurable disease by RECIST 1.1', 'entities': [['10', '13', 'lower_bound']]}, 'NCT02439450'), ({'text': 'either serum iron <50mcg/dl (regardless of phosphate or intact FGF23 concentration)', 'entities': [['8', '18', 'clinical_variable'], ['20', '28', 'upper_bound']]}, 'NCT02233322'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03101956'), ({'text': 'Ca <10.5 mg/dl', 'entities': [['1', '3', 'clinical_variable'], ['5', '15', 'upper_bound']]}, 'NCT01572480'), ({'text': 'Age e18 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02452008'), ({'text': 'cannot lie comfortably on their back for up to one hour', 'entities': [['48', '56', 'upper_bound']]}, 'NCT01581580'), ({'text': 'Scheduled for closed reduction with percutaneous pinning under general anesthesia', 'entities': [['64', '82', 'treatment']]}, 'NCT02056288'), ({'text': 'Irregular sleep-wake rhythms (based on the actigraphy recordings)', 'entities': [['1', '29', 'chronic_disease']]}, 'NCT03053908'), ({'text': 'aged 3 months to < 18 years', 'entities': [['1', '5', 'age'], ['6', '14', 'lower_bound'], ['20', '28', 'upper_bound']]}, 'NCT02016924'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status < 2', 'entities': [['1', '61', 'clinical_variable'], ['64', '65', 'upper_bound']]}, 'NCT02535325'), ({'text': 'Hypotension (office BP < 110/70 mm Hg)', 'entities': [['1', '12', 'chronic_disease'], ['21', '23', 'clinical_variable'], ['26', '38', 'upper_bound']]}, 'NCT02497300'), ({'text': 'Significant acute illness within the two weeks prior to dosing', 'entities': [['13', '26', 'chronic_disease'], ['38', '53', 'upper_bound']]}, 'NCT02852239'), ({'text': "Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures", 'entities': [['51', '71', 'chronic_disease']]}, 'NCT02124772'), ({'text': 'Patients currently receiving cancer therapy', 'entities': [['30', '44', 'treatment']]}, 'NCT01625234'), ({'text': 'Prior autologous stem cell transplantation < 1 month, or allogeneic stem cell transplantation < 3 months prior to C1D1', 'entities': [['1', '43', 'treatment'], ['46', '53', 'upper_bound'], ['58', '94', 'treatment'], ['97', '111', 'upper_bound']]}, 'NCT02343042'), ({'text': 'measured creatinine clearance <40 mL/min', 'entities': [['10', '30', 'clinical_variable'], ['32', '41', 'upper_bound']]}, 'NCT02508467'), ({'text': 'Leukocytes >= 3,000/mcL', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'lower_bound']]}, 'NCT02589522'), ({'text': 'Patients with 1-3 brain metastases, each < 3 cm by contrast MRI, with stable systemic disease and ECOG score of 0-2, who would otherwise be eligible for SRS/stereotactic radiation therapy (SRT) alone should not be enrolled into this study unless WBRT is recommended due to any medical reasons or logistic limitations as determined by the treating physician', 'entities': [['15', '16', 'lower_bound'], ['17', '18', 'upper_bound'], ['44', '48', 'upper_bound'], ['61', '64', 'treatment'], ['71', '94', 'chronic_disease'], ['99', '109', 'clinical_variable'], ['113', '114', 'lower_bound'], ['115', '116', 'upper_bound'], ['154', '194', 'treatment'], ['247', '251', 'treatment']]}, 'NCT02589522'), ({'text': 'Biologic (anti-neoplastic agent): 7 day must have elapsed from the start of protocol therapy since the completion of therapy with a biologic agent', 'entities': [['1', '33', 'treatment'], ['77', '93', 'treatment'], ['118', '147', 'treatment']]}, 'NCT02945800'), ({'text': 'Child-Pugh score A within 14 days prior to study entry', 'entities': [['1', '17', 'clinical_variable'], ['27', '40', 'upper_bound']]}, 'NCT01730937'), ({'text': 'Uncontrolled hypertension', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT01620216'), ({'text': 'aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration', 'entities': [['1', '8', 'treatment'], ['36', '48', 'upper_bound'], ['70', '80', 'treatment']]}, 'NCT02520778'), ({'text': 'alanine aminotransferase (ALT) >3 x the upper limit of normal (ULN)', 'entities': [['1', '31', 'clinical_variable'], ['33', '68', 'lower_bound']]}, 'NCT02561988'), ({'text': 'Active or clinically significant cardiac disease including: Congestive heart failure-New York Heart Association (NYHA) > class II, Active coronary artery disease, Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, Unstable angina (anginal symptoms at rest), new onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization', 'entities': [['61', '85', 'chronic_disease'], ['86', '119', 'clinical_variable'], ['122', '130', 'lower_bound'], ['139', '162', 'chronic_disease'], ['172', '183', 'chronic_disease'], ['194', '217', 'treatment'], ['229', '242', 'treatment'], ['246', '253', 'treatment'], ['255', '270', 'chronic_disease'], ['264', '270', 'chronic_disease'], ['323', '331', 'upper_bound'], ['357', '378', 'chronic_disease'], ['386', '394', 'upper_bound']]}, 'NCT02048371'), ({'text': 'Platelets >= 100,000/mcL', 'entities': [['1', '10', 'clinical_variable'], ['14', '25', 'lower_bound']]}, 'NCT02535325'), ({'text': 'depression or psychosis', 'entities': [['1', '11', 'chronic_disease'], ['15', '24', 'chronic_disease']]}, 'NCT03007745'), ({'text': 'One of the following VT events while not being treated with amiodarone, sotalol, or another class I or class III antiarrhythmic drug) within the last 6 months', 'entities': [['22', '24', 'chronic_disease'], ['61', '71', 'treatment'], ['73', '80', 'treatment'], ['93', '133', 'treatment'], ['146', '159', 'upper_bound']]}, 'NCT02830360'), ({'text': 'Life expectancy > 4 weeks', 'entities': [['1', '16', 'clinical_variable'], ['19', '26', 'lower_bound']]}, 'NCT02208362'), ({'text': 'Patients with high risk AML in CR1 or after first relapse or with primary refractory disease or minimal residual disease', 'entities': [['25', '28', 'cancer'], ['105', '121', 'chronic_disease']]}, 'NCT00368355'), ({'text': 'Urothelial transitional cell cancer, triple negative breast cancer, ovarian cancer or non small cell lunch cancer that are candidates for a cisplatin-based combination', 'entities': [['12', '36', 'cancer'], ['38', '67', 'cancer'], ['69', '83', 'cancer'], ['87', '114', 'cancer'], ['141', '168', 'treatment']]}, 'NCT01920061'), ({'text': 'severe anemia with hgb level <8 g/dL', 'entities': [['8', '14', 'chronic_disease'], ['20', '29', 'clinical_variable'], ['31', '37', 'upper_bound']]}, 'NCT01947673'), ({'text': 'Use of an investigational drug within 30 days of randomization, or within 5 half-lives of the investigational drug (the longer period will apply)', 'entities': [['11', '29', 'treatment'], ['11', '31', 'treatment'], ['39', '46', 'upper_bound'], ['75', '87', 'upper_bound']]}, 'NCT02946892'), ({'text': 'Impaired hepatic function', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT02845336'), ({'text': 'patients using hormonal contraceptives as one of the methods, the contraceptive should be stabilized for at least 3 months prior to screening', 'entities': [['10', '39', 'contraception_consent'], ['115', '129', 'lower_bound']]}, 'NCT02560766'), ({'text': 'Total bilirubin level d 1.5 x institutional upper limit of normal (ULN)', 'entities': [['1', '22', 'clinical_variable'], ['25', '72', 'upper_bound']]}, 'NCT02346526'), ({'text': 'Loss or lack of benefit from appropriate CI without the possibility for revision or contralateral implantation', 'entities': [['73', '111', 'treatment']]}, 'NCT02310399'), ({'text': 'Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as e 10 mm with CT scan, as e 20 mm by chest x-ray, or e 10 mm with calipers by clinical exam per RECIST 1.1', 'entities': [['136', '141', 'lower_bound'], ['147', '154', 'treatment'], ['161', '166', 'lower_bound'], ['170', '181', 'treatment'], ['199', '207', 'treatment']]}, 'NCT02369458'), ({'text': 'If the CrCl based on the CKD-EPI formula is <40 mL/min, the patient will have a 24 hr urine collection to measure CrCl', 'entities': [['8', '12', 'clinical_variable'], ['46', '55', 'upper_bound'], ['81', '86', 'upper_bound']]}, 'NCT02538198'), ({'text': 'Patients with documented allergy to egg products', 'entities': [['37', '49', 'allergy_name']]}, 'NCT02495415'), ({'text': 'Patients requiring therapeutic anticoagulation (e.g. warfarin, low-molecular weight heparin, or other anticoagulant) or with history of any bleeding diathesis. Aspirin or low-dose warfarin for catheter maintenance is allowed', 'entities': [['20', '47', 'treatment'], ['54', '62', 'treatment'], ['85', '92', 'treatment'], ['103', '116', 'treatment'], ['141', '159', 'chronic_disease'], ['161', '168', 'treatment']]}, 'NCT02582827'), ({'text': 'Patients older than age 18 with ischemic symptoms (stable or unstable angina or NSTEMI without thrombosis of the target lesion on coronary angiography) or evidence of myocardial ischemia in the presence of e 50% de novo stenosis located in native coronary vessels (max. 2 lesions in one or 2 separate vessels)', 'entities': [['21', '24', 'age'], ['25', '27', 'lower_bound'], ['52', '58', 'chronic_disease'], ['62', '77', 'chronic_disease'], ['81', '87', 'chronic_disease'], ['96', '106', 'chronic_disease'], ['131', '151', 'treatment'], ['168', '187', 'chronic_disease'], ['209', '212', 'lower_bound'], ['271', '280', 'upper_bound'], ['291', '309', 'upper_bound']]}, 'NCT02594501'), ({'text': 'History of malignancy', 'entities': [['12', '22', 'cancer']]}, 'NCT02920710'), ({'text': 'Prior treatment with any investigational drug within the preceding 2 weeks', 'entities': [['1', '16', 'treatment'], ['26', '46', 'treatment'], ['58', '75', 'upper_bound']]}, 'NCT02531932'), ({'text': 'cryosurgery, cryotherapy or cryoablation', 'entities': [['1', '12', 'treatment'], ['14', '25', 'treatment'], ['29', '41', 'treatment']]}, 'NCT02225548'), ({'text': 'Patients with known bone marrow metastatic disease will be eligible for study if they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions)', 'entities': [['21', '51', 'cancer'], ['122', '134', 'treatment'], ['195', '216', 'treatment']]}, 'NCT02323880'), ({'text': 'spinal block, are unsafe to undergo BBBD chemotherapy and are not eligible', 'entities': [['1', '13', 'treatment'], ['37', '54', 'treatment']]}, 'NCT00293475'), ({'text': 'With clinically significant atrial and/or ventricular arrhythmias, including but not limited to: atrial fibrillation, ventricular tachycardia, second- or third-degree heart block or have a history of ischemic heart disease and/or chest pain', 'entities': [['29', '38', 'chronic_disease'], ['43', '66', 'chronic_disease'], ['98', '117', 'chronic_disease'], ['119', '142', 'chronic_disease'], ['144', '179', 'chronic_disease'], ['231', '241', 'chronic_disease']]}, 'NCT01967823'), ({'text': 'Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['47', '82', 'contraception_consent'], ['84', '127', 'contraception_consent'], ['131', '141', 'contraception_consent'], ['172', '182', 'upper_bound']]}, 'NCT02342782'), ({'text': 'Presence of T3 or T4 disease', 'entities': [['13', '15', 'cancer'], ['19', '29', 'cancer']]}, 'NCT02159703'), ({'text': 'Significant alcohol withdrawal (CIWA-Ar score greater than 7. Patients presenting at screening in withdrawal may be referred for detoxification and reassessed within 30 days)', 'entities': [['33', '46', 'clinical_variable'], ['60', '61', 'lower_bound'], ['167', '174', 'upper_bound']]}, 'NCT02061293'), ({'text': 'Speak English', 'entities': [['1', '14', 'language_fluency']]}, 'NCT01970293'), ({'text': 'with a prenatal diagnosis of HLHS', 'entities': [['30', '34', 'chronic_disease']]}, 'NCT01856049'), ({'text': 'Inability to have an MRI scan or lumbar puncture', 'entities': [['22', '30', 'treatment'], ['34', '49', 'treatment']]}, 'NCT02254863'), ({'text': 'Subjects with primary CNS tumors are eligible', 'entities': [['23', '33', 'cancer']]}, 'NCT02576431'), ({'text': 'Presence of e CTCAE grade 2 toxicity (except alopecia of any grade) due to prior cancer therapy, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.03)', 'entities': [['15', '20', 'clinical_variable'], ['21', '28', 'lower_bound'], ['46', '54', 'chronic_disease'], ['76', '96', 'treatment']]}, 'NCT02979366'), ({'text': 'AST and alanine aminotransferase < 2.5 times the upper limit of normal', 'entities': [['1', '33', 'clinical_variable'], ['36', '71', 'upper_bound']]}, 'NCT01913106'), ({'text': 'Implant or prosthesis or scar tissue within the path of the HIFU beam', 'entities': [['1', '8', 'treatment'], ['12', '22', 'treatment'], ['61', '70', 'treatment']]}, 'NCT02076906'), ({'text': 'significant pulmonary embolus within 6 months of enrollment', 'entities': [['13', '30', 'chronic_disease'], ['38', '46', 'upper_bound']]}, 'NCT02169037'), ({'text': 'fibrillary astrocytomas (FA)', 'entities': [['1', '29', 'cancer']]}, 'NCT01884740'), ({'text': 'Documented disease progression (either radiographic or biochemical) on at least 1 novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate prostate cancer or nonmetastatic (M0) CRPC', 'entities': [['40', '52', 'treatment'], ['56', '67', 'treatment'], ['81', '82', 'lower_bound'], ['83', '105', 'treatment'], ['107', '119', 'treatment'], ['127', '146', 'treatment'], ['147', '157', 'treatment'], ['167', '176', 'treatment'], ['180', '195', 'cancer'], ['213', '232', 'treatment'], ['241', '265', 'cancer'], ['269', '292', 'cancer']]}, 'NCT03148795'), ({'text': 'Major ABO incompatibility', 'entities': [['7', '26', 'chronic_disease']]}, 'NCT01804634'), ({'text': 'Confirmed diagnosis of breast cancer (not metastatic)', 'entities': [['24', '37', 'cancer']]}, 'NCT02637349'), ({'text': 'Age e18 years of age', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound'], ['18', '21', 'age']]}, 'NCT01903330'), ({'text': 'IS withdrawal resumes no later than 14 days after darTregs infusion', 'entities': [['37', '50', 'upper_bound'], ['51', '68', 'treatment']]}, 'NCT02474199'), ({'text': 'Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or medical (e.g. infectious) illness', 'entities': [['86', '95', 'treatment'], ['108', '119', 'chronic_disease']]}, 'NCT01804465'), ({'text': 'Subcutaneous panniculitis-like T-cell lymphoma', 'entities': [['1', '47', 'cancer']]}, 'NCT02232516'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, active infection, poorly controlled hypertension, diabetes mellitus or other serious medical or psychiatric conditions that could interfere with adherence to or completion of this study', 'entities': [['66', '82', 'chronic_disease'], ['102', '114', 'chronic_disease'], ['116', '133', 'chronic_disease'], ['162', '184', 'chronic_disease']]}, 'NCT01959698'), ({'text': 'Any prior treatment with either a MEK, RAS, or RAF inhibitor for advanced or metastatic NSCLC', 'entities': [['5', '61', 'treatment'], ['66', '74', 'cancer'], ['78', '94', 'cancer']]}, 'NCT02503358'), ({'text': 'active second malignancy unless non-melanoma skin cancer or cervical cancer in situ', 'entities': [['1', '25', 'cancer'], ['33', '57', 'cancer'], ['61', '84', 'cancer']]}, 'NCT01743950'), ({'text': 'Participants must have histologically confirmed diagnosis of a solid tumor for which no curative therapy exists', 'entities': [['64', '75', 'cancer'], ['89', '105', 'treatment']]}, 'NCT01434316'), ({'text': 'Prior dose-intense therapy within 56 days of initiating treatment in this study', 'entities': [['7', '27', 'treatment'], ['35', '42', 'upper_bound'], ['57', '66', 'treatment']]}, 'NCT01453088'), ({'text': 'Visual acuity d20/100 in the worst eye', 'entities': [['1', '14', 'clinical_variable'], ['16', '22', 'upper_bound']]}, 'NCT01367444'), ({'text': 'Moderate to Severe Traumatic Brain Injury (M-STBI) (blast and blunt)', 'entities': [['1', '51', 'chronic_disease']]}, 'NCT02310633'), ({'text': 'hiatal hernia repair with posterior cruroplasty', 'entities': [['1', '48', 'treatment']]}, 'NCT02969187'), ({'text': '8-13.99 years for Phase 2', 'entities': [['1', '2', 'lower_bound'], ['3', '14', 'upper_bound']]}, 'NCT01757418'), ({'text': 'Acute Lymphoblastic Leukemia in high risk CR1', 'entities': [['1', '29', 'cancer']]}, 'NCT02167958'), ({'text': 'Healthy, as determined by health history questionnaire, blood chemistries, 12-lead ECG', 'entities': [['84', '87', 'clinical_variable']]}, 'NCT01983462'), ({'text': 'history of epilepsy (in self or first degree relatives)', 'entities': [['12', '20', 'chronic_disease']]}, 'NCT03038269'), ({'text': "If a male patient's sexual partner is of childbearing potential, the male patient must acknowledge that they will consistently use an acceptable method of contraception (defined above) from baseline through Day 28", 'entities': [['6', '18', 'gender'], ['6', '10', 'gender'], ['128', '169', 'contraception_consent']]}, 'NCT02469857'), ({'text': 'Weight > 300 pounds', 'entities': [['1', '7', 'clinical_variable'], ['10', '20', 'lower_bound']]}, 'NCT02819440'), ({'text': 'hydrocephalus', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02122328'), ({'text': 'At least 4 weeks since receiving any investigational drug', 'entities': [['10', '17', 'lower_bound'], ['38', '58', 'treatment']]}, 'NCT02101736'), ({'text': 'Patients with a history of or current gastric ulcers', 'entities': [['39', '53', 'chronic_disease']]}, 'NCT02245841'), ({'text': 'Recent (<3 months) infrainguinal revascularization (surgery or endovascular revascularization) or revascularization planned during study period', 'entities': [['10', '18', 'upper_bound'], ['20', '51', 'treatment'], ['34', '51', 'treatment'], ['53', '94', 'treatment']]}, 'NCT02770547'), ({'text': 'healthy individuals with no history of stroke or neural injury', 'entities': [['40', '46', 'chronic_disease']]}, 'NCT02570256'), ({'text': 'Known intolerance of niacin or ascorbic acid (including known G6PD deficiency)', 'entities': [['22', '28', 'treatment'], ['32', '45', 'treatment'], ['63', '78', 'chronic_disease']]}, 'NCT02195232'), ({'text': 'There is no limit to the number of prior chemotherapy regimens received', 'entities': [['36', '54', 'treatment']]}, 'NCT02311361'), ({'text': 'A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice)', 'entities': [['16', '21', 'gender'], ['76', '90', 'treatment']]}, 'NCT02536794'), ({'text': 'abnormal reticular skin hyperpigmentation', 'entities': [['10', '42', 'chronic_disease']]}, 'NCT02162420'), ({'text': 'Subject has had previous exposure to Orencia (abatacept)', 'entities': [['38', '45', 'treatment']]}, 'NCT03059888'), ({'text': 'Patients with promyelocytic leukemia (French-American-British [FAB] M3)', 'entities': [['15', '37', 'cancer']]}, 'NCT02521493'), ({'text': "Head CT with contrast is allowed in place of MRI at baseline and throughout the study if MRI is contraindicated and a participant's CNS lesions are clearly measurable on the head CT", 'entities': [['1', '8', 'treatment'], ['46', '49', 'treatment'], ['133', '144', 'chronic_disease'], ['175', '182', 'treatment']]}, 'NCT01494662'), ({'text': 'Isolated ventriculomegaly (atrium 10-19 mm) may or may not be used', 'entities': [['10', '26', 'chronic_disease'], ['28', '34', 'clinical_variable'], ['35', '37', 'lower_bound'], ['38', '43', 'upper_bound']]}, 'NCT02122328'), ({'text': 'Aspartylglucosaminuria', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02171104'), ({'text': 'Pregnant women are excluded from this study because navitoclax, dabrafenib, and trametinib may have teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drugs, breastfeeding should be discontinued if the mother is treated with the study drugs', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender'], ['53', '63', 'treatment'], ['65', '75', 'treatment'], ['81', '91', 'treatment'], ['237', '246', 'treatment'], ['270', '281', 'treatment']]}, 'NCT01989585'), ({'text': 'cortisol level >18 ug/dL at 30 minutes post stimulation', 'entities': [['1', '15', 'clinical_variable'], ['17', '25', 'lower_bound']]}, 'NCT02527421'), ({'text': 'Bradycardia of less than 40 beats/min', 'entities': [['1', '12', 'clinical_variable'], ['26', '38', 'upper_bound']]}, 'NCT03111121'), ({'text': 'Clinical staged III or IV HNSCC that is not amenable to surgical resection', 'entities': [['1', '16', 'clinical_variable'], ['17', '20', 'lower_bound'], ['24', '26', 'upper_bound'], ['27', '32', 'cancer'], ['57', '75', 'treatment']]}, 'NCT02567422'), ({'text': 'biventricular pacing', 'entities': [['1', '21', 'treatment']]}, 'NCT02816736'), ({'text': 'Unable or unwilling discontinue current behavioral therapy', 'entities': [['41', '59', 'treatment']]}, 'NCT02483468'), ({'text': 'Left Ventricular Shortening Fraction (LVSF) > 28% confirmed by echocardiogram', 'entities': [['1', '44', 'clinical_variable'], ['47', '50', 'lower_bound']]}, 'NCT02624258'), ({'text': 'Intraocular pressure e25 mmHg in the study eye (glaucoma patients maintained on no more than 2 topical medications with IOP <25 mmHg are allowed to participate)', 'entities': [['1', '21', 'clinical_variable'], ['23', '24', 'lower_bound'], ['49', '57', 'chronic_disease'], ['96', '115', 'treatment'], ['121', '124', 'clinical_variable']]}, 'NCT01280669'), ({'text': 'Newly diagnosed MCL: Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty', 'entities': [['17', '20', 'cancer'], ['90', '97', 'treatment']]}, 'NCT01880567'), ({'text': 'Low (d25) or High BMI (e35)', 'entities': [['7', '9', 'upper_bound'], ['19', '22', 'bmi'], ['25', '27', 'lower_bound']]}, 'NCT03160547'), ({'text': 'Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment and/or were cleared by MSK cardiology', 'entities': [['28', '51', 'chronic_disease'], ['113', '120', 'upper_bound']]}, 'NCT01815359'), ({'text': 'Patients with clinically incomplete KD', 'entities': [['26', '39', 'chronic_disease']]}, 'NCT01917721'), ({'text': 'Subject with active peptic ulceration', 'entities': [['21', '38', 'chronic_disease']]}, 'NCT02225548'), ({'text': 'high serum levels of vascular endothelial growth factor D (VGEF-D)(1)', 'entities': [['22', '67', 'treatment']]}, 'NCT01799538'), ({'text': 'Chemotherapeutic Agent', 'entities': [['1', '23', 'treatment']]}, 'NCT02310464'), ({'text': 'Scheduled to undergo surgery at IU Health North Hospital that will results in a temporary or permanent colostomy or ileostomy for a benign or malignant disease process', 'entities': [['22', '29', 'treatment'], ['104', '113', 'treatment'], ['117', '126', 'treatment'], ['133', '160', 'cancer']]}, 'NCT02036268'), ({'text': 'Premature infants and neonates < 37 weeks corrected gestational age', 'entities': [['34', '42', 'upper_bound'], ['65', '68', 'age']]}, 'NCT01937884'), ({'text': 'History of chronic obstructive pulmonary disease (COPD)', 'entities': [['12', '56', 'chronic_disease']]}, 'NCT01983462'), ({'text': 'estimated glomerular filtration rate (eGFR) < 30', 'entities': [['1', '44', 'clinical_variable'], ['47', '49', 'upper_bound']]}, 'NCT02519543'), ({'text': 'less than or equal to 40 years of age', 'entities': [['23', '31', 'upper_bound'], ['35', '38', 'age']]}, 'NCT01763970'), ({'text': 'Confirmed chart diagnosis of a HIV and receiving HIV treatment at the participating HIV clinic', 'entities': [['32', '35', 'chronic_disease'], ['50', '63', 'treatment']]}, 'NCT02460900'), ({'text': 'received an investigational drug or used an experimental medical device within 30 days prior to screening, or who gave a blood donation of e one pint within 8 weeks prior to screening', 'entities': [['13', '33', 'treatment'], ['80', '93', 'upper_bound'], ['142', '145', 'lower_bound'], ['158', '171', 'upper_bound']]}, 'NCT02502006'), ({'text': 'Female 18-35 years of age, inclusive', 'entities': [['1', '7', 'gender'], ['8', '10', 'lower_bound'], ['11', '19', 'upper_bound'], ['23', '26', 'age']]}, 'NCT03081390'), ({'text': 'AST (SGOT) and ALT (SGPT) d 2.5 x ULN', 'entities': [['1', '11', 'clinical_variable'], ['16', '26', 'clinical_variable'], ['29', '38', 'upper_bound']]}, 'NCT02807272'), ({'text': 'Transfusion of at least 4 units of blood and/or four doses of intravenous iron over the preceding four months', 'entities': [['1', '12', 'treatment'], ['25', '41', 'lower_bound'], ['63', '79', 'treatment'], ['89', '110', 'lower_bound']]}, 'NCT02287558'), ({'text': 'Patients may have received prior surgery provided that at least 28 days have elapsed since major surgery (thoracic or other major surgeries) and the patient has recovered from all associated toxicities', 'entities': [['28', '41', 'treatment'], ['65', '72', 'lower_bound'], ['92', '105', 'treatment'], ['107', '115', 'treatment'], ['125', '140', 'treatment']]}, 'NCT01941316'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02926729'), ({'text': 'Coagulopathy with INR >1.5', 'entities': [['1', '13', 'chronic_disease'], ['19', '22', 'clinical_variable'], ['24', '27', 'lower_bound']]}, 'NCT02679560'), ({'text': 'severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 89% or less at rest on room air', 'entities': [['47', '57', 'clinical_variable'], ['62', '66', 'clinical_variable'], ['138', '141', 'upper_bound']]}, 'NCT02531932'), ({'text': 'A prior, unrelated, breast cancer', 'entities': [['21', '34', 'cancer']]}, 'NCT02352025'), ({'text': "Calculated GFR of d 40 mL/min/1.73 m2 using the subject's measured serum creatinine", 'entities': [['12', '15', 'clinical_variable'], ['21', '38', 'upper_bound'], ['68', '84', 'clinical_variable']]}, 'NCT02464878'), ({'text': 'Known allergy to polymethylmethacrylate, tobramycin or vancomycin', 'entities': [['18', '40', 'allergy_name'], ['42', '52', 'allergy_name'], ['56', '66', 'allergy_name']]}, 'NCT01373099'), ({'text': 'Total bilirubin =< 1.5 x ULN', 'entities': [['7', '16', 'clinical_variable'], ['20', '29', 'upper_bound']]}, 'NCT01532687'), ({'text': 'active suicidality as measured by a most severe suicide ideation score of 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS)', 'entities': [['1', '19', 'chronic_disease'], ['49', '71', 'clinical_variable'], ['75', '76', 'lower_bound'], ['80', '81', 'upper_bound'], ['89', '136', 'clinical_variable']]}, 'NCT02838797'), ({'text': 'Willingness and ability to personally complete neurocognitive testing (without assistance) and willingness to complete the QOL testing, (either personally or with assistance)', 'entities': [['48', '70', 'treatment'], ['124', '135', 'treatment']]}, 'NCT00887146'), ({'text': 'moderately severe cognitive impairment defined as > 2 errors on a brief cognitive screener', 'entities': [['12', '39', 'clinical_variable'], ['53', '61', 'lower_bound']]}, 'NCT01983228'), ({'text': 'Active infection requiring systemic treatment', 'entities': [['1', '17', 'chronic_disease'], ['28', '46', 'treatment']]}, 'NCT01994382'), ({'text': 'Confounding underlying medical illnesses which may cause fatigue (e.g., severe Anemia not controlled by medication, per self-report corroborated by medical chart review (e.g., Hb<10gm/dl)', 'entities': [['24', '41', 'chronic_disease'], ['80', '86', 'chronic_disease'], ['105', '115', 'treatment'], ['177', '179', 'clinical_variable'], ['180', '187', 'upper_bound']]}, 'NCT03119363'), ({'text': '-positive and/or PR-positive/HER2- disease and received no more than 1 prior non-hormonally-directed or cytotoxic therapy in the MBC setting', 'entities': [['30', '34', 'cancer'], ['70', '71', 'upper_bound'], ['72', '141', 'treatment']]}, 'NCT01969643'), ({'text': 'must not have received neoadjuvant chemotherapy for the present disease', 'entities': [['24', '48', 'treatment']]}, 'NCT02658565'), ({'text': 'Patients with fasting serum triglycerides > 300 and/or with hypertriglyceridemia requiring medication', 'entities': [['15', '42', 'clinical_variable'], ['45', '48', 'lower_bound'], ['61', '81', 'chronic_disease'], ['92', '102', 'treatment']]}, 'NCT02495415'), ({'text': 'History of major stroke', 'entities': [['18', '24', 'chronic_disease']]}, 'NCT02301546'), ({'text': 'Willing to undergo at least two periodontal exams', 'entities': [['29', '32', 'lower_bound']]}, 'NCT02333227'), ({'text': 'Known infection with HIV, hepatitis B or C', 'entities': [['22', '25', 'chronic_disease'], ['27', '43', 'chronic_disease']]}, 'NCT01059786'), ({'text': 'Aplastic Anemia', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02828592'), ({'text': 'Newly diagnosed patients with acromegaly who have not had surgery or medical therapy', 'entities': [['31', '41', 'chronic_disease'], ['59', '66', 'treatment'], ['70', '85', 'treatment']]}, 'NCT01538966'), ({'text': 'Subjects must have received no more than 2 prior therapies for this disease', 'entities': [['42', '49', 'upper_bound'], ['50', '59', 'treatment']]}, 'NCT03121352'), ({'text': 'no upper limit for number of prior therapies', 'entities': [['30', '45', 'treatment']]}, 'NCT01896999'), ({'text': 'Child-Pugh C, not eligible for liver transplantation (TXP), surgical resection, ablation, locoregional or systemic therapy', 'entities': [['32', '59', 'treatment'], ['61', '79', 'treatment'], ['81', '89', 'treatment'], ['91', '103', 'treatment'], ['107', '123', 'treatment']]}, 'NCT02556619'), ({'text': 'Subjects must have a known or presumed radiological diagnosis of glioblastoma (GBM)', 'entities': [['66', '84', 'cancer']]}, 'NCT02359097'), ({'text': 'Presence of ulcerative colitis (UC), indeterminate colitis, ischemic colitis, fulminant colitis, or toxic mega-colon', 'entities': [['13', '36', 'chronic_disease'], ['38', '59', 'chronic_disease'], ['61', '77', 'chronic_disease'], ['79', '96', 'chronic_disease'], ['101', '117', 'chronic_disease']]}, 'NCT03077412'), ({'text': "Bilirubin (Gilbert's Disease) < 3.0 mg/dL", 'entities': [['1', '10', 'clinical_variable'], ['12', '29', 'chronic_disease'], ['33', '42', 'upper_bound']]}, 'NCT02132598'), ({'text': 'Disseminated intravascular coagulation', 'entities': [['1', '39', 'chronic_disease']]}, 'NCT02074436'), ({'text': 'age 45-79', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT02607917'), ({'text': 'Histologically proven invasive breast carcinoma with triple negative receptor status (Estrogen receptor, Progesterone receptor and HER2 negative by IHC and FISH)', 'entities': [['23', '48', 'cancer'], ['87', '104', 'treatment'], ['106', '127', 'treatment'], ['132', '145', 'treatment'], ['149', '152', 'treatment'], ['157', '161', 'treatment']]}, 'NCT02977468'), ({'text': 'Acute or currently active/requiring antiviral therapy hepatic or biliary disease', 'entities': [['37', '54', 'treatment'], ['55', '62', 'chronic_disease'], ['66', '81', 'chronic_disease']]}, 'NCT01670877'), ({'text': 'Absolute neutrophil count >= 1,000/mcL', 'entities': [['1', '26', 'clinical_variable'], ['30', '39', 'lower_bound']]}, 'NCT02122172'), ({'text': 'Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease', 'entities': [['34', '44', 'cancer'], ['52', '59', 'upper_bound']]}, 'NCT02942095'), ({'text': 'Platelets > 100,000/mm3', 'entities': [['1', '10', 'clinical_variable'], ['13', '24', 'lower_bound']]}, 'NCT02688647'), ({'text': 'Receiving chemotherapy during study period', 'entities': [['11', '23', 'treatment']]}, 'NCT02589938'), ({'text': 'No history of CD4 prior to or at the time of lymphoma diagnosis < 300 cells/mm³', 'entities': [['15', '18', 'chronic_disease'], ['46', '64', 'clinical_variable'], ['67', '80', 'upper_bound']]}, 'NCT01415752'), ({'text': '<18 years of age', 'entities': [['2', '10', 'upper_bound'], ['14', '17', 'age']]}, 'NCT02960113'), ({'text': 'Albumin 2.4 g/dL; Total bilirubin 2 mg/dL; INR 1.5', 'entities': [['1', '8', 'clinical_variable'], ['25', '34', 'clinical_variable'], ['44', '47', 'clinical_variable']]}, 'NCT02013778'), ({'text': 'Active serious infections not controlled by antibiotics', 'entities': [['1', '26', 'chronic_disease'], ['45', '56', 'treatment']]}, 'NCT00107289'), ({'text': 'use of medications known to cause fatty liver for > 2 consecutive weeks in past year (i.e. systemic glucocorticoids, tetracycline, anabolic steroids, valproic acid)', 'entities': [['8', '19', 'treatment'], ['35', '46', 'chronic_disease'], ['53', '72', 'lower_bound'], ['92', '116', 'treatment'], ['118', '130', 'treatment'], ['132', '149', 'treatment'], ['151', '164', 'treatment']]}, 'NCT02412540'), ({'text': 'Radiotherapy within 14 days before randomization', 'entities': [['1', '13', 'treatment'], ['21', '35', 'upper_bound']]}, 'NCT02389517'), ({'text': 'Patients with tumors primarily of the body or tail of the pancreas requiring a distal pancreaticoduodenectomy', 'entities': [['15', '21', 'cancer'], ['80', '110', 'treatment']]}, 'NCT01918644'), ({'text': 'Age 21-65', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT02164422'), ({'text': 'Patients with inoperable conditions with resectable disease (T1-2NoMo)', 'entities': [['62', '70', 'cancer']]}, 'NCT03073785'), ({'text': 'angina and/or evidence of acute myocardial ischemia during a treadmill test', 'entities': [['1', '7', 'chronic_disease'], ['27', '52', 'chronic_disease']]}, 'NCT02636530'), ({'text': 'Enrollment in a Phase I trial', 'entities': [['17', '30', 'treatment']]}, 'NCT01829958'), ({'text': 'severe claustrophobia', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02206945'), ({'text': 'antifungal agents (systemic)', 'entities': [['1', '29', 'treatment']]}, 'NCT02233868'), ({'text': 'myasthenia gravis', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02008136'), ({'text': 'admitted with a burn affecting >10% total body surface area', 'entities': [['33', '36', 'lower_bound']]}, 'NCT03108820'), ({'text': 'Total bilirubin < 2 X institutional upper limit of normal (ULN)', 'entities': [['1', '16', 'clinical_variable'], ['19', '64', 'upper_bound']]}, 'NCT02177838'), ({'text': 'Epithelial ovarian cancer (including primary peritoneal disease and/or fallopian tube carcinomas and/or endometrial adenocarcinomas)', 'entities': [['1', '26', 'cancer'], ['46', '64', 'cancer'], ['72', '97', 'cancer'], ['105', '132', 'cancer']]}, 'NCT02533674'), ({'text': 'Scheduled to receive neoadjuvant chemotherapy for the treatment of newly diagnosed, locally advanced breast cancer or scheduled to receive neoadjuvant endocrine therapy with the eventual goal of surgery of newly diagnosed clinical stage II-III ER+ HER2- breast cancer (for the endocrine therapy cohort)', 'entities': [['22', '46', 'treatment'], ['93', '115', 'cancer'], ['140', '169', 'treatment'], ['152', '169', 'treatment'], ['196', '203', 'treatment'], ['232', '268', 'cancer']]}, 'NCT02891681'), ({'text': 'Alcoholic hepatitis', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT01811368'), ({'text': 'If malignancy-associated microcalcifications were initially present, the post-excision mammography must be negative', 'entities': [['4', '14', 'cancer'], ['74', '99', 'treatment']]}, 'NCT00909909'), ({'text': 'Serious medical risk such as cancer, recent cardiac event', 'entities': [['30', '36', 'cancer']]}, 'NCT02932748'), ({'text': 'Patients should have no contraindications to having a contrast enhanced MRI scan', 'entities': [['73', '81', 'treatment']]}, 'NCT02031250'), ({'text': 'pre-eclampsia', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02624765'), ({'text': 'at least 28 days before she starts taking lenalidomide', 'entities': [['10', '17', 'lower_bound'], ['43', '55', 'treatment']]}, 'NCT01754857'), ({'text': 'Fine needle aspiration (FNA) or core needle biopsy of axillary node', 'entities': [['1', '29', 'treatment'], ['33', '68', 'treatment']]}, 'NCT01953588'), ({'text': 'Pre-operative use of analgesics', 'entities': [['22', '32', 'treatment']]}, 'NCT02534168'), ({'text': 'Female patients who are pregnant or lactating', 'entities': [['1', '16', 'gender'], ['21', '33', 'pregnancy']]}, 'NCT01312857'), ({'text': 'Able to receive HDR brachytherapy ANC e 1.5 cells/mm3 and PLT e100,000/mm3', 'entities': [['17', '34', 'treatment'], ['35', '38', 'clinical_variable'], ['41', '54', 'lower_bound'], ['59', '62', 'clinical_variable'], ['64', '75', 'lower_bound']]}, 'NCT02199236'), ({'text': 'Subject has an acute illness at the time of the sleep study', 'entities': [['16', '29', 'chronic_disease']]}, 'NCT01169155'), ({'text': 'patients must not have received these therapies for 3 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of these therapies', 'entities': [['39', '48', 'treatment'], ['53', '66', 'upper_bound'], ['88', '103', 'treatment']]}, 'NCT01434316'), ({'text': 'Have a history of a seizure', 'entities': [['21', '28', 'chronic_disease']]}, 'NCT02452008'), ({'text': 'Patient must have evaluable or measurable disease documented by clinical or radiographic criteria or bone marrow disease present at study entr', 'entities': [['102', '121', 'chronic_disease']]}, 'NCT01614197'), ({'text': 'Surgery', 'entities': [['1', '8', 'treatment']]}, 'NCT02700178'), ({'text': 'age 10 or older', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT02553265'), ({'text': 'At increased risk of HIV acquisition defined as documentation of one or more of the following risk factors', 'entities': [['22', '25', 'chronic_disease'], ['66', '69', 'lower_bound']]}, 'NCT02256631'), ({'text': 'Patients who received chemotherapy directed at the present disease', 'entities': [['23', '35', 'treatment']]}, 'NCT02658565'), ({'text': 'Left Ventricular Ejection Fraction > 30%', 'entities': [['1', '35', 'clinical_variable'], ['38', '41', 'lower_bound']]}, 'NCT01364363'), ({'text': 'Prior treatment with anti-PD-1 or PD-L1 therapies', 'entities': [['1', '16', 'treatment'], ['22', '31', 'treatment'], ['35', '50', 'treatment']]}, 'NCT02927301'), ({'text': 'Patients previously treated with temozolomide, cyclophosphamide, and/or etoposide are eligible for enrollment', 'entities': [['34', '46', 'treatment'], ['48', '64', 'treatment'], ['73', '82', 'treatment']]}, 'NCT02502708'), ({'text': 'Negative pregnancy test in women of child-bearing potential', 'entities': [['1', '19', 'pregnancy'], ['28', '33', 'gender']]}, 'NCT03128008'), ({'text': 'over 18 years of age', 'entities': [['6', '14', 'lower_bound'], ['18', '21', 'age']]}, 'NCT02958189'), ({'text': 'Post-menopausal women', 'entities': [['17', '22', 'gender']]}, 'NCT02080221'), ({'text': 'Current psychiatric instability, including very severe depression/ anxiety as indicated by PHQ-9 or GAD-7 e20', 'entities': [['9', '32', 'chronic_disease'], ['49', '66', 'chronic_disease'], ['68', '75', 'chronic_disease'], ['92', '97', 'clinical_variable'], ['101', '106', 'clinical_variable'], ['108', '110', 'lower_bound']]}, 'NCT02061553'), ({'text': 'Specific mental health issues such as schizophrenia or bipolar disorder', 'entities': [['10', '30', 'chronic_disease'], ['39', '52', 'chronic_disease'], ['56', '72', 'chronic_disease']]}, 'NCT02601027'), ({'text': 'PLT >= 50 000/mcL', 'entities': [['1', '4', 'clinical_variable'], ['8', '18', 'lower_bound']]}, 'NCT02520791'), ({'text': 'Subject is currently participating in an investigational drug or device clinical trial that would interfere with the observations of this study', 'entities': [['42', '62', 'treatment']]}, 'NCT02365467'), ({'text': 'New York Heart Association (NYHA) Class III or IV heart failure', 'entities': [['35', '44', 'lower_bound'], ['48', '50', 'upper_bound'], ['51', '64', 'chronic_disease']]}, 'NCT02538198'), ({'text': 'metastatic disease', 'entities': [['1', '11', 'cancer']]}, 'NCT02166190'), ({'text': 'stroke', 'entities': [['1', '7', 'chronic_disease']]}, 'NCT03096288'), ({'text': 'Life expectancy e18 weeks', 'entities': [['1', '16', 'clinical_variable'], ['18', '26', 'lower_bound']]}, 'NCT02439450'), ({'text': 'any psychotic disorder including schizophrenia', 'entities': [['5', '23', 'chronic_disease'], ['34', '47', 'chronic_disease']]}, 'NCT02553161'), ({'text': 'metastatic lesion (ratio < 2 and HER2 copy number < 4)', 'entities': [['1', '18', 'clinical_variable'], ['28', '29', 'upper_bound'], ['34', '50', 'clinical_variable'], ['53', '54', 'upper_bound']]}, 'NCT02536794'), ({'text': 'Major surgery 28 days prior to study entry excluding minor procedures (dental work, skin biopsy, etc.), celiac plexus block, and biliary stent placement', 'entities': [['1', '14', 'treatment'], ['15', '28', 'upper_bound'], ['72', '83', 'treatment'], ['85', '96', 'treatment'], ['105', '124', 'treatment'], ['130', '153', 'treatment']]}, 'NCT03153410'), ({'text': 'CABG', 'entities': [['1', '5', 'treatment']]}, 'NCT02088554'), ({'text': 'the 3 values have to be below 150/90 mm Hg for eligibility and can only be obtained after 2 days of the last change in anti-hypertensive medication', 'entities': [['31', '43', 'upper_bound'], ['91', '97', 'upper_bound'], ['120', '148', 'treatment']]}, 'NCT01684397'), ({'text': 'Liver mass (e 1 cm) that is a non-HCC primary malignancy (cholangiocarcinoma)', 'entities': [['1', '11', 'clinical_variable'], ['15', '19', 'lower_bound'], ['31', '57', 'cancer'], ['59', '77', 'cancer']]}, 'NCT02379377'), ({'text': 'clinical signs and symptoms consistent with meningitis detected upon sepsis evaluation', 'entities': [['45', '55', 'chronic_disease']]}, 'NCT02621944'), ({'text': 'Most caudal renal artery to aortoiliac bifurcation length e100mm', 'entities': [['29', '58', 'clinical_variable'], ['60', '65', 'lower_bound']]}, 'NCT01726257'), ({'text': 'Cancers with exon 20 mutations', 'entities': [['1', '8', 'cancer']]}, 'NCT02091141'), ({'text': 'Life-threatening illness, medical condition or organ system dysfunction which, in the investigator s opinion, could compromise the subject s safety, interfere with the absorption or metabolism of ibrutinib and fludarabine, or put the study outcomes at undue risk', 'entities': [['1', '25', 'chronic_disease'], ['27', '44', 'chronic_disease'], ['48', '72', 'chronic_disease'], ['197', '206', 'treatment'], ['211', '222', 'treatment']]}, 'NCT02514083'), ({'text': 'AML (Arm B): Relapsed/refractory/unable to tolerate conventional chemotherapy', 'entities': [['1', '4', 'cancer'], ['66', '78', 'treatment']]}, 'NCT01869114'), ({'text': 'Women who have already had their standard of care post-NAT mammogram and/or breast MRI', 'entities': [['1', '6', 'gender']]}, 'NCT03070340'), ({'text': 'It is expected that patients will have received upfront standard of care therapy for their respected disease', 'entities': [['74', '81', 'treatment']]}, 'NCT01804634'), ({'text': 'patients with a history of CNS metastases that have been previously treated may enroll if sequential imaging shows not evidence for active disease', 'entities': [['28', '42', 'cancer']]}, 'NCT02304458'), ({'text': 'Women', 'entities': [['1', '6', 'gender']]}, 'NCT02974985'), ({'text': 'Women who are breast feeding or pregnant as evidenced by positive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) done within 14 days of first dosing and urine test within 72 hours of first dosing', 'entities': [['1', '6', 'gender'], ['33', '41', 'pregnancy'], ['58', '82', 'pregnancy'], ['97', '108', 'clinical_variable'], ['109', '116', 'lower_bound'], ['157', '164', 'upper_bound'], ['203', '211', 'upper_bound']]}, 'NCT02553642'), ({'text': 'Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 3 months', 'entities': [['73', '116', 'contraception_consent'], ['124', '132', 'pregnancy'], ['133', '139', 'gender'], ['255', '263', 'lower_bound']]}, 'NCT02494258'), ({'text': 'Metastatic', 'entities': [['1', '11', 'cancer']]}, 'NCT02953860'), ({'text': 'Refractory to induction chemotherapy with COG ANBL0532 or standard chemotherapy', 'entities': [['15', '37', 'treatment'], ['43', '55', 'treatment'], ['59', '80', 'treatment']]}, 'NCT01804634'), ({'text': 'Uncontrolled inter-current illness including, but not limited to ongoing or active infection (> grade 2 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version 4.0), congestive heart failure (> New York Heart Association (NYHA) class 2), active coronary artery disease (CAD), cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin), uncontrolled hypertension and any condition which could jeopardize the safety of the patient and his/her compliance in the study', 'entities': [['14', '35', 'chronic_disease'], ['77', '93', 'chronic_disease'], ['97', '104', 'lower_bound'], ['137', '191', 'clinical_variable'], ['206', '230', 'chronic_disease'], ['234', '267', 'clinical_variable'], ['268', '275', 'lower_bound'], ['285', '314', 'chronic_disease'], ['316', '335', 'chronic_disease'], ['346', '369', 'treatment'], ['381', '394', 'treatment'], ['398', '405', 'treatment'], ['408', '433', 'chronic_disease']]}, 'NCT01360606'), ({'text': 'Subjects enrolled in other clinical studies taking any unknown or not-FDA approved medications', 'entities': [['22', '44', 'treatment'], ['84', '95', 'treatment']]}, 'NCT02234193'), ({'text': 'Previous history of bariatric surgery', 'entities': [['21', '38', 'treatment']]}, 'NCT03005951'), ({'text': 'Females', 'entities': [['1', '8', 'gender']]}, 'NCT02421315'), ({'text': 'Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial', 'entities': [['11', '22', 'chronic_disease'], ['26', '51', 'chronic_disease']]}, 'NCT02541565'), ({'text': 'Evidence of chronic active hepatitis or cirrhosis', 'entities': [['13', '37', 'chronic_disease'], ['41', '50', 'chronic_disease']]}, 'NCT01810588'), ({'text': 'Has been diagnosed with Lupus', 'entities': [['25', '30', 'chronic_disease']]}, 'NCT02506192'), ({'text': 'kidney (renal cell carcinoma)', 'entities': [['9', '29', 'cancer']]}, 'NCT00720785'), ({'text': 'History/physical examination within 21 days prior to study entry', 'entities': [['37', '50', 'upper_bound']]}, 'NCT01622868'), ({'text': 'Type 1 diabetes and type 2 diabetic patient on insulin', 'entities': [['1', '27', 'chronic_disease'], ['48', '55', 'treatment']]}, 'NCT03008070'), ({'text': 'Retroperitoneal/hilar adenopathy concerning for locally advanced disease', 'entities': [['1', '33', 'chronic_disease']]}, 'NCT02885649'), ({'text': 'Aortic neck angle d 90Ú', 'entities': [['1', '18', 'clinical_variable'], ['21', '24', 'upper_bound']]}, 'NCT02489539'), ({'text': 'patients with synchronous or previous ipsilateral LCIS', 'entities': [['39', '55', 'cancer']]}, 'NCT01872975'), ({'text': 'patients unable or unwilling to provide informed consent for surgery or enrollment in a clinical trial', 'entities': [['62', '69', 'treatment']]}, 'NCT01974609'), ({'text': 'other prior cortical or retinal transient ischemic attack (TIA)', 'entities': [['33', '64', 'chronic_disease']]}, 'NCT02169739'), ({'text': 'pregnancy testing is not required for post-menopausal or surgically sterilized', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01701986'), ({'text': 'Chronic inflammatory condition, autoimmune disease, or infectious processes (e.g., active tuberculosis, Human Immunodeficiency Virus, rheumatoid arthritis, systemic lupus erythematosus, hepatitis B or C)', 'entities': [['33', '51', 'chronic_disease'], ['84', '103', 'chronic_disease'], ['105', '133', 'chronic_disease'], ['135', '155', 'chronic_disease'], ['157', '185', 'chronic_disease'], ['187', '203', 'chronic_disease']]}, 'NCT02570672'), ({'text': 'CD19+ leukemia', 'entities': [['7', '15', 'cancer']]}, 'NCT02374333'), ({'text': 'IPSS >/= intermediate-2', 'entities': [['1', '5', 'clinical_variable']]}, 'NCT01515527'), ({'text': 'between the age of 18 and 80 years old', 'entities': [['13', '16', 'age'], ['20', '22', 'lower_bound'], ['27', '35', 'upper_bound']]}, 'NCT02189889'), ({'text': 'Any maternal-fetal conditions associated with high odds of premature delivery or death', 'entities': [['5', '30', 'chronic_disease']]}, 'NCT02624765'), ({'text': 'cardiomyopathy', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02624765'), ({'text': 'Must be e 18 years of age', 'entities': [['11', '19', 'lower_bound'], ['23', '26', 'age']]}, 'NCT02578901'), ({'text': 'Previous spinal surgery in the lumbar or sacral area (L1 through Sacrum)', 'entities': [['1', '24', 'treatment']]}, 'NCT02271100'), ({'text': 'Age 45 years or older (older control group)', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT01787682'), ({'text': 'KPS >= 70%', 'entities': [['1', '4', 'clinical_variable'], ['8', '11', 'lower_bound']]}, 'NCT02146924'), ({'text': 'Post-primary radiotherapy: PSA >= 2 ng/ml above a post-radiotherapy nadir', 'entities': [['1', '26', 'treatment'], ['28', '31', 'clinical_variable'], ['35', '42', 'lower_bound'], ['51', '74', 'treatment']]}, 'NCT02217709'), ({'text': 'significant aortic valve stenosis', 'entities': [['13', '34', 'chronic_disease']]}, 'NCT01568177'), ({'text': 'Patients must not have major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks of beginning Avastin or the anticipation of need for major surgical procedure during the course of the study', 'entities': [['24', '48', 'treatment'], ['50', '61', 'treatment'], ['102', '109', 'upper_bound'], ['123', '130', 'treatment']]}, 'NCT02314377'), ({'text': 'In active spinal litigation', 'entities': [['11', '17', 'chronic_disease']]}, 'NCT02555280'), ({'text': 'Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain tablets', 'entities': [['36', '66', 'chronic_disease'], ['101', '116', 'treatment'], ['138', '153', 'treatment'], ['155', '180', 'treatment'], ['206', '233', 'chronic_disease']]}, 'NCT01306045'), ({'text': 'Risk for gastric aspiration (ie; ileus, esophageal or bowel obstruction, active vomiting)', 'entities': [['10', '28', 'treatment'], ['34', '39', 'chronic_disease'], ['41', '51', 'chronic_disease'], ['55', '72', 'chronic_disease']]}, 'NCT02464696'), ({'text': 'under age 18', 'entities': [['7', '10', 'age'], ['11', '13', 'upper_bound']]}, 'NCT02136186'), ({'text': 'c-MET amplification will be determined by FISH ratio (c-MET/CEP7) > 2.0, based on testing of the primary tumor and/or site of metastatic disease', 'entities': [['43', '47', 'treatment'], ['55', '65', 'clinical_variable'], ['69', '72', 'lower_bound'], ['106', '111', 'cancer'], ['127', '145', 'cancer']]}, 'NCT02132598'), ({'text': 'In addition, male subjects whose partners are or become pregnant must continue to use condoms for 7 days after stopping study medications', 'entities': [['14', '27', 'gender'], ['50', '65', 'pregnancy'], ['83', '94', 'contraception_consent'], ['99', '111', 'lower_bound'], ['127', '138', 'treatment']]}, 'NCT01943851'), ({'text': 'Untreated arterial hypertension', 'entities': [['11', '32', 'chronic_disease']]}, 'NCT02416102'), ({'text': 'Any medical or psychological condition or situation deemed by the PI to put the patient at increased risk of complications or noncompliance', 'entities': [['16', '39', 'chronic_disease']]}, 'NCT02378428'), ({'text': 'failed medical treatment with either oral anti-histamine or nasal steroid spray', 'entities': [['38', '57', 'treatment'], ['61', '80', 'treatment']]}, 'NCT01695967'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02041936'), ({'text': 'Subject is at least 18 years old', 'entities': [['21', '29', 'lower_bound']]}, 'NCT01905709'), ({'text': 'Injury < 6 months prior to enrollment', 'entities': [['10', '24', 'upper_bound']]}, 'NCT01821690'), ({'text': 'The subjects must be on PAH-specific therapies for at least 4 months and on a stable dose for at least 4 weeks prior to enrollment into study', 'entities': [['25', '47', 'treatment'], ['61', '69', 'lower_bound'], ['104', '117', 'lower_bound']]}, 'NCT03145298'), ({'text': 'history of basal cell cancer is allowed', 'entities': [['12', '29', 'cancer']]}, 'NCT02581787'), ({'text': 'History of pelvic irradiation', 'entities': [['12', '30', 'treatment']]}, 'NCT02167009'), ({'text': 'History of acute myocardial infarction or cerebrovascular accident within the past 6 months', 'entities': [['12', '39', 'chronic_disease'], ['43', '67', 'chronic_disease'], ['79', '92', 'upper_bound']]}, 'NCT00788164'), ({'text': 'Females of childbearing potential', 'entities': [['1', '8', 'gender']]}, 'NCT02538198'), ({'text': 'Age 18-70 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '16', 'upper_bound']]}, 'NCT02200445'), ({'text': 'ANC < 1500/uL', 'entities': [['1', '4', 'clinical_variable'], ['7', '14', 'upper_bound']]}, 'NCT02278315'), ({'text': 'with no pharmacologic changes expected or made during the 12-month study', 'entities': [['59', '67', 'upper_bound']]}, 'NCT02402647'), ({'text': 'Diagnosed with antibody positive T1DM in the past 3 months', 'entities': [['16', '38', 'chronic_disease'], ['46', '59', 'upper_bound']]}, 'NCT01269034'), ({'text': 'Between the age of 18 and 65', 'entities': [['13', '16', 'age'], ['20', '22', 'lower_bound'], ['27', '29', 'upper_bound']]}, 'NCT02874898'), ({'text': 'Presence of active malignancy in another organ system other than the hematopoietic, except when driven by viruses in which case the immune reconstitution after transplant may control the malignancy', 'entities': [['20', '30', 'cancer'], ['161', '171', 'treatment']]}, 'NCT01861106'), ({'text': 'HIV negative', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT01807611'), ({'text': 'Hemoglobin: e9 g/dL or e5.6 mmol/L', 'entities': [['1', '11', 'clinical_variable'], ['14', '20', 'lower_bound'], ['25', '35', 'lower_bound']]}, 'NCT02710396'), ({'text': 'Recent ingestion of a potential allergen (e.g. nuts) where recipient has a known allergy to this (these) agent(s)', 'entities': [['48', '52', 'allergy_name']]}, 'NCT02134392'), ({'text': 'Presence of significant valve disease defined by the site cardiologist', 'entities': [['25', '38', 'chronic_disease']]}, 'NCT03088033'), ({'text': 'Age 18 years', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT02579096'), ({'text': 'Neurological condition that could impair spontaneous ventilation (e.g., C5 or higher spinal cord injury as this could affect the clinical course and cloud interpretation of the ventilator-free day endpoint', 'entities': [['73', '75', 'lower_bound'], ['86', '104', 'clinical_variable']]}, 'NCT02582957'), ({'text': 'Have an archived tumor block available to submit unstained slides for PD-L1 expression, basal and luminal subtype analysis', 'entities': [['18', '23', 'cancer']]}, 'NCT02365766'), ({'text': 'platelet counts > 50,000/mm3', 'entities': [['1', '16', 'clinical_variable'], ['19', '29', 'lower_bound']]}, 'NCT02343042'), ({'text': 'Individuals who meet the eligibility criteria for EGFR germline mutation testing but who do not have advanced cancer as defined in 3.1.1 may enroll for EGFR germline mutation testing only and will not be eligible for the treatment or NOS arms', 'entities': [['51', '55', 'clinical_variable'], ['222', '231', 'treatment']]}, 'NCT01306045'), ({'text': 'based on multi-disciplinary tumor board discussion, patients are candidates for tri-modality treatment', 'entities': [['29', '34', 'cancer'], ['81', '103', 'treatment']]}, 'NCT02857218'), ({'text': 'Self-report smoking at least 10 cigarettes/day', 'entities': [['30', '47', 'lower_bound']]}, 'NCT02266784'), ({'text': 'Subjects who have lesions within 2 cm of central structures, will be eligible on a case by-case basis', 'entities': [['34', '38', 'upper_bound']]}, 'NCT02581384'), ({'text': 'CKD (eGFR > 60 mL/min/1.73m2) with urine albumin-to-creatinine ratio e 300 mg/g', 'entities': [['1', '4', 'chronic_disease'], ['6', '10', 'clinical_variable'], ['13', '29', 'lower_bound'], ['42', '69', 'clinical_variable'], ['72', '80', 'lower_bound']]}, 'NCT02497300'), ({'text': 'precluding study therapy at the time of registration', 'entities': [['18', '25', 'treatment']]}, 'NCT01617161'), ({'text': 'radiation within 2 weeks prior to the first dose of study drug', 'entities': [['1', '10', 'treatment'], ['18', '31', 'upper_bound']]}, 'NCT01876511'), ({'text': 'Subject is female', 'entities': [['12', '18', 'gender']]}, 'NCT02404012'), ({'text': 'Hypersensitivity to pembrolizumab, any of its excipients, paclitaxel, or any of its excipients', 'entities': [['21', '34', 'allergy_name'], ['47', '57', 'treatment'], ['59', '69', 'treatment']]}, 'NCT02581982'), ({'text': 'Men', 'entities': [['1', '4', 'gender']]}, 'NCT02250664'), ({'text': 'therapeutic anticoagulation being administered', 'entities': [['1', '28', 'treatment']]}, 'NCT03078504'), ({'text': 'Patient is a pregnant woman', 'entities': [['14', '22', 'pregnancy'], ['23', '28', 'gender']]}, 'NCT00881660'), ({'text': 'female e 18 years of age', 'entities': [['1', '7', 'gender'], ['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT03138733'), ({'text': 'Dose expansion cohorts: Patients with histologically or cytologically confirmed diagnosis of 1 of specified tumors with measurable disease per RECIST 1.1 or Lugano criteria. Some patients may have been previously treated with a PD-1 or PD-L1 inhibitor', 'entities': [['109', '115', 'cancer'], ['229', '252', 'treatment']]}, 'NCT03005782'), ({'text': 'Transmural myocardial infarction within the last 6 months', 'entities': [['1', '33', 'chronic_disease'], ['45', '58', 'upper_bound']]}, 'NCT01220583'), ({'text': 'Participation in any investigational drug study within 4 weeks preceding the start of study treatment', 'entities': [['18', '48', 'treatment'], ['56', '63', 'upper_bound'], ['93', '102', 'treatment']]}, 'NCT02178709'), ({'text': 'Active prostatitis or urinary tract infection', 'entities': [['8', '19', 'chronic_disease'], ['23', '46', 'chronic_disease']]}, 'NCT02167009'), ({'text': 'fallopian tube or primary peritoneal carcinoma', 'entities': [['1', '47', 'cancer']]}, 'NCT01690468'), ({'text': 'Chronic kidney disease - including baseline proteinuria (>300mg/24-hr, p/c ratio >0.3, or persistent 1+ proteinuria*) or creatinine >1.2', 'entities': [['1', '23', 'chronic_disease'], ['45', '56', 'clinical_variable'], ['59', '70', 'lower_bound'], ['72', '81', 'clinical_variable'], ['83', '86', 'lower_bound'], ['122', '132', 'clinical_variable'], ['134', '137', 'lower_bound']]}, 'NCT02299414'), ({'text': 'Meets criteria for lifetime or current tobacco, alcohol and/or opioid use disorder regardless of addiction treatment status', 'entities': [['108', '117', 'treatment']]}, 'NCT02907944'), ({'text': 'cerebral hemorrhage', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02796209'), ({'text': 'scheduled to undergo endoscopic sinus surgery', 'entities': [['22', '46', 'treatment']]}, 'NCT02748070'), ({'text': 'Known history of hypersensitivity following infusions of human blood or blood components', 'entities': [['45', '89', 'allergy_name']]}, 'NCT02525861'), ({'text': 'estimated GFR < 30ml/min/1.73m(2) based on CKD-EPI', 'entities': [['11', '14', 'clinical_variable'], ['17', '34', 'upper_bound']]}, 'NCT02514083'), ({'text': 'at least 150 days must have elapsed if prior total body irradiation (TBI), craniospinal XRT or if >= 50% radiation of pelvis', 'entities': [['10', '18', 'lower_bound'], ['40', '74', 'treatment'], ['59', '68', 'treatment'], ['76', '92', 'treatment'], ['102', '105', 'lower_bound']]}, 'NCT02323880'), ({'text': 'Patients who have participated in MK-3475 Merck studies', 'entities': [['35', '56', 'treatment']]}, 'NCT03121352'), ({'text': 'Patients must have histologically or cytologically confirmed advanced solid tumor that is refractory to standard treatment or for which no standard treatment exists, with evaluable disease', 'entities': [['71', '82', 'cancer'], ['105', '123', 'treatment']]}, 'NCT02484404'), ({'text': 'Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic)', 'entities': [['29', '42', 'treatment'], ['49', '63', 'treatment'], ['65', '80', 'treatment'], ['84', '96', 'treatment']]}, 'NCT01894061'), ({'text': 'Hemoglobin e 8.0 g/dL (the use of transfusion or other intervention to achieve hemoglobin e 8.0 g/dL is acceptable)', 'entities': [['1', '11', 'clinical_variable'], ['14', '22', 'lower_bound'], ['35', '46', 'treatment'], ['80', '90', 'clinical_variable']]}, 'NCT01220583'), ({'text': '</=8 weeks prior to screening', 'entities': [['4', '17', 'upper_bound']]}, 'NCT02394028'), ({'text': 'Confirmed UTI (Urinary Tract Infection) diagnosis', 'entities': [['11', '40', 'chronic_disease']]}, 'NCT01595529'), ({'text': 'Type 1 diabetes', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02130687'), ({'text': 'cytotoxic chemotherapy', 'entities': [['1', '23', 'treatment']]}, 'NCT02669173'), ({'text': 'At least half of infants in the antepartum cohort must be < 3 days at enrollment, including 3 of the first 6 infants enrolled', 'entities': [['61', '67', 'upper_bound']]}, 'NCT02369406'), ({'text': 'A total of 39 patients with PSD as defined by an ejection fraction of less than 40%, no clinical signs or symptoms of congestive heart failure, a minimal distance on 6-minute walk of equal or >450 meters will be recruited and calculated creatinine clearance of equal or less than 90 ml/min and greater than 30 ml/min, using the (MDRD-measurement of renal dysfunction, formula) assessed within the past 24 months', 'entities': [['29', '32', 'chronic_disease'], ['50', '67', 'clinical_variable'], ['81', '84', 'upper_bound'], ['119', '143', 'chronic_disease'], ['155', '163', 'clinical_variable'], ['194', '204', 'lower_bound'], ['227', '258', 'clinical_variable'], ['281', '290', 'upper_bound'], ['308', '317', 'lower_bound'], ['350', '367', 'chronic_disease'], ['398', '412', 'upper_bound']]}, 'NCT01970176'), ({'text': 'ECOG performance status 0 or 2', 'entities': [['1', '24', 'clinical_variable'], ['25', '26', 'lower_bound'], ['30', '31', 'upper_bound']]}, 'NCT02452008'), ({'text': 'Patients with locally advanced, previously untreated squamous cell carcinoma of the vulva', 'entities': [['54', '90', 'cancer']]}, 'NCT01595061'), ({'text': 'Body weight >300 lbs', 'entities': [['14', '21', 'lower_bound']]}, 'NCT02721303'), ({'text': 'A family history of HBOC is defined by NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian guideline', 'entities': [['21', '25', 'cancer']]}, 'NCT02203513'), ({'text': 'Persistently elevated creatinine, hepatic transaminases, or alkaline phosphatase (i.e., confirmed on repeat)', 'entities': [['23', '33', 'clinical_variable'], ['35', '56', 'clinical_variable'], ['61', '81', 'clinical_variable']]}, 'NCT01428089'), ({'text': 'pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT02152995'), ({'text': 'Albumin<2.0mg/dl, within 4 weeks of screening (if tested as part of routine clinical care)', 'entities': [['1', '8', 'clinical_variable'], ['9', '17', 'upper_bound'], ['26', '33', 'upper_bound']]}, 'NCT03058679'), ({'text': 'Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2', 'entities': [['58', '106', 'clinical_variable'], ['110', '111', 'lower_bound'], ['119', '120', 'upper_bound']]}, 'NCT02101853'), ({'text': 'Report engaging in one or more occasions of condomless anal and/or vaginal intercourse with an HIV-negative or unknown HIV serostatus sex partner in the 3 months prior to study enrollment', 'entities': [['96', '99', 'chronic_disease'], ['154', '168', 'upper_bound']]}, 'NCT03004170'), ({'text': 'ECOG performance status 0-1', 'entities': [['1', '24', 'clinical_variable'], ['25', '26', 'lower_bound'], ['27', '28', 'upper_bound']]}, 'NCT02311361'), ({'text': 'Age >70 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02050113'), ({'text': 'Participant endorses current suicidal ideation with intent or plan', 'entities': [['30', '47', 'chronic_disease']]}, 'NCT02452203'), ({'text': 'AST and ALT d 3.0 x ULN, independently of the presence of liver metastases', 'entities': [['1', '4', 'clinical_variable'], ['9', '12', 'clinical_variable'], ['15', '24', 'upper_bound'], ['59', '75', 'cancer']]}, 'NCT02533674'), ({'text': 'trying to become pregnant', 'entities': [['1', '26', 'pregnancy']]}, 'NCT02949726'), ({'text': 'Malignant neuroleptic hyperthermia', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT01184547'), ({'text': 'Patients taking concurrent medication that is metabolized by the CYP3A4 isoenzyme', 'entities': [['17', '38', 'treatment'], ['66', '82', 'treatment']]}, 'NCT01925378'), ({'text': 'Either no evidence of GVHD or minimal clinical evidence of acute GVHD and chronic GVHD while off of systemic immunosuppressive therapy for at least 28 days', 'entities': [['23', '27', 'chronic_disease'], ['60', '70', 'chronic_disease'], ['75', '87', 'chronic_disease'], ['101', '135', 'treatment'], ['149', '156', 'lower_bound']]}, 'NCT01087294'), ({'text': 'active bowel inflammation (e.g., diverticulitis)', 'entities': [['8', '26', 'chronic_disease'], ['34', '48', 'chronic_disease']]}, 'NCT03072238'), ({'text': 'have completed local (radiation) therapy and have discontinued the use of corticosteroids or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment', 'entities': [['23', '32', 'treatment'], ['34', '41', 'treatment'], ['75', '90', 'treatment'], ['151', '165', 'lower_bound'], ['181', '190', 'treatment']]}, 'NCT02541903'), ({'text': 'Any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation)', 'entities': [['16', '26', 'chronic_disease'], ['30', '55', 'chronic_disease'], ['63', '95', 'chronic_disease'], ['97', '141', 'chronic_disease'], ['143', '164', 'treatment']]}, 'NCT02413047'), ({'text': 'The patient must be free of symptoms of uncontrolled cardiac disease, and must not have compromised cardiac function detected by ECHO or by gated cardiac blood flow scan', 'entities': [['41', '69', 'chronic_disease'], ['130', '134', 'treatment'], ['141', '170', 'treatment']]}, 'NCT00630565'), ({'text': 'Serum creatinine =< 1.5 x the ULN', 'entities': [['1', '17', 'clinical_variable'], ['21', '34', 'upper_bound']]}, 'NCT02048722'), ({'text': 'Women of childbearing potential must use a reliable method of contraception from screening until 1 month after end of study medication', 'entities': [['1', '6', 'gender'], ['38', '76', 'contraception_consent'], ['98', '111', 'upper_bound'], ['125', '135', 'treatment']]}, 'NCT02178566'), ({'text': 'allergy to local anesthetic, or allergy to opioids', 'entities': [['12', '28', 'allergy_name'], ['44', '51', 'allergy_name']]}, 'NCT02826668'), ({'text': 'Low dose aspirin, low-dose warfarin, and prophylactic low molecular weight heparin', 'entities': [['10', '17', 'treatment'], ['28', '36', 'treatment'], ['42', '83', 'treatment']]}, 'NCT02101736'), ({'text': 'Male gender', 'entities': [['1', '5', 'gender']]}, 'NCT02335138'), ({'text': 'Less than 18 months disease-free interval', 'entities': [['11', '20', 'upper_bound']]}, 'NCT02035085'), ({'text': 'Patients less than 18 yrs old', 'entities': [['20', '26', 'upper_bound']]}, 'NCT01333046'), ({'text': 'Platelet count > 50 thousands/uL', 'entities': [['1', '15', 'clinical_variable'], ['18', '33', 'lower_bound']]}, 'NCT02724540'), ({'text': 'sensitivity to dental materials being used, including SDF', 'entities': [['55', '58', 'allergy_name']]}, 'NCT02601833'), ({'text': 'percutaneous nephrolithotomy [PNL]', 'entities': [['1', '35', 'treatment']]}, 'NCT02944825'), ({'text': 'History of transvaginal mesh implant', 'entities': [['12', '37', 'treatment']]}, 'NCT02573883'), ({'text': "Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)", 'entities': [['19', '22', 'cancer'], ['37', '65', 'cancer']]}, 'NCT02656303'), ({'text': 'Autoimmune peripheral neuropathy', 'entities': [['12', '33', 'chronic_disease']]}, 'NCT02418195'), ({'text': 'Active infection requiring current antibiotic therapy', 'entities': [['1', '17', 'chronic_disease'], ['36', '54', 'treatment']]}, 'NCT02744677'), ({'text': 'caregiver permission for the child to participate as well as assent from the child (>7 years)', 'entities': [['86', '93', 'lower_bound']]}, 'NCT03066596'), ({'text': 'Patients 18-80 years of age', 'entities': [['10', '12', 'lower_bound'], ['13', '21', 'upper_bound'], ['25', '28', 'age']]}, 'NCT02959632'), ({'text': 'The subject is known to be positive for the human immunodeficiency virus (HIV)', 'entities': [['45', '79', 'chronic_disease']]}, 'NCT01037790'), ({'text': 'Subjects receiving L-asparaginase as part of their current cycle of treatment', 'entities': [['20', '34', 'treatment'], ['69', '78', 'treatment']]}, 'NCT02578901'), ({'text': 'Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive', 'entities': [['12', '37', 'chronic_disease'], ['39', '78', 'chronic_disease'], ['89', '123', 'chronic_disease']]}, 'NCT02942095'), ({'text': 'Hemoglobin >= 9 g/dL (5.6 mmol/L)', 'entities': [['1', '11', 'clinical_variable'], ['15', '34', 'lower_bound']]}, 'NCT01532687'), ({'text': 'The participant has active brain metastases or epidural disease', 'entities': [['28', '44', 'cancer'], ['48', '64', 'chronic_disease']]}, 'NCT01822522'), ({'text': '(>=18 years of age)', 'entities': [['4', '12', 'lower_bound'], ['16', '19', 'age']]}, 'NCT02367092'), ({'text': 'Maximum diameter e50 mm', 'entities': [['1', '17', 'clinical_variable'], ['19', '24', 'lower_bound']]}, 'NCT02489539'), ({'text': 'Patients with a history of an anaphylactic reaction to irinotecan', 'entities': [['56', '66', 'allergy_name']]}, 'NCT02574455'), ({'text': 'Known to have lymphoma related to HIV or acquired immune deficiency syndrome (AIDS)', 'entities': [['15', '23', 'cancer'], ['35', '38', 'chronic_disease'], ['42', '84', 'chronic_disease']]}, 'NCT02320292'), ({'text': 'Have no active GVHD and require no immunosuppression', 'entities': [['16', '20', 'chronic_disease'], ['36', '53', 'treatment']]}, 'NCT02374333'), ({'text': 'No access to a telephone to conduct follow-up surveys', 'entities': [['1', '25', 'technology_access']]}, 'NCT03066596'), ({'text': 'Patients must have two CB units available which are matched with the patient at 4, 5, or 6/6 human leukocyte antigen (HLA) class I (serological) and II (molecular) antigens; each cord must contain at least 1.5 x 10^7 total nucleated cells/Kg recipient body weight (pre-thaw); cord blood units will be procured through the National Marrow Donor Program (NMDP)', 'entities': [['81', '82', 'lower_bound'], ['90', '91', 'upper_bound'], ['94', '173', 'clinical_variable'], ['207', '217', 'lower_bound'], ['218', '242', 'clinical_variable']]}, 'NCT01619761'), ({'text': 'Karnofsky or Lansky performance status of greater than or equal to 60% or ECOG performance status of 2 or less', 'entities': [['1', '10', 'clinical_variable'], ['14', '39', 'clinical_variable'], ['68', '71', 'lower_bound'], ['75', '98', 'clinical_variable'], ['102', '103', 'upper_bound']]}, 'NCT02579967'), ({'text': 'Subject has a healthy, non-diseased aortic proximal seal zone of at least 20 mm from the distal end of the LCC ostium to the beginning of the disease, including at least 10 mm between the LSA and the LCC', 'entities': [['75', '80', 'lower_bound'], ['171', '176', 'lower_bound']]}, 'NCT02365467'), ({'text': 'Creatinine clearance or radioisotope GFR > 60 mL/min/1.73 m2', 'entities': [['1', '21', 'clinical_variable'], ['25', '41', 'clinical_variable'], ['44', '61', 'lower_bound']]}, 'NCT02624258'), ({'text': 'Receiving treatment for a medical condition requiring chronic use of systemic steroids', 'entities': [['70', '87', 'treatment']]}, 'NCT01474889'), ({'text': 'Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin', 'entities': [['16', '26', 'cancer'], ['50', '66', 'cancer'], ['70', '102', 'cancer']]}, 'NCT02464878'), ({'text': 'known or suspected allergy to iodine or shellfish', 'entities': [['31', '37', 'allergy_name'], ['41', '50', 'allergy_name']]}, 'NCT02495753'), ({'text': 'Known chronic liver disease, end stage renal disease, or creatinine clearance <30 mL/min as defined by Cockcroft-Gault equation', 'entities': [['7', '28', 'chronic_disease'], ['30', '53', 'chronic_disease'], ['58', '78', 'clinical_variable'], ['80', '89', 'upper_bound'], ['104', '128', 'clinical_variable']]}, 'NCT01912612'), ({'text': 'Females who are pregnant', 'entities': [['1', '8', 'gender'], ['13', '25', 'pregnancy']]}, 'NCT01576575'), ({'text': 'Absolute neutrophil count (ANC) e 1000/mm3', 'entities': [['1', '32', 'clinical_variable'], ['35', '43', 'lower_bound']]}, 'NCT02259621'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01681589'), ({'text': 'Teeth with signs and symptoms of reversible pulpitis', 'entities': [['34', '53', 'chronic_disease']]}, 'NCT02298504'), ({'text': 'Patients who are having sex that can lead to pregnancy must agree to use adequate contraception (hormonal, barrier method of birth control, or abstinence) for the duration of study participation', 'entities': [['46', '55', 'pregnancy'], ['61', '155', 'contraception_consent']]}, 'NCT02780401'), ({'text': 'Alanine aminotransferase (ALT) levels e60 IU/mL', 'entities': [['1', '38', 'clinical_variable'], ['40', '48', 'lower_bound']]}, 'NCT03073343'), ({'text': 'Alkaline phosphatase < 4 x ULN', 'entities': [['1', '21', 'clinical_variable'], ['24', '31', 'upper_bound']]}, 'NCT02419495'), ({'text': 'History of abdominal radiation treatment', 'entities': [['12', '41', 'treatment']]}, 'NCT03058029'), ({'text': 'Hemoglobin >= 10.0 g/dl', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'lower_bound']]}, 'NCT02535312'), ({'text': 'Able to conduct research activities in English or Spanish', 'entities': [['1', '58', 'language_fluency']]}, 'NCT02801747'), ({'text': 'LV dysfunction', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT03145298'), ({'text': 'Prior treatment with immunotherapy agents', 'entities': [['1', '42', 'treatment']]}, 'NCT02671435'), ({'text': 'Patients e 18 years of age', 'entities': [['12', '20', 'lower_bound'], ['24', '27', 'age']]}, 'NCT02582827'), ({'text': 'Chronic myeloid leukemia (CML) second chronic phase or accelerated phase', 'entities': [['1', '31', 'cancer']]}, 'NCT01619761'), ({'text': 'History of human immunodeficiency virus (HIV) or HIV-positive patients on combination antiretroviral therapy are ineligible', 'entities': [['12', '46', 'chronic_disease'], ['42', '45', 'chronic_disease'], ['87', '109', 'treatment']]}, 'NCT01591356'), ({'text': 'Overactive bladder without obstructive symptoms (i.e. decrease in force of stream, hesitancy, intermittency, post-void dribbling)', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT01589263'), ({'text': 'B1: Refractory or relapsed neuroblastoma', 'entities': [['5', '15', 'cancer'], ['19', '41', 'cancer']]}, 'NCT02124772'), ({'text': 'Solid Tumor Expansion Cohort: CD4+ cell count greater than 200 cells/mm^3 obtained within 2 weeks prior to enrollment at any U.S. laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent', 'entities': [['1', '12', 'cancer'], ['31', '46', 'clinical_variable'], ['60', '74', 'lower_bound'], ['91', '104', 'upper_bound']]}, 'NCT02408861'), ({'text': 'Diagnosis of advanced cancer (defined as locally advanced, metastatic recurrent, or incurable disease)', 'entities': [['14', '29', 'cancer']]}, 'NCT03021486'), ({'text': 'asymptomatic viremia', 'entities': [['14', '21', 'chronic_disease']]}, 'NCT02424968'), ({'text': 'Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than 3 years or indolent tumors for which observation over three years is a reasonable option', 'entities': [['13', '25', 'cancer'], ['44', '68', 'cancer'], ['92', '120', 'cancer'], ['217', '224', 'lower_bound'], ['271', '282', 'lower_bound']]}, 'NCT01815359'), ({'text': 'Decreased renal function evidenced by GFR < 60 ml/min/1.73m2', 'entities': [['39', '42', 'clinical_variable'], ['45', '61', 'upper_bound']]}, 'NCT00929006'), ({'text': 'evidence of fibrosis on bone marrow biopsy', 'entities': [['13', '21', 'chronic_disease'], ['25', '43', 'treatment']]}, 'NCT00044304'), ({'text': 'Have non-musculoskeletal pain syndromes (headache, facial pain, chest pain, visceral abdominal pain) if these are the sole source of pain, but can be present as co-morbid conditions as long as a patient has a primary musculoskeletal pain condition defined s above', 'entities': [['6', '40', 'chronic_disease'], ['218', '248', 'chronic_disease']]}, 'NCT02979574'), ({'text': 'Uncontrolled relapse of malignancy', 'entities': [['25', '35', 'cancer']]}, 'NCT02532452'), ({'text': 'Subjects with history of significant cardio pulmonary disorders', 'entities': [['38', '64', 'chronic_disease']]}, 'NCT02485418'), ({'text': 'Therapeutic anticoagulation requiring international normalized ratio (INR) > 2.0', 'entities': [['1', '28', 'treatment'], ['39', '75', 'clinical_variable'], ['78', '81', 'lower_bound']]}, 'NCT02020707'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status 0-2', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['64', '65', 'upper_bound']]}, 'NCT03153982'), ({'text': 'Prior ipsilateral knee surgery such as ligament reconstruction or osteotomy', 'entities': [['7', '31', 'treatment'], ['40', '63', 'treatment'], ['67', '76', 'treatment']]}, 'NCT03053453'), ({'text': 'Age 18 to 80 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['11', '19', 'upper_bound']]}, 'NCT03094663'), ({'text': 'angioplasty', 'entities': [['1', '12', 'treatment']]}, 'NCT02875301'), ({'text': 'Chronic pain syndromes', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02744352'), ({'text': 'History of rheumatoid arthritis', 'entities': [['12', '32', 'chronic_disease']]}, 'NCT03032432'), ({'text': '0-84 days postnatal age at time of first study dose or when enrolled into the non-intervention cohort', 'entities': [['1', '2', 'lower_bound'], ['3', '10', 'upper_bound'], ['21', '24', 'age']]}, 'NCT02913612'), ({'text': 'Bilirubin =< 1.5 x ULN (CTCAE v 3.0 grade 1)', 'entities': [['1', '10', 'clinical_variable'], ['14', '23', 'upper_bound']]}, 'NCT00492778'), ({'text': 'Soft tissue sarcomas (Rhabdomyosarcoma, Ewing sarcoma, Primitive Neuroectodermal Tumor or other high-risk extracranial solid tumors)', 'entities': [['1', '21', 'cancer'], ['23', '39', 'cancer'], ['41', '54', 'cancer'], ['56', '87', 'cancer'], ['107', '132', 'cancer']]}, 'NCT02508038'), ({'text': 'Subjects with known diabetes and those taking metformin, sulfonylureas, thiazolidinediones or insulin for any reason', 'entities': [['21', '29', 'chronic_disease'], ['47', '56', 'treatment'], ['58', '71', 'treatment'], ['73', '91', 'treatment'], ['95', '102', 'treatment']]}, 'NCT02122185'), ({'text': 'Hysterectomy at the time of sacrocolpopexy', 'entities': [['1', '13', 'treatment'], ['29', '43', 'treatment']]}, 'NCT02908841'), ({'text': 'Metallic implants', 'entities': [['1', '18', 'treatment']]}, 'NCT02457832'), ({'text': 'Willing to remain abstinent for the 14 days before the baseline assessments and throughout the two scans', 'entities': [['37', '44', 'upper_bound']]}, 'NCT01964404'), ({'text': 'History of cancer', 'entities': [['12', '18', 'cancer']]}, 'NCT02911792'), ({'text': 'GFR > 59', 'entities': [['1', '4', 'clinical_variable'], ['7', '9', 'lower_bound']]}, 'NCT01750567'), ({'text': 'e3 VT episodes within 24 hours', 'entities': [['2', '3', 'lower_bound'], ['4', '15', 'clinical_variable'], ['23', '31', 'upper_bound']]}, 'NCT02830360'), ({'text': 'AST(SGOT), ALT(SGPT), and alkaline phosphatase d 3 times the upper limit of normal', 'entities': [['1', '10', 'clinical_variable'], ['12', '21', 'clinical_variable'], ['27', '47', 'clinical_variable'], ['50', '83', 'upper_bound']]}, 'NCT02259621'), ({'text': 'Taking Phosphodiesterase (PDE) 5 inhibitors (e.g., Viagra®, Cialis®, Levitra®, or Revatio®); PDE 3 inhibitors (e.g., cilostazol, milrinone, or vesnarinone); lithium', 'entities': [['8', '44', 'treatment'], ['52', '59', 'treatment'], ['61', '68', 'treatment'], ['70', '78', 'treatment'], ['83', '91', 'treatment'], ['94', '110', 'treatment'], ['118', '128', 'treatment'], ['130', '139', 'treatment'], ['144', '155', 'treatment'], ['158', '165', 'treatment']]}, 'NCT01983462'), ({'text': 'Any patient falling within age group with granulation tissue around G tube site', 'entities': [['28', '31', 'age']]}, 'NCT02519738'), ({'text': '18 years or older', 'entities': [['1', '9', 'lower_bound']]}, 'NCT02323100'), ({'text': 'Previous documented diagnosis of cardiac arrhythmia by holter monitor, event monitor, ECG', 'entities': [['34', '52', 'chronic_disease'], ['56', '70', 'chronic_disease'], ['72', '85', 'chronic_disease'], ['87', '90', 'chronic_disease']]}, 'NCT03001765'), ({'text': 'Currently receiving any investigational agents', 'entities': [['25', '47', 'treatment']]}, 'NCT02584309'), ({'text': 'Significant liver disease defined as known cirrhosis or elevated transaminases of at least 3-fold upper limit of normal', 'entities': [['13', '26', 'chronic_disease'], ['44', '53', 'chronic_disease'], ['92', '93', 'lower_bound']]}, 'NCT03060473'), ({'text': 'History of acute pancreatitis within one year of study or history of chronic pancreatitis', 'entities': [['12', '30', 'chronic_disease'], ['38', '46', 'upper_bound'], ['70', '90', 'chronic_disease']]}, 'NCT02272998'), ({'text': "Kaposi's sarcoma restricted to the skin, unless subject considered cured", 'entities': [['1', '17', 'cancer']]}, 'NCT02159027'), ({'text': 'Life expectancy of less than 6 months', 'entities': [['1', '16', 'clinical_variable'], ['30', '38', 'upper_bound']]}, 'NCT01992861'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT03153319'), ({'text': 'non-pregnant female', 'entities': [['1', '13', 'pregnancy'], ['14', '20', 'gender']]}, 'NCT02004028'), ({'text': "Two consecutive HIV DNA tests with no DNA detected in at least 850,000 PBMCs assayed (performed in the study's designated central laboratory) at least 8 weeks apart", 'entities': [['17', '20', 'chronic_disease'], ['64', '77', 'lower_bound'], ['152', '159', 'lower_bound']]}, 'NCT02140255'), ({'text': 'Active chronic infection such as hepatitis B or C or an active malignancy that requires systemic chemotherapy', 'entities': [['1', '25', 'chronic_disease'], ['34', '50', 'chronic_disease'], ['64', '74', 'cancer'], ['89', '110', 'treatment']]}, 'NCT02610374'), ({'text': 'Patients with a known nonmalignant disease that is not clearly defined will need to be discussed with the protocol principal investigator (PI) (Dr. Lauri Burroughs) and potentially the nonmalignant board to determine if they are eligible for HCT on this study', 'entities': [['23', '43', 'cancer']]}, 'NCT00919503'), ({'text': 'All tumors must test positive for Rb expression', 'entities': [['5', '11', 'cancer']]}, 'NCT01037790'), ({'text': 'Echocardiogram demonstrated left ventricular ejection fraction >= 40%', 'entities': [['1', '15', 'clinical_variable'], ['67', '70', 'lower_bound']]}, 'NCT01562626'), ({'text': 'Stable, motor-complete paraplegia', 'entities': [['9', '34', 'chronic_disease']]}, 'NCT03026816'), ({'text': 'Males', 'entities': [['1', '6', 'gender']]}, 'NCT02332850'), ({'text': 'age to <18 years old', 'entities': [['1', '4', 'age'], ['9', '17', 'upper_bound']]}, 'NCT03003390'), ({'text': 'Patients must have received at least one regimen for systemic disease which may be cytotoxic or oral tyrosine kinase inhibitor therapy', 'entities': [['54', '70', 'chronic_disease'], ['84', '93', 'treatment'], ['97', '135', 'treatment']]}, 'NCT02132598'), ({'text': 'Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control* (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 120 days after the final study drug administration', 'entities': [['1', '13', 'gender'], ['24', '46', 'gender'], ['89', '207', 'contraception_consent'], ['279', '293', 'upper_bound']]}, 'NCT02236013'), ({'text': 'Use of any antiplatelet therapy (except aspirin and clopidogrel)', 'entities': [['12', '32', 'treatment'], ['41', '48', 'treatment'], ['53', '64', 'treatment']]}, 'NCT02539160'), ({'text': 'LAA closure with the WATCHMAN device is planned', 'entities': [['1', '37', 'treatment']]}, 'NCT03088072'), ({'text': 'A score < 80 on the Core Language score of the Clinical Evaluation of Language Fundamentals', 'entities': [['11', '13', 'upper_bound'], ['21', '92', 'clinical_variable']]}, 'NCT02483910'), ({'text': 'Established diagnosis of affective psychotic illness (Bipolar disorder or MDD with psychotic features) or psychosis secondary to substance use or a medical illness', 'entities': [['36', '53', 'chronic_disease'], ['55', '71', 'chronic_disease'], ['75', '78', 'chronic_disease'], ['107', '126', 'chronic_disease']]}, 'NCT02069925'), ({'text': 'a fully Human leukocyte antigen (HLA)-matched (10/10) related donor', 'entities': [['9', '38', 'clinical_variable']]}, 'NCT02928991'), ({'text': 'Patients will have recovered from toxicities from prior systemic anticancer treatment or local therapies', 'entities': [['51', '86', 'treatment'], ['90', '105', 'treatment']]}, 'NCT02541903'), ({'text': "Bilirubin < 2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 times ULN)", 'entities': [['1', '10', 'clinical_variable'], ['13', '52', 'upper_bound'], ['75', '93', 'chronic_disease'], ['110', '125', 'clinical_variable'], ['131', '142', 'upper_bound']]}, 'NCT02120222'), ({'text': 'Transmural myocardial infarction within the last 6 months', 'entities': [['1', '33', 'chronic_disease'], ['45', '58', 'upper_bound']]}, 'NCT03077243'), ({'text': 'History of interstitial lung disease/pneumonitis', 'entities': [['12', '37', 'chronic_disease'], ['38', '49', 'chronic_disease']]}, 'NCT02592551'), ({'text': 'Regularly exercise at least 30 minutes 3 times per week', 'entities': [['29', '56', 'lower_bound']]}, 'NCT02411318'), ({'text': 'Patients on non-aspirin anti-coagulation (Coumadin, heparins, or clopidogrel) or with documented bleeding disorders will be excluded due to risk of bleeding with biopsy', 'entities': [['43', '51', 'treatment'], ['53', '61', 'treatment'], ['66', '77', 'treatment'], ['98', '116', 'chronic_disease'], ['163', '169', 'treatment']]}, 'NCT03096418'), ({'text': 'For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception', 'entities': [['5', '24', 'gender'], ['7', '24', 'gender'], ['74', '128', 'contraception_consent']]}, 'NCT03178552'), ({'text': 'Liver function: ALT and AST =< 2.5 times the institutional upper limits of normal', 'entities': [['17', '20', 'clinical_variable'], ['25', '28', 'clinical_variable'], ['32', '82', 'upper_bound']]}, 'NCT02146924'), ({'text': 'Bilirubin < 1.5 mg/dL', 'entities': [['1', '10', 'clinical_variable'], ['13', '22', 'upper_bound']]}, 'NCT02303977'), ({'text': 'Hemoglobin e 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb e 8.0 g/dL is acceptable)', 'entities': [['1', '11', 'clinical_variable'], ['14', '22', 'lower_bound'], ['86', '89', 'clinical_variable']]}, 'NCT01554410'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02834403'), ({'text': 'Stage III/IV oral cavity or paranasal sinus cancers in patients who refuse surgery or are unfit for surgery', 'entities': [['1', '10', 'lower_bound'], ['11', '13', 'lower_bound'], ['29', '52', 'cancer'], ['76', '83', 'treatment']]}, 'NCT02031250'), ({'text': '0.025 mmol per kg body weight for Gadoxetic acid and 0.1 mmol per kg body weight for all other agents', 'entities': [['35', '49', 'treatment']]}, 'NCT01853163'), ({'text': 'Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (HCVAb)', 'entities': [['27', '61', 'chronic_disease'], ['63', '98', 'chronic_disease'], ['103', '137', 'chronic_disease']]}, 'NCT03140527'), ({'text': 'Clinically significant ECG assessments should be reviewed by the site cardiologist prior to study entry', 'entities': [['24', '27', 'treatment']]}, 'NCT01943851'), ({'text': 'Partial thromboplastin time (PTT) within normal limits (±15%)', 'entities': [['1', '55', 'clinical_variable'], ['58', '61', 'lower_bound']]}, 'NCT02921022'), ({'text': 'whose weight has remained stable for six months', 'entities': [['38', '48', 'upper_bound']]}, 'NCT02217345'), ({'text': 'ECG without evidence of clinically significant arrhythmia or ischemia', 'entities': [['1', '4', 'treatment'], ['48', '58', 'chronic_disease'], ['62', '70', 'chronic_disease']]}, 'NCT02501473'), ({'text': 'Part A: Patients with recurrent or refractory solid tumors, including lymphoma and CNS tumors', 'entities': [['47', '59', 'cancer'], ['71', '79', 'cancer'], ['84', '94', 'cancer']]}, 'NCT02323880'), ({'text': 'Prior therapy with one second line hormonal therapy is allowed (i.e. bicalutamide, nilutamide, flutamide, ketoconazole, abiraterone, enzalutamide, ARN-509)', 'entities': [['1', '14', 'treatment'], ['36', '52', 'treatment'], ['70', '82', 'treatment'], ['84', '94', 'treatment'], ['96', '105', 'treatment'], ['107', '119', 'treatment'], ['121', '132', 'treatment'], ['134', '146', 'treatment'], ['148', '155', 'treatment']]}, 'NCT02995330'), ({'text': 'Cystic fibrosis', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02554383'), ({'text': 'ECOG performance status d2', 'entities': [['1', '24', 'clinical_variable'], ['26', '27', 'upper_bound']]}, 'NCT01670877'), ({'text': 'Patients that have an intolerance to Toradol', 'entities': [['38', '45', 'treatment']]}, 'NCT02219581'), ({'text': 'Patients who have received a solid organ transplantation', 'entities': [['30', '57', 'treatment']]}, 'NCT02354547'), ({'text': 'Substantial cognitive impairment', 'entities': [['1', '33', 'chronic_disease']]}, 'NCT02778282'), ({'text': 'Patients must have at least one confirmed and evaluable tumor site', 'entities': [['57', '62', 'cancer']]}, 'NCT01811498'), ({'text': "Bilirubin < 1.5 mg/dL with the exception of patients thought to have Gilbert's syndrome, who may have a total bilirubin above 1.5 mg/dL", 'entities': [['1', '10', 'clinical_variable'], ['70', '88', 'chronic_disease'], ['111', '120', 'clinical_variable']]}, 'NCT01434472'), ({'text': 'Estimated gestational age less than 24 0/7 weeks', 'entities': [['11', '26', 'clinical_variable'], ['37', '49', 'upper_bound']]}, 'NCT02913495'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01061515'), ({'text': 'Recovery from e grade 2 toxicities of prior therapy regimen to grade 1 or baseline, with the exception of anemia and lymphopenia and chronic residual toxicities', 'entities': [['17', '24', 'lower_bound'], ['39', '60', 'treatment'], ['107', '113', 'chronic_disease'], ['118', '129', 'chronic_disease']]}, 'NCT02349867'), ({'text': 'Patients who have received pelvic external beam radiotherapy are not eligible', 'entities': [['28', '61', 'treatment']]}, 'NCT02037048'), ({'text': 'Age <18 years', 'entities': [['1', '4', 'age'], ['6', '14', 'upper_bound']]}, 'NCT02327403'), ({'text': 'Peritoneal or hemodialysis within 90 days or anticipation that dialysis or ultrafiltration of any form will be required during the study period', 'entities': [['1', '11', 'treatment'], ['15', '27', 'treatment'], ['19', '27', 'treatment'], ['35', '42', 'upper_bound'], ['76', '91', 'treatment']]}, 'NCT02058095'), ({'text': 'Presence of an serious illness, uncontrolled illness, or active infection requiring IV antibiotics', 'entities': [['16', '31', 'chronic_disease'], ['58', '74', 'chronic_disease'], ['85', '99', 'treatment']]}, 'NCT03146663'), ({'text': 'Those with leptomeningeal metastases as the only site of CNS disease', 'entities': [['12', '37', 'cancer'], ['58', '69', 'chronic_disease']]}, 'NCT01494662'), ({'text': 'Time elapsed since amputation more than 6 months but less than 15 years', 'entities': [['20', '30', 'treatment'], ['41', '49', 'lower_bound'], ['64', '72', 'upper_bound']]}, 'NCT01293214'), ({'text': 'psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders', 'entities': [['1', '21', 'chronic_disease'], ['34', '49', 'chronic_disease'], ['39', '49', 'chronic_disease'], ['56', '69', 'chronic_disease'], ['71', '87', 'chronic_disease'], ['107', '133', 'chronic_disease']]}, 'NCT02567448'), ({'text': 'osteoporosis by axial bone density (spine, hip or forearm bone mineral density (BMD) T-score d -2.5 SD)', 'entities': [['1', '13', 'chronic_disease'], ['59', '93', 'clinical_variable'], ['97', '103', 'upper_bound']]}, 'NCT02589600'), ({'text': 'Alkaline phosphatase < 2.5xULN', 'entities': [['1', '21', 'clinical_variable'], ['24', '31', 'upper_bound']]}, 'NCT02578732'), ({'text': 'Negative pregnancy test (if female of childbearing potential)', 'entities': [['1', '19', 'pregnancy'], ['29', '35', 'gender']]}, 'NCT01945814'), ({'text': 'At least 21 years old', 'entities': [['10', '18', 'lower_bound']]}, 'NCT02964039'), ({'text': 'HIV-infected', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT02907944'), ({'text': 'patients who are found to be pathologically node-positive at the time of surgery, based on sentinel node biopsy alone, are candidates for A011202, a study developed by the Alliance in Oncology, an NCI Cooperative Group', 'entities': [['74', '81', 'treatment'], ['92', '112', 'treatment']]}, 'NCT01872975'), ({'text': 'Neuropsychiatric Inventory (NPI) agitation/aggression subscale score > 4. On each subscale (frequency X severity), a score higher than 4 represents moderate to severe symptoms', 'entities': [['1', '69', 'clinical_variable'], ['72', '73', 'lower_bound'], ['105', '113', 'clinical_variable']]}, 'NCT02129348'), ({'text': 'Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic glucocorticoids within 28 days of the first planned dose of PROSTVAC-V/F', 'entities': [['81', '88', 'lower_bound'], ['93', '117', 'treatment'], ['125', '132', 'upper_bound'], ['162', '174', 'treatment']]}, 'NCT02772562'), ({'text': 'Uncontrolled bacterial, viral or fungal infection defined as currently taking medication and progression of clinical symptoms', 'entities': [['14', '23', 'chronic_disease'], ['25', '30', 'chronic_disease'], ['34', '50', 'chronic_disease'], ['79', '89', 'treatment']]}, 'NCT02424968'), ({'text': 'Pregnant and/or breastfeeding', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02573493'), ({'text': 'Subjects with recurrent disease > 6 months after adjuvant or neoadjuvant platinum-based chemotherapy, who also subsequently progressed during or after a platinum-doublet regimen given to treat the recurrences, are eligible and do not count as another line of therapy for advanced disease', 'entities': [['35', '43', 'lower_bound'], ['50', '101', 'treatment'], ['154', '209', 'treatment'], ['260', '288', 'treatment']]}, 'NCT01928576'), ({'text': 'Active serious infections not controlled by antibiotics', 'entities': [['45', '56', 'treatment']]}, 'NCT01920737'), ({'text': 'investigational anticancer agent within 14 days or 4 halflives, whichever is longer, up to a maximum wash-out period of 28 days prior to the initiation of study drug administration', 'entities': [['17', '33', 'treatment'], ['41', '48', 'upper_bound'], ['121', '134', 'upper_bound']]}, 'NCT02908906'), ({'text': 'lobular', 'entities': [['1', '8', 'cancer']]}, 'NCT01766297'), ({'text': 'Major psychiatric illness', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT02563574'), ({'text': 'Must have completed at last 2 months of current endocrine therapy prior to registration', 'entities': [['29', '37', 'upper_bound'], ['49', '66', 'treatment']]}, 'NCT03092635'), ({'text': 'Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomization', 'entities': [['1', '49', 'treatment'], ['57', '64', 'upper_bound'], ['68', '83', 'upper_bound']]}, 'NCT02091141'), ({'text': "The participant has any clinically significant medical, psychiatric, or cognitive illness, or any other uncontrolled medical condition (eg, unstable angina, transient ischemic attack) that, in the opinion of the investigator, would impede the participant's ability to comply with the study procedures, pose increased risk to the participant's safety, or confound the interpretation of study results", 'entities': [['48', '55', 'chronic_disease'], ['57', '68', 'chronic_disease'], ['73', '90', 'chronic_disease'], ['141', '156', 'chronic_disease'], ['158', '183', 'chronic_disease']]}, 'NCT02525861'), ({'text': 'RRP (Recurrent Respiratory Papillomatosis)', 'entities': [['1', '43', 'chronic_disease']]}, 'NCT02634957'), ({'text': 'Hemoglobin < 10 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['14', '21', 'upper_bound']]}, 'NCT02937350'), ({'text': 'Willing and able to comply with scheduled visits, treatment plan and laboratory tests', 'entities': [['51', '60', 'treatment']]}, 'NCT02098161'), ({'text': "History of TBI, psychiatric illness (DSM criteria) and or organic brain syndrome (e.g. Alzheimer's)", 'entities': [['12', '15', 'chronic_disease'], ['17', '36', 'chronic_disease'], ['59', '81', 'chronic_disease'], ['88', '99', 'chronic_disease']]}, 'NCT02366754'), ({'text': 'Age e 18 years old', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT03096288'), ({'text': 'Contraindications to MRI scans (eg, claustrophobia, metal in body)', 'entities': [['22', '31', 'treatment'], ['37', '51', 'chronic_disease']]}, 'NCT02231073'), ({'text': 'Use of all other prescription medications, except required pre-op medications and birth control, is prohibited within 3 days of dosing with study drug', 'entities': [['18', '42', 'treatment'], ['60', '78', 'treatment'], ['119', '125', 'upper_bound'], ['141', '151', 'treatment']]}, 'NCT01959204'), ({'text': 'Have an ICD-9 diagnosis code consistent with endocarditis', 'entities': [['46', '58', 'chronic_disease']]}, 'NCT02216227'), ({'text': 'Women of childbearing potential must have a negative serum ²-hCG pregnancy test or a negative urine pregnancy test', 'entities': [['1', '6', 'gender'], ['45', '75', 'pregnancy'], ['86', '110', 'pregnancy']]}, 'NCT02495545'), ({'text': 'Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening', 'entities': [['1', '31', 'chronic_disease'], ['33', '66', 'clinical_variable'], ['67', '76', 'lower_bound'], ['91', '99', 'upper_bound']]}, 'NCT02132598'), ({'text': 'Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing)', 'entities': [['24', '37', 'chronic_disease'], ['45', '55', 'clinical_variable'], ['69', '79', 'lower_bound'], ['84', '105', 'clinical_variable']]}, 'NCT01940757'), ({'text': 'Normal Karyotype', 'entities': [['8', '17', 'treatment']]}, 'NCT02530073'), ({'text': 'Patient must be >18 years of age', 'entities': [['18', '26', 'lower_bound'], ['30', '33', 'age']]}, 'NCT02213497'), ({'text': 'minimal residual disease (MRD) positivity', 'entities': [['1', '31', 'chronic_disease']]}, 'NCT01660607'), ({'text': 'Enrollment into this study may occur in tandem with other clinical therapeutics trials occurring at Vanderbilt University Medical Center (VUMC) as long as this trial does not violate protocol or inclusion criteria of that study', 'entities': [['53', '87', 'treatment']]}, 'NCT02937402'), ({'text': 'suicidal ideation with plan or intent', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02927847'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT02588612'), ({'text': 'pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest', 'entities': [['70', '78', 'chronic_disease'], ['82', '106', 'chronic_disease'], ['150', '164', 'chronic_disease']]}, 'NCT02728284'), ({'text': 'Absolute neutrophil count >= 1500/uL', 'entities': [['1', '26', 'clinical_variable'], ['30', '37', 'lower_bound']]}, 'NCT02451553'), ({'text': 'Diabetes mellitus, defined as pre-existing diagnosis, fasting blood glucose > 125 mg/dl, or glycosylated hemoglobin >/= 6.5%', 'entities': [['1', '18', 'chronic_disease'], ['55', '76', 'clinical_variable'], ['79', '88', 'lower_bound'], ['93', '116', 'clinical_variable'], ['121', '125', 'lower_bound']]}, 'NCT01950234'), ({'text': 'Creatinine within normal institutional limits or creatinine clearance greater than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal', 'entities': [['1', '11', 'clinical_variable'], ['19', '46', 'clinical_variable'], ['50', '70', 'clinical_variable'], ['96', '114', 'lower_bound'], ['133', '150', 'clinical_variable'], ['157', '177', 'clinical_variable']]}, 'NCT01624090'), ({'text': 'past 90 days', 'entities': [['1', '13', 'upper_bound']]}, 'NCT02964182'), ({'text': 'Patients who have received prior solid organ transplantation', 'entities': [['28', '61', 'treatment']]}, 'NCT02304458'), ({'text': 'Patients may not have had prior SGT-53', 'entities': [['27', '39', 'treatment']]}, 'NCT02354547'), ({'text': 'Have received an autologous or allogeneic stem-cell transplant', 'entities': [['18', '63', 'treatment']]}, 'NCT02107703'), ({'text': 'Mini Mental Exam < 24 or a diagnosis of dementia', 'entities': [['1', '17', 'clinical_variable'], ['20', '22', 'upper_bound'], ['41', '49', 'chronic_disease']]}, 'NCT01973283'), ({'text': 'Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to treatment', 'entities': [['43', '66', 'cancer'], ['74', '82', 'upper_bound'], ['92', '101', 'treatment']]}, 'NCT03077243'), ({'text': 'prior history of liver disease with transaminases more than 3 times the upper limit of normal for age', 'entities': [['18', '31', 'chronic_disease'], ['61', '94', 'lower_bound'], ['99', '102', 'age']]}, 'NCT03073070'), ({'text': 'Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields', 'entities': [['1', '19', 'treatment'], ['79', '96', 'treatment']]}, 'NCT01730937'), ({'text': 'No contraindications to MRI (e.g. pacemaker, aneurysm clips, severe claustrophobia)', 'entities': [['25', '28', 'treatment'], ['35', '44', 'treatment'], ['46', '60', 'treatment'], ['69', '83', 'chronic_disease']]}, 'NCT02776891'), ({'text': 'Prior radiation therapy', 'entities': [['1', '24', 'treatment']]}, 'NCT01737502'), ({'text': 'Prior radioembolization to the liver', 'entities': [['1', '24', 'treatment']]}, 'NCT02762266'), ({'text': 'father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment', 'entities': [['103', '117', 'upper_bound'], ['135', '150', 'treatment']]}, 'NCT02407171'), ({'text': "patients with lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, albinism, or other dermatologic or ocular condition that contraindicates the use of methoxsalen or markedly enhances photosensitivity in the investigator's judgment", 'entities': [['15', '34', 'chronic_disease'], ['36', '59', 'chronic_disease'], ['61', '90', 'chronic_disease'], ['92', '111', 'chronic_disease'], ['113', '134', 'chronic_disease'], ['136', '144', 'chronic_disease'], ['155', '167', 'chronic_disease'], ['171', '187', 'chronic_disease'], ['220', '231', 'treatment']]}, 'NCT02181257'), ({'text': 'Total bilirubin d 1.5 x ULN for age, direct bilirubin d ULN for age', 'entities': [['1', '16', 'clinical_variable'], ['19', '28', 'upper_bound'], ['33', '36', 'age'], ['38', '54', 'clinical_variable']]}, 'NCT02512926'), ({'text': 'child bearing potential terminated by surgery, radiation, menopause or current use of two approved methods of birth control', 'entities': [['39', '46', 'treatment'], ['48', '57', 'treatment'], ['80', '124', 'contraception_consent']]}, 'NCT01668082'), ({'text': 'Absolute neutrophil count (ANC) greater than or equal to 1500/mm3 (greater than or equal to 1.5 X 103/uL)', 'entities': [['1', '32', 'clinical_variable'], ['58', '66', 'lower_bound'], ['93', '105', 'lower_bound']]}, 'NCT02501096'), ({'text': 'breast cancer in situ with full surgical resection', 'entities': [['1', '22', 'cancer'], ['28', '51', 'treatment']]}, 'NCT01919619'), ({'text': 'Known positive serology for HIV', 'entities': [['29', '32', 'chronic_disease']]}, 'NCT03056339'), ({'text': 'Phase II: greater than or equal to 3 and less than or equal to 35 years of age', 'entities': [['36', '37', 'lower_bound'], ['64', '72', 'upper_bound'], ['76', '79', 'age']]}, 'NCT02390752'), ({'text': 'Prior radiation to the liver (Prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration.)', 'entities': [['1', '29', 'treatment'], ['31', '68', 'treatment'], ['105', '118', 'lower_bound']]}, 'NCT01312857'), ({'text': 'Evidence of an acute myocardial infarction d 1 month (30 days) before randomization', 'entities': [['16', '43', 'chronic_disease'], ['46', '53', 'upper_bound']]}, 'NCT02675114'), ({'text': 'HPV negative OPSCC as determined by determined by PCR', 'entities': [['1', '4', 'chronic_disease'], ['14', '19', 'cancer'], ['51', '54', 'treatment']]}, 'NCT02072148'), ({'text': 'have had documented evidence of menopause based on FSH and estradiol concentrations prior to initiation of HRT', 'entities': [['52', '55', 'treatment'], ['60', '84', 'clinical_variable'], ['108', '111', 'treatment']]}, 'NCT01532687'), ({'text': 'Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period', 'entities': [['15', '73', 'contraception_consent'], ['101', '113', 'upper_bound'], ['124', '133', 'treatment']]}, 'NCT01269853'), ({'text': 'Current or previous ocular disease in the study eye that in the opinion of the investigator may confound assessment of the macula, the retina, or central vision other that diabetic retinopathy', 'entities': [['21', '35', 'chronic_disease'], ['173', '193', 'chronic_disease']]}, 'NCT01988246'), ({'text': 'Total serum bilirubin =< 2.0 mg/dL', 'entities': [['1', '22', 'clinical_variable'], ['26', '35', 'upper_bound']]}, 'NCT02456857'), ({'text': 'Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs', 'entities': [['38', '61', 'allergy_name'], ['106', '120', 'allergy_name']]}, 'NCT02044120'), ({'text': 'Able to read or understand English at a 6th grade level', 'entities': [['1', '35', 'language_fluency'], ['41', '56', 'lower_bound']]}, 'NCT02637349'), ({'text': 'Patients receiving targeted therapy (non-cytotoxic systemic therapy) for NSCLC in the first-line setting', 'entities': [['20', '36', 'treatment'], ['38', '68', 'treatment'], ['74', '79', 'cancer']]}, 'NCT03137771'), ({'text': 'Palpable spleen e 5 cm that is below the costal margin on physical examination', 'entities': [['1', '16', 'clinical_variable'], ['19', '23', 'lower_bound']]}, 'NCT02158858'), ({'text': 'Subjects enrolled in other trials involving platelet transfusions, anti-fibrinolytics, platelet growth factors or other pro-coagulant agents', 'entities': [['45', '66', 'treatment'], ['68', '86', 'treatment'], ['88', '111', 'treatment'], ['121', '141', 'treatment']]}, 'NCT02578901'), ({'text': 'Subject has had major surgery', 'entities': [['17', '30', 'treatment']]}, 'NCT02393794'), ({'text': 'Patients not on stable doses of immunomodulators or biologics for at least 8 weeks', 'entities': [['33', '49', 'treatment'], ['53', '62', 'treatment'], ['76', '83', 'lower_bound']]}, 'NCT02392286'), ({'text': 'Genotypically confirmed DMD, with genetic deletion amenable to exon 45 or exon 53 skipping', 'entities': [['25', '28', 'chronic_disease']]}, 'NCT02500381'), ({'text': 'Hematocrit <35%', 'entities': [['1', '11', 'clinical_variable'], ['13', '16', 'upper_bound']]}, 'NCT02362308'), ({'text': 'Hemoglobin < 10.5 or hematocrit < 32', 'entities': [['1', '11', 'clinical_variable'], ['14', '18', 'upper_bound'], ['22', '32', 'clinical_variable'], ['35', '37', 'upper_bound']]}, 'NCT02591173'), ({'text': 'HIV-positive patients on combination antiretroviral therapy, because of the potential for pharmacokinetic interactions with vismodegib', 'entities': [['1', '4', 'chronic_disease'], ['38', '60', 'treatment'], ['125', '135', 'treatment']]}, 'NCT01835626'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01666080'), ({'text': 'Patients may receive platelet or red blood cell transfusions to maintain hemoglobin and platelets at clinical appropriate levels', 'entities': [['22', '30', 'treatment'], ['34', '61', 'treatment'], ['74', '84', 'clinical_variable'], ['89', '98', 'clinical_variable'], ['102', '129', 'clinical_variable']]}, 'NCT01099644'), ({'text': 'medical condition that would interfere with walking and training for 30 minutes', 'entities': [['1', '18', 'chronic_disease'], ['70', '80', 'upper_bound']]}, 'NCT02266004'), ({'text': 'Albumin e 3.0 g/dL', 'entities': [['1', '8', 'clinical_variable'], ['11', '19', 'lower_bound']]}, 'NCT02553642'), ({'text': 'Any history of congenital long QT syndrome', 'entities': [['16', '43', 'chronic_disease']]}, 'NCT01822522'), ({'text': 'History of or current relevant CNS pathology', 'entities': [['32', '35', 'chronic_disease']]}, 'NCT02290951'), ({'text': 'Age e18 years old', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02522871'), ({'text': 'enrolled in the lenalidomide cohort must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program', 'entities': [['17', '29', 'treatment'], ['66', '75', 'pregnancy']]}, 'NCT02446457'), ({'text': 'Patients treated for tuberculosis with no recurrence in 3 years are permitted', 'entities': [['22', '34', 'chronic_disease'], ['57', '64', 'upper_bound']]}, 'NCT02043548'), ({'text': 'Autism diagnosis', 'entities': [['1', '7', 'chronic_disease']]}, 'NCT02764138'), ({'text': 'Features atypical of idiopathic Parkinson s disease', 'entities': [['10', '52', 'chronic_disease']]}, 'NCT01581580'), ({'text': 'At least 21 days after the last dose of myelosuppressive chemotherapy', 'entities': [['10', '17', 'lower_bound'], ['41', '70', 'treatment']]}, 'NCT02354547'), ({'text': 'HIV antibody or viral load positive', 'entities': [['1', '13', 'clinical_variable'], ['17', '27', 'clinical_variable']]}, 'NCT02707692'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status 0-2', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['64', '65', 'upper_bound']]}, 'NCT02098161'), ({'text': 'Vaccines and immunotherapy All of these exceptions should be confirmed with the Principal Investigator (PI) prior to registration', 'entities': [['1', '27', 'treatment']]}, 'NCT02312245'), ({'text': 'Heterotopic ossification of the knee region', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT01983475'), ({'text': 'used nicotine replacement, bupropion or other pharmacotherapies as cessation aids in the past month', 'entities': [['6', '26', 'treatment'], ['28', '37', 'treatment'], ['41', '64', 'treatment']]}, 'NCT02250534'), ({'text': 'At study screening, patient is receiving anti-epileptic medications to control active seizures', 'entities': [['42', '68', 'treatment'], ['87', '95', 'chronic_disease']]}, 'NCT02366754'), ({'text': 'Cardiac disease', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02740595'), ({'text': 'Patients who suffer from generalized anxiety disorder', 'entities': [['38', '54', 'chronic_disease']]}, 'NCT02046330'), ({'text': 'Individuals electing surgery to treat their POP', 'entities': [['22', '29', 'treatment']]}, 'NCT01886794'), ({'text': 'For men and women of reproductive potential, agreement to use an effective contraceptive method from the time of screening and throughout their time on study', 'entities': [['5', '8', 'gender'], ['13', '18', 'gender'], ['46', '96', 'contraception_consent']]}, 'NCT02921022'), ({'text': 'other retinal disease', 'entities': [['7', '22', 'chronic_disease']]}, 'NCT02402660'), ({'text': 'No evidence of metastatic disease', 'entities': [['16', '34', 'cancer']]}, 'NCT02562716'), ({'text': 'Patients with oxygen saturation of <92% on room air by pulse oximetry', 'entities': [['15', '32', 'clinical_variable'], ['37', '40', 'upper_bound']]}, 'NCT01876511'), ({'text': 'Must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks and discomforts', 'entities': [['192', '199', 'treatment']]}, 'NCT01360606'), ({'text': 'Severe CF liver disease, as defined by portal hypertension', 'entities': [['8', '24', 'chronic_disease'], ['40', '59', 'chronic_disease']]}, 'NCT01851694'), ({'text': 'Plexiform neurofibroma that is progressive OR causing significant morbidity', 'entities': [['1', '23', 'cancer']]}, 'NCT02101736'), ({'text': 'Uncorrectable coagulopathy', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT02089607'), ({'text': 'Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days)', 'entities': [['17', '51', 'chronic_disease'], ['55', '74', 'chronic_disease'], ['78', '85', 'upper_bound']]}, 'NCT02830360'), ({'text': 'Has any current primary diagnosis other than MDD, where primary diagnosis is defined as the primary source of current distress and functional impairment', 'entities': [['46', '49', 'chronic_disease']]}, 'NCT03188185'), ({'text': 'DSM-IV or DSM-5 diagnosis of schizophrenia or schizoaffective disorder', 'entities': [['30', '43', 'chronic_disease'], ['47', '71', 'chronic_disease']]}, 'NCT02968602'), ({'text': 'A baseline carbon monoxide (CO) reading less than or equal to 8ppm', 'entities': [['12', '32', 'clinical_variable'], ['63', '67', 'lower_bound']]}, 'NCT02837510'), ({'text': 'A diagnosis of CMML, unless in morphologic CR', 'entities': [['16', '20', 'cancer']]}, 'NCT02566304'), ({'text': 'undergoing anatomic lung resection for bullous disease, lung abscess or bronchiectasis', 'entities': [['12', '35', 'treatment'], ['40', '55', 'chronic_disease'], ['57', '69', 'chronic_disease'], ['73', '87', 'chronic_disease']]}, 'NCT02282462'), ({'text': 'Participation in another experimental therapeutic protocol within 6 months prior to baseline and during the study period', 'entities': [['18', '59', 'treatment'], ['67', '81', 'upper_bound']]}, 'NCT02234934'), ({'text': 'Women of childbearing potential must have a negative serum pregnancy test prior to study entry', 'entities': [['1', '6', 'gender'], ['45', '69', 'pregnancy']]}, 'NCT01849146'), ({'text': 'Lipase and amylase =< 2.0 x ULN and no radiologic or clinical evidence of pancreatitis', 'entities': [['1', '19', 'clinical_variable'], ['23', '32', 'upper_bound'], ['75', '87', 'chronic_disease']]}, 'NCT02496208'), ({'text': 'Age e19 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02459119'), ({'text': 'Other clinical concerns as documented by a site investigator that would predict (more likely to happen than not to happen) a risk of severe complications or very poor outcome during or after Stage II surgical repair', 'entities': [['134', '154', 'chronic_disease'], ['192', '216', 'treatment']]}, 'NCT01883076'), ({'text': 'Burkitt-like Lymphoma', 'entities': [['1', '22', 'cancer']]}, 'NCT01994382'), ({'text': 'Burkitt and/or precursor lymphoblastic leukemia/lymphoma', 'entities': [['1', '8', 'cancer'], ['16', '48', 'cancer'], ['49', '57', 'cancer']]}, 'NCT02213913'), ({'text': 'Clinically stable condition and not suffering from a respiratory tract infection or exacerbation of their disease (defined as a combination of increased cough, sputum purulence, shortness of breath, systemic symptoms such as fever, and a decrease in FEV1 > 10% compared with values when clinically stable in the preceding year) at least 4 weeks prior to the first test day', 'entities': [['54', '81', 'chronic_disease'], ['251', '255', 'clinical_variable'], ['258', '261', 'lower_bound'], ['338', '351', 'lower_bound']]}, 'NCT01787682'), ({'text': 'Have been diagnosed with a GI malabsorption disorder', 'entities': [['28', '53', 'chronic_disease']]}, 'NCT02778867'), ({'text': 'Pregnant or breast-feeding', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02642939'), ({'text': 'Known inborn errors of metabolism', 'entities': [['7', '34', 'chronic_disease']]}, 'NCT02579265'), ({'text': 'Multifunctional enzyme deficiency', 'entities': [['1', '34', 'chronic_disease']]}, 'NCT02171104'), ({'text': 'Patients must agree to pre- and post-treatment biopsies', 'entities': [['48', '56', 'treatment']]}, 'NCT02324608'), ({'text': 'positive sweat chloride 60 mEq/liter (by pilocarpine iontophoresis)', 'entities': [['10', '24', 'clinical_variable'], ['25', '37', 'upper_bound']]}, 'NCT02498535'), ({'text': 'Patients age 7-18 years old', 'entities': [['10', '13', 'age'], ['14', '15', 'lower_bound'], ['16', '24', 'upper_bound']]}, 'NCT02485418'), ({'text': 'Any cytogenetic abnormality in the bone marrow that is known to be associated with or predictive of myelodysplasia is excluded', 'entities': [['5', '47', 'cancer'], ['101', '115', 'cancer']]}, 'NCT02342782'), ({'text': 'Subjects may not have presence of active CNS disease or extramedullary disease', 'entities': [['42', '53', 'chronic_disease'], ['57', '79', 'cancer']]}, 'NCT02663622'), ({'text': 'Active lung cancer or history of lung cancer if it has been less than 2 years since lung resection or other treatment', 'entities': [['8', '19', 'cancer'], ['71', '78', 'upper_bound'], ['85', '99', 'treatment'], ['103', '118', 'treatment']]}, 'NCT02252588'), ({'text': 'severe dyspepsia', 'entities': [['8', '17', 'chronic_disease']]}, 'NCT01696734'), ({'text': 'Known active hepatitis C virus', 'entities': [['14', '31', 'chronic_disease']]}, 'NCT02401347'), ({'text': 'Age < 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'upper_bound']]}, 'NCT02323581'), ({'text': 'No patients that are known to be pregnant or nursing', 'entities': [['34', '42', 'pregnancy']]}, 'NCT00632853'), ({'text': 'undifferentiated/poorly differentiated carcinoma', 'entities': [['40', '49', 'cancer']]}, 'NCT02442323'), ({'text': 'Receiving any immunomodulator therapy within the past 3 months', 'entities': [['15', '38', 'treatment'], ['50', '63', 'upper_bound']]}, 'NCT02413047'), ({'text': 'Serum glutamic oxaloacetic transaminase (SGOT) (AST) d 2.5 x ULN', 'entities': [['1', '53', 'clinical_variable'], ['56', '65', 'upper_bound']]}, 'NCT02143726'), ({'text': 'Platelet count less than 100,000 cells/microliter (µL)', 'entities': [['1', '15', 'clinical_variable'], ['26', '55', 'upper_bound']]}, 'NCT02765633'), ({'text': 'No other active malignancy, except localized nonmelanotic skin cancer or any cancer that, in the judgment of the investigator, has been treated with curative intent and will not interfere with the study treatment plan and response assessment', 'entities': [['10', '27', 'cancer'], ['46', '70', 'cancer'], ['64', '70', 'cancer']]}, 'NCT00670358'), ({'text': 'cognitive or physical impairment that precludes study participation', 'entities': [['1', '33', 'chronic_disease']]}, 'NCT02161211'), ({'text': 'Patients with history of recurrent venous thromboembolism (deep venous thrombosis or pulmonary embolism) or history of venous thromboembolism', 'entities': [['36', '58', 'chronic_disease'], ['60', '82', 'chronic_disease'], ['86', '104', 'chronic_disease']]}, 'NCT02272998'), ({'text': 'has not yet had his/her thirteenth birthday', 'entities': [['25', '35', 'upper_bound'], ['36', '44', 'clinical_variable']]}, 'NCT01169155'), ({'text': 'HER2-overexpressing breast cancer (3+ staining by immunohistochemistry or HER2 gene amplification by fluorescent in situ hybridization [FISH] or silver in situ hybridization [SISH] >= 2.0)', 'entities': [['1', '5', 'clinical_variable'], ['21', '34', 'cancer'], ['51', '71', 'treatment'], ['75', '98', 'treatment'], ['102', '142', 'treatment'], ['146', '181', 'treatment'], ['185', '188', 'lower_bound']]}, 'NCT01622868'), ({'text': 'Histologic evidence of predominantly squamous cell NSCLC', 'entities': [['38', '57', 'cancer']]}, 'NCT02309892'), ({'text': 'Laboratory abnormalities defined as a hepatic panel greater than three times the upper limit of normal, or fasting glucose of < 60 or >120 mg/dl, or positive pregnancy test', 'entities': [['39', '52', 'clinical_variable'], ['66', '103', 'lower_bound'], ['108', '123', 'clinical_variable'], ['129', '131', 'lower_bound'], ['136', '145', 'upper_bound'], ['159', '168', 'pregnancy']]}, 'NCT02370732'), ({'text': 'Bowel obstruction below (distal to) ligament of Treitz', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02270450'), ({'text': 'Prior therapy with BCG', 'entities': [['1', '23', 'treatment']]}, 'NCT02553642'), ({'text': 'Are willing to participate in daily tweets or texts for up to 3 months', 'entities': [['16', '52', 'technology_access'], ['63', '71', 'upper_bound']]}, 'NCT02958189'), ({'text': 'Concomitant medications', 'entities': [['1', '24', 'treatment']]}, 'NCT02323880'), ({'text': 'Claustrophobia, metal implants, etc., affecting feasibility and/or safety of the fMRI scanning', 'entities': [['1', '15', 'chronic_disease'], ['82', '95', 'treatment']]}, 'NCT02393742'), ({'text': 'history of any cancer', 'entities': [['16', '22', 'cancer']]}, 'NCT02914171'), ({'text': 'Insomnia Severity Index questionnaire score <10', 'entities': [['1', '44', 'clinical_variable'], ['46', '48', 'upper_bound']]}, 'NCT02910648'), ({'text': 'No sooner than 45 days but no later than 90 days after allogeneic HSCT', 'entities': [['16', '23', 'lower_bound'], ['42', '55', 'upper_bound'], ['56', '71', 'treatment']]}, 'NCT02400255'), ({'text': 'To be eligible for the Part II fulvestrant-naïve ER+ cohort, prior treatment with fulvestrant is not allowed', 'entities': [['32', '43', 'treatment'], ['62', '94', 'treatment']]}, 'NCT01670877'), ({'text': 'Extracorporeal circulation therapy with Liposorber® LA-15 System cannot be tolerated due to severe cardiac insufficiency, acute myocardial infarction, severe cardiac arrhythmia, acute apoplexy, severe uncontrollable hypertension, or severe uncontrollable hypotension', 'entities': [['1', '65', 'treatment'], ['100', '121', 'chronic_disease'], ['123', '150', 'chronic_disease'], ['159', '177', 'chronic_disease'], ['185', '193', 'chronic_disease'], ['202', '229', 'chronic_disease'], ['241', '267', 'chronic_disease']]}, 'NCT02235857'), ({'text': 'Confirmed diagnosis of Stage IIIb/IV malignant melanoma or castration resistant adenocarcinoma of prostate (CRPC)', 'entities': [['24', '34', 'lower_bound'], ['35', '37', 'upper_bound'], ['38', '56', 'cancer'], ['60', '114', 'chronic_disease']]}, 'NCT02285101'), ({'text': 'Functionally ambulatory (self-reported ability to walk across a small room without assistance) during the 30 days prior to admission', 'entities': [['107', '120', 'upper_bound']]}, 'NCT03166371'), ({'text': 'Have WEE PRNT80 < 1:40 for booster series', 'entities': [['6', '16', 'clinical_variable'], ['19', '23', 'upper_bound']]}, 'NCT02466750'), ({'text': 'Documented diagnosis of sickle cell disease (SS or S-² thalassemia genotype)', 'entities': [['25', '44', 'chronic_disease'], ['46', '48', 'chronic_disease'], ['52', '76', 'chronic_disease']]}, 'NCT01757418'), ({'text': 'women who are pregnant or plan to become pregnant during the study', 'entities': [['1', '6', 'gender'], ['11', '23', 'pregnancy'], ['27', '50', 'pregnancy']]}, 'NCT02684201'), ({'text': 'Any surgical therapy in the area of the oral cavity or pharynx within the last 2 weeks', 'entities': [['5', '21', 'treatment'], ['75', '87', 'upper_bound']]}, 'NCT03085147'), ({'text': 'Parkinson disease', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT03108820'), ({'text': 'planning to become pregnant while enrolled in the study, up to the End of Study visit', 'entities': [['1', '28', 'pregnancy']]}, 'NCT02924402'), ({'text': 'Complex karyotype(e3 clonal chromosomal abnormalities)', 'entities': [['1', '18', 'clinical_variable'], ['20', '21', 'lower_bound'], ['22', '54', 'chronic_disease']]}, 'NCT01660607'), ({'text': 'Have not received any leukemia treatment within 1 week prior to starting study drug', 'entities': [['23', '41', 'treatment'], ['49', '61', 'upper_bound']]}, 'NCT01620216'), ({'text': 'Attends daycare with infants less than 6 months of age', 'entities': [['40', '48', 'upper_bound'], ['52', '55', 'age']]}, 'NCT01893554'), ({'text': 'Diagnosed with breast, colorectal, or prostate cancer (stages I-III)', 'entities': [['16', '69', 'cancer']]}, 'NCT03035773'), ({'text': 'Alkaline phosphatase < 3 x upper limit of normal', 'entities': [['1', '21', 'clinical_variable'], ['24', '49', 'upper_bound']]}, 'NCT01972919'), ({'text': 'Uncontrolled or significant cardiovascular disease', 'entities': [['29', '51', 'chronic_disease']]}, 'NCT02061761'), ({'text': 'Forced vital capacity <70% predicted', 'entities': [['1', '22', 'clinical_variable'], ['24', '27', 'upper_bound']]}, 'NCT03069716'), ({'text': 'ECOG performance status 0-1', 'entities': [['1', '24', 'clinical_variable'], ['25', '26', 'lower_bound'], ['27', '28', 'upper_bound']]}, 'NCT01871454'), ({'text': 'For two level disease, there may be up to a stable Grade I spondylolisthesis or equivalent retrolisthesis at ONLY ONE of the two contiguous affected levels as determined on flexion/extension films by the investigator', 'entities': [['52', '77', 'chronic_disease'], ['92', '106', 'chronic_disease']]}, 'NCT02555280'), ({'text': 'Capsular bag tearing beyond the point where the surgeon thinks it is in the best interest of the patient to have a capsular ring implanted', 'entities': [['116', '139', 'treatment']]}, 'NCT02332369'), ({'text': '> 40 kg', 'entities': [['3', '8', 'lower_bound']]}, 'NCT03016871'), ({'text': 'Hemoglobin e 7 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['14', '20', 'lower_bound']]}, 'NCT02516696'), ({'text': 'Current psychiatric illness', 'entities': [['9', '28', 'chronic_disease']]}, 'NCT02726906'), ({'text': 'Patients younger than 18 years old', 'entities': [['23', '31', 'upper_bound']]}, 'NCT01686659'), ({'text': 'Hemoglobin e 8.0 gm/dL; transfusion permitted to achieve this level', 'entities': [['1', '11', 'clinical_variable'], ['14', '23', 'lower_bound'], ['25', '36', 'treatment']]}, 'NCT01553071'), ({'text': 'Be healthy and psychologically stable as determined by screening for medical and psychiatric problems via a personal interview, a medical questionnaire, a physical examination, an electrocardiogram (ECG), and routine medical blood and urinalysis laboratory tests', 'entities': [['82', '102', 'chronic_disease'], ['181', '204', 'treatment']]}, 'NCT02243813'), ({'text': 'plans for carotid endarterectomy', 'entities': [['11', '33', 'treatment']]}, 'NCT03068442'), ({'text': 'History of hypersensitivity or adverse reaction to bupivacaine or narcotics', 'entities': [['52', '63', 'allergy_name'], ['67', '76', 'allergy_name']]}, 'NCT02969187'), ({'text': 'Any previously treated breast carcinoma', 'entities': [['24', '40', 'cancer']]}, 'NCT01766297'), ({'text': 'Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment', 'entities': [['15', '30', 'chronic_disease'], ['32', '40', 'chronic_disease'], ['42', '51', 'chronic_disease'], ['53', '82', 'chronic_disease'], ['97', '124', 'treatment']]}, 'NCT02912572'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status 0-2', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['64', '65', 'upper_bound']]}, 'NCT01953588'), ({'text': 'History of or known esophageal stricture or gross esophageal anatomic abnormalities', 'entities': [['21', '84', 'chronic_disease']]}, 'NCT03090607'), ({'text': 'undergone coronary artery bypass grafting', 'entities': [['11', '42', 'treatment']]}, 'NCT02664909'), ({'text': 'unipolar, nonpsychotic major depression (by SCID, DSM-V)', 'entities': [['1', '9', 'chronic_disease'], ['11', '40', 'chronic_disease']]}, 'NCT02891564'), ({'text': 'Subject with uncontrolled atrial fibrillation/flutter at screening (defined as ventricular response rate e 100 bpm)', 'entities': [['27', '46', 'chronic_disease'], ['80', '105', 'clinical_variable'], ['108', '115', 'lower_bound']]}, 'NCT02225548'), ({'text': 'Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy and continuing through the last dose of study therapy and for 90 days after the final dose of study drug', 'entities': [['1', '14', 'gender'], ['22', '70', 'contraception_consent'], ['109', '116', 'treatment'], ['179', '192', 'upper_bound'], ['211', '221', 'treatment']]}, 'NCT02585973'), ({'text': 'estimated glomerular filtration rate (eGFR) > 60 ml/min', 'entities': [['1', '44', 'clinical_variable'], ['47', '56', 'lower_bound']]}, 'NCT02589977'), ({'text': 'other psychiatric disorder', 'entities': [['7', '27', 'chronic_disease']]}, 'NCT02946268'), ({'text': 'sustained Hgb d8 g/dL and/or sustained ANC d1000/mm3', 'entities': [['11', '14', 'clinical_variable'], ['16', '22', 'upper_bound'], ['40', '43', 'clinical_variable'], ['45', '53', 'upper_bound']]}, 'NCT03002519'), ({'text': 'all participants of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 6 months after the last dose of study drug', 'entities': [['49', '83', 'contraception_consent'], ['90', '120', 'contraception_consent'], ['160', '174', 'upper_bound'], ['192', '202', 'treatment']]}, 'NCT01822522'), ({'text': 'Treatment for vascular problems', 'entities': [['1', '32', 'treatment']]}, 'NCT02982772'), ({'text': 'Absolute Lymphocytes e800/uL', 'entities': [['1', '21', 'clinical_variable'], ['23', '29', 'lower_bound']]}, 'NCT02384954'), ({'text': 'Absolute granulocyte count d 1,500/ul', 'entities': [['1', '27', 'clinical_variable'], ['30', '38', 'upper_bound']]}, 'NCT00906984'), ({'text': 'Subject is scheduled to undergo surgical intervention(s) as part of the standard care for management of intra-thoracic infection', 'entities': [['105', '129', 'chronic_disease']]}, 'NCT02803164'), ({'text': 'Patient has received other investigational drugs within 28 days before enrollment', 'entities': [['57', '64', 'upper_bound']]}, 'NCT02324439'), ({'text': 'Use of inhaled or topical corticosteroid is permitted', 'entities': [['8', '41', 'treatment']]}, 'NCT03104699'), ({'text': 'Primary Diagnosis of OA for TKA', 'entities': [['22', '24', 'chronic_disease'], ['29', '32', 'treatment']]}, 'NCT02926248'), ({'text': 'Participant is male and e 12 to d 75 years old at the time of screening', 'entities': [['16', '20', 'gender'], ['27', '29', 'lower_bound'], ['35', '43', 'upper_bound']]}, 'NCT02895945'), ({'text': 'History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 (VX-970) or cisplatin', 'entities': [['102', '116', 'allergy_name'], ['120', '129', 'allergy_name']]}, 'NCT02567422'), ({'text': 'Organ dysfunction felt to be due to the conditioning for the first transplant', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT00472329'), ({'text': 'More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)', 'entities': [['11', '21', 'lower_bound'], ['50', '72', 'treatment'], ['180', '187', 'upper_bound'], ['227', '235', 'chronic_disease'], ['239', '247', 'chronic_disease']]}, 'NCT01967823'), ({'text': '2002 AJCC clinical cancer stage as determined by either urologist or radiation oncologist must be T1c - T2b, N0, M0', 'entities': [['20', '26', 'cancer'], ['99', '102', 'lower_bound'], ['105', '108', 'upper_bound']]}, 'NCT02339948'), ({'text': 'Patients are allowed to have received prior anti-angiogenesis therapy with the exception of prior cediranib', 'entities': [['39', '70', 'treatment'], ['93', '108', 'treatment']]}, 'NCT02484404'), ({'text': 'BMI', 'entities': [['1', '4', 'bmi']]}, 'NCT03082157'), ({'text': 'portal hypertension', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02464878'), ({'text': 'Active diabetes insipidus', 'entities': [['8', '26', 'chronic_disease']]}, 'NCT02422641'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT03123068'), ({'text': "A diagnosis of Crohn's disease or Inflammatory Bowel Disease", 'entities': [['16', '31', 'chronic_disease'], ['35', '61', 'chronic_disease']]}, 'NCT02200445'), ({'text': 'History of CNS disease (e.g. brain metastases, seizure disorder)', 'entities': [['12', '23', 'chronic_disease'], ['30', '46', 'cancer'], ['48', '64', 'chronic_disease']]}, 'NCT03137121'), ({'text': 'Cardiovascular problems', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02487082'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02261519'), ({'text': 'Ophthalmological conditions', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT02503358'), ({'text': 'Single unrelated umbilical cord blood unit with 0-2 antigen mismatch and minimum cell dose of >5 x 10^7 nucleated cells/kg as per current institutional guidelines', 'entities': [['18', '43', 'clinical_variable'], ['49', '50', 'lower_bound'], ['51', '52', 'upper_bound'], ['53', '69', 'clinical_variable'], ['74', '91', 'clinical_variable'], ['96', '123', 'lower_bound']]}, 'NCT01652092'), ({'text': 'Refractory, defined as tumor progression after initiation of standard first line therapy without having achieved a prior partial or complete remission OR Biopsy proven residual disease at the completion of planned standard initial front-line therapy', 'entities': [['24', '29', 'cancer'], ['71', '89', 'treatment'], ['232', '250', 'treatment']]}, 'NCT02520713'), ({'text': 'Cerebral palsy, or associated movement disorders such as dystonia, spasticity, and/or hypertonia', 'entities': [['1', '15', 'chronic_disease'], ['58', '66', 'chronic_disease'], ['68', '78', 'chronic_disease'], ['87', '97', 'chronic_disease']]}, 'NCT01681888'), ({'text': 'Adequate liver function as defined by a serum bilirubin <1.8, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5X upper limit of normal', 'entities': [['41', '56', 'clinical_variable'], ['58', '61', 'upper_bound'], ['63', '95', 'clinical_variable'], ['99', '129', 'clinical_variable'], ['132', '158', 'upper_bound']]}, 'NCT01760655'), ({'text': 'Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1', 'entities': [['74', '86', 'cancer']]}, 'NCT02498613'), ({'text': 'Age > 21 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT00904046'), ({'text': 'Immunization with a live/attenuated vaccine within 30 days of enrollment', 'entities': [['1', '44', 'treatment'], ['52', '59', 'upper_bound']]}, 'NCT03135171'), ({'text': 'Inability to speak English or Spanish', 'entities': [['1', '38', 'language_fluency']]}, 'NCT02358681'), ({'text': 'White blood cell (WBC) > 2,000/dl', 'entities': [['1', '23', 'clinical_variable'], ['26', '34', 'lower_bound']]}, 'NCT02208362'), ({'text': 'History of seizure disorder', 'entities': [['12', '28', 'chronic_disease']]}, 'NCT01912612'), ({'text': 'Absolute neutrophil count (ANC) e1 x 10^9/L', 'entities': [['1', '32', 'clinical_variable'], ['34', '44', 'lower_bound']]}, 'NCT02290951'), ({'text': 'bipolar disorder', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02607514'), ({'text': 'Any contraindications to MR imaging', 'entities': [['26', '36', 'treatment']]}, 'NCT02249520'), ({'text': 'peripheral nerve disease', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02219555'), ({'text': 'Participation in a clinical trial within the last 30 days', 'entities': [['20', '34', 'treatment'], ['46', '58', 'upper_bound']]}, 'NCT02132130'), ({'text': 'Leukocytes >= 3,000/mcL', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'lower_bound']]}, 'NCT02535325'), ({'text': 'Participants who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Corticosteroid treatment is allowed', 'entities': [['27', '39', 'treatment'], ['43', '55', 'treatment'], ['72', '79', 'upper_bound'], ['84', '96', 'treatment'], ['100', '111', 'treatment'], ['247', '271', 'treatment']]}, 'NCT02425904'), ({'text': 'Major surgery within 4 weeks before C1D1', 'entities': [['1', '14', 'treatment'], ['22', '29', 'upper_bound'], ['37', '41', 'treatment']]}, 'NCT02649790'), ({'text': 'Presence of an adult at home during the exercise training sessions for patients < 14 years of age', 'entities': [['83', '91', 'upper_bound'], ['95', '98', 'age']]}, 'NCT02519946'), ({'text': 'Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment', 'entities': [['34', '67', 'contraception_consent'], ['118', '135', 'upper_bound'], ['136', '145', 'treatment']]}, 'NCT02133196'), ({'text': 'Newly diagnosed MCL: Platelet count > 50,000/mm^3', 'entities': [['17', '20', 'cancer'], ['22', '36', 'clinical_variable'], ['39', '50', 'lower_bound']]}, 'NCT01880567'), ({'text': 'History of anaphylactic reaction to contrast material that cannot be adequately premedicated', 'entities': [['12', '33', 'allergy_name']]}, 'NCT02266719'), ({'text': 'egative serum pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards & Guidelines), from assays obtained <2 weeks prior to study enrollment', 'entities': [['1', '24', 'pregnancy'], ['34', '49', 'gender'], ['66', '69', 'age'], ['152', '165', 'upper_bound']]}, 'NCT01697930'), ({'text': 'e 20 pack year smoking history', 'entities': [['3', '5', 'lower_bound']]}, 'NCT02696980'), ({'text': 'Enrolled in any clinical medication trial within the past 30 days', 'entities': [['13', '42', 'treatment'], ['54', '66', 'upper_bound']]}, 'NCT02570984'), ({'text': 'History of acute or chronic gastrointestinal tract disorder that, in the opinion of the principal investigator would preclude ingestion or absorption of the study product (e.g., prior gastric bypass surgery, short bowel syndrome, inflammatory bowel disease, celiac disease, acute/chronic pancreatitis, or chronic upper gastrointestinal bleeding', 'entities': [['12', '60', 'chronic_disease'], ['179', '207', 'treatment'], ['209', '229', 'chronic_disease'], ['231', '257', 'chronic_disease'], ['259', '273', 'chronic_disease'], ['275', '301', 'chronic_disease'], ['306', '345', 'chronic_disease']]}, 'NCT03166371'), ({'text': 'History of dementia', 'entities': [['12', '20', 'chronic_disease']]}, 'NCT02872857'), ({'text': 'Consistent corrected QT (QTc) > 450 msec for men and > 470 msec for women by Fridericia formula, on 3 separate electrocardiograms (ECGs); patients with a history of long QTc syndrome or personal or family history of ventricular arrhythmias will be excluded', 'entities': [['1', '30', 'clinical_variable'], ['33', '41', 'lower_bound'], ['46', '49', 'gender'], ['56', '64', 'lower_bound'], ['69', '74', 'gender'], ['112', '137', 'treatment'], ['166', '183', 'chronic_disease'], ['217', '240', 'chronic_disease']]}, 'NCT02503709'), ({'text': 'Creatinine =< 2 mg/dL', 'entities': [['1', '11', 'clinical_variable'], ['15', '22', 'upper_bound']]}, 'NCT01371630'), ({'text': 'ECOG performance status less than or equal to 2', 'entities': [['1', '24', 'clinical_variable'], ['47', '48', 'upper_bound']]}, 'NCT01989546'), ({'text': 'Treatment with any investigational drug in the 1 month preceding the study', 'entities': [['1', '10', 'treatment'], ['48', '55', 'upper_bound']]}, 'NCT02130687'), ({'text': 'ALL without curative options for therapy, including those not eligible for allogeneic SCT', 'entities': [['1', '4', 'cancer'], ['34', '41', 'treatment'], ['76', '90', 'treatment']]}, 'NCT02374333'), ({'text': 'Alkaline phosphatase < 2.5 upper limit of normal (ULN) (< 10 x ULN in presence of bone metastases)', 'entities': [['1', '21', 'clinical_variable'], ['24', '55', 'upper_bound'], ['59', '67', 'upper_bound'], ['83', '98', 'cancer']]}, 'NCT02479230'), ({'text': 'Completed fractionated radiation therapy (to 60 Gy for high grade gliomas) or stereotactic radiosurgery or hypofractionated radiation therapy (e.g. for brain metastases, anaplastic meningiomas), without or with concurrent chemotherapy', 'entities': [['24', '41', 'treatment'], ['67', '74', 'cancer'], ['79', '104', 'treatment'], ['108', '142', 'treatment'], ['153', '169', 'cancer'], ['171', '193', 'cancer'], ['212', '235', 'treatment']]}, 'NCT01604512'), ({'text': 'Patients with prior radiation therapy or chemotherapy or a prior malignancy of any type will be excluded', 'entities': [['15', '38', 'treatment'], ['42', '54', 'treatment'], ['66', '76', 'cancer']]}, 'NCT02448173'), ({'text': 'Underactive (d120 mins/wk moderate intensity PA)', 'entities': [['15', '26', 'upper_bound']]}, 'NCT02925481'), ({'text': 'Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus)', 'entities': [['28', '66', 'treatment'], ['68', '77', 'treatment'], ['79', '91', 'treatment'], ['93', '103', 'treatment']]}, 'NCT02531932'), ({'text': "Any severe medical condition that, in the enrollee's opinion, is likely to compromise the participant's ability to complete the trial", 'entities': [['12', '29', 'chronic_disease']]}, 'NCT02579096'), ({'text': 'Stroke onset at least 6 months before enrollment', 'entities': [['1', '7', 'chronic_disease'], ['23', '31', 'lower_bound']]}, 'NCT02658630'), ({'text': 'traumatic brain injury', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT01570816'), ({'text': 'Diagnosis of possible or probable AD by standard NIA criteria (McKahnn et al, 1984; McKhann et all, 2011)', 'entities': [['35', '37', 'chronic_disease']]}, 'NCT02129348'), ({'text': 'Patients with severe active infection', 'entities': [['22', '38', 'chronic_disease']]}, 'NCT02291848'), ({'text': 'Age >18 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT01928576'), ({'text': 'histologically proven initial diagnosis of primary malignant brain tumor, with no known curative treatment options', 'entities': [['44', '73', 'cancer'], ['98', '107', 'treatment']]}, 'NCT02502708'), ({'text': 'patients who have suffered a myocardial infarction', 'entities': [['30', '51', 'chronic_disease']]}, 'NCT02664909'), ({'text': 'Contraindication to anticoagulation (i.e., heparin, warfarin or another commercially available anticoagulation medication)', 'entities': [['21', '36', 'treatment'], ['44', '51', 'treatment'], ['53', '61', 'treatment']]}, 'NCT01959425'), ({'text': 'Unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of study medication', 'entities': [['68', '94', 'chronic_disease']]}, 'NCT01858168'), ({'text': 'diffuse large B-cell lymphoma (DLBCL)', 'entities': [['1', '38', 'cancer']]}, 'NCT02594384'), ({'text': 'Subject with known congenital bleeding disorders or platelet dysfunction', 'entities': [['21', '49', 'chronic_disease'], ['53', '73', 'chronic_disease']]}, 'NCT02074436'), ({'text': 'No opportunistic infection within 30 days of study entry (at Day -10)', 'entities': [['4', '27', 'chronic_disease'], ['35', '42', 'upper_bound']]}, 'NCT02016924'), ({'text': 'Hemoglobin e8.5 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['13', '21', 'lower_bound']]}, 'NCT02991651'), ({'text': 'Stable treatment (e.g., applied behavior analysis), speech therapy, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation', 'entities': [['1', '17', 'treatment'], ['25', '50', 'treatment'], ['53', '67', 'treatment'], ['69', '95', 'treatment'], ['99', '125', 'treatment'], ['139', '152', 'lower_bound']]}, 'NCT03131635'), ({'text': 'Hemoglobin greater than or equal to 8.0 g/dl. (Turnstile II - Chemotherapy/Cell Infusion)', 'entities': [['1', '11', 'clinical_variable'], ['37', '45', 'lower_bound'], ['63', '75', 'treatment'], ['76', '89', 'treatment']]}, 'NCT00338377'), ({'text': 'A history of retinal vein occlusion (RVO) or risks factors for RVO', 'entities': [['14', '42', 'chronic_disease'], ['38', '41', 'chronic_disease']]}, 'NCT02881242'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02905188'), ({'text': 'Refractory to or relapsed after at least 1 prior treatment regimen', 'entities': [['42', '43', 'lower_bound']]}, 'NCT02535286'), ({'text': 'Type 2 DM with HbA1C treated with metformin, sulfonylurea, insulin, or combination OR age-matched, non-diabetic obese (BMI > 30 kg/m^2) OR age-matched lean, healthy control subjects (BMI < 25 kg/m^2)', 'entities': [['1', '10', 'chronic_disease'], ['16', '21', 'treatment'], ['35', '44', 'treatment'], ['46', '58', 'treatment'], ['60', '67', 'treatment'], ['100', '118', 'chronic_disease'], ['120', '123', 'bmi'], ['126', '135', 'lower_bound'], ['190', '199', 'upper_bound']]}, 'NCT02272556'), ({'text': 'Received >12 hour of CRRT (not including SCUF on ECMO) during this hospital admission or prior to transfer from an outside hospital', 'entities': [['11', '18', 'lower_bound'], ['22', '26', 'treatment'], ['42', '46', 'treatment'], ['50', '54', 'treatment'], ['68', '86', 'treatment']]}, 'NCT02820350'), ({'text': 'Busulfan dose may be adjusted according to pharmacokinetics targeting a daily AUC of 5000 ¼mol-min/L, per institution standard of practice', 'entities': [['1', '9', 'treatment'], ['79', '82', 'clinical_variable'], ['86', '101', 'upper_bound']]}, 'NCT01951885'), ({'text': 'Subjects with histologically confirmed locally advanced/unresectable or metastatic melanoma', 'entities': [['73', '92', 'chronic_disease']]}, 'NCT02553642'), ({'text': 'currently trying to become pregnant', 'entities': [['21', '36', 'pregnancy']]}, 'NCT03053518'), ({'text': "prior Grave's disease now euthyroid clinically and by laboratory testing", 'entities': [['7', '22', 'chronic_disease']]}, 'NCT02152956'), ({'text': 'Female patients must agree to use contraception for at least 5 days following the last dose of study medication', 'entities': [['1', '16', 'gender'], ['22', '48', 'contraception_consent'], ['62', '68', 'lower_bound']]}, 'NCT01625923'), ({'text': 'Subjects who are pregnant or breast-feeding at entry', 'entities': [['14', '26', 'pregnancy']]}, 'NCT02310464'), ({'text': 'Subjects using prescription or over-the-counter medication or cosmetics containing: retinoids, glycolic acid, salicylic acid or any other remedies that might affect the healing process', 'entities': [['49', '59', 'treatment'], ['85', '94', 'treatment']]}, 'NCT02234193'), ({'text': 'Known or suspected hypersensitivity to any monoclonal antibody or any study drug component', 'entities': [['44', '63', 'allergy_name'], ['71', '91', 'allergy_name']]}, 'NCT03006302'), ({'text': 'articipants in all combination therapy arms must have recurrent or metastatic NSCLC and previously received platinum-based therapy and progressed either during or after anti-programmed death ligand 1 (PDL1)-based therapy', 'entities': [['20', '44', 'treatment'], ['55', '84', 'cancer'], ['109', '131', 'treatment'], ['170', '221', 'treatment']]}, 'NCT02988960'), ({'text': 'Evidence of esophageal and/or gastric varices', 'entities': [['13', '46', 'chronic_disease']]}, 'NCT03059030'), ({'text': 'diagnosed with a neuromuscular disease', 'entities': [['18', '39', 'chronic_disease']]}, 'NCT02359825'), ({'text': 'Leukocytes >= 3,000/mcL', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'lower_bound']]}, 'NCT01989585'), ({'text': 'No neuropsychiatric comorbidities', 'entities': [['4', '34', 'chronic_disease']]}, 'NCT03100370'), ({'text': 'Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted', 'entities': [['5', '21', 'treatment'], ['38', '53', 'cancer'], ['84', '87', 'upper_bound'], ['132', '159', 'treatment']]}, 'NCT01042522'), ({'text': 'uncontrolled angina', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02585973'), ({'text': 'Previous infusion of CD19 CAR T cells at another institution', 'entities': [['1', '38', 'treatment']]}, 'NCT01430390'), ({'text': 'Renal insufficiency defined by estimated glomerular filtration rate (based on modified Schwartz formula) <50 ml/min, or need for renal replacement therapy', 'entities': [['1', '20', 'chronic_disease'], ['32', '68', 'clinical_variable'], ['107', '116', 'upper_bound'], ['130', '155', 'treatment']]}, 'NCT02007239'), ({'text': 'lymphoma', 'entities': [['1', '9', 'cancer']]}, 'NCT02374333'), ({'text': 'Concurrent therapy with strong inhibitors or inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) or cytochrome P450 family 2, subfamily C, polypeptide 8 (CYP2C8) due to concerning possible drug-drug interactions', 'entities': [['1', '42', 'treatment'], ['58', '82', 'treatment'], ['84', '95', 'treatment'], ['97', '119', 'treatment'], ['123', '147', 'treatment'], ['149', '160', 'treatment'], ['162', '184', 'treatment']]}, 'NCT02012296'), ({'text': 'Significant respiratory distress requiring supplemental oxygen >40%', 'entities': [['13', '33', 'chronic_disease'], ['44', '63', 'treatment'], ['65', '68', 'lower_bound']]}, 'NCT02477423'), ({'text': 'Serum Creatinine >/= 2.0 mg/dL', 'entities': [['1', '17', 'clinical_variable'], ['22', '31', 'lower_bound']]}, 'NCT03116997'), ({'text': 'Prostate-specific Antigen (PSA) d 100 ng/mL within (+/-) 4 months of signing of consent', 'entities': [['1', '32', 'clinical_variable'], ['35', '44', 'upper_bound'], ['58', '66', 'upper_bound']]}, 'NCT02307058'), ({'text': 'antidiarrheal preparations', 'entities': [['1', '14', 'treatment']]}, 'NCT02233868'), ({'text': 'Patients with histologically confirmed locally advanced or metastatic cholangiocarcinomas in Arm 3', 'entities': [['60', '90', 'cancer']]}, 'NCT02990481'), ({'text': 'Diagnosis of OSA from previous PSG', 'entities': [['14', '17', 'chronic_disease'], ['32', '35', 'treatment']]}, 'NCT02858154'), ({'text': 'the subject has been off systemic immunosuppressive medications (including but not limited to: cyclosporine, tacrolimus, mycophenolate mofetil, or corticosteroids) for at least 1 month prior to the first dose of GSK525762', 'entities': [['35', '64', 'treatment'], ['96', '108', 'treatment'], ['110', '120', 'treatment'], ['122', '143', 'treatment'], ['148', '163', 'treatment'], ['178', '191', 'lower_bound'], ['213', '222', 'treatment']]}, 'NCT01943851'), ({'text': 'receiving dopamine agonists, nitrates, alpha-receptor blocking agents, or antihypertensive medication (see other exclusionary medications listed below)', 'entities': [['11', '28', 'treatment'], ['30', '38', 'treatment'], ['40', '70', 'treatment'], ['75', '102', 'treatment']]}, 'NCT02225548'), ({'text': 'Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin', 'entities': [['32', '39', 'cancer'], ['89', '101', 'upper_bound'], ['103', '126', 'cancer'], ['132', '181', 'cancer']]}, 'NCT02876302'), ({'text': 'Follicular lymphoma (any grade)', 'entities': [['1', '20', 'cancer']]}, 'NCT02078102'), ({'text': 'Patients with advanced malignant hepatic tumors', 'entities': [['24', '48', 'cancer']]}, 'NCT01333046'), ({'text': 'Age greater than or equal to 3 years and less than 22 years of age at the time of diagnosis (may enroll on Strata W, S or N), OR (2) age is greater than or equal to 22 years and less than 40 years AND patient has SHH medulloblastoma (must enroll on Stratum S)', 'entities': [['1', '4', 'age'], ['30', '37', 'lower_bound'], ['64', '67', 'age'], ['189', '197', 'upper_bound'], ['214', '233', 'cancer']]}, 'NCT01878617'), ({'text': 'Subject has an intramural hematoma of the descending thoracic aorta', 'entities': [['16', '35', 'chronic_disease']]}, 'NCT02365467'), ({'text': 'facility-based cardiac rehabilitation', 'entities': [['16', '38', 'treatment']]}, 'NCT02918175'), ({'text': 'Serious non-healing wound, ulcer, or bone fracture', 'entities': [['9', '26', 'chronic_disease'], ['28', '33', 'chronic_disease'], ['38', '51', 'chronic_disease']]}, 'NCT02135588'), ({'text': 'History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT)', 'entities': [['12', '36', 'chronic_disease'], ['47', '78', 'chronic_disease'], ['80', '98', 'chronic_disease'], ['112', '140', 'chronic_disease']]}, 'NCT01532687'), ({'text': 'Fasting triglycerides =< 300 mg/dL (3.42 mmol/L)', 'entities': [['1', '22', 'clinical_variable'], ['26', '49', 'upper_bound']]}, 'NCT02503722'), ({'text': "Euthyroid participants with a history of Grave's disease (participants suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to first dose of study drug)", 'entities': [['42', '57', 'chronic_disease'], ['242', '252', 'treatment']]}, 'NCT02520791'), ({'text': 'Subject has a known hypersensitivity to any of the excipients of nivolumab, cisplatin or romidepsin', 'entities': [['66', '75', 'allergy_name'], ['77', '86', 'allergy_name'], ['90', '100', 'allergy_name']]}, 'NCT02393794'), ({'text': 'Subjects enrolled in Part B or Part C must have at least 1 lesion that may qualify as a target lesion', 'entities': [['58', '59', 'lower_bound']]}, 'NCT02799095'), ({'text': 'Eastern Cooperative Oncology Group performance status 0 or 1', 'entities': [['1', '54', 'clinical_variable'], ['55', '56', 'lower_bound'], ['60', '61', 'upper_bound']]}, 'NCT01969643'), ({'text': 'Patients must not have received prior exposure to nivolumab; for patients enrolled in parts C, D and E, patients must not have received prior nivolumab or ipilimumab', 'entities': [['51', '60', 'treatment'], ['137', '152', 'treatment'], ['156', '166', 'treatment']]}, 'NCT02304458'), ({'text': 'acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy', 'entities': [['1', '16', 'chronic_disease'], ['44', '66', 'chronic_disease'], ['70', '79', 'chronic_disease'], ['83', '89', 'treatment']]}, 'NCT01652092'), ({'text': "Agree to report any adverse events (AEs) that may or may not be associated with administration of the vaccine for at least 28 days after administration and agree to report all serious adverse events (for example, resulting in hospitalization) for the duration of the subject's participation in the study", 'entities': [['103', '110', 'treatment'], ['124', '137', 'lower_bound'], ['227', '242', 'treatment']]}, 'NCT02466750'), ({'text': 'Active urinary tract disease or biopsy of the prostate within the past 6 weeks', 'entities': [['8', '29', 'chronic_disease'], ['33', '55', 'treatment'], ['67', '79', 'upper_bound']]}, 'NCT01589263'), ({'text': "subject's mother was < 18 years old at the time of pregnancy", 'entities': [['24', '32', 'upper_bound'], ['52', '61', 'pregnancy']]}, 'NCT02936284'), ({'text': 'Patients whose cancer requires immediate attention or who would otherwise suffer a disadvantage by participating in this trial', 'entities': [['16', '22', 'cancer']]}, 'NCT02360579'), ({'text': 'History of serious mental illnesses (e.g., schizophrenia and bipolar disorder)', 'entities': [['12', '36', 'chronic_disease'], ['44', '57', 'chronic_disease'], ['62', '78', 'chronic_disease']]}, 'NCT02898597'), ({'text': 'LGK974 with PDR001: Dose expansion: patients with pancreatic cancer, or TNBC, or melanoma, or head and neck cancer', 'entities': [['1', '19', 'treatment'], ['51', '68', 'cancer'], ['73', '77', 'cancer'], ['82', '90', 'cancer'], ['95', '115', 'cancer']]}, 'NCT01351103'), ({'text': 'initiating radiotherapy for HNC', 'entities': [['12', '24', 'treatment'], ['29', '32', 'cancer']]}, 'NCT02409485'), ({'text': 'Escalation Stage 2: patients who have not yet received therapy with any JAK-STAT inhibitory agents or patients on at least 8 weeks of a steady dose of ruxolitinib', 'entities': [['56', '99', 'treatment'], ['124', '131', 'lower_bound'], ['152', '163', 'treatment']]}, 'NCT02493530'), ({'text': 'Female subject is pregnant', 'entities': [['1', '15', 'gender'], ['19', '27', 'pregnancy']]}, 'NCT01366612'), ({'text': 'Smokers using more than 10 cigarettes or equivalent per day', 'entities': [['25', '27', 'lower_bound']]}, 'NCT02532543'), ({'text': 'epilepsy or other major neurological disorder', 'entities': [['1', '9', 'chronic_disease'], ['19', '46', 'chronic_disease']]}, 'NCT02206945'), ({'text': 'Unstable weight (>4% change during the last 2 months before entering the study)', 'entities': [['10', '16', 'clinical_variable'], ['19', '21', 'lower_bound'], ['40', '53', 'upper_bound']]}, 'NCT02706288'), ({'text': 'Any person older than 22 years of age', 'entities': [['23', '31', 'lower_bound'], ['35', '38', 'age']]}, 'NCT02421276'), ({'text': 'Age e 30 at signing of consent', 'entities': [['1', '4', 'age'], ['7', '9', 'lower_bound']]}, 'NCT02997709'), ({'text': 'Have history of significant drug sensitivity or drug allergy', 'entities': [['29', '33', 'allergy_name']]}, 'NCT02285114'), ({'text': 'Refractory anemia with ringed sideroblasts (RARS)', 'entities': [['1', '18', 'chronic_disease'], ['45', '49', 'clinical_variable']]}, 'NCT02016781'), ({'text': 'Hemoglobin e 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb e 8.0 g/dl is acceptable.)', 'entities': [['1', '11', 'clinical_variable'], ['14', '22', 'lower_bound'], ['41', '52', 'treatment'], ['86', '89', 'clinical_variable']]}, 'NCT01972919'), ({'text': 'Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)', 'entities': [['1', '31', 'clinical_variable'], ['36', '68', 'clinical_variable'], ['72', '105', 'upper_bound'], ['110', '117', 'upper_bound'], ['135', '151', 'cancer']]}, 'NCT02456857'), ({'text': 'Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 family 3, subfamily A, polypeptide 4/5 (3A4/5); (a one-week wash-out period is necessary for patients who are already on these treatments)', 'entities': [['23', '32', 'treatment'], ['221', '231', 'treatment']]}, 'NCT02522715'), ({'text': 'No evidence of disease progression: defined as increase in tumor size of >25% or new lesions', 'entities': [['75', '78', 'lower_bound']]}, 'NCT01526603'), ({'text': 'Diabetes (gestational or pre-gestational)', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02866279'), ({'text': 'Subject is pregnant', 'entities': [['12', '20', 'pregnancy']]}, 'NCT02532621'), ({'text': 'Patients undergoing one- or two-level anterior cervical discectomy and fusion surgery for radiculopathy or myelopathy symptoms', 'entities': [['39', '67', 'treatment'], ['72', '86', 'treatment'], ['91', '104', 'chronic_disease'], ['108', '118', 'chronic_disease']]}, 'NCT02376205'), ({'text': 'Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program', 'entities': [['1', '8', 'gender'], ['64', '73', 'pregnancy']]}, 'NCT01619761'), ({'text': 'Allergy or intolerance to study medication', 'entities': [['27', '43', 'allergy_name']]}, 'NCT01850758'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03135522'), ({'text': '18 - 65 years of age', 'entities': [['1', '3', 'lower_bound'], ['6', '14', 'upper_bound'], ['18', '21', 'age']]}, 'NCT02796300'), ({'text': 'Patients with significant (>grade 2) pelvic organ prolapse', 'entities': [['38', '59', 'chronic_disease']]}, 'NCT01953263'), ({'text': 'IHC 2+ and FISH negative', 'entities': [['1', '4', 'treatment'], ['12', '16', 'treatment']]}, 'NCT02595372'), ({'text': 'Preexisting sensory grade 3 neuropathy', 'entities': [['13', '39', 'chronic_disease']]}, 'NCT01261728'), ({'text': 'Not on antihypertensive medications', 'entities': [['8', '36', 'treatment']]}, 'NCT03105661'), ({'text': 'Uncontrolled Diabetes', 'entities': [['14', '22', 'chronic_disease']]}, 'NCT03085485'), ({'text': 'Subjects must agree to use adequate contraception beginning at the signing of the ICF until at least 6 months after the last dose of study drug', 'entities': [['15', '50', 'contraception_consent'], ['102', '116', 'lower_bound'], ['134', '144', 'treatment']]}, 'NCT02346526'), ({'text': 'Eastern Cooperative Oncology Group performance status of 0 or 1', 'entities': [['1', '54', 'clinical_variable'], ['58', '59', 'lower_bound'], ['63', '64', 'upper_bound']]}, 'NCT03005782'), ({'text': 'No HIV seropositivity', 'entities': [['4', '7', 'chronic_disease']]}, 'NCT00788164'), ({'text': 'Unstable and chronic (e.g, severe diabetes) medical conditions', 'entities': [['28', '43', 'chronic_disease']]}, 'NCT02137122'), ({'text': 'moderate intensity physical activity in the past 6 months)', 'entities': [['45', '58', 'upper_bound']]}, 'NCT03058146'), ({'text': '>= 45 years of age and has not had menses for >= 2 years, amenorrheic for < 2 years without hysterectomy and oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation, or post hysterectomy, oophorectomy or tubal ligation', 'entities': [['4', '12', 'lower_bound'], ['16', '19', 'age'], ['59', '70', 'clinical_variable'], ['93', '105', 'treatment'], ['110', '122', 'treatment'], ['233', '250', 'treatment'], ['268', '282', 'treatment']]}, 'NCT02535312'), ({'text': 'The patient has Eastern Cooperative Oncology Group (ECOG) performance status 0-1', 'entities': [['17', '77', 'clinical_variable'], ['78', '79', 'lower_bound'], ['80', '81', 'upper_bound']]}, 'NCT02152254'), ({'text': 'Ulcer expected to be treated with any advanced therapeutics (e.g., HBOT)', 'entities': [['1', '6', 'chronic_disease'], ['68', '72', 'treatment']]}, 'NCT02312570'), ({'text': 'No pre-existing chronic infectious disease', 'entities': [['17', '43', 'chronic_disease']]}, 'NCT01026532'), ({'text': 'Any medical comorbidity which might result in life-expectancy < 1 year', 'entities': [['47', '62', 'clinical_variable'], ['65', '71', 'upper_bound']]}, 'NCT01275716'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT02780401'), ({'text': 'Oral contraceptives are disallowed', 'entities': [['1', '20', 'treatment']]}, 'NCT02169089'), ({'text': 'Age: 0 to 50 years', 'entities': [['1', '4', 'age'], ['6', '7', 'lower_bound'], ['11', '19', 'upper_bound']]}, 'NCT01652092'), ({'text': 'Acute or chronic severe renal insufficiency', 'entities': [['1', '44', 'chronic_disease']]}, 'NCT01653093'), ({'text': 'Occlusion of the SMV or PV with insufficient normal vein above and below with which to perform venous reconstruction', 'entities': [['18', '21', 'chronic_disease'], ['25', '27', 'chronic_disease'], ['96', '117', 'treatment']]}, 'NCT02427841'), ({'text': 'Patients who are pregnant', 'entities': [['14', '26', 'pregnancy']]}, 'NCT02483728'), ({'text': 'Patients with acute hematological malignancies', 'entities': [['21', '47', 'cancer']]}, 'NCT02272998'), ({'text': 'history of seizures or current seizure disorder without medication', 'entities': [['12', '20', 'chronic_disease'], ['32', '48', 'chronic_disease']]}, 'NCT02378714'), ({'text': 'Prior malignancy other than acute leukemia is allowed, provided it is in remission and there is no plan to treat the malignancy at the time of registration', 'entities': [['7', '17', 'cancer'], ['29', '43', 'cancer'], ['74', '83', 'treatment']]}, 'NCT01925131'), ({'text': 'Woman of childbearing potential that is pregnant', 'entities': [['1', '6', 'gender'], ['41', '49', 'pregnancy']]}, 'NCT02819843'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02016924'), ({'text': 'Clinical stage T1c-T2aN0M0', 'entities': [['16', '19', 'cancer'], ['20', '27', 'cancer']]}, 'NCT02290366'), ({'text': 'serious cardiac arrhythmia requiring medication', 'entities': [['9', '27', 'chronic_disease']]}, 'NCT02383927'), ({'text': 'active psychosis, severe depression (score of 4 on question 1.3 of the Movement Disorder Society-United Parkinson Disease Rating Scale)', 'entities': [['1', '17', 'chronic_disease'], ['19', '36', 'chronic_disease']]}, 'NCT02838797'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1', 'entities': [['1', '66', 'clinical_variable'], ['67', '68', 'lower_bound'], ['72', '73', 'upper_bound']]}, 'NCT02048722'), ({'text': 'The subject has known elevated bilirubin levels (hyperbilirubinemia)', 'entities': [['32', '48', 'clinical_variable'], ['50', '68', 'chronic_disease']]}, 'NCT03151330'), ({'text': 'Inadequate bone marrow reserve within past 28 days prior to study treatment', 'entities': [['44', '57', 'upper_bound'], ['67', '76', 'treatment']]}, 'NCT02576444'), ({'text': 'Positive result on urine drug screen or breathalyzer test during initial or update visit under the screening protocol (14-AA-0181) most proximal to enrollment', 'entities': [['41', '53', 'treatment']]}, 'NCT00713492'), ({'text': 'Birth weight e2000 grams', 'entities': [['1', '13', 'clinical_variable'], ['15', '25', 'lower_bound']]}, 'NCT02369406'), ({'text': 'osteopenia', 'entities': [['1', '11', 'chronic_disease']]}, 'NCT02555280'), ({'text': 'Serum creatinine less than or equal to 1.6 mg/dl. (Turnstile II - Chemotherapy/Cell Infusion-Inclusion Criteria)', 'entities': [['1', '17', 'clinical_variable'], ['40', '49', 'upper_bound'], ['67', '79', 'treatment'], ['80', '93', 'treatment']]}, 'NCT00338377'), ({'text': 'Ascites refractory to medical therapy', 'entities': [['1', '19', 'chronic_disease'], ['23', '38', 'treatment']]}, 'NCT02013778'), ({'text': 'Patients with degenerative neurological disorders or spinal cord injuries', 'entities': [['15', '50', 'chronic_disease']]}, 'NCT02776475'), ({'text': 'Child-Pugh score of B and C (see Appendix 13.4)', 'entities': [['1', '28', 'clinical_variable']]}, 'NCT02285101'), ({'text': "Limitation of the patient's ability to comply with the treatment or follow-up protocol", 'entities': [['56', '65', 'treatment']]}, 'NCT02533674'), ({'text': "Participants with vitiligo, resolved childhood asthma or atopy, hypothyroidism, or Sjogren's syndrome, as well as participants requiring only intranasal steroids, intermittent use of bronchodilators, local steroid injections, or physiologic replacement doses of prednisone (d 10 mg/d) are not excluded from this study", 'entities': [['19', '27', 'chronic_disease'], ['48', '54', 'chronic_disease'], ['58', '63', 'chronic_disease'], ['65', '79', 'chronic_disease'], ['84', '102', 'chronic_disease'], ['143', '162', 'treatment'], ['184', '199', 'treatment'], ['201', '225', 'treatment'], ['230', '273', 'treatment'], ['277', '284', 'upper_bound']]}, 'NCT02362997'), ({'text': 'Administration of any other local anesthetic in the 2 hours prior to the study enrollment', 'entities': [['29', '45', 'treatment'], ['53', '66', 'upper_bound']]}, 'NCT02679560'), ({'text': "Sufficient inflammation to require systemic treatment and, based on the Investigator's decision, warrants intravitreal treatment", 'entities': [['36', '54', 'treatment'], ['107', '129', 'treatment']]}, 'NCT01280669'), ({'text': 'Age e 10 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02723994'), ({'text': 'Patients with a history of inflammatory bowel disease', 'entities': [['28', '54', 'chronic_disease']]}, 'NCT02451488'), ({'text': 'Criteria E: at least 2/6 arousal & reactivity symptoms', 'entities': [['22', '25', 'lower_bound']]}, 'NCT02479906'), ({'text': 'Symptomatic congestive heart failure', 'entities': [['13', '37', 'chronic_disease']]}, 'NCT02232516'), ({'text': 'Patients with active brain metastases or carcinomatous meningitis are excluded from this clinical trial', 'entities': [['22', '38', 'cancer'], ['42', '66', 'cancer']]}, 'NCT02535312'), ({'text': 'Be free of dementia, and able to cognitively and physically give informed consent', 'entities': [['12', '20', 'chronic_disease']]}, 'NCT03070535'), ({'text': 'absence of regular menses (including current pregnancy, recent pregnancy, or active breast feeding) unwilling to take either cyclic or combined OCs', 'entities': [['46', '55', 'pregnancy']]}, 'NCT02214550'), ({'text': "Patients must have a previously documented histologic diagnosis of multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL), and be eligible to undergo autologous PBSC transplantation on institutional protocols", 'entities': [['68', '89', 'cancer'], ['93', '121', 'cancer'], ['150', '181', 'treatment']]}, 'NCT02078102'), ({'text': 'Subject with a history of a positive test for Hepatitis B surface antigen (HbsAg) or Hepatitis C', 'entities': [['47', '82', 'chronic_disease'], ['86', '97', 'chronic_disease']]}, 'NCT02225548'), ({'text': 'Persistent or intermittent elevation in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels', 'entities': [['41', '71', 'clinical_variable'], ['72', '111', 'clinical_variable']]}, 'NCT02143726'), ({'text': 'Positive for presence of human immunodeficiency virus type 1 or 2 (HIV-1 and HIV-2), hepatitis B virus (HBV), or hepatitis C (HCV)', 'entities': [['26', '66', 'chronic_disease'], ['68', '73', 'chronic_disease'], ['78', '83', 'chronic_disease'], ['86', '109', 'chronic_disease'], ['114', '131', 'chronic_disease']]}, 'NCT02140554'), ({'text': 'Concurrent medical condition or disease other than 21-hydroxylase deficiency that may interfere with linear growth or that requires concomitant therapy that is likely to interfere with study procedures or results', 'entities': [['1', '40', 'chronic_disease'], ['52', '77', 'chronic_disease'], ['133', '152', 'treatment']]}, 'NCT02574910'), ({'text': 'Neurological level of injury between T1-T6 (High Paraplegia)', 'entities': [['1', '29', 'clinical_variable'], ['38', '40', 'lower_bound'], ['41', '43', 'upper_bound'], ['50', '60', 'chronic_disease']]}, 'NCT02508311'), ({'text': 'Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months', 'entities': [['1', '16', 'chronic_disease'], ['24', '48', 'chronic_disease'], ['59', '74', 'treatment'], ['86', '99', 'upper_bound']]}, 'NCT01220583'), ({'text': "Crohn's Disease/Inflammatory Bowel Disease", 'entities': [['1', '16', 'chronic_disease'], ['17', '43', 'chronic_disease']]}, 'NCT01962415'), ({'text': "Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the safety monitoring requirements and completion of treatment according to this protocol", 'entities': [['20', '39', 'chronic_disease'], ['163', '172', 'treatment']]}, 'NCT02192359'), ({'text': 'Bipolar disorder', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02901041'), ({'text': 'Previous adverse reaction to any anaesthetic', 'entities': [['34', '45', 'allergy_name']]}, 'NCT03089905'), ({'text': 'Must agree to not become pregnant or breast feed a child during treatment on this protocol', 'entities': [['15', '34', 'pregnancy'], ['65', '74', 'treatment']]}, 'NCT02004275'), ({'text': 'History of abnormal bleeding and coagulopathy', 'entities': [['12', '29', 'chronic_disease'], ['34', '46', 'chronic_disease']]}, 'NCT00147056'), ({'text': 'PET-CT with focal lesion with increased uptake without underlying osteolytic bone destruction', 'entities': [['1', '7', 'clinical_variable']]}, 'NCT01572480'), ({'text': 'Patient population: all patients with CLI (critical limb ischemia) and tissue loss scheduled for endovascular intervention for femoral popliteal occlusive or multilevel disease', 'entities': [['39', '67', 'chronic_disease'], ['98', '123', 'treatment'], ['128', '155', 'treatment'], ['159', '177', 'chronic_disease']]}, 'NCT02758847'), ({'text': 'Physician diagnosis of chronic heart failure, American Heart Association Stage C-D', 'entities': [['24', '45', 'chronic_disease'], ['47', '83', 'clinical_variable']]}, 'NCT01807897'), ({'text': 'within 28 days before start of trial treatment', 'entities': [['8', '15', 'upper_bound']]}, 'NCT03104699'), ({'text': 'Have metal that would make an MRI scan unsafe such as: cardiac pacemaker, insulin infusion pump, implanted drug infusion devise, cochlear or ear implant, transdermal medication patch (nitroglycerine), any metallic implants or objects, body piercing that cannot be removed, bone or joint pin, screw, nail, plate, wire sutures or surgical staples, shunts, cerebral aneurysms clips, shrapnel or other metal embedded (such as from war wounds or accidents or previous work in metal fields or machines that may have left any metallic fragments in or near your eyes)', 'entities': [['56', '73', 'treatment'], ['75', '96', 'treatment'], ['98', '128', 'treatment'], ['130', '138', 'treatment'], ['142', '153', 'treatment'], ['155', '183', 'treatment'], ['185', '199', 'treatment'], ['274', '278', 'treatment'], ['282', '291', 'treatment'], ['293', '298', 'treatment'], ['300', '304', 'treatment'], ['306', '311', 'treatment'], ['313', '325', 'treatment'], ['329', '345', 'treatment'], ['347', '353', 'treatment'], ['355', '379', 'treatment'], ['381', '389', 'treatment']]}, 'NCT02504866'), ({'text': 'Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade <=1 severity (Common Terminology Criteria for Adverse Events [CTCAE] v4.03, or later versions)', 'entities': [['23', '35', 'treatment'], ['37', '49', 'treatment'], ['61', '82', 'treatment'], ['94', '107', 'treatment'], ['143', '144', 'upper_bound']]}, 'NCT02323191'), ({'text': 'patients who have progressed on anti-PD-1 therapy in the adjuvant setting are also allowed', 'entities': [['33', '50', 'treatment']]}, 'NCT02910700'), ({'text': 'Suicidal ideation in past year', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02910648'), ({'text': 'e 18 to 65 years of age', 'entities': [['3', '5', 'lower_bound'], ['9', '17', 'upper_bound'], ['21', '24', 'age']]}, 'NCT02193191'), ({'text': 'Having one relative with a confirmed psychotic disorder', 'entities': [['38', '56', 'chronic_disease']]}, 'NCT02102113'), ({'text': 'Acute bleeding associated with a fall in hemoglobin level by e2 g/dL', 'entities': [['42', '58', 'clinical_variable'], ['63', '69', 'lower_bound']]}, 'NCT02329327'), ({'text': 'Significant allergy to a pharmaceutical therapy that, in the opinion of the investigator, poses an increased risk to the participant', 'entities': [['26', '48', 'allergy_name']]}, 'NCT02013154'), ({'text': 'Known immunodeficiency such as HIV infection', 'entities': [['7', '23', 'chronic_disease'], ['32', '45', 'chronic_disease']]}, 'NCT03131037'), ({'text': 'Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)', 'entities': [['14', '181', 'treatment'], ['173', '181', 'treatment'], ['193', '203', 'treatment'], ['229', '233', 'treatment']]}, 'NCT02437370'), ({'text': 'Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies', 'entities': [['16', '24', 'clinical_variable'], ['59', '66', 'lower_bound']]}, 'NCT02301117'), ({'text': 'Treatment indicated based on demonstration of at least one of the following no more than 4 weeks from the time of enrollment, and no less than 6 months after prior cladribine and no less than 4 weeks after other prior treatment', 'entities': [['1', '10', 'treatment'], ['56', '59', 'lower_bound'], ['144', '152', 'lower_bound'], ['159', '175', 'treatment'], ['213', '228', 'treatment']]}, 'NCT01059786'), ({'text': 'Prior use of duloxetine or milnacipran', 'entities': [['14', '24', 'treatment'], ['28', '39', 'treatment']]}, 'NCT01912612'), ({'text': 'Known allergy to Nitinol, stainless steel, or polyester', 'entities': [['18', '25', 'allergy_name'], ['27', '42', 'allergy_name'], ['47', '56', 'allergy_name']]}, 'NCT00483249'), ({'text': 'surgery on the heart or aorta that requires sternotomy or thoracotomy', 'entities': [['1', '8', 'treatment'], ['45', '55', 'treatment'], ['59', '70', 'treatment']]}, 'NCT02361944'), ({'text': 'History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias', 'entities': [['12', '36', 'chronic_disease']]}, 'NCT03072238'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT01811498'), ({'text': "HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme linked immunosorbent assay [ELISA], test kit, and confirmed by Western blot or other approved test); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status", 'entities': [['1', '4', 'chronic_disease'], ['1', '16', 'chronic_disease'], ['68', '82', 'treatment'], ['127', '168', 'treatment']]}, 'NCT02408861'), ({'text': 'Second or third line triple negative breast cancer (TNBC)', 'entities': [['22', '58', 'cancer']]}, 'NCT02264678'), ({'text': 'Urine volume <0.5ml/kg/h for 6 hours', 'entities': [['1', '13', 'clinical_variable'], ['15', '25', 'upper_bound']]}, 'NCT02820350'), ({'text': 'Regular clinical practice already excludes pregnant patients from gadolinium contrast due to unknown effects on the fetus', 'entities': [['44', '52', 'pregnancy']]}, 'NCT02095678'), ({'text': "must have sustained all available treatment options (radiation, chemotherapy, surgery) as verified by the Dana Farber Cancer Institute's Head and Neck Tumor Board", 'entities': [['35', '44', 'treatment'], ['54', '63', 'treatment'], ['65', '77', 'treatment'], ['79', '86', 'treatment']]}, 'NCT02085941'), ({'text': 'Non-penetrating SCI at neurologic level from C2 to C8', 'entities': [['17', '20', 'chronic_disease'], ['24', '40', 'clinical_variable'], ['46', '48', 'lower_bound'], ['52', '54', 'upper_bound']]}, 'NCT02524379'), ({'text': 'severe brain injury', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02260258'), ({'text': 'subject has unstable angina', 'entities': [['13', '28', 'chronic_disease']]}, 'NCT02637947'), ({'text': 'First allogeneic hematopoietic stem cell transplantation (HSCT) using myeloablative conditioning (MAC), non-myeloablative (NMA), or reduced-intensity conditioning (RIC) preparative regimens', 'entities': [['1', '64', 'treatment'], ['71', '103', 'treatment'], ['105', '128', 'treatment'], ['133', '190', 'treatment']]}, 'NCT02400255'), ({'text': 'History of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the IMP, use of percutaneous endoscopic gastrostomy (PEG) tubes', 'entities': [['35', '48', 'chronic_disease'], ['66', '90', 'chronic_disease'], ['157', '160', 'treatment'], ['169', '216', 'treatment']]}, 'NCT02516813'), ({'text': 'Any trauma to the breast within the last 90 days', 'entities': [['5', '25', 'chronic_disease'], ['37', '49', 'upper_bound']]}, 'NCT02511301'), ({'text': 'ALT and AST =< 2.5 times the institutional upper limits of normal', 'entities': [['1', '4', 'clinical_variable'], ['9', '12', 'clinical_variable'], ['16', '66', 'upper_bound']]}, 'NCT02146924'), ({'text': 'creatinine less than or equal to 1.5 times institutional upper limit of normal', 'entities': [['1', '11', 'clinical_variable'], ['34', '79', 'upper_bound']]}, 'NCT01989546'), ({'text': 'Immunoparesis with reduction of 2 uninvolved immunoglobulin isotypes', 'entities': [['1', '14', 'treatment'], ['46', '69', 'clinical_variable']]}, 'NCT01572480'), ({'text': 'Age e18 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02479620'), ({'text': 'Subject has a known history of severe anaphylactic reaction secondary to medication intake or serious blood dyscrasias', 'entities': [['32', '60', 'chronic_disease'], ['95', '119', 'chronic_disease']]}, 'NCT02477839'), ({'text': 'no sign of lymph node or metastatic disease', 'entities': [['26', '36', 'cancer']]}, 'NCT02064673'), ({'text': 'Prior or planned androgen deprivation or bilateral orchiectomy', 'entities': [['1', '38', 'treatment'], ['42', '63', 'treatment']]}, 'NCT01617161'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03081390'), ({'text': 'squamous and basal cell [skin cancers]', 'entities': [['1', '9', 'cancer'], ['14', '39', 'cancer']]}, 'NCT02459769'), ({'text': 'Active, uncontrolled infection', 'entities': [['9', '31', 'chronic_disease']]}, 'NCT01666080'), ({'text': 'Measurable disease determined using guidelines of Response Evaluation Criteria In Solid Tumors (RECIST 1.1)', 'entities': [['83', '95', 'cancer']]}, 'NCT02581215'), ({'text': 'Currently receiving any other investigational agents or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of MK-3475', 'entities': [['31', '52', 'treatment'], ['31', '53', 'treatment'], ['125', '147', 'treatment'], ['155', '162', 'upper_bound'], ['184', '191', 'treatment']]}, 'NCT02296684'), ({'text': 'Patients with a primary diagnosis of a motility disorder', 'entities': [['40', '57', 'chronic_disease']]}, 'NCT03105362'), ({'text': 'Ability to be off prednisone and other immunosuppressive drugs for at least 14 days before first dose of study drug', 'entities': [['19', '29', 'treatment'], ['40', '63', 'treatment'], ['77', '91', 'lower_bound']]}, 'NCT02191098'), ({'text': 'current therapy with coumadin or Pradaxa', 'entities': [['22', '30', 'treatment'], ['34', '41', 'treatment']]}, 'NCT01695967'), ({'text': 'Steroid hormone use (antiandrogen therapy [ADT]) within the past 12 months', 'entities': [['1', '16', 'treatment'], ['22', '48', 'treatment'], ['61', '75', 'upper_bound']]}, 'NCT02454517'), ({'text': 'Patients older than 18 y.o', 'entities': [['21', '27', 'lower_bound']]}, 'NCT02376205'), ({'text': 'Age< 18 yrs, or> 90 yrs', 'entities': [['1', '4', 'age'], ['6', '12', 'upper_bound'], ['18', '24', 'lower_bound']]}, 'NCT02548104'), ({'text': 'History of mania or hypomania', 'entities': [['12', '17', 'chronic_disease'], ['21', '30', 'chronic_disease']]}, 'NCT02737930'), ({'text': 'Major surgery within 30 days prior or during the study period', 'entities': [['1', '14', 'treatment'], ['22', '35', 'upper_bound']]}, 'NCT02520791'), ({'text': 'Known nutritional deficiency (vitamin B12, vitamin D, iron or zinc) within 3 months prior to the study start', 'entities': [['76', '90', 'upper_bound']]}, 'NCT02268448'), ({'text': "Retinal disease that may limit the visual potential of the eye such as retinopathy of prematurity or Stargardt's retinopathy Optic nerve disease that may limit the visual potential of the eye", 'entities': [['1', '16', 'chronic_disease'], ['72', '98', 'chronic_disease'], ['102', '145', 'chronic_disease']]}, 'NCT01547429'), ({'text': 'Patients must have progressed on, been intolerant of or refused prior oxaliplatin- and irinotecan-containing chemotherapeutic regimen, and have disease that is not amenable to potentially curative resection', 'entities': [['65', '134', 'treatment']]}, 'NCT02484404'), ({'text': 'patients with PSC, confirmed by laboratory tests, imaging, and/or liver biopsy', 'entities': [['15', '18', 'chronic_disease'], ['33', '49', 'treatment'], ['51', '58', 'treatment'], ['67', '79', 'treatment']]}, 'NCT02712736'), ({'text': 'Anticoagulants or antiplatelet agents except for low-dose, 81 mg aspirin', 'entities': [['1', '15', 'treatment'], ['19', '38', 'treatment'], ['66', '73', 'treatment']]}, 'NCT01989585'), ({'text': 'patients with no previous history of documented CNS involvement and with no clinical signs or symptoms consistent with CNS involvement are not required to have completed a lumbar puncture before registration', 'entities': [['173', '188', 'treatment']]}, 'NCT01925131'), ({'text': 'neurologic is deficit defined as manual muscle testing less than 3/5', 'entities': [['34', '55', 'clinical_variable'], ['66', '69', 'upper_bound']]}, 'NCT02226159'), ({'text': 'Presence of focal motor deficits in the upper extremities', 'entities': [['13', '33', 'chronic_disease']]}, 'NCT01681589'), ({'text': 'Any medical or psychiatric condition, such as organic brain disorder, dementia, or psychotic disorder', 'entities': [['47', '69', 'chronic_disease'], ['71', '79', 'chronic_disease'], ['84', '102', 'chronic_disease']]}, 'NCT02174315'), ({'text': 'Subacute or chronic stroke; interval of at least 3month and interval of at least 6 months from stroke to time of enrollment', 'entities': [['13', '27', 'chronic_disease'], ['21', '27', 'chronic_disease'], ['50', '56', 'lower_bound'], ['82', '90', 'lower_bound']]}, 'NCT01948739'), ({'text': 'History of HCT less than 2 years prior to enrollment', 'entities': [['12', '15', 'chronic_disease'], ['26', '39', 'upper_bound']]}, 'NCT03153319'), ({'text': 'Hemoglobin or hematocrit <75% of the lower limit of normal range', 'entities': [['1', '11', 'clinical_variable'], ['15', '25', 'clinical_variable'], ['27', '30', 'upper_bound']]}, 'NCT02932410'), ({'text': 'Treatment-refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy', 'entities': [['1', '34', 'treatment'], ['48', '74', 'clinical_variable'], ['77', '85', 'lower_bound'], ['93', '102', 'clinical_variable'], ['105', '112', 'lower_bound'], ['143', '168', 'treatment']]}, 'NCT02152995'), ({'text': 'Subjects who have had an attempted prior sterilization procedure', 'entities': [['36', '65', 'treatment']]}, 'NCT03127722'), ({'text': 'should have a bone scan within (+/-) 4 months of signing of consent that is without evidence of metastasis', 'entities': [['15', '24', 'treatment'], ['38', '46', 'upper_bound'], ['97', '107', 'cancer']]}, 'NCT02307058'), ({'text': 'History of propylene glycol sensitivity/allergy', 'entities': [['12', '28', 'allergy_name']]}, 'NCT01782599'), ({'text': 'Creatinine < 1.6 mg/dL', 'entities': [['1', '11', 'clinical_variable'], ['14', '23', 'upper_bound']]}, 'NCT01619761'), ({'text': 'BMI <28', 'entities': [['1', '4', 'bmi'], ['6', '8', 'upper_bound']]}, 'NCT00678145'), ({'text': 'Any > grade 1 (according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTC AE) v.4.03) adverse reaction unresolved from previous treatments or not readily managed and controlled with supportive care', 'entities': [['7', '14', 'lower_bound'], ['169', '179', 'treatment']]}, 'NCT03143985'), ({'text': 'Patients for whom busulfan/ melphalan consolidation therapy following treatment with 131I-MIBG is planned', 'entities': [['19', '60', 'treatment'], ['71', '95', 'treatment']]}, 'NCT02378428'), ({'text': 'No plasma HIV RNA detected by testing performed at the local CLIA-certified (US sites) or VQA-certified (non-US sites) laboratory, after criteria above have been confirmed, with specimen collection for the assay within 14 days prior to Step 3 Entry', 'entities': [['11', '14', 'chronic_disease'], ['220', '233', 'upper_bound']]}, 'NCT02140255'), ({'text': 'planning to become pregnant during the study period', 'entities': [['1', '28', 'pregnancy']]}, 'NCT02554903'), ({'text': '2 incidences of blast-related mTBI according to the American Congress of Rehabilitation Medicine', 'entities': [['31', '35', 'chronic_disease']]}, 'NCT00857207'), ({'text': 'Adequate organ function defined as in the judgment of the investigator, there is not irreversible organ damage that would preclude the patient from meeting the organ function inclusion criteria for HSCT listed in section 2.3.4 by the intended time of HSCT (6-8 weeks after randomization) or preclude patients from receiving horse ATG', 'entities': [['199', '203', 'treatment'], ['258', '259', 'lower_bound'], ['260', '267', 'upper_bound'], ['325', '334', 'treatment']]}, 'NCT02845596'), ({'text': 'Contraindication to IV contrast', 'entities': [['21', '32', 'allergy_name']]}, 'NCT02873598'), ({'text': 'e18 years of age', 'entities': [['2', '10', 'lower_bound'], ['14', '17', 'age']]}, 'NCT01811498'), ({'text': 'Able to read, speak and understand English', 'entities': [['1', '43', 'language_fluency']]}, 'NCT02043392'), ({'text': 'Has a life expectancy of at least 3 months', 'entities': [['7', '22', 'clinical_variable'], ['35', '43', 'lower_bound']]}, 'NCT02319369'), ({'text': 'Weight stable within 5 percent for the last 6 months', 'entities': [['1', '7', 'clinical_variable'], ['22', '31', 'upper_bound'], ['40', '53', 'upper_bound']]}, 'NCT02455193'), ({'text': "Neurological disorders (stroke, Alzheimer's, Parkinson's, epilepsy, etc.)", 'entities': [['1', '23', 'chronic_disease'], ['25', '31', 'chronic_disease'], ['33', '44', 'chronic_disease'], ['46', '57', 'chronic_disease'], ['59', '67', 'chronic_disease']]}, 'NCT02394704'), ({'text': 'platelet transfusion dependenc', 'entities': [['1', '21', 'treatment']]}, 'NCT02143830'), ({'text': 'When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative', 'entities': [['43', '50', 'treatment'], ['60', '71', 'treatment']]}, 'NCT01993810'), ({'text': 'Untreated sleep apnea disorder, narcolepsy, REM sleep behavior disorder, parasomnia, restless leg syndrome or other sleep disorder', 'entities': [['11', '31', 'chronic_disease'], ['33', '43', 'chronic_disease'], ['45', '72', 'chronic_disease'], ['74', '84', 'chronic_disease'], ['86', '107', 'chronic_disease'], ['117', '131', 'chronic_disease']]}, 'NCT03019133'), ({'text': 'Active hormone therapy', 'entities': [['1', '23', 'treatment']]}, 'NCT03063892'), ({'text': 'Also excluded are concomitant use of organic nitrates, alpha-blockers, amlodipine, or cimetidine', 'entities': [['38', '54', 'treatment'], ['56', '70', 'treatment'], ['72', '82', 'treatment'], ['87', '97', 'treatment']]}, 'NCT02335242'), ({'text': 'Significant cognitive impairment or Dementia (MoCA < 25)', 'entities': [['13', '33', 'chronic_disease'], ['47', '51', 'clinical_variable'], ['54', '56', 'upper_bound']]}, 'NCT03029884'), ({'text': 'Active uncontrolled infection', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02072356'), ({'text': 'History of hypersensitivity to pregabalin or gabapentin', 'entities': [['32', '42', 'allergy_name'], ['46', '56', 'allergy_name']]}, 'NCT02277548'), ({'text': 'Patients with a prior cumulative cisplatin dose > 300 mg/m^2 (pertains to Arm A only)', 'entities': [['17', '48', 'treatment'], ['51', '61', 'lower_bound']]}, 'NCT02535312'), ({'text': 'Karnofsky score >60%', 'entities': [['1', '16', 'clinical_variable'], ['18', '21', 'lower_bound']]}, 'NCT02905188'), ({'text': 'Renal insufficiency, defined as creatinine level greater than the upper limit of normal for age', 'entities': [['1', '20', 'chronic_disease'], ['33', '49', 'clinical_variable'], ['93', '96', 'age']]}, 'NCT02074631'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02074436'), ({'text': 'Have a Fagerstrom Test for Nicotine Dependence (FTND) score of at least 3 and a Carbon Monoxide (CO) level greater than or equal to 11 ppm', 'entities': [['8', '60', 'clinical_variable'], ['73', '74', 'lower_bound'], ['81', '107', 'clinical_variable'], ['133', '139', 'lower_bound']]}, 'NCT01954966'), ({'text': 'normal fasting glucose and hemoglobin A1c less than or equal to 6%, normal Hb, no glucosuria, normal renal function (based on normal serum creatinine + Cystatin C), urine albumin:creatinine ratio, protein:creatinine ratio, and GFR > 80 as calculated by the CKD-Epi equation and normal lab urinalysis', 'entities': [['8', '23', 'clinical_variable'], ['28', '42', 'clinical_variable'], ['65', '67', 'upper_bound'], ['76', '78', 'clinical_variable'], ['83', '93', 'clinical_variable'], ['95', '116', 'clinical_variable'], ['134', '150', 'clinical_variable'], ['153', '163', 'clinical_variable'], ['166', '196', 'clinical_variable'], ['198', '222', 'clinical_variable'], ['228', '231', 'clinical_variable'], ['234', '236', 'lower_bound']]}, 'NCT02404870'), ({'text': 'The patient has peripheral neuropathy >= grade 2', 'entities': [['17', '38', 'clinical_variable'], ['42', '49', 'lower_bound']]}, 'NCT02152254'), ({'text': 'Abnormal liver function, defined as e3x upper limit of normal (ULN) of aspartate aminotransferase (AST), alanine aminotransferase (ALT) or known cirrhosis', 'entities': [['38', '68', 'lower_bound'], ['72', '104', 'clinical_variable'], ['106', '136', 'clinical_variable'], ['146', '155', 'chronic_disease']]}, 'NCT02323100'), ({'text': 'Cognitive impairment', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT03073811'), ({'text': 'Chronic treatment with corticosteroids or other immunosuppressive agents', 'entities': [['1', '39', 'treatment'], ['49', '73', 'treatment']]}, 'NCT02397083'), ({'text': 'Potential subjects with cancer who are on active chemotherapeutic treatment or who take drugs with hematological effects', 'entities': [['25', '31', 'cancer'], ['43', '76', 'treatment']]}, 'NCT01623167'), ({'text': 'Liver biopsy is optional to assess for iron overload in chronically transfused patients', 'entities': [['1', '13', 'treatment']]}, 'NCT01461837'), ({'text': 'pulmonary disease', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02793921'), ({'text': 'Currently taking antipsychotic regimen with no dose changes in last 30 days', 'entities': [['18', '39', 'treatment'], ['64', '76', 'upper_bound']]}, 'NCT02118610'), ({'text': 'Current treatment with systemic steroid therapy', 'entities': [['9', '48', 'treatment']]}, 'NCT01804465'), ({'text': 'T1-2N0M0 with risk of pelvic lymph nodes involvement >25% by Roach formula [(2/3xPSA) + (Gleason Score - 6)x10], or any T3-4N0M0', 'entities': [['1', '9', 'cancer'], ['23', '53', 'clinical_variable'], ['55', '58', 'lower_bound'], ['121', '129', 'cancer']]}, 'NCT02177292'), ({'text': 'combination of prednisone <10 mg/day (or equivalent dose of another corticosteroid) and other systemic immunosuppressant', 'entities': [['16', '26', 'treatment'], ['28', '37', 'upper_bound'], ['69', '83', 'treatment'], ['95', '121', 'treatment']]}, 'NCT01280669'), ({'text': 'History of allergy to KLH, QS-21, OPT-821, or glucan', 'entities': [['23', '26', 'allergy_name'], ['28', '33', 'allergy_name'], ['35', '42', 'allergy_name'], ['47', '53', 'allergy_name']]}, 'NCT00911560'), ({'text': 'Active infection defined as infectious disease testing indicating that patient blood is reactive for Hep B, C and/or HIV and confirmed using PCR to measure viral load', 'entities': [['1', '17', 'chronic_disease'], ['29', '47', 'chronic_disease'], ['102', '110', 'chronic_disease'], ['118', '121', 'chronic_disease'], ['142', '145', 'treatment']]}, 'NCT01333046'), ({'text': 'Women of childbearing potential must have a negative serum pregnancy test', 'entities': [['1', '6', 'gender'], ['45', '69', 'pregnancy']]}, 'NCT02465060'), ({'text': 'Subject has or is suspected of having central nervous system (CNS) leukemia', 'entities': [['39', '76', 'cancer']]}, 'NCT02577406'), ({'text': 'diagnosis of pregestational diabetes', 'entities': [['14', '37', 'chronic_disease']]}, 'NCT02086448'), ({'text': 'another product with equivalent caloric and nutrient content may be substituted for Boost®] measured at 60 and 90 min after start of consumption', 'entities': [['105', '107', 'lower_bound'], ['112', '124', 'upper_bound']]}, 'NCT02464878'), ({'text': 'Patients must have at least one confirmed and evaluable tumor site', 'entities': [['57', '62', 'cancer']]}, 'NCT01269853'), ({'text': 'who are unwilling to use highly-effective methods to prevent pregnancy', 'entities': [['62', '71', 'pregnancy']]}, 'NCT02030015'), ({'text': 'Subjects found to have significant sleep disorders', 'entities': [['36', '51', 'chronic_disease']]}, 'NCT01433315'), ({'text': 'Patients who are receiving any other investigational agents', 'entities': [['38', '60', 'treatment']]}, 'NCT02122185'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT01515527'), ({'text': 'Implanted pacemaker, defibrillator or deep brain stimulator, other implanted electronic devices in the brain or documented clinically significant arrhythmias', 'entities': [['11', '20', 'treatment'], ['22', '35', 'treatment'], ['39', '60', 'treatment'], ['147', '158', 'chronic_disease']]}, 'NCT01894061'), ({'text': 'Imminent risk of suicide', 'entities': [['18', '25', 'chronic_disease']]}, 'NCT02046330'), ({'text': 'High Tumor Mutation Burden', 'entities': [['1', '27', 'treatment']]}, 'NCT02869789'), ({'text': "Cannot tolerate study drugs' maximum doses", 'entities': [['17', '28', 'treatment']]}, 'NCT01681264'), ({'text': 'Medical condition making it unlikely that the infant will survive to 96 weeks', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02369406'), ({'text': 'Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['47', '82', 'contraception_consent'], ['84', '92', 'contraception_consent'], ['96', '127', 'contraception_consent'], ['131', '141', 'contraception_consent'], ['172', '182', 'upper_bound']]}, 'NCT02112565'), ({'text': 'History of severe hypersensitivity reaction to any monoclonal antibody', 'entities': [['52', '71', 'allergy_name']]}, 'NCT02656706'), ({'text': 'Failure from anti-EGFR therapy will be defined as progressive disease by RECIST (Version 1.1) after at least two months of therapy', 'entities': [['14', '31', 'treatment'], ['24', '31', 'treatment'], ['110', '120', 'lower_bound']]}, 'NCT02942095'), ({'text': 'All allograft patients > 2 years of age', 'entities': [['26', '33', 'lower_bound'], ['37', '40', 'age']]}, 'NCT02124174'), ({'text': 'serum B12 level greater than or equal to 1000 pg/ml', 'entities': [['1', '16', 'clinical_variable'], ['42', '52', 'lower_bound']]}, 'NCT00044304'), ({'text': 'Chemotherapy-sensitive (complete or partial response', 'entities': [['1', '13', 'treatment']]}, 'NCT02167958'), ({'text': 'Existing dental condition/dental infection', 'entities': [['10', '43', 'chronic_disease']]}, 'NCT03029442'), ({'text': 'Lesions identified on other imaging modalities (e.g. PSMA or choline PET) that are not visualized on CT and/or MRI or radionuclide bone scan', 'entities': [['1', '8', 'cancer'], ['29', '47', 'treatment'], ['54', '58', 'treatment'], ['62', '73', 'treatment'], ['102', '104', 'treatment'], ['112', '115', 'treatment'], ['119', '141', 'treatment']]}, 'NCT03009981'), ({'text': 'Serum ALT/AST less than or equal to 2.5 times the upper limit of normal', 'entities': [['1', '14', 'clinical_variable'], ['37', '72', 'upper_bound']]}, 'NCT02111850'), ({'text': 'Major psychiatric diagnosis (e.g. major depression, schizophrenia, bipolar disorder)', 'entities': [['35', '51', 'chronic_disease'], ['53', '66', 'chronic_disease'], ['68', '84', 'chronic_disease']]}, 'NCT02428205'), ({'text': 'Active diverticulitis', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02876510'), ({'text': 'age at study entry >= 6 months to < 18 years', 'entities': [['1', '4', 'age'], ['23', '31', 'lower_bound'], ['37', '45', 'upper_bound']]}, 'NCT02639546'), ({'text': 'Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management', 'entities': [['13', '19', 'chronic_disease'], ['21', '30', 'chronic_disease'], ['32', '37', 'chronic_disease'], ['48', '57', 'chronic_disease'], ['68', '85', 'treatment']]}, 'NCT03056339'), ({'text': 'presence of a rapidly progressive disease not permitting time to identify an unrelated donor', 'entities': [['23', '42', 'chronic_disease']]}, 'NCT00368355'), ({'text': 'History of moderate to severe Obstructive sleep apnea (OSA)', 'entities': [['24', '60', 'chronic_disease']]}, 'NCT02824263'), ({'text': 'Metallic artifacts/implants in head and/or torso', 'entities': [['1', '28', 'treatment']]}, 'NCT03188042'), ({'text': 'Platelets e 100,000/mcl', 'entities': [['1', '10', 'clinical_variable'], ['13', '24', 'lower_bound']]}, 'NCT02296684'), ({'text': 'Subject has had a surgical bowel resection within the past 6 months prior to screening or is planning any resection during the study period', 'entities': [['19', '43', 'treatment'], ['34', '43', 'treatment'], ['55', '68', 'upper_bound']]}, 'NCT03169894'), ({'text': 'Subject has a life expectancy of less than 1 year', 'entities': [['15', '30', 'clinical_variable'], ['44', '50', 'upper_bound']]}, 'NCT02365467'), ({'text': 'Has insurance coverage or is willing to pay for protocol therapy (rituximab x 4 or Zevalin x 1)', 'entities': [['49', '65', 'treatment'], ['67', '76', 'treatment'], ['84', '91', 'treatment']]}, 'NCT02320292'), ({'text': 'history of previous chemotherapy or radiation therapy', 'entities': [['21', '33', 'treatment'], ['37', '54', 'treatment']]}, 'NCT03038867'), ({'text': 'Pregnant or breast-feeding women are excluded', 'entities': [['1', '9', 'pregnancy'], ['28', '33', 'gender']]}, 'NCT01371630'), ({'text': 'Abnormal EEG, Brainstem Auditory Evoked Response (BAER), and/or Visual Evoked Potentials (VEP)', 'entities': [['10', '13', 'treatment'], ['15', '56', 'treatment'], ['65', '95', 'treatment']]}, 'NCT02254863'), ({'text': 'Patients with adequate renal function, Creatinine d 1.5 mg/dl', 'entities': [['40', '50', 'clinical_variable'], ['53', '62', 'upper_bound']]}, 'NCT02844751'), ({'text': 'consumption of drugs or alcohol (>40g/d)', 'entities': [['35', '40', 'lower_bound']]}, 'NCT02258438'), ({'text': 'Diffuse large B cell lymphoma', 'entities': [['1', '30', 'cancer']]}, 'NCT02078102'), ({'text': 'Hypersensitivity to edoxaban', 'entities': [['21', '29', 'allergy_name']]}, 'NCT03088072'), ({'text': 'Initiation of high dose vitamin E (>400 IU per day) or other medications which could alter NASH histology at any time after baseline liver biopsy or during the trial', 'entities': [['25', '34', 'treatment'], ['37', '43', 'lower_bound'], ['62', '73', 'treatment'], ['125', '146', 'treatment']]}, 'NCT02412540'), ({'text': 'Pregnancy or breastfeeding', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02457702'), ({'text': 'Patients with only a 1 out of 8 mismatch in the GVH direction will be classified in the matched related category', 'entities': [['22', '23', 'lower_bound'], ['31', '32', 'upper_bound']]}, 'NCT01760655'), ({'text': 'Females', 'entities': [['1', '8', 'gender']]}, 'NCT02233868'), ({'text': 'Disease: MZL; Criteria for diagnosis: histopathologic confirmation', 'entities': [['10', '13', 'cancer']]}, 'NCT02339922'), ({'text': 'Administration of an investigational therapeutic within 30 days of cycle 1, day -2', 'entities': [['22', '49', 'treatment'], ['57', '64', 'upper_bound']]}, 'NCT02565901'), ({'text': 'a CT of the pelvis and abdomen with IV and oral (PO) contrast performed using multi-detector CT and equal or less than 5 mm slice thickness', 'entities': [['3', '5', 'treatment'], ['120', '124', 'upper_bound']]}, 'NCT00492778'), ({'text': 'Histologically confirmed diagnosis of adenocarcinoma of the prostate', 'entities': [['39', '69', 'cancer']]}, 'NCT03071328'), ({'text': 'Post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test', 'entities': [['17', '22', 'gender'], ['58', '64', 'lower_bound'], ['128', '137', 'pregnancy']]}, 'NCT03042689'), ({'text': 'Isosorbide mononitrate should not be used in patients with severe anemia, severe hypotension, closed angle glaucoma or severe hypovolaemia', 'entities': [['1', '23', 'treatment'], ['67', '73', 'chronic_disease'], ['82', '93', 'chronic_disease'], ['95', '116', 'chronic_disease'], ['127', '139', 'chronic_disease']]}, 'NCT03171480'), ({'text': 'Platelet count < 75 × 10^3/¼L', 'entities': [['1', '15', 'clinical_variable'], ['18', '30', 'upper_bound']]}, 'NCT02723994'), ({'text': 'Newly diagnosed de-novo DLBCL or primary mediastinal B-cell lymphoma that will be treated with an anthracycline-containing regimen (rituximab-cyclophosphamide, doxorubicin hydrochloride, prednisone [R-CHOP] or equivalent)', 'entities': [['25', '30', 'cancer'], ['34', '69', 'cancer'], ['99', '131', 'treatment'], ['133', '142', 'treatment'], ['143', '159', 'treatment'], ['161', '186', 'treatment'], ['188', '207', 'treatment']]}, 'NCT01787409'), ({'text': 'Female or male patients with reproductive potential who do not agree to use an accepted effective method of contraception during the study treatment period and for at least 3 months following completion of study treatment', 'entities': [['1', '24', 'gender'], ['57', '122', 'contraception_consent'], ['134', '149', 'treatment'], ['174', '182', 'lower_bound']]}, 'NCT02187848'), ({'text': 'Patients with a diagnosis of hematological malignancy undergoing a related donor haploidentical HCT', 'entities': [['30', '54', 'cancer']]}, 'NCT03159702'), ({'text': 'Treatment with any other concomitant medication not allowed within 5 (Omega) half-lives prior to study Phase III', 'entities': [['1', '10', 'treatment'], ['26', '48', 'treatment'], ['68', '69', 'upper_bound']]}, 'NCT02543983'), ({'text': 'Permanent AF not treated with AV node ablation within 2 weeks from the CRT implant', 'entities': [['11', '13', 'chronic_disease'], ['31', '47', 'treatment'], ['55', '62', 'upper_bound'], ['72', '83', 'treatment']]}, 'NCT02006069'), ({'text': 'greater than first degree heart block', 'entities': [['14', '26', 'lower_bound'], ['27', '38', 'clinical_variable']]}, 'NCT02620579'), ({'text': 'Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy', 'entities': [['53', '87', 'chronic_disease'], ['121', '143', 'treatment']]}, 'NCT02312245'), ({'text': 'Daily oral dose of loop diuretic', 'entities': [['20', '33', 'treatment']]}, 'NCT02476409'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT03158519'), ({'text': 'Lung disease resulting in dyspnea at rest', 'entities': [['1', '13', 'chronic_disease'], ['27', '34', 'chronic_disease']]}, 'NCT02236000'), ({'text': 'Age 18 years and older', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT02340650'), ({'text': 'Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan', 'entities': [['60', '63', 'lower_bound'], ['169', '174', 'lower_bound'], ['213', '218', 'lower_bound'], ['224', '238', 'treatment']]}, 'NCT01827384'), ({'text': 'a mPAP > 30 mmHg following a 500-1000 ml normal saline bolus', 'entities': [['3', '7', 'clinical_variable'], ['10', '17', 'lower_bound'], ['30', '33', 'lower_bound'], ['34', '41', 'upper_bound'], ['42', '61', 'clinical_variable']]}, 'NCT01445821'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02727062'), ({'text': 'Females may not be lactating or pregnant at Screening or Baseline', 'entities': [['1', '8', 'gender'], ['33', '41', 'pregnancy']]}, 'NCT01871727'), ({'text': 'men/women of child-bearing potential who are unwilling to employ adequate contraception', 'entities': [['1', '10', 'gender'], ['46', '88', 'contraception_consent']]}, 'NCT02172651'), ({'text': 'Previous diagnosis of diabetes, fasting glucose e126 mg/dL, or a hemoglobin A1c e6.5%', 'entities': [['23', '31', 'chronic_disease'], ['33', '48', 'clinical_variable'], ['50', '59', 'lower_bound'], ['66', '80', 'clinical_variable'], ['82', '86', 'lower_bound']]}, 'NCT01422746'), ({'text': 'ECT within the past 6 months', 'entities': [['1', '4', 'treatment'], ['16', '29', 'upper_bound']]}, 'NCT02473250'), ({'text': 'Type 1 or 2 diabetes mellitus', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02496611'), ({'text': 'Fetal anomaly in either twin or imminent fetal demise. This includes lethal anomalies, or anomalies that may lead to early delivery or increased risk of neonatal death e.g., gastroschisis, spina bifida, serious karyotypic abnormalities). An ultrasound examination from 14 weeks 0 days to 23 weeks 6 days by project EDC (estimated date of conception) must be performed prior to randomization to evaluate the fetuses for anomalies', 'entities': [['1', '14', 'chronic_disease'], ['70', '86', 'chronic_disease'], ['175', '188', 'chronic_disease'], ['190', '202', 'chronic_disease'], ['212', '236', 'chronic_disease'], ['270', '285', 'lower_bound'], ['289', '304', 'upper_bound']]}, 'NCT02518594'), ({'text': 'a primary major DSM-IV psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), unrelated to cocaine', 'entities': [['47', '60', 'chronic_disease'], ['62', '78', 'chronic_disease']]}, 'NCT02302976'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02553941'), ({'text': 'Have received recent (within 28 days prior to randomization) yellow fever vaccination', 'entities': [['30', '43', 'upper_bound'], ['62', '86', 'treatment']]}, 'NCT02107703'), ({'text': 'Patients with serum creatinine values >1.7mg/dl or glomerular filtration rates less than 50', 'entities': [['15', '38', 'clinical_variable'], ['40', '48', 'lower_bound'], ['52', '79', 'clinical_variable'], ['90', '92', 'upper_bound']]}, 'NCT02592473'), ({'text': 'Patients with active systemic, pulmonary, or pericardial infection', 'entities': [['15', '67', 'chronic_disease']]}, 'NCT02306954'), ({'text': 'Patient currently has unresolved toxicities for which ceritinib dosing has been interrupted in the parent study', 'entities': [['55', '64', 'treatment']]}, 'NCT02584933'), ({'text': 'Spinal Cord Injured', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02307565'), ({'text': 'History of seizures within last 10 years', 'entities': [['12', '20', 'chronic_disease'], ['33', '41', 'upper_bound']]}, 'NCT01801072'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT01835626'), ({'text': 'coagulation disorders', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02495415'), ({'text': 'Chronic treatment with strong CYP3A4 inhibitor/ inducer, acid reducing agent, Proton pump inhibitors', 'entities': [['9', '18', 'treatment'], ['31', '56', 'treatment'], ['58', '77', 'treatment'], ['79', '101', 'treatment']]}, 'NCT01994382'), ({'text': 'No more than 1 line of anthracycline-containing chemotherapy prior to ASCT, and no more than 3 lines of therapy total prior to ASCT for arms A and B; no more than 1 line of therapy prior to ASCT for arm C', 'entities': [['14', '15', 'lower_bound'], ['24', '61', 'treatment'], ['54', '61', 'treatment'], ['62', '75', 'treatment'], ['94', '95', 'lower_bound']]}, 'NCT02362997'), ({'text': 'Not currently a candidate for curative treatment', 'entities': [['31', '49', 'treatment']]}, 'NCT02587598'), ({'text': 'Validated clinical prediction model estimates probability of malignancy is e 85%', 'entities': [['47', '72', 'clinical_variable'], ['78', '81', 'lower_bound']]}, 'NCT02950337'), ({'text': 'If total bilirubin is =< 2, fractionation is not required for eligibility determination', 'entities': [['10', '19', 'clinical_variable'], ['26', '27', 'upper_bound']]}, 'NCT01787487'), ({'text': 'For the non-small cell lung cancer (NSCLC) and melanoma cohorts, participants must have progressed on or after prior treatment with one anti-PD-1, anti-PD-L1, or anti-PDL2 agent', 'entities': [['9', '43', 'chronic_disease'], ['48', '56', 'cancer'], ['112', '146', 'treatment'], ['148', '158', 'treatment'], ['163', '178', 'treatment']]}, 'NCT02501096'), ({'text': 'e 5 mm by imaging/pathology of core to ensure enough pre- and post-treatment tissue for analysis', 'entities': [['3', '7', 'lower_bound']]}, 'NCT01980823'), ({'text': 'Cardiac: left ventricular ejection fraction e 45%, normal EKG or approved by Cardiology for transplant', 'entities': [['10', '44', 'clinical_variable'], ['47', '50', 'lower_bound'], ['93', '103', 'treatment']]}, 'NCT02582775'), ({'text': 'On digoxin', 'entities': [['4', '11', 'treatment']]}, 'NCT02744430'), ({'text': 'fall from height greater than 10 feet', 'entities': [['11', '17', 'clinical_variable'], ['31', '38', 'lower_bound']]}, 'NCT00870064'), ({'text': 'Primary valvular disease', 'entities': [['9', '25', 'chronic_disease']]}, 'NCT02053246'), ({'text': 'Patients with impaired pulmonary function as evidenced by diffusion capacity of the lung for carbon monoxide (DLCO) < 50% of predicted (or, if unable to perform pulmonary function tests, then oxygen [O2] saturation < 92% on room air)', 'entities': [['59', '116', 'clinical_variable'], ['119', '122', 'upper_bound'], ['162', '186', 'treatment'], ['193', '215', 'clinical_variable'], ['218', '221', 'upper_bound']]}, 'NCT00919503'), ({'text': 'Patients with FIGO 2009 Stage IVB endometrial cancer', 'entities': [['25', '53', 'cancer']]}, 'NCT02501954'), ({'text': 'COH Clinical Pathology confirms IL13R alpha 2+ tumor expression by immunohistochemistry (>= 20%, 1+)', 'entities': [['48', '53', 'cancer'], ['68', '88', 'treatment'], ['93', '96', 'lower_bound']]}, 'NCT02208362'), ({'text': 'for research participants who are at a high risk of recurrence, they must have historical bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML or BPDCN', 'entities': [['178', '181', 'cancer'], ['185', '190', 'cancer']]}, 'NCT02159495'), ({'text': 'Willingness to use adequate contraception to avoid pregnancy or impregnation until 2 weeks after discontinuing study agent', 'entities': [['1', '42', 'contraception_consent'], ['52', '61', 'pregnancy'], ['65', '77', 'pregnancy'], ['84', '97', 'upper_bound'], ['112', '123', 'treatment']]}, 'NCT02273362'), ({'text': 'show evidence of significant psychiatric or cognitive impairment that would limit effective participation as confirmed during informed consent', 'entities': [['30', '41', 'chronic_disease'], ['45', '65', 'chronic_disease']]}, 'NCT02796027'), ({'text': 'Subject with a current diagnosis of ulcerative colitis or indeterminate colitis', 'entities': [['37', '55', 'chronic_disease'], ['59', '80', 'chronic_disease']]}, 'NCT03104413'), ({'text': 'History of inborn error of metabolism', 'entities': [['12', '38', 'chronic_disease']]}, 'NCT02174016'), ({'text': 'Gastrointestinal surgery in the past', 'entities': [['1', '25', 'treatment']]}, 'NCT01675154'), ({'text': 'Platelets e 100,000 cells/mm3', 'entities': [['1', '10', 'clinical_variable'], ['13', '30', 'lower_bound']]}, 'NCT02040610'), ({'text': 'Known or suspected estrogen-dependent neoplasia', 'entities': [['20', '48', 'cancer']]}, 'NCT01895881'), ({'text': 'Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area', 'entities': [['50', '59', 'treatment'], ['61', '74', 'treatment'], ['79', '91', 'treatment']]}, 'NCT02021279'), ({'text': 'Pathologically confirmed Gastric', 'entities': [['26', '33', 'chronic_disease']]}, 'NCT01970306'), ({'text': 'Platelet count e 100 x 109/L (e100,000 per mm3)', 'entities': [['1', '15', 'clinical_variable'], ['18', '29', 'lower_bound'], ['32', '47', 'lower_bound']]}, 'NCT02762006'), ({'text': 'Caucasian or Non-Caucasian', 'entities': [['1', '27', 'ethnicity']]}, 'NCT02968602'), ({'text': '4/6 or better match (HLA A, B, DRB1)', 'entities': [['22', '27', 'clinical_variable'], ['29', '30', 'clinical_variable'], ['32', '36', 'clinical_variable']]}, 'NCT02181478'), ({'text': 'Any implanted electrical device (pacemaker, vagus nerve stimulator implant, etc.) or prior treatment with a vagus nerve stimulator', 'entities': [['5', '32', 'treatment'], ['34', '43', 'treatment'], ['45', '75', 'treatment'], ['86', '131', 'treatment']]}, 'NCT02394704'), ({'text': 'Participants must have preserved renal function as defined by a serum creatinine level of < 3 mg/dL', 'entities': [['65', '87', 'clinical_variable'], ['93', '100', 'upper_bound']]}, 'NCT02128230'), ({'text': 'Availability of HLA identical or single HLA locus mismatched family donor or 10/10 matched unrelated donor at the allelic level (HLA alleles A, B, C, DR, and DQ)', 'entities': [['115', '128', 'clinical_variable']]}, 'NCT01174108'), ({'text': 'Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol 12 Pregnant or breast-feeding women. 13 Patients unwilling or unable to comply with the protocol', 'entities': [['57', '75', 'chronic_disease'], ['82', '114', 'chronic_disease'], ['116', '137', 'chronic_disease'], ['228', '236', 'pregnancy'], ['255', '260', 'gender']]}, 'NCT01925573'), ({'text': 'Subjects will be enrolled based on confirmed histology diagnosis of the NPC', 'entities': [['73', '76', 'cancer']]}, 'NCT02578641'), ({'text': 'Patient has active tuberculosis and/or is being treated for tuberculosis at screening', 'entities': [['13', '32', 'chronic_disease'], ['20', '32', 'chronic_disease']]}, 'NCT00799864'), ({'text': 'Subjects who endorse a history of prior head trauma and score 1.5 standard deviations below the mean on Trail-making A & B', 'entities': [['41', '52', 'clinical_variable'], ['63', '66', 'upper_bound']]}, 'NCT02473250'), ({'text': 'Active liver disease', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT01895777'), ({'text': 'Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes', 'entities': [['1', '26', 'chronic_disease'], ['30', '56', 'chronic_disease'], ['62', '77', 'treatment']]}, 'NCT02393794'), ({'text': 'Platelets e 100,000 cells/mm3', 'entities': [['1', '10', 'clinical_variable'], ['13', '30', 'lower_bound']]}, 'NCT01972919'), ({'text': 'Hemiplegia or hemiparesis', 'entities': [['1', '11', 'chronic_disease'], ['15', '26', 'chronic_disease']]}, 'NCT02369770'), ({'text': 'A minimum of 1 year since completion of gonoadotoxic therapy', 'entities': [['14', '20', 'lower_bound'], ['41', '61', 'treatment']]}, 'NCT01421095'), ({'text': 'self-identify as American Indian or Alaska Native', 'entities': [['18', '33', 'ethnicity'], ['37', '50', 'ethnicity']]}, 'NCT02825771'), ({'text': 'defined as at least one lesion that can be accurately measured in at least one dimension', 'entities': [['25', '31', 'chronic_disease']]}, 'NCT02272998'), ({'text': 'Uncontrolled hypertension or cardiovascular disease', 'entities': [['1', '26', 'chronic_disease'], ['30', '52', 'chronic_disease']]}, 'NCT02508311'), ({'text': 'Mother is taking any glucocorticoids. Although unlikely to be preventative, the use of steroids may confound the interpretation of results. The final point of intense discussion centered around whether another exclusion should be the use of HCQ in the first pregnancy in which CHB occurred. While one could argue that in these mothers HCQ was not effective and perhaps will not be again, this assumption remains speculative and thus prior absence of efficacy of HCQ will not constitute an exclusion criteria', 'entities': [['22', '37', 'treatment'], ['88', '96', 'treatment'], ['242', '245', 'treatment'], ['259', '268', 'pregnancy'], ['278', '281', 'chronic_disease']]}, 'NCT01379573'), ({'text': 'History of vasculitides (autoimmune or idiopathic)', 'entities': [['12', '24', 'chronic_disease'], ['26', '36', 'chronic_disease'], ['40', '50', 'chronic_disease']]}, 'NCT02582827'), ({'text': 'Women of childbearing potential and men must agree to use adequate contraception beginning at the signing of the consent until at least 3 months after the last dose of study drug', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['46', '81', 'contraception_consent'], ['137', '145', 'lower_bound']]}, 'NCT02728050'), ({'text': 'radiation therapy', 'entities': [['1', '18', 'treatment']]}, 'NCT02359825'), ({'text': 'Current diagnosis of major depressive disorder', 'entities': [['22', '47', 'chronic_disease']]}, 'NCT03152409'), ({'text': 'Radiographic procedures (e.g., Gd-enhanced MRI or CT scans) documenting existing lesions must have been performed within three weeks of treatment on this research study', 'entities': [['122', '133', 'upper_bound']]}, 'NCT01811498'), ({'text': 'contraindication to contrast-enhanced MRI', 'entities': [['21', '42', 'treatment']]}, 'NCT02460835'), ({'text': 'Is on chronic anticoagulation other than antiplatelet medications', 'entities': [['7', '30', 'treatment'], ['42', '66', 'treatment']]}, 'NCT02810704'), ({'text': 'Calculated glomerular filtration rate (GFR) >45 mL/min/1.73m2', 'entities': [['12', '44', 'clinical_variable'], ['46', '62', 'lower_bound']]}, 'NCT02191098'), ({'text': 'Suitable candidate for myeloablative or reduced intensity conditioning allogeneic HSCT using PBSC or marrow as stem cell resource', 'entities': [['24', '37', 'treatment'], ['72', '87', 'chronic_disease']]}, 'NCT01773395'), ({'text': 'other serious medical illnesses (in the opinion of the site investigator)', 'entities': [['15', '32', 'chronic_disease']]}, 'NCT02159027'), ({'text': 'history of drug or alcohol abuse within the last 6 months', 'entities': [['45', '58', 'upper_bound']]}, 'NCT02502006'), ({'text': 'Recipients who have had a stem cell transplant must be at least 28 days after stem cell infusion', 'entities': [['27', '47', 'treatment'], ['65', '72', 'lower_bound'], ['79', '97', 'treatment']]}, 'NCT02532452'), ({'text': 'Subjects with resectable and borderline resectable pancreatic cancer', 'entities': [['30', '69', 'cancer']]}, 'NCT01676259'), ({'text': 'MDS - Marrow blasts must be > 5% and disease failed at least 1 prior hypomethylating agent', 'entities': [['1', '20', 'clinical_variable'], ['31', '33', 'lower_bound'], ['62', '63', 'upper_bound'], ['70', '91', 'treatment']]}, 'NCT02576301'), ({'text': 'Hereditary developmental defects such as Amelogenesis Imperfecta and Dentinogenesis Imperfecta', 'entities': [['42', '65', 'chronic_disease'], ['70', '95', 'chronic_disease']]}, 'NCT02601833'), ({'text': 'The subject has previously been or is currently being treated with oral antimalarial agents including hydroxychloroquine, chloroquine, or quinacrine', 'entities': [['68', '92', 'treatment'], ['103', '121', 'treatment'], ['110', '121', 'treatment'], ['139', '149', 'treatment']]}, 'NCT03030118'), ({'text': 'Hemoglobin e 9.0 g/dl', 'entities': [['1', '11', 'clinical_variable'], ['14', '22', 'lower_bound']]}, 'NCT02350764'), ({'text': 'Cutaneous subcutaneous soft tissue, or superficial lymphatic metastasis not suitable for surgical resection', 'entities': [['1', '35', 'cancer'], ['52', '72', 'cancer']]}, 'NCT02819843'), ({'text': 'Life expectancy of less than 1 year', 'entities': [['1', '16', 'clinical_variable'], ['30', '36', 'upper_bound']]}, 'NCT02016924'), ({'text': 'History of clinically significant stroke', 'entities': [['35', '41', 'chronic_disease']]}, 'NCT02033941'), ({'text': 'vancomycin and/or ursodiol tablets', 'entities': [['1', '11', 'treatment'], ['19', '35', 'treatment']]}, 'NCT02748616'), ({'text': 'Fewer than 3 (2 or less) nodal masses > 3 cm', 'entities': [['26', '38', 'clinical_variable'], ['41', '45', 'lower_bound']]}, 'NCT02320292'), ({'text': 'untreatable claustrophobia', 'entities': [['13', '27', 'chronic_disease']]}, 'NCT01568177'), ({'text': '< 3 times upper limit of normal (ULN)', 'entities': [['3', '38', 'upper_bound']]}, 'NCT02128906'), ({'text': 'Participants of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 8 weeks after T cell infusion', 'entities': [['45', '105', 'contraception_consent'], ['117', '126', 'treatment'], ['144', '157', 'lower_bound'], ['158', '173', 'treatment']]}, 'NCT02146924'), ({'text': 'History of relevant coronary heart disease or myocardial infarction within last 3 years', 'entities': [['21', '43', 'chronic_disease'], ['47', '68', 'chronic_disease'], ['76', '88', 'upper_bound']]}, 'NCT02383927'), ({'text': 'SCID confirmed diagnosis of Schizophrenia or Schizoaffective Disorder', 'entities': [['29', '42', 'chronic_disease'], ['46', '70', 'chronic_disease']]}, 'NCT03037983'), ({'text': 'PD Hoehn and Yahr stage 2-4', 'entities': [['1', '3', 'chronic_disease'], ['4', '24', 'clinical_variable'], ['25', '26', 'lower_bound'], ['27', '28', 'upper_bound']]}, 'NCT01742182'), ({'text': 'Donor cellular engraftment of at least 2.5% from the non-myeloablative procedure', 'entities': [['1', '27', 'clinical_variable'], ['40', '44', 'lower_bound'], ['54', '81', 'treatment']]}, 'NCT02452697'), ({'text': 'Known immunodeficiency disorders, either primary or acquired', 'entities': [['7', '33', 'chronic_disease']]}, 'NCT02439450'), ({'text': 'Platelet count greater than or equal to 100,000/mm(3)', 'entities': [['1', '15', 'clinical_variable'], ['41', '54', 'lower_bound']]}, 'NCT01993719'), ({'text': 'Has an active infection requiring systemic therapy', 'entities': [['8', '24', 'chronic_disease'], ['35', '51', 'treatment']]}, 'NCT02977468'), ({'text': 'Psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT02465060'), ({'text': 'No prior chemotherapy for pancreatic cancer', 'entities': [['4', '22', 'treatment'], ['27', '44', 'cancer']]}, 'NCT02080221'), ({'text': 'Hemoglobin e 9 g/dL (transfusions are acceptable)', 'entities': [['1', '11', 'clinical_variable'], ['14', '20', 'lower_bound'], ['22', '34', 'treatment']]}, 'NCT02178709'), ({'text': 'At least 18 years of age or older', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT01804465'), ({'text': 'Central or lateral neck lymphadenopathy suspicious for PTC', 'entities': [['1', '40', 'cancer'], ['56', '59', 'treatment']]}, 'NCT02609685'), ({'text': 'Patients with chronic liver disease', 'entities': [['15', '36', 'chronic_disease']]}, 'NCT02579096'), ({'text': 'donated blood in the last 20 days', 'entities': [['22', '34', 'upper_bound']]}, 'NCT02966444'), ({'text': 'patients with prostate cancer may continue luteinizing hormone-releasing hormone (LHRH) agonists or antagonists', 'entities': [['15', '30', 'cancer'], ['44', '88', 'clinical_variable']]}, 'NCT01827384'), ({'text': 'referred for physical therapy for mobility/gait training to regain functional walking and ambulation', 'entities': [['14', '30', 'treatment']]}, 'NCT03135145'), ({'text': 'Abnormal cardiac valve morphology (>= grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study); subjects with moderate valvular thickening should not be entered on study', 'entities': [['1', '34', 'clinical_variable'], ['39', '46', 'lower_bound'], ['62', '76', 'treatment'], ['126', '139', 'chronic_disease'], ['140', '148', 'chronic_disease']]}, 'NCT01989585'), ({'text': 'Participants may not have had chemotherapy wafer placement at surgery', 'entities': [['31', '59', 'treatment'], ['63', '70', 'treatment']]}, 'NCT01985087'), ({'text': 'Need for concurrent other cytoreductive chemotherapy', 'entities': [['27', '53', 'treatment']]}, 'NCT02152956'), ({'text': 'Emergent cardiac surgery', 'entities': [['1', '25', 'treatment']]}, 'NCT02836899'), ({'text': 'pulp necrosis', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02298504'), ({'text': 'Anaplastic large cell lymphoma, ALK-positive', 'entities': [['1', '31', 'cancer'], ['33', '36', 'treatment']]}, 'NCT02232516'), ({'text': "Ewing's Family Tumors (ES/PNET/DSRCT) - metastatic at time of diagnosis and/or relapsed after therapy", 'entities': [['1', '22', 'cancer'], ['24', '26', 'cancer'], ['27', '31', 'cancer'], ['32', '37', 'cancer'], ['41', '51', 'cancer'], ['89', '102', 'treatment']]}, 'NCT01505569'), ({'text': 'when repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible', 'entities': [['27', '35', 'upper_bound']]}, 'NCT02519322'), ({'text': 'NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD, requiring the combined presence of steatosis (any degree e 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed d 6 months before screening in the study or at screening and confirmed by central reading during the screening period', 'entities': [['1', '5', 'chronic_disease'], ['93', '98', 'chronic_disease'], ['150', '156', 'clinical_variable'], ['159', '161', 'lower_bound'], ['244', '256', 'treatment'], ['269', '277', 'upper_bound']]}, 'NCT03008070'), ({'text': 'Active infection requiring parenteral antibiotics, antivirals, or antifungals within 2 weeks prior to first dose of study drug', 'entities': [['1', '17', 'chronic_disease'], ['39', '50', 'treatment'], ['52', '62', 'treatment'], ['67', '78', 'treatment'], ['86', '99', 'upper_bound'], ['117', '127', 'treatment']]}, 'NCT02771626'), ({'text': 'Patients whose tumor is in an organ that communicates with the peritoneum and peritoneal sampling at time of primary excision shows evidence of disease', 'entities': [['16', '21', 'cancer']]}, 'NCT02429349'), ({'text': 'Measurable disease as defined by RECIST v1.1 criteria. Baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to Enrollment', 'entities': [['96', '99', 'cancer'], ['141', '154', 'upper_bound']]}, 'NCT02503358'), ({'text': 'Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the lenalidomide REMS® program', 'entities': [['1', '8', 'gender'], ['64', '73', 'pregnancy']]}, 'NCT02213913'), ({'text': 'The effects of bevacizumab on developing fetus or nursing infant are not known', 'entities': [['16', '27', 'treatment']]}, 'NCT01894061'), ({'text': 'Life expectancy of greater than 3 months', 'entities': [['1', '16', 'clinical_variable'], ['33', '41', 'lower_bound']]}, 'NCT01851369'), ({'text': 'biologic therapies in the opinion of the investigator', 'entities': [['1', '19', 'treatment']]}, 'NCT02819635'), ({'text': 'Absolute neutrophil count e 1,000/mcl', 'entities': [['1', '26', 'clinical_variable'], ['29', '38', 'lower_bound']]}, 'NCT02369458'), ({'text': 'Shortening fraction of e 27% by echocardiogram', 'entities': [['1', '20', 'clinical_variable'], ['26', '29', 'lower_bound'], ['33', '47', 'clinical_variable']]}, 'NCT01614197'), ({'text': 'Pregnancy (positive urine pregnancy test)', 'entities': [['1', '10', 'pregnancy'], ['27', '36', 'pregnancy']]}, 'NCT01883258'), ({'text': 'active pregnancy', 'entities': [['1', '17', 'pregnancy']]}, 'NCT02485639'), ({'text': 'Use of any medication known to significantly affect appetite (anti-depressants are allowable)', 'entities': [['63', '79', 'treatment']]}, 'NCT02721303'), ({'text': '30 to 80 years old', 'entities': [['1', '3', 'lower_bound'], ['7', '15', 'upper_bound']]}, 'NCT02098876'), ({'text': '> 6 years 5 months', 'entities': [['3', '19', 'lower_bound']]}, 'NCT02483910'), ({'text': 'Use of benzodiazepines or anticonvulsants within 2 weeks prior to study (to be ruled out by a urine drug screen)', 'entities': [['8', '23', 'treatment'], ['27', '42', 'treatment'], ['50', '63', 'upper_bound'], ['95', '112', 'treatment']]}, 'NCT02355002'), ({'text': 'Any unstable serious co-existing medical condition(s) including but not limited to myocardial infarction, coronary artery disease requiring coronary bypass surgery, unstable angina, clinically evident congestive heart failure within 6 months prior to the screening visit', 'entities': [['34', '54', 'chronic_disease'], ['84', '105', 'chronic_disease'], ['141', '164', 'treatment'], ['166', '181', 'chronic_disease'], ['202', '226', 'chronic_disease'], ['234', '248', 'upper_bound']]}, 'NCT01703117'), ({'text': "Any condition, including neurological or psychiatric illness, which per investigators' judgement may increase subject risk", 'entities': [['26', '61', 'chronic_disease']]}, 'NCT02781103'), ({'text': 'activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants, performed within 28 days of treatment initiation', 'entities': [['1', '45', 'clinical_variable'], ['41', '43', 'clinical_variable'], ['41', '44', 'clinical_variable'], ['49', '58', 'upper_bound'], ['87', '108', 'treatment'], ['177', '191', 'treatment'], ['210', '217', 'upper_bound'], ['221', '230', 'treatment']]}, 'NCT02446457'), ({'text': 'Patients with history of clinically significant bleeding disorder', 'entities': [['49', '66', 'chronic_disease']]}, 'NCT02272998'), ({'text': 'Symptomatic biliary disease', 'entities': [['13', '28', 'chronic_disease']]}, 'NCT01811368'), ({'text': 'Histologically diagnosed neuroendocrine tumor or other tumor with probable somatostatin receptors subtype 2', 'entities': [['26', '46', 'cancer'], ['41', '46', 'cancer']]}, 'NCT02441062'), ({'text': 'Patient does not have metastatic disease', 'entities': [['23', '41', 'cancer']]}, 'NCT02843945'), ({'text': 'Treatment sensitive HIV and, if on anti-HIV therapy, HIV viral load < 50 copies/mm^3 within 28 days prior to registration', 'entities': [['1', '10', 'treatment'], ['21', '24', 'chronic_disease'], ['36', '52', 'treatment'], ['54', '68', 'clinical_variable'], ['71', '85', 'upper_bound'], ['93', '106', 'upper_bound']]}, 'NCT02004275'), ({'text': 'Patients must be e 12 months and <22 years of age at the time of study registration', 'entities': [['20', '29', 'lower_bound'], ['35', '43', 'upper_bound'], ['47', '50', 'age']]}, 'NCT01130077'), ({'text': 'No NSAID or acetaminophen within 1 hour of infusion', 'entities': [['4', '9', 'treatment'], ['13', '26', 'treatment'], ['34', '40', 'upper_bound']]}, 'NCT02485418'), ({'text': 'BMI = 20-45 kg/m2', 'entities': [['1', '4', 'bmi'], ['7', '9', 'lower_bound'], ['10', '18', 'upper_bound']]}, 'NCT02911792'), ({'text': 'No evidence of distant metastases', 'entities': [['16', '34', 'cancer']]}, 'NCT02468024'), ({'text': 'Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure', 'entities': [['8', '20', 'chronic_disease'], ['24', '41', 'chronic_disease'], ['49', '63', 'upper_bound'], ['67', '82', 'treatment']]}, 'NCT02000115'), ({'text': 'ECOG score 0-1 with no known cardiac, pulmonary or renal dysfunction', 'entities': [['1', '11', 'clinical_variable'], ['12', '13', 'lower_bound'], ['14', '15', 'upper_bound'], ['30', '37', 'chronic_disease'], ['39', '48', 'chronic_disease'], ['52', '69', 'chronic_disease']]}, 'NCT02174549'), ({'text': 'Known contraindications or relative contraindications to certolizumab', 'entities': [['58', '70', 'allergy_name']]}, 'NCT03152058'), ({'text': 'Less than 18 years of age', 'entities': [['11', '19', 'upper_bound'], ['23', '26', 'age']]}, 'NCT02652247'), ({'text': 'No or limited cognitive/developmental delays', 'entities': [['7', '45', 'chronic_disease']]}, 'NCT02310399'), ({'text': 'for the purposes of enrollment and toxicity monitoring the ULN for ALT will be 45 unit per liter (U/L)', 'entities': [['68', '71', 'clinical_variable'], ['80', '103', 'upper_bound']]}, 'NCT02124772'), ({'text': 'one marrow biopsy demonstrating cellularity of <25% (at least 2 weeks from last dose of G-CSF)', 'entities': [['33', '44', 'clinical_variable'], ['49', '52', 'upper_bound'], ['63', '70', 'lower_bound'], ['89', '94', 'clinical_variable']]}, 'NCT02928991'), ({'text': 'Structural heart disease requiring surgical treatment', 'entities': [['1', '25', 'chronic_disease'], ['36', '54', 'treatment']]}, 'NCT02393885'), ({'text': 'ct > 30%', 'entities': [['1', '3', 'clinical_variable'], ['6', '9', 'lower_bound']]}, 'NCT01757418'), ({'text': 'Previous episode of neurocardiogenic snycopy', 'entities': [['21', '45', 'chronic_disease']]}, 'NCT03038269'), ({'text': 'Subjects who have a serum creatinine > 2 x upper limit of normal (ULN)', 'entities': [['21', '37', 'clinical_variable'], ['40', '71', 'lower_bound']]}, 'NCT03097588'), ({'text': 'Be classified in breast cancer stage grouping 0 to III according to the American Joint Committee on Cancer Classification of Malignant Tumors (TNM) Staging System (2013)', 'entities': [['18', '31', 'cancer'], ['47', '48', 'lower_bound'], ['52', '55', 'upper_bound']]}, 'NCT02982564'), ({'text': 'alopecia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02215096'), ({'text': 'No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery', 'entities': [['4', '22', 'treatment'], ['73', '82', 'treatment']]}, 'NCT01508390'), ({'text': 'substrates of CYP 3A4/5 or CYP1A2 that are sensitive or have a narrow therapeutic window at least three weeks prior to study registration', 'entities': [['15', '24', 'treatment'], ['28', '34', 'treatment'], ['64', '89', 'treatment'], ['99', '116', 'lower_bound']]}, 'NCT02503722'), ({'text': 'for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment', 'entities': [['5', '25', 'chronic_disease'], ['65', '72', 'treatment'], ['120', '134', 'upper_bound']]}, 'NCT02210078'), ({'text': "Any leukemia specific marker (such as t(9:22) or t(4:11)) documented in the patient's leukemia cells pre transplant on a post transplant evaluation", 'entities': [['5', '13', 'cancer'], ['102', '116', 'treatment'], ['122', '148', 'treatment']]}, 'NCT02050347'), ({'text': 'Impaired lower extremity sensation confirmed by a score of < 12 on the Fugl-Meyer Sensory Assessment', 'entities': [['62', '64', 'upper_bound'], ['72', '101', 'clinical_variable']]}, 'NCT02667392'), ({'text': 'Patients must have adequate organ and marrow function (documented within 14 days prior to registration)', 'entities': [['74', '87', 'upper_bound']]}, 'NCT02232516'), ({'text': 'Presence of major congenital anomaly', 'entities': [['19', '37', 'chronic_disease']]}, 'NCT01072370'), ({'text': 'Prior autologous SCT in the prior 12 months', 'entities': [['1', '21', 'treatment'], ['29', '44', 'upper_bound']]}, 'NCT02512497'), ({'text': 'Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up', 'entities': [['7', '37', 'cancer'], ['85', '100', 'treatment']]}, 'NCT01872975'), ({'text': 'Previous aortic surgery', 'entities': [['1', '24', 'treatment']]}, 'NCT02050113'), ({'text': 'in addition to routine contraceptive methods, effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation', 'entities': [['111', '118', 'treatment'], ['131', '148', 'pregnancy'], ['175', '195', 'pregnancy'], ['210', '222', 'treatment'], ['224', '246', 'treatment'], ['250', '274', 'treatment']]}, 'NCT01925131'), ({'text': 'Not pregnant', 'entities': [['1', '13', 'pregnancy']]}, 'NCT02905591'), ({'text': 'Serum urate level 6.8 mg/dl', 'entities': [['1', '18', 'clinical_variable']]}, 'NCT02579096'), ({'text': 'Unable to have TraceIT hydrogel placement < 8 weeks prior to beginning radiation treatment', 'entities': [['16', '42', 'clinical_variable'], ['45', '58', 'upper_bound'], ['72', '91', 'treatment']]}, 'NCT03125226'), ({'text': 'Subjects who are compulsorily detained for treatment of either a psychiatric or physical (infection disease) illness', 'entities': [['18', '39', 'treatment'], ['44', '53', 'treatment'], ['66', '117', 'chronic_disease']]}, 'NCT02519322'), ({'text': 'Willing to receive HCV treatment on-site at DoSA clinics', 'entities': [['20', '33', 'treatment']]}, 'NCT03127358'), ({'text': 'Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon', 'entities': [['64', '71', 'treatment'], ['88', '111', 'treatment']]}, 'NCT01815359'), ({'text': 'Confirmed in utero HIV infection', 'entities': [['20', '33', 'chronic_disease']]}, 'NCT02140255'), ({'text': 'Total bilirubin <1. 5 x ULN', 'entities': [['1', '16', 'clinical_variable'], ['18', '28', 'upper_bound']]}, 'NCT02578732'), ({'text': 'All women (who could bear children) not using a medically approved method of contraception (surgical sterilization, intrauterine device, or a combined method using at least 2 of the following: diaphragm, condom, spermicide) will be excluded', 'entities': [['1', '10', 'gender'], ['37', '91', 'contraception_consent'], ['93', '115', 'contraception_consent'], ['117', '136', 'contraception_consent'], ['174', '175', 'lower_bound'], ['194', '203', 'contraception_consent'], ['205', '211', 'contraception_consent'], ['213', '223', 'contraception_consent']]}, 'NCT00739362'), ({'text': 'other neurological disorder', 'entities': [['7', '28', 'chronic_disease']]}, 'NCT03087799'), ({'text': 'Cerebral aneurysm', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02479906'), ({'text': 'he former will be operationally defined using NCI Toxicity Criteria (Grade 2 or higher)', 'entities': [['47', '68', 'clinical_variable'], ['70', '77', 'lower_bound']]}, 'NCT02232165'), ({'text': 'Chemotherapy was administered for 2-6 cycles with any combination', 'entities': [['1', '13', 'treatment'], ['35', '36', 'lower_bound'], ['37', '38', 'upper_bound']]}, 'NCT02843945'), ({'text': 'Prior chemotherapy, prior EGFR targeted therapy, or prior radiation therapy for HNSCC', 'entities': [['1', '19', 'treatment'], ['21', '48', 'treatment'], ['53', '76', 'treatment'], ['81', '86', 'cancer']]}, 'NCT02573493'), ({'text': 'Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible', 'entities': [['15', '16', 'upper_bound'], ['26', '42', 'clinical_variable'], ['62', '78', 'upper_bound']]}, 'NCT02111850'), ({'text': 'evidence of active suicidality or psychosis (brief screen conducted by SWer in clinic using DSM-V cross cutting symptom inventory) to assess for psychosis', 'entities': [['35', '44', 'chronic_disease']]}, 'NCT03186872'), ({'text': 'Previous treatment with any other investigational agent in the 4 weeks prior to study drug administration (Cycle 1 Day 1)', 'entities': [['10', '19', 'treatment'], ['35', '56', 'treatment'], ['64', '77', 'upper_bound']]}, 'NCT02152956'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02353728'), ({'text': 'Planning to leave area > 2 month during the next 18 months', 'entities': [['26', '33', 'lower_bound'], ['45', '59', 'upper_bound']]}, 'NCT02577549'), ({'text': 'ages 12-19 years', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '17', 'upper_bound']]}, 'NCT02412540'), ({'text': 'calcitonin therapy for more than 3 months', 'entities': [['1', '19', 'treatment'], ['34', '42', 'lower_bound']]}, 'NCT01968590'), ({'text': 'Are e18 but d65 years of age', 'entities': [['6', '8', 'lower_bound'], ['14', '22', 'upper_bound'], ['26', '29', 'age']]}, 'NCT03158974'), ({'text': 'Insulin-dependent or uncontrolled diabetes mellitus (DM)', 'entities': [['1', '18', 'chronic_disease'], ['22', '57', 'chronic_disease']]}, 'NCT02374021'), ({'text': 'score greater than 85 on all sub-scales of the Bayley Scale of Infant Development (BSID-II)', 'entities': [['20', '22', 'lower_bound'], ['48', '92', 'clinical_variable']]}, 'NCT02813889'), ({'text': 'Positive pregnancy test', 'entities': [['10', '19', 'pregnancy']]}, 'NCT02724631'), ({'text': 'Women of childbearing potential must have a negative pregnancy test (urine or blood) pre-operatively as per the standard hospital policy', 'entities': [['1', '6', 'gender'], ['45', '63', 'pregnancy']]}, 'NCT02910726'), ({'text': 'At least 6 months post injury', 'entities': [['10', '18', 'lower_bound']]}, 'NCT00857207'), ({'text': 'Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available', 'entities': [['1', '19', 'cancer'], ['97', '109', 'treatment']]}, 'NCT02166905'), ({'text': 'Female subjects of childbearing potential must have a negative pregnancy test', 'entities': [['1', '16', 'gender'], ['55', '73', 'pregnancy']]}, 'NCT02268448'), ({'text': 'Stable on tezacaftor/ivacaftor dosing for both label indication and per label dosing for a minimum of 1 month at the time dosing', 'entities': [['11', '21', 'treatment'], ['22', '31', 'treatment'], ['103', '110', 'upper_bound']]}, 'NCT03140527'), ({'text': 'Patients with active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases', 'entities': [['35', '65', 'chronic_disease'], ['145', '180', 'chronic_disease'], ['182', '201', 'chronic_disease'], ['204', '212', 'chronic_disease'], ['214', '223', 'chronic_disease'], ['225', '249', 'chronic_disease'], ['255', '270', 'chronic_disease']]}, 'NCT02688309'), ({'text': 'All subjects must have previously received trastuzumab or other HER2 targeted therapies', 'entities': [['44', '55', 'treatment'], ['65', '88', 'treatment']]}, 'NCT01976169'), ({'text': 'Ongoing or uncontrolled, symptomatic congestive heart failure (Class III or IV as defined by the NYHA functional classification system', 'entities': [['38', '62', 'chronic_disease']]}, 'NCT01306045'), ({'text': 'This group of patients must have received at least 1 and up to 3 prior chemotherapy regimens in the advanced setting', 'entities': [['52', '53', 'lower_bound'], ['64', '65', 'upper_bound'], ['66', '117', 'treatment']]}, 'NCT01990209'), ({'text': 'Uncontrolled Heart Failure or NYHA Class III or IV heart failure', 'entities': [['1', '27', 'chronic_disease'], ['31', '65', 'chronic_disease']]}, 'NCT01959425'), ({'text': 'Any other malignancy that required active chemotherapy within the previous 12 months prior to registration and the disease is not currently progressing and/or metastatic. The exception is basal cell or squamous cell carcinoma of the skin, which were treated with local resection only or carcinoma in situ of the cervix', 'entities': [['11', '21', 'cancer'], ['43', '55', 'treatment'], ['67', '91', 'upper_bound'], ['189', '199', 'cancer'], ['203', '238', 'cancer'], ['288', '319', 'cancer']]}, 'NCT01954576'), ({'text': 'Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy', 'entities': [['1', '17', 'treatment'], ['35', '42', 'lower_bound'], ['74', '99', 'treatment'], ['118', '131', 'treatment']]}, 'NCT03110107'), ({'text': 'American Society of Anesthesiologists (ASA) physical status e 3', 'entities': [['1', '60', 'clinical_variable'], ['63', '64', 'lower_bound']]}, 'NCT02534168'), ({'text': 'Inability (illiteracy, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study', 'entities': [['24', '37', 'chronic_disease']]}, 'NCT02273375'), ({'text': 'Need for emergent CABG', 'entities': [['10', '23', 'clinical_variable']]}, 'NCT00928356'), ({'text': 'Having received Botox/collagen/fat injections or other methods of augmentation with injected or implanted material in the treated area within 9 months of treatment or during the study (if face is treated)', 'entities': [['17', '22', 'treatment'], ['23', '31', 'treatment'], ['32', '46', 'treatment'], ['67', '115', 'treatment'], ['143', '151', 'upper_bound'], ['155', '164', 'treatment']]}, 'NCT02468453'), ({'text': 'CGI of 4', 'entities': [['1', '4', 'clinical_variable']]}, 'NCT02118610'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status (PS) d 1', 'entities': [['1', '66', 'clinical_variable'], ['69', '70', 'upper_bound']]}, 'NCT03123055'), ({'text': 'Tumor o6-methylguanine-DNA-methyltransferase promoter methylation status must be determined', 'entities': [['1', '6', 'cancer'], ['7', '73', 'clinical_variable']]}, 'NCT01985087'), ({'text': 'Subjects must have histologically or cytologically confirmed adenocarcinoma of the pancreas', 'entities': [['62', '92', 'cancer']]}, 'NCT02427841'), ({'text': 'Pulmonary: FEV1, FVC, DLCO (diffusion capacity) e 40% predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then O2 saturation > 92% on room air', 'entities': [['12', '16', 'clinical_variable'], ['18', '21', 'clinical_variable'], ['23', '27', 'clinical_variable'], ['51', '54', 'lower_bound'], ['80', '90', 'clinical_variable'], ['161', '164', 'lower_bound']]}, 'NCT02167958'), ({'text': "No other serious concomitant medical illnesses or uncontrolled active infection that would jeopardize the patient's ability to receive the regimen with reasonable safety", 'entities': [['64', '80', 'chronic_disease'], ['140', '147', 'treatment']]}, 'NCT00001337'), ({'text': 'previously unable to tolerate acetylcholinesterase inhibitors and as a result, are no longer on the medication for at least 2 months', 'entities': [['31', '62', 'allergy_name'], ['125', '133', 'lower_bound']]}, 'NCT01703117'), ({'text': '16 to 85 years of age', 'entities': [['1', '3', 'lower_bound'], ['7', '15', 'upper_bound'], ['19', '22', 'age']]}, 'NCT03059888'), ({'text': 'Haploidentical by HLA-typing', 'entities': [['1', '15', 'treatment']]}, 'NCT02508038'), ({'text': "Parent or biological family member with Alzheimer's disease", 'entities': [['41', '60', 'chronic_disease']]}, 'NCT02471833'), ({'text': 'received at least one intravenous bolus dose of a sedative/opioid medication in the previous 24 hours (fentanyl, hydromorphone, ketamine, morphine, midazolam, diazepam, lorazepam, propofol, haloperidol, dexmedetomidine)', 'entities': [['19', '22', 'lower_bound'], ['85', '102', 'upper_bound'], ['104', '112', 'treatment'], ['114', '127', 'treatment'], ['129', '137', 'treatment'], ['139', '147', 'treatment'], ['149', '158', 'treatment'], ['160', '168', 'treatment'], ['170', '179', 'treatment'], ['181', '189', 'treatment'], ['191', '202', 'treatment'], ['204', '219', 'treatment']]}, 'NCT02819141'), ({'text': 'Currently taking a bisphosphonate medication', 'entities': [['20', '45', 'treatment']]}, 'NCT02580604'), ({'text': 'new disease sites or 20% growth of index lesions) within 6 months of registration', 'entities': [['36', '49', 'clinical_variable'], ['58', '66', 'upper_bound']]}, 'NCT02048371'), ({'text': 'Time interval of 5 weeks (± 1 week) between visits for at least two visits immediately preceding study enrollment', 'entities': [['65', '68', 'lower_bound']]}, 'NCT03034772'), ({'text': 'History of any cardiac events including coronary revascularization or ischemic symptoms', 'entities': [['16', '30', 'chronic_disease'], ['41', '67', 'treatment']]}, 'NCT02111850'), ({'text': 'Unrelated donor: An 8/10, 9/10 or 10/10 matched unrelated adult donor (MUD) will be required for study entry', 'entities': [['41', '76', 'clinical_variable']]}, 'NCT01966367'), ({'text': 'Apgar score < 5 at 10 minutes', 'entities': [['1', '12', 'clinical_variable'], ['15', '16', 'upper_bound']]}, 'NCT02811263'), ({'text': 'Multi-system organ failure including acute or chronic renal failure', 'entities': [['1', '27', 'chronic_disease'], ['38', '68', 'chronic_disease']]}, 'NCT02914171'), ({'text': 'IPEX syndrome', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT01962415'), ({'text': 'SSI score of 2 or more (indicates any residual suicidal thoughts)', 'entities': [['1', '10', 'clinical_variable'], ['14', '15', 'lower_bound']]}, 'NCT02543983'), ({'text': 'Nonimmunocompromized male or female who failed to respond adequately to other topical prescription treatment for AD or for whom those treatments are not advisable', 'entities': [['4', '21', 'chronic_disease'], ['22', '36', 'gender'], ['79', '109', 'treatment'], ['114', '116', 'chronic_disease'], ['135', '145', 'treatment']]}, 'NCT03058783'), ({'text': "Use of St. John's wort is prohibited from 28 days before dosing until 14 days after dosing", 'entities': [['8', '23', 'treatment'], ['43', '50', 'upper_bound'], ['71', '78', 'upper_bound']]}, 'NCT01959204'), ({'text': 'CD25 assay-positive tumor, defined as detectable CD25 on greater than or equal to 20% of total lymphoid infiltrate in biopsied lesions by immunohistochemistry', 'entities': [['1', '5', 'clinical_variable'], ['6', '11', 'treatment'], ['21', '26', 'cancer'], ['83', '86', 'lower_bound'], ['96', '115', 'cancer'], ['119', '135', 'treatment'], ['139', '159', 'treatment']]}, 'NCT01871727'), ({'text': 'Bilirubin d 1.5 mg/dL (d 3.0 mg/dL with liver metastasis)', 'entities': [['1', '10', 'clinical_variable'], ['13', '22', 'upper_bound'], ['26', '35', 'upper_bound'], ['41', '57', 'cancer']]}, 'NCT01618357'), ({'text': 'Clinical and molecular diagnosis of Retinitis Pigmentosa associated with Usher Syndrome type 1B', 'entities': [['37', '57', 'chronic_disease'], ['74', '96', 'chronic_disease']]}, 'NCT01505062'), ({'text': 'Subject has a neurological condition', 'entities': [['15', '37', 'chronic_disease']]}, 'NCT02361554'), ({'text': 'Must have the ability to converse and read English', 'entities': [['15', '51', 'language_fluency']]}, 'NCT03024320'), ({'text': 'Prior immunotherapy with checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor or CTL4-antagonist or similar agent) must have been completed more than 1 month prior to the T cell infusion', 'entities': [['1', '45', 'treatment'], ['52', '65', 'treatment'], ['67', '81', 'treatment'], ['85', '100', 'treatment'], ['154', '167', 'lower_bound'], ['175', '190', 'treatment']]}, 'NCT02414269'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status 0-1', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['64', '65', 'upper_bound']]}, 'NCT02503709'), ({'text': 'Suicidal ideation in the past month', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02250534'), ({'text': 'no clinical signs or symptoms of congestive heart failure', 'entities': [['34', '58', 'chronic_disease']]}, 'NCT02058095'), ({'text': 'Diagnosed depression or other condition that may impact QoL', 'entities': [['11', '21', 'chronic_disease']]}, 'NCT02615353'), ({'text': 'Have a historically positive HIV test or test positive at screening for HIV', 'entities': [['30', '33', 'chronic_disease']]}, 'NCT02347891'), ({'text': 'An interval of at least 12 weeks must have elapsed since the completion of initial radiation therapy', 'entities': [['25', '33', 'lower_bound'], ['76', '101', 'treatment']]}, 'NCT02208362'), ({'text': 'Uncorrectable coagulopathy', 'entities': [['15', '27', 'chronic_disease']]}, 'NCT02240498'), ({'text': 'Stratum 3: Patient must have a hemoglobinopathy receiving a minimally mismatched unrelated donor transplant with bone marrow or single or double umbilical cord blood product', 'entities': [['32', '48', 'chronic_disease'], ['98', '108', 'treatment']]}, 'NCT00920972'), ({'text': 'Treatment with any anti-diabetic medication other than insulin within 4 weeks of enrollment', 'entities': [['1', '63', 'treatment'], ['71', '78', 'upper_bound']]}, 'NCT01474889'), ({'text': 'Renal function defined as a calculated or measured glomerular filtration rate (GFR) >= 30 mL/min', 'entities': [['29', '84', 'clinical_variable'], ['88', '97', 'lower_bound']]}, 'NCT02419495'), ({'text': 'Control subjects will include patients referred for an upper endoscopy for evaluation of non-reflux symptoms such as iron deficiency anemia', 'entities': [['56', '71', 'treatment'], ['118', '140', 'chronic_disease']]}, 'NCT02081404'), ({'text': 'Must be willing to undergo tumor biopsy at study entry for biologic correlates', 'entities': [['28', '40', 'treatment'], ['60', '79', 'treatment']]}, 'NCT02044120'), ({'text': 'viscosupplementation or intra-articular steroid injection to the affected knee within the prior one month', 'entities': [['1', '21', 'treatment'], ['25', '79', 'treatment'], ['91', '106', 'upper_bound']]}, 'NCT02272218'), ({'text': 'Research participant must be at least 2 weeks out from having received the last dose of investigational agent', 'entities': [['39', '46', 'lower_bound'], ['89', '110', 'treatment']]}, 'NCT02159495'), ({'text': 'External beam radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after total body irradiation (TBI), craniospinal XRT or if radiation to >= 50% of the pelvis', 'entities': [['1', '38', 'treatment'], ['34', '37', 'treatment'], ['39', '64', 'treatment'], ['87', '100', 'lower_bound'], ['115', '129', 'lower_bound'], ['130', '158', 'treatment'], ['160', '176', 'treatment'], ['199', '202', 'lower_bound']]}, 'NCT02304458'), ({'text': 'Participant has optic nerve atrophy beyond modest pallor', 'entities': [['17', '36', 'chronic_disease']]}, 'NCT02862938'), ({'text': 'Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment', 'entities': [['79', '99', 'treatment'], ['107', '134', 'treatment']]}, 'NCT01618357'), ({'text': 'there should be a least a 1-week interval between last dose of endocrine therapy and protocol therapy', 'entities': [['27', '33', 'lower_bound'], ['64', '81', 'treatment'], ['86', '102', 'treatment']]}, 'NCT01697293'), ({'text': 'Subjects who are pregnant or nursing or unwilling to use contraception during and for 30 days after taking the study drug (both males and females)', 'entities': [['18', '26', 'pregnancy'], ['41', '71', 'contraception_consent'], ['87', '100', 'upper_bound'], ['112', '122', 'treatment'], ['129', '146', 'gender']]}, 'NCT02578901'), ({'text': 'Diagnosis of invasive gynecologic malignancy stages 1-4', 'entities': [['23', '45', 'cancer'], ['53', '54', 'lower_bound'], ['55', '56', 'upper_bound']]}, 'NCT03037346'), ({'text': 'Patients must have Zubrod performance status 0-2', 'entities': [['20', '45', 'clinical_variable'], ['46', '47', 'lower_bound'], ['48', '49', 'upper_bound']]}, 'NCT01925131'), ({'text': 'Undergoing hip and knee revisions', 'entities': [['12', '34', 'treatment']]}, 'NCT02216227'), ({'text': 'congestive heart failure (New York Heart Association class III or IV)', 'entities': [['1', '25', 'chronic_disease'], ['27', '59', 'clinical_variable'], ['60', '63', 'lower_bound'], ['67', '69', 'upper_bound']]}, 'NCT02595866'), ({'text': 'revious myeloablative autologous transplant is permitted but not required', 'entities': [['9', '44', 'treatment']]}, 'NCT02593123'), ({'text': 'breastfeeding females', 'entities': [['15', '22', 'gender']]}, 'NCT01864109'), ({'text': 'II disorder including Major Depression', 'entities': [['1', '12', 'chronic_disease'], ['23', '39', 'chronic_disease']]}, 'NCT02875301'), ({'text': 'Prolonged QTc on pre-operative EKG', 'entities': [['1', '14', 'clinical_variable']]}, 'NCT02989597'), ({'text': 'BMI 18-25 kg/m2', 'entities': [['1', '4', 'bmi'], ['5', '7', 'lower_bound'], ['8', '16', 'upper_bound']]}, 'NCT03070184'), ({'text': 'pacemakers and metal clips located in the patient', 'entities': [['1', '11', 'treatment'], ['16', '27', 'treatment']]}, 'NCT02421380'), ({'text': 'Patients that present with free pulmonary insufficiency', 'entities': [['33', '56', 'chronic_disease']]}, 'NCT02967315'), ({'text': '=< 1.5 x ULN', 'entities': [['4', '13', 'upper_bound']]}, 'NCT01877382'), ({'text': 'Patients must have measurable disease, which includes lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as e 2 cm with conventional techniques OR e 1 cm by spiral CT scan', 'entities': [['107', '110', 'lower_bound'], ['160', '164', 'lower_bound'], ['170', '193', 'treatment'], ['199', '203', 'lower_bound'], ['207', '221', 'treatment']]}, 'NCT00632853'), ({'text': 'ECOG performance status less than or equal to 2 (Performance Status Criteria)', 'entities': [['1', '24', 'clinical_variable'], ['47', '48', 'upper_bound']]}, 'NCT02487095'), ({'text': 'Body weight at least 17 kg', 'entities': [['1', '12', 'clinical_variable'], ['22', '27', 'lower_bound']]}, 'NCT01200940'), ({'text': 'Received another investigational new drug (IND) within 5 half-lives of that agent before the planned commencement of SC IL-2', 'entities': [['18', '48', 'treatment'], ['56', '68', 'upper_bound']]}, 'NCT02200445'), ({'text': 'severe orthostatic hypotension', 'entities': [['8', '31', 'chronic_disease']]}, 'NCT02253316'), ({'text': 'Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be filled within 7 days as required by RevAssist)', 'entities': [['1', '8', 'gender'], ['54', '87', 'pregnancy'], ['124', '133', 'lower_bound'], ['141', '143', 'lower_bound'], ['146', '153', 'upper_bound'], ['171', '185', 'upper_bound'], ['201', '213', 'treatment'], ['263', '269', 'upper_bound']]}, 'NCT01433965'), ({'text': 'history of hyperparathyroidism', 'entities': [['12', '31', 'chronic_disease']]}, 'NCT02826382'), ({'text': 'Has acute heart, kidney, liver, respiratory failure or trauma', 'entities': [['5', '16', 'chronic_disease'], ['18', '24', 'chronic_disease'], ['26', '31', 'chronic_disease'], ['33', '52', 'chronic_disease'], ['56', '62', 'chronic_disease']]}, 'NCT03137498'), ({'text': 'The definition of p16(+) disease is diffuse nuclear and cytoplasmic staining in e 70% of tumor cells', 'entities': [['19', '33', 'chronic_disease'], ['57', '77', 'clinical_variable'], ['83', '86', 'lower_bound'], ['90', '95', 'cancer']]}, 'NCT02128906'), ({'text': 'from birth to < 18 years of age', 'entities': [['17', '25', 'upper_bound'], ['29', '32', 'age']]}, 'NCT02687906'), ({'text': 'Clinically-significant cardiac arrhythmias', 'entities': [['24', '43', 'chronic_disease']]}, 'NCT01822522'), ({'text': 'measured creatinine clearance e60 mL/min', 'entities': [['1', '30', 'clinical_variable'], ['32', '41', 'lower_bound']]}, 'NCT02266745'), ({'text': 'Platelets >= 100,000/mcL', 'entities': [['1', '10', 'clinical_variable'], ['14', '25', 'lower_bound']]}, 'NCT01989585'), ({'text': 'Cervical lesions must provide for a minimum of 1mm thickness of restorative material while maintaining natural tooth contour', 'entities': [['1', '17', 'chronic_disease'], ['48', '51', 'lower_bound']]}, 'NCT03153969'), ({'text': 'evidence of progressive infection by imaging studies', 'entities': [['13', '34', 'chronic_disease']]}, 'NCT00959140'), ({'text': 'Subjects may be rescreened if the blood pressure is successfully and promptly controlled within 5 days using conventional anti-hypertensive therapy to achieve optimal blood pressure control (<140/90 mmHg)', 'entities': [['97', '103', 'upper_bound'], ['123', '148', 'treatment'], ['160', '190', 'clinical_variable'], ['193', '204', 'upper_bound']]}, 'NCT02611063'), ({'text': 'Subject has an electrical implant or metallic, abdominal implants', 'entities': [['16', '34', 'treatment'], ['38', '46', 'treatment'], ['48', '66', 'treatment']]}, 'NCT02429830'), ({'text': 'Patients with a known hypersensitivity to any component of this drug', 'entities': [['43', '69', 'allergy_name']]}, 'NCT02553265'), ({'text': 'Patients must be between the ages of 18 and 80', 'entities': [['30', '34', 'age'], ['38', '40', 'lower_bound'], ['45', '47', 'upper_bound']]}, 'NCT02107261'), ({'text': 'WBC greater than or equal to 3000/mm(3)', 'entities': [['1', '4', 'clinical_variable'], ['30', '40', 'lower_bound']]}, 'NCT01993719'), ({'text': 'On scheduled strong or moderate CYP3A4 inhibitors (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole; amprenavir, aprepitant, atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil) within one week of study enrollment', 'entities': [['14', '50', 'treatment'], ['52', '62', 'treatment'], ['64', '78', 'treatment'], ['80', '90', 'treatment'], ['92', '101', 'treatment'], ['103', '115', 'treatment'], ['117', '129', 'treatment'], ['131', '140', 'treatment'], ['141', '150', 'treatment'], ['152', '162', 'treatment'], ['164', '174', 'treatment'], ['176', '186', 'treatment'], ['188', '200', 'treatment'], ['213', '223', 'treatment'], ['225', '235', 'treatment'], ['237', '250', 'treatment'], ['252', '264', 'treatment'], ['266', '276', 'treatment'], ['278', '288', 'treatment'], ['290', '300', 'treatment'], ['302', '315', 'treatment'], ['317', '326', 'treatment'], ['338', '347', 'treatment'], ['349', '361', 'treatment'], ['363', '374', 'treatment'], ['376', '389', 'treatment'], ['391', '407', 'treatment'], ['409', '417', 'treatment'], ['419', '428', 'treatment'], ['437', '445', 'upper_bound']]}, 'NCT03040726'), ({'text': 'Absolute neutrophil count (ANC) e 1,000 cells/mm3 based upon CBC/differential obtained within 4 weeks prior to registration on study', 'entities': [['1', '32', 'clinical_variable'], ['35', '50', 'lower_bound'], ['95', '108', 'upper_bound']]}, 'NCT01697371'), ({'text': 'Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study', 'entities': [['1', '9', 'pregnancy'], ['29', '56', 'pregnancy']]}, 'NCT02741791'), ({'text': 'Disease that has not received prior radiation, radiosurgery, chemotherapy, or other investigational treatment directed at the brain tumor at any time. Previous surgical procedures', 'entities': [['31', '46', 'treatment'], ['48', '60', 'treatment'], ['62', '74', 'treatment'], ['85', '110', 'treatment'], ['127', '138', 'cancer']]}, 'NCT02507232'), ({'text': 'Evidence or history of bleeding diathesis or coagulopathy', 'entities': [['24', '42', 'chronic_disease'], ['46', '58', 'chronic_disease']]}, 'NCT02459119'), ({'text': 'Volunteers with adequately controlled hypertension and hyperlipidemia', 'entities': [['39', '51', 'chronic_disease'], ['56', '70', 'chronic_disease']]}, 'NCT02502006'), ({'text': 'History of bipolar disorder', 'entities': [['12', '28', 'chronic_disease']]}, 'NCT02826577'), ({'text': 'Regimens for transplantation', 'entities': [['1', '29', 'treatment']]}, 'NCT02338232'), ({'text': 'History of vitreoretinal surgery or scleral buckling within 90 days prior to Day 0 in the study eye', 'entities': [['12', '33', 'treatment'], ['37', '53', 'treatment'], ['61', '74', 'upper_bound']]}, 'NCT01280669'), ({'text': 'English speaking', 'entities': [['1', '17', 'language_fluency']]}, 'NCT03039036'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT02985554'), ({'text': 'Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or myocardial infarction within the past 6 months', 'entities': [['34', '59', 'chronic_disease'], ['71', '90', 'chronic_disease'], ['92', '116', 'chronic_disease'], ['118', '124', 'chronic_disease'], ['129', '150', 'chronic_disease'], ['162', '175', 'upper_bound']]}, 'NCT01415882'), ({'text': 'Optimal medical therapy for heart failure', 'entities': [['1', '24', 'treatment'], ['29', '42', 'chronic_disease']]}, 'NCT01128816'), ({'text': 'stable dose of metformin monotherapy >=1,000 mg per day or MTD per day for at least 8 weeks prior to screening', 'entities': [['16', '37', 'clinical_variable'], ['40', '56', 'lower_bound'], ['85', '98', 'lower_bound']]}, 'NCT03170518'), ({'text': 'Patients who are older than 17 years will not be enrolled', 'entities': [['29', '37', 'lower_bound']]}, 'NCT02030015'), ({'text': 'Subjects with active infection requiring oral or IV antibiotics within one month of first dose of study medication', 'entities': [['15', '31', 'chronic_disease'], ['42', '46', 'treatment'], ['50', '64', 'treatment'], ['72', '81', 'upper_bound'], ['99', '115', 'treatment']]}, 'NCT02429934'), ({'text': 'OAB caused by a neurological condition', 'entities': [['1', '4', 'chronic_disease'], ['17', '39', 'chronic_disease']]}, 'NCT02097121'), ({'text': 'injury greater than 1 year', 'entities': [['21', '27', 'lower_bound']]}, 'NCT02323698'), ({'text': 'NYHA II - IV', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02574650'), ({'text': 'Ages greater than or equal to 18 years and less than or equal to 70 years', 'entities': [['1', '5', 'age'], ['31', '39', 'lower_bound'], ['66', '74', 'upper_bound']]}, 'NCT00720785'), ({'text': 'Seizure at onset of stroke', 'entities': [['1', '8', 'chronic_disease'], ['21', '27', 'chronic_disease']]}, 'NCT02453373'), ({'text': 'Women of childbearing potential or sexually active males must be willing to use effective contraception throughout their participation in the treatment phase of the study', 'entities': [['1', '6', 'gender'], ['52', '57', 'gender'], ['66', '104', 'contraception_consent'], ['143', '152', 'treatment']]}, 'NCT02158234'), ({'text': 'OR High-risk AML (by ELN criteria; See Appendix C) in complete remission (CR) and has either refused hematopoietic stem cell transplantation OR is currently not eligible for hematopoietic stem cell transplantation OR for whom hematopoietic stem cell transplantation is being reserved for later relapse. This is inclusive of patients with minimal residual disease evidenced by cytogenetics, molecular testing, and/or flow cytometry', 'entities': [['102', '141', 'treatment'], ['339', '363', 'cancer'], ['377', '389', 'treatment'], ['391', '408', 'treatment'], ['417', '431', 'treatment']]}, 'NCT01898793'), ({'text': 'Total bilirubin < 3 x the upper limit of normal (ULN), +/- 7 days from date of ICF signing', 'entities': [['1', '16', 'clinical_variable'], ['19', '54', 'upper_bound']]}, 'NCT02498951'), ({'text': 'Verbal and performance scale IQ e 80 (both subtests of the WISC-V e 70)', 'entities': [['1', '32', 'clinical_variable'], ['35', '37', 'lower_bound'], ['60', '66', 'clinical_variable'], ['69', '71', 'lower_bound']]}, 'NCT02918864'), ({'text': 'aged 18 to 65 years old', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['12', '20', 'upper_bound']]}, 'NCT02232191'), ({'text': 'Spinal cord injury C8 level or higher', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT01659541'), ({'text': 'In the judgment of the HF specialist investigator at the site, the subject has been adequately treated per applicable standards, including for coronary artery disease, left ventricular dysfunction, mitral regurgitation and heart failure (e.g., with cardiac resynchronization therapy, revascularization, and/or GDMT)', 'entities': [['144', '167', 'chronic_disease'], ['169', '197', 'chronic_disease'], ['199', '219', 'chronic_disease'], ['224', '237', 'chronic_disease'], ['250', '283', 'treatment'], ['285', '302', 'treatment'], ['311', '315', 'treatment']]}, 'NCT01626079'), ({'text': '(e.g., known or suspected congestive heart failure; asthma requiring intermittent systemic corticosteroids; etc.)', 'entities': [['27', '51', 'chronic_disease'], ['53', '59', 'chronic_disease'], ['83', '107', 'treatment']]}, 'NCT01422746'), ({'text': 'Patients whose decline in lung function (FEV1) is related to either Restrictive Chronic Lung Allograft Dysfunction (CLAD) or other causes that do not represent BOS such as pneumonia, heart failure, etc', 'entities': [['42', '46', 'clinical_variable'], ['81', '122', 'chronic_disease'], ['161', '164', 'chronic_disease'], ['173', '182', 'chronic_disease'], ['184', '197', 'chronic_disease']]}, 'NCT02181257'), ({'text': 'uncontrolled diabetes (defined as metabolically unstable by the Investigator)', 'entities': [['14', '22', 'chronic_disease']]}, 'NCT02836574'), ({'text': 'Subject has undergone a facial dermabrasion or chemical peel treatment within 3 months of treatment or during the study (if face is treated)', 'entities': [['25', '44', 'treatment'], ['48', '71', 'treatment'], ['62', '71', 'treatment'], ['79', '87', 'upper_bound']]}, 'NCT02468453'), ({'text': 'who were intolerant of a gemcitabine containing regimen', 'entities': [['26', '37', 'treatment']]}, 'NCT02923921'), ({'text': 'Thrombus in the left atrium or the left atrial appendage, determined by echocardiography (either at baseline TTE (or equivalent diagnostic test) or intraoperative TEE)', 'entities': [['1', '9', 'chronic_disease'], ['73', '89', 'treatment']]}, 'NCT02393885'), ({'text': 'Presence of significant social and cognitive disability, based on the Cognitive Style and Social Cognition Eligibility Interview (Hogarty et al., 2004)', 'entities': [['36', '56', 'chronic_disease']]}, 'NCT03170453'), ({'text': 'Entry into the study is limited to no more than 8 weeks from the date of surgery', 'entities': [['49', '56', 'upper_bound'], ['74', '81', 'treatment']]}, 'NCT02501954'), ({'text': 'Average pain of at least 4 on a numeric rating scale in the previous week (NRS; ranging from 0 to 10)', 'entities': [['26', '27', 'lower_bound'], ['76', '79', 'clinical_variable'], ['94', '95', 'lower_bound'], ['99', '101', 'upper_bound']]}, 'NCT02627495'), ({'text': 'Have no contraindications for the use of sildenafil', 'entities': [['42', '52', 'treatment']]}, 'NCT02335242'), ({'text': 'Prostate volume less than 50 cc', 'entities': [['1', '16', 'clinical_variable'], ['27', '32', 'upper_bound']]}, 'NCT01913106'), ({'text': 'Use of any medications known to affect the serum androgen level', 'entities': [['44', '64', 'clinical_variable']]}, 'NCT02881242'), ({'text': 'A documented Karnofsky performance status of at least 70', 'entities': [['14', '42', 'clinical_variable'], ['55', '57', 'lower_bound']]}, 'NCT02600156'), ({'text': 'Participants with neuroblastoma with only metaiodobenzylguanidine (MIBG)-positive evaluable disease may be enrolled', 'entities': [['19', '32', 'cancer'], ['43', '73', 'treatment']]}, 'NCT02332668'), ({'text': 'Subjects with infiltrating lobular histologies', 'entities': [['15', '35', 'cancer']]}, 'NCT01185132'), ({'text': 'Comorbid disorder (e.g., Attention Deficit Hyperactivity Disorder, Obsessive Compulsive Disorder, Oppositional Defiant Disorder) will be allowed provided that the anxiety symptoms are of primary concern to parents and comorbid symptoms are not of sufficient severity to require immediate treatment other than that provided by the current study', 'entities': [['1', '18', 'chronic_disease'], ['26', '66', 'chronic_disease'], ['68', '97', 'chronic_disease'], ['99', '128', 'chronic_disease']]}, 'NCT03135990'), ({'text': 'Participants must score 14 or greater on the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR)', 'entities': [['25', '27', 'lower_bound'], ['46', '112', 'clinical_variable']]}, 'NCT02556606'), ({'text': 'Patient has a history of multiple sclerosis', 'entities': [['26', '44', 'chronic_disease']]}, 'NCT02862938'), ({'text': 'Subject is a surgical candidate, i.e. is able to undergo general anesthesia and laparoscopic surgery', 'entities': [['58', '76', 'treatment'], ['81', '101', 'treatment']]}, 'NCT02429830'), ({'text': 'Heart failure due to primary valvular heart disease', 'entities': [['1', '14', 'chronic_disease'], ['30', '52', 'chronic_disease']]}, 'NCT01128816'), ({'text': 'Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible', 'entities': [['41', '48', 'upper_bound'], ['100', '124', 'cancer'], ['157', '166', 'cancer']]}, 'NCT01943851'), ({'text': 'uncontrolled diabetes; cardiovascular disease including congestive heart failure New York Heart Association [NYHA] class III or IV, myocardial infarction within 6 months, and poorly controlled hypertension; chronic renal failure; or active uncontrolled infection', 'entities': [['1', '22', 'chronic_disease'], ['24', '46', 'chronic_disease'], ['57', '81', 'chronic_disease'], ['82', '115', 'clinical_variable'], ['116', '125', 'lower_bound'], ['129', '131', 'upper_bound'], ['133', '154', 'chronic_disease'], ['162', '170', 'upper_bound'], ['183', '206', 'chronic_disease'], ['208', '229', 'chronic_disease'], ['234', '263', 'chronic_disease']]}, 'NCT02532231'), ({'text': 'Symptomatic metastatic brain or meningeal tumors', 'entities': [['1', '29', 'cancer'], ['33', '49', 'cancer']]}, 'NCT02466009'), ({'text': 'Planned chemotherapy for (neo)adjuvant treatment', 'entities': [['9', '21', 'treatment']]}, 'NCT02565498'), ({'text': 'Disseminated intravascular coagulation as evidenced by prothrombin time or partial thromboplastin time e 2X the ULN or platelets < 50% of the lower limit of normal', 'entities': [['1', '39', 'chronic_disease'], ['56', '72', 'clinical_variable'], ['76', '103', 'clinical_variable'], ['106', '116', 'lower_bound'], ['120', '129', 'clinical_variable'], ['132', '164', 'upper_bound']]}, 'NCT02687906'), ({'text': 'Patients with pleural effusion or abdominal/peritoneal ascites, except the finding of physiological levels of fluid', 'entities': [['15', '31', 'chronic_disease'], ['35', '63', 'chronic_disease']]}, 'NCT01562626'), ({'text': '1 to 30 years of age', 'entities': [['1', '2', 'lower_bound'], ['6', '14', 'upper_bound'], ['18', '21', 'age']]}, 'NCT02703272'), ({'text': 'Diabetes mellitus requiring drug therapy', 'entities': [['1', '18', 'chronic_disease'], ['29', '41', 'treatment']]}, 'NCT00001651'), ({'text': 'At least 7 days since completion of hematopoietic growth factors', 'entities': [['10', '16', 'lower_bound']]}, 'NCT02101736'), ({'text': 'Known active hepatitis B and/or hepatitis C infection', 'entities': [['7', '25', 'chronic_disease'], ['33', '54', 'chronic_disease']]}, 'NCT02552953'), ({'text': 'Currently has a copper IUD in place', 'entities': [['24', '27', 'contraception_consent']]}, 'NCT02002260'), ({'text': 'Disseminated and/or nonresectable malignant tumor involving bone', 'entities': [['35', '50', 'cancer']]}, 'NCT02015390'), ({'text': 'Civilians along with potential participants that cannot understand, speak or read English', 'entities': [['69', '90', 'language_fluency']]}, 'NCT02571478'), ({'text': 'Presence of another malignancy requiring current treatment that would preclude the use of all of the study treatments or the ability to monitor the natural history of MCD untreated', 'entities': [['21', '31', 'cancer'], ['50', '59', 'treatment'], ['108', '118', 'treatment'], ['168', '171', 'chronic_disease']]}, 'NCT00092222'), ({'text': 'Serum creatinine less than or equal to 2x upper limit of normal', 'entities': [['1', '17', 'clinical_variable'], ['40', '64', 'upper_bound']]}, 'NCT01953900'), ({'text': 'Gastrointestinal disorder affecting absorption', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT03148795'), ({'text': 'No uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) disease', 'entities': [['17', '33', 'chronic_disease'], ['42', '62', 'chronic_disease'], ['73', '109', 'chronic_disease']]}, 'NCT02047474'), ({'text': 'Surgery including lower extremity revascularization, coronary revascularization with stenting', 'entities': [['1', '8', 'treatment'], ['35', '52', 'treatment'], ['54', '80', 'treatment']]}, 'NCT02593110'), ({'text': 'Treatment with ultraviolet (UV) light (including tanning) during the 3 weeks prior to inclusion in this study', 'entities': [['1', '58', 'treatment'], ['70', '83', 'upper_bound']]}, 'NCT02615249'), ({'text': 'treatment for prostate cancer', 'entities': [['15', '30', 'cancer']]}, 'NCT02680535'), ({'text': 'Patients must not have grade 2 or greater peripheral sensory neuropathy', 'entities': [['24', '31', 'lower_bound'], ['43', '72', 'clinical_variable']]}, 'NCT01896999'), ({'text': 'Lesions in or close to scar tissue (< 1cm)', 'entities': [['1', '8', 'clinical_variable'], ['39', '42', 'upper_bound']]}, 'NCT02638935'), ({'text': 'FEV1 <85% and >35% at screening and baseline', 'entities': [['1', '5', 'clinical_variable'], ['7', '10', 'upper_bound'], ['16', '19', 'lower_bound']]}, 'NCT02498535'), ({'text': 'Patients with serum aspartate aminotransferase, alanine aminotransferase > 2.5 X the upper limit of normal (ULN) and bilirubin >1.5 ULN', 'entities': [['15', '47', 'clinical_variable'], ['49', '73', 'clinical_variable'], ['76', '113', 'lower_bound'], ['118', '127', 'clinical_variable'], ['129', '136', 'lower_bound']]}, 'NCT02340156'), ({'text': 'Males of child bearing potential must agree to practice effective barrier contraception during the entire study treatment period and through 6 months) after the last dose of study drug, (includes males surgically sterilized (i.e. status post vasectomy)', 'entities': [['1', '6', 'gender'], ['39', '88', 'contraception_consent'], ['113', '122', 'treatment'], ['142', '150', 'lower_bound'], ['197', '202', 'gender'], ['203', '224', 'treatment'], ['238', '252', 'treatment']]}, 'NCT02503358'), ({'text': 'Latent tuberculosis currently being treated with isoniazid (INH) or other therapy for latent tuberculosis given according to local health authority guidelines', 'entities': [['1', '20', 'chronic_disease'], ['50', '65', 'treatment'], ['75', '82', 'treatment'], ['87', '106', 'chronic_disease']]}, 'NCT02108860'), ({'text': '5-FC', 'entities': [['1', '5', 'treatment']]}, 'NCT01562626'), ({'text': 'Proteinuria >1 gram/day at time of possible conversion', 'entities': [['1', '12', 'clinical_variable'], ['14', '24', 'lower_bound']]}, 'NCT02974686'), ({'text': 'Previous treatment for cancer is acceptable if patient still has ovarian function', 'entities': [['10', '19', 'treatment'], ['24', '30', 'cancer']]}, 'NCT01558544'), ({'text': 'Effective birth control includes (a) intrauterine device (IUD) plus 1 barrier method; (b) stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus 1 barrier method; (c) 2 barrier methods', 'entities': [['143', '151', 'lower_bound']]}, 'NCT02688647'), ({'text': 'History of allergic reactions attributed to compounds of similar chemical or biologic composition to TRC102 or pemetrexed and cisplatin', 'entities': [['102', '108', 'allergy_name'], ['112', '122', 'allergy_name'], ['127', '136', 'allergy_name']]}, 'NCT02535312'), ({'text': 'Invasive primary tumor or metastatic tissue confirmation of HER2-positive status', 'entities': [['10', '23', 'cancer'], ['27', '37', 'cancer']]}, 'NCT01494662'), ({'text': 'primary diagnosis of a DSM-IV depressive disorder', 'entities': [['24', '50', 'chronic_disease']]}, 'NCT01794559'), ({'text': 'The effects of AZD9291 and necitumumab on the developing human fetus are unknown', 'entities': [['16', '23', 'treatment'], ['28', '39', 'treatment']]}, 'NCT02496663'), ({'text': 'Patient with confirmed del11q mutation may be included if untreated', 'entities': [['24', '39', 'chronic_disease']]}, 'NCT01750567'), ({'text': 'Subjects who are pregnant', 'entities': [['14', '26', 'pregnancy']]}, 'NCT00075387'), ({'text': 'Women who are pre-menopausal must have a negative serum pregnancy test', 'entities': [['1', '6', 'gender'], ['42', '66', 'pregnancy']]}, 'NCT02106598'), ({'text': 'CXR normal except hyperinflation', 'entities': [['1', '4', 'treatment']]}, 'NCT02154568'), ({'text': 'Inability to tolerate one or more TMS strengths', 'entities': [['23', '26', 'lower_bound']]}, 'NCT02565199'), ({'text': 'Substance abuse/dependence (not including caffeine or nicotine) within one-month period prior to study entry or during study participation', 'entities': [['72', '94', 'upper_bound']]}, 'NCT03037983'), ({'text': 'Infection not adequately responding to appropriate therapy', 'entities': [['52', '59', 'treatment']]}, 'NCT01623167'), ({'text': 'including MI or CVA within 3 months prior to treatment', 'entities': [['11', '13', 'chronic_disease'], ['17', '20', 'chronic_disease'], ['28', '42', 'upper_bound']]}, 'NCT03002519'), ({'text': 'Cardiac arrest occurring while admitted to the hospital, with sustained (>20 minutes) return of spontaneous circulation (ROSC)', 'entities': [['1', '15', 'chronic_disease'], ['75', '85', 'lower_bound'], ['87', '127', 'clinical_variable']]}, 'NCT02974257'), ({'text': 'In sustained clinical remission for the last 6 months while receiving treatment with either etanercept, infliximab, or adalimumab, and greater than or equal to 1 DMARD (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine). DAS28 should be less than 2.6 on each visit over the preceding 6 months, with at least one visit 2-4 months before enrollment. If there is no visit 6 months before enrollment, the nearest visit in the 6-12 month period before enrollment should be considered and have a DAS28 less than 2.6', 'entities': [['41', '54', 'upper_bound'], ['46', '47', 'lower_bound'], ['46', '54', 'upper_bound'], ['71', '80', 'treatment'], ['93', '103', 'treatment'], ['105', '115', 'treatment'], ['120', '130', 'treatment'], ['161', '162', 'lower_bound'], ['170', '182', 'treatment'], ['184', '202', 'treatment'], ['204', '217', 'treatment'], ['219', '230', 'treatment'], ['232', '243', 'treatment'], ['245', '257', 'treatment'], ['259', '271', 'treatment'], ['279', '292', 'treatment'], ['295', '300', 'clinical_variable'], ['298', '299', 'lower_bound'], ['321', '324', 'upper_bound'], ['382', '385', 'lower_bound'], ['394', '402', 'upper_bound'], ['443', '458', 'upper_bound'], ['498', '506', 'upper_bound']]}, 'NCT01793519'), ({'text': 'Male patients', 'entities': [['1', '14', 'gender']]}, 'NCT02560766'), ({'text': 'Clinical chorioamnionitis', 'entities': [['10', '26', 'chronic_disease']]}, 'NCT02469519'), ({'text': 'dependence within the preceding 3 months', 'entities': [['23', '41', 'upper_bound']]}, 'NCT02397889'), ({'text': 'A history of active tuberculosis within the past 3 years even if treated', 'entities': [['14', '33', 'chronic_disease'], ['45', '57', 'upper_bound']]}, 'NCT02108860'), ({'text': 'Patients with a history of documented anaphylaxis or contraindication to any of the study medications or standardized intra-operative medications. These include dilaudid, fentanyl, and bupivacaine', 'entities': [['162', '170', 'allergy_name'], ['172', '180', 'allergy_name'], ['186', '197', 'allergy_name']]}, 'NCT02523443'), ({'text': 'lactating women may not participate due to the embryotoxic effects of protocol treatment', 'entities': [['11', '16', 'gender'], ['71', '89', 'treatment']]}, 'NCT02724540'), ({'text': 'Current use of nicotine replacement therapy or other nicotine products', 'entities': [['16', '44', 'treatment']]}, 'NCT02067975'), ({'text': 'Patients under the age of 50', 'entities': [['20', '23', 'age'], ['27', '29', 'upper_bound']]}, 'NCT01570998'), ({'text': 'Carotid surgery or stenting within 30 days prior to subject registration', 'entities': [['1', '16', 'treatment'], ['20', '28', 'treatment'], ['36', '49', 'upper_bound']]}, 'NCT01626079'), ({'text': 'Current hematologic', 'entities': [['9', '20', 'chronic_disease']]}, 'NCT01999179'), ({'text': 'It must be started prior to the start of radiotherapy', 'entities': [['42', '54', 'treatment']]}, 'NCT02307058'), ({'text': 'heterotopic ossification', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02115685'), ({'text': 'Undergoing bilateral hip or knee replacement', 'entities': [['12', '45', 'treatment']]}, 'NCT02810704'), ({'text': 'e 18 years', 'entities': [['3', '11', 'lower_bound']]}, 'NCT02260258'), ({'text': 'Use of an antidepressant, beta blocker or erectile dysfunction medication at the time of study screening', 'entities': [['11', '25', 'treatment'], ['27', '39', 'treatment'], ['43', '74', 'treatment']]}, 'NCT02957149'), ({'text': 'Smoking 5 or more cigarettes, little cigars and/or cigarillos per day, on average, within the 2 months preceding the screening visit and expired carbon monoxide (CO) greater than or equal to 6 parts per million (ppm) (if less than or equal to 5, then positive cotinine test)', 'entities': [['95', '103', 'upper_bound'], ['146', '166', 'clinical_variable'], ['192', '217', 'lower_bound']]}, 'NCT02271919'), ({'text': 'Standard treatment is not available', 'entities': [['1', '19', 'treatment']]}, 'NCT02219711'), ({'text': 'Not requiring supplemental oxygen or mechanical ventilation', 'entities': [['15', '34', 'treatment'], ['38', '60', 'treatment']]}, 'NCT02146924'), ({'text': 'Current use of medication that may involve potentially dangerous interaction with propranolol', 'entities': [['83', '94', 'treatment']]}, 'NCT01555554'), ({'text': 'Recurrent or refractory malignant lymphoma or Hodgkin lymphoma', 'entities': [['25', '43', 'cancer'], ['47', '63', 'cancer']]}, 'NCT01810588'), ({'text': 'Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection', 'entities': [['25', '59', 'chronic_disease'], ['61', '78', 'chronic_disease'], ['92', '121', 'chronic_disease']]}, 'NCT02172651'), ({'text': 'Women who are pregnant', 'entities': [['1', '6', 'gender'], ['15', '23', 'pregnancy']]}, 'NCT02164422'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01952730'), ({'text': 'Patients who are not candidates for, intolerant, or relapsed/refractory to ruxolitinib', 'entities': [['76', '87', 'allergy_name']]}, 'NCT02098161'), ({'text': 'Women who are lactating/breastfeeding or who plan to breastfeed while on sudy through 1 week after receiving the last dose of study drug', 'entities': [['1', '6', 'gender'], ['87', '99', 'upper_bound'], ['127', '137', 'treatment']]}, 'NCT02520427'), ({'text': 'patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria', 'entities': [['32', '44', 'chronic_disease'], ['59', '69', 'treatment'], ['109', '118', 'lower_bound']]}, 'NCT01908777'), ({'text': 'Platelets e 100,000 cells/ mm3', 'entities': [['1', '10', 'clinical_variable'], ['13', '31', 'lower_bound']]}, 'NCT02913430'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02421315'), ({'text': 'Serious suicide', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02562430'), ({'text': 'expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia', 'entities': [['101', '110', 'chronic_disease']]}, 'NCT02696902'), ({'text': 'Subject is likely to tolerate medication cross-taper to monotherapy with a mood stabilizer (valproate, lamotrigine or lithium)', 'entities': [['31', '41', 'treatment'], ['42', '53', 'treatment'], ['57', '68', 'treatment'], ['76', '91', 'treatment'], ['93', '102', 'treatment'], ['104', '115', 'treatment'], ['119', '126', 'treatment']]}, 'NCT02473250'), ({'text': 'Total bilirubin d1.5 x upper limit of normal', 'entities': [['7', '16', 'clinical_variable'], ['18', '45', 'upper_bound']]}, 'NCT01433965'), ({'text': 'any investigational agent after the last dose of oral azacitidine administered as part of the parent oral azacitidine study', 'entities': [['50', '66', 'treatment']]}, 'NCT02494258'), ({'text': 'unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, or dementia', 'entities': [['49', '66', 'chronic_disease'], ['68', '83', 'chronic_disease'], ['115', '123', 'chronic_disease']]}, 'NCT03069924'), ({'text': 'any immunosuppressant', 'entities': [['5', '22', 'treatment']]}, 'NCT02971202'), ({'text': 'Women of childbearing potential must have a negative pregnancy serum test at screening', 'entities': [['1', '6', 'gender'], ['45', '63', 'pregnancy']]}, 'NCT02466685'), ({'text': 'Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina', 'entities': [['13', '35', 'chronic_disease'], ['45', '87', 'clinical_variable'], ['89', '97', 'lower_bound'], ['111', '132', 'chronic_disease'], ['137', '161', 'chronic_disease'], ['169', '183', 'upper_bound'], ['211', '222', 'chronic_disease'], ['227', '242', 'chronic_disease']]}, 'NCT03178552'), ({'text': 'Severe congestive heart failure symptoms (New York Heart Association [NYHA] Stage IV)', 'entities': [['1', '32', 'chronic_disease'], ['77', '85', 'chronic_disease']]}, 'NCT03006770'), ({'text': 'No active coronary artery disease', 'entities': [['11', '34', 'chronic_disease']]}, 'NCT02199236'), ({'text': 'Acute coronary syndrome within seven days', 'entities': [['1', '24', 'chronic_disease'], ['32', '42', 'upper_bound']]}, 'NCT02145260'), ({'text': 'Abnormal HRT & TWA (core lab interpretation) on Holter performed', 'entities': [['10', '13', 'treatment'], ['16', '19', 'treatment']]}, 'NCT00673842'), ({'text': 'plaque burden>70%', 'entities': [['1', '14', 'clinical_variable'], ['15', '18', 'lower_bound']]}, 'NCT02316886'), ({'text': 'Investigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to enrollment', 'entities': [['1', '24', 'treatment'], ['32', '39', 'upper_bound'], ['43', '55', 'upper_bound']]}, 'NCT02215096'), ({'text': 'Known allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)', 'entities': [['18', '27', 'allergy_name'], ['31', '43', 'treatment'], ['74', '85', 'treatment']]}, 'NCT02512926'), ({'text': 'Therapeutic use of anticoagulants', 'entities': [['20', '34', 'treatment']]}, 'NCT02656706'), ({'text': 'At least one ovary', 'entities': [['10', '13', 'lower_bound']]}, 'NCT01421095'), ({'text': 'for patients with creatinine levels above institutional normal', 'entities': [['19', '36', 'clinical_variable']]}, 'NCT02465060'), ({'text': 'treatment with biologic agents within 4 weeks prior to treatment with APS001F (6 weeks for mitomycin C or nitrosoureas)', 'entities': [['1', '31', 'treatment'], ['39', '52', 'upper_bound'], ['56', '78', 'treatment'], ['92', '103', 'treatment'], ['107', '119', 'treatment']]}, 'NCT01562626'), ({'text': "The patient's pre-surgical hematocrit is d 48", 'entities': [['15', '38', 'clinical_variable'], ['44', '46', 'upper_bound']]}, 'NCT00737893'), ({'text': 'Hemoglobin e 6 gm/dL', 'entities': [['1', '11', 'clinical_variable'], ['14', '21', 'lower_bound']]}, 'NCT02193191'), ({'text': 'Previous pelvic radiotherapy', 'entities': [['10', '29', 'treatment']]}, 'NCT02353819'), ({'text': 'Planned enrollment during this study coincides with enrollment in another therapeutic drug study', 'entities': [['67', '97', 'treatment']]}, 'NCT01595529'), ({'text': 'For subjects with metastatic melanoma, prior treatment with CTLA-4-blocking antibody is permissible', 'entities': [['19', '38', 'cancer'], ['40', '55', 'treatment'], ['61', '85', 'treatment']]}, 'NCT03104699'), ({'text': 'Is severely depressed or anxious as determined by the PHQ-4', 'entities': [['13', '22', 'chronic_disease'], ['26', '33', 'chronic_disease'], ['55', '60', 'treatment']]}, 'NCT02909387'), ({'text': 'topical calcineurin inhibitors (tacrolimus, pimecrolimus)', 'entities': [['1', '31', 'treatment'], ['33', '43', 'treatment'], ['45', '57', 'treatment']]}, 'NCT02573883'), ({'text': 'Known sensitivity or allergic reactions to valacyclovir', 'entities': [['44', '56', 'allergy_name']]}, 'NCT03131037'), ({'text': 'Synchronous or previous contralateral invasive breast cancer or DCIS', 'entities': [['25', '61', 'cancer'], ['65', '69', 'cancer']]}, 'NCT01872975'), ({'text': 'Veterans who are engaged in treatment for non-PTSD symptoms (e.g., 12-step programs) will be eligible', 'entities': [['47', '51', 'chronic_disease']]}, 'NCT02774642'), ({'text': 'age by decile', 'entities': [['1', '4', 'age']]}, 'NCT02607748'), ({'text': 'Axillary lymphadenectomy with or without SN isolation procedure', 'entities': [['1', '64', 'treatment']]}, 'NCT02488967'), ({'text': 'Previous chemotherapy/immunotherapy within 3 weeks before study entry', 'entities': [['1', '22', 'treatment'], ['23', '36', 'treatment'], ['44', '51', 'upper_bound']]}, 'NCT02227199'), ({'text': "Life expectancy must be estimated by patient's physician at > 6 months", 'entities': [['1', '16', 'clinical_variable'], ['63', '71', 'lower_bound']]}, 'NCT02398773'), ({'text': 'Subjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage IB, or Stage IIA', 'entities': [['44', '68', 'cancer']]}, 'NCT02448381'), ({'text': 'minimally invasive surgery/procedures', 'entities': [['11', '38', 'treatment']]}, 'NCT02329327'), ({'text': 'Impaired renal function', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02796209'), ({'text': 'Estimated survival of 5 years or greater, as determined by treating physician', 'entities': [['1', '19', 'clinical_variable'], ['23', '30', 'lower_bound']]}, 'NCT02600156'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT01360606'), ({'text': 'Lansky performance status or Karnofsky performance status of >= 50 percent', 'entities': [['1', '26', 'clinical_variable'], ['30', '58', 'clinical_variable'], ['65', '75', 'lower_bound']]}, 'NCT02639546'), ({'text': 'Central review or MRI required prior to enrollment', 'entities': [['19', '22', 'treatment']]}, 'NCT02101736'), ({'text': 'A full thickness diabetic foot ulcer with a viable wound bed', 'entities': [['18', '37', 'chronic_disease']]}, 'NCT02312596'), ({'text': 'Adequate vital organ function: Left ventricular ejection fraction (LVEF) e 45% by multigated acquisition (MUGA) scan or echocardiogram; Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing lung capacity oxygenation (DLCO) e 50% of predicted values on pulmonary function tests; Transaminases (AST, ALT) < 3 times upper limit of normal values; Creatinine clearance e 50cc/min', 'entities': [['32', '73', 'clinical_variable'], ['76', '79', 'lower_bound'], ['83', '117', 'treatment'], ['121', '135', 'treatment'], ['137', '182', 'clinical_variable'], ['184', '211', 'clinical_variable'], ['217', '259', 'clinical_variable'], ['262', '265', 'lower_bound'], ['289', '313', 'treatment'], ['315', '328', 'clinical_variable'], ['330', '333', 'clinical_variable'], ['335', '338', 'clinical_variable'], ['342', '371', 'upper_bound'], ['380', '400', 'clinical_variable'], ['403', '411', 'lower_bound']]}, 'NCT01795573'), ({'text': 'age e 21 years old', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT03115359'), ({'text': 'Excluded are those in the following risk groups: Low risk; High risk with more than 1 high risk factor; Locally advanced/very high risk=T3b-T4; Metastatic: N1 or M1', 'entities': [['85', '86', 'lower_bound'], ['137', '140', 'cancer'], ['141', '143', 'cancer'], ['145', '155', 'cancer']]}, 'NCT01436968'), ({'text': 'Adequate cardiac function, defined as left ventricular ejection fraction greater than 40 percent', 'entities': [['10', '26', 'chronic_disease'], ['39', '73', 'clinical_variable'], ['87', '97', 'lower_bound']]}, 'NCT02186418'), ({'text': 'Patients with poorly controlled diabetes mellitus (fasting blood glucose level > 200 mg/dL)', 'entities': [['33', '50', 'chronic_disease'], ['52', '79', 'clinical_variable'], ['82', '91', 'lower_bound']]}, 'NCT02379377'), ({'text': 'Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment', 'entities': [['12', '40', 'chronic_disease'], ['124', '139', 'treatment']]}, 'NCT02343042'), ({'text': 'common variable immunodeficiency', 'entities': [['1', '33', 'chronic_disease']]}, 'NCT01050855'), ({'text': 'Tumors of mixed histology', 'entities': [['1', '7', 'cancer']]}, 'NCT03101566'), ({'text': 'Planning to become pregnant', 'entities': [['20', '28', 'pregnancy']]}, 'NCT01964261'), ({'text': 'Hemoglobin e 9.0 g/dL Absolute neutrophil count (ANC) e 1.5 × 109/L (> 1500 per mm3) Platelet count e 100 × 109/L (>100,000 per mm3) Serum bilirubin d 1.5× institutional upper limit of normal (ULN)AST<3.0 Creatinine clearance >50mL/miN Aspartate transaminase (AST) and alanine transaminase (ALT) d 2.5 × ULN (d 5 × ULN if documented liver metastasis are present)', 'entities': [['1', '11', 'clinical_variable'], ['14', '22', 'lower_bound'], ['23', '54', 'clinical_variable'], ['57', '68', 'lower_bound'], ['72', '84', 'lower_bound'], ['86', '100', 'clinical_variable'], ['103', '114', 'lower_bound'], ['117', '132', 'lower_bound'], ['134', '149', 'clinical_variable'], ['152', '198', 'upper_bound'], ['198', '201', 'clinical_variable'], ['202', '205', 'upper_bound'], ['206', '226', 'clinical_variable'], ['228', '236', 'lower_bound'], ['237', '265', 'clinical_variable'], ['270', '296', 'clinical_variable'], ['299', '308', 'upper_bound'], ['301', '308', 'upper_bound'], ['334', '350', 'cancer']]}, 'NCT02592551'), ({'text': 'History of mild to moderate TBI', 'entities': [['12', '32', 'chronic_disease']]}, 'NCT03050801'), ({'text': 'Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I/II, Hepatitis B, Hepatitis C)', 'entities': [['130', '151', 'chronic_disease'], ['153', '170', 'cancer'], ['172', '191', 'chronic_disease'], ['200', '203', 'chronic_disease'], ['205', '214', 'chronic_disease'], ['216', '227', 'chronic_disease'], ['229', '240', 'chronic_disease']]}, 'NCT01964859'), ({'text': 'Chronic liver disease', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02700451'), ({'text': 'total proctocolectomy', 'entities': [['7', '22', 'treatment']]}, 'NCT02370056'), ({'text': 'Serum alkaline phosphatase =< 5 x ULN', 'entities': [['1', '27', 'clinical_variable'], ['31', '38', 'upper_bound']]}, 'NCT01754857'), ({'text': 'Abnormal TSH (subjects with adequately treated hypothyroidism, reflected by normal TSH values', 'entities': [['10', '13', 'clinical_variable'], ['48', '62', 'chronic_disease']]}, 'NCT00594217'), ({'text': 'high-risk AML including', 'entities': [['11', '14', 'cancer']]}, 'NCT02181478'), ({'text': 'Untreated or unstable proliferative diabetic retinopathy', 'entities': [['23', '57', 'chronic_disease']]}, 'NCT02464878'), ({'text': 'Temperature > 37.5 º Celsius, 99.5 º Fahrenheit', 'entities': [['1', '12', 'clinical_variable'], ['15', '29', 'lower_bound'], ['31', '48', 'lower_bound']]}, 'NCT02404155'), ({'text': 'Participant must lack a healthy, HLA-identical related or unrelated donor unless s/he has a borderline organ function that will preclude the recipient from receiving a curative therapy due to the need of post-HSCT immunosuppressive therapy', 'entities': [['169', '185', 'treatment'], ['205', '240', 'treatment']]}, 'NCT02162511'), ({'text': 'Squamous head', 'entities': [['1', '14', 'cancer']]}, 'NCT02423863'), ({'text': '> 30 Gy over multiple treatments', 'entities': [['3', '8', 'upper_bound'], ['14', '33', 'treatment']]}, 'NCT00906984'), ({'text': 'Males', 'entities': [['1', '6', 'gender']]}, 'NCT01568177'), ({'text': 'patients receiving corticosteroids must have been on a stable dosage regimen for a minimum of 4 weeks prior to the first treatment with Everolimus', 'entities': [['20', '35', 'treatment'], ['95', '108', 'upper_bound'], ['116', '147', 'treatment']]}, 'NCT02531932'), ({'text': 'surgery must have been completed at least 4 weeks prior to day 1', 'entities': [['1', '8', 'treatment'], ['43', '56', 'lower_bound']]}, 'NCT01824836'), ({'text': 'Laboratory evidence of hematologic disease (hemoglobin <11.5 g/dl [females] or <12.5 g/dl [males]; absolute leukocyte count <3.6 or >10.7 x 103/mm3; absolute neutrophil count [ANC] <1.7 x 103/mm3; absolute lymphocyte count <0.7 x 103/mm3; or platelet count <140 x 103/mm3)', 'entities': [['24', '43', 'chronic_disease'], ['45', '55', 'clinical_variable'], ['57', '66', 'upper_bound'], ['68', '75', 'gender'], ['70', '75', 'gender'], ['81', '90', 'upper_bound'], ['100', '124', 'clinical_variable'], ['126', '129', 'upper_bound'], ['134', '148', 'lower_bound'], ['135', '148', 'upper_bound'], ['150', '181', 'clinical_variable'], ['183', '196', 'upper_bound'], ['198', '223', 'clinical_variable'], ['243', '257', 'clinical_variable'], ['259', '272', 'upper_bound']]}, 'NCT01940757'), ({'text': 'Clinical diagnosis of schizophrenia, schizoaffective disorder, psychosis Not Otherwise Specified (NOS), Unspecified Schizophrenia Spectrum Disorder, Schizophrenia Spectrum Disorder, Specified', 'entities': [['23', '36', 'chronic_disease'], ['38', '62', 'chronic_disease'], ['64', '73', 'chronic_disease'], ['105', '130', 'chronic_disease'], ['117', '148', 'chronic_disease'], ['131', '148', 'chronic_disease']]}, 'NCT01973270'), ({'text': 'COPD or Asthma requiring steroid treatment', 'entities': [['1', '5', 'chronic_disease'], ['9', '15', 'chronic_disease'], ['26', '43', 'treatment']]}, 'NCT02506192'), ({'text': 'Patients undergoing primary liver transplantation', 'entities': [['21', '50', 'treatment']]}, 'NCT02515708'), ({'text': 'Locally-advanced or metastatic malignancy with an NTRK1, NTRK2, or NTRK3 gene fusion identified through molecular assays', 'entities': [['32', '42', 'cancer'], ['105', '121', 'treatment']]}, 'NCT02576431'), ({'text': 'rior radiotherapy to doses e 45 Gy to the area of recurrence, e 6 months prior to enrollment', 'entities': [['1', '18', 'treatment'], ['22', '27', 'clinical_variable'], ['30', '35', 'lower_bound'], ['65', '79', 'lower_bound']]}, 'NCT02158234'), ({'text': 'Total bilirubin d 1.5 x ULN (upper limit of normal)', 'entities': [['1', '16', 'clinical_variable'], ['19', '52', 'upper_bound']]}, 'NCT02091999'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of 0-3', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'lower_bound'], ['67', '68', 'upper_bound']]}, 'NCT02734771'), ({'text': 'any significant medical condition that contra-indicates treatment with either aripiprazole or fluoxetine', 'entities': [['57', '66', 'treatment'], ['79', '91', 'treatment'], ['95', '105', 'treatment']]}, 'NCT02357849'), ({'text': 'Documented diagnosis of Ph+ Chronic phase CML', 'entities': [['43', '46', 'cancer']]}, 'NCT02353728'), ({'text': 'Polycystic Ovarian Syndrome', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT02866279'), ({'text': 'Subjects with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the subject to cooperate and participate in the study', 'entities': [['68', '82', 'chronic_disease']]}, 'NCT02799095'), ({'text': 'less than 24 months of age if same room contact is expected within 14 days of vaccination or 7 days after booster', 'entities': [['11', '20', 'upper_bound'], ['24', '27', 'age'], ['68', '75', 'upper_bound'], ['79', '90', 'treatment']]}, 'NCT00186927'), ({'text': 'Evidence of severe IUGR (intrauterine growth restriction) (<5th percentile for gestational age) in either fetus', 'entities': [['13', '58', 'chronic_disease'], ['61', '75', 'upper_bound'], ['80', '95', 'clinical_variable']]}, 'NCT02518594'), ({'text': 'Creatinine 2X or less of upper limit of normal for age', 'entities': [['1', '11', 'clinical_variable'], ['12', '14', 'upper_bound'], ['52', '55', 'age']]}, 'NCT01333046'), ({'text': 'Malignant melanoma, papillary thyroid cancer, colorectal cancer, or hematologic malignancy including multiple myeloma', 'entities': [['1', '19', 'cancer'], ['21', '45', 'cancer'], ['47', '64', 'cancer'], ['69', '91', 'cancer'], ['111', '118', 'cancer']]}, 'NCT02091141'), ({'text': 'Bilirubin less than or equal to 2 x upper limit of normal', 'entities': [['1', '10', 'clinical_variable'], ['33', '58', 'upper_bound']]}, 'NCT01696734'), ({'text': 'cochlear implants', 'entities': [['1', '18', 'treatment']]}, 'NCT02922569'), ({'text': 'Previous radiation treatment for head and neck mucosal primary cancers within the past 5 years (i.e. oropharynx, nasopharynx, hypopharynx, larynx, and oral cavity)', 'entities': [['10', '19', 'treatment'], ['34', '71', 'cancer'], ['83', '95', 'upper_bound']]}, 'NCT01893307'), ({'text': 'Candidate for neoadjuvant endocrine therapy or chemotherapy', 'entities': [['15', '44', 'treatment'], ['48', '60', 'treatment']]}, 'NCT02204098'), ({'text': 'Inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of [1-13C] pyruvate injection)', 'entities': [['39', '42', 'lower_bound']]}, 'NCT02421380'), ({'text': 'History of head injury', 'entities': [['12', '23', 'chronic_disease']]}, 'NCT01964404'), ({'text': 'active skin disease with open wounds present below knee of treated limb', 'entities': [['8', '20', 'chronic_disease']]}, 'NCT02369770'), ({'text': 'Known human immunodeficiency virus (HIV)-positive patient', 'entities': [['7', '41', 'chronic_disease']]}, 'NCT01620216'), ({'text': 'Prior radiation and any chemotherapy, must have been completed >4 months prior to biopsy-proven recurrence or second primary site disease', 'entities': [['1', '16', 'treatment'], ['25', '37', 'treatment'], ['65', '79', 'lower_bound'], ['83', '89', 'treatment']]}, 'NCT02544880'), ({'text': 'Calculated creatinine clearance e 60ml/min by Cockcroft-Gault formula', 'entities': [['1', '32', 'clinical_variable'], ['35', '43', 'lower_bound']]}, 'NCT01433965'), ({'text': 'Concurrent or planned systemic chemotherapy, radiotherapy, new hormonal or anti-HER2 directed therapy directed at management of breast cancer', 'entities': [['1', '11', 'treatment'], ['15', '44', 'treatment'], ['46', '58', 'treatment'], ['60', '72', 'treatment'], ['76', '102', 'treatment'], ['129', '142', 'cancer']]}, 'NCT02422641'), ({'text': 'Major surgery within 4 weeks of starting study treatment', 'entities': [['1', '14', 'treatment'], ['22', '29', 'upper_bound'], ['48', '57', 'treatment']]}, 'NCT02535533'), ({'text': 'prior treatment with crizotinib is permitted only in ALK', 'entities': [['1', '32', 'treatment']]}, 'NCT02568267'), ({'text': 'Enlarging lymph nodes greater than 2cm', 'entities': [['1', '22', 'clinical_variable'], ['36', '39', 'lower_bound']]}, 'NCT01059786'), ({'text': 'A patient with an intracerebral hemorrhage', 'entities': [['19', '43', 'chronic_disease']]}, 'NCT02329327'), ({'text': 'Age 6 months to 21 years at the time of enrollment', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound'], ['17', '25', 'upper_bound']]}, 'NCT02286154'), ({'text': 'Serum creatinine e1.3 mg/dL', 'entities': [['1', '17', 'clinical_variable'], ['19', '28', 'lower_bound']]}, 'NCT01757418'), ({'text': 'Current use of antipsychotics or anticonvulsant medications', 'entities': [['16', '30', 'treatment'], ['34', '60', 'treatment']]}, 'NCT02301546'), ({'text': 'History of seizures during the last 2 years or diagnosis of epilepsy', 'entities': [['12', '20', 'chronic_disease'], ['32', '44', 'upper_bound'], ['61', '69', 'chronic_disease']]}, 'NCT02781103'), ({'text': 'Eastern Collaborative Oncology Group (ECOG) performance status of 0 or 1 at screening', 'entities': [['1', '63', 'clinical_variable'], ['67', '68', 'lower_bound'], ['72', '73', 'upper_bound']]}, 'NCT03072238'), ({'text': 'active infection including seropositive HIV, Hepatitis B or C', 'entities': [['1', '17', 'chronic_disease'], ['41', '44', 'chronic_disease'], ['46', '62', 'chronic_disease']]}, 'NCT02252081'), ({'text': 'Subjects with uncontrolled or debilitating medical conditions, including but not limited to subjects with uncontrolled diabetes, hematologic disorders, cancers, immunosuppression, severe cardiovascular disease, or uncontrolled thyroid disease', 'entities': [['107', '128', 'chronic_disease'], ['130', '151', 'chronic_disease'], ['153', '160', 'cancer'], ['162', '179', 'chronic_disease'], ['181', '210', 'chronic_disease'], ['215', '243', 'chronic_disease']]}, 'NCT03100435'), ({'text': 'Over the age of 19 years old', 'entities': [['10', '13', 'age'], ['17', '25', 'lower_bound']]}, 'NCT02774642'), ({'text': 'In order to identify subjects at risk for the development of NSF, the American College of Radiology (http://acr.org) recommends obtaining a medical history and a glomerular filtration rate (GFR) assessment within six weeks of MR', 'entities': [['163', '195', 'clinical_variable'], ['214', '223', 'upper_bound']]}, 'NCT01653080'), ({'text': 'Pregnancy as detected by a urine test', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02452203'), ({'text': 'Absence of CRT with class I indication criteria for biventricular pacing (left bundle branch block pattern and Q-wave/R-wave/S-wave (QRS) duration e150 milliseconds (ms))', 'entities': [['53', '73', 'treatment'], ['112', '147', 'clinical_variable'], ['149', '170', 'lower_bound']]}, 'NCT02806570'), ({'text': 'For females of childbearing potential, negative serum pregnancy test', 'entities': [['5', '12', 'gender'], ['40', '64', 'pregnancy']]}, 'NCT02465268'), ({'text': 'Unilaterally implanted with HiRes 90K" Advantage cochlear implant with HiFocus" Helix® and HiFocus" 1j electrode', 'entities': [['29', '39', 'treatment'], ['50', '66', 'treatment'], ['72', '80', 'treatment'], ['81', '87', 'treatment'], ['92', '113', 'treatment']]}, 'NCT02189798'), ({'text': 'Peripheral neuropathy > CTCAE grade 1', 'entities': [['1', '22', 'clinical_variable'], ['31', '38', 'lower_bound']]}, 'NCT02309892'), ({'text': 'Patients who have not fully recovered from toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment)', 'entities': [['44', '54', 'chronic_disease'], ['62', '77', 'treatment'], ['68', '77', 'treatment'], ['83', '98', 'treatment'], ['100', '112', 'treatment'], ['122', '144', 'treatment']]}, 'NCT01562626'), ({'text': 'ALT d2.5 × ULN', 'entities': [['1', '4', 'clinical_variable'], ['6', '15', 'upper_bound']]}, 'NCT03104699'), ({'text': 'Uncontrolled Diabetes (HbA1C > 8.5 measured within 3 months prior to date of consent)', 'entities': [['1', '22', 'chronic_disease'], ['24', '29', 'clinical_variable'], ['32', '35', 'lower_bound'], ['52', '66', 'upper_bound']]}, 'NCT02770547'), ({'text': 'schizophrenia', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT03149783'), ({'text': 'chemotherapy treatment', 'entities': [['1', '13', 'treatment']]}, 'NCT01754298'), ({'text': 'individuals outside the age range (i.e., younger than 10 or older than 24)', 'entities': [['25', '28', 'age'], ['55', '57', 'upper_bound'], ['72', '74', 'lower_bound']]}, 'NCT02706145'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02560623'), ({'text': 'Connective tissue disease (CTD)', 'entities': [['1', '32', 'chronic_disease']]}, 'NCT02891850'), ({'text': 'subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the duration of the study', 'entities': [['20', '51', 'treatment'], ['59', '68', 'treatment'], ['103', '114', 'treatment'], ['128', '142', 'lower_bound']]}, 'NCT02547818'), ({'text': 'defined as entering one of the two-year First Episode Clinic treatment programs as a de novo patient (new disease) or having been diagnosed >2 years ago and had at least six visits in the past 12 months (prevalent disease)', 'entities': [['62', '71', 'treatment'], ['142', '153', 'lower_bound'], ['171', '174', 'lower_bound'], ['189', '203', 'upper_bound']]}, 'NCT02188121'), ({'text': 'within past 6 months', 'entities': [['8', '21', 'upper_bound']]}, 'NCT03065972'), ({'text': 'TMP-SMX', 'entities': [['1', '4', 'treatment'], ['5', '8', 'treatment']]}, 'NCT01595529'), ({'text': 'Neurologic deficits related to intraparenchymal brain, spinal cord and/or cauda equina involvement', 'entities': [['1', '20', 'chronic_disease'], ['32', '54', 'chronic_disease'], ['56', '67', 'chronic_disease'], ['75', '87', 'chronic_disease']]}, 'NCT02920710'), ({'text': 'Prior excisional biopsy of the primary invasive breast cancer', 'entities': [['1', '24', 'treatment'], ['32', '62', 'cancer']]}, 'NCT02276443'), ({'text': 'Patients treated with prostacyclin, prostacyclin analog or selexipag within 3 months prior to screening', 'entities': [['23', '35', 'treatment'], ['37', '56', 'treatment'], ['60', '69', 'treatment'], ['77', '91', 'upper_bound']]}, 'NCT03078907'), ({'text': 'Known allergy or other contraindications to the study medications , which include dilaudid, bupivacaine, ropivacaine', 'entities': [['83', '91', 'allergy_name'], ['93', '104', 'allergy_name'], ['106', '117', 'allergy_name']]}, 'NCT03151434'), ({'text': 'known to be HIV positive', 'entities': [['13', '16', 'chronic_disease']]}, 'NCT02106988'), ({'text': 'Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids', 'entities': [['15', '23', 'chronic_disease'], ['25', '47', 'chronic_disease'], ['58', '69', 'chronic_disease'], ['126', '141', 'treatment']]}, 'NCT02985554'), ({'text': 'Participants with a positive urine culture should have the urinalysis and urine culture repeated after completion of antibiotics and prior to MDC injection', 'entities': [['118', '129', 'treatment'], ['143', '156', 'treatment']]}, 'NCT01011777'), ({'text': 'Study drug intended to be administered within 60 minutes of the baseline/qualifying NCCT', 'entities': [['1', '11', 'treatment'], ['47', '57', 'upper_bound']]}, 'NCT02930018'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT03066648'), ({'text': 'History of schizophrenia or bipolar disorder', 'entities': [['12', '25', 'chronic_disease'], ['29', '45', 'chronic_disease']]}, 'NCT02950233'), ({'text': 'aldosterone-to-renin ratio of e40 in absence of an ACE inhibitor', 'entities': [['1', '27', 'clinical_variable'], ['32', '34', 'lower_bound'], ['52', '65', 'treatment']]}, 'NCT02362308'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT02657993'), ({'text': 'ECOG PS 0-1', 'entities': [['1', '8', 'clinical_variable'], ['9', '10', 'lower_bound'], ['11', '12', 'upper_bound']]}, 'NCT02451553'), ({'text': 'Iliac anatomy must allow for the delivery of the arch branch device which is loaded within a 20F-24F sheath', 'entities': [['94', '97', 'lower_bound'], ['98', '108', 'upper_bound']]}, 'NCT02089607'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02441140'), ({'text': 'Blood coagulation parameters: INR d 1.5', 'entities': [['1', '29', 'clinical_variable'], ['31', '34', 'clinical_variable'], ['37', '40', 'upper_bound']]}, 'NCT01894061'), ({'text': 'Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not', 'entities': [['49', '57', 'treatment']]}, 'NCT02942095'), ({'text': 'Coagulopathy defined by prothrombin time < 50% of control; partial thromboplastin time (PTT) > 50 sec, or international normalized ratio (INR) > 1.5), on chronic anticoagulation, or platelet count <75,000', 'entities': [['1', '13', 'chronic_disease'], ['25', '41', 'clinical_variable'], ['44', '47', 'upper_bound'], ['60', '93', 'clinical_variable'], ['96', '102', 'lower_bound'], ['107', '143', 'clinical_variable'], ['146', '149', 'lower_bound'], ['155', '178', 'treatment'], ['183', '197', 'clinical_variable'], ['199', '205', 'upper_bound']]}, 'NCT01942018'), ({'text': 'Able to understand and adhere to dietary and medication restrictions as recommended for the safe use of phenelzine', 'entities': [['46', '56', 'treatment'], ['105', '115', 'treatment']]}, 'NCT02217709'), ({'text': 'willing to be in a study where they might receive text messages', 'entities': [['51', '64', 'technology_access']]}, 'NCT02709317'), ({'text': 'Subjects not diagnosed with ACDC', 'entities': [['29', '33', 'chronic_disease']]}, 'NCT01585402'), ({'text': 'non-melanoma skin cancers', 'entities': [['1', '26', 'cancer']]}, 'NCT02583893'), ({'text': 'Subjects with a diagnosis/previous history of sinusoidal obstruction syndrome (also called veno-occlusive disease)', 'entities': [['47', '78', 'chronic_disease'], ['92', '114', 'chronic_disease']]}, 'NCT02578901'), ({'text': 'A history of clinically significant EKG abnormalities', 'entities': [['37', '54', 'chronic_disease']]}, 'NCT02911467'), ({'text': 'All female patients with reproductive potential must have a negative pregnancy test prior to Day 1', 'entities': [['1', '20', 'gender'], ['61', '79', 'pregnancy']]}, 'NCT01903330'), ({'text': 'Hydronephrosis associated with tumor on biopsy will be considered invasive by definition', 'entities': [['1', '15', 'chronic_disease'], ['32', '37', 'cancer'], ['41', '47', 'treatment']]}, 'NCT01261728'), ({'text': 'clinically significant papilledema', 'entities': [['24', '35', 'chronic_disease']]}, 'NCT02343549'), ({'text': 'Clinical levels posttraumatic stress symptoms (&gt;33 as measured by the IES-R)', 'entities': [['17', '37', 'chronic_disease']]}, 'NCT02925481'), ({'text': 'Esomeprazole (Nexium)', 'entities': [['1', '22', 'treatment']]}, 'NCT02595372'), ({'text': 'Premature infants between 28 and 34 6/7 weeks', 'entities': [['27', '29', 'lower_bound'], ['34', '46', 'upper_bound']]}, 'NCT02478684'), ({'text': 'Contraindication to ketamine', 'entities': [['21', '29', 'allergy_name']]}, 'NCT02165449'), ({'text': 'Previous recreational use of ketamine or PCP', 'entities': [['30', '38', 'treatment'], ['42', '45', 'treatment']]}, 'NCT02397889'), ({'text': 'Radiation: Patients must have received their last fraction of craniospinal radiation', 'entities': [['63', '85', 'treatment']]}, 'NCT02457845'), ({'text': 'Patients with a second HNSCC primary tumor are eligible for this study, provided more than 2 years have elapsed since the first diagnosis of HNSCC, the original tumor was managed with surgery only (no adjuvant chemotherapy/radiotherapy), and has not recurred', 'entities': [['24', '29', 'cancer'], ['30', '43', 'cancer'], ['38', '43', 'cancer'], ['92', '99', 'lower_bound'], ['185', '192', 'treatment'], ['203', '223', 'treatment'], ['224', '236', 'treatment']]}, 'NCT02128906'), ({'text': 'A familial haploidentical donor without homozygous sickle cell disease', 'entities': [['12', '26', 'treatment'], ['41', '71', 'chronic_disease']]}, 'NCT01461837'), ({'text': 'unstable angina pectoris (requiring nitrates', 'entities': [['1', '25', 'chronic_disease'], ['37', '45', 'treatment']]}, 'NCT02762006'), ({'text': 'chewed betel nut for at least 1 year, and at a rate of at least 3 days per week', 'entities': [['31', '37', 'lower_bound'], ['65', '80', 'lower_bound']]}, 'NCT02942745'), ({'text': 'inflammatory arthritis', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT03148379'), ({'text': 'Between 18-80 years of age', 'entities': [['9', '11', 'lower_bound'], ['12', '20', 'upper_bound'], ['24', '27', 'age']]}, 'NCT01760005'), ({'text': 'Patients with a suspected placenta accreta or placenta previa', 'entities': [['27', '43', 'chronic_disease'], ['47', '62', 'chronic_disease']]}, 'NCT02762773'), ({'text': 'Current developmental level determined to be developmentally delayed per The Mullen Scales of Early Learning (MSEL) or Differential Ability Scale (DAS; depending on participant age)', 'entities': [['74', '116', 'clinical_variable'], ['120', '146', 'clinical_variable'], ['148', '151', 'clinical_variable'], ['178', '181', 'age']]}, 'NCT03152383'), ({'text': 'Receipt of any organ transplantation, including allogeneic stem-cell transplantation', 'entities': [['16', '37', 'treatment'], ['49', '85', 'treatment']]}, 'NCT03104699'), ({'text': 'Unintended weight loss >10% in 6 months preceding study entry', 'entities': [['1', '23', 'clinical_variable'], ['25', '28', 'lower_bound'], ['32', '40', 'upper_bound']]}, 'NCT02588612'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT03068780'), ({'text': 'No current, active suicidal intent', 'entities': [['20', '35', 'chronic_disease']]}, 'NCT00285935'), ({'text': '< 85% reported adherence to prescribed doses', 'entities': [['3', '6', 'upper_bound'], ['7', '45', 'clinical_variable']]}, 'NCT02369406'), ({'text': 'blood pressure <=160/90 mmHg with or without medication', 'entities': [['1', '15', 'clinical_variable'], ['18', '29', 'upper_bound']]}, 'NCT00065676'), ({'text': 'age 40-80', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT03085485'), ({'text': 'Patients with acute renal failure', 'entities': [['15', '34', 'chronic_disease']]}, 'NCT01917721'), ({'text': 'Any previous neurological intervention including DBS or ablative brain lesions, any metal in the head, and any type of implanted stimulator', 'entities': [['50', '53', 'treatment'], ['57', '79', 'cancer'], ['120', '140', 'treatment']]}, 'NCT02056873'), ({'text': 'Received first dose of ART within 48 hours of birth on a regimen including 2 NRTIs and at least one other agent (e.g., NVP, RAL, LPV/r)', 'entities': [['24', '27', 'treatment'], ['35', '43', 'upper_bound'], ['78', '83', 'treatment'], ['97', '100', 'lower_bound'], ['120', '123', 'treatment'], ['125', '128', 'treatment'], ['130', '135', 'treatment']]}, 'NCT02140255'), ({'text': 'History of active or latent tuberculosis (TB), recurrent opportunistic infections, severe disseminated viral infections and organ transplant', 'entities': [['22', '46', 'chronic_disease'], ['72', '82', 'chronic_disease'], ['104', '120', 'chronic_disease'], ['125', '141', 'treatment']]}, 'NCT02171429'), ({'text': 'External beam radiation therapy (XRT): At least 14 days after local palliative XRT (small port)', 'entities': [['1', '38', 'treatment'], ['49', '56', 'lower_bound'], ['69', '83', 'treatment']]}, 'NCT02323880'), ({'text': 'Diagnosed with prostate cancer', 'entities': [['16', '31', 'cancer']]}, 'NCT02969577'), ({'text': 'T4 lesions', 'entities': [['1', '11', 'cancer']]}, 'NCT00819208'), ({'text': 'Gestational age at FETO procedure 30 weeks 0 days to 31 weeks 6 days in this moderate category', 'entities': [['1', '16', 'age'], ['35', '50', 'lower_bound'], ['54', '69', 'upper_bound']]}, 'NCT02986087'), ({'text': 'intracranial aneurysm clip', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT03076333'), ({'text': 'No family history of diabetes', 'entities': [['22', '30', 'chronic_disease']]}, 'NCT01028846'), ({'text': 'Weight less than 48 kg (106 lbs) in subjects less than 18 years of age', 'entities': [['1', '7', 'clinical_variable'], ['18', '33', 'upper_bound'], ['56', '64', 'upper_bound'], ['68', '71', 'age']]}, 'NCT01524536'), ({'text': 'Cardiovascular disorders', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT01822522'), ({'text': 'hepatitis C virus (HCV) disease', 'entities': [['1', '32', 'chronic_disease']]}, 'NCT02770547'), ({'text': 'Leukemia with active CNS involvement', 'entities': [['1', '9', 'cancer']]}, 'NCT01773395'), ({'text': 'History of hepatic disease or infection with hepatitis B, C', 'entities': [['12', '27', 'chronic_disease'], ['46', '60', 'chronic_disease']]}, 'NCT01883258'), ({'text': 'Rifabutin (e.g. Mycobutin)', 'entities': [['1', '10', 'treatment'], ['17', '26', 'treatment']]}, 'NCT01869114'), ({'text': 'Stage I or II disease', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02451982'), ({'text': 'Definitive clinical or radiologic evidence of metastatic disease; required imaging studies must have been performed within 90 days prior to randomization', 'entities': [['47', '65', 'cancer'], ['124', '137', 'upper_bound']]}, 'NCT02488967'), ({'text': 'Patients with evidence of Hepatitis B or Hepatitis C PCR positivity', 'entities': [['27', '38', 'chronic_disease'], ['42', '53', 'chronic_disease'], ['54', '57', 'treatment']]}, 'NCT02663622'), ({'text': 'Definitive clinical or radiologic evidence of metastatic disease', 'entities': [['47', '65', 'cancer']]}, 'NCT01872975'), ({'text': 'Tumor tissue EBV positive', 'entities': [['1', '6', 'cancer'], ['14', '17', 'treatment']]}, 'NCT01956084'), ({'text': 'Use of pressors', 'entities': [['8', '16', 'treatment']]}, 'NCT02145260'), ({'text': 'one prior therapy with high dose IL-2 or anti-programmed cell death (PD)-1 compound alone or in combination with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) targeting drug', 'entities': [['5', '90', 'treatment'], ['97', '181', 'treatment']]}, 'NCT01684397'), ({'text': 'No locally advanced or metastatic cancer requiring systemic therapy within 5 years prior to registration', 'entities': [['4', '20', 'cancer'], ['24', '41', 'cancer'], ['52', '68', 'treatment'], ['76', '89', 'upper_bound']]}, 'NCT02194738'), ({'text': 'History of breast cancer or other estrogen-dependent neoplasms', 'entities': [['12', '25', 'cancer'], ['35', '53', 'chronic_disease']]}, 'NCT03183102'), ({'text': 'Allergy to Lidocaine', 'entities': [['12', '21', 'allergy_name']]}, 'NCT02803359'), ({'text': 'Patients must have liver tumors requiring a major liver resection, defined as removing at least three anatomical segments in patients without liver disease and two segments in patients with cirrhosis/fibrosis of the liver', 'entities': [['20', '32', 'cancer'], ['45', '66', 'treatment'], ['97', '102', 'lower_bound'], ['143', '156', 'chronic_disease'], ['191', '200', 'chronic_disease'], ['201', '222', 'chronic_disease']]}, 'NCT03179995'), ({'text': 'Pregnant and nursing women are excluded from this study because there is an unknown but potential risk of adverse events related to higher-dose vitamin D3 and colon or liver surgery (and associated perioperative medications and anesthesia) on the human fetus', 'entities': [['1', '9', 'pregnancy'], ['22', '27', 'gender'], ['145', '155', 'treatment'], ['169', '182', 'treatment'], ['199', '224', 'treatment']]}, 'NCT02172651'), ({'text': 'liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis', 'entities': [['1', '14', 'chronic_disease'], ['23', '32', 'chronic_disease'], ['34', '58', 'chronic_disease'], ['62', '90', 'chronic_disease']]}, 'NCT02579044'), ({'text': 'Actively psychotic or demented persons', 'entities': [['10', '19', 'chronic_disease'], ['23', '31', 'chronic_disease']]}, 'NCT02283333'), ({'text': 'Uncontrolled bacterial, viral, or fungal infection at the time of pre-UCBT cytoreduction', 'entities': [['14', '23', 'chronic_disease'], ['25', '30', 'chronic_disease'], ['35', '51', 'chronic_disease'], ['67', '89', 'treatment']]}, 'NCT02254863'), ({'text': 'medically documented (e.g., EMS report, hospital record, physician record) TBI as a result of a blow to the head requiring admission to an acute inpatient rehabilitation unit', 'entities': [['76', '79', 'chronic_disease']]}, 'NCT02695043'), ({'text': 'Vitamin K antagonist (VKA)', 'entities': [['1', '27', 'treatment']]}, 'NCT02329327'), ({'text': 'ubjects with atrial fibrillation controlled for >30 days prior to dosing', 'entities': [['14', '33', 'chronic_disease'], ['50', '63', 'lower_bound']]}, 'NCT02124772'), ({'text': 'No other concurrent treatment for lymphoma', 'entities': [['21', '30', 'treatment'], ['35', '43', 'cancer']]}, 'NCT00670358'), ({'text': 'Girls, who are sexually active and able to become pregnant, not using safe and effective birth control methods, or not willing to continue practicing these birth control methods, during the trial and until 30 days after the end of the trial (or after the last intake of the investigational medication)', 'entities': [['1', '6', 'gender'], ['36', '59', 'pregnancy'], ['61', '111', 'contraception_consent'], ['116', '178', 'contraception_consent'], ['207', '214', 'upper_bound'], ['275', '301', 'treatment']]}, 'NCT00980538'), ({'text': 'Clopidogrel', 'entities': [['1', '12', 'treatment']]}, 'NCT01624090'), ({'text': 'New York Heart Association class 3-4 heart failure', 'entities': [['1', '33', 'clinical_variable'], ['34', '35', 'lower_bound'], ['36', '37', 'upper_bound'], ['38', '51', 'chronic_disease']]}, 'NCT01754857'), ({'text': 'receiving allopurinol/cimetidine/antivirals they must be discontinued prior to starting this protocol', 'entities': [['11', '22', 'treatment'], ['23', '33', 'treatment'], ['34', '44', 'treatment']]}, 'NCT02524275'), ({'text': 'Very fast PSA doubling time of less than 4 weeks, if the absolute PSA is > 2 ng/mL', 'entities': [['11', '14', 'clinical_variable'], ['42', '49', 'upper_bound'], ['76', '83', 'lower_bound']]}, 'NCT03087903'), ({'text': 'radiation therapy for bladder cancer', 'entities': [['1', '18', 'treatment'], ['23', '37', 'cancer']]}, 'NCT02324582'), ({'text': 'Cohort Expansion Phase: Subjects with asymptomatic CNS metastases for at least four weeks before study drug treatment', 'entities': [['52', '66', 'cancer'], ['80', '97', 'lower_bound'], ['98', '118', 'treatment']]}, 'NCT02310464'), ({'text': 'within 30 days or 5 half-lives whichever is longer prior to receiving the first dose of study treatment', 'entities': [['8', '15', 'upper_bound'], ['19', '31', 'upper_bound'], ['89', '104', 'treatment']]}, 'NCT01532687'), ({'text': 'English speaking', 'entities': [['1', '17', 'language_fluency']]}, 'NCT02563574'), ({'text': 'Active ulcerative colitis with an Adapted Mayo score of 5 to 9 points', 'entities': [['1', '26', 'chronic_disease'], ['35', '53', 'clinical_variable'], ['57', '58', 'lower_bound'], ['62', '63', 'upper_bound']]}, 'NCT02819635'), ({'text': 'Baseline aspartate aminotransferase (AST)', 'entities': [['10', '42', 'clinical_variable']]}, 'NCT00075387'), ({'text': '21 years of age or older at the time of consent', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT02000115'), ({'text': 'Extensive nodal involvement is defined as metastatic disease involving any nodal region outside of the involved breast', 'entities': [['43', '61', 'cancer']]}, 'NCT02876302'), ({'text': 'Have implanted cardiac pacemaker or defibrillator, cochlear implant or nerve stimulator', 'entities': [['6', '33', 'treatment'], ['37', '50', 'treatment'], ['52', '68', 'treatment'], ['72', '88', 'treatment']]}, 'NCT02366754'), ({'text': 'Patients who have had a total hysterectomy (removal of uterus and cervix) or trachelectomy (removal of cervix)', 'entities': [['31', '43', 'treatment'], ['78', '91', 'treatment']]}, 'NCT02864147'), ({'text': 'Patients who have received chemotherapy, small molecule targeted therapy or radiation within the 2 weeks of first dose of study drugs', 'entities': [['28', '40', 'treatment'], ['42', '73', 'treatment'], ['77', '86', 'treatment'], ['98', '105', 'upper_bound'], ['123', '134', 'treatment']]}, 'NCT03121352'), ({'text': 'Current gastrointestinal (GI) bleeding', 'entities': [['9', '39', 'chronic_disease']]}, 'NCT03042767'), ({'text': 'Suspected/confirmed endocarditis', 'entities': [['21', '33', 'chronic_disease']]}, 'NCT02453373'), ({'text': 'Co-morbidities requiring systemic corticosteroid therapy greater than 10 mg of prednisone per day, or equivalent, or a change in corticosteroid dose within the 3 months prior to Visit 1', 'entities': [['26', '57', 'treatment'], ['35', '49', 'treatment'], ['71', '76', 'lower_bound'], ['80', '90', 'treatment'], ['161', '175', 'upper_bound']]}, 'NCT03030118'), ({'text': 'Less than 14 days post bladder biopsy, TUR, or traumatic catheterization', 'entities': [['11', '18', 'upper_bound'], ['19', '38', 'treatment'], ['40', '43', 'treatment'], ['48', '73', 'treatment']]}, 'NCT02324582'), ({'text': 'A baseline CT chest/abdomen/pelvis and bone scan or PET/CT', 'entities': [['3', '49', 'treatment'], ['53', '59', 'treatment']]}, 'NCT02531932'), ({'text': 'Have clinical diagnosis of RP', 'entities': [['28', '30', 'chronic_disease']]}, 'NCT02464436'), ({'text': 'Absolute neutrophil count >= 1,500/mcL', 'entities': [['1', '26', 'clinical_variable'], ['30', '39', 'lower_bound']]}, 'NCT01849146'), ({'text': 'Cardiovascular disease', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02650206'), ({'text': 'other major neurological disorder', 'entities': [['7', '34', 'chronic_disease']]}, 'NCT03105700'), ({'text': 'Presence of severe renal disease (BUN 50% greater than normal or creatinine clearance <60 mL/min) or hepatic disease', 'entities': [['13', '33', 'chronic_disease'], ['35', '38', 'clinical_variable'], ['39', '42', 'lower_bound'], ['66', '86', 'clinical_variable'], ['88', '97', 'upper_bound'], ['102', '117', 'chronic_disease']]}, 'NCT01341080'), ({'text': 'Prior treatment with an agent targeting the exportin', 'entities': [['1', '53', 'treatment']]}, 'NCT02419495'), ({'text': 'Active mucositis or acute graft versus host disease of the gastrointestinal tract', 'entities': [['1', '17', 'chronic_disease'], ['21', '52', 'chronic_disease']]}, 'NCT02543866'), ({'text': "Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol", 'entities': [['24', '43', 'chronic_disease'], ['132', '141', 'treatment']]}, 'NCT02339922'), ({'text': 'Protocol treatment is to begin within 2 working days of patient randomization', 'entities': [['10', '19', 'treatment'], ['39', '40', 'upper_bound']]}, 'NCT02273375'), ({'text': 'Adequate organ and marrow function no more than 28 days prior to the start of neoadjuvant endocrine therapy or chemotherapy', 'entities': [['49', '62', 'upper_bound'], ['91', '108', 'treatment'], ['112', '124', 'treatment']]}, 'NCT02204098'), ({'text': 'Myelopathy with bladder dysfunction', 'entities': [['1', '11', 'chronic_disease'], ['17', '36', 'chronic_disease']]}, 'NCT01568918'), ({'text': 'Significant motor impairment', 'entities': [['13', '29', 'chronic_disease']]}, 'NCT02430051'), ({'text': 'All patients who have received anti-CD19 directed CART therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CD19-directed CART cells or from any CD19 CART trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology', 'entities': [['32', '41', 'treatment'], ['51', '63', 'treatment'], ['107', '115', 'treatment'], ['107', '135', 'treatment'], ['159', '183', 'treatment'], ['196', '211', 'treatment']]}, 'NCT02445222'), ({'text': 'Residents within the health department jurisdiction with newly diagnosed HIV infection who have not linked to medical care within 90 days', 'entities': [['74', '87', 'chronic_disease'], ['131', '138', 'upper_bound']]}, 'NCT02693145'), ({'text': 'Any medical or psychological condition that in the opinion of the principal investigator would interfere with safe completion of the trial', 'entities': [['5', '12', 'chronic_disease'], ['16', '39', 'chronic_disease']]}, 'NCT03135171'), ({'text': 'Prior participation in a clinical study of viagenpumatucel-L (HS-110)', 'entities': [['44', '70', 'treatment']]}, 'NCT02439450'), ({'text': 'Severe uncontrolled hypertension (SBP e 180 mmHg and/or DBP e 110 mmHg)', 'entities': [['21', '33', 'chronic_disease'], ['35', '38', 'clinical_variable'], ['41', '49', 'lower_bound'], ['57', '60', 'clinical_variable'], ['63', '71', 'lower_bound']]}, 'NCT02574650'), ({'text': 'Patients with the following predisposing factors for osmotic demyelinating syndrome (ODS), assessed by the study investigator judgment, will be excluded: chronic alcoholism at the time of study, severe liver disease, marked malnutrition, and risk for chronic hypoxia', 'entities': [['54', '90', 'chronic_disease'], ['203', '216', 'chronic_disease'], ['252', '267', 'chronic_disease']]}, 'NCT02476409'), ({'text': 'Patient is currently receiving treatment with ceritinib within a Novartis-sponsored study which has fulfilled the requirements for the primary objective and, in the opinion of the Investigator, would benefit from continued treatment', 'entities': [['32', '41', 'treatment'], ['47', '56', 'treatment']]}, 'NCT02584933'), ({'text': 'no greater than grade 2 injury to MCL or LCL and absence of PCL injury', 'entities': [['17', '24', 'upper_bound']]}, 'NCT02913404'), ({'text': 'Presenting for pain related to acute cancer therapy', 'entities': [['32', '52', 'treatment']]}, 'NCT02990377'), ({'text': 'Corticosteroid medication use during this pregnancy', 'entities': [['1', '26', 'treatment'], ['43', '52', 'pregnancy']]}, 'NCT03011801'), ({'text': 'Fanconi anemia', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT00358657'), ({'text': 'Serum creatinine within normal range with a creatinine clearance >= 30 ml/min', 'entities': [['1', '17', 'clinical_variable'], ['45', '65', 'clinical_variable'], ['69', '78', 'lower_bound']]}, 'NCT01918644'), ({'text': 'Severe hypertension (HTN) (office BP e 160/100 mm Hg)', 'entities': [['8', '26', 'chronic_disease'], ['35', '37', 'clinical_variable'], ['40', '53', 'lower_bound']]}, 'NCT02497300'), ({'text': 'Hemoglobin (Hb) > 9 g/dL', 'entities': [['1', '16', 'clinical_variable'], ['19', '25', 'lower_bound']]}, 'NCT02397083'), ({'text': 'Recurrent Depression - in the current episode, have not responded to at least 2 adequate antidepressant trials (using Antidepressant Treatment History Form criteria)', 'entities': [['11', '21', 'chronic_disease'], ['79', '80', 'lower_bound'], ['90', '111', 'treatment']]}, 'NCT02165449'), ({'text': 'accept PAP as primary/sole OSA therapy', 'entities': [['8', '11', 'treatment'], ['28', '39', 'treatment']]}, 'NCT03109210'), ({'text': 'e 20 mL/min for SVd, SPVd, and SDd Arms', 'entities': [['3', '12', 'lower_bound']]}, 'NCT02343042'), ({'text': 'Patients must have disease that is not amenable to potentially curative resection', 'entities': [['64', '82', 'treatment']]}, 'NCT02311361'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT02706288'), ({'text': 'COPD or HF exacerbation in the previous month', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT03003780'), ({'text': 'Subjects with baseline peripheral neuropathy that exceeds Grade 1', 'entities': [['15', '45', 'clinical_variable'], ['59', '66', 'lower_bound']]}, 'NCT02393794'), ({'text': 'a history or evidence of current clinically significant uncontrolled arrhythmias (clarification', 'entities': [['70', '81', 'chronic_disease']]}, 'NCT02124772'), ({'text': 'Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy', 'entities': [['109', '121', 'treatment'], ['132', '147', 'treatment'], ['152', '161', 'pregnancy']]}, 'NCT01760005'), ({'text': 'Any joint contracture or severe spasticity in the affected upper extremity, as measured by a Modified Ashworth Score > than 3 out of 4', 'entities': [['33', '43', 'chronic_disease'], ['94', '117', 'clinical_variable'], ['125', '126', 'lower_bound'], ['134', '135', 'upper_bound']]}, 'NCT03100370'), ({'text': 'History of heart defect', 'entities': [['12', '24', 'chronic_disease']]}, 'NCT02272049'), ({'text': 'total gastrectomy', 'entities': [['1', '18', 'treatment']]}, 'NCT02127398'), ({'text': 'Concomitant use or prior use in the preceding 6 months of any investigational drug', 'entities': [['37', '55', 'upper_bound']]}, 'NCT01900093'), ({'text': 'Normal GFR (glomerular filtration rate) >60', 'entities': [['1', '40', 'clinical_variable'], ['42', '44', 'lower_bound']]}, 'NCT02158793'), ({'text': 'No botulinum toxin injections in the last 6 months', 'entities': [['4', '30', 'treatment'], ['38', '51', 'upper_bound']]}, 'NCT02008136'), ({'text': 'Subject has failed treatment with an approved therapeutic dose of an anti-TNF± monoclonal antibody treatment', 'entities': [['20', '29', 'treatment'], ['70', '109', 'treatment']]}, 'NCT03169894'), ({'text': 'A bilateral oophorectomy (ovariectomy)', 'entities': [['3', '25', 'treatment'], ['27', '38', 'treatment']]}, 'NCT01532687'), ({'text': 'Non-measurable disease (< 1 cm) by CT (Kinetic Studies Arm only; disease-free participants can be enrolled in the Dosimetry Studies Arm)', 'entities': [['1', '23', 'clinical_variable'], ['27', '31', 'upper_bound'], ['36', '38', 'treatment']]}, 'NCT02469129'), ({'text': 'Organ Transplant: Patients may NOT be the recipients of an organ transplant', 'entities': [['1', '17', 'treatment'], ['60', '76', 'treatment']]}, 'NCT02495415'), ({'text': 'Karnofsky performance status e 80%', 'entities': [['1', '29', 'clinical_variable'], ['32', '35', 'lower_bound']]}, 'NCT00715611'), ({'text': 'males', 'entities': [['1', '6', 'gender']]}, 'NCT02308904'), ({'text': 'Stratum 2: Patient must have thalassemia receiving an unrelated donor transplant with bone marrow or umbilical cord blood stem cells', 'entities': [['30', '41', 'chronic_disease'], ['71', '81', 'treatment']]}, 'NCT00920972'), ({'text': 'Possessing a mobile device (smart phone, tablet, laptop) capable of accessing the application and website', 'entities': [['1', '106', 'technology_access']]}, 'NCT02531711'), ({'text': 'scheduled for elective amputation', 'entities': [['15', '34', 'treatment']]}, 'NCT02383979'), ({'text': 'HIV and Hepatitis are OK if stable', 'entities': [['1', '4', 'chronic_disease'], ['9', '18', 'chronic_disease']]}, 'NCT02418195'), ({'text': 'Montgomery Asberg Depression Rating Scale (MADRS) greater than 7 and MADRS total less than 30', 'entities': [['1', '50', 'clinical_variable'], ['44', '49', 'clinical_variable'], ['64', '65', 'lower_bound'], ['92', '94', 'upper_bound']]}, 'NCT03043573'), ({'text': 'Prior hepatic arterial therapy', 'entities': [['7', '31', 'treatment']]}, 'NCT02724540'), ({'text': 'Adults unable to consent, infants, children, teenagers, pregnant patients and prisoners will be excluded', 'entities': [['57', '65', 'pregnancy']]}, 'NCT03010137'), ({'text': 'Must begin enrollment in study within one week of being determined eligible', 'entities': [['39', '47', 'upper_bound']]}, 'NCT02792257'), ({'text': 'Total bilirubin less than or equal to 3.0', 'entities': [['1', '16', 'clinical_variable'], ['39', '42', 'upper_bound']]}, 'NCT01582191'), ({'text': 'patients with pleural effusions that have become too small for thoracentesis at the time of registration would be permitted on study, indicating a significant response to first-line chemotherapy', 'entities': [['15', '32', 'chronic_disease'], ['183', '195', 'treatment']]}, 'NCT03137771'), ({'text': 'Diffuse Large B-Cell Lymphoma', 'entities': [['1', '30', 'cancer']]}, 'NCT02393157'), ({'text': 'Karnofsky Performance Status e70%', 'entities': [['1', '29', 'clinical_variable'], ['31', '34', 'lower_bound']]}, 'NCT02921022'), ({'text': '40-52 years of age', 'entities': [['1', '3', 'lower_bound'], ['4', '12', 'upper_bound'], ['16', '19', 'age']]}, 'NCT01895881'), ({'text': 'Estimated life expectancy e 12 weeks', 'entities': [['11', '26', 'clinical_variable'], ['29', '37', 'lower_bound']]}, 'NCT02808442'), ({'text': 'Voided volume greater than 125 ml', 'entities': [['1', '14', 'clinical_variable'], ['28', '34', 'lower_bound']]}, 'NCT01589263'), ({'text': 'B-cell hematologic malignancies expected to express the cluster of differentiation 20 (CD20) antigen who have relapsed after or failed to respond to at least one prior treatment regimen and for whom there is no available therapy expected to improve survival', 'entities': [['1', '32', 'cancer'], ['159', '162', 'lower_bound'], ['163', '186', 'treatment'], ['222', '229', 'treatment']]}, 'NCT02500407'), ({'text': 'Prior treatment with CD47', 'entities': [['1', '26', 'treatment']]}, 'NCT02953509'), ({'text': 'History of Diabetes Mellitus', 'entities': [['12', '29', 'chronic_disease']]}, 'NCT02803359'), ({'text': 'Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent', 'entities': [['1', '25', 'treatment'], ['61', '70', 'upper_bound'], ['74', '84', 'treatment']]}, 'NCT02311361'), ({'text': 'Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['47', '82', 'contraception_consent'], ['84', '92', 'contraception_consent'], ['96', '127', 'contraception_consent'], ['129', '139', 'contraception_consent']]}, 'NCT02272998'), ({'text': 'Age < 60 years and amenorrheic for at least 1 year with follicle-stimulating hormone (FSH) and plasma estradiol levels in the postmenopausal range', 'entities': [['1', '4', 'age'], ['7', '15', 'upper_bound'], ['45', '51', 'lower_bound']]}, 'NCT02515110'), ({'text': "Receiving statin or aspirin therapy pre-injury, as potentially being assigned for Control would increase patient's risks", 'entities': [['11', '17', 'treatment'], ['21', '36', 'treatment']]}, 'NCT02901067'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, hepatitis B infection, hepatitis C infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['77', '93', 'chronic_disease'], ['95', '116', 'chronic_disease'], ['118', '139', 'chronic_disease'], ['153', '177', 'chronic_disease'], ['179', '203', 'chronic_disease'], ['205', '223', 'chronic_disease'], ['228', '265', 'chronic_disease']]}, 'NCT02393690'), ({'text': 'Subject has previously been treated for multiple myeloma', 'entities': [['41', '57', 'cancer']]}, 'NCT02516696'), ({'text': 'Major neurological disorders (dementia, multiple sclerosis, epilepsy, etc)', 'entities': [['7', '29', 'chronic_disease'], ['31', '39', 'chronic_disease'], ['41', '59', 'chronic_disease'], ['61', '69', 'chronic_disease']]}, 'NCT03058146'), ({'text': 'Previous cardiac surgery within 1 year of surgical procedure', 'entities': [['10', '25', 'treatment'], ['33', '39', 'upper_bound']]}, 'NCT02856594'), ({'text': 'Patients must have relapsed after first line chemotherapy', 'entities': [['46', '58', 'treatment']]}, 'NCT01896999'), ({'text': 'Liver dysfunction with elevation of liver enzymes and bilirubin levels to e 3X ULN or Internationalized Normalized Ratio (INR) e2 or lactate dehydrogenase (LDH) > 2.5X ULN', 'entities': [['1', '18', 'chronic_disease'], ['37', '50', 'clinical_variable'], ['55', '71', 'clinical_variable'], ['77', '83', 'lower_bound'], ['87', '127', 'clinical_variable'], ['129', '130', 'lower_bound'], ['134', '161', 'clinical_variable'], ['164', '172', 'lower_bound']]}, 'NCT02468778'), ({'text': 'Serum albumin >= 2.8 g/dL (within 2 weeks prior to enrollment)', 'entities': [['1', '14', 'clinical_variable'], ['18', '26', 'lower_bound'], ['35', '48', 'upper_bound']]}, 'NCT02408861'), ({'text': 'Male or female subjects', 'entities': [['1', '24', 'gender']]}, 'NCT02947945'), ({'text': 'fever, splenomegaly, cytopenia involving e2 cell lines (Hemoglobin <9 g/dL', 'entities': [['1', '6', 'clinical_variable'], ['8', '20', 'clinical_variable'], ['22', '31', 'clinical_variable'], ['43', '44', 'lower_bound'], ['57', '67', 'clinical_variable'], ['69', '75', 'upper_bound']]}, 'NCT02400463'), ({'text': 'Personal- and/or family history of medullary thyroid carcinoma', 'entities': [['36', '63', 'cancer']]}, 'NCT02496611'), ({'text': 'Recurrent high grade glioma', 'entities': [['11', '28', 'cancer']]}, 'NCT02344355'), ({'text': 'No history of ulcer disease or GI bleeding', 'entities': [['15', '28', 'chronic_disease'], ['32', '43', 'chronic_disease']]}, 'NCT02389465'), ({'text': 'Men and women of reproductive potential may not participate unless they agree to use an effective contraceptive method', 'entities': [['1', '4', 'gender'], ['9', '14', 'gender'], ['73', '119', 'contraception_consent']]}, 'NCT02893982'), ({'text': 'Anaplastic large cell lymphoma', 'entities': [['1', '31', 'cancer']]}, 'NCT02232516'), ({'text': 'Men and women', 'entities': [['1', '14', 'gender']]}, 'NCT02960763'), ({'text': 'Tetracycline', 'entities': [['1', '13', 'treatment']]}, 'NCT03181516'), ({'text': 'Liver cirrhosis', 'entities': [['7', '16', 'chronic_disease']]}, 'NCT01904136'), ({'text': 'does not fulfill the ACR criteria for OA', 'entities': [['39', '41', 'chronic_disease']]}, 'NCT02272218'), ({'text': 'Treatment of persistent or relapsed reactivation or infection', 'entities': [['1', '10', 'treatment'], ['53', '62', 'chronic_disease']]}, 'NCT02510417'), ({'text': 'Sexually active women of child-bearing potential', 'entities': [['17', '22', 'gender']]}, 'NCT00075387'), ({'text': 'Patients with a diagnosis of spinal cord ependymoma, myxopapillary ependymoma, subependymoma, ependymoblastoma, or mixed glioma', 'entities': [['30', '52', 'cancer'], ['54', '78', 'cancer'], ['80', '93', 'cancer'], ['95', '111', 'cancer'], ['116', '128', 'cancer']]}, 'NCT01096368'), ({'text': 'Fertile patients must use an effective form of contraception during study treatment', 'entities': [['23', '61', 'contraception_consent']]}, 'NCT00788164'), ({'text': 'a measured left ventricular ejection fraction <=35%', 'entities': [['12', '46', 'clinical_variable'], ['49', '52', 'upper_bound']]}, 'NCT02121158'), ({'text': "Calculated creatinine clearance (CrCl) e 50 ml/minute (using Cockcroft and Gault's formula; see APPENDIX 2)", 'entities': [['1', '39', 'clinical_variable'], ['42', '54', 'lower_bound']]}, 'NCT02533674'), ({'text': 'untreatable allergy to contrast media', 'entities': [['24', '38', 'allergy_name']]}, 'NCT02169037'), ({'text': 'Patient was treated on the standard of care arm of B1931022 and failed therapy', 'entities': [['52', '60', 'treatment'], ['72', '79', 'treatment']]}, 'NCT01925131'), ({'text': 'Eligibility for TAVR', 'entities': [['17', '21', 'treatment']]}, 'NCT02597985'), ({'text': 'Women of childbearing potential must have a negative pregnancy test within 7 days before enrollment', 'entities': [['1', '6', 'gender'], ['45', '63', 'pregnancy'], ['76', '89', 'upper_bound']]}, 'NCT01822522'), ({'text': 'Patients greater than or equal to 12 years old', 'entities': [['35', '43', 'lower_bound']]}, 'NCT00001337'), ({'text': 'known bleeding/clotting disorders', 'entities': [['7', '34', 'chronic_disease']]}, 'NCT02209545'), ({'text': 'who is screened for ODD or CD as measured by the Disruptive Behavior Disorder Rating Scale, Impairment Scale, and Iowa Conners Scale', 'entities': [['21', '24', 'chronic_disease'], ['50', '91', 'clinical_variable'], ['93', '109', 'clinical_variable'], ['115', '133', 'clinical_variable']]}, 'NCT03081195'), ({'text': 'Traveling across 2 or more time zones within past 3 months', 'entities': [['18', '19', 'lower_bound'], ['46', '59', 'upper_bound']]}, 'NCT02298790'), ({'text': 'Life expectancy of at least 12 weeks (3 months)', 'entities': [['1', '16', 'clinical_variable'], ['29', '48', 'lower_bound']]}, 'NCT02459119'), ({'text': 'A urine pregnancy test will be performed within 48 hours before the RNA CART19 infusion', 'entities': [['9', '18', 'pregnancy'], ['49', '57', 'upper_bound'], ['69', '79', 'treatment']]}, 'NCT02624258'), ({'text': 'Uncontrolled hypertension', 'entities': [['14', '26', 'chronic_disease']]}, 'NCT02680574'), ({'text': 'History of allergic reactions to compounds of similar chemical or biologic composition to GM-CSF', 'entities': [['34', '97', 'allergy_name']]}, 'NCT01773395'), ({'text': 'Contraindication to aspirin or dipyridamole, including history of recent or severe GI bleeding, hemoglobin <9 mg/dL, platelet count of <30,000 /mm3 or unstable platelet coun', 'entities': [['21', '28', 'allergy_name'], ['32', '44', 'allergy_name'], ['84', '95', 'chronic_disease'], ['97', '107', 'clinical_variable'], ['109', '116', 'upper_bound'], ['118', '132', 'clinical_variable'], ['118', '131', 'clinical_variable'], ['137', '148', 'upper_bound']]}, 'NCT01781611'), ({'text': 'Treatment plan for bladder must include at least 4 weeks of daily radiation treatment (most patients will receive chemotherapy concurrent with radiation, but this is not required for trial enrollment)', 'entities': [['1', '10', 'treatment'], ['50', '57', 'lower_bound'], ['67', '86', 'treatment'], ['67', '76', 'treatment'], ['115', '127', 'treatment']]}, 'NCT03125226'), ({'text': 'Patients must be age 18 to 85 years', 'entities': [['18', '21', 'age'], ['22', '24', 'lower_bound'], ['28', '36', 'upper_bound']]}, 'NCT01239095'), ({'text': 'Subject is currently receiving or intending to receive anti-coagulants for therapeutic purposes', 'entities': [['56', '71', 'treatment']]}, 'NCT02549937'), ({'text': 'severe traumatic brain injury', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02746458'), ({'text': 'MAINTENANCE THERAPY', 'entities': [['1', '20', 'treatment']]}, 'NCT02003222'), ({'text': 'Inability to comply with medical therapy or follow-up', 'entities': [['26', '41', 'treatment']]}, 'NCT01904136'), ({'text': 'Patients with relapsed multiple myeloma who have already received one or more standard treatment regimens', 'entities': [['15', '40', 'cancer'], ['67', '70', 'lower_bound'], ['79', '106', 'treatment']]}, 'NCT01415882'), ({'text': 'Patients who are pregnant or plan to become pregnant', 'entities': [['14', '26', 'pregnancy'], ['30', '53', 'treatment']]}, 'NCT02413970'), ({'text': 'Suicide attempt in past 6 months', 'entities': [['1', '16', 'chronic_disease'], ['20', '33', 'upper_bound']]}, 'NCT02250534'), ({'text': 'Vaccination with live attenuated vaccine within 28 days prior to day 1 of PROSTVAC-V/F administration', 'entities': [['1', '41', 'treatment'], ['49', '62', 'upper_bound'], ['75', '87', 'treatment']]}, 'NCT02772562'), ({'text': 'Patients with known hemorrhagic and coagulation disorder', 'entities': [['21', '57', 'chronic_disease']]}, 'NCT03040778'), ({'text': 'any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks before the start of treatment', 'entities': [['57', '71', 'treatment'], ['75', '90', 'treatment'], ['155', '162', 'upper_bound']]}, 'NCT03113695'), ({'text': 'Aspartate aminotransferase (AST) =< 2.5 x ULN', 'entities': [['1', '33', 'clinical_variable'], ['37', '46', 'upper_bound']]}, 'NCT01620216'), ({'text': 'Burn injury experienced <48 hours prior to admission to the Burn Center for care', 'entities': [['1', '24', 'clinical_variable'], ['26', '40', 'upper_bound']]}, 'NCT02409810'), ({'text': 'History of arrhythmia, including atrial fibrillation', 'entities': [['12', '22', 'chronic_disease'], ['34', '53', 'chronic_disease']]}, 'NCT02497300'), ({'text': "Peripheral neuropathy of grade 2 or greater severity as defined by the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 'entities': [['1', '22', 'chronic_disease'], ['26', '33', 'lower_bound']]}, 'NCT01959698'), ({'text': '2 or more measurable sites of disease as defined by either RECIST 1.1, or cutaneous lesions at least 1 cm in greatest dimension', 'entities': [['1', '2', 'lower_bound'], ['75', '92', 'cancer'], ['102', '106', 'lower_bound']]}, 'NCT02407171'), ({'text': 'Have borderline resectable or unresectable locally advanced disease or metastatic disease', 'entities': [['6', '27', 'cancer'], ['72', '90', 'cancer']]}, 'NCT02442323'), ({'text': 'Pregnant (or anticipate pregnancy during the study period)', 'entities': [['1', '9', 'pregnancy'], ['14', '34', 'pregnancy']]}, 'NCT01793519'), ({'text': 'between the ages of 6 months - 10 years of age at the time of entry into the study', 'entities': [['13', '17', 'age'], ['13', '16', 'age'], ['21', '29', 'lower_bound'], ['32', '40', 'upper_bound']]}, 'NCT02335242'), ({'text': 'Patients must not have grade 2 or greater peripheral sensory n', 'entities': [['24', '31', 'lower_bound']]}, 'NCT01896999'), ({'text': 'prescription or over the counter medications that can interact with Scopolamine, such as anticholinergic medications (e.g. belladonna alkaloids, antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants), cold medicines, cough suppressants', 'entities': [['34', '45', 'treatment'], ['69', '80', 'treatment'], ['90', '117', 'treatment'], ['124', '144', 'treatment'], ['146', '160', 'treatment'], ['162', '171', 'treatment'], ['173', '198', 'treatment'], ['204', '220', 'treatment'], ['223', '237', 'treatment'], ['239', '257', 'treatment']]}, 'NCT01900301'), ({'text': 'Cessation of menses for 12 months or more', 'entities': [['25', '34', 'lower_bound']]}, 'NCT02341235'), ({'text': '50 - 95 years old', 'entities': [['1', '3', 'lower_bound'], ['6', '14', 'upper_bound']]}, 'NCT01703117'), ({'text': 'Intra-abdominal abscess', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02496208'), ({'text': "Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)", 'entities': [['31', '44', 'chronic_disease'], ['55', '87', 'chronic_disease'], ['111', '129', 'chronic_disease'], ['133', '156', 'chronic_disease']]}, 'NCT01625923'), ({'text': 'women of reproductive potential', 'entities': [['1', '6', 'gender']]}, 'NCT01701986'), ({'text': 'Patients who have had prior treatment with any PARP inhibitor in combination with temozolomide', 'entities': [['29', '38', 'treatment'], ['48', '62', 'treatment'], ['83', '95', 'treatment']]}, 'NCT01827384'), ({'text': 'Hypertrophic cardiomyopathy with or without obstruction (HOCM)', 'entities': [['1', '28', 'chronic_disease'], ['58', '62', 'clinical_variable']]}, 'NCT02000115'), ({'text': 'Enrolment in any other clinical treatment study throughout the duration of the SAR422459 study', 'entities': [['33', '42', 'treatment']]}, 'NCT01367444'), ({'text': 'Only patients with type 2 diabetes will be enrolled in this study', 'entities': [['20', '35', 'chronic_disease']]}, 'NCT02587936'), ({'text': 'A first-degree relative with NF1', 'entities': [['30', '33', 'chronic_disease']]}, 'NCT02390752'), ({'text': 'Double (aortic plus mitral) valve replacement', 'entities': [['1', '46', 'treatment']]}, 'NCT00291525'), ({'text': 'More than four additional diagnosed brain metastases', 'entities': [['11', '15', 'lower_bound'], ['37', '53', 'cancer']]}, 'NCT02514915'), ({'text': 'History of seizures', 'entities': [['12', '20', 'chronic_disease']]}, 'NCT03063892'), ({'text': 'Enlargement in the area of central macular retinal thinning/photoreceptor loss by ocular coherence tomography at a rate of e0.5 mm^2', 'entities': [['83', '110', 'treatment'], ['116', '120', 'clinical_variable'], ['125', '133', 'lower_bound']]}, 'NCT01367444'), ({'text': 'Healthy Subjects undergoing thyroid or other open neck surgeries', 'entities': [['29', '65', 'treatment']]}, 'NCT02803359'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01631617'), ({'text': 'Hemoglobin 9 g/dl or more', 'entities': [['1', '11', 'clinical_variable'], ['12', '18', 'lower_bound']]}, 'NCT03162731'), ({'text': 'Patients must have histologically proven stage IIIB, IV or recurrent non-small cell lung cancer', 'entities': [['42', '52', 'cancer'], ['54', '56', 'cancer'], ['70', '96', 'cancer']]}, 'NCT01928576'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01827384'), ({'text': 'Diagnosed with a Voice disorder', 'entities': [['18', '32', 'chronic_disease']]}, 'NCT03129880'), ({'text': 'Dependence on daytime mechanical ventilation (invasive or non-invasive, including Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPap) at the time of the screening visit', 'entities': [['83', '125', 'treatment'], ['129', '169', 'treatment']]}, 'NCT02437110'), ({'text': 'Intrauterine device (IUD)', 'entities': [['1', '26', 'contraception_consent']]}, 'NCT02360579'), ({'text': 'Young Mania Rating Scale <12', 'entities': [['1', '25', 'clinical_variable'], ['27', '29', 'upper_bound']]}, 'NCT02466685'), ({'text': 'history of vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis after age 50 yr', 'entities': [['96', '99', 'age'], ['100', '105', 'lower_bound']]}, 'NCT02822378'), ({'text': 'Patients who require use of coumarin-derivative anticoagulants such as warfarin are excluded', 'entities': [['49', '63', 'treatment'], ['72', '80', 'treatment']]}, 'NCT01989546'), ({'text': 'Patients who are currently on warfarin, enoxaparin, heparin, or a factor Xa inhibiting anti-coagulation medication', 'entities': [['31', '39', 'treatment'], ['41', '51', 'treatment'], ['53', '60', 'treatment'], ['67', '76', 'treatment'], ['88', '115', 'treatment']]}, 'NCT02588027'), ({'text': 'Patients with an ECOG performance status of 0, 1, or 2, and estimated survival of > 12 weeks', 'entities': [['18', '41', 'clinical_variable'], ['45', '46', 'lower_bound'], ['54', '55', 'upper_bound'], ['85', '93', 'lower_bound']]}, 'NCT02495415'), ({'text': 'body mass index > 50 kg/m2', 'entities': [['1', '16', 'bmi'], ['19', '27', 'lower_bound']]}, 'NCT02989597'), ({'text': 'Inability to obtain intravenous access or intraosseous', 'entities': [['21', '39', 'treatment'], ['43', '55', 'treatment']]}, 'NCT02086500'), ({'text': 'Subject has received a targeted agent against an IDH2 mutation', 'entities': [['24', '38', 'treatment']]}, 'NCT02577406'), ({'text': 'Patients must have a calculated creatinine clearance of >= 35', 'entities': [['33', '53', 'clinical_variable'], ['60', '62', 'lower_bound']]}, 'NCT03073785'), ({'text': 'Absolute neutrophil count (ANC) > 1500', 'entities': [['1', '32', 'clinical_variable'], ['35', '39', 'lower_bound']]}, 'NCT01802346'), ({'text': 'Uncontrolled active infection', 'entities': [['14', '30', 'chronic_disease']]}, 'NCT01952730'), ({'text': 'Absolute neutrophil count e 1,500', 'entities': [['1', '26', 'clinical_variable'], ['29', '34', 'lower_bound']]}, 'NCT02466009'), ({'text': 'history of chronic opioid use', 'entities': [['12', '26', 'treatment']]}, 'NCT01974609'), ({'text': '28 days since prior chemotherapy', 'entities': [['1', '8', 'upper_bound'], ['15', '33', 'treatment']]}, 'NCT00075387'), ({'text': 'Subject is pregnant', 'entities': [['12', '20', 'pregnancy']]}, 'NCT02478255'), ({'text': 'Patients not eligible for chemotherapy with taxane and/or anthracycline based chemotherapy regimens', 'entities': [['27', '39', 'treatment'], ['45', '51', 'treatment'], ['59', '72', 'treatment']]}, 'NCT02276443'), ({'text': 'The VA of the study eye should be greater than or equal to19 E-ETDRS letters (i.e., 20/400 or better)', 'entities': [['5', '7', 'clinical_variable'], ['59', '61', 'lower_bound'], ['85', '91', 'lower_bound']]}, 'NCT02564978'), ({'text': 'Chronic major psychiatric disorders (schizophrenia, major recurrent affective disorder)', 'entities': [['15', '36', 'chronic_disease'], ['38', '51', 'chronic_disease'], ['69', '87', 'chronic_disease']]}, 'NCT03058146'), ({'text': 'breastfeeding females', 'entities': [['15', '22', 'gender']]}, 'NCT02331095'), ({'text': 'known allergy to Lidocaine', 'entities': [['18', '27', 'allergy_name']]}, 'NCT03072381'), ({'text': 'adequately treated non-melanoma skin cancer', 'entities': [['20', '44', 'cancer']]}, 'NCT02273375'), ({'text': 'CKD Stages 4 and 5 (estimated CrCl <30 mL/min)', 'entities': [['1', '11', 'clinical_variable'], ['12', '13', 'lower_bound'], ['18', '19', 'upper_bound'], ['21', '35', 'clinical_variable'], ['37', '46', 'upper_bound']]}, 'NCT02467478'), ({'text': 'For patients enrolled in Arm B (first stage of phase II of TRC102 and pemetrexed) measurable disease is required according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural mesothelioma', 'entities': [['212', '224', 'cancer'], ['304', '334', 'cancer']]}, 'NCT02535312'), ({'text': 'Presence of gastrointestinal disease that would significantly affect compound absorption', 'entities': [['13', '37', 'chronic_disease']]}, 'NCT01943851'), ({'text': 'The patient has refractory nausea and vomiting or chronic gastrointestinal diseases (e.g., inflammatory bowel disease)', 'entities': [['28', '34', 'chronic_disease'], ['39', '47', 'chronic_disease'], ['59', '84', 'chronic_disease'], ['92', '118', 'chronic_disease']]}, 'NCT02152254'), ({'text': 'Thrombectomy, thrombolytic therapy, or insertion of a caval filter to treat the index VTE', 'entities': [['1', '13', 'treatment'], ['15', '35', 'treatment'], ['55', '67', 'treatment'], ['87', '90', 'chronic_disease']]}, 'NCT02464969'), ({'text': 'Baseline pre bronchodilator FEV1 should be e45% and d85% of predicted normal value and not vary by more than ±20% from the screening visit FEV1 value', 'entities': [['29', '33', 'clinical_variable'], ['45', '48', 'lower_bound'], ['54', '57', 'upper_bound'], ['111', '114', 'lower_bound']]}, 'NCT02495168'), ({'text': 'Current or planned pregnancy', 'entities': [['1', '29', 'pregnancy']]}, 'NCT02737202'), ({'text': 'Adenocarcinoma of the pancreas', 'entities': [['1', '31', 'cancer']]}, 'NCT02349867'), ({'text': 'Diagnosis of SRED', 'entities': [['14', '18', 'chronic_disease']]}, 'NCT00606411'), ({'text': 'Unstable angina pectoris, cardiac arrhythmia', 'entities': [['1', '25', 'chronic_disease'], ['27', '45', 'chronic_disease']]}, 'NCT02567422'), ({'text': 'all women of childbearing potential must agree to use a reliable birth control method (oral contraceptive pills, intrauterine device, Nexplanon, DepoProvera, or permanent sterilization, etc., or another acceptable method as determined by the investigator) during the entire period of the trial (3 years), and must not intend to become pregnant during study participation and for 3 months after treatment is discontinued', 'entities': [['5', '10', 'gender'], ['42', '86', 'contraception_consent'], ['88', '112', 'contraception_consent'], ['114', '133', 'contraception_consent'], ['135', '144', 'contraception_consent'], ['146', '157', 'contraception_consent'], ['162', '185', 'contraception_consent'], ['296', '303', 'upper_bound'], ['329', '344', 'pregnancy'], ['380', '394', 'upper_bound'], ['395', '404', 'treatment']]}, 'NCT02437851'), ({'text': 'Impaired renal function or known significant renal disease', 'entities': [['1', '24', 'chronic_disease'], ['46', '59', 'chronic_disease']]}, 'NCT02527681'), ({'text': 'Listed for cardiac transplant as a status 1A or 1B', 'entities': [['12', '30', 'treatment']]}, 'NCT01187368'), ({'text': 'have a tumor which is EGFR-T790M positive', 'entities': [['8', '13', 'cancer'], ['23', '33', 'cancer']]}, 'NCT02520778'), ({'text': 'Pregestational diabetes', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02640638'), ({'text': 'Other malignancies within the past 3 years', 'entities': [['7', '19', 'cancer'], ['31', '43', 'upper_bound']]}, 'NCT02531932'), ({'text': 'History of major medical disease impacting study', 'entities': [['12', '33', 'chronic_disease']]}, 'NCT02910648'), ({'text': 'Moderately to severely active UC as determined by the MCS', 'entities': [['31', '33', 'chronic_disease']]}, 'NCT02171429'), ({'text': 'Prior treatment with Rituximab', 'entities': [['7', '16', 'treatment'], ['22', '31', 'treatment']]}, 'NCT00977977'), ({'text': 'Recent treatment with a standing 2GA, e.g., receiving a standing 2GA in the past 6 months', 'entities': [['1', '37', 'treatment'], ['25', '37', 'treatment'], ['77', '90', 'upper_bound']]}, 'NCT02188121'), ({'text': 'Claustrophobia precluding chamber or hood tolerance', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT01986205'), ({'text': 'Men must agree to not donate sperm while on the study and for at least 3 months after the last dose of study drug(s)', 'entities': [['1', '4', 'gender'], ['72', '80', 'lower_bound']]}, 'NCT02960555'), ({'text': 'History of clinically significant endocrine disorders (common mild endocrine disorders', 'entities': [['35', '54', 'chronic_disease']]}, 'NCT02460783'), ({'text': 'advanced gastric adenocarcinoma (including GEJ) patients with ATM deficient tumours', 'entities': [['10', '32', 'cancer'], ['63', '84', 'cancer']]}, 'NCT02264678'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02436408'), ({'text': 'Prior or planned bariatric surgery', 'entities': [['1', '35', 'treatment']]}, 'NCT03037502'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02312596'), ({'text': 'major depressive disorder', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT02709980'), ({'text': 'Patients must be eligible to receive nivolumab in combination with ipilimumab treatment per institutional guidelines', 'entities': [['38', '88', 'treatment']]}, 'NCT02978443'), ({'text': 'Prostate specific antigen (PSA) d 10 ng/mL within 90 days prior to registration', 'entities': [['1', '32', 'clinical_variable'], ['35', '43', 'upper_bound'], ['51', '64', 'upper_bound']]}, 'NCT02163317'), ({'text': 'Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study', 'entities': [['34', '86', 'contraception_consent']]}, 'NCT02036853'), ({'text': 'Demonstrated ability to achieve > 50% predicted inspiratory capacity based on ideal body weight using IS within the first 24 hours of admission', 'entities': [['35', '38', 'lower_bound'], ['123', '131', 'upper_bound']]}, 'NCT02749968'), ({'text': "Total bilirubin =< 1.5 x upper limit of normal (ULN) (patients with Gilbert's syndrome may have serum bilirubin > 1.5 ULN)", 'entities': [['1', '16', 'clinical_variable'], ['20', '53', 'upper_bound'], ['69', '87', 'chronic_disease'], ['97', '112', 'clinical_variable'], ['115', '122', 'lower_bound']]}, 'NCT02496663'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT01793519'), ({'text': 'Life expectancy of >= 3 months', 'entities': [['1', '16', 'clinical_variable'], ['23', '31', 'lower_bound']]}, 'NCT02192359'), ({'text': 'Moderate pulmonary hypoplasia with ultrasound O/E LHR <30% and liver-up at the time of surgery', 'entities': [['10', '30', 'chronic_disease'], ['47', '54', 'clinical_variable'], ['56', '59', 'upper_bound'], ['88', '95', 'treatment']]}, 'NCT02986087'), ({'text': 'A score of 24 or greater on the MMSE (Mini-Mental State Examination)', 'entities': [['12', '14', 'lower_bound'], ['33', '69', 'clinical_variable']]}, 'NCT03180905'), ({'text': 'Fixed pulmonary artery systolic pressure >70 mmHg', 'entities': [['1', '41', 'clinical_variable'], ['43', '50', 'lower_bound']]}, 'NCT02806570'), ({'text': 'Patients with a known allergy to Benadryl', 'entities': [['34', '42', 'allergy_name']]}, 'NCT02769156'), ({'text': "English is the patient's primary language", 'entities': [['1', '42', 'language_fluency']]}, 'NCT03001765'), ({'text': 'Clinically significant respiratory disorders with impaired respiratory effort or difficulty taking inhaled drugs', 'entities': [['24', '45', 'chronic_disease'], ['51', '71', 'chronic_disease']]}, 'NCT02547818'), ({'text': 'Active autoimmune disease', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT01952730'), ({'text': 'Lovaza" (prescription fish oil) and not willing to go off Lovaza for 3 weeks prior to enrollment to end of study', 'entities': [['1', '7', 'treatment'], ['70', '83', 'upper_bound']]}, 'NCT03122912'), ({'text': 'Women who are unable to stand for 10-minute segments', 'entities': [['1', '6', 'gender']]}, 'NCT02690116'), ({'text': 'consideration should be given to drain the effusion prior to chemotherapy administration', 'entities': [['53', '74', 'treatment']]}, 'NCT00715611'), ({'text': 'Uncontrolled diabetes mellitus', 'entities': [['14', '31', 'chronic_disease']]}, 'NCT01829958'), ({'text': 'not post-menopausal for 12 months or without previous surgical sterilization', 'entities': [['25', '34', 'upper_bound'], ['46', '77', 'treatment']]}, 'NCT01696734'), ({'text': 'e18 years of age', 'entities': [['2', '10', 'lower_bound'], ['14', '17', 'age']]}, 'NCT02648347'), ({'text': 'Concurrent therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any immunosuppressive drug therapy (except dexamethasone or prednisone)', 'entities': [['1', '19', 'treatment'], ['49', '52', 'chronic_disease'], ['54', '63', 'treatment'], ['65', '77', 'treatment'], ['79', '90', 'treatment'], ['92', '103', 'treatment'], ['105', '116', 'treatment'], ['118', '127', 'treatment'], ['129', '138', 'treatment'], ['147', '177', 'treatment'], ['186', '199', 'treatment'], ['203', '213', 'treatment']]}, 'NCT02457845'), ({'text': 'Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and will also need to use contraceptives', 'entities': [['1', '6', 'gender'], ['45', '78', 'pregnancy'], ['91', '97', 'upper_bound'], ['120', '138', 'contraception_consent']]}, 'NCT02269280'), ({'text': 'Central nervous system disease or disorder other than stroke', 'entities': [['1', '31', 'chronic_disease'], ['55', '61', 'chronic_disease']]}, 'NCT03067818'), ({'text': 'Eligibility of subjects receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics (i.e., cytochrome P450, family 3, subfamily A, polypeptide 4 [CYP450], P-glycoprotein [PgP]) of any of the study drugs', 'entities': [['153', '168', 'treatment'], ['170', '178', 'treatment'], ['180', '191', 'treatment'], ['193', '215', 'treatment'], ['217', '237', 'treatment'], ['253', '264', 'treatment']]}, 'NCT01827384'), ({'text': 'A parent or guardian must be available for giving consent for pediatric subjects under 18 years of age', 'entities': [['88', '96', 'upper_bound'], ['100', '103', 'age']]}, 'NCT00092222'), ({'text': 'Upright forced vital capacity of at least 50 percent (%)', 'entities': [['1', '30', 'clinical_variable'], ['43', '57', 'lower_bound']]}, 'NCT02655614'), ({'text': 'Treatment with Sandostatin LAR within 4 weeks', 'entities': [['1', '31', 'treatment'], ['39', '46', 'upper_bound']]}, 'NCT02441062'), ({'text': "History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina)", 'entities': [['35', '54', 'chronic_disease'], ['58', '77', 'chronic_disease'], ['85', '104', 'chronic_disease']]}, 'NCT03122691'), ({'text': 'No prior chemotherapy, radiation therapy, or surgery for this malignancy will be allowed', 'entities': [['1', '22', 'treatment'], ['24', '41', 'treatment'], ['46', '53', 'treatment'], ['63', '73', 'cancer']]}, 'NCT02037048'), ({'text': 'Pregnant and lactating females', 'entities': [['1', '9', 'pregnancy'], ['24', '31', 'gender']]}, 'NCT02572856'), ({'text': 'Fluency in English', 'entities': [['1', '19', 'language_fluency']]}, 'NCT02266329'), ({'text': 'Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration', 'entities': [['1', '16', 'chronic_disease'], ['20', '36', 'chronic_disease'], ['59', '70', 'treatment']]}, 'NCT03137771'), ({'text': 'Known seropositive and requiring anti-viral therapy for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) defined by PCR', 'entities': [['34', '52', 'treatment'], ['57', '91', 'chronic_disease'], ['93', '116', 'chronic_disease'], ['120', '143', 'chronic_disease']]}, 'NCT02309580'), ({'text': 'Unstable cardiovascular', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02120222'), ({'text': 'quit attempt in the past 30 days resulting in > 3 days of abstinence', 'entities': [['21', '33', 'upper_bound'], ['49', '55', 'lower_bound']]}, 'NCT02250534'), ({'text': 'history of brain metastases', 'entities': [['12', '28', 'cancer']]}, 'NCT02950337'), ({'text': 'Subject is pregnant', 'entities': [['12', '20', 'pregnancy']]}, 'NCT02404012'), ({'text': 'Patients with controlled thyroid disease, or the presence of auto-antibodies without clinical autoimmune disease', 'entities': [['26', '41', 'chronic_disease'], ['95', '113', 'chronic_disease']]}, 'NCT01976585'), ({'text': 'Performance status defined by Karnofsky or Lansky > 60 (except for patients with posterior fossa syndrome)', 'entities': [['31', '40', 'clinical_variable'], ['44', '50', 'clinical_variable'], ['53', '55', 'lower_bound'], ['82', '106', 'chronic_disease']]}, 'NCT02114229'), ({'text': 'Subject with a total serum testosterone level e 300 ng/dL, with or without supplementation', 'entities': [['16', '46', 'clinical_variable'], ['49', '58', 'lower_bound']]}, 'NCT02225548'), ({'text': 'Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea)', 'entities': [['1', '30', 'treatment'], ['41', '54', 'lower_bound'], ['72', '101', 'treatment'], ['120', '131', 'treatment']]}, 'NCT02390752'), ({'text': 'age >/= 18 years', 'entities': [['1', '4', 'age'], ['9', '17', 'lower_bound']]}, 'NCT02451488'), ({'text': 'patient only on CNI (cyclosporine or tacrolimus) and steroids', 'entities': [['17', '20', 'chronic_disease'], ['22', '34', 'treatment'], ['38', '48', 'treatment'], ['54', '62', 'treatment']]}, 'NCT02327403'), ({'text': 'Prior therapy is allowed; for patients enrolled in the Phase I portion of the study, patients may have received any number of prior lines of therapy including treatment with a BRAF and/or MEK inhibitor; prior navitoclax use will not be allowed, unless the patient received < 7 days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression', 'entities': [['1', '14', 'treatment'], ['7', '14', 'treatment'], ['160', '181', 'treatment'], ['189', '202', 'treatment'], ['204', '220', 'treatment'], ['210', '220', 'treatment'], ['276', '282', 'upper_bound']]}, 'NCT01989585'), ({'text': 'HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with LY2606368', 'entities': [['1', '4', 'chronic_disease'], ['38', '60', 'treatment']]}, 'NCT02203513'), ({'text': 'Progressive disease after androgen deprivation, as defined by PSA Working Group 2 and/or RECIST criteria', 'entities': [['27', '47', 'treatment'], ['63', '66', 'clinical_variable']]}, 'NCT01804465'), ({'text': 'Biopsy-proven recurrent or second primary HNSCC of the oral cavity, oropharynx, hypopharynx or larynx', 'entities': [['1', '7', 'treatment'], ['43', '48', 'cancer']]}, 'NCT02544880'), ({'text': 'Hearing level >71 dB, as measured with a standard audiometer at frequencies between 8 and 20 kHz', 'entities': [['1', '14', 'clinical_variable'], ['16', '21', 'lower_bound']]}, 'NCT02481765'), ({'text': "Subject has any clinically significant medical or psychiatric disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent", 'entities': [['51', '70', 'chronic_disease']]}, 'NCT02516696'), ({'text': 'Patients taking: metoclopramide, domperidone, risperidone or other dopamine blockers', 'entities': [['18', '32', 'treatment'], ['34', '45', 'treatment'], ['47', '58', 'treatment'], ['62', '85', 'treatment']]}, 'NCT02553265'), ({'text': 'Currently meets DSM-IV-TR criteria for MDD', 'entities': [['40', '43', 'chronic_disease']]}, 'NCT02149823'), ({'text': 'Subjects will be enrolled in 9th through 11th grade in the 6 recruited communities', 'entities': [['30', '33', 'lower_bound'], ['42', '52', 'upper_bound']]}, 'NCT02448134'), ({'text': 'This also may include other medical conditions where the medically accountable investigator in the study does not think it would be in the best interest of the participant to participate in the study', 'entities': [['29', '47', 'chronic_disease']]}, 'NCT02118610'), ({'text': 'scheduled to receive pelvic nodal irradiation', 'entities': [['22', '46', 'treatment']]}, 'NCT01868386'), ({'text': 'agede18 added to the waitlist in the last year with no potential live donors', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound']]}, 'NCT03099434'), ({'text': 'Known allergy or intolerance to the study medications: ASA, clopidogrel, coumadin and its derivatives', 'entities': [['56', '59', 'allergy_name'], ['61', '72', 'allergy_name'], ['74', '82', 'allergy_name']]}, 'NCT02594501'), ({'text': 'Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening (within 28 days before C1D1) and prior radiographic assessments', 'entities': [['21', '60', 'cancer'], ['78', '102', 'treatment'], ['106', '132', 'treatment'], ['169', '183', 'upper_bound']]}, 'NCT02323191'), ({'text': 'females', 'entities': [['1', '8', 'gender']]}, 'NCT02724631'), ({'text': 'DONOR: Related donors who are identical for one HLA haplotype', 'entities': [['49', '62', 'clinical_variable']]}, 'NCT00358657'), ({'text': 'History of syncope with venipuncture', 'entities': [['12', '19', 'chronic_disease'], ['25', '37', 'treatment']]}, 'NCT02940288'), ({'text': 'Diagnosed with stage III/IV pancreatic cancer', 'entities': [['16', '46', 'cancer']]}, 'NCT03117556'), ({'text': 'Until information regarding exposure toxicity and exposure-response relationships are available with PLX3397, concomitant strong CYP3A4 inhibitors and inducers are not permitted in the event they alter the systemic exposure to PLX3397 (see Attachment 1 for a list of common CYP3A4 inhibitors and inducers)', 'entities': [['102', '109', 'treatment'], ['123', '160', 'treatment'], ['130', '160', 'treatment']]}, 'NCT02584647'), ({'text': 'motor, visual, or auditory handicap that prevents computer use (e.g., unresolved posterior fossa syndrome) are not eligible to participate in this trial', 'entities': [['82', '106', 'chronic_disease']]}, 'NCT01503086'), ({'text': 'Previous biliary drainage by ERCP/PTC', 'entities': [['1', '38', 'treatment']]}, 'NCT01774019'), ({'text': 'Patients aged 18 years or older, as no dosing or adverse event data are currently available on the use of afatinib in patients <18 years of age', 'entities': [['10', '13', 'age'], ['10', '14', 'age'], ['107', '115', 'treatment']]}, 'NCT01522768'), ({'text': 'Absolute neutrophil count (ANC) >= 1,500/uL, performed within 28 days prior to registration', 'entities': [['1', '32', 'clinical_variable'], ['36', '44', 'lower_bound'], ['63', '76', 'upper_bound']]}, 'NCT02227199'), ({'text': 'Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment', 'entities': [['66', '78', 'treatment'], ['113', '122', 'treatment']]}, 'NCT02020707'), ({'text': 'Model for end stage liver diseases (MELD) score of > 40', 'entities': [['1', '48', 'clinical_variable'], ['54', '56', 'lower_bound']]}, 'NCT01481974'), ({'text': 'requires at least 3 criteria from the CSM', 'entities': [['19', '20', 'lower_bound'], ['39', '42', 'clinical_variable']]}, 'NCT02347891'), ({'text': 'Partial lipodystrophy (either genetic or acquired)', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02262806'), ({'text': 'age 18-51 years of age', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '16', 'upper_bound']]}, 'NCT01921634'), ({'text': 'Dehydration Grade >1 NCI-CTCAE v4.0', 'entities': [['1', '18', 'clinical_variable'], ['20', '21', 'lower_bound']]}, 'NCT02459119'), ({'text': 'Prostate cancer treated primarily with open, laparoscopic or robotically assisted prostatectomy', 'entities': [['1', '16', 'cancer'], ['40', '44', 'treatment'], ['46', '58', 'treatment'], ['62', '96', 'treatment']]}, 'NCT00969111'), ({'text': 'Early treatment for single or multiple infections. Multiple infections with one reactivation and one controlled infection are eligible to enroll', 'entities': [['7', '16', 'treatment'], ['21', '50', 'chronic_disease'], ['40', '49', 'chronic_disease'], ['52', '71', 'chronic_disease']]}, 'NCT01945814'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01986075'), ({'text': 'Organic or pseudo-obstruction, primary eating or swallowing disorders, positive pregnancy test result, psychogenic vomiting, peritoneal dialysis, drug dependent, morbid obesity, active malignancy', 'entities': [['1', '30', 'chronic_disease'], ['40', '70', 'chronic_disease'], ['72', '90', 'pregnancy'], ['104', '124', 'chronic_disease'], ['126', '145', 'treatment'], ['163', '177', 'chronic_disease'], ['186', '196', 'cancer']]}, 'NCT03123809'), ({'text': 'English speaking', 'entities': [['1', '17', 'language_fluency']]}, 'NCT03051347'), ({'text': 'Insufficient English language skills to complete all questionnaires', 'entities': [['1', '37', 'language_fluency']]}, 'NCT02287337'), ({'text': 'age 35-75 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '16', 'upper_bound']]}, 'NCT03078530'), ({'text': 'Currently receiving circulatory support including ECMO, Impella, TandemLife or equivalents; or any durable VAD', 'entities': [['51', '55', 'treatment'], ['57', '64', 'treatment'], ['66', '91', 'treatment'], ['100', '111', 'treatment']]}, 'NCT02645539'), ({'text': 'Without history of a psychotic disorder among parents, siblings, or children', 'entities': [['22', '40', 'chronic_disease']]}, 'NCT02536846'), ({'text': 'Absolute neutrophil count 1500/ul or more', 'entities': [['1', '26', 'clinical_variable'], ['27', '34', 'lower_bound']]}, 'NCT03162731'), ({'text': 'History of significant bleeding disorder unrelated to cancer', 'entities': [['24', '41', 'chronic_disease'], ['55', '61', 'cancer']]}, 'NCT01620216'), ({'text': 'Clinical stage T3 - T4', 'entities': [['1', '15', 'clinical_variable'], ['16', '18', 'lower_bound'], ['21', '23', 'upper_bound']]}, 'NCT02339948'), ({'text': 'at least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02106650'), ({'text': 'History of malignancy within the past five years or any evidence of persistent malignancy, except fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ which has been treated or excised in a curative procedure', 'entities': [['12', '22', 'cancer'], ['34', '49', 'upper_bound'], ['113', '123', 'cancer'], ['127', '163', 'cancer'], ['168', '194', 'cancer'], ['234', '252', 'treatment']]}, 'NCT02108860'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02982226'), ({'text': 'Serum M protein e 0.5 /dL (e5 g/L)', 'entities': [['1', '16', 'clinical_variable'], ['19', '26', 'lower_bound'], ['29', '34', 'lower_bound']]}, 'NCT03143985'), ({'text': 'coagulopathy', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT00167219'), ({'text': 'Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at screening for patients of child-bearing potential within one week prior to enrollment', 'entities': [['1', '74', 'pregnancy'], ['140', '154', 'upper_bound']]}, 'NCT02315196'), ({'text': 'alopecia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02343549'), ({'text': 'Non-english speaking population will be excluded from the study due to lack of sufficient resources to pay for translator and interpreter services', 'entities': [['1', '21', 'language_fluency']]}, 'NCT02095678'), ({'text': 'Weight loss greater than or equal to 10% within the previous 6 months', 'entities': [['1', '12', 'clinical_variable'], ['38', '41', 'lower_bound'], ['53', '70', 'upper_bound']]}, 'NCT02514083'), ({'text': 'Calculated creatinine clearance e 30 mL/min or serum creatinine d 1.5 mg/dL', 'entities': [['1', '32', 'clinical_variable'], ['35', '44', 'lower_bound'], ['48', '64', 'clinical_variable'], ['67', '76', 'upper_bound']]}, 'NCT02401347'), ({'text': 'Meet revised ACR criteria and 2012 SLICC criteria for SLE and have: a) a baseline SLEDAI-2K greater than or equal to 4 and <20 or a clinical SLEDAI-2K greater than or equal to 2 (not considering anti-dsDNA or complement levels) and b) lack of BILAG A flare at baseline', 'entities': [['31', '33', 'upper_bound'], ['31', '32', 'lower_bound'], ['74', '92', 'clinical_variable'], ['118', '119', 'lower_bound'], ['133', '151', 'clinical_variable']]}, 'NCT02338999'), ({'text': 'Serious medical illnesses such as end-stage renal disease, liver failure or heart failure that, in the opinion of the Investigator, may interfere with the conduct of the study', 'entities': [['1', '26', 'chronic_disease'], ['35', '58', 'chronic_disease'], ['60', '73', 'chronic_disease'], ['77', '90', 'chronic_disease']]}, 'NCT02261519'), ({'text': 'Is able to provide written informed consent (or authorized representative), comply with protocol visits and procedures, and take oral medication, and does not have any active infection or comorbidity that would interfere with therapy', 'entities': [['130', '145', 'treatment'], ['169', '185', 'chronic_disease'], ['227', '234', 'treatment']]}, 'NCT02319369'), ({'text': 'BSA must be >0.67 and <2.5 m2', 'entities': [['1', '4', 'clinical_variable'], ['14', '18', 'lower_bound'], ['24', '30', 'upper_bound']]}, 'NCT01878617'), ({'text': 'Be able to walk unassisted for at least 10 minutes', 'entities': [['41', '51', 'lower_bound']]}, 'NCT02400554'), ({'text': 'Investigator determination that the patient is an appropriate candidate for reduced intensity allogeneic SCT with the standard Massey Cancer Center-Virginia Commonwealth Health System Bone Marrow Transplant MCC-VCUHS BMT Program regimen employed in this trial', 'entities': [['77', '109', 'treatment'], ['128', '237', 'treatment']]}, 'NCT02593123'), ({'text': 'Patients scheduled to be treated with adjuvant consolidation chemotherapy at the conclusion of their standard chemoradiation', 'entities': [['39', '74', 'treatment'], ['111', '125', 'treatment']]}, 'NCT02466971'), ({'text': 'Creatinine d IULN OR Creatinine clearance e 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal', 'entities': [['1', '11', 'clinical_variable'], ['22', '42', 'clinical_variable'], ['45', '63', 'lower_bound'], ['82', '99', 'clinical_variable']]}, 'NCT02584309'), ({'text': 'Age 18 years or older', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT02693990'), ({'text': 'Have an isolated rectocele', 'entities': [['9', '27', 'chronic_disease']]}, 'NCT02680145'), ({'text': 'Male participants of reproductive potential must agree to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study medication', 'entities': [['1', '18', 'gender'], ['50', '98', 'contraception_consent'], ['131', '147', 'treatment'], ['156', '164', 'upper_bound']]}, 'NCT02332668'), ({'text': 'Prior radiotherapy to a dose of e50Gy', 'entities': [['1', '19', 'treatment'], ['25', '29', 'clinical_variable'], ['34', '38', 'lower_bound']]}, 'NCT02516969'), ({'text': 'Have dementia', 'entities': [['6', '14', 'chronic_disease']]}, 'NCT03134274'), ({'text': "Women between 50 and 55 years old who haven't had a period for a year, will need FSH test", 'entities': [['1', '6', 'gender'], ['15', '17', 'lower_bound'], ['22', '30', 'upper_bound'], ['82', '85', 'clinical_variable']]}, 'NCT01842399'), ({'text': "Subject must have adequate organ function as indicated by the following laboratory values: a) Absolute Neutrophil count (ANC) >=1.0 x10^9 per liter (/L) (without G-CSF support); b) Platelets >= 75 x10^9/L; c) Hemoglobin >80 grams per deciliter (g/dL) (without transfusion support within 7 days from start of leukapheresis); d) Prothrombin Time or International Normalized Ratio (INR) <=1.5 times upper limit of normal (ULN) unless receiving therapeutic anticoagulation. e) Partial Thromboplastin Time (PTT) <=1.5 times upper limit of normal (ULN) unless receiving therapeutic anticoagulation. f) Calculated or measured creatinine clearance >=40 milliliters per minute (mL/min); g) Serum total bilirubin <=1.5 times ULN (unless subject had documented Gilbert's Syndrome); h) Alanine aminotransferase (ALT)/Serum Glutamic Pyruvic Transaminase (SGPT) <=2.5 times ULN", 'entities': [['95', '126', 'clinical_variable'], ['129', '153', 'lower_bound'], ['182', '191', 'clinical_variable'], ['195', '205', 'lower_bound'], ['210', '220', 'clinical_variable'], ['222', '251', 'lower_bound'], ['288', '294', 'upper_bound'], ['309', '322', 'treatment'], ['328', '384', 'clinical_variable'], ['387', '424', 'upper_bound'], ['442', '469', 'treatment'], ['474', '507', 'clinical_variable'], ['597', '640', 'clinical_variable'], ['643', '677', 'lower_bound'], ['682', '703', 'clinical_variable'], ['706', '719', 'upper_bound'], ['751', '769', 'chronic_disease'], ['775', '848', 'clinical_variable'], ['851', '864', 'upper_bound']]}, 'NCT02588612'), ({'text': 'Ability to complete evaluation surveys in English', 'entities': [['1', '50', 'language_fluency']]}, 'NCT03025139'), ({'text': 'Subject agrees to have a liver biopsy performed after 24 weeks of treatment', 'entities': [['26', '38', 'treatment'], ['55', '63', 'lower_bound']]}, 'NCT03008070'), ({'text': 'Cardiac pacemaker', 'entities': [['9', '18', 'treatment']]}, 'NCT00147056'), ({'text': 'men who are sexually active must be willing and able to use medically acceptable forms of contraception throughout the treatment phase of the trial and for 6 months after completion of M6620 (VX-970) administration', 'entities': [['1', '4', 'gender'], ['37', '104', 'contraception_consent'], ['120', '129', 'treatment'], ['157', '165', 'upper_bound'], ['186', '200', 'treatment']]}, 'NCT02567422'), ({'text': 'Pts with known sensitivity to any immunomodulatory drugs (IMiDs)', 'entities': [['35', '65', 'allergy_name']]}, 'NCT01464034'), ({'text': 'patients should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits', 'entities': [['49', '54', 'treatment'], ['68', '81', 'lower_bound']]}, 'NCT02495168'), ({'text': 'Creatinine d 1.5 x ULN or creatinine clearance (CrCl) e40 mL/min', 'entities': [['1', '11', 'clinical_variable'], ['14', '23', 'upper_bound'], ['27', '54', 'clinical_variable'], ['56', '65', 'lower_bound']]}, 'NCT02259621'), ({'text': 'Regular access to a smart phone or computer', 'entities': [['9', '44', 'technology_access']]}, 'NCT03158519'), ({'text': 'Female subjects', 'entities': [['1', '16', 'gender']]}, 'NCT02762032'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03104725'), ({'text': 'Known HIV seropositivity', 'entities': [['7', '10', 'chronic_disease']]}, 'NCT02332850'), ({'text': '=< 1.4 mg/dL (female patients age >= 13 years)', 'entities': [['4', '13', 'upper_bound'], ['15', '30', 'gender'], ['31', '34', 'age'], ['38', '46', 'lower_bound']]}, 'NCT02323880'), ({'text': 'Current untreated major depression defined by Geriatric Depression Scale > 20', 'entities': [['47', '73', 'clinical_variable'], ['76', '78', 'lower_bound']]}, 'NCT01703117'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT02474199'), ({'text': 'Paraproteinemia with platelet inhibition', 'entities': [['1', '16', 'chronic_disease'], ['22', '41', 'treatment']]}, 'NCT02578901'), ({'text': 'Patients with HPV-positive or p16-positive oropharyngeal SCCA', 'entities': [['15', '18', 'chronic_disease'], ['31', '62', 'cancer']]}, 'NCT02296684'), ({'text': 'Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times the institutional upper limits of normal', 'entities': [['1', '31', 'clinical_variable'], ['36', '68', 'clinical_variable'], ['72', '120', 'upper_bound']]}, 'NCT02159495'), ({'text': 'Females of childbearing potential should have a negative serum beta-HCG test within 48 hours of beginning DLI and/or DUK-CPG-01 unless contraception is used after initial testing', 'entities': [['1', '8', 'gender'], ['49', '72', 'pregnancy'], ['85', '93', 'upper_bound'], ['136', '149', 'contraception_consent']]}, 'NCT02452697'), ({'text': 'Patients with CMV disease', 'entities': [['15', '26', 'chronic_disease']]}, 'NCT02210078'), ({'text': 'Presence of another malignancy with the exception of cervical carcinoma in situ and stage I basal or squamous cell carcinoma of the skin', 'entities': [['21', '31', 'cancer'], ['54', '80', 'cancer'], ['85', '137', 'cancer']]}, 'NCT01648023'), ({'text': 'Patients may be transfused or receive erythropoietic treatment to meet this criterion', 'entities': [['39', '63', 'treatment']]}, 'NCT02451423'), ({'text': 'sites are encouraged to conduct appropriate evaluation for declining allograft function including bronchoscopy with bronchoalveolar lavage (BAL) and lung biopsies if clinically appropriate to exclude other potential causes of allograft dysfunction', 'entities': [['99', '145', 'treatment'], ['150', '163', 'treatment']]}, 'NCT02181257'), ({'text': 'Sustained a mild traumatic brain injury more than 1 year ago', 'entities': [['13', '40', 'chronic_disease'], ['51', '57', 'lower_bound']]}, 'NCT02849223'), ({'text': 'Receiving or about to receive chemotherapy or biologic anti-cancer treatment although hormonal manipulation therapies for breast and prostate malignancies are permitted', 'entities': [['31', '43', 'treatment'], ['47', '77', 'treatment'], ['87', '118', 'treatment'], ['123', '129', 'cancer'], ['134', '155', 'cancer']]}, 'NCT02469857'), ({'text': 'Myelofibrosis subjects must have been treated with ruxolitinib for e 6 months with a stable dose for e 8 weeks (acceptable doses are 5 mg twice daily [BID] to 25 mg BID)', 'entities': [['1', '14', 'cancer'], ['52', '63', 'treatment'], ['70', '78', 'lower_bound'], ['104', '111', 'lower_bound']]}, 'NCT02587598'), ({'text': 'Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)', 'entities': [['15', '29', 'cancer'], ['46', '62', 'chronic_disease'], ['88', '95', 'cancer'], ['146', '162', 'chronic_disease']]}, 'NCT02747888'), ({'text': 'Cytologically confirmed atypical hyperplasia', 'entities': [['25', '45', 'cancer']]}, 'NCT02494869'), ({'text': 'unstable angina pectoris', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02253316'), ({'text': 'Have suspicious of malignancy in ultrasound', 'entities': [['20', '30', 'cancer']]}, 'NCT01901562'), ({'text': 'Body mass index (BMI) between 18 and 40 kg/m2, inclusive', 'entities': [['1', '22', 'bmi'], ['31', '33', 'lower_bound'], ['38', '46', 'upper_bound']]}, 'NCT02741791'), ({'text': 'non-melanoma skin cancer', 'entities': [['1', '25', 'cancer']]}, 'NCT02501954'), ({'text': 'Full scale IQ lower than 70', 'entities': [['12', '14', 'clinical_variable'], ['26', '28', 'upper_bound']]}, 'NCT02734602'), ({'text': 'Subjects must have platelet count greater than 25,000 per microliter at baseline and at the start of study (day 1, cycle 1) visit', 'entities': [['20', '34', 'clinical_variable'], ['48', '69', 'lower_bound']]}, 'NCT02092324'), ({'text': 'patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate =< 1 g of protein in 24 hours to be eligible', 'entities': [['32', '34', 'lower_bound'], ['35', '42', 'clinical_variable'], ['35', '46', 'clinical_variable'], ['50', '69', 'treatment'], ['148', '151', 'upper_bound'], ['166', '174', 'upper_bound']]}, 'NCT02020707'), ({'text': 'Correct any identified hypokalemia and/or hypomagnesemia and repeat ECG to confirm exclusion of patient due to QTc', 'entities': [['24', '35', 'chronic_disease'], ['43', '57', 'chronic_disease']]}, 'NCT02349867'), ({'text': 'Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, cardiac arrhythmias, or congestive heart failure, and unstable angina or myocardial infarction within the past 6 months', 'entities': [['34', '59', 'chronic_disease'], ['84', '96', 'chronic_disease'], ['98', '117', 'chronic_disease'], ['122', '146', 'chronic_disease'], ['152', '167', 'chronic_disease'], ['171', '192', 'chronic_disease'], ['204', '217', 'upper_bound']]}, 'NCT02339922'), ({'text': 'Patients for whom complete cavity shaving is planned (sites where this is the routine practice of the investigator will also be excluded from participation in the study)', 'entities': [['28', '42', 'treatment']]}, 'NCT02406599'), ({'text': 'any age and any racial or ethnic group', 'entities': [['5', '8', 'age']]}, 'NCT01668082'), ({'text': 'creatinine d 2.3 mg/dl', 'entities': [['1', '11', 'clinical_variable'], ['14', '23', 'upper_bound']]}, 'NCT01648023'), ({'text': 'Total bilirubin d 2 x ULN', 'entities': [['7', '16', 'clinical_variable'], ['19', '26', 'upper_bound']]}, 'NCT01660607'), ({'text': 'Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida or herniated cervical disk', 'entities': [['106', '121', 'chronic_disease'], ['123', '135', 'chronic_disease'], ['139', '162', 'chronic_disease']]}, 'NCT02446210'), ({'text': 'Race/ ethnicity: African American/ Black or Latino/ Hispanic', 'entities': [['18', '34', 'ethnicity'], ['36', '41', 'ethnicity'], ['45', '51', 'ethnicity'], ['53', '61', 'ethnicity']]}, 'NCT03037502'), ({'text': '>3 lesions or 2 lesions with one being >5cm', 'entities': [['2', '3', 'lower_bound'], ['4', '11', 'clinical_variable'], ['41', '44', 'lower_bound']]}, 'NCT02556619'), ({'text': 'Prior exposure to a SINE compound, including selinexor', 'entities': [['46', '55', 'treatment']]}, 'NCT02343042'), ({'text': 'Subject must have a weight consistent with a recommended weight range for their age at the time of screening', 'entities': [['81', '84', 'age']]}, 'NCT03067129'), ({'text': 'Malignancy', 'entities': [['1', '11', 'cancer']]}, 'NCT02272556'), ({'text': 'Subject with any underlying cardiovascular condition, including unstable angina pectoris, which preclude sexual activity', 'entities': [['29', '53', 'chronic_disease'], ['65', '89', 'chronic_disease']]}, 'NCT02225548'), ({'text': 'Hepatorenal syndrome', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02826343'), ({'text': 'Lactating females must agree not to breast feed while taking ibrutinib', 'entities': [['11', '18', 'gender']]}, 'NCT02309580'), ({'text': 'individuals with positive HCV antibody and without detectable HCV RNA are permitted to enroll', 'entities': [['27', '30', 'chronic_disease']]}, 'NCT02016924'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT02068092'), ({'text': 'Blood dyscrasia or bleeding diathesis', 'entities': [['7', '16', 'chronic_disease'], ['20', '38', 'chronic_disease']]}, 'NCT02539160'), ({'text': 'Completely resected NSCLC with negative margins (R0)', 'entities': [['21', '26', 'cancer']]}, 'NCT02194738'), ({'text': 'history of chronic obstructive pulmonary disease, pleural effusion, and/or myocardial disease', 'entities': [['12', '49', 'chronic_disease'], ['51', '67', 'chronic_disease'], ['76', '94', 'chronic_disease']]}, 'NCT02829268'), ({'text': 'Sarcoma Patients must be 14 years of age or older', 'entities': [['1', '8', 'cancer'], ['26', '34', 'lower_bound'], ['38', '41', 'age']]}, 'NCT02423863'), ({'text': 'Karnofsky/Lansky status (depending on age) >= 70%', 'entities': [['1', '24', 'clinical_variable'], ['39', '42', 'age'], ['47', '50', 'lower_bound']]}, 'NCT02833805'), ({'text': '18-40yrs of age', 'entities': [['1', '3', 'lower_bound'], ['4', '9', 'upper_bound'], ['13', '16', 'age']]}, 'NCT02966444'), ({'text': 'are taking a digitalis preparation or calcium channel blocker', 'entities': [['14', '35', 'treatment'], ['39', '62', 'treatment']]}, 'NCT02933034'), ({'text': 'History of congenital adrenal hyperplasia or 17-hydroxyprogesterone > 300 ng/dL, which suggests the possibility of congenital adrenal hyperplasia', 'entities': [['12', '42', 'chronic_disease'], ['46', '68', 'clinical_variable'], ['71', '80', 'lower_bound']]}, 'NCT01422746'), ({'text': 'Uncontrolled glaucoma (topical medications allowed)', 'entities': [['14', '22', 'chronic_disease'], ['24', '43', 'treatment']]}, 'NCT02091999'), ({'text': 'Sweat Chloride > 30 mEq/L)', 'entities': [['1', '15', 'clinical_variable'], ['18', '26', 'lower_bound']]}, 'NCT03085485'), ({'text': 'History of significant developmental or learning disorder that may affect participation and confound interpretation of study results', 'entities': [['24', '58', 'chronic_disease']]}, 'NCT02106052'), ({'text': 'Life expectancy of greater than 6 months', 'entities': [['1', '16', 'clinical_variable'], ['33', '41', 'lower_bound']]}, 'NCT02993900'), ({'text': 'Medical contraindication to surgery', 'entities': [['29', '36', 'treatment']]}, 'NCT01835626'), ({'text': 'HbA1c = 7.5% to 12%', 'entities': [['1', '6', 'clinical_variable'], ['9', '13', 'lower_bound'], ['17', '20', 'upper_bound']]}, 'NCT02911792'), ({'text': 'significant systemic ventricular outflow obstruction', 'entities': [['22', '53', 'chronic_disease']]}, 'NCT02946892'), ({'text': 'minimal prior therapy', 'entities': [['9', '22', 'treatment']]}, 'NCT01371630'), ({'text': 'Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)])', 'entities': [['8', '23', 'chronic_disease'], ['87', '96', 'treatment'], ['226', '249', 'chronic_disease'], ['251', '285', 'chronic_disease']]}, 'NCT02728050'), ({'text': 'Tumor confirmed by arteriography', 'entities': [['1', '6', 'cancer']]}, 'NCT02379377'), ({'text': 'Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42 days must have elapsed since systemically administered radiopharmaceutical therapy', 'entities': [['1', '28', 'treatment'], ['36', '57', 'treatment'], ['59', '68', 'treatment'], ['74', '81', 'lower_bound'], ['132', '159', 'treatment']]}, 'NCT02304458'), ({'text': 'Gastrointestinal stromal tumor (GIST)', 'entities': [['1', '38', 'cancer']]}, 'NCT02533674'), ({'text': 'Decrease in insulin requirements greater than or equal to 40%', 'entities': [['13', '33', 'clinical_variable'], ['59', '62', 'lower_bound']]}, 'NCT02262806'), ({'text': 'Subjects with peritoneal disease who have failed prior standard chemotherapy and have histologic confirmation of epithelial ovarian cancer or metastatic colorectal cancer (CRC) including cancer originating from the appendix', 'entities': [['15', '33', 'cancer'], ['50', '77', 'treatment'], ['114', '139', 'cancer'], ['143', '177', 'cancer']]}, 'NCT02963831'), ({'text': 'All women must be pre-menopausal', 'entities': [['5', '10', 'gender']]}, 'NCT02717832'), ({'text': 'Ability to understand and the willingness to sign a written informed consent and Health Insurance Portability and Accountability Act (HIPPA) document', 'entities': [['12', '77', 'contraception_consent']]}, 'NCT01620216'), ({'text': 'Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 28 days prior to enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrollment', 'entities': [['5', '18', 'treatment'], ['30', '42', 'treatment'], ['44', '56', 'treatment'], ['44', '78', 'treatment'], ['80', '96', 'treatment'], ['101', '114', 'treatment'], ['122', '135', 'upper_bound'], ['236', '249', 'upper_bound']]}, 'NCT02070549'), ({'text': 'a known history of hypersensitivity to ferumoxytol', 'entities': [['40', '51', 'allergy_name']]}, 'NCT02857218'), ({'text': 'for women of childbearing potential only', 'entities': [['5', '10', 'gender']]}, 'NCT02320292'), ({'text': 'Liver transaminases greater than 3 times the upper limit of normal', 'entities': [['1', '20', 'clinical_variable'], ['34', '67', 'lower_bound']]}, 'NCT02335905'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT01720836'), ({'text': 'structural brain lesion', 'entities': [['12', '24', 'chronic_disease']]}, 'NCT03038269'), ({'text': 'Other active cancer', 'entities': [['14', '20', 'cancer']]}, 'NCT02219711'), ({'text': 'Reduced awareness of hypoglycemia manifested by a Clarke score of 4 or more measured upon study enrollment', 'entities': [['22', '34', 'chronic_disease'], ['51', '63', 'clinical_variable'], ['67', '68', 'lower_bound']]}, 'NCT02464878'), ({'text': 'Age 17 years or younger', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT02696603'), ({'text': 'Unevaluated abnormal vaginal bleeding or abnormal pap smear in the previous year', 'entities': [['13', '38', 'chronic_disease'], ['42', '60', 'chronic_disease']]}, 'NCT01648751'), ({'text': 'Life expectancy of e 3 months', 'entities': [['1', '16', 'clinical_variable'], ['22', '30', 'lower_bound']]}, 'NCT02454010'), ({'text': 'Uncontrolled diabetes mellitus or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment', 'entities': [['14', '31', 'chronic_disease'], ['150', '170', 'treatment']]}, 'NCT01445821'), ({'text': 'Women who are pregnant', 'entities': [['1', '6', 'gender'], ['11', '23', 'pregnancy']]}, 'NCT02493530'), ({'text': 'Prior GI surgery except for cholecystectomy, appendectomy, or Nissen fundoplication', 'entities': [['7', '17', 'treatment'], ['29', '44', 'treatment'], ['46', '58', 'treatment'], ['63', '84', 'treatment']]}, 'NCT02798458'), ({'text': 'Patients with acute infections (viral, bacterial, or fungal infections requiring therapy)', 'entities': [['15', '31', 'chronic_disease'], ['33', '38', 'chronic_disease'], ['40', '49', 'chronic_disease'], ['54', '71', 'chronic_disease'], ['82', '89', 'treatment']]}, 'NCT01913106'), ({'text': 'Patients for whom surgery would be deemed appropriate rather than radiotherapy', 'entities': [['19', '26', 'treatment'], ['67', '79', 'treatment']]}, 'NCT02581384'), ({'text': 'Corticosteroid use within 2 weeks of study treatment', 'entities': [['1', '15', 'treatment'], ['27', '34', 'upper_bound']]}, 'NCT02454010'), ({'text': 'The interval between IV/oral steroids administration and first dose of OBI-833/OBI-821 must be more than pharmacological duration or 5 half-lives of administered steroids, whichever is longer', 'entities': [['22', '38', 'treatment'], ['30', '38', 'treatment'], ['72', '79', 'treatment'], ['80', '87', 'treatment'], ['134', '146', 'lower_bound']]}, 'NCT02310464'), ({'text': "Hepatic: ALT/AST </= 2.5 x ULN or </= 5 x ULN if documented liver metastases, Total bilirubin </= 1.5 mg/dL, except in subjects with Gilbert's Syndrome in whom total bilirubin must be </= 3.0 mg/dL", 'entities': [['10', '13', 'clinical_variable'], ['14', '17', 'clinical_variable'], ['22', '31', 'upper_bound'], ['24', '31', 'upper_bound'], ['61', '77', 'cancer'], ['85', '94', 'clinical_variable'], ['99', '108', 'upper_bound'], ['134', '152', 'chronic_disease'], ['189', '198', 'upper_bound']]}, 'NCT03056339'), ({'text': 'Prior treatment for GBM (other than surgical resection)', 'entities': [['21', '24', 'cancer'], ['37', '55', 'treatment']]}, 'NCT02617589'), ({'text': 'Multifocal disease, lymph node or distant metastases', 'entities': [['1', '19', 'cancer'], ['21', '31', 'cancer'], ['35', '53', 'cancer']]}, 'NCT01659203'), ({'text': 'Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug', 'entities': [['8', '18', 'chronic_disease'], ['20', '36', 'clinical_variable'], ['49', '61', 'lower_bound'], ['70', '83', 'upper_bound'], ['105', '115', 'treatment']]}, 'NCT02501096'), ({'text': 'Documented typical symptoms of GERD for longer than 6 months', 'entities': [['32', '36', 'chronic_disease'], ['53', '61', 'lower_bound']]}, 'NCT02429830'), ({'text': 'BMI < 40 kg/m2', 'entities': [['1', '4', 'bmi'], ['7', '15', 'upper_bound']]}, 'NCT02209636'), ({'text': 'Subject eyes will lack other preexisting ocular pathology or condition that may confound treatment effects, including diabetic retinopathy, previous retinal detachment, iris neovascularization, amblyopia, optic nerve atrophy or recurrent severe anterior or posterior segment inflammation of unknown etiology', 'entities': [['91', '100', 'treatment'], ['120', '140', 'chronic_disease'], ['151', '169', 'chronic_disease'], ['171', '194', 'chronic_disease'], ['196', '205', 'chronic_disease'], ['207', '226', 'chronic_disease']]}, 'NCT02561104'), ({'text': 'No prior treatment with any targeted agent', 'entities': [['4', '43', 'treatment']]}, 'NCT02213289'), ({'text': 'Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses', 'entities': [['8', '27', 'chronic_disease'], ['38', '62', 'treatment'], ['64', '85', 'chronic_disease'], ['130', '147', 'chronic_disease']]}, 'NCT01174121'), ({'text': 'mitral regurgitation secondary to left ventricular dysfunction', 'entities': [['1', '21', 'chronic_disease'], ['35', '63', 'chronic_disease']]}, 'NCT03136029'), ({'text': 'Musculoskeletal conditions which preclude participation in an exercise training program', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT02991677'), ({'text': 'Patients with known active central nervous system (CNS) disease', 'entities': [['28', '64', 'chronic_disease']]}, 'NCT02530034'), ({'text': 'Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions', 'entities': [['14', '22', 'chronic_disease'], ['48', '61', 'chronic_disease']]}, 'NCT03056287'), ({'text': 'Any eye condition, disease, or history of trauma in either eye, which can impair vision, except cataract or cataract surgery', 'entities': [['5', '18', 'chronic_disease'], ['43', '63', 'chronic_disease'], ['109', '125', 'treatment']]}, 'NCT03023059'), ({'text': 'smoke 10+ cigarettes/day for past 6 months', 'entities': [['7', '10', 'lower_bound'], ['30', '43', 'upper_bound']]}, 'NCT01989507'), ({'text': 'Patients who are positive for human immunodeficiency virus (HIV)', 'entities': [['31', '65', 'chronic_disease']]}, 'NCT00919503'), ({'text': 'Cytogenetic abnormalities known to be associated with hematopoietic defect on peripheral blood or bone marrow', 'entities': [['1', '26', 'chronic_disease'], ['55', '75', 'chronic_disease']]}, 'NCT02234934'), ({'text': 'Completely resected non-small cell lung cancer with negative margins (R0)', 'entities': [['21', '47', 'cancer']]}, 'NCT02194738'), ({'text': 'Patients with a neutropenic episode during the first cycle of chemotherapy or at high risk for a neutropenic episode during future chemotherapy cycles at the treating physicians discretion', 'entities': [['63', '75', 'treatment']]}, 'NCT01238120'), ({'text': 'Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen are eligible for this study', 'entities': [['26', '50', 'chronic_disease'], ['71', '78', 'treatment']]}, 'NCT02451423'), ({'text': 'Prior prostatectomy or cryotherapy of the prostate', 'entities': [['1', '20', 'treatment'], ['24', '51', 'treatment']]}, 'NCT02334579'), ({'text': 'Patients who are receiving adjuvant chemoradiation after surgical resection of the primary site of disease', 'entities': [['28', '51', 'treatment'], ['58', '76', 'treatment']]}, 'NCT02567422'), ({'text': 'Inability to speak and understand either English or Spanish', 'entities': [['1', '60', 'language_fluency']]}, 'NCT02752165'), ({'text': 'Patients with prior exposure to rTMS', 'entities': [['33', '37', 'treatment']]}, 'NCT03037983'), ({'text': 'Positive urine pregnancy test for female subjects of childbearing potential', 'entities': [['1', '25', 'pregnancy'], ['35', '50', 'gender']]}, 'NCT02527265'), ({'text': 'Performance status (ECOG) between 0-3', 'entities': [['1', '26', 'clinical_variable'], ['35', '36', 'lower_bound'], ['37', '38', 'upper_bound']]}, 'NCT02424955'), ({'text': 'New York Heart Association Classification III or IV heart disease', 'entities': [['1', '42', 'clinical_variable'], ['43', '46', 'lower_bound'], ['50', '52', 'upper_bound'], ['53', '66', 'chronic_disease']]}, 'NCT02106598'), ({'text': 'Must be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy', 'entities': [['23', '32', 'treatment'], ['40', '48', 'upper_bound'], ['52', '59', 'treatment'], ['63', '70', 'lower_bound'], ['90', '102', 'treatment']]}, 'NCT01766297'), ({'text': 'undergoing additional orthopedic procedures at time of epiphysiodesis', 'entities': [['23', '44', 'treatment'], ['56', '70', 'treatment']]}, 'NCT02260856'), ({'text': 'HIV positive', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT01140087'), ({'text': 'Individuals < 20 years old', 'entities': [['15', '23', 'upper_bound']]}, 'NCT03040804'), ({'text': 'History of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell)', 'entities': [['12', '30', 'cancer'], ['42', '54', 'upper_bound'], ['86', '105', 'cancer'], ['107', '112', 'cancer'], ['116', '129', 'cancer']]}, 'NCT02347891'), ({'text': 'Ingested medication (e.g. systemic corticosteroids) within 48 hours preceding the draw that the researchers believe may have an effect on immune response or the immune system', 'entities': [['1', '20', 'treatment'], ['27', '51', 'treatment'], ['60', '78', 'upper_bound']]}, 'NCT02411318'), ({'text': 'shockwave lithotripsy [SWL]', 'entities': [['1', '28', 'treatment']]}, 'NCT02944825'), ({'text': 'Adequate renal function with creatinine d 2.0 mg/dL', 'entities': [['30', '40', 'clinical_variable'], ['43', '52', 'upper_bound']]}, 'NCT02109627'), ({'text': 'Body weight greater than 300 pounds', 'entities': [['1', '12', 'clinical_variable'], ['26', '36', 'lower_bound']]}, 'NCT02095808'), ({'text': 'should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately', 'entities': [['10', '15', 'gender'], ['16', '31', 'pregnancy'], ['23', '31', 'pregnancy']]}, 'NCT01959698'), ({'text': 'Positive hepatitis B, hepatitis C, HIV or tuberculosis test results at screening', 'entities': [['10', '21', 'chronic_disease'], ['23', '34', 'chronic_disease'], ['36', '39', 'chronic_disease'], ['43', '55', 'chronic_disease']]}, 'NCT02962895'), ({'text': 'Concomitant medications', 'entities': [['1', '24', 'treatment']]}, 'NCT02354547'), ({'text': 'Concurrent anti-retroviral therapy that would inactivate the investigational agent', 'entities': [['12', '35', 'treatment']]}, 'NCT01505062'), ({'text': 'Conditions which would increase risk of lactic acidosis', 'entities': [['41', '56', 'chronic_disease']]}, 'NCT01750567'), ({'text': 'patient have a clinical symptoms of Carpal Tunnel Syndrome (CTS)', 'entities': [['37', '65', 'chronic_disease']]}, 'NCT02219555'), ({'text': 'Exposure to chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier', 'entities': [['13', '25', 'treatment'], ['29', '41', 'treatment'], ['58', '65', 'lower_bound'], ['70', '81', 'treatment'], ['85', '96', 'treatment']]}, 'NCT01947140'), ({'text': 'Intended initial treatment to include e2 cycles of R-CHOP, R-EPOCH or R-CEPP using standard doses and schedule.(68, 69) R-CHOP chemoimmunotherapy may be given every 14 days or every 21 days', 'entities': [['18', '27', 'treatment'], ['52', '58', 'treatment'], ['60', '67', 'treatment'], ['71', '77', 'treatment'], ['128', '146', 'treatment']]}, 'NCT01829958'), ({'text': 'Adults (male and female)', 'entities': [['9', '24', 'gender']]}, 'NCT02422641'), ({'text': 'No active tobacco use (>10 years tobacco free interval, <20pk/yr. history)', 'entities': [['25', '33', 'lower_bound'], ['58', '65', 'upper_bound']]}, 'NCT02072148'), ({'text': 'Hgb A1C e7', 'entities': [['1', '8', 'clinical_variable'], ['10', '11', 'lower_bound']]}, 'NCT02433977'), ({'text': 'Patients who are known to be human immunodeficiency virus (HIV)-seropositive', 'entities': [['30', '64', 'chronic_disease']]}, 'NCT01823198'), ({'text': 'Recent cardiac revascularization (PTCA, Stent or CABG) in the 4 weeks prior to enrollment or planned for the 3 months following', 'entities': [['8', '33', 'treatment'], ['35', '39', 'treatment'], ['41', '46', 'treatment'], ['50', '54', 'treatment'], ['63', '76', 'upper_bound'], ['110', '118', 'upper_bound']]}, 'NCT02006069'), ({'text': 'Serum sodium > 125 mmol/L', 'entities': [['1', '13', 'clinical_variable'], ['16', '26', 'lower_bound']]}, 'NCT02546583'), ({'text': 'Best-corrected visual acuity of 73 to 24 letters', 'entities': [['16', '29', 'clinical_variable'], ['33', '35', 'lower_bound'], ['39', '49', 'upper_bound']]}, 'NCT02403128'), ({'text': 'Known history of HIV or clinical manifestations of AIDS', 'entities': [['18', '21', 'chronic_disease'], ['52', '56', 'chronic_disease']]}, 'NCT02401035'), ({'text': 'less than 4 weeks old at diagnosis', 'entities': [['11', '18', 'upper_bound']]}, 'NCT02564796'), ({'text': 'Creatinine d 1.5 x ULN, or creatinine clearance e 50 mL/min (estimated by Cockcroft-Gault or measured)', 'entities': [['1', '11', 'clinical_variable'], ['14', '23', 'upper_bound'], ['28', '48', 'clinical_variable'], ['51', '60', 'lower_bound']]}, 'NCT02178709'), ({'text': 'Have fetal ultrasound within 6 weeks prior to enrollment confirming a normal-appearing, intrauterine, singleton pregnancy of gestational age < 16 weeks at time of enrollment', 'entities': [['30', '43', 'upper_bound'], ['113', '122', 'pregnancy'], ['126', '141', 'clinical_variable'], ['144', '152', 'upper_bound']]}, 'NCT02163434'), ({'text': 'Patients with a history of anaphylactic allergy to eggs or egg products, manifested by one or more of the following symptoms: generalized urticaria, difficulty in breathing, swelling of the mouth and throat, hypotension, or shock. (Subjects with nonanaphylactic allergies to eggs or egg products may be enrolled in the study, but must be watched carefully for 1 h following the administration of SONAZOID)', 'entities': [['28', '48', 'chronic_disease'], ['52', '56', 'allergy_name'], ['60', '72', 'allergy_name'], ['247', '272', 'chronic_disease']]}, 'NCT02489045'), ({'text': 'Prior history of head and neck cancer', 'entities': [['18', '38', 'cancer']]}, 'NCT03077243'), ({'text': 'are receiving no treatment', 'entities': [['18', '27', 'treatment']]}, 'NCT01280669'), ({'text': 'Willingness to donate blood for biomarker studies related to the type of therapies used in this trial and the tumor types being treated', 'entities': [['111', '116', 'cancer']]}, 'NCT02355535'), ({'text': 'The transplant must have been performed >= 90 days prior to registration', 'entities': [['44', '57', 'lower_bound']]}, 'NCT01925131'), ({'text': 'Eastern Collaborative Oncology Group (ECOG) Performance Status of 0-1 (Appendix 1)', 'entities': [['1', '63', 'clinical_variable'], ['67', '68', 'lower_bound'], ['69', '70', 'upper_bound']]}, 'NCT02266745'), ({'text': 'for >= 1 year and be greater than 45 years of age', 'entities': [['8', '14', 'lower_bound'], ['35', '43', 'lower_bound'], ['47', '50', 'age']]}, 'NCT01532687'), ({'text': 'Known history of drug or alcohol addiction (prior or present addiction or addiction treatment)', 'entities': [['75', '94', 'treatment']]}, 'NCT01576575'), ({'text': 'between 18 to 60 years of age, inclusive', 'entities': [['9', '11', 'lower_bound'], ['15', '23', 'upper_bound'], ['27', '30', 'age']]}, 'NCT02466685'), ({'text': 'Karnofsky performance status (KPS) of >= 70%', 'entities': [['1', '35', 'clinical_variable'], ['42', '45', 'lower_bound']]}, 'NCT02146924'), ({'text': 'Cancer within 5 years (except for completely excised cervical carcinoma in situ or excised non-melanoma skin cancer)', 'entities': [['1', '7', 'cancer'], ['15', '22', 'upper_bound'], ['54', '80', 'cancer'], ['92', '116', 'cancer']]}, 'NCT02270970'), ({'text': 'History of prolonged QTc interval (>500 ms)', 'entities': [['12', '34', 'clinical_variable'], ['37', '43', 'lower_bound']]}, 'NCT03021486'), ({'text': 'benign non-enhancing periportal lymphadenopathy is not unusual in the presence of hepatitis and is permitted, even if the sum of enlarged nodes is > 2.0 cm', 'entities': [['33', '48', 'cancer'], ['83', '92', 'chronic_disease'], ['123', '144', 'clinical_variable'], ['150', '156', 'lower_bound']]}, 'NCT01730937'), ({'text': 'Known history of Human Immunodeficiency Virus (HIV (HIV1/2 antibodies)', 'entities': [['18', '51', 'chronic_disease']]}, 'NCT02587962'), ({'text': 'Patient must have a history and physical within 2 weeks prior to the start of any protocol therapy', 'entities': [['49', '62', 'upper_bound'], ['83', '99', 'treatment']]}, 'NCT01618357'), ({'text': 'Self- reported CPP defined as pelvic pain that is non-cyclical and of at least 6 months duration and refractory to other treatments', 'entities': [['80', '88', 'lower_bound']]}, 'NCT02781103'), ({'text': 'the recent receipt (within 3 months) of erythropoietin stimulating agent, IV iron therapy, or blood transfusion', 'entities': [['28', '36', 'upper_bound'], ['41', '73', 'treatment'], ['75', '90', 'treatment'], ['95', '112', 'treatment']]}, 'NCT03037931'), ({'text': 'history of pulmonary embolism', 'entities': [['12', '30', 'chronic_disease']]}, 'NCT02664909'), ({'text': 'myelodysplastic syndrome that have failed hypomethylating agents', 'entities': [['1', '25', 'cancer']]}, 'NCT03042689'), ({'text': 'Subjects who have received prior radiotherapy to any portion of the abdominal cavity or pelvis', 'entities': [['34', '46', 'treatment']]}, 'NCT02672098'), ({'text': "Total bilirubin =< 1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome (< 5 if liver involvement with primary tumor)", 'entities': [['1', '16', 'clinical_variable'], ['20', '53', 'upper_bound'], ['22', '23', 'upper_bound'], ['69', '87', 'chronic_disease'], ['127', '132', 'cancer']]}, 'NCT02272998'), ({'text': 'ACR in the previous 6 months', 'entities': [['1', '4', 'clinical_variable'], ['12', '29', 'upper_bound']]}, 'NCT02327403'), ({'text': 'steroid inhaler', 'entities': [['1', '16', 'treatment']]}, 'NCT02152956'), ({'text': 'Maintenance therapy does not count as a separate line of therapy', 'entities': [['1', '20', 'treatment'], ['13', '20', 'treatment']]}, 'NCT02350764'), ({'text': 'e18 years', 'entities': [['2', '10', 'lower_bound']]}, 'NCT02498535'), ({'text': 'Dry weight of <15 kg', 'entities': [['1', '11', 'clinical_variable'], ['16', '21', 'upper_bound']]}, 'NCT02820350'), ({'text': '30 to 80 years of age', 'entities': [['1', '3', 'lower_bound'], ['7', '15', 'upper_bound'], ['19', '22', 'age']]}, 'NCT02131389'), ({'text': 'Foster youth ages 11-15 years', 'entities': [['14', '18', 'age'], ['19', '21', 'lower_bound'], ['22', '30', 'upper_bound']]}, 'NCT03157895'), ({'text': 'coronary artery revascularization', 'entities': [['1', '34', 'treatment']]}, 'NCT02911792'), ({'text': 'Subject has esophageal', 'entities': [['13', '23', 'cancer']]}, 'NCT02429830'), ({'text': 'BMI of 26-39 kg/m2 at the time of diagnosis', 'entities': [['1', '4', 'bmi'], ['8', '10', 'lower_bound'], ['11', '19', 'upper_bound']]}, 'NCT02244814'), ({'text': 'Known positive for human immunodeficiency virus (HIV) or with known active infectious hepatitis, type A, B or C', 'entities': [['20', '54', 'chronic_disease'], ['69', '112', 'chronic_disease']]}, 'NCT01787487'), ({'text': 'Sub-foveal lesion hemorrhage obscuring >50% of lesion', 'entities': [['1', '39', 'clinical_variable'], ['41', '44', 'lower_bound']]}, 'NCT02988895'), ({'text': 'Prothrombin time (PT) or international normalized ratio (INR) =< 1.2 x upper limit of normal (ULN)', 'entities': [['1', '22', 'clinical_variable'], ['26', '62', 'clinical_variable'], ['66', '99', 'upper_bound']]}, 'NCT01532687'), ({'text': 'Thrombocytopenia (<50)', 'entities': [['1', '17', 'clinical_variable'], ['20', '22', 'upper_bound']]}, 'NCT02798458'), ({'text': 'HIV-positive', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT01804634'), ({'text': 'Pregnant females', 'entities': [['1', '9', 'pregnancy'], ['10', '17', 'gender']]}, 'NCT02451683'), ({'text': 'Known sensitivity to any of the ingredients of the investigational product enfortumab vedotin (ASG-22CE)', 'entities': [['76', '105', 'allergy_name']]}, 'NCT02091999'), ({'text': 'Lung disease, such as emphysema, chronic bronchitis, asthma that is not well-controlled, or bullous lung disease that raises the risk for pulmonary barotrauma due to air trapping', 'entities': [['1', '13', 'chronic_disease'], ['23', '32', 'chronic_disease'], ['34', '52', 'chronic_disease'], ['54', '60', 'chronic_disease'], ['93', '113', 'chronic_disease'], ['139', '159', 'chronic_disease']]}, 'NCT01986205'), ({'text': 'Zubrod Performance Status 0-2', 'entities': [['1', '26', 'clinical_variable'], ['27', '28', 'lower_bound'], ['29', '30', 'upper_bound']]}, 'NCT01835626'), ({'text': 'Available autologous transduced cytotoxic T lymphocytes with greater than or equal to 20% expression of GD2 CAR', 'entities': [['11', '56', 'clinical_variable'], ['87', '90', 'lower_bound']]}, 'NCT01953900'), ({'text': 'Adult lung transplant recipients e 18 years of age who meet the diagnostic criteria for AMR and who have underwent PFT testing unless intubated and transbronchial biopsy prior to enrollment', 'entities': [['7', '22', 'treatment'], ['36', '44', 'lower_bound'], ['48', '51', 'age'], ['149', '170', 'treatment']]}, 'NCT02474927'), ({'text': 'Corrected visual acuity worse than 20/50', 'entities': [['1', '24', 'clinical_variable'], ['36', '41', 'lower_bound']]}, 'NCT03004807'), ({'text': 'current alcohol, benzodiazepine, barbiturate use with physiologic dependence as determined during screening history and physical', 'entities': [['18', '32', 'treatment'], ['34', '45', 'treatment']]}, 'NCT02187198'), ({'text': 'Adverse cytogenetics: -5, deletion (del) 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 or complex karyotype (> 3 abnormalities)', 'entities': [['81', '82', 'lower_bound'], ['114', '131', 'clinical_variable']]}, 'NCT01823198'), ({'text': 'Baseline neuropathy >grade 1', 'entities': [['1', '20', 'clinical_variable'], ['22', '29', 'lower_bound']]}, 'NCT01976169'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02989662'), ({'text': 'Self-report HIV-negative or unknown status', 'entities': [['13', '16', 'chronic_disease']]}, 'NCT03167606'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02622295'), ({'text': 'Seizure disorder', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT03016351'), ({'text': 'Cognitive impairment', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02317523'), ({'text': 'Contraindications to SPECT/CT, pregnancy, breastfeeding, chronic renal disease (eGFR < 60 ml/min/1.73m2), proteinuria, genetic diseases of the kidney, inborn defects of lipid metabolism, alcohol abuse, liver disease (patients with highly elevated total bilirubin, elevated liver enzymes AST, ALT and alkaline phosphatase and those with an established liver disease), anemia, and pharmacological treatment with insulin or insulin-sensitizing drugs such as thiazolidinediones (TZD)', 'entities': [['22', '27', 'treatment'], ['25', '27', 'treatment'], ['32', '41', 'pregnancy'], ['58', '79', 'chronic_disease'], ['81', '85', 'clinical_variable'], ['88', '104', 'upper_bound'], ['107', '118', 'treatment'], ['120', '150', 'treatment'], ['170', '186', 'chronic_disease'], ['203', '216', 'chronic_disease'], ['248', '263', 'clinical_variable'], ['288', '291', 'clinical_variable'], ['293', '296', 'clinical_variable'], ['301', '321', 'clinical_variable'], ['368', '374', 'chronic_disease'], ['380', '447', 'treatment'], ['456', '480', 'treatment']]}, 'NCT02975986'), ({'text': 'Inaccessibility of the acardiac twin due to a retroverted uterus, severe maternal obesity, uterine fibroids, bowel or placental superposition', 'entities': [['67', '90', 'chronic_disease'], ['92', '108', 'chronic_disease'], ['110', '142', 'chronic_disease']]}, 'NCT02621645'), ({'text': 'At least 4 weeks must have elapsed since completion of antibody-directed therapy', 'entities': [['10', '17', 'lower_bound'], ['56', '81', 'treatment']]}, 'NCT02568267'), ({'text': 'Cardiac disorders: cardiomyopathy, angina, CAD', 'entities': [['1', '18', 'chronic_disease'], ['20', '34', 'chronic_disease'], ['36', '42', 'chronic_disease'], ['44', '47', 'chronic_disease']]}, 'NCT02299414'), ({'text': 'Severe known renal impairment defined as requiring dialysis (hemo- or peritoneal) or if known a creatinine clearance < 29 mL/min', 'entities': [['1', '30', 'chronic_disease'], ['52', '60', 'treatment'], ['62', '66', 'treatment'], ['71', '81', 'treatment'], ['97', '117', 'clinical_variable'], ['120', '129', 'upper_bound']]}, 'NCT02930018'), ({'text': 'Patients must have histologically confirmed malignancy (including non-squamous cell histologies and unknown primary tumors)', 'entities': [['45', '55', 'cancer'], ['67', '84', 'cancer'], ['109', '123', 'cancer']]}, 'NCT02727062'), ({'text': 'having the ability to read and write in English', 'entities': [['23', '48', 'language_fluency']]}, 'NCT01087346'), ({'text': 'd470 msec for females required on screening ECG', 'entities': [['2', '10', 'upper_bound'], ['15', '22', 'clinical_variable'], ['45', '48', 'treatment']]}, 'NCT02585973'), ({'text': 'have a GOG Performance Status of 0, 1, or 2', 'entities': [['8', '30', 'clinical_variable'], ['34', '35', 'lower_bound'], ['43', '44', 'upper_bound']]}, 'NCT01925378'), ({'text': 'Albumin >= 3 g/dL', 'entities': [['1', '8', 'clinical_variable'], ['12', '18', 'lower_bound']]}, 'NCT02419495'), ({'text': 'Be male OIF/OEF veteran or active duty', 'entities': [['4', '8', 'gender']]}, 'NCT02308202'), ({'text': 'Patients must be recovered from the acute toxicities of any prior chemo/radio/immunotherapy or BMT', 'entities': [['61', '72', 'treatment'], ['73', '78', 'treatment'], ['79', '92', 'treatment'], ['96', '99', 'treatment']]}, 'NCT01804634'), ({'text': 'Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical examination, EKG, and/or laboratory screening test', 'entities': [['207', '210', 'treatment'], ['219', '244', 'treatment']]}, 'NCT02204098'), ({'text': 'Age 18-65', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT01865162'), ({'text': 'Surgery for primary or metastatic disease after chemotherapy following a response is allowed', 'entities': [['1', '8', 'treatment'], ['24', '42', 'cancer'], ['49', '61', 'treatment']]}, 'NCT02584309'), ({'text': "Mature B ALL (Burkitt's-like leukemia)", 'entities': [['8', '39', 'cancer']]}, 'NCT02003222'), ({'text': 'Age less than 8 years', 'entities': [['1', '4', 'age'], ['15', '22', 'upper_bound']]}, 'NCT02646787'), ({'text': 'fasting glucose e 126 mg/dl', 'entities': [['1', '16', 'clinical_variable'], ['19', '28', 'lower_bound']]}, 'NCT00930228'), ({'text': 'Men and women of childbearing potential must be willing to practice an effective method of birth control during treatment and at least 4 months after treatment is finished', 'entities': [['1', '14', 'gender'], ['49', '105', 'contraception_consent'], ['113', '122', 'treatment'], ['136', '144', 'lower_bound']]}, 'NCT01920737'), ({'text': 'Resistant organisms not sensitive to available IV antibiotics, oral antibiotics, or heat stable antibiotic additives to bone cement with documented elution characteristics', 'entities': [['48', '62', 'treatment'], ['64', '80', 'treatment'], ['85', '117', 'treatment']]}, 'NCT02734134'), ({'text': 'not on immunosuppression for prevention of graft-versus-host disease', 'entities': [['44', '69', 'chronic_disease']]}, 'NCT02309580'), ({'text': 'The test must have a sensitivity of at least 50 mIU/mL', 'entities': [['46', '55', 'lower_bound']]}, 'NCT03143985'), ({'text': 'Retinitis Pigmentosa', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02841540'), ({'text': 'Severe atheromatosis vascular disease that precludes arterial cannulization', 'entities': [['8', '38', 'chronic_disease'], ['54', '76', 'treatment']]}, 'NCT01648023'), ({'text': 'Stem cell infusion without TBI: No evidence of active graft vs. host disease and at least 56 days must have elapsed after transplant or stem cell infusion', 'entities': [['1', '19', 'treatment'], ['28', '31', 'chronic_disease'], ['55', '77', 'chronic_disease'], ['91', '98', 'lower_bound'], ['123', '133', 'treatment'], ['137', '155', 'treatment']]}, 'NCT02323880'), ({'text': 'with documented diagnosis of late onset (defined as first manifestation of signs and symptoms at e1 month of age) OTC deficiency, confirmed via enzymatic, biochemical, or molecular testing', 'entities': [['99', '106', 'lower_bound'], ['110', '113', 'age'], ['115', '129', 'chronic_disease'], ['145', '154', 'treatment'], ['156', '167', 'treatment'], ['172', '189', 'treatment']]}, 'NCT02991144'), ({'text': 'Female creatinine clearance = (140 - age in years) x (weight in Kg) x 0.85 / (serum Cr in mg/dl x 72) (use of creatinine clearance per protocol based on chemotherapy regimen) Hepatic function, as follows: (d 14 days prior to treatment start)', 'entities': [['1', '7', 'gender'], ['8', '28', 'clinical_variable'], ['38', '41', 'age'], ['55', '61', 'clinical_variable'], ['79', '87', 'clinical_variable'], ['154', '166', 'treatment'], ['209', '222', 'upper_bound'], ['226', '235', 'treatment']]}, 'NCT01312857'), ({'text': 'Serum phosphorus >= lower limit of normal (LLN) (within 1 week of study entry)', 'entities': [['1', '17', 'clinical_variable'], ['21', '48', 'clinical_variable'], ['57', '63', 'upper_bound']]}, 'NCT01822522'), ({'text': 'Patients with a CRP greater than 100 mg/L within 30 days of anticipated transplant', 'entities': [['17', '20', 'clinical_variable'], ['34', '42', 'lower_bound'], ['50', '57', 'upper_bound']]}, 'NCT02629120'), ({'text': 'Diagnosis of immunodeficiency or active autoimmune condition', 'entities': [['14', '30', 'chronic_disease'], ['41', '61', 'chronic_disease']]}, 'NCT03129061'), ({'text': 'Absolute neutrophil count (ANC) e1.25 x 109/L', 'entities': [['1', '32', 'clinical_variable'], ['34', '46', 'lower_bound']]}, 'NCT01990209'), ({'text': 'ECOG performance status d2 (Karnofsky e60%, Lansky e60%', 'entities': [['1', '24', 'clinical_variable'], ['26', '27', 'upper_bound'], ['29', '38', 'clinical_variable'], ['40', '43', 'lower_bound'], ['45', '51', 'clinical_variable']]}, 'NCT02112617'), ({'text': 'Lifetime history of Bipolar Disorder', 'entities': [['21', '37', 'chronic_disease']]}, 'NCT02316574'), ({'text': 'Poor kidney and liver functions', 'entities': [['1', '32', 'chronic_disease']]}, 'NCT02187848'), ({'text': 'history of other malignancies', 'entities': [['18', '30', 'cancer']]}, 'NCT02176161'), ({'text': 'total or direct bilirubin d 1.5mg/dL; SGPT (ALT) d 3xULN', 'entities': [['1', '26', 'clinical_variable'], ['29', '37', 'upper_bound'], ['39', '49', 'clinical_variable'], ['52', '57', 'upper_bound']]}, 'NCT02583893'), ({'text': 'Platelet count >= 50,000/mm^3; note: platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment', 'entities': [['1', '15', 'clinical_variable'], ['19', '30', 'lower_bound'], ['126', '139', 'upper_bound']]}, 'NCT02542657'), ({'text': 'Hip fracture requiring surgical intervention', 'entities': [['24', '45', 'treatment']]}, 'NCT03063892'), ({'text': 'The total area of GA lesions combined should be less than 7.0 MPS disc areas (DA) (17.78 mm(2)) as evident on FAF imaging', 'entities': [['5', '29', 'clinical_variable'], ['59', '96', 'upper_bound'], ['111', '122', 'treatment']]}, 'NCT02564978'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02143050'), ({'text': 'Patients with a history of basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix', 'entities': [['28', '60', 'cancer'], ['77', '100', 'cancer']]}, 'NCT02152254'), ({'text': 'Patients with chronic liver and kidney disease', 'entities': [['15', '28', 'chronic_disease'], ['33', '47', 'chronic_disease']]}, 'NCT01917721'), ({'text': 'Complete or partial response by IWG Working Group or ICML Criteria to maximum of one salvage line of chemotherapy without pre-HDT/ASCT salvage radiotherapy', 'entities': [['102', '114', 'treatment'], ['136', '156', 'treatment']]}, 'NCT02570542'), ({'text': 'male or female', 'entities': [['1', '5', 'gender'], ['9', '15', 'gender']]}, 'NCT02169037'), ({'text': 'e 18 years of age', 'entities': [['3', '11', 'lower_bound'], ['15', '18', 'age']]}, 'NCT02476409'), ({'text': 'Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 10 - 14 days prior to and again within 24 hours prior to starting REVLIMID®', 'entities': [['1', '8', 'gender'], ['54', '87', 'pregnancy'], ['100', '102', 'lower_bound'], ['105', '112', 'upper_bound'], ['139', '153', 'upper_bound'], ['166', '175', 'treatment']]}, 'NCT03113695'), ({'text': 'Acquired immune deficiency syndrome (AIDS) or AIDS-related complex', 'entities': [['1', '43', 'treatment'], ['47', '67', 'chronic_disease']]}, 'NCT01597518'), ({'text': 'Prior Aural Rehabilitation with cochlear implant', 'entities': [['7', '27', 'treatment'], ['33', '49', 'treatment']]}, 'NCT03157492'), ({'text': 'tamponade', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT02816736'), ({'text': 'Pre-operative hemoglobin >8 g/dl', 'entities': [['1', '25', 'clinical_variable'], ['27', '33', 'lower_bound']]}, 'NCT02911831'), ({'text': 'Must not have had history of breast cancer', 'entities': [['30', '43', 'cancer']]}, 'NCT02924441'), ({'text': 'Serum creatinine d 2 x the upper limit of normal within 4 weeks of registration', 'entities': [['1', '17', 'clinical_variable'], ['20', '49', 'upper_bound'], ['57', '64', 'upper_bound']]}, 'NCT01684904'), ({'text': 'ages 18+', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound']]}, 'NCT02714140'), ({'text': 'Age greater than or equal to 15 years and less than or equal to 70 years', 'entities': [['1', '4', 'age'], ['30', '38', 'lower_bound'], ['65', '73', 'upper_bound']]}, 'NCT01967823'), ({'text': 'Age 18 years or older', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT02557321'), ({'text': 'whole blood HCT<33', 'entities': [['1', '16', 'clinical_variable'], ['17', '19', 'upper_bound']]}, 'NCT03073070'), ({'text': '6 weeks from a nitrosourea chemotherapy', 'entities': [['16', '40', 'treatment']]}, 'NCT01865162'), ({'text': 'over 250 lbs body weight', 'entities': [['6', '13', 'lower_bound'], ['14', '25', 'clinical_variable']]}, 'NCT02355912'), ({'text': 'Total bilirubin d 1.25 x ULN', 'entities': [['1', '16', 'clinical_variable'], ['19', '29', 'upper_bound']]}, 'NCT02080221'), ({'text': 'Lesions of 5cm or less in maximum diameter', 'entities': [['1', '8', 'clinical_variable'], ['12', '15', 'upper_bound']]}, 'NCT01494324'), ({'text': 'Poorly controlled hypertension, diabetes mellitus, active or uncontrolled hepatitis', 'entities': [['19', '31', 'chronic_disease'], ['33', '50', 'chronic_disease'], ['75', '84', 'chronic_disease']]}, 'NCT03004287'), ({'text': 'Serum Creatinine less than or equal to 1.6 mg/dl', 'entities': [['7', '17', 'clinical_variable'], ['40', '49', 'upper_bound']]}, 'NCT01993719'), ({'text': 'biopsy proven metastatic disease', 'entities': [['15', '33', 'chronic_disease']]}, 'NCT02286843'), ({'text': 'Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or CT scan of the brain with contrast within 60 days prior to registration', 'entities': [['1', '38', 'treatment'], ['81', '101', 'treatment'], ['123', '136', 'upper_bound']]}, 'NCT01993810'), ({'text': 'Patient may have previously had azacitidine or decitabine will be eligible to enroll on Arm A (MDS)', 'entities': [['33', '44', 'treatment'], ['48', '58', 'treatment'], ['96', '99', 'chronic_disease']]}, 'NCT01869114'), ({'text': 'Normal subjects or patients with OSA', 'entities': [['34', '37', 'chronic_disease']]}, 'NCT01738009'), ({'text': 'Evidence of donor engraftment as defined by institutional standard T cell chimerism > 50%', 'entities': [['13', '30', 'treatment'], ['68', '84', 'clinical_variable'], ['87', '90', 'lower_bound']]}, 'NCT02400255'), ({'text': 'Serum phosphorus, calcium, magnesium and potassium e LLN', 'entities': [['1', '17', 'clinical_variable'], ['19', '26', 'clinical_variable'], ['28', '37', 'clinical_variable'], ['42', '51', 'clinical_variable']]}, 'NCT02132598'), ({'text': 'has been hospitalized or treated for suicidal behavior in the past 5 years', 'entities': [['38', '55', 'chronic_disease'], ['63', '75', 'upper_bound']]}, 'NCT03036280'), ({'text': 'M-stage determined by physical exam, CT and/or MRI, and bone scan', 'entities': [['1', '8', 'cancer'], ['38', '40', 'treatment'], ['48', '51', 'treatment'], ['57', '66', 'treatment']]}, 'NCT01508390'), ({'text': 'have an allergy to gadolinium (Gd) contrast material', 'entities': [['20', '53', 'allergy_name']]}, 'NCT02857218'), ({'text': 'Subjects who participated in an investigational drug or device study within 28 days prior to study entry', 'entities': [['33', '53', 'treatment'], ['57', '69', 'treatment'], ['77', '90', 'upper_bound']]}, 'NCT01676259'), ({'text': 'Patients that undergo arthroscopic rotator cuff repair only', 'entities': [['23', '48', 'treatment']]}, 'NCT02588027'), ({'text': 'Women of childbearing potential and men must agree to use a medically accepted form of birth control during the treatment', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['46', '101', 'contraception_consent'], ['113', '122', 'treatment']]}, 'NCT02349867'), ({'text': 'Patients who have undergone gastric bypass procedures will be excluded (gastric lap band is acceptable)', 'entities': [['29', '54', 'treatment']]}, 'NCT02654236'), ({'text': 'History of chronic pancreatitis', 'entities': [['12', '32', 'chronic_disease']]}, 'NCT02992483'), ({'text': 'Negative serum pregnancy test within 2 weeks prior to registration for women of childbearing potential', 'entities': [['1', '25', 'pregnancy'], ['38', '51', 'upper_bound'], ['72', '77', 'gender']]}, 'NCT01871454'), ({'text': 'has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)', 'entities': [['52', '73', 'lower_bound'], ['115', '146', 'upper_bound']]}, 'NCT02452697'), ({'text': 'Active hepatitis B or C infection determined by serology and/or nucleic acid testing (NAT)', 'entities': [['8', '34', 'chronic_disease']]}, 'NCT02833805'), ({'text': 'Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) according to WHO classification (2008) documented within 28 days prior to enrollment', 'entities': [['49', '85', 'cancer'], ['143', '156', 'upper_bound']]}, 'NCT02236013'), ({'text': 'Potential participants must have a CO test result of e5ppm', 'entities': [['36', '50', 'clinical_variable'], ['55', '59', 'lower_bound']]}, 'NCT03176784'), ({'text': 'Distal femur fractures', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02679560'), ({'text': 'In subjects <18 years of age, these MRI findings are exclusionary, unless in the opinion of the Investigator, a liver biopsy could provide additional data to confirm eligibility and would be safe to perform', 'entities': [['14', '22', 'upper_bound'], ['26', '29', 'age'], ['37', '40', 'treatment'], ['113', '125', 'treatment']]}, 'NCT02140554'), ({'text': 'Patients must have an ECOG score equal to or less than 2', 'entities': [['23', '33', 'clinical_variable'], ['56', '57', 'upper_bound']]}, 'NCT01449149'), ({'text': 'Uncontrolled medical illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['14', '29', 'chronic_disease'], ['72', '88', 'chronic_disease'], ['102', '126', 'chronic_disease'], ['128', '152', 'chronic_disease'], ['154', '172', 'chronic_disease'], ['177', '214', 'chronic_disease']]}, 'NCT02480036'), ({'text': 'Appropriate organ function as outlined below must be observed within 8 weeks of entering this trial', 'entities': [['70', '77', 'upper_bound']]}, 'NCT02234934'), ({'text': 'Patients who are receiving any other investigational agents', 'entities': [['38', '60', 'treatment']]}, 'NCT02520791'), ({'text': 'baseline HR < 60 or > 100 bpm, manual read of QT by cardiologist is required, with Fridericia correction applied to determine QTc', 'entities': [['1', '12', 'clinical_variable'], ['15', '17', 'upper_bound'], ['23', '30', 'lower_bound']]}, 'NCT02349867'), ({'text': 'Pregnant women because ONC201 is novel agent with unknown potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ONC201, breastfeeding should be discontinued if the mother is treated with ONC201', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender'], ['24', '30', 'treatment'], ['73', '84', 'treatment'], ['209', '218', 'treatment']]}, 'NCT02525692'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT02148796'), ({'text': 'Hemoglobin >8.0 mg/dL without red blood cell transfusion d 3 days prior to C1D1', 'entities': [['1', '11', 'clinical_variable'], ['13', '22', 'lower_bound'], ['31', '57', 'clinical_variable'], ['60', '72', 'upper_bound']]}, 'NCT02863991'), ({'text': 'Age 18-24', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT03078153'), ({'text': 'Men', 'entities': [['1', '4', 'gender']]}, 'NCT01931202'), ({'text': 'Not previously treated with anti-VEGF injections', 'entities': [['29', '49', 'treatment']]}, 'NCT03023059'), ({'text': 'Radiation therapy', 'entities': [['1', '18', 'treatment']]}, 'NCT02204098'), ({'text': 'History of bladder calculi (stones)', 'entities': [['12', '36', 'chronic_disease']]}, 'NCT01589263'), ({'text': 'Women and members of all races and ethnic groups are eligible for this trial', 'entities': [['1', '6', 'gender']]}, 'NCT00703105'), ({'text': 'clinically-significant hematemesis or gastrointestinal bleeding', 'entities': [['24', '35', 'chronic_disease'], ['39', '64', 'chronic_disease']]}, 'NCT01639508'), ({'text': 'Life expectancy > 12 weeks', 'entities': [['1', '16', 'clinical_variable'], ['19', '27', 'lower_bound']]}, 'NCT01903330'), ({'text': 'Coagulopathy with international normalized ratio (INR) > 2.0 or', 'entities': [['1', '13', 'chronic_disease'], ['19', '55', 'clinical_variable'], ['58', '61', 'lower_bound']]}, 'NCT02937402'), ({'text': 'Production of < 100 mmol of sodium output on Visit 1 of the study', 'entities': [['17', '25', 'upper_bound']]}, 'NCT02546583'), ({'text': 'History of stroke within the prior 3 months', 'entities': [['12', '18', 'chronic_disease'], ['30', '44', 'upper_bound']]}, 'NCT02806570'), ({'text': 'Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within 3 days prior to study initiation', 'entities': [['1', '6', 'gender'], ['45', '78', 'pregnancy'], ['102', '114', 'upper_bound']]}, 'NCT02340156'), ({'text': 'Diagnosis of Type 1 Diabetes', 'entities': [['14', '29', 'chronic_disease']]}, 'NCT01626586'), ({'text': 'absolute neutrophil count e 1,000/mcL', 'entities': [['1', '26', 'clinical_variable'], ['29', '38', 'lower_bound']]}, 'NCT02362997'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02271711'), ({'text': 'Patients with active infection or fever (patients on antibiotics for infection or patients getting over a cold or seasonal virus are not excluded), or known historical or active infection with HIV, hepatitis B, or hepatitis C', 'entities': [['15', '31', 'chronic_disease'], ['54', '65', 'treatment'], ['194', '197', 'chronic_disease'], ['199', '210', 'chronic_disease'], ['215', '226', 'chronic_disease']]}, 'NCT02578732'), ({'text': 'Recent hospitalization in the last 90 days', 'entities': [['8', '23', 'treatment'], ['31', '43', 'upper_bound']]}, 'NCT02531295'), ({'text': 'Karnofsky performance status of e 60%', 'entities': [['1', '29', 'clinical_variable'], ['35', '38', 'lower_bound']]}, 'NCT01811368'), ({'text': 'Adequate hepatocellular function: aspartate aminotransferase (AST) and alanine transaminase (ALT) d 3x upper limit of normal within institutional limits; bilirubin d 1.5 mg/dl', 'entities': [['35', '67', 'clinical_variable'], ['72', '98', 'clinical_variable'], ['101', '125', 'upper_bound'], ['155', '164', 'clinical_variable'], ['167', '176', 'upper_bound']]}, 'NCT01690468'), ({'text': 'At least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT01906385'), ({'text': 'atients may have received prior Carfilzomib (sensitive, relapsed and refractory all eligible) but must be > 4 weeks from last dosing of Carfilzomib', 'entities': [['27', '44', 'treatment'], ['33', '44', 'treatment'], ['109', '116', 'lower_bound']]}, 'NCT02332850'), ({'text': 'Newly-diagnosed chemo-naïve or recurrent after curative-intent surgery', 'entities': [['48', '71', 'treatment']]}, 'NCT02213289'), ({'text': 'Bupivacaine sensitivity', 'entities': [['1', '12', 'allergy_name']]}, 'NCT02996227'), ({'text': 'Histologically confirmed metastatic gastric or esophagogastric junction (type I,II,III Siewert) adenocarcinoma', 'entities': [['26', '44', 'cancer'], ['48', '72', 'chronic_disease'], ['97', '111', 'cancer']]}, 'NCT02213289'), ({'text': 'infections which longer > 6 months prior to screening', 'entities': [['27', '41', 'lower_bound']]}, 'NCT02502006'), ({'text': 'failure of at least one anti-arrhythmic drug', 'entities': [['21', '24', 'lower_bound'], ['25', '45', 'treatment']]}, 'NCT03168659'), ({'text': 'Contraindication to abdominal surgery, fetoscopic surgery, or general anesthesia', 'entities': [['21', '38', 'treatment'], ['40', '58', 'treatment'], ['63', '81', 'treatment']]}, 'NCT00881660'), ({'text': 'current pregnancy', 'entities': [['1', '18', 'pregnancy']]}, 'NCT03043963'), ({'text': 'Cardiac impairment due to local extension of lymphoma will not be an exclusion criterion in the absence of other cardiac disease', 'entities': [['1', '19', 'chronic_disease'], ['46', '54', 'cancer'], ['114', '129', 'chronic_disease']]}, 'NCT01599559'), ({'text': 'Subjects who are pregnant', 'entities': [['14', '26', 'pregnancy']]}, 'NCT02952365'), ({'text': 'Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before registration', 'entities': [['27', '38', 'treatment'], ['79', '86', 'upper_bound']]}, 'NCT02048722'), ({'text': 'Treatment with topical atropine within the past 4 weeks', 'entities': [['1', '10', 'treatment'], ['44', '56', 'upper_bound']]}, 'NCT01584076'), ({'text': 'Reporting no HIV primary care appointments in the prior 6 months', 'entities': [['14', '17', 'chronic_disease'], ['51', '65', 'upper_bound']]}, 'NCT03081559'), ({'text': 'Patient agrees that if randomized to Arms C or D, and proceed onto Arms G or H, they must register into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist', 'entities': [['109', '137', 'treatment'], ['119', '128', 'treatment']]}, 'NCT01415752'), ({'text': 'Mitral valve insufficiency > moderate grade', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT03043742'), ({'text': 'Receipt of or anticipated need for blood products, immunoglobulin, or immunosuppressive therapy. This includes infants who require hepatitis B immunoglobulin (HBIG) but does not require exclusion of infants who receive hepatitis B vaccine in the newborn period', 'entities': [['52', '66', 'treatment'], ['71', '96', 'treatment'], ['132', '165', 'treatment'], ['220', '239', 'treatment']]}, 'NCT02256631'), ({'text': 'Referred by physician to CR with echocardiographic evidence of HFpEF defined as an ejection fraction e 50 %', 'entities': [['34', '51', 'treatment'], ['84', '101', 'clinical_variable'], ['104', '108', 'lower_bound']]}, 'NCT02762825'), ({'text': 'AST/SGOT and ALT/SPGT d 2.5 X institutional upper limit of normal', 'entities': [['1', '4', 'clinical_variable'], ['5', '9', 'clinical_variable'], ['14', '17', 'clinical_variable'], ['18', '22', 'clinical_variable'], ['25', '66', 'upper_bound']]}, 'NCT02507232'), ({'text': 'Recovered from any previous therapy-related toxicity to Grade 1 or to their clinical baseline at study entry', 'entities': [['20', '36', 'treatment']]}, 'NCT02423525'), ({'text': 'an oral contraceptive** (with additional barrier method)', 'entities': [['4', '22', 'contraception_consent']]}, 'NCT02501096'), ({'text': 'Abnormal prolactin. Mild elevations may be seen in overweight girls, and elevations <1.5 times the upper limit of normal will be accepted in this group', 'entities': [['1', '19', 'chronic_disease'], ['26', '36', 'ethnicity'], ['86', '121', 'upper_bound']]}, 'NCT01422746'), ({'text': 'orogastric', 'entities': [['1', '11', 'treatment']]}, 'NCT02127398'), ({'text': 'history of neurologic deficit to the brachial plexus', 'entities': [['12', '22', 'chronic_disease']]}, 'NCT02907983'), ({'text': 'English or Spanish literate', 'entities': [['1', '28', 'language_fluency']]}, 'NCT02488057'), ({'text': 'SLEDAI e4 or e1 BILAG A or B at screening, despite standard of care', 'entities': [['1', '7', 'clinical_variable'], ['9', '10', 'lower_bound'], ['15', '16', 'lower_bound'], ['17', '29', 'clinical_variable']]}, 'NCT01781611'), ({'text': 'history of chronic renal failure', 'entities': [['12', '33', 'chronic_disease']]}, 'NCT02664909'), ({'text': 'Histologically confirmed diagnosis of initial or recurrent anal or vulvar high-grade squamous intraepithelial lesion diagnosed on or after 1/1/2014', 'entities': [['86', '117', 'cancer']]}, 'NCT03051516'), ({'text': 'Plasma Platelet count of less than 100 x 109/L', 'entities': [['1', '22', 'clinical_variable'], ['36', '47', 'upper_bound']]}, 'NCT02352480'), ({'text': 'HGB <8 g/dL', 'entities': [['1', '4', 'clinical_variable'], ['6', '12', 'upper_bound']]}, 'NCT02770326'), ({'text': 'History of allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinib', 'entities': [['102', '111', 'allergy_name']]}, 'NCT02272998'), ({'text': "Only patients who receive infusions in the integrated Cell and Gene Therapy (CAGT) Transplant program at Texas Children's Hospital (TCH) or Houston Methodist Hospital (HMH)", 'entities': [['44', '102', 'treatment']]}, 'NCT02475707'), ({'text': 'Vision is impaired- more than 20/60 in worst eye (with prescription eyewear)', 'entities': [['31', '36', 'lower_bound']]}, 'NCT02307565'), ({'text': 'Poorly controlled T2DM, defined as Hgb A1C>8.7%', 'entities': [['19', '23', 'chronic_disease'], ['36', '43', 'clinical_variable'], ['44', '48', 'lower_bound']]}, 'NCT02130687'), ({'text': 'Spinal or hip joint surgery or prosthesis', 'entities': [['1', '28', 'treatment'], ['32', '42', 'treatment']]}, 'NCT03101956'), ({'text': 'English-speaking as needed to complete cognitive testing and follow study procedures', 'entities': [['1', '17', 'language_fluency']]}, 'NCT03058146'), ({'text': 'Proteinuria e1 gram/day in spot urine protein/creatinine ratio', 'entities': [['1', '12', 'clinical_variable'], ['14', '24', 'lower_bound']]}, 'NCT02327403'), ({'text': 'Women', 'entities': [['1', '6', 'gender']]}, 'NCT00900575'), ({'text': 'Subjects being treated with tamoxifen, estrogens, or progestins that have not been stable for >4 weeks', 'entities': [['29', '38', 'treatment'], ['40', '49', 'treatment'], ['54', '64', 'treatment'], ['96', '103', 'lower_bound']]}, 'NCT02514070'), ({'text': 'Hearing loss due to any other cause that would not be expected to respond to hair cell regeneration', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02132130'), ({'text': 'no history of brain injury or neurological disease', 'entities': [['15', '27', 'chronic_disease'], ['31', '51', 'chronic_disease']]}, 'NCT02155699'), ({'text': 'Has negative serum or urine pregnancy test for subjects of childbearing potential', 'entities': [['5', '19', 'pregnancy'], ['23', '38', 'pregnancy']]}, 'NCT02411656'), ({'text': 'Subject requires treatment with concomitant drugs that target serotonin 5HT1R or 5HT2BR receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject', 'entities': [['18', '50', 'treatment']]}, 'NCT02236013'), ({'text': 'Tonsillar hypertrophy e2 based on a standardized scale of 0-4', 'entities': [['1', '22', 'clinical_variable'], ['24', '25', 'lower_bound'], ['59', '60', 'lower_bound'], ['61', '62', 'upper_bound']]}, 'NCT02562040'), ({'text': 'Participation in another interventional investigative study of a cardiovascular drug or device within 30 days prior to CABG', 'entities': [['18', '60', 'treatment'], ['66', '95', 'treatment'], ['103', '116', 'upper_bound'], ['120', '124', 'treatment']]}, 'NCT01313533'), ({'text': '(postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)', 'entities': [['17', '22', 'gender'], ['63', '72', 'lower_bound']]}, 'NCT02394535'), ({'text': 'Enrollment in a clinical study evaluating another device or drug, within the past 6 months', 'entities': [['78', '91', 'upper_bound']]}, 'NCT01959425'), ({'text': 'Patients who are currently pregnant', 'entities': [['18', '36', 'pregnancy']]}, 'NCT02950337'), ({'text': 'Availability of an archival or new pre-treatment tissue sample is required if molecular testing was not performed by Foundation Medicine. Any available tumor tissue sample can be submitted. The tissue sample must be submitted within 4 weeks after enrollment', 'entities': [['36', '49', 'treatment'], ['153', '158', 'cancer'], ['234', '241', 'upper_bound']]}, 'NCT02091141'), ({'text': 'children with BMI >35', 'entities': [['15', '18', 'bmi'], ['20', '22', 'lower_bound']]}, 'NCT01695980'), ({'text': 'International normalized ratio (INR) < 1.5 x institutional ULN', 'entities': [['1', '37', 'clinical_variable'], ['40', '45', 'upper_bound'], ['46', '63', 'clinical_variable']]}, 'NCT01620216'), ({'text': 'No brain metastasis is > 2 cm in diameter at the time of registration', 'entities': [['4', '20', 'cancer'], ['26', '42', 'lower_bound']]}, 'NCT02382549'), ({'text': 'Kefzol (cefazolin)', 'entities': [['1', '19', 'treatment']]}, 'NCT03181516'), ({'text': 'Adequate treatment is defined as meeting the current recommendations of the Centers of Disease Control and Prevention (CDC), National Institutes of Health (NIH) and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA) guidelines33', 'entities': [['10', '19', 'treatment']]}, 'NCT02159027'), ({'text': 'Features suggestive of other causes of parkinsonism, including cerebrovascular disease or history of major head trauma', 'entities': [['40', '52', 'chronic_disease'], ['64', '87', 'chronic_disease']]}, 'NCT03049033'), ({'text': 'Current inotropic therapy or use of inotropes in the past 6 months', 'entities': [['9', '26', 'treatment'], ['37', '46', 'treatment'], ['54', '67', 'lower_bound']]}, 'NCT02816736'), ({'text': 'Bilateral disease (diagnosed cancer in both breasts)', 'entities': [['30', '52', 'cancer']]}, 'NCT02406599'), ({'text': 'Have access to a home or mobile computer (desktop, laptop, tablet, or smart phone)', 'entities': [['6', '83', 'technology_access']]}, 'NCT02701998'), ({'text': 'Have a cell phone that is able to receive text messages', 'entities': [['1', '56', 'technology_access']]}, 'NCT02436070'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT02562430'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02826681'), ({'text': 'Treatment with monoaminoxidase inhibitors, tricyclic antidepressants or Beta-adrenergic receptor antagonists or long acting anticholinergic bronchodilators who are unable to be discontinued for at least seven days before enrollment', 'entities': [['1', '42', 'treatment'], ['44', '69', 'treatment'], ['73', '109', 'treatment'], ['113', '156', 'treatment'], ['204', '214', 'lower_bound']]}, 'NCT01799538'), ({'text': 'Treatment with an investigational anti-cancer agent within 4 weeks prior to enrollment into the study', 'entities': [['1', '52', 'treatment'], ['60', '73', 'upper_bound']]}, 'NCT02207465'), ({'text': 'Relapsed or progressive disease at the primary site and/or regional lymph nodes after initial treatment (e.g. Surgery, radiotherapy or chemoradiotherapy) with no potentially curative option (i.e. surgery or radiation)', 'entities': [['13', '32', 'chronic_disease'], ['87', '104', 'treatment'], ['111', '118', 'treatment'], ['120', '132', 'treatment'], ['136', '153', 'treatment'], ['197', '204', 'treatment'], ['208', '217', 'treatment']]}, 'NCT02865135'), ({'text': 'Serum creatinine d3xupper limit of normal for age', 'entities': [['1', '17', 'clinical_variable'], ['19', '42', 'upper_bound'], ['47', '50', 'age']]}, 'NCT02356653'), ({'text': 'Uncontrolled diabetes, hypertension, or other contra-indication to increased dosage of glucocorticoids', 'entities': [['14', '22', 'chronic_disease'], ['24', '36', 'chronic_disease'], ['88', '103', 'treatment']]}, 'NCT02725177'), ({'text': 'Ultrasound or CT estimate of prostate volume > 80 grams', 'entities': [['1', '11', 'treatment'], ['15', '17', 'treatment'], ['18', '45', 'clinical_variable'], ['48', '56', 'lower_bound']]}, 'NCT02353819'), ({'text': 'All adult Fontan patients who have no contraindications for magnetic resonance imaging (MRI) will be eligible for the study', 'entities': [['61', '93', 'treatment']]}, 'NCT03154476'), ({'text': 'For cancer, patients with active illness or metastases', 'entities': [['5', '11', 'cancer'], ['45', '55', 'cancer']]}, 'NCT02129348'), ({'text': 'MDD Participants with Suicide Attempt', 'entities': [['1', '4', 'chronic_disease'], ['23', '38', 'chronic_disease']]}, 'NCT02418195'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT03076333'), ({'text': 'BMI > 35 due to the effects of obesity on cytokine activity and risk for sleep disordered breathing', 'entities': [['1', '4', 'bmi'], ['7', '9', 'lower_bound'], ['32', '39', 'chronic_disease']]}, 'NCT02270619'), ({'text': 'Current or past Axis I Diagnostic and Statistical Manual (DSM-IV) disorder based on the MINI', 'entities': [['17', '75', 'chronic_disease']]}, 'NCT02410954'), ({'text': 'Baseline peripheral neuropathy/paresthesia grade e 1', 'entities': [['1', '31', 'clinical_variable'], ['32', '43', 'clinical_variable'], ['52', '53', 'lower_bound']]}, 'NCT02178709'), ({'text': 'Positive serology for hepatitis C (HC) defined as a positive test for HCAb', 'entities': [['23', '39', 'chronic_disease'], ['71', '75', 'chronic_disease']]}, 'NCT02213913'), ({'text': 'vitamin K antagonists', 'entities': [['1', '22', 'treatment']]}, 'NCT03096288'), ({'text': 'patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction', 'entities': [['63', '76', 'chronic_disease'], ['78', '87', 'chronic_disease'], ['118', '137', 'chronic_disease'], ['158', '177', 'chronic_disease'], ['179', '197', 'chronic_disease'], ['241', '263', 'chronic_disease'], ['435', '454', 'chronic_disease']]}, 'NCT00358657'), ({'text': 'On anti-VEGF injections for at least 3 months', 'entities': [['4', '24', 'treatment'], ['38', '46', 'lower_bound']]}, 'NCT03023059'), ({'text': 'Current use of psychotropic medications, except antidepressants taken at a stable dose for 2 weeks, to maximize generalizability of sample', 'entities': [['16', '40', 'treatment'], ['49', '64', 'treatment']]}, 'NCT02808702'), ({'text': 'High risk of relapse after HSCT, defined as the presence of minimal residual disease as measured by flow cytometry in the absence of evidence of morphologic disease on a bone marrow biopsy prior to HSCT', 'entities': [['28', '32', 'treatment'], ['61', '85', 'cancer'], ['101', '115', 'treatment']]}, 'NCT01841333'), ({'text': 'Patients with active malignancies other than NSCLC or patients with prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers', 'entities': [['15', '34', 'cancer'], ['46', '51', 'cancer'], ['69', '104', 'treatment'], ['185', '193', 'cancer'], ['197', '220', 'cancer']]}, 'NCT02520778'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02417415'), ({'text': 'History of clinically-significant gastrointestinal (GI) disease', 'entities': [['35', '64', 'chronic_disease']]}, 'NCT02628535'), ({'text': 'Term (>36 week gestation)', 'entities': [['8', '15', 'lower_bound'], ['16', '25', 'clinical_variable']]}, 'NCT02121184'), ({'text': 'Axillary node dissection', 'entities': [['1', '25', 'treatment']]}, 'NCT01872975'), ({'text': 'Cancer', 'entities': [['1', '7', 'cancer']]}, 'NCT01464164'), ({'text': 'Subjects with a past history or current diagnosis of arterial or venous thromboembolic disease including acute coronary syndrome, peripheral vascular disease and retinal arterial or venous thrombosis', 'entities': [['54', '62', 'chronic_disease'], ['66', '87', 'chronic_disease'], ['106', '129', 'chronic_disease'], ['131', '158', 'chronic_disease'], ['163', '179', 'chronic_disease'], ['183', '200', 'chronic_disease']]}, 'NCT02578901'), ({'text': 'jet velocity greater than 4.0 m/s', 'entities': [['1', '13', 'clinical_variable'], ['27', '34', 'lower_bound']]}, 'NCT02000115'), ({'text': 'Medically appropriate candidate for radical nephroureterectomy or ureterectomy as per MSKCC or a participating site attending urologic oncologist', 'entities': [['37', '63', 'treatment'], ['51', '63', 'treatment']]}, 'NCT01261728'), ({'text': 'e12 and d75 years of age', 'entities': [['2', '4', 'lower_bound'], ['10', '18', 'upper_bound'], ['22', '25', 'age']]}, 'NCT02495168'), ({'text': 'Creatinine less than or equal to 1.5 mg/dL or creatinine clearance by Cockcroft-Gault formula greater than or equal to 60 mL/min', 'entities': [['1', '11', 'clinical_variable'], ['34', '43', 'upper_bound'], ['47', '67', 'clinical_variable'], ['120', '129', 'lower_bound']]}, 'NCT02487095'), ({'text': 'Severe or fulminant C. difficile colitis', 'entities': [['11', '41', 'chronic_disease']]}, 'NCT02134392'), ({'text': 'Negative pregnancy test', 'entities': [['1', '19', 'pregnancy']]}, 'NCT01821781'), ({'text': 'history of ossicular reconstruction', 'entities': [['12', '36', 'treatment']]}, 'NCT01976429'), ({'text': 'Traumatic brain injury', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02992899'), ({'text': 'Provided the patient has been allowed at least 4 weeks to recover from surgical debulking, no additional recovery time is required for port placement', 'entities': [['48', '55', 'lower_bound'], ['72', '90', 'treatment']]}, 'NCT01061515'), ({'text': 'age 7-18 years', 'entities': [['1', '4', 'age'], ['5', '6', 'lower_bound'], ['7', '15', 'upper_bound']]}, 'NCT01421810'), ({'text': '> 470 ms for females based on triplicate ECG', 'entities': [['3', '9', 'lower_bound'], ['14', '21', 'gender'], ['42', '45', 'treatment']]}, 'NCT01877382'), ({'text': 'intensive care unit admission and/or requiring intubation', 'entities': [['1', '30', 'treatment'], ['48', '58', 'treatment']]}, 'NCT02272634'), ({'text': 'Less than 18 years of age', 'entities': [['11', '19', 'upper_bound'], ['23', '26', 'age']]}, 'NCT02260856'), ({'text': 'Proven or suspected immunosuppressive disorder', 'entities': [['21', '47', 'chronic_disease']]}, 'NCT00788164'), ({'text': 'Histologically, or cytologically documented, advanced stage, malignant adult solid tumors (except prostate cancer) that are refractory to, or recurrent from, standard therapy or for which no curative standard therapy exists', 'entities': [['78', '90', 'cancer'], ['99', '114', 'cancer'], ['159', '175', 'treatment'], ['192', '217', 'treatment']]}, 'NCT00967577'), ({'text': 'Actively homicidal or suicidal with an imminent plan', 'entities': [['10', '31', 'chronic_disease']]}, 'NCT02778282'), ({'text': 'Participants who have been receiving warfarin (Coumadin®) therapy', 'entities': [['38', '66', 'treatment']]}, 'NCT02765633'), ({'text': 'Current use of ivacaftor (Kalydeco), lumacaftor/ivacaftor combination, or other corrector or potentiator (Symdeko) less than 30 days from Screening', 'entities': [['16', '36', 'treatment'], ['38', '58', 'treatment'], ['81', '115', 'treatment'], ['126', '133', 'upper_bound']]}, 'NCT02323100'), ({'text': 'labile hypertension', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT01737502'), ({'text': 'Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during the study and for 30 days after the final dose of imatinib', 'entities': [['1', '6', 'gender'], ['50', '55', 'gender'], ['83', '100', 'pregnancy'], ['191', '204', 'upper_bound'], ['223', '231', 'treatment']]}, 'NCT01742299'), ({'text': 'women', 'entities': [['1', '6', 'gender']]}, 'NCT02695433'), ({'text': 'Serum albumin e 3.0 g/dL', 'entities': [['1', '14', 'clinical_variable'], ['17', '25', 'lower_bound']]}, 'NCT03009981'), ({'text': 'aged 18 to 50 years', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['12', '20', 'upper_bound']]}, 'NCT01954966'), ({'text': 'Patients with evidence of synthetic dysfunction or severe cirrhosis requiring deferral of conditioning as recommended by a gastroenterology specialist', 'entities': [['27', '48', 'chronic_disease'], ['59', '68', 'chronic_disease']]}, 'NCT00919503'), ({'text': 'Patients must have received a biologic therapy (e.g. interleukin 2)', 'entities': [['31', '47', 'treatment'], ['54', '67', 'treatment']]}, 'NCT02120222'), ({'text': 'Females of childbearing potential who refuse to practice effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 30-days after the last vaccination', 'entities': [['1', '8', 'gender'], ['39', '133', 'contraception_consent'], ['188', '195', 'upper_bound'], ['211', '222', 'treatment']]}, 'NCT02544880'), ({'text': 'Performing less than or equal to 120 minutes of structured moderate-intensity or strenuous-intensity exercise per week', 'entities': [['34', '45', 'upper_bound']]}, 'NCT02494869'), ({'text': 'Clinically significant pulmonary compromise within 28 days of first dose, including pneumonia, pneumonitis, requirement for supplemental oxygen). use to maintain adequate oxygenation, or pleural effusion sufficient to warrant pleurocentesis or any history of e Grade 3 drug induced or radiation pneumonitis', 'entities': [['52', '59', 'upper_bound'], ['85', '94', 'chronic_disease'], ['96', '107', 'chronic_disease'], ['188', '204', 'chronic_disease'], ['227', '241', 'treatment'], ['262', '269', 'lower_bound'], ['286', '307', 'chronic_disease']]}, 'NCT02628535'), ({'text': 'Has a known history of active TB (Bacillus Tuberculosis)', 'entities': [['24', '57', 'chronic_disease']]}, 'NCT02710396'), ({'text': 'Infant Medulloblastoma: Children less than 8 months of age at the time of definitive surgery (for histopathologic diagnosis), any histology, any metastatic state, with total or sub-total resection', 'entities': [['8', '23', 'cancer'], ['44', '52', 'upper_bound'], ['56', '59', 'age'], ['75', '93', 'treatment'], ['188', '197', 'treatment']]}, 'NCT01505569'), ({'text': 'Patient has received intra-articular GdCA or per any other non-i.v. route', 'entities': [['22', '42', 'treatment'], ['60', '74', 'treatment']]}, 'NCT01853163'), ({'text': 'Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS)', 'entities': [['32', '66', 'chronic_disease'], ['70', '112', 'chronic_disease']]}, 'NCT03144245'), ({'text': 'Patients must have histologic or radiographic proof of a primary liver malignancy suitable for radiation therapy', 'entities': [['58', '82', 'cancer'], ['96', '113', 'treatment']]}, 'NCT02893982'), ({'text': 'Score below 82 on the Clinical Evaluation of Language Fundamentals', 'entities': [['13', '15', 'upper_bound'], ['23', '67', 'clinical_variable']]}, 'NCT01829360'), ({'text': 'Have inflammatory breast cancer or a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years', 'entities': [['19', '32', 'cancer'], ['26', '32', 'cancer'], ['74', '97', 'cancer'], ['101', '132', 'cancer'], ['172', '179', 'treatment'], ['197', '204', 'lower_bound']]}, 'NCT02107703'), ({'text': 'bleeding diathesis not correctable by usual forms of therapy', 'entities': [['1', '19', 'chronic_disease'], ['54', '61', 'treatment']]}, 'NCT02724540'), ({'text': 'Requires concomitant use of potent cytochrome P450 3A4 inhibitors (such as ketoconazole, itraconazole, erythromycin, saquinavir), or concomitant use of ritonavir', 'entities': [['29', '66', 'treatment'], ['76', '88', 'treatment'], ['90', '102', 'treatment'], ['104', '116', 'treatment'], ['118', '128', 'treatment'], ['153', '162', 'treatment']]}, 'NCT02335242'), ({'text': 'Individuals with preoperative ventricular arrhythmia requiring medical management', 'entities': [['18', '53', 'chronic_disease']]}, 'NCT02914171'), ({'text': 'Receiving or have received within 30 days any experimental systemic medication', 'entities': [['35', '42', 'upper_bound'], ['60', '79', 'treatment']]}, 'NCT02193490'), ({'text': 'Need for acute psychiatric hospitalization or is suicidal in the opinion of the study physician', 'entities': [['16', '43', 'treatment'], ['50', '58', 'chronic_disease']]}, 'NCT02346201'), ({'text': 'Known HIV infection', 'entities': [['7', '20', 'chronic_disease']]}, 'NCT00085982'), ({'text': 'congestive heart failure', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02793921'), ({'text': 'Patients must have evidence of acute leukemia in their peripheral blood or bone marrow', 'entities': [['32', '46', 'cancer']]}, 'NCT01925131'), ({'text': 'unstable angina within 6 months prior to the day of planned surgery', 'entities': [['1', '16', 'chronic_disease'], ['24', '38', 'upper_bound'], ['61', '68', 'treatment']]}, 'NCT02755116'), ({'text': 'Diagnosed with in situ or metastatic breast', 'entities': [['19', '44', 'cancer']]}, 'NCT03035773'), ({'text': 'Pts who have received prior treatment with pomalidomide (Phase II only)', 'entities': [['23', '38', 'treatment'], ['44', '72', 'treatment']]}, 'NCT01464034'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02355002'), ({'text': 'inability to take oral medication', 'entities': [['24', '34', 'treatment']]}, 'NCT02332850'), ({'text': 'During Phase I: patients who have received these drugs within 14 days or within 5 half-lives of the drug (whichever is longer) prior to study initiation will be excluded', 'entities': [['63', '70', 'upper_bound'], ['81', '93', 'upper_bound']]}, 'NCT02390752'), ({'text': '< 40% by Multi Gated Acquisition Scan (MUGA)', 'entities': [['3', '6', 'upper_bound'], ['10', '45', 'clinical_variable']]}, 'NCT02393794'), ({'text': 'History of cancer other than non-melanoma skin cancer within two years prior to enrollment based on patient self-report', 'entities': [['12', '18', 'cancer'], ['30', '54', 'cancer'], ['62', '77', 'upper_bound']]}, 'NCT02945969'), ({'text': 'Infusion of epinephrine, dopamine, dobutamine or milrinone at time of enrollment', 'entities': [['13', '24', 'treatment'], ['26', '34', 'treatment'], ['36', '46', 'treatment'], ['50', '59', 'treatment']]}, 'NCT02369900'), ({'text': 'Subjects with cochlear implants', 'entities': [['15', '32', 'treatment']]}, 'NCT02573246'), ({'text': 'with hematologic malignancies including chronic myelomonocytic leukemia (CMML) or myelodysplasia (MDS) that transform to acute leukemia while actively receiving hypomethylating agents (i.e. decitabine or azacytidine) will be considered induction failures and thus are eligible', 'entities': [['6', '30', 'cancer'], ['41', '79', 'cancer'], ['83', '103', 'cancer'], ['122', '136', 'cancer'], ['162', '184', 'treatment'], ['191', '201', 'treatment'], ['205', '216', 'treatment']]}, 'NCT01620216'), ({'text': 'Patients with any pre-existing hematological disease', 'entities': [['32', '53', 'chronic_disease']]}, 'NCT02577731'), ({'text': 'genetic syndromes', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT01695967'), ({'text': 'Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy known to interact with CYP isoenzymes are ineligible; in addition, HIV patients with CD4 count < 200 cells/uL are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated', 'entities': [['1', '35', 'chronic_disease'], ['31', '34', 'chronic_disease'], ['57', '91', 'treatment'], ['115', '129', 'treatment'], ['177', '186', 'clinical_variable'], ['189', '201', 'upper_bound']]}, 'NCT02503709'), ({'text': 'Patients with known floxuridine, leucovorin ,or mitomycin allergy', 'entities': [['21', '32', 'allergy_name'], ['34', '44', 'allergy_name'], ['49', '58', 'allergy_name']]}, 'NCT01815359'), ({'text': 'Total bilirubin =< 1.5 X institutional upper limit of normal', 'entities': [['1', '16', 'clinical_variable'], ['20', '61', 'upper_bound']]}, 'NCT02503709'), ({'text': 'Relapsed or refractory CD30+ lymphoma that has either achieved < PR to brentuximab vedotin (minimum of 2 cycles), progressed while receiving brentuximab vedotin, or progressed within 6 months of the last dose of brentuximab vedotin', 'entities': [['1', '38', 'cancer'], ['72', '91', 'treatment'], ['184', '192', 'upper_bound']]}, 'NCT01703949'), ({'text': 'recent single event multilevel lower extremity orthopedic surgery or selective dorsal rhizotomy', 'entities': [['21', '66', 'treatment'], ['70', '96', 'treatment']]}, 'NCT03135145'), ({'text': 'Subject with a history of angioedema', 'entities': [['27', '37', 'chronic_disease']]}, 'NCT03051282'), ({'text': 'Total bilirubin d 2', 'entities': [['7', '16', 'clinical_variable'], ['19', '20', 'upper_bound']]}, 'NCT02576301'), ({'text': 'History or current pelvic malignancy or radiation', 'entities': [['20', '37', 'cancer']]}, 'NCT02495389'), ({'text': 'Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times institutional upper limit of normal with or without liver metastasis (within 21 days prior to study entry)', 'entities': [['1', '33', 'clinical_variable'], ['38', '68', 'clinical_variable'], ['72', '117', 'upper_bound'], ['134', '150', 'cancer'], ['159', '166', 'upper_bound']]}, 'NCT01622868'), ({'text': 'Individuals requiring cavopulmonary shunt at the time of surgical Ebstein repair', 'entities': [['23', '42', 'treatment'], ['58', '74', 'treatment']]}, 'NCT02914171'), ({'text': 'Restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study', 'entities': [['1', '45', 'chronic_disease']]}, 'NCT01815359'), ({'text': 'Pregnant or breastfeeding', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02192398'), ({'text': 'Neurological: research participant without clinically significant encephalopathy/new focal deficits', 'entities': [['67', '81', 'chronic_disease'], ['86', '100', 'chronic_disease']]}, 'NCT02159495'), ({'text': 'Subjects who have cervical radicular pain without significant neurologic deficit', 'entities': [['19', '42', 'chronic_disease'], ['63', '81', 'chronic_disease']]}, 'NCT02226159'), ({'text': 'Relapsed/refractory MCL: Known human immunodeficiency virus (HIV) infection', 'entities': [['21', '24', 'cancer'], ['32', '76', 'chronic_disease']]}, 'NCT01880567'), ({'text': 'Consumes >14 alcoholic drinks per week', 'entities': [['11', '13', 'lower_bound']]}, 'NCT02448498'), ({'text': 'Cardiac Pacemaker', 'entities': [['1', '18', 'treatment']]}, 'NCT02166190'), ({'text': 'myocardial infarction within 12 months before study entry', 'entities': [['1', '22', 'clinical_variable'], ['30', '39', 'upper_bound']]}, 'NCT01599559'), ({'text': 'Subject has a history of cancer in the last 5 years', 'entities': [['26', '32', 'cancer']]}, 'NCT03059888'), ({'text': 'Patients may be pre- or post-menopausal; pre-menopausal patients must be on ovarian suppression and must be adequately suppressed on LHRH agonists with estradiol levels in the post-menopausal range', 'entities': [['77', '96', 'treatment']]}, 'NCT02913430'), ({'text': 'Active infection with hepatitis C virus (HCV)', 'entities': [['1', '17', 'chronic_disease'], ['23', '34', 'chronic_disease']]}, 'NCT02320292'), ({'text': 'Women of child-bearing potential must have a negative pregnancy test within 7 days of initiating study', 'entities': [['1', '6', 'gender'], ['46', '64', 'pregnancy'], ['77', '83', 'upper_bound']]}, 'NCT02524275'), ({'text': 'Any patient regardless of sex, with a diagnosis of Hodgkin or non-Hodgkin lymphoma', 'entities': [['52', '59', 'cancer'], ['63', '83', 'cancer']]}, 'NCT01333046'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01534104'), ({'text': 'a child that received a one-time dose of I.M. or I.V. medication (i.e. in ER or clinic) prior to starting on the one of the four oral medications is eligible for enrollment', 'entities': [['25', '28', 'lower_bound'], ['42', '46', 'treatment'], ['50', '65', 'treatment'], ['125', '129', 'upper_bound'], ['130', '146', 'treatment']]}, 'NCT01595529'), ({'text': 'had previous exposure to Folotyn within 6 months of study enrollment', 'entities': [['26', '33', 'treatment'], ['41', '49', 'upper_bound']]}, 'NCT02106650'), ({'text': 'All other criteria required for renal transplantation', 'entities': [['33', '54', 'treatment']]}, 'NCT02128802'), ({'text': 'Effects of the study drug on the developing human fetus are unknown. Thus, women of childbearing potential and men must agree to use effective contraception, defined as 2 barrier methods, or 1 barrier method with a spermicide, an intrauterine device or use of oral female contraceptive', 'entities': [['76', '81', 'gender'], ['78', '81', 'gender'], ['121', '157', 'contraception_consent'], ['216', '226', 'contraception_consent']]}, 'NCT03104699'), ({'text': 'History of liver disease and/or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 3 times upper limit of normal (ULN)', 'entities': [['12', '25', 'chronic_disease'], ['33', '65', 'clinical_variable'], ['69', '99', 'clinical_variable'], ['110', '145', 'lower_bound']]}, 'NCT02087826'), ({'text': 'Individuals with a history of a different malignancy', 'entities': [['43', '53', 'cancer']]}, 'NCT03075826'), ({'text': 'Patients with chronic kidney disease stage with eGFR < 30 ml/min (CKD stage IV and V)', 'entities': [['15', '37', 'chronic_disease'], ['49', '53', 'clinical_variable'], ['56', '65', 'upper_bound'], ['67', '85', 'chronic_disease']]}, 'NCT02046395'), ({'text': 'Skeletal maturity', 'entities': [['1', '18', 'clinical_variable']]}, 'NCT01923662'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status d 2; performance status of 3 will be accepted if impairment is caused by DLBCL complications and improvement is expected once therapy is initiated', 'entities': [['1', '61', 'clinical_variable'], ['43', '61', 'clinical_variable'], ['64', '65', 'upper_bound'], ['89', '90', 'upper_bound'], ['188', '195', 'treatment']]}, 'NCT02073097'), ({'text': 'Absence of dementia', 'entities': [['12', '20', 'chronic_disease']]}, 'NCT02457832'), ({'text': 'ARM 2 - BPDCN: Research participants with a diagnosis of BPDCN, according to World Health Organization (WHO) classification by hematopathology, who underwent at least 1 line of systemic therapy for BPDCN and who have persistent or recurrent disease', 'entities': [['9', '14', 'cancer'], ['168', '169', 'lower_bound'], ['178', '194', 'treatment']]}, 'NCT02159495'), ({'text': 'Have received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening', 'entities': [['17', '28', 'treatment'], ['102', '124', 'treatment']]}, 'NCT02171429'), ({'text': 'hemoglobin < 10 gm/dL', 'entities': [['1', '11', 'clinical_variable'], ['14', '22', 'upper_bound']]}, 'NCT02501473'), ({'text': 'Primary language is English', 'entities': [['1', '28', 'language_fluency']]}, 'NCT02404402'), ({'text': 'No radiotherapy within 2 weeks', 'entities': [['4', '16', 'treatment'], ['24', '31', 'upper_bound']]}, 'NCT03093909'), ({'text': 'Age: 18 -75 years', 'entities': [['1', '4', 'age'], ['6', '8', 'lower_bound'], ['10', '18', 'upper_bound']]}, 'NCT03145298'), ({'text': 'Steroid inhalers and topical steroids may be used', 'entities': [['1', '17', 'treatment'], ['22', '38', 'treatment']]}, 'NCT02401035'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02801539'), ({'text': 'Patients must have had node negative (pN0) disease found at the time of surgery', 'entities': [['24', '51', 'cancer'], ['73', '80', 'treatment']]}, 'NCT02203695'), ({'text': 'Patient expected to weaned from parenteral nutrition in 30 days', 'entities': [['33', '53', 'treatment'], ['57', '64', 'upper_bound']]}, 'NCT00969332'), ({'text': 'Body mass index: 25.0 to 29.9 kg/m2', 'entities': [['1', '16', 'bmi'], ['18', '22', 'lower_bound'], ['26', '36', 'upper_bound']]}, 'NCT02253368'), ({'text': 'in accordance with the BMI range typical for the age', 'entities': [['24', '27', 'bmi'], ['50', '53', 'age']]}, 'NCT02495168'), ({'text': 'e Age 60 years (no upper age limit)', 'entities': [['3', '6', 'age'], ['7', '15', 'lower_bound'], ['26', '29', 'age']]}, 'NCT02191969'), ({'text': 'Patient scheduled to undergo ambulatory surgery under general anesthesia', 'entities': [['30', '48', 'treatment']]}, 'NCT02755116'), ({'text': 'Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year', 'entities': [['1', '26', 'contraception_consent'], ['30', '55', 'contraception_consent'], ['100', '111', 'upper_bound']]}, 'NCT01532687'), ({'text': 'Cardiac arrhythmia', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT01737502'), ({'text': 'Inability to wear NovoTTF-100A System for an average of 18 hours per 24 hours', 'entities': [['19', '38', 'treatment'], ['57', '65', 'upper_bound']]}, 'NCT02343549'), ({'text': 'History of myasthenia gravis or acute narrow angle glaucoma', 'entities': [['12', '29', 'chronic_disease'], ['33', '60', 'chronic_disease']]}, 'NCT03021486'), ({'text': 'COPD exacerbation requiring treatment within 6 weeks of the screening visit', 'entities': [['1', '18', 'chronic_disease'], ['29', '38', 'treatment'], ['46', '53', 'upper_bound']]}, 'NCT02416102'), ({'text': 'Buccal plate dehiscence and/or fenestration >3mm at study site following extraction', 'entities': [['1', '24', 'clinical_variable'], ['32', '44', 'clinical_variable'], ['46', '49', 'lower_bound']]}, 'NCT02532543'), ({'text': 'Performance status of 0, 1, or 2', 'entities': [['1', '19', 'clinical_variable'], ['23', '24', 'lower_bound'], ['32', '33', 'upper_bound']]}, 'NCT02807883'), ({'text': 'Age > 21 years old', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02672098'), ({'text': "Documented diagnosis of Crohn's disease", 'entities': [['25', '40', 'chronic_disease']]}, 'NCT03058679'), ({'text': 'Patients with minor bleeding (e.g. epistaxis, haematuria) who can be managed with standard supportive care', 'entities': [['36', '45', 'chronic_disease'], ['47', '57', 'chronic_disease']]}, 'NCT02815670'), ({'text': 'CD123 positivity must be confirmed by either flow cytometry or immunohistochemistry within 90 days of study entry', 'entities': [['51', '60', 'clinical_variable'], ['64', '84', 'clinical_variable'], ['92', '99', 'upper_bound']]}, 'NCT02159495'), ({'text': 'Hepatitis B core antibody (Anti-HBc)', 'entities': [['1', '37', 'treatment']]}, 'NCT02508038'), ({'text': 'adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, other solid tumors, Hodgkin lymphoma, or non-Hodgkin lymphoma curatively treated with no evidence of disease for > 5 years', 'entities': [['20', '43', 'cancer'], ['64', '78', 'cancer'], ['100', '112', 'cancer'], ['114', '130', 'cancer'], ['135', '155', 'cancer'], ['209', '216', 'lower_bound']]}, 'NCT00819208'), ({'text': 'Patients with documented immunodeficiency such as HIV infection', 'entities': [['26', '42', 'chronic_disease'], ['51', '64', 'chronic_disease']]}, 'NCT01562626'), ({'text': 'Patients with dilation of the right or left anterior descending coronary artery beyond a z-score of +3 during the acute febrile phase of KD', 'entities': [['90', '97', 'clinical_variable'], ['102', '103', 'lower_bound'], ['138', '140', 'chronic_disease']]}, 'NCT01917721'), ({'text': 'Must have no contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment', 'entities': [['86', '96', 'treatment'], ['132', '147', 'allergy_name'], ['152', '172', 'allergy_name'], ['174', '189', 'allergy_name'], ['238', '247', 'chronic_disease'], ['251', '269', 'chronic_disease']]}, 'NCT01941316'), ({'text': 'Poorly controlled hypertension, diabetes mellitus, or other serious medical illness or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol', 'entities': [['19', '31', 'chronic_disease'], ['33', '50', 'chronic_disease'], ['69', '84', 'chronic_disease'], ['88', '107', 'chronic_disease'], ['164', '173', 'treatment']]}, 'NCT00734877'), ({'text': 'Immediate family member with a known or suspected Familial Cancer Syndrome', 'entities': [['51', '75', 'chronic_disease']]}, 'NCT02140554'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02359097'), ({'text': 'Participants who have a history of moderate to severe hepatic impairment (eg, Child-Pugh Class B or C)', 'entities': [['36', '73', 'chronic_disease'], ['79', '102', 'chronic_disease']]}, 'NCT02956486'), ({'text': 'Stable renal disease without evidence of renal progression in the past 28 days prior to dosing', 'entities': [['8', '21', 'chronic_disease'], ['67', '85', 'upper_bound']]}, 'NCT02852239'), ({'text': 'HIV-1 infected treatment-experienced, virologically suppressed males', 'entities': [['1', '4', 'chronic_disease'], ['16', '25', 'treatment'], ['64', '69', 'gender']]}, 'NCT02016924'), ({'text': 'Women of childbearing potential, defined as < 60 years of age, will require pregnancy testing', 'entities': [['1', '6', 'gender'], ['47', '55', 'upper_bound'], ['59', '62', 'age'], ['77', '86', 'pregnancy']]}, 'NCT02370095'), ({'text': 'Suicidal ideation', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT01964261'), ({'text': 'Patients with 2 or 3 risk factors will require a negative bone scan for eligibility', 'entities': [['15', '16', 'lower_bound'], ['20', '21', 'upper_bound'], ['59', '68', 'treatment']]}, 'NCT02040610'), ({'text': 'Chronotropic incompetence on recent (within 6 months) clinical or screening exercise test, defined as heart rate reserve (HRR) <0.80 or <0.62 if on beta blockers', 'entities': [['1', '26', 'chronic_disease'], ['45', '53', 'upper_bound'], ['55', '90', 'treatment'], ['103', '127', 'clinical_variable'], ['129', '133', 'upper_bound'], ['138', '142', 'upper_bound'], ['149', '162', 'treatment']]}, 'NCT02145351'), ({'text': 'Women of childbearing potential (not surgically sterile or less than 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 6 months after the last dose', 'entities': [['1', '6', 'gender'], ['38', '56', 'treatment'], ['70', '77', 'upper_bound'], ['99', '147', 'contraception_consent'], ['157', '193', 'contraception_consent'], ['232', '246', 'upper_bound']]}, 'NCT02592707'), ({'text': 'BMI 18.5-35 kg/m2', 'entities': [['1', '4', 'bmi'], ['5', '9', 'lower_bound'], ['10', '18', 'upper_bound']]}, 'NCT01433315'), ({'text': '18 to 70 years of age', 'entities': [['1', '3', 'lower_bound'], ['7', '15', 'upper_bound'], ['19', '22', 'age']]}, 'NCT02079857'), ({'text': 'Medical lab data (historical) of severe B cell dysfunction (low or absent IgG levels, failed immune response to vaccines)', 'entities': [['41', '59', 'chronic_disease'], ['75', '85', 'clinical_variable'], ['113', '121', 'treatment']]}, 'NCT01306019'), ({'text': "Reside within 75 miles of St. Louis Children's Hospital", 'entities': [['15', '23', 'upper_bound']]}, 'NCT02572791'), ({'text': 'Clinically significant congestive heart failure (known LVEF <= 45%, cor pulmonale, diastolic heart failure, etc', 'entities': [['24', '48', 'chronic_disease'], ['56', '60', 'clinical_variable'], ['64', '67', 'upper_bound'], ['69', '82', 'chronic_disease'], ['84', '107', 'chronic_disease']]}, 'NCT03085485'), ({'text': 'between 2.0 and 5 years 11 months', 'entities': [['9', '12', 'lower_bound'], ['17', '34', 'upper_bound']]}, 'NCT03131635'), ({'text': 'Hoehn and Yahr stage V subjects', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT01341080'), ({'text': 'Women', 'entities': [['1', '6', 'gender']]}, 'NCT03135171'), ({'text': 'received cytotoxic chemotherapy for either metastatic HSPC or CRPC within the last 12 weeks or other investigational agents within 4 weeks', 'entities': [['10', '32', 'treatment'], ['55', '59', 'cancer'], ['63', '67', 'cancer'], ['79', '92', 'upper_bound'], ['132', '139', 'upper_bound']]}, 'NCT03137758'), ({'text': 'Self-reported multiple sclerosis and confirmed by the physician', 'entities': [['15', '33', 'chronic_disease']]}, 'NCT02694666'), ({'text': 'Not pregnant or nursing, and report using oral, implant, injection or barrier contraceptives, or report being surgically sterile, or post menopausal', 'entities': [['1', '13', 'pregnancy'], ['37', '93', 'contraception_consent']]}, 'NCT02250664'), ({'text': 'Allogeneic stem cell transplantation is allowed provided the patient is >= 1 year from transplant at time of registration, is not on immunosuppressive therapy to treat/prevent graft-versus-host disease', 'entities': [['1', '37', 'treatment'], ['22', '32', 'treatment'], ['76', '82', 'lower_bound'], ['134', '159', 'treatment'], ['177', '202', 'chronic_disease']]}, 'NCT02004275'), ({'text': 'Unmutated (>98% homology to germline) IGHV4-34+expressing HCL/HCLv', 'entities': [['1', '10', 'clinical_variable'], ['13', '16', 'lower_bound']]}, 'NCT01059786'), ({'text': 'The effects of radiation on the developing human fetus are not well described. For this reason, women of child-bearing potential and non-sterilized men who are sexually active with a woman of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately', 'entities': [['97', '102', 'gender'], ['99', '102', 'gender'], ['184', '189', 'gender'], ['222', '257', 'contraception_consent'], ['259', '302', 'contraception_consent'], ['304', '314', 'contraception_consent'], ['361', '376', 'treatment'], ['393', '408', 'pregnancy'], ['400', '408', 'pregnancy']]}, 'NCT03141359'), ({'text': 'Total bilirubin =< 2.0 × the upper limit of the normal range (ULN)', 'entities': [['1', '16', 'clinical_variable'], ['20', '67', 'upper_bound']]}, 'NCT02542657'), ({'text': 'psychiatric conditions that might impact study compliance', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02928874'), ({'text': 'Uncontrolled hypertension (>140/90mmHg)', 'entities': [['14', '26', 'chronic_disease'], ['29', '39', 'lower_bound']]}, 'NCT01743950'), ({'text': 'Requirement for live vaccine exposure that would be expected to occur during the time frame of the study', 'entities': [['22', '29', 'treatment']]}, 'NCT03153319'), ({'text': '18 years of age or older', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT01269853'), ({'text': 'other major medical illnesses of the cardiovascular or respiratory systems or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['7', '30', 'chronic_disease'], ['79', '98', 'chronic_disease'], ['99', '116', 'chronic_disease']]}, 'NCT01553071'), ({'text': 'Histologically proven recurrent meningioma or aggressive meningioma', 'entities': [['33', '43', 'cancer']]}, 'NCT01967823'), ({'text': 'HIV positive', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT00920972'), ({'text': 'alopecia and sensory neuropathy =< grade 2', 'entities': [['1', '9', 'clinical_variable'], ['14', '32', 'clinical_variable'], ['36', '43', 'upper_bound']]}, 'NCT02520778'), ({'text': 'Unwilling or unable to refrain from use within 24 hours of scheduled study procedures', 'entities': [['48', '56', 'upper_bound']]}, 'NCT02233868'), ({'text': 'History of another primary invasive malignancy that has not been definitively treated or in remission for at least 2 years', 'entities': [['28', '47', 'cancer'], ['79', '86', 'treatment'], ['116', '123', 'lower_bound']]}, 'NCT02532231'), ({'text': 'Presence of current rectovaginal anovaginal or enterovesicular fistulae', 'entities': [['21', '33', 'chronic_disease'], ['34', '44', 'chronic_disease'], ['48', '72', 'chronic_disease']]}, 'NCT03077412'), ({'text': 'Concomitant use of bisphosphonates or RANK-ligand inhibitors is allowed', 'entities': [['20', '35', 'treatment'], ['39', '61', 'treatment']]}, 'NCT01676753'), ({'text': 'Known hypersensitivity to orteronel or to orteronel excipients, which are listed by formulation in the Investigator Brochure', 'entities': [['27', '36', 'allergy_name']]}, 'NCT01990209'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03022292'), ({'text': 'Tumor d 4 cm maximum diameter, including clinical stage IA and selected IB by PET/CT scan of the chest and upper abdomen performed within 60 days prior to registration', 'entities': [['1', '6', 'clinical_variable'], ['9', '30', 'upper_bound'], ['79', '82', 'treatment'], ['83', '121', 'treatment'], ['139', '152', 'upper_bound']]}, 'NCT02468024'), ({'text': 'drugs with sulfa moiety (e.g. sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics)', 'entities': [['31', '43', 'treatment'], ['45', '58', 'treatment'], ['60', '89', 'treatment'], ['91', '100', 'treatment'], ['106', '120', 'treatment']]}, 'NCT02901041'), ({'text': 'Personal Health Questionnaire Depression Scale (PHQ-8)> 15', 'entities': [['1', '55', 'clinical_variable'], ['57', '59', 'lower_bound']]}, 'NCT02907983'), ({'text': 'MR stage T3a without other high risk factors permitted at investigator discretion', 'entities': [['1', '13', 'cancer']]}, 'NCT02353819'), ({'text': 'have pathologically documented, definitely diagnosed advanced MTC that has progressed within 14 months prior to the Screening Visit and was not previously treat with cabozantinib and/or vandetanib', 'entities': [['63', '66', 'cancer'], ['94', '109', 'upper_bound'], ['167', '179', 'treatment'], ['187', '197', 'treatment']]}, 'NCT03037385'), ({'text': 'Age 1 - 17 years', 'entities': [['1', '4', 'age'], ['5', '6', 'lower_bound'], ['9', '17', 'upper_bound']]}, 'NCT01495637'), ({'text': 'Inherited predisposition to bleeding or thrombosis, INR >2, PT and PTT >1.5x ULN', 'entities': [['41', '51', 'chronic_disease'], ['53', '56', 'clinical_variable'], ['58', '59', 'lower_bound'], ['61', '63', 'clinical_variable'], ['68', '71', 'clinical_variable'], ['73', '81', 'lower_bound']]}, 'NCT02496585'), ({'text': 'Age >/= 18 years', 'entities': [['1', '4', 'age'], ['9', '17', 'lower_bound']]}, 'NCT02229565'), ({'text': 'Antithymocyte globulin (ATG) as part of the conditioning regimen', 'entities': [['1', '29', 'treatment']]}, 'NCT01795573'), ({'text': 'Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control (CDC) definition (HIV testing is not required for entry into this protocol)', 'entities': [['1', '43', 'chronic_disease'], ['109', '112', 'chronic_disease']]}, 'NCT01220583'), ({'text': 'A known hypersensitivity or contraindication to aspirin, heparin, ticlopidine (Ticlid), or clopidogrel (Plavix), or sensitivity to contrast media which cannot be adequately premedicated', 'entities': [['49', '56', 'allergy_name'], ['58', '65', 'allergy_name'], ['67', '87', 'allergy_name'], ['92', '112', 'allergy_name'], ['132', '146', 'allergy_name']]}, 'NCT02000115'), ({'text': 'Clinically or radiographically significant evidence of stroke', 'entities': [['56', '62', 'chronic_disease']]}, 'NCT02769000'), ({'text': 'Donors greater than or equal to 18 years of age must be the same individual whose cells were used as the source for the patient s original stem cell transplant', 'entities': [['33', '41', 'lower_bound'], ['45', '48', 'age'], ['140', '160', 'treatment']]}, 'NCT01087294'), ({'text': 'Does not speak/understand English enough to benefit from the psychotherapeutic intervention', 'entities': [['6', '34', 'language_fluency'], ['62', '92', 'treatment']]}, 'NCT02573246'), ({'text': 'Patients must be 18 years of age or older', 'entities': [['18', '26', 'lower_bound'], ['30', '33', 'age']]}, 'NCT02492867'), ({'text': 'basal or squamous cell carcinoma of the skin', 'entities': [['1', '45', 'cancer']]}, 'NCT03104699'), ({'text': 'Histologically confirmed refractory locally-advanced unresectable or metastatic pancreatic or biliary cancer', 'entities': [['70', '91', 'cancer'], ['95', '109', 'cancer']]}, 'NCT02451553'), ({'text': 'History of gastric or duodenal ulcer', 'entities': [['12', '37', 'chronic_disease']]}, 'NCT03058029'), ({'text': 'Absolute neutrophil count >1200/mm3', 'entities': [['1', '26', 'clinical_variable'], ['28', '36', 'lower_bound']]}, 'NCT02578641'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02687906'), ({'text': 'suspected aortic dissection', 'entities': [['11', '28', 'chronic_disease']]}, 'NCT02594501'), ({'text': 'Haploidentical related donors for pediatric recipients must be 6 years of age or older', 'entities': [['1', '15', 'treatment'], ['64', '71', 'lower_bound'], ['75', '78', 'age']]}, 'NCT01861106'), ({'text': 'Histologically-confirmed metastatic or recurrent HER2-negative (via IHC or FISH) breast cancer or other histologically-confirmed metastatic solid tumor', 'entities': [['26', '36', 'cancer'], ['50', '54', 'cancer'], ['69', '72', 'treatment'], ['76', '80', 'treatment'], ['82', '95', 'cancer'], ['130', '152', 'cancer']]}, 'NCT02401347'), ({'text': "Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of < 30 mL/min/1.73 m2", 'entities': [['1', '22', 'chronic_disease'], ['56', '64', 'treatment'], ['78', '82', 'clinical_variable'], ['88', '105', 'upper_bound']]}, 'NCT02524379'), ({'text': 'Severe edema', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02535832'), ({'text': 'Patients with renal failure and renal insufficiency', 'entities': [['15', '28', 'chronic_disease'], ['33', '52', 'chronic_disease']]}, 'NCT02967315'), ({'text': 'Thrombolysis within 6 weeks prior to enrollment', 'entities': [['1', '13', 'treatment'], ['21', '34', 'upper_bound']]}, 'NCT02331095'), ({'text': 'the subject has a history of allergic reaction to aspirin or progesterone', 'entities': [['51', '58', 'allergy_name'], ['62', '74', 'allergy_name']]}, 'NCT03151330'), ({'text': 'Fluent in English as assessed on the initial phone contact', 'entities': [['1', '18', 'language_fluency']]}, 'NCT03007745'), ({'text': 'stage I (140-159/90-99 mmHg) subjects with essential hypertension', 'entities': [['10', '13', 'lower_bound'], ['14', '28', 'upper_bound'], ['44', '66', 'chronic_disease']]}, 'NCT01996449'), ({'text': 'Karnofsky performance status of 70 or above', 'entities': [['1', '29', 'clinical_variable'], ['33', '35', 'lower_bound']]}, 'NCT02333162'), ({'text': 'Subject diagnosed according to the SCID I as suffering from any other major Axis I disorder, such as Psychotic Disorder, Bipolar affective disorder, OCD', 'entities': [['71', '92', 'chronic_disease'], ['102', '120', 'chronic_disease'], ['122', '148', 'chronic_disease'], ['150', '153', 'chronic_disease']]}, 'NCT02479906'), ({'text': 'Patients must be on no more than 0.1 mg/kg/day, max 4 mg/day dexamethasone for at least one week before study registration', 'entities': [['34', '47', 'upper_bound'], ['53', '61', 'upper_bound'], ['62', '75', 'treatment'], ['89', '97', 'lower_bound']]}, 'NCT01795313'), ({'text': 'HgB e 9.0 g/dL', 'entities': [['1', '4', 'clinical_variable'], ['7', '15', 'lower_bound']]}, 'NCT02585973'), ({'text': "may receive corrective magnesium supplementation but should continue to receive either prophylactic weekly infusion of magnesium and/or oral magnesium supplementation (eg, magnesium oxide) at the investigator's discretion", 'entities': [['13', '49', 'treatment'], ['88', '100', 'treatment'], ['108', '129', 'treatment'], ['137', '167', 'treatment'], ['173', '188', 'treatment']]}, 'NCT02128906'), ({'text': 'subjects 60-69 years of age who have one or more comorbidities', 'entities': [['10', '12', 'lower_bound'], ['13', '21', 'upper_bound'], ['25', '28', 'age']]}, 'NCT02947347'), ({'text': 'Patients with metastatic disease outside of the pelvis', 'entities': [['15', '25', 'cancer']]}, 'NCT01954173'), ({'text': 'Pain severity over the past seven days of four or greater on a 0-10 scale', 'entities': [['1', '14', 'clinical_variable'], ['24', '39', 'upper_bound'], ['43', '47', 'lower_bound'], ['64', '65', 'lower_bound'], ['66', '68', 'upper_bound']]}, 'NCT02423772'), ({'text': 'AST (SGOT)/ALT (SGPT) <2.5 x institutional upper limit of normal', 'entities': [['1', '22', 'clinical_variable'], ['24', '65', 'upper_bound']]}, 'NCT02873598'), ({'text': 'Ambulatory outpatients with breast (including ductal carcinoma in situ [DCIS]) cancer', 'entities': [['47', '78', 'cancer'], ['80', '86', 'cancer']]}, 'NCT02332928'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03185130'), ({'text': 'Male or Female', 'entities': [['1', '15', 'gender']]}, 'NCT02508311'), ({'text': 'between 4-18 years old', 'entities': [['9', '10', 'lower_bound'], ['11', '19', 'upper_bound']]}, 'NCT03073070'), ({'text': 'Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment', 'entities': [['9', '21', 'gender'], ['22', '63', 'contraception_consent'], ['79', '88', 'upper_bound']]}, 'NCT01434472'), ({'text': 'Liver disease/dysfunction (Child-Pugh score e 6), prior liver transplant, heart failure (NYHA Class III or IV); gastrointestinal bleeding', 'entities': [['1', '14', 'chronic_disease'], ['15', '26', 'chronic_disease'], ['28', '44', 'clinical_variable'], ['47', '48', 'lower_bound'], ['51', '73', 'treatment'], ['75', '88', 'treatment'], ['113', '138', 'chronic_disease']]}, 'NCT02570854'), ({'text': 'Clinical stage T1c or T2a', 'entities': [['1', '26', 'cancer']]}, 'NCT02600156'), ({'text': 'Life expectancy e 6 weeks', 'entities': [['1', '16', 'clinical_variable'], ['19', '26', 'lower_bound']]}, 'NCT02135588'), ({'text': 'presence of bipolar, psychotic or substance-abuse disorders', 'entities': [['13', '20', 'chronic_disease'], ['22', '31', 'chronic_disease'], ['35', '60', 'chronic_disease']]}, 'NCT02466126'), ({'text': 'Current pregnancy, breastfeeding or plans to become pregnant during the study', 'entities': [['1', '18', 'pregnancy'], ['37', '61', 'pregnancy']]}, 'NCT02945969'), ({'text': 'Late stage heart failure in NYHA Class IIIb or IV for at least 45 of past 60 days', 'entities': [['1', '25', 'chronic_disease'], ['29', '39', 'clinical_variable'], ['40', '44', 'lower_bound'], ['48', '50', 'upper_bound'], ['64', '66', 'lower_bound'], ['70', '82', 'upper_bound']]}, 'NCT01627821'), ({'text': 'history of gastrointestinal blood loss', 'entities': [['12', '39', 'chronic_disease']]}, 'NCT03073070'), ({'text': 'Baseline PSA > 2.5 ng/mL and d 10 ng/mL AND free PSA e 25% of total PSA (no biopsy required)', 'entities': [['1', '13', 'clinical_variable'], ['10', '13', 'clinical_variable'], ['16', '25', 'lower_bound'], ['32', '40', 'upper_bound'], ['56', '59', 'lower_bound'], ['77', '83', 'treatment']]}, 'NCT02167009'), ({'text': 'Bicarbonate <18 mmol/L', 'entities': [['1', '12', 'clinical_variable'], ['14', '23', 'upper_bound']]}, 'NCT02496611'), ({'text': 'Phase II: extensive stage small cell lung cancer with progression or recurrence after exactly one platinum-containing regimen', 'entities': [['27', '49', 'cancer'], ['99', '126', 'treatment']]}, 'NCT01941316'), ({'text': 'age between 18-80', 'entities': [['1', '4', 'age'], ['13', '15', 'lower_bound'], ['16', '18', 'upper_bound']]}, 'NCT02989597'), ({'text': 'No unstable angina pectoris < 6 months', 'entities': [['4', '28', 'clinical_variable'], ['31', '39', 'upper_bound']]}, 'NCT02384954'), ({'text': "Hodgkin's Lymphoma that has failed or are intolerant of Brentuximab, Grey Zone Lymphoma, ALCL, and mantle cell lymphoma", 'entities': [['1', '19', 'cancer'], ['57', '68', 'treatment'], ['70', '88', 'cancer'], ['90', '94', 'cancer'], ['100', '120', 'cancer']]}, 'NCT02203903'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status d1', 'entities': [['1', '61', 'clinical_variable'], ['63', '64', 'upper_bound']]}, 'NCT02290951'), ({'text': 'Males and females', 'entities': [['1', '6', 'gender'], ['11', '18', 'gender']]}, 'NCT02474667'), ({'text': 'has a history of food allergy', 'entities': [['18', '22', 'allergy_name']]}, 'NCT02589353'), ({'text': 'Osteomyelitis--compatible findings on plain radiograph, computed tomography, bone scan, magnetic resonance imaging, or positron emission tomography', 'entities': [['1', '14', 'chronic_disease'], ['40', '56', 'treatment'], ['58', '77', 'treatment'], ['79', '88', 'treatment'], ['90', '116', 'treatment'], ['121', '149', 'treatment']]}, 'NCT02099240'), ({'text': 'Patients who have history of PR prolongation (grade 2 or higher) or atrioventricular (AV) block', 'entities': [['30', '45', 'clinical_variable'], ['47', '54', 'lower_bound'], ['69', '96', 'chronic_disease']]}, 'NCT02276443'), ({'text': 'Other causes of heart failure other than diastolic dysfunction, such as restrictive cardiomyopathy or infiltrative cardiomyopathy', 'entities': [['17', '30', 'chronic_disease'], ['42', '63', 'chronic_disease'], ['73', '99', 'chronic_disease'], ['103', '130', 'chronic_disease']]}, 'NCT02053246'), ({'text': 'Negative skin test to panel of 12 allergens, including dust mite and cat allergen', 'entities': [['56', '65', 'allergy_name'], ['70', '73', 'allergy_name']]}, 'NCT02230189'), ({'text': 'Presence of esophageal motility disorder', 'entities': [['13', '41', 'chronic_disease']]}, 'NCT03090607'), ({'text': 'oral opioid treatment for > 3 months at a current dose of > 100 milligram (mg) morphine per day or equivalent', 'entities': [['1', '22', 'treatment'], ['29', '37', 'lower_bound'], ['61', '79', 'lower_bound'], ['80', '88', 'treatment']]}, 'NCT02100956'), ({'text': 'Any prior therapy (chemotherapy, radiation or surgery) for pancreatic adenocarcinoma other than biliary decompression', 'entities': [['5', '18', 'treatment'], ['20', '32', 'treatment'], ['34', '43', 'treatment'], ['47', '54', 'treatment'], ['60', '85', 'cancer'], ['97', '118', 'treatment']]}, 'NCT02427841'), ({'text': 'Adults (ages 21-50)', 'entities': [['9', '13', 'age'], ['14', '16', 'lower_bound'], ['17', '19', 'upper_bound']]}, 'NCT02819440'), ({'text': 'Subjects with confirmed Hepatitis A, B or C', 'entities': [['25', '44', 'chronic_disease']]}, 'NCT02004028'), ({'text': 'Has an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2', 'entities': [['8', '68', 'clinical_variable'], ['69', '70', 'lower_bound'], ['74', '75', 'upper_bound']]}, 'NCT02319369'), ({'text': 'Patients with carotid occlusion', 'entities': [['15', '32', 'chronic_disease']]}, 'NCT03068442'), ({'text': 'have previous therapy with talimogene laherparepvec, oncolyic viruses, or tumor vaccine', 'entities': [['6', '52', 'treatment'], ['54', '70', 'treatment'], ['75', '88', 'treatment']]}, 'NCT02509507'), ({'text': "concomitant central nervous system disease that could influence cognition, such as large vessel territory stroke, Alzheimer's disease, Parkinson's disease, or Lewy body dementia", 'entities': [['13', '43', 'chronic_disease'], ['84', '113', 'chronic_disease'], ['115', '134', 'chronic_disease'], ['136', '155', 'chronic_disease'], ['160', '178', 'chronic_disease']]}, 'NCT02544373'), ({'text': 'History of severe traumatic brain injuries', 'entities': [['12', '43', 'chronic_disease']]}, 'NCT03090672'), ({'text': 'Positive screening tests for HIV, HCV or HBV', 'entities': [['30', '33', 'chronic_disease'], ['35', '38', 'chronic_disease'], ['42', '45', 'chronic_disease']]}, 'NCT02460783'), ({'text': 'Severe Cardiac disease in pregnancy with marked functional limitations (NYHA Class III and IV)', 'entities': [['8', '23', 'chronic_disease'], ['27', '36', 'pregnancy']]}, 'NCT02025426'), ({'text': 'be able to sit in a chair for more than 15 minutes at a time', 'entities': [['41', '51', 'lower_bound']]}, 'NCT03015272'), ({'text': 'with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer or prior ovarian/breast cancer in patients with BRCA associated breast cancer', 'entities': [['43', '48', 'cancer'], ['52', '75', 'cancer'], ['77', '105', 'cancer'], ['129', '144', 'cancer'], ['154', '161', 'cancer'], ['162', '175', 'cancer']]}, 'NCT02393794'), ({'text': 'participation in any nonpharmacological treatment (including CBT) for pain, sleep, fatigue, or mood outside the current study', 'entities': [['22', '66', 'treatment']]}, 'NCT02688569'), ({'text': 'uncontrolled hypertension', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT02426476'), ({'text': 'Patients must have adequate immune system function, with no known immunodeficiency disease', 'entities': [['67', '91', 'chronic_disease']]}, 'NCT02844738'), ({'text': 'Any patient taking a bisphosphonate for heterotopic ossification (HO)', 'entities': [['22', '36', 'treatment'], ['41', '70', 'chronic_disease']]}, 'NCT01983475'), ({'text': '21-50 years old', 'entities': [['1', '3', 'lower_bound'], ['4', '12', 'upper_bound']]}, 'NCT02536846'), ({'text': 'Not pregnant and not nursing', 'entities': [['5', '13', 'pregnancy']]}, 'NCT02578732'), ({'text': 'Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (CTCAE grade 1)', 'entities': [['1', '10', 'clinical_variable'], ['33', '66', 'upper_bound']]}, 'NCT01042522'), ({'text': 'galectin-3 level > 26 ng/ml', 'entities': [['1', '17', 'clinical_variable'], ['20', '28', 'lower_bound']]}, 'NCT03133793'), ({'text': 'Body weight > 5th percentile for age', 'entities': [['1', '12', 'clinical_variable'], ['15', '29', 'lower_bound'], ['34', '37', 'age']]}, 'NCT02401035'), ({'text': 'Patients unable to undergo MRI imaging because of having an artificial heart valve, metal plate, pin, or other metallic objects in their body or is unable to complete all the MRI scans required for this study', 'entities': [['28', '39', 'treatment']]}, 'NCT02446886'), ({'text': 'stroke', 'entities': [['1', '7', 'chronic_disease']]}, 'NCT03123731'), ({'text': 'Patients with > Grade 1 neuropathy at screening', 'entities': [['17', '24', 'lower_bound'], ['25', '35', 'clinical_variable']]}, 'NCT01554371'), ({'text': 'FEV1 > 90% predicted', 'entities': [['1', '5', 'clinical_variable'], ['8', '11', 'lower_bound']]}, 'NCT02154568'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT02342782'), ({'text': 'atrial fibrillation from a reversible cause (e.g., surgery, hyperthyroidism, pericarditis)', 'entities': [['1', '20', 'chronic_disease'], ['52', '59', 'treatment'], ['61', '76', 'chronic_disease'], ['78', '90', 'chronic_disease']]}, 'NCT02169037'), ({'text': 'Patients treated before with any biological or small molecule or medication under investigation for the treatment of RA', 'entities': [['34', '44', 'treatment'], ['48', '62', 'treatment'], ['66', '76', 'treatment'], ['105', '114', 'treatment'], ['118', '120', 'chronic_disease']]}, 'NCT01864265'), ({'text': 'plans to become pregnant during the course of the study', 'entities': [['1', '25', 'pregnancy']]}, 'NCT03104517'), ({'text': 'Patients with a history of or active autoimmune disease', 'entities': [['38', '56', 'chronic_disease']]}, 'NCT02536794'), ({'text': 'Patients with disease that is suitable for local therapy administered', 'entities': [['44', '57', 'treatment']]}, 'NCT03036098'), ({'text': 'infertile female', 'entities': [['11', '17', 'gender']]}, 'NCT02489539'), ({'text': 'Bilirubin =< 1.5 x ULN', 'entities': [['1', '10', 'clinical_variable'], ['14', '23', 'upper_bound']]}, 'NCT01877382'), ({'text': 'Age >/= 18 years', 'entities': [['1', '4', 'age'], ['9', '17', 'lower_bound']]}, 'NCT01950234'), ({'text': 'Men and women, at least 18 years of age', 'entities': [['1', '4', 'gender'], ['9', '14', 'gender'], ['25', '33', 'lower_bound'], ['37', '40', 'age']]}, 'NCT02429934'), ({'text': 'history of gallbladder problems or gallstones, or biliary obstruction', 'entities': [['12', '32', 'chronic_disease'], ['36', '46', 'chronic_disease'], ['51', '70', 'chronic_disease']]}, 'NCT02064673'), ({'text': 'pregnant females', 'entities': [['1', '9', 'pregnancy'], ['10', '17', 'gender']]}, 'NCT02277782'), ({'text': 'BP >160/90', 'entities': [['1', '3', 'clinical_variable'], ['5', '11', 'lower_bound']]}, 'NCT00065676'), ({'text': 'Zubrod Performance Status 0-2', 'entities': [['1', '26', 'clinical_variable'], ['27', '28', 'lower_bound'], ['29', '30', 'upper_bound']]}, 'NCT02353819'), ({'text': "Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study", 'entities': [['36', '43', 'chronic_disease'], ['47', '68', 'chronic_disease']]}, 'NCT02199236'), ({'text': 'age: 21-45 yrs', 'entities': [['1', '4', 'age'], ['6', '8', 'lower_bound'], ['9', '15', 'upper_bound']]}, 'NCT02047721'), ({'text': 'agree not to seek additional alcohol or other substance abuse treatment during the study period', 'entities': [['63', '72', 'treatment']]}, 'NCT02409888'), ({'text': 'with pulmonary veno-occlusive disease', 'entities': [['6', '38', 'chronic_disease']]}, 'NCT02932410'), ({'text': 'Subjects with a history of symptomatic interstitial lung disease', 'entities': [['40', '65', 'chronic_disease']]}, 'NCT02259621'), ({'text': 'Late stage renal failure with estimated glomerular filtration rate (eGFR)', 'entities': [['12', '25', 'chronic_disease'], ['31', '74', 'clinical_variable']]}, 'NCT02095678'), ({'text': 'Patients with history of histologically-confirmed malignant solid tumor (histology confirmed by MSKCC Department of Pathology.)', 'entities': [['51', '60', 'cancer'], ['61', '72', 'cancer']]}, 'NCT02421380'), ({'text': 'Cognitive impairment and/or capacity impairment preventing reliable outcome measures self-report', 'entities': [['1', '21', 'chronic_disease'], ['29', '48', 'chronic_disease']]}, 'NCT02326818'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT02370732'), ({'text': 'Patients who were previously treated with cediranib are ineligible', 'entities': [['19', '52', 'treatment']]}, 'NCT02484404'), ({'text': 'Known history of hepatitis C or known active hepatitis B infection', 'entities': [['18', '29', 'chronic_disease'], ['46', '67', 'chronic_disease']]}, 'NCT02932280'), ({'text': 'Pervasive Developmental Disorders (PDD) or mental retardation', 'entities': [['1', '40', 'chronic_disease'], ['44', '62', 'chronic_disease']]}, 'NCT02922335'), ({'text': 'Less than or equal to 10 days of age', 'entities': [['23', '30', 'upper_bound'], ['34', '37', 'age']]}, 'NCT02140255'), ({'text': 'Any investigational drug or device within 30 days of Screening or within 6 half-lives of the investigational drug (whichever is longer)', 'entities': [['5', '35', 'treatment'], ['5', '25', 'treatment'], ['43', '50', 'upper_bound'], ['74', '86', 'upper_bound']]}, 'NCT02323100'), ({'text': 'History of prior malignancy. However, cancer survivors who have undergone potentially curative therapy may be considered for stem cell donation on a case-by-case basis', 'entities': [['18', '28', 'cancer'], ['39', '45', 'cancer'], ['96', '103', 'treatment']]}, 'NCT01861106'), ({'text': 'be enrolled in the Fabry Registry and receiving Fabrazyme while lactating', 'entities': [['49', '58', 'treatment']]}, 'NCT00230607'), ({'text': 'Myelodysplastic syndrome with isolated del(5q) (5q-syndrome)', 'entities': [['1', '25', 'cancer'], ['49', '60', 'chronic_disease']]}, 'NCT02016781'), ({'text': 'recent myocardial infarction (within the last 6 months)', 'entities': [['8', '29', 'chronic_disease'], ['42', '55', 'upper_bound']]}, 'NCT02595866'), ({'text': 'Female participants must agree to abstain from sexual relations that could result in pregnancy or use a reliable form of birth control during the study', 'entities': [['1', '20', 'gender'], ['86', '95', 'pregnancy']]}, 'NCT02266329'), ({'text': 'ALT (alanine aminotransferase, SCPT) d 5 x Upper LImit of Normal (ULN) for age', 'entities': [['1', '37', 'clinical_variable'], ['40', '71', 'upper_bound'], ['76', '79', 'age']]}, 'NCT02508038'), ({'text': 'Females of childbearing potential must have negative pregnancy test', 'entities': [['1', '8', 'gender'], ['45', '63', 'pregnancy']]}, 'NCT02928991'), ({'text': 'Newly diagnosed and recurrent high grade gliomas (WHO grades III & IV)', 'entities': [['31', '71', 'cancer']]}, 'NCT02781792'), ({'text': 'Concomitant enrollment in any other drug/device clinical trial', 'entities': [['31', '63', 'treatment']]}, 'NCT01986205'), ({'text': 'TNBC determination as per local institution as per standard guidelines', 'entities': [['1', '5', 'cancer']]}, 'NCT02574455'), ({'text': 'Patients must be age e18 years', 'entities': [['18', '21', 'age'], ['23', '31', 'lower_bound']]}, 'NCT02471911'), ({'text': 'A sinus communicating with the prosthesis', 'entities': [['32', '42', 'treatment']]}, 'NCT02734134'), ({'text': 'Consistent use of NSAIDs within 48 hours of procedure', 'entities': [['19', '25', 'treatment'], ['33', '41', 'upper_bound']]}, 'NCT02844751'), ({'text': 'Older than 18 years of age', 'entities': [['12', '20', 'lower_bound'], ['24', '27', 'age']]}, 'NCT02680145'), ({'text': 'TIA or stroke in the last 1 month', 'entities': [['1', '4', 'chronic_disease'], ['8', '14', 'chronic_disease'], ['22', '34', 'upper_bound']]}, 'NCT00147056'), ({'text': 'Underlying hypoproliferative anemia (i.e. myelodysplasia)', 'entities': [['12', '36', 'chronic_disease'], ['43', '57', 'cancer']]}, 'NCT02287558'), ({'text': 'Life expectancy of e 3 months', 'entities': [['1', '16', 'clinical_variable'], ['22', '30', 'lower_bound']]}, 'NCT02702492'), ({'text': "Bilirubin <1.5 x ULN [unless bilirubin rise is due to Gilbert's syndrome (as defined by >80% unconjugated hyperbilirubinemia) or of nonhepatic origin]", 'entities': [['1', '10', 'clinical_variable'], ['12', '21', 'upper_bound'], ['30', '39', 'clinical_variable'], ['55', '73', 'chronic_disease'], ['90', '93', 'lower_bound'], ['94', '125', 'chronic_disease']]}, 'NCT02309580'), ({'text': 'Current or anticipated use of strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazadone, ritonavir, and atazanavir)', 'entities': [['38', '55', 'treatment'], ['62', '74', 'treatment'], ['76', '90', 'treatment'], ['92', '102', 'treatment'], ['104', '113', 'treatment'], ['119', '129', 'treatment']]}, 'NCT02053909'), ({'text': 'any prior solid organ transplant or prior hematopoietic stem cell transplant', 'entities': [['5', '33', 'treatment'], ['37', '77', 'treatment']]}, 'NCT02378714'), ({'text': 'Previously undergone e 2 cycles of lenalidomide and a proteasome inhibitor (in separate therapeutic regimens [not for maintenance] or in combination)', 'entities': [['24', '32', 'lower_bound'], ['36', '48', 'treatment'], ['55', '75', 'treatment']]}, 'NCT02343042'), ({'text': 'Able to speak English at a level sufficient to undergo study procedures', 'entities': [['1', '22', 'language_fluency']]}, 'NCT02762604'), ({'text': 'Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition', 'entities': [['1', '23', 'chronic_disease'], ['31', '43', 'chronic_disease']]}, 'NCT03102320'), ({'text': 'Participants who are currently receiving nitrosoureas or who have received this therapy 6 weeks prior to registration', 'entities': [['42', '54', 'treatment'], ['89', '102', 'upper_bound']]}, 'NCT02382549'), ({'text': 'Have a history of renal transplant', 'entities': [['19', '35', 'treatment']]}, 'NCT02682407'), ({'text': 'women with a history of breast cancer or a BRCA mutation', 'entities': [['1', '6', 'gender'], ['25', '38', 'cancer'], ['44', '57', 'cancer']]}, 'NCT03180086'), ({'text': 'Any factor that precludes MRI scan including presence of metal or exposure to metal work (e.g. metal grinder/worker) and claustrophobia', 'entities': [['27', '35', 'treatment'], ['122', '136', 'chronic_disease']]}, 'NCT02159027'), ({'text': 'Histological or cytological documentation of adenocarcinoma of the colon or rectum', 'entities': [['46', '60', 'cancer']]}, 'NCT02138617'), ({'text': 'Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events', 'entities': [['21', '37', 'cancer']]}, 'NCT02567422'), ({'text': 'Active uncontrolled serious infection', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT02865135'), ({'text': 'Previous diagnosis of grade 1 or 2, stage I or II endometrioid endometrial cancers (type I cancers) as confirmed during surgical intervention for treatment', 'entities': [['23', '83', 'cancer'], ['85', '99', 'cancer'], ['121', '142', 'treatment'], ['147', '156', 'treatment']]}, 'NCT02465541'), ({'text': 'Congenital anomalies', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02847689'), ({'text': '12-lead electrocardiogram (ECG) conducted at the screening visit within normal limits or abnormal but not clinically significant to the Investigator', 'entities': [['9', '32', 'clinical_variable']]}, 'NCT02495168'), ({'text': 'Cardiovascular disorders', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02496208'), ({'text': 'Acute myeloid leukemia with high risk features', 'entities': [['1', '23', 'cancer']]}, 'NCT01760655'), ({'text': 'Any of the following exclusionary criteria related to the use of electrocardiogram (history of rash from adhesives)', 'entities': [['66', '83', 'treatment']]}, 'NCT02428205'), ({'text': 'Untreated rampant caries and uncontrolled periodontal disease', 'entities': [['11', '25', 'chronic_disease'], ['43', '62', 'chronic_disease']]}, 'NCT02532543'), ({'text': 'Absolute neutrophil count (ANC) >= 1,500/mcL', 'entities': [['1', '32', 'clinical_variable'], ['36', '45', 'lower_bound']]}, 'NCT02437370'), ({'text': "a second lesion accessible for biopsy must also be present; patients must have at least one 'target lesion' to be used to assess response on this protocol as defined by Response Evaluation Criteria in Solid Tumors (RECIST)", 'entities': [['32', '38', 'treatment'], ['89', '92', 'lower_bound']]}, 'NCT01591356'), ({'text': 'Diabetes type 2 (DM) group: diagnosis and treatment for type 2 DM with non-insulin oral or injectable agents', 'entities': [['1', '21', 'chronic_disease'], ['57', '66', 'chronic_disease'], ['72', '88', 'treatment'], ['92', '109', 'treatment']]}, 'NCT02415556'), ({'text': 'new-onset angina within 3 months before randomization', 'entities': [['11', '17', 'chronic_disease'], ['25', '33', 'upper_bound']]}, 'NCT03042689'), ({'text': 'History of hypertensive crisis or hypertensive encephalopathy within 3 years prior to registration', 'entities': [['12', '31', 'chronic_disease'], ['35', '62', 'chronic_disease'], ['70', '83', 'upper_bound']]}, 'NCT02498613'), ({'text': 'Hepatic: AST < 3 x upper normal', 'entities': [['10', '13', 'clinical_variable'], ['16', '32', 'upper_bound']]}, 'NCT01505569'), ({'text': 'Terminal illness', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02905370'), ({'text': 'Patients who are currently taking Coumadin or Coumadin derivatives other than to maintain patency of venous access lines', 'entities': [['35', '43', 'treatment'], ['47', '67', 'treatment']]}, 'NCT02340156'), ({'text': 'Negative pregnancy test for all females at screening and baseline', 'entities': [['1', '19', 'pregnancy'], ['33', '40', 'gender']]}, 'NCT02560766'), ({'text': 'Patients who are pregnant', 'entities': [['14', '26', 'pregnancy']]}, 'NCT02269293'), ({'text': 'primary cutaneous type', 'entities': [['1', '23', 'cancer']]}, 'NCT01787409'), ({'text': 'sedatives', 'entities': [['1', '10', 'treatment']]}, 'NCT02724540'), ({'text': 'It is highly recommended but not required that SGOT or SGPT be =< 1.5 upper limit of normal', 'entities': [['48', '52', 'clinical_variable'], ['56', '60', 'clinical_variable'], ['67', '92', 'upper_bound']]}, 'NCT01993810'), ({'text': 'Suitable arterial anatomy for endovascular repair', 'entities': [['31', '50', 'treatment']]}, 'NCT00483249'), ({'text': 'Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible', 'entities': [['28', '43', 'cancer']]}, 'NCT02272998'), ({'text': 'Anti-platelet therapy', 'entities': [['1', '22', 'treatment']]}, 'NCT02278315'), ({'text': 'Extensive intraductal component', 'entities': [['1', '32', 'clinical_variable']]}, 'NCT01570998'), ({'text': "Total bilirubin less than or equal to the institution's upper limit of normal", 'entities': [['1', '16', 'clinical_variable']]}, 'NCT02474173'), ({'text': 'Patients who do not complete the duration of treatment of negative pressure wound therapy (7 days), or patients who do not follow up for a minimum of 30 days from the date of surgery will be excluded', 'entities': [['59', '90', 'treatment'], ['151', '158', 'lower_bound'], ['176', '183', 'treatment']]}, 'NCT03010137'), ({'text': 'History of other previous cancer that would interfere with the determination of safety or efficacy', 'entities': [['27', '33', 'cancer']]}, 'NCT02568267'), ({'text': 'Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment', 'entities': [['68', '89', 'treatment'], ['102', '124', 'treatment'], ['132', '139', 'upper_bound'], ['161', '170', 'treatment']]}, 'NCT02437370'), ({'text': 'Intolerance or contraindications to aspirin or clopidogrel (including thrombocytopenia, prolonged INR)', 'entities': [['37', '44', 'allergy_name'], ['48', '59', 'allergy_name'], ['71', '87', 'allergy_name'], ['89', '102', 'allergy_name']]}, 'NCT02169739'), ({'text': 'Eligible for infusional 5-FU or capecitabine', 'entities': [['25', '29', 'treatment'], ['33', '45', 'treatment']]}, 'NCT02199236'), ({'text': 'symptomatic congestive heart failure', 'entities': [['1', '37', 'chronic_disease']]}, 'NCT02843568'), ({'text': 'Any of the following within 6 months prior to starting study drug: myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft (CABG), Congestive Heart Failure (CHF), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA), Pulmonary Embolism (PE)', 'entities': [['29', '43', 'upper_bound'], ['56', '66', 'treatment'], ['68', '94', 'chronic_disease'], ['103', '118', 'chronic_disease'], ['120', '155', 'treatment'], ['157', '187', 'chronic_disease'], ['189', '219', 'chronic_disease'], ['221', '252', 'chronic_disease'], ['254', '277', 'chronic_disease']]}, 'NCT01894061'), ({'text': 'Patients with known Lidocaine/Acetylcysteine allergies', 'entities': [['21', '30', 'allergy_name'], ['31', '45', 'allergy_name']]}, 'NCT01585103'), ({'text': 'Urine cotinine level e 100 ng/ml (NicAlert® reading e 3)', 'entities': [['1', '21', 'clinical_variable'], ['24', '33', 'lower_bound'], ['35', '44', 'clinical_variable'], ['55', '56', 'lower_bound']]}, 'NCT02968602'), ({'text': 'Evidence of untreated infection', 'entities': [['23', '32', 'chronic_disease']]}, 'NCT02271711'), ({'text': 'unstable angina pectoris', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02857218'), ({'text': "Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements", 'entities': [['1', '8', 'chronic_disease'], ['12', '36', 'chronic_disease']]}, 'NCT02478255'), ({'text': 'Clinical history compatible with T1D with disease onset < 40 years of age', 'entities': [['34', '37', 'chronic_disease'], ['43', '56', 'clinical_variable'], ['59', '67', 'upper_bound'], ['71', '74', 'age']]}, 'NCT02464878'), ({'text': 'Prior systemic cytotoxic chemotherapy or systemic anthracycline', 'entities': [['16', '38', 'treatment'], ['42', '64', 'treatment']]}, 'NCT02177695'), ({'text': 'Ischemic lesions in the index leg stable for at least 2 weeks', 'entities': [['1', '17', 'chronic_disease'], ['55', '62', 'lower_bound']]}, 'NCT03006770'), ({'text': 'laboratory evidence of diabetes', 'entities': [['24', '32', 'chronic_disease']]}, 'NCT03099590'), ({'text': 'Current diagnosis of major depressive disorder (DSM-IV-TR), single episode, recurrent or chronic, without psychotic features, as detected by MINI and clinical exam', 'entities': [['22', '47', 'chronic_disease']]}, 'NCT02332291'), ({'text': 'medications: oral steroids', 'entities': [['1', '12', 'treatment'], ['14', '27', 'treatment']]}, 'NCT02347995'), ({'text': 'Uncontrolled hyperthyroidism', 'entities': [['14', '29', 'chronic_disease']]}, 'NCT02346201'), ({'text': "Known bleeding diathesis (eg, von Willebrand's disease) or hemophilia", 'entities': [['7', '25', 'chronic_disease'], ['31', '55', 'chronic_disease'], ['60', '70', 'chronic_disease']]}, 'NCT02309580'), ({'text': 'Women who are pregnant or plan to become pregnant', 'entities': [['1', '6', 'gender'], ['15', '23', 'pregnancy'], ['27', '50', 'pregnancy']]}, 'NCT02131467'), ({'text': 'Able to complete study assessments in English or Spanish language', 'entities': [['39', '66', 'language_fluency']]}, 'NCT02844465'), ({'text': 'Patients who have a documented forced expiratory volume in 1 second (FEV1) of d 60%', 'entities': [['70', '74', 'clinical_variable'], ['81', '84', 'upper_bound']]}, 'NCT02360579'), ({'text': 'Chronic leukemias', 'entities': [['9', '18', 'cancer']]}, 'NCT02356653'), ({'text': 'Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject', 'entities': [['1', '34', 'contraception_consent']]}, 'NCT02481310'), ({'text': 'Amphetamines', 'entities': [['1', '13', 'treatment']]}, 'NCT01842399'), ({'text': 'Male sex at birth', 'entities': [['1', '5', 'gender']]}, 'NCT02335138'), ({'text': 'Participant has a requirement of acyclovir and/or related products during study duration', 'entities': [['34', '43', 'treatment']]}, 'NCT02862938'), ({'text': 'Abnormal brain magnetic resonance imaging (MRI) scan, including severe atrophy, hydrocephalus, stroke, structural lesions, demyelinating lesions, or infectious lesions that would potentially confound the outcome or safety of the surgery as judged by the study neurosurgeon', 'entities': [['10', '53', 'treatment'], ['65', '79', 'chronic_disease'], ['81', '94', 'chronic_disease'], ['96', '102', 'chronic_disease'], ['104', '122', 'chronic_disease'], ['124', '145', 'chronic_disease'], ['150', '168', 'chronic_disease'], ['230', '237', 'treatment']]}, 'NCT02056873'), ({'text': 'Pregnant or lactating women', 'entities': [['1', '9', 'pregnancy'], ['23', '28', 'gender']]}, 'NCT03017118'), ({'text': '5 contrast-enhancing lesion on screening MRI performed within one week of administration of mangafodipir', 'entities': [['42', '45', 'treatment'], ['63', '71', 'upper_bound'], ['93', '105', 'treatment']]}, 'NCT01326715'), ({'text': 'Age: 21 to 70', 'entities': [['1', '4', 'age'], ['6', '8', 'lower_bound'], ['12', '14', 'upper_bound']]}, 'NCT02781701'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02495935'), ({'text': 'Subject suffers from an uncomplicated ventral hernia that requires surgical repair with the use of an implant to reinforce or replace weakened or missing tissue', 'entities': [['39', '53', 'chronic_disease'], ['68', '161', 'treatment']]}, 'NCT03074474'), ({'text': 'Patients undergoing elective laparoscopic surgery', 'entities': [['21', '50', 'treatment']]}, 'NCT02708836'), ({'text': 'nursing (lactating) women', 'entities': [['21', '26', 'gender']]}, 'NCT02321501'), ({'text': 'psychiatric comorbid condition', 'entities': [['1', '31', 'chronic_disease']]}, 'NCT02709980'), ({'text': 'abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis]', 'entities': [['10', '34', 'clinical_variable'], ['38', '45', 'lower_bound'], ['61', '75', 'treatment'], ['120', '138', 'chronic_disease'], ['139', '147', 'chronic_disease']]}, 'NCT02124772'), ({'text': 'BMI between 20-33', 'entities': [['1', '4', 'bmi'], ['13', '15', 'lower_bound'], ['16', '18', 'upper_bound']]}, 'NCT01576575'), ({'text': 'Previous or concurrent cytotoxic chemotherapy for prostate cancer', 'entities': [['24', '46', 'treatment'], ['51', '66', 'cancer']]}, 'NCT02040610'), ({'text': 'Scarring or infection in the area being treated', 'entities': [['13', '22', 'chronic_disease']]}, 'NCT02075671'), ({'text': "Poor liver function: bilirubin >2.5 mg/dl (not due to hemolysis, Gilbert's or primary malignancy), AST/ALT > 3X ULN", 'entities': [['22', '31', 'clinical_variable'], ['33', '42', 'lower_bound'], ['55', '64', 'chronic_disease'], ['66', '97', 'chronic_disease'], ['100', '103', 'clinical_variable'], ['104', '107', 'clinical_variable'], ['110', '116', 'lower_bound']]}, 'NCT02416206'), ({'text': 'TS must be causing incapacitation with severe distress, self-injurious behavior, and/or quality of life disruption', 'entities': [['1', '3', 'cancer']]}, 'NCT02056873'), ({'text': 'Patients with active invasive cancers, other than MPM, that require additional treatment, except non-melanomatous skin cancer, superficial bladder or cervical cancer, and early-stage prostate cancer', 'entities': [['22', '38', 'cancer'], ['51', '54', 'cancer'], ['80', '89', 'treatment'], ['98', '126', 'cancer'], ['128', '147', 'cancer'], ['151', '166', 'cancer'], ['184', '199', 'cancer']]}, 'NCT02153229'), ({'text': 'Verapamil (e.g., Calan SR, Isoptin, Verelan)', 'entities': [['1', '10', 'treatment'], ['18', '26', 'treatment'], ['28', '35', 'treatment'], ['37', '44', 'treatment']]}, 'NCT02583893'), ({'text': 'Uncontrolled hypertension despite appropriate medical therapy (blood pressure [BP] greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening visit)', 'entities': [['14', '26', 'chronic_disease'], ['47', '62', 'treatment'], ['64', '83', 'clinical_variable'], ['97', '105', 'lower_bound'], ['119', '126', 'lower_bound'], ['140', '141', 'upper_bound'], ['177', '187', 'upper_bound']]}, 'NCT02217709'), ({'text': 'Have received chemotherapy in the last 12 months', 'entities': [['15', '27', 'treatment'], ['35', '49', 'upper_bound']]}, 'NCT01901562'), ({'text': 'History of hypersensitivity to the contrast agent perflutren', 'entities': [['51', '61', 'allergy_name']]}, 'NCT02424955'), ({'text': '> 4 weeks from prior therapy completion (including radiation and/or surgery)', 'entities': [['3', '10', 'lower_bound'], ['16', '29', 'treatment'], ['52', '61', 'treatment'], ['69', '76', 'treatment']]}, 'NCT02419495'), ({'text': 'Confirmed hepatocellular carcinoma (HCC)', 'entities': [['11', '41', 'cancer']]}, 'NCT02762266'), ({'text': 'Have history of anaphylaxis to milk', 'entities': [['32', '36', 'allergy_name']]}, 'NCT02778867'), ({'text': 'Male and female subjects', 'entities': [['1', '5', 'gender'], ['10', '16', 'gender']]}, 'NCT01474889'), ({'text': 'youth with primary conditions not specified for exclusion (e.g., eating disorders, schizophrenia) will be screened', 'entities': [['66', '82', 'chronic_disease'], ['84', '97', 'chronic_disease']]}, 'NCT02567266'), ({'text': 'A history of hypertension, coronary artery disease, heart failure, stroke, diabetes, malignancy, chronic pulmonary, kidney or rheumatologic disease, muscle pain/fatigue, smoking within the past 5 years, regular use of any medications', 'entities': [['14', '26', 'chronic_disease'], ['28', '51', 'chronic_disease'], ['53', '66', 'chronic_disease'], ['68', '74', 'chronic_disease'], ['76', '84', 'chronic_disease'], ['86', '96', 'cancer'], ['98', '115', 'chronic_disease'], ['117', '148', 'chronic_disease'], ['190', '202', 'upper_bound'], ['223', '234', 'treatment']]}, 'NCT03122639'), ({'text': 'Co-morbidities of non-psychotic behavioral disorders, including PTSD and mild Traumatic Brain Injury (mTBI) are eligible to participate', 'entities': [['1', '53', 'chronic_disease'], ['65', '69', 'chronic_disease'], ['74', '108', 'chronic_disease']]}, 'NCT01794559'), ({'text': 'Have an ALT or AST > 5.0 x the upper limit of normal', 'entities': [['9', '12', 'clinical_variable'], ['16', '19', 'clinical_variable'], ['22', '53', 'lower_bound']]}, 'NCT02682407'), ({'text': 'Women who are pregnant', 'entities': [['1', '6', 'gender'], ['11', '23', 'pregnancy']]}, 'NCT03068130'), ({'text': 'planned surgery requiring general anesthesia during the pharmacotherapy period', 'entities': [['9', '16', 'treatment'], ['57', '72', 'treatment']]}, 'NCT03179163'), ({'text': 'Hemoglobin >= 9 g/dL without transfusion dependency', 'entities': [['1', '11', 'clinical_variable'], ['15', '21', 'lower_bound']]}, 'NCT02581982'), ({'text': 'Previously diagnosed type 1 Diabetes', 'entities': [['22', '37', 'chronic_disease']]}, 'NCT02362308'), ({'text': 'hypertension, renal disease, thrombophilias, rheumatologic disease, preeclampsia, steroid use, history of pancreatitis, infectious disease, or intrauterine growth restriction', 'entities': [['1', '13', 'chronic_disease'], ['15', '28', 'chronic_disease'], ['30', '44', 'chronic_disease'], ['46', '67', 'chronic_disease'], ['69', '81', 'chronic_disease'], ['83', '90', 'treatment'], ['107', '119', 'chronic_disease'], ['121', '139', 'chronic_disease'], ['144', '175', 'chronic_disease']]}, 'NCT02244814'), ({'text': 'Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm² to 50 cm² in size aged e21 days and <9 months)', 'entities': [['41', '67', 'clinical_variable'], ['71', '77', 'lower_bound'], ['81', '87', 'upper_bound'], ['96', '100', 'age'], ['102', '109', 'lower_bound'], ['115', '123', 'upper_bound']]}, 'NCT03068780'), ({'text': 'Subject (male and female) of childbearing/reproductive potential must agree to use double-barrier contraceptive measures or avoid intercourse during the study', 'entities': [['10', '25', 'gender'], ['71', '112', 'contraception_consent']]}, 'NCT01877382'), ({'text': 'Inability to speak and / or read English', 'entities': [['14', '41', 'language_fluency']]}, 'NCT03029884'), ({'text': 'Treatment with intravenous immunoglobulin given at an immunomodulatory dosage or plasma exchange within the past 3 months', 'entities': [['1', '10', 'treatment'], ['16', '42', 'treatment'], ['109', '122', 'upper_bound']]}, 'NCT02108860'), ({'text': 'Known hypersensitivity to thalidomide, lenalidomide or ipilimumab', 'entities': [['27', '38', 'allergy_name'], ['40', '52', 'allergy_name'], ['56', '66', 'allergy_name']]}, 'NCT01919619'), ({'text': 'non-muscle invasive bladder cancer', 'entities': [['1', '35', 'cancer']]}, 'NCT02176161'), ({'text': 'Exhibit symptomatic AERD within three weeks of starting treatment by demonstrating a score of at least 20 on the Sino-nasal Outcome Test (SNOT) - 22', 'entities': [['21', '25', 'chronic_disease'], ['33', '44', 'upper_bound'], ['57', '66', 'treatment'], ['104', '106', 'lower_bound'], ['114', '149', 'clinical_variable']]}, 'NCT03028350'), ({'text': 'Patient with documented hypersensitivity to any of the components of the chemotherapy program', 'entities': [['74', '86', 'treatment']]}, 'NCT02115295'), ({'text': 'hemoglobin<9.0', 'entities': [['1', '11', 'clinical_variable'], ['12', '15', 'upper_bound']]}, 'NCT02907983'), ({'text': 'Uncontrolled hypertension or diabetes', 'entities': [['1', '26', 'chronic_disease'], ['30', '38', 'chronic_disease']]}, 'NCT02538198'), ({'text': 'major trauma (fractures or complete ligamentous tears) to the study hand or wrist', 'entities': [['7', '13', 'chronic_disease']]}, 'NCT02219555'), ({'text': 'The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', 'entities': [['20', '80', 'clinical_variable'], ['84', '85', 'lower_bound'], ['89', '90', 'upper_bound']]}, 'NCT01037790'), ({'text': 'Participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma (excluding steroids) unless an emergency situation requires local tumor treatment', 'entities': [['29', '47', 'treatment'], ['51', '84', 'treatment'], ['96', '104', 'treatment'], ['151', '156', 'cancer'], ['157', '166', 'treatment']]}, 'NCT01871766'), ({'text': 'Alanine aminotransferase (ALT) > 3X ULN', 'entities': [['1', '31', 'clinical_variable'], ['34', '40', 'lower_bound']]}, 'NCT02332928'), ({'text': 'Albumin: > 30 g/L', 'entities': [['1', '8', 'clinical_variable'], ['12', '18', 'lower_bound']]}, 'NCT02592707'), ({'text': 'Patients with a history of prior solid organ / hematopoietic transplantation', 'entities': [['34', '77', 'treatment']]}, 'NCT02579096'), ({'text': 'Physiologically incapable of becoming pregnant, postmenopausal, or negative pregnancy test and agree to use adequate contraception (e.g., oral contraceptive, double barrier method, intra-uterine device, intra-muscular contraceptive)', 'entities': [['30', '47', 'pregnancy'], ['68', '86', 'pregnancy'], ['96', '131', 'contraception_consent'], ['139', '157', 'contraception_consent'], ['159', '180', 'contraception_consent'], ['182', '202', 'contraception_consent'], ['204', '232', 'contraception_consent']]}, 'NCT02433626'), ({'text': 'Previous Coronary Artery Bypass Graft (CABG)', 'entities': [['10', '44', 'treatment']]}, 'NCT02277613'), ({'text': 'Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina', 'entities': [['13', '35', 'chronic_disease'], ['45', '71', 'clinical_variable'], ['72', '87', 'chronic_disease'], ['89', '97', 'lower_bound'], ['111', '132', 'chronic_disease'], ['137', '161', 'chronic_disease'], ['169', '183', 'upper_bound'], ['207', '216', 'treatment'], ['218', '237', 'chronic_disease'], ['242', '257', 'chronic_disease']]}, 'NCT02091141'), ({'text': 'Recent history (<6 months) of substance or alcohol abuse or dependence (DSM-IV criteria)', 'entities': [['18', '26', 'upper_bound']]}, 'NCT02440815'), ({'text': 'These include a diagnosis of Dementia', 'entities': [['30', '38', 'chronic_disease']]}, 'NCT03136029'), ({'text': 'hydroxyurea or corticosteroid therapy, which may be continued through Cycle 1', 'entities': [['1', '12', 'treatment'], ['16', '38', 'treatment']]}, 'NCT02509546'), ({'text': '12 to 45 years of age', 'entities': [['1', '3', 'lower_bound'], ['7', '15', 'upper_bound'], ['19', '22', 'age']]}, 'NCT02308904'), ({'text': 'Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless or clinical stability', 'entities': [['18', '57', 'cancer'], ['65', '89', 'cancer'], ['124', '140', 'cancer'], ['239', '255', 'lower_bound'], ['263', '292', 'treatment'], ['277', '292', 'treatment'], ['422', '430', 'treatment'], ['444', '456', 'lower_bound']]}, 'NCT02286687'), ({'text': 'Dementia based on a definition validated in people with MS using the MACFIMS (> 2 SD below the mean on at least one memory test and > 2 SD below the mean on at least one neuropsychological test in another domain)', 'entities': [['1', '9', 'chronic_disease'], ['70', '77', 'clinical_variable'], ['81', '85', 'lower_bound'], ['113', '116', 'lower_bound'], ['171', '194', 'clinical_variable']]}, 'NCT02106052'), ({'text': 'Medication-free for at least 2 weeks or medicated with a permissible medication', 'entities': [['30', '37', 'lower_bound']]}, 'NCT02727972'), ({'text': 'Hemoglobin A1C of greater than or equal to 6.5% or a fasting blood glucose of greater than or equal to 126 mg/dL', 'entities': [['1', '15', 'clinical_variable'], ['44', '48', 'lower_bound'], ['54', '75', 'clinical_variable'], ['104', '113', 'lower_bound']]}, 'NCT01573429'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02469857'), ({'text': "History of epilepsy, major head trauma, or any neurological illness other than Tourette's syndrome which might impair the subject's cognition or psychiatric functioning per the investigator's judgment", 'entities': [['12', '20', 'chronic_disease'], ['22', '39', 'chronic_disease'], ['48', '68', 'chronic_disease'], ['80', '99', 'chronic_disease']]}, 'NCT02261519'), ({'text': 'Patient has received any of the following drugs or blood products within 7 days of Screening', 'entities': [['43', '66', 'treatment'], ['74', '80', 'upper_bound']]}, 'NCT02329327'), ({'text': 'No systemic or B symptoms', 'entities': [['16', '26', 'chronic_disease']]}, 'NCT02320292'), ({'text': 'Hormonal contraceptive use (past 6 mo.)', 'entities': [['1', '27', 'contraception_consent'], ['29', '39', 'upper_bound']]}, 'NCT03183102'), ({'text': 'Serum urate of d 5 mg/dL (300 µmol/L) or less', 'entities': [['1', '12', 'clinical_variable'], ['18', '38', 'upper_bound']]}, 'NCT02903446'), ({'text': 'Use of antiplatelet agents other than low-dose aspirin as described', 'entities': [['8', '27', 'chronic_disease'], ['48', '55', 'treatment']]}, 'NCT02272998'), ({'text': 'Presence of any clinically significant gastrointestinal (GI) abnormality or other condition(s) that may alter absorption such as malabsorption syndrome or major resection of the stomach or substantial portion of the small intestine', 'entities': [['40', '73', 'chronic_disease'], ['130', '152', 'chronic_disease']]}, 'NCT02215096'), ({'text': 'Subjects on chronic inhaled antibiotic therapy are eligible if they can continue their usual antibiotic regimen, or remain on their off-cycle period, for the duration of study drug exposure', 'entities': [['13', '47', 'treatment'], ['94', '112', 'treatment']]}, 'NCT02323100'), ({'text': 'At least 2 weeks washout period post chemotherapy, any prior protocol therapy, lapatinib, other targeted or biologic therapy, or radiation therapy is required prior to study entry', 'entities': [['10', '17', 'lower_bound'], ['33', '50', 'treatment'], ['56', '78', 'treatment'], ['80', '89', 'treatment'], ['97', '105', 'treatment'], ['109', '125', 'treatment'], ['130', '147', 'treatment']]}, 'NCT01494662'), ({'text': 'Histologically confirmed colorectal adenocarcinoma', 'entities': [['26', '51', 'cancer']]}, 'NCT02466009'), ({'text': 'ASIA scale A, B or C at neurological level C5-T12', 'entities': [['25', '43', 'clinical_variable'], ['44', '46', 'lower_bound'], ['47', '50', 'upper_bound']]}, 'NCT02139436'), ({'text': 'autoimmune disease', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02900794'), ({'text': 'Patients with a known history of infection with hepatitis B or hepatitis C virus (active, previously treated, or both) will not be eligible due to the increased risk of hepatotoxicity and viral reactivation associated with systemic chemotherapy', 'entities': [['34', '43', 'chronic_disease'], ['49', '60', 'chronic_disease'], ['64', '81', 'chronic_disease'], ['170', '184', 'chronic_disease'], ['224', '245', 'treatment']]}, 'NCT02037048'), ({'text': 'high-grade primary central nervous system lymphoma (PCNSL) as documented by brain biopsy', 'entities': [['12', '59', 'cancer']]}, 'NCT00293475'), ({'text': 'Caucasian', 'entities': [['1', '10', 'ethnicity']]}, 'NCT02642640'), ({'text': 'at least 4 hyperbaric oxygen sessions for chronic clinical indications (possible indications include diabetic lower extremity wounds or refractory osteomyelitis)', 'entities': [['10', '11', 'lower_bound'], ['12', '29', 'treatment'], ['102', '133', 'chronic_disease'], ['137', '161', 'chronic_disease']]}, 'NCT02563678'), ({'text': 'CML', 'entities': [['1', '4', 'cancer']]}, 'NCT00368355'), ({'text': 'RA', 'entities': [['1', '3', 'chronic_disease']]}, 'NCT02373644'), ({'text': 'Assigned male at birth', 'entities': [['10', '14', 'gender']]}, 'NCT03175159'), ({'text': 'Life expectancy of greater than 3 months', 'entities': [['1', '16', 'clinical_variable'], ['33', '41', 'lower_bound']]}, 'NCT01989585'), ({'text': 'Prior chemotherapy for advanced or metastatic disease', 'entities': [['1', '19', 'treatment'], ['36', '54', 'cancer']]}, 'NCT02584309'), ({'text': 'Newly diagnosed MCL: Serum bilirubin < 1.5 mg/dl', 'entities': [['17', '20', 'cancer'], ['22', '37', 'clinical_variable'], ['40', '49', 'upper_bound']]}, 'NCT01880567'), ({'text': 'prior therapy (administered in the neoadjuvant, adjuvant, and/or metastatic setting) with an anthracycline, a taxane, and capecitabine (prior anthracycline can be omitted if not medically appropriate or contraindicated for the patient)', 'entities': [['1', '14', 'treatment'], ['36', '47', 'treatment'], ['39', '47', 'treatment'], ['66', '84', 'treatment'], ['94', '107', 'treatment'], ['111', '117', 'treatment'], ['123', '135', 'treatment'], ['137', '156', 'treatment']]}, 'NCT02915744'), ({'text': "Bilirubin =< 2 x upper limit of normal (ULN) (unless documented Gilbert's syndrome, for which bilirubin =< 3 x upper limit of normal [ULN] is permitted) (obtained within 2 weeks prior to registration)", 'entities': [['1', '10', 'clinical_variable'], ['14', '45', 'lower_bound'], ['65', '83', 'chronic_disease'], ['95', '104', 'clinical_variable'], ['108', '139', 'upper_bound'], ['171', '184', 'upper_bound']]}, 'NCT01896999'), ({'text': 'Ability to swallow and retain orally-administered medication and does not have any clinically significant gastro-intestinal abnormalities (e.g., malabsorption syndrome or major resection of the stomach or bowel)', 'entities': [['51', '61', 'treatment'], ['107', '138', 'chronic_disease'], ['146', '168', 'chronic_disease'], ['178', '211', 'treatment']]}, 'NCT02535325'), ({'text': 'Patients must have an expected survival without treatment of > 60 days and must be free of major infection including human immunodeficiency virus (HIV)', 'entities': [['49', '58', 'treatment'], ['64', '71', 'lower_bound'], ['98', '107', 'chronic_disease'], ['118', '152', 'chronic_disease']]}, 'NCT01434472'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02719327'), ({'text': 'Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug', 'entities': [['18', '24', 'chronic_disease'], ['28', '52', 'chronic_disease'], ['60', '74', 'upper_bound'], ['96', '106', 'treatment']]}, 'NCT02004028'), ({'text': 'acute Chronic Infections', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02506192'), ({'text': 'severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)', 'entities': [['1', '14', 'chronic_disease'], ['16', '26', 'clinical_variable'], ['29', '35', 'upper_bound'], ['40', '45', 'gender'], ['42', '45', 'gender'], ['52', '58', 'upper_bound']]}, 'NCT02620449'), ({'text': 'Primary lesion with radiosensitive histology (i.e., small cell carcinoma, germ-cell tumors, lymphoma, leukemia, and multiple myeloma)', 'entities': [['53', '73', 'cancer'], ['75', '91', 'cancer'], ['93', '101', 'cancer'], ['103', '111', 'cancer'], ['117', '133', 'cancer']]}, 'NCT02886572'), ({'text': 'Clinically significant electrolyte disorders including sodium < 130 or > 145 and/or potassium < 3.0 or > 5.5 and/or magnesium < 1.6 or > 2.6', 'entities': [['24', '45', 'chronic_disease'], ['56', '62', 'clinical_variable'], ['65', '68', 'upper_bound'], ['74', '77', 'lower_bound'], ['85', '94', 'clinical_variable'], ['97', '100', 'upper_bound'], ['106', '109', 'lower_bound'], ['117', '126', 'clinical_variable'], ['129', '132', 'upper_bound'], ['138', '141', 'lower_bound']]}, 'NCT01696734'), ({'text': 'use of medications that adversely affect glucose metabolism (such as glucocorticoid-containing medications or atypical antipsychotics)', 'entities': [['8', '19', 'treatment'], ['42', '60', 'clinical_variable'], ['70', '84', 'clinical_variable'], ['111', '134', 'clinical_variable']]}, 'NCT02535169'), ({'text': "diagnosis of Paget's disease, hyperthyroidism, hyperparathyroidism, or other medical condition that affects bone health", 'entities': [['14', '29', 'chronic_disease'], ['31', '46', 'chronic_disease'], ['48', '67', 'chronic_disease']]}, 'NCT01968590'), ({'text': 'previous endometrial ablation', 'entities': [['1', '30', 'treatment']]}, 'NCT02646930'), ({'text': 'Documented diagnosis of symptomatic continuous persistent or longstanding persistent non-valvular atrial fibrillation', 'entities': [['86', '118', 'chronic_disease']]}, 'NCT02513797'), ({'text': 'Have a positive PPD test result or history of previously treated TB, or positive interferon-gamma release assay (IGRA) test', 'entities': [['17', '20', 'chronic_disease'], ['66', '68', 'bmi']]}, 'NCT01773707'), ({'text': 'A PN is defined as a neurofibroma that has grown along the length of a nerve and may involve multiple fascicles and branches', 'entities': [['22', '34', 'chronic_disease']]}, 'NCT02390752'), ({'text': 'Already actively participating in formal, facility-based cardiac rehabilitation', 'entities': [['58', '80', 'treatment']]}, 'NCT02196038'), ({'text': 'if remission bone marrow is available beyond 30 days a new bone marrow evaluation is required to assess remission status', 'entities': [['39', '53', 'upper_bound']]}, 'NCT02122081'), ({'text': 'unstable angina pectoris', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03035890'), ({'text': 'Known allergy/sensitivity to esmolol or history of asthma/COPD', 'entities': [['30', '37', 'treatment'], ['52', '58', 'chronic_disease'], ['59', '63', 'chronic_disease']]}, 'NCT02369900'), ({'text': 'Complete remission of hematological malignancy prior to transplantation', 'entities': [['23', '47', 'cancer']]}, 'NCT02611063'), ({'text': 'Patients on dialysis or with unstable renal function (a change of >0.5 mg/dL in SCr concentration in patients with a SCr of <2 mg/dL or a 20% change in SCr in patients with a SCr of e2 mg/dL)', 'entities': [['13', '21', 'treatment'], ['68', '77', 'lower_bound'], ['81', '84', 'clinical_variable']]}, 'NCT02764359'), ({'text': 'dementia or MCI', 'entities': [['1', '9', 'chronic_disease'], ['13', '16', 'chronic_disease']]}, 'NCT02891564'), ({'text': 'Currently using antibiotics and/or anti fungal agent (however, topical antibiotics are permitted)', 'entities': [['17', '28', 'treatment'], ['36', '53', 'treatment'], ['64', '83', 'treatment']]}, 'NCT01562626'), ({'text': 'Prior treatment with anthracyclines', 'entities': [['1', '36', 'treatment']]}, 'NCT02584309'), ({'text': 'Fugl-Meyer LE motor score <34', 'entities': [['1', '26', 'clinical_variable'], ['28', '30', 'upper_bound']]}, 'NCT03056287'), ({'text': 'Patients must satisfy the criteria for a diagnosis of one of the severe neurological autoimmune disorders outlined', 'entities': [['73', '106', 'chronic_disease']]}, 'NCT00716066'), ({'text': 'death treated with expected curative outcome (such as, but not limited to, adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent and absence of PSA relapse, or ductal carcinoma in situ of the breast treated surgically with curative intent)', 'entities': [['95', '126', 'cancer'], ['128', '133', 'cancer'], ['137', '162', 'cancer'], ['174', '189', 'cancer'], ['250', '274', 'cancer']]}, 'NCT02451423'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02100956'), ({'text': 'Ability to lay in supine or elevated position for 7 hours', 'entities': [['51', '58', 'upper_bound']]}, 'NCT01787682'), ({'text': 'Prior or known adverse reactions to PDE5 inhibitors, poly-ICLC (Hiltonol®), and prior dose(s) of Influenza vaccine including but not limited to their components', 'entities': [['37', '51', 'treatment'], ['54', '75', 'treatment'], ['98', '115', 'treatment']]}, 'NCT02544880'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT02236013'), ({'text': 'within 7 days prior to the date of allocation/randomization', 'entities': [['8', '20', 'upper_bound']]}, 'NCT02332668'), ({'text': 'The effects of M6620 (VX-970) on the developing human fetus are unknown', 'entities': [['16', '30', 'treatment']]}, 'NCT02567422'), ({'text': 'Gleason score d 7 prostate cancers', 'entities': [['1', '14', 'clinical_variable'], ['17', '18', 'upper_bound'], ['19', '35', 'cancer']]}, 'NCT02639065'), ({'text': 'The subject has a current diagnosis of schizophrenia, bipolar disorder, or other psychotic disorder, or a non-psychotic diagnosis such as major depressive disorder, post-traumatic stress disorder, panic disorder, eating disorder, or substance use disorder', 'entities': [['40', '53', 'chronic_disease'], ['55', '71', 'chronic_disease'], ['82', '100', 'chronic_disease'], ['139', '164', 'chronic_disease'], ['166', '196', 'chronic_disease'], ['198', '212', 'chronic_disease'], ['214', '229', 'chronic_disease']]}, 'NCT02354703'), ({'text': 'American Urological Association (AUA) =< 18 with or without medical management', 'entities': [['1', '38', 'clinical_variable'], ['42', '44', 'upper_bound']]}, 'NCT02470897'), ({'text': 'any cancer curatively treated >3 years prior to study entry', 'entities': [['5', '11', 'cancer'], ['32', '45', 'lower_bound']]}, 'NCT02578641'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT02041936'), ({'text': 'History of allergic reactions attributed to compounds of similar chemical or biologic composition to irinotecan', 'entities': [['102', '112', 'allergy_name']]}, 'NCT02192359'), ({'text': 'Asthma', 'entities': [['1', '7', 'chronic_disease']]}, 'NCT02025465'), ({'text': 'Patients must not have had standard of care chemotherapy, radiotherapy, or major surgery within the last 2 weeks prior to entering the study', 'entities': [['45', '57', 'treatment'], ['59', '71', 'treatment'], ['76', '89', 'treatment'], ['101', '119', 'upper_bound']]}, 'NCT02311361'), ({'text': 'For dose escalation monotherapy: CLL, HL, NHL, MM', 'entities': [['5', '32', 'treatment'], ['34', '37', 'cancer'], ['39', '41', 'cancer'], ['43', '46', 'cancer'], ['48', '50', 'cancer']]}, 'NCT02061761'), ({'text': 'Congenital heart disease with shunt closure more than 6 months ago (no open shunts, confirmed by RHC no less than 4 months after surgery)', 'entities': [['1', '25', 'chronic_disease'], ['55', '67', 'lower_bound'], ['115', '129', 'upper_bound'], ['130', '137', 'treatment']]}, 'NCT02562235'), ({'text': 'coronary artery bypass grafting', 'entities': [['1', '32', 'treatment']]}, 'NCT02816736'), ({'text': '2-7 within 365 days of registration', 'entities': [['1', '2', 'lower_bound'], ['3', '4', 'upper_bound'], ['12', '20', 'upper_bound']]}, 'NCT01950351'), ({'text': 'Peripheral Neuropathy >= grade 1', 'entities': [['1', '22', 'clinical_variable'], ['26', '33', 'lower_bound']]}, 'NCT01802346'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection', 'entities': [['84', '93', 'chronic_disease']]}, 'NCT02417701'), ({'text': 'potassium >= 5.5 meq/L at the end of run-in', 'entities': [['1', '10', 'clinical_variable'], ['14', '23', 'lower_bound']]}, 'NCT02593110'), ({'text': 'Patient-reported worst pain score between 5 and 10 (inclusive) on a 0-10 scale (assessed verbally)', 'entities': [['24', '34', 'clinical_variable'], ['43', '44', 'lower_bound'], ['49', '51', 'upper_bound'], ['50', '51', 'lower_bound']]}, 'NCT01912612'), ({'text': 'Histologically or cytologically confirmed, immunotherapy naïve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment', 'entities': [['44', '63', 'treatment'], ['67', '77', 'treatment'], ['91', '101', 'cancer'], ['122', '148', 'cancer'], ['174', '183', 'treatment']]}, 'NCT03123783'), ({'text': 'At Screening and Visit 1 (Baseline/Day 1), have had DLE covering at least 5% of total body surface area (BSA) or SLE with DLE covering at least 2% of BSA as determined by the hand print method (one palm is equivalent to 1% BSA)', 'entities': [['53', '56', 'clinical_variable'], ['75', '77', 'lower_bound'], ['81', '110', 'clinical_variable'], ['114', '126', 'clinical_variable'], ['145', '147', 'lower_bound']]}, 'NCT03159936'), ({'text': 'All fetal diagnoses of complex congenital heart disease diagnosed by fetal echocardiogram requiring cardiac repair with Blalock-Taussig Shunt or Right Ventricle to Pulmonary Artery conduit', 'entities': [['32', '56', 'chronic_disease'], ['70', '90', 'treatment'], ['101', '189', 'treatment']]}, 'NCT02766998'), ({'text': 'Malignant diagnosis in any cancer type at any stage', 'entities': [['28', '34', 'cancer']]}, 'NCT02408406'), ({'text': 'Significant abnormalities of the aorta, such as aneurysms, coarctation of the aorta, or an extremely tortuous aorta', 'entities': [['13', '39', 'chronic_disease'], ['49', '58', 'chronic_disease'], ['60', '84', 'chronic_disease'], ['102', '116', 'chronic_disease']]}, 'NCT02645539'), ({'text': 'Patients who have had chemotherapy', 'entities': [['23', '35', 'treatment']]}, 'NCT02536794'), ({'text': 'Presence of known untreated brain metastases', 'entities': [['29', '45', 'cancer']]}, 'NCT03131037'), ({'text': 'Ixazomib is a substrate of CYP3A4 and CYP1A2', 'entities': [['1', '9', 'treatment'], ['15', '34', 'treatment'], ['39', '45', 'treatment']]}, 'NCT02004275'), ({'text': 'patients with long-standing stable grade 2 neuropathy or prior grade 2 treatment-related hypothyroidism requiring treatment, provided free T4 within normal range, may be considered eligible after discussion with the study principal investigator (PI)', 'entities': [['58', '81', 'treatment'], ['72', '81', 'treatment'], ['90', '104', 'chronic_disease']]}, 'NCT02498613'), ({'text': 'Diagnosis of aphasia with naming deficits and concurrent lexical/semantic impairment', 'entities': [['14', '21', 'chronic_disease'], ['58', '65', 'chronic_disease'], ['66', '85', 'chronic_disease']]}, 'NCT02916524'), ({'text': 'Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks', 'entities': [['1', '22', 'treatment'], ['118', '130', 'upper_bound']]}, 'NCT01943851'), ({'text': 'Research participants who have tested human immunodeficiency virus (HIV) positive, or have active hepatitis B or C infection based on testing performed within 4 weeks of enrollment', 'entities': [['39', '73', 'chronic_disease'], ['99', '125', 'chronic_disease'], ['160', '167', 'upper_bound']]}, 'NCT02159495'), ({'text': 'Gastrointestinal ulceration', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT03028012'), ({'text': 'Presence of metastatic disease or gross orbital involvement', 'entities': [['13', '31', 'cancer'], ['35', '60', 'cancer']]}, 'NCT02792036'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01954576'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02544373'), ({'text': 'Patients with a documented allergy to ropivacaine', 'entities': [['39', '50', 'allergy_name']]}, 'NCT03149783'), ({'text': 'AST/ALT > 3 x ULN of the local reference range', 'entities': [['1', '4', 'clinical_variable'], ['5', '8', 'clinical_variable'], ['11', '18', 'lower_bound']]}, 'NCT01568255'), ({'text': 'Had a myocardial infraction within the past 6 months', 'entities': [['7', '28', 'chronic_disease'], ['40', '53', 'upper_bound']]}, 'NCT01238120'), ({'text': 'No change in active cardiac medications for 2 weeks prior to randomization, beta-blockers must be started 3 months prior to randomization', 'entities': [['21', '40', 'treatment'], ['45', '58', 'upper_bound'], ['77', '90', 'treatment'], ['107', '121', 'upper_bound']]}, 'NCT01128816'), ({'text': 'Documented adenocarcinoma of the pancreas', 'entities': [['12', '26', 'cancer']]}, 'NCT03006302'), ({'text': 'Life expectancy <3 months as determined by oncologist', 'entities': [['1', '16', 'clinical_variable'], ['18', '26', 'upper_bound']]}, 'NCT02543723'), ({'text': 'Platelets >= 100,000/mcL (within 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration)', 'entities': [['1', '10', 'clinical_variable'], ['14', '25', 'lower_bound'], ['34', '47', 'upper_bound'], ['90', '103', 'upper_bound'], ['107', '116', 'treatment']]}, 'NCT02465060'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT03043807'), ({'text': 'Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease if the liver is involved with metastatic disease', 'entities': [['8', '23', 'chronic_disease'], ['51', '61', 'clinical_variable'], ['121', '139', 'cancer']]}, 'NCT02542202'), ({'text': 'anti-inflammatory drugs (systemic)', 'entities': [['1', '24', 'treatment']]}, 'NCT02233868'), ({'text': 'Patients on stable doses of bisphosphonates or denosumab which have been started no less than 4 weeks prior to enrollment may continue on this medication', 'entities': [['29', '44', 'treatment'], ['48', '57', 'treatment'], ['95', '108', 'upper_bound'], ['144', '154', 'treatment']]}, 'NCT02555189'), ({'text': 'Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject', 'entities': [['18', '27', 'treatment'], ['33', '50', 'treatment']]}, 'NCT02236013'), ({'text': 'Inability to swallow pills equivalent in size to the 5 mg donepezil tablet', 'entities': [['59', '75', 'treatment']]}, 'NCT01584076'), ({'text': 'Tumors that are HER2 1+, 2+ or 3+ by IHC or have a Vysis FISH result greater than 1.8', 'entities': [['1', '7', 'cancer'], ['17', '21', 'clinical_variable'], ['22', '23', 'lower_bound'], ['32', '33', 'upper_bound'], ['38', '41', 'clinical_variable'], ['52', '69', 'clinical_variable'], ['83', '86', 'lower_bound']]}, 'NCT01730118'), ({'text': 'total hip arthroplasty', 'entities': [['1', '23', 'treatment']]}, 'NCT02507505'), ({'text': 'Subjects on warfarin therapy', 'entities': [['13', '29', 'treatment']]}, 'NCT02664168'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02810704'), ({'text': 'gastrointestinal perforation', 'entities': [['1', '29', 'chronic_disease']]}, 'NCT02101736'), ({'text': 'History of parenteral nutrition use with SOLE prior to HCT', 'entities': [['12', '59', 'treatment']]}, 'NCT02512718'), ({'text': 'Low-risk: Embryonal, botryoid, spindle cell tumors only (Subset 1: Stage 1, Group I; Stage 1 Group I; Stage 1 Group III orbital only; Stage 2 Group I; Stage 2 Group II) (Subset 2: Stage 1 Group III non orbit; Stage 3 Group I, II)', 'entities': [['11', '20', 'cancer'], ['22', '30', 'cancer'], ['32', '51', 'cancer']]}, 'NCT01871766'), ({'text': 'Not have concurrent use of ethyol', 'entities': [['28', '34', 'treatment']]}, 'NCT03137121'), ({'text': 'Life expectancy of e 12 weeks in the opinion of the investigator and medical monitor', 'entities': [['1', '16', 'clinical_variable'], ['22', '30', 'lower_bound']]}, 'NCT02582827'), ({'text': 'Known pre-existing interstitial lung disease', 'entities': [['20', '45', 'chronic_disease']]}, 'NCT02541903'), ({'text': 'Current use of anticoagulants', 'entities': [['16', '30', 'treatment']]}, 'NCT02719327'), ({'text': 'Currently receiving cancer therapy (chemotherapy, radiation therapy, immuno- therapy, biologic therapy, hormonal therapy, surgery, and/or tumour embolization)', 'entities': [['21', '35', 'treatment'], ['37', '49', 'treatment'], ['51', '68', 'treatment'], ['70', '85', 'treatment'], ['87', '103', 'treatment'], ['105', '121', 'treatment'], ['123', '130', 'treatment'], ['139', '158', 'treatment']]}, 'NCT01943851'), ({'text': 'Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours', 'entities': [['26', '43', 'chronic_disease'], ['93', '106', 'upper_bound']]}, 'NCT02524379'), ({'text': 'History of cardiovascular disease such as heart angioplasty/stent or bypass surgery, myocardial infarction, stroke, heart failure with or without left ventricular ejection fraction <40%, cardiomyopathy, valvular heart disease, cardiomyopathy, heart transplantation, Type 2 and Type 1 diabetes', 'entities': [['12', '34', 'chronic_disease'], ['43', '60', 'treatment'], ['61', '84', 'treatment'], ['86', '107', 'chronic_disease'], ['109', '115', 'chronic_disease'], ['117', '130', 'chronic_disease'], ['147', '181', 'clinical_variable'], ['183', '186', 'upper_bound'], ['188', '202', 'chronic_disease'], ['204', '226', 'chronic_disease'], ['244', '265', 'treatment'], ['267', '293', 'chronic_disease']]}, 'NCT01983462'), ({'text': 'Subjects who have been drinking > 5 alcoholic drinks daily for the last year', 'entities': [['35', '36', 'lower_bound']]}, 'NCT03097588'), ({'text': 'History of serious mental illness such as schizophrenia, schizo-affective disorder, or well-documented bipolar disorder', 'entities': [['12', '34', 'chronic_disease'], ['43', '56', 'chronic_disease'], ['58', '83', 'chronic_disease'], ['104', '120', 'chronic_disease']]}, 'NCT02061553'), ({'text': 'Patients who have undergone complete surgical resection of the recurrent tumor and have no evidence of residual disease evaluable clinically and by CT or MRI imaging, following resection', 'entities': [['38', '56', 'treatment'], ['47', '56', 'treatment'], ['74', '79', 'cancer'], ['149', '151', 'treatment'], ['155', '166', 'treatment']]}, 'NCT00492778'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status more than 1', 'entities': [['1', '61', 'clinical_variable'], ['72', '73', 'lower_bound']]}, 'NCT02187848'), ({'text': 'Clinical evidence of vitiligo or other forms of depigmenting illness', 'entities': [['22', '30', 'chronic_disease']]}, 'NCT02595866'), ({'text': 'Previously treated with class I and class III antiarrhythmic drugs', 'entities': [['25', '32', 'treatment'], ['37', '67', 'treatment']]}, 'NCT02347111'), ({'text': 'Immunoparesis (this term refers to the patient having low uninvolved immunoglobulins in peripheral blood, for example if a patient has IgA smoldering multiple myeloma, then either having a low IgM and/or low IgG will qualify as a risk factor for progression to multiple myeloma)', 'entities': [['140', '167', 'cancer']]}, 'NCT02960555'), ({'text': 'Self-reported or clinically documented history of significant fluctuations (>5% change) in weight within 3 months prior to screening for this trial', 'entities': [['78', '87', 'lower_bound'], ['92', '98', 'clinical_variable'], ['106', '120', 'upper_bound']]}, 'NCT03038620'), ({'text': '18-65 years old', 'entities': [['1', '3', 'lower_bound'], ['4', '12', 'upper_bound']]}, 'NCT01681264'), ({'text': 'Serum total bilirubin =< 1.5 x ULN (direct bilirubin =< ULN if total bilirubin [bili] > 1.5 x ULN)', 'entities': [['1', '22', 'clinical_variable'], ['37', '53', 'clinical_variable'], ['64', '86', 'clinical_variable']]}, 'NCT02286687'), ({'text': 'Prior autologous stem cell transplant d 3 months prior to starting CC-90002', 'entities': [['1', '38', 'treatment'], ['41', '55', 'upper_bound'], ['68', '76', 'treatment']]}, 'NCT02367196'), ({'text': 'Patients with a creatinine <2x normal for age', 'entities': [['17', '27', 'clinical_variable'], ['29', '38', 'upper_bound'], ['43', '46', 'age']]}, 'NCT01956084'), ({'text': 'overweight but weight stable (less than +/- 3kg over previous 6 months) male and female adults (n=24) will be recruited', 'entities': [['5', '11', 'clinical_variable'], ['41', '48', 'upper_bound'], ['54', '71', 'upper_bound'], ['73', '95', 'gender']]}, 'NCT02258438'), ({'text': 'Abscess', 'entities': [['1', '8', 'chronic_disease']]}, 'NCT02392286'), ({'text': 'Known significant hypersensitivity to any beta-lactam antibiotic', 'entities': [['43', '65', 'allergy_name']]}, 'NCT02687906'), ({'text': 'Neurological or medical conditions that would interfere with MRI scanning (e.g. history of stroke, seizure, brain tumor, brain infection, multiple sclerosis, metal device in body, pregnancy, claustrophobia)', 'entities': [['1', '13', 'chronic_disease'], ['17', '35', 'chronic_disease'], ['62', '65', 'treatment'], ['92', '98', 'chronic_disease'], ['100', '107', 'chronic_disease'], ['109', '120', 'cancer'], ['122', '137', 'chronic_disease'], ['139', '157', 'chronic_disease'], ['159', '171', 'treatment'], ['181', '190', 'pregnancy'], ['192', '206', 'chronic_disease']]}, 'NCT02316574'), ({'text': 'Aniridia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02332369'), ({'text': 'laparoscopic roux-en-y gastric bypass', 'entities': [['1', '38', 'treatment']]}, 'NCT03187379'), ({'text': 'Subjects who have been on systemic steroids will require a 6-week washout period', 'entities': [['27', '44', 'treatment']]}, 'NCT02264236'), ({'text': 'who wish to become pregnant during the study period', 'entities': [['20', '28', 'pregnancy']]}, 'NCT03058783'), ({'text': 'Access to internet', 'entities': [['1', '19', 'technology_access']]}, 'NCT03132415'), ({'text': 'Hemoglobin > 9 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['14', '20', 'lower_bound']]}, 'NCT02048722'), ({'text': 'biopsy proven benign', 'entities': [['1', '7', 'treatment']]}, 'NCT01766297'), ({'text': 'ALT, AST or bilirubin e 1.5x ULN within 4 weeks prior to baseline', 'entities': [['1', '4', 'clinical_variable'], ['6', '9', 'clinical_variable'], ['13', '22', 'clinical_variable'], ['25', '33', 'lower_bound'], ['41', '54', 'upper_bound']]}, 'NCT02570854'), ({'text': 'Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhea e Grade 2, and malabsorption syndrome)', 'entities': [['20', '49', 'chronic_disease'], ['166', '178', 'treatment'], ['184', '202', 'chronic_disease'], ['235', '243', 'clinical_variable'], ['246', '253', 'lower_bound'], ['259', '281', 'chronic_disease']]}, 'NCT01990209'), ({'text': 'The male partner should use a condom', 'entities': [['5', '9', 'gender']]}, 'NCT01333046'), ({'text': 'Life expectancy <2 years', 'entities': [['1', '16', 'clinical_variable'], ['18', '25', 'upper_bound']]}, 'NCT02396199'), ({'text': 'Diagnosis of Chronic Heart Failure; under regular care by cardiologist', 'entities': [['14', '35', 'chronic_disease']]}, 'NCT01787682'), ({'text': 'the investigators will offer to re-contact patients 90 days after a health event or after 90 days of sobriety', 'entities': [['53', '66', 'lower_bound'], ['85', '98', 'lower_bound'], ['102', '110', 'chronic_disease']]}, 'NCT02830074'), ({'text': 'Patients with end-stage renal disease on hemodialysis', 'entities': [['15', '38', 'chronic_disease'], ['42', '54', 'treatment']]}, 'NCT02539160'), ({'text': 'Pts with HbSS or SB0 thalassemia', 'entities': [['10', '14', 'chronic_disease'], ['18', '33', 'chronic_disease']]}, 'NCT02373241'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02145260'), ({'text': 'Patients with less than 6 months of expected battery life on their device established at office testing', 'entities': [['25', '33', 'upper_bound']]}, 'NCT02776475'), ({'text': 'Serum creatinine within normal range', 'entities': [['1', '17', 'clinical_variable']]}, 'NCT02744430'), ({'text': 'Oral anticoagulants prescribed for IPF', 'entities': [['1', '20', 'treatment'], ['36', '39', 'chronic_disease']]}, 'NCT02688647'), ({'text': 'Pregnant or breast-feeding women', 'entities': [['1', '9', 'pregnancy'], ['28', '33', 'gender']]}, 'NCT02592707'), ({'text': 'psychiatric disorder', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02859142'), ({'text': 'Creatinine less than or equal to 1.4mg/dL and estimated glomerular filtration rate greater than 45 ml/min/1.73 m2', 'entities': [['1', '11', 'clinical_variable'], ['34', '42', 'upper_bound'], ['57', '83', 'clinical_variable'], ['97', '114', 'lower_bound']]}, 'NCT02981329'), ({'text': 'Women and men must agree not to donate eggs (ova, oocytes) or sperm, respectively, during the study and for 90 days after the last dose of study drug', 'entities': [['1', '14', 'gender'], ['109', '116', 'upper_bound']]}, 'NCT03145181'), ({'text': "Diagnosis of idiopathic Parkinson's disease that is optimally treated (motor fluctuations <20% of subject's awake time)", 'entities': [['14', '44', 'chronic_disease'], ['72', '90', 'clinical_variable'], ['92', '95', 'upper_bound']]}, 'NCT02225548'), ({'text': 'History of type 2 diabetes', 'entities': [['12', '27', 'chronic_disease']]}, 'NCT02460783'), ({'text': 'Thumbnail abnormalities on either hand (such as due to chemotherapy or trauma, or artificial nails) that are likely to alter pain perception during testing', 'entities': [['1', '24', 'chronic_disease'], ['56', '68', 'treatment']]}, 'NCT01912612'), ({'text': 'patient has any serious medical problems which may preclude receiving this type of treatment', 'entities': [['25', '41', 'chronic_disease'], ['84', '93', 'treatment']]}, 'NCT01312857'), ({'text': 'In cohort 3, eligible patients must have measurable Central Nervous System disease', 'entities': [['53', '83', 'chronic_disease']]}, 'NCT01494662'), ({'text': 'Hypertension', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02130687'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['67', '68', 'upper_bound']]}, 'NCT03179995'), ({'text': 'insulin therapy', 'entities': [['1', '16', 'treatment']]}, 'NCT02408120'), ({'text': 'have progression of disease on a 3rd generation EGFR-TKI such as AZD9291, rociletinib, HM61713', 'entities': [['66', '73', 'treatment'], ['75', '86', 'treatment'], ['88', '95', 'treatment']]}, 'NCT02496663'), ({'text': 'Participation in another concurrent treatment protocol', 'entities': [['37', '46', 'treatment']]}, 'NCT02013778'), ({'text': 'Grade 2 renal dysfunction', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT02074436'), ({'text': 'AST(SGOT)/ALT(SGPT) d 3.0 x IULN', 'entities': [['1', '10', 'clinical_variable'], ['11', '20', 'clinical_variable'], ['23', '33', 'upper_bound']]}, 'NCT02584309'), ({'text': 'history of stroke', 'entities': [['12', '18', 'chronic_disease']]}, 'NCT03120728'), ({'text': 'Current use of a prohibited medication', 'entities': [['18', '39', 'treatment']]}, 'NCT02152995'), ({'text': 'patients with exposure to other JAK-STAT inhibitory agents', 'entities': [['27', '59', 'treatment']]}, 'NCT02493530'), ({'text': 'Histologically or cytologically proven metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed', 'entities': [['40', '50', 'cancer'], ['71', '83', 'cancer'], ['97', '113', 'treatment']]}, 'NCT03104699'), ({'text': 'No condition (e.g., severe arthritis, central pain) that would interfere with valid administration of the motor function tests', 'entities': [['21', '37', 'chronic_disease'], ['39', '51', 'chronic_disease']]}, 'NCT01948739'), ({'text': 'creatinine <1.3mg/dl', 'entities': [['1', '11', 'clinical_variable'], ['13', '21', 'upper_bound']]}, 'NCT01976169'), ({'text': 'Major surgery, other than diagnostic surgery, within 4 weeks prior to first dose, without complete recovery', 'entities': [['1', '14', 'treatment'], ['54', '67', 'upper_bound']]}, 'NCT02383927'), ({'text': "Patients with total bilirubin >= 2.0 times upper limit of normal unless felt to be related the underlying leukemia by the treating physician or hemolysis or Gilbert's disease", 'entities': [['15', '30', 'clinical_variable'], ['34', '65', 'lower_bound'], ['107', '115', 'cancer'], ['145', '154', 'chronic_disease'], ['158', '175', 'chronic_disease']]}, 'NCT01409161'), ({'text': 'Prior systemic cancer-directed treatments or investigational modalities d 5 half lives or 4 weeks prior to starting CC-90002, whichever is shorter', 'entities': [['16', '22', 'cancer'], ['75', '76', 'upper_bound'], ['91', '104', 'upper_bound']]}, 'NCT02367196'), ({'text': 'Histological confirmation of malignancy (primary or metastatic tumor)', 'entities': [['30', '40', 'cancer'], ['42', '69', 'cancer']]}, 'NCT02843165'), ({'text': 'History of interstitial lung disease', 'entities': [['12', '37', 'chronic_disease']]}, 'NCT02394535'), ({'text': 'No evidence of nodal involvement or distant metastases', 'entities': [['16', '33', 'cancer'], ['37', '55', 'cancer']]}, 'NCT01799135'), ({'text': 'breath alcohol level > 0.01 (one re-screen allowed)', 'entities': [['1', '21', 'clinical_variable'], ['24', '28', 'lower_bound']]}, 'NCT02796391'), ({'text': 'Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 5 times upper limit of normal (UNL)', 'entities': [['1', '33', 'clinical_variable'], ['37', '67', 'clinical_variable'], ['70', '105', 'lower_bound']]}, 'NCT02072356'), ({'text': 'has had significant bowel resection that would preclude adequate absorption (for oral therapy only)', 'entities': [['21', '36', 'treatment'], ['82', '94', 'treatment']]}, 'NCT02152254'), ({'text': 'Diffusion capacity of the lung for carbon monoxide (DLCO) < 40%', 'entities': [['1', '58', 'clinical_variable'], ['61', '64', 'upper_bound']]}, 'NCT02122081'), ({'text': 'between one month and <18 years of age (inclusive) at the time of signing the informed consent form', 'entities': [['9', '18', 'lower_bound'], ['24', '32', 'upper_bound'], ['36', '39', 'age']]}, 'NCT02124772'), ({'text': 'Congenital hearing loss (for purpose of this study, onset prior to age 2 years*). *Based on critical period for speech and language development', 'entities': [['1', '24', 'chronic_disease'], ['68', '71', 'age'], ['72', '79', 'upper_bound']]}, 'NCT02189798'), ({'text': 'DNA index = 1', 'entities': [['1', '10', 'clinical_variable'], ['13', '14', 'lower_bound']]}, 'NCT02245997'), ({'text': 'No Paget disease of the nipple', 'entities': [['4', '31', 'cancer']]}, 'NCT00909909'), ({'text': '18 years to d 65 years of age', 'entities': [['1', '9', 'lower_bound'], ['15', '23', 'upper_bound'], ['27', '30', 'age']]}, 'NCT03159936'), ({'text': 'Known carrier or infection for HIV/Hep B or C. HCV ab+ must be PCR-. HBV ab+ must be HBsAg- or undetectable DNA', 'entities': [['32', '35', 'chronic_disease'], ['36', '46', 'chronic_disease'], ['48', '55', 'chronic_disease'], ['70', '77', 'chronic_disease']]}, 'NCT01994382'), ({'text': 'children d 10 years old', 'entities': [['12', '20', 'upper_bound']]}, 'NCT02076906'), ({'text': 'all medical conditions stable and well controlled, medications allowed include asthma medication (albuterol only), hypercholesterolemia medication and psychiatric medication', 'entities': [['52', '63', 'treatment'], ['80', '97', 'treatment'], ['99', '108', 'treatment'], ['116', '147', 'treatment'], ['152', '174', 'treatment']]}, 'NCT01438073'), ({'text': 'Patients who have had major surgical procedures or significant traumatic injury within 28 days prior to study treatment', 'entities': [['64', '80', 'chronic_disease'], ['88', '101', 'upper_bound'], ['111', '120', 'treatment']]}, 'NCT02073097'), ({'text': 'Controlled brain metastases that require continuous high dose corticosteroid use within 4 weeks of Day 1', 'entities': [['12', '28', 'cancer'], ['63', '77', 'treatment'], ['89', '96', 'upper_bound']]}, 'NCT02383927'), ({'text': 'No prior systemic therapy for NDMM is permitted other than pulse dose dexamethasone (maximum dose of 160 mg)', 'entities': [['4', '26', 'treatment'], ['31', '35', 'cancer'], ['71', '84', 'treatment'], ['102', '108', 'upper_bound']]}, 'NCT02343042'), ({'text': 'Acute grief (< 1 month)', 'entities': [['1', '12', 'clinical_variable'], ['16', '23', 'upper_bound']]}, 'NCT02332291'), ({'text': 'New York Heart Association class III or IV heart failure', 'entities': [['1', '33', 'clinical_variable'], ['34', '37', 'lower_bound'], ['41', '43', 'upper_bound'], ['44', '57', 'chronic_disease']]}, 'NCT02277548'), ({'text': "Anti-depressants (tricyclics, SSRI's, selective and nonselective MAOIs, Wellbutrin/Zyban)", 'entities': [['1', '17', 'treatment'], ['19', '29', 'treatment'], ['31', '37', 'treatment'], ['66', '71', 'treatment'], ['73', '83', 'treatment'], ['84', '89', 'treatment']]}, 'NCT02837510'), ({'text': 'Main portal vein thrombosis (Vp4) as documented on imaging', 'entities': [['6', '28', 'chronic_disease'], ['52', '59', 'treatment']]}, 'NCT02519348'), ({'text': 'inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease', 'entities': [['1', '8', 'treatment'], ['12', '28', 'treatment'], ['33', '52', 'treatment'], ['61', '66', 'lower_bound'], ['73', '83', 'treatment'], ['135', '153', 'chronic_disease']]}, 'NCT02519322'), ({'text': 'First/primary propose treatment modality is voice therapy', 'entities': [['23', '41', 'treatment'], ['45', '58', 'treatment']]}, 'NCT03129880'), ({'text': 'prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of the first protocol treatment or who has not recovered (i.e., d Grade 1 or at baseline) from adverse events due to a previously administered agent', 'entities': [['1', '19', 'treatment'], ['21', '52', 'treatment'], ['57', '74', 'treatment'], ['82', '89', 'upper_bound'], ['112', '121', 'treatment'], ['156', '163', 'upper_bound']]}, 'NCT02407171'), ({'text': 'Previous treatment with cobimetinib or any other mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitor', 'entities': [['1', '36', 'treatment'], ['50', '129', 'treatment']]}, 'NCT02091141'), ({'text': 'English is spoken in the home and at least one parent is able to read, write and speak English', 'entities': [['1', '30', 'language_fluency'], ['44', '47', 'lower_bound'], ['58', '95', 'language_fluency']]}, 'NCT02483910'), ({'text': 'myocardial infarction within 6 months before randomization', 'entities': [['1', '22', 'chronic_disease'], ['30', '38', 'upper_bound']]}, 'NCT03042689'), ({'text': 'Uncontrolled hypertension (systolic blood pressure [BP] > 150 mm Hg or diastolic BP of > 90 mm Hg)', 'entities': [['14', '26', 'chronic_disease'], ['28', '56', 'clinical_variable'], ['59', '68', 'lower_bound'], ['72', '84', 'clinical_variable'], ['90', '98', 'lower_bound']]}, 'NCT01684397'), ({'text': 'Enrollment post partum with an anticipated next pregnancy within 18 months', 'entities': [['49', '58', 'pregnancy'], ['66', '75', 'upper_bound']]}, 'NCT02333227'), ({'text': 'Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN = 135 U/L', 'entities': [['1', '45', 'clinical_variable'], ['47', '77', 'clinical_variable'], ['82', '89', 'upper_bound'], ['92', '99', 'upper_bound']]}, 'NCT02323880'), ({'text': 'On established chemotherapy regimen for pancreas cancer, which will be continued over the time of study', 'entities': [['16', '28', 'treatment'], ['41', '56', 'cancer']]}, 'NCT02985801'), ({'text': 'failure to one induction course of chemotherapy are eligible', 'entities': [['36', '48', 'treatment']]}, 'NCT00501826'), ({'text': 'Patients may not receive concurrent chemotherapy, radiotherapy or immunotherapy, nor have received any investigational agents', 'entities': [['37', '49', 'treatment'], ['51', '63', 'treatment'], ['67', '80', 'treatment']]}, 'NCT01620216'), ({'text': 'Current smoking or history of smoking in the past 12 months', 'entities': [['46', '60', 'upper_bound']]}, 'NCT02494141'), ({'text': 'Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIV-protease inhibitors, retinoic acid derivatives and interferons', 'entities': [['11', '32', 'chronic_disease'], ['40', '48', 'chronic_disease'], ['50', '63', 'chronic_disease'], ['65', '79', 'chronic_disease'], ['96', '108', 'treatment'], ['117', '149', 'treatment'], ['151', '159', 'treatment'], ['161', '184', 'treatment'], ['186', '211', 'treatment'], ['216', '227', 'treatment']]}, 'NCT01675154'), ({'text': 'Unstable angina pectoris or coronary angioplasty, or stenting', 'entities': [['1', '25', 'chronic_disease'], ['29', '49', 'treatment'], ['54', '62', 'treatment']]}, 'NCT02465060'), ({'text': 'Previous treatment with Botox (possible antibodies)', 'entities': [['25', '30', 'treatment']]}, 'NCT02160288'), ({'text': 'Current or history of proliferative retinopathy', 'entities': [['23', '48', 'chronic_disease']]}, 'NCT03006770'), ({'text': 'Recurrent ovarian cancer', 'entities': [['11', '25', 'cancer']]}, 'NCT02828618'), ({'text': 'SLEDAI2K score e4 indicating active disease', 'entities': [['1', '15', 'clinical_variable'], ['17', '18', 'lower_bound']]}, 'NCT02429934'), ({'text': 'As of July 2018, only high risk MDS patients will be eligible as Arm B is closed. As of October 2017, those patients with MDS who have received prior treatment will now be enrolled in Arm A as Arm C is closed', 'entities': [['33', '36', 'chronic_disease'], ['145', '160', 'treatment']]}, 'NCT01869114'), ({'text': 'Viral load of < 50 copies HIV messenger ribonucleic acid (mRNA)/mm^3 if on combination antiretroviral therapy (cART) or < 25,000 copies HIV mRNA if not on cART', 'entities': [['17', '26', 'upper_bound'], ['27', '30', 'chronic_disease'], ['31', '69', 'clinical_variable'], ['88', '117', 'treatment'], ['123', '129', 'upper_bound'], ['137', '145', 'clinical_variable']]}, 'NCT01925131'), ({'text': 'Endometrial proliferation, hyperplasia, or malignancy at screening', 'entities': [['1', '26', 'chronic_disease'], ['28', '39', 'chronic_disease'], ['44', '54', 'cancer']]}, 'NCT01895881'), ({'text': '6-60 months post-treatment (surgery, chemotherapy, and/or radiation therapy) for cancer', 'entities': [['1', '2', 'lower_bound'], ['3', '12', 'upper_bound'], ['29', '36', 'treatment'], ['38', '50', 'treatment'], ['59', '76', 'treatment'], ['82', '88', 'cancer']]}, 'NCT03060096'), ({'text': 'Reduction of any acute toxicity from radiation treatment to grade 1', 'entities': [['38', '57', 'treatment']]}, 'NCT02496585'), ({'text': 'Other significant EKG abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)', 'entities': [['19', '36', 'chronic_disease'], ['47', '94', 'chronic_disease'], ['96', '115', 'chronic_disease'], ['120', '131', 'chronic_disease'], ['133', '149', 'clinical_variable'], ['160', '168', 'upper_bound']]}, 'NCT02512497'), ({'text': 'Currently receiving another investigational drug', 'entities': [['29', '49', 'treatment']]}, 'NCT02574728'), ({'text': 'The subject has any evidence of an endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib', 'entities': [['36', '48', 'cancer'], ['52', '71', 'cancer'], ['79', '86', 'upper_bound'], ['112', '124', 'treatment']]}, 'NCT01639508'), ({'text': 'not intending to become pregnant or breast feed', 'entities': [['1', '33', 'pregnancy']]}, 'NCT01433315'), ({'text': 'Females who regularly work at a bar, hotel or restaurant establishment and serve alcohol to patrons', 'entities': [['1', '8', 'gender']]}, 'NCT02714140'), ({'text': 'Untreated subjects with FPG d200 mg/dL (d11.2 mmol/L)at both Screening Visits and either FPG e126 mg/dL (e7.0 mmol/L) at both Screening Visits or FPG <126 mg/dL (<7.0 mmol/L) at one (1) or both Screening Visits with HbA1c e6.5% (e48 mmol/mol)', 'entities': [['25', '28', 'clinical_variable'], ['30', '39', 'upper_bound'], ['42', '53', 'upper_bound'], ['217', '222', 'clinical_variable'], ['224', '228', 'lower_bound'], ['231', '242', 'lower_bound']]}, 'NCT03058029'), ({'text': 'under treatment for arterial or venous peripheral vascular disease', 'entities': [['7', '16', 'treatment'], ['40', '67', 'chronic_disease']]}, 'NCT02033616'), ({'text': 'Patients who have received systemic treatment (up to 4 cycles of induction chemotherapy, or up to 6 months of targeted therapy)', 'entities': [['28', '46', 'treatment'], ['54', '55', 'upper_bound'], ['66', '88', 'treatment'], ['99', '107', 'upper_bound'], ['111', '127', 'treatment']]}, 'NCT01993810'), ({'text': 'For cohort of patients that are already on ruxolitinib therapy: on therapy with ruxolitinib for at least for 6 months, and on stable dose for last 2 months, before starting therapy with sotatercept', 'entities': [['44', '63', 'treatment'], ['68', '92', 'treatment'], ['110', '118', 'lower_bound'], ['143', '156', 'upper_bound'], ['174', '198', 'treatment']]}, 'NCT01712308'), ({'text': 'Biopsy with less than 20% of tumor removed', 'entities': [['1', '7', 'treatment'], ['23', '26', 'upper_bound'], ['30', '35', 'cancer']]}, 'NCT02617589'), ({'text': 'Patients will be ineligible if any prior therapeutic radiation therapy > 500 cGy has been delivered', 'entities': [['54', '71', 'treatment'], ['74', '81', 'lower_bound']]}, 'NCT02112617'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 at study entry', 'entities': [['1', '61', 'clinical_variable'], ['68', '69', 'upper_bound']]}, 'NCT01754857'), ({'text': 'use of one or more diabetes medications', 'entities': [['8', '11', 'lower_bound'], ['20', '40', 'clinical_variable']]}, 'NCT03054519'), ({'text': 'within the ages of 18-85', 'entities': [['12', '16', 'age'], ['20', '22', 'lower_bound'], ['23', '25', 'upper_bound']]}, 'NCT03144206'), ({'text': 'Aminoglutethimide; approximate half-life: 15 hours; washout period required: 4 days', 'entities': [['1', '18', 'treatment'], ['20', '41', 'clinical_variable'], ['43', '51', 'upper_bound'], ['53', '76', 'clinical_variable'], ['78', '84', 'upper_bound']]}, 'NCT02522715'), ({'text': 'Antidiuretic: conivaptan', 'entities': [['1', '13', 'treatment'], ['15', '25', 'treatment']]}, 'NCT01822522'), ({'text': 'Suicidal ideation', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT03104205'), ({'text': 'Report no significant use of other tobacco or nicotine products within the past month (more than 9 days in the past 30)', 'entities': [['98', '104', 'lower_bound'], ['112', '119', 'upper_bound']]}, 'NCT02250664'), ({'text': 'Subjects under the age of 21', 'entities': [['20', '23', 'age'], ['27', '29', 'lower_bound']]}, 'NCT02952365'), ({'text': 'Cytology report with a High Grade Squamous Intra Epithelial Lesion HSIL or have histologically proven CIN 2/3 or CIN 3 diagnosed by cervical biopsy between 2 and 8 weeks prior to enrollment. For a patient to be eligible, the Cytology report must state High Grade Squamous Intra Epithelial Lesion HSIL or the pathology report must clearly state CIN 2/3 or CIN 3 or must state moderate-severe dysplasia, moderate severe dyskaryosis, severe dysplasia, or severe dyskaryosis. Patients with a diagnosis of CIN 2 alone or moderate dysplasia or dyskaryosis alone are not eligible for this study', 'entities': [['24', '72', 'chronic_disease'], ['103', '108', 'chronic_disease'], ['103', '110', 'chronic_disease'], ['107', '108', 'lower_bound'], ['114', '119', 'chronic_disease'], ['133', '148', 'treatment'], ['163', '176', 'upper_bound'], ['392', '401', 'chronic_disease'], ['419', '430', 'chronic_disease']]}, 'NCT01925378'), ({'text': 'Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less', 'entities': [['26', '46', 'treatment'], ['93', '100', 'lower_bound']]}, 'NCT03145181'), ({'text': 'vasectomy at least 6 months prior to starting study treatment period and those whose female sexual partner(s) are more than 55 years of age and postmenopausal for at least 2 years or surgically sterile (tubal ligation, hysterectomy, or bilateral oophorectomy) agree to use at least a condom', 'entities': [['1', '10', 'treatment'], ['20', '34', 'lower_bound'], ['47', '62', 'treatment'], ['86', '92', 'gender'], ['125', '133', 'lower_bound'], ['137', '140', 'age'], ['173', '180', 'lower_bound'], ['204', '218', 'contraception_consent'], ['220', '232', 'contraception_consent'], ['237', '259', 'contraception_consent'], ['285', '291', 'contraception_consent']]}, 'NCT02522715'), ({'text': 'Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, during the treatment portion of the study and for 4 months after completion of hetIL-15 administration', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['47', '82', 'contraception_consent'], ['116', '125', 'treatment'], ['155', '169', 'upper_bound']]}, 'NCT02452268'), ({'text': 'Wilson disease', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02412540'), ({'text': 'Patients must have had estrogen receptor (ER) analysis performed on the primary breast tumor before neoadjuvant therapy according to current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for hormone receptor testing', 'entities': [['81', '93', 'cancer'], ['101', '120', 'treatment']]}, 'NCT01872975'), ({'text': 'evidence of 1-4 brain metastases', 'entities': [['13', '14', 'lower_bound'], ['15', '16', 'upper_bound'], ['17', '33', 'cancer']]}, 'NCT01891318'), ({'text': 'Patients with worsening depression that has not been addressed clinically', 'entities': [['25', '35', 'chronic_disease']]}, 'NCT02013492'), ({'text': 'Resolution of all chemotherapy or radiation-related toxicities d CTCAE Grade 1 severity, except for alopecia and hematologic toxicity', 'entities': [['19', '31', 'treatment'], ['35', '44', 'treatment'], ['72', '79', 'upper_bound'], ['101', '109', 'chronic_disease']]}, 'NCT01903330'), ({'text': 'Patient who recently underwent a surgery involving linear surgical skin incisions of 5cm or more', 'entities': [['34', '41', 'treatment'], ['52', '82', 'treatment'], ['86', '89', 'lower_bound']]}, 'NCT03020420'), ({'text': 'Known underlying higher risk thrombophilias including antiphospholipid antibody syndrome, antithrombin, protein C or protein S deficiencies, or homozygosity or compound heterozygosity for prothrombin G20210A or Factor V R506Q mutations', 'entities': [['30', '44', 'chronic_disease'], ['55', '89', 'chronic_disease'], ['105', '140', 'chronic_disease'], ['161', '184', 'chronic_disease'], ['189', '208', 'chronic_disease'], ['212', '226', 'treatment']]}, 'NCT01999179'), ({'text': 'metal biliary stents', 'entities': [['1', '21', 'treatment']]}, 'NCT02427841'), ({'text': 'No prior use of sorafenib or an mammalian target of rapamycin (mTOR) (including phosphoinositide 3-kinase [PI3k] or protein kinase B [AKT]) inhibitor for the treatment of thyroid cancer', 'entities': [['17', '26', 'treatment'], ['33', '69', 'treatment'], ['81', '113', 'treatment'], ['117', '150', 'treatment'], ['159', '168', 'treatment'], ['172', '186', 'cancer']]}, 'NCT02143726'), ({'text': 'these patients are at increased risk of lethal infections when treated with marrow suppressive therapy', 'entities': [['41', '58', 'chronic_disease'], ['77', '103', 'treatment']]}, 'NCT02573493'), ({'text': 'Patients with morphological evidence of myelodysplasia or leukemia', 'entities': [['41', '55', 'cancer'], ['59', '67', 'cancer']]}, 'NCT01720147'), ({'text': 'daily smokers with carbon monoxide readings less than 10ppm', 'entities': [['55', '60', 'upper_bound']]}, 'NCT02478697'), ({'text': "total bilirubin =< upper normal institutional limits (except for patients with Gilbert's disease who are eligible despite elevated serum bilirubin level", 'entities': [['1', '16', 'clinical_variable'], ['80', '97', 'chronic_disease'], ['132', '153', 'clinical_variable']]}, 'NCT02122185'), ({'text': 'Major surgery within 14 days before enrollment', 'entities': [['1', '14', 'treatment'], ['22', '36', 'upper_bound']]}, 'NCT02542657'), ({'text': 'Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories (using tissue and/or blood) demonstrating HER2 overexpression or amplification. Participants must have one of the following tumor types: biliary cancer, salivary cancer, or bladder cancer', 'entities': [['208', '211', 'lower_bound'], ['229', '234', 'cancer'], ['242', '256', 'cancer'], ['258', '273', 'cancer'], ['278', '292', 'cancer']]}, 'NCT02091141'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT00044304'), ({'text': 'Platelet count < 40,000/¼L', 'entities': [['1', '15', 'clinical_variable'], ['18', '27', 'upper_bound']]}, 'NCT02159027'), ({'text': 'oral antibiotics within two weeks of first dose', 'entities': [['1', '17', 'treatment'], ['25', '34', 'upper_bound']]}, 'NCT02270970'), ({'text': 'Claustrophobic', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02095808'), ({'text': 'Hypersensitivity to everolimus, sirolimus, or other rapamycin deriviatives', 'entities': [['21', '31', 'allergy_name'], ['33', '42', 'allergy_name'], ['53', '75', 'allergy_name']]}, 'NCT02974686'), ({'text': 'Birth weight 500-1000 grams', 'entities': [['1', '13', 'clinical_variable'], ['14', '17', 'lower_bound'], ['18', '28', 'upper_bound']]}, 'NCT02943746'), ({'text': 'Patient at high-risk for surgery by meeting a minimum of one major criteria or two minor criteria', 'entities': [['26', '33', 'treatment'], ['58', '61', 'lower_bound']]}, 'NCT02468024'), ({'text': 'currently pregnant', 'entities': [['1', '19', 'pregnancy']]}, 'NCT03113136'), ({'text': 'Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period', 'entities': [['1', '16', 'gender'], ['68', '92', 'pregnancy']]}, 'NCT01990209'), ({'text': 'Fasting plasma glucose e126mg/dL', 'entities': [['1', '23', 'clinical_variable'], ['25', '33', 'lower_bound']]}, 'NCT02130687'), ({'text': 'The patient must have stage 0, I, or II breast cancer; if stage II, the tumor size must be 3 cm or less', 'entities': [['23', '30', 'lower_bound'], ['38', '40', 'upper_bound'], ['41', '54', 'cancer'], ['59', '67', 'cancer'], ['73', '78', 'cancer'], ['92', '96', 'upper_bound']]}, 'NCT01245712'), ({'text': 'Have a malignancy', 'entities': [['8', '18', 'cancer']]}, 'NCT02682407'), ({'text': 'Prior febuxostat use', 'entities': [['7', '17', 'treatment']]}, 'NCT02579096'), ({'text': 'Clinical evidence of extra-central nervous system (CNS) (systemic) non-Hodgkin lymphoma', 'entities': [['68', '88', 'cancer']]}, 'NCT02498951'), ({'text': 'treatment with intrathecal therapy is recommended during protocol treatment but CNS analysis during treatment is not required', 'entities': [['1', '10', 'treatment'], ['16', '35', 'treatment']]}, 'NCT01925131'), ({'text': 'This includes angina (stable or unstable), MI, TIA, or CVA', 'entities': [['15', '42', 'chronic_disease'], ['44', '46', 'chronic_disease'], ['48', '51', 'chronic_disease'], ['56', '59', 'chronic_disease']]}, 'NCT02008656'), ({'text': 'Undergone molecular testing for integral biomarkers including immunohistochemical staining', 'entities': [['63', '91', 'treatment']]}, 'NCT02456857'), ({'text': 'Alternative diagnosis for cause of dyspnea, increased sputum or cough', 'entities': [['36', '43', 'chronic_disease'], ['45', '61', 'chronic_disease'], ['65', '70', 'chronic_disease']]}, 'NCT01742338'), ({'text': 'Stroke, transient ischemic attack, unstable angina, myocardial infarction or congestive heart failure (New York Heart Association Grade II or greater) within the past 12 months', 'entities': [['1', '7', 'chronic_disease'], ['9', '34', 'chronic_disease'], ['36', '51', 'chronic_disease'], ['53', '74', 'chronic_disease'], ['78', '102', 'chronic_disease'], ['104', '130', 'clinical_variable'], ['131', '139', 'lower_bound'], ['163', '177', 'upper_bound']]}, 'NCT01903330'), ({'text': 'Patients on chronic nitrate therapy or alpha-blockers', 'entities': [['13', '36', 'treatment'], ['40', '54', 'treatment']]}, 'NCT01817751'), ({'text': 'Forced vital capacity (FVC) >= 50%', 'entities': [['1', '28', 'clinical_variable'], ['32', '35', 'lower_bound']]}, 'NCT01701986'), ({'text': 'Any history of ventricular arrhythmia', 'entities': [['16', '38', 'chronic_disease']]}, 'NCT01620216'), ({'text': 'HIV Positive at baseline', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT03086057'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02995590'), ({'text': 'filgrastim, sargramostim, and erythropoietin', 'entities': [['1', '11', 'treatment'], ['13', '25', 'treatment'], ['31', '45', 'treatment']]}, 'NCT02076906'), ({'text': 'Prior history of venous thromboembolism', 'entities': [['18', '40', 'chronic_disease']]}, 'NCT02278692'), ({'text': 'patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count e (350) cells/microliter, and no known detectable viral load, at the time of study entry', 'entities': [['18', '21', 'chronic_disease'], ['69', '78', 'treatment'], ['84', '128', 'treatment'], ['140', '149', 'clinical_variable'], ['153', '156', 'lower_bound']]}, 'NCT01730937'), ({'text': 'Minimum age 18 years (no upper age limit)', 'entities': [['9', '12', 'age'], ['13', '21', 'lower_bound']]}, 'NCT02901314'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02536846'), ({'text': 'Karnofsky performance status > 60', 'entities': [['1', '29', 'clinical_variable'], ['32', '34', 'lower_bound']]}, 'NCT03159702'), ({'text': 'Patients must have a diagnosis of one of the following B-NHL malignancies', 'entities': [['56', '74', 'cancer']]}, 'NCT02339922'), ({'text': 'Malabsorption syndrome or other illness that could affect oral absorption', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT03069469'), ({'text': 'liver transaminases > 2 times the upper limit of normal', 'entities': [['1', '20', 'clinical_variable'], ['23', '56', 'lower_bound']]}, 'NCT02971202'), ({'text': 'Allergic to PPIs', 'entities': [['13', '17', 'allergy_name']]}, 'NCT02081404'), ({'text': 'Enrollment or planned enrollment in another randomized clinical trial during the study period', 'entities': [['37', '70', 'treatment']]}, 'NCT02476409'), ({'text': 'Absence of a non-aneurysmal aortic segment in the distal thoracic aorta above the diaphragmatic hiatus', 'entities': [['51', '72', 'chronic_disease']]}, 'NCT02089607'), ({'text': 'Reactive Arthritis, or IBD associated Arthritis', 'entities': [['1', '19', 'chronic_disease'], ['24', '48', 'chronic_disease']]}, 'NCT02506192'), ({'text': 'Because radiation is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately', 'entities': [['9', '18', 'treatment'], ['47', '52', 'gender'], ['49', '52', 'gender'], ['93', '128', 'contraception_consent'], ['130', '138', 'contraception_consent'], ['142', '173', 'contraception_consent'], ['175', '185', 'contraception_consent'], ['262', '267', 'gender'], ['268', '283', 'pregnancy'], ['275', '283', 'pregnancy']]}, 'NCT02112617'), ({'text': 'schizoaffective', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02674529'), ({'text': 'Negativity for Hepatitis B and C, HIV, and HTLV1/2 within 30 days of donation', 'entities': [['16', '33', 'chronic_disease'], ['35', '38', 'chronic_disease'], ['44', '51', 'chronic_disease'], ['59', '66', 'upper_bound']]}, 'NCT02670837'), ({'text': 'Participants may not have received inhaled or systemic corticosteroids for respiratory related illness ever, or for other conditions in the month prior to randomization', 'entities': [['36', '71', 'treatment']]}, 'NCT02148796'), ({'text': 'between 18 -24 weeks', 'entities': [['9', '11', 'lower_bound'], ['13', '21', 'upper_bound']]}, 'NCT03052270'), ({'text': 'Prior work in the hyperbaric chamber in the last 72 hours', 'entities': [['19', '37', 'treatment'], ['50', '58', 'upper_bound']]}, 'NCT02563678'), ({'text': 'Prior history of hypersensitivity to Sildenafil', 'entities': [['38', '48', 'allergy_name']]}, 'NCT02682147'), ({'text': 'Burkitt Lymphoma', 'entities': [['1', '17', 'cancer']]}, 'NCT02393157'), ({'text': 'Acute intracranial or intratumoral hemorrhage > Grade 1 either by MRI or CT scan d2 weeks of screening', 'entities': [['7', '46', 'clinical_variable'], ['49', '56', 'lower_bound'], ['67', '70', 'treatment'], ['74', '81', 'treatment'], ['83', '90', 'upper_bound']]}, 'NCT02302235'), ({'text': 'Paroxysmal nocturnal hemoglobinuria (PNH) associated with life-threatening thrombosis, and/or cytopenia, and/or transfusion dependence and/or recurrent and debilitating hemolytic crisis', 'entities': [['1', '42', 'chronic_disease'], ['76', '86', 'chronic_disease'], ['95', '104', 'chronic_disease']]}, 'NCT01174108'), ({'text': 'serum creatinine d 2 mg/dl, total bilirubin d 3', 'entities': [['1', '17', 'clinical_variable'], ['20', '27', 'upper_bound'], ['29', '44', 'clinical_variable'], ['47', '48', 'upper_bound']]}, 'NCT02207465'), ({'text': 'between the ages of 18 and 50', 'entities': [['13', '17', 'age'], ['21', '23', 'lower_bound'], ['28', '30', 'upper_bound']]}, 'NCT02386293'), ({'text': 'age e18 years d 70 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound'], ['17', '25', 'upper_bound']]}, 'NCT02679560'), ({'text': 'Life expectancy of more than 3 months', 'entities': [['1', '16', 'clinical_variable'], ['30', '38', 'lower_bound']]}, 'NCT02389517'), ({'text': 'Female subjects who are pregnant', 'entities': [['1', '16', 'gender'], ['25', '33', 'pregnancy']]}, 'NCT03097588'), ({'text': 'History of epileptic seizures', 'entities': [['12', '30', 'chronic_disease']]}, 'NCT01647321'), ({'text': 'Resolution of any effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade =< 1 and to baseline laboratory values as defined below', 'entities': [['30', '43', 'treatment'], ['52', '60', 'chronic_disease'], ['65', '170', 'clinical_variable'], ['174', '175', 'upper_bound']]}, 'NCT01591356'), ({'text': 'Cardiac: Echocardiogram shortening fraction >27%', 'entities': [['10', '44', 'clinical_variable'], ['46', '49', 'lower_bound']]}, 'NCT01050855'), ({'text': 'Subjects with mucosal diseases (e.g., erosive lichen planus) in the localized area around the study implant site', 'entities': [['15', '31', 'chronic_disease'], ['39', '60', 'chronic_disease']]}, 'NCT02953392'), ({'text': 'Male or female patients with a confirmed diagnosis of MS by McDonald criteria', 'entities': [['1', '5', 'gender'], ['9', '24', 'gender'], ['55', '57', 'chronic_disease']]}, 'NCT01950234'), ({'text': 'Patients with evidence of myelodysplasia', 'entities': [['27', '41', 'cancer']]}, 'NCT00716066'), ({'text': 'Relapsed or Refractory iNHL that has progressed during or following 1 or more prior systemic rituximab-containing (or another treatment of an anti-CD20 antibody-containing) regimens for lymphoma', 'entities': [['1', '28', 'cancer'], ['69', '70', 'lower_bound'], ['79', '182', 'treatment'], ['187', '195', 'cancer']]}, 'NCT02384954'), ({'text': 'Hepatitis C', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT02641093'), ({'text': 'current or past (<6 months) engagement in PCST for cancer', 'entities': [['19', '27', 'upper_bound'], ['52', '58', 'cancer']]}, 'NCT02791646'), ({'text': 'impaired renal function (eGFR < 60ml/min)', 'entities': [['1', '24', 'chronic_disease'], ['26', '30', 'clinical_variable'], ['33', '41', 'upper_bound']]}, 'NCT02085941'), ({'text': 'LVEF <40%', 'entities': [['1', '5', 'clinical_variable'], ['7', '10', 'upper_bound']]}, 'NCT02828592'), ({'text': 'Able and willing to give informed consent, and to undergo staging including PET scanning', 'entities': [['77', '89', 'treatment']]}, 'NCT01599559'), ({'text': 'Patients with active brain metastases or carcinomatous meningitis are excluded from this clinical trial. Patients with treated brain metastases, whose brain metastatic disease has remained stable for greater than or equal to 4 weeks without requiring steroid and anti-seizure medications are eligible to participate', 'entities': [['22', '38', 'cancer'], ['42', '66', 'cancer'], ['152', '176', 'clinical_variable'], ['226', '233', 'lower_bound'], ['252', '259', 'treatment'], ['264', '288', 'treatment']]}, 'NCT01851369'), ({'text': 'Pregnant at the time of data collection', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02565407'), ({'text': 'Age 18-60', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT02531880'), ({'text': 'limited palliative radiation', 'entities': [['9', '29', 'treatment']]}, 'NCT02908906'), ({'text': 'Exposure to any biological therapy or investigational biological agent within 90 days prior to the screening evaluation or have received any other investigational treatment 30 days prior to the screening evaluation', 'entities': [['17', '35', 'treatment'], ['39', '71', 'treatment'], ['79', '92', 'upper_bound'], ['148', '173', 'treatment']]}, 'NCT03162250'), ({'text': 'Patients requiring daily finger-stick blood glucose measurements', 'entities': [['26', '52', 'clinical_variable']]}, 'NCT02905591'), ({'text': 'have co-morbidities such that the surgeon and cardiologist Co-Investigators concur that the predicted risk of operative mortality is e15% or a minimum STS score of 8%', 'entities': [['111', '130', 'clinical_variable'], ['135', '138', 'lower_bound'], ['152', '161', 'clinical_variable'], ['165', '167', 'lower_bound']]}, 'NCT02000115'), ({'text': 'At least 2 symptoms measurable (score e 1) using the Myelofibrosis Symptom Assessment Form Version 4.0 (MFSAF v4.0)', 'entities': [['10', '11', 'lower_bound'], ['41', '42', 'lower_bound'], ['54', '116', 'clinical_variable']]}, 'NCT02158858'), ({'text': 'Previous history of Topiramate or Topamax use for any condition', 'entities': [['21', '42', 'treatment']]}, 'NCT00606411'), ({'text': 'Karnofsky e 60% for patients > 16 years of age', 'entities': [['1', '10', 'clinical_variable'], ['13', '16', 'lower_bound'], ['32', '40', 'lower_bound'], ['44', '47', 'age']]}, 'NCT02393157'), ({'text': 'those that are asymptomatic confirmed by post-Fontan procedure transthoracic echocardiogram, or other imaging techniques', 'entities': [['16', '28', 'chronic_disease'], ['42', '92', 'treatment']]}, 'NCT02846532'), ({'text': 'prednisone d 5 mg/day or equivalent', 'entities': [['1', '11', 'clinical_variable'], ['14', '22', 'upper_bound']]}, 'NCT02401347'), ({'text': 'Congestive heart failure', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02824263'), ({'text': 'Uncontrolled chronic asthma', 'entities': [['22', '28', 'chronic_disease']]}, 'NCT02547818'), ({'text': 'Uncontrolled inter-current illness including, but not limited to ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, or serious, uncontrolled cardiac arrhythmia, that might jeopardize the ability of the patient to receive the therapy program outlined in this protocol with reasonable safety', 'entities': [['104', '127', 'treatment'], ['141', '165', 'chronic_disease'], ['167', '191', 'chronic_disease'], ['218', '236', 'chronic_disease'], ['302', '309', 'treatment']]}, 'NCT03073785'), ({'text': 'Age > 16 years, 1.7 mg/dL (male) and 1.4 mg/dL (female)', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound'], ['28', '32', 'gender'], ['49', '55', 'gender']]}, 'NCT02389309'), ({'text': 'Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4', 'entities': [['12', '23', 'treatment'], ['27', '45', 'treatment'], ['88', '94', 'treatment']]}, 'NCT01620216'), ({'text': 'corrected diffusing capacity of lung for carbon monoxide (DLCO) at 60 percent of predicted or above', 'entities': [['21', '64', 'clinical_variable'], ['68', '78', 'lower_bound']]}, 'NCT03088709'), ({'text': 'Maximum tumor length of 7 cm at time of brachytherapy treatment start', 'entities': [['1', '21', 'clinical_variable'], ['25', '29', 'lower_bound'], ['41', '64', 'treatment']]}, 'NCT02199236'), ({'text': 'Severe medical co-morbidity including cardiovascular disorder, lung disorder, kidney disease, chronic neurological disease, hematological disease, or frailty that impacts tolerability of the surgery as judged by the screening physicians', 'entities': [['39', '62', 'chronic_disease'], ['64', '77', 'chronic_disease'], ['79', '93', 'chronic_disease'], ['103', '123', 'chronic_disease'], ['125', '146', 'chronic_disease'], ['192', '199', 'treatment']]}, 'NCT02056873'), ({'text': 'Subjects of reproductive potential who have not agreed to use effective contraception', 'entities': [['45', '86', 'contraception_consent']]}, 'NCT02101736'), ({'text': 'prior HCC', 'entities': [['7', '10', 'cancer']]}, 'NCT02379377'), ({'text': 'Diagnosis of acute bacterial skin and skin structure infection (ABSSSI), with a regional or systemic sign of infection', 'entities': [['14', '72', 'chronic_disease']]}, 'NCT03137173'), ({'text': 'Secondary AML (prior therapy or hematologic malignancy)', 'entities': [['1', '14', 'cancer'], ['16', '29', 'treatment'], ['33', '55', 'cancer']]}, 'NCT01760655'), ({'text': 'lack of a telephone number or stable mailing address', 'entities': [['11', '27', 'technology_access']]}, 'NCT02629731'), ({'text': 'Use of direct thrombin inhibitors (bivalirudin, argatroban, desirudin, dabigatran etexilate), or direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)', 'entities': [['8', '34', 'treatment'], ['36', '47', 'treatment'], ['49', '59', 'treatment'], ['61', '70', 'treatment'], ['72', '92', 'treatment'], ['98', '125', 'treatment'], ['127', '138', 'treatment'], ['140', '148', 'treatment'], ['150', '158', 'treatment']]}, 'NCT02679560'), ({'text': 'Systemic illnesses or organ diseases that may affect bone (except type 1 or type 2 diabetes mellitus)', 'entities': [['1', '19', 'chronic_disease'], ['23', '37', 'chronic_disease'], ['67', '101', 'chronic_disease']]}, 'NCT02440581'), ({'text': 'should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately', 'entities': [['10', '15', 'gender'], ['16', '31', 'pregnancy'], ['52', '63', 'pregnancy']]}, 'NCT02146924'), ({'text': 'Have histologically confirmed adenocarcinoma of the pancreas', 'entities': [['31', '61', 'cancer']]}, 'NCT02442323'), ({'text': 'Macular ischemia (defined as greater than 5 disc areas), as assessed by the investigator', 'entities': [['1', '17', 'clinical_variable'], ['43', '44', 'lower_bound']]}, 'NCT03085784'), ({'text': 'Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study', 'entities': [['1', '19', 'pregnancy'], ['55', '99', 'contraception_consent']]}, 'NCT01474889'), ({'text': 'Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody', 'entities': [['1', '32', 'treatment'], ['34', '44', 'treatment'], ['46', '56', 'treatment'], ['58', '68', 'treatment'], ['73', '130', 'treatment']]}, 'NCT02587962'), ({'text': 'Pregnant or lactating female', 'entities': [['1', '9', 'pregnancy'], ['23', '29', 'gender']]}, 'NCT02519322'), ({'text': 'diastolic blood pressure >90 at screening', 'entities': [['1', '25', 'clinical_variable'], ['27', '29', 'lower_bound']]}, 'NCT02418195'), ({'text': 'diagnosis of non-fluent or dysfluent aphasia', 'entities': [['14', '45', 'chronic_disease']]}, 'NCT00903266'), ({'text': 'Adequate pulmonary function defined as < Grade 3 hypoxia', 'entities': [['1', '28', 'clinical_variable'], ['42', '49', 'upper_bound'], ['50', '57', 'chronic_disease']]}, 'NCT02374333'), ({'text': 'Total bilirubin d1.5 mg/dL', 'entities': [['1', '16', 'clinical_variable'], ['18', '27', 'upper_bound']]}, 'NCT02106650'), ({'text': 'Patients with brain metastases diagnosed greater than 1 year prior to study entry may be considered if they received sterilizing therapy to the CNS (resection or radiation) and have been CNS recurrence-free for the 1-year period', 'entities': [['15', '31', 'cancer'], ['55', '67', 'lower_bound'], ['118', '137', 'treatment'], ['150', '159', 'treatment'], ['163', '172', 'treatment'], ['216', '229', 'upper_bound']]}, 'NCT02203513'), ({'text': 'Oral contraceptives', 'entities': [['1', '20', 'contraception_consent']]}, 'NCT01597518'), ({'text': 'Permitted concomitant medications include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including topical steroids, topical antibiotics, and topical antifungal agents', 'entities': [['23', '34', 'treatment'], ['43', '66', 'treatment'], ['84', '107', 'chronic_disease'], ['109', '118', 'treatment'], ['124', '143', 'treatment'], ['155', '171', 'treatment'], ['173', '192', 'treatment'], ['198', '223', 'treatment']]}, 'NCT01893554'), ({'text': 'Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally', 'entities': [['26', '35', 'chronic_disease'], ['37', '55', 'chronic_disease'], ['57', '70', 'chronic_disease']]}, 'NCT02577406'), ({'text': 'Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v. 5.0) grade 2 or higher from previous anti-cancer therapy, except alopecia or an endocrine toxicity related to immunotherapy (e.g. thyroiditis/hypothyroidism, adrenal insufficiency, hypophysitis) requiring replacement therapy, at the time of randomization', 'entities': [['129', '136', 'lower_bound'], ['152', '180', 'treatment'], ['189', '197', 'chronic_disease'], ['234', '247', 'treatment'], ['254', '265', 'chronic_disease'], ['266', '280', 'chronic_disease'], ['282', '303', 'chronic_disease'], ['305', '317', 'chronic_disease'], ['329', '348', 'treatment']]}, 'NCT01989585'), ({'text': 'nondilated cardiomyopathy', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT02946892'), ({'text': 'Received another investigational device or drug within 30 days of enrollment Received allograft, autograft or xenograft within 30 days of enrollment', 'entities': [['18', '48', 'treatment'], ['56', '63', 'upper_bound'], ['87', '96', 'treatment'], ['98', '107', 'treatment'], ['111', '120', 'treatment']]}, 'NCT02312518'), ({'text': 'EIC >= 25% of the lumpectomy specimen involved with ductal carcinoma in situ', 'entities': [['1', '4', 'clinical_variable'], ['8', '11', 'lower_bound'], ['19', '29', 'treatment'], ['53', '77', 'cancer']]}, 'NCT01570998'), ({'text': 'Clinical diagnosis of IPF by established means', 'entities': [['23', '26', 'chronic_disease']]}, 'NCT02478268'), ({'text': 'Severe ventricular dysfunction with LVEF <20% as measured by resting echocardiogram', 'entities': [['1', '31', 'chronic_disease'], ['37', '41', 'clinical_variable'], ['43', '46', 'upper_bound']]}, 'NCT02000115'), ({'text': 'e 1 prior regimen (min 2 cycles) with antibody conjugate, cytotoxic chemotherapy, or TKI alone or in combination', 'entities': [['3', '4', 'lower_bound'], ['5', '18', 'treatment'], ['24', '25', 'lower_bound'], ['39', '57', 'treatment'], ['59', '81', 'treatment'], ['86', '89', 'treatment']]}, 'NCT01994382'), ({'text': 'Patients must have had at least a computed tomography (CT) of the chest, abdomen, and pelvis within 4 weeks of registration in the trial', 'entities': [['35', '59', 'treatment'], ['101', '108', 'upper_bound']]}, 'NCT02542202'), ({'text': 'Other than DIAN study, current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the US Code of Federal Regulations (CFR)', 'entities': [['50', '65', 'upper_bound']]}, 'NCT02414178'), ({'text': 'Age greater than or equal to 18 years', 'entities': [['1', '4', 'age'], ['30', '38', 'lower_bound']]}, 'NCT01730118'), ({'text': 'Bi-dimensionally measurable disease', 'entities': [['1', '36', 'chronic_disease']]}, 'NCT01996865'), ({'text': 'Patients of childbearing or child- fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this study', 'entities': [['64', '123', 'contraception_consent']]}, 'NCT00924027'), ({'text': 'Subjects taking any lipid modification therapy, including but not limited to statins, fibrates and bile acid sequestrants', 'entities': [['21', '47', 'treatment'], ['78', '85', 'treatment'], ['87', '95', 'treatment'], ['100', '122', 'treatment']]}, 'NCT02322203'), ({'text': 'Because insufficient dosing or adverse event data are currently available on the use of Avelumab in participants < 18 years of age', 'entities': [['89', '97', 'treatment'], ['116', '124', 'upper_bound'], ['128', '131', 'age']]}, 'NCT02912572'), ({'text': 'Class III/IV heart failure or known left ventricular ejection fraction (LVEF) < 50%', 'entities': [['1', '10', 'lower_bound'], ['11', '13', 'upper_bound'], ['14', '27', 'chronic_disease'], ['37', '78', 'clinical_variable'], ['81', '84', 'upper_bound']]}, 'NCT02177695'), ({'text': 'Those with active respiratory infections requiring cancellation of surgery', 'entities': [['19', '41', 'chronic_disease'], ['68', '75', 'treatment']]}, 'NCT02793375'), ({'text': 'Patients are excluded if there is radiographic or cerebrospinal fluid (CSF) evidence of leptomeningeal disease', 'entities': [['89', '111', 'cancer']]}, 'NCT01644591'), ({'text': 'Patients with idiopathic VT defined as VT that originates from a region without evidence of scar detected by MRI or voltage mapping in a patient without other evidence of heart disease that is not causing significant depression of ventricular function', 'entities': [['15', '28', 'chronic_disease'], ['26', '28', 'chronic_disease'], ['110', '113', 'treatment'], ['117', '132', 'treatment'], ['172', '185', 'chronic_disease'], ['218', '228', 'chronic_disease']]}, 'NCT01791543'), ({'text': 'Peripheral absolute neutrophil count (ANC) >/= 1000/uL', 'entities': [['12', '43', 'clinical_variable'], ['48', '55', 'lower_bound']]}, 'NCT02110069'), ({'text': 'Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery', 'entities': [['1', '14', 'treatment'], ['27', '45', 'treatment'], ['54', '67', 'upper_bound']]}, 'NCT02807272'), ({'text': 'If sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods) due to unknown risk of teratogenicity of ramucirumab', 'entities': [['68', '97', 'contraception_consent'], ['99', '126', 'contraception_consent'], ['169', '180', 'treatment']]}, 'NCT02581215'), ({'text': 'Known hypersensitivity to PPIs or to any substituted benzimidazole or to any of the excipients', 'entities': [['27', '31', 'allergy_name'], ['54', '67', 'treatment']]}, 'NCT02401035'), ({'text': 'Pathologic confirmation of invasive breast cancer diagnosed by core needle biopsy', 'entities': [['37', '50', 'cancer'], ['64', '82', 'treatment']]}, 'NCT01953588'), ({'text': 'Use of over the counter pain medications (NSAIDs, etc.) on the day of MRI scan', 'entities': [['8', '41', 'treatment'], ['43', '49', 'treatment'], ['71', '79', 'treatment']]}, 'NCT02064296'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02562066'), ({'text': 'For Stratum 2: CD4 cell count between 100-200 cells/mm^3 obtained within 2 weeks prior to enrollment at any U.S. laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent', 'entities': [['16', '30', 'clinical_variable'], ['39', '42', 'lower_bound'], ['43', '57', 'upper_bound'], ['74', '87', 'upper_bound']]}, 'NCT02408861'), ({'text': 'The subjects will not have the ability to sit independently by one year of age or the ability to walk by 18 months of age', 'entities': [['76', '79', 'age']]}, 'NCT01072370'), ({'text': 'all subjects will be allowed to have previously failed one biologic DMARD, and up to forty (40) percent of subjects will be allowed to have previously failed two biologic DMARDs provided that washout periods are respected', 'entities': [['69', '74', 'treatment'], ['172', '178', 'treatment']]}, 'NCT03000439'), ({'text': 'Eastern Cooperative Oncology Group performance status (ECOG PS) d 2 (Appendix A)', 'entities': [['1', '64', 'clinical_variable'], ['67', '68', 'upper_bound']]}, 'NCT02865135'), ({'text': 'Age < 22 years (eligible until 22nd birthday)', 'entities': [['1', '4', 'age'], ['7', '15', 'upper_bound']]}, 'NCT01871766'), ({'text': 'Men', 'entities': [['1', '4', 'gender']]}, 'NCT01676259'), ({'text': 'Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x the upper limit of normal', 'entities': [['1', '31', 'clinical_variable'], ['36', '68', 'clinical_variable'], ['72', '101', 'lower_bound']]}, 'NCT02122081'), ({'text': 'Prior experimental (non-FDA approved) therapies and immunotherapies', 'entities': [['1', '68', 'treatment']]}, 'NCT02576444'), ({'text': 'Other optic comorbidity than glaucoma', 'entities': [['30', '38', 'chronic_disease']]}, 'NCT03188042'), ({'text': 'Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2', 'entities': [['26', '86', 'clinical_variable'], ['93', '94', 'upper_bound']]}, 'NCT02536794'), ({'text': 'MI or stroke in the last 3 months will be excluded', 'entities': [['1', '3', 'chronic_disease'], ['7', '13', 'chronic_disease'], ['21', '34', 'upper_bound']]}, 'NCT02525692'), ({'text': 'Participants who are pregnant', 'entities': [['18', '30', 'pregnancy']]}, 'NCT02335671'), ({'text': 'Patients with a known human immunodeficiency virus infection (HIV 1/2 antibodies) or acquired immunodeficiency syndrome (HIV/AIDS)', 'entities': [['23', '82', 'chronic_disease'], ['86', '131', 'chronic_disease']]}, 'NCT03162731'), ({'text': 'suspect she is pregnant while participating in this study', 'entities': [['16', '24', 'pregnancy']]}, 'NCT02536794'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of <=1', 'entities': [['1', '61', 'clinical_variable'], ['67', '68', 'upper_bound']]}, 'NCT01943851'), ({'text': 'History of previous infection with hookworm or residence for more than 6 months in a hookworm-endemic area', 'entities': [['21', '30', 'chronic_disease'], ['72', '80', 'lower_bound']]}, 'NCT01940757'), ({'text': 'Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) e1.0 x 10^9/L; absolute lymphocyte count (ALC) e0.5 x 10^9/L; platelets e100 x 10^9/L; hemoglobin e8 g/dL', 'entities': [['31', '84', 'clinical_variable'], ['86', '98', 'lower_bound'], ['100', '131', 'clinical_variable'], ['133', '145', 'lower_bound'], ['147', '156', 'clinical_variable'], ['158', '170', 'lower_bound'], ['172', '182', 'clinical_variable'], ['184', '190', 'lower_bound']]}, 'NCT02549833'), ({'text': 'Concurrent use of other anti-cancer agents or treatments', 'entities': [['25', '43', 'treatment'], ['47', '57', 'treatment']]}, 'NCT01754857'), ({'text': 'testosterone (less than or equal to 260 ng/dl)', 'entities': [['1', '13', 'clinical_variable'], ['37', '46', 'upper_bound']]}, 'NCT02404870'), ({'text': 'Pregnant or lactating women', 'entities': [['1', '9', 'pregnancy'], ['23', '28', 'gender']]}, 'NCT02252432'), ({'text': 'Third degree heart block', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02464696'), ({'text': 'Chronic Cardiovascular Disease (including but not limited to: congestive heart failure, previous myocardial infarction, any cardiomyopathy, any arrhythmia, or previous cardiac surgery)', 'entities': [['9', '31', 'chronic_disease'], ['63', '87', 'chronic_disease'], ['98', '119', 'chronic_disease'], ['125', '139', 'chronic_disease'], ['145', '155', 'chronic_disease'], ['169', '184', 'treatment']]}, 'NCT02193373'), ({'text': 'Calculated creatinine clearance (Cr Cl) >= 50 ml/min', 'entities': [['1', '40', 'clinical_variable'], ['44', '53', 'lower_bound']]}, 'NCT00293475'), ({'text': 'Middle or deep third penetration, clinical tumor >= 4 cm', 'entities': [['44', '49', 'cancer'], ['53', '57', 'lower_bound']]}, 'NCT01101451'), ({'text': 'Patients cannot tolerate concurrent chemotherapy', 'entities': [['37', '49', 'treatment']]}, 'NCT02492867'), ({'text': 'Patients who received a stem cell transplant =< 12 months from the start of therapy', 'entities': [['25', '45', 'treatment'], ['49', '58', 'upper_bound'], ['77', '84', 'treatment']]}, 'NCT02530034'), ({'text': 'Receipt of any aerosolized experimental or investigational drugs within 1 month of enrollment', 'entities': [['44', '65', 'treatment'], ['73', '80', 'upper_bound']]}, 'NCT02129803'), ({'text': 'contraindication to MRI', 'entities': [['21', '24', 'treatment']]}, 'NCT02047721'), ({'text': 'Neurologic deficits in patients with CNS tumors must be stable for a minimum of 1 week prior to study entry', 'entities': [['1', '20', 'chronic_disease'], ['38', '48', 'cancer'], ['81', '93', 'upper_bound']]}, 'NCT01505569'), ({'text': 'Speak English as their primary language', 'entities': [['1', '14', 'language_fluency']]}, 'NCT03101085'), ({'text': 'Subjects must have had one prior systemic chemotherapeutic regimen for management of persistent, recurrent, or metastatic carcinoma of the cervix (e.g., paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab)', 'entities': [['112', '146', 'cancer'], ['154', '164', 'treatment'], ['165', '174', 'treatment'], ['197', '208', 'treatment']]}, 'NCT03104699'), ({'text': 'Subject has history (within previous 5 years) of clinically significant pulmonary hypertension, uncontrolled systemic hypertension or hypertensive crisis, symptomatic heart failure, cardiomyopathy, myocardial infarction, unstable/severe angina pectoris, cardiac arrhythmia requiring medication, coronary/peripheral artery bypass graft, aneurysm or aneurysm repair, angioplasty, cerebrovascular accident, transient ischemic attack or the left ventricular ejection fraction (LVEF) less than 50%', 'entities': [['29', '45', 'upper_bound'], ['73', '95', 'chronic_disease'], ['83', '95', 'chronic_disease'], ['135', '154', 'chronic_disease'], ['168', '181', 'chronic_disease'], ['183', '197', 'chronic_disease'], ['199', '220', 'chronic_disease'], ['222', '253', 'chronic_disease'], ['255', '273', 'chronic_disease'], ['284', '294', 'treatment'], ['296', '335', 'treatment'], ['337', '345', 'chronic_disease'], ['349', '364', 'treatment'], ['366', '377', 'treatment'], ['405', '430', 'chronic_disease'], ['438', '479', 'clinical_variable'], ['490', '493', 'upper_bound']]}, 'NCT01946074'), ({'text': 'Any surgical or medical condition which might alter pharmacokinetics of drug (e.g. renal transplant, liver failure, liver transplant)', 'entities': [['84', '100', 'treatment'], ['102', '115', 'chronic_disease'], ['117', '133', 'treatment']]}, 'NCT02169089'), ({'text': 'Open or needle abdominal biopsy findings consistent with LAM', 'entities': [['1', '32', 'treatment'], ['58', '61', 'chronic_disease']]}, 'NCT02737202'), ({'text': 'Patients who have ever received HPV vaccination (at least one dose of HPV vaccine)', 'entities': [['33', '48', 'treatment'], ['59', '62', 'lower_bound'], ['71', '82', 'treatment']]}, 'NCT03023631'), ({'text': 'Patients with HIV infection', 'entities': [['15', '18', 'chronic_disease']]}, 'NCT02203903'), ({'text': 'The American Society of Anesthesiologists (ASA) Physical Status 1-3', 'entities': [['1', '64', 'clinical_variable'], ['65', '66', 'lower_bound'], ['67', '68', 'upper_bound']]}, 'NCT02548104'), ({'text': 'female subjects', 'entities': [['1', '16', 'gender']]}, 'NCT00065676'), ({'text': 'Apixaban', 'entities': [['1', '9', 'treatment']]}, 'NCT02925923'), ({'text': 'Neurologic, neurodevelopmental or neurodegenerative disorders', 'entities': [['1', '11', 'chronic_disease'], ['13', '31', 'chronic_disease'], ['35', '62', 'chronic_disease']]}, 'NCT02134392'), ({'text': 'previously diagnosed with another malignancy and have any evidence of residual disease', 'entities': [['35', '45', 'cancer']]}, 'NCT02481310'), ({'text': 'New York Heart Association (NYHA) Class III or IV', 'entities': [['1', '40', 'clinical_variable'], ['41', '44', 'lower_bound'], ['48', '50', 'upper_bound']]}, 'NCT01676259'), ({'text': 'Patients of all ages will be eligible', 'entities': [['17', '21', 'age']]}, 'NCT02425904'), ({'text': 'Pathologically proven recurrent disease or a second primary (squamous cell carcinoma of the head and neck, nasopharyngeal cancer, salivary gland cancer, or thyroid cancer) within the head and neck region, deemed to be unresectable or resected with gross residual disease remaining (determined by either operative/pathology report or post-surgical imaging)', 'entities': [['62', '106', 'cancer'], ['108', '129', 'cancer'], ['131', '152', 'cancer'], ['157', '171', 'cancer'], ['255', '271', 'cancer']]}, 'NCT02474368'), ({'text': 'Known cardiac valvular disease (e.g. bicuspid aortic valve) or arterial aneurysm(s) that may allow a nidus of infection', 'entities': [['7', '31', 'chronic_disease'], ['38', '59', 'chronic_disease'], ['64', '81', 'chronic_disease'], ['102', '120', 'chronic_disease']]}, 'NCT01562626'), ({'text': 'This is a score of e10/12 on ESC', 'entities': [['21', '26', 'lower_bound'], ['30', '33', 'clinical_variable']]}, 'NCT02404155'), ({'text': 'Healthy males', 'entities': [['9', '14', 'gender']]}, 'NCT01910818'), ({'text': 'Use of grapefruit- or Seville orange-containing products within 48 hours prior to Day 1 and through the last PK sampling point on Day 20', 'entities': [['8', '18', 'treatment'], ['23', '57', 'treatment'], ['65', '73', 'upper_bound']]}, 'NCT03140527'), ({'text': 'breastfeeding should be discontinued while the patient is on this trial and for 30 days following last dose of study drug', 'entities': [['81', '88', 'lower_bound']]}, 'NCT01827384'), ({'text': 'Not having knee pain', 'entities': [['12', '21', 'chronic_disease']]}, 'NCT02577549'), ({'text': 'Patients who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists', 'entities': [['18', '42', 'treatment'], ['65', '73', 'treatment'], ['77', '84', 'treatment']]}, 'NCT02048722'), ({'text': 'Steroids must be completed alongside last dose of chemotherapy', 'entities': [['1', '9', 'treatment'], ['51', '63', 'treatment']]}, 'NCT02465060'), ({'text': 'Use of beta blockers or corticosteriods', 'entities': [['8', '21', 'treatment'], ['25', '40', 'treatment']]}, 'NCT02411318'), ({'text': 'Primary in-situ (or locally-recurrent) tumor must be present and, in the opinion of radiation oncology, be amenable to radiation therapy as planned in the protocol', 'entities': [['85', '94', 'treatment'], ['120', '137', 'treatment']]}, 'NCT02311361'), ({'text': 'serotonin selective reuptake inhibitors (SSRI) (2 weeks)', 'entities': [['1', '47', 'treatment']]}, 'NCT02907983'), ({'text': 'Families with a high suspicion of hereditary thyroid cancer/nodules', 'entities': [['46', '68', 'cancer']]}, 'NCT02747888'), ({'text': 'Subjects with significant history of systemic immunosuppression due to drugs or infection with HIV or HTLV 1', 'entities': [['38', '64', 'chronic_disease'], ['96', '99', 'chronic_disease'], ['103', '109', 'chronic_disease']]}, 'NCT02448381'), ({'text': 'Age 18 to 70 years of age', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['11', '19', 'upper_bound'], ['23', '26', 'age']]}, 'NCT02512497'), ({'text': 'Severe life, threatening infection', 'entities': [['26', '35', 'chronic_disease']]}, 'NCT01189786'), ({'text': 'Subject has a diagnosis of mental retardation', 'entities': [['28', '46', 'chronic_disease']]}, 'NCT02361554'), ({'text': 'without previously documented EF <30% (within the past 5 years)', 'entities': [['31', '33', 'clinical_variable'], ['35', '38', 'upper_bound'], ['51', '63', 'upper_bound']]}, 'NCT03088033'), ({'text': 'History of other malignancy in the past 2 years', 'entities': [['18', '28', 'cancer'], ['36', '48', 'upper_bound']]}, 'NCT02857218'), ({'text': 'Patients will be sedentary, defined here as no regular physical activity for at least the prior 6 months and current activity level will be documented by an activity questionnaire', 'entities': [['91', '105', 'upper_bound']]}, 'NCT03136029'), ({'text': 'Subjects without placement of a biopsy clip at the diagnostic procedure who are unwilling to undergo clip placement', 'entities': [['102', '116', 'treatment']]}, 'NCT03043794'), ({'text': 'Recently started (< 8 weeks prior to randomization) or planned cardiopulmonary rehabilitation program based on exercise', 'entities': [['21', '34', 'upper_bound']]}, 'NCT02981082'), ({'text': 'Metastases location within 2cm of GI tract', 'entities': [['1', '11', 'cancer'], ['28', '31', 'upper_bound']]}, 'NCT01697371'), ({'text': 'Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)', 'entities': [['18', '29', 'chronic_disease'], ['37', '51', 'chronic_disease'], ['56', '67', 'chronic_disease'], ['75', '82', 'clinical_variable']]}, 'NCT02977468'), ({'text': 'A negative serum or pregnancy test is required no more than 7 days before study entry', 'entities': [['21', '30', 'pregnancy'], ['61', '74', 'lower_bound']]}, 'NCT02204098'), ({'text': 'women with regular menstrual cycles and no evidence of hyperandrogenism', 'entities': [['1', '6', 'gender'], ['56', '72', 'chronic_disease']]}, 'NCT00594217'), ({'text': 'Patients with acute preoperative neurological deficit, myocardial infarction, or cardiac event who have not returned to baseline for at least 30-days prior to enrollment', 'entities': [['15', '54', 'chronic_disease'], ['56', '77', 'chronic_disease'], ['143', '156', 'lower_bound']]}, 'NCT01812174'), ({'text': 'not pregnant', 'entities': [['1', '13', 'pregnancy']]}, 'NCT02310633'), ({'text': 'Ejection fraction < 50%', 'entities': [['1', '18', 'clinical_variable'], ['21', '24', 'upper_bound']]}, 'NCT02966665'), ({'text': 'Diseases and conditions that would increase the morbidity and mortality of spinal cord injury surgery (e.g. cardiopulmonary issues)', 'entities': [['76', '102', 'treatment'], ['109', '124', 'chronic_disease']]}, 'NCT03026816'), ({'text': 'Subjects with known cardiovascular disease, thyroid disease', 'entities': [['21', '43', 'chronic_disease'], ['45', '60', 'chronic_disease']]}, 'NCT02979327'), ({'text': 'Bilateral Neck Radiation', 'entities': [['11', '25', 'treatment']]}, 'NCT01893307'), ({'text': 'extreme obesity (BMI e 35 kg/m2)', 'entities': [['9', '16', 'chronic_disease'], ['18', '21', 'bmi'], ['24', '32', 'lower_bound']]}, 'NCT02620449'), ({'text': 'The patient is on anticoagulation therapy', 'entities': [['19', '42', 'treatment']]}, 'NCT00737893'), ({'text': 'Hormonal therapy (e.g. leuprolide, goserelin, triptorelin, degarelix)', 'entities': [['1', '17', 'treatment'], ['24', '34', 'treatment'], ['36', '45', 'treatment'], ['47', '58', 'treatment'], ['60', '69', 'treatment']]}, 'NCT03043807'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT03096366'), ({'text': 'Total bilirubin within normal institutional limits', 'entities': [['1', '16', 'clinical_variable']]}, 'NCT03121352'), ({'text': 'Age greater than or equal to18 and less than or equal to 75 years', 'entities': [['1', '4', 'age'], ['29', '31', 'lower_bound'], ['58', '66', 'upper_bound']]}, 'NCT01553214'), ({'text': 'myocarditis', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT01568177'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02703220'), ({'text': 'Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician', 'entities': [['9', '14', 'gender'], ['22', '62', 'contraception_consent'], ['70', '79', 'treatment'], ['97', '111', 'lower_bound']]}, 'NCT02143050'), ({'text': 'Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence during study treatment and 12 months after the last dose of alisertib', 'entities': [['74', '122', 'contraception_consent'], ['139', '149', 'contraception_consent'], ['177', '192', 'upper_bound'], ['210', '219', 'treatment']]}, 'NCT02114229'), ({'text': 'GCS < 8 or inadequate airway protective reflexes', 'entities': [['1', '4', 'clinical_variable'], ['7', '8', 'upper_bound']]}, 'NCT02464696'), ({'text': 'Major surgery within 2 weeks of the first dose of study drug', 'entities': [['1', '14', 'treatment'], ['22', '29', 'upper_bound']]}, 'NCT03069469'), ({'text': 'A history of any major surgery within 6 weeks prior to dosing', 'entities': [['24', '31', 'treatment'], ['39', '52', 'upper_bound']]}, 'NCT02281409'), ({'text': 'White blood cells (WBC) >= 3,000/mcL', 'entities': [['1', '24', 'clinical_variable'], ['28', '37', 'lower_bound']]}, 'NCT01591356'), ({'text': 'Active cancer or infection', 'entities': [['8', '14', 'cancer'], ['18', '27', 'chronic_disease']]}, 'NCT03118050'), ({'text': 'Patients with a new diagnosis of a T1/T2 tongue cancer', 'entities': [['36', '55', 'cancer']]}, 'NCT02584270'), ({'text': 'pregnant or nursing women', 'entities': [['1', '9', 'pregnancy'], ['21', '26', 'gender']]}, 'NCT02122185'), ({'text': 'History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)', 'entities': [['37', '65', 'chronic_disease'], ['69', '101', 'chronic_disease']]}, 'NCT01989585'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 (See Appendix 8)', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['64', '65', 'upper_bound']]}, 'NCT02128906'), ({'text': 'No chronic medical conditions other than seasonal or environmental allergies', 'entities': [['42', '50', 'allergy_name'], ['54', '67', 'allergy_name']]}, 'NCT01433315'), ({'text': 'Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast', 'entities': [['7', '17', 'cancer'], ['36', '52', 'upper_bound'], ['80', '87', 'cancer'], ['129', '163', 'cancer'], ['165', '191', 'cancer'], ['196', '229', 'cancer']]}, 'NCT02656706'), ({'text': 'Women of childbearing age must agree to use an approved method of contraception for the duration of the study', 'entities': [['1', '6', 'gender'], ['23', '26', 'age'], ['32', '80', 'contraception_consent']]}, 'NCT03152409'), ({'text': 'Life expectancy <2 years', 'entities': [['1', '16', 'clinical_variable'], ['18', '25', 'upper_bound']]}, 'NCT01726257'), ({'text': 'with any therapy over the course of their disease', 'entities': [['10', '17', 'treatment']]}, 'NCT02004275'), ({'text': 'Squamous or non-squamous histology', 'entities': [['1', '25', 'cancer']]}, 'NCT02259621'), ({'text': 'Mobitz Type II second degree AV block (or higher AV block)', 'entities': [['1', '38', 'chronic_disease'], ['30', '38', 'chronic_disease']]}, 'NCT02453373'), ({'text': 'age 18 years and older', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT01901055'), ({'text': 'For patients not eligible for anti-testosterone therapy, hormone therapy with LHRH agonist alone will be permitted on case by case basis by study P.I', 'entities': [['31', '56', 'treatment'], ['58', '91', 'treatment']]}, 'NCT02353819'), ({'text': 'anticholinergics', 'entities': [['1', '17', 'treatment']]}, 'NCT02233868'), ({'text': 'include, but are not limited to, cancers with high risk of ovarian metastasis such as leukemia and non-Hodgkin lymphoma', 'entities': [['34', '41', 'cancer'], ['60', '78', 'cancer'], ['87', '95', 'cancer'], ['100', '120', 'cancer']]}, 'NCT02429349'), ({'text': 'Patients who have an ongoing SAE from a clinical study that is assessed by the investigator as related to bardoxolone methyl', 'entities': [['107', '125', 'treatment']]}, 'NCT03068130'), ({'text': 'No previous treatment with olaparib or any other drug sharing the same target. Prior treatment with PARP inhibitor monotherapy is allowed in the combination arms', 'entities': [['13', '36', 'treatment'], ['80', '127', 'treatment']]}, 'NCT02576444'), ({'text': 'Presence of bleeding diathesis', 'entities': [['13', '31', 'chronic_disease']]}, 'NCT02479230'), ({'text': 'endovascular revascularization', 'entities': [['1', '31', 'treatment']]}, 'NCT03006770'), ({'text': 'Recent history (within last month) of vaginal infection or vaginitis', 'entities': [['39', '56', 'chronic_disease'], ['60', '69', 'chronic_disease']]}, 'NCT02431897'), ({'text': 'Age between 18 and 60 years', 'entities': [['1', '4', 'age'], ['13', '15', 'lower_bound'], ['20', '28', 'upper_bound']]}, 'NCT02416674'), ({'text': 'Severe major organ toxicity', 'entities': [['14', '28', 'chronic_disease']]}, 'NCT00107289'), ({'text': 'Tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy', 'entities': [['1', '7', 'cancer'], ['124', '130', 'treatment'], ['175', '182', 'lower_bound'], ['207', '224', 'treatment']]}, 'NCT02269293'), ({'text': 'Patients with known active cancer and chemotherapy or radiation therapy', 'entities': [['21', '34', 'cancer'], ['39', '51', 'treatment'], ['55', '72', 'treatment']]}, 'NCT03090672'), ({'text': 'Performance Level Karnofsky e 50%', 'entities': [['1', '28', 'clinical_variable'], ['31', '34', 'lower_bound']]}, 'NCT02101736'), ({'text': 'severely symptomatic congestive heart failure', 'entities': [['1', '46', 'chronic_disease']]}, 'NCT02950337'), ({'text': 'breast feeding women', 'entities': [['16', '21', 'gender']]}, 'NCT02891850'), ({'text': 'SLE patients requiring prednisone >10 mg/day', 'entities': [['1', '4', 'chronic_disease'], ['24', '34', 'clinical_variable'], ['36', '45', 'lower_bound']]}, 'NCT03152058'), ({'text': 'Patients with history of HIV disease are also excluded from the study', 'entities': [['26', '37', 'chronic_disease']]}, 'NCT02530463'), ({'text': 'Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions (see Appendix 2) and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI', 'entities': [['1', '31', 'chronic_disease'], ['43', '76', 'clinical_variable'], ['77', '85', 'lower_bound'], ['89', '91', 'upper_bound'], ['128', '145', 'clinical_variable'], ['147', '150', 'upper_bound'], ['154', '163', 'treatment'], ['168', '171', 'upper_bound'], ['175', '189', 'treatment'], ['197', '200', 'treatment']]}, 'NCT01908777'), ({'text': 'Use of any weight loss drugs', 'entities': [['12', '29', 'treatment']]}, 'NCT02721303'), ({'text': 'Most recent prostate specific antigen (PSA) within 60 days of enrollment', 'entities': [['13', '44', 'clinical_variable'], ['52', '59', 'upper_bound']]}, 'NCT02470897'), ({'text': 'Central nervous system metastases, including lymphomatous meningitis', 'entities': [['1', '34', 'cancer'], ['46', '69', 'cancer']]}, 'NCT01947140'), ({'text': 'Have used nicotine replacement, bupropion or other pharmacotherapies as cessation aids in the past month', 'entities': [['11', '31', 'treatment'], ['33', '42', 'treatment'], ['52', '69', 'treatment']]}, 'NCT02250664'), ({'text': 'Sexually active male subjects must use a barrier method of contraception during the study and agree to continue the use of male contraception for at least 30 days after the last dose of IP', 'entities': [['17', '30', 'gender'], ['36', '73', 'contraception_consent'], ['95', '142', 'contraception_consent'], ['156', '163', 'lower_bound'], ['187', '189', 'treatment']]}, 'NCT02250157'), ({'text': 'Age >= 40 and any surgical therapy', 'entities': [['1', '4', 'age'], ['8', '10', 'lower_bound'], ['19', '35', 'treatment']]}, 'NCT00887146'), ({'text': 'Pregnant or nursing women', 'entities': [['1', '9', 'pregnancy'], ['21', '26', 'gender']]}, 'NCT02122185'), ({'text': "Histologically confirmed solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, germ cell tumors, primary brain tumors, NF-1 associated PF and LCH", 'entities': [['26', '38', 'cancer'], ['81', '97', 'cancer'], ['120', '128', 'cancer'], ['130', '160', 'cancer'], ['162', '174', 'cancer'], ['176', '189', 'cancer'], ['191', '203', 'cancer'], ['205', '219', 'cancer'], ['221', '237', 'cancer'], ['261', '265', 'cancer'], ['277', '279', 'cancer'], ['284', '287', 'cancer']]}, 'NCT02124772'), ({'text': "Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study drug (i.e., any significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the patient's risk by participating in this study)", 'entities': [['104', '114', 'treatment']]}, 'NCT02166905'), ({'text': 'Patients who have had chemotherapy or RT within 3 weeks prior to start of the study agents, or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier', 'entities': [['23', '35', 'treatment'], ['39', '41', 'treatment'], ['49', '62', 'upper_bound'], ['79', '91', 'treatment'], ['182', '197', 'lower_bound']]}, 'NCT02498613'), ({'text': 'Any clinically-significant medication condition or therapy that would preclude treatment with ketamine, to include: Recent myocardial infarction', 'entities': [['28', '38', 'treatment'], ['52', '59', 'treatment'], ['80', '103', 'treatment'], ['124', '145', 'chronic_disease']]}, 'NCT02418195'), ({'text': '9/10 donors where all the HLA sequences have the same antigen/peptide binding domains in key exons to the patient. This can result in identical protein sequences between patient and donor. Allele mismatches in p and g groups can be considered acceptable due to the exact matching which exists in the binding domains', 'entities': [['27', '30', 'clinical_variable'], ['55', '62', 'clinical_variable'], ['63', '70', 'clinical_variable'], ['190', '196', 'clinical_variable']]}, 'NCT01174108'), ({'text': 'Part D1: Patients with relapsed or refractory neuroblastoma', 'entities': [['47', '60', 'chronic_disease']]}, 'NCT02304458'), ({'text': 'Inability to perform a temporary or permanent open surgical or endovascular iliac conduit for patients with inadequate femoral/iliac access', 'entities': [['47', '82', 'treatment']]}, 'NCT02266719'), ({'text': 'Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes', 'entities': [['1', '26', 'chronic_disease'], ['30', '56', 'chronic_disease'], ['62', '77', 'treatment']]}, 'NCT01908777'), ({'text': 'Traumatic or non-traumatic paraplegia >6 months in duration', 'entities': [['1', '38', 'chronic_disease'], ['40', '48', 'lower_bound']]}, 'NCT02314221'), ({'text': 'Does not speak or read English', 'entities': [['1', '31', 'language_fluency']]}, 'NCT03132415'), ({'text': 'Use of topical or oral complementary/alternative medicine (CAM) agents within 4 weeks of initiation of treatment', 'entities': [['24', '64', 'treatment'], ['79', '86', 'upper_bound'], ['104', '113', 'treatment']]}, 'NCT01631617'), ({'text': 'Major fetal anomaly', 'entities': [['1', '6', 'chronic_disease']]}, 'NCT03171480'), ({'text': 'Between 30 and 75 years of age', 'entities': [['9', '11', 'lower_bound'], ['16', '24', 'upper_bound'], ['28', '31', 'age']]}, 'NCT02233868'), ({'text': 'Neurologic function: Neuropathy (sensory and motor) less than or equal to Grade 1', 'entities': [['22', '32', 'chronic_disease'], ['75', '82', 'upper_bound']]}, 'NCT02269293'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02694029'), ({'text': 'Current medical illness unrelated to CP', 'entities': [['9', '24', 'chronic_disease'], ['38', '40', 'chronic_disease']]}, 'NCT03038269'), ({'text': 'Medicare recipients and were hospitalized at least one time in the past year', 'entities': [['52', '55', 'lower_bound']]}, 'NCT01929005'), ({'text': 'Sickle cell disease', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT01050855'), ({'text': 'Patients may not be receiving any other investigational agents', 'entities': [['41', '63', 'treatment']]}, 'NCT01054196'), ({'text': 'Presence of uncontrolled infection', 'entities': [['13', '35', 'chronic_disease']]}, 'NCT01532687'), ({'text': "Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies that in the investigator's opinion would put the patient at an increased risk", 'entities': [['28', '53', 'chronic_disease'], ['85', '92', 'chronic_disease'], ['117', '128', 'chronic_disease'], ['130', '139', 'chronic_disease'], ['141', '170', 'chronic_disease'], ['172', '210', 'chronic_disease']]}, 'NCT02578732'), ({'text': 'Has a life expectancy of at least 3 months', 'entities': [['7', '22', 'clinical_variable'], ['35', '43', 'lower_bound']]}, 'NCT03110354'), ({'text': 'BMI <35 and > 60 kg/m2', 'entities': [['1', '4', 'bmi'], ['6', '8', 'upper_bound'], ['15', '23', 'lower_bound']]}, 'NCT02969187'), ({'text': 'Non-professional tattoo within last 6 months', 'entities': [['32', '45', 'upper_bound']]}, 'NCT01459107'), ({'text': 'have received prior radiation therapy to index lesions e 28 days prior to registration on this protocol if there has been documented progression by RECIST criteria', 'entities': [['15', '38', 'treatment'], ['42', '55', 'clinical_variable'], ['58', '71', 'lower_bound']]}, 'NCT02143726'), ({'text': 'history of seizures', 'entities': [['12', '20', 'chronic_disease']]}, 'NCT02266004'), ({'text': 'Patients with focal task-specific dystonia of one or both hands', 'entities': [['35', '43', 'chronic_disease']]}, 'NCT02107261'), ({'text': 'Platelets e 100,000 per mm3', 'entities': [['1', '10', 'clinical_variable'], ['13', '28', 'lower_bound']]}, 'NCT02344355'), ({'text': 'contraindications to cardiac magnetic resonance imaging (CMR)', 'entities': [['22', '62', 'treatment']]}, 'NCT02589977'), ({'text': 'Major congenital malformations including congenital cleft palate, cytogenetic abnormalities, or serious chronic disorders', 'entities': [['53', '65', 'chronic_disease'], ['67', '92', 'chronic_disease'], ['105', '122', 'chronic_disease']]}, 'NCT01893554'), ({'text': 'Receipt of licensed vaccines within 14 days before or after immunization (30 days for live vaccines)', 'entities': [['12', '29', 'treatment'], ['37', '44', 'upper_bound'], ['61', '73', 'treatment'], ['75', '82', 'upper_bound'], ['87', '100', 'treatment']]}, 'NCT02776761'), ({'text': 'Myxofibrosarcoma', 'entities': [['1', '17', 'cancer']]}, 'NCT02584309'), ({'text': 'Completes at least 1 injection in the study by 8 weeks of age', 'entities': [['20', '21', 'lower_bound'], ['48', '55', 'lower_bound'], ['59', '62', 'age']]}, 'NCT02564796'), ({'text': 'greater than or equal to 1 cigarette/little cigar per day', 'entities': [['26', '27', 'lower_bound']]}, 'NCT02964182'), ({'text': 'stated desire to become pregnant during the study period', 'entities': [['18', '33', 'pregnancy']]}, 'NCT02463305'), ({'text': 'heart failure', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT03058146'), ({'text': 'Hemoglobin more or equal than 2 grams/dL below the institutional level of normal', 'entities': [['1', '11', 'clinical_variable'], ['31', '41', 'lower_bound']]}, 'NCT02960555'), ({'text': 'Uncontrolled bacterial, viral or fungal infections', 'entities': [['1', '51', 'chronic_disease']]}, 'NCT02356653'), ({'text': 'with relapsed or refractory AML', 'entities': [['6', '32', 'cancer']]}, 'NCT02632721'), ({'text': 'Patients must not have a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment', 'entities': [['37', '54', 'chronic_disease'], ['56', '84', 'chronic_disease'], ['89', '112', 'chronic_disease'], ['120', '134', 'upper_bound']]}, 'NCT02314377'), ({'text': 'Women of child bearing potential and male patients who are not surgically sterile must be willing to practice contraceptive methods for the duration of the study and for 30-days following the last dose of study medication. Female patients must be postmenopausal (greater than 12 months from onset of menopause) or surgically sterile (have undergone bilateral oophorectomy or hysterectomy). Women of child bearing potential and women < 12 months since onset of menopause must agree to use an acceptable contraception method. If employing contraception, 2 of the following precautions must be used: vasectomy of partner, tubal ligation, vaginal diaphragm, intrauterine device, oral contraceptives (same oral contraceptive for a minimum of 3 months prior to screening), birth control injections, birth control implant, condom and spermicidal (gel/foam/cream/vaginal suppository)', 'entities': [['1', '6', 'gender'], ['38', '42', 'gender'], ['91', '132', 'contraception_consent'], ['171', '178', 'upper_bound'], ['206', '222', 'treatment'], ['224', '239', 'gender'], ['350', '372', 'treatment'], ['376', '388', 'treatment'], ['428', '433', 'gender'], ['476', '523', 'contraception_consent'], ['598', '607', 'contraception_consent'], ['620', '634', 'contraception_consent'], ['636', '653', 'contraception_consent'], ['655', '674', 'contraception_consent'], ['676', '695', 'contraception_consent'], ['738', '752', 'lower_bound'], ['768', '792', 'contraception_consent'], ['794', '815', 'contraception_consent'], ['817', '823', 'contraception_consent'], ['828', '839', 'contraception_consent']]}, 'NCT02582827'), ({'text': 'Women who are pregnant or nursing (lactating) women', 'entities': [['1', '6', 'gender'], ['11', '23', 'pregnancy'], ['47', '52', 'gender']]}, 'NCT02397083'), ({'text': 'Serum creatinine >1.5 times the upper limit of normal', 'entities': [['1', '17', 'clinical_variable'], ['19', '54', 'lower_bound']]}, 'NCT01703117'), ({'text': 'who require syndactyly release surgery with skin grafting for one, or more, web spaces on their hand(s)', 'entities': [['13', '58', 'treatment']]}, 'NCT03107546'), ({'text': 'myocardial infarction or cerebrovascular accident within the past six months', 'entities': [['1', '22', 'chronic_disease'], ['26', '50', 'chronic_disease'], ['62', '77', 'upper_bound']]}, 'NCT01947673'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status d2 (see Appendix A)', 'entities': [['1', '61', 'clinical_variable'], ['63', '64', 'upper_bound']]}, 'NCT02474368'), ({'text': 'Patients receiving CYP3A substrates with narrow therapeutic indices, strong CYP3A inhibitors, and strong CYP3A inducers', 'entities': [['20', '68', 'treatment'], ['70', '93', 'treatment'], ['99', '120', 'treatment']]}, 'NCT01625234'), ({'text': 'Medicare/Medicaid eligible Proven venous disease', 'entities': [['35', '49', 'chronic_disease']]}, 'NCT02312518'), ({'text': 'hepatic encephalopathy', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02562755'), ({'text': 'Bone marrow (BM) harvest required to reach adequate cell dose for transplant', 'entities': [['67', '77', 'treatment']]}, 'NCT02342782'), ({'text': 'e 18 years of age', 'entities': [['3', '11', 'lower_bound'], ['15', '18', 'age']]}, 'NCT02462590'), ({'text': 'Biopsy within six months of date of registration', 'entities': [['1', '7', 'treatment'], ['15', '25', 'upper_bound']]}, 'NCT01508390'), ({'text': 'pregnant women are excluded from this study', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT03097588'), ({'text': 'Patients greater than or equal to 16 years of age', 'entities': [['35', '43', 'lower_bound'], ['47', '50', 'age']]}, 'NCT02315612'), ({'text': 'A minimum of 1 measurable Target Lesion that can be accurately measured by calipers, computed tomography (CT) or magnetic resonance imaging (MRI)', 'entities': [['14', '15', 'upper_bound'], ['86', '110', 'treatment'], ['114', '146', 'treatment']]}, 'NCT02557321'), ({'text': 'Measurable metastatic disease', 'entities': [['12', '30', 'cancer']]}, 'NCT02213289'), ({'text': 'degenerative spondylolisthesis with objective evidence of neurologic impairment', 'entities': [['1', '31', 'chronic_disease'], ['59', '80', 'chronic_disease']]}, 'NCT02184520'), ({'text': 'Known active infection with HIV', 'entities': [['7', '23', 'chronic_disease'], ['29', '32', 'chronic_disease']]}, 'NCT01676259'), ({'text': 'Sentinel lymphadenectomy alone', 'entities': [['1', '25', 'treatment']]}, 'NCT02488967'), ({'text': 'Anemia (hemoglobin < 8 g/dl)', 'entities': [['1', '7', 'chronic_disease'], ['9', '19', 'clinical_variable'], ['22', '28', 'upper_bound']]}, 'NCT02234934'), ({'text': 'Participants must verify understanding of the protocol by a score greater than or equal to 80% on the Ketamine Response consent quiz', 'entities': [['92', '95', 'lower_bound'], ['103', '133', 'clinical_variable']]}, 'NCT02543983'), ({'text': 'Clinically significant unstable medical disorders', 'entities': [['24', '50', 'chronic_disease']]}, 'NCT02762032'), ({'text': 'Patients must not have New York Heart Association Grade II or greater congestive heart failure', 'entities': [['24', '50', 'clinical_variable'], ['51', '59', 'lower_bound'], ['71', '95', 'chronic_disease']]}, 'NCT02314377'), ({'text': 'greater than or equal to 12 years of age', 'entities': [['26', '34', 'lower_bound'], ['38', '41', 'age']]}, 'NCT01280669'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of 0-2', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'lower_bound'], ['67', '68', 'upper_bound']]}, 'NCT01532687'), ({'text': 'Myopathic or rheumatologic disease that impacts physical function', 'entities': [['1', '10', 'chronic_disease'], ['14', '35', 'chronic_disease']]}, 'NCT03187951'), ({'text': 'FEV1 testing is required for patients suspected of having COPD and subjects must be excluded if FEV1 < 50% of predicted normal', 'entities': [['1', '5', 'clinical_variable'], ['59', '63', 'chronic_disease'], ['104', '107', 'upper_bound']]}, 'NCT03067571'), ({'text': 'Specific to obese subjects only (to exclude obese subjects with metabolic syndrome)', 'entities': [['65', '83', 'chronic_disease']]}, 'NCT02833207'), ({'text': 'Active extramedullary AML in testes or central nervous system (CNS)', 'entities': [['23', '26', 'cancer']]}, 'NCT02520427'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03181893'), ({'text': 'Recurrent painful events (at least 3 in the 2 years prior to enrollment or prior to chronic chronic RBC transfusion therapy, exchange transfusion or erythrocyte pheresis)', 'entities': [['36', '37', 'lower_bound'], ['45', '58', 'upper_bound'], ['101', '124', 'treatment'], ['126', '146', 'treatment'], ['162', '170', 'treatment']]}, 'NCT02675959'), ({'text': 'Residual disease at the time of transplant (bulky or minimal) or post transplant relapse as evidenced by PCR positivity, specific cytogenetic abnormalities, an abnormal population on flow cytometry or increased blasts on bone marrow biopsy or in the peripheral blood', 'entities': [['1', '17', 'cancer'], ['33', '43', 'treatment'], ['66', '81', 'treatment'], ['184', '198', 'treatment'], ['222', '240', 'treatment']]}, 'NCT02050347'), ({'text': 'Active tuberculosis (TB) or history of latent TB that has not been treated', 'entities': [['8', '25', 'chronic_disease'], ['40', '49', 'chronic_disease']]}, 'NCT03077412'), ({'text': 'Patients who have had previous treatment with bevacizumab, and or NovoTTF 100A system', 'entities': [['23', '58', 'treatment'], ['67', '79', 'treatment']]}, 'NCT01894061'), ({'text': 'Total bilirubin d2mg/dl', 'entities': [['1', '16', 'clinical_variable'], ['18', '24', 'upper_bound']]}, 'NCT02446093'), ({'text': 'Adult men and women', 'entities': [['7', '10', 'gender'], ['15', '20', 'gender']]}, 'NCT02990000'), ({'text': 'Stable ART for at least 36 months', 'entities': [['8', '11', 'treatment'], ['25', '34', 'lower_bound']]}, 'NCT02191098'), ({'text': 'Life expectancy < 2 years', 'entities': [['1', '16', 'clinical_variable'], ['19', '26', 'upper_bound']]}, 'NCT02100722'), ({'text': 'Recent weight loss of >5 lbs in past 6 mo', 'entities': [['8', '19', 'clinical_variable'], ['24', '29', 'lower_bound'], ['33', '42', 'upper_bound']]}, 'NCT02721303'), ({'text': 'Progression within 6 months of adjuvant chemotherapy or definitive chemoradiation will count as one line of therapy', 'entities': [['20', '28', 'upper_bound'], ['32', '53', 'treatment'], ['57', '82', 'treatment']]}, 'NCT02991651'), ({'text': 'Hgb e7.0 g/dl', 'entities': [['1', '4', 'clinical_variable'], ['6', '14', 'lower_bound']]}, 'NCT02905188'), ({'text': 'Histologic confirmation of the original primary tumor is required via pathology report', 'entities': [['41', '54', 'cancer']]}, 'NCT03104699'), ({'text': 'Subjects with three or more drug allergies from separate drug classes', 'entities': [['15', '20', 'lower_bound']]}, 'NCT02359097'), ({'text': 'Already using coconut oil specifically for catamenial epilepsy within the month prior to enrollment (okay if patient only using for cooking throughout the month)', 'entities': [['44', '63', 'chronic_disease']]}, 'NCT02426047'), ({'text': 'Previous treatment with tocilizumab or other cytokine-targeted biologic disease modifying antirheumatic drugs (including adalimumab, certolizumab, etanercept, golimumab, infliximab, anakinra) within 3 months of enrollment', 'entities': [['10', '19', 'treatment'], ['25', '36', 'treatment'], ['46', '110', 'treatment'], ['122', '132', 'treatment'], ['134', '146', 'treatment'], ['148', '158', 'treatment'], ['160', '169', 'treatment'], ['171', '181', 'treatment'], ['183', '191', 'treatment'], ['200', '208', 'upper_bound']]}, 'NCT03135171'), ({'text': 'Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens', 'entities': [['11', '29', 'chronic_disease']]}, 'NCT02312245'), ({'text': 'Patients may have asymptomatic CNS 1 or CNS 2 disease, but not CNS 3 or symptomatic CNS disease', 'entities': [['32', '37', 'cancer'], ['41', '54', 'cancer'], ['64', '69', 'cancer'], ['85', '96', 'cancer']]}, 'NCT02512926'), ({'text': 'Patients must agree to forgo any other treatments, including but not limited to cytotoxic or biologic chemotherapies, that are intended to treat the recurrent GBM while receiving treatment with NovoTTF Therapy', 'entities': [['40', '49', 'treatment'], ['40', '50', 'treatment'], ['81', '90', 'treatment'], ['94', '117', 'treatment'], ['160', '163', 'cancer'], ['195', '210', 'treatment']]}, 'NCT01954576'), ({'text': 'Subject has AML secondary to chronic myelogenous leukemia', 'entities': [['13', '16', 'cancer'], ['30', '58', 'cancer']]}, 'NCT02577406'), ({'text': 'No major sensory or motor impairment that would preclude valid cognitive testing (e.g., unresolved posterior fossa syndrome, blindness, poorly controlled seizures/photosensitive epilepsy, psychosis) or a major psychological condition that would preclude completion of the intervention (e.g., significant oppositionality, autism spectrum disorder, severe anxiety or depressive symptoms)', 'entities': [['10', '37', 'chronic_disease'], ['100', '124', 'chronic_disease'], ['126', '135', 'chronic_disease'], ['155', '163', 'chronic_disease'], ['164', '187', 'chronic_disease'], ['189', '198', 'chronic_disease'], ['211', '234', 'chronic_disease'], ['322', '346', 'chronic_disease'], ['355', '362', 'chronic_disease'], ['366', '385', 'chronic_disease']]}, 'NCT01878617'), ({'text': 'Prior chemotherapy for metastatic squamous cell carcinoma of the head and neck', 'entities': [['1', '19', 'treatment'], ['24', '79', 'cancer']]}, 'NCT02524275'), ({'text': 'Non-diary based UAS scores e 2 at either the screening visit (Week -3), at the run-in visit (Week -2), or on Day 1', 'entities': [['1', '27', 'clinical_variable'], ['30', '31', 'lower_bound']]}, 'NCT03111628'), ({'text': 'patients e18 years-of-age', 'entities': [['11', '19', 'lower_bound'], ['23', '26', 'age']]}, 'NCT01990209'), ({'text': 'Flat anterior chamber', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02332369'), ({'text': 'Creatinine clearance > 30 ml/min', 'entities': [['1', '21', 'clinical_variable'], ['24', '33', 'lower_bound']]}, 'NCT01644591'), ({'text': 'Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior study registration', 'entities': [['39', '61', 'chronic_disease'], ['69', '82', 'upper_bound']]}, 'NCT02669173'), ({'text': 'Patients who have received prior inhibitor of VEGF signaling and a poly (ADP-ribose) polymerases (PARP) inhibitor administered in combination; unless administered in combination, patients who received a prior PARP inhibitor or a prior VEGF-signaling inhibitor agent are allowed after discussing with the PI', 'entities': [['28', '114', 'treatment'], ['204', '224', 'treatment'], ['230', '260', 'treatment']]}, 'NCT02498613'), ({'text': 'Neutropenia measured as absolute neutrophil count (ANC) measured in cells per microliter of blood of < 1500 at screening visit', 'entities': [['1', '12', 'chronic_disease'], ['25', '56', 'clinical_variable'], ['104', '108', 'upper_bound']]}, 'NCT01597518'), ({'text': 'history of severe head injury', 'entities': [['19', '30', 'chronic_disease']]}, 'NCT02397889'), ({'text': 'History of malignancy within the past 5 years except for non-melanoma skin cancer', 'entities': [['12', '22', 'cancer'], ['34', '46', 'upper_bound'], ['58', '82', 'cancer']]}, 'NCT03034213'), ({'text': "Serious concomitant systemic disorders (including active infections) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator; this includes scleroderma", 'entities': [['51', '68', 'chronic_disease'], ['230', '241', 'chronic_disease']]}, 'NCT02177838'), ({'text': 'Be currently suicidal as assessed by DSM 5 and the Beck Depression Inventory', 'entities': [['14', '22', 'chronic_disease'], ['38', '43', 'clinical_variable'], ['52', '77', 'clinical_variable']]}, 'NCT01782599'), ({'text': 'Patients with oxygen saturation of <92% on room air by pulse oximetry', 'entities': [['15', '32', 'clinical_variable'], ['37', '40', 'upper_bound']]}, 'NCT02451982'), ({'text': 'English-speaking adults', 'entities': [['1', '17', 'language_fluency']]}, 'NCT00875342'), ({'text': '10% or more increase in serum thyroglobulin (on thyroid-stimulating hormone [TSH]-suppression) within 9 months of RAI treatment', 'entities': [['1', '4', 'lower_bound'], ['25', '44', 'clinical_variable'], ['49', '94', 'treatment'], ['103', '111', 'upper_bound'], ['115', '128', 'treatment']]}, 'NCT02143726'), ({'text': '> 3 years of age', 'entities': [['3', '10', 'lower_bound'], ['14', '17', 'age']]}, 'NCT02534168'), ({'text': 'Sex at birth other than male', 'entities': [['25', '29', 'gender']]}, 'NCT02335138'), ({'text': 'Acute or currently active hepatic or biliary disease requiring antiviral therapy', 'entities': [['27', '34', 'chronic_disease'], ['38', '53', 'chronic_disease'], ['64', '81', 'treatment']]}, 'NCT01670877'), ({'text': 'Gastrointestinal perforation, abdominal fistula, intra- abdominal abscess within 1 year', 'entities': [['1', '29', 'chronic_disease'], ['31', '48', 'chronic_disease'], ['50', '74', 'chronic_disease'], ['82', '88', 'upper_bound']]}, 'NCT01906385'), ({'text': 'Patients with melanoma of uveal/ocular origin', 'entities': [['15', '39', 'cancer']]}, 'NCT02360579'), ({'text': 'Evidence of distant metastases M1', 'entities': [['13', '34', 'cancer']]}, 'NCT00809991'), ({'text': 'score of 14 or higher for motor or vocal tics only and 22 or higher for Tourette syndrome and present during the baseline assessment', 'entities': [['10', '12', 'lower_bound'], ['56', '58', 'lower_bound'], ['73', '90', 'chronic_disease']]}, 'NCT02067819'), ({'text': '(either the influenza virus, pneumococcal or meningococcal vaccine)', 'entities': [['13', '28', 'chronic_disease'], ['30', '42', 'treatment'], ['46', '67', 'treatment']]}, 'NCT01967238'), ({'text': 'At least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02427581'), ({'text': 'negative for lung cancer', 'entities': [['14', '25', 'cancer']]}, 'NCT03135522'), ({'text': 'IQ estimate of 70 or higher', 'entities': [['1', '3', 'clinical_variable'], ['16', '18', 'lower_bound']]}, 'NCT02067819'), ({'text': 'Chromosomal or congenital anomalies; congenital infections; > grade II IVH', 'entities': [['1', '36', 'chronic_disease'], ['38', '59', 'chronic_disease']]}, 'NCT01913288'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT00625417'), ({'text': 'Hypercalciuric CaP stone formers', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT01754779'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['77', '93', 'chronic_disease'], ['107', '131', 'chronic_disease'], ['136', '173', 'chronic_disease']]}, 'NCT02584309'), ({'text': 'Individuals with a history of or current medical illness including unstable angina, myocardial infarction, congestive heart failure or other cardiac condition, hypotension, renal or hepatic disorders, endocrine disorders, prostate or other cancer, pancreatitis, or a seizure disorder', 'entities': [['68', '83', 'chronic_disease'], ['85', '106', 'chronic_disease'], ['108', '132', 'chronic_disease'], ['142', '159', 'chronic_disease'], ['161', '172', 'chronic_disease'], ['174', '179', 'chronic_disease'], ['183', '200', 'chronic_disease'], ['202', '221', 'chronic_disease'], ['223', '231', 'cancer'], ['241', '247', 'cancer'], ['249', '261', 'chronic_disease'], ['268', '284', 'chronic_disease']]}, 'NCT02500602'), ({'text': 'Metastases to brain per prior clinical evaluation', 'entities': [['1', '20', 'cancer']]}, 'NCT03085095'), ({'text': 'for whom no effective therapy or standard of care exists', 'entities': [['23', '30', 'treatment']]}, 'NCT02549937'), ({'text': 'Karnofsky > 60%', 'entities': [['1', '10', 'clinical_variable'], ['13', '16', 'lower_bound']]}, 'NCT01553071'), ({'text': 'Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy', 'entities': [['1', '14', 'gender'], ['22', '70', 'contraception_consent'], ['109', '116', 'treatment']]}, 'NCT02710396'), ({'text': 'temporary prior measures to control blood counts, such as apheresis or Hydrea are allowed', 'entities': [['37', '49', 'clinical_variable'], ['59', '68', 'treatment'], ['72', '78', 'treatment']]}, 'NCT02257138'), ({'text': 'Family history of problems with anesthesia (including but not limited to malignant hyperthermia)', 'entities': [['33', '43', 'treatment'], ['74', '96', 'chronic_disease']]}, 'NCT02768727'), ({'text': 'Symptoms of respiratory dysfunction', 'entities': [['13', '36', 'chronic_disease']]}, 'NCT01993719'), ({'text': 'Participants will have at least one parent/guardian who can communicate with the study staff to allow assessment of study outcomes', 'entities': [['33', '36', 'lower_bound']]}, 'NCT02148796'), ({'text': 'patients who require chronic inotropic therapy', 'entities': [['22', '47', 'treatment']]}, 'NCT02816736'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT00715611'), ({'text': 'Zubrod performance status 0-1', 'entities': [['1', '26', 'clinical_variable'], ['27', '28', 'lower_bound'], ['29', '30', 'upper_bound']]}, 'NCT01913106'), ({'text': 'greater than 18 years of age', 'entities': [['14', '22', 'lower_bound'], ['26', '29', 'age']]}, 'NCT02738749'), ({'text': 'cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin', 'entities': [['1', '24', 'cancer'], ['30', '67', 'cancer']]}, 'NCT01600040'), ({'text': 'thromboembolic event requiring therapeutic anticoagulation', 'entities': [['1', '15', 'chronic_disease'], ['32', '59', 'treatment']]}, 'NCT02101736'), ({'text': 'Metastatic or unresectable solid tumor malignancy', 'entities': [['28', '50', 'cancer']]}, 'NCT02219711'), ({'text': 'Prior therapy with mTor inhibitors', 'entities': [['1', '35', 'treatment']]}, 'NCT03049189'), ({'text': 'Pulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted normal value', 'entities': [['27', '72', 'clinical_variable'], ['77', '118', 'clinical_variable'], ['133', '135', 'clinical_variable'], ['140', '143', 'lower_bound']]}, 'NCT02094794'), ({'text': 'Biopsy proven plasmacytoma (should be measured within 28 days prior to initial investigational agent dosing)', 'entities': [['1', '7', 'treatment'], ['15', '27', 'cancer'], ['55', '68', 'upper_bound'], ['80', '101', 'treatment']]}, 'NCT02332850'), ({'text': 'Women of child-bearing potential (WOCBP) must be willing to use acceptable means of birth control', 'entities': [['1', '6', 'gender'], ['50', '98', 'contraception_consent']]}, 'NCT02865135'), ({'text': 'Parallel aortic wall with <20% diameter change and without significant calcification and/or thrombus in the selected area of seal zone', 'entities': [['1', '21', 'clinical_variable'], ['28', '40', 'upper_bound']]}, 'NCT02089607'), ({'text': "WBC >13,000/cm3 or < 5, 000 cm3, or electrolytes that are outside the host institution's range of normal Radiation therapy, chemotherapy, immunosuppressive therapy or chronic steroid use within 30 days of enrollment", 'entities': [['1', '4', 'clinical_variable'], ['6', '16', 'lower_bound'], ['22', '32', 'upper_bound'], ['106', '123', 'treatment'], ['125', '137', 'treatment'], ['139', '164', 'treatment'], ['168', '183', 'treatment'], ['195', '202', 'upper_bound']]}, 'NCT02312570'), ({'text': 'Inability to monitor the QT interval on ECG', 'entities': [['41', '44', 'treatment']]}, 'NCT02353728'), ({'text': 'Measurable disease (assessed within 28 days prior to day 1)', 'entities': [['1', '19', 'chronic_disease'], ['37', '50', 'upper_bound']]}, 'NCT02939183'), ({'text': 'Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness', 'entities': [['86', '95', 'treatment']]}, 'NCT03153982'), ({'text': 'Patients receiving other treatment for breast cancer (includes standard hormonal therapy, chemotherapy, biologic therapy, immunotherapy, or radiation therapy)', 'entities': [['26', '35', 'treatment'], ['40', '53', 'cancer'], ['64', '89', 'treatment'], ['91', '103', 'treatment'], ['105', '121', 'treatment'], ['123', '136', 'treatment'], ['141', '158', 'treatment']]}, 'NCT01990209'), ({'text': 'Patients who have a history of another primary malignancy unless the patient has been disease free for >/= 3 years', 'entities': [['48', '58', 'cancer'], ['108', '115', 'lower_bound']]}, 'NCT02321501'), ({'text': 'Primary Central Nervous System (CNS) vasculitis', 'entities': [['1', '48', 'chronic_disease']]}, 'NCT00716066'), ({'text': "Axis II personality disorders that are the primary purpose of treatment, or would interfere with a patient's safety or compliance, as determined by the investigator during open-ended psychiatric interview", 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02019940'), ({'text': 'Participants with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on the Screening chest CT scan', 'entities': [['32', '61', 'chronic_disease'], ['63', '83', 'chronic_disease'], ['98', '109', 'chronic_disease'], ['111', '133', 'chronic_disease']]}, 'NCT03123055'), ({'text': 'Anticipated length of stay of at least 72 hours', 'entities': [['40', '48', 'lower_bound']]}, 'NCT02749968'), ({'text': 'Patients aged e18 years with newly diagnosed obstructive sleep apnea (OSA) who were never treated with CPAP', 'entities': [['10', '14', 'age'], ['16', '24', 'lower_bound'], ['46', '75', 'chronic_disease'], ['104', '108', 'treatment']]}, 'NCT03122639'), ({'text': 'Patients diagnosed with another primary malignancy within 3 years prior to study start', 'entities': [['33', '51', 'cancer'], ['59', '72', 'upper_bound']]}, 'NCT02608125'), ({'text': 'Ongoing or active infection', 'entities': [['12', '28', 'chronic_disease']]}, 'NCT02193191'), ({'text': 'Adequate baseline laboratory values collected no more than 7 days before starting study treatment', 'entities': [['60', '73', 'lower_bound'], ['89', '98', 'treatment']]}, 'NCT02367040'), ({'text': 'HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated', 'entities': [['1', '4', 'chronic_disease'], ['38', '60', 'treatment'], ['195', '205', 'chronic_disease'], ['224', '250', 'treatment']]}, 'NCT02070549'), ({'text': 'Objective memory impairment for age, documented by scoring below the education adjusted cutoff of the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale Third Edition (the maximum score is 25)', 'entities': [['1', '28', 'chronic_disease'], ['33', '36', 'age'], ['224', '226', 'upper_bound']]}, 'NCT02547818'), ({'text': 'HIV positive patients or patients on chemotherapy', 'entities': [['1', '4', 'chronic_disease'], ['38', '50', 'treatment']]}, 'NCT02734134'), ({'text': 'comorbidity score of 5 or higher', 'entities': [['1', '18', 'clinical_variable'], ['22', '23', 'lower_bound']]}, 'NCT00719888'), ({'text': 'this will be defined as a primary tumor < 10 cm in size or a primary lesion which can be treated to a dose of >= 8 Gy x 5 without excessive perceived risk of toxicity', 'entities': [['27', '40', 'cancer'], ['43', '48', 'upper_bound'], ['114', '115', 'lower_bound']]}, 'NCT02542202'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'lower_bound'], ['70', '71', 'upper_bound']]}, 'NCT02730481'), ({'text': 'are currently taking antipsychotic medication, lithium or valproic acid', 'entities': [['22', '46', 'treatment'], ['48', '55', 'treatment'], ['59', '72', 'treatment']]}, 'NCT03154151'), ({'text': 'Individuals with CD4+ cell counts at screening of less than 200 cells/mm^3', 'entities': [['18', '34', 'clinical_variable'], ['61', '75', 'upper_bound']]}, 'NCT02016924'), ({'text': 'Treatment with corticosteroids, including oral steroids (i.e. prednisone, dexamethasone), continuous use of topical steroid creams or ointments or any steroid-containing inhalers', 'entities': [['1', '31', 'treatment'], ['43', '56', 'treatment'], ['63', '73', 'treatment'], ['75', '88', 'treatment'], ['109', '144', 'treatment'], ['152', '179', 'treatment']]}, 'NCT02264236'), ({'text': 'triglycerides > 200', 'entities': [['1', '14', 'clinical_variable'], ['17', '20', 'lower_bound']]}, 'NCT03070535'), ({'text': 'Participants must have biopsy confirmed and clinical stage 1 or stage 2 breast carcinoma', 'entities': [['24', '30', 'treatment'], ['54', '61', 'lower_bound'], ['65', '72', 'upper_bound'], ['73', '89', 'cancer']]}, 'NCT02335671'), ({'text': 'Cyclothymia', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT02481245'), ({'text': "Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years)", 'entities': [['15', '23', 'chronic_disease'], ['25', '40', 'chronic_disease'], ['45', '54', 'chronic_disease'], ['69', '87', 'treatment'], ['100', '112', 'upper_bound']]}, 'NCT02403193'), ({'text': 'History of allergy or hypersensitivity to any of the constituents of the ABI-011 formulation', 'entities': [['74', '93', 'allergy_name']]}, 'NCT02582827'), ({'text': 'Clinically stable in the last 4 weeks with no evidence of COPD exacerbation', 'entities': [['26', '38', 'upper_bound'], ['59', '76', 'chronic_disease']]}, 'NCT03085485'), ({'text': 'Hemoglobin e 8.0 g/dl', 'entities': [['1', '11', 'clinical_variable'], ['14', '22', 'lower_bound']]}, 'NCT02040610'), ({'text': 'Leukocytes e 3,000/mm3', 'entities': [['1', '11', 'clinical_variable'], ['14', '23', 'lower_bound']]}, 'NCT02876302'), ({'text': 'measurable soft tissue disease by computed tomography (CT)', 'entities': [['12', '31', 'chronic_disease']]}, 'NCT03072238'), ({'text': 'forced expiratory volume in 1 second (FEV1) below 40%', 'entities': [['1', '44', 'clinical_variable'], ['51', '54', 'upper_bound']]}, 'NCT02416102'), ({'text': 'No studies have been performed to assess potential metabolic and transport interactions of TRC102', 'entities': [['92', '98', 'treatment']]}, 'NCT02535312'), ({'text': 'Radiation treatment is administered 12 weeks or greater after their first dose of study drug', 'entities': [['1', '20', 'treatment'], ['37', '45', 'lower_bound'], ['83', '93', 'treatment']]}, 'NCT02553642'), ({'text': 'pre-diabetic', 'entities': [['5', '13', 'chronic_disease']]}, 'NCT02488057'), ({'text': 'Parent with bipolar disorder or schizophrenia', 'entities': [['13', '29', 'chronic_disease'], ['33', '46', 'chronic_disease']]}, 'NCT00183482'), ({'text': 'ALT d 2.5 x the ULN', 'entities': [['1', '4', 'clinical_variable'], ['7', '20', 'upper_bound']]}, 'NCT01864109'), ({'text': 'Ongoing treatment with radiotherapy to thorax, cytotoxic or biological therapies for this malignancy', 'entities': [['9', '18', 'treatment'], ['24', '36', 'treatment'], ['48', '57', 'treatment'], ['61', '81', 'treatment'], ['91', '101', 'cancer']]}, 'NCT02496585'), ({'text': 'Histologically confirmed Follicular Lymphoma (Grade 1, 2 or 3a), Marginal Zone Lymphoma, or Mantle Cell Lymphoma', 'entities': [['26', '64', 'cancer'], ['66', '88', 'cancer'], ['93', '113', 'cancer']]}, 'NCT01996865'), ({'text': 'Female patients planning a pregnancy during the course of the study', 'entities': [['1', '16', 'gender'], ['17', '37', 'pregnancy']]}, 'NCT02056470'), ({'text': 'ASA physical status 1,2 or 3', 'entities': [['1', '20', 'clinical_variable'], ['21', '22', 'lower_bound'], ['28', '29', 'upper_bound']]}, 'NCT03181542'), ({'text': 'defined as Stage IB', 'entities': [['12', '20', 'cancer']]}, 'NCT00846742'), ({'text': 'Cochlear implants', 'entities': [['1', '18', 'treatment']]}, 'NCT02924363'), ({'text': 'Had prior exposure to gene vector delivery products within 6 months', 'entities': [['60', '68', 'upper_bound']]}, 'NCT02340156'), ({'text': 'active peptic ulcer disease', 'entities': [['8', '28', 'chronic_disease']]}, 'NCT01639508'), ({'text': 'Partial response of >50% reduction in bidirectional area of masses and SUV reduction to <8 in PET avid areas Subjects must have evaluable disease', 'entities': [['22', '25', 'lower_bound'], ['26', '67', 'clinical_variable'], ['72', '85', 'clinical_variable'], ['90', '91', 'upper_bound'], ['95', '98', 'treatment']]}, 'NCT02059239'), ({'text': "No other causes of chronic liver disease (autoimmune, primary biliary cholangitis, Hepatitis B virus (HBV), hepatitis C virus (HCV), Wilson's, ±-1-antitrypsin deficiency, hemochromatosis, etc&)", 'entities': [['20', '41', 'chronic_disease'], ['43', '53', 'chronic_disease'], ['55', '82', 'chronic_disease'], ['84', '107', 'chronic_disease'], ['109', '132', 'chronic_disease'], ['134', '142', 'chronic_disease'], ['144', '170', 'chronic_disease'], ['172', '187', 'chronic_disease']]}, 'NCT03008070'), ({'text': 'Previously treated with an anti-DKK-1 therapy', 'entities': [['1', '46', 'treatment']]}, 'NCT02013154'), ({'text': '60 years and older', 'entities': [['1', '9', 'lower_bound']]}, 'NCT02489019'), ({'text': 'Blind or deaf', 'entities': [['1', '6', 'chronic_disease'], ['10', '14', 'chronic_disease']]}, 'NCT02522494'), ({'text': 'Creatinine clearance >= 45 mL/min as calculated by the standard Cockcroft-Gault equation using age, actual weight, creatinine and gender', 'entities': [['1', '21', 'clinical_variable'], ['25', '34', 'lower_bound'], ['96', '99', 'age']]}, 'NCT02349867'), ({'text': 'Male creatinine clearance = (140 -age in years) x (weight in Kg) / (serum Cr in mg/dl x 72)', 'entities': [['1', '5', 'gender'], ['6', '26', 'clinical_variable'], ['35', '38', 'age'], ['69', '77', 'clinical_variable']]}, 'NCT01312857'), ({'text': 'GFR < 50 estimated by Cockroft-Gault', 'entities': [['1', '4', 'clinical_variable'], ['7', '9', 'upper_bound']]}, 'NCT03085485'), ({'text': 'Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy or not amendable to a curative treatment', 'entities': [['1', '6', 'cancer'], ['53', '65', 'treatment'], ['126', '144', 'treatment']]}, 'NCT02990481'), ({'text': 'HIV positive', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT02566304'), ({'text': 'Prothrombin Complex Concentrate products (PCC) or recombinant factor VIIa (rfVIIa)', 'entities': [['1', '47', 'treatment'], ['51', '83', 'treatment']]}, 'NCT02329327'), ({'text': 'allergy to CHG', 'entities': [['12', '15', 'allergy_name']]}, 'NCT02395614'), ({'text': 'Clinically significant cardiac disease (NY Heart Association Class III or IV), including chronic arrhythmias, or pulmonary disease', 'entities': [['24', '39', 'chronic_disease'], ['90', '109', 'chronic_disease'], ['114', '131', 'chronic_disease']]}, 'NCT01920737'), ({'text': 'significant anemia (hemoglobin <11g/dL)', 'entities': [['13', '19', 'chronic_disease'], ['21', '31', 'clinical_variable'], ['33', '39', 'upper_bound']]}, 'NCT02823665'), ({'text': 'Participated in a therapeutic clinical study within 3 weeks before study drug treatment', 'entities': [['19', '45', 'treatment'], ['53', '67', 'upper_bound'], ['68', '88', 'treatment']]}, 'NCT01877382'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT02500407'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02169739'), ({'text': 'Low blood pressure with BP less than 100/50 mmHg', 'entities': [['1', '19', 'clinical_variable'], ['38', '49', 'upper_bound']]}, 'NCT02411773'), ({'text': 'Planning to get pregnant in the next 2 months', 'entities': [['1', '25', 'pregnancy'], ['33', '46', 'upper_bound']]}, 'NCT02531880'), ({'text': 'Significant liver disease as defined as Aspartate Transaminase (AST) or Alanine Transaminase (ALT) twice than normal', 'entities': [['13', '26', 'chronic_disease'], ['41', '69', 'clinical_variable'], ['73', '99', 'clinical_variable']]}, 'NCT02366871'), ({'text': 'Patients must have been treated with at least 10 mg/day of prednisone or equivalent or one or more immunomodulating agents (hydroxychloroquine, methotrexate, azathioprine, leflunomide) for >3 months before screening', 'entities': [['47', '56', 'lower_bound'], ['60', '70', 'treatment'], ['125', '143', 'treatment'], ['145', '157', 'treatment'], ['159', '171', 'treatment'], ['173', '184', 'treatment'], ['191', '199', 'lower_bound']]}, 'NCT02265874'), ({'text': 'Pneumonia', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT02905370'), ({'text': 'diagnostic and Statistical Manual IV diagnosis of panic disorder, generalized anxiety disorder', 'entities': [['51', '65', 'chronic_disease'], ['67', '95', 'chronic_disease']]}, 'NCT02161211'), ({'text': 'Serum total bilirubin =< 1.5 X ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN', 'entities': [['1', '22', 'clinical_variable'], ['26', '35', 'upper_bound'], ['39', '55', 'clinical_variable'], ['81', '103', 'clinical_variable'], ['106', '113', 'lower_bound']]}, 'NCT02437370'), ({'text': 'Previous radiation to both breasts', 'entities': [['1', '35', 'treatment']]}, 'NCT01905046'), ({'text': 'Intravesical chemo- or biologic therapy', 'entities': [['1', '19', 'treatment'], ['24', '40', 'treatment']]}, 'NCT02451423'), ({'text': 'Hemoglobin >= 9 g/dL without transfusion within 7 days prior to enrollment', 'entities': [['1', '11', 'clinical_variable'], ['15', '21', 'lower_bound'], ['49', '61', 'upper_bound']]}, 'NCT02535325'), ({'text': 'evidence of cardiovascular or metabolic diseases', 'entities': [['13', '27', 'chronic_disease'], ['31', '49', 'chronic_disease']]}, 'NCT02001142'), ({'text': 'Non English speaking', 'entities': [['1', '21', 'language_fluency']]}, 'NCT02490631'), ({'text': 'Prior treatment with intracystic P-32 or intracystic bleomycin', 'entities': [['1', '16', 'treatment'], ['22', '38', 'treatment'], ['42', '63', 'treatment']]}, 'NCT02792582'), ({'text': 'treated non-melanoma/melanoma skin cancer', 'entities': [['9', '42', 'cancer']]}, 'NCT01918644'), ({'text': 'Bone lesions: lytic lesions, severe osteopenia or pathologic fractures', 'entities': [['1', '13', 'chronic_disease'], ['15', '28', 'chronic_disease'], ['37', '47', 'chronic_disease'], ['51', '71', 'chronic_disease']]}, 'NCT02101944'), ({'text': 'Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)', 'entities': [['1', '53', 'chronic_disease']]}, 'NCT02251431'), ({'text': "Subject has an infection or is suffering from current or has a history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: photodermatoses, active acne, excessive skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage), varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course", 'entities': [['16', '25', 'chronic_disease'], ['126', '154', 'chronic_disease'], ['187', '202', 'chronic_disease'], ['204', '215', 'chronic_disease'], ['217', '239', 'chronic_disease'], ['241', '250', 'chronic_disease'], ['252', '258', 'chronic_disease'], ['260', '264', 'chronic_disease'], ['266', '273', 'chronic_disease'], ['314', '329', 'chronic_disease'], ['365', '382', 'chronic_disease'], ['386', '398', 'chronic_disease'], ['399', '417', 'treatment']]}, 'NCT02468453'), ({'text': 'Is a known drug or alcohol abuser or has a psychological disorder that could affect the ability to complete patient reported questionnaires', 'entities': [['44', '66', 'chronic_disease']]}, 'NCT02131389'), ({'text': 'bleeding disorders', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT03028831'), ({'text': '<45 years of age who are at least 6 months after initial hematopoietic stem cell transplant (HSCT)', 'entities': [['2', '10', 'upper_bound'], ['14', '17', 'age'], ['35', '43', 'lower_bound'], ['58', '99', 'treatment']]}, 'NCT01685411'), ({'text': 'Pre-menopausal women will undergo a urine pregnancy test within 24 hours of drug administration', 'entities': [['16', '21', 'gender'], ['43', '52', 'pregnancy'], ['65', '73', 'upper_bound']]}, 'NCT02414178'), ({'text': 'Histologically confirmed GBM (WHO grade IV); rare GBM variants (e.g. gliosarcoma, giant cell GBM, small cell GBM, GBM with oligodendroglioma features, GBM with PNET features) are allowed. Patients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of GBM is made', 'entities': [['26', '44', 'cancer'], ['26', '29', 'cancer'], ['70', '81', 'cancer'], ['83', '97', 'cancer'], ['99', '113', 'cancer'], ['115', '141', 'cancer'], ['152', '165', 'cancer'], ['245', '261', 'cancer']]}, 'NCT01954576'), ({'text': 'Multicentricity', 'entities': [['1', '16', 'cancer']]}, 'NCT01688388'), ({'text': 'Ejection fraction (EF) < 50% at Screening', 'entities': [['1', '23', 'clinical_variable'], ['26', '29', 'upper_bound']]}, 'NCT02343042'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status d2', 'entities': [['1', '61', 'clinical_variable'], ['63', '64', 'upper_bound']]}, 'NCT02204098'), ({'text': 'Protracted or recurrent infections requiring unusually long or repeated courses of antibiotics', 'entities': [['25', '35', 'chronic_disease'], ['84', '95', 'treatment']]}, 'NCT02579967'), ({'text': 'History of prior or synchronous malignancy', 'entities': [['21', '43', 'cancer']]}, 'NCT02172651'), ({'text': 'Use of as needed narcotic pain medication 48 hours prior to MRI scan', 'entities': [['18', '26', 'treatment'], ['32', '42', 'treatment'], ['43', '57', 'upper_bound'], ['61', '64', 'treatment']]}, 'NCT02064296'), ({'text': 'Adequate pulmonary function with FEV1, FVC and DLCO >/=50% of expected corrected for hemoglobin and/or volume', 'entities': [['34', '38', 'clinical_variable'], ['40', '43', 'clinical_variable'], ['48', '52', 'clinical_variable'], ['56', '59', 'lower_bound'], ['86', '96', 'clinical_variable']]}, 'NCT02861417'), ({'text': 'No other anti-cancer therapy (chemotherapy, biological therapy, radiation therapy) is permitted during HIFU treatment and post treatment follow up for tolerability', 'entities': [['10', '29', 'treatment'], ['31', '43', 'treatment'], ['45', '63', 'treatment'], ['65', '82', 'treatment'], ['104', '118', 'treatment'], ['109', '118', 'treatment']]}, 'NCT02076906'), ({'text': 'Patients must have had a previous histological verification of a solid tumor at the original diagnosis and/or recurrence including brain tumors; for patients with brain stem gliomas and optic pathway tumors, the requirement for histological evaluation may be waived', 'entities': [['66', '77', 'cancer'], ['132', '144', 'cancer'], ['164', '182', 'cancer'], ['187', '207', 'cancer']]}, 'NCT02389309'), ({'text': 'Presence of neurological, infectious, or neoplastic disease', 'entities': [['13', '25', 'chronic_disease'], ['27', '37', 'chronic_disease'], ['42', '60', 'chronic_disease']]}, 'NCT03099590'), ({'text': 'Specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less', 'entities': [['15', '20', 'chronic_disease'], ['22', '29', 'chronic_disease'], ['31', '38', 'chronic_disease'], ['40', '49', 'chronic_disease'], ['51', '67', 'chronic_disease'], ['72', '91', 'chronic_disease'], ['106', '113', 'upper_bound']]}, 'NCT00107289'), ({'text': 'Elevated liver function levels greater than 2.5 times the normal limit from laboratory tests conducted within 30 days prior to surgery', 'entities': [['10', '31', 'clinical_variable'], ['45', '71', 'lower_bound'], ['111', '124', 'upper_bound'], ['128', '135', 'treatment']]}, 'NCT02191488'), ({'text': 'Diagnosis or treatment for alcohol or drug abuse in the past two years as reported during phone screen (e.g., alcohol, opioids, cocaine, or stimulants)', 'entities': [['57', '71', 'upper_bound']]}, 'NCT02837510'), ({'text': 'Allergy to egg, fish, or soy/legume products', 'entities': [['12', '15', 'allergy_name'], ['17', '21', 'allergy_name'], ['26', '29', 'allergy_name'], ['30', '45', 'allergy_name']]}, 'NCT02512718'), ({'text': 'Allergic to Bovine products such as Bovine Collagen Nerve Cuff', 'entities': [['13', '28', 'allergy_name'], ['37', '52', 'allergy_name'], ['53', '63', 'allergy_name']]}, 'NCT01809002'), ({'text': 'Diagnosis or history of asthma', 'entities': [['25', '31', 'chronic_disease']]}, 'NCT02580604'), ({'text': "Neither the caregiver nor Alzheimer's patient can be diagnosed with a terminal illness with a life expectancy of less than 1 year", 'entities': [['27', '36', 'chronic_disease'], ['95', '110', 'clinical_variable'], ['124', '130', 'upper_bound']]}, 'NCT02317523'), ({'text': 'does not have access to sorafenib', 'entities': [['25', '34', 'treatment']]}, 'NCT02508467'), ({'text': 'Ongoing Non STEMI with biomarkers (cardiac troponin) still rising', 'entities': [['13', '18', 'chronic_disease']]}, 'NCT02100722'), ({'text': 'Receiving active CPR when admitted to the PICU', 'entities': [['18', '21', 'treatment']]}, 'NCT01937884'), ({'text': 'Uncontrolled hypertension, defined as blood pressure (BP) of e160/95', 'entities': [['14', '26', 'chronic_disease'], ['39', '58', 'clinical_variable'], ['63', '69', 'lower_bound']]}, 'NCT01908777'), ({'text': 'required medical or surgical intervention to restore hemostasis', 'entities': [['11', '42', 'treatment'], ['54', '64', 'treatment']]}, 'NCT03003390'), ({'text': 'Patients must have histologically-proven locally-recurrent or metastatic solid tumor', 'entities': [['63', '85', 'cancer']]}, 'NCT02013492'), ({'text': 'Dementias of any type', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT02848417'), ({'text': 'BMI > 50', 'entities': [['1', '4', 'bmi'], ['7', '9', 'lower_bound']]}, 'NCT02989571'), ({'text': 'must not have any history of brain metastases', 'entities': [['30', '46', 'cancer']]}, 'NCT02950337'), ({'text': 'patient is planning to undergo another elective joint procedure during the 6-mo period of participation', 'entities': [['40', '64', 'treatment'], ['76', '80', 'upper_bound']]}, 'NCT01772329'), ({'text': 'between 6 months to 10 months post transplant', 'entities': [['9', '17', 'lower_bound'], ['21', '30', 'upper_bound'], ['31', '46', 'treatment']]}, 'NCT01433965'), ({'text': 'Part B3: patients with relapsed or refractory rhabdomyosarcoma', 'entities': [['47', '63', 'cancer']]}, 'NCT02304458'), ({'text': 'Patients with LHON and the G11778A mitochondrial DNA mutation', 'entities': [['15', '19', 'chronic_disease'], ['28', '49', 'clinical_variable']]}, 'NCT02161380'), ({'text': 'Current use of anticoagulants (warfarin, heparin, direct thrombin inhibitors) at therapeutic levels', 'entities': [['16', '30', 'treatment'], ['32', '40', 'treatment'], ['42', '49', 'treatment'], ['51', '77', 'treatment']]}, 'NCT02519322'), ({'text': 'Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inducers of CYP3A4 (at least 3 weeks prior)', 'entities': [['96', '105', 'treatment'], ['107', '118', 'treatment'], ['122', '140', 'treatment'], ['172', '178', 'treatment'], ['189', '202', 'lower_bound']]}, 'NCT02496663'), ({'text': 'Chronic Myelogenous leukemia, MDS', 'entities': [['1', '29', 'cancer'], ['31', '34', 'cancer']]}, 'NCT02203903'), ({'text': 'sedentary (less than 1 hour of planned physical activity by self-report)', 'entities': [['22', '28', 'upper_bound']]}, 'NCT02047721'), ({'text': 'The mesio-distal distance of the tooth gap at bone level must be at least 6.8 mm to allow for placement of the Ø3.8 mm implant with a minimal distance of 1.5 mm from the implant shoulder to the adjacent tooth at bone level', 'entities': [['75', '81', 'lower_bound'], ['112', '119', 'lower_bound'], ['155', '161', 'lower_bound']]}, 'NCT02953392'), ({'text': 'Patients with Hepatitis C Virus (HCV) infection may be included if all other liver function eligibility criteria are met', 'entities': [['15', '38', 'chronic_disease']]}, 'NCT02570854'), ({'text': 'Contra-indicated for treatment with carboplatin', 'entities': [['37', '48', 'allergy_name']]}, 'NCT02264678'), ({'text': 'Has a known malignancy (other than breast cancer) except basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy', 'entities': [['13', '23', 'cancer'], ['36', '49', 'cancer'], ['58', '78', 'cancer'], ['82', '117', 'cancer'], ['130', '145', 'cancer'], ['177', '193', 'treatment']]}, 'NCT02411656'), ({'text': 'Abnormal intracranial ultrasound findings of either fetus to include', 'entities': [['10', '33', 'treatment']]}, 'NCT02122328'), ({'text': 'patients with tumors expressing or likely to be expressing CEACAM5 which includes colorectal cancer (CRC), non-squamous non-small cell lung cancer (NSCLC), gastric adenocarcinoma, squamous cell carcinoma of the cervix, pancreas adenocarcinoma, bladder transitional cell carcinoma, cholangiocarcinoma, epithelial ovarian cancer and endometrial adenocarcinoma', 'entities': [['15', '21', 'cancer'], ['83', '106', 'cancer'], ['108', '155', 'cancer'], ['157', '179', 'cancer'], ['181', '218', 'cancer'], ['220', '243', 'cancer'], ['253', '280', 'cancer'], ['282', '300', 'cancer'], ['302', '327', 'cancer'], ['332', '358', 'cancer']]}, 'NCT02187848'), ({'text': 'pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT00540761'), ({'text': 'consent to be randomized to active or sham TNS treatment', 'entities': [['39', '57', 'treatment']]}, 'NCT02377089'), ({'text': 'Concomitant treatment of strong CYP3A4 inducers or inhibitors', 'entities': [['1', '62', 'treatment']]}, 'NCT02101736'), ({'text': 'Any unresolved bowel or bile duct obstruction', 'entities': [['16', '21', 'chronic_disease'], ['25', '46', 'chronic_disease']]}, 'NCT01972919'), ({'text': 'IPSS <8', 'entities': [['1', '5', 'clinical_variable'], ['7', '8', 'upper_bound']]}, 'NCT03062111'), ({'text': '>50 years with otherwise similar eligibility criteria', 'entities': [['2', '10', 'lower_bound']]}, 'NCT03076034'), ({'text': 'To be eligible for Cohorts 1-4, patients must have failed one or two prior lines of systemic therapy for advanced/metastatic disease', 'entities': [['85', '101', 'treatment'], ['115', '133', 'cancer']]}, 'NCT02414139'), ({'text': 'at least two of the following muscles: left/right gluteus maximus, left/right erector spinae, left/right quadratus lumborum', 'entities': [['10', '13', 'lower_bound']]}, 'NCT02329652'), ({'text': 'Intensive outpatient treatment (defined as e3 visits each week) for substance abuse (AA, NA meetings, or less intensive counseling at baseline will be allowed)', 'entities': [['1', '31', 'treatment'], ['45', '46', 'lower_bound'], ['86', '88', 'clinical_variable']]}, 'NCT02582905'), ({'text': 'Participants of childbearing age must use effective contraception for at least 6 months following completion of treatment', 'entities': [['30', '33', 'age'], ['39', '66', 'contraception_consent'], ['80', '88', 'lower_bound'], ['113', '122', 'treatment']]}, 'NCT02343549'), ({'text': 'Foley catheter in place for greater than 1 week duration', 'entities': [['1', '15', 'clinical_variable'], ['42', '48', 'lower_bound']]}, 'NCT02579161'), ({'text': 'ECOG performance status score of 2 or less', 'entities': [['1', '30', 'clinical_variable'], ['34', '35', 'upper_bound']]}, 'NCT00975520'), ({'text': "Patients with bone disease (ie. osteogenesis imperfecta, cancer, osteoporosis, Paget's disease)", 'entities': [['15', '27', 'chronic_disease'], ['33', '56', 'chronic_disease'], ['58', '64', 'cancer'], ['66', '78', 'chronic_disease'], ['80', '95', 'chronic_disease']]}, 'NCT02193841'), ({'text': 'Non-English speaking', 'entities': [['1', '21', 'language_fluency']]}, 'NCT02128802'), ({'text': 'with potentially curative therapy, or in situ cervical cancer', 'entities': [['6', '34', 'treatment'], ['39', '62', 'cancer']]}, 'NCT02332668'), ({'text': 'The participating child will have at least one parent who has overweight or obesity (BMI>25) and who must agree to attend all parent/child treatment meetings as the participating parent', 'entities': [['44', '47', 'upper_bound'], ['63', '73', 'chronic_disease'], ['77', '84', 'chronic_disease'], ['86', '89', 'bmi'], ['90', '92', 'lower_bound']]}, 'NCT02873715'), ({'text': 'Age 18 years and older', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT02188121'), ({'text': 'Treatment with radiation therapy within 14 days prior to study entry', 'entities': [['1', '33', 'treatment'], ['41', '54', 'upper_bound']]}, 'NCT02013154'), ({'text': 'Known pregnancy', 'entities': [['7', '16', 'pregnancy']]}, 'NCT02750319'), ({'text': 'Unstable angina and/or myocardial infarction within 6 months prior to screening', 'entities': [['1', '16', 'chronic_disease'], ['24', '45', 'chronic_disease'], ['53', '67', 'upper_bound']]}, 'NCT02624258'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['14', '34', 'chronic_disease'], ['77', '93', 'chronic_disease'], ['95', '119', 'chronic_disease'], ['121', '139', 'chronic_disease'], ['144', '181', 'chronic_disease']]}, 'NCT01670877'), ({'text': 'Clinically significant uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal', 'entities': [['37', '50', 'chronic_disease'], ['52', '63', 'chronic_disease'], ['65', '70', 'chronic_disease'], ['72', '79', 'chronic_disease'], ['81', '97', 'chronic_disease']]}, 'NCT01893307'), ({'text': 'Fetal Diagnosis of Isolated Left CDH with liver up', 'entities': [['20', '51', 'chronic_disease']]}, 'NCT02530073'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02679560'), ({'text': 'Previous treatment with alectinib or any other ALK inhibitor', 'entities': [['25', '34', 'treatment'], ['48', '61', 'treatment']]}, 'NCT02091141'), ({'text': 'who were treated with prior JAK inhibitors for aGvHD', 'entities': [['29', '43', 'treatment'], ['48', '53', 'chronic_disease']]}, 'NCT03112603'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02911831'), ({'text': 'Mental retardation or amnestic or other cognitive disorders', 'entities': [['1', '19', 'chronic_disease'], ['23', '31', 'chronic_disease'], ['41', '60', 'chronic_disease']]}, 'NCT02431806'), ({'text': 'Immunoglobulin A (IgA) deficiency', 'entities': [['1', '34', 'chronic_disease']]}, 'NCT02094118'), ({'text': 'Significant new injury that would prevent use of a prosthesis: The ability to consistently wear a prosthesis and perform activities of daily living and specific performance tasks is necessary to evaluate the relative benefits of the interventions', 'entities': [['52', '62', 'treatment']]}, 'NCT02349035'), ({'text': 'Although not mandatory, patients with evidence of current or previous active myositis', 'entities': [['78', '86', 'chronic_disease']]}, 'NCT02245841'), ({'text': 'first episode of nephrotic syndrome', 'entities': [['18', '36', 'chronic_disease']]}, 'NCT03141970'), ({'text': 'Age >=18', 'entities': [['1', '4', 'age'], ['7', '9', 'lower_bound']]}, 'NCT02109627'), ({'text': 'Urine protein/creatinine ratio (UPCR) d 1 mg/mg (113.2 mg/mmol) creatinine or 24-hr urine protein of < 1 g', 'entities': [['1', '38', 'clinical_variable'], ['15', '25', 'clinical_variable'], ['41', '64', 'upper_bound'], ['79', '98', 'clinical_variable'], ['104', '107', 'upper_bound']]}, 'NCT01639508'), ({'text': 'At least 4 weeks must have passed since the last directed intervention to the protocol-treated lesion', 'entities': [['10', '17', 'lower_bound']]}, 'NCT02893982'), ({'text': 'life expectancy less than 12 months (the followup period of the trial)', 'entities': [['1', '16', 'clinical_variable'], ['27', '36', 'upper_bound']]}, 'NCT02169037'), ({'text': 'Patients with recurrent endometrial cancer', 'entities': [['15', '43', 'cancer']]}, 'NCT02501954'), ({'text': 'Three vessel CAD, defined as e 50% diameter stenosis by visual estimation in each of the three major epicardial vessels or major side branches, but not involving left main coronary artery, and amenable to revascularization by both PCI and CABG as determined by the Heart Team', 'entities': [['1', '17', 'clinical_variable'], ['32', '44', 'lower_bound'], ['206', '223', 'treatment'], ['232', '235', 'treatment'], ['240', '244', 'treatment']]}, 'NCT02100722'), ({'text': 'Bulky disease in the fissure preventing lung-sparing pleural IMRT', 'entities': [['1', '14', 'chronic_disease'], ['54', '66', 'treatment']]}, 'NCT00715611'), ({'text': 'Negative pregnancy test in childbearing age women', 'entities': [['1', '19', 'pregnancy'], ['41', '44', 'age'], ['45', '50', 'gender']]}, 'NCT02479906'), ({'text': 'For Part B (LY2835219 + anastrozole): Except for ongoing therapy with anastrozole, the participant must not have received prior systemic endocrine therapy for metastatic disease', 'entities': [['13', '22', 'treatment'], ['25', '36', 'treatment'], ['58', '82', 'treatment'], ['123', '155', 'treatment'], ['160', '178', 'chronic_disease']]}, 'NCT02057133'), ({'text': 'Patients with breast cancer, gastric, gastroesophageal junction or other cancers with 1+ to 3+ HER2/neu expression by IHC or a Vysis FISH result > 2.2', 'entities': [['15', '28', 'cancer'], ['30', '37', 'cancer'], ['39', '64', 'cancer'], ['74', '81', 'cancer'], ['96', '100', 'clinical_variable'], ['128', '145', 'clinical_variable'], ['148', '151', 'lower_bound']]}, 'NCT01730118'), ({'text': 'Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, liver, thyroid pathology; subjects on medications for any medical condition', 'entities': [['25', '42', 'chronic_disease'], ['51', '63', 'chronic_disease'], ['65', '79', 'chronic_disease'], ['81', '90', 'chronic_disease'], ['92', '97', 'chronic_disease'], ['99', '104', 'chronic_disease'], ['106', '123', 'chronic_disease'], ['137', '148', 'treatment']]}, 'NCT02402088'), ({'text': 'Absolute neutrophil count > 1,500/microliter', 'entities': [['1', '26', 'clinical_variable'], ['29', '45', 'lower_bound']]}, 'NCT01985087'), ({'text': 'increased risk of bradycardia', 'entities': [['19', '30', 'chronic_disease']]}, 'NCT02925923'), ({'text': 'Teeth adjacent (mesial and distal) to study site must consist of two stable natural teeth with minimal restorations, without signs of periodontal bone loss (> 3 mm) and/or significant soft tissue deficiencies', 'entities': [['135', '156', 'clinical_variable'], ['160', '164', 'lower_bound'], ['185', '209', 'chronic_disease']]}, 'NCT02532543'), ({'text': 'The effects of ABT-888 and SCH727965 on the developing human fetus are unknown; for this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation', 'entities': [['16', '23', 'treatment'], ['28', '37', 'treatment'], ['98', '103', 'gender'], ['100', '103', 'gender'], ['143', '178', 'contraception_consent'], ['180', '223', 'contraception_consent'], ['225', '235', 'contraception_consent']]}, 'NCT01434316'), ({'text': 'Patients who require supplemental oxygen other than for sleep apnea', 'entities': [['57', '68', 'chronic_disease']]}, 'NCT01349101'), ({'text': 'Other current malignancy (except squamous or basal cell skin cancers)', 'entities': [['15', '25', 'cancer'], ['34', '42', 'cancer'], ['46', '69', 'cancer']]}, 'NCT02446093'), ({'text': 'Negative urine pregnancy test, if female, and willingness to use an effective method of contraception during the entire study period whether the patient is male or female', 'entities': [['1', '25', 'pregnancy'], ['35', '41', 'gender'], ['47', '102', 'contraception_consent'], ['157', '171', 'gender']]}, 'NCT02285101'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01841333'), ({'text': 'Solid tumors must have a lesion evaluable by RECIST criteria version 1.1', 'entities': [['1', '13', 'cancer']]}, 'NCT02932280'), ({'text': 'non-pregnant', 'entities': [['1', '13', 'pregnancy']]}, 'NCT02663622'), ({'text': 'Females of childbearing potential are required to have a negative urine ²-human chorionic gonadotropin (²-hCG) pregnancy test result obtained during screening', 'entities': [['1', '8', 'gender'], ['58', '121', 'pregnancy']]}, 'NCT02544880'), ({'text': 'Estimated GFR <30 mL/min/1.73m2', 'entities': [['1', '14', 'clinical_variable'], ['16', '32', 'upper_bound']]}, 'NCT02638454'), ({'text': 'chronic intestinal pseudo-obstruction', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT03105362'), ({'text': 'Known infectious liver disease', 'entities': [['18', '31', 'chronic_disease']]}, 'NCT00085982'), ({'text': 'Carbamylated albumin (C-Alb) > 7.7 mmol/mol', 'entities': [['1', '29', 'clinical_variable'], ['32', '44', 'lower_bound']]}, 'NCT02472834'), ({'text': 'Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest', 'entities': [['13', '35', 'chronic_disease'], ['49', '79', 'cancer'], ['93', '100', 'chronic_disease']]}, 'NCT01670877'), ({'text': 'Reports a fall within the past 1 year OR self-reports that they are concerned about falling', 'entities': [['27', '38', 'upper_bound']]}, 'NCT02737839'), ({'text': 'Prior lines of therapy must include a proteasome inhibitor (PI) (eg, bortezomib, carfilzomib)', 'entities': [['1', '23', 'treatment'], ['39', '64', 'treatment'], ['70', '80', 'treatment'], ['82', '93', 'treatment']]}, 'NCT02519452'), ({'text': 'History of brain tumor', 'entities': [['12', '23', 'cancer']]}, 'NCT03053908'), ({'text': 'Patient is receiving another investigational agent for the treatment of cancer', 'entities': [['30', '51', 'treatment'], ['60', '69', 'treatment'], ['73', '79', 'cancer']]}, 'NCT02466971'), ({'text': 'Life expectancy of at least 24 months', 'entities': [['1', '16', 'clinical_variable'], ['29', '38', 'lower_bound']]}, 'NCT01787409'), ({'text': 'Taking nitrates or niacin', 'entities': [['8', '16', 'treatment'], ['20', '26', 'treatment']]}, 'NCT02317523'), ({'text': 'In-situ carcinoma is allowed', 'entities': [['1', '18', 'cancer']]}, 'NCT02207465'), ({'text': 'Women who experienced stillbirth (&gt;20 wks gestation) within past 24 mos', 'entities': [['1', '6', 'gender'], ['64', '75', 'upper_bound']]}, 'NCT02925481'), ({'text': 'head trauma with loss of consciousness', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT02469389'), ({'text': 'either partner is currently on PrEP and fully adherent, or enrolled in any other HIV prevention study', 'entities': [['32', '36', 'treatment'], ['82', '85', 'chronic_disease']]}, 'NCT03048838'), ({'text': 'Osmolality levels of > 330 mmol/kg', 'entities': [['1', '18', 'clinical_variable'], ['24', '35', 'lower_bound']]}, 'NCT02918864'), ({'text': 'Other major medical problem (e.g., history of seizures)', 'entities': [['7', '28', 'chronic_disease'], ['47', '55', 'chronic_disease']]}, 'NCT02483468'), ({'text': 'Ages 18-79 years', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '17', 'upper_bound']]}, 'NCT02075671'), ({'text': 'Bifurcation lesion requiring 2 stenting technique', 'entities': [['1', '19', 'chronic_disease'], ['32', '40', 'treatment']]}, 'NCT02316886'), ({'text': 'Concomitant use of warfarin or other Vit K antagonists', 'entities': [['20', '28', 'treatment'], ['38', '55', 'treatment']]}, 'NCT02446236'), ({'text': 'Hepatitis C', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT03088709'), ({'text': 'Absolute peripheral blood myeloblast count greater than 20,000/mm3', 'entities': [['1', '43', 'clinical_variable'], ['57', '67', 'lower_bound']]}, 'NCT02576301'), ({'text': 'weight less than or equal to 350 lbs (weight limit for MRI scanner)', 'entities': [['1', '7', 'clinical_variable'], ['30', '37', 'upper_bound'], ['56', '67', 'treatment']]}, 'NCT02460783'), ({'text': 'Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition)', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT03045341'), ({'text': 'Males and females', 'entities': [['1', '18', 'gender']]}, 'NCT03076658'), ({'text': 'Eastern Cooperative Oncology Group performance status 0 or 1', 'entities': [['1', '54', 'clinical_variable'], ['55', '56', 'lower_bound'], ['60', '61', 'upper_bound']]}, 'NCT02323191'), ({'text': 'Use of glucocorticoids continuously for more than 3 months, use of anticonvulsants', 'entities': [['8', '23', 'treatment'], ['51', '59', 'lower_bound'], ['68', '83', 'treatment']]}, 'NCT03076034'), ({'text': 'Treatment with central alpha agonists (clonidine)', 'entities': [['1', '50', 'treatment']]}, 'NCT02411773'), ({'text': 'IH that requires systemic therapy (defined by dynamic complication scale >3)', 'entities': [['1', '3', 'chronic_disease'], ['18', '34', 'treatment'], ['47', '73', 'clinical_variable'], ['75', '76', 'lower_bound']]}, 'NCT02913612'), ({'text': 'gastric indications include upper abdominal pain dyspepsia abnormal gastric imaging iron deficiency anemia gastric ulcer management of GI blood loss without active bleeding reflux weight loss', 'entities': [['101', '107', 'chronic_disease'], ['116', '121', 'chronic_disease']]}, 'NCT02197351'), ({'text': 'Males', 'entities': [['1', '6', 'gender']]}, 'NCT03171168'), ({'text': 'Subject is between 0 - 17 years of age', 'entities': [['20', '21', 'lower_bound'], ['24', '32', 'upper_bound'], ['36', '39', 'age']]}, 'NCT02053766'), ({'text': 'Multicentric disease (e.g. in both hemispheres)', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02685605'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02301663'), ({'text': 'All patients should have received at least one line of chemotherapy in either the advanced or adjuvant setting and hormonal therapy (where appropriate)', 'entities': [['44', '47', 'lower_bound'], ['56', '68', 'treatment'], ['116', '132', 'treatment']]}, 'NCT02393794'), ({'text': 'at least one positive (Scale A) SOPS score of 3-5, i.e., moderate, moderately severe or severe', 'entities': [['10', '13', 'lower_bound'], ['33', '43', 'clinical_variable'], ['47', '48', 'lower_bound'], ['49', '50', 'upper_bound']]}, 'NCT02357849'), ({'text': 'all adverse events due to prior therapy have resolved to a grade 1 or better (except alopecia and lymphopenia) by start of treatment', 'entities': [['27', '40', 'treatment'], ['60', '67', 'lower_bound'], ['86', '94', 'chronic_disease'], ['99', '110', 'chronic_disease'], ['124', '133', 'treatment']]}, 'NCT02465060'), ({'text': 'similar psychosocial interventions', 'entities': [['9', '35', 'treatment']]}, 'NCT02567266'), ({'text': 'diagnosis of TSC associated with cystic lung lesions', 'entities': [['14', '17', 'chronic_disease']]}, 'NCT01799538'), ({'text': 'Severe infection within 4 weeks prior to initiation of study treatment', 'entities': [['8', '17', 'chronic_disease'], ['25', '38', 'upper_bound'], ['62', '71', 'treatment']]}, 'NCT02091141'), ({'text': 'Cardiac ejection fraction of >= 50% by echocardiogram or multi gated acquisition scan (MUGA)', 'entities': [['1', '26', 'clinical_variable'], ['33', '36', 'lower_bound'], ['40', '54', 'treatment'], ['58', '93', 'treatment']]}, 'NCT02342782'), ({'text': 'Forced Expiratory Flow at 25-75% of predicted(FEF25-75) > 79% of predicted', 'entities': [['1', '56', 'clinical_variable'], ['59', '75', 'lower_bound']]}, 'NCT02682147'), ({'text': 'Patients with active compartment syndrome', 'entities': [['22', '42', 'chronic_disease']]}, 'NCT02015390'), ({'text': 'Pts who have received prior treatment with both carfilzomib & pomalidomide (Phase I only)', 'entities': [['49', '60', 'treatment'], ['63', '75', 'treatment']]}, 'NCT01464034'), ({'text': 'Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory)', 'entities': [['20', '54', 'chronic_disease'], ['50', '53', 'chronic_disease']]}, 'NCT01925573'), ({'text': 'Creatinine above normal limits', 'entities': [['1', '11', 'clinical_variable']]}, 'NCT02867124'), ({'text': 'Patients are allowed to have received prior PARP inhibitors (PARPi), and/or anti-angiogenesis therapy', 'entities': [['39', '68', 'treatment'], ['77', '102', 'treatment']]}, 'NCT02484404'), ({'text': 'Current use of systemic immunosuppressant(s), or prior anti-cancer therapy to include: lenalidomide, fludarabine, or alemtuzumab within 12 months; radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1', 'entities': [['16', '45', 'treatment'], ['50', '75', 'treatment'], ['88', '100', 'treatment'], ['102', '113', 'treatment'], ['118', '129', 'treatment'], ['137', '146', 'upper_bound'], ['148', '168', 'treatment'], ['176', '184', 'upper_bound'], ['186', '189', 'treatment'], ['193', '216', 'treatment'], ['224', '231', 'upper_bound'], ['236', '248', 'treatment'], ['249', '261', 'treatment'], ['262', '277', 'treatment'], ['278', '309', 'treatment'], ['317', '330', 'upper_bound']]}, 'NCT02600897'), ({'text': 'fungal', 'entities': [['1', '7', 'chronic_disease']]}, 'NCT02593123'), ({'text': 'Have received more than 3 prior chemotherapy regimens', 'entities': [['25', '32', 'lower_bound'], ['33', '54', 'treatment']]}, 'NCT02442635'), ({'text': 'Active hepatitis C virus (HCV) infection', 'entities': [['8', '41', 'chronic_disease']]}, 'NCT02016924'), ({'text': 'e18 years of age', 'entities': [['2', '10', 'lower_bound'], ['14', '17', 'age']]}, 'NCT02680574'), ({'text': 'Pediatric or adult (ages 12-76 years) HCT recipient with grade II-IV steroid refractory or steroid-dependent acute GVHD, defined as any one of the following', 'entities': [['21', '25', 'age'], ['26', '28', 'lower_bound'], ['29', '37', 'upper_bound'], ['39', '42', 'treatment'], ['58', '66', 'lower_bound'], ['67', '69', 'upper_bound'], ['70', '88', 'chronic_disease'], ['92', '120', 'chronic_disease']]}, 'NCT02525029'), ({'text': 'Left ventricular ejection fraction (LVEF) >= 40%. For recipients < 13 years old, shortening fraction >= 26% may be used instead', 'entities': [['1', '42', 'clinical_variable'], ['46', '49', 'lower_bound'], ['68', '76', 'upper_bound'], ['82', '101', 'clinical_variable'], ['105', '108', 'lower_bound']]}, 'NCT02833805'), ({'text': 'involved free light chain > = 10mg/dL provided serum free light chain ratio is abnormal', 'entities': [['10', '26', 'clinical_variable'], ['31', '38', 'lower_bound'], ['48', '70', 'clinical_variable']]}, 'NCT01054196'), ({'text': 'e 8 years of education', 'entities': [['3', '10', 'lower_bound'], ['14', '23', 'clinical_variable']]}, 'NCT02547818'), ({'text': 'Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events', 'entities': [['25', '41', 'cancer'], ['71', '85', 'treatment'], ['161', '183', 'chronic_disease']]}, 'NCT02195232'), ({'text': 'Donors under the age of 18 who cannot assent based on their developmental stage will not be included', 'entities': [['18', '21', 'age'], ['25', '27', 'lower_bound']]}, 'NCT02452697'), ({'text': '10 subjects with Normal Muscle Mass and 10 subjects with Low Muscle Mass as determined by DXA scan (70-85 years of age cohort) Low Muscle Mass is defined as Class I Sarcopenia, Skeletal Muscle Index within 1 to 2 standard deviations from the sex-specific mean of young adults', 'entities': [['1', '2', 'lower_bound'], ['18', '36', 'clinical_variable'], ['58', '73', 'clinical_variable'], ['101', '103', 'lower_bound'], ['104', '112', 'upper_bound'], ['116', '119', 'age'], ['158', '176', 'chronic_disease'], ['178', '199', 'clinical_variable'], ['212', '213', 'upper_bound']]}, 'NCT02638454'), ({'text': 'any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome', 'entities': [['93', '106', 'chronic_disease'], ['108', '120', 'chronic_disease'], ['133', '149', 'chronic_disease']]}, 'NCT02503722'), ({'text': 'Allergy or contraindication to iohexol and/or bumetanide', 'entities': [['32', '39', 'allergy_name'], ['47', '57', 'allergy_name']]}, 'NCT02593526'), ({'text': 'Treated hypertension', 'entities': [['9', '21', 'chronic_disease']]}, 'NCT02471833'), ({'text': 'diabetes', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02307565'), ({'text': 'urinary tract infection', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02329652'), ({'text': 'For investigational drugs for which 5 half-lives is less than 21 days, a minimum of 10 days between termination of the investigational drug and administration of orteronel is required', 'entities': [['5', '26', 'treatment'], ['5', '25', 'treatment'], ['63', '70', 'upper_bound'], ['85', '92', 'lower_bound']]}, 'NCT01990209'), ({'text': 'In our experience with the younger children, we find that their participation in serial blood tests and MRI scans improves greatly when they are at least 5 years of age', 'entities': [['155', '162', 'lower_bound'], ['166', '169', 'age']]}, 'NCT00085982'), ({'text': 'resected basal cell carcinoma', 'entities': [['10', '30', 'cancer']]}, 'NCT02845596'), ({'text': 'BMI for age and gender > 85th percentile (but no greater than 100% overweight)', 'entities': [['1', '4', 'bmi'], ['9', '12', 'age'], ['26', '41', 'lower_bound'], ['63', '67', 'upper_bound']]}, 'NCT02979860'), ({'text': 'Phenytoin', 'entities': [['1', '10', 'treatment']]}, 'NCT01597518'), ({'text': 'Completion of Study B5201002', 'entities': [['15', '29', 'treatment']]}, 'NCT02433158'), ({'text': 'uncontrolled arrhythmia', 'entities': [['14', '24', 'chronic_disease']]}, 'NCT02793921'), ({'text': 'Liver tumors must not be estimated to invade approximately more than one-third of the liver', 'entities': [['1', '13', 'cancer']]}, 'NCT02509507'), ({'text': 'History of drug or alcohol abuse within 6 months prior to dosing', 'entities': [['41', '55', 'upper_bound']]}, 'NCT02852239'), ({'text': 'e 30% blasts in blood or BM', 'entities': [['3', '13', 'lower_bound']]}, 'NCT02353728'), ({'text': 'History of (hypo)mania', 'entities': [['12', '23', 'chronic_disease']]}, 'NCT02397889'), ({'text': 'Patients with a feeding tube previously placed', 'entities': [['17', '29', 'treatment']]}, 'NCT02027948'), ({'text': 'Allergy or intolerance to tetracyclines AND known renal insufficiency (defined as a glomerular filtration rate (GFR) < 30 ml within the previous 90 days)', 'entities': [['27', '40', 'allergy_name'], ['85', '117', 'clinical_variable'], ['120', '125', 'upper_bound'], ['137', '153', 'upper_bound']]}, 'NCT02759120'), ({'text': "Has prolonged corrected QT interval by Fridericia's method (QTcF) at rest, where the mean QTcF interval is > 450 milliseconds (ms) based on triplicate electrocardiograms (ECGs)", 'entities': [['25', '66', 'clinical_variable'], ['91', '104', 'clinical_variable'], ['110', '131', 'lower_bound'], ['141', '177', 'treatment']]}, 'NCT03110354'), ({'text': 'Patients must have a complete history and physical examination within 28 days prior to registration', 'entities': [['71', '84', 'upper_bound']]}, 'NCT02352025'), ({'text': 'Prior systemic chemotherapy, immunotherapy, or biological therapy, radiation therapy and/or surgery are allowed', 'entities': [['1', '28', 'treatment'], ['30', '43', 'treatment'], ['48', '66', 'treatment'], ['68', '85', 'treatment'], ['93', '100', 'treatment']]}, 'NCT03175978'), ({'text': 'FVC % e 50% normal predicted value', 'entities': [['1', '4', 'clinical_variable'], ['9', '12', 'lower_bound']]}, 'NCT02688647'), ({'text': 'Active peptic ulcer disease', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT01822522'), ({'text': 'Consume more than three (8 oz.) servings of coffee, caffeinated soft drinks/tea (12 oz.) per day (caffeine cohort)', 'entities': [['26', '31', 'lower_bound'], ['82', '88', 'lower_bound']]}, 'NCT02411318'), ({'text': 'History of cervical cancer or high-grade cervical dysplasia', 'entities': [['12', '27', 'cancer'], ['42', '60', 'chronic_disease']]}, 'NCT02157610'), ({'text': 'Documented total asthma symptom score of e1 for at least 2 days during the Run-in Period', 'entities': [['12', '38', 'clinical_variable'], ['43', '44', 'lower_bound'], ['58', '64', 'lower_bound']]}, 'NCT02495168'), ({'text': 'Patients with angiographic evidence of carotid dissection', 'entities': [['15', '27', 'treatment'], ['40', '58', 'chronic_disease']]}, 'NCT02453373'), ({'text': 'modafinil', 'entities': [['1', '10', 'treatment']]}, 'NCT02131467'), ({'text': 'Absolute neutrophil count e1,500/mcL', 'entities': [['1', '26', 'clinical_variable'], ['28', '37', 'lower_bound']]}, 'NCT02991651'), ({'text': 'Organ transplants', 'entities': [['1', '18', 'treatment']]}, 'NCT02513485'), ({'text': 'Blood pressure that is not controlled despite > 2 oral agents (systolic blood pressure [SBP] > 160 and diastolic blood pressure [DBP] > 90 documented during the screening period with no subsequent blood pressure readings < 160/100)', 'entities': [['1', '15', 'clinical_variable'], ['49', '50', 'lower_bound'], ['64', '93', 'clinical_variable'], ['96', '99', 'lower_bound'], ['104', '134', 'clinical_variable'], ['137', '139', 'lower_bound'], ['187', '212', 'clinical_variable'], ['224', '231', 'upper_bound']]}, 'NCT02012296'), ({'text': 'Receiving other forms of anticoagulation', 'entities': [['26', '41', 'treatment']]}, 'NCT02342444'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02323126'), ({'text': 'Concurrent chronic systemic immunotherapy, chemotherapy or hormone therapy', 'entities': [['12', '42', 'treatment'], ['44', '56', 'treatment'], ['60', '75', 'treatment']]}, 'NCT02309892'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02608125'), ({'text': 'Scheduled (every 3 months or more frequently) IV or oral steroids in the year prior to enrolment', 'entities': [['53', '66', 'treatment']]}, 'NCT03161028'), ({'text': 'Platelet count less than 100,000/mm3', 'entities': [['1', '15', 'clinical_variable'], ['26', '37', 'upper_bound']]}, 'NCT02453373'), ({'text': 'Subjects with known primary or acquired immunodeficiency', 'entities': [['41', '57', 'chronic_disease']]}, 'NCT01631617'), ({'text': 'Subject currently has a significant medical condition (other than MS) including the following: neurological, psychiatric, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular (including uncontrolled hypertension), gastrointestinal, urological disorder, or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study', 'entities': [['67', '69', 'chronic_disease'], ['96', '108', 'chronic_disease'], ['110', '121', 'chronic_disease'], ['123', '132', 'chronic_disease'], ['134', '141', 'chronic_disease'], ['143', '148', 'chronic_disease'], ['150', '163', 'chronic_disease'], ['165', '174', 'chronic_disease'], ['176', '190', 'chronic_disease'], ['202', '227', 'chronic_disease'], ['230', '246', 'chronic_disease'], ['248', '267', 'chronic_disease'], ['301', '310', 'chronic_disease']]}, 'NCT02446886'), ({'text': 'Undergoing percutaneous coronary intervention for any clinical indication', 'entities': [['12', '46', 'treatment']]}, 'NCT01275716'), ({'text': 'Disease free of other malignancies beside the AML or MDS for e 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast', 'entities': [['23', '35', 'cancer'], ['47', '50', 'clinical_variable'], ['54', '57', 'clinical_variable'], ['64', '71', 'lower_bound'], ['108', '118', 'cancer'], ['120', '155', 'cancer'], ['160', '201', 'cancer']]}, 'NCT01433965'), ({'text': 'Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)', 'entities': [['59', '72', 'allergy_name']]}, 'NCT02799095'), ({'text': 'Use of oral or systemic steroids (e.g. prednisone or equivalent) > 20 mg daily in the last four weeks before starting treatment', 'entities': [['8', '12', 'treatment'], ['16', '33', 'treatment'], ['40', '50', 'treatment'], ['68', '73', 'lower_bound'], ['87', '102', 'upper_bound']]}, 'NCT03028350'), ({'text': 'Severe risk for suicide (i.e., suicide attempt within past 6 months)', 'entities': [['32', '47', 'chronic_disease'], ['55', '68', 'upper_bound']]}, 'NCT02513225'), ({'text': 'Uncontrolled diabetes mellitus (Hba1c higher than 7) or chronically uncontrolled hypertension', 'entities': [['14', '31', 'chronic_disease'], ['33', '38', 'clinical_variable'], ['51', '52', 'lower_bound'], ['82', '94', 'chronic_disease']]}, 'NCT01703117'), ({'text': 'Macular hole', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02564978'), ({'text': 'Those with ground glass opacities and <50% solid component will be excluded', 'entities': [['12', '34', 'clinical_variable'], ['40', '43', 'upper_bound']]}, 'NCT02468024'), ({'text': 'History of hemibody external radiotherapy as assessed by medical record review', 'entities': [['12', '42', 'treatment']]}, 'NCT02715583'), ({'text': 'patients with tumors of any histological origin with documented genetic alterations upstream in the Wnt signaling pathway (e.g. RNF43 or RSPO fusion) are eligible with prior agreement with Novartis', 'entities': [['15', '21', 'cancer']]}, 'NCT01351103'), ({'text': 'chronic rhinosinusitis with polyps (CRSwNP)', 'entities': [['1', '44', 'chronic_disease']]}, 'NCT02748070'), ({'text': 'Prednisone dose at time of enrollment of e 5 mg/day and d 20 mg/day', 'entities': [['1', '11', 'treatment'], ['44', '52', 'lower_bound'], ['59', '68', 'upper_bound']]}, 'NCT01940094'), ({'text': 'Patients being treated with Natalizumab, Rituximab, and Cyclophosphamide', 'entities': [['29', '40', 'treatment'], ['42', '51', 'treatment'], ['57', '73', 'treatment']]}, 'NCT02446886'), ({'text': 'Use of another investigational drug within the past two months', 'entities': [['48', '63', 'upper_bound']]}, 'NCT02033941'), ({'text': 'Planned resection of the tumor', 'entities': [['9', '31', 'treatment']]}, 'NCT01534104'), ({'text': 'A score of 5 or higher on the gastroparesis subscale or 5 or higher on the constipation subscale of the Gastrointestinal Symptoms in Neurodegenerative Disease Scale', 'entities': [['12', '13', 'lower_bound'], ['31', '53', 'clinical_variable'], ['76', '165', 'clinical_variable']]}, 'NCT02838797'), ({'text': 'Biopsy consistent with malignancy', 'entities': [['1', '7', 'treatment'], ['24', '34', 'cancer']]}, 'NCT02242526'), ({'text': 'For subjects with ALL or AML, presence of >5% blasts in the bone marrow (based on a bone marrow aspirate/biopsy sample with e200 nucleated cells and the presence of bone marrow spicules)', 'entities': [['19', '22', 'cancer'], ['26', '29', 'cancer'], ['44', '46', 'lower_bound'], ['85', '112', 'treatment'], ['126', '129', 'lower_bound'], ['130', '145', 'clinical_variable']]}, 'NCT02931110'), ({'text': 'Cooperative, patient scheduled for amputation, with time and availability to do fMRI prior to their operative date', 'entities': [['36', '46', 'treatment']]}, 'NCT02383979'), ({'text': "Symptomatic patients (from 6 years to 26 years old) with early or childhood-onset SMD (age at disease onset <18 years) with at least one pathogenic mutant ABCA4 allele on each chromosome confirmed by direct sequencing and co-segregation analysis within the patient's family", 'entities': [['28', '35', 'lower_bound'], ['39', '47', 'upper_bound'], ['88', '91', 'age'], ['110', '118', 'upper_bound']]}, 'NCT01367444'), ({'text': 'Meet established criteria for diffuse or limited SSc and evidence of pulmonary at high risk of progression with or without progressive skin disease', 'entities': [['50', '53', 'cancer'], ['136', '148', 'chronic_disease']]}, 'NCT02370693'), ({'text': 'anti-hypertensive medications are permitted', 'entities': [['1', '30', 'treatment']]}, 'NCT02272998'), ({'text': 'Abnormal oral soft tissue findings (e.g., open sores, lesions)', 'entities': [['43', '53', 'chronic_disease'], ['55', '62', 'chronic_disease']]}, 'NCT03032705'), ({'text': 'Be 50 years of age or older at some point during study participation', 'entities': [['4', '12', 'lower_bound'], ['16', '19', 'age']]}, 'NCT03004170'), ({'text': 'Platelet count e 60 x 109/L, Hemoglobin e 8.5 g/dL, WBC e 2000/¼L International normalized ratio (INR) must be d 2.3', 'entities': [['1', '15', 'clinical_variable'], ['18', '28', 'lower_bound'], ['30', '40', 'clinical_variable'], ['43', '51', 'lower_bound'], ['53', '56', 'clinical_variable'], ['59', '66', 'lower_bound'], ['67', '103', 'clinical_variable'], ['114', '117', 'upper_bound']]}, 'NCT01360606'), ({'text': 'Patients who have had a prior autologous transplant', 'entities': [['25', '52', 'treatment']]}, 'NCT01619761'), ({'text': 'Subject has immeasurable MM (no measurable monoclonal protein, free light chains in blood or urine, or measureable plasmacytoma on radiologic scanning)', 'entities': [['26', '28', 'cancer'], ['116', '128', 'cancer'], ['132', '151', 'treatment']]}, 'NCT02516696'), ({'text': 'History of traumatic brain injury', 'entities': [['12', '34', 'chronic_disease']]}, 'NCT02460692'), ({'text': 'free for >= 5 years so as not to interfere with interpretation of radiographic response', 'entities': [['13', '20', 'lower_bound']]}, 'NCT01896999'), ({'text': 'Patients who cannot receive cyclophosphamide', 'entities': [['29', '45', 'treatment']]}, 'NCT01349101'), ({'text': 'At least one measurable viable tumor in the liver', 'entities': [['10', '13', 'lower_bound'], ['32', '50', 'cancer']]}, 'NCT02562755'), ({'text': 'Patients who have had surgery at the site of the suspected lesion within 1 month', 'entities': [['23', '30', 'treatment'], ['74', '81', 'upper_bound']]}, 'NCT02079181'), ({'text': 'Histologically or cytologically documented, locally advanced or metastatic solid malignancy of any type during the dose escalation phase, that has progressed on available standard systemic therapy', 'entities': [['65', '92', 'cancer'], ['172', '197', 'treatment']]}, 'NCT02549937'), ({'text': 'any type of autologous or allogeneic HSCT', 'entities': [['13', '42', 'treatment']]}, 'NCT02210078'), ({'text': 'demonstrate an increase in FEV1 of 12% and 200 mL within 30 minutes after administration of 400 µg salbutamol/360 µg albuterol (or equivalent dose) at Visit 101 All patients must perform a reversibility test at Visit 101', 'entities': [['28', '32', 'clinical_variable'], ['58', '68', 'upper_bound'], ['100', '110', 'treatment'], ['118', '127', 'treatment']]}, 'NCT02554786'), ({'text': 'Meet diagnostic criteria for IBS', 'entities': [['30', '33', 'chronic_disease']]}, 'NCT03087799'), ({'text': 'Patients with severe liver disease', 'entities': [['22', '35', 'chronic_disease']]}, 'NCT03040778'), ({'text': 'Subjects presenting with maxillary sinus pathology', 'entities': [['26', '51', 'chronic_disease']]}, 'NCT02953392'), ({'text': 'Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to each PET/MRI', 'entities': [['1', '6', 'gender'], ['45', '78', 'pregnancy'], ['101', '113', 'upper_bound']]}, 'NCT03076333'), ({'text': 'Transaminases (AST and/or ALT) =< 2.5 x ULN', 'entities': [['16', '19', 'clinical_variable'], ['27', '30', 'clinical_variable'], ['35', '44', 'upper_bound']]}, 'NCT02451553'), ({'text': 'Patients who are pregnant, or who plan to become pregnant in the next 12 months', 'entities': [['14', '26', 'pregnancy'], ['35', '58', 'pregnancy'], ['66', '80', 'upper_bound']]}, 'NCT02226159'), ({'text': 'History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan', 'entities': [['12', '41', 'chronic_disease'], ['43', '63', 'chronic_disease'], ['71', '95', 'chronic_disease'], ['98', '122', 'chronic_disease'], ['111', '122', 'chronic_disease'], ['127', '149', 'chronic_disease'], ['204', '233', 'treatment']]}, 'NCT02091141'), ({'text': 'Major surgery requiring a prolonged hospitalization or recovery within 21 days before day 1 of study drug', 'entities': [['1', '14', 'treatment'], ['72', '79', 'upper_bound'], ['96', '106', 'treatment']]}, 'NCT02401347'), ({'text': 'Age 50 or older', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT02414607'), ({'text': 'Pregnant and nursing patients are excluded because the effects of ONC201on a fetus or nursing child are unknown', 'entities': [['1', '9', 'pregnancy'], ['67', '73', 'treatment']]}, 'NCT02392572'), ({'text': 'younger than 18 and older than 81 years of age', 'entities': [['14', '16', 'lower_bound'], ['32', '40', 'upper_bound'], ['44', '47', 'age']]}, 'NCT02395614'), ({'text': 'Daily or regular use of prescription or OTC medications known to interact with alcohol in the 2-week period prior to assessment', 'entities': [['25', '56', 'treatment'], ['95', '101', 'upper_bound']]}, 'NCT00713492'), ({'text': 'Significant medical illness or organ failure', 'entities': [['13', '28', 'chronic_disease'], ['32', '45', 'chronic_disease']]}, 'NCT02462161'), ({'text': 'Symptomatic uncontrolled coronary artery disease or ejection fraction < 40%', 'entities': [['26', '49', 'chronic_disease'], ['53', '70', 'chronic_disease'], ['73', '76', 'upper_bound']]}, 'NCT02122081'), ({'text': 'Sexually active males must use a condom during intercourse while taking the drug and for 3 months after stopping study drug and should not father a child in this period; a condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid', 'entities': [['17', '22', 'gender'], ['28', '59', 'contraception_consent'], ['90', '104', 'upper_bound'], ['114', '124', 'treatment'], ['224', '227', 'gender']]}, 'NCT02098161'), ({'text': 'Cyclosporin e.g. (Neoral or Sandimmune)', 'entities': [['1', '12', 'treatment'], ['19', '25', 'treatment'], ['29', '39', 'treatment']]}, 'NCT01869114'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02373241'), ({'text': 'Evidence or history of toxic megacolon', 'entities': [['24', '39', 'chronic_disease']]}, 'NCT02463305'), ({'text': 'less than 18 years of age', 'entities': [['11', '19', 'upper_bound'], ['23', '26', 'age']]}, 'NCT02544880'), ({'text': 'BCC/SCC in area with compromised lymphatic drainage or vascular supply', 'entities': [['1', '4', 'cancer'], ['5', '8', 'cancer']]}, 'NCT02131805'), ({'text': 'For the dose escalation phase, the trial population will be limited to solid tumor types', 'entities': [['78', '83', 'cancer']]}, 'NCT01591356'), ({'text': 'Allergy desensitization injections', 'entities': [['1', '35', 'treatment']]}, 'NCT02382549'), ({'text': 'Status 1 heart transplant or prior orthotopic heart transplantation', 'entities': [['1', '26', 'treatment'], ['30', '68', 'treatment']]}, 'NCT01626079'), ({'text': 'Excessive self-reported daily caffeine intake, defined as intake exceeding 1000 mg or the equivalent of 8 cups of coffee', 'entities': [['31', '39', 'treatment'], ['76', '83', 'lower_bound']]}, 'NCT02067975'), ({'text': 'Existence of haploidentical first degree relative who passes standard donor evaluations for bone marrow and kidney donation', 'entities': [['14', '28', 'treatment']]}, 'NCT01758042'), ({'text': 'Pulmonary', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT02146924'), ({'text': 'Patients with uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms) within 1 month prior to conditioning', 'entities': [['28', '37', 'chronic_disease'], ['39', '44', 'chronic_disease'], ['48', '65', 'chronic_disease'], ['90', '99', 'treatment'], ['150', '163', 'upper_bound']]}, 'NCT02165007'), ({'text': 'Patients with gross residual tumor after surgical resection', 'entities': [['21', '35', 'cancer'], ['42', '60', 'treatment']]}, 'NCT02245997'), ({'text': 'Pregnant or lactating', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02629120'), ({'text': 'Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease', 'entities': [['34', '44', 'cancer'], ['52', '59', 'upper_bound'], ['157', '173', 'cancer']]}, 'NCT02389517'), ({'text': 'No previous chemotherapy', 'entities': [['13', '25', 'treatment']]}, 'NCT01859819'), ({'text': 'Patients with known macular degeneration or uncontrolled glaucoma', 'entities': [['21', '41', 'chronic_disease'], ['58', '66', 'chronic_disease']]}, 'NCT02120222'), ({'text': 'Age is > or = 18 and < or = 79 years of age', 'entities': [['1', '4', 'age'], ['15', '17', 'lower_bound'], ['29', '37', 'upper_bound'], ['41', '44', 'age']]}, 'NCT01983462'), ({'text': 'History of uncontrolled hyperlipidemia', 'entities': [['12', '39', 'chronic_disease']]}, 'NCT01865162'), ({'text': 'age e18 to 54', 'entities': [['1', '4', 'age'], ['6', '8', 'lower_bound'], ['12', '14', 'upper_bound']]}, 'NCT02577731'), ({'text': 'Premenopausal women must have a negative pregnancy test and must agree to use barrier contraception throughout the study period', 'entities': [['15', '20', 'gender'], ['33', '51', 'pregnancy'], ['66', '100', 'contraception_consent']]}, 'NCT01802346'), ({'text': 'Prior chemotherapy', 'entities': [['7', '19', 'treatment']]}, 'NCT01434316'), ({'text': 'Cytoreduction therapy with plasmapheresis or hydroxyurea acceptable', 'entities': [['1', '22', 'treatment'], ['28', '42', 'treatment'], ['46', '57', 'treatment']]}, 'NCT02109627'), ({'text': 'Previously received a HSCT', 'entities': [['23', '27', 'treatment']]}, 'NCT01461837'), ({'text': 'hepatic insufficiency', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT01525901'), ({'text': 'prior colon resection', 'entities': [['1', '22', 'treatment']]}, 'NCT03011788'), ({'text': 'No history of serious medical or neurological illness', 'entities': [['15', '30', 'chronic_disease'], ['34', '54', 'chronic_disease']]}, 'NCT02437773'), ({'text': 'protein C deficiency', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02366871'), ({'text': 'Platelet count d 100,000 per mm3', 'entities': [['1', '15', 'clinical_variable'], ['18', '33', 'upper_bound']]}, 'NCT02207439'), ({'text': 'Current pregnancy', 'entities': [['1', '18', 'pregnancy']]}, 'NCT03060772'), ({'text': 'History of neurological or psychiatric disorder', 'entities': [['12', '24', 'chronic_disease'], ['28', '48', 'chronic_disease']]}, 'NCT02298790'), ({'text': 'Age 5 to 6 years', 'entities': [['1', '4', 'age'], ['5', '6', 'lower_bound'], ['10', '17', 'upper_bound']]}, 'NCT01829360'), ({'text': 'Drugs/substances known to inhibit methadone metabolism: macrolide antibiotics e.g., erythromycin, cimetidine, astemizole, voriconazole, grapefruit juice', 'entities': [['35', '44', 'treatment'], ['57', '78', 'treatment'], ['85', '97', 'treatment'], ['99', '109', 'treatment'], ['111', '121', 'treatment'], ['123', '135', 'treatment'], ['137', '153', 'treatment']]}, 'NCT02252432'), ({'text': 'Previous treatment with corticosteroid for TED for >2wks', 'entities': [['1', '39', 'treatment'], ['44', '47', 'chronic_disease'], ['53', '57', 'lower_bound']]}, 'NCT02845336'), ({'text': 'Use of parenteral (IV or IM) antibiotics (antibacterials, antivirals, anti-fungals, or anti parasitic agents) within 60 days of Day', 'entities': [['8', '41', 'treatment'], ['43', '57', 'treatment'], ['59', '69', 'treatment'], ['71', '83', 'treatment'], ['88', '109', 'treatment'], ['118', '125', 'upper_bound']]}, 'NCT02347891'), ({'text': 'Active Suicidality', 'entities': [['8', '19', 'chronic_disease']]}, 'NCT02206945'), ({'text': 'Histologically or cytologically confirmed diagnosis of metastatic NSCLC according to the 7th edition of the AJCC Cancer Staging Manual', 'entities': [['67', '72', 'cancer']]}, 'NCT02336451'), ({'text': 'CPPD diagnosed by Ryan /McCarty criteria', 'entities': [['1', '5', 'chronic_disease']]}, 'NCT02243631'), ({'text': 'Newly diagnosed high-grade gliomas with metastatic disease within the CNS requiring craniospinal radiation therapy. Patients may or may not have received chemotherapy during radiation, but cannot have received chemotherapy after radiation therapy was completed', 'entities': [['28', '35', 'cancer'], ['41', '59', 'cancer'], ['85', '115', 'treatment'], ['98', '107', 'treatment'], ['108', '115', 'treatment'], ['155', '167', 'treatment']]}, 'NCT01130077'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02404155'), ({'text': 'patients must not be taking anticoagulants, with the exception of aspirin or other non-steroidal anti-inflammatory medications', 'entities': [['29', '43', 'treatment'], ['67', '74', 'treatment'], ['84', '127', 'treatment']]}, 'NCT02237183'), ({'text': 'Dysplasia', 'entities': [['1', '10', 'cancer']]}, 'NCT02634957'), ({'text': 'Neck pain of at least moderate severity (NDI score greater than or equal to 15)', 'entities': [['42', '51', 'clinical_variable'], ['77', '79', 'lower_bound']]}, 'NCT03100539'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['77', '93', 'chronic_disease'], ['95', '131', 'chronic_disease'], ['133', '157', 'chronic_disease'], ['159', '177', 'chronic_disease'], ['182', '201', 'chronic_disease']]}, 'NCT02217709'), ({'text': 'Diagnosed with mental illness other than active depression Neurological condition other than that which resulted in aphasia', 'entities': [['16', '30', 'chronic_disease'], ['49', '59', 'chronic_disease'], ['60', '82', 'chronic_disease'], ['117', '124', 'chronic_disease']]}, 'NCT02916524'), ({'text': 'Primary speaking language is English', 'entities': [['9', '37', 'language_fluency']]}, 'NCT02593526'), ({'text': 'Subjects who have participated in a clinical study more recently than one month before the current study', 'entities': [['71', '80', 'lower_bound']]}, 'NCT01972113'), ({'text': 'Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with entinostat, azacitidine, or Nivolumab breastfeeding should be discontinued if the mother is treated on this protocol', 'entities': [['99', '108', 'treatment'], ['128', '138', 'treatment'], ['140', '151', 'treatment'], ['156', '165', 'treatment']]}, 'NCT01928576'), ({'text': 'alpha mannosidosis', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT01962415'), ({'text': 'Patients on antiplatelet agents including Clopidogrel, unless discontinued for 5 days prior to the sponge procedure', 'entities': [['13', '32', 'treatment'], ['43', '54', 'treatment']]}, 'NCT02560623'), ({'text': 'Women that are breastfeeding or of childbearing potential and not protected by a medically acceptable', 'entities': [['1', '6', 'gender']]}, 'NCT02964182'), ({'text': 'Nonalcoholic fatty liver disease (NAFLD) diagnosis confirmed by liver biopsy or MRI', 'entities': [['1', '41', 'chronic_disease'], ['65', '77', 'treatment'], ['81', '84', 'treatment']]}, 'NCT03042767'), ({'text': 'History of allergy to study drug components', 'entities': [['23', '44', 'allergy_name']]}, 'NCT02259621'), ({'text': 'have no history of epileptic seizures', 'entities': [['20', '38', 'chronic_disease']]}, 'NCT02427997'), ({'text': 'Absolute neutrophil count e 1,500/mcL', 'entities': [['1', '26', 'clinical_variable'], ['29', '38', 'lower_bound']]}, 'NCT02085941'), ({'text': 'enrollment must occur within 4 calendar months following completion of CRT', 'entities': [['30', '47', 'upper_bound']]}, 'NCT01503086'), ({'text': 'In the event that a patient does not have a smart mobile device (i.e., one that can support the study application), one will be provided for the patient', 'entities': [['29', '64', 'technology_access']]}, 'NCT03006718'), ({'text': 'HIV positive', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT02472834'), ({'text': '+1 or more vitreous haze (according to Standardization of Uveitis Nomenclature (SUN) criteria)', 'entities': [['1', '3', 'lower_bound'], ['12', '25', 'clinical_variable']]}, 'NCT02911116'), ({'text': 'Alcohol use of more than 4 drinks per day', 'entities': [['26', '42', 'lower_bound']]}, 'NCT03088592'), ({'text': 'subjects with prior, curatively-treated squamous cell or basal cell carcinoma of the skin or carcinoma in situ of the cervix will be eligible for participation in this study', 'entities': [['41', '90', 'cancer'], ['94', '125', 'cancer']]}, 'NCT02448173'), ({'text': 'serum bilirubin d 1.5 x ULN', 'entities': [['1', '16', 'clinical_variable'], ['19', '28', 'upper_bound']]}, 'NCT02531932'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02290028'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01738009'), ({'text': 'Pancreatitis (acute or chronic)', 'entities': [['1', '32', 'chronic_disease']]}, 'NCT02650206'), ({'text': 'New York Heart Association (NYHA) > Class II', 'entities': [['1', '34', 'clinical_variable'], ['37', '45', 'lower_bound']]}, 'NCT03042689'), ({'text': 'Brain metastasis and/or leptomeningeal disease (known or suspected)', 'entities': [['1', '17', 'cancer'], ['25', '47', 'cancer']]}, 'NCT02309892'), ({'text': 'Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study', 'entities': [['46', '62', 'treatment']]}, 'NCT02397083'), ({'text': 'The participant requires emergency surgery', 'entities': [['36', '43', 'treatment']]}, 'NCT02895945'), ({'text': 'IVIg will also be allowed as an immunomodulatory agent', 'entities': [['1', '5', 'treatment'], ['33', '55', 'treatment']]}, 'NCT02043548'), ({'text': 'Acute non-cardiovascular illness or systemic infection', 'entities': [['7', '33', 'chronic_disease'], ['46', '55', 'chronic_disease']]}, 'NCT01791543'), ({'text': 'Females of childbearing potential (FCBP) must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide, during lenalidomide therapy, during dose interruptions, and for at least 28 days following discontinuation of lenalidomide therapy', 'entities': [['1', '8', 'gender'], ['54', '114', 'contraception_consent'], ['118', '163', 'contraception_consent'], ['256', '270', 'lower_bound'], ['256', '263', 'lower_bound'], ['280', '292', 'treatment'], ['301', '321', 'treatment']]}, 'NCT02232516'), ({'text': 'Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication', 'entities': [['1', '15', 'gender'], ['56', '89', 'pregnancy'], ['97', '111', 'upper_bound'], ['149', '159', 'treatment']]}, 'NCT02541565'), ({'text': 'Subjects 19-89 years of age', 'entities': [['10', '12', 'lower_bound'], ['13', '21', 'upper_bound'], ['25', '28', 'age']]}, 'NCT00926237'), ({'text': 'Subjects who require rTMS, ECT, diathermy, or repeat MRI procedures to treat a medical condition', 'entities': [['22', '26', 'treatment'], ['28', '31', 'treatment'], ['33', '42', 'treatment'], ['47', '97', 'treatment']]}, 'NCT02924194'), ({'text': 'Patients with adequate blood coagulation activity, PT(INR) < 1.5, APTT', 'entities': [['52', '59', 'clinical_variable'], ['62', '65', 'upper_bound'], ['67', '71', 'clinical_variable']]}, 'NCT02844751'), ({'text': 'History of tuberculosis (TB) or TB exposure', 'entities': [['12', '44', 'chronic_disease']]}, 'NCT02179853'), ({'text': 'Patients on therapeutic anticoagulation', 'entities': [['13', '40', 'treatment']]}, 'NCT01624090'), ({'text': 'The cancer must be unresectable', 'entities': [['5', '11', 'cancer']]}, 'NCT00906984'), ({'text': 'Neoadjuvant chemotherapy was administered', 'entities': [['1', '25', 'treatment']]}, 'NCT02515110'), ({'text': 'e 18 years old', 'entities': [['3', '11', 'lower_bound']]}, 'NCT03034213'), ({'text': 'Clinically significant medical illness, including thyroid disorders', 'entities': [['24', '39', 'chronic_disease'], ['51', '68', 'chronic_disease']]}, 'NCT01794559'), ({'text': 'POEMS syndrome', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT01464034'), ({'text': 'Anticipated TPN treatment for at least one month', 'entities': [['13', '26', 'treatment'], ['40', '49', 'lower_bound']]}, 'NCT00862446'), ({'text': 'History or evidence of retinal pathology according to protocol-defined criteria, including serous retinopathy', 'entities': [['92', '110', 'chronic_disease']]}, 'NCT02639546'), ({'text': 'Confirmed HCC based on histopathological findings from tumor tissues', 'entities': [['11', '14', 'cancer'], ['56', '61', 'cancer']]}, 'NCT02519348'), ({'text': 'Participant in other clinical trials', 'entities': [['16', '37', 'treatment']]}, 'NCT02843945'), ({'text': 'General anesthesia', 'entities': [['1', '19', 'treatment']]}, 'NCT02548104'), ({'text': 'Current treatment with any chemotherapeutic agent', 'entities': [['9', '18', 'treatment'], ['28', '50', 'treatment']]}, 'NCT01306019'), ({'text': 'Failure to successfully complete the 2-week study run-in, defined as unable to tolerate metformin', 'entities': [['89', '98', 'treatment']]}, 'NCT03054519'), ({'text': 'uncorrected coagulopathy', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02826668'), ({'text': 'willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and at least 6 months after the last dose of brentuximab vedotin', 'entities': [['1', '53', 'contraception_consent'], ['63', '85', 'contraception_consent'], ['87', '107', 'contraception_consent'], ['109', '134', 'contraception_consent'], ['136', '158', 'contraception_consent'], ['163', '173', 'contraception_consent'], ['218', '226', 'lower_bound'], ['250', '269', 'treatment']]}, 'NCT03007030'), ({'text': 'Have diagnosed with multiple or sessile papilloma by ultrasound, mammography and/or ductoscopy', 'entities': [['21', '50', 'cancer'], ['54', '64', 'treatment'], ['66', '77', 'treatment'], ['85', '95', 'treatment']]}, 'NCT01901562'), ({'text': 'Patients on monoclonal antibody preparations directed to TNF±', 'entities': [['13', '62', 'treatment']]}, 'NCT02646930'), ({'text': 'Diagnosis of DIPG', 'entities': [['14', '18', 'cancer']]}, 'NCT02442297'), ({'text': 'Prescription of antipsychotic medication for at least 60 days and constant dose for 30 days prior to study entry (either first or second generation antipsychotics permitted)', 'entities': [['17', '41', 'treatment'], ['55', '62', 'lower_bound'], ['85', '98', 'upper_bound'], ['149', '163', 'treatment']]}, 'NCT02067975'), ({'text': 'Participation in a clinical trial of another Investigational Drug or Investigational Device within the past 30 days', 'entities': [['46', '66', 'treatment'], ['70', '92', 'treatment']]}, 'NCT01597518'), ({'text': 'Major surgical procedure', 'entities': [['1', '25', 'treatment']]}, 'NCT02317991'), ({'text': 'Previous treatment with Thalidomide or other imid drugs within previous 12 months', 'entities': [['1', '56', 'treatment'], ['64', '82', 'upper_bound']]}, 'NCT02287558'), ({'text': 'ECOG Performance Status score of >3', 'entities': [['1', '30', 'clinical_variable'], ['35', '36', 'lower_bound']]}, 'NCT01648023'), ({'text': 'Karnofsky rating 70-100', 'entities': [['1', '10', 'clinical_variable'], ['18', '20', 'lower_bound'], ['21', '24', 'upper_bound']]}, 'NCT00147056'), ({'text': 'extreme OSA accompanied by signs of cardiopulmonary compromise (RDI>60 respiratory events per hour with severe nocturnal hypoxia or unstable ECG rhythms on PSG), will be excluded unless they are randomized to immediate PAP arm', 'entities': [['9', '12', 'chronic_disease'], ['37', '63', 'chronic_disease'], ['65', '68', 'clinical_variable'], ['69', '71', 'lower_bound'], ['112', '129', 'chronic_disease']]}, 'NCT02544373'), ({'text': 'women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the point of study entry and for the duration of all active treatments', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['47', '140', 'contraception_consent']]}, 'NCT01918644'), ({'text': 'ECOG performance status 0-2. (KPS > 50)', 'entities': [['1', '24', 'clinical_variable'], ['25', '26', 'lower_bound'], ['27', '28', 'upper_bound'], ['31', '34', 'clinical_variable'], ['37', '39', 'lower_bound']]}, 'NCT02344355'), ({'text': 'Any current medical condition, psychiatric disorder, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study', 'entities': [['32', '52', 'chronic_disease']]}, 'NCT02815917'), ({'text': 'Received seasonal flu vaccination at least 6 weeks prior to first trial injection (and not more recently)', 'entities': [['44', '57', 'lower_bound']]}, 'NCT02707692'), ({'text': 'Patients with biliary obstruction must be stented prior to initiating treatment', 'entities': [['71', '80', 'treatment']]}, 'NCT02446093'), ({'text': 'Phenylketonuria (PKU)', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02918981'), ({'text': 'male', 'entities': [['1', '5', 'gender']]}, 'NCT03114891'), ({'text': 'Diagnosed as respiratory or circulatory instability', 'entities': [['14', '52', 'chronic_disease']]}, 'NCT03062462'), ({'text': 'active infection', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT03060564'), ({'text': 'having signs or symptoms of acute or chronic graft-versus-host disease', 'entities': [['29', '71', 'chronic_disease']]}, 'NCT02939183'), ({'text': 'ECOG performance status of d 2 at study entry', 'entities': [['1', '24', 'clinical_variable'], ['30', '31', 'upper_bound']]}, 'NCT02309580'), ({'text': 'Any attempt or intent of suicide in the last 6 months', 'entities': [['26', '33', 'chronic_disease'], ['41', '54', 'upper_bound']]}, 'NCT02056873'), ({'text': 'Active Hepatitis B or C', 'entities': [['8', '24', 'chronic_disease']]}, 'NCT02845596'), ({'text': 'Black/African American, Latino or Asian', 'entities': [['1', '23', 'ethnicity'], ['25', '31', 'ethnicity'], ['35', '40', 'ethnicity']]}, 'NCT03078153'), ({'text': 'White blood cell (WBC) count >= 3,500/mm^3', 'entities': [['1', '29', 'clinical_variable'], ['33', '43', 'lower_bound']]}, 'NCT02524275'), ({'text': 'The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document. Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control. Women of childbearing potential must have a negative pregnancy test at screening', 'entities': [['158', '171', 'gender'], ['178', '242', 'contraception_consent'], ['248', '262', 'gender'], ['263', '269', 'contraception_consent'], ['310', '318', 'upper_bound'], ['342', '355', 'treatment'], ['365', '384', 'contraception_consent'], ['444', '515', 'contraception_consent'], ['517', '522', 'gender'], ['561', '579', 'pregnancy']]}, 'NCT01639508'), ({'text': 'Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks prior to study enrollment', 'entities': [['14', '23', 'chronic_disease'], ['25', '30', 'chronic_disease'], ['32', '38', 'chronic_disease'], ['40', '53', 'chronic_disease'], ['64', '73', 'chronic_disease'], ['85', '102', 'chronic_disease'], ['161', '190', 'treatment'], ['179', '190', 'treatment'], ['194', '209', 'treatment'], ['274', '287', 'upper_bound']]}, 'NCT02498951'), ({'text': 'Any condition that would preclude the safe experience of a benign laboratory stressor including seizure disorder', 'entities': [['97', '113', 'chronic_disease']]}, 'NCT03099070'), ({'text': 'ges of 25 and 40 years', 'entities': [['8', '10', 'lower_bound'], ['15', '23', 'upper_bound']]}, 'NCT01968590'), ({'text': '<45 years of age', 'entities': [['2', '10', 'upper_bound'], ['14', '17', 'age']]}, 'NCT01685411'), ({'text': 'Known allergy to cangrelor or known sensitivity to any component of cangrelor', 'entities': [['18', '27', 'allergy_name']]}, 'NCT02765633'), ({'text': 'Patients with PNH without underlying bone marrow aplasia', 'entities': [['15', '18', 'chronic_disease'], ['38', '57', 'chronic_disease']]}, 'NCT02928991'), ({'text': 'Cohort 4b will have participants with progressive brain metastases', 'entities': [['51', '67', 'cancer']]}, 'NCT01494662'), ({'text': 'quinidine', 'entities': [['1', '10', 'treatment']]}, 'NCT02905591'), ({'text': 'Baseline chest computed tomography (CT) with or without contrast must be performed within 6 months (180 days) prior to randomization to ensure no evidence of disease', 'entities': [['10', '40', 'treatment'], ['91', '116', 'upper_bound']]}, 'NCT02201992'), ({'text': 'Inability to comply with the photosensitivity precautions associated with the study', 'entities': [['30', '46', 'allergy_name']]}, 'NCT02191488'), ({'text': 'Patients must not have received prior navitoclax, unless the patient received < 7 days of navitoclax lead-in on this or another study and had to stop for reasons other than toxicity or disease progression', 'entities': [['39', '49', 'treatment'], ['81', '87', 'upper_bound']]}, 'NCT01989585'), ({'text': 'platelets <50,000/uL', 'entities': [['1', '10', 'clinical_variable'], ['12', '21', 'upper_bound']]}, 'NCT02162420'), ({'text': 'Organic nitrates in any form, either regularly or intermittently', 'entities': [['1', '17', 'treatment']]}, 'NCT02335242'), ({'text': 'Known history of uncontrolled sleep apnea syndrome or other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease or a requirement for supplemental oxygen', 'entities': [['31', '51', 'chronic_disease'], ['138', '175', 'chronic_disease']]}, 'NCT02114229'), ({'text': "Diagnosed with Raynaud's syndrome", 'entities': [['16', '34', 'chronic_disease']]}, 'NCT02192398'), ({'text': 'Men and women with a stable symptomatic claudication for e6 months', 'entities': [['1', '14', 'gender'], ['59', '67', 'lower_bound']]}, 'NCT02770547'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01349101'), ({'text': 'inflammatory bowel disease', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT01269034'), ({'text': 'Congestive heart failure III/IV as defined by New York Heart Association (NYHA)', 'entities': [['1', '32', 'chronic_disease'], ['47', '80', 'clinical_variable']]}, 'NCT01473628'), ({'text': 'SAF Activity score of 3 or 4 (>2)', 'entities': [['1', '19', 'clinical_variable'], ['23', '24', 'lower_bound'], ['28', '29', 'upper_bound'], ['32', '33', 'lower_bound']]}, 'NCT03008070'), ({'text': 'Possession of a smartphone OR of a mobile telephone with text messaging AND an e-mail account AND web access OR willingness to be provided with, and utilize, a smartphone for the duration of the study', 'entities': [['1', '109', 'technology_access'], ['113', '171', 'technology_access']]}, 'NCT02454907'), ({'text': 'e 18 years of age', 'entities': [['3', '11', 'lower_bound'], ['15', '18', 'age']]}, 'NCT02250157'), ({'text': 'Uncontrolled seizure disorder', 'entities': [['14', '30', 'chronic_disease']]}, 'NCT02159027'), ({'text': 'Must have confirmed Chronic Granulomatous Disease', 'entities': [['21', '50', 'chronic_disease']]}, 'NCT02629120'), ({'text': 'other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol', 'entities': [['26', '45', 'chronic_disease'], ['102', '111', 'treatment']]}, 'NCT03004287'), ({'text': 'Immunohistochemistry (IHC) 0-1+', 'entities': [['1', '27', 'clinical_variable'], ['28', '29', 'lower_bound'], ['30', '31', 'upper_bound']]}, 'NCT02488967'), ({'text': 'Fulminant liver failure', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT01811368'), ({'text': 'Planning to quit smoking in the next 30 days', 'entities': [['33', '45', 'upper_bound']]}, 'NCT02250534'), ({'text': 'known HIV carrier', 'entities': [['7', '10', 'chronic_disease']]}, 'NCT01553942'), ({'text': 'Must not be pregnant or breastfeeding', 'entities': [['13', '21', 'pregnancy']]}, 'NCT00967785'), ({'text': 'The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be re-screened 4 weeks after the clinical resolution of an exacerbation)', 'entities': [['35', '57', 'chronic_disease'], ['115', '128', 'upper_bound']]}, 'NCT02525861'), ({'text': 'Creatinine clearance', 'entities': [['1', '21', 'clinical_variable']]}, 'NCT02358187'), ({'text': 'medication contraindications for smoking cessation (smoking cessation may change the bioavailability of antipsychotics, warfarin, theophylline and insulin)', 'entities': [['105', '119', 'treatment'], ['121', '129', 'treatment'], ['131', '143', 'treatment'], ['148', '155', 'treatment']]}, 'NCT01989507'), ({'text': 'Maternal uterine anomaly', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02986087'), ({'text': 'Imaging by magnetic resonance imaging (MRI), ultrasound and/or mammogram and physical exam to document lesions size must be performed within 30 days of study entry', 'entities': [['142', '149', 'upper_bound']]}, 'NCT02315196'), ({'text': 'For patients with organ confined renal tumors to be enrolled, the renal mass must be >= 1 cm in diameter on computed tomography (CT) or magnetic resonance imaging (MRI) and can be any clinical stage T1a-T4 (non-metastatic); a histologic diagnosis is not required for enrollment; the primary imaging site would be kidney', 'entities': [['40', '46', 'cancer'], ['67', '77', 'clinical_variable'], ['89', '105', 'lower_bound'], ['109', '133', 'treatment'], ['137', '169', 'clinical_variable'], ['200', '203', 'lower_bound'], ['204', '206', 'upper_bound']]}, 'NCT02526511'), ({'text': 'Patients must have a Lansky Play Scale17 of 60% (<16 yrs old), Karnofsky score 60% (>16 yrs old), or ECOG score of < or equal to 2 and a life expectancy of 2 months', 'entities': [['22', '41', 'clinical_variable'], ['45', '48', 'upper_bound'], ['64', '79', 'clinical_variable'], ['102', '112', 'clinical_variable'], ['130', '131', 'upper_bound'], ['138', '153', 'clinical_variable'], ['157', '165', 'upper_bound']]}, 'NCT02378428'), ({'text': 'Cyclosporine', 'entities': [['1', '13', 'treatment']]}, 'NCT02474368'), ({'text': '7-9 years of age', 'entities': [['1', '2', 'lower_bound'], ['3', '10', 'upper_bound'], ['14', '17', 'age']]}, 'NCT02928874'), ({'text': 'Other disorders associated with a high risk of fistula formation including percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy', 'entities': [['76', '132', 'treatment'], ['140', '155', 'upper_bound'], ['180', '187', 'treatment']]}, 'NCT02496208'), ({'text': 'inability to speak English that would preclude study participation', 'entities': [['1', '27', 'language_fluency']]}, 'NCT02709980'), ({'text': 'schizophrenia, depression with psychotic features, bipolar disorder, any psychosis', 'entities': [['1', '14', 'chronic_disease'], ['16', '26', 'chronic_disease'], ['52', '68', 'chronic_disease'], ['74', '83', 'chronic_disease']]}, 'NCT02951455'), ({'text': 'No psychiatric illness/social situation that would limit compliance', 'entities': [['4', '23', 'chronic_disease']]}, 'NCT02384954'), ({'text': 'Any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g. warfarin) after islet transplantation (low-dose aspirin treatment [325 mg PO] is allowed)', 'entities': [['5', '17', 'chronic_disease'], ['59', '80', 'treatment'], ['87', '95', 'treatment'], ['103', '123', 'treatment'], ['126', '152', 'treatment']]}, 'NCT02464878'), ({'text': 'Concomitant administration of medications that affect thyroid function test including Cholestyramine, Sucralfate, Amiodarone, Lithium, Dopamine, Dobutamine and Dilantin at enrollment', 'entities': [['31', '42', 'treatment'], ['87', '101', 'treatment'], ['103', '113', 'treatment'], ['115', '125', 'treatment'], ['127', '134', 'treatment'], ['136', '144', 'treatment'], ['146', '156', 'treatment'], ['161', '169', 'treatment']]}, 'NCT02577367'), ({'text': 'At least one of the stenoses must cause e 50% reduction of the sinus lumen diameter', 'entities': [['10', '13', 'lower_bound'], ['43', '46', 'lower_bound'], ['64', '84', 'clinical_variable']]}, 'NCT01407809'), ({'text': 'Ascending aortic aneurysm or dissection repair not requiring circulatory arrest', 'entities': [['11', '26', 'chronic_disease'], ['30', '47', 'treatment']]}, 'NCT02088554'), ({'text': 'platelets > or = 70,000', 'entities': [['1', '10', 'clinical_variable'], ['18', '24', 'lower_bound']]}, 'NCT02013492'), ({'text': 'Require systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/day prednisone', 'entities': [['41', '56', 'treatment'], ['87', '96', 'lower_bound'], ['97', '107', 'treatment']]}, 'NCT03084640'), ({'text': 'IQ < 80', 'entities': [['1', '3', 'clinical_variable'], ['6', '8', 'upper_bound']]}, 'NCT03170453'), ({'text': 'Patients must not have signs of bowel perforation or acute abdomen as evidenced by free air on radiologic imaging or peritonitis on physical exam within 2 days prior to registration', 'entities': [['33', '50', 'chronic_disease'], ['54', '67', 'chronic_disease'], ['96', '114', 'treatment'], ['118', '129', 'chronic_disease'], ['154', '166', 'upper_bound']]}, 'NCT02270450'), ({'text': 'Participants must have the ability to safely undergo bronchoscopy in the judgment of the investigators', 'entities': [['54', '66', 'treatment']]}, 'NCT02237183'), ({'text': 'Patient has a history of opioid dependence requiring rehabilitation or the use of opioid antagonists', 'entities': [['54', '68', 'treatment'], ['83', '101', 'treatment']]}, 'NCT02423876'), ({'text': 'Current problematic drug or alcohol use that impacts functioning and study engagement, as deemed by a treatment provider', 'entities': [['103', '112', 'treatment']]}, 'NCT02535923'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT02557321'), ({'text': 'Evidence of other chronic liver disease', 'entities': [['19', '40', 'chronic_disease']]}, 'NCT02412540'), ({'text': 'Patients with up to stable Grade I spondylolisthesis at two contiguous levels', 'entities': [['28', '53', 'chronic_disease']]}, 'NCT02555280'), ({'text': 'Prior approval from insurance company to obtain oral temozolomide for the duration of the study', 'entities': [['54', '66', 'treatment']]}, 'NCT01858168'), ({'text': 'narcolepsy', 'entities': [['1', '11', 'chronic_disease']]}, 'NCT03007745'), ({'text': 'contraindication to MRI scanning, e.g. presence of a ferromagnetic object, including orthodontic braces, or claustrophobia', 'entities': [['109', '123', 'chronic_disease']]}, 'NCT03183388'), ({'text': 'Progression will be considered if additional N1 or N2 disease develop during chemotherapy', 'entities': [['46', '62', 'chronic_disease'], ['78', '90', 'treatment']]}, 'NCT02592551'), ({'text': 'Contraindications to resistance training, including a self-reported history of intracranial or retinal bleeding in the last year or Diabetes with active proliferative retinopathy', 'entities': [['22', '41', 'allergy_name'], ['80', '92', 'chronic_disease'], ['96', '112', 'chronic_disease'], ['133', '141', 'chronic_disease'], ['154', '179', 'chronic_disease']]}, 'NCT02992275'), ({'text': 'Females of child-bearing potential must have a negative pregnancy test', 'entities': [['1', '8', 'gender'], ['48', '66', 'pregnancy']]}, 'NCT00967577'), ({'text': 'Acute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 2 weeks before enrollment', 'entities': [['7', '16', 'treatment'], ['24', '33', 'chronic_disease'], ['45', '73', 'chronic_disease'], ['78', '109', 'chronic_disease'], ['151', '165', 'upper_bound']]}, 'NCT02437851'), ({'text': 'Use of systemic immunosuppressant agents including anti-metabolites, glucocorticoids, TNF antagonists, antibodies to IL6 or IL6R, calcineurin inhibitors, mTOR antagonists', 'entities': [['8', '41', 'treatment'], ['52', '68', 'treatment'], ['70', '85', 'treatment'], ['87', '102', 'treatment'], ['104', '129', 'treatment'], ['131', '153', 'treatment'], ['155', '171', 'treatment']]}, 'NCT02772562'), ({'text': 'Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy', 'entities': [['15', '39', 'cancer'], ['67', '81', 'treatment'], ['89', '110', 'treatment'], ['120', '143', 'treatment']]}, 'NCT03123783'), ({'text': 'Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years', 'entities': [['34', '55', 'cancer'], ['79', '103', 'cancer'], ['152', '162', 'cancer'], ['188', '203', 'upper_bound']]}, 'NCT01042522'), ({'text': 'Patients who completed induction treatment followed by autologous stem cell transplant as initial therapy for symptomatic myeloma as per IMWG criteria and initiated Revlimid (lenalidomide) maintenance', 'entities': [['24', '43', 'treatment'], ['56', '87', 'treatment'], ['91', '106', 'treatment'], ['123', '130', 'cancer'], ['166', '174', 'treatment'], ['176', '188', 'treatment']]}, 'NCT02389517'), ({'text': 'Ability to initiate ART within 7 days after birth', 'entities': [['21', '24', 'treatment'], ['32', '38', 'upper_bound']]}, 'NCT02369406'), ({'text': 'Not proficient in English', 'entities': [['1', '26', 'language_fluency']]}, 'NCT02743039'), ({'text': 'aged 18 to30 years', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['11', '19', 'upper_bound']]}, 'NCT01495819'), ({'text': 'Anticipation of need for major surgical procedure during the course of the study', 'entities': [['26', '40', 'treatment']]}, 'NCT01903330'), ({'text': 'Prior history of brachial neuritis or Guillain-Barré syndrome', 'entities': [['18', '35', 'chronic_disease'], ['39', '62', 'chronic_disease']]}, 'NCT02465268'), ({'text': 'who become pregnant during the study', 'entities': [['12', '20', 'pregnancy']]}, 'NCT03053518'), ({'text': 'Prior radiation therapy (RT) (any site) with concurrent lapatinib defined as 1 or more days on which the patient received both radiation therapy and lapatinib on the same day', 'entities': [['1', '29', 'treatment'], ['7', '24', 'treatment'], ['57', '66', 'treatment'], ['78', '79', 'lower_bound']]}, 'NCT01622868'), ({'text': 'Patient who have had previous treatment with selinexor', 'entities': [['22', '55', 'treatment']]}, 'NCT02269293'), ({'text': 'Prior Diagnosis of moderate to severe COPD', 'entities': [['20', '43', 'chronic_disease']]}, 'NCT02946658'), ({'text': 'Patient has received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) d 28 days or limited field radiation for palliation d 14 days prior to starting trial medications or has not recovered from side effects of such therapy', 'entities': [['22', '45', 'treatment'], ['38', '45', 'treatment'], ['57', '103', 'treatment'], ['107', '114', 'upper_bound'], ['126', '141', 'treatment'], ['159', '172', 'upper_bound'], ['191', '202', 'treatment']]}, 'NCT02493530'), ({'text': 'Patients with aneurysms of the right or left main coronary arteries during the acute febrile phase of KD', 'entities': [['15', '24', 'chronic_disease'], ['80', '105', 'chronic_disease']]}, 'NCT01917721'), ({'text': 'Subjects age 18 years or older', 'entities': [['10', '13', 'age'], ['14', '22', 'lower_bound']]}, 'NCT02383979'), ({'text': 'HLA-mismatched donors will be prioritized over HLA-matched to maximize an allogeneic benefit', 'entities': [['1', '4', 'treatment']]}, 'NCT01804634'), ({'text': 'First dose of cabozantinib occurs at least 28 days after surgery, and the subject has recovered from the effects of surgery', 'entities': [['15', '27', 'treatment'], ['44', '51', 'lower_bound'], ['58', '65', 'treatment']]}, 'NCT02132598'), ({'text': 'Hepatitis C', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT02635360'), ({'text': 'for women, not breastfeeding or pregnant', 'entities': [['5', '10', 'gender'], ['33', '41', 'pregnancy']]}, 'NCT00914823'), ({'text': 'Patients with refractory KD after initial treatment with IVIG and dilated coronary arteries on an echocardiogram during the first month of KD', 'entities': [['26', '28', 'chronic_disease'], ['58', '62', 'treatment'], ['99', '113', 'treatment']]}, 'NCT01917721'), ({'text': 'Patients should not have received any other investigational agents within the past 4 weeks', 'entities': [['45', '67', 'treatment'], ['79', '91', 'upper_bound']]}, 'NCT02498613'), ({'text': 'BMI >40 kg/M(2) due to the limits of the treadmill, elliptical machine and MRI scanner', 'entities': [['1', '4', 'bmi'], ['6', '16', 'lower_bound']]}, 'NCT02504866'), ({'text': 'Type 2 diabetes diagnosed per 2013 American Diabetes Association criteria', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02548351'), ({'text': 'Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN', 'entities': [['1', '31', 'clinical_variable'], ['36', '68', 'clinical_variable'], ['72', '81', 'upper_bound']]}, 'NCT01532687'), ({'text': 'Known history of claustrophobia', 'entities': [['18', '32', 'chronic_disease']]}, 'NCT02095678'), ({'text': 'Greater than 18 years old', 'entities': [['14', '22', 'lower_bound']]}, 'NCT02601027'), ({'text': 'Patients must not have a serious medical or psychiatric illness likely to interfere with study participation', 'entities': [['34', '41', 'chronic_disease'], ['45', '64', 'chronic_disease']]}, 'NCT01415752'), ({'text': 'Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy', 'entities': [['1', '7', 'chronic_disease'], ['9', '31', 'chronic_disease'], ['33', '38', 'chronic_disease'], ['43', '60', 'chronic_disease'], ['72', '88', 'treatment']]}, 'NCT01676259'), ({'text': 'Use of medications known to affect the macula, including hydroxychloroquinine (Plaquenil) and phenothiozines (e.g., thioridazine [Mellaril], chloropromazine [Thorazine]) or supplemental niacin e3 grams/day', 'entities': [['8', '19', 'treatment'], ['58', '90', 'treatment'], ['95', '109', 'treatment'], ['117', '140', 'treatment'], ['142', '169', 'treatment'], ['187', '193', 'treatment'], ['195', '206', 'lower_bound']]}, 'NCT01988246'), ({'text': 'History of any serious adverse reaction to either a corticosteroid or rituximab not including rituximab infusion reactions d Grade 3', 'entities': [['53', '67', 'treatment'], ['71', '80', 'treatment'], ['95', '123', 'clinical_variable'], ['126', '133', 'upper_bound']]}, 'NCT01829958'), ({'text': 'Subject is currently taking Aggrenox®', 'entities': [['29', '38', 'treatment']]}, 'NCT02532621'), ({'text': 'ongoing or active infection', 'entities': [['12', '28', 'chronic_disease']]}, 'NCT03035890'), ({'text': 'Prior diagnosis of myelodysplastic syndrome or acute myeloid leukemia', 'entities': [['20', '44', 'cancer'], ['48', '70', 'cancer']]}, 'NCT03148795'), ({'text': 'high-risk myeloproliferative neoplasm', 'entities': [['11', '38', 'cancer']]}, 'NCT02728050'), ({'text': 'Malignancy (within past 5 years)', 'entities': [['1', '11', 'cancer'], ['20', '32', 'upper_bound']]}, 'NCT01459107'), ({'text': 'Age >= 50 years', 'entities': [['1', '4', 'age'], ['8', '16', 'lower_bound']]}, 'NCT02480036'), ({'text': 'Diabetes mellitus', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT00977977'), ({'text': 'pregnant patients are ineligible', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02037048'), ({'text': 'previous endoscopy with biopsies demonstrating >20 eosinophils/high powered field on duodenal mucosal biopsies', 'entities': [['1', '33', 'treatment'], ['49', '51', 'lower_bound'], ['52', '63', 'clinical_variable'], ['86', '111', 'treatment']]}, 'NCT02484248'), ({'text': 'If taking antidepressant, anxiolytic, hypnotic, or stimulant medications, no change anticipated in these medications during the month prior to enrollment', 'entities': [['11', '25', 'treatment'], ['27', '37', 'treatment'], ['39', '47', 'treatment'], ['52', '73', 'treatment']]}, 'NCT01821690'), ({'text': 'Age e18 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02249520'), ({'text': 'Creatinine within normal institutional limits', 'entities': [['1', '11', 'clinical_variable']]}, 'NCT01697293'), ({'text': 'Adult primary caregiver of children treated for leukemia or lymphoblastic lymphoma (LL) and daily contact with the child', 'entities': [['49', '57', 'cancer'], ['61', '88', 'cancer']]}, 'NCT03178617'), ({'text': 'Subject has nonepileptic events that could be confused with seizures', 'entities': [['13', '32', 'chronic_disease'], ['61', '69', 'chronic_disease']]}, 'NCT02477839'), ({'text': 'Active untreated infection', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT02390752'), ({'text': 'hip flexion range greater or equal to 90 degrees', 'entities': [['1', '18', 'clinical_variable'], ['39', '49', 'lower_bound']]}, 'NCT01570816'), ({'text': 'Anaplastic large cell lymphoma (T and null cell type)', 'entities': [['1', '54', 'chronic_disease']]}, 'NCT01787409'), ({'text': "A QT interval corrected for heart rate using the Bazett's formula QTcB >= 480 msec", 'entities': [['50', '71', 'clinical_variable'], ['75', '83', 'lower_bound']]}, 'NCT02070549'), ({'text': 'History of vascular surgery in lower limbs or current lower limb vascular dysfunction', 'entities': [['12', '43', 'treatment']]}, 'NCT02064296'), ({'text': 'men who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period', 'entities': [['1', '4', 'gender'], ['33', '100', 'contraception_consent']]}, 'NCT02465268'), ({'text': 'Men of reproductive potential may not participate unless they agree to use an effective contraceptive method', 'entities': [['1', '4', 'gender'], ['63', '109', 'contraception_consent']]}, 'NCT02353819'), ({'text': 'Human anti-hu3F8 antibody (HAHA) titer >1300 Elisa unites/ml', 'entities': [['1', '39', 'clinical_variable'], ['41', '61', 'lower_bound']]}, 'NCT03033303'), ({'text': 'Chronic treatment with high dose corticosteroids or other immunosuppressive agents. Topical, inhaled, and low dose oral corticosteroids are allowed provided stable dosing for at least 2 weeks', 'entities': [['1', '83', 'treatment'], ['85', '92', 'treatment'], ['94', '101', 'treatment'], ['107', '136', 'treatment'], ['185', '192', 'lower_bound']]}, 'NCT02321501'), ({'text': 'intercurrent illness', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT03006302'), ({'text': 'unstable angina', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02178566'), ({'text': 'donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment', 'entities': [['1', '32', 'treatment'], ['36', '43', 'treatment'], ['51', '58', 'upper_bound']]}, 'NCT02210078'), ({'text': 'pre-pregnancy', 'entities': [['1', '14', 'pregnancy']]}, 'NCT02685761'), ({'text': 'medical history (including concomitant medications) within 60 days of planned first administration of vaccine', 'entities': [['28', '51', 'treatment'], ['60', '67', 'upper_bound']]}, 'NCT02466750'), ({'text': '>6oz alcohol/week', 'entities': [['2', '5', 'lower_bound']]}, 'NCT03029806'), ({'text': 'Current beta-blocker use', 'entities': [['9', '21', 'treatment']]}, 'NCT02793921'), ({'text': 'History of severe mental illness', 'entities': [['12', '33', 'chronic_disease']]}, 'NCT02155946'), ({'text': 'subcortical or cortical infarct confirmed with MRI', 'entities': [['1', '12', 'chronic_disease'], ['16', '32', 'chronic_disease'], ['48', '51', 'treatment']]}, 'NCT02445768'), ({'text': 'No active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ', 'entities': [['11', '21', 'cancer'], ['56', '80', 'cancer'], ['84', '101', 'cancer']]}, 'NCT02400463'), ({'text': 'Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance', 'entities': [['16', '33', 'chronic_disease'], ['43', '63', 'chronic_disease']]}, 'NCT02441062'), ({'text': 'Received prior or anticipated myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant', 'entities': [['10', '111', 'treatment']]}, 'NCT02203903'), ({'text': 'intended pregnancy', 'entities': [['10', '19', 'pregnancy']]}, 'NCT02997943'), ({'text': 'Amiodarone, sotalol, ibutilide, dofetilide', 'entities': [['1', '11', 'treatment'], ['13', '20', 'treatment'], ['22', '31', 'treatment'], ['33', '43', 'treatment']]}, 'NCT02389309'), ({'text': 'Patients must have bilirubin =< 2 x IULN within 7 days prior to registration (unless the bilirubin is primarily unconjugated)', 'entities': [['20', '29', 'clinical_variable'], ['33', '41', 'upper_bound'], ['49', '61', 'upper_bound']]}, 'NCT01925131'), ({'text': 'Grade 3 or 4 major organ irAEs following treatment with anti-PD-1/PD-L1', 'entities': [['42', '72', 'treatment']]}, 'NCT01174121'), ({'text': 'A subject will not be excluded because of pancytopenia related to disease', 'entities': [['43', '55', 'chronic_disease']]}, 'NCT02315612'), ({'text': 'History of poor adherence to treatment', 'entities': [['30', '39', 'treatment']]}, 'NCT02593526'), ({'text': 'must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide', 'entities': [['6', '43', 'contraception_consent'], ['77', '122', 'contraception_consent'], ['215', '222', 'lower_bound'], ['248', '260', 'treatment']]}, 'NCT02538198'), ({'text': 'Any medical condition that would increase risk for study participation (such as sinus infection or other condition blocking access to the olfactory epithelium)', 'entities': [['81', '96', 'chronic_disease']]}, 'NCT02595749'), ({'text': 'History of radiation pneumonitis in the radiation field (fibrosis) is permitted', 'entities': [['12', '33', 'chronic_disease'], ['12', '21', 'treatment'], ['58', '66', 'chronic_disease']]}, 'NCT02451423'), ({'text': 'electrolyte imbalances on basic metabolic panel', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02134392'), ({'text': 'An homologous recombination deficiency (HRD) score e 42 on the HRD Assay as assessed on a tumor biopsy sample', 'entities': [['4', '45', 'clinical_variable'], ['54', '56', 'lower_bound'], ['91', '96', 'cancer'], ['97', '103', 'treatment']]}, 'NCT02401347'), ({'text': '18 years of age or older', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT02501954'), ({'text': 'Patients must be e18 years of age', 'entities': [['19', '27', 'lower_bound'], ['31', '34', 'age']]}, 'NCT03119467'), ({'text': 'ALT or AST >2 times the upper limit of normal', 'entities': [['1', '4', 'clinical_variable'], ['8', '11', 'clinical_variable'], ['13', '46', 'lower_bound']]}, 'NCT02496611'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01059786'), ({'text': 'Allergy or hypersensitivity to components of the emactuzumab formulation or to components of the atezolizumab formulation', 'entities': [['50', '61', 'allergy_name'], ['98', '110', 'allergy_name']]}, 'NCT02323191'), ({'text': 'Mini-Mental State Examination (MMSE) between 8 and 24', 'entities': [['1', '37', 'clinical_variable'], ['46', '47', 'lower_bound'], ['52', '54', 'upper_bound']]}, 'NCT01816152'), ({'text': "family member or acquaintance with Alzheimer's disease or memory loss, OR a person diagnosed with mild memory loss (including mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease)", 'entities': [['36', '55', 'chronic_disease'], ['132', '152', 'chronic_disease']]}, 'NCT03149380'), ({'text': 'Measurable disease based on RECIST v1.1', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02592707'), ({'text': 'There is no evidence to suggest secondary forms of membranous nephropathy', 'entities': [['52', '74', 'chronic_disease']]}, 'NCT00977977'), ({'text': 'Lactating Females', 'entities': [['11', '18', 'gender']]}, 'NCT02946658'), ({'text': 'The subject has tumor abutting, invading or encasing any major blood vessels', 'entities': [['17', '22', 'cancer']]}, 'NCT02132598'), ({'text': 'severe auditory/visual impairment', 'entities': [['8', '34', 'chronic_disease']]}, 'NCT02481713'), ({'text': 'Active tuberculosis', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT00085982'), ({'text': "Crohn's disease", 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02985801'), ({'text': 'Acute coronary syndrome, Transient ischemic attack, CVA or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months', 'entities': [['1', '24', 'chronic_disease'], ['26', '51', 'chronic_disease'], ['53', '56', 'chronic_disease'], ['60', '82', 'chronic_disease'], ['94', '107', 'upper_bound'], ['111', '148', 'treatment'], ['160', '173', 'upper_bound']]}, 'NCT02169089'), ({'text': 'Patients suffering from familial hemophagocytic lymphohistiocytosis (f HLH)', 'entities': [['25', '76', 'chronic_disease']]}, 'NCT03113760'), ({'text': 'myocardial infarction in the preceding 6 months', 'entities': [['1', '22', 'chronic_disease'], ['40', '48', 'upper_bound']]}, 'NCT02101944'), ({'text': 'Histologically confirmed metastatic breast cancer', 'entities': [['26', '50', 'cancer']]}, 'NCT02398773'), ({'text': 'Pleural effusion or ascites that causes > grade 1 dyspnea', 'entities': [['1', '17', 'chronic_disease'], ['21', '28', 'chronic_disease'], ['43', '50', 'lower_bound'], ['51', '58', 'clinical_variable']]}, 'NCT02581215'), ({'text': 'Subjects with elevated uric acid levels greater than 10 mg/dL or gout', 'entities': [['15', '40', 'clinical_variable'], ['54', '62', 'lower_bound'], ['66', '70', 'chronic_disease']]}, 'NCT02322203'), ({'text': 'Paralysis of ischemic or traumatic origin', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT01459107'), ({'text': 'depression as part of bipolar disorder or schizophrenia or schizoaffective disorder', 'entities': [['23', '39', 'chronic_disease'], ['43', '56', 'chronic_disease'], ['60', '84', 'chronic_disease']]}, 'NCT02809677'), ({'text': 'Current use of cyclophosphamide or having received cyclophosphamide within the last year', 'entities': [['16', '32', 'treatment']]}, 'NCT02338999'), ({'text': 'Major psychiatric disorder or degenerative mental disease (such as multiple sclerosis)', 'entities': [['7', '27', 'chronic_disease'], ['31', '58', 'chronic_disease'], ['68', '86', 'chronic_disease']]}, 'NCT01986205'), ({'text': 'Have a screening ECG with QTc > 450 msec if male', 'entities': [['18', '21', 'treatment'], ['27', '30', 'clinical_variable'], ['33', '41', 'lower_bound'], ['45', '49', 'gender']]}, 'NCT02278367'), ({'text': 'and/or larger than 5 cm in diameter and enlarging at a rate of more than 5 mm/year', 'entities': [['20', '36', 'lower_bound'], ['74', '83', 'lower_bound']]}, 'NCT00483249'), ({'text': 'Previous treatment with ixazomib or pomalidomide', 'entities': [['1', '33', 'treatment'], ['37', '49', 'treatment']]}, 'NCT02542657'), ({'text': 'Biliary obstruction', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02166190'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT02402088'), ({'text': 'HIV (active or seropositive)', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT01459107'), ({'text': 'Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal', 'entities': [['1', '33', 'clinical_variable'], ['34', '82', 'clinical_variable'], ['83', '113', 'clinical_variable'], ['114', '160', 'clinical_variable'], ['164', '203', 'upper_bound']]}, 'NCT01849146'), ({'text': 'Chediak', 'entities': [['1', '8', 'chronic_disease']]}, 'NCT01962415'), ({'text': 'No leukemic phase', 'entities': [['4', '18', 'cancer']]}, 'NCT02320292'), ({'text': 'Prior systemic treatment or radiation therapy is allowed for patients with resectable liver metastases', 'entities': [['16', '25', 'treatment'], ['29', '46', 'treatment'], ['87', '103', 'cancer']]}, 'NCT02172651'), ({'text': 'Subjects with active glomerulonephritis (>3 g protein/24h and/or active urine sediment)', 'entities': [['22', '40', 'chronic_disease'], ['43', '46', 'lower_bound']]}, 'NCT02429934'), ({'text': 'Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition that investigators suspect may prohibit use of the investigational product, affect interpretation of study results, or put the patient at high risk', 'entities': [['16', '34', 'chronic_disease'], ['168', '191', 'treatment']]}, 'NCT02549937'), ({'text': 'First relapse of B-ALL, allowable sites of disease include isolated bone marrow, combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular; extramedullary sites are limited to the CNS and testicles', 'entities': [['18', '23', 'cancer']]}, 'NCT02101853'), ({'text': 'Women of childbearing potential is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months', 'entities': [['1', '6', 'gender'], ['72', '77', 'gender'], ['102', '114', 'treatment'], ['156', '187', 'upper_bound']]}, 'NCT02400255'), ({'text': '>18 years of age', 'entities': [['2', '10', 'lower_bound'], ['14', '17', 'age']]}, 'NCT01999179'), ({'text': 'Prior therapy with a PI3K delta inhibitor', 'entities': [['1', '14', 'treatment'], ['22', '42', 'treatment']]}, 'NCT02793583'), ({'text': 'Known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug formulations', 'entities': [['18', '32', 'allergy_name'], ['36', '47', 'allergy_name']]}, 'NCT03086369'), ({'text': 'Have an active infection at time of randomization', 'entities': [['9', '25', 'chronic_disease']]}, 'NCT01773707'), ({'text': 'Clinical diagnosis of T1DM and using insulin for at least 1 year', 'entities': [['23', '27', 'chronic_disease'], ['38', '45', 'treatment'], ['59', '65', 'lower_bound']]}, 'NCT02527265'), ({'text': 'pregnant women between 220/7 to 316/7 weeks gestation who present with regular uterine contractions defined as at least one contraction every 10 minutes for 30 minutes with at least one of the following:', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender'], ['24', '29', 'lower_bound'], ['33', '44', 'upper_bound'], ['45', '54', 'clinical_variable']]}, 'NCT02438371'), ({'text': 'Partial brain radiotherapy (i.e., less than or equal to 40% of total brain volume) within the last two weeks', 'entities': [['1', '27', 'treatment'], ['57', '60', 'upper_bound'], ['64', '82', 'clinical_variable'], ['95', '109', 'upper_bound']]}, 'NCT02422641'), ({'text': 'Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment', 'entities': [['72', '96', 'chronic_disease'], ['108', '134', 'chronic_disease'], ['136', '156', 'chronic_disease'], ['160', '178', 'chronic_disease'], ['186', '194', 'upper_bound'], ['207', '222', 'treatment']]}, 'NCT02048371'), ({'text': 'Body-mass index >95th percentile in ages 6-17 or >40 kg/m2 in ages 18-25', 'entities': [['1', '16', 'bmi'], ['18', '33', 'lower_bound'], ['37', '41', 'age'], ['42', '43', 'lower_bound'], ['44', '46', 'upper_bound'], ['51', '59', 'lower_bound'], ['68', '70', 'lower_bound'], ['71', '73', 'upper_bound']]}, 'NCT02494141'), ({'text': 'Vaccination with a live attenuated virus in the preceding 6 weeks', 'entities': [['1', '41', 'treatment'], ['49', '66', 'upper_bound']]}, 'NCT01757418'), ({'text': 'cystic fibrosis', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT01364467'), ({'text': 'adults greater than or equal to 18 years', 'entities': [['33', '41', 'lower_bound']]}, 'NCT00977977'), ({'text': 'Patients who have received prior radiotherapy or chemotherapy for another malignancy', 'entities': [['34', '46', 'treatment'], ['50', '62', 'treatment'], ['75', '85', 'cancer']]}, 'NCT02324439'), ({'text': 'following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method', 'entities': [['80', '83', 'treatment']]}, 'NCT02519322'), ({'text': 'CoA-Oxidase Deficiency', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02171104'), ({'text': 'Haematological malignancy associated with human immunodeficiency virus (HIV) infection or solid organ transplant or history of known Hepatitis B Antigen or positive Hepatitis C antibody (confirmed by Recombinant ImmunoBlot Assay [RIBA], if available or alternately confirmed by Hepatitis C Virus [HCV] Ribonucleic acid [RNA])', 'entities': [['16', '26', 'cancer'], ['43', '87', 'chronic_disease'], ['91', '113', 'treatment'], ['134', '153', 'treatment'], ['166', '186', 'treatment'], ['201', '236', 'treatment'], ['279', '302', 'chronic_disease'], ['303', '325', 'treatment']]}, 'NCT01943851'), ({'text': "significant blood donation (investigator's judgement) within four weeks prior to first administration of study medication or planned during the trial", 'entities': [['62', '78', 'upper_bound']]}, 'NCT03165227'), ({'text': 'acute decompensated HF', 'entities': [['21', '23', 'chronic_disease']]}, 'NCT02589977'), ({'text': 'Subject is a pregnant female', 'entities': [['14', '22', 'pregnancy'], ['23', '29', 'gender']]}, 'NCT02365467'), ({'text': 'Definitive clinical or radiographic evidence of distant metastasis or adenopathy below the clavicles', 'entities': [['49', '67', 'cancer'], ['71', '81', 'chronic_disease']]}, 'NCT02567422'), ({'text': 'Availability of a HLA matched sibling for allogeneic transplantation', 'entities': [['43', '69', 'treatment']]}, 'NCT01512888'), ({'text': 'Curatively treated non-melanoma skin malignancy, cervical cancer in situ, or prostatic intraepithelial neoplasia without evidence of prostate cancer', 'entities': [['20', '48', 'cancer'], ['50', '73', 'cancer'], ['78', '113', 'cancer'], ['134', '149', 'cancer']]}, 'NCT02172651'), ({'text': 'Chronic corticosteroid dependence', 'entities': [['9', '23', 'treatment']]}, 'NCT02271711'), ({'text': 'Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['90', '106', 'chronic_disease'], ['111', '130', 'chronic_disease']]}, 'NCT02073097'), ({'text': 'Prior biologic therapies (=< 1 cycle of prior decitabine or azacitidine), targeted therapies, or single agent chemotherapy is allowed', 'entities': [['1', '25', 'treatment'], ['30', '37', 'upper_bound'], ['41', '57', 'treatment'], ['61', '72', 'treatment'], ['75', '93', 'treatment'], ['98', '123', 'treatment']]}, 'NCT02131597'), ({'text': 'Presence of CNS metastases', 'entities': [['13', '27', 'cancer']]}, 'NCT00412594'), ({'text': 'Patients must be candidates for neoadjuvant paclitaxel chemotherapy by their treating oncologist', 'entities': [['33', '68', 'treatment']]}, 'NCT03096418'), ({'text': 'e6 months after transplantation', 'entities': [['2', '16', 'lower_bound'], ['17', '32', 'treatment']]}, 'NCT02327403'), ({'text': 'Age of >= 18 years', 'entities': [['1', '4', 'age'], ['11', '19', 'lower_bound']]}, 'NCT02452697'), ({'text': 'Patients with uncontrolled brain metastases', 'entities': [['28', '44', 'cancer']]}, 'NCT01928576'), ({'text': 'claustrophobia', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT01653093'), ({'text': 'incomplete spinal cord injury', 'entities': [['12', '30', 'chronic_disease']]}, 'NCT01961557'), ({'text': 'Diagnosis of unknown primary squamous cell carcinoma of the head and neck', 'entities': [['22', '74', 'cancer']]}, 'NCT02573493'), ({'text': 'have a diagnosis of head/neck cance', 'entities': [['21', '36', 'cancer']]}, 'NCT02589938'), ({'text': 'Intraventricular hemorrhage (IVH) e grade 3', 'entities': [['1', '34', 'clinical_variable'], ['37', '44', 'lower_bound']]}, 'NCT02214589'), ({'text': 'Patients anticipated to receive metronidazole after enrollment', 'entities': [['33', '46', 'treatment']]}, 'NCT02692651'), ({'text': 'Paralysis resulting from neurological disorder such as low cervical/thoracic spinal cord injuries (C6-T12', 'entities': [['1', '10', 'chronic_disease'], ['26', '47', 'chronic_disease'], ['60', '68', 'chronic_disease'], ['69', '98', 'chronic_disease']]}, 'NCT01923662'), ({'text': 'Non-diabetic or with Type 2 Diabetes Mellitus', 'entities': [['22', '46', 'chronic_disease']]}, 'NCT03118050'), ({'text': 'Abnormal sodium or potassium concentrations (confirmed on repeat); bicarbonate concentrations <20 or >30 (confirmed on repeat)', 'entities': [['68', '94', 'clinical_variable'], ['96', '98', 'upper_bound'], ['103', '105', 'lower_bound']]}, 'NCT00594217'), ({'text': 'Multiple myeloma', 'entities': [['1', '17', 'cancer']]}, 'NCT02338232'), ({'text': '=< 2 prior cytotoxic chemotherapy regimen', 'entities': [['4', '5', 'upper_bound'], ['6', '42', 'treatment']]}, 'NCT02535312'), ({'text': 'Absent C-peptide (< 0.3 ng/mL)', 'entities': [['8', '17', 'clinical_variable'], ['21', '30', 'upper_bound']]}, 'NCT01474889'), ({'text': 'History of stroke or transient ischemic attack within 6 months prior to registration', 'entities': [['12', '18', 'chronic_disease'], ['22', '47', 'chronic_disease'], ['55', '69', 'upper_bound']]}, 'NCT02498613'), ({'text': 'white blood cell (WBC)count >= 3,000/mm3', 'entities': [['1', '28', 'clinical_variable'], ['32', '41', 'lower_bound']]}, 'NCT01562626'), ({'text': 'Complex neck pain (e.g. cervical radiculopathy or recent whiplash injury)', 'entities': [['25', '47', 'chronic_disease']]}, 'NCT03100539'), ({'text': 'depressed left ventricular ejection fraction (LVEF; previously documented LVEF < 50% without documentation of recovery)', 'entities': [['11', '45', 'clinical_variable'], ['47', '51', 'clinical_variable'], ['82', '85', 'upper_bound']]}, 'NCT03072238'), ({'text': 'Prothrombin time (PT) or international normalized ratio (INR), and partial thromboplastin time (PTT) =< 1.5 x upper limit of normal unless subject is receiving anticoagulants', 'entities': [['1', '22', 'clinical_variable'], ['26', '62', 'clinical_variable'], ['68', '101', 'clinical_variable'], ['105', '132', 'upper_bound'], ['161', '175', 'treatment']]}, 'NCT02524275'), ({'text': 'Patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded, unless the malignancy has been in documented remission without treatment for e 3 years prior to enrollment', 'entities': [['17', '27', 'cancer'], ['55', '62', 'treatment'], ['176', '185', 'treatment'], ['192', '205', 'lower_bound']]}, 'NCT02734771'), ({'text': 'Serious co-morbid medical conditions, including clinically-significant cardiac disease', 'entities': [['19', '37', 'chronic_disease']]}, 'NCT02278250'), ({'text': 'AHI below 15', 'entities': [['1', '4', 'clinical_variable'], ['11', '13', 'upper_bound']]}, 'NCT02816255'), ({'text': 'antifungal agents and some antibiotics', 'entities': [['1', '18', 'treatment'], ['28', '39', 'treatment']]}, 'NCT02925923'), ({'text': 'multiple sclerosis', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02329652'), ({'text': 'Has a histologically or cytologically documented advanced solid tumor or lymphoma that has relapsed from or is refractory to standard treatment', 'entities': [['59', '70', 'cancer'], ['74', '82', 'cancer'], ['126', '144', 'treatment']]}, 'NCT01877382'), ({'text': 'Uncontrolled diabetes mellitus', 'entities': [['1', '31', 'chronic_disease']]}, 'NCT02405078'), ({'text': 'Sensory deficits at site of QST, such as peripheral neuropathy', 'entities': [['29', '32', 'clinical_variable'], ['42', '63', 'chronic_disease']]}, 'NCT01681264'), ({'text': 'fasting glucose greater than126 mg/dL', 'entities': [['1', '16', 'clinical_variable'], ['29', '38', 'lower_bound']]}, 'NCT01851694'), ({'text': 'Renal dysfunction (GFR less than 60 mL/min)', 'entities': [['1', '18', 'chronic_disease'], ['20', '23', 'clinical_variable'], ['34', '43', 'upper_bound']]}, 'NCT01842399'), ({'text': 'received blood product transfusions within 90 days prior to screening', 'entities': [['10', '36', 'treatment'], ['44', '57', 'upper_bound']]}, 'NCT02829268'), ({'text': 'alopecia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02309892'), ({'text': 'Pleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea)', 'entities': [['1', '17', 'chronic_disease'], ['21', '28', 'chronic_disease'], ['68', '75', 'lower_bound'], ['76', '83', 'clinical_variable']]}, 'NCT02048722'), ({'text': "For patients with Gilbert's syndrome or suspected mild veno-occlusive disease, bilirubin d 3 x ULN is permitted", 'entities': [['19', '37', 'chronic_disease'], ['41', '78', 'chronic_disease'], ['80', '89', 'clinical_variable'], ['92', '99', 'upper_bound']]}, 'NCT03159702'), ({'text': 'Any MPM histology (epithelial, mixed, sarcomatoid)', 'entities': [['5', '8', 'cancer'], ['20', '30', 'cancer'], ['39', '50', 'cancer']]}, 'NCT02592551'), ({'text': 'Tumor located in the brainstem', 'entities': [['1', '6', 'cancer']]}, 'NCT01891318'), ({'text': 'The scars must be deemed stable for a period of 3 months or have a suitable contralateral control before initiation of treatment. This will be determined by objective measurements of scar erythema, pliability, induration, thickness at enrollment and again at 3 months', 'entities': [['49', '57', 'upper_bound'], ['184', '197', 'chronic_disease']]}, 'NCT01910818'), ({'text': 'English-speaking (The SHUTiTM program is only available in English)', 'entities': [['1', '17', 'language_fluency']]}, 'NCT03151083'), ({'text': 'Ongoing treatment with calcium-channel blockers', 'entities': [['9', '18', 'treatment'], ['24', '48', 'treatment']]}, 'NCT01326715'), ({'text': 'No patients with recurrence of lung cancer after prior resection', 'entities': [['32', '43', 'cancer'], ['50', '65', 'treatment']]}, 'NCT02194738'), ({'text': 'clinically significant EKG abnormalities, or serious general medical illness', 'entities': [['24', '27', 'clinical_variable']]}, 'NCT02149823'), ({'text': 'Newly diagnosed, drug naïve, hyperfiltering and normofiltration patients with type 2 diabetes mellitus (T2DM)', 'entities': [['79', '110', 'chronic_disease']]}, 'NCT02911792'), ({'text': 'have no previous history of psychosis or substance dependence or abuse within the six months prior to Screening', 'entities': [['29', '38', 'chronic_disease'], ['83', '99', 'upper_bound']]}, 'NCT02640950'), ({'text': 'Use within 30 days prior to the Baseline Visit', 'entities': [['12', '25', 'upper_bound']]}, 'NCT02527421'), ({'text': 'Patients enrolling in the triple negative breast cancer (ER-/PR-/Her2-) group, Cohort 3, must have a negative family history of HBOC syndrome, or negative gBRCA1/2m test', 'entities': [['27', '56', 'cancer'], ['58', '60', 'clinical_variable'], ['62', '64', 'clinical_variable'], ['66', '70', 'clinical_variable'], ['129', '133', 'cancer'], ['156', '165', 'treatment']]}, 'NCT02203513'), ({'text': 'Since KRAS mutation is present in more than 90% of pancreatic cancer with 98% of the mutation found at codon 12, we expect majority of patients with pancreatic ductal adenocarcinoma', 'entities': [['45', '48', 'lower_bound'], ['52', '69', 'cancer'], ['75', '78', 'upper_bound'], ['150', '182', 'cancer']]}, 'NCT02942095'), ({'text': 'Subject has chronic systemic pain syndrome (e.g. fibromyalgia, painful bladder syndrome)', 'entities': [['13', '43', 'chronic_disease'], ['50', '62', 'chronic_disease'], ['64', '88', 'chronic_disease']]}, 'NCT02021279'), ({'text': 'Patient has previously received partial or total knee arthroplasty for the ipsilateral knee', 'entities': [['13', '92', 'treatment']]}, 'NCT02255383'), ({'text': 'Bone marrow with tumor cells seen on routine morphology (not by NSE staining only) of bilateral aspirate and/or biopsy on one bone marrow sample', 'entities': [['18', '23', 'cancer'], ['87', '105', 'treatment'], ['113', '119', 'treatment']]}, 'NCT02495415'), ({'text': 'Low risk AML in complete remission 1, will not be candidates for this study', 'entities': [['10', '13', 'cancer']]}, 'NCT02124174'), ({'text': 'Blood pressure >200/120 mm Hg', 'entities': [['1', '15', 'clinical_variable'], ['17', '30', 'lower_bound']]}, 'NCT02317523'), ({'text': 'those who are actively psychotic', 'entities': [['24', '33', 'chronic_disease']]}, 'NCT02305537'), ({'text': 'Diabetes or use of anti-diabetic medications', 'entities': [['1', '9', 'chronic_disease'], ['20', '45', 'treatment']]}, 'NCT03070184'), ({'text': 'Placement in a restricted setting (e.g. detox or residential treatment) for e 2 weeks out of past 28 days prior to screening visit, or placement in a restricted setting at anytime during study participation', 'entities': [['41', '46', 'treatment'], ['50', '71', 'treatment'], ['79', '86', 'lower_bound'], ['99', '112', 'upper_bound']]}, 'NCT02845453'), ({'text': 'History of a seizure disorder or requirement for anti-seizure medication', 'entities': [['14', '21', 'chronic_disease'], ['50', '73', 'treatment']]}, 'NCT02561988'), ({'text': '<1000 microns as determined by angiography', 'entities': [['2', '14', 'upper_bound']]}, 'NCT02988895'), ({'text': 'Hiatal hernia larger than 2cm', 'entities': [['1', '14', 'chronic_disease'], ['27', '30', 'lower_bound']]}, 'NCT01942018'), ({'text': 'History of any solid organ or bone marrow transplant', 'entities': [['16', '27', 'treatment'], ['31', '53', 'treatment']]}, 'NCT02903446'), ({'text': 'GFR <60 mg/g regardless of proteinuria', 'entities': [['1', '4', 'clinical_variable'], ['6', '13', 'upper_bound']]}, 'NCT02169089'), ({'text': 'malignancy within 3 years of study enrollment', 'entities': [['1', '11', 'treatment'], ['19', '26', 'upper_bound']]}, 'NCT02393794'), ({'text': 'Patient has body habitus or other medical condition which prevents adequate delineation of the aorta', 'entities': [['13', '25', 'chronic_disease']]}, 'NCT02489539'), ({'text': 'MSKCC patients without a histologic diagnosis of cancer of the breast, bladder, kidney, colon, testicles, lungs, prostate, or lymphoid malignancy (including all types of lymphoma) will not be eligible for the AMDeC sponsored component of the study', 'entities': [['50', '70', 'cancer'], ['72', '79', 'cancer'], ['81', '87', 'cancer'], ['89', '94', 'cancer'], ['96', '105', 'cancer'], ['107', '112', 'cancer'], ['114', '122', 'cancer'], ['127', '146', 'cancer'], ['171', '179', 'cancer']]}, 'NCT00579514'), ({'text': 'In stratum 1, patients must have failed one prior systemic chemotherapy regimen. In stratum 2, RDD patients must have failed treatment with corticosteroid. ECD patients who have confirmed BRAF V600E mutation must have failed treatment with a BRAF inhibitor or are not considered to be eligible for such treatment', 'entities': [['45', '80', 'treatment'], ['96', '99', 'chronic_disease'], ['126', '135', 'treatment'], ['141', '155', 'treatment'], ['157', '160', 'chronic_disease'], ['226', '257', 'treatment']]}, 'NCT02425904'), ({'text': 'e Grade 2 hypoalbuminemia (< 3.0 g/dL)', 'entities': [['3', '10', 'lower_bound'], ['11', '26', 'clinical_variable'], ['30', '38', 'upper_bound']]}, 'NCT02561988'), ({'text': 'Positive for human immunodeficiency virus (HIV) or hepatitis B or C', 'entities': [['14', '48', 'chronic_disease'], ['52', '68', 'chronic_disease']]}, 'NCT02600897'), ({'text': 'female at least 18 years of age', 'entities': [['1', '7', 'gender'], ['17', '25', 'lower_bound'], ['29', '32', 'age']]}, 'NCT02797795'), ({'text': "Central nervous system abnormalities (e.g., cerebral aneurysm), seizures (convulsions, epilepsy), Tourette's syndrome or presence of motor tics, or abnormal electroencephalograms", 'entities': [['1', '37', 'chronic_disease'], ['45', '62', 'chronic_disease'], ['65', '73', 'chronic_disease'], ['88', '96', 'chronic_disease'], ['99', '118', 'chronic_disease'], ['134', '144', 'chronic_disease'], ['158', '179', 'treatment']]}, 'NCT02346201'), ({'text': 'Currently breast feeding, pregnant or planning to conceive or father Children from screening through 120 Days after last dose of study drug', 'entities': [['27', '35', 'pregnancy'], ['39', '59', 'pregnancy'], ['102', '116', 'upper_bound'], ['130', '140', 'treatment']]}, 'NCT02587962'), ({'text': 'Spinal column fracture with epidural hematoma', 'entities': [['1', '23', 'chronic_disease'], ['29', '46', 'chronic_disease']]}, 'NCT02901067'), ({'text': '18 years of age', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT02041936'), ({'text': 'with known or suspected CHD with inconclusive echocardiographic exams', 'entities': [['25', '28', 'chronic_disease']]}, 'NCT02752191'), ({'text': 'Undergo elective Urologic surgery requiring post-operative inpatient stay', 'entities': [['9', '34', 'treatment']]}, 'NCT02771431'), ({'text': 'High-grade glioma has recurred or progressed after prior treatment with brain radiation and temozolomide', 'entities': [['1', '18', 'chronic_disease'], ['52', '67', 'treatment'], ['73', '88', 'treatment'], ['93', '105', 'treatment']]}, 'NCT02192359'), ({'text': 'Prior anticoagulant therapy use is allowed provided therapy is discontinued at least 7 days prior to the breast biopsy in order to reduce the risk of bleeding', 'entities': [['1', '28', 'treatment'], ['21', '28', 'treatment'], ['86', '98', 'lower_bound'], ['93', '119', 'treatment']]}, 'NCT02068092'), ({'text': 'Monoclonal antibodies =< 14 days', 'entities': [['1', '22', 'clinical_variable'], ['26', '33', 'upper_bound']]}, 'NCT02860000'), ({'text': 'Non-Ductal Pathology: Lobular or Colloid type presence', 'entities': [['1', '11', 'cancer']]}, 'NCT02540330'), ({'text': 'Be 18 years of age or older at time of enrollment', 'entities': [['4', '12', 'lower_bound'], ['16', '19', 'age']]}, 'NCT02341209'), ({'text': 'subjects of child-bearing potential will have a urine pregnancy test performed the day of surgery', 'entities': [['55', '64', 'pregnancy'], ['91', '98', 'treatment']]}, 'NCT02755116'), ({'text': 'Other medical or psychiatric disorder placing the subject at undue risk for treatment complications', 'entities': [['7', '14', 'chronic_disease'], ['18', '38', 'chronic_disease'], ['77', '86', 'treatment']]}, 'NCT02393794'), ({'text': 'Medical contraindication to MRI', 'entities': [['29', '32', 'treatment']]}, 'NCT02169739'), ({'text': 'Active central nervous system (CNS) disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma; a lumbar puncture demonstrating DLBCL at the time of registration to this study is not exclusion for study enrollment', 'entities': [['8', '44', 'chronic_disease'], ['68', '86', 'chronic_disease'], ['100', '120', 'chronic_disease'], ['154', '159', 'cancer']]}, 'NCT01959698'), ({'text': 'active cancer other than non-melanoma skin or low-risk prostate cancer', 'entities': [['8', '14', 'cancer'], ['26', '71', 'cancer']]}, 'NCT03170375'), ({'text': 'Subjects with primary liver cancer or hepatic metastasis', 'entities': [['23', '35', 'cancer'], ['39', '57', 'cancer']]}, 'NCT02266745'), ({'text': 'Female patients who are nursing or have a positive pregnancy test during screening', 'entities': [['1', '16', 'gender'], ['43', '61', 'pregnancy']]}, 'NCT02481310'), ({'text': 'Patients must undergo peripheral blood stem cell collection or marrow harvest while in remission and must not be expected to have better outcomes with allogeneic transplantation', 'entities': [['23', '60', 'treatment'], ['64', '78', 'treatment'], ['152', '178', 'treatment']]}, 'NCT00630565'), ({'text': 'Radiation therapy to head and neck (excluding eyes), and internal organs of chest, abdomen or pelvis in the month prior to enrollment', 'entities': [['1', '18', 'treatment']]}, 'NCT02512497'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02930018'), ({'text': 'Shoulder pseudoparalysis due to chronic rotator cuff dysfunction with or without glenohumeral arthritis', 'entities': [['1', '25', 'chronic_disease'], ['33', '65', 'chronic_disease'], ['82', '104', 'chronic_disease']]}, 'NCT01697865'), ({'text': "Certified or Master's level social worker, a nurse with an RN and at least two years' experience working with older adults and their family members evaluated on an individual basis by the PIs)", 'entities': [['76', '85', 'lower_bound']]}, 'NCT02347202'), ({'text': 'patient had symptoms of numbness or tingling for at least 4 weeks in at least two digits on one hand that include thumb, index, long or radial border of ring finger', 'entities': [['59', '66', 'lower_bound'], ['79', '82', 'lower_bound']]}, 'NCT02219555'), ({'text': 'Recent esophageal, gastric or bowel surgery (within 3 weeks of study enrollment)', 'entities': [['1', '44', 'treatment'], ['53', '60', 'upper_bound']]}, 'NCT02464696'), ({'text': 'Have clinical symptomatic congestive heart failure defined at >= Class II of the New York Heart Association functional classification system or LVEF < 50% at baseline', 'entities': [['27', '51', 'chronic_disease'], ['82', '134', 'clinical_variable'], ['145', '149', 'clinical_variable'], ['152', '155', 'upper_bound']]}, 'NCT01954316'), ({'text': 'Patients e18 years old scheduled for elective thoracic surgery', 'entities': [['11', '19', 'lower_bound'], ['38', '63', 'treatment']]}, 'NCT02750319'), ({'text': 'History (within the last 3 months) or presence of stroke/cerebrovascular accident', 'entities': [['21', '34', 'upper_bound'], ['51', '57', 'chronic_disease'], ['58', '82', 'chronic_disease']]}, 'NCT01582191'), ({'text': 'There are no limits on prior lines of therapy; however, patients must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study (except alopecia)', 'entities': [['39', '46', 'treatment'], ['161', '185', 'treatment'], ['216', '224', 'chronic_disease']]}, 'NCT02503709'), ({'text': 'Diabetic subjects must have a BMI greater than or equal to 30', 'entities': [['31', '34', 'bmi'], ['60', '62', 'lower_bound']]}, 'NCT00065676'), ({'text': 'Radiographically compromised vertebral bodies at any lumbar level(s) caused by current or past trauma or tumor', 'entities': [['96', '102', 'chronic_disease'], ['106', '111', 'cancer']]}, 'NCT02555280'), ({'text': 'INR d1.7 (for patients with hepatocellular carcinoma only)', 'entities': [['1', '4', 'clinical_variable'], ['6', '9', 'upper_bound'], ['29', '53', 'cancer']]}, 'NCT02932956'), ({'text': 'Diffusing capacity of the lung for carbon monoxide (DLCO) >= 50%', 'entities': [['1', '58', 'clinical_variable'], ['62', '65', 'lower_bound']]}, 'NCT01701986'), ({'text': 'History of hearing loss', 'entities': [['12', '24', 'chronic_disease']]}, 'NCT02819440'), ({'text': 'Repeated (2 or more over a 1-week period) fasting self-monitoring of blood glucose (SMBG) measurements >270 milligram/deciliter (mg/dL) (>15 millimole/liter [mmol/L]) during the pretreatment phase, despite reinforcement of diet and exercise counseling', 'entities': [['11', '12', 'lower_bound'], ['51', '103', 'clinical_variable'], ['105', '136', 'lower_bound'], ['139', '166', 'lower_bound']]}, 'NCT03170518'), ({'text': 'Abnormal prolactin (mild elevations may be seen in PCOS, and elevations < 1.5 times the upper limit of normal will be accepted in this group) (confirmed on repeat)', 'entities': [['10', '19', 'clinical_variable'], ['52', '56', 'chronic_disease'], ['75', '110', 'upper_bound']]}, 'NCT00594217'), ({'text': 'Due to undergo elective major amputation of the lower extremity (above the knee amputation (AKA), below the knee amputation (BKA), total knee amputation (TKA), transmetatarsal amputation (TMA), toe amputation) from all causes', 'entities': [['25', '64', 'treatment'], ['66', '97', 'treatment'], ['99', '130', 'treatment'], ['132', '159', 'treatment'], ['161', '193', 'treatment'], ['195', '209', 'treatment']]}, 'NCT02341963'), ({'text': 'A history of allergy to progesterone or estradiol will constitute grounds', 'entities': [['25', '37', 'allergy_name'], ['41', '50', 'allergy_name']]}, 'NCT00594217'), ({'text': 'Psychiatric disorder impeding competence or compliance', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02262806'), ({'text': 'Duration of SCI e1 year', 'entities': [['13', '16', 'clinical_variable'], ['18', '24', 'lower_bound']]}, 'NCT02379156'), ({'text': 'carcinoma in situ of the cervix', 'entities': [['1', '32', 'cancer']]}, 'NCT02585973'), ({'text': 'approximately >2x/week of moderate (or greater) exercise', 'entities': [['16', '23', 'lower_bound']]}, 'NCT02663934'), ({'text': 'Inability to comply with treatment and follow-up schedule', 'entities': [['26', '35', 'treatment']]}, 'NCT02287337'), ({'text': 'History of interstitial lung disease or pneumonitis', 'entities': [['12', '37', 'chronic_disease'], ['41', '52', 'chronic_disease']]}, 'NCT02910700'), ({'text': 'Patients with a known allergy to acetaminophen', 'entities': [['34', '47', 'allergy_name']]}, 'NCT02994940'), ({'text': 'NYHA Grade III or greater congestive heart failure', 'entities': [['1', '5', 'clinical_variable'], ['6', '15', 'lower_bound'], ['27', '51', 'chronic_disease']]}, 'NCT02383927'), ({'text': 'History of angioedema while taking an ACE inhibitor', 'entities': [['12', '22', 'chronic_disease'], ['39', '52', 'treatment']]}, 'NCT02130687'), ({'text': 'Decrease in episodes of pancreatitis', 'entities': [['25', '37', 'chronic_disease']]}, 'NCT02262806'), ({'text': 'Clinically significant hearing impairment, as judged by the Principal Investigator', 'entities': [['24', '42', 'chronic_disease']]}, 'NCT02266745'), ({'text': 'Between 18 and 35 years of age', 'entities': [['9', '11', 'lower_bound'], ['16', '24', 'upper_bound'], ['28', '31', 'age']]}, 'NCT01973270'), ({'text': 'Prior treatment with a PARP inhibitor', 'entities': [['1', '38', 'treatment']]}, 'NCT02401347'), ({'text': 'L-transposition of the great arteries', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT01379573'), ({'text': '18 years of age or older', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT02153229'), ({'text': 'the patients enrolled to the immunotherapy naïve group of the phase IB dose expansion', 'entities': [['30', '43', 'treatment']]}, 'NCT02403193'), ({'text': 'Have a spinal cord injury that is ASIA Impairment Scale (AIS) grade of A, B or C', 'entities': [['8', '26', 'chronic_disease']]}, 'NCT02307565'), ({'text': 'Serum creatinine >1.7mg/dL', 'entities': [['1', '17', 'clinical_variable'], ['19', '27', 'lower_bound']]}, 'NCT02167009'), ({'text': 'Hemoglobin >= 9 g/dL (or >= 5.6 mmol/L)', 'entities': [['1', '11', 'clinical_variable'], ['15', '21', 'lower_bound'], ['29', '39', 'lower_bound']]}, 'NCT02286687'), ({'text': 'Inflammatory bowel disease', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT02778867'), ({'text': 'Patient with active CNS disease', 'entities': [['21', '32', 'chronic_disease']]}, 'NCT02512497'), ({'text': 'men treated or enrolled on this protocol must have either had a prior vasectomy or agree to use effective contraception prior to the study, during the study, and for 3 months after the last dose of the drug; males should avoid fathering children during and for at least three months after therapy is completed', 'entities': [['1', '4', 'gender'], ['65', '80', 'treatment'], ['84', '120', 'contraception_consent'], ['167', '181', 'upper_bound'], ['209', '214', 'gender'], ['271', '289', 'lower_bound'], ['290', '297', 'treatment']]}, 'NCT02520791'), ({'text': 'treatment with MAO inhibitors within the last 14 days', 'entities': [['1', '10', 'treatment'], ['16', '30', 'treatment'], ['42', '54', 'upper_bound']]}, 'NCT01627301'), ({'text': 'Subjects with active herpes simplex or herpes zoster', 'entities': [['22', '36', 'chronic_disease'], ['40', '53', 'chronic_disease']]}, 'NCT02281409'), ({'text': 'Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation and behavior in past year', 'entities': [['1', '48', 'clinical_variable'], ['53', '70', 'chronic_disease']]}, 'NCT02101554'), ({'text': 'History of positivity for human immunodeficiency virus', 'entities': [['27', '55', 'chronic_disease']]}, 'NCT02923921'), ({'text': 'Subject has uncontrolled metastases to the central nervous system (CNS)', 'entities': [['26', '36', 'cancer']]}, 'NCT01946074'), ({'text': 'Prior use of regorafenib', 'entities': [['14', '25', 'treatment']]}, 'NCT02048722'), ({'text': 'Congenital long QT syndrome or family history of long QT syndrome', 'entities': [['1', '28', 'chronic_disease'], ['12', '28', 'chronic_disease']]}, 'NCT02520778'), ({'text': 'symptomatic congestive heart failure', 'entities': [['13', '37', 'chronic_disease']]}, 'NCT02583893'), ({'text': 'Children less than 12 years of age (marrow) or less than 18 years of age (PBSC)', 'entities': [['20', '28', 'upper_bound'], ['32', '35', 'age'], ['58', '66', 'upper_bound'], ['75', '79', 'treatment']]}, 'NCT02100891'), ({'text': 'Osteosarcoma with metastatic disease beyond the lungs', 'entities': [['1', '13', 'cancer']]}, 'NCT01804634'), ({'text': 'Participants with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)', 'entities': [['19', '49', 'cancer'], ['53', '90', 'cancer']]}, 'NCT02834780'), ({'text': 'incapacitating cardiac and/or pulmonary disorders', 'entities': [['1', '23', 'chronic_disease'], ['31', '50', 'chronic_disease']]}, 'NCT02836574'), ({'text': 'No prior history of caffeine sensitivity or allergy', 'entities': [['21', '29', 'allergy_name']]}, 'NCT01940822'), ({'text': 'Conjugated bilirubin greater than 2 mg/dL', 'entities': [['1', '21', 'clinical_variable'], ['35', '42', 'lower_bound']]}, 'NCT00738101'), ({'text': 'Uncontrolled hypertension (systolic blood pressure; [SBP] greater than 180 or diastolic blood pressure; [DBP] greater than 110)', 'entities': [['14', '26', 'chronic_disease'], ['28', '58', 'clinical_variable'], ['72', '75', 'lower_bound'], ['79', '110', 'clinical_variable'], ['124', '127', 'lower_bound']]}, 'NCT02271919'), ({'text': 'Prior monoclonal antibody, within 4 weeks prior to first dose of study drug', 'entities': [['1', '26', 'treatment'], ['35', '48', 'upper_bound'], ['66', '76', 'treatment']]}, 'NCT02587962'), ({'text': "Patients with any other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with the patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results, will not be eligible", 'entities': [['25', '42', 'chronic_disease'], ['54', '68', 'treatment']]}, 'NCT02037048'), ({'text': 'FEV1 <50%', 'entities': [['1', '5', 'clinical_variable'], ['7', '10', 'upper_bound']]}, 'NCT02950337'), ({'text': 'The child is being treated for cancer and returning to the medical center (CCHMC or OUHSC)', 'entities': [['32', '38', 'cancer']]}, 'NCT02505165'), ({'text': 'subjects with HL with no available curative treatment options (such as autologous SCT)', 'entities': [['15', '17', 'chronic_disease'], ['36', '54', 'treatment'], ['72', '86', 'treatment']]}, 'NCT02624258'), ({'text': 'must have a negative pregnancy test within 14 days of study entry', 'entities': [['13', '31', 'pregnancy'], ['44', '51', 'upper_bound']]}, 'NCT02781792'), ({'text': 'Age >= 16 years: 1.7 for males and 1.4 for females', 'entities': [['1', '4', 'age'], ['8', '16', 'lower_bound'], ['26', '31', 'gender'], ['44', '51', 'gender']]}, 'NCT02304458'), ({'text': 'Lichen planus', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT00788164'), ({'text': 'Prior autologous or allogeneic organ or tissue transplantation', 'entities': [['1', '17', 'treatment'], ['21', '37', 'treatment'], ['41', '63', 'treatment']]}, 'NCT02581215'), ({'text': 'patients undergoing reduced intensity conditioning, only those regimens in which the expected neutropenia is e 7 days are permitted and the patient must reside in the hospital', 'entities': [['21', '51', 'treatment'], ['95', '106', 'clinical_variable'], ['112', '118', 'lower_bound']]}, 'NCT03016130'), ({'text': 'Type 1 or Type 2 diabetes mellitus requiring insulin at study entry', 'entities': [['1', '35', 'chronic_disease'], ['46', '53', 'treatment']]}, 'NCT03072238'), ({'text': 'Blockage of the urinary tract', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02849639'), ({'text': 'Moderate response (Grade 2, 10-50% residual tumor)', 'entities': [['29', '31', 'lower_bound'], ['32', '35', 'upper_bound'], ['36', '50', 'clinical_variable']]}, 'NCT02639065'), ({'text': 'Persistent minimal residual disease after transplantation must be demonstrated by morphology karyotype, FISH, flow cytometry or RT-PCR', 'entities': [['20', '36', 'cancer'], ['43', '58', 'treatment'], ['83', '103', 'treatment'], ['105', '109', 'treatment'], ['111', '125', 'treatment'], ['129', '135', 'treatment']]}, 'NCT01430390'), ({'text': 'may not be on anti-coagulants (warfarin, etc.) other than low-molecular weight heparin (LMWH)', 'entities': [['15', '30', 'treatment'], ['32', '40', 'treatment'], ['80', '87', 'treatment'], ['89', '93', 'treatment']]}, 'NCT01849146'), ({'text': 'Myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities', 'entities': [['1', '22', 'chronic_disease'], ['30', '44', 'upper_bound'], ['62', '88', 'clinical_variable'], ['89', '98', 'lower_bound'], ['102', '104', 'upper_bound'], ['105', '118', 'chronic_disease'], ['120', '139', 'chronic_disease'], ['161', '184', 'chronic_disease'], ['189', '209', 'treatment'], ['228', '236', 'chronic_disease']]}, 'NCT02114229'), ({'text': 'Women possibly or known to be pregnant', 'entities': [['1', '6', 'gender'], ['19', '39', 'pregnancy']]}, 'NCT02043392'), ({'text': 'Concomitant diseases/conditions', 'entities': [['1', '32', 'chronic_disease']]}, 'NCT02533674'), ({'text': 'Treatment with radiotherapy within 2 weeks prior to the first BTCT4465A (Mosunetuzumab) administration', 'entities': [['1', '28', 'treatment'], ['36', '49', 'upper_bound'], ['63', '72', 'treatment'], ['74', '87', 'treatment']]}, 'NCT02500407'), ({'text': 'EGFR wild-type NSCLC', 'entities': [['1', '5', 'clinical_variable'], ['16', '21', 'cancer']]}, 'NCT02323126'), ({'text': 'diabetes status', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02975986'), ({'text': 'Suspected gastrointestinal perforation', 'entities': [['11', '39', 'chronic_disease']]}, 'NCT02007239'), ({'text': 'Any groin incision on index leg within 12 weeks prior to treatment initiation', 'entities': [['40', '54', 'upper_bound'], ['58', '67', 'treatment']]}, 'NCT02389023'), ({'text': 'Patient acceptance to have a tumor biopsy of an accessible lesion at 2 time points (baseline and on study)', 'entities': [['30', '35', 'cancer']]}, 'NCT03006302'), ({'text': 'patients are not considered to have a currently active malignancy if they have completed anti-cancer therapy, are considered by their physician to be at less than 30% risk of relapse and at least 2 years have lapsed', 'entities': [['56', '66', 'cancer'], ['90', '109', 'treatment'], ['164', '167', 'upper_bound'], ['197', '204', 'lower_bound']]}, 'NCT01959698'), ({'text': 'Chantix', 'entities': [['1', '8', 'treatment']]}, 'NCT02964182'), ({'text': 'patients that are pregnant', 'entities': [['15', '27', 'pregnancy']]}, 'NCT02465060'), ({'text': 'any known blood clotting disorder', 'entities': [['11', '34', 'chronic_disease']]}, 'NCT03130777'), ({'text': 'Individuals with PiMZ deficiency are not allowed in the study', 'entities': [['18', '33', 'chronic_disease']]}, 'NCT03114020'), ({'text': 'Topical corticosteroid within the past 2 weeks', 'entities': [['1', '23', 'treatment'], ['35', '47', 'upper_bound']]}, 'NCT03159936'), ({'text': 'Use of steroids or certain other immunomodulatory agents (i.e. azathioprine) in the past 2 weeks', 'entities': [['8', '16', 'treatment'], ['34', '57', 'treatment'], ['64', '76', 'treatment'], ['85', '97', 'upper_bound']]}, 'NCT02981173'), ({'text': 'females', 'entities': [['1', '8', 'gender']]}, 'NCT01983475'), ({'text': 'nursing women', 'entities': [['9', '14', 'gender']]}, 'NCT01918644'), ({'text': 'prior history of CREST for HD', 'entities': [['28', '30', 'chronic_disease']]}, 'NCT02402647'), ({'text': "Idiopathic Parkinson's Disease (UK Brain Bank Criteria)", 'entities': [['1', '31', 'chronic_disease']]}, 'NCT02838797'), ({'text': 'diagnosed with preoperative anemia', 'entities': [['29', '35', 'chronic_disease']]}, 'NCT02189889'), ({'text': 'Child must be recipient of needs based Medicaid or family income must be at or below 150% Health and Human Services (HHS) Poverty Guidelines', 'entities': [['86', '90', 'upper_bound']]}, 'NCT03074877'), ({'text': 'Patients taking immunosuppressive medications', 'entities': [['17', '46', 'treatment']]}, 'NCT02738749'), ({'text': 'Patient must not have a history of or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis', 'entities': [['60', '93', 'cancer'], ['97', '126', 'cancer']]}, 'NCT02101034'), ({'text': 'Use of real-time CGM in past 2 years', 'entities': [['25', '37', 'upper_bound']]}, 'NCT03078491'), ({'text': 'Treated or exposed to FVIII concentrates or cryoprecipitate for at least 150 exposure days', 'entities': [['23', '41', 'treatment'], ['45', '60', 'clinical_variable'], ['74', '77', 'lower_bound']]}, 'NCT03061201'), ({'text': 'grade 2 CHF 5 Patients with cirrhosis, or active viral or non-viral hepatitis', 'entities': [['29', '38', 'chronic_disease'], ['50', '78', 'chronic_disease']]}, 'NCT01925573'), ({'text': 'cardiac pacemaker', 'entities': [['1', '18', 'treatment']]}, 'NCT02473536'), ({'text': 'Have a history of allergic reaction to lidocaine (self-report, medical history)', 'entities': [['40', '49', 'allergy_name']]}, 'NCT02233868'), ({'text': 'Failure to respond to conservative measures in the form of oral medication and physical therapy', 'entities': [['60', '75', 'treatment'], ['80', '96', 'treatment']]}, 'NCT02073292'), ({'text': 'nitroglycerin', 'entities': [['1', '14', 'treatment']]}, 'NCT02964182'), ({'text': 'Morning Cortisol <5 g/dL', 'entities': [['9', '17', 'treatment'], ['19', '25', 'upper_bound']]}, 'NCT01421797'), ({'text': 'Current or recent illness', 'entities': [['19', '26', 'chronic_disease']]}, 'NCT02193373'), ({'text': "Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities", 'entities': [['17', '37', 'chronic_disease'], ['69', '71', 'chronic_disease'], ['81', '100', 'chronic_disease'], ['102', '124', 'chronic_disease'], ['126', '146', 'chronic_disease'], ['148', '177', 'chronic_disease'], ['179', '190', 'cancer'], ['192', '222', 'chronic_disease'], ['224', '240', 'chronic_disease'], ['242', '259', 'chronic_disease'], ['261', '279', 'chronic_disease'], ['371', '401', 'chronic_disease']]}, 'NCT02547818'), ({'text': 'Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule', 'entities': [['5', '18', 'chronic_disease'], ['20', '28', 'chronic_disease'], ['30', '42', 'chronic_disease'], ['47', '69', 'chronic_disease']]}, 'NCT02995330'), ({'text': 'Patients with confirmed diagnosis of peripheral T-cell lymphoma (PTCL) follicular type or angioimmunoblastic T-cell lymphoma (AITL) that is refractory to at least one line of therapy', 'entities': [['38', '71', 'cancer'], ['91', '132', 'cancer'], ['164', '167', 'lower_bound'], ['176', '183', 'treatment']]}, 'NCT02520791'), ({'text': 'Total hip arthroplasty', 'entities': [['1', '23', 'treatment']]}, 'NCT02376153'), ({'text': 'Patients must not have serious, non-healing wound, ulcer, or bone fracture', 'entities': [['33', '50', 'chronic_disease'], ['52', '57', 'chronic_disease'], ['62', '75', 'chronic_disease']]}, 'NCT02314377'), ({'text': 'Active uncontrolled infection, including known history of HIV/AIDS or hepatitis B or C', 'entities': [['8', '30', 'chronic_disease'], ['59', '62', 'chronic_disease'], ['63', '67', 'chronic_disease'], ['71', '87', 'chronic_disease']]}, 'NCT02995330'), ({'text': 'Patients with inflammatory arthritis', 'entities': [['15', '37', 'chronic_disease']]}, 'NCT02219581'), ({'text': 'Actively planning to become pregnant in the next 8 months', 'entities': [['22', '37', 'pregnancy'], ['45', '58', 'upper_bound']]}, 'NCT02593526'), ({'text': 'have progressive disease on or after platinum based chemotherapy', 'entities': [['6', '25', 'chronic_disease'], ['38', '65', 'treatment']]}, 'NCT02496663'), ({'text': 'Sufficient fluency, of both the potential participant and caregiver, in written and spoken English to participate in study visits, physical exams, and outcome assessments', 'entities': [['73', '99', 'language_fluency']]}, 'NCT02346201'), ({'text': 'active cognitive/behavioral therapy initiated within the last 3 months (continuation of established maintenance therapy that has been going on for longer than 3 months will not be grounds for exclusion)', 'entities': [['1', '36', 'treatment'], ['58', '71', 'upper_bound'], ['63', '71', 'lower_bound'], ['101', '120', 'treatment']]}, 'NCT02206945'), ({'text': 'An established diagnosis of scleroderma', 'entities': [['29', '40', 'chronic_disease']]}, 'NCT01445821'), ({'text': 'Prescription opiate use disorder', 'entities': [['14', '33', 'chronic_disease']]}, 'NCT02483468'), ({'text': 'Current use of tobacco cessation medications', 'entities': [['16', '45', 'treatment']]}, 'NCT02157610'), ({'text': 'Score e26 on the 30-item Mini Mental State Examination', 'entities': [['8', '10', 'lower_bound'], ['18', '55', 'clinical_variable']]}, 'NCT03118050'), ({'text': 'History of bipolar disorder, delirium, dementia, amnestic disorder, schizophrenia and other psychotic disorders', 'entities': [['12', '28', 'chronic_disease'], ['30', '38', 'chronic_disease'], ['40', '48', 'chronic_disease'], ['50', '67', 'chronic_disease'], ['69', '82', 'chronic_disease'], ['93', '112', 'chronic_disease']]}, 'NCT03169543'), ({'text': 'atients less than 18 years of age', 'entities': [['19', '27', 'upper_bound'], ['31', '34', 'age']]}, 'NCT02588027'), ({'text': 'Currently taking edaravone unless after completion of at least the second 14-day drug-treatment period, as long as Day 1 occurs during a drug-free period at least 24 hours after the last edaravone dose and at least 5 days prior to the first dose of the next cycle', 'entities': [['18', '27', 'treatment'], ['68', '74', 'lower_bound'], ['164', '172', 'lower_bound'], ['216', '228', 'lower_bound']]}, 'NCT02655614'), ({'text': 'Karnofsky e 60% performance status', 'entities': [['1', '10', 'clinical_variable'], ['13', '16', 'lower_bound'], ['17', '35', 'clinical_variable']]}, 'NCT02332850'), ({'text': "Major medical or psychiatric illness, which in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up", 'entities': [['7', '14', 'chronic_disease'], ['18', '37', 'chronic_disease'], ['104', '113', 'treatment']]}, 'NCT01045148'), ({'text': 'Screening plasma HIV RNA < 50 copies/ml within 3 months of entry', 'entities': [['18', '25', 'clinical_variable'], ['28', '40', 'upper_bound'], ['48', '56', 'upper_bound']]}, 'NCT02159027'), ({'text': 'History of severe hepatic impairment (Child-Pugh score of 10-15)', 'entities': [['19', '37', 'chronic_disease'], ['39', '55', 'clinical_variable'], ['59', '61', 'lower_bound'], ['62', '64', 'upper_bound']]}, 'NCT02872857'), ({'text': 'in the perioperative liver transplantation period', 'entities': [['8', '43', 'treatment']]}, 'NCT01653093'), ({'text': 'More than 3 histologically positive axillary nodes', 'entities': [['11', '12', 'lower_bound'], ['37', '51', 'cancer']]}, 'NCT01245712'), ({'text': 'alopecia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02533674'), ({'text': 'Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (e New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication', 'entities': [['39', '61', 'chronic_disease'], ['63', '96', 'chronic_disease'], ['100', '114', 'upper_bound'], ['131', '152', 'chronic_disease'], ['187', '202', 'chronic_disease'], ['204', '228', 'chronic_disease'], ['296', '314', 'chronic_disease']]}, 'NCT02912572'), ({'text': 'Patients undergoing redo-CABG', 'entities': [['21', '30', 'treatment']]}, 'NCT02053909'), ({'text': 'any history of seizure disorder', 'entities': [['16', '32', 'chronic_disease']]}, 'NCT02562430'), ({'text': 'PT/PTT within normal limits', 'entities': [['1', '7', 'clinical_variable']]}, 'NCT01624090'), ({'text': 'one dose of vincristine', 'entities': [['13', '24', 'treatment']]}, 'NCT02553460'), ({'text': 'DONOR: Unrelated Umbilical Cord Blood: Any cord blood units with < 1.5 x 10^7 total nucleated cells per kilogram recipient weight', 'entities': [['18', '38', 'clinical_variable'], ['44', '60', 'clinical_variable'], ['68', '113', 'upper_bound'], ['124', '130', 'clinical_variable']]}, 'NCT00919503'), ({'text': 'Women are asked to avoid pregnancy until completion of Condition', 'entities': [['1', '6', 'gender'], ['26', '35', 'pregnancy']]}, 'NCT02258438'), ({'text': 'Patient has systolic EF<20% as assessed by echocardiography', 'entities': [['13', '24', 'clinical_variable'], ['25', '28', 'upper_bound'], ['44', '60', 'treatment']]}, 'NCT02088554'), ({'text': 'marginal zone lymphoma (MZL)', 'entities': [['1', '29', 'cancer']]}, 'NCT02594384'), ({'text': 'must not have less than 50% donor chimerism in either peripheral blood or bone marrow', 'entities': [['25', '28', 'upper_bound']]}, 'NCT01956084'), ({'text': 'History of grade 3-4 immediate hypersensitivity reaction to paclitaxel', 'entities': [['12', '19', 'lower_bound'], ['20', '21', 'upper_bound'], ['32', '48', 'chronic_disease'], ['61', '71', 'allergy_name']]}, 'NCT02474173'), ({'text': 'Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis', 'entities': [['35', '46', 'chronic_disease'], ['61', '69', 'treatment']]}, 'NCT02411656'), ({'text': 'COPD subjects', 'entities': [['1', '5', 'chronic_disease']]}, 'NCT02726347'), ({'text': 'Have a smartphone', 'entities': [['1', '18', 'technology_access']]}, 'NCT03087123'), ({'text': 'Any patient known to have an LVEF less than or equal to 45%', 'entities': [['30', '34', 'clinical_variable'], ['57', '60', 'upper_bound']]}, 'NCT01993719'), ({'text': 'PSA > 20 ng/ml', 'entities': [['1', '4', 'clinical_variable'], ['7', '15', 'lower_bound']]}, 'NCT01045148'), ({'text': 'severe systemic hypertension (e 220/120 mmHg)', 'entities': [['8', '29', 'clinical_variable'], ['33', '45', 'lower_bound']]}, 'NCT01568177'), ({'text': 'Abnormal bone marrow function [absolute neutrophil count (ANC)<1500/mm3, platelet count <100,000/mm3, hemoglobin <9 g/dL]', 'entities': [['32', '63', 'clinical_variable'], ['64', '72', 'upper_bound'], ['74', '88', 'clinical_variable'], ['90', '101', 'upper_bound'], ['103', '113', 'clinical_variable'], ['115', '121', 'upper_bound']]}, 'NCT03043807'), ({'text': 'Lesion length d 40', 'entities': [['1', '14', 'clinical_variable'], ['17', '19', 'upper_bound']]}, 'NCT02316886'), ({'text': 'No co-infection with Human Immunodeficiency Virus (HIV) or hepatitis B virus (HBsAg positive) or hepatitis C virus (HCV RNA positive), CMV, adenovirus, parvovirus B 19 or toxoplasmosis', 'entities': [['22', '56', 'chronic_disease'], ['60', '71', 'chronic_disease'], ['98', '109', 'chronic_disease'], ['136', '139', 'chronic_disease'], ['141', '151', 'chronic_disease'], ['153', '168', 'chronic_disease'], ['172', '185', 'chronic_disease']]}, 'NCT02234934'), ({'text': 'Double/triple hit lymphomas', 'entities': [['1', '7', 'cancer'], ['8', '28', 'cancer']]}, 'NCT02471911'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) d 1', 'entities': [['1', '42', 'clinical_variable'], ['45', '46', 'upper_bound']]}, 'NCT02016781'), ({'text': 'For subjects with liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase d 5 x ULN', 'entities': [['19', '35', 'cancer'], ['37', '67', 'clinical_variable'], ['72', '98', 'clinical_variable'], ['101', '108', 'upper_bound']]}, 'NCT01037790'), ({'text': 'Unstable angina', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02074436'), ({'text': 'Is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.)', 'entities': [['19', '41', 'chronic_disease'], ['48', '68', 'chronic_disease'], ['70', '99', 'chronic_disease'], ['101', '120', 'chronic_disease'], ['122', '150', 'chronic_disease']]}, 'NCT02131389'), ({'text': 'stable medical condition without cardiopulmonary disease', 'entities': [['34', '57', 'chronic_disease']]}, 'NCT02339233'), ({'text': 'Enrolled in another investigational study evaluating a drug or device', 'entities': [['13', '42', 'treatment']]}, 'NCT01791543'), ({'text': 'Have undergone chemotherapy or radiation therapy within the previous one month', 'entities': [['16', '28', 'treatment'], ['32', '49', 'treatment'], ['61', '79', 'upper_bound']]}, 'NCT02079181'), ({'text': 'history of solid organ transplant', 'entities': [['12', '34', 'treatment']]}, 'NCT02479698'), ({'text': 'Research participants being treated for severe infection or who are recovering from major surgery', 'entities': [['85', '98', 'treatment']]}, 'NCT02208362'), ({'text': 'age 18 to 70 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['11', '19', 'upper_bound']]}, 'NCT02464878'), ({'text': 'Women of child bearing potential', 'entities': [['1', '6', 'gender']]}, 'NCT02656706'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02400463'), ({'text': 'Hypogammaglobulinemia, dysglobulinemia, or impaired response to vaccination', 'entities': [['1', '22', 'chronic_disease'], ['24', '39', 'chronic_disease'], ['44', '76', 'chronic_disease']]}, 'NCT02579967'), ({'text': 'Known history of hypersensitivity reaction or intolerability to Ace Inh or ARB', 'entities': [['65', '72', 'allergy_name'], ['76', '79', 'allergy_name']]}, 'NCT02046395'), ({'text': 'Stable medication (IMM/5ASA) use or no medication use for the past 6 weeks', 'entities': [['1', '18', 'treatment'], ['8', '18', 'treatment'], ['20', '23', 'treatment'], ['24', '28', 'treatment'], ['63', '75', 'upper_bound']]}, 'NCT02922881'), ({'text': 'Primary unresectable rectal cancer', 'entities': [['22', '35', 'cancer']]}, 'NCT02008656'), ({'text': 'Recipient must be at least 28 days after stem cell infusion', 'entities': [['28', '35', 'lower_bound'], ['42', '60', 'treatment']]}, 'NCT02048332'), ({'text': 'Clinically significant congestive heart failure, unstable angina pectoris', 'entities': [['24', '48', 'chronic_disease'], ['50', '65', 'chronic_disease']]}, 'NCT01676753'), ({'text': 'Subject has radiation therapy within 4 weeks prior to the first study dose', 'entities': [['13', '30', 'treatment'], ['38', '51', 'upper_bound']]}, 'NCT02236013'), ({'text': 'Women of childbearing potential must agree to use effective contraceptives (as discussed with their physician) while participating in this study', 'entities': [['1', '6', 'gender'], ['38', '75', 'contraception_consent']]}, 'NCT03186937'), ({'text': 'Have an Eastern Cooperative Oncology Group performance status of =< 1', 'entities': [['9', '62', 'clinical_variable'], ['69', '70', 'upper_bound']]}, 'NCT02489422'), ({'text': 'Known hepatitis B surface antigen positivity', 'entities': [['7', '18', 'chronic_disease']]}, 'NCT02004275'), ({'text': 'May be receiving treatment with phosphate and calcitriol, but must be willing to undergo dose adjustments by the investigators if iron resolves the phosphate wasting defect', 'entities': [['18', '27', 'treatment'], ['33', '42', 'treatment'], ['47', '57', 'treatment'], ['149', '173', 'chronic_disease']]}, 'NCT02233322'), ({'text': 'severe or life-threatening medical illness, such as other serious cardiopulmonary conditions (e.g. congenital heart disease, cystic fibrosis, alpha-1-antitrypsin disease) or cancer, which would confound the assessment of asthma, anxiety, depression or quality of life', 'entities': [['11', '43', 'chronic_disease'], ['67', '93', 'chronic_disease'], ['100', '124', 'chronic_disease'], ['126', '141', 'chronic_disease'], ['143', '170', 'chronic_disease'], ['175', '181', 'cancer'], ['222', '228', 'chronic_disease'], ['230', '237', 'chronic_disease'], ['239', '249', 'chronic_disease']]}, 'NCT02809677'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['14', '34', 'chronic_disease'], ['76', '92', 'chronic_disease'], ['106', '130', 'chronic_disease'], ['132', '156', 'chronic_disease'], ['161', '198', 'chronic_disease']]}, 'NCT01434316'), ({'text': 'Gestational hypertension', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03011567'), ({'text': '1+ cigarettes per day', 'entities': [['1', '2', 'lower_bound']]}, 'NCT02378714'), ({'text': 'B2: Recurrent or unresectable low grade gliomas with BRAF tandem duplication with fusion', 'entities': [['31', '89', 'cancer']]}, 'NCT02124772'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT02411318'), ({'text': 'Known left ventricular ejection fraction <30%', 'entities': [['7', '41', 'clinical_variable'], ['43', '46', 'upper_bound']]}, 'NCT02100722'), ({'text': 'English as native and preferred language', 'entities': [['1', '41', 'language_fluency']]}, 'NCT02155946'), ({'text': 'N2 or N3 disease detected clinically or by imaging', 'entities': [['1', '3', 'cancer'], ['7', '17', 'cancer'], ['44', '51', 'treatment']]}, 'NCT01872975'), ({'text': 'Treatment with chronic systemic glucocorticoid therapy (more than 7 consecutive days in 1 month)', 'entities': [['1', '55', 'treatment'], ['67', '85', 'lower_bound'], ['89', '96', 'upper_bound']]}, 'NCT02362308'), ({'text': 'Women who are pregnant or nursing', 'entities': [['1', '6', 'gender'], ['11', '23', 'pregnancy']]}, 'NCT02053246'), ({'text': 'Current physical activity levels do not meet the recommended guidelines (e 150 minutes of moderate-to-vigorous or e 75 minutes of vigorous physical activity/week) as calculated using the Leisure Time Exercise Questionnaire (LTEQ)', 'entities': [['76', '87', 'lower_bound'], ['117', '127', 'lower_bound'], ['188', '230', 'clinical_variable']]}, 'NCT00819208'), ({'text': 'Serum creatinine =< 1.6 mg/dL and creatinine clearance >= 30 ml/min', 'entities': [['1', '17', 'clinical_variable'], ['21', '30', 'upper_bound'], ['35', '55', 'clinical_variable'], ['59', '68', 'lower_bound']]}, 'NCT01919619'), ({'text': 'Received intravenous corticosteroids within 14 days prior to Screening or during the Screening Period', 'entities': [['10', '37', 'treatment'], ['45', '58', 'upper_bound']]}, 'NCT02819635'), ({'text': 'those who exhibit severe behavioral disinhibition or aggression', 'entities': [['26', '64', 'chronic_disease']]}, 'NCT02305537'), ({'text': 'Claustrophobia', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02721303'), ({'text': "Patient's donor must be a related or unrelated human leukocyte antigen (HLA) 8/8 allele-level match (HLA-A, B, C and DRB1)", 'entities': [['48', '77', 'clinical_variable'], ['102', '107', 'clinical_variable'], ['109', '110', 'clinical_variable'], ['112', '113', 'clinical_variable'], ['118', '122', 'clinical_variable']]}, 'NCT01951885'), ({'text': 'Enrollees will be asked to hold the doses of the current medications stable over the course of enrollment (though changes in medications after enrollment will not exclude them from on-going participation)', 'entities': [['50', '69', 'treatment'], ['58', '69', 'treatment']]}, 'NCT02391402'), ({'text': 'Age e18 years or age of majority at the participating site, whichever is greater', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound'], ['18', '21', 'age']]}, 'NCT02541903'), ({'text': 'Impaired renal function', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02514083'), ({'text': 'except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer', 'entities': [['31', '41', 'cancer'], ['45', '70', 'cancer'], ['82', '97', 'cancer']]}, 'NCT02008656'), ({'text': 'Symptomatic, progressive or corticosteroids-requiring documented brain metastases or leptomeningeal disease involvement', 'entities': [['66', '82', 'cancer'], ['86', '108', 'cancer']]}, 'NCT02533674'), ({'text': 'Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin. These potential risks may also apply to other agents used in this study', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender'], ['53', '65', 'treatment'], ['71', '84', 'treatment'], ['243', '252', 'treatment']]}, 'NCT02195232'), ({'text': 'Women diagnosed with cancer', 'entities': [['1', '6', 'gender'], ['22', '28', 'cancer']]}, 'NCT02802787'), ({'text': 'Subjects must agree to avoid consuming alcohol within 72 hours of each rTMS session', 'entities': [['55', '63', 'upper_bound'], ['72', '84', 'treatment']]}, 'NCT00926237'), ({'text': 'History of syncope', 'entities': [['12', '19', 'chronic_disease']]}, 'NCT02178566'), ({'text': 'No history of any (mild to severe) TBI (as defined by DOD / VA; confirmed by medical records and in person Ohio State University TBI Instrument)', 'entities': [['36', '39', 'chronic_disease']]}, 'NCT02920788'), ({'text': 'Use of CNS active drugs', 'entities': [['8', '24', 'treatment']]}, 'NCT02544503'), ({'text': 'total bilirubin d 2.0 mg/dl', 'entities': [['1', '16', 'clinical_variable'], ['19', '28', 'upper_bound']]}, 'NCT00703105'), ({'text': 'Chemotherapy, Tyrosine Kinase Inhibitor therapy, radiation therapy or hormonal therapy within 2 weeks', 'entities': [['1', '13', 'treatment'], ['15', '48', 'treatment'], ['50', '67', 'treatment'], ['71', '87', 'treatment'], ['95', '102', 'upper_bound']]}, 'NCT02771626'), ({'text': 'INR<1.5 *for patients on Coumadin general clinical guidelines for IR ablation will be followed', 'entities': [['1', '4', 'clinical_variable'], ['5', '8', 'upper_bound'], ['67', '78', 'treatment']]}, 'NCT01494324'), ({'text': 'Receiving pyrimethamine, cimetidine, rifampin or cephalexin', 'entities': [['11', '24', 'treatment'], ['26', '36', 'treatment'], ['38', '46', 'treatment'], ['50', '60', 'treatment']]}, 'NCT01905046'), ({'text': 'Dementia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02522494'), ({'text': 'HIV or AIDS related illness', 'entities': [['1', '4', 'chronic_disease'], ['8', '12', 'chronic_disease'], ['21', '28', 'chronic_disease']]}, 'NCT02339233'), ({'text': 'Hepatitis C antibody (Anti-HCV)', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT02508038'), ({'text': 'clinically significant repetitive ventricular arrhythmias despite antiarrhythmic treatment', 'entities': [['35', '58', 'chronic_disease'], ['67', '91', 'treatment']]}, 'NCT02253316'), ({'text': 'Patients with diabetes will be excluded due to the possibility that the autonomic dysfunction results from a peripheral neuropathy', 'entities': [['15', '23', 'chronic_disease'], ['110', '131', 'chronic_disease']]}, 'NCT03032328'), ({'text': 'PD after a conventional-dose salvage (cisplatin + ifosfamide -based) regimen', 'entities': [['12', '37', 'treatment'], ['39', '48', 'treatment'], ['51', '61', 'treatment']]}, 'NCT01505569'), ({'text': 'PTSD', 'entities': [['1', '5', 'chronic_disease']]}, 'NCT02553161'), ({'text': 'Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV)', 'entities': [['34', '49', 'chronic_disease'], ['55', '89', 'chronic_disease'], ['91', '114', 'chronic_disease'], ['118', '141', 'chronic_disease']]}, 'NCT02334865'), ({'text': 'Total bilirubin d2.5 x ULN (if the participant is receiving atazanavir, a total bilirubin of d5 x ULN is acceptable)', 'entities': [['7', '16', 'clinical_variable'], ['18', '27', 'upper_bound'], ['20', '27', 'upper_bound'], ['61', '71', 'treatment']]}, 'NCT02572323'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status =< 2', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'upper_bound']]}, 'NCT01591356'), ({'text': 'tuberculosis', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02536794'), ({'text': 'History of organ allograft (including corneal transplant)', 'entities': [['39', '57', 'treatment']]}, 'NCT02048371'), ({'text': 'Corrected DLCO e50%', 'entities': [['11', '15', 'clinical_variable'], ['17', '20', 'lower_bound']]}, 'NCT02078102'), ({'text': 'Clinical stages T1a to T2b PSA of less than 10 ng per ml', 'entities': [['28', '31', 'clinical_variable'], ['45', '56', 'upper_bound']]}, 'NCT00809991'), ({'text': 'Estimated GFR greater than or equal to 60, tested within 1 week of scan', 'entities': [['1', '14', 'clinical_variable'], ['40', '42', 'lower_bound'], ['58', '64', 'upper_bound']]}, 'NCT02531880'), ({'text': 'Live in RI or MA within 20 miles of Providence and plan to remain in the area for the next 6 months', 'entities': [['25', '33', 'upper_bound'], ['87', '100', 'upper_bound']]}, 'NCT01970293'), ({'text': 'fertile men who are sexually active must agree to use a highly effective method of contraception (less than [<] 1 percent [%] / year failure rate) during the study and for 90 days after the last dose of study drug', 'entities': [['9', '12', 'gender'], ['42', '97', 'contraception_consent'], ['113', '126', 'upper_bound'], ['173', '180', 'upper_bound']]}, 'NCT03145181'), ({'text': 'subjects with an eGFR of < 30 mL/min/1.73 m^2', 'entities': [['18', '22', 'clinical_variable'], ['28', '46', 'upper_bound']]}, 'NCT01653080'), ({'text': 'still receiving antibacterial drug treatment for CDI', 'entities': [['17', '45', 'treatment'], ['50', '53', 'chronic_disease']]}, 'NCT03182907'), ({'text': 'ECOG performance status d 1', 'entities': [['1', '24', 'clinical_variable'], ['27', '28', 'upper_bound']]}, 'NCT02573493'), ({'text': 'Stoke or heart attack in the prior 3 months', 'entities': [['1', '6', 'chronic_disease'], ['10', '22', 'chronic_disease'], ['30', '44', 'upper_bound']]}, 'NCT02953431'), ({'text': 'Any active malignancy or any history of a malignancy or lymphoma', 'entities': [['12', '22', 'cancer'], ['57', '65', 'cancer']]}, 'NCT02310867'), ({'text': 'Chronic hepatitis B or hepatitis C infection', 'entities': [['9', '20', 'chronic_disease'], ['24', '35', 'chronic_disease']]}, 'NCT01754857'), ({'text': 'prior receipt of more than 3 sessions of Thinking Skills for Work (TSW) Cognitive Remediation', 'entities': [['28', '29', 'lower_bound']]}, 'NCT03005574'), ({'text': 'Use of UDP glucuronosyltransferase 1 family, polypeptide A9 (UGT1A9) inhibitor including: diclofenac, imipramine, and ketoconazole', 'entities': [['8', '35', 'treatment'], ['46', '79', 'treatment'], ['91', '101', 'treatment'], ['103', '113', 'treatment'], ['119', '131', 'treatment']]}, 'NCT02166905'), ({'text': 'Alcohol use of more than 4 drinks per day', 'entities': [['26', '34', 'lower_bound']]}, 'NCT02924194'), ({'text': 'Dyskeratosis Congenita (DC)', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT01962415'), ({'text': 'Organ malfunction, including (but not limited to) liver disease, pulmonary disease, ischemic heart disease, heart failure, stroke, peripheral vascular disease', 'entities': [['1', '18', 'chronic_disease'], ['51', '64', 'chronic_disease'], ['66', '83', 'chronic_disease'], ['85', '107', 'chronic_disease'], ['109', '122', 'chronic_disease'], ['124', '130', 'chronic_disease'], ['132', '159', 'chronic_disease']]}, 'NCT00862433'), ({'text': 'Severe depression at screening per the Patient Health Questionnaire-8 (PHQ-8)', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02544373'), ({'text': 'English speaking', 'entities': [['1', '17', 'language_fluency']]}, 'NCT02159560'), ({'text': 'Hypertrophic obstructive or restrictive or post partum cardiomyopathy', 'entities': [['14', '25', 'treatment'], ['29', '40', 'treatment'], ['44', '70', 'treatment']]}, 'NCT01128816'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02338232'), ({'text': 'Pathologic T1 or T2 disease, resected with negative margins ( 2mm) Pathologic N2a, N2b, or N2c disease', 'entities': [['1', '28', 'cancer'], ['68', '103', 'cancer']]}, 'NCT02159703'), ({'text': 'Women of childbearing potential (WCBP) must agree to use highly effective methods of birth control throughout the duration of the study until 6 months following the last dose of study drug', 'entities': [['1', '6', 'gender'], ['45', '99', 'contraception_consent'], ['143', '151', 'upper_bound']]}, 'NCT02915744'), ({'text': 'at least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02269293'), ({'text': 'Children < 18 years', 'entities': [['12', '20', 'upper_bound']]}, 'NCT03176693'), ({'text': 'There has been no evident growth of any brain metastasis since the most recent treatment', 'entities': [['41', '57', 'cancer']]}, 'NCT02382549'), ({'text': 'Patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry', 'entities': [['37', '71', 'treatment'], ['106', '122', 'lower_bound']]}, 'NCT02257424'), ({'text': 'aged 18 or older', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound']]}, 'NCT02796027'), ({'text': 'End-stage renal disease (i.e., any patient requiring or advised to undergo dialysis)', 'entities': [['1', '24', 'chronic_disease'], ['76', '84', 'treatment']]}, 'NCT02346253'), ({'text': 'Current CBT and/or formal mindfulness/meditation training', 'entities': [['9', '12', 'treatment']]}, 'NCT02808702'), ({'text': 'Body mass index within 15% of normal', 'entities': [['1', '16', 'bmi'], ['24', '37', 'upper_bound']]}, 'NCT03169543'), ({'text': 'Age e 70 years OR KPS d 70', 'entities': [['1', '4', 'age'], ['7', '9', 'upper_bound'], ['7', '15', 'lower_bound'], ['19', '22', 'clinical_variable']]}, 'NCT01829958'), ({'text': 'Hearing or vision impairments that would affect their ability to perform the test', 'entities': [['1', '8', 'chronic_disease'], ['12', '30', 'chronic_disease']]}, 'NCT03180905'), ({'text': 'for women, not breastfeeding or pregnant', 'entities': [['5', '10', 'gender'], ['33', '41', 'pregnancy']]}, 'NCT01438073'), ({'text': '21-65 years old', 'entities': [['1', '3', 'lower_bound'], ['4', '16', 'upper_bound']]}, 'NCT02377089'), ({'text': 'Hemoglobinopathies', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT01810588'), ({'text': 'Current use of antihypertensive medication', 'entities': [['16', '43', 'treatment']]}, 'NCT02755116'), ({'text': 'Subjects must have a left ventricular ejection fraction (LVEF) of e 45%', 'entities': [['22', '63', 'clinical_variable'], ['69', '72', 'lower_bound']]}, 'NCT02583893'), ({'text': 'Life expectancy less than 2 years', 'entities': [['1', '16', 'clinical_variable'], ['27', '34', 'upper_bound']]}, 'NCT02316886'), ({'text': 'Currently taking a concomitant medication', 'entities': [['20', '42', 'treatment']]}, 'NCT02730481'), ({'text': 'Platelets > 100,000/µ (transfusion independent)', 'entities': [['1', '10', 'clinical_variable'], ['13', '22', 'lower_bound']]}, 'NCT02358187'), ({'text': 'Patient pain visual analog scale (VAS) e40', 'entities': [['14', '39', 'clinical_variable'], ['41', '43', 'lower_bound']]}, 'NCT02272218'), ({'text': 'Anesthesia time is less than one hour', 'entities': [['1', '11', 'treatment'], ['30', '38', 'upper_bound']]}, 'NCT02053766'), ({'text': 'procedures not requiring cardiopulmonary bypass', 'entities': [['26', '48', 'treatment']]}, 'NCT02554253'), ({'text': 'Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) scale', 'entities': [['30', '31', 'lower_bound'], ['35', '36', 'upper_bound'], ['44', '91', 'clinical_variable']]}, 'NCT02857270'), ({'text': 'The estimated creatinine clearance (CrCl) must be equal or greater than 60 mL/min/1.73 m2 as calculated by the Cockcroft-Gault Formula', 'entities': [['5', '42', 'clinical_variable'], ['73', '90', 'lower_bound']]}, 'NCT00959140'), ({'text': 'Patients will be evaluated using the Acute Asthma Intensity Research Score (AAIRS) which has been validated at Vanderbilt University Medical Center and is currently the standard of care when triaging patients with asthma', 'entities': [['38', '83', 'clinical_variable'], ['215', '221', 'chronic_disease']]}, 'NCT02458482'), ({'text': 'has any concurrent medical condition or disease (eg, active systemic infection, laboratory abnormalities) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study', 'entities': [['61', '79', 'chronic_disease']]}, 'NCT03067571'), ({'text': 'Allowed concomitant medications will include mesalamine compounds if used for at least 8 weeks and at a stable dose for at least 4 weeks, as well as thiopurines (azathioprine, 6-mercaptopurine) if used at a stable dose for at least 3 months', 'entities': [['9', '32', 'treatment'], ['46', '66', 'treatment'], ['88', '95', 'lower_bound'], ['130', '137', 'lower_bound'], ['150', '161', 'treatment'], ['163', '175', 'treatment'], ['177', '193', 'treatment'], ['233', '241', 'lower_bound']]}, 'NCT02463305'), ({'text': 'Body mass index: <40 kg/sq meter', 'entities': [['1', '16', 'bmi'], ['19', '33', 'upper_bound']]}, 'NCT03118050'), ({'text': 'Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer within the last five years', 'entities': [['34', '55', 'cancer'], ['79', '103', 'cancer'], ['115', '130', 'upper_bound']]}, 'NCT02658565'), ({'text': 'Patient undergoing any emergency surgery prior to treatment', 'entities': [['34', '41', 'treatment']]}, 'NCT03034213'), ({'text': 'Significant active physical illness', 'entities': [['20', '36', 'chronic_disease']]}, 'NCT02473250'), ({'text': 'Not able to speak English', 'entities': [['1', '26', 'language_fluency']]}, 'NCT02989805'), ({'text': 'Currently on psychotropic medications with dosage unchanged for less than four weeks prior to study entry OR plan to make changes in medication within 2 months after starting the study', 'entities': [['14', '38', 'treatment'], ['27', '37', 'treatment'], ['75', '91', 'upper_bound'], ['152', '160', 'upper_bound']]}, 'NCT02573246'), ({'text': 'Lung transplant recipient (combined organ transplant recipients, e.g. heart-lung or liver-lung recipients, are eligible)', 'entities': [['1', '16', 'treatment'], ['37', '53', 'treatment']]}, 'NCT02181257'), ({'text': 'High-Risk aGVHD (ARM 1): Pediatric or adult (ages 12-76 years) HCT recipients with high-risk acute GVHD, as determined by the refined MN acute GVHD risk score: http://z.umn.edu/MNAcuteGVHDRiskScore OR high risk on the basis of blood biomarkers (Ann Arbor Score 3 or amphiregulin e 33 pg/ml)', 'entities': [['11', '16', 'chronic_disease'], ['12', '16', 'chronic_disease'], ['46', '50', 'age'], ['51', '53', 'lower_bound'], ['54', '62', 'upper_bound'], ['64', '67', 'treatment'], ['267', '279', 'clinical_variable'], ['282', '290', 'lower_bound']]}, 'NCT02525029'), ({'text': 'Women who are pregnant or breastfeeding (lactating)', 'entities': [['1', '6', 'gender'], ['11', '23', 'pregnancy']]}, 'NCT02582827'), ({'text': 'Patients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 month', 'entities': [['27', '39', 'treatment'], ['32', '39', 'treatment'], ['41', '54', 'treatment'], ['56', '68', 'treatment'], ['112', '124', 'upper_bound']]}, 'NCT02542202'), ({'text': 'Prior radiation castration with amenorrhea for at least 6 months', 'entities': [['1', '27', 'treatment'], ['33', '43', 'chronic_disease'], ['57', '65', 'lower_bound']]}, 'NCT01824836'), ({'text': 'Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) d upper limit of normal (ULN) or < 2.5 x ULN in the presence of liver metastases', 'entities': [['1', '64', 'clinical_variable'], ['100', '109', 'upper_bound'], ['129', '145', 'cancer']]}, 'NCT02584647'), ({'text': 'severe ischemia cardiac disease', 'entities': [['8', '32', 'chronic_disease']]}, 'NCT02355912'), ({'text': 'Adequate renal function as demonstrated by serum creatinine d 1.5 x ULN or 24-hour urine creatinine clearance calculation e 60 mL/min', 'entities': [['44', '60', 'clinical_variable'], ['63', '83', 'upper_bound'], ['90', '122', 'clinical_variable'], ['125', '134', 'lower_bound']]}, 'NCT02250157'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01893307'), ({'text': 'In the case that a patient had a tumor sample acquired prior to consenting to the study and this tumor sample is acceptable for processing as described in Appendix 4 (i.e. frozen sample stored) and the tumor sample was acquired within 60 days of starting treatment, this is acceptable and a new biopsy will not be required', 'entities': [['34', '39', 'cancer'], ['236', '243', 'upper_bound'], ['256', '265', 'treatment'], ['296', '302', 'treatment']]}, 'NCT02553642'), ({'text': '<18 years of age', 'entities': [['2', '10', 'upper_bound'], ['14', '17', 'age']]}, 'NCT02599116'), ({'text': 'Subjects with premalignant lesion, or potentially premalignant lesion, of the oral cavity mucosa (leukoplakia or erythroplakia)', 'entities': [['15', '34', 'cancer'], ['99', '110', 'chronic_disease'], ['114', '127', 'chronic_disease']]}, 'NCT00542373'), ({'text': 'Current or recent (within 3 months of study drug administration) gastrointestinal disease or gastrointestinal surgery that, in the opinion of the investigator and the BMS Medical Monitor, could impact the absorption of the study drug', 'entities': [['27', '35', 'upper_bound'], ['66', '90', 'chronic_disease'], ['94', '118', 'treatment']]}, 'NCT01707394'), ({'text': 'The measured CrCl must also be greater than or equal to 60 ml/min', 'entities': [['14', '18', 'clinical_variable'], ['57', '66', 'lower_bound']]}, 'NCT01572480'), ({'text': 'antidepressants', 'entities': [['1', '16', 'treatment']]}, 'NCT02703220'), ({'text': 'AST and ALT < 3 x upper limit of normal (ULN), and total bilirubin <1.5 x ULN', 'entities': [['1', '12', 'clinical_variable'], ['15', '46', 'upper_bound'], ['52', '67', 'clinical_variable'], ['69', '78', 'upper_bound']]}, 'NCT02213913'), ({'text': 'Contraindications to lithium in this study include: resting tremor causing functional impairment, history of falls in the last month, untreated thyroid disease or any abnormal thyroid function test (T3, T4, or TSH)', 'entities': [['22', '29', 'treatment'], ['76', '97', 'chronic_disease'], ['145', '160', 'chronic_disease']]}, 'NCT02129348'), ({'text': 'Histologic confirmation may be from the primary tumor site, or from another metastatic site (systemic lymph node, etc)', 'entities': [['49', '54', 'cancer'], ['94', '113', 'cancer']]}, 'NCT01644591'), ({'text': 'serious uncontrolled psychiatric problem (other than posttraumatic stress disorder)', 'entities': [['1', '41', 'chronic_disease'], ['54', '83', 'chronic_disease']]}, 'NCT02667119'), ({'text': 'Atrial fibrillation', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02762825'), ({'text': 'History of changes in baseline LVEF that occurred during prior treatment with anti-HER2 treatment', 'entities': [['32', '36', 'clinical_variable'], ['58', '73', 'treatment'], ['79', '98', 'treatment']]}, 'NCT01730118'), ({'text': 'Symptomatic or unstable brain metastases', 'entities': [['1', '41', 'cancer']]}, 'NCT02576431'), ({'text': 'EGFR mutation with exon 19 deletion or L858R mutation (Exon 21) or ALK rearrangement positive must have failed prior TKI therapy', 'entities': [['112', '129', 'treatment']]}, 'NCT02403193'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02106312'), ({'text': 'Patients with large-cell neuroendocrine carcinomas are not eligible', 'entities': [['15', '51', 'cancer']]}, 'NCT02273375'), ({'text': 'Current evidence of GVHD > grade 2 or bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis Pregnancy or lactating (female of childbearing potential)', 'entities': [['21', '25', 'clinical_variable'], ['28', '35', 'lower_bound'], ['39', '72', 'chronic_disease'], ['74', '88', 'chronic_disease'], ['93', '112', 'pregnancy'], ['127', '133', 'gender']]}, 'NCT02203903'), ({'text': 'Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2', 'entities': [['23', '83', 'clinical_variable'], ['87', '88', 'upper_bound']]}, 'NCT02232516'), ({'text': 'Bilirubin =< 1.5 x ULN', 'entities': [['1', '10', 'clinical_variable'], ['14', '23', 'upper_bound']]}, 'NCT01595061'), ({'text': 'Cancer patients who are actively undergoing chemotherapy at screening or who have received chemotherapy within 3 months prior to screening', 'entities': [['1', '7', 'cancer'], ['45', '57', 'treatment'], ['112', '126', 'upper_bound']]}, 'NCT02570854'), ({'text': 'Non-Hodgkin lymphoma relapsing after auto-HSCT', 'entities': [['1', '21', 'cancer'], ['32', '47', 'treatment']]}, 'NCT02508038'), ({'text': 'immunotherapy', 'entities': [['1', '14', 'treatment']]}, 'NCT02671435'), ({'text': 'A bone marrow biopsy must be performed within four weeks prior to Cycle 1 Day 1 treatment to establish the baseline fibrosis score, and consent is required prior to that bone marrow biopsy to assure tissue is collected for protocol mandated testing', 'entities': [['3', '21', 'treatment'], ['47', '63', 'upper_bound'], ['81', '90', 'treatment'], ['117', '131', 'clinical_variable']]}, 'NCT02493530'), ({'text': 'Suffering from severe depression (as defined by a score of >30 in the Beck Depression Inventory)', 'entities': [['23', '33', 'chronic_disease'], ['61', '63', 'lower_bound'], ['71', '96', 'clinical_variable']]}, 'NCT02627495'), ({'text': 'Gynecologic cancer cohort only: histologic proof of epithelial cervical, endometrial, ovarian, fallopian, or primary peritoneal cancers', 'entities': [['1', '19', 'cancer'], ['53', '72', 'cancer'], ['74', '85', 'cancer'], ['87', '94', 'cancer'], ['96', '105', 'cancer'], ['110', '136', 'cancer']]}, 'NCT02020707'), ({'text': 'edoxaban', 'entities': [['1', '9', 'treatment']]}, 'NCT03096288'), ({'text': 'Active optic glioma or other low-grade glioma requiring treatment with chemotherapy or radiation therapy', 'entities': [['8', '20', 'chronic_disease'], ['57', '66', 'treatment'], ['72', '84', 'treatment'], ['88', '105', 'treatment']]}, 'NCT02101736'), ({'text': 'Pathological evidence of GBM using WHO classification criteria', 'entities': [['26', '29', 'cancer']]}, 'NCT02343549'), ({'text': 'serum HbA1c level greater than 10% at the Screening Visit', 'entities': [['1', '18', 'clinical_variable'], ['32', '35', 'lower_bound']]}, 'NCT02836574'), ({'text': 'Clinical or radiographic evidence of metastatic disease. Metastatic workup is not required, but is recommended for patients with clinical stage III disease', 'entities': [['38', '56', 'cancer'], ['58', '75', 'treatment'], ['130', '156', 'chronic_disease']]}, 'NCT01953588'), ({'text': 'Patients who are sufficiently ill to warrant replacement of their diseased natural or prosthetic valve, based on standard cardiovascular diagnostic workups', 'entities': [['123', '156', 'treatment']]}, 'NCT01812174'), ({'text': 'Patients must have a histologically confirmed diagnosis of aggressive B-cell lymphoma (diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL], etc.) expressing the CD20 antigen and have failed at least one prior standard systemic therapy', 'entities': [['71', '86', 'cancer'], ['88', '125', 'cancer'], ['127', '148', 'cancer'], ['209', '212', 'lower_bound'], ['213', '244', 'treatment']]}, 'NCT01434472'), ({'text': 'Major trauma or major surgery within 28 days prior to the initiation of AMV564 treatment', 'entities': [['1', '13', 'chronic_disease'], ['17', '30', 'treatment'], ['38', '51', 'upper_bound'], ['73', '89', 'treatment']]}, 'NCT03144245'), ({'text': 'chronic fatigue syndrome', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03053453'), ({'text': "Serious uncontrolled medical disorder or active infection that in the investigator's opinion would impair the patient's ability to receive study treatment", 'entities': [['22', '38', 'chronic_disease'], ['42', '58', 'chronic_disease'], ['146', '155', 'treatment']]}, 'NCT02403193'), ({'text': 'age 10 - 17 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['10', '18', 'upper_bound']]}, 'NCT02075047'), ({'text': 'any inhaled, intranasal, topical or vaginal corticosteroids', 'entities': [['5', '12', 'treatment'], ['14', '24', 'treatment'], ['26', '33', 'treatment'], ['37', '60', 'treatment']]}, 'NCT02418195'), ({'text': 'male or female participants of childbearing age who are not willing, or whose partners are not willing, to use contraception during the study', 'entities': [['1', '5', 'gender'], ['9', '28', 'gender'], ['45', '48', 'age'], ['57', '125', 'contraception_consent']]}, 'NCT02838797'), ({'text': 'Metastatic RCC', 'entities': [['1', '15', 'cancer']]}, 'NCT02885649'), ({'text': 'Immunosuppressants such as tacrolimus, leflunomide or tofacitinib, roflumilast, pimecrolimus', 'entities': [['1', '19', 'treatment'], ['28', '38', 'treatment'], ['40', '51', 'treatment'], ['55', '66', 'treatment'], ['68', '79', 'treatment'], ['81', '93', 'treatment']]}, 'NCT02349867'), ({'text': 'Receiving Warfarin', 'entities': [['11', '19', 'treatment']]}, 'NCT01905046'), ({'text': 'Current dementia', 'entities': [['9', '17', 'chronic_disease']]}, 'NCT02461927'), ({'text': 'AST(SGOT)/ALT(SGPT) < = 2.5 X upper limit of normal', 'entities': [['1', '10', 'clinical_variable'], ['11', '20', 'clinical_variable'], ['25', '52', 'upper_bound']]}, 'NCT01054196'), ({'text': 'Significant organ system dysfunction (e.g., diabetes requiring medications, severe pulmonary, disorders of the gastrointestinal tract, kidney or cardiovascular disease)', 'entities': [['45', '53', 'chronic_disease'], ['84', '93', 'chronic_disease'], ['95', '134', 'chronic_disease'], ['136', '142', 'chronic_disease'], ['146', '168', 'chronic_disease']]}, 'NCT02786251'), ({'text': 'Significant food allergies which would make the subject unable to consume the food provided (ex: shellfish, soy or egg allergy)', 'entities': [['13', '17', 'allergy_name'], ['98', '107', 'allergy_name'], ['109', '112', 'allergy_name'], ['116', '119', 'allergy_name']]}, 'NCT01802346'), ({'text': 'Hiistory of ventricular arrhythmia', 'entities': [['13', '35', 'chronic_disease']]}, 'NCT02576301'), ({'text': 'Current or previous treatment with any other experimental treatment (other than deflazacort) within 12 weeks prior to Week 1', 'entities': [['21', '30', 'treatment'], ['46', '68', 'treatment'], ['81', '92', 'treatment'], ['101', '115', 'upper_bound']]}, 'NCT02500381'), ({'text': 'Available for clinic follow-up for minimum 1yr', 'entities': [['44', '47', 'upper_bound']]}, 'NCT02431897'), ({'text': 'need for oral anticoagulation therapy', 'entities': [['10', '38', 'treatment']]}, 'NCT02925923'), ({'text': 'Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) < 1.3 x upper limit of normal (ULN)', 'entities': [['1', '22', 'clinical_variable'], ['23', '59', 'clinical_variable'], ['64', '97', 'clinical_variable'], ['100', '133', 'upper_bound']]}, 'NCT01989585'), ({'text': 'Prior treatment with gemcitabine-containing therapy for advanced disease (adjuvant therapy is allowed, provided not more than six cycles were administered and relapse occurred more than six months after the last drug administration)', 'entities': [['1', '16', 'treatment'], ['22', '52', 'treatment'], ['75', '91', 'treatment'], ['127', '137', 'upper_bound'], ['187', '197', 'lower_bound']]}, 'NCT02533674'), ({'text': 'Prior trastuzumab and lapatinib therapy', 'entities': [['1', '18', 'treatment'], ['23', '40', 'treatment']]}, 'NCT01494662'), ({'text': 'prior carpal tunnel surgery on the hand to be operated on', 'entities': [['1', '28', 'treatment']]}, 'NCT01974609'), ({'text': 'Allergic rhinitis', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02493257'), ({'text': 'Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normal', 'entities': [['1', '33', 'clinical_variable'], ['35', '81', 'clinical_variable'], ['83', '113', 'clinical_variable'], ['115', '159', 'clinical_variable'], ['163', '204', 'upper_bound']]}, 'NCT02466971'), ({'text': 'Left Ventricular Ejection Fraction (LVEF) between e 25 and d 45%', 'entities': [['1', '42', 'clinical_variable'], ['53', '55', 'lower_bound'], ['62', '64', 'upper_bound']]}, 'NCT02277613'), ({'text': 'Concomitant conditions that may affect significantly the evaluation of balance or gait, including orthopedic, rheumatologic or other neurological diseases', 'entities': [['99', '109', 'chronic_disease'], ['111', '124', 'chronic_disease'], ['134', '155', 'chronic_disease']]}, 'NCT02879136'), ({'text': 'ECOG performance status 0-2', 'entities': [['1', '24', 'clinical_variable'], ['25', '26', 'lower_bound'], ['27', '28', 'upper_bound']]}, 'NCT02913430'), ({'text': 'inability to use effective contraceptive methods during the study', 'entities': [['1', '49', 'contraception_consent']]}, 'NCT01908777'), ({'text': 'have NYHA Grade IV heart failure', 'entities': [['6', '33', 'chronic_disease']]}, 'NCT02933034'), ({'text': 'Women must be post-menopausal for at least 1 year before enrolling in the study, or be one year out from a hysterectomy', 'entities': [['1', '6', 'gender'], ['44', '50', 'lower_bound'], ['108', '120', 'treatment']]}, 'NCT03070535'), ({'text': 'Biological male at birth and current male gender identity', 'entities': [['12', '16', 'gender']]}, 'NCT03086057'), ({'text': 'Immune suppression therapy less than 1 year prior to enrollment', 'entities': [['1', '27', 'treatment'], ['38', '50', 'upper_bound']]}, 'NCT03153319'), ({'text': 'Active infection or other active medical condition that could be eminently life-threatening, including active blood clotting or bleeding diathesis', 'entities': [['1', '17', 'chronic_disease'], ['111', '125', 'chronic_disease'], ['129', '147', 'chronic_disease']]}, 'NCT02033616'), ({'text': 'Prior chemotherapy (last 4 weeks)', 'entities': [['1', '19', 'treatment'], ['21', '33', 'upper_bound']]}, 'NCT00412594'), ({'text': 'Heavy caffeine use (greater than 500 mg on a regular, daily basis)', 'entities': [['34', '40', 'lower_bound']]}, 'NCT03099590'), ({'text': 'Considered an active drug user by HCV provider and self-reported drug use within the past month', 'entities': [['35', '38', 'chronic_disease'], ['86', '96', 'upper_bound']]}, 'NCT02573376'), ({'text': 'Previous intolerance to carfilzomib', 'entities': [['25', '36', 'treatment']]}, 'NCT02474927'), ({'text': 'Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) with conventional techniques or as >= 10 mm (>= 1 cm) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam', 'entities': [['43', '46', 'lower_bound'], ['121', '129', 'clinical_variable'], ['153', '166', 'clinical_variable'], ['207', '212', 'lower_bound'], ['217', '221', 'lower_bound'], ['261', '266', 'lower_bound'], ['271', '275', 'lower_bound'], ['282', '318', 'treatment'], ['320', '352', 'treatment'], ['357', '365', 'treatment']]}, 'NCT02474173'), ({'text': 'You are unwilling to use effective contraceptive methods for duration of study (hormonal or barrier', 'entities': [['9', '57', 'contraception_consent']]}, 'NCT02404870'), ({'text': 'Not pregnant', 'entities': [['1', '13', 'pregnancy']]}, 'NCT00909909'), ({'text': 'Zellweger syndrome', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02171104'), ({'text': 'Ejection fraction of > 40% by Multigated Acquisition Scan (MUGA) or echocardiogram', 'entities': [['1', '18', 'clinical_variable'], ['24', '27', 'lower_bound'], ['31', '65', 'treatment'], ['69', '83', 'treatment']]}, 'NCT02508038'), ({'text': 'hypertension', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02139436'), ({'text': 'Uncorrectable abnormal coagulation parameters (platelet count d75000/mm3 or INR e2.0 or fibrinogen d1.5 g/l)', 'entities': [['48', '62', 'clinical_variable'], ['64', '73', 'upper_bound'], ['77', '80', 'clinical_variable'], ['89', '99', 'clinical_variable'], ['101', '108', 'upper_bound']]}, 'NCT02468778'), ({'text': 'Severe active infection requiring systemic treatment within 14 days before the first dose of study treatment', 'entities': [['15', '24', 'chronic_disease'], ['35', '53', 'treatment'], ['44', '53', 'treatment'], ['61', '75', 'upper_bound']]}, 'NCT02496208'), ({'text': 'Insomnia Severity Index (ISI) score > or = 10', 'entities': [['1', '36', 'clinical_variable'], ['44', '46', 'lower_bound']]}, 'NCT02709980'), ({'text': 'Corneal thickness between 480 and 620 microns', 'entities': [['1', '18', 'clinical_variable'], ['27', '30', 'lower_bound'], ['35', '46', 'upper_bound']]}, 'NCT02852057'), ({'text': 'inflammatory bowel disease', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT02120222'), ({'text': 'Use of antipsychotic medications', 'entities': [['8', '33', 'treatment']]}, 'NCT02862210'), ({'text': 'Patients with non-healing surgical wounds', 'entities': [['27', '35', 'treatment']]}, 'NCT01554371'), ({'text': 'Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 28 days prior to randomization)', 'entities': [['1', '16', 'clinical_variable'], ['20', '53', 'upper_bound'], ['67', '80', 'upper_bound']]}, 'NCT02393690'), ({'text': 'duration of sever to profound hearing loss of 30 years or greater', 'entities': [['31', '43', 'chronic_disease'], ['47', '55', 'lower_bound']]}, 'NCT02379819'), ({'text': 'Non-Alzheimer dementia', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02359864'), ({'text': 'Male or female, age at the time of signing informed consent', 'entities': [['1', '15', 'gender'], ['17', '20', 'age']]}, 'NCT02527200'), ({'text': 'who receive aromatase inhibitors for prevention or treatment of breast cancer', 'entities': [['13', '33', 'treatment'], ['52', '61', 'treatment'], ['65', '78', 'cancer']]}, 'NCT03112590'), ({'text': 'surgical menopause or lack of menses >24 months', 'entities': [['1', '37', 'clinical_variable'], ['39', '48', 'lower_bound']]}, 'NCT02578732'), ({'text': 'Male patients must agree to use a barrier method of contraception or agree to abstain from heterosexual activity for the duration of the study', 'entities': [['1', '14', 'gender'], ['20', '66', 'contraception_consent']]}, 'NCT01473628'), ({'text': 'Enrollment in any other clinical study from screening up to Day 100', 'entities': [['19', '39', 'treatment']]}, 'NCT02508038'), ({'text': 'Circulating CAR T cells must be <5% in peripheral blood', 'entities': [['1', '24', 'clinical_variable'], ['34', '36', 'upper_bound']]}, 'NCT02315612'), ({'text': 'Short Physical Performance Battery score d9', 'entities': [['1', '41', 'clinical_variable'], ['43', '44', 'upper_bound']]}, 'NCT02567227'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT03023449'), ({'text': 'Coronary artery disease', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02991677'), ({'text': 'Participants will be considered to have a relapsed disease if they showed a duration of response of at least 24 weeks after their first line of therapy', 'entities': [['110', '118', 'lower_bound'], ['131', '152', 'treatment']]}, 'NCT02564744'), ({'text': 'Women eligible to take tamoxifen must be offered tamoxifen prevention as part of their clinical care and have refused tamoxifen treatment', 'entities': [['1', '6', 'gender'], ['24', '33', 'treatment'], ['119', '138', 'treatment']]}, 'NCT01905046'), ({'text': 'Subjects have met one or more criteria for discontinuation as stipulated in the parent oral azacitidine study', 'entities': [['88', '110', 'treatment']]}, 'NCT02494258'), ({'text': 'Absolute neutrophil count >= 1,500/mcL', 'entities': [['1', '26', 'clinical_variable'], ['30', '39', 'lower_bound']]}, 'NCT02496663'), ({'text': 'creatinine within institutional normal limits (WNL)', 'entities': [['1', '11', 'clinical_variable']]}, 'NCT01553071'), ({'text': 'History of a low absolute neutrophil count', 'entities': [['18', '43', 'clinical_variable']]}, 'NCT02404155'), ({'text': 'Comorbid psychiatric disease such as schizophrenia, or active substance abusers (except nicotine)', 'entities': [['1', '29', 'chronic_disease'], ['38', '51', 'chronic_disease']]}, 'NCT01681589'), ({'text': 'Women of childbearing age/menstruating must have a negative pregnancy test prior to initiation of radiation therapy', 'entities': [['1', '6', 'gender'], ['23', '26', 'age'], ['52', '70', 'pregnancy'], ['99', '116', 'treatment']]}, 'NCT02112617'), ({'text': 'Conditions that would preclude randomization to either the drug (e.g., prolonged QT interval, known allergy to or intolerance of escitalopram) or exercise (e.g., musculoskeletal problems or abnormal cardiac response to exercise)', 'entities': [['82', '84', 'clinical_variable'], ['130', '142', 'allergy_name'], ['163', '187', 'chronic_disease']]}, 'NCT02516332'), ({'text': 'Autologous stem cell infusion including boost infusion: >= 42 days', 'entities': [['1', '30', 'treatment'], ['41', '55', 'treatment'], ['60', '67', 'lower_bound']]}, 'NCT02304458'), ({'text': 'approximately 9 years of education', 'entities': [['15', '22', 'upper_bound']]}, 'NCT02663934'), ({'text': 'institution of protocol therapy may proceed when the total bilirubin falls to 4.0 mg/dL or lower', 'entities': [['25', '32', 'treatment'], ['54', '69', 'clinical_variable'], ['79', '88', 'upper_bound']]}, 'NCT03073785'), ({'text': 'Age greater than or equal to 18 years of age', 'entities': [['1', '4', 'age'], ['30', '38', 'lower_bound'], ['42', '45', 'age']]}, 'NCT01989546'), ({'text': 'Is able and willing to provide bone marrow biopsies/aspirates as requested by the protocol', 'entities': [['37', '62', 'treatment']]}, 'NCT02319369'), ({'text': 'Life expectancy greater than 6 months', 'entities': [['1', '16', 'clinical_variable'], ['30', '38', 'lower_bound']]}, 'NCT02252081'), ({'text': 'Impaired renal function (serum creatinine equal or more than 1.6 mg/dl)', 'entities': [['1', '24', 'chronic_disease'], ['26', '42', 'clinical_variable'], ['62', '71', 'lower_bound']]}, 'NCT02784535'), ({'text': 'Patients with a known hypersensitivity to gemcitabine (Arm B only)', 'entities': [['43', '54', 'treatment']]}, 'NCT02437370'), ({'text': 'platelet count >/=75,000/mm^3', 'entities': [['1', '15', 'clinical_variable'], ['19', '30', 'lower_bound']]}, 'NCT03084640'), ({'text': 'Oral steroid use within 30 days of surgery', 'entities': [['1', '13', 'treatment'], ['25', '32', 'upper_bound'], ['36', '43', 'treatment']]}, 'NCT02748070'), ({'text': 'Pathologically proven primary cervical cancer I-IIA with squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy', 'entities': [['31', '46', 'cancer'], ['47', '48', 'lower_bound'], ['49', '52', 'upper_bound'], ['58', '81', 'cancer'], ['83', '106', 'cancer'], ['110', '124', 'cancer'], ['167', '179', 'treatment'], ['185', '207', 'treatment']]}, 'NCT01101451'), ({'text': 'Eastern Cooperative Oncology Group performance status of 0-1', 'entities': [['1', '54', 'clinical_variable'], ['58', '59', 'lower_bound'], ['60', '61', 'upper_bound']]}, 'NCT02068092'), ({'text': 'Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent', 'entities': [['29', '46', 'treatment']]}, 'NCT02542657'), ({'text': 'Enrollment on ANBL00B1 or APEC14B1 is required for all newly diagnosed patients', 'entities': [['15', '23', 'treatment'], ['27', '35', 'treatment']]}, 'NCT02176967'), ({'text': 'planning to become pregnant at any time during the study', 'entities': [['20', '28', 'pregnancy']]}, 'NCT02562066'), ({'text': 'Participants proven to have multiple myeloma (MM) diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria', 'entities': [['29', '50', 'cancer']]}, 'NCT02519452'), ({'text': 'Known active hepatitis B infection (defined as presence of Hep B sAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier', 'entities': [['14', '25', 'chronic_disease'], ['60', '65', 'chronic_disease'], ['97', '108', 'chronic_disease'], ['143', '148', 'chronic_disease'], ['167', '170', 'chronic_disease']]}, 'NCT02423525'), ({'text': 'FEV1% predicted e 35%', 'entities': [['1', '6', 'clinical_variable'], ['19', '22', 'lower_bound']]}, 'NCT03085485'), ({'text': 'Non-drinkers (alcohol-na(SqrRoot) ve individuals or current abstainers) or individuals with no experience drinking 5 or more drinks on one occasion in their lifetime', 'entities': [['116', '117', 'lower_bound']]}, 'NCT00713492'), ({'text': 'Any of the following within 6 months before the first dose of study treatment', 'entities': [['29', '37', 'upper_bound'], ['63', '78', 'treatment']]}, 'NCT01822522'), ({'text': 'lomerular filtration rate (GFR) < 60 ml/min/1.73 m2', 'entities': [['1', '32', 'clinical_variable'], ['35', '52', 'upper_bound']]}, 'NCT02826343'), ({'text': 'Presence of distant metastatic (M1) disease', 'entities': [['13', '44', 'cancer']]}, 'NCT02159703'), ({'text': 'Documented histologically confirmed adenocarcinoma of the prostate', 'entities': [['37', '51', 'cancer']]}, 'NCT03043807'), ({'text': 'Debrided ulcer size between 2 cm2 and 200 cm2', 'entities': [['10', '15', 'chronic_disease'], ['29', '34', 'lower_bound'], ['39', '46', 'upper_bound']]}, 'NCT02352454'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02417415'), ({'text': 'Clinically significant elevation of GGT (>1.5xULN), bilirubin (>1.25xULN, direct 35%), or INR (>1.2, excluding patients on anti-coagulant therapies) or other clinically significant abnormal laboratory value in the opinion of the investigator', 'entities': [['37', '40', 'clinical_variable'], ['43', '50', 'lower_bound'], ['53', '62', 'clinical_variable'], ['65', '73', 'lower_bound'], ['65', '68', 'lower_bound'], ['91', '94', 'clinical_variable'], ['124', '148', 'treatment']]}, 'NCT02347891'), ({'text': 'patients discovered to have greater than or equal to 2 or greater proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate less than or equal to 1g of protein in 24 hours', 'entities': [['54', '55', 'lower_bound'], ['67', '74', 'clinical_variable'], ['67', '78', 'chronic_disease'], ['82', '101', 'treatment'], ['131', '133', 'upper_bound'], ['199', '201', 'upper_bound']]}, 'NCT02343549'), ({'text': '40 - 64 years of age', 'entities': [['1', '3', 'lower_bound'], ['6', '14', 'upper_bound'], ['18', '21', 'age']]}, 'NCT02225548'), ({'text': 'Hemoglobin <6.5 g/dl (must be measured within 30 days of MRI)', 'entities': [['1', '11', 'clinical_variable'], ['13', '21', 'upper_bound'], ['47', '54', 'upper_bound'], ['58', '61', 'treatment']]}, 'NCT01389024'), ({'text': 'renal transplantation or serum creatinine > 1.5 mg/dL', 'entities': [['1', '22', 'treatment'], ['26', '42', 'clinical_variable'], ['45', '54', 'lower_bound']]}, 'NCT02971202'), ({'text': 'Patients scheduled for open reduction and internal fixation of a distal radius fracture', 'entities': [['24', '88', 'treatment']]}, 'NCT02744352'), ({'text': 'A minimum average rating of a moderate deficit (3 or greater on a 0-4 scale) on any symptom domain within the affect motivation factor of the Clinical Assessment Interview for Negative Symptoms (CAINS)', 'entities': [['49', '50', 'lower_bound'], ['67', '68', 'lower_bound'], ['69', '70', 'upper_bound']]}, 'NCT02469389'), ({'text': 'Antidepressants: nefazodone', 'entities': [['1', '16', 'treatment'], ['18', '28', 'treatment']]}, 'NCT02516670'), ({'text': 'Pervasive developmental disorder', 'entities': [['1', '33', 'chronic_disease']]}, 'NCT02418195'), ({'text': 'Patients may not have evidence of coagulopathy or bleeding diathesis', 'entities': [['35', '47', 'chronic_disease'], ['51', '69', 'chronic_disease']]}, 'NCT02498613'), ({'text': "Other medical or psychological conditions that would make participation unsafe or inhibit our ability to test our primary hypothesis, e.g. Parkinson's disease, severe dementia", 'entities': [['140', '159', 'chronic_disease'], ['161', '176', 'chronic_disease']]}, 'NCT02763228'), ({'text': 'Participants should not have hypertension (BP above 150/100)', 'entities': [['30', '42', 'chronic_disease'], ['44', '46', 'clinical_variable'], ['53', '60', 'lower_bound']]}, 'NCT02308202'), ({'text': 'Cystolithiasis within the past 3 months', 'entities': [['1', '15', 'chronic_disease'], ['27', '40', 'upper_bound']]}, 'NCT02167009'), ({'text': 'history of speech/language disorder or a Reading Disability (RD)', 'entities': [['12', '36', 'chronic_disease'], ['42', '65', 'chronic_disease']]}, 'NCT02234557'), ({'text': 'Patients with a diagnosis of osteoarthritis (OA)', 'entities': [['30', '49', 'chronic_disease']]}, 'NCT02501733'), ({'text': 'Gastric bypass', 'entities': [['1', '15', 'treatment']]}, 'NCT02937350'), ({'text': 'Patients with central nervous system (CNS) lymphoma are not eligible for the trial unless the disease had been treated and the subject remains without symptoms with no active CNS lymphoma', 'entities': [['15', '52', 'cancer'], ['176', '188', 'cancer']]}, 'NCT02594384'), ({'text': 'Participant must agree not to donate blood during the study and for 7 months after last dose', 'entities': [['69', '77', 'upper_bound']]}, 'NCT02436408'), ({'text': 'All pts must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure', 'entities': [['49', '56', 'lower_bound'], ['63', '72', 'pregnancy']]}, 'NCT01464034'), ({'text': 'Prior external beam radiation therapy resulting in greater than 20% total bone marrow receiving greater than 20 Gy', 'entities': [['1', '38', 'treatment'], ['65', '68', 'lower_bound'], ['110', '115', 'lower_bound']]}, 'NCT02278315'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT01059786'), ({'text': 'Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of 3 years', 'entities': [['7', '26', 'cancer'], ['35', '63', 'cancer'], ['103', '110', 'lower_bound']]}, 'NCT01554410'), ({'text': 'Severe peripheral vascular disease (i.e., severe claudication [pain occurring after less than 200 meters of walking], rest pain, ischemic ulceration or gangrene) in subjects whose Injectable Lesions are located in an extremity', 'entities': [['8', '35', 'chronic_disease'], ['50', '62', 'clinical_variable'], ['95', '105', 'upper_bound'], ['130', '149', 'chronic_disease']]}, 'NCT02557321'), ({'text': 'Taking levodopa in any form', 'entities': [['8', '16', 'treatment']]}, 'NCT03104725'), ({'text': 'Unable to verbally communicate in English', 'entities': [['1', '42', 'language_fluency']]}, 'NCT02593526'), ({'text': 'Starting, stopping, or changing the dose of over the counter or prescription non-steroidal anti-inflammatory drugs (NSAIDs) in the three months prior to Visit 1', 'entities': [['78', '124', 'treatment'], ['132', '150', 'upper_bound']]}, 'NCT03030118'), ({'text': 'Erythrocytes: e 3.5*12^9/L', 'entities': [['1', '13', 'clinical_variable'], ['17', '27', 'lower_bound']]}, 'NCT02592707'), ({'text': 'Main contraindications for acupcunture in this study', 'entities': [['28', '39', 'treatment']]}, 'NCT02926378'), ({'text': 'Low cognitive functioning (IQ less than 70)', 'entities': [['28', '30', 'clinical_variable'], ['41', '43', 'upper_bound']]}, 'NCT02926677'), ({'text': 'GT > 2.5 x ULN IF Alkaline phosphatase > 2.5 x ULN', 'entities': [['1', '3', 'clinical_variable'], ['6', '15', 'lower_bound'], ['19', '39', 'clinical_variable']]}, 'NCT01697930'), ({'text': 'Serum creatinine d 1.6 mg/dl', 'entities': [['1', '17', 'clinical_variable'], ['20', '29', 'upper_bound']]}, 'NCT01913106'), ({'text': 'The investigators will also exclude patients that are already receiving psychotherapy or MH counseling for PTSD outside of PC', 'entities': [['73', '86', 'treatment'], ['90', '103', 'treatment'], ['108', '112', 'chronic_disease']]}, 'NCT02685358'), ({'text': 'Prescribed opioids for the treatment of chronic pain for the past 90 days or longer', 'entities': [['12', '19', 'treatment'], ['28', '37', 'treatment'], ['41', '53', 'chronic_disease'], ['62', '74', 'upper_bound']]}, 'NCT02423772'), ({'text': 'Hemoglobin >= 8.0 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['15', '23', 'lower_bound']]}, 'NCT01415882'), ({'text': 'Use of anticonvulsants', 'entities': [['8', '23', 'treatment']]}, 'NCT01539109'), ({'text': 'History of cancer within the last 5 years', 'entities': [['12', '18', 'cancer'], ['30', '42', 'upper_bound']]}, 'NCT02502006'), ({'text': 'Electroconvulsive Therapy within 6 months prior to screening', 'entities': [['1', '26', 'treatment'], ['34', '48', 'upper_bound']]}, 'NCT02261519'), ({'text': 'Must have at least one bi-dimensionally measurable lesion e1.5 cm) documented by CT scan', 'entities': [['20', '23', 'lower_bound'], ['52', '58', 'clinical_variable'], ['60', '66', 'lower_bound'], ['82', '89', 'treatment']]}, 'NCT02290951'), ({'text': 'Subjects with topographic evidence of keratoconus', 'entities': [['39', '50', 'chronic_disease']]}, 'NCT02952365'), ({'text': 'male', 'entities': [['1', '5', 'gender']]}, 'NCT03006770'), ({'text': 'Contraception: Women of child-bearing potential must agree to use an effective method of birth control during treatment and for 3 months after receiving their last dose of study drug', 'entities': [['16', '21', 'gender'], ['54', '103', 'contraception_consent'], ['111', '120', 'treatment'], ['129', '143', 'upper_bound'], ['173', '183', 'treatment']]}, 'NCT02390752'), ({'text': 'Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication', 'entities': [['1', '9', 'chronic_disease'], ['11', '20', 'chronic_disease'], ['22', '29', 'chronic_disease'], ['31', '41', 'chronic_disease'], ['46', '75', 'chronic_disease'], ['101', '108', 'chronic_disease'], ['122', '147', 'treatment']]}, 'NCT01608438'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02979366'), ({'text': 'For Cohorts 1-3, 5 and 6: patients must have breast and/or epithelial or endometrioid ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer histologically or cytologically confirmed at the NCI that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective', 'entities': [['46', '52', 'cancer'], ['60', '70', 'cancer'], ['74', '101', 'cancer'], ['103', '128', 'cancer'], ['137', '158', 'cancer']]}, 'NCT02203513'), ({'text': 'Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status < 2', 'entities': [['23', '83', 'clinical_variable'], ['86', '87', 'upper_bound']]}, 'NCT02315196'), ({'text': 'platelets e 100,000/mm3', 'entities': [['1', '10', 'clinical_variable'], ['13', '24', 'lower_bound']]}, 'NCT02207465'), ({'text': 'Age 60 or older', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT02037139'), ({'text': 'Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity', 'entities': [['1', '15', 'chronic_disease'], ['17', '28', 'chronic_disease'], ['32', '55', 'chronic_disease'], ['59', '64', 'chronic_disease']]}, 'NCT03070145'), ({'text': 'men', 'entities': [['1', '4', 'gender']]}, 'NCT02122172'), ({'text': 'Have a history of not tolerating previous MRI scans without medication', 'entities': [['43', '46', 'treatment'], ['61', '71', 'treatment']]}, 'NCT02263729'), ({'text': 'cytogenetic abnormalities associated with myelodysplastic syndromes', 'entities': [['1', '26', 'chronic_disease'], ['43', '68', 'cancer']]}, 'NCT02928991'), ({'text': 'CBC/Platelets: Hemoglobin (HgB) greater than 10.0g/dl; white blood cell (WBC) count greater than 3000/mcl; Platelet count greater than 125,000/mcl', 'entities': [['1', '14', 'clinical_variable'], ['5', '13', 'clinical_variable'], ['16', '32', 'clinical_variable'], ['46', '54', 'lower_bound'], ['56', '84', 'clinical_variable'], ['98', '106', 'lower_bound'], ['136', '147', 'lower_bound']]}, 'NCT01925378'), ({'text': 'Archival tumor tissue or a newly obtained biopsy must be available prior to the first dose of study drug for biomarker analysis', 'entities': [['10', '15', 'cancer'], ['95', '105', 'treatment']]}, 'NCT02501096'), ({'text': 'Alpha mannosidosis', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02171104'), ({'text': 'Patient has renal failure, defined as dialysis therapy or GFR<30 mL/min/1.73 m2', 'entities': [['13', '26', 'chronic_disease'], ['39', '55', 'treatment'], ['59', '62', 'clinical_variable'], ['63', '80', 'upper_bound']]}, 'NCT02088554'), ({'text': 'age 18 - 50 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['10', '18', 'upper_bound']]}, 'NCT02302976'), ({'text': 'Blood (packed red blood cells, platelets) transfusions within 1 month prior to study start', 'entities': [['1', '55', 'treatment'], ['63', '76', 'upper_bound']]}, 'NCT02576444'), ({'text': 'Progression of acute GVHD within 3 days of systemic corticosteroids of at least 2 mg/kg prednisone or equivalent', 'entities': [['16', '26', 'chronic_disease'], ['34', '40', 'upper_bound'], ['44', '68', 'treatment'], ['81', '88', 'lower_bound'], ['89', '99', 'treatment']]}, 'NCT02525029'), ({'text': 'Stable medication for sleep for at least 1 month', 'entities': [['42', '49', 'lower_bound']]}, 'NCT03087799'), ({'text': 'Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)', 'entities': [['2', '31', 'clinical_variable'], ['36', '68', 'clinical_variable'], ['72', '81', 'upper_bound'], ['74', '81', 'lower_bound']]}, 'NCT02048722'), ({'text': 'Plan pregnancy in the next year', 'entities': [['6', '15', 'pregnancy']]}, 'NCT02002260'), ({'text': 'No disease manifestations that would be scored as a major element in the BVAS/WG', 'entities': [['74', '78', 'clinical_variable'], ['79', '81', 'clinical_variable']]}, 'NCT02108860'), ({'text': 'cardiovascular disease or elevated plasma lipids', 'entities': [['1', '23', 'chronic_disease'], ['27', '49', 'chronic_disease']]}, 'NCT02517307'), ({'text': 'Male patients must use highly effective contraception during the study and for 30 days after the final dose of imatinib', 'entities': [['1', '14', 'gender'], ['20', '54', 'contraception_consent'], ['80', '87', 'upper_bound'], ['112', '120', 'treatment']]}, 'NCT01742299'), ({'text': 'Patients must have histologically or cytologically confirmed cholangiocarcinoma that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (various solid tumors cohort, cholangiocarcinoma group only)', 'entities': [['62', '80', 'cancer'], ['138', '145', 'treatment'], ['242', '254', 'cancer']]}, 'NCT02587962'), ({'text': 'Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately', 'entities': [['10', '15', 'gender'], ['23', '31', 'pregnancy']]}, 'NCT02876302'), ({'text': 'Participation in a headache support group or other activity such as meditation or yoga intended to mitigate headache or other chronic pain must be stable for at least 4 weeks prior to beginning the preliminary screening period and should be intended to be continued for the duration of the trial. Participants will be encouraged to defer enrolling in such activities until they have completed the treatment trial', 'entities': [['168', '181', 'lower_bound'], ['398', '413', 'treatment']]}, 'NCT02266329'), ({'text': 'Currently taking psychotropic or other systemic medications', 'entities': [['18', '30', 'treatment'], ['40', '60', 'treatment']]}, 'NCT02149823'), ({'text': 'Hodgkin lymphoma (HL)', 'entities': [['1', '22', 'cancer']]}, 'NCT02593123'), ({'text': 'Prior bariatric surgery', 'entities': [['1', '24', 'treatment']]}, 'NCT02251431'), ({'text': 'Subject does not fit into 129Xe vest coil used for MRI', 'entities': [['52', '55', 'treatment']]}, 'NCT01280994'), ({'text': 'Significant unstable medical morbidity within the past 6 months', 'entities': [['51', '64', 'upper_bound']]}, 'NCT02910648'), ({'text': 'Currently engaged or planning to engage in other treatment during the course of the study (including behavior therapy, or other types of individual, family, or group psychotherapy/counseling)', 'entities': [['44', '59', 'treatment'], ['102', '118', 'treatment'], ['138', '148', 'treatment'], ['150', '156', 'treatment'], ['161', '180', 'treatment'], ['181', '191', 'treatment']]}, 'NCT02573246'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02437773'), ({'text': 'ANC > 1000/mm3 without the support of filgrastim', 'entities': [['1', '4', 'clinical_variable'], ['7', '15', 'lower_bound'], ['39', '49', 'treatment']]}, 'NCT01174121'), ({'text': 'Bilirubin =< 2.0 x upper limit of institutional normal value', 'entities': [['1', '10', 'clinical_variable'], ['14', '61', 'upper_bound']]}, 'NCT00293475'), ({'text': 'Subjects with known allergies to product components (silicone adhesives and polyurethane films (direct contact with wound), acrylic adhesives (direct contact with skin), polyethylene fabrics and super-absorbent powders (polyacrylates) (within the dressing)', 'entities': [['54', '72', 'allergy_name'], ['77', '95', 'allergy_name'], ['125', '142', 'allergy_name'], ['171', '191', 'allergy_name'], ['196', '235', 'allergy_name']]}, 'NCT02664168'), ({'text': 'Hematopoietic Cell Transplantation-Specific Comorbidity Index score (HCT-CI) =< 4 for patients in Cohort 1 and > 4 for Cohort 2', 'entities': [['1', '77', 'clinical_variable']]}, 'NCT02122081'), ({'text': "Uncontrolled or progressive systemic disease or other concurrent condition which in the Investigator's opinion makes HD-MTX an undesirable treatment option for the patient or would jeopardize compliance", 'entities': [['1', '13', 'chronic_disease'], ['17', '45', 'chronic_disease'], ['55', '75', 'chronic_disease'], ['118', '124', 'treatment'], ['140', '149', 'treatment']]}, 'NCT02422641'), ({'text': 'Caregiver is able to speak and understand either English or Spanish', 'entities': [['14', '68', 'language_fluency']]}, 'NCT03066596'), ({'text': 'Physical Exam defined by >50% obstruction', 'entities': [['1', '14', 'clinical_variable'], ['27', '30', 'lower_bound']]}, 'NCT01695967'), ({'text': 'women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropic [HCG]) within 72 hours prior enrollment and the start of nivolumab', 'entities': [['1', '6', 'gender'], ['45', '78', 'pregnancy'], ['105', '112', 'lower_bound'], ['166', '169', 'clinical_variable'], ['179', '193', 'upper_bound'], ['222', '231', 'treatment']]}, 'NCT02408861'), ({'text': 'History of noncompliance with previous medical and psychosocial treatment efforts', 'entities': [['31', '74', 'treatment']]}, 'NCT02056873'), ({'text': '18-65 year old male and female patients with primary cervical dystonia', 'entities': [['1', '3', 'lower_bound'], ['4', '11', 'upper_bound'], ['16', '40', 'gender'], ['46', '71', 'chronic_disease']]}, 'NCT02131467'), ({'text': 'Active GI hemorrhage within 2 weeks of study enrollment', 'entities': [['8', '21', 'chronic_disease'], ['29', '36', 'upper_bound']]}, 'NCT02013778'), ({'text': 'Patients with metastatic disease', 'entities': [['15', '33', 'cancer']]}, 'NCT03042897'), ({'text': 'systemic illness affecting central nervous system (CNS) function', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02856412'), ({'text': 'Currently taking medications that are not recommended to be taken in conjunction with alcohol', 'entities': [['18', '29', 'treatment']]}, 'NCT02411318'), ({'text': 'at least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02468453'), ({'text': 'schizophrenia', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02481245'), ({'text': 'Patients with active infection, un-resolving more than grade 2 transplant-related toxicities', 'entities': [['15', '31', 'chronic_disease'], ['56', '63', 'lower_bound']]}, 'NCT02985554'), ({'text': 'Negative pregnancy test done =< 7 days prior to registration/randomization, for women of childbearing potential only', 'entities': [['1', '19', 'pregnancy'], ['33', '45', 'upper_bound'], ['81', '86', 'gender']]}, 'NCT01905046'), ({'text': 'Temperature less than 100.4 F', 'entities': [['1', '12', 'clinical_variable'], ['23', '30', 'upper_bound']]}, 'NCT03185130'), ({'text': 'Donors with Grade 2-3 traumatic liver laceration', 'entities': [['13', '20', 'lower_bound'], ['21', '22', 'upper_bound'], ['33', '49', 'chronic_disease']]}, 'NCT02515708'), ({'text': 'Have a counter indication to EEG', 'entities': [['30', '33', 'treatment']]}, 'NCT02826577'), ({'text': 'Isosorbide mononitrate should not be used in cases of acute myocardial infarction with low filling pressure, acute circulatory failure (shock, vascular collapse), or hypertrophic obstructive cardiomyopathy (HOCM), constrictive pericarditis, low cardiac filling pressures, aortic/mitral valve stenosis and diseases associated with a raised intra-cranial pressure e.g following a head trauma and including cerebral hemorrhage', 'entities': [['1', '23', 'treatment'], ['55', '82', 'chronic_disease'], ['110', '162', 'chronic_disease'], ['167', '213', 'chronic_disease'], ['215', '240', 'chronic_disease'], ['242', '271', 'chronic_disease'], ['273', '301', 'chronic_disease'], ['306', '362', 'chronic_disease'], ['379', '390', 'chronic_disease'], ['405', '424', 'chronic_disease']]}, 'NCT03171480'), ({'text': 'Pulse oximetry of > 90% on room air', 'entities': [['1', '15', 'clinical_variable'], ['21', '24', 'lower_bound']]}, 'NCT01945814'), ({'text': 'Allergies to milk consumption', 'entities': [['14', '18', 'allergy_name']]}, 'NCT02918981'), ({'text': 'Subjects who have had radiotherapy to a target within 3 cm of the IVC tumor thrombus', 'entities': [['23', '35', 'treatment'], ['55', '59', 'upper_bound'], ['67', '85', 'clinical_variable']]}, 'NCT02473536'), ({'text': 'Active systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active or uncompensated major medical illnesses', 'entities': [['1', '27', 'chronic_disease'], ['45', '69', 'treatment'], ['72', '93', 'chronic_disease'], ['137', '154', 'chronic_disease']]}, 'NCT02133196'), ({'text': 'e1 hospitalization in past 12 months', 'entities': [['2', '3', 'lower_bound'], ['28', '37', 'lower_bound']]}, 'NCT02965508'), ({'text': 'Patients age <18', 'entities': [['10', '13', 'age'], ['15', '17', 'upper_bound']]}, 'NCT02829060'), ({'text': 'BMI > 27', 'entities': [['1', '4', 'bmi'], ['7', '9', 'lower_bound']]}, 'NCT01028846'), ({'text': 'Able to take enteral medication', 'entities': [['14', '32', 'treatment']]}, 'NCT01720147'), ({'text': 'Alanine aminotransaminase (ALT)', 'entities': [['1', '32', 'treatment']]}, 'NCT02549937'), ({'text': 'Infectious disease within the last month', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT03123068'), ({'text': 'Speak and read English', 'entities': [['1', '23', 'language_fluency']]}, 'NCT01782599'), ({'text': "Gaenslen's test (right)", 'entities': [['1', '16', 'treatment']]}, 'NCT02373644'), ({'text': 'active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive protocol treatment', 'entities': [['1', '30', 'chronic_disease'], ['43', '60', 'chronic_disease'], ['71', '86', 'chronic_disease'], ['152', '161', 'treatment']]}, 'NCT02106650'), ({'text': 'Hepatic transaminases (AST and ALT)', 'entities': [['24', '27', 'clinical_variable'], ['32', '35', 'clinical_variable']]}, 'NCT02016924'), ({'text': 'cirrhosis', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT03007745'), ({'text': '>300 mg/dL protein in spot urinalysis', 'entities': [['2', '11', 'lower_bound'], ['12', '19', 'clinical_variable']]}, 'NCT01757418'), ({'text': 'Has an active serious bacterial infection requiring systemic antimicrobial therapy', 'entities': [['23', '42', 'chronic_disease'], ['53', '83', 'treatment']]}, 'NCT02437370'), ({'text': 'Currently involved in another non-observational SCI research study or receiving another investigational drug', 'entities': [['89', '109', 'treatment']]}, 'NCT02524379'), ({'text': 'Alanine transaminase (ALT) =< 3 x ULN', 'entities': [['1', '27', 'clinical_variable'], ['31', '38', 'upper_bound']]}, 'NCT01905046'), ({'text': 'Experienced any of the following toxicities with prior gemcitabine adminstration (if given): capillary leak syndrome, posterior reversible encephalopathy, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, unexplained dyspnea or other evidence of severe pulmonary toxicity, or severe hepatic toxicity', 'entities': [['50', '67', 'treatment'], ['94', '117', 'chronic_disease'], ['119', '154', 'chronic_disease'], ['156', '181', 'chronic_disease'], ['183', '218', 'chronic_disease'], ['220', '239', 'chronic_disease'], ['268', '286', 'chronic_disease'], ['298', '314', 'chronic_disease']]}, 'NCT02349867'), ({'text': 'Plan to relocate to another center within the next 7-8 months', 'entities': [['52', '53', 'lower_bound'], ['54', '62', 'upper_bound']]}, 'NCT02593526'), ({'text': 'No acute worsening of pulmonary function in the past 30 days', 'entities': [['49', '61', 'upper_bound']]}, 'NCT01280994'), ({'text': 'Other concurrent infection (e.g., pneumonia, acute otitis media, streptococcal pharyngitis)', 'entities': [['7', '27', 'chronic_disease'], ['35', '44', 'chronic_disease'], ['46', '64', 'chronic_disease'], ['66', '91', 'chronic_disease']]}, 'NCT02554383'), ({'text': 'Patients must have normal organ and marrow function within 30 days of registration', 'entities': [['60', '67', 'upper_bound']]}, 'NCT02542202'), ({'text': 'presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within in last 12 months', 'entities': [['16', '36', 'treatment'], ['53', '69', 'chronic_disease'], ['73', '87', 'treatment'], ['89', '106', 'treatment'], ['110', '113', 'treatment'], ['125', '139', 'upper_bound']]}, 'NCT02209545'), ({'text': 'documented or suspected infection of the site prior to surgery', 'entities': [['56', '63', 'treatment']]}, 'NCT01773694'), ({'text': 'No other prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the patient has been disease-free for 5 years', 'entities': [['16', '26', 'cancer'], ['68', '78', 'chronic_disease'], ['82', '107', 'cancer'], ['101', '107', 'cancer'], ['109', '132', 'cancer'], ['203', '210', 'upper_bound']]}, 'NCT01618357'), ({'text': 'Females who are sexually active and able to become pregnant must agree to use birth control for duration of study if randomized to Saxenda/Placebo', 'entities': [['1', '8', 'gender'], ['52', '60', 'pregnancy'], ['66', '92', 'contraception_consent'], ['132', '139', 'treatment'], ['140', '147', 'treatment']]}, 'NCT03115424'), ({'text': 'Current smoker (expired CO e 10 ppm)', 'entities': [['17', '27', 'clinical_variable'], ['30', '36', 'lower_bound']]}, 'NCT02067975'), ({'text': 'Karnofsky performance status >= 70%', 'entities': [['1', '29', 'clinical_variable'], ['33', '36', 'lower_bound']]}, 'NCT01827384'), ({'text': 'Severe psychiatric disease', 'entities': [['8', '27', 'chronic_disease']]}, 'NCT02471430'), ({'text': 'contraception should be continued for a period of 30 days plus the time required for the study drug to undergo 5 half-lives', 'entities': [['51', '58', 'upper_bound'], ['112', '113', 'upper_bound']]}, 'NCT02519322'), ({'text': 'Use of a prohibited concomitant medication that cannot be safely discontinued or substituted', 'entities': [['21', '43', 'treatment']]}, 'NCT01990209'), ({'text': 'Patients must not have received any prior chemotherapy, radiation therapy, or endocrine therapy for their current breast cancer', 'entities': [['37', '55', 'treatment'], ['57', '74', 'treatment'], ['79', '96', 'treatment'], ['115', '128', 'cancer']]}, 'NCT02095184'), ({'text': 'brain metastases status will determine cohort allocation', 'entities': [['1', '17', 'cancer']]}, 'NCT02910700'), ({'text': 'Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck', 'entities': [['56', '79', 'cancer']]}, 'NCT02101034'), ({'text': 'Intractable seizures', 'entities': [['13', '21', 'chronic_disease']]}, 'NCT02254863'), ({'text': 'Cosmetic procedures (e.g., superficial chemical peels, exfoliation or microdermabrasion of the face) within 2 months prior to Visit 1', 'entities': [['109', '123', 'upper_bound']]}, 'NCT02075671'), ({'text': 'Unstable angina', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02842658'), ({'text': 'Patients with known or suspected prostate disease based on clinical data', 'entities': [['34', '50', 'cancer']]}, 'NCT01653093'), ({'text': 'International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless subject is receiving anticoagulant therapy', 'entities': [['1', '37', 'clinical_variable'], ['41', '62', 'clinical_variable'], ['66', '75', 'upper_bound'], ['104', '125', 'treatment']]}, 'NCT02541565'), ({'text': '>5 % weight change in the prior 6 months', 'entities': [['2', '5', 'lower_bound'], ['6', '19', 'clinical_variable'], ['27', '41', 'upper_bound']]}, 'NCT01883258'), ({'text': 'total bilirubin e2 x ULN', 'entities': [['1', '16', 'clinical_variable'], ['18', '25', 'lower_bound']]}, 'NCT02585973'), ({'text': 'Left ventricular ejection fraction (LVEF) greater than or equal to 40% by 2D echocardiogram (ECHO) or MUGA, or left ventricular shortening fraction greater than or equal to 20% by ECHO for patients receiving MAC, RIC, or RIC-MMF, or LVEF greater than or equal to 30% if the patient has radiologic evidence of aortic, renal, or coronary artery vasculitis. LVEF greater than or equal to 30% for patients receiving IOC', 'entities': [['1', '42', 'clinical_variable'], ['37', '41', 'clinical_variable'], ['68', '71', 'lower_bound'], ['75', '99', 'treatment'], ['94', '98', 'treatment'], ['103', '107', 'treatment'], ['112', '148', 'clinical_variable'], ['174', '177', 'lower_bound'], ['209', '212', 'treatment'], ['214', '217', 'treatment'], ['222', '229', 'treatment'], ['264', '267', 'lower_bound'], ['413', '416', 'treatment']]}, 'NCT02579967'), ({'text': 'Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy', 'entities': [['72', '88', 'treatment']]}, 'NCT02990481'), ({'text': 'Histologically proven diagnosis of a prior thoracic malignancy treated with thoracic external beam radiotherapy with or without systemic chemotherapy', 'entities': [['44', '63', 'cancer'], ['77', '112', 'treatment'], ['129', '150', 'treatment']]}, 'NCT01871454'), ({'text': 'Patients must have no evidence of active graft-versus-host disease at the time of the CD8+ memory T-cell infusion', 'entities': [['42', '67', 'chronic_disease'], ['87', '114', 'treatment']]}, 'NCT02424968'), ({'text': 'physician-confirmed diagnosis of HF', 'entities': [['34', '36', 'chronic_disease']]}, 'NCT02589977'), ({'text': 'Presence of TAAA', 'entities': [['13', '17', 'chronic_disease']]}, 'NCT02323581'), ({'text': 'Patients who have received previously a high dose chemotherapy regimen and autologous transplant', 'entities': [['51', '63', 'treatment'], ['76', '97', 'treatment']]}, 'NCT01270724'), ({'text': 'Patients who have received prior immunotherapy', 'entities': [['28', '47', 'treatment']]}, 'NCT01795313'), ({'text': 'Participation in another interventional study that influences gestational age at delivery or neonatal morbidity or mortality', 'entities': [['18', '46', 'treatment'], ['63', '78', 'clinical_variable']]}, 'NCT02518594'), ({'text': 'Have a contraindication to the use of metformin', 'entities': [['39', '48', 'allergy_name']]}, 'NCT02903511'), ({'text': 'Age >21 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02243631'), ({'text': 'Previous transuretheral resection of the prostate (TURP) or cryotherapy to the prostate', 'entities': [['10', '57', 'treatment'], ['61', '72', 'treatment']]}, 'NCT02353819'), ({'text': 'Platelet count e75,000/µL', 'entities': [['1', '15', 'clinical_variable'], ['17', '26', 'lower_bound']]}, 'NCT02076906'), ({'text': 'Has refractory GI disease with refractory nausea/vomiting, inflammatory bowel disease, or bowel resection that would prevent absorption', 'entities': [['16', '26', 'chronic_disease'], ['60', '86', 'chronic_disease'], ['91', '106', 'treatment']]}, 'NCT01572480'), ({'text': 'currently taking an antidepressant as defined by the MGH-ATRQ, in the current episode and are willing to take bupropion or placebo as augmentation, since we are using subjects as their own controls and we are comparing changes within subjects', 'entities': [['21', '35', 'treatment'], ['111', '120', 'treatment'], ['124', '131', 'treatment']]}, 'NCT02562430'), ({'text': 'Uncontrolled intercurrent illness', 'entities': [['14', '34', 'chronic_disease']]}, 'NCT02159703'), ({'text': 'Prostate volume as assessed by TRUS > 60 cc', 'entities': [['1', '16', 'clinical_variable'], ['32', '36', 'treatment'], ['39', '44', 'lower_bound']]}, 'NCT02339948'), ({'text': 'ECOG performance status of 0, 1 or 2', 'entities': [['1', '24', 'clinical_variable'], ['28', '29', 'lower_bound'], ['36', '37', 'upper_bound']]}, 'NCT03175978'), ({'text': 'Uses of inhaled and topical steroids are allowed', 'entities': [['21', '36', 'treatment']]}, 'NCT02310464'), ({'text': 'Decreased processing speed (defined as 0.5 SD below age-adjusted norms on the Digit Symbol Test)', 'entities': [['40', '43', 'lower_bound'], ['53', '56', 'age']]}, 'NCT02744391'), ({'text': 'Mitral valve orifice area < 4.0 cm2 assessed by site based on a transthoracic echocardiogram (TTE) within 90 days prior to subject registration', 'entities': [['1', '26', 'clinical_variable'], ['29', '36', 'upper_bound'], ['65', '99', 'treatment'], ['107', '120', 'upper_bound']]}, 'NCT01626079'), ({'text': 'Ongoing immunosuppressive therapy (prednisone or equivalent d10 mg daily allowed as clinically warranted)', 'entities': [['1', '34', 'treatment'], ['36', '46', 'treatment'], ['62', '73', 'upper_bound']]}, 'NCT02493530'), ({'text': 'ctive, known or suspected autoimmune disease', 'entities': [['27', '45', 'chronic_disease']]}, 'NCT02869789'), ({'text': 'Post HNC primary treatment', 'entities': [['1', '27', 'treatment']]}, 'NCT03030859'), ({'text': 'Females of child-bearing potential must be willing to practice acceptable methods of birth control', 'entities': [['1', '8', 'gender']]}, 'NCT02124772'), ({'text': 'Unequivocal evidence of progressive disease on contrast-enhanced brain computerized tomography (CT) or magnetic resonance imaging (MRI) as defined by Response Assessment in Neuro-Oncology Criteria (RANO), or have documented recurrent glioblastoma on diagnostic biopsy', 'entities': [['72', '100', 'treatment'], ['104', '136', 'treatment'], ['235', '247', 'cancer'], ['262', '268', 'treatment']]}, 'NCT02525692'), ({'text': 'Steroids less than 0.5 mg/kg/day prednisone (or equivalent)', 'entities': [['1', '9', 'treatment'], ['20', '33', 'upper_bound'], ['34', '44', 'treatment']]}, 'NCT02203903'), ({'text': 'Diagnosis of inflammatory breast cancer', 'entities': [['14', '40', 'cancer']]}, 'NCT02315196'), ({'text': 'Patients requiring warfarin therapy are excluded, low molecular weight heparin is permitted', 'entities': [['20', '36', 'treatment'], ['51', '79', 'treatment']]}, 'NCT01676753'), ({'text': 'Subject has active malignant tumors other than AML or myelodysplastic syndrome (MDS)', 'entities': [['20', '36', 'cancer'], ['48', '51', 'cancer'], ['55', '85', 'cancer']]}, 'NCT02236013'), ({'text': 'females', 'entities': [['1', '8', 'gender']]}, 'NCT02322203'), ({'text': 'Adequate renal function defined as creatinine less than or equal to 1.5 X ULN (upper limit of normal) or calculated creatinine clearance greater than or equal to 40 mL/min per the Cockcroft and Gault formula with creatinine levels greater than 1.5 X ULN', 'entities': [['36', '46', 'clinical_variable'], ['69', '102', 'upper_bound'], ['69', '78', 'lower_bound'], ['106', '137', 'clinical_variable'], ['163', '172', 'lower_bound'], ['214', '231', 'clinical_variable']]}, 'NCT02501096'), ({'text': 'Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation is d 60 days prior to the date of registration', 'entities': [['1', '38', 'treatment'], ['21', '38', 'treatment'], ['43', '58', 'cancer'], ['114', '127', 'upper_bound']]}, 'NCT02064036'), ({'text': 'Women with metastatic breast cancer (measurable or evaluable including bone metastases only)', 'entities': [['1', '6', 'gender'], ['12', '36', 'cancer'], ['72', '87', 'cancer']]}, 'NCT02531932'), ({'text': 'Phantom limb pain', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT03029884'), ({'text': 'Any other cancer from which the patient has been disease-free for less than 5 years (except treated and cured basal-cell or squamous-cell skin cancer, superficial bladder cancer, or treated carcinoma in situ of the cervix, breast, or bladder and treated localized prostate cancer with undetectable PSA for 2 years)', 'entities': [['11', '17', 'cancer'], ['77', '84', 'upper_bound'], ['111', '121', 'cancer'], ['125', '150', 'cancer'], ['152', '178', 'cancer'], ['164', '171', 'cancer'], ['191', '222', 'cancer'], ['224', '230', 'cancer'], ['265', '280', 'cancer'], ['307', '314', 'upper_bound']]}, 'NCT02535533'), ({'text': 'Previous radiation in the operated breast', 'entities': [['1', '42', 'treatment']]}, 'NCT02406599'), ({'text': 'Histopathologically or cytologically confirmed NSCLC', 'entities': [['48', '53', 'cancer']]}, 'NCT02504489'), ({'text': 'On histological examination, the tumor must be ductal carcinoma in situ (DCIS) or invasive adenocarcinoma of the breast', 'entities': [['34', '39', 'cancer'], ['48', '79', 'cancer'], ['92', '120', 'cancer']]}, 'NCT01245712'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT01573429'), ({'text': 'Women of childbearing potential and male participants must practice adequate contraception', 'entities': [['1', '6', 'gender'], ['37', '54', 'gender'], ['78', '91', 'contraception_consent']]}, 'NCT01993810'), ({'text': 'Patients with primary platinum refractory disease defined as progression during or within 3 months after receiving first-line platinum based chemotherapy', 'entities': [['23', '50', 'cancer'], ['91', '105', 'upper_bound'], ['127', '154', 'treatment']]}, 'NCT02203513'), ({'text': 'Renal: GFR e 50 ml/min/1.73m2', 'entities': [['8', '11', 'clinical_variable'], ['14', '30', 'lower_bound']]}, 'NCT01505569'), ({'text': 'Patients with pre-existing retinal disease on ophthalmologic exam will be excluded due to potential eye toxicities known to be associated with onalespib', 'entities': [['28', '43', 'chronic_disease'], ['144', '153', 'treatment']]}, 'NCT02503709'), ({'text': 'Bradycardia (resting heart rate < 60 bpm) will be reviewed by a study physician', 'entities': [['1', '12', 'chronic_disease'], ['14', '32', 'clinical_variable'], ['35', '41', 'upper_bound']]}, 'NCT02192398'), ({'text': 'Extensive liver tumor burden, defined as more than 75% of the liver', 'entities': [['11', '29', 'cancer'], ['52', '55', 'lower_bound']]}, 'NCT01360606'), ({'text': 'Access to a computer with internet and the ability to complete daily online surveys', 'entities': [['1', '35', 'technology_access']]}, 'NCT03058679'), ({'text': 'Willingness to authorize collection of tissue from surgically-resected liver or clinical liver biopsy for analyses', 'entities': [['52', '77', 'treatment'], ['90', '102', 'treatment']]}, 'NCT02273362'), ({'text': 'antiasthma agents that are systemic corticosteroids', 'entities': [['1', '18', 'treatment'], ['28', '52', 'treatment']]}, 'NCT02233868'), ({'text': 'Veterans with Stages III and IV Chronic Kidney Disease (CKD)', 'entities': [['15', '61', 'chronic_disease']]}, 'NCT02411773'), ({'text': 'Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 8 weeks use of radioimmunotherapy within 3 months', 'entities': [['1', '31', 'treatment'], ['39', '46', 'upper_bound'], ['80', '87', 'upper_bound'], ['95', '113', 'treatment'], ['121', '129', 'upper_bound']]}, 'NCT01996865'), ({'text': 'The diagnosis of bipolar disorder or schizophrenia or schizoaffective disorder', 'entities': [['18', '34', 'chronic_disease'], ['38', '51', 'chronic_disease'], ['55', '79', 'chronic_disease']]}, 'NCT02862210'), ({'text': 'Presence of regional nodal disease or unequivocal distant metastases', 'entities': [['13', '35', 'chronic_disease']]}, 'NCT02565498'), ({'text': 'Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the Study Chair', 'entities': [['45', '83', 'treatment'], ['110', '123', 'treatment'], ['128', '134', 'chronic_disease']]}, 'NCT02451423'), ({'text': 'Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup', 'entities': [['52', '70', 'cancer']]}, 'NCT01993810'), ({'text': 'The subject is pregnant', 'entities': [['16', '24', 'pregnancy']]}, 'NCT01037790'), ({'text': 'CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms', 'entities': [['1', '3', 'treatment'], ['7', '39', 'treatment'], ['89', '107', 'chronic_disease']]}, 'NCT02542202'), ({'text': 'Documented LVEF less than or equal to 45% tested in patients', 'entities': [['12', '16', 'clinical_variable'], ['39', '42', 'upper_bound']]}, 'NCT01967823'), ({'text': 'Patients are excluded if they have a history of metastatic cancer in addition to melanoma or a history of uncontrolled non-metastatic cancer', 'entities': [['49', '59', 'cancer'], ['60', '66', 'cancer']]}, 'NCT01644591'), ({'text': 'Male subjects should agree to use adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of therapy', 'entities': [['1', '14', 'gender'], ['22', '67', 'contraception_consent'], ['106', '113', 'treatment'], ['122', '136', 'upper_bound']]}, 'NCT02525692'), ({'text': 'Participant has diabetic macular edema and/or diabetic retinopathy', 'entities': [['17', '39', 'chronic_disease'], ['47', '67', 'chronic_disease']]}, 'NCT02862938'), ({'text': 'Currently (within 30 days prior to enrollment) taking specific pulmonary arterial hypertension therapy (e.g., bosentan, ambrisentan, tadalafil, sildenafil, epoprostenol, treprostinil, iloprost, beraprost), sildenafil and tadalafil for erectile dysfunction is permitted', 'entities': [['19', '32', 'upper_bound'], ['64', '103', 'treatment'], ['111', '119', 'treatment'], ['121', '132', 'treatment'], ['134', '143', 'treatment'], ['145', '155', 'treatment'], ['157', '169', 'treatment'], ['171', '183', 'treatment'], ['185', '193', 'treatment'], ['195', '204', 'treatment'], ['236', '256', 'chronic_disease']]}, 'NCT02178566'), ({'text': 'Life expectancy > 12 weeks or e 24 weeks for Part 3 and Part 4 MF subjects', 'entities': [['1', '16', 'clinical_variable'], ['19', '27', 'lower_bound'], ['33', '41', 'lower_bound']]}, 'NCT02587598'), ({'text': 'Patients with any prior chemotherapy regimens', 'entities': [['19', '46', 'treatment']]}, 'NCT02565901'), ({'text': 'psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02417701'), ({'text': 'Age 50-89 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '16', 'upper_bound']]}, 'NCT03082612'), ({'text': 'females', 'entities': [['1', '8', 'gender']]}, 'NCT01011777'), ({'text': 'Age 30-100', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '11', 'upper_bound']]}, 'NCT01841957'), ({'text': 'vaccine', 'entities': [['1', '8', 'treatment']]}, 'NCT01595529'), ({'text': 'Not reachable consistently by telephone', 'entities': [['1', '40', 'technology_access']]}, 'NCT02969577'), ({'text': 'Major depression that is not substance-induced)', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT03154580'), ({'text': 'Chest radiograph or CT scan within </= 3 months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency', 'entities': [['1', '17', 'treatment'], ['21', '28', 'treatment'], ['40', '54', 'upper_bound'], ['85', '92', 'cancer'], ['96', '130', 'cancer'], ['134', '147', 'cancer'], ['174', '199', 'chronic_disease']]}, 'NCT02464696'), ({'text': 'Inability to read and understand English', 'entities': [['1', '41', 'language_fluency']]}, 'NCT02415660'), ({'text': 'History of cerebral infection / hemorrhage', 'entities': [['12', '30', 'chronic_disease'], ['33', '43', 'chronic_disease']]}, 'NCT02359864'), ({'text': 'Technical limitations precluding fetoscopic surgery', 'entities': [['34', '52', 'treatment']]}, 'NCT02530073'), ({'text': 'Subjects must NOT be taking metformin or have been on metformin in the past 6 months', 'entities': [['29', '38', 'treatment'], ['72', '85', 'upper_bound']]}, 'NCT02437812'), ({'text': 'Active infection', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02131467'), ({'text': 'Willigness to use contraception', 'entities': [['1', '32', 'contraception_consent']]}, 'NCT02362997'), ({'text': 'transferrin saturation (TS) test and serum ferritin (SF) test', 'entities': [['1', '33', 'treatment'], ['38', '62', 'treatment']]}, 'NCT02359097'), ({'text': 'Total bilirubin =< 1.5 mg/dL, unless increase is due to hemolysis or congenital disorder', 'entities': [['1', '16', 'clinical_variable'], ['20', '29', 'upper_bound'], ['57', '66', 'chronic_disease'], ['70', '89', 'chronic_disease']]}, 'NCT02257138'), ({'text': 'Undergoing allogeneic HSC transplantation after a myeloablative TBI-, busulfan-, or (non-myeloablative) melphalan-based pre-transplant conditioning regimen', 'entities': [['12', '42', 'treatment'], ['51', '68', 'treatment'], ['71', '79', 'treatment'], ['85', '135', 'treatment']]}, 'NCT02338232'), ({'text': 'Uncontrolled hypertension', 'entities': [['14', '26', 'chronic_disease']]}, 'NCT02648347'), ({'text': 'Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular or systemic administration', 'entities': [['61', '74', 'upper_bound']]}, 'NCT02862938'), ({'text': 'Urine protein to creatinine ratio (UPC) < 0.3 g/l', 'entities': [['1', '40', 'clinical_variable'], ['43', '50', 'upper_bound']]}, 'NCT02110069'), ({'text': 'Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug', 'entities': [['21', '35', 'treatment'], ['37', '49', 'treatment'], ['51', '68', 'treatment'], ['70', '83', 'treatment'], ['88', '104', 'treatment'], ['109', '141', 'treatment']]}, 'NCT02519322'), ({'text': 'Hemoglobin >= 9 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['15', '21', 'lower_bound']]}, 'NCT02047474'), ({'text': 'Has a less than 6 month life expectancy', 'entities': [['17', '24', 'upper_bound'], ['25', '40', 'clinical_variable']]}, 'NCT02442635'), ({'text': 'Has a malignancy that is known to contain a non synonymous mutation, insertion, or deletion in the TP53 gene determined previously or at screening', 'entities': [['7', '17', 'cancer']]}, 'NCT02319369'), ({'text': 'N3 nodal disease', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02592551'), ({'text': 'Infections requiring administration of ganciclovir', 'entities': [['1', '11', 'chronic_disease'], ['40', '51', 'treatment']]}, 'NCT00914628'), ({'text': 'Hemoglobinopathies per protocol', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT01966367'), ({'text': 'self-identify as Latino/Hispanic or identify as having a main partner who identifies as Latino/Hispanic', 'entities': [['18', '33', 'ethnicity']]}, 'NCT03048838'), ({'text': 'Age e 18 years at the time of informed consent', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02343042'), ({'text': 'History of clinically symptomatic pancreatitis within last year', 'entities': [['23', '47', 'chronic_disease']]}, 'NCT01851694'), ({'text': 'The last dose of colony stimulating factors', 'entities': [['18', '44', 'treatment']]}, 'NCT02076906'), ({'text': 'Receiving erythropoietin (EPO) therapy', 'entities': [['11', '39', 'treatment']]}, 'NCT02570854'), ({'text': 'Patients enrolled at Dose Level 6 or higher in the phase I portion of the trial must have at least one tumor mass suitable and easily accessible for excisional biopsy, or alternatively, accessible for CT or ultrasound guided core needle biopsy', 'entities': [['100', '103', 'lower_bound'], ['104', '109', 'cancer'], ['150', '167', 'treatment'], ['202', '204', 'treatment'], ['208', '218', 'treatment'], ['226', '244', 'treatment']]}, 'NCT01562626'), ({'text': 'immunosuppressive drugs (e.g., steroids)', 'entities': [['1', '24', 'treatment'], ['32', '40', 'treatment']]}, 'NCT00186927'), ({'text': 'Enrolled in grades 3-7', 'entities': [['13', '21', 'lower_bound'], ['22', '23', 'upper_bound']]}, 'NCT02877875'), ({'text': 'ages 40-60', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '11', 'upper_bound']]}, 'NCT02974985'), ({'text': 'nursing women', 'entities': [['9', '14', 'gender']]}, 'NCT02991651'), ({'text': 'Down syndrome', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02512926'), ({'text': 'The effects of propranolol on the developing human fetus may be detrimental', 'entities': [['16', '27', 'treatment']]}, 'NCT02013492'), ({'text': 'Active vitamin D analogue use (i.e. calcitriol, paricalcitol, doxercalciferol)', 'entities': [['8', '17', 'treatment'], ['37', '47', 'treatment'], ['49', '61', 'treatment'], ['63', '78', 'treatment']]}, 'NCT02209636'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02411318'), ({'text': 'conservative treatment of tennis elbow is recommended as standard of care treatment', 'entities': [['27', '39', 'chronic_disease']]}, 'NCT01897259'), ({'text': 'Cancer treated with curative surgery without chemotherapy/radiation therapy > 5 years previously will be allowed', 'entities': [['1', '7', 'cancer'], ['21', '37', 'treatment'], ['46', '58', 'treatment'], ['59', '76', 'treatment'], ['79', '86', 'lower_bound']]}, 'NCT02016781'), ({'text': 'patient must be off the drug for at least 5 half-lives prior to registration to the treatment step (Step 1, 3, 5, 7)', 'entities': [['43', '44', 'lower_bound'], ['85', '94', 'treatment']]}, 'NCT02465060'), ({'text': 'Participant must have evidence of early or intermediate AMD as defined by characteristic presence of drusen and/or pigmentary changes', 'entities': [['57', '60', 'chronic_disease']]}, 'NCT02564978'), ({'text': 'History of or concurrent non-invasive UC involving a portion of urinary tract outside of the bladder', 'entities': [['26', '41', 'cancer']]}, 'NCT03171493'), ({'text': 'Patients may have received prior post-operative platinum based chemotherapy as per standard of care', 'entities': [['28', '57', 'treatment'], ['64', '76', 'treatment']]}, 'NCT02273375'), ({'text': 'pregnancy tests must be obtained in girls who are post-menarchal', 'entities': [['1', '10', 'pregnancy'], ['37', '42', 'gender']]}, 'NCT02304458'), ({'text': 'Adjuvant HER2-targeted therapy and endocrine therapy may still be ongoing at the time of study enrollment', 'entities': [['1', '31', 'treatment'], ['36', '53', 'treatment']]}, 'NCT03143894'), ({'text': 'Females of childbearing potential should have a negative serum beta-HCG test within 1 week of beginning apheresis', 'entities': [['1', '8', 'gender'], ['49', '72', 'pregnancy'], ['85', '91', 'upper_bound']]}, 'NCT02452697'), ({'text': 'required manual disimpaction anytime prior to randomization or disimpaction during in-patient hospitalization within one year prior to randomization', 'entities': [['118', '132', 'upper_bound']]}, 'NCT02559817'), ({'text': 'abnormal nocturnal BP load (>25% of sleep BP readings >95th percentile as defined by AHA ABPM guidelines)', 'entities': [['1', '22', 'clinical_variable'], ['20', '22', 'clinical_variable'], ['30', '33', 'lower_bound'], ['56', '71', 'lower_bound']]}, 'NCT02373241'), ({'text': 'BMI <30 kg/m2', 'entities': [['1', '4', 'bmi'], ['6', '14', 'upper_bound']]}, 'NCT02918981'), ({'text': 'Active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold, or HIV infection', 'entities': [['25', '34', 'chronic_disease'], ['46', '61', 'treatment'], ['72', '105', 'chronic_disease'], ['124', '137', 'chronic_disease']]}, 'NCT01908777'), ({'text': 'For Stratum 1: CD4+ cell count greater than 200 cells/mm^3 obtained within 2 weeks prior to enrollment at any United States (U.S.) laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent', 'entities': [['16', '31', 'clinical_variable'], ['45', '59', 'lower_bound'], ['76', '89', 'upper_bound']]}, 'NCT02408861'), ({'text': 'Developmental delay', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT03005951'), ({'text': 'Advanced dementia', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT01697865'), ({'text': 'Ability to initiate the first hyperbaric oxygen treatment within 14 hours of admission in patients requiring a craniotomy/craniectomy or major surgical procedure', 'entities': [['25', '58', 'treatment'], ['66', '74', 'upper_bound'], ['112', '122', 'treatment'], ['123', '134', 'treatment'], ['138', '162', 'treatment']]}, 'NCT02407028'), ({'text': '18 years of age and older', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT02410707'), ({'text': 'no phone access', 'entities': [['4', '16', 'technology_access']]}, 'NCT01530958'), ({'text': 'Resection of a sub-aortic membrane not requiring myectomy', 'entities': [['1', '35', 'treatment'], ['50', '58', 'treatment']]}, 'NCT02088554'), ({'text': 'Patients who are currently participating in other clinical trials of compounds that my change IKAP gene expression', 'entities': [['45', '66', 'treatment']]}, 'NCT02276716'), ({'text': 'Hypertension (BP >140/90) present at screening', 'entities': [['1', '13', 'chronic_disease'], ['15', '17', 'clinical_variable'], ['19', '25', 'lower_bound']]}, 'NCT03152058'), ({'text': 'Pregnant woman can be included because study involves local intervention, no new drugs', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT01910818'), ({'text': 'Mental/emotional/developmental disability', 'entities': [['1', '42', 'chronic_disease']]}, 'NCT02959671'), ({'text': 'Performance status score 0-1', 'entities': [['1', '25', 'clinical_variable'], ['26', '27', 'lower_bound'], ['28', '29', 'upper_bound']]}, 'NCT02110992'), ({'text': 'The effects of nivolumab on the developing human fetus are unknown', 'entities': [['16', '25', 'treatment']]}, 'NCT02259621'), ({'text': 'Currently using concomitant medications that are strong inhibitors or inducers of CYP3A4', 'entities': [['83', '89', 'treatment']]}, 'NCT02857270'), ({'text': 'Major surgery within 4 weeks', 'entities': [['1', '14', 'treatment'], ['22', '29', 'upper_bound']]}, 'NCT02366819'), ({'text': 'Active infection requiring parenteral antibiotics', 'entities': [['1', '17', 'chronic_disease'], ['28', '50', 'treatment']]}, 'NCT02020707'), ({'text': 'MRI findings suggestive of active hepatitis, significant fibrosis, inconclusive evidence of cirrhosis, or liver iron concentration e15 mg/g require follow-up liver biopsy in subjects e18 years of age', 'entities': [['1', '4', 'treatment'], ['35', '44', 'chronic_disease'], ['58', '66', 'chronic_disease'], ['93', '102', 'chronic_disease'], ['107', '131', 'clinical_variable'], ['133', '140', 'lower_bound'], ['159', '171', 'treatment'], ['185', '193', 'lower_bound'], ['197', '200', 'age']]}, 'NCT02140554'), ({'text': 'clinically relevant arrhythmias', 'entities': [['21', '32', 'chronic_disease']]}, 'NCT03165227'), ({'text': 'Measured creatinine clearance <20 ml/min', 'entities': [['10', '30', 'clinical_variable'], ['32', '41', 'upper_bound']]}, 'NCT01366612'), ({'text': 'Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study', 'entities': [['84', '93', 'treatment']]}, 'NCT01983462'), ({'text': 'A shorter washout may be allowed if participant is experiencing progressive disease despite ongoing treatment', 'entities': [['93', '110', 'treatment']]}, 'NCT01871727'), ({'text': 'aged 18 years', 'entities': [['1', '5', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02180412'), ({'text': 'antihistamines (sedating)', 'entities': [['1', '15', 'treatment']]}, 'NCT02233868'), ({'text': 'Uncontrolled viral, bacterial, or fungal infections', 'entities': [['14', '19', 'chronic_disease'], ['21', '30', 'chronic_disease'], ['35', '52', 'chronic_disease']]}, 'NCT01804634'), ({'text': 'with at least one lesion > 20 mm and d 50 mm in maximal diameter and determined to be appropriate for SRS and gross total resection; all other brain metastases are appropriate for SRS', 'entities': [['15', '18', 'lower_bound'], ['28', '33', 'lower_bound'], ['40', '45', 'upper_bound'], ['103', '106', 'treatment'], ['144', '160', 'cancer']]}, 'NCT01891318'), ({'text': 'Subject weighs >=4 kg to <30 kg at Visit 1', 'entities': [['9', '15', 'clinical_variable'], ['18', '22', 'lower_bound'], ['27', '32', 'upper_bound']]}, 'NCT02477839'), ({'text': 'Presence of metastatic disease', 'entities': [['13', '31', 'cancer']]}, 'NCT02456857'), ({'text': 'MCL', 'entities': [['1', '4', 'cancer']]}, 'NCT02561988'), ({'text': 'Patients with prior malignancies are allowed, provided they have been treated with curative intent and have no evidence of active disease', 'entities': [['21', '33', 'cancer'], ['84', '99', 'treatment']]}, 'NCT02303977'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of 0-1', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'lower_bound'], ['67', '68', 'upper_bound']]}, 'NCT02120222'), ({'text': 'History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years', 'entities': [['12', '18', 'cancer'], ['30', '42', 'upper_bound'], ['51', '71', 'cancer'], ['73', '100', 'cancer'], ['102', '117', 'cancer'], ['121', '138', 'cancer'], ['180', '192', 'lower_bound']]}, 'NCT01760005'), ({'text': 'Prior systemic chemotherapy for the current cancer', 'entities': [['7', '28', 'treatment'], ['45', '51', 'cancer']]}, 'NCT02567422'), ({'text': 'BMI <16', 'entities': [['1', '4', 'bmi'], ['6', '8', 'upper_bound']]}, 'NCT03058679'), ({'text': 'Dose interruptions up to 7 days due to medical necessity are allowed', 'entities': [['26', '32', 'upper_bound']]}, 'NCT02836574'), ({'text': 'caused by at least one pathogenic MYO7A mutation on both alleles', 'entities': [['20', '23', 'lower_bound'], ['24', '49', 'chronic_disease']]}, 'NCT01505062'), ({'text': 'Uncontrolled diabetes mellitus (fasting plasma glucose > 130 mg/dL despite optimal medical management of hyperglycemia)', 'entities': [['14', '31', 'chronic_disease'], ['33', '55', 'clinical_variable'], ['58', '67', 'lower_bound'], ['106', '119', 'chronic_disease']]}, 'NCT02417701'), ({'text': 'Deep brain stimulator implants', 'entities': [['1', '31', 'treatment']]}, 'NCT02457832'), ({'text': 'Patients must have disease amenable to biopsy at the time of enrollment as biopsies are required for study participation', 'entities': [['40', '46', 'treatment'], ['76', '84', 'treatment']]}, 'NCT01928576'), ({'text': 'Is receiving concomitant treatment with a strong inhibitor or inducer of CYP3A4/5', 'entities': [['14', '82', 'treatment']]}, 'NCT01877382'), ({'text': 'Baseline corrected QT interval (QTcF) < 480 ms', 'entities': [['1', '38', 'clinical_variable'], ['41', '47', 'upper_bound']]}, 'NCT02907918'), ({'text': 'Patients taking anticoagulants, such as warfarin, heparin, aspirin, pentoxifylline, clopidogrel or ticlopidine', 'entities': [['17', '31', 'treatment'], ['41', '49', 'treatment'], ['51', '58', 'treatment'], ['60', '67', 'treatment'], ['69', '83', 'treatment'], ['85', '96', 'treatment'], ['100', '111', 'treatment']]}, 'NCT02276716'), ({'text': 'X-linked Lymphoproliferative Disease (XLP)', 'entities': [['1', '43', 'chronic_disease']]}, 'NCT01652092'), ({'text': 'DCIS or Stage I-III primary invasive carcinoma of the breast', 'entities': [['1', '5', 'cancer'], ['9', '16', 'lower_bound'], ['17', '20', 'upper_bound'], ['21', '61', 'cancer']]}, 'NCT03113825'), ({'text': 'Any condition that requires or is likely to require treatment with systemic corticosteroids within the Core Study Period and short term follow-up', 'entities': [['53', '92', 'treatment']]}, 'NCT02281409'), ({'text': 'Premenopausal females who are not practicing acceptable contraceptive methods Participation in another trial with an investigational drug', 'entities': [['15', '22', 'gender'], ['31', '78', 'contraception_consent'], ['96', '109', 'treatment']]}, 'NCT02911792'), ({'text': 'Documented human immunodeficiency virus (HIV) infection, genital warts, chancroid, or pelvic inflammatory disease that will require long term treatment', 'entities': [['12', '56', 'chronic_disease'], ['58', '71', 'chronic_disease'], ['73', '82', 'chronic_disease'], ['87', '114', 'chronic_disease'], ['143', '152', 'treatment']]}, 'NCT02382419'), ({'text': 'Patients with estimated fetal weight >5000 grams', 'entities': [['25', '37', 'clinical_variable'], ['39', '49', 'lower_bound']]}, 'NCT02762773'), ({'text': 'Have MRI or TMS contraindications such as pre-injury claustrophobia, metal in eyes/face or brain', 'entities': [['6', '9', 'treatment'], ['13', '16', 'treatment'], ['54', '68', 'chronic_disease']]}, 'NCT02366754'), ({'text': "must have histologically or cytologically confirmed relapsed or primary refractory lymphoma (including Hodgkin's Lymphoma) staged with Positron Emission Tomography (PET) scan to have", 'entities': [['84', '92', 'cancer'], ['104', '122', 'cancer'], ['136', '175', 'treatment']]}, 'NCT02059239'), ({'text': 'Patients who are known to be human immunodeficiency virus (HIV)+ are eligible providing they meet all of the following additional criteria within 28 days prior to registration', 'entities': [['30', '64', 'chronic_disease'], ['147', '160', 'upper_bound']]}, 'NCT01925131'), ({'text': 'known allergy to dogs', 'entities': [['18', '22', 'allergy_name']]}, 'NCT03059407'), ({'text': 'Chronic active hepatitis B infection as defined by presence of HBsAg', 'entities': [['1', '37', 'chronic_disease'], ['64', '69', 'clinical_variable']]}, 'NCT01896921'), ({'text': 'Subject has a hemodynamically significant congenital heart disease', 'entities': [['43', '67', 'chronic_disease']]}, 'NCT02477839'), ({'text': 'Growth factors (e.g. Procrit®, Aranesp®, Neulasta®)', 'entities': [['22', '29', 'treatment'], ['32', '39', 'treatment'], ['42', '50', 'treatment']]}, 'NCT02382549'), ({'text': 'Flaxseed supplementation may be contraindicated in patients with acute abdomen, esophageal stricture or perforation, dysphagia, GI obstruction or ileus, acute intestinal inflammation or unexplained abdominal pain. Patients with any of these conditions will be excluded from this trial as the high fiber content of flaxseed may make these conditions worse', 'entities': [['1', '9', 'treatment'], ['66', '79', 'chronic_disease'], ['81', '116', 'chronic_disease'], ['118', '127', 'chronic_disease'], ['129', '143', 'chronic_disease'], ['147', '152', 'chronic_disease'], ['154', '183', 'chronic_disease']]}, 'NCT02324439'), ({'text': 'End Stage Renal Disease (ESRD) or documented history of renal replacement / dialysis', 'entities': [['1', '31', 'chronic_disease'], ['57', '74', 'treatment'], ['77', '85', 'treatment']]}, 'NCT02513797'), ({'text': 'Males', 'entities': [['1', '6', 'gender']]}, 'NCT01943851'), ({'text': 'must agree to use highly effective contraception (see list below) prior to study entry, for the duration of study participation, and for 3 months after completion of study', 'entities': [['6', '49', 'contraception_consent'], ['138', '152', 'upper_bound']]}, 'NCT01827384'), ({'text': 'hormone therapy for prostate cancer', 'entities': [['1', '16', 'treatment'], ['21', '36', 'cancer']]}, 'NCT02452268'), ({'text': 'Patients with abnormal bladder capacity (i.e., less than 100 cc)', 'entities': [['15', '40', 'clinical_variable'], ['58', '64', 'upper_bound']]}, 'NCT01953263'), ({'text': "Participants with known Li-Fraumeni or Cowden's Disease", 'entities': [['25', '36', 'cancer'], ['40', '56', 'cancer']]}, 'NCT02335671'), ({'text': '>5 × ULN if hepatic metastases', 'entities': [['2', '9', 'lower_bound'], ['13', '31', 'cancer']]}, 'NCT03037385'), ({'text': 'Surgery within the past 8 weeks', 'entities': [['1', '8', 'treatment'], ['20', '32', 'upper_bound']]}, 'NCT02606045'), ({'text': 'Any non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #24) that patients experienced from treatments in previous clinical studies must have resolved to d Grade 2 by Cycle 1 Day 1', 'entities': [['5', '33', 'clinical_variable'], ['46', '67', 'chronic_disease'], ['140', '150', 'treatment'], ['154', '179', 'treatment'], ['204', '211', 'upper_bound']]}, 'NCT02343042'), ({'text': 'Patients must have histologically documented or cytologically confirmed Hodgkin lymphoma', 'entities': [['73', '89', 'cancer']]}, 'NCT03016871'), ({'text': 'currently treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix, breast, or bladder, or surgically removed melanoma in situ of the skin (stage 0) with histologically confirmed free margins of excision', 'entities': [['19', '32', 'cancer'], ['37', '69', 'cancer'], ['71', '102', 'cancer'], ['104', '110', 'cancer'], ['115', '122', 'cancer'], ['146', '174', 'cancer']]}, 'NCT02232516'), ({'text': 'Patients with more than one malignant primary colon cancer will be excluded', 'entities': [['25', '28', 'lower_bound'], ['29', '59', 'cancer']]}, 'NCT02448173'), ({'text': 'Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration at moderate to high risk for recurrence', 'entities': [['70', '94', 'cancer'], ['102', '110', 'upper_bound']]}, 'NCT02064036'), ({'text': 'Zubrod performance status 0-3', 'entities': [['1', '26', 'clinical_variable'], ['27', '28', 'lower_bound'], ['29', '30', 'upper_bound']]}, 'NCT01371630'), ({'text': 'Ongoing infection > grade 2', 'entities': [['9', '18', 'clinical_variable'], ['21', '28', 'lower_bound']]}, 'NCT02466009'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03145298'), ({'text': 'Medically stable - cleared for surgery', 'entities': [['32', '39', 'treatment']]}, 'NCT02329652'), ({'text': 'Serum M-protein e 0.5 g/dL by serum protein electrophoresis (SPEP) or, for IgA myeloma, by quantitative IgA', 'entities': [['1', '16', 'clinical_variable'], ['19', '27', 'lower_bound'], ['31', '67', 'treatment'], ['76', '87', 'cancer']]}, 'NCT02343042'), ({'text': 'ALT and AST less than or equal to 3 x upper limits of normal', 'entities': [['1', '4', 'clinical_variable'], ['9', '12', 'clinical_variable'], ['35', '61', 'upper_bound']]}, 'NCT01059786'), ({'text': 'Performance Status: ECOG 0-1', 'entities': [['1', '19', 'clinical_variable'], ['21', '25', 'clinical_variable'], ['26', '27', 'lower_bound'], ['28', '29', 'upper_bound']]}, 'NCT01730118'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status d 1', 'entities': [['1', '61', 'clinical_variable'], ['64', '65', 'upper_bound']]}, 'NCT02963831'), ({'text': 'Women with laparotomy incisions left open due to case classification as contaminated or dirty', 'entities': [['1', '6', 'gender'], ['12', '32', 'treatment']]}, 'NCT02682316'), ({'text': 'wound greater than 1cm in length', 'entities': [['20', '23', 'lower_bound']]}, 'NCT00870064'), ({'text': 'use of any investigational drug within 28 days before start of trial treatment', 'entities': [['12', '32', 'treatment'], ['40', '47', 'upper_bound']]}, 'NCT03104699'), ({'text': 'Female patients must be at least 1 year postmenopausal or surgically sterile; or must agree to use a medically acceptable form of contraception', 'entities': [['1', '16', 'gender'], ['34', '40', 'lower_bound'], ['87', '144', 'contraception_consent']]}, 'NCT01912612'), ({'text': 'Patients with pathologically confirmed pancreatic cancer referred for image guided radiation therapy (IGRT)', 'entities': [['40', '57', 'cancer'], ['71', '108', 'treatment']]}, 'NCT02332863'), ({'text': 'Hepatocellular carcinoma (HCC) patients are not required to have histologically or cytologically confirmed malignancy, patients are considered eligible based on tumor markers and/or imaging assessment', 'entities': [['1', '31', 'cancer'], ['108', '118', 'cancer'], ['162', '167', 'cancer']]}, 'NCT02070549'), ({'text': 'Stage IIIC', 'entities': [['1', '11', 'cancer']]}, 'NCT02143050'), ({'text': 'Transmural myocardial infarction within 3 months prior to study entry', 'entities': [['1', '33', 'chronic_disease'], ['41', '55', 'upper_bound']]}, 'NCT01972919'), ({'text': 'Moderate or severe depression', 'entities': [['13', '30', 'chronic_disease']]}, 'NCT02544503'), ({'text': 'Hepatitis B surface antigen (HBsAg)', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT02508038'), ({'text': 'Patients must have a performance status of e to 60', 'entities': [['22', '40', 'clinical_variable'], ['49', '51', 'lower_bound']]}, 'NCT01130077'), ({'text': 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of autism spectrum disorder (ASD) established by clinical assessment, corroborated by the Social Communication Questionnaire and the Autism Diagnostic Observational Schedule', 'entities': [['38', '54', 'chronic_disease'], ['91', '121', 'chronic_disease']]}, 'NCT02483910'), ({'text': 'History of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment', 'entities': [['31', '49', 'chronic_disease'], ['82', '90', 'chronic_disease'], ['92', '109', 'chronic_disease'], ['114', '123', 'chronic_disease'], ['138', '156', 'treatment']]}, 'NCT02013154'), ({'text': 'Willing to have buccal administration of misoprostol or a placebo at least one hour pre-procedure', 'entities': [['42', '53', 'treatment'], ['59', '66', 'treatment'], ['76', '79', 'lower_bound']]}, 'NCT02209545'), ({'text': 'Significant medical problem (e.g. uncontrolled diabetes)', 'entities': [['35', '56', 'chronic_disease']]}, 'NCT02901041'), ({'text': 'Karnofsky (KPS) Performance status of >= 70%', 'entities': [['1', '16', 'clinical_variable'], ['42', '45', 'lower_bound']]}, 'NCT01810588'), ({'text': 'known localized high risk prostate cancer (PSA >10, Gleason 8-10 or clinical stage >T2c) with evidence of disease on standard imaging', 'entities': [['27', '42', 'cancer'], ['44', '47', 'clinical_variable'], ['53', '60', 'clinical_variable'], ['61', '62', 'lower_bound'], ['69', '83', 'clinical_variable'], ['85', '88', 'lower_bound']]}, 'NCT03181867'), ({'text': 'HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with capecitabine and/or bevacizumab', 'entities': [['1', '4', 'chronic_disease'], ['26', '60', 'treatment'], ['139', '151', 'treatment'], ['159', '170', 'treatment']]}, 'NCT02669173'), ({'text': 'Prematurity, birth weight <2,500 grams', 'entities': [['14', '26', 'clinical_variable'], ['28', '39', 'upper_bound']]}, 'NCT03181516'), ({'text': 'Patient must have had pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy) based on either a positive fine needle aspirate (FNA) (demonstrating malignant cells) or positive core needle biopsy (demonstrating invasive adenocarcinoma)', 'entities': [['101', '120', 'treatment'], ['149', '175', 'treatment'], ['211', '238', 'treatment'], ['263', '277', 'cancer']]}, 'NCT01872975'), ({'text': 'Untreated life-threatening arrhythmia', 'entities': [['28', '38', 'chronic_disease']]}, 'NCT01445821'), ({'text': 'Donors must be >= 17 years of age', 'entities': [['19', '27', 'lower_bound'], ['31', '34', 'age']]}, 'NCT02122081'), ({'text': 'has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure', 'entities': [['28', '50', 'chronic_disease'], ['78', '110', 'clinical_variable'], ['111', '112', 'lower_bound'], ['116', '117', 'upper_bound'], ['118', '142', 'chronic_disease']]}, 'NCT02268253'), ({'text': 'Any allergy or intolerance to ionic and nonionic contrast media, anticoagulants, or antiplatelet therapy drugs that cannot be adequately premedicated', 'entities': [['31', '36', 'allergy_name'], ['41', '64', 'allergy_name'], ['66', '80', 'allergy_name'], ['85', '111', 'allergy_name']]}, 'NCT02468778'), ({'text': 'Direct bilirubin of =< 2 mg/dL', 'entities': [['1', '17', 'clinical_variable'], ['24', '31', 'upper_bound']]}, 'NCT01787487'), ({'text': 'Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of acute ischemia or active conduction system abnormalities', 'entities': [['14', '20', 'chronic_disease'], ['42', '65', 'chronic_disease'], ['94', '102', 'chronic_disease'], ['113', '144', 'chronic_disease']]}, 'NCT01898793'), ({'text': 'Current infection', 'entities': [['9', '18', 'chronic_disease']]}, 'NCT02490631'), ({'text': 'The student-athlete has already participated in the study during which he/she took Riboflavin', 'entities': [['84', '94', 'treatment']]}, 'NCT02772237'), ({'text': 'Plasma oxalate concentration e10 ¼mol/L in total plasma oxalate', 'entities': [['1', '29', 'clinical_variable'], ['31', '64', 'lower_bound']]}, 'NCT03116685'), ({'text': 'Undergoing Outpatient ERCP', 'entities': [['23', '27', 'treatment']]}, 'NCT03098082'), ({'text': 'Patients with any evidence of clinically significant liver abnormalities, or any liver transaminase level > 1.5 x ULN at initial screening, or > 5 x ULN during treatment', 'entities': [['54', '73', 'chronic_disease'], ['82', '106', 'clinical_variable'], ['109', '118', 'lower_bound'], ['111', '118', 'lower_bound'], ['161', '170', 'treatment']]}, 'NCT02019940'), ({'text': 'Patients e 18 years old', 'entities': [['12', '20', 'lower_bound']]}, 'NCT02207439'), ({'text': 'ECOG performance status d2 ( see Appendix A)', 'entities': [['1', '24', 'clinical_variable'], ['26', '27', 'upper_bound']]}, 'NCT02811679'), ({'text': 'Clinically significant peripheral neuropathy at the time of study entry', 'entities': [['24', '45', 'chronic_disease']]}, 'NCT02013154'), ({'text': 'agree to use two methods of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy', 'entities': [['1', '42', 'contraception_consent'], ['75', '88', 'treatment'], ['97', '111', 'upper_bound']]}, 'NCT02446457'), ({'text': 'Uncontrolled hypertension, defined as a resting blood pressure > 140/90 mmHg', 'entities': [['1', '26', 'chronic_disease'], ['49', '63', 'clinical_variable'], ['66', '77', 'lower_bound']]}, 'NCT02504866'), ({'text': 'Patients with documented e Grade 2 diarrhea or colitis as a result of previous treatment with immune checkpoint inhibitor(s) must have been asymptomatic for at least 6 months and/or had a normal colonoscopy post-immune checkpoint inhibitor treatment, by visual assessment, prior to tumor resection', 'entities': [['28', '44', 'lower_bound'], ['48', '55', 'chronic_disease'], ['71', '125', 'treatment'], ['167', '175', 'lower_bound'], ['196', '207', 'treatment'], ['231', '250', 'treatment'], ['283', '298', 'treatment']]}, 'NCT02360579'), ({'text': 'Death expected within 6 months (inferred by PCP permission to randomize)', 'entities': [['1', '15', 'clinical_variable'], ['23', '31', 'upper_bound']]}, 'NCT02185417'), ({'text': 'Cancer diagnosis', 'entities': [['1', '7', 'cancer']]}, 'NCT03181750'), ({'text': 'breast-feed during protocol treatment and for 3 months after last dose of Talimogene Laherparepvec', 'entities': [['29', '38', 'treatment'], ['47', '55', 'upper_bound'], ['75', '99', 'treatment']]}, 'NCT02819843'), ({'text': 'concurrent physical therapy', 'entities': [['12', '28', 'treatment']]}, 'NCT02274116'), ({'text': 'Subjects with any previously untreated or concurrent cancer unrelated to angiosarcoma', 'entities': [['54', '60', 'cancer'], ['74', '86', 'cancer']]}, 'NCT02048722'), ({'text': 'Has unresolved toxicities from previous anticancer therapy', 'entities': [['41', '59', 'treatment']]}, 'NCT03110354'), ({'text': 'have not recovered from the side effects of any major surgery (defined as requiring general anesthesia but excluding a procedure for insertion of central venous access)', 'entities': [['49', '62', 'treatment'], ['85', '103', 'treatment']]}, 'NCT02579044'), ({'text': 'Life expectancy of less than 6 months', 'entities': [['1', '16', 'clinical_variable'], ['30', '38', 'upper_bound']]}, 'NCT03006770'), ({'text': 'Liver: Patient with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, bridging fibrosis, and the degree of portal hypertension', 'entities': [['56', '69', 'chronic_disease'], ['179', '187', 'chronic_disease'], ['207', '226', 'chronic_disease']]}, 'NCT02100891'), ({'text': 'Age > 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT03179995'), ({'text': 'active, uncontrolled infection', 'entities': [['1', '7', 'chronic_disease'], ['9', '31', 'chronic_disease']]}, 'NCT02179359'), ({'text': 'placement of pacemaker', 'entities': [['14', '23', 'treatment']]}, 'NCT02417701'), ({'text': 'Donors who are HIV positive', 'entities': [['16', '19', 'chronic_disease']]}, 'NCT01956084'), ({'text': 'Platelet count e 100,000/Kmcl', 'entities': [['1', '15', 'clinical_variable'], ['18', '30', 'lower_bound']]}, 'NCT01864109'), ({'text': 'for whom the current dose level of cisplatin in combination with pemetrexed is appropriate', 'entities': [['36', '45', 'treatment']]}, 'NCT02535312'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02391987'), ({'text': 'Diagnosis of non-penetrating TBI', 'entities': [['30', '33', 'chronic_disease']]}, 'NCT02504866'), ({'text': 'Patients must have Eastern Cooperative Oncology Group (ECOG)performance status of 0-1', 'entities': [['20', '79', 'clinical_variable'], ['83', '84', 'lower_bound'], ['85', '86', 'upper_bound']]}, 'NCT02203695'), ({'text': 'Women who are pregnant', 'entities': [['1', '6', 'gender'], ['15', '23', 'pregnancy']]}, 'NCT02324608'), ({'text': 'must have GOG performance status 0, 1, or 2', 'entities': [['11', '33', 'clinical_variable'], ['34', '35', 'lower_bound'], ['43', '44', 'upper_bound']]}, 'NCT02658565'), ({'text': 'HIV-infected individuals in HIV care', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT02797262'), ({'text': 'Age e 18 years of age', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound'], ['19', '22', 'age']]}, 'NCT03095118'), ({'text': 'Confirmed diagnosis of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)', 'entities': [['24', '58', 'cancer'], ['62', '91', 'cancer']]}, 'NCT02937402'), ({'text': 'Post-menopausal women', 'entities': [['17', '22', 'gender']]}, 'NCT03029442'), ({'text': 'Kidney tumor has been completely resected 4 to 12 weeks prior to randomization', 'entities': [['1', '13', 'cancer'], ['43', '44', 'lower_bound'], ['48', '62', 'upper_bound']]}, 'NCT03138512'), ({'text': 'Anticipated initiation, change, or discontinuation of a hormonal contraceptive within the next 6 months', 'entities': [['91', '104', 'upper_bound']]}, 'NCT02426047'), ({'text': 'ventricular rate less than 50 beats/min', 'entities': [['1', '17', 'clinical_variable'], ['28', '40', 'upper_bound']]}, 'NCT02393794'), ({'text': 'Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period', 'entities': [['1', '16', 'gender'], ['89', '99', 'treatment'], ['147', '156', 'treatment']]}, 'NCT01532687'), ({'text': 'Females of childbearing potential and male subjects with female partners of childbearing potential must agree to avoid pregnancy by using an adequate method of contraception (2 barrier method or 1 barrier method with a spermicide or intrauterine device for 2 weeks prior to screening, during and 12 weeks after the last dose of trial medication; adequate methods of contraception are provided as examples; other acceptable and effective methods of birth control are also permitted (e.g., abstinence)', 'entities': [['1', '8', 'gender'], ['39', '52', 'gender'], ['58', '64', 'gender'], ['105', '174', 'contraception_consent'], ['258', '271', 'upper_bound'], ['297', '305', 'upper_bound']]}, 'NCT02960555'), ({'text': 'Medications not recommended per the SOF/LDV prescribing information (e.g., tipranavir and other P-gp inducers, tenofovir disoproxil fumarate plus cobicistat, rosuvastatin, amiodarone)', 'entities': [['76', '86', 'treatment'], ['97', '110', 'treatment'], ['112', '157', 'treatment'], ['159', '171', 'treatment'], ['173', '183', 'treatment']]}, 'NCT02573376'), ({'text': 'For patients with intracranial bleeding, there must be a reasonable expectation that andexanet treatment will commence within 2 hours of the baseline imaging evaluation', 'entities': [['19', '40', 'chronic_disease'], ['86', '105', 'treatment'], ['127', '134', 'upper_bound']]}, 'NCT02329327'), ({'text': 'Women whom requires left chest wall post-mastectomy radiation with or without bolus', 'entities': [['1', '6', 'gender'], ['21', '62', 'treatment'], ['79', '84', 'treatment']]}, 'NCT02694029'), ({'text': 'blood pressure > 150/90 mm Hg', 'entities': [['1', '15', 'clinical_variable'], ['18', '30', 'lower_bound']]}, 'NCT02129348'), ({'text': "inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis", 'entities': [['1', '27', 'chronic_disease'], ['39', '57', 'chronic_disease'], ['62', '77', 'chronic_disease'], ['80', '94', 'chronic_disease'], ['96', '109', 'chronic_disease'], ['123', '134', 'chronic_disease'], ['138', '150', 'chronic_disease']]}, 'NCT01639508'), ({'text': 'Patients taking daily doses of systemic corticosteroids greater than the equivalent of 40mg prednisone', 'entities': [['32', '56', 'treatment'], ['88', '92', 'lower_bound'], ['93', '103', 'treatment']]}, 'NCT02245841'), ({'text': 'History of hypersensitivity to any compound in the tetracycline antibiotics group', 'entities': [['52', '64', 'allergy_name']]}, 'NCT02290951'), ({'text': 'Known HIV positivity', 'entities': [['7', '10', 'chronic_disease']]}, 'NCT02379520'), ({'text': 'History of uncontrolled seizure disorder or active central nervous system disease', 'entities': [['25', '41', 'chronic_disease'], ['52', '82', 'chronic_disease']]}, 'NCT01871727'), ({'text': 'Willingness to use effective contraceptive methods for the duration of the study', 'entities': [['30', '51', 'contraception_consent']]}, 'NCT00862433'), ({'text': 'Any systemic illness or unstable medical condition that might pose additional risk, including: cardiac, unstable metabolic or endocrine disturbances, renal or liver disease, past history of renal calculi, hyperuricemia, hypercalcemia, mitochondrial disease, known disorder of fatty acid metabolism, porphyria, carnitine deficiency and pancreatitis', 'entities': [['96', '103', 'chronic_disease'], ['127', '149', 'chronic_disease'], ['151', '156', 'chronic_disease'], ['160', '173', 'chronic_disease'], ['191', '204', 'chronic_disease'], ['206', '219', 'chronic_disease'], ['221', '234', 'chronic_disease'], ['236', '257', 'chronic_disease'], ['265', '298', 'chronic_disease'], ['300', '309', 'chronic_disease'], ['311', '331', 'chronic_disease'], ['336', '348', 'chronic_disease']]}, 'NCT01865162'), ({'text': 'non-melanoma skin cancer; cervical carcinoma in situ on biopsy or squamous intraepithelial lesion on Papanicolaou (PAP) smear; localized prostate cancer (Gleason score < 6); or resected melanoma in situ', 'entities': [['1', '25', 'cancer'], ['27', '53', 'cancer'], ['67', '98', 'cancer'], ['102', '126', 'treatment'], ['128', '153', 'cancer'], ['155', '168', 'clinical_variable'], ['171', '172', 'upper_bound'], ['187', '203', 'cancer']]}, 'NCT03144245'), ({'text': 'Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification', 'entities': [['7', '10', 'lower_bound'], ['14', '16', 'upper_bound'], ['17', '30', 'chronic_disease'], ['49', '82', 'clinical_variable']]}, 'NCT02582827'), ({'text': 'Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection)', 'entities': [['28', '34', 'cancer'], ['46', '61', 'upper_bound'], ['74', '104', 'cancer'], ['114', '129', 'treatment']]}, 'NCT02429934'), ({'text': 'Patients who have known allergic reactions to IV contrast dye despite standard prophylaxis', 'entities': [['47', '62', 'allergy_name']]}, 'NCT01676753'), ({'text': 'Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline)', 'entities': [['34', '50', 'cancer'], ['149', '165', 'lower_bound'], ['187', '202', 'treatment']]}, 'NCT02710396'), ({'text': 'Some cohort exceptions allow anti-PD-1 therapy', 'entities': [['30', '47', 'treatment']]}, 'NCT02771626'), ({'text': 'MIBG-avid malignant CCT and evaluable disease on MIBG scan at time of enrollment on protocol', 'entities': [['1', '5', 'treatment'], ['21', '24', 'treatment'], ['50', '59', 'treatment']]}, 'NCT00107289'), ({'text': 'At least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02204098'), ({'text': 'Those already receiving ketamine or methadone prior to surgery', 'entities': [['25', '33', 'treatment'], ['37', '46', 'treatment'], ['47', '63', 'treatment']]}, 'NCT02252432'), ({'text': 'Tumors which have not been sequenced for POLE mutations (i.e. their POLE mutations status is unknown) but are MSS', 'entities': [['1', '7', 'cancer']]}, 'NCT02912572'), ({'text': 'Intraocular surgery within 90 days prior to Day 0 in the study eye', 'entities': [['1', '20', 'treatment'], ['28', '41', 'upper_bound']]}, 'NCT01280669'), ({'text': 'Cardiomyopathy', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02496208'), ({'text': 'Sexually active male and female subjects of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment', 'entities': [['17', '41', 'gender'], ['154', '168', 'upper_bound'], ['169', '178', 'treatment']]}, 'NCT02579044'), ({'text': 'Drug resistant epilepsy participants will be defined as having clinically documented seizures with consistent EEG evidence as defined by the 1981 International Classification of Epileptic Seizures, refractory to standard anti-seizure treatment for at least one year prior to enrolling in this study and with an average of at least one seizure per month', 'entities': [['86', '94', 'chronic_disease'], ['86', '93', 'chronic_disease'], ['111', '114', 'clinical_variable'], ['222', '244', 'treatment'], ['258', '261', 'lower_bound'], ['258', '272', 'lower_bound']]}, 'NCT02531880'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02828618'), ({'text': 'Pregnancy or lactation', 'entities': [['1', '10', 'pregnancy']]}, 'NCT00391170'), ({'text': 'Any radiation therapy (RT) for the currently diagnosed breast cancer prior to study enrollment', 'entities': [['5', '27', 'treatment'], ['56', '69', 'cancer']]}, 'NCT02515110'), ({'text': 'The participant has prothrombin time (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) test >= 1.3 x the laboratory ULN within 7 days before the first dose of study treatment', 'entities': [['21', '42', 'clinical_variable'], ['42', '79', 'clinical_variable'], ['83', '116', 'clinical_variable'], ['125', '149', 'lower_bound'], ['157', '170', 'upper_bound'], ['195', '204', 'treatment']]}, 'NCT01822522'), ({'text': 'retrograde intrarenal surgery [RIRS]', 'entities': [['1', '37', 'treatment']]}, 'NCT02944825'), ({'text': 'Patients with known human immunodeficiency virus (HIV) or hepatitis B or C', 'entities': [['21', '55', 'chronic_disease'], ['59', '70', 'chronic_disease'], ['74', '75', 'chronic_disease']]}, 'NCT02304458'), ({'text': 'Progression of metastatic bone disease on bone scan with > 2 new lesions', 'entities': [['16', '39', 'cancer'], ['43', '52', 'treatment'], ['60', '61', 'lower_bound']]}, 'NCT02565901'), ({'text': 'Completely resected stage III (lymph node positive) or resected stage IV disease', 'entities': [['12', '52', 'cancer'], ['56', '81', 'cancer']]}, 'NCT02656706'), ({'text': 'Concurrent immunotherapy', 'entities': [['12', '25', 'treatment']]}, 'NCT02581384'), ({'text': 'lactating females', 'entities': [['11', '18', 'gender']]}, 'NCT02245841'), ({'text': 'women of childbearing potential and men with a sexual partner of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['135', '144', 'pregnancy']]}, 'NCT01620216'), ({'text': 'hematologic disease', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT01893307'), ({'text': 'Thrombocytopenia (platelets<100,000 cells/microL)', 'entities': [['1', '17', 'chronic_disease'], ['19', '28', 'clinical_variable'], ['29', '49', 'upper_bound']]}, 'NCT01419561'), ({'text': 'patients currently receiving pregabalin treatment', 'entities': [['30', '50', 'treatment']]}, 'NCT00351611'), ({'text': 'History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies', 'entities': [['57', '62', 'allergy_name'], ['64', '73', 'allergy_name'], ['77', '105', 'allergy_name']]}, 'NCT02043548'), ({'text': 'Diagnostic core biopsy specimens must be reviewed by a faculty pathologist at SKCCC or MSKCC', 'entities': [['12', '23', 'treatment']]}, 'NCT02259621'), ({'text': 'History of recurrent (more than one episode) herpes zoster or disseminated (a single episode) herpes zoster or disseminated (a single episode) herpes simplex', 'entities': [['46', '59', 'chronic_disease'], ['144', '158', 'chronic_disease']]}, 'NCT01500551'), ({'text': 'Myelodysplastic syndromes (MDS), Intermediate-1 (INT-1), intermediate-2 (INT-2) or high Revised International Prognostic Scoring System (IPSS-R) score that has failed at least 1 first line therap', 'entities': [['1', '32', 'cancer'], ['34', '56', 'cancer'], ['58', '80', 'cancer'], ['190', '196', 'treatment']]}, 'NCT02181478'), ({'text': 'Treatment-refractory hypertension defined as a blood pressure of systolic > 140 mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive therapy', 'entities': [['1', '34', 'chronic_disease'], ['48', '74', 'clinical_variable'], ['77', '85', 'lower_bound'], ['93', '102', 'clinical_variable'], ['105', '112', 'lower_bound'], ['143', '168', 'treatment']]}, 'NCT02070549'), ({'text': 'Progressive disease', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02342782'), ({'text': 'Currently participating and receiving study therapy in, or has participated in a study of an investigational agent and received study therapy or used an investigational device', 'entities': [['45', '52', 'treatment'], ['94', '115', 'treatment'], ['154', '176', 'treatment']]}, 'NCT02332668'), ({'text': 'Life expectancy of greater than 3 months', 'entities': [['1', '16', 'clinical_variable'], ['33', '41', 'lower_bound']]}, 'NCT01811368'), ({'text': 'Has a known history of human immunodeficiency virus (HIV)', 'entities': [['24', '58', 'chronic_disease']]}, 'NCT02411656'), ({'text': 'Tumors arising outside of the CNS', 'entities': [['1', '7', 'cancer']]}, 'NCT01449149'), ({'text': 'Prior treatment with stem cells', 'entities': [['1', '32', 'treatment']]}, 'NCT02833792'), ({'text': 'Women with severe chronic illness and high likelihood of preterm birth and/or expected long-term hospitalizations during pregnancy', 'entities': [['1', '6', 'gender'], ['98', '113', 'treatment'], ['122', '131', 'pregnancy']]}, 'NCT02341300'), ({'text': 'Hospital admission for acute pulmonary exacerbation of CF (using Fuchs criteria 4/10)', 'entities': [['1', '19', 'treatment'], ['24', '52', 'chronic_disease']]}, 'NCT02129803'), ({'text': 'Placement of an intrauterine device (IUD) or intrauterine system (IUS)', 'entities': [['17', '42', 'contraception_consent'], ['46', '71', 'contraception_consent']]}, 'NCT01827384'), ({'text': 'Requirement of ventilatory support', 'entities': [['16', '35', 'treatment']]}, 'NCT02254863'), ({'text': 'Personal or first-degree relative with a seizure history', 'entities': [['42', '49', 'chronic_disease']]}, 'NCT00739362'), ({'text': 'Uncontrolled Epilepsy', 'entities': [['14', '22', 'chronic_disease']]}, 'NCT02627495'), ({'text': 'Enrolled in a concurrent clinical trial', 'entities': [['15', '40', 'treatment']]}, 'NCT03090607'), ({'text': 'Age e18 and d 80 years', 'entities': [['1', '4', 'age'], ['6', '8', 'lower_bound'], ['15', '23', 'upper_bound']]}, 'NCT02685605'), ({'text': 'Prominent suicidal or homicidal ideation', 'entities': [['1', '19', 'chronic_disease'], ['23', '41', 'chronic_disease']]}, 'NCT02856412'), ({'text': 'Use of systemic antibiotics in 12 months preceding baseline sampling', 'entities': [['8', '28', 'treatment'], ['32', '60', 'upper_bound']]}, 'NCT01631617'), ({'text': 'hearing loss no worse than 30 decibel (dB) HL (PTA 0.5-3 kHz), in better ear, with the difference in ears being less than 15 dB PTA', 'entities': [['1', '13', 'clinical_variable'], ['28', '46', 'lower_bound'], ['48', '51', 'clinical_variable'], ['52', '55', 'lower_bound'], ['56', '61', 'upper_bound'], ['123', '132', 'upper_bound']]}, 'NCT02748109'), ({'text': 'ALT < 5 times the ULN for age', 'entities': [['1', '4', 'clinical_variable'], ['7', '22', 'upper_bound'], ['27', '30', 'age']]}, 'NCT02624258'), ({'text': 'Tumor between 1 cm and 6 cm', 'entities': [['1', '6', 'cancer'], ['15', '19', 'lower_bound'], ['24', '28', 'upper_bound']]}, 'NCT01799135'), ({'text': 'Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP). The following are exceptions to this criterion: " Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection) " Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent " Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)', 'entities': [['25', '53', 'treatment'], ['61', '68', 'upper_bound'], ['94', '122', 'treatment'], ['174', '184', 'treatment'], ['186', '193', 'treatment'], ['195', '211', 'treatment'], ['216', '240', 'treatment'], ['246', '271', 'treatment'], ['275', '299', 'treatment'], ['303', '320', 'treatment'], ['335', '340', 'upper_bound'], ['348', '358', 'treatment'], ['379', '387', 'treatment'], ['441', '462', 'treatment']]}, 'NCT02516241'), ({'text': 'age 21 or older', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT01975597'), ({'text': 'Histologic or cytologic diagnosis of adenocarcinoma non-small cell lung cancer', 'entities': [['1', '11', 'cancer'], ['38', '52', 'cancer'], ['53', '79', 'cancer']]}, 'NCT02303977'), ({'text': 'Adequate renal function as evidenced by serum creatinine less than or equal to 1.8 mg/dL (158 umol/L)', 'entities': [['41', '57', 'clinical_variable'], ['80', '102', 'upper_bound']]}, 'NCT01871727'), ({'text': 'all other anti-platelet', 'entities': [['11', '24', 'treatment']]}, 'NCT02907983'), ({'text': 'must be e 12 months and <22 years of age at the time of study registration', 'entities': [['11', '20', 'lower_bound'], ['26', '34', 'upper_bound'], ['38', '41', 'age']]}, 'NCT01795313'), ({'text': 'Non-DM group with similar age range as the DM group', 'entities': [['27', '30', 'age']]}, 'NCT02415556'), ({'text': 'Women and men with intermediate coronary stenoses (>20% but <50% luminal diameter stenosis assessed visually at the time of angiography) will undergo clinically indicated IVUS testing based on the judgment of the operator; those determined to have flow FFR or obstructing stenosis will be excluded from the overall study', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['20', '50', 'chronic_disease'], ['53', '56', 'lower_bound'], ['62', '65', 'upper_bound'], ['66', '91', 'clinical_variable']]}, 'NCT00573027'), ({'text': 'Karnofsky performance status >50%', 'entities': [['1', '29', 'clinical_variable'], ['31', '34', 'lower_bound']]}, 'NCT01886105'), ({'text': 'Sexually active men must also use acceptable contraceptive methods for the duration of time on study and for at least 16 weeks after the last dose of study drug', 'entities': [['17', '20', 'gender'], ['31', '59', 'contraception_consent'], ['119', '133', 'lower_bound'], ['151', '161', 'treatment']]}, 'NCT02392572'), ({'text': 'Tacrolimus (e.g. Prograf) - May cause liver transplant rejection or serious side effects in patients on sirolimus', 'entities': [['1', '11', 'treatment'], ['18', '25', 'treatment'], ['39', '55', 'treatment'], ['105', '114', 'treatment']]}, 'NCT01869114'), ({'text': 'Staging of cutaneous melanoma will be based on the revised AJCC staging system', 'entities': [['12', '30', 'cancer']]}, 'NCT02382549'), ({'text': 'Negative hepatitis C virus (HCV) antibody test at screening', 'entities': [['10', '33', 'chronic_disease']]}, 'NCT03125902'), ({'text': 'unilaterally implanted with HiRes90K" Advantage cochlear implant with HiFocus" Mid-Scala electrode and fit with an ear-level sound processor (i.e. Naída family device)', 'entities': [['29', '65', 'treatment'], ['71', '99', 'treatment'], ['148', '167', 'treatment']]}, 'NCT02189798'), ({'text': 'behavioral treatment for TBI that could affect the outcome of this study', 'entities': [['1', '21', 'treatment'], ['26', '29', 'chronic_disease']]}, 'NCT02922569'), ({'text': 'Acute myocardial infarction', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT02409810'), ({'text': 'Negative pregnancy test performed =< 7 days prior to registration for women of childbearing potential only', 'entities': [['1', '19', 'pregnancy'], ['38', '50', 'upper_bound'], ['71', '76', 'gender']]}, 'NCT02393690'), ({'text': 'Subjects with MIBC not meeting the above criteria are still eligible provided the patient declines neoadjuvant cisplatin-based chemotherapy, after specific informed consent describing the known benefits of cisplatin-based chemotherapy', 'entities': [['100', '140', 'treatment'], ['112', '140', 'treatment']]}, 'NCT02451423'), ({'text': 'ECOG performance status d 2', 'entities': [['1', '24', 'clinical_variable'], ['27', '28', 'upper_bound']]}, 'NCT02158858'), ({'text': 'Individuals with bleeding disorders', 'entities': [['18', '36', 'chronic_disease']]}, 'NCT02914171'), ({'text': 'Calculated creatinine clearance e 60ml/min', 'entities': [['1', '32', 'clinical_variable'], ['35', '43', 'lower_bound']]}, 'NCT02193191'), ({'text': 'Subjects with locally advanced, unresectable primary tumors', 'entities': [['46', '60', 'cancer']]}, 'NCT02427841'), ({'text': 'Donors must not be pregnant', 'entities': [['8', '28', 'pregnancy']]}, 'NCT02579967'), ({'text': 'Fibrosarcoma', 'entities': [['1', '13', 'cancer']]}, 'NCT02584309'), ({'text': 'Patients may have received chemotherapy or radiation for a previous, curatively treated non-HNSCC malignancy', 'entities': [['28', '40', 'treatment'], ['44', '53', 'treatment'], ['89', '109', 'cancer']]}, 'NCT02128906'), ({'text': 'Life expectancy of greater than 8 weeks in the opinion of the referring clinician', 'entities': [['1', '16', 'clinical_variable'], ['33', '40', 'lower_bound']]}, 'NCT02085941'), ({'text': 'Salicylate sensitivity', 'entities': [['1', '11', 'allergy_name']]}, 'NCT03152409'), ({'text': 'Hematologic Absolute neutrophil count (ANC) >/= 1.5 X 109/L', 'entities': [['13', '44', 'clinical_variable'], ['49', '60', 'lower_bound']]}, 'NCT02656706'), ({'text': 'Men', 'entities': [['1', '4', 'gender']]}, 'NCT02291978'), ({'text': 'Patient is at least 18 years of age', 'entities': [['21', '29', 'lower_bound'], ['33', '36', 'age']]}, 'NCT03034811'), ({'text': 'rade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events [CTCAE], version [v]', 'entities': [['1', '7', 'lower_bound'], ['8', '9', 'upper_bound']]}, 'NCT02177838'), ({'text': 'Known allergy to ixazomib, its analogues, or excipients in the various formulations of ixazomib', 'entities': [['18', '26', 'allergy_name']]}, 'NCT02339922'), ({'text': 'atracurium', 'entities': [['1', '11', 'treatment']]}, 'NCT02041936'), ({'text': 'International Normalized Ratio (INR) < 1.5 (except if patient is on oral anticoagulation therapy)', 'entities': [['1', '37', 'clinical_variable'], ['40', '43', 'upper_bound'], ['69', '97', 'treatment']]}, 'NCT02533674'), ({'text': 'Problem with or allergy to anticoagulation', 'entities': [['28', '43', 'allergy_name']]}, 'NCT02433210'), ({'text': 'bleeding esophageal varices', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT02562755'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02425566'), ({'text': 'Chronic hypertension receiving antihypertensive treatment', 'entities': [['1', '21', 'chronic_disease'], ['32', '58', 'treatment']]}, 'NCT02872935'), ({'text': 'Prior Therapy: Therapy with monoclonal antibodies and/or chemotherapy must be stopped at least 7 days prior to anti-CD19 CAR-transduced T cell infusion, and recovery of treatment-associated toxicity to less than or equal to grade 2 is required prior to infusion of cells', 'entities': [['1', '14', 'treatment'], ['16', '50', 'treatment'], ['58', '70', 'treatment'], ['96', '102', 'lower_bound'], ['112', '152', 'treatment'], ['170', '179', 'treatment'], ['225', '232', 'upper_bound']]}, 'NCT01087294'), ({'text': 'Rheumatoid arthritis (and other collagen vascular disease)', 'entities': [['1', '21', 'chronic_disease'], ['33', '58', 'chronic_disease']]}, 'NCT02312596'), ({'text': 'mycophenolate mofetil', 'entities': [['1', '22', 'treatment']]}, 'NCT02245841'), ({'text': 'Exposure to any investigational drug or procedure with 1 month prior to study entry or enrollment in concurrent study which may interfere with interpretation of study results', 'entities': [['17', '37', 'treatment'], ['56', '69', 'upper_bound']]}, 'NCT02946658'), ({'text': 'Use of depo medroxyprogesterone within 6 months of screening', 'entities': [['8', '32', 'treatment'], ['40', '48', 'upper_bound']]}, 'NCT03120728'), ({'text': 'nursing women', 'entities': [['9', '14', 'gender']]}, 'NCT02458014'), ({'text': 'The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities', 'entities': [['18', '27', 'treatment'], ['114', '117', 'chronic_disease']]}, 'NCT01174121'), ({'text': 'Presence of malignancy or other irreversible disease or condition for which the six month mortality is estimated to exceed 50% (e.g., chronic liver disease with a Child-Pugh Score of 10-15, malignancy refractory to treatment) as this could affect the clinical course and cloud interpretation of the endpoints', 'entities': [['13', '23', 'cancer'], ['81', '90', 'upper_bound'], ['91', '100', 'clinical_variable'], ['124', '127', 'lower_bound'], ['135', '156', 'chronic_disease'], ['164', '180', 'clinical_variable'], ['184', '186', 'lower_bound'], ['187', '189', 'upper_bound'], ['216', '225', 'treatment']]}, 'NCT02582957'), ({'text': 'Iliac artery access: i) e 6mm diameter, and absence of severe calcification and tortuosity ii) Or, planned creation of surgical conduit for TAAA device delivery f. For patients with associated common iliac artery aneurysms (>20mm diameter), adequate internal and external iliac artery landing zones and common iliac artery luminal diameter (for iliac branch device use): i. e 10mm long segment of healthy internal iliac artery for branch attachment ii. Internal iliac diameter e 5mm and d 12mm iii. External iliac diameter e 6mm diameter, and absence of severe calcification and tortuosity iv. Minimum common iliac artery luminal diameter e 14mm v. Or, in patients with bilateral common iliac artery aneurysms without suitable anatomy, planned surgical bypass to maintain patency of at least one internal iliac artery', 'entities': [['27', '39', 'lower_bound'], ['120', '136', 'treatment'], ['201', '223', 'clinical_variable'], ['226', '239', 'lower_bound'], ['295', '298', 'lower_bound'], ['311', '340', 'clinical_variable'], ['346', '365', 'treatment'], ['377', '381', 'lower_bound'], ['454', '477', 'clinical_variable'], ['480', '483', 'lower_bound'], ['490', '494', 'upper_bound'], ['500', '523', 'clinical_variable'], ['642', '646', 'lower_bound'], ['745', '760', 'treatment']]}, 'NCT02323581'), ({'text': 'Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative pregnancy test within 14 days prior to study registration', 'entities': [['1', '6', 'gender'], ['56', '68', 'treatment'], ['92', '110', 'pregnancy'], ['123', '136', 'upper_bound']]}, 'NCT02515110'), ({'text': 'History of psychiatric disorder which may compromise compliance with this protocol or which does not allow for appropriate informed consent', 'entities': [['12', '32', 'chronic_disease']]}, 'NCT01087294'), ({'text': 'Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN', 'entities': [['1', '33', 'clinical_variable'], ['38', '68', 'clinical_variable'], ['72', '79', 'upper_bound']]}, 'NCT02047474'), ({'text': 'Untreated, uncontrolled Sleep apnea', 'entities': [['25', '36', 'chronic_disease']]}, 'NCT00147056'), ({'text': 'intra-abdominal abscess. Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating study treatment even if abscess occurred more than 6 months before the first dose of study treatment', 'entities': [['1', '24', 'chronic_disease'], ['120', '129', 'treatment'], ['165', '180', 'lower_bound']]}, 'NCT02101736'), ({'text': 'other psychotic disorders', 'entities': [['7', '26', 'chronic_disease']]}, 'NCT02133898'), ({'text': 'Minimal use of chlorhexidine bathing', 'entities': [['16', '37', 'treatment']]}, 'NCT03118232'), ({'text': 'Relapsed or refractory to at least 2 lines of therapy AND', 'entities': [['36', '37', 'lower_bound'], ['47', '54', 'treatment']]}, 'NCT02520791'), ({'text': 'Unstable angina', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02418195'), ({'text': 'Subject has a known photosensitivity to the study laser wavelength, history of ingesting medications known to induce photosensitivity, or history of seizure disorders due to light', 'entities': [['21', '37', 'allergy_name'], ['51', '67', 'treatment'], ['90', '101', 'treatment'], ['150', '167', 'chronic_disease']]}, 'NCT02468453'), ({'text': 'Adjuvant immunotherapy/ biologics', 'entities': [['1', '23', 'treatment'], ['25', '34', 'treatment']]}, 'NCT02578641'), ({'text': 'Radiation therapy, chemotherapy, chronic steroid use or immunosuppressive therapy within 30 days of enrollment', 'entities': [['1', '18', 'treatment'], ['20', '32', 'treatment'], ['34', '49', 'treatment'], ['57', '82', 'treatment'], ['90', '97', 'upper_bound']]}, 'NCT02312596'), ({'text': 'Maximum PSA =< 20 ng/ml (not within 20 days after biopsy)', 'entities': [['9', '12', 'clinical_variable'], ['16', '24', 'upper_bound'], ['37', '44', 'upper_bound']]}, 'NCT02470897'), ({'text': 'Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection', 'entities': [['7', '41', 'chronic_disease'], ['43', '66', 'chronic_disease'], ['71', '94', 'chronic_disease']]}, 'NCT02152995'), ({'text': "Individuals who know they have an Alzheimer's disease-causing mutation or are unaware of their genetic status and have an autosomal dominant Alzheimer's disease (ADAD) mutation in their family", 'entities': [['35', '54', 'chronic_disease'], ['123', '168', 'chronic_disease']]}, 'NCT01760005'), ({'text': 'Upper or lower respiratory tract infection within 2 weeks prior to screening and baseline (day1)', 'entities': [['1', '43', 'chronic_disease'], ['51', '64', 'upper_bound']]}, 'NCT03114020'), ({'text': 'Eastern Clinical Oncology Group performance status 0 or 1', 'entities': [['1', '51', 'clinical_variable'], ['52', '53', 'lower_bound'], ['57', '58', 'upper_bound']]}, 'NCT01918683'), ({'text': 'Use of topical corticosteroids (on the face) 1 month prior to Visit 1', 'entities': [['8', '31', 'treatment'], ['46', '59', 'upper_bound']]}, 'NCT02075671'), ({'text': 'psychosis', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT02394704'), ({'text': 'must be planned to initiate HLH-directed therapy within 24 hours of study enrollment', 'entities': [['29', '49', 'treatment'], ['57', '65', 'upper_bound']]}, 'NCT02007239'), ({'text': 'Patients must have serum creatinine =< 2 x institutional upper limits of normal (IULN) within 7 days prior to registration', 'entities': [['26', '36', 'clinical_variable'], ['40', '43', 'upper_bound'], ['44', '87', 'clinical_variable'], ['95', '107', 'upper_bound']]}, 'NCT01925131'), ({'text': 'No prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)', 'entities': [['10', '29', 'cancer'], ['38', '66', 'cancer'], ['105', '112', 'lower_bound'], ['127', '158', 'cancer'], ['160', '171', 'cancer'], ['176', '182', 'cancer']]}, 'NCT01220583'), ({'text': 'CNS only disease on recent imaging', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT02286843'), ({'text': 'Patients who have congenital heart defects', 'entities': [['19', '43', 'chronic_disease']]}, 'NCT02460653'), ({'text': '18 years of Age', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT03098082'), ({'text': 'Glucose levels of > 11 mmol/L or < 2.8 mmol/L', 'entities': [['1', '15', 'clinical_variable'], ['21', '30', 'lower_bound'], ['36', '46', 'upper_bound']]}, 'NCT02918864'), ({'text': '18 years of age', 'entities': [['13', '16', 'age']]}, 'NCT02769156'), ({'text': 'Positive lymph nodes or metastatic disease from prostate cancer by imaging studies (CT or MRI), unless biopsy proven to be negative', 'entities': [['1', '21', 'cancer'], ['25', '43', 'cancer'], ['49', '64', 'cancer'], ['85', '87', 'treatment'], ['91', '94', 'treatment'], ['104', '110', 'treatment']]}, 'NCT02353819'), ({'text': 'Any conditions that could potentially alter immune function (AIDS, multiple sclerosis, uncontrolled diabetes, renal failure)', 'entities': [['62', '66', 'chronic_disease'], ['68', '86', 'chronic_disease'], ['101', '109', 'chronic_disease'], ['111', '124', 'chronic_disease']]}, 'NCT02549833'), ({'text': 'Squamous or small cell carcinoma of the bladder, renal medullary carcinoma (RMC), sarcomatoid bladder and renal cell carcinomas, plasmacytoid carcinoma of the bladder or other rare bladder/kidney cancer histology', 'entities': [['1', '9', 'cancer'], ['13', '48', 'cancer'], ['41', '48', 'cancer'], ['50', '81', 'cancer'], ['83', '102', 'cancer'], ['107', '128', 'cancer'], ['130', '167', 'cancer'], ['190', '203', 'cancer']]}, 'NCT02496208'), ({'text': 'History of other cancer within 2 years (except non-melanoma cutaneous malignancies and cervical carcinoma in situ)', 'entities': [['18', '24', 'cancer'], ['32', '39', 'upper_bound'], ['48', '83', 'cancer'], ['88', '114', 'cancer']]}, 'NCT02501473'), ({'text': 'Media opacity obscuring a view of the fundus or any other reason for vision loss other than radiation retinopathy', 'entities': [['93', '114', 'chronic_disease']]}, 'NCT03085784'), ({'text': 'Known liver disease', 'entities': [['7', '20', 'chronic_disease']]}, 'NCT03076021'), ({'text': 'hypothyroidism', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT03133013'), ({'text': 'poorly differentiated carcinoma of the oropharynx, larynx', 'entities': [['23', '32', 'cancer']]}, 'NCT02128906'), ({'text': 'Patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography (CT), magnetic resonance imaging (MRI), medical photograph (skin or oral lesion), plain x-ray, or other conventional technique and a greatest transverse diameter of 1 cm or greater; or palpable lesions with both diameters >= 2 cm; further, at least 1 of these lesions must be positive by positron emission tomography (PET) scan (i.e., Deauville score of 4 or more)', 'entities': [['111', '135', 'treatment'], ['137', '169', 'treatment'], ['171', '189', 'treatment'], ['213', '224', 'treatment'], ['273', '292', 'clinical_variable'], ['296', '300', 'lower_bound'], ['296', '297', 'lower_bound'], ['316', '332', 'clinical_variable'], ['356', '360', 'lower_bound'], ['419', '458', 'treatment'], ['466', '481', 'clinical_variable'], ['485', '486', 'lower_bound']]}, 'NCT02227199'), ({'text': 'BMI (body mass index) corresponding to equal or above 30 kg/m^2 for adults by international cut-off points1 and equal or above the 95th percentile for age and sex (for diagnosis of obesity)', 'entities': [['1', '22', 'clinical_variable'], ['55', '64', 'lower_bound'], ['132', '147', 'lower_bound'], ['152', '155', 'age'], ['182', '189', 'chronic_disease']]}, 'NCT02527200'), ({'text': 'Alcohol intake >12oz per week, as well as tobacco or recreational drug use', 'entities': [['1', '15', 'clinical_variable'], ['17', '30', 'lower_bound']]}, 'NCT02871648'), ({'text': 'intravenous vasopressor/inotropic agent other than norepinephrine (ie dobutamine, dopamine, vasopressin, epinephrine)', 'entities': [['13', '24', 'treatment'], ['25', '40', 'treatment'], ['52', '66', 'treatment'], ['55', '66', 'treatment'], ['71', '81', 'treatment'], ['83', '91', 'treatment'], ['93', '104', 'treatment']]}, 'NCT03078504'), ({'text': 'diagnosed with breast cancer, lung cancer, or gastro-intestinal cancer', 'entities': [['16', '29', 'cancer'], ['31', '42', 'cancer'], ['47', '71', 'cancer']]}, 'NCT02261558'), ({'text': 'Patients with vision primarily limited by superficial opacities and irregularities that could be removed by PTK while leaving at least 250 µm', 'entities': [['109', '112', 'treatment'], ['136', '142', 'lower_bound']]}, 'NCT01243931'), ({'text': 'e weeks from a non-nitrosourea chemotherapy (all [a-c] in order to allow recovery from the potential of severe toxicity related to these treatments)', 'entities': [['16', '44', 'treatment']]}, 'NCT01865162'), ({'text': 'Females', 'entities': [['1', '8', 'gender']]}, 'NCT02891759'), ({'text': 'menstruating females must have a negative serum or urine pregnancy test within 14 days of study treatment start', 'entities': [['14', '21', 'gender'], ['52', '67', 'pregnancy'], ['80', '87', 'upper_bound'], ['97', '106', 'treatment']]}, 'NCT02171104'), ({'text': 'History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias > Grade 2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], Version 4.0), thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion restrictive cardiomyopathy) within 6 months prior to first dose of study drug', 'entities': [['12', '33', 'chronic_disease'], ['56', '78', 'chronic_disease'], ['88', '99', 'clinical_variable'], ['102', '109', 'lower_bound'], ['213', '234', 'chronic_disease'], ['240', '260', 'chronic_disease'], ['262', '280', 'chronic_disease'], ['297', '319', 'chronic_disease'], ['335', '352', 'chronic_disease'], ['358', '405', 'chronic_disease'], ['414', '428', 'upper_bound'], ['446', '456', 'treatment']]}, 'NCT01990209'), ({'text': 'Patients who have previously received pembrolizumab or PD-/L1 blockade therapy', 'entities': [['39', '52', 'treatment'], ['56', '79', 'treatment']]}, 'NCT02706353'), ({'text': 'focal neurological deficit(s) that may or may not be transient, with severity of injury not exceeding loss of consciousness 30 minutes, Glasgow Coma Scale <13-15 after 30 minutes, or posttraumatic amnesia >24 hrs', 'entities': [['1', '27', 'chronic_disease'], ['137', '155', 'clinical_variable'], ['157', '159', 'lower_bound'], ['160', '162', 'upper_bound'], ['184', '205', 'chronic_disease'], ['207', '213', 'lower_bound']]}, 'NCT02266329'), ({'text': 'History of bleeding diathesis or coagulopathy', 'entities': [['12', '30', 'chronic_disease'], ['34', '46', 'chronic_disease']]}, 'NCT02000115'), ({'text': 'fasting triglycerides > 400 mg/dL', 'entities': [['1', '22', 'clinical_variable'], ['25', '34', 'lower_bound']]}, 'NCT02971202'), ({'text': 'Patients that are 12-18 months of age with INSS Stage 4 and all 3 favorable biologic features (ie, non- amplified MYCN, favorable pathology, and DNA index > 1)', 'entities': [['19', '21', 'lower_bound'], ['19', '20', 'lower_bound'], ['22', '31', 'upper_bound'], ['35', '38', 'age'], ['44', '56', 'clinical_variable'], ['146', '155', 'clinical_variable']]}, 'NCT01505569'), ({'text': 'They must be able to provide written informed consent and must have sufficient proficiency in the English language to understand and complete interviews, questionnaires, and all other study procedures', 'entities': [['64', '115', 'language_fluency']]}, 'NCT02452203'), ({'text': 'Leukocytes e 3,000/mcL', 'entities': [['1', '11', 'clinical_variable'], ['14', '23', 'lower_bound']]}, 'NCT02584309'), ({'text': 'AST/ALT <6 times ULN', 'entities': [['1', '8', 'clinical_variable'], ['10', '21', 'upper_bound']]}, 'NCT02013492'), ({'text': 'Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1', 'entities': [['23', '83', 'clinical_variable'], ['87', '88', 'lower_bound'], ['89', '90', 'upper_bound']]}, 'NCT02037048'), ({'text': 'Age 4-14 years', 'entities': [['1', '4', 'age'], ['5', '6', 'lower_bound'], ['7', '15', 'upper_bound']]}, 'NCT02365090'), ({'text': 'Patients who relapse after receiving a one or more courses of fludarabine, bendamustine, cytoxan, rituxan, chlorambucil, or campath based therapy', 'entities': [['40', '43', 'lower_bound'], ['63', '74', 'treatment'], ['76', '88', 'treatment'], ['90', '97', 'treatment'], ['99', '106', 'treatment'], ['108', '120', 'treatment'], ['125', '146', 'treatment']]}, 'NCT01750567'), ({'text': 'Certain exceptions are permitted, including topical medications, vitamins, and hormonal contraceptives', 'entities': [['45', '64', 'treatment'], ['66', '74', 'treatment'], ['80', '103', 'treatment']]}, 'NCT01200940'), ({'text': 'Documented laboratory-confirmed clostridium difficile infection', 'entities': [['33', '64', 'chronic_disease']]}, 'NCT02134392'), ({'text': "Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's disease) leading to progressive bone deterioration", 'entities': [['29', '45', 'chronic_disease'], ['52', '71', 'chronic_disease'], ['78', '96', 'chronic_disease'], ['103', '118', 'chronic_disease']]}, 'NCT02521103'), ({'text': 'History of uncontrolled diabetes mellitus or diabetic neuropathy within 3 months of the first dose of study drug', 'entities': [['25', '42', 'chronic_disease'], ['46', '65', 'chronic_disease'], ['73', '81', 'upper_bound'], ['103', '113', 'treatment']]}, 'NCT02091999'), ({'text': 'treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed', 'entities': [['9', '33', 'cancer'], ['35', '52', 'cancer'], ['57', '91', 'cancer'], ['176', '185', 'treatment']]}, 'NCT02131597'), ({'text': 'Patients who are taking any herbal (alternative) medicines are NOT eligible for participation', 'entities': [['29', '59', 'treatment']]}, 'NCT02536794'), ({'text': 'Coma suspected to de due to primarily non-TBI causes', 'entities': [['39', '46', 'chronic_disease']]}, 'NCT02407028'), ({'text': 'lumbar puncture', 'entities': [['1', '16', 'treatment']]}, 'NCT03041441'), ({'text': 'Absolute neutrophil count e 1,000/K/mcl', 'entities': [['1', '26', 'clinical_variable'], ['29', '40', 'lower_bound']]}, 'NCT01864109'), ({'text': 'Known Celiac disease', 'entities': [['7', '21', 'chronic_disease']]}, 'NCT03035799'), ({'text': 'Age 60 years or older', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT02332291'), ({'text': 'Concurrent hematologic or non-hematologic malignancy requiring treatment', 'entities': [['12', '23', 'cancer'], ['27', '53', 'cancer'], ['64', '73', 'treatment']]}, 'NCT02253316'), ({'text': "the patient's disease must be considered refractory to conventional/standard therapy, or a disease for which no conventional therapy exists and is progressive", 'entities': [['56', '85', 'treatment'], ['113', '133', 'treatment']]}, 'NCT02389309'), ({'text': 'Use of antibiotics to which O. formigenes is sensitive, including current antibiotic use, or antibiotics use within 14 days of initiating study medication', 'entities': [['8', '19', 'treatment'], ['8', '18', 'treatment'], ['117', '124', 'upper_bound']]}, 'NCT03116685'), ({'text': 'Patients who have lesions predisposing to chronic volume overload (i.e. patients with significant residual postoperative ventricular septal defects (VSD), or large aorto-pulmonary collaterals or more than moderate tricuspid insufficiency) since all these hemodynamic conditions can influence the late function of the right ventricle and potentially affect the response of the right side of the heart in changes in volume status', 'entities': [['122', '154', 'chronic_disease'], ['215', '238', 'chronic_disease'], ['256', '278', 'chronic_disease']]}, 'NCT02967315'), ({'text': 'Female subjects of childbearing potential must have a negative serum pregnancy test upon study entry', 'entities': [['1', '16', 'gender'], ['55', '79', 'pregnancy']]}, 'NCT02514083'), ({'text': '>= 60 years of age', 'entities': [['4', '12', 'lower_bound'], ['16', '19', 'age']]}, 'NCT01824836'), ({'text': 'Subjects with serum aspartate transaminase (AST) greater than 3 times the upper limit of normal (level >102 U/L)', 'entities': [['15', '49', 'clinical_variable'], ['63', '96', 'lower_bound'], ['98', '103', 'clinical_variable'], ['105', '112', 'lower_bound']]}, 'NCT02929589'), ({'text': 'left ventricular ejection fraction > 45%', 'entities': [['1', '35', 'clinical_variable'], ['38', '41', 'lower_bound']]}, 'NCT00357565'), ({'text': 'Treatment with intraocular or periocular steroids in the study eye within 3 months prior to surgery', 'entities': [['1', '10', 'treatment'], ['16', '27', 'treatment'], ['31', '50', 'treatment'], ['75', '89', 'upper_bound'], ['93', '100', 'treatment']]}, 'NCT01988246'), ({'text': 'Known active hepatitis A, B, or C infection', 'entities': [['7', '44', 'chronic_disease']]}, 'NCT02120222'), ({'text': 'Known severe inflammatory disease such as systemic lupus erythematosis, known autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis; Screen + for RF, ANA, HIV, Hepatitis B or C', 'entities': [['7', '34', 'chronic_disease'], ['43', '71', 'chronic_disease'], ['79', '98', 'chronic_disease'], ['108', '126', 'chronic_disease'], ['128', '148', 'chronic_disease'], ['172', '175', 'chronic_disease'], ['177', '193', 'chronic_disease']]}, 'NCT02389465'), ({'text': 'at least 8th grade education', 'entities': [['10', '13', 'lower_bound']]}, 'NCT02859142'), ({'text': '< 30 days for intravenously-administered cytotoxic chemotherapy and/or monoclonal antibodies', 'entities': [['3', '10', 'upper_bound'], ['42', '64', 'treatment'], ['72', '93', 'treatment']]}, 'NCT01434472'), ({'text': 'Use of an investigational drug in the 3 months prior to screening and must agree to not participate in any drug or device study while enrolled in this study', 'entities': [['11', '31', 'treatment'], ['39', '53', 'upper_bound']]}, 'NCT02382419'), ({'text': 'Creatinine clearance > 60 mL/min/1.73 m2 for subjects with above normal AST and ALT with alkaline phosphatase within < 1.5 times upper limit of normal', 'entities': [['1', '21', 'clinical_variable'], ['24', '41', 'lower_bound'], ['73', '76', 'clinical_variable'], ['81', '84', 'clinical_variable'], ['90', '110', 'clinical_variable'], ['120', '151', 'upper_bound']]}, 'NCT01720836'), ({'text': 'have a current uncontrolled medical illness, neurological disorder affecting the central nervous system, or history of head injury', 'entities': [['29', '44', 'chronic_disease'], ['46', '67', 'chronic_disease'], ['120', '131', 'chronic_disease']]}, 'NCT03154151'), ({'text': 'Patients without any evidence of systemic disease, either receiving systemic treatment or on active observation (Cohort D)', 'entities': [['34', '50', 'chronic_disease'], ['69', '87', 'treatment']]}, 'NCT00338377'), ({'text': 'Anemia (hemoglobin<12.0g/dL)', 'entities': [['1', '7', 'chronic_disease'], ['9', '19', 'clinical_variable'], ['20', '28', 'upper_bound']]}, 'NCT01419561'), ({'text': 'with moderate to severe hypophonia', 'entities': [['25', '35', 'chronic_disease']]}, 'NCT02265315'), ({'text': 'Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks including chemotherapy, radiation therapy, antibody based therapy, etc', 'entities': [['30', '50', 'treatment'], ['100', '107', 'upper_bound'], ['118', '130', 'treatment'], ['132', '149', 'treatment'], ['151', '173', 'treatment']]}, 'NCT02321501'), ({'text': 'Grade 3 or higher bleeding event d 3 months prior to randomization', 'entities': [['1', '8', 'lower_bound'], ['19', '33', 'clinical_variable'], ['36', '50', 'upper_bound']]}, 'NCT02581215'), ({'text': 'White blood cell (WBC) >= 3,000/mm^3', 'entities': [['1', '23', 'clinical_variable'], ['27', '37', 'lower_bound']]}, 'NCT01817751'), ({'text': 'Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment', 'entities': [['28', '49', 'chronic_disease'], ['51', '66', 'chronic_disease'], ['71', '94', 'chronic_disease'], ['102', '110', 'upper_bound']]}, 'NCT02501954'), ({'text': 'Have a history of additional risk factors for Torsades de Pointes (TdP)', 'entities': [['47', '72', 'chronic_disease']]}, 'NCT02278367'), ({'text': "Patients must have a diagnosis of relapsed or refractory CD22-positive acute leukemia including B-ALL, mixed phenotype leukemia (biphenotypic), or Burkitt's leukemia based on World Health Organization (WHO) classification", 'entities': [['72', '86', 'cancer'], ['97', '102', 'cancer'], ['104', '128', 'cancer'], ['148', '166', 'cancer']]}, 'NCT01925131'), ({'text': 'Intra-articular corticosteroids in the affected joint within three months', 'entities': [['1', '32', 'treatment'], ['62', '74', 'upper_bound']]}, 'NCT02243631'), ({'text': 'Patients must have histologically or cytologically proven pancreatic adenocarcinoma', 'entities': [['59', '84', 'cancer']]}, 'NCT02562716'), ({'text': 'Patients must have recovered from all toxicities related to prior anticancer therapies to grade d 1 (CTCAE v 4.03)', 'entities': [['61', '87', 'treatment'], ['99', '100', 'upper_bound']]}, 'NCT02336451'), ({'text': 'GMFCS 1-3', 'entities': [['1', '6', 'clinical_variable'], ['7', '8', 'lower_bound'], ['9', '10', 'upper_bound']]}, 'NCT02259140'), ({'text': 'Any corticosteroid therapy for indications other than cGvHD at doses > 1 mg/kg/day methylprednisolone or equivalent within 7 days of Cycle 1 Day 1', 'entities': [['5', '27', 'treatment'], ['55', '60', 'clinical_variable'], ['72', '83', 'lower_bound'], ['84', '102', 'treatment'], ['124', '130', 'upper_bound']]}, 'NCT03112603'), ({'text': 'Participation in another clinical treatment trial while on study', 'entities': [['35', '44', 'treatment']]}, 'NCT01972919'), ({'text': 'a decrease in cardiac output with fluid challenge (500 - 1000 cc Normal Saline (NS) in 10 minutes)', 'entities': [['35', '50', 'clinical_variable'], ['52', '55', 'lower_bound'], ['58', '65', 'upper_bound'], ['66', '84', 'clinical_variable']]}, 'NCT01445821'), ({'text': 'Age between 18 to 64 years', 'entities': [['1', '4', 'age'], ['13', '15', 'lower_bound'], ['19', '27', 'upper_bound']]}, 'NCT02165449'), ({'text': 'Pregnancy, abortion or miscarriage in the two months prior to enrollment or plans to conceive during the course of study participation', 'entities': [['1', '10', 'pregnancy'], ['43', '59', 'upper_bound'], ['77', '94', 'pregnancy']]}, 'NCT02473250'), ({'text': 'No more than 1 antigen mismatch at HLA-A, -B, -C, -DRB1 or -DQB1 locus for unrelated donor with peripheral blood and bone marrow as the hematopoietic stem cell source', 'entities': [['14', '15', 'upper_bound']]}, 'NCT02400255'), ({'text': "Subject has QTc interval (ie, Fridericia's correction [QTcF]) e 450 ms or other factors that increase the risk of QT prolongation or arrhythmic events (eg, heart failure, hypokalemia, family history of long QT interval syndrome) at screening", 'entities': [['13', '25', 'clinical_variable'], ['31', '61', 'clinical_variable'], ['65', '71', 'lower_bound'], ['134', '151', 'chronic_disease'], ['157', '170', 'chronic_disease'], ['172', '183', 'chronic_disease']]}, 'NCT02577406'), ({'text': 'No immunosuppressive medication (i.e., steroid therapy or other immunosuppressive/immunomodulating drugs [e.g., cyclosporine]) within the past 2 months', 'entities': [['4', '32', 'treatment'], ['40', '55', 'treatment'], ['65', '105', 'treatment'], ['113', '125', 'treatment'], ['139', '152', 'upper_bound']]}, 'NCT00788164'), ({'text': 'Subjects must be able to undergo either a contrast enhanced MRI or CT', 'entities': [['61', '64', 'treatment'], ['68', '70', 'treatment']]}, 'NCT02473536'), ({'text': 'Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study', 'entities': [['1', '15', 'gender'], ['70', '122', 'contraception_consent'], ['132', '154', 'contraception_consent'], ['156', '176', 'contraception_consent'], ['178', '203', 'contraception_consent'], ['205', '227', 'contraception_consent'], ['232', '242', 'contraception_consent']]}, 'NCT02370693'), ({'text': '>/= 10 % blasts', 'entities': [['5', '9', 'lower_bound'], ['10', '16', 'clinical_variable']]}, 'NCT01515527'), ({'text': 'Subjects will be otherwise healthy women and female minors', 'entities': [['36', '41', 'gender'], ['46', '52', 'gender']]}, 'NCT00383656'), ({'text': 'Tumor tissue (archived or fresh) is required and must be available to be shipped to GSK or site specific laboratory', 'entities': [['1', '6', 'cancer']]}, 'NCT02124772'), ({'text': 'Current use of laxatives (MiraLax, Ex-lax, senna, herbal supplements), linaclotide, lubiprostone, and prucalopride to treat constipation- patients using these medications will be eligible to participate if they can discontinue the medication at least 3 days (72 hrs.) before the date of screening and are willing to stay off them till the study is complete', 'entities': [['16', '25', 'treatment'], ['27', '34', 'treatment'], ['36', '42', 'treatment'], ['44', '49', 'treatment'], ['51', '69', 'treatment'], ['72', '83', 'treatment'], ['85', '97', 'treatment'], ['103', '115', 'treatment'], ['252', '266', 'lower_bound'], ['252', '258', 'lower_bound']]}, 'NCT02877394'), ({'text': 'IPSS voiding symptoms score must be less than 18', 'entities': [['1', '28', 'clinical_variable'], ['47', '49', 'upper_bound']]}, 'NCT02339948'), ({'text': 'Myelodysplastic syndrome', 'entities': [['1', '25', 'cancer']]}, 'NCT01810588'), ({'text': 'Individuals considered an immediate suicide risk or who are likely to require hospitalization during the course of the study', 'entities': [['37', '44', 'chronic_disease']]}, 'NCT02500602'), ({'text': 'patients with bilineal leukemia are excluded', 'entities': [['15', '32', 'cancer']]}, 'NCT01925131'), ({'text': 'Suitable candidate for surgery', 'entities': [['24', '31', 'treatment']]}, 'NCT02366871'), ({'text': 'The subject has had an assessment of all extracranial disease sites (e.g., by computerized tomography (CT) scan, positron emission tomography-CT, and bone scan as appropriate) within 28 days before the first dose of cabozantinib', 'entities': [['42', '62', 'chronic_disease'], ['79', '112', 'treatment'], ['114', '145', 'treatment'], ['151', '160', 'treatment'], ['184', '198', 'upper_bound'], ['217', '229', 'treatment']]}, 'NCT02132598'), ({'text': 'BMI >37', 'entities': [['1', '4', 'bmi'], ['6', '8', 'lower_bound']]}, 'NCT03076658'), ({'text': 'Patients must have relapsed after high-dose therapy and autologous transplantation or be ineligible for high-dose therapy and autologous transplantation; patients that have failed autologous transplantation are those with persistent disease > 30 days after transplant; those ineligible for autologous transplant include those with chemoresistant disease (i.e., patients who have not achieved a partial response or better with their most recent chemotherapy regimen), are expected to have a poor outcome from autologous transplant (e.g., DLBCL relapsing within one year of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone [R-CHOP]-like chemotherapy, double hit lymphoma, v-myc myelocytomatosis viral oncogene homolog (avian) positive [MYC+] lymphoma, persistent positron emission tomography [PET] positivity after chemotherapy), are unable to collect sufficient or tumor-free autologous stem cells per Seattle Cancer Care Alliance (SCCA) standard practice, are unable to tolerate the high-dose autologous conditioning regimens, or who refuse a high-dose autologous transplant regimen', 'entities': [['35', '52', 'treatment'], ['57', '83', 'treatment'], ['57', '78', 'treatment'], ['68', '78', 'treatment'], ['244', '257', 'lower_bound'], ['332', '354', 'cancer'], ['445', '457', 'treatment'], ['445', '465', 'treatment'], ['538', '543', 'cancer'], ['561', '569', 'upper_bound'], ['573', '582', 'treatment'], ['584', '600', 'treatment'], ['602', '627', 'treatment'], ['629', '648', 'treatment'], ['650', '687', 'treatment'], ['689', '708', 'cancer'], ['801', '835', 'treatment'], ['904', '909', 'cancer'], ['915', '936', 'treatment'], ['1023', '1065', 'treatment'], ['1083', '1122', 'treatment']]}, 'NCT01434472'), ({'text': 'Not recovered from toxicity due to all prior therapies', 'entities': [['40', '55', 'treatment']]}, 'NCT02594384'), ({'text': 'have progression of disease on erlotinib, gefitinib or afatinib as last previous systemic treatment', 'entities': [['32', '41', 'treatment'], ['43', '52', 'treatment'], ['56', '64', 'treatment'], ['68', '100', 'treatment']]}, 'NCT02496663'), ({'text': 'History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization* or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy', 'entities': [['12', '36', 'chronic_disease'], ['49', '75', 'treatment'], ['90', '119', 'treatment'], ['135', '159', 'treatment'], ['167', '174', 'upper_bound'], ['223', '230', 'lower_bound'], ['234', '235', 'upper_bound'], ['273', '287', 'treatment']]}, 'NCT02273375'), ({'text': 'Patients who are at least 18 years of age', 'entities': [['27', '35', 'lower_bound'], ['39', '42', 'age']]}, 'NCT03135782'), ({'text': 'CNS3 leukemia', 'entities': [['1', '14', 'cancer']]}, 'NCT02723994'), ({'text': 'hemodynamic instability', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT03174834'), ({'text': 'Evidence of coronary heart disease', 'entities': [['13', '35', 'chronic_disease']]}, 'NCT02471430'), ({'text': 'patients with confirmed non-alcoholic fatty liver disease (NAFLD) where pioglitazone has been reported to have a therapeutic role', 'entities': [['25', '66', 'chronic_disease'], ['73', '85', 'treatment']]}, 'NCT02338999'), ({'text': 'Contralateral Total Knee Arthroplasty', 'entities': [['1', '38', 'treatment']]}, 'NCT03053453'), ({'text': 'Concurrent pressure sores or urinary tract infection', 'entities': [['30', '53', 'chronic_disease']]}, 'NCT01608438'), ({'text': 'Tissue acquisition: Patient must agree to provide the required research biopsies at baseline, week 4 and at surgery for integral and integrated biomarker and correlative studies', 'entities': [['73', '81', 'treatment'], ['109', '116', 'treatment']]}, 'NCT01953588'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02981082'), ({'text': 'sufficient severity of OCD symptoms', 'entities': [['24', '27', 'chronic_disease']]}, 'NCT03182075'), ({'text': '0 to 55 years', 'entities': [['1', '2', 'lower_bound'], ['6', '14', 'upper_bound']]}, 'NCT01666080'), ({'text': 'Major gastrointestinal surgery (e.g. significant bowel resection or diversion) within 3 months before enrollment (this does not include appendectomy or cholecystectomy), or any history of total colectomy or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e., restrictive procedures such as banding, are permitted)', 'entities': [['1', '31', 'treatment'], ['38', '78', 'treatment'], ['87', '95', 'upper_bound'], ['137', '149', 'treatment'], ['153', '168', 'treatment'], ['195', '204', 'treatment'], ['208', '225', 'treatment']]}, 'NCT03183128'), ({'text': 'Psychotic or bipolar spectrum disorder (as assessed at screening)', 'entities': [['1', '10', 'chronic_disease'], ['14', '39', 'chronic_disease']]}, 'NCT02370732'), ({'text': 'Subject has had previous surgical or endovascular treatment of an infra-renal aortic aneurysm <30 days of implantation of investigational device', 'entities': [['17', '34', 'treatment'], ['38', '60', 'treatment'], ['67', '94', 'clinical_variable'], ['96', '103', 'upper_bound'], ['123', '145', 'treatment']]}, 'NCT02365467'), ({'text': 'brain tumors', 'entities': [['1', '13', 'cancer']]}, 'NCT02520713'), ({'text': 'Hemoglobin >= 9 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['15', '21', 'lower_bound']]}, 'NCT02562716'), ({'text': 'Use of an IL-1 antagonist within the 3 months prior to enrollment', 'entities': [['11', '26', 'treatment'], ['38', '52', 'upper_bound']]}, 'NCT02179853'), ({'text': 'Nursing women', 'entities': [['9', '14', 'gender']]}, 'NCT00887146'), ({'text': 'Patients with cancer judged to be stage 4 are not eligible', 'entities': [['15', '21', 'cancer']]}, 'NCT01239095'), ({'text': 'Acceptance onto a lung transplant waiting list', 'entities': [['19', '34', 'treatment']]}, 'NCT02019641'), ({'text': 'Monoclonal antibodies: At least 3 half-lives of the antibody after the last dose of a monoclonal antibody', 'entities': [['1', '22', 'treatment'], ['33', '45', 'lower_bound'], ['87', '106', 'treatment']]}, 'NCT02390752'), ({'text': 'Insulin treatment', 'entities': [['1', '18', 'treatment']]}, 'NCT00862433'), ({'text': 'anhedonia', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT02469389'), ({'text': 'Patients who have received prior hematocrit (HCT) within three months of enrollment for reduced intensity regimen and within six months for myeloablative regimen/reduced toxicity regimens', 'entities': [['28', '50', 'treatment'], ['58', '70', 'upper_bound'], ['126', '136', 'upper_bound'], ['141', '162', 'treatment'], ['163', '188', 'treatment']]}, 'NCT01966367'), ({'text': 'Any active history of a known autoimmune disease', 'entities': [['31', '49', 'chronic_disease']]}, 'NCT01928576'), ({'text': 'Patients on chronic transfusion therapy for severe disease symptoms other than those listed above, and which interfere with normal life activities', 'entities': [['13', '40', 'treatment']]}, 'NCT02186418'), ({'text': 'Creatinine clearance e 45 ml/min determined by 24-hour collection', 'entities': [['1', '21', 'clinical_variable'], ['24', '33', 'lower_bound']]}, 'NCT02128906'), ({'text': 'All females of childbearing potential must have a blood test or urine study', 'entities': [['1', '12', 'gender']]}, 'NCT02128906'), ({'text': 'over the age of 18 years', 'entities': [['10', '13', 'age'], ['17', '25', 'lower_bound']]}, 'NCT03046771'), ({'text': 'Patients with history of prior pelvic irradiation', 'entities': [['26', '50', 'treatment']]}, 'NCT02592473'), ({'text': 'Patients that do not have smart phone and/or device for app usage', 'entities': [['15', '66', 'technology_access']]}, 'NCT02219581'), ({'text': 'life expectancy < 1 year', 'entities': [['1', '16', 'clinical_variable'], ['19', '25', 'upper_bound']]}, 'NCT03179085'), ({'text': 'Duration e 1 month at first visit', 'entities': [['12', '19', 'lower_bound']]}, 'NCT02352467'), ({'text': 'transfusion dependent', 'entities': [['1', '22', 'treatment']]}, 'NCT02162420'), ({'text': 'total bilirubin less than or equal to (<=) 1.5 times the upper limit of normal (ULN) of each institution', 'entities': [['1', '16', 'clinical_variable'], ['44', '85', 'upper_bound']]}, 'NCT03084640'), ({'text': 'females', 'entities': [['1', '8', 'gender']]}, 'NCT00085982'), ({'text': 'under the age of 18', 'entities': [['11', '14', 'age'], ['18', '20', 'upper_bound']]}, 'NCT03000998'), ({'text': 'Age greater than or equal to 18 and less than or equal to 65 years', 'entities': [['1', '4', 'age'], ['30', '32', 'lower_bound'], ['59', '67', 'upper_bound']]}, 'NCT01433965'), ({'text': 'high suicide risk based on the Columbia Suicide Severity Rating Scale', 'entities': [['6', '13', 'chronic_disease'], ['32', '70', 'clinical_variable']]}, 'NCT02378714'), ({'text': 'The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan', 'entities': [['29', '47', 'chronic_disease'], ['51', '74', 'chronic_disease'], ['85', '88', 'treatment'], ['92', '125', 'treatment']]}, 'NCT01906385'), ({'text': 'Patients with cognitive impairment precluding informed consent', 'entities': [['15', '35', 'chronic_disease']]}, 'NCT02991534'), ({'text': 'Contraindications to anesthesia for procedure', 'entities': [['22', '32', 'allergy_name']]}, 'NCT02770326'), ({'text': 'Documented moderate to severe restrictive lung disease defined as: total lung capacity < 60% of predicted value', 'entities': [['31', '55', 'chronic_disease'], ['68', '87', 'clinical_variable'], ['90', '93', 'upper_bound']]}, 'NCT02554903'), ({'text': 'Anti-cancer Agents: Anti-cancer agents are not permitted within 21 days prior to start of POPI', 'entities': [['1', '19', 'treatment'], ['21', '39', 'treatment'], ['65', '78', 'upper_bound'], ['91', '95', 'treatment']]}, 'NCT01618357'), ({'text': 'Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks', 'entities': [['69', '83', 'treatment'], ['87', '104', 'clinical_variable'], ['112', '128', 'upper_bound']]}, 'NCT02379520'), ({'text': 'Life expectancy of greater than 3 months', 'entities': [['1', '16', 'clinical_variable'], ['33', '41', 'lower_bound']]}, 'NCT02520778'), ({'text': 'Exercise level of <20 minutes per week', 'entities': [['1', '15', 'clinical_variable'], ['20', '30', 'upper_bound']]}, 'NCT02875301'), ({'text': "Subjects with a known history of acute adrenal crisis, Addison's disease or decreased adrenal output, low pituitary function or pituitary tumors", 'entities': [['34', '54', 'chronic_disease'], ['56', '73', 'chronic_disease'], ['77', '101', 'chronic_disease'], ['129', '145', 'cancer']]}, 'NCT02527421'), ({'text': 'gastrointestinal perforation', 'entities': [['1', '29', 'chronic_disease']]}, 'NCT01639508'), ({'text': 'Medications that, in the opinion of the investigator may confound the outcome or increase the risk to the subject (tamsulosin hydrochloride (Flomax) or other medications with similar side-effects (floppy iris syndrome)', 'entities': [['116', '149', 'treatment'], ['198', '218', 'chronic_disease']]}, 'NCT03179397'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status must be level 0 or 1 within 60 days prior to registration', 'entities': [['1', '61', 'clinical_variable'], ['76', '77', 'lower_bound'], ['81', '82', 'upper_bound'], ['90', '103', 'upper_bound']]}, 'NCT02163317'), ({'text': 'unstable cardiovascular disease within 3 months prior to baseline or other cardiovascular disease requiring hospitalization', 'entities': [['1', '32', 'chronic_disease'], ['10', '32', 'chronic_disease'], ['40', '54', 'upper_bound']]}, 'NCT02378714'), ({'text': 'patient must not have any uncontrolled intercurrent illness such as ongoing or active infection', 'entities': [['40', '60', 'chronic_disease'], ['80', '96', 'chronic_disease']]}, 'NCT02465060'), ({'text': 'ages 9.0 to 15.6 years old', 'entities': [['1', '5', 'age'], ['6', '9', 'lower_bound'], ['13', '23', 'upper_bound'], ['24', '27', 'age']]}, 'NCT02021578'), ({'text': '18 - 90 years of age', 'entities': [['1', '3', 'lower_bound'], ['6', '14', 'upper_bound'], ['18', '21', 'age']]}, 'NCT03123068'), ({'text': 'Platelets >= 100,000/mcL', 'entities': [['1', '10', 'clinical_variable'], ['14', '25', 'lower_bound']]}, 'NCT02437370'), ({'text': 'Ages 18-70 years', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '17', 'upper_bound']]}, 'NCT02484300'), ({'text': 'Psychiatric disorders', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT03070535'), ({'text': 'use marijuana >2 x/week, or use of illegal drugs', 'entities': [['16', '24', 'lower_bound']]}, 'NCT02706288'), ({'text': 'uncontrolled infection', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02353728'), ({'text': 'Diagnosed with at least 6 regular uterine contractions in an observation period of no more than 60 minutes', 'entities': [['25', '26', 'lower_bound'], ['35', '55', 'chronic_disease'], ['97', '107', 'upper_bound']]}, 'NCT02487797'), ({'text': "Immunosuppression or immunocompromised for reasons not directly related to patient's malignancy (e.g. HIV or kidney transplant)", 'entities': [['86', '96', 'cancer'], ['103', '106', 'chronic_disease'], ['110', '127', 'treatment']]}, 'NCT02544880'), ({'text': 'Renal: Creatinine >1.5 x ULN or creatinine clearance < 60 mL/min, from assays obtained <2 weeks prior to study enrollment', 'entities': [['8', '18', 'lower_bound'], ['20', '29', 'lower_bound'], ['33', '53', 'clinical_variable'], ['56', '65', 'upper_bound'], ['72', '78', 'clinical_variable'], ['89', '102', 'upper_bound']]}, 'NCT01697930'), ({'text': 'Male subjects of reproductive potential in the combination treatment', 'entities': [['1', '14', 'gender']]}, 'NCT02509507'), ({'text': 'Prior diagnosis of congenital heart disease or cancer', 'entities': [['20', '44', 'chronic_disease'], ['48', '54', 'cancer']]}, 'NCT02444689'), ({'text': "Immunosuppressant's", 'entities': [['1', '20', 'treatment']]}, 'NCT02762032'), ({'text': 'Concurrent treatment with another anti-estrogen', 'entities': [['1', '48', 'treatment']]}, 'NCT02540330'), ({'text': 'Known HIV-infected patients', 'entities': [['7', '10', 'chronic_disease']]}, 'NCT02835729'), ({'text': 'planning to become pregnant', 'entities': [['1', '28', 'pregnancy']]}, 'NCT02819843'), ({'text': 'Known allergy to any of the treatment components', 'entities': [['29', '38', 'treatment']]}, 'NCT02581215'), ({'text': 'Recurrent or metastatic cancer that is of known or suspected breast origin - may be biopsy proven or identified on standard imaging (e.g. CT, bone scan, MRI, FDG PET/CT)', 'entities': [['1', '10', 'cancer'], ['14', '31', 'cancer'], ['85', '91', 'treatment'], ['139', '141', 'treatment'], ['143', '152', 'treatment'], ['154', '157', 'treatment'], ['159', '169', 'treatment']]}, 'NCT02409316'), ({'text': 'Patients with pre-existing severe restrictive pulmonary disease (FVC less than 40% of predicted)', 'entities': [['35', '64', 'chronic_disease'], ['66', '69', 'clinical_variable'], ['80', '83', 'upper_bound']]}, 'NCT00368355'), ({'text': 'Platelets e 100 x 109/L', 'entities': [['1', '10', 'clinical_variable'], ['13', '24', 'lower_bound']]}, 'NCT01925573'), ({'text': 'patients with previously treated (surgery, radiation or both), clinically inactive brain metastases, who have not received corticosteroid therapy within three weeks of starting protocol therapy', 'entities': [['35', '42', 'treatment'], ['44', '53', 'treatment'], ['84', '100', 'cancer'], ['124', '146', 'treatment'], ['154', '165', 'upper_bound'], ['178', '194', 'treatment']]}, 'NCT01553071'), ({'text': 'Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as evidence of new optic disc cupping, evidence of new visual field defects, and intraocular pressure > 21 mmHg', 'entities': [['95', '98', 'chronic_disease'], ['102', '105', 'chronic_disease'], ['192', '212', 'clinical_variable'], ['215', '222', 'lower_bound']]}, 'NCT01989585'), ({'text': 'Patient has any currently active Acquired Immunodeficiency Syndrome (AIDS) defining illness', 'entities': [['34', '75', 'chronic_disease']]}, 'NCT00799864'), ({'text': 'Pulmonary air leaks', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02164734'), ({'text': 'History of anaphylaxis to cat allergen', 'entities': [['12', '23', 'chronic_disease'], ['27', '39', 'allergy_name']]}, 'NCT02230189'), ({'text': 'Patients must have histologically or cytologically confirmed stage IV non-small cell lung cancer', 'entities': [['62', '97', 'cancer']]}, 'NCT02991651'), ({'text': 'obstructive sleep apnea warranting adenotonsillectomy', 'entities': [['1', '24', 'chronic_disease'], ['36', '54', 'treatment']]}, 'NCT01695967'), ({'text': 'Idiopathic calcium nephrolithiasis with renal phosphate leak', 'entities': [['1', '35', 'clinical_variable'], ['41', '61', 'clinical_variable']]}, 'NCT02016235'), ({'text': 'Children with immunodeficiency', 'entities': [['15', '31', 'chronic_disease']]}, 'NCT01364467'), ({'text': '< 350 lbs', 'entities': [['3', '10', 'upper_bound']]}, 'NCT02997943'), ({'text': 'Small molecule or antibody targeted therapy is permissible <14 days from start of trial treatment', 'entities': [['1', '44', 'treatment'], ['61', '68', 'upper_bound'], ['83', '98', 'treatment']]}, 'NCT03104699'), ({'text': 'Arterial ischemic event (e.g., unstable angina, myocardial infarction, stroke) within 6 months of study entry', 'entities': [['1', '24', 'cancer'], ['32', '47', 'chronic_disease'], ['49', '70', 'chronic_disease'], ['72', '78', 'chronic_disease'], ['87', '95', 'upper_bound']]}, 'NCT02669173'), ({'text': 'Atypical teratoid rhabdoid tumor (ATRT)', 'entities': [['1', '40', 'cancer']]}, 'NCT02451215'), ({'text': 'Presence of tumor cells in the brain or spinal cord which are symptomatic or require treatment', 'entities': [['13', '52', 'cancer'], ['63', '95', 'treatment']]}, 'NCT03143153'), ({'text': 'Be in good physical health without serious illness or change in health or medication (not including methadone or buprenorphine dose) in the past three months as determined by the license medical professional at each site', 'entities': [['36', '51', 'chronic_disease'], ['101', '110', 'treatment'], ['114', '127', 'treatment'], ['141', '158', 'upper_bound']]}, 'NCT02250664'), ({'text': 'Candidate for fulvestrant therapy', 'entities': [['15', '34', 'treatment']]}, 'NCT02953860'), ({'text': 'Moderate or high risk of suicide as assessed with MINI', 'entities': [['26', '33', 'chronic_disease']]}, 'NCT03058952'), ({'text': 'active or planned use of rhGH, anabolic steroids (other than replacement doses of testosterone), anti-TNFa therapy or other biologic (tocilizumab, Xelijanz, etc.)', 'entities': [['26', '30', 'treatment'], ['32', '49', 'treatment'], ['98', '115', 'treatment'], ['125', '133', 'treatment'], ['135', '146', 'treatment'], ['148', '156', 'treatment']]}, 'NCT02572323'), ({'text': 'Patient has a currently active or history of repeated local infection at the surgical site', 'entities': [['61', '70', 'chronic_disease']]}, 'NCT02469662'), ({'text': 'Smoke at least 10 cigarettes daily', 'entities': [['16', '18', 'lower_bound']]}, 'NCT02968602'), ({'text': 'not African-American', 'entities': [['1', '21', 'ethnicity']]}, 'NCT02386293'), ({'text': 'Age: 18 years or older', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02832115'), ({'text': 'Diabetes mellitus (type I or II) that is adequately controlled', 'entities': [['1', '18', 'chronic_disease'], ['20', '26', 'lower_bound'], ['30', '32', 'upper_bound']]}, 'NCT02312596'), ({'text': 'Women with allergy to Latex', 'entities': [['1', '6', 'gender'], ['23', '28', 'allergy_name']]}, 'NCT02710968'), ({'text': 'Subjects at any cancer stage will be enrolled', 'entities': [['17', '23', 'cancer']]}, 'NCT02584244'), ({'text': 'Pts may receive RBC or platelet transfusions, if clinically indicated, in accordance with institutional guidelines', 'entities': [['17', '20', 'treatment'], ['24', '45', 'treatment']]}, 'NCT01464034'), ({'text': 'Clinically significant electrocardiogram abnormalities including second degree (Type II) or third degree atrioventricular block', 'entities': [['24', '41', 'treatment'], ['66', '128', 'chronic_disease']]}, 'NCT02215096'), ({'text': 'Pulmonary arterial hypertension (PAH) diagnosis', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT02932410'), ({'text': 'Lesions in previously irradiated areas (or other local therapy) should not be selected as target lesions, unless treatment was e 3 months prior to Screening, and there has been demonstrated disease progression in that particular lesion', 'entities': [['50', '63', 'treatment'], ['114', '123', 'treatment'], ['130', '144', 'lower_bound']]}, 'NCT02360579'), ({'text': 'History of stroke', 'entities': [['12', '18', 'chronic_disease']]}, 'NCT02457832'), ({'text': 'hepatopulmonary syndrome with uncontrolled hypoxia', 'entities': [['1', '25', 'chronic_disease'], ['31', '51', 'chronic_disease']]}, 'NCT03106220'), ({'text': 'Untreated hyper/hypothyroidism', 'entities': [['1', '31', 'chronic_disease']]}, 'NCT02467478'), ({'text': 'weight >350 lbs', 'entities': [['1', '7', 'clinical_variable'], ['9', '16', 'lower_bound']]}, 'NCT02589977'), ({'text': 'HAM-D 21 score e 16 (MDD participants)', 'entities': [['1', '15', 'clinical_variable'], ['18', '20', 'lower_bound'], ['22', '25', 'chronic_disease']]}, 'NCT02418195'), ({'text': 'Pre-dialysis SBP >180 mmHg', 'entities': [['1', '13', 'treatment'], ['14', '17', 'clinical_variable'], ['19', '27', 'lower_bound']]}, 'NCT02145260'), ({'text': 'Symptomatic Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation refractory to a minimum of one Class I or Class III AADs', 'entities': [['1', '43', 'chronic_disease'], ['47', '101', 'chronic_disease'], ['143', '147', 'treatment']]}, 'NCT02393885'), ({'text': 'Patients receiving ongoing treatment with any other investigational agents', 'entities': [['20', '37', 'treatment'], ['53', '75', 'treatment']]}, 'NCT02232516'), ({'text': 'Females of reproductive potential', 'entities': [['1', '8', 'gender']]}, 'NCT02446457'), ({'text': 'For Combination therapy, participant must not have had prior exposure to Rovalpituzumab Tesirine or a pyrrolobenzodiazepine (PBD) based drug', 'entities': [['5', '24', 'treatment'], ['74', '97', 'treatment'], ['103', '130', 'treatment']]}, 'NCT03000257'), ({'text': 'e NCI-CTCAE version 4.03 Grade 2 dyspnea', 'entities': [['26', '33', 'lower_bound'], ['34', '41', 'clinical_variable']]}, 'NCT02048371'), ({'text': 'Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration', 'entities': [['1', '16', 'chronic_disease'], ['20', '36', 'chronic_disease'], ['47', '70', 'treatment']]}, 'NCT02470897'), ({'text': 'The treating physician will follow the adverse reporting guidelines as outlined in further detail below for pregnancies', 'entities': [['109', '120', 'pregnancy']]}, 'NCT01054196'), ({'text': 'Report drinking on 80% of days in the past 90 days', 'entities': [['39', '51', 'upper_bound']]}, 'NCT03099590'), ({'text': 'Gestational Age d 42 weeks', 'entities': [['1', '16', 'clinical_variable'], ['19', '27', 'upper_bound']]}, 'NCT02583360'), ({'text': 'Patients with current active ESC-R Enterobacteriaceae infection who have not yet completed antibiotic treatment will be excluded until their treatment is completed', 'entities': [['30', '64', 'chronic_disease'], ['92', '112', 'treatment'], ['103', '112', 'treatment']]}, 'NCT02543866'), ({'text': 'The presence of severe hepatic disease (direct bilirubin >3x upper limit of normal and AST > 5x upper limit of normal)', 'entities': [['17', '39', 'chronic_disease'], ['48', '57', 'clinical_variable'], ['59', '61', 'lower_bound'], ['62', '83', 'clinical_variable'], ['88', '91', 'clinical_variable'], ['94', '96', 'lower_bound']]}, 'NCT01189786'), ({'text': 'Non-small cell lung cancer patients enrolling to MK-3475 as first protocol therapy (no prior anti-PD-1 therapy)', 'entities': [['1', '27', 'cancer'], ['50', '57', 'treatment'], ['76', '83', 'treatment'], ['88', '111', 'treatment']]}, 'NCT02407171'), ({'text': 'Known HIV-positive individuals', 'entities': [['7', '10', 'chronic_disease']]}, 'NCT02344355'), ({'text': 'Able to undergo patch testing', 'entities': [['17', '30', 'treatment']]}, 'NCT02483728'), ({'text': 'psychiatric problems', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02989662'), ({'text': 'Participants with symptomatic bradycardia', 'entities': [['19', '42', 'chronic_disease']]}, 'NCT02091141'), ({'text': 'diffusion capacity of the lung of carbon monoxide (DLCO) is not required to be measured, however if it is measured, patient is excluded if DLCO < 35%', 'entities': [['52', '56', 'clinical_variable'], ['147', '150', 'upper_bound']]}, 'NCT01811368'), ({'text': 'Men', 'entities': [['1', '4', 'gender']]}, 'NCT02451488'), ({'text': 'Fever (>38 degrees C)', 'entities': [['1', '6', 'clinical_variable'], ['9', '21', 'lower_bound']]}, 'NCT01419561'), ({'text': 'Patients who already received oral vancomycin or metronidazole (either oral or intravenous) for > 24 hours within the preceding 72 hours at the time of enrollment', 'entities': [['36', '46', 'treatment'], ['50', '63', 'treatment'], ['80', '91', 'treatment'], ['99', '107', 'lower_bound'], ['129', '137', 'upper_bound']]}, 'NCT02692651'), ({'text': 'Significant hepatic disease', 'entities': [['13', '28', 'chronic_disease']]}, 'NCT02844907'), ({'text': 'High Risk with a single high risk feature is defined as having only one of the following: PSA>20 ng/ml, Gleason score 8-10, or T3a', 'entities': [['91', '94', 'clinical_variable'], ['95', '103', 'lower_bound'], ['105', '118', 'clinical_variable'], ['119', '120', 'lower_bound'], ['121', '123', 'upper_bound']]}, 'NCT01436968'), ({'text': 'Adequate bone marrow function as shown by: ANC e 1.5 x 10^9/L, Platelets e 75 x 10^9/L, Hb >9 g/dL', 'entities': [['44', '47', 'clinical_variable'], ['50', '62', 'lower_bound'], ['64', '73', 'clinical_variable'], ['76', '87', 'lower_bound'], ['89', '91', 'clinical_variable'], ['93', '99', 'lower_bound']]}, 'NCT02531932'), ({'text': 'BMI d40 kg/m2', 'entities': [['1', '4', 'bmi'], ['6', '14', 'upper_bound']]}, 'NCT02946268'), ({'text': 'Absence of hormonal contraception, fertility therapy, or insulin-sensitizing medication in the three months prior to enrollment', 'entities': [['36', '53', 'treatment'], ['58', '88', 'treatment'], ['96', '114', 'upper_bound']]}, 'NCT01785719'), ({'text': 'Significant hypersensitivity to study drug', 'entities': [['33', '43', 'allergy_name']]}, 'NCT03013543'), ({'text': '18 to 65 years old with a BMI of 35 kg/m2 or greater who will be undergoing bariatric surgery (VSG and RYGB)', 'entities': [['1', '3', 'lower_bound'], ['7', '15', 'upper_bound'], ['27', '30', 'bmi'], ['34', '42', 'lower_bound'], ['77', '94', 'treatment'], ['96', '99', 'treatment'], ['104', '108', 'treatment']]}, 'NCT02406885'), ({'text': 'Historical value of ejection fraction d 40% within 24 months of screening visit', 'entities': [['21', '38', 'clinical_variable'], ['41', '44', 'upper_bound'], ['52', '61', 'upper_bound']]}, 'NCT03037931'), ({'text': 'DLCO/VA and FEV1 e 50% of predicted on PFTs', 'entities': [['1', '8', 'clinical_variable'], ['13', '17', 'clinical_variable'], ['20', '23', 'lower_bound']]}, 'NCT02452268'), ({'text': 'Patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery', 'entities': [['33', '51', 'pregnancy'], ['78', '83', 'gender'], ['113', '127', 'upper_bound'], ['140', '161', 'treatment']]}, 'NCT00338377'), ({'text': 'Clinically significant underlying pulmonary disease as measured by pulmonary function tests', 'entities': [['35', '52', 'chronic_disease'], ['68', '92', 'treatment']]}, 'NCT02306954'), ({'text': 'those subjects with known HTN should be under these values while under pharmaceutical therapy', 'entities': [['27', '30', 'chronic_disease'], ['72', '94', 'treatment']]}, 'NCT02584244'), ({'text': 'Must have unresectable primary tumor or metastases', 'entities': [['24', '37', 'cancer'], ['41', '51', 'cancer']]}, 'NCT01886105'), ({'text': "Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation", 'entities': [['1', '27', 'chronic_disease'], ['34', '52', 'chronic_disease'], ['54', '69', 'chronic_disease'], ['81', '108', 'chronic_disease'], ['132', '143', 'chronic_disease']]}, 'NCT01532687'), ({'text': 'Proficient in Chinese (Mandarin or Cantonese), Spanish or English', 'entities': [['1', '66', 'language_fluency']]}, 'NCT02695043'), ({'text': 'Active inflammatory gastrointestinal disease, such as inflammatory bowel disease', 'entities': [['8', '45', 'chronic_disease'], ['55', '81', 'chronic_disease']]}, 'NCT02543866'), ({'text': 'clinical evidence of congestive heart failure', 'entities': [['22', '46', 'chronic_disease']]}, 'NCT01947673'), ({'text': 'no maximum age limit', 'entities': [['12', '15', 'age']]}, 'NCT02027948'), ({'text': 'Sufficient understanding of English', 'entities': [['1', '36', 'language_fluency']]}, 'NCT03012815'), ({'text': 'Participants who regularly (>= 2 times per week) use drugs that alter the pH of the gastrointestinal (GI) tract, such as proton pump inhibitors (PPI) and antacids', 'entities': [['32', '39', 'lower_bound'], ['122', '150', 'treatment'], ['155', '163', 'treatment']]}, 'NCT02273362'), ({'text': 'Grade > 2 peripheral neuropathy', 'entities': [['9', '10', 'lower_bound'], ['11', '32', 'chronic_disease']]}, 'NCT00734877'), ({'text': 'Patients with untreated brain metastases. Patients with treated brain metastases who demonstrate control of brain metastases with follow-up imaging 4 or more weeks after initial therapy are eligible', 'entities': [['25', '41', 'cancer'], ['149', '150', 'lower_bound'], ['179', '186', 'treatment']]}, 'NCT02575404'), ({'text': 'breastfeeding women', 'entities': [['15', '20', 'gender']]}, 'NCT02427841'), ({'text': 'Clinically significant iron-deficiency anemia', 'entities': [['40', '46', 'chronic_disease']]}, 'NCT01326715'), ({'text': 'Presence of cardiac condition, asthma, obstructive pulmonary disease, seizure disorder, urinary incontinence, and/or peptic ulcer disease receiving concurrent NSAIDs', 'entities': [['13', '20', 'chronic_disease'], ['32', '38', 'chronic_disease'], ['40', '69', 'chronic_disease'], ['71', '87', 'chronic_disease'], ['89', '109', 'chronic_disease'], ['118', '138', 'chronic_disease'], ['160', '166', 'treatment']]}, 'NCT01584076'), ({'text': 'Newly diagnosed prostate cancer pathologically proven by prostate biopsy', 'entities': [['17', '32', 'cancer'], ['58', '73', 'treatment']]}, 'NCT02420977'), ({'text': 'Prior systemic chemotherapy for any reason', 'entities': [['1', '28', 'treatment']]}, 'NCT00969111'), ({'text': 'Patients who already have OncoPlex or other equivalent gene sequencing assay (eg Foundation One, Perthera, Caris etc) test results available from prior tumor biopsy are eligible to participate, without the needed of a repeat tumor biopsy, but the test results need to be provided to the study principal investigator', 'entities': [['27', '35', 'treatment'], ['147', '165', 'treatment'], ['153', '165', 'treatment']]}, 'NCT02451553'), ({'text': 'history of trialing one or more antidepressant medications with little to no PTSD symptom improvement', 'entities': [['33', '59', 'treatment'], ['78', '82', 'chronic_disease']]}, 'NCT02655692'), ({'text': 'thoracic surgery', 'entities': [['1', '17', 'treatment']]}, 'NCT02570984'), ({'text': 'Karnofsky performance status (KPS) >= 70', 'entities': [['1', '35', 'clinical_variable'], ['39', '41', 'lower_bound']]}, 'NCT02159495'), ({'text': 'Congestive heart failure', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT01184547'), ({'text': 'Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures which are not controlled, any brain metastases and/or epidural disease, or history of cerebrovascular accident (CVA, stroke) within six months prior to the first date of study treatment', 'entities': [['64', '75', 'chronic_disease'], ['87', '106', 'cancer'], ['108', '116', 'chronic_disease'], ['147', '163', 'chronic_disease'], ['171', '187', 'chronic_disease'], ['203', '227', 'chronic_disease'], ['229', '232', 'chronic_disease'], ['234', '240', 'chronic_disease'], ['249', '265', 'upper_bound']]}, 'NCT02269293'), ({'text': 'Major psychiatric diagnosis with comorbid sleep problems', 'entities': [['1', '28', 'chronic_disease'], ['43', '57', 'chronic_disease']]}, 'NCT03087799'), ({'text': 'Pleural effusion or ascites that causes respiratory compromise, grade 2 dyspnea', 'entities': [['1', '17', 'chronic_disease'], ['21', '28', 'chronic_disease'], ['65', '80', 'chronic_disease']]}, 'NCT02466009'), ({'text': 'Subject is not a candidate for standard revascularization treatment options for peripheral arterial disease', 'entities': [['32', '68', 'treatment'], ['81', '108', 'chronic_disease']]}, 'NCT02551679'), ({'text': 'For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose', 'entities': [['10', '34', 'gender'], ['113', '125', 'upper_bound']]}, 'NCT02471911'), ({'text': 'Safety substudy in 20 IDDM patients only: Insulin-treated type 2 diabetics with a C-peptide of <0.8 ng/mLd and fasting blood glucose >150 mg/dL will be excluded even without history of hypoglycemia during finger stick measurements', 'entities': [['23', '27', 'chronic_disease'], ['43', '75', 'chronic_disease'], ['83', '92', 'clinical_variable'], ['97', '107', 'upper_bound'], ['112', '133', 'clinical_variable'], ['135', '144', 'lower_bound'], ['186', '198', 'chronic_disease']]}, 'NCT02415556'), ({'text': 'Adult T-cell lymphoma/leukemia (ATLL)', 'entities': [['1', '38', 'cancer']]}, 'NCT02232516'), ({'text': 'skin cancer', 'entities': [['1', '12', 'cancer']]}, 'NCT02636283'), ({'text': 'Has symptoms of pelvic organ prolapse', 'entities': [['17', '38', 'chronic_disease']]}, 'NCT01648751'), ({'text': 'Patients with a primary bony tumor', 'entities': [['17', '35', 'cancer']]}, 'NCT02555280'), ({'text': 'BMI outside the range (below the 5th percentile or above the 95th percentile) for height', 'entities': [['1', '4', 'bmi'], ['34', '48', 'upper_bound'], ['62', '77', 'lower_bound']]}, 'NCT02687906'), ({'text': 'Negative testing for relevant communicable diseases', 'entities': [['31', '52', 'chronic_disease']]}, 'NCT02508038'), ({'text': 'Patients with bilateral uveitis who are receiving systemic immunosuppressive therapy (e.g., methotrexate, cyclosporine, cyclophosphamide, chlorambucil, mycophenolate mofetil, tacrolimus, or azathioprine) other than prednisone or other corticosteroids for the treatment of uveitis and the uveitis in the fellow eye, in the opinion of the Investigator, cannot be controlled with standard local therapies alone', 'entities': [['15', '32', 'chronic_disease'], ['25', '32', 'chronic_disease'], ['51', '85', 'treatment'], ['93', '105', 'treatment'], ['107', '119', 'treatment'], ['121', '137', 'treatment'], ['139', '151', 'treatment'], ['153', '166', 'treatment'], ['167', '174', 'treatment'], ['176', '186', 'treatment'], ['191', '203', 'treatment'], ['216', '226', 'treatment'], ['236', '251', 'treatment'], ['260', '269', 'treatment'], ['378', '402', 'treatment']]}, 'NCT01280669'), ({'text': "Prolongation of corrected QT interval by Fridericia's method (QTcF) at rest, where the mean QTcF interval is > 450 milliseconds (ms) for males", 'entities': [['17', '68', 'clinical_variable'], ['93', '106', 'clinical_variable'], ['112', '133', 'lower_bound'], ['138', '143', 'gender']]}, 'NCT01877382'), ({'text': 'neuroendocrine differentiation', 'entities': [['1', '31', 'cancer']]}, 'NCT02565901'), ({'text': 'for tumors of the body and tail of the pancreas, involvement of the splenic artery and vein of any degree is considered resectable disease', 'entities': [['5', '11', 'cancer'], ['121', '139', 'cancer']]}, 'NCT02562716'), ({'text': 'Must be cognitively intact and free of serious psychiatric illness (as determined by referring physician)', 'entities': [['48', '67', 'chronic_disease']]}, 'NCT02871752'), ({'text': 'must not have received botox injections in the prior six months', 'entities': [['48', '64', 'upper_bound']]}, 'NCT02339233'), ({'text': 'Measurable contrast-enhancing progressive or recurrent GBM by MRI imaging d two weeks before screening', 'entities': [['56', '59', 'cancer'], ['63', '66', 'clinical_variable'], ['77', '86', 'upper_bound']]}, 'NCT01865162'), ({'text': 'Radiation directed at target lesion within 28 days of registration', 'entities': [['1', '10', 'treatment'], ['30', '36', 'chronic_disease'], ['44', '51', 'upper_bound']]}, 'NCT02048722'), ({'text': 'Serum potassium > 3.8 mmol/L', 'entities': [['1', '16', 'clinical_variable'], ['19', '29', 'lower_bound']]}, 'NCT02393794'), ({'text': 'Breath CO > 80 ppm', 'entities': [['1', '10', 'clinical_variable'], ['13', '19', 'lower_bound']]}, 'NCT02250534'), ({'text': 'At least half of subjects must have evidence of sleep onset insomnia or delayed sleep phase disorder', 'entities': [['49', '69', 'chronic_disease'], ['73', '101', 'chronic_disease']]}, 'NCT02374918'), ({'text': 'Hepatitis B surface antigen (+) or Hepatitis C positive in preceding six months', 'entities': [['1', '12', 'chronic_disease'], ['36', '47', 'chronic_disease'], ['70', '80', 'upper_bound']]}, 'NCT02378428'), ({'text': 'Any other active malignancy requiring systemic therapy', 'entities': [['18', '28', 'cancer'], ['39', '55', 'treatment']]}, 'NCT02387216'), ({'text': 'Any active malignancy', 'entities': [['12', '22', 'cancer']]}, 'NCT02539160'), ({'text': 'Adult aged > 18 years and d 45 years', 'entities': [['7', '11', 'age'], ['14', '22', 'lower_bound'], ['29', '37', 'upper_bound']]}, 'NCT02481765'), ({'text': 'a major acute psychiatric disorder', 'entities': [['3', '35', 'chronic_disease']]}, 'NCT03046121'), ({'text': 'is adjacent to a lesion that is either filled or will receive a filling at the time of enrollment', 'entities': [['18', '24', 'chronic_disease']]}, 'NCT02591147'), ({'text': 'Able to walk at least 100 meters without assistance (Expanded Disability Severity Scale score equivalent 0-5.5)', 'entities': [['23', '33', 'lower_bound'], ['24', '25', 'lower_bound'], ['54', '94', 'clinical_variable'], ['108', '111', 'upper_bound']]}, 'NCT02106052'), ({'text': 'Montgomery Asberg Depression Rating Scale < 20', 'entities': [['1', '42', 'clinical_variable'], ['45', '47', 'upper_bound']]}, 'NCT02466685'), ({'text': 'female patients who have a negative serum or urine pregnancy test before enrollment and agree to use two highly effective forms of contraception (oral, injected or implanted hormonal contraception and condom; intrauterine device and condom; diaphragm with spermicidal gel and condom) during the trial and for 90 days afterward (90 days after the end of AMV564 treatment)', 'entities': [['1', '16', 'gender'], ['28', '61', 'pregnancy'], ['89', '145', 'contraception_consent']]}, 'NCT03144245'), ({'text': 'Receipt of a live vaccine within 30 days of the start of treatment', 'entities': [['14', '26', 'treatment'], ['34', '41', 'upper_bound'], ['58', '67', 'treatment']]}, 'NCT02362997'), ({'text': 'Pregnant women are excluded from this study because paclitaxel, doxorubicin, and cyclophosphamide have the potential for teratogenic or abortifacient effects', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender'], ['53', '63', 'treatment'], ['65', '76', 'treatment'], ['82', '98', 'treatment']]}, 'NCT02876302'), ({'text': 'Psoriasis', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT00788164'), ({'text': 'men', 'entities': [['1', '4', 'gender']]}, 'NCT02075710'), ({'text': 'completed >4 months prior to biopsy-proven recurrence or second primary site disease', 'entities': [['12', '26', 'lower_bound'], ['30', '36', 'treatment']]}, 'NCT02544880'), ({'text': 'congestive heart failure within the preceding 12 months', 'entities': [['1', '25', 'chronic_disease'], ['37', '56', 'upper_bound']]}, 'NCT02562755'), ({'text': 'Currently on antidepressant', 'entities': [['14', '28', 'treatment']]}, 'NCT02669030'), ({'text': 'Active ophthalmic disease, neovascularization of the cornea within 1 mm of the intended ablation zone, or lens opacity', 'entities': [['8', '26', 'chronic_disease'], ['28', '60', 'chronic_disease'], ['68', '72', 'upper_bound']]}, 'NCT02030990'), ({'text': 'Extramedullary disease with localized immature blasts', 'entities': [['1', '23', 'cancer']]}, 'NCT02353728'), ({'text': 'ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that in the opinion of investigators would jeopardize patient safety of data integrity', 'entities': [['12', '28', 'chronic_disease'], ['42', '66', 'chronic_disease'], ['68', '92', 'chronic_disease'], ['94', '112', 'chronic_disease'], ['117', '154', 'chronic_disease']]}, 'NCT02237183'), ({'text': 'History of allogeneic hematopoietic stem cell transplantation within 60-90 days of enrollment', 'entities': [['12', '62', 'treatment'], ['70', '72', 'lower_bound'], ['73', '80', 'upper_bound']]}, 'NCT00391170'), ({'text': 'Female subjects must agree to use a medically acceptable contraceptives including', 'entities': [['1', '16', 'gender'], ['22', '72', 'contraception_consent']]}, 'NCT02482376'), ({'text': 'ECOG performance status less than 2 (Phase I), less than or equal to 1(Phase II)', 'entities': [['1', '24', 'clinical_variable'], ['35', '36', 'upper_bound'], ['70', '71', 'upper_bound']]}, 'NCT01851369'), ({'text': 'Current cancer or cancer that has been in remission for < 5 years', 'entities': [['9', '15', 'cancer'], ['59', '66', 'upper_bound']]}, 'NCT02786251'), ({'text': 'For patients with multiple cutaneous BCCs at baseline that are not designated by the investigator as target lesions, treatment of these non-target BCCs with surgery may be permitted but must be discussed with Data Coordinator prior to any surgical procedure', 'entities': [['19', '42', 'cancer'], ['38', '42', 'cancer'], ['118', '127', 'treatment'], ['158', '165', 'treatment'], ['227', '258', 'treatment']]}, 'NCT01835626'), ({'text': 'plans to become pregnant during the course of this study', 'entities': [['1', '25', 'pregnancy']]}, 'NCT01547429'), ({'text': 'Pulmonary vein stenosis in one or more of the pulmonary veins', 'entities': [['1', '24', 'chronic_disease'], ['28', '31', 'lower_bound']]}, 'NCT02393885'), ({'text': 'Closed head injury (impaired brain function resulting from externally inflicted trauma without penetrating injury as defined below) at least 6 months prior to enrollment', 'entities': [['1', '19', 'chronic_disease'], ['21', '44', 'chronic_disease'], ['142', '156', 'lower_bound']]}, 'NCT01821690'), ({'text': 'bilateral reconstruction using other techniques', 'entities': [['11', '25', 'treatment']]}, 'NCT02395614'), ({'text': 'temperature > 38.0 degrees centigrade', 'entities': [['1', '12', 'clinical_variable'], ['15', '38', 'lower_bound']]}, 'NCT02469519'), ({'text': 'Dose Escalation, Renal insufficiency, NSCLC and CPI-Treated Expansion Cohorts', 'entities': [['18', '37', 'chronic_disease'], ['39', '44', 'cancer'], ['49', '52', 'treatment']]}, 'NCT02091999'), ({'text': 'Willing and able to give informed consent in either English or Spanish', 'entities': [['53', '60', 'language_fluency'], ['64', '71', 'language_fluency']]}, 'NCT02661386'), ({'text': 'Must be able to speak and understand English', 'entities': [['17', '45', 'language_fluency']]}, 'NCT03060096'), ({'text': 'Active fistula', 'entities': [['8', '15', 'chronic_disease']]}, 'NCT02770326'), ({'text': 'Patients with the following characteristics (depth of stromal invasion and lymphovascular space involvement to be pathologically confirmed)', 'entities': [['46', '71', 'clinical_variable'], ['76', '108', 'cancer']]}, 'NCT01101451'), ({'text': 'Healthy adult male', 'entities': [['15', '19', 'gender']]}, 'NCT02776761'), ({'text': 'You have less than two active areas of cutaneous lupus', 'entities': [['20', '23', 'upper_bound'], ['40', '55', 'chronic_disease']]}, 'NCT01776190'), ({'text': 'Primidone [Brand Name: Mysoline]', 'entities': [['1', '10', 'treatment'], ['24', '32', 'treatment']]}, 'NCT02796391'), ({'text': 'Currently receiving other systemic therapy for metastatic colorectal cancer', 'entities': [['21', '43', 'treatment'], ['48', '76', 'cancer']]}, 'NCT02466009'), ({'text': 'Prostate volume as assessed by TRUS must be less than 60 cc. 3.1.5', 'entities': [['1', '16', 'clinical_variable'], ['55', '67', 'upper_bound']]}, 'NCT02339948'), ({'text': 'Life expectancy <180 days', 'entities': [['1', '16', 'clinical_variable'], ['18', '26', 'upper_bound']]}, 'NCT02127398'), ({'text': 'Has known active Hepatitis B (e.g., HBsAg reactive)', 'entities': [['18', '29', 'chronic_disease'], ['37', '42', 'chronic_disease']]}, 'NCT02710396'), ({'text': 'Cumulative doxorubicin dose >= 400mg/m^2 (>450 mg/m^2 for malignant soft tissue and bone tumor patients) or cumulative epirubicin dose >= 800mg/m^2', 'entities': [['12', '23', 'treatment'], ['32', '41', 'lower_bound'], ['44', '54', 'lower_bound'], ['59', '80', 'cancer'], ['85', '95', 'cancer'], ['120', '130', 'treatment'], ['139', '148', 'lower_bound']]}, 'NCT01730118'), ({'text': 'Patients with any other known concurrent severe and/or uncontrolled medical condition', 'entities': [['69', '86', 'chronic_disease']]}, 'NCT02532231'), ({'text': 'Epithelioid or biphasic histology subtype', 'entities': [['1', '42', 'cancer']]}, 'NCT00715611'), ({'text': 'trying to become pregnant during the study period', 'entities': [['1', '26', 'pregnancy']]}, 'NCT03112902'), ({'text': 'Patients with current hemodynamic instability (current hypotension systolic blood pressure <100 mmHg, sustained heart rate < 60 beats/min without a pacemaker, symptomatic bradycardia, or second or third degree heart block)', 'entities': [['23', '46', 'chronic_disease'], ['56', '91', 'clinical_variable'], ['93', '101', 'upper_bound'], ['103', '123', 'clinical_variable'], ['126', '138', 'upper_bound'], ['160', '183', 'chronic_disease'], ['188', '222', 'chronic_disease']]}, 'NCT02409810'), ({'text': 'aged between 18-100', 'entities': [['1', '5', 'age'], ['14', '16', 'lower_bound'], ['17', '20', 'upper_bound']]}, 'NCT03122145'), ({'text': 'Availability of Cryopreserved peripheral blood stem cells with a CD34 dose of at least 2x106/kg', 'entities': [['66', '70', 'treatment'], ['88', '96', 'lower_bound']]}, 'NCT02416206'), ({'text': 'Known diffuse alveolar hemorrhage from vasculitis', 'entities': [['15', '50', 'chronic_disease']]}, 'NCT02370095'), ({'text': 'Visual acuity d20/200 in the worst eye', 'entities': [['1', '14', 'clinical_variable'], ['16', '22', 'upper_bound']]}, 'NCT01367444'), ({'text': 'Langerhans Cell Histiocytosis (LCH)', 'entities': [['1', '36', 'cancer']]}, 'NCT01652092'), ({'text': 'one or 2 UCB units may be used to achieve the required cell dose', 'entities': [['10', '19', 'clinical_variable']]}, 'NCT00719888'), ({'text': 'platelet count less than 10,000/mm(3)', 'entities': [['1', '15', 'clinical_variable'], ['26', '38', 'upper_bound']]}, 'NCT00044304'), ({'text': 'Prior radiation therapy (RT) after the initial diagnosis will be allowed', 'entities': [['1', '29', 'treatment']]}, 'NCT02549833'), ({'text': 'Patients undergoing open elective liver resection for primary liver pathology (benign or malignant) or secondary metastatic liver disease, including patients undergoing concomitant surgical procedures (such as colorectal resection or debulking procedures), with no contraindication to the insertion of an epidural catheter (localized infection, septicemia, or pre-operative coagulopathy)', 'entities': [['21', '50', 'treatment'], ['114', '138', 'cancer'], ['170', '201', 'treatment'], ['211', '231', 'treatment'], ['235', '255', 'treatment'], ['306', '323', 'treatment'], ['325', '344', 'chronic_disease'], ['346', '356', 'chronic_disease'], ['361', '387', 'treatment']]}, 'NCT02523443'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring systemic therapy, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, immunosuppression, autoimmune conditions, underlying pulmonary disease, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['14', '34', 'chronic_disease'], ['77', '93', 'chronic_disease'], ['104', '120', 'treatment'], ['134', '158', 'chronic_disease'], ['160', '184', 'chronic_disease'], ['186', '204', 'chronic_disease'], ['206', '223', 'treatment'], ['225', '246', 'chronic_disease'], ['259', '276', 'chronic_disease'], ['281', '300', 'chronic_disease'], ['301', '318', 'chronic_disease']]}, 'NCT02296684'), ({'text': "Concomitant systemic treatment with chronic use (based on the investigator's judgment) of corticosteroids, anti-histamine or non-steroidal anti-inflammatory drugs, and other platelet inhibitory agents", 'entities': [['13', '31', 'treatment'], ['91', '106', 'treatment'], ['108', '122', 'treatment'], ['126', '163', 'treatment'], ['169', '201', 'treatment']]}, 'NCT02166905'), ({'text': 'Patients shall provide results of tumor testing for epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) rearrangement', 'entities': [['35', '40', 'cancer'], ['53', '92', 'clinical_variable'], ['93', '137', 'clinical_variable']]}, 'NCT02642939'), ({'text': 'Any other known conditions other than heart failure that could limit survival to < 6 months', 'entities': [['39', '52', 'chronic_disease'], ['70', '78', 'clinical_variable'], ['84', '92', 'upper_bound']]}, 'NCT02441101'), ({'text': 'Total bilirubin d1.5 x institutional upper limit of normal (ULN)', 'entities': [['1', '16', 'clinical_variable'], ['18', '65', 'upper_bound']]}, 'NCT02991651'), ({'text': 'The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone for adrenal insufficiency) is allowed', 'entities': [['12', '35', 'treatment'], ['40', '58', 'treatment'], ['66', '81', 'treatment'], ['86', '107', 'chronic_disease']]}, 'NCT02451423'), ({'text': 'planned pregnancy during the follow-up period (since exposure to an insecticide is involved)', 'entities': [['1', '18', 'pregnancy']]}, 'NCT02613585'), ({'text': 'History of chronic pain or daily pain medication used for another medical problem', 'entities': [['12', '24', 'chronic_disease'], ['39', '49', 'treatment']]}, 'NCT02358850'), ({'text': 'Patients older than 40 years of age', 'entities': [['21', '29', 'lower_bound'], ['33', '36', 'age']]}, 'NCT02429349'), ({'text': 'Women on oral contraceptives, peri and post menopausal women, and those with hysterectomies', 'entities': [['1', '6', 'gender'], ['10', '29', 'contraception_consent'], ['56', '61', 'gender'], ['78', '92', 'treatment']]}, 'NCT02402088'), ({'text': 'pregnant females', 'entities': [['1', '9', 'pregnancy'], ['10', '17', 'gender']]}, 'NCT02155699'), ({'text': 'Must be 18 years of age or older', 'entities': [['9', '17', 'lower_bound'], ['21', '24', 'age']]}, 'NCT02245841'), ({'text': 'More than 5 discrete intrahepatic parenchymal foci of HCC', 'entities': [['11', '12', 'lower_bound']]}, 'NCT01730937'), ({'text': 'Progression free interval or treatment free interval of less than 12 months since the last rituximab containing treatment (including rituximab maintenance). For patients considered unwilling/unfit to receive chemotherapy : progression free interval or treatment free interval of less than 6 months since the last rituximab containing treatment (including rituximab maintenance), as assessed by the investigator', 'entities': [['30', '39', 'treatment'], ['67', '76', 'upper_bound'], ['92', '101', 'treatment'], ['209', '221', 'treatment'], ['290', '298', 'upper_bound']]}, 'NCT02367040'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2', 'entities': [['1', '67', 'clinical_variable'], ['68', '69', 'lower_bound'], ['72', '73', 'upper_bound']]}, 'NCT02072356'), ({'text': 'patient was proven to have TNBC, defined from standard pathologic assays as negative for ER and PR (< 10% tumor staining) and negative for HER2 (immunohistochemistry [IHC] score < 3, gene copy number not amplified)', 'entities': [['28', '32', 'cancer'], ['47', '73', 'treatment'], ['103', '106', 'upper_bound'], ['107', '121', 'treatment'], ['146', '178', 'clinical_variable'], ['181', '182', 'upper_bound']]}, 'NCT02276443'), ({'text': 'thrombophlebitis', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT01954966'), ({'text': 'Plasma cell count if determined by flow cytometry, >= 200/150,000 events', 'entities': [['1', '18', 'clinical_variable'], ['36', '50', 'clinical_variable'], ['55', '66', 'lower_bound']]}, 'NCT02547662'), ({'text': "Patient has bone stock that is inadequate for support or fixation of the prosthesis, or is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's disease) leading to progressive bone deterioration", 'entities': [['109', '125', 'chronic_disease'], ['132', '151', 'chronic_disease'], ['158', '176', 'chronic_disease'], ['183', '198', 'chronic_disease']]}, 'NCT01917929'), ({'text': 'immobility casts or splints within the last 6 months for tennis elbow', 'entities': [['1', '17', 'treatment'], ['21', '28', 'treatment'], ['45', '53', 'upper_bound']]}, 'NCT01897259'), ({'text': 'Treatment with anti-thymocyte globulin (ATG) within 14 days prior to start date', 'entities': [['16', '45', 'treatment'], ['53', '66', 'upper_bound']]}, 'NCT03144245'), ({'text': 'Patient is not expected to require e48 hours of intubation', 'entities': [['37', '45', 'lower_bound'], ['49', '59', 'treatment']]}, 'NCT02442102'), ({'text': 'Injury arising from penetrating mechanism', 'entities': [['21', '42', 'chronic_disease']]}, 'NCT01597518'), ({'text': 'Subjects taking moderate or strong inhibitors or inducers of CYP3A4', 'entities': [['62', '68', 'treatment']]}, 'NCT03085485'), ({'text': 'On treatment with low-dose aspirin (81mg/day) and clopidogrel (75mg/day)', 'entities': [['4', '13', 'treatment'], ['28', '35', 'treatment'], ['51', '62', 'treatment']]}, 'NCT02539160'), ({'text': 'Intranasal, inhaled, and topical steroids', 'entities': [['1', '42', 'treatment']]}, 'NCT02776761'), ({'text': 'Peak inspiratory pressure (PIP) > 30 cmH2O', 'entities': [['1', '32', 'clinical_variable'], ['35', '43', 'lower_bound']]}, 'NCT01504373'), ({'text': 'metabolic syndrome', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT03170375'), ({'text': 'Patient does not have a support person (ie. Spouse, partner, mother) available to support the patient for the duration of the pregnancy', 'entities': [['127', '136', 'pregnancy']]}, 'NCT03044821'), ({'text': 'No diagnosis of inflammatory bowel disease', 'entities': [['17', '43', 'chronic_disease']]}, 'NCT01508390'), ({'text': 'Active or suspected neoplasia', 'entities': [['21', '30', 'chronic_disease']]}, 'NCT01970345'), ({'text': 'At least 2 weeks beyond high dose systemic corticosteroids (however, low dose corticosteroids < 20 mg prednisone or equivalent daily are permitted)', 'entities': [['10', '17', 'lower_bound'], ['35', '59', 'treatment'], ['70', '94', 'clinical_variable'], ['97', '113', 'upper_bound']]}, 'NCT02574455'), ({'text': 'Ascites refractory to medical therapy', 'entities': [['1', '19', 'chronic_disease'], ['23', '38', 'treatment']]}, 'NCT01918683'), ({'text': 'Yale Global Tic Severity Scale (YGTSS) must be e35/50 for at least 12 months; Motor Tic subscore must be e15', 'entities': [['1', '39', 'clinical_variable'], ['49', '54', 'lower_bound'], ['68', '77', 'lower_bound'], ['79', '97', 'clinical_variable'], ['107', '109', 'lower_bound']]}, 'NCT02056873'), ({'text': 'Completely resected hepatic metastases without current evidence of other metastatic disease', 'entities': [['21', '39', 'cancer'], ['74', '92', 'cancer']]}, 'NCT01312857'), ({'text': 'cardiac issues as above', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02864147'), ({'text': 'chronic steroids', 'entities': [['1', '17', 'treatment']]}, 'NCT02490631'), ({'text': 'Co-morbid respiratory disease', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02436070'), ({'text': 'Neuropathy, grade 2 or greater by NCI-CTCAE, v 4.0', 'entities': [['1', '11', 'chronic_disease'], ['13', '20', 'lower_bound']]}, 'NCT02366819'), ({'text': 'Patients currently undergoing treatment for any type of cancer', 'entities': [['57', '63', 'cancer']]}, 'NCT02911831'), ({'text': 'Concomitant medications: the following drugs need to be stopped at the time of beginning therapy: patient cannot be on liver enzyme inducing anticonvulsants; patients must not have received growth factors to support the number or function of white cells or platelets within the past 7 days and pegfilgrastim within the past 14 days', 'entities': [['1', '24', 'treatment'], ['90', '97', 'treatment'], ['142', '157', 'treatment'], ['279', '290', 'upper_bound'], ['295', '308', 'treatment'], ['320', '332', 'upper_bound']]}, 'NCT02389309'), ({'text': 'Planned or recent (d 4 weeks) PCI', 'entities': [['22', '29', 'upper_bound'], ['31', '34', 'treatment']]}, 'NCT02816736'), ({'text': 'History of exercise intolerance', 'entities': [['12', '32', 'chronic_disease']]}, 'NCT02504866'), ({'text': 'Research participant has >= 1% chimeric antigen receptor (CAR) modified T cells in the peripheral blood', 'entities': [['29', '31', 'lower_bound'], ['32', '63', 'clinical_variable']]}, 'NCT02146924'), ({'text': 'history of hypertensive crisis or hypertensive encephalopathy, stroke, TIA, symptomatic peripheral vascular disease', 'entities': [['12', '31', 'chronic_disease'], ['35', '62', 'chronic_disease'], ['64', '70', 'chronic_disease'], ['72', '75', 'chronic_disease'], ['89', '116', 'chronic_disease']]}, 'NCT01925573'), ({'text': 'with symptomatic dysphagia (dysphagia score e2) EGOO that is diagnosed by high resolution manometry', 'entities': [['6', '27', 'chronic_disease'], ['29', '44', 'clinical_variable'], ['46', '47', 'lower_bound'], ['49', '53', 'clinical_variable']]}, 'NCT01942018'), ({'text': 'At least one of the previous CDI episodes must have been confirmed by a stool assay for C. difficile', 'entities': [['10', '13', 'lower_bound'], ['30', '33', 'chronic_disease'], ['89', '101', 'chronic_disease']]}, 'NCT02667418'), ({'text': 'Bypass graft lesion', 'entities': [['1', '13', 'treatment']]}, 'NCT02316886'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02857283'), ({'text': 'Women of childbearing age must be on regular use of an accepted contraceptive method(s)', 'entities': [['1', '6', 'gender'], ['23', '26', 'age'], ['38', '88', 'contraception_consent']]}, 'NCT03029884'), ({'text': "Subject has moderate to severe, active CD as evidenced Simple Endoscopy Score for Crohn's Disease (SES-CD) score of e7, and histological confirmation", 'entities': [['40', '42', 'chronic_disease'], ['56', '113', 'clinical_variable'], ['118', '119', 'lower_bound']]}, 'NCT03169894'), ({'text': 'Study patient is an adult of legal consent age', 'entities': [['44', '47', 'age']]}, 'NCT02806570'), ({'text': 'Cohort 7: Treatment-naïve patients with cMET mutations regardless of cMET GCN', 'entities': [['11', '20', 'treatment'], ['41', '55', 'treatment']]}, 'NCT02414139'), ({'text': 'At least 2 weeks should have elapsed since any biologic therapy', 'entities': [['10', '17', 'lower_bound'], ['48', '64', 'treatment']]}, 'NCT00107289'), ({'text': 'Primary tumors of any head and neck (oral cavity, oropharynx, hypopharynx, or larynx) site will be included', 'entities': [['1', '15', 'cancer']]}, 'NCT03153982'), ({'text': 'meet criteria for current or lifetime MDD without psychotic features', 'entities': [['39', '42', 'chronic_disease']]}, 'NCT02378714'), ({'text': 'Histologically proven squamous cell carcinoma of the head and neck with measurable disease that is either recurrent after attempted cure with surgery and/or radiation therapy or newly diagnosed disease with distant metastases or incurable at diagnosis', 'entities': [['23', '67', 'cancer'], ['143', '150', 'treatment'], ['158', '175', 'treatment'], ['208', '226', 'cancer']]}, 'NCT02524275'), ({'text': 'Cardiac: ejection fraction e 45% or no clinical evidence of heart failure', 'entities': [['10', '27', 'clinical_variable'], ['30', '33', 'lower_bound'], ['61', '74', 'chronic_disease']]}, 'NCT01505569'), ({'text': 'Triple-negative disease and received 2-4 prior non-hormonally-directed therapies in the MBC setting (not enrolling new patients)', 'entities': [['1', '16', 'cancer'], ['38', '39', 'lower_bound'], ['40', '47', 'upper_bound'], ['48', '81', 'treatment'], ['89', '92', 'clinical_variable']]}, 'NCT01969643'), ({'text': 'ECOG Performance Status of 0 or 1', 'entities': [['1', '24', 'clinical_variable'], ['28', '29', 'lower_bound'], ['33', '34', 'upper_bound']]}, 'NCT02503358'), ({'text': 'Must be willing to discontinue psychotherapy for substance use disorder (except A.A.)', 'entities': [['32', '45', 'treatment']]}, 'NCT02901041'), ({'text': "Currently taking a levodopa containing medication for Parkinson's disease", 'entities': [['20', '28', 'treatment'], ['55', '74', 'chronic_disease']]}, 'NCT02589340'), ({'text': 'past or current evidence of immunologically mediated disease', 'entities': [['29', '61', 'chronic_disease']]}, 'NCT02471430'), ({'text': 'Subject has had prior radiation', 'entities': [['23', '32', 'treatment']]}, 'NCT02635360'), ({'text': 'Platelet count >100,000 cells/mcL', 'entities': [['1', '15', 'clinical_variable'], ['17', '34', 'lower_bound']]}, 'NCT02422641'), ({'text': 'Patients must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast', 'entities': [['96', '130', 'cancer']]}, 'NCT01554371'), ({'text': 'e 3 swollen and/or tender joints of the hands', 'entities': [['3', '4', 'lower_bound']]}, 'NCT01864265'), ({'text': 'Women of child-bearing potential as long as she agrees to use a recognized method of birth control (e.g. oral contraceptive , IUD, condoms or other barrier methods etc.) Hysterectomy or menopause must be clinically documented', 'entities': [['1', '6', 'gender'], ['49', '99', 'contraception_consent'], ['106', '124', 'contraception_consent'], ['127', '130', 'contraception_consent'], ['132', '139', 'contraception_consent'], ['149', '164', 'contraception_consent'], ['171', '183', 'treatment']]}, 'NCT01449149'), ({'text': 'smoked tobacco during the prior 30 days', 'entities': [['27', '40', 'upper_bound']]}, 'NCT02506829'), ({'text': 'Major psychiatric disorders such as Schizophrenia', 'entities': [['1', '28', 'chronic_disease'], ['37', '50', 'chronic_disease']]}, 'NCT02762604'), ({'text': 'women of child-bearing potential and men must agree to use adequate contraception using one of the methods listed below prior to study entry, for the duration of study participation, and for 3 months for women and 6 months for men following the date of the last dose of AZD9291 and/or necitumumab', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['47', '82', 'contraception_consent'], ['192', '200', 'upper_bound'], ['215', '223', 'upper_bound'], ['271', '278', 'treatment'], ['286', '297', 'treatment']]}, 'NCT02496663'), ({'text': 'alopecia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02152995'), ({'text': 'Not fluent in English', 'entities': [['1', '22', 'language_fluency']]}, 'NCT02875301'), ({'text': 'e18 years old)', 'entities': [['2', '10', 'lower_bound']]}, 'NCT01430390'), ({'text': 'Patient with primary liver tumor or metastasis scheduled for Stereotactic Ablative Radiotherapy (SABR)', 'entities': [['22', '33', 'cancer'], ['37', '47', 'cancer'], ['62', '103', 'treatment']]}, 'NCT02424955'), ({'text': "Subjects with known Barrett's Esophagus (BE)", 'entities': [['21', '45', 'chronic_disease']]}, 'NCT02560623'), ({'text': 'Patients with retinitis pigmentosa, previous diagnosis of nonischemic optic neuropathy, untreated proliferative retinopathy or unexplained visual disturbance', 'entities': [['15', '35', 'chronic_disease'], ['71', '87', 'chronic_disease'], ['99', '124', 'chronic_disease']]}, 'NCT01970176'), ({'text': '=< 2 lines of prior systemic therapy for patients with progressive locally-advanced disease', 'entities': [['4', '5', 'upper_bound'], ['15', '92', 'treatment']]}, 'NCT02451553'), ({'text': 'Participation in nuclear medicine protocols in the last year', 'entities': [['18', '44', 'treatment']]}, 'NCT02473250'), ({'text': 'with angina and/or evidence of myocardial ischemia', 'entities': [['6', '12', 'chronic_disease'], ['32', '51', 'chronic_disease']]}, 'NCT02100722'), ({'text': 'Major surgery (e.g. thoracic, abdominal, vascular, neurosurgery)', 'entities': [['1', '14', 'treatment'], ['21', '29', 'treatment'], ['31', '40', 'treatment'], ['42', '50', 'treatment'], ['52', '64', 'treatment']]}, 'NCT02272998'), ({'text': 'Within 14 days prior to registration: Absolute neutrophil count >= 1.5 x 10^9 cells/L', 'entities': [['8', '21', 'upper_bound'], ['39', '64', 'clinical_variable'], ['68', '86', 'lower_bound']]}, 'NCT02565901'), ({'text': 'Known or suspected allergy to pamidronate or related products', 'entities': [['31', '42', 'allergy_name']]}, 'NCT02074631'), ({'text': 'Currently participating in or has participated in an investigational drug or medical device study within 30 days or five drug half-lives, whichever is longer, prior to enrollment into this study', 'entities': [['54', '74', 'treatment'], ['78', '92', 'treatment'], ['106', '113', 'upper_bound'], ['117', '137', 'upper_bound']]}, 'NCT02474667'), ({'text': 'Subjects with BILAG A in any system outside the musculoskeletal system', 'entities': [['15', '20', 'clinical_variable']]}, 'NCT02429934'), ({'text': 'No concurrent erythropoiesis-stimulating agents', 'entities': [['15', '48', 'treatment']]}, 'NCT01220583'), ({'text': 'cytology (analysis from cerebral spinal fluid [CSF] or vitrectomy)', 'entities': [['56', '66', 'treatment']]}, 'NCT00293475'), ({'text': 'Absolute neutrophil count less than 500/microL', 'entities': [['1', '26', 'clinical_variable'], ['37', '47', 'upper_bound']]}, 'NCT01623167'), ({'text': 'Participants must be deemed Rancho Los Amigos score of 7 or higher', 'entities': [['29', '52', 'clinical_variable'], ['56', '57', 'lower_bound']]}, 'NCT02498262'), ({'text': 'Blood glucose =< 126 mg/dL fasting or =< 140 mg/dL nonfasting', 'entities': [['1', '14', 'clinical_variable'], ['18', '35', 'upper_bound'], ['42', '62', 'upper_bound']]}, 'NCT02122185'), ({'text': 'Known human immunodeficiency virus (HIV-1) infection or chronic hepatitis B, or C', 'entities': [['7', '53', 'chronic_disease'], ['65', '82', 'chronic_disease']]}, 'NCT02446236'), ({'text': 'HbA1c greater than or equal to 8% but less than 14%', 'entities': [['1', '6', 'clinical_variable'], ['32', '34', 'lower_bound'], ['49', '52', 'upper_bound']]}, 'NCT02927639'), ({'text': 'Diagnosis of other active malignancy', 'entities': [['27', '37', 'cancer']]}, 'NCT03158519'), ({'text': 'Presence of a non-healing wound, non-healing ulcer, or benign bone fracture (patients with stress insufficiency fractures e.g. from osteoporosis or pathological fracture from tumor are eligible for study)', 'entities': [['133', '145', 'chronic_disease'], ['149', '170', 'chronic_disease'], ['176', '181', 'cancer']]}, 'NCT02048371'), ({'text': 'A history of prior treatment with ipilimumab or prior cluster of differentiation 137 (CD137) agonist or CTLA-4 inhibitor or agonist', 'entities': [['14', '132', 'treatment']]}, 'NCT01804465'), ({'text': 'Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated', 'entities': [['78', '100', 'treatment']]}, 'NCT02876302'), ({'text': 'Total bilirubin =< 4 mg/dL', 'entities': [['1', '16', 'clinical_variable'], ['20', '27', 'upper_bound']]}, 'NCT02424968'), ({'text': 'Participants must not have an invasive infection at time of protocol entry', 'entities': [['31', '49', 'chronic_disease']]}, 'NCT01783535'), ({'text': 'Known neurologic, chromosomal or congenital anomaly which is likely to be associated with poor neurobehavioural outcome', 'entities': [['7', '17', 'chronic_disease'], ['19', '30', 'chronic_disease'], ['34', '52', 'chronic_disease']]}, 'NCT03089905'), ({'text': 'Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels', 'entities': [['28', '58', 'treatment'], ['169', '191', 'chronic_disease'], ['195', '225', 'treatment'], ['229', '235', 'treatment']]}, 'NCT02152995'), ({'text': 'Current or past diagnoses of other Axis I psychiatric disorders', 'entities': [['36', '64', 'chronic_disease']]}, 'NCT02332291'), ({'text': 'Patients taking oral anticoagulants', 'entities': [['22', '36', 'treatment']]}, 'NCT03040778'), ({'text': 'signs and symptoms of diabetes', 'entities': [['23', '31', 'chronic_disease']]}, 'NCT02723266'), ({'text': 'Patients must have recovered from toxicities of prior therapy', 'entities': [['49', '62', 'treatment']]}, 'NCT01553071'), ({'text': 'Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive ABBV-951', 'entities': [['105', '113', 'treatment']]}, 'NCT03033498'), ({'text': 'No response will be lack of clinical benefit after at least 6 cycles of HMA therapy', 'entities': [['61', '62', 'lower_bound'], ['73', '84', 'treatment']]}, 'NCT02530463'), ({'text': 'All females must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta-human chorionic gonadotropin [²-hCG]) at the Screening Visit and the Baseline Visit', 'entities': [['1', '12', 'gender'], ['25', '58', 'pregnancy'], ['73', '84', 'clinical_variable'], ['85', '92', 'lower_bound']]}, 'NCT02501096'), ({'text': 'Patients with mild to moderate Irritable Bowel Syndrome (IBS) and mild to moderate anxiety or depression', 'entities': [['32', '62', 'chronic_disease'], ['84', '91', 'chronic_disease'], ['95', '105', 'chronic_disease']]}, 'NCT03035799'), ({'text': 'adequately treated non-melanomatous carcinoma of the skin', 'entities': [['20', '58', 'cancer']]}, 'NCT03072238'), ({'text': 'For subjects on cycled therapy, at least 2 cycles of drug need to have been completed prior to baseline', 'entities': [['17', '31', 'treatment'], ['42', '43', 'lower_bound']]}, 'NCT02498535'), ({'text': 'has any form of known cardiac arrhythmia', 'entities': [['23', '41', 'chronic_disease']]}, 'NCT02478268'), ({'text': 'total bilirubin d2.5 X institutional upper limit of normal', 'entities': [['1', '16', 'clinical_variable'], ['18', '59', 'upper_bound']]}, 'NCT02427581'), ({'text': 'Use of topical retinoids (on the face) within 1 month prior to Visit 1', 'entities': [['8', '25', 'treatment'], ['47', '60', 'upper_bound']]}, 'NCT02075671'), ({'text': 'GFR < or equal to 35', 'entities': [['1', '4', 'clinical_variable'], ['19', '21', 'upper_bound']]}, 'NCT03059355'), ({'text': 'Disease status: Phase I: Patients with refractory solid tumors including patients with NF1 and MPNST must have evaluable disease, patients with refractory leukemia must have M2 or M3 bone marrow', 'entities': [['51', '63', 'cancer'], ['88', '91', 'cancer'], ['96', '101', 'cancer'], ['156', '164', 'cancer']]}, 'NCT02390752'), ({'text': 'Have been prescribed at least one antihypertensive or oral anti-diabetic medication', 'entities': [['35', '51', 'treatment'], ['55', '84', 'treatment']]}, 'NCT01643473'), ({'text': 'Cochlear aplasia or severe hypoplasia', 'entities': [['1', '17', 'chronic_disease'], ['28', '38', 'chronic_disease']]}, 'NCT02310399'), ({'text': 'Patients with active Hepatitis B and C', 'entities': [['22', '39', 'chronic_disease']]}, 'NCT02861417'), ({'text': 'LVEF e35%', 'entities': [['1', '5', 'clinical_variable'], ['7', '10', 'lower_bound']]}, 'NCT02574650'), ({'text': 'Patients must be either untreated or have not had more than one cycle of systemic MM therapy', 'entities': [['61', '64', 'lower_bound'], ['74', '93', 'treatment']]}, 'NCT00734877'), ({'text': 'e20 years of age', 'entities': [['2', '10', 'lower_bound'], ['14', '17', 'age']]}, 'NCT03168776'), ({'text': 'Must be 60-90 years old', 'entities': [['9', '11', 'lower_bound'], ['12', '20', 'upper_bound']]}, 'NCT02792257'), ({'text': 'Being actively listed for, or under active consideration for, an organ transplant of any kind, including lung transplantation', 'entities': [['66', '82', 'treatment'], ['106', '126', 'treatment']]}, 'NCT03145298'), ({'text': 'Those unable to understand, read, or write in English are not eligible', 'entities': [['7', '54', 'language_fluency']]}, 'NCT02639208'), ({'text': 'Multiple (at least 2) hypointense lesions of size 0.3-1.5 cm at largest dimension (including rostro-caudal extent) only in the cerebral hemispheres on FLAIR or T1 in patients whose qualifying event is clinically hemispheric', 'entities': [['20', '21', 'lower_bound'], ['23', '42', 'clinical_variable'], ['51', '54', 'lower_bound'], ['55', '61', 'upper_bound']]}, 'NCT02169739'), ({'text': 'Clinically negative lymph nodes as established by imaging (abdominal and pelvic CT or abdominal and pelvic MRI), nodal sampling, or dissection within 90 days prior to registration', 'entities': [['60', '83', 'treatment'], ['87', '111', 'treatment'], ['114', '128', 'treatment'], ['133', '143', 'treatment'], ['151', '164', 'upper_bound']]}, 'NCT02353819'), ({'text': 'women trying to get pregnant', 'entities': [['1', '6', 'gender'], ['21', '29', 'pregnancy']]}, 'NCT01897259'), ({'text': 'Enteropathy-type T-cell lymphoma', 'entities': [['1', '33', 'cancer']]}, 'NCT01787409'), ({'text': 'Parts H, and I: Must be able and willing to undergo mandatory tumor biopsies prior to study treatment and at the time of discontinuation from study treatment', 'entities': [['63', '68', 'cancer'], ['93', '102', 'treatment']]}, 'NCT02057133'), ({'text': 'Patients with bilirubin less than or equal to 2 times upper limit of normal, AST less than or equal to 3 times upper limit of normal, and Hgb greater than or equal to 7.0 (transfusion allowed)', 'entities': [['15', '24', 'clinical_variable'], ['47', '76', 'upper_bound'], ['78', '81', 'clinical_variable'], ['104', '133', 'upper_bound'], ['139', '142', 'clinical_variable'], ['168', '171', 'lower_bound'], ['173', '184', 'treatment']]}, 'NCT02291848'), ({'text': 'Have end stage renal disease', 'entities': [['6', '29', 'chronic_disease']]}, 'NCT02516670'), ({'text': 'Caregiver has the ability to read, speak and write English or Spanish', 'entities': [['19', '70', 'language_fluency']]}, 'NCT03181516'), ({'text': 'Castration-resistant prostate cancer', 'entities': [['1', '37', 'cancer']]}, 'NCT03093272'), ({'text': 'breastfeeding females', 'entities': [['15', '22', 'gender']]}, 'NCT03181893'), ({'text': 'lactating female', 'entities': [['11', '17', 'gender']]}, 'NCT02301117'), ({'text': 'Alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN for patients with liver involvement)', 'entities': [['1', '27', 'clinical_variable'], ['31', '38', 'upper_bound'], ['43', '50', 'upper_bound']]}, 'NCT02860000'), ({'text': 'At least a 20% decrease in FEV1 during the immediate response following inhaled antigen challenge', 'entities': [['12', '15', 'lower_bound'], ['28', '32', 'clinical_variable']]}, 'NCT02401074'), ({'text': 'Participants must be in first recurrence or have disease that is primarily refractory to conventional therapy', 'entities': [['90', '110', 'treatment']]}, 'NCT02703272'), ({'text': 'metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for 2 weeks after treatment is complete and within 14 days of the first dose of nivolumab administration', 'entities': [['1', '11', 'cancer'], ['107', '114', 'upper_bound'], ['121', '130', 'treatment'], ['154', '161', 'upper_bound'], ['183', '192', 'treatment']]}, 'NCT02910700'), ({'text': 'Known psychological problems', 'entities': [['7', '29', 'chronic_disease']]}, 'NCT01584076'), ({'text': 'Cirrhosis', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT02955537'), ({'text': 'Preexisting renal failure and liver disorders', 'entities': [['13', '26', 'chronic_disease'], ['31', '46', 'chronic_disease']]}, 'NCT02703220'), ({'text': 'Family history of toxic epidermal necrolysis', 'entities': [['19', '45', 'chronic_disease']]}, 'NCT01631617'), ({'text': 'increased intracranial pressure', 'entities': [['1', '32', 'chronic_disease']]}, 'NCT02665338'), ({'text': 'RAEB-1, RCMD+/-RS, or MDS NOS with stable disease for 6 months (as documented by serial bone marrow examinations) in the absence of any therapy but growth factors or transfusion support. Patients who require treatment to control their disease must show chemo-responsiveness', 'entities': [['1', '7', 'chronic_disease'], ['9', '18', 'cancer'], ['23', '30', 'cancer'], ['55', '63', 'upper_bound'], ['137', '144', 'treatment'], ['149', '163', 'treatment'], ['167', '186', 'treatment'], ['209', '218', 'treatment']]}, 'NCT02566304'), ({'text': 'History of long bone fractures since the SCI, secondary to osteoporosis', 'entities': [['60', '72', 'chronic_disease']]}, 'NCT02943915'), ({'text': 'Females of childbearing potential (FCBP)', 'entities': [['1', '8', 'gender']]}, 'NCT02577406'), ({'text': 'pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02914834'), ({'text': 'For patients < 8 years old or unable to undergo pulmonary function testing: no evidence of dyspnea at rest; no need for supplemental oxygen; oxygen saturation > 92% on room air', 'entities': [['16', '23', 'upper_bound'], ['92', '99', 'chronic_disease'], ['142', '159', 'clinical_variable'], ['162', '165', 'lower_bound']]}, 'NCT02833805'), ({'text': 'platelet transfusions', 'entities': [['1', '22', 'treatment']]}, 'NCT01880567'), ({'text': 'use of opiate analgesics for prostate cancer pain within 4 week of treatment start', 'entities': [['8', '25', 'treatment'], ['30', '45', 'cancer'], ['58', '64', 'upper_bound'], ['68', '77', 'treatment']]}, 'NCT03137758'), ({'text': 'Carbamazepine (e.g., Tegretol)', 'entities': [['1', '14', 'treatment'], ['22', '30', 'treatment']]}, 'NCT02583893'), ({'text': 'Women of childbearing potential who refuse a pregnancy test (performed during screening)', 'entities': [['1', '6', 'gender'], ['46', '55', 'pregnancy']]}, 'NCT01668082'), ({'text': 'Known human immunodeficiency virus (HIV) positive', 'entities': [['7', '41', 'chronic_disease']]}, 'NCT01415882'), ({'text': 'History of eating disorder', 'entities': [['12', '27', 'chronic_disease']]}, 'NCT02527265'), ({'text': 'have a biopsy of tumor taken after progression on last EGFR-TKI that indicates preservation of EGFR-T790M post-progression on 3rd generation EGFR-TKI with biopsy confirmation by central testing prior to treatment (if EGFR-T790M status is unknown, patients may consent for trial and for biopsy, and testing for EGFR T790M will be performed as part of initial biopsy for trial)', 'entities': [['8', '14', 'treatment'], ['18', '23', 'cancer'], ['56', '64', 'treatment'], ['96', '106', 'treatment'], ['142', '162', 'treatment'], ['195', '213', 'treatment'], ['311', '321', 'treatment']]}, 'NCT02496663'), ({'text': 'Patients with known disorders associated with hemolysis', 'entities': [['47', '56', 'chronic_disease']]}, 'NCT02535312'), ({'text': 'Baseline Barthel Index Functional Score > 70, functional at home', 'entities': [['1', '40', 'clinical_variable'], ['43', '45', 'lower_bound']]}, 'NCT01777035'), ({'text': 'Temperature < 35°C on admission to Emergency Department', 'entities': [['1', '12', 'clinical_variable'], ['15', '19', 'upper_bound']]}, 'NCT02453373'), ({'text': 'Patients must be at least 4 weeks from previous therapy (chemotherapy, hormonal therapy, and radiation therapy, or investigational agents; 6 weeks for mitomycin C)', 'entities': [['27', '34', 'lower_bound'], ['40', '56', 'treatment'], ['58', '70', 'treatment'], ['72', '88', 'treatment'], ['94', '111', 'treatment'], ['116', '138', 'treatment'], ['140', '147', 'lower_bound'], ['152', '163', 'treatment']]}, 'NCT02203513'), ({'text': 'Significant change in corticosteroid dose within the past 4 weeks, or other immunosuppressive medication within the past 6 months', 'entities': [['54', '66', 'upper_bound'], ['77', '105', 'treatment'], ['117', '130', 'upper_bound']]}, 'NCT02920710'), ({'text': 'Uncontrolled bacterial, viral or fungal infections', 'entities': [['1', '51', 'chronic_disease']]}, 'NCT02928991'), ({'text': 'Males must agree with their partner to use two forms of contraception for at least three months following SAR422459 administration', 'entities': [['1', '6', 'gender'], ['12', '70', 'contraception_consent'], ['84', '96', 'lower_bound'], ['107', '131', 'treatment']]}, 'NCT01367444'), ({'text': 'creatinine d 1.5 times upper limit of normal (ULN) for age or Glomerular filtration rate (GFR) >70 mL/min/1.73m2', 'entities': [['1', '11', 'clinical_variable'], ['14', '51', 'upper_bound'], ['56', '59', 'age'], ['63', '95', 'clinical_variable'], ['97', '113', 'lower_bound']]}, 'NCT02579044'), ({'text': 'Presence of GI bleeding', 'entities': [['13', '24', 'chronic_disease']]}, 'NCT01562626'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02379156'), ({'text': 'Report any condition that in the opinion of investigators would reduce the likelihood of adherence to the study protocol, such as terminal illness, planning to relocate, a history of substance abuse or other significant psychiatric problems, etc', 'entities': [['131', '147', 'chronic_disease'], ['221', '241', 'chronic_disease']]}, 'NCT02701998'), ({'text': 'Subjects are on medications that serve as CYP3A4/5 inhibitors or CYP3A4 inducers including, but are not limited to, valproic acid, macrolide antibiotics, antifungal drugs, St. John wort, ACE inhibitors, nefazodone (antidepressant), calcium channel blockers, H2-receptor antagonists, anti-HIV or AIDS drugs, and antiepileptic drugs', 'entities': [['17', '28', 'treatment'], ['43', '62', 'treatment'], ['66', '81', 'treatment'], ['117', '130', 'treatment'], ['132', '153', 'treatment'], ['155', '171', 'treatment'], ['173', '186', 'treatment'], ['188', '202', 'treatment'], ['204', '214', 'treatment'], ['216', '230', 'treatment'], ['233', '257', 'treatment'], ['259', '282', 'treatment'], ['284', '306', 'treatment'], ['312', '331', 'treatment']]}, 'NCT01681264'), ({'text': 'Patients must have failed at least 2 lines of stand therapy as outlined for the specific diseases', 'entities': [['36', '37', 'lower_bound'], ['47', '60', 'treatment']]}, 'NCT00716066'), ({'text': 'The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination', 'entities': [['5', '10', 'cancer'], ['39', '67', 'cancer']]}, 'NCT02488967'), ({'text': 'Known to be serologically positive for HIV and receiving antiviral therapy', 'entities': [['40', '43', 'chronic_disease'], ['58', '75', 'treatment']]}, 'NCT01858168'), ({'text': 'Documented hypersensitivity to dexamethasone', 'entities': [['32', '45', 'allergy_name']]}, 'NCT00391170'), ({'text': 'Chronic illnesses including hematologic, pulmonary, and autoimmune diseases and endocrinopathies, except for stable controlled diabetes or cardiovascular disease in the view of the investigator and stable testosterone or thyroid medication use', 'entities': [['1', '18', 'chronic_disease'], ['29', '40', 'chronic_disease'], ['42', '51', 'chronic_disease'], ['57', '76', 'chronic_disease'], ['81', '97', 'chronic_disease'], ['128', '136', 'chronic_disease'], ['140', '162', 'chronic_disease'], ['206', '218', 'treatment'], ['222', '240', 'treatment']]}, 'NCT02159027'), ({'text': 'leukocytes greater than or equal to 3,000/mcL', 'entities': [['1', '11', 'clinical_variable'], ['37', '46', 'lower_bound']]}, 'NCT02203513'), ({'text': 'No history of life threatening or recurrent thrombosis/embolism (unless on anticoagulation therapy during study treatment)', 'entities': [['45', '55', 'chronic_disease'], ['56', '64', 'chronic_disease'], ['76', '99', 'treatment'], ['113', '122', 'treatment']]}, 'NCT00670358'), ({'text': 'Creatinine clearance less than 50 cc/min based on a 24 hour urine collection', 'entities': [['1', '21', 'clinical_variable'], ['32', '41', 'upper_bound']]}, 'NCT00720785'), ({'text': 'Negative HIV antigen and antibody, Hepatitis B surface antigen and Hepatitis C antibody within 3 months prior to enrollment', 'entities': [['10', '13', 'chronic_disease'], ['36', '47', 'chronic_disease'], ['68', '79', 'chronic_disease'], ['96', '110', 'upper_bound']]}, 'NCT02311621'), ({'text': 'Patients who progressed during or within one month of completing platinum-based chemotherapy', 'entities': [['42', '51', 'upper_bound'], ['66', '93', 'treatment']]}, 'NCT01941316'), ({'text': 'History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis', 'entities': [['12', '30', 'chronic_disease'], ['38', '44', 'upper_bound'], ['87', '107', 'chronic_disease']]}, 'NCT02353728'), ({'text': 'Patients with active hepatitis B or hepatitis C are excluded', 'entities': [['15', '33', 'chronic_disease'], ['37', '48', 'chronic_disease']]}, 'NCT01928576'), ({'text': '> 12.5 mg/dl (> 3.1 mmol/L) despite intervention to normalize levels', 'entities': [['3', '13', 'lower_bound'], ['17', '27', 'lower_bound']]}, 'NCT02128906'), ({'text': 'Willing to abstain from alcohol completely for 24 hours on 3 separate occasions', 'entities': [['48', '56', 'upper_bound']]}, 'NCT02316574'), ({'text': 'Has had prior systemic cancer cytotoxic chemotherapy within the past four weeks at the time of the start of the lymphodepletion regimen', 'entities': [['9', '53', 'treatment'], ['65', '80', 'upper_bound'], ['113', '128', 'treatment']]}, 'NCT00338377'), ({'text': 'Taking any psychotropic medication', 'entities': [['12', '35', 'treatment']]}, 'NCT01964404'), ({'text': 'History of head injury with substantial loss of consciousness', 'entities': [['12', '23', 'chronic_disease']]}, 'NCT02064296'), ({'text': 'Progressive disease after 1-3 prior chemotherapy regimens (perioperative chemotherapy within 12 months will be considered one regimen)', 'entities': [['1', '20', 'chronic_disease'], ['27', '28', 'lower_bound'], ['29', '30', 'upper_bound'], ['31', '58', 'treatment'], ['60', '86', 'treatment'], ['94', '103', 'upper_bound']]}, 'NCT02459119'), ({'text': 'Prior history of heart failure with this diagnosis for at least 1 month with preserved or reduced left ventricular ejection fraction', 'entities': [['18', '31', 'chronic_disease'], ['65', '72', 'lower_bound']]}, 'NCT02476409'), ({'text': 'Creatinine =< 1.5 mg/dL to receive weekly cisplatin', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'upper_bound'], ['43', '52', 'treatment']]}, 'NCT02466971'), ({'text': 'Free rupture of the aneurysm', 'entities': [['1', '29', 'chronic_disease']]}, 'NCT00488696'), ({'text': "Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk", 'entities': [['5', '29', 'chronic_disease'], ['31', '48', 'chronic_disease'], ['53', '77', 'chronic_disease']]}, 'NCT02553941'), ({'text': 'Agree to undergo DBS if indicated to treat medically refractory movement disorder', 'entities': [['18', '21', 'treatment'], ['65', '82', 'chronic_disease']]}, 'NCT01581580'), ({'text': 'English-language comprehension and cognitive ability sufficient to give informed consent and to cooperate with the intervention', 'entities': [['1', '31', 'language_fluency']]}, 'NCT01948739'), ({'text': "Any condition likely to result in the patient's death within the next 12 months", 'entities': [['66', '80', 'upper_bound']]}, 'NCT02524379'), ({'text': 'Use of Phosphodiesterase Type 5 (PDE5) inhibitors such as vardenafil (Levitra®), Tadalafil (Cialis®)', 'entities': [['8', '50', 'treatment'], ['59', '80', 'treatment'], ['82', '101', 'treatment']]}, 'NCT02544880'), ({'text': 'Patients must have histologically or cytologically confirmed small cell lung carcinoma that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care. (various solid tumors cohort, SCLC group only)', 'entities': [['62', '87', 'cancer'], ['145', '152', 'treatment'], ['249', '261', 'cancer'], ['270', '274', 'cancer']]}, 'NCT02587962'), ({'text': 'patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits', 'entities': [['28', '52', 'chronic_disease'], ['53', '63', 'chronic_disease']]}, 'NCT02101853'), ({'text': 'cardiac transplantation or other cardiac surgery planned within the 12 month followup period of the trial', 'entities': [['1', '24', 'treatment'], ['34', '49', 'treatment'], ['69', '77', 'upper_bound']]}, 'NCT02169037'), ({'text': 'Platelet count >= 75 x 10^9/L', 'entities': [['1', '15', 'clinical_variable'], ['19', '30', 'lower_bound']]}, 'NCT02389517'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02180412'), ({'text': 'Subject has an active autoimmune disease in the past 2 years', 'entities': [['23', '41', 'chronic_disease'], ['49', '61', 'upper_bound']]}, 'NCT02635360'), ({'text': 'Other lung diseases, such as sarcoidosis, bronchiectasis or active lung infection', 'entities': [['7', '20', 'chronic_disease'], ['30', '41', 'chronic_disease'], ['43', '57', 'chronic_disease'], ['70', '82', 'chronic_disease']]}, 'NCT02230189'), ({'text': 'molecular evidence of other homologous recombination deficiency', 'entities': [['29', '64', 'chronic_disease']]}, 'NCT02952534'), ({'text': 'Exclusion criteria will be any motor or sensory impairment as defined by neurologic exam and/or scaled motor scores below 8 for CA on the Bayley III and cognitive impairment or delays as described for the CP group', 'entities': [['74', '89', 'clinical_variable'], ['97', '116', 'clinical_variable'], ['123', '124', 'upper_bound']]}, 'NCT02567630'), ({'text': 'Erythromycin (e.g. Akne-Mycin, Ery-Tab)', 'entities': [['1', '13', 'treatment'], ['20', '30', 'treatment'], ['32', '39', 'treatment']]}, 'NCT01869114'), ({'text': 'Patients with severe sickle cell disease', 'entities': [['22', '41', 'chronic_disease']]}, 'NCT02165007'), ({'text': 'Immunodeficiency', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT03014687'), ({'text': 'Patients must be classified post-operatively as Stage IB (e 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria', 'entities': [['49', '57', 'lower_bound'], ['61', '64', 'lower_bound'], ['80', '88', 'clinical_variable'], ['97', '101', 'upper_bound']]}, 'NCT02273375'), ({'text': 'Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids', 'entities': [['29', '45', 'cancer'], ['56', '76', 'treatment'], ['110', '117', 'treatment'], ['119', '128', 'treatment'], ['137', '152', 'treatment']]}, 'NCT02592551'), ({'text': 'Acute onset need for 4 liters per minute (LPM) or more of supplemental oxygen to maintain PaO2 > 60 mmHg or arterial O2 saturation > 90% by pulse oximetry', 'entities': [['91', '95', 'clinical_variable'], ['98', '105', 'lower_bound'], ['109', '131', 'clinical_variable'], ['134', '137', 'lower_bound']]}, 'NCT02370095'), ({'text': 'If a female of childbearing potential, must have a negative pregnancy test prior to enrollment', 'entities': [['6', '12', 'gender'], ['52', '70', 'pregnancy']]}, 'NCT03069469'), ({'text': 'Primary cutaneous anaplastic large cell lymphoma', 'entities': [['1', '49', 'cancer']]}, 'NCT01908777'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02311621'), ({'text': 'Ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation', 'entities': [['12', '28', 'chronic_disease'], ['39', '62', 'treatment'], ['78', '87', 'treatment']]}, 'NCT02567422'), ({'text': 'Age greater than 18 years at time of first study drug administration', 'entities': [['1', '4', 'age'], ['18', '26', 'lower_bound'], ['44', '54', 'treatment']]}, 'NCT02314377'), ({'text': 'psychiatric or medical conditions that make participation unsafe', 'entities': [['1', '34', 'chronic_disease']]}, 'NCT03182075'), ({'text': 'with primary autonomic failure (Parkinson Disease, Multiple System Atrophy, and Pure Autonomic Failure) and supine hypertension', 'entities': [['6', '31', 'chronic_disease'], ['33', '50', 'chronic_disease'], ['52', '75', 'chronic_disease'], ['81', '103', 'chronic_disease'], ['109', '128', 'chronic_disease']]}, 'NCT02417415'), ({'text': 'Severe cone-rod dysfunction with no detectable or severely abnormal full-field electroretinogram responses', 'entities': [['8', '28', 'chronic_disease'], ['69', '97', 'treatment']]}, 'NCT01367444'), ({'text': 'Meet DSM-IV criteria for major depressive episode in the past six months', 'entities': [['26', '50', 'chronic_disease'], ['58', '73', 'upper_bound']]}, 'NCT01782599'), ({'text': 'willing to engage in pharmacotherapy treatment at the CABS specialty clinic', 'entities': [['22', '47', 'treatment']]}, 'NCT02003690'), ({'text': 'Omenn Syndrome', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT01962415'), ({'text': 'Life expectancy of at least 6 months', 'entities': [['1', '16', 'clinical_variable'], ['29', '37', 'lower_bound']]}, 'NCT02346526'), ({'text': 'Age 6-12 years at enrollment', 'entities': [['1', '4', 'age'], ['5', '6', 'lower_bound'], ['7', '15', 'upper_bound']]}, 'NCT01200940'), ({'text': 'Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom. Females of child-bearing potential must be willing to utilize one of the more effective birth control methods during the study unless female has had a hysterectomy or tubal ligation', 'entities': [['32', '39', 'treatment'], ['52', '60', 'pregnancy'], ['61', '66', 'gender'], ['104', '108', 'gender'], ['124', '136', 'contraception_consent'], ['138', '145', 'gender'], ['181', '247', 'contraception_consent'], ['272', '278', 'gender'], ['289', '301', 'contraception_consent'], ['305', '319', 'contraception_consent']]}, 'NCT02291848'), ({'text': 'MDS: Low/intermediate-1 IPSS risk category patients are eligible only if they have failed prior therapy or are transfusion-dependent', 'entities': [['1', '4', 'cancer'], ['91', '104', 'treatment'], ['112', '123', 'treatment']]}, 'NCT01795573'), ({'text': 'Vagus nerve stimulation, ECT, or rTMS, or other somatic antidepressant treatment during current episode', 'entities': [['1', '24', 'treatment'], ['26', '29', 'treatment'], ['34', '38', 'treatment'], ['49', '81', 'treatment']]}, 'NCT03079297'), ({'text': 'GGT must be less than 2.5 x institutional upper limit of normal', 'entities': [['1', '4', 'clinical_variable'], ['23', '64', 'upper_bound']]}, 'NCT01614197'), ({'text': 'Histologically confirmed angiosarcoma', 'entities': [['26', '38', 'cancer']]}, 'NCT02048722'), ({'text': 'Contraindications to angiography and selective visceral catheterization such as bleeding, diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)', 'entities': [['22', '33', 'treatment']]}, 'NCT03059030'), ({'text': '(MUGA) LVEF >45%)', 'entities': [['1', '12', 'clinical_variable'], ['14', '17', 'lower_bound']]}, 'NCT00630565'), ({'text': 'Participants who have received prior therapy with other anti-CD37-targeting therapy', 'entities': [['32', '45', 'treatment'], ['51', '84', 'treatment']]}, 'NCT02564744'), ({'text': 'Receipt of another cancer therapy (targeted therapy, chemotherapy, investigational therapy, immunotherapy, radiotherapy or surgery) which is yielding an overall response (by response criteria in this study)', 'entities': [['20', '34', 'treatment'], ['36', '52', 'treatment'], ['54', '66', 'treatment'], ['68', '91', 'treatment'], ['93', '106', 'treatment'], ['108', '120', 'treatment'], ['124', '131', 'treatment']]}, 'NCT02819843'), ({'text': 'anti-resorptive drug use in the last 2 years', 'entities': [['1', '21', 'treatment'], ['38', '45', 'upper_bound']]}, 'NCT02636530'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT03124355'), ({'text': 'Age 18 or greater', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT01573754'), ({'text': 'Patients with an active foot ulcer', 'entities': [['25', '35', 'chronic_disease']]}, 'NCT02356848'), ({'text': 'unstable angina', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT01568177'), ({'text': 'the tumor size is >= 4 cm', 'entities': [['5', '15', 'clinical_variable'], ['22', '26', 'lower_bound']]}, 'NCT02194738'), ({'text': 'Currently diagnosed with anemia (fatigue-related factor)', 'entities': [['26', '32', 'chronic_disease']]}, 'NCT02690116'), ({'text': 'For the combination cohorts (Cohorts 5 and 6 in Part 1) and Part 2, subjects with metastatic melanoma or NSCLC do not need to have received prior therapy', 'entities': [['83', '102', 'cancer'], ['106', '111', 'cancer'], ['141', '154', 'treatment']]}, 'NCT02509507'), ({'text': 'Participants who do not meet criteria for either CLE or SLE', 'entities': [['50', '53', 'chronic_disease'], ['57', '60', 'chronic_disease']]}, 'NCT01516788'), ({'text': 'Subjects already being treated with lidocaine patch or other vehicle for chronic pain', 'entities': [['37', '52', 'treatment']]}, 'NCT03112720'), ({'text': 'Diagnosis of Myasthenia gravis', 'entities': [['14', '31', 'chronic_disease']]}, 'NCT03055767'), ({'text': 'Presence of a left ventricular assist device', 'entities': [['15', '45', 'treatment']]}, 'NCT01807897'), ({'text': 'History of GI surgery or placement of gastric pacemaker', 'entities': [['12', '22', 'treatment'], ['39', '56', 'treatment']]}, 'NCT01625923'), ({'text': 'Poor renal function: Creatinine >2.0 mg/dl or creatinine clearance < 40 mL/min (calculated creatinine clearance is permitted)', 'entities': [['22', '32', 'clinical_variable'], ['34', '43', 'lower_bound'], ['47', '67', 'clinical_variable'], ['70', '79', 'upper_bound']]}, 'NCT02416206'), ({'text': 'Aspartate aminotransferase (AST) less than 2 x upper limit of normal', 'entities': [['1', '33', 'clinical_variable'], ['44', '69', 'upper_bound']]}, 'NCT01696734'), ({'text': 'CrCl (calculated) = (140 Age) times Mass (in kilograms)', 'entities': [['1', '5', 'clinical_variable'], ['26', '29', 'age']]}, 'NCT01572480'), ({'text': 'must not have been on steroid therapy for at least 4 weeks', 'entities': [['23', '38', 'treatment'], ['52', '59', 'lower_bound']]}, 'NCT03121352'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT01187368'), ({'text': 'Clinical diagnosis of moderate to severe COPD, with an obstructive pattern on pulmonary function tests', 'entities': [['42', '46', 'chronic_disease']]}, 'NCT02178566'), ({'text': 'Subject has a history of generalized convulsive status epilepticus <=2 months prior to Screening (Visit 1)', 'entities': [['26', '67', 'clinical_variable'], ['70', '84', 'upper_bound']]}, 'NCT02477839'), ({'text': 'If on steroids, on a stable dose of the medication for at least 3 months', 'entities': [['7', '15', 'treatment'], ['65', '73', 'lower_bound']]}, 'NCT02298491'), ({'text': 'Lung cancer', 'entities': [['1', '12', 'cancer']]}, 'NCT00924027'), ({'text': 'Iron-deficiency anemia', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02531880'), ({'text': 'Composite lymphomas, which include both diffuse DLBCL and another histology (most commonly follicular lymphoma) in the same lymph node', 'entities': [['11', '20', 'cancer'], ['49', '54', 'cancer'], ['92', '111', 'cancer']]}, 'NCT02541565'), ({'text': 'Able to take ARVs by mouth, nasogastric tube, or gastrostomy tube', 'entities': [['14', '18', 'treatment']]}, 'NCT02140255'), ({'text': 'Patients with B-lineage', 'entities': [['15', '24', 'cancer']]}, 'NCT02807883'), ({'text': 'MMSE d 24', 'entities': [['1', '5', 'clinical_variable'], ['8', '10', 'upper_bound']]}, 'NCT02479906'), ({'text': 'This may include clinical stage IB (e4cm), II and IIIA(see Appendix A)', 'entities': [['27', '35', 'clinical_variable'], ['38', '41', 'lower_bound']]}, 'NCT02259621'), ({'text': 'Total bilirubin d 2.0 X upper limit of institutional normal (ULN)', 'entities': [['1', '16', 'clinical_variable'], ['19', '66', 'upper_bound']]}, 'NCT02191098'), ({'text': 'Diagnosis of AL amyloidosis by standard criteria (evidence of plasma cell dyscrasia with appropriate tissue staining for AL)', 'entities': [['14', '28', 'chronic_disease'], ['63', '84', 'chronic_disease']]}, 'NCT01683825'), ({'text': 'Significant cardiovascular disease with NYHA Class II, III or IV symptoms, or hypertrophic cardiomegaly, or restrictive cardiomegaly, or myocardial infarction', 'entities': [['13', '35', 'chronic_disease'], ['41', '45', 'clinical_variable'], ['46', '54', 'lower_bound'], ['63', '65', 'upper_bound'], ['79', '104', 'chronic_disease'], ['109', '133', 'chronic_disease'], ['138', '159', 'chronic_disease']]}, 'NCT01572480'), ({'text': 'Inherited bone marrow failure syndromes (IBMFS)', 'entities': [['1', '48', 'chronic_disease']]}, 'NCT02845596'), ({'text': 'Arm E: Pregnant or breastfeeding', 'entities': [['8', '16', 'pregnancy']]}, 'NCT01505569'), ({'text': 'patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG)', 'entities': [['51', '61', 'cancer'], ['129', '146', 'cancer'], ['140', '145', 'cancer'], ['148', '169', 'cancer'], ['188', '201', 'cancer']]}, 'NCT02323880'), ({'text': 'Renal failure', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02943590'), ({'text': 'GFR 15-29 ml/min 1.73m2', 'entities': [['1', '4', 'clinical_variable'], ['5', '7', 'lower_bound'], ['8', '24', 'upper_bound']]}, 'NCT03065972'), ({'text': 'Phase 2: e 3 and d 21 years of age at diagnosis', 'entities': [['12', '13', 'lower_bound'], ['20', '28', 'upper_bound'], ['32', '35', 'age']]}, 'NCT02932280'), ({'text': 'mucinous carcinoma', 'entities': [['1', '19', 'cancer']]}, 'NCT02442323'), ({'text': 'Hepatic failure', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02564796'), ({'text': 'type 1 or 2 diabetes mellitus', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT02075710'), ({'text': 'as long as PT or PTT is within therapeutic range of intended use of anticoagulants, or subject is shown to have an antiphospholipid antibody on workup', 'entities': [['69', '83', 'treatment']]}, 'NCT02541565'), ({'text': 'Visual Analog Scale back pain score of at least 50 mm on a 100 mm scale', 'entities': [['1', '20', 'clinical_variable'], ['21', '30', 'chronic_disease'], ['49', '54', 'lower_bound'], ['60', '72', 'upper_bound']]}, 'NCT02555280'), ({'text': 'Ankle pressure (AP) d70 mmHg or TP d50 mmHg in the index leg', 'entities': [['1', '20', 'clinical_variable'], ['22', '29', 'upper_bound'], ['33', '35', 'clinical_variable'], ['37', '44', 'upper_bound']]}, 'NCT03006770'), ({'text': 'Females with skin piercings (aka microdermal anchor surface or microdermal piercings) in either or both breasts', 'entities': [['1', '8', 'gender']]}, 'NCT01755208'), ({'text': 'Presence of anterior knee pain around the patella during ascending/descending stairs, squatting, and/or running for at least 3 months', 'entities': [['126', '134', 'lower_bound']]}, 'NCT02890485'), ({'text': 'Subjects whose medical care or safety may be at risk from undergoing a Magnetic Resonance Imaging examination (e.g. pacemaker, metal implants, certain types of heart valves)', 'entities': [['72', '98', 'treatment'], ['117', '126', 'treatment']]}, 'NCT02966665'), ({'text': 'promyelocytic leukemia (APML)', 'entities': [['1', '30', 'cancer']]}, 'NCT02520427'), ({'text': 'Clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association (NYHA) Class 3 or 4, congestive heart failure, uncontrolled or unstable angina, history of myocardial infarction or stroke within 6 months prior to study entry, or clinically significant arrhythmias not controlled by medication', 'entities': [['24', '46', 'chronic_disease'], ['74', '120', 'chronic_disease'], ['122', '146', 'chronic_disease'], ['164', '179', 'chronic_disease'], ['192', '213', 'chronic_disease'], ['217', '223', 'chronic_disease'], ['231', '245', 'upper_bound'], ['288', '299', 'chronic_disease']]}, 'NCT03143985'), ({'text': 'History of psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent', 'entities': [['12', '49', 'chronic_disease']]}, 'NCT02639065'), ({'text': 'daily tobacco smoking in the last six months and at least one instance of tobacco smoking in the last three months', 'entities': [['30', '45', 'upper_bound'], ['59', '62', 'lower_bound'], ['98', '115', 'upper_bound']]}, 'NCT03028350'), ({'text': 'polymyositis or inclusion body myositis', 'entities': [['1', '13', 'chronic_disease'], ['17', '40', 'chronic_disease']]}, 'NCT02245841'), ({'text': 'lobular carcinoma in situ, contralateral ductal carcinoma in situ, or contralateral invasive ductal and/or lobular cancer (and no prior adjuvant chemotherapy for previous breast malignancy)', 'entities': [['1', '26', 'cancer'], ['28', '66', 'cancer'], ['71', '100', 'cancer'], ['108', '122', 'cancer'], ['131', '158', 'treatment'], ['172', '189', 'cancer']]}, 'NCT01697293'), ({'text': 'The following laboratory values obtained =< 21 days prior to registration; complete blood count (CBC), sodium, potassium, aspartate aminotransferase (AST), bilirubin and creatinine are to be obtained pre-study', 'entities': [['45', '58', 'upper_bound'], ['76', '102', 'clinical_variable']]}, 'NCT02312245'), ({'text': 'e10 mm and < 60 mm with neck CT scan', 'entities': [['2', '7', 'lower_bound'], ['14', '19', 'upper_bound'], ['25', '37', 'treatment']]}, 'NCT02474368'), ({'text': '> 18 years of age', 'entities': [['3', '11', 'lower_bound'], ['15', '18', 'age']]}, 'NCT02143050'), ({'text': 'The subject is currently or has been treated with immunosuppressive, immune modifying, or cytotoxic medications as listed in Section 7.2', 'entities': [['51', '68', 'treatment'], ['70', '86', 'treatment'], ['91', '112', 'treatment']]}, 'NCT03030118'), ({'text': 'Disorders that require treatment with the same medications used for RLS', 'entities': [['69', '72', 'chronic_disease']]}, 'NCT02826681'), ({'text': 'Subjects with concomitant malignancy or a previous malignancy within the past three years', 'entities': [['27', '37', 'cancer'], ['74', '90', 'upper_bound']]}, 'NCT02437812'), ({'text': 'Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities', 'entities': [['38', '51', 'chronic_disease'], ['59', '95', 'chronic_disease']]}, 'NCT03008408'), ({'text': 'Age e18 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02985554'), ({'text': 'Infant must be born between the gestational ages of 28 0/7 weeks and 34 6/7 weeks', 'entities': [['33', '49', 'clinical_variable'], ['53', '65', 'lower_bound'], ['70', '82', 'upper_bound']]}, 'NCT02477423'), ({'text': 'Patients who have started first line mFOLFOX6 therapy (+/-trastuzumab for HER2 amplified tumors) may be considered for trial participation if they have received no more than 4 doses of therapy at the time of consent and screening', 'entities': [['27', '54', 'treatment'], ['47', '54', 'treatment'], ['59', '70', 'treatment'], ['75', '96', 'cancer'], ['175', '182', 'upper_bound']]}, 'NCT02213289'), ({'text': 'Patients with hypersensitivity to docetaxel or polysorbate 80 (Arm A only)', 'entities': [['35', '44', 'allergy_name'], ['48', '62', 'allergy_name']]}, 'NCT02437370'), ({'text': 'Unstable/active disease or potential contraindications with both study medications, e.g., diabetes, unstable angina or recent acute coronary syndrome, pregnancy, very high risk factors on the screening labs', 'entities': [['72', '83', 'treatment'], ['91', '99', 'chronic_disease'], ['101', '116', 'chronic_disease'], ['127', '150', 'chronic_disease'], ['152', '161', 'pregnancy']]}, 'NCT02188121'), ({'text': 'd 5 x IULN if liver metastases', 'entities': [['3', '11', 'upper_bound'], ['15', '31', 'cancer']]}, 'NCT02393794'), ({'text': 'No DSM-IV-TR/DSM-5 Axis I Disorder (documented by SCID)', 'entities': [['20', '35', 'chronic_disease']]}, 'NCT02067975'), ({'text': 'Moderate to severe central or mixed central and obstructive sleep apnea, defined as an apnea-hypopnea index (AHI) 15 events per hour, with a central AHI >5 events/hour', 'entities': [['20', '72', 'chronic_disease'], ['88', '114', 'clinical_variable'], ['142', '153', 'clinical_variable'], ['155', '168', 'lower_bound']]}, 'NCT01807897'), ({'text': 'unstable angina pectoris', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03069924'), ({'text': 'Uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease (COPD), pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study', 'entities': [['38', '55', 'chronic_disease'], ['63', '107', 'chronic_disease'], ['109', '131', 'chronic_disease']]}, 'NCT03143985'), ({'text': "patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as SLE, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome", 'entities': [['28', '61', 'chronic_disease'], ['63', '81', 'chronic_disease'], ['83', '120', 'chronic_disease'], ['122', '145', 'chronic_disease'], ['147', '164', 'chronic_disease'], ['166', '193', 'chronic_disease'], ['202', '205', 'chronic_disease'], ['207', '233', 'chronic_disease'], ['235', '246', 'chronic_disease'], ['248', '280', 'chronic_disease'], ['282', '289', 'chronic_disease'], ['291', '309', 'chronic_disease'], ['311', '320', 'chronic_disease'], ['353', '385', 'chronic_disease'], ['387', '411', 'chronic_disease'], ['416', '437', 'chronic_disease']]}, 'NCT02985554'), ({'text': 'Patients with a known history of malignancy with a disease-free interval <3 years prior to enrollment', 'entities': [['34', '44', 'cancer'], ['75', '88', 'upper_bound']]}, 'NCT02950337'), ({'text': 'Prior ipsilateral carotid endarterectomy', 'entities': [['1', '41', 'treatment']]}, 'NCT02169739'), ({'text': 'Estrogen therapy (including birth control) in the previous year', 'entities': [['1', '17', 'treatment']]}, 'NCT01648751'), ({'text': 'Active fungal, viral, bacterial, or protozoal infection requiring IV treatment', 'entities': [['1', '14', 'chronic_disease'], ['16', '21', 'chronic_disease'], ['23', '32', 'chronic_disease'], ['37', '56', 'chronic_disease'], ['67', '79', 'treatment']]}, 'NCT01614197'), ({'text': 'Have a clinical history of malignancy within 3 years', 'entities': [['28', '38', 'cancer'], ['46', '53', 'upper_bound']]}, 'NCT03059355'), ({'text': 'hematologic disease', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02397889'), ({'text': 'International normal ratio (INR) < 1.3 or d institutional ULN (or d 3.0 if on therapeutic anticoagulation)', 'entities': [['1', '33', 'clinical_variable'], ['36', '39', 'upper_bound'], ['69', '72', 'upper_bound'], ['79', '106', 'treatment']]}, 'NCT02091999'), ({'text': 'Suspicious microcalcifications, or densities (in the ipsilateral or contralateral breast as documented on mammogram or breast ultrasound) unless biopsied and found to be benign', 'entities': [['1', '31', 'cancer'], ['107', '116', 'treatment'], ['120', '137', 'treatment'], ['146', '154', 'treatment']]}, 'NCT01245712'), ({'text': 'On echocardiogram tricuspid annular peak systolic excursion (TAPSE) d 1.8 cm or, grade II or worse Right Ventricular (RV) or Left Ventricular (LV) diastolic dysfunction', 'entities': [['4', '18', 'treatment'], ['19', '68', 'clinical_variable'], ['71', '77', 'upper_bound'], ['82', '90', 'lower_bound'], ['100', '122', 'chronic_disease'], ['126', '169', 'chronic_disease']]}, 'NCT01445821'), ({'text': 'Hypothyroidism or hyperthyroidism', 'entities': [['1', '15', 'chronic_disease'], ['19', '34', 'chronic_disease']]}, 'NCT00409435'), ({'text': '3 month washout for leflunomide, IVIg or cyclophosphamide', 'entities': [['1', '8', 'upper_bound'], ['21', '32', 'treatment'], ['34', '38', 'treatment'], ['42', '58', 'treatment']]}, 'NCT02043548'), ({'text': 'Use of medications that strongly alter CYP3A4 activity', 'entities': [['8', '19', 'treatment'], ['40', '46', 'clinical_variable']]}, 'NCT02819440'), ({'text': 'Patients who have had prior treatment with PARPi are not eligible', 'entities': [['23', '49', 'treatment']]}, 'NCT02484404'), ({'text': 'Diagnosis of immunodeficiency or receiving systemic steroid therapy or immunosuppressive therapy within 7 days prior to planned first dose of trial treatment', 'entities': [['14', '30', 'chronic_disease'], ['44', '68', 'treatment'], ['72', '97', 'treatment'], ['105', '117', 'upper_bound']]}, 'NCT02641093'), ({'text': 'Fludrocortisone acetate is a current home medication', 'entities': [['1', '24', 'treatment']]}, 'NCT03129542'), ({'text': "Taking investigational or commercial agents or therapies with the intent to treat the subject's malignancy other than those therapies permitted", 'entities': [['8', '23', 'treatment'], ['27', '44', 'treatment'], ['48', '57', 'treatment'], ['97', '107', 'cancer']]}, 'NCT02092324'), ({'text': 'Taking any other medications, including over the counter supplements with the exception of oral contraceptives for women', 'entities': [['116', '121', 'gender']]}, 'NCT02536846'), ({'text': 'Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered to be ambulatory for the purpose of assessing the performance score', 'entities': [['44', '53', 'chronic_disease']]}, 'NCT02114229'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02266784'), ({'text': 'Patients who are HIV positive', 'entities': [['18', '21', 'chronic_disease']]}, 'NCT00472329'), ({'text': 'Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration', 'entities': [['1', '16', 'chronic_disease'], ['20', '36', 'chronic_disease'], ['47', '70', 'treatment']]}, 'NCT02542202'), ({'text': 'Contraindications for MRI (pacemakers, ferrous metal implants or shrapnel in or around the head, etc.)', 'entities': [['23', '26', 'treatment'], ['28', '38', 'treatment'], ['40', '62', 'treatment']]}, 'NCT02460783'), ({'text': 'Intra-cardiac defibrillators', 'entities': [['1', '29', 'treatment']]}, 'NCT02465060'), ({'text': 'Diagnosis or recurrence of invasive cancer other than the present cancer within 3 years (except basal or squamous cell carcinoma of the skin that has been definitively treated)', 'entities': [['28', '43', 'cancer'], ['37', '43', 'cancer'], ['81', '88', 'upper_bound'], ['97', '102', 'cancer'], ['106', '141', 'cancer']]}, 'NCT02419495'), ({'text': 'Prior surgery for an aneurysm', 'entities': [['1', '14', 'treatment'], ['22', '30', 'chronic_disease']]}, 'NCT02263729'), ({'text': 'Patients with metastatic disease', 'entities': [['15', '33', 'cancer']]}, 'NCT02578732'), ({'text': 'Participating in another investigational device or drug study within 1 year of treatment', 'entities': [['18', '62', 'treatment'], ['70', '76', 'upper_bound'], ['80', '89', 'treatment']]}, 'NCT02489539'), ({'text': 'infliximab and rituximab', 'entities': [['1', '11', 'treatment'], ['16', '25', 'treatment']]}, 'NCT02245841'), ({'text': 'All patients who have two or more histologic diagnoses of the same primary tumor type involving the above sites', 'entities': [['68', '81', 'cancer']]}, 'NCT00579514'), ({'text': 'Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms', 'entities': [['23', '47', 'chronic_disease'], ['49', '62', 'chronic_disease'], ['64', '88', 'chronic_disease'], ['90', '115', 'chronic_disease'], ['117', '136', 'chronic_disease']]}, 'NCT02960763'), ({'text': 'Cervical dilation visually d 5cm on sterile speculum exam', 'entities': [['1', '27', 'clinical_variable'], ['30', '33', 'upper_bound']]}, 'NCT02939742'), ({'text': 'Hemolysis, Elevated Liver Enzymes, Low Platelet (HELLP) Syndrome', 'entities': [['1', '10', 'chronic_disease'], ['12', '34', 'chronic_disease'], ['36', '65', 'chronic_disease']]}, 'NCT03011567'), ({'text': 'Age 7-25 inclusive', 'entities': [['1', '4', 'age'], ['5', '6', 'lower_bound'], ['7', '9', 'upper_bound']]}, 'NCT02067819'), ({'text': 'age greater than or equal to 75 years', 'entities': [['1', '4', 'age'], ['30', '38', 'lower_bound']]}, 'NCT02554253'), ({'text': 'Clinically significant neurologic event (stroke) or any neurologic deficit lasting >24 hours that is accompanied by an infarct on cerebral MRI', 'entities': [['42', '48', 'chronic_disease'], ['57', '75', 'clinical_variable'], ['85', '93', 'lower_bound'], ['131', '143', 'treatment']]}, 'NCT01461837'), ({'text': 'No prior allogeneic HCT, and no autologous HCT within the previous 12 months', 'entities': [['4', '24', 'treatment'], ['33', '47', 'treatment'], ['59', '77', 'upper_bound']]}, 'NCT01807611'), ({'text': "Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results", 'entities': [['27', '40', 'chronic_disease'], ['44', '61', 'chronic_disease']]}, 'NCT02048371'), ({'text': 'Age <18', 'entities': [['1', '4', 'age'], ['6', '8', 'upper_bound']]}, 'NCT01902810'), ({'text': 'Treatment with colchicine', 'entities': [['16', '26', 'treatment']]}, 'NCT02576301'), ({'text': 'history of abdominal fistula', 'entities': [['12', '29', 'chronic_disease']]}, 'NCT02120222'), ({'text': 'receiving immunosuppressive therapy', 'entities': [['11', '36', 'treatment']]}, 'NCT02268253'), ({'text': 'Inability to localise surgical bed on CT scans and/or surgical margins (cm) not known', 'entities': [['39', '47', 'treatment']]}, 'NCT00975520'), ({'text': 'with body weight lower than the 3rd percentile', 'entities': [['6', '17', 'clinical_variable'], ['33', '47', 'upper_bound']]}, 'NCT01895777'), ({'text': 'Platelet count e 100,000/mcL', 'entities': [['1', '15', 'clinical_variable'], ['18', '29', 'lower_bound']]}, 'NCT02706249'), ({'text': 'Patients with active (grade 2-4) acute graft versus host disease (GVHD), chronic GVHD or an overt autoimmune disease (e.g. hemolytic anemia) requiring glucocorticosteroid treatment (>0.5 mg/kg/day prednisone or its equivalent) as treatment', 'entities': [['23', '30', 'lower_bound'], ['31', '32', 'upper_bound'], ['34', '72', 'chronic_disease'], ['74', '86', 'chronic_disease'], ['93', '117', 'chronic_disease'], ['124', '140', 'chronic_disease'], ['152', '181', 'treatment'], ['172', '181', 'treatment'], ['184', '197', 'lower_bound'], ['198', '208', 'treatment']]}, 'NCT01430390'), ({'text': 'systemic illness that are thought to be affecting cognition (e.g., seizure disorder, demyelinating disorder, etc.)', 'entities': [['1', '17', 'chronic_disease'], ['68', '84', 'chronic_disease'], ['86', '108', 'chronic_disease']]}, 'NCT02301546'), ({'text': 'Has been receiving anti-PD-1 or anti-PD-L1 immunotherapy for at least four weeks', 'entities': [['20', '29', 'treatment'], ['33', '57', 'treatment'], ['71', '81', 'lower_bound']]}, 'NCT03176173'), ({'text': 'Prior treatment with a BET inhibitor', 'entities': [['1', '37', 'treatment']]}, 'NCT02158858'), ({'text': 'HER2 must negative as shown be either 0 or 1+ by immunohistochemistry (if 2+, in situ hybridization method used to define HER2) OR by a HER2: 17 centromere signal of <2.0 using a standard in situ hybridization method', 'entities': [['1', '5', 'clinical_variable'], ['39', '40', 'lower_bound'], ['44', '46', 'upper_bound'], ['146', '163', 'clinical_variable'], ['168', '171', 'upper_bound']]}, 'NCT03186937'), ({'text': 'recent (<1 year) surgical, neurological, metabolic or lower limb musculoskeletal problem that might impair the ambulation measures in the study, such as severe knee or hip osteoarthritis', 'entities': [['10', '16', 'upper_bound'], ['18', '26', 'treatment'], ['28', '40', 'chronic_disease'], ['55', '81', 'chronic_disease'], ['169', '187', 'chronic_disease']]}, 'NCT02629731'), ({'text': 'Patients must have at least one focus of metastatic disease that is amenable to pre-and on-treatment biopsy', 'entities': [['29', '32', 'lower_bound'], ['42', '60', 'cancer'], ['92', '108', 'treatment']]}, 'NCT02484404'), ({'text': 'Pathologically confirmed diagnosis of breast cancer with radiographic evidence of incurable, unresectable, locally advanced or metastatic disease (LA/MBC)', 'entities': [['39', '52', 'cancer'], ['128', '146', 'cancer']]}, 'NCT01969643'), ({'text': 'The diagnosis of idiopathic PD will be based on the UK Brain Bank Criteria', 'entities': [['18', '31', 'chronic_disease']]}, 'NCT01581580'), ({'text': 'ECOG performance status d 1', 'entities': [['1', '24', 'clinical_variable'], ['27', '28', 'upper_bound']]}, 'NCT02172651'), ({'text': 'Current use of opioid pain medications', 'entities': [['16', '39', 'treatment']]}, 'NCT02964741'), ({'text': 'Fluent in English and able to communicate adequately for participation in the experimental protocol', 'entities': [['1', '18', 'language_fluency']]}, 'NCT02061553'), ({'text': 'a creatinine clearance of at least 60 mL/(min*1.73m2)', 'entities': [['3', '23', 'clinical_variable'], ['36', '54', 'lower_bound']]}, 'NCT02905591'), ({'text': 'subjects with PCOS will have hyperandrogenism, whether it is clinical (e.g., hirsutism) or biochemical (i.e., elevated plasma T)', 'entities': [['15', '19', 'chronic_disease'], ['30', '46', 'chronic_disease'], ['78', '87', 'chronic_disease']]}, 'NCT00930228'), ({'text': 'History of primary immunodeficiency', 'entities': [['12', '36', 'chronic_disease']]}, 'NCT03030118'), ({'text': 'Prior topical retinoid use', 'entities': [['1', '23', 'treatment']]}, 'NCT02991651'), ({'text': 'Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4.03), grade =< 1, or to the levels dictated in the inclusion/exclusion criteria', 'entities': [['28', '53', 'treatment'], ['89', '163', 'clinical_variable'], ['167', '168', 'upper_bound']]}, 'NCT02553941'), ({'text': 'American Heart Association Stage B-D Heart failure due to ischemic, idiopathic or hypertensive causes, present for at least 3 months', 'entities': [['1', '51', 'chronic_disease'], ['59', '67', 'chronic_disease'], ['69', '79', 'chronic_disease'], ['83', '95', 'chronic_disease'], ['125', '133', 'lower_bound']]}, 'NCT01128816'), ({'text': 'Age >18 years', 'entities': [['1', '4', 'age'], ['6', '14', 'lower_bound']]}, 'NCT02905188'), ({'text': 'Subjects of childbearing potential who are unwilling to take appropriate precautions (from screening through follow-up) to avoid becoming pregnant or fathering a child', 'entities': [['124', '147', 'pregnancy']]}, 'NCT01787487'), ({'text': 'Cardiac arrest as cause for respiratory failure', 'entities': [['1', '15', 'chronic_disease'], ['29', '48', 'chronic_disease']]}, 'NCT01777035'), ({'text': 'Receiving oral or injected antispasticity medications during study treatment', 'entities': [['19', '54', 'treatment']]}, 'NCT02639390'), ({'text': 'demonstrated myopic degeneration', 'entities': [['14', '33', 'chronic_disease']]}, 'NCT02988895'), ({'text': 'Prior surgical resection or ablation of liver metastases is acceptable', 'entities': [['1', '25', 'treatment'], ['29', '37', 'treatment'], ['41', '57', 'cancer']]}, 'NCT02724540'), ({'text': 'Re-transplantation or multi-organ transplantation', 'entities': [['1', '19', 'treatment'], ['23', '50', 'treatment']]}, 'NCT02519946'), ({'text': 'KD d6 months of enrollment', 'entities': [['1', '3', 'clinical_variable'], ['5', '13', 'upper_bound']]}, 'NCT01865162'), ({'text': 'Presence of any contraindications to MRI scanning. For example: cardiac pacemaker, metal implants, claustrophobia, pregnancy, cannot lie still in an fMRI scanner', 'entities': [['38', '50', 'treatment'], ['65', '82', 'treatment'], ['84', '98', 'treatment'], ['100', '114', 'chronic_disease'], ['116', '125', 'pregnancy'], ['150', '162', 'treatment']]}, 'NCT03046017'), ({'text': 'Patient has previously undergone open surgical intervention on the operative hip', 'entities': [['39', '60', 'treatment']]}, 'NCT01917929'), ({'text': 'Placement of a pacemaker for control of rhythm', 'entities': [['16', '25', 'treatment']]}, 'NCT02503722'), ({'text': 'Presence of a known coagulation abnormality, thrombocytopenia, or bleeding diathesis that may preclude the safe use of acupuncture', 'entities': [['21', '44', 'chronic_disease'], ['46', '62', 'chronic_disease'], ['67', '85', 'chronic_disease']]}, 'NCT02064296'), ({'text': 'Radiographic or clinical evidence of local-regional tumor recurrence', 'entities': [['53', '58', 'cancer']]}, 'NCT02203695'), ({'text': 'Subjects with CNS (Central Nervous System) metastases including brain metastases who have completed a course of radiotherapy are eligible for the study provided they are clinically stable', 'entities': [['15', '54', 'cancer'], ['65', '81', 'cancer'], ['113', '125', 'treatment']]}, 'NCT01976169'), ({'text': 'estimated survival of less than one year', 'entities': [['33', '41', 'upper_bound']]}, 'NCT01503086'), ({'text': 'Hemoglobin A1C greater than 7', 'entities': [['1', '15', 'clinical_variable'], ['29', '30', 'lower_bound']]}, 'NCT03059355'), ({'text': '2 to 60 months after the index MI', 'entities': [['1', '2', 'lower_bound'], ['6', '15', 'upper_bound']]}, 'NCT00673842'), ({'text': 'Known hypersensitivity or contraindication to Minocycline or other tetracycline', 'entities': [['47', '58', 'allergy_name'], ['68', '80', 'allergy_name']]}, 'NCT02133872'), ({'text': 'Patients with a life expectancy of < 3 months', 'entities': [['17', '32', 'clinical_variable'], ['38', '46', 'upper_bound']]}, 'NCT03018418'), ({'text': 'Platelets >= 100,000/uL (mcL)', 'entities': [['1', '10', 'clinical_variable'], ['14', '30', 'lower_bound']]}, 'NCT01827384'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT01668082'), ({'text': 'History of allergic reaction to local anesthetics', 'entities': [['33', '50', 'allergy_name']]}, 'NCT02679560'), ({'text': 'Anyone with 1 or more characteristics of frailty', 'entities': [['13', '14', 'lower_bound']]}, 'NCT01973283'), ({'text': 'age 18-65 with episodic migraine with or without aura (ICHD-II) and/or morning onset', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound'], ['16', '64', 'chronic_disease'], ['72', '85', 'chronic_disease']]}, 'NCT03097536'), ({'text': 'Acute cardiac surgery', 'entities': [['1', '22', 'treatment']]}, 'NCT02905370'), ({'text': 'other neurological disease', 'entities': [['7', '27', 'chronic_disease']]}, 'NCT02139436'), ({'text': 'Subjects who have contraindications for receiving Y-90 therapy and any routine procedures and imaging associated with Y-90 therapy', 'entities': [['51', '63', 'treatment']]}, 'NCT02966223'), ({'text': 'Patients on corticosteroids or any immunosuppressive drugs', 'entities': [['13', '28', 'treatment'], ['36', '59', 'treatment']]}, 'NCT01913106'), ({'text': 'Diagnosis of non-ST elevation myocardial infarction (NSTEMI)', 'entities': [['14', '61', 'chronic_disease']]}, 'NCT02277613'), ({'text': 'Have a pre-operative estimated hernia defect of 200 cm2 OR multiple hernia defects whose combined area is e an estimated 200 cm2', 'entities': [['8', '45', 'clinical_variable'], ['49', '56', 'lower_bound'], ['60', '83', 'clinical_variable']]}, 'NCT02587403'), ({'text': 'Serum calcium (ionized or adjusted for albumin) < 7 mg/dl (1.75 mmol/L)', 'entities': [['1', '14', 'clinical_variable'], ['51', '72', 'upper_bound']]}, 'NCT02128906'), ({'text': 'Treatment for non-hematologic malignancy greater than 6 months prior to enrollment is acceptable', 'entities': [['1', '10', 'treatment'], ['15', '41', 'cancer'], ['55', '69', 'lower_bound']]}, 'NCT02109627'), ({'text': 'physicians have determined that such established therapy is not sufficiently efficacious', 'entities': [['50', '57', 'treatment']]}, 'NCT02152254'), ({'text': 'Institutionalized women with subacute illnesses surviving or discharged in < 3 years', 'entities': [['19', '24', 'gender'], ['78', '85', 'upper_bound']]}, 'NCT02589600'), ({'text': 'Women of child bearing potential (not postmenopausal for at least one year) will not be admitted into this study unless they are found to have a negative HCG test during screening', 'entities': [['1', '6', 'gender'], ['67', '75', 'lower_bound']]}, 'NCT02901041'), ({'text': 'Patients with septicemia or severe infection', 'entities': [['15', '25', 'chronic_disease'], ['29', '45', 'chronic_disease']]}, 'NCT01101451'), ({'text': 'not using steroids for at least 7 days prior to trial treatment', 'entities': [['11', '19', 'treatment'], ['33', '45', 'lower_bound']]}, 'NCT02710396'), ({'text': 'Expected survival e 8 months', 'entities': [['1', '18', 'clinical_variable'], ['21', '29', 'lower_bound']]}, 'NCT03067051'), ({'text': 'Unable to understand or speak English due to a cognitive impairment', 'entities': [['1', '38', 'language_fluency'], ['48', '68', 'chronic_disease']]}, 'NCT02442102'), ({'text': 'Inability to withhold antiplatelet/anticoagulation agents perioperatively', 'entities': [['23', '58', 'treatment']]}, 'NCT03026816'), ({'text': 'Previous antibody-based therapy is allowed as long as e 28 days has elapsed from last dose to study treatment', 'entities': [['10', '32', 'treatment'], ['57', '64', 'lower_bound']]}, 'NCT02454010'), ({'text': 'Combination regimens that include an anti-estrogen and any biologic, or targeted therapy, are permitted (e.g., any CDK inhibitor, everolimus, or any other novel biologics), and are considered to be a single hormonal therapy based regimen', 'entities': [['38', '51', 'treatment'], ['60', '68', 'treatment'], ['73', '89', 'treatment'], ['116', '129', 'treatment'], ['131', '141', 'treatment'], ['156', '171', 'treatment'], ['208', '224', 'treatment']]}, 'NCT02188745'), ({'text': 'Confirmed diagnosis of primary or secondary AML [any subtype except acute promyelocytic leukemia (APL)] according to World Health Organization (WHO) classification', 'entities': [['24', '48', 'cancer'], ['69', '103', 'cancer']]}, 'NCT02152956'), ({'text': 'Subjects who are e 3 months post-renal transplant who are taking appropriate calcineurin inhibitor (CNI) based maintenance immunosuppression ([tacrolimus alone or in conjunction with sirolimus, mycophenolate mofetil, myfortic, or azathioprine; or cyclosporine in conjunction with sirolimus, mycophenolate mofetil, or myfortic] ± Prednisone d 10 mg/day)', 'entities': [['20', '28', 'lower_bound'], ['144', '154', 'treatment'], ['184', '193', 'treatment'], ['195', '216', 'treatment'], ['218', '226', 'treatment'], ['231', '243', 'treatment'], ['248', '290', 'treatment'], ['330', '340', 'treatment'], ['343', '352', 'upper_bound']]}, 'NCT02464878'), ({'text': 'Patients with alpha thalassemia two or more gene deletions or any alpha-globin structural variants sickle cell disease', 'entities': [['15', '32', 'chronic_disease'], ['100', '119', 'chronic_disease']]}, 'NCT02186418'), ({'text': 'level of radiographic bone level has the distance from CEJ to interproximal crest up to 4 mm', 'entities': [['10', '33', 'clinical_variable'], ['89', '93', 'upper_bound']]}, 'NCT02864862'), ({'text': 'Has an ECOG PS of 0, 1, or 2', 'entities': [['8', '15', 'clinical_variable'], ['19', '20', 'lower_bound'], ['28', '29', 'upper_bound']]}, 'NCT02355535'), ({'text': 'Age 35-65', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT02535832'), ({'text': 'Documented history of a psychotic disorder in a first-degree relative', 'entities': [['25', '43', 'chronic_disease']]}, 'NCT02556606'), ({'text': 'pregnant or breastfeeding', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01652092'), ({'text': 'Prior malignancy (other than breast cancer) unless diagnosed and definitively treated more than 5 years prior to randomization', 'entities': [['7', '17', 'cancer'], ['30', '43', 'cancer'], ['97', '110', 'lower_bound'], ['114', '127', 'treatment']]}, 'NCT02915744'), ({'text': 'ECOG (Eastern Cooperative Oncology Group)', 'entities': [['1', '42', 'clinical_variable']]}, 'NCT02106312'), ({'text': 'Prior radiation therapy is not an exclusion however, patient must have documented progression at the radiation site', 'entities': [['1', '24', 'treatment'], ['7', '16', 'treatment']]}, 'NCT02324608'), ({'text': 'Baseline PSA d 2.5ng/mL', 'entities': [['1', '13', 'clinical_variable'], ['16', '24', 'upper_bound']]}, 'NCT02167009'), ({'text': 'At least 7 days after the last dose of a biologic agent', 'entities': [['10', '22', 'lower_bound'], ['42', '56', 'treatment']]}, 'NCT02354547'), ({'text': 'Males', 'entities': [['1', '6', 'gender']]}, 'NCT02404688'), ({'text': 'acquired bony nonunion (not congenital) treatable by segmental resection and reconstruction', 'entities': [['10', '23', 'chronic_disease'], ['54', '73', 'treatment'], ['78', '92', 'treatment']]}, 'NCT02015390'), ({'text': 'Esophageal stricture', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT01942018'), ({'text': 'Current hematologic malignancies', 'entities': [['9', '33', 'cancer']]}, 'NCT03086369'), ({'text': 'Current or previous use of glucose-lowering agents or insulin', 'entities': [['28', '51', 'treatment'], ['55', '62', 'treatment']]}, 'NCT02462161'), ({'text': 'Own non-Kindle Smartphone iOS 7 or above, or Android 2.3 or above', 'entities': [['1', '66', 'technology_access']]}, 'NCT02823379'), ({'text': 'Pre-existing ocular pathology other than refractive error', 'entities': [['1', '30', 'chronic_disease'], ['42', '58', 'chronic_disease']]}, 'NCT02786706'), ({'text': 'Prior treatment with Doxil, topotecan, Gemzar or Taxol chemotherapy for platinum-resistant cancer', 'entities': [['1', '15', 'treatment'], ['22', '27', 'treatment'], ['29', '38', 'treatment'], ['40', '46', 'treatment'], ['50', '68', 'treatment'], ['92', '98', 'cancer']]}, 'NCT02312245'), ({'text': 'History of additional risk factors for torsade de pointes', 'entities': [['40', '58', 'chronic_disease']]}, 'NCT02568267'), ({'text': 'patients undergoing any surgical treatment of benign and malignant lesions by any physician in the Dermatology department', 'entities': [['25', '43', 'treatment'], ['47', '53', 'cancer'], ['58', '75', 'cancer']]}, 'NCT01773694'), ({'text': 'Subjects with a known hypersensitivity to polysorbate 20 (contraindicated with the use of Alloderm®)', 'entities': [['43', '57', 'allergy_name'], ['91', '100', 'allergy_name']]}, 'NCT03057730'), ({'text': 'Women that know they are pregnant or breastfeeding', 'entities': [['1', '6', 'gender'], ['22', '34', 'pregnancy']]}, 'NCT01420887'), ({'text': 'Prostate Specific Antigen Doubling Time < 6 months', 'entities': [['1', '40', 'clinical_variable'], ['43', '51', 'upper_bound']]}, 'NCT02176161'), ({'text': 'With a score equal to or less than 35 on the FACIT-Fatigue scale (see below)', 'entities': [['36', '38', 'upper_bound'], ['46', '65', 'clinical_variable']]}, 'NCT03119363'), ({'text': 'Patients with conditions requiring immunosuppressive medications or chronic infections (including HIV infection, hepatitis B and C)', 'entities': [['36', '65', 'treatment'], ['69', '87', 'chronic_disease'], ['99', '112', 'chronic_disease'], ['114', '131', 'chronic_disease']]}, 'NCT03121352'), ({'text': 'Patients younger than 65 years old', 'entities': [['23', '31', 'upper_bound']]}, 'NCT02505035'), ({'text': 'Treated with antibiotics in the last 2 months', 'entities': [['14', '25', 'treatment'], ['33', '46', 'upper_bound']]}, 'NCT02252588'), ({'text': 'Administration of G-CSF after haploidentical HCT', 'entities': [['19', '24', 'treatment'], ['31', '49', 'treatment']]}, 'NCT00914628'), ({'text': 'Patients with a diagnosis of COPD, emphysema, or chronic bronchitis', 'entities': [['30', '34', 'chronic_disease'], ['36', '45', 'chronic_disease'], ['50', '68', 'chronic_disease']]}, 'NCT01742338'), ({'text': 'The patient is scheduled to undergo percutaneous coronary intervention with MitraClip procedure', 'entities': [['37', '71', 'treatment'], ['77', '86', 'treatment']]}, 'NCT02924363'), ({'text': 'Platelets >= 100,000/mcL', 'entities': [['1', '10', 'clinical_variable'], ['14', '25', 'lower_bound']]}, 'NCT02122185'), ({'text': 'Patients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intent', 'entities': [['73', '87', 'cancer'], ['112', '130', 'cancer'], ['132', '140', 'upper_bound'], ['157', '167', 'lower_bound'], ['192', '199', 'treatment']]}, 'NCT02387216'), ({'text': 'One or more psychosis-risk syndromes as defined by the Structured Interview for Psychosis-Risk Syndromes (SIPS)', 'entities': [['1', '4', 'lower_bound'], ['13', '22', 'chronic_disease']]}, 'NCT02404194'), ({'text': 'have chronic, non-malignant, neuro-musculoskeletal pain', 'entities': [['6', '13', 'chronic_disease'], ['15', '28', 'cancer'], ['30', '56', 'chronic_disease']]}, 'NCT02426476'), ({'text': 'Participants with active suicidal ideation with specific plan and intent or suicide-related behaviors within 2 months of consent as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)', 'entities': [['26', '43', 'chronic_disease'], ['77', '102', 'chronic_disease'], ['110', '118', 'upper_bound'], ['149', '196', 'clinical_variable']]}, 'NCT02922569'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['14', '34', 'chronic_disease'], ['77', '93', 'chronic_disease'], ['107', '131', 'chronic_disease'], ['133', '157', 'chronic_disease'], ['159', '177', 'chronic_disease'], ['182', '219', 'chronic_disease']]}, 'NCT02985554'), ({'text': 'Females who are of childbearing potential and unwilling to practice abstinence or use at least two methods of contraception (oral contraceptives, barrier methods, approved contraceptive implant) during the entire study period', 'entities': [['1', '8', 'gender']]}, 'NCT02687906'), ({'text': 'hemoglobin <9 gm/dL', 'entities': [['1', '11', 'clinical_variable'], ['13', '20', 'upper_bound']]}, 'NCT03170375'), ({'text': 'History of other malignancies', 'entities': [['18', '30', 'cancer']]}, 'NCT02012296'), ({'text': 'EKG evidence at baseline screening of any clinically significant conduction abnormalities or arrhythmias', 'entities': [['1', '4', 'treatment'], ['94', '105', 'chronic_disease']]}, 'NCT02164422'), ({'text': 'RBC transfusion- dependence (defined as >/= 10 cc/kg of RBC per 28 days average)', 'entities': [['1', '4', 'clinical_variable'], ['1', '16', 'treatment'], ['45', '53', 'lower_bound'], ['65', '72', 'upper_bound']]}, 'NCT01464164'), ({'text': 'Adequate liver function per protocol', 'entities': [['10', '24', 'chronic_disease']]}, 'NCT01966367'), ({'text': 'White blood cells 2000/ul or more', 'entities': [['1', '18', 'clinical_variable'], ['19', '26', 'lower_bound']]}, 'NCT03162731'), ({'text': 'suggested regimens to replace protease inhibitor therapy include dolutegravir given with tenofovir/emtricitabine; raltegravir given with tenofovir and emtricitabine; once daily combinations that use pharmacologic boosters may not be used', 'entities': [['11', '19', 'treatment'], ['31', '57', 'treatment'], ['66', '78', 'treatment'], ['90', '99', 'treatment'], ['100', '113', 'treatment'], ['115', '126', 'treatment']]}, 'NCT02465060'), ({'text': 'Hgb greater than or equal to 7.0', 'entities': [['1', '4', 'clinical_variable'], ['30', '33', 'lower_bound']]}, 'NCT01333046'), ({'text': 'Hypothyroidism (fatigue-related factor)', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02690116'), ({'text': 'Animal reproductive studies have not been conducted with trametinib; therefore, the study drug must not be administered to pregnant women or nursing mothers; women of childbearing potential should be advised to avoid pregnancy and use effective methods of contraception; men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception; if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib, the potential hazard to the fetus should be explained to the patient and partner (as applicable)', 'entities': [['58', '68', 'treatment'], ['124', '132', 'pregnancy'], ['133', '138', 'gender'], ['135', '138', 'gender'], ['218', '227', 'pregnancy'], ['232', '270', 'contraception_consent'], ['283', '289', 'gender'], ['347', '362', 'treatment'], ['366', '402', 'contraception_consent'], ['409', '423', 'gender']]}, 'NCT02070549'), ({'text': 'congestive heart failure', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03030859'), ({'text': 'Prolonged corrected QT interval', 'entities': [['21', '32', 'clinical_variable']]}, 'NCT02203695'), ({'text': 'women of child-bearing', 'entities': [['1', '6', 'gender']]}, 'NCT02273375'), ({'text': 'Age 18 or older', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT02652247'), ({'text': 'Clinically significant cardiovascular disorders', 'entities': [['24', '48', 'chronic_disease']]}, 'NCT02431806'), ({'text': 'Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer', 'entities': [['55', '64', 'lower_bound'], ['65', '69', 'upper_bound'], ['70', '96', 'cancer']]}, 'NCT02492867'), ({'text': 'cured squamous cell cancer', 'entities': [['7', '27', 'cancer']]}, 'NCT02169089'), ({'text': 'Vasectomized male subject or vasectomized partner of female subjects', 'entities': [['14', '26', 'gender'], ['54', '69', 'gender']]}, 'NCT02520778'), ({'text': 'No evidence of suspicious microcalcifications in the breast before the start of radiotherapy', 'entities': [['81', '93', 'treatment']]}, 'NCT00909909'), ({'text': 'Subjects must either: (i) have relapsed within 6 months after (or progressed during) their last platinum regimen (this may be their primary/ adjuvant regimen); or (ii) have progressed after 2 or more prior platinum regimens (regardless of duration since most recent platinum regimen); or (iii) can not tolerate platinum therapy due to hypersensitivity or other allergic reactions', 'entities': [['48', '62', 'upper_bound'], ['97', '113', 'treatment'], ['133', '158', 'treatment'], ['207', '224', 'treatment'], ['312', '328', 'treatment']]}, 'NCT02534922'), ({'text': 'Subjects with clinically significant signs of uncal herniation, such as acute pupillary enlargement, rapidly developing motor changes (over hours), or rapidly decreasing level of consciousness', 'entities': [['47', '63', 'chronic_disease']]}, 'NCT02359097'), ({'text': 'Non-resectable squamous cell carcinoma of the penis', 'entities': [['16', '52', 'cancer']]}, 'NCT02496208'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02576444'), ({'text': 'vascular disease (1 point)', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02169037'), ({'text': 'Some common examples include inhibitors such as erythromycin, fluoxetine, gemfibrozil, and inducers such as rifampicin, carbamazepine, phenytoin, efavirenz, and nevirapine', 'entities': [['30', '40', 'treatment'], ['49', '61', 'treatment'], ['63', '73', 'treatment'], ['75', '86', 'treatment'], ['92', '100', 'treatment'], ['109', '119', 'treatment'], ['121', '134', 'treatment'], ['136', '145', 'treatment'], ['147', '156', 'treatment'], ['162', '172', 'treatment']]}, 'NCT02584647'), ({'text': 'Interstitial lung disease with ongoing signs and symptoms at the time of informed consent', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT02048371'), ({'text': 'Living within the DC metropolitan statistical area and anticipate remaining within the DC area for the next 6 months', 'entities': [['104', '117', 'upper_bound']]}, 'NCT03078153'), ({'text': 'Planned elective surgery during the study year', 'entities': [['9', '25', 'treatment']]}, 'NCT02826681'), ({'text': 'hypopharynx with no evidence of distant metastasis', 'entities': [['33', '51', 'cancer']]}, 'NCT02128906'), ({'text': 'Use of antiarrhythmic drugs', 'entities': [['8', '28', 'treatment']]}, 'NCT00673842'), ({'text': 'Patient or parent/legal guardian or representative has a psychiatric illness that would prevent the patient or parent/legal guardian or representative from giving informed consent and/or assent', 'entities': [['58', '77', 'chronic_disease']]}, 'NCT02851407'), ({'text': 'Transformed lymphoma', 'entities': [['13', '21', 'cancer']]}, 'NCT02078102'), ({'text': 'creatinin clearance of >1.3 mg/dL', 'entities': [['1', '20', 'clinical_variable'], ['25', '34', 'upper_bound']]}, 'NCT02397889'), ({'text': 'Neurological diagnosis of amnestic mild cognitive impairment (aMCI)', 'entities': [['27', '68', 'chronic_disease']]}, 'NCT03112902'), ({'text': 'Age newborn up until the twenty-second birthday', 'entities': [['1', '4', 'age']]}, 'NCT02421276'), ({'text': 'Alcohol or substance use disorder up to one month prior to first testing session', 'entities': [['41', '56', 'upper_bound']]}, 'NCT03152409'), ({'text': 'an injury severity score (ISS) of 9 or greater', 'entities': [['4', '31', 'clinical_variable'], ['35', '36', 'lower_bound']]}, 'NCT03108820'), ({'text': 'A histologically or pathologically confirmed diagnosis of AML based on WHO classification with or without extramedullary disease except for central nervous system disease', 'entities': [['59', '62', 'cancer'], ['107', '129', 'cancer'], ['141', '171', 'chronic_disease']]}, 'NCT02835729'), ({'text': 'Age between 18-85 years', 'entities': [['1', '4', 'age'], ['13', '15', 'lower_bound'], ['16', '24', 'upper_bound']]}, 'NCT02465034'), ({'text': 'Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale', 'entities': [['20', '21', 'lower_bound'], ['25', '26', 'upper_bound'], ['34', '81', 'treatment']]}, 'NCT02562755'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT03114891'), ({'text': 'Newly diagnosed MCL: Creatinine (Cr) Clearance >= 30 mL/min', 'entities': [['17', '20', 'cancer'], ['22', '47', 'clinical_variable'], ['51', '60', 'lower_bound']]}, 'NCT01880567'), ({'text': 'No history of a horseshoe kidney', 'entities': [['17', '33', 'chronic_disease']]}, 'NCT01508390'), ({'text': 'pre-hypertension or stage one hypertension (BP e120/80 and <160/100)', 'entities': [['5', '17', 'chronic_disease'], ['45', '47', 'clinical_variable'], ['49', '55', 'lower_bound'], ['61', '68', 'upper_bound']]}, 'NCT03043963'), ({'text': 'six months or more post-injury', 'entities': [['1', '11', 'lower_bound']]}, 'NCT02329652'), ({'text': 'Patients must not have hypersensitivity to bortezomib, boron, or mannitol', 'entities': [['44', '54', 'treatment'], ['56', '61', 'treatment'], ['66', '74', 'treatment']]}, 'NCT01415752'), ({'text': '1-4mm Breslow depth', 'entities': [['1', '2', 'lower_bound'], ['3', '6', 'upper_bound'], ['7', '20', 'clinical_variable']]}, 'NCT02451488'), ({'text': 'Progressive or recalcitrant neuropathy or neuritis, except for isolated intermittent ulnar neuritis', 'entities': [['16', '39', 'chronic_disease'], ['43', '51', 'chronic_disease'], ['86', '100', 'chronic_disease']]}, 'NCT01420887'), ({'text': 'Total body irradiation (TBI) (e 1200 cGy) and etoposide (60 mg/kg)', 'entities': [['1', '29', 'clinical_variable'], ['33', '41', 'lower_bound'], ['47', '56', 'treatment']]}, 'NCT01951885'), ({'text': 'Must have a disease that is relapsed/refractory to all potentially curative standard treatment regimens', 'entities': [['68', '95', 'treatment']]}, 'NCT02124772'), ({'text': 'Age > 18 with a hematological malignancy', 'entities': [['1', '4', 'age'], ['7', '9', 'lower_bound'], ['17', '41', 'cancer']]}, 'NCT02074436'), ({'text': 'Allergies or sensitivity to any of the ingredients of the meal', 'entities': [['40', '63', 'allergy_name']]}, 'NCT03081390'), ({'text': 'Cefoxitin', 'entities': [['1', '10', 'treatment']]}, 'NCT03181516'), ({'text': 'verapamil', 'entities': [['1', '10', 'treatment']]}, 'NCT02594111'), ({'text': 'Hemosiderosis/hemochromatosis (patients can still be included in 2nd branch without ferumoxytol)', 'entities': [['1', '14', 'chronic_disease'], ['15', '30', 'chronic_disease'], ['85', '96', 'treatment']]}, 'NCT01542879'), ({'text': 'plan to become pregnant in the next 3 months', 'entities': [['1', '24', 'pregnancy'], ['32', '45', 'upper_bound']]}, 'NCT03162978'), ({'text': 'Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times ULN', 'entities': [['33', '42', 'clinical_variable'], ['45', '84', 'upper_bound'], ['90', '122', 'clinical_variable'], ['127', '157', 'clinical_variable'], ['160', '171', 'upper_bound']]}, 'NCT01464034'), ({'text': 'Isolated sensory deficit, motor intact', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02232165'), ({'text': 'patients who have not had an orchiectomy must be maintained on effective GnRH analogue/antagonist therapy', 'entities': [['30', '41', 'treatment'], ['74', '87', 'treatment'], ['88', '106', 'treatment']]}, 'NCT02565901'), ({'text': 'SVT with fetal hydrops (irrespective of duration)', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT02624765'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02074631'), ({'text': 'Major of psychotropic agents and antidepressants', 'entities': [['10', '29', 'treatment'], ['34', '49', 'treatment']]}, 'NCT02133885'), ({'text': 'Strong inhibitors of cytochrome P450, family 1, subfamily A, polypeptide 2 (CYP1A2)', 'entities': [['1', '37', 'treatment'], ['62', '84', 'treatment']]}, 'NCT02542657'), ({'text': 'Patient has been adequately informed of risks and requirements of the trial and is willing and able to provide informed consent for participation in the clinical trial', 'entities': [['154', '168', 'treatment']]}, 'NCT02088554'), ({'text': 'Documented allergy to NSAIDs', 'entities': [['23', '29', 'allergy_name']]}, 'NCT02700451'), ({'text': 'Known HIV infection', 'entities': [['7', '20', 'chronic_disease']]}, 'NCT02819440'), ({'text': 'Patient must be willing to undergo additional biopsy of breast tumor or lymph node', 'entities': [['47', '53', 'treatment'], ['57', '69', 'cancer']]}, 'NCT03096418'), ({'text': 'Acute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia', 'entities': [['1', '29', 'cancer'], ['41', '68', 'cancer'], ['72', '94', 'cancer']]}, 'NCT00719888'), ({'text': "Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; hepatic or biliary disease that is acute or currently active or that requires antiviral therapy (with the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment)", 'entities': [['1', '22', 'chronic_disease'], ['82', '89', 'chronic_disease'], ['93', '108', 'chronic_disease'], ['160', '177', 'treatment'], ['215', '233', 'chronic_disease'], ['235', '258', 'chronic_disease'], ['260', '276', 'cancer'], ['288', '309', 'chronic_disease']]}, 'NCT01622868'), ({'text': 'ECOG performance status 0-2', 'entities': [['1', '24', 'clinical_variable'], ['25', '26', 'lower_bound'], ['27', '28', 'upper_bound']]}, 'NCT02541903'), ({'text': 'Current diagnosis of plasma cell leukemia', 'entities': [['22', '42', 'cancer']]}, 'NCT01464034'), ({'text': 'History of an adverse reaction to Cortrosyn" or similar test reagents', 'entities': [['35', '45', 'allergy_name']]}, 'NCT02340169'), ({'text': 'Unexplained fever and/or untreated, active infection', 'entities': [['13', '18', 'chronic_disease'], ['37', '53', 'chronic_disease']]}, 'NCT01473784'), ({'text': 'women', 'entities': [['1', '6', 'gender']]}, 'NCT02808702'), ({'text': 'Absolute neutrophil count (ANC) >= 1500/mm^3', 'entities': [['1', '32', 'clinical_variable'], ['36', '45', 'lower_bound']]}, 'NCT02860000'), ({'text': 'Locally advanced disease is considered to include involved lymph nodes of the neck', 'entities': [['1', '25', 'cancer']]}, 'NCT01835626'), ({'text': 'Clinical diagnosis of stable plaque psoriasis with involvement of e 10% body surface area', 'entities': [['30', '46', 'chronic_disease'], ['69', '72', 'lower_bound'], ['73', '90', 'clinical_variable']]}, 'NCT02340169'), ({'text': 'History of plasma cell leukemia or MM CNS involvement', 'entities': [['12', '32', 'cancer'], ['36', '42', 'cancer']]}, 'NCT02253316'), ({'text': 'Must have HIV-1 plasma viral load at screening greater than equal to 500 HIV-1 ribonucleic acid (RNA) copies/mL', 'entities': [['11', '14', 'chronic_disease'], ['70', '112', 'lower_bound']]}, 'NCT00799864'), ({'text': 'Any neurological disorder', 'entities': [['5', '26', 'chronic_disease']]}, 'NCT01973270'), ({'text': 'Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will be excluded from participation, due to the unknown effects of PLX3397 on a growing fetus or newborn child', 'entities': [['17', '29', 'pregnancy'], ['55', '70', 'pregnancy'], ['167', '174', 'treatment']]}, 'NCT02390752'), ({'text': 'Taking chronic anti-anxiety', 'entities': [['16', '28', 'treatment']]}, 'NCT03112824'), ({'text': 'clear cell cancer', 'entities': [['1', '18', 'cancer']]}, 'NCT01600040'), ({'text': 'Anticipated extubation within 24 hours of enrollment', 'entities': [['31', '39', 'upper_bound']]}, 'NCT02652247'), ({'text': 'Subject has experienced >=2 partial-onset seizures with or without secondary generalization during each consecutive 7-day period during the 2 weeks prior to Visit 1', 'entities': [['27', '28', 'lower_bound'], ['43', '51', 'chronic_disease'], ['141', '154', 'upper_bound']]}, 'NCT02477839'), ({'text': 'Serious and imminent suicidal or homicidal risk', 'entities': [['13', '30', 'chronic_disease'], ['34', '48', 'chronic_disease']]}, 'NCT02165449'), ({'text': 'urine output < 500 ml/day', 'entities': [['1', '13', 'clinical_variable'], ['16', '26', 'upper_bound']]}, 'NCT02464696'), ({'text': 'patients 18 to 39 years of age will be eligible only if the investigator has determined that the patient has comorbidity(ies) precluding conventional allogeneic transplantation with full intensity myeloablative conditioning', 'entities': [['10', '12', 'lower_bound'], ['16', '24', 'upper_bound'], ['28', '31', 'age'], ['138', '177', 'treatment'], ['183', '224', 'treatment']]}, 'NCT02593123'), ({'text': 'Prior treatment (surgical or endovascular) of the target aneurysm', 'entities': [['7', '16', 'treatment'], ['58', '66', 'chronic_disease']]}, 'NCT02259504'), ({'text': 'Recent (e.g 1year) arterial thrombotic events (peripheral arterial disease, thrombotic stroke)', 'entities': [['20', '46', 'chronic_disease'], ['48', '75', 'chronic_disease'], ['77', '94', 'chronic_disease']]}, 'NCT03085485'), ({'text': 'Have received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor. For the endocrine naïve cohort: In addition, have received treatment with any prior endocrine therapy', 'entities': [['15', '48', 'treatment'], ['61', '72', 'treatment'], ['74', '95', 'treatment'], ['98', '109', 'treatment'], ['111', '121', 'treatment'], ['130', '146', 'treatment'], ['207', '249', 'treatment']]}, 'NCT02107703'), ({'text': 'Life expectancy of at least 6 months', 'entities': [['1', '16', 'clinical_variable'], ['29', '37', 'lower_bound']]}, 'NCT03113825'), ({'text': 'adenocarcinoma subtypes', 'entities': [['1', '15', 'cancer']]}, 'NCT02442323'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02357784'), ({'text': 'For subjects with DLBCL, FL, MCL, HL, or CLL/SLL: presence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of e1 lesion that measures e2.0 cm in the longest dimension [LD] and e1.0 cm in the longest perpendicular dimension [LPD] as assessed by computed tomography [CT])', 'entities': [['19', '24', 'cancer'], ['26', '28', 'cancer'], ['30', '33', 'cancer'], ['35', '37', 'cancer'], ['42', '45', 'cancer'], ['46', '49', 'cancer'], ['194', '200', 'lower_bound'], ['236', '242', 'lower_bound']]}, 'NCT02931110'), ({'text': 'A history of amblyopia in the study eye', 'entities': [['14', '23', 'chronic_disease']]}, 'NCT02464436'), ({'text': 'Hemoglobin of less than 10.5 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['25', '34', 'upper_bound']]}, 'NCT02352480'), ({'text': 'Dehydration > grade 1', 'entities': [['1', '12', 'clinical_variable'], ['15', '22', 'lower_bound']]}, 'NCT02048722'), ({'text': 'Omeprazole (Prilosec, Zegerid)', 'entities': [['1', '11', 'treatment'], ['13', '21', 'treatment'], ['23', '30', 'treatment']]}, 'NCT02595372'), ({'text': 'Males', 'entities': [['1', '6', 'gender']]}, 'NCT02285101'), ({'text': 'Tubular carcinoma', 'entities': [['1', '18', 'cancer']]}, 'NCT00909909'), ({'text': 'History of autoimmune disease', 'entities': [['12', '30', 'chronic_disease']]}, 'NCT02452268'), ({'text': 'nursing females', 'entities': [['9', '16', 'gender']]}, 'NCT01900301'), ({'text': 'Creatinine clearance < 30 ml/min', 'entities': [['1', '21', 'clinical_variable'], ['24', '33', 'upper_bound']]}, 'NCT01464164'), ({'text': '1 prior line of systemic therapy for multiple myeloma, where a line of therapy for myeloma is defined as 1 or more planned cycles of single agent or combination therapy, as well as a planned series of treatment regimens administered in a sequential manner (e.g. lenalidomide, bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide maintenance therapy would be considered 1 line of prior therapy)', 'entities': [['1', '2', 'lower_bound'], ['17', '33', 'treatment'], ['26', '33', 'treatment'], ['38', '54', 'cancer'], ['47', '54', 'cancer'], ['134', '146', 'treatment'], ['150', '169', 'treatment'], ['202', '220', 'treatment'], ['263', '275', 'treatment'], ['277', '287', 'treatment'], ['292', '323', 'treatment'], ['349', '385', 'treatment'], ['395', '427', 'treatment'], ['458', '471', 'treatment']]}, 'NCT02004275'), ({'text': 'for 30 days after the study drug discontinuation', 'entities': [['5', '18', 'upper_bound'], ['23', '33', 'treatment']]}, 'NCT02495168'), ({'text': 'serum M-protein of > = 500mg/dL', 'entities': [['1', '16', 'clinical_variable'], ['24', '32', 'lower_bound']]}, 'NCT01054196'), ({'text': 'Use of any investigational product or investigational medical device within 28 days before day 1 of study drug', 'entities': [['39', '69', 'treatment'], ['77', '84', 'upper_bound']]}, 'NCT02401347'), ({'text': 'Intake of greater than 15 mg of prednisone or equivalent per day', 'entities': [['24', '29', 'lower_bound'], ['33', '43', 'treatment']]}, 'NCT03181893'), ({'text': 'For Part E (LY2835219 + exemestane + everolimus): The participant must have received prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy with either exemestane or exemestane + everolimus', 'entities': [['25', '35', 'treatment'], ['38', '48', 'treatment'], ['86', '118', 'treatment'], ['111', '118', 'treatment'], ['133', '136', 'lower_bound'], ['137', '169', 'treatment'], ['171', '182', 'treatment'], ['184', '193', 'treatment'], ['199', '217', 'cancer']]}, 'NCT02057133'), ({'text': 'Head trauma with loss of consciousness for more than 30 minutes (self-report, medical history)', 'entities': [['1', '12', 'chronic_disease'], ['54', '64', 'lower_bound']]}, 'NCT02233868'), ({'text': 'Frontal Lobe impairment will be determined by 1.5 standard deviations below the mean on either the D-KEFS Color Word Interference Testorthe EXAMINER composite score', 'entities': [['1', '24', 'chronic_disease'], ['100', '165', 'clinical_variable']]}, 'NCT00857207'), ({'text': 'Known or suspected impairment of immunological functions, including maternal history of positive HIV test, receiving immunosuppressive therapy including systemic corticosteroids, or bone marrow/solid organ transplant recipients (topical steroids, topical antibiotics, and topical antifungal medications are acceptable)', 'entities': [['20', '57', 'chronic_disease'], ['98', '101', 'chronic_disease'], ['118', '178', 'treatment'], ['183', '217', 'treatment'], ['230', '246', 'treatment'], ['248', '267', 'treatment'], ['273', '303', 'treatment']]}, 'NCT01893554'), ({'text': 'Women with uterine hyperplasia - in pre-menopausal women hyperplasia >18mm and in post-menopausal women hyperplasia of >10mm Prior therapy with mifepristone', 'entities': [['1', '6', 'gender'], ['12', '31', 'chronic_disease'], ['20', '31', 'clinical_variable'], ['52', '57', 'gender'], ['71', '75', 'lower_bound'], ['121', '125', 'lower_bound'], ['126', '157', 'treatment']]}, 'NCT02642939'), ({'text': 'with maximum tumor diameter =< 5 cm under consideration for stereotactic ablative body radiotherapy (SABR) as definitive primary treatment', 'entities': [['14', '28', 'clinical_variable'], ['32', '36', 'upper_bound'], ['61', '107', 'treatment'], ['122', '139', 'treatment']]}, 'NCT02581787'), ({'text': 'subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study', 'entities': [['44', '62', 'chronic_disease'], ['63', '71', 'chronic_disease']]}, 'NCT02465060'), ({'text': 'Diagnosis of colorectal or head and neck cancer', 'entities': [['14', '24', 'cancer'], ['28', '48', 'cancer']]}, 'NCT01874860'), ({'text': 'Intercranial or intraspinal surgery, stroke, serious head trauma during preceding 3 months', 'entities': [['1', '13', 'treatment'], ['17', '36', 'treatment'], ['38', '44', 'chronic_disease'], ['46', '65', 'chronic_disease'], ['83', '91', 'upper_bound']]}, 'NCT02453373'), ({'text': 'no history of a medication reaction requiring emergency medical care', 'entities': [['17', '27', 'treatment']]}, 'NCT01438073'), ({'text': 'Patients with uncontrolled seizure disorder', 'entities': [['28', '44', 'chronic_disease']]}, 'NCT02101853'), ({'text': 'Experiencing grade 2 or greater diarrhea', 'entities': [['14', '21', 'lower_bound'], ['33', '41', 'chronic_disease']]}, 'NCT01670877'), ({'text': 'Treatment with endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE5) inhibitors, i.v., subcutaneous (s.c.), or oral prostanoids, or guanylate cyclase stimulators within 7 days prior to Baseline RHC or study treatment initiation', 'entities': [['1', '54', 'treatment'], ['56', '93', 'treatment'], ['101', '113', 'treatment'], ['125', '141', 'treatment'], ['146', '175', 'treatment'], ['183', '195', 'treatment'], ['221', '230', 'treatment']]}, 'NCT02554903'), ({'text': 'AVN', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT01754298'), ({'text': 'Women of childbearing potential must have a urine pregnancy test proven negative within 14 days prior to randomization', 'entities': [['1', '6', 'gender'], ['51', '60', 'pregnancy'], ['89', '102', 'upper_bound']]}, 'NCT02273375'), ({'text': 'Unmanaged psychosis or manic episodes in past year', 'entities': [['11', '20', 'chronic_disease'], ['24', '38', 'chronic_disease']]}, 'NCT02774642'), ({'text': 'nursing women', 'entities': [['9', '14', 'gender']]}, 'NCT02524275'), ({'text': 'Any condition that, in the opinion of the investigator, would interfere with the interpretation of study results or subject safety including non-malignant FDG avid diseases such as sarcoidosis or other granulomatous disease', 'entities': [['156', '159', 'treatment'], ['182', '193', 'chronic_disease'], ['203', '224', 'chronic_disease']]}, 'NCT02405078'), ({'text': 'Total bilirubin < 1.5 upper limit of normal (ULN)', 'entities': [['1', '16', 'clinical_variable'], ['19', '50', 'upper_bound']]}, 'NCT02520791'), ({'text': 'Serum Glutamic-Oxaloacetic Transaminase (SGOT) d 2.5 × ULN (d 5.0 × ULN with liver metastasis)', 'entities': [['1', '47', 'clinical_variable'], ['50', '55', 'upper_bound'], ['56', '59', 'clinical_variable'], ['63', '68', 'upper_bound'], ['78', '94', 'cancer']]}, 'NCT01618357'), ({'text': 'Prior radiation therapy to the pelvis', 'entities': [['1', '38', 'treatment']]}, 'NCT01954173'), ({'text': 'A negative urine culture must be demonstrated prior to MDC injection', 'entities': [['56', '69', 'treatment']]}, 'NCT01011777'), ({'text': 'Positive urine culture [defined as a single isolated bacterial species population of greater than 100,000 Colony Forming Units (CFU)]', 'entities': [['38', '82', 'clinical_variable'], ['99', '133', 'lower_bound']]}, 'NCT02744430'), ({'text': 'Age > 18 months (> 547 days) with unfavorable pathology, regardless of MYCN status', 'entities': [['1', '4', 'age'], ['7', '16', 'lower_bound'], ['20', '28', 'lower_bound']]}, 'NCT01505569'), ({'text': 'Subjects with tumors potentially highly sensitive to tipifarnib (HRAS mutant VAF e 35%) may be enrolled despite a serum albumin < 3.5 g/dL', 'entities': [['15', '21', 'cancer'], ['54', '64', 'allergy_name'], ['66', '81', 'clinical_variable'], ['84', '87', 'lower_bound'], ['115', '128', 'clinical_variable'], ['131', '139', 'upper_bound']]}, 'NCT02383927'), ({'text': 'Alkaline phosphatase =< 3 x ULN', 'entities': [['1', '21', 'clinical_variable'], ['25', '32', 'upper_bound']]}, 'NCT02320292'), ({'text': 'Bilirubin d 2 times ULN', 'entities': [['1', '10', 'clinical_variable'], ['13', '24', 'upper_bound']]}, 'NCT01415752'), ({'text': 'alanine aminotransferase (ALT) >5x the upper limit of normal (ULN)', 'entities': [['1', '31', 'clinical_variable'], ['33', '67', 'lower_bound']]}, 'NCT02508467'), ({'text': 'pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02219555'), ({'text': 'Nonarteritic Anterior Ischemic Optic Neuropathy', 'entities': [['1', '48', 'chronic_disease']]}, 'NCT00737893'), ({'text': 'English or Spanish speaking', 'entities': [['1', '28', 'language_fluency']]}, 'NCT02731326'), ({'text': 'Have ocular symptoms or signs of TED with a clinical activity score (CAS) of at least 3', 'entities': [['34', '37', 'chronic_disease'], ['45', '74', 'clinical_variable'], ['87', '88', 'lower_bound']]}, 'NCT02845336'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02446457'), ({'text': 'Negative serum pregnancy test within 7 days of the administration of the first treatment dose for women of childbearing potential (WOCBP)', 'entities': [['1', '25', 'pregnancy'], ['38', '44', 'upper_bound'], ['99', '104', 'gender']]}, 'NCT02834403'), ({'text': 'Severe coronary heart disease', 'entities': [['8', '30', 'chronic_disease']]}, 'NCT03078907'), ({'text': "Patients who have a noncardiac progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient", 'entities': [['21', '51', 'chronic_disease']]}, 'NCT01812174'), ({'text': 'Patients who are known to have allergy to mouse proteins', 'entities': [['43', '57', 'allergy_name']]}, 'NCT01823198'), ({'text': 'Has received no prior therapy for DLBCL or HT with the exception of a course of prednisone of less than or equal to 7 days given for lymphoma related symptoms; prior therapy for follicular lymphoma is accepted, but no prior anthracycline-containing therapy', 'entities': [['17', '30', 'treatment'], ['35', '40', 'cancer'], ['44', '46', 'chronic_disease'], ['81', '91', 'treatment'], ['117', '123', 'upper_bound'], ['134', '142', 'cancer'], ['179', '198', 'cancer'], ['219', '257', 'treatment']]}, 'NCT02734771'), ({'text': 'Active preterm labor with cervical dilation > 6 cm', 'entities': [['27', '44', 'clinical_variable'], ['47', '51', 'lower_bound']]}, 'NCT02983240'), ({'text': 'Corneal epithelial defect larger than 1 mm2 in either eye', 'entities': [['1', '19', 'clinical_variable'], ['39', '44', 'lower_bound']]}, 'NCT02193490'), ({'text': 'Evidence or history of bleeding diathesis or coagulopathy', 'entities': [['24', '42', 'chronic_disease'], ['46', '58', 'chronic_disease']]}, 'NCT02048722'), ({'text': 'previous acromioclavicular surgery', 'entities': [['10', '35', 'treatment']]}, 'NCT03060564'), ({'text': 'The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies; including investigational biologic agents) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatment', 'entities': [['26', '48', 'treatment'], ['60', '98', 'treatment'], ['103', '118', 'treatment'], ['126', '135', 'treatment'], ['139', '149', 'treatment'], ['161', '192', 'treatment'], ['201', '208', 'upper_bound'], ['213', '225', 'treatment'], ['227', '238', 'treatment'], ['246', '260', 'upper_bound'], ['285', '294', 'treatment']]}, 'NCT02132598'), ({'text': 'Contraindications to PET, PET-CT or MR (e.g. electronic medical devices, inability to lie still for long periods) that make it unsafe for the individual to participate', 'entities': [['22', '25', 'treatment'], ['27', '33', 'treatment'], ['37', '39', 'treatment'], ['46', '72', 'treatment']]}, 'NCT02414178'), ({'text': 'INTERMEDIATE RISK: CS T2b, Gleason d7, PSA<20, Nx-0, Mx-0, or CS T1a-T2b, Gleason 2-6, PSAe10 & <20, Nx-0, Mx-0, or CS T1a-T2b, Gleason 7, PSAd20, Nx-0, Mx-0', 'entities': [['23', '26', 'upper_bound'], ['24', '25', 'lower_bound'], ['28', '35', 'clinical_variable'], ['37', '38', 'upper_bound'], ['40', '43', 'clinical_variable'], ['44', '46', 'upper_bound'], ['66', '69', 'lower_bound'], ['85', '86', 'upper_bound'], ['92', '94', 'lower_bound']]}, 'NCT02334579'), ({'text': 'informative tumor marker(s)', 'entities': [['13', '18', 'cancer']]}, 'NCT02266745'), ({'text': "Severe Alzheimer's disease and other dementias as determined by neuropsychological testing and neurological evaluation", 'entities': [['1', '27', 'chronic_disease'], ['38', '47', 'chronic_disease'], ['65', '91', 'clinical_variable'], ['96', '119', 'clinical_variable']]}, 'NCT01703117'), ({'text': 'Uncontrolled arrhythmias', 'entities': [['14', '25', 'chronic_disease']]}, 'NCT02178566'), ({'text': 'Age 40-79, women must be post-menopausal', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '10', 'upper_bound'], ['12', '17', 'gender']]}, 'NCT02209636'), ({'text': '(polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)', 'entities': [['2', '16', 'chronic_disease'], ['18', '30', 'chronic_disease'], ['32', '46', 'chronic_disease']]}, 'NCT01464034'), ({'text': 'Ischemic or hemorrhagic stroke (with confirmatory neuroimaging) that occurred more than 6 months before entering the study', 'entities': [['1', '31', 'chronic_disease'], ['89', '97', 'lower_bound']]}, 'NCT02639390'), ({'text': 'e 18 years old at the time of informed consent', 'entities': [['3', '11', 'lower_bound']]}, 'NCT02178709'), ({'text': 'Subject has IDH2 gene mutations tested centrally (using the investigational use onlyPCR assay, Abbott RealTime IDH2) in samples of bone marrow aspirate and peripheral blood, and confirmed positive in bone marrow aspirate and/or peripheral blood', 'entities': [['81', '94', 'treatment'], ['96', '116', 'treatment']]}, 'NCT02577406'), ({'text': 'renal insufficiency with an estimated glomerular filtration (EGF) <= 30', 'entities': [['1', '20', 'chronic_disease'], ['29', '66', 'clinical_variable'], ['70', '72', 'upper_bound']]}, 'NCT02680535'), ({'text': 'Mild visual function loss, defined as grades 0,1 or 2 on the Humphrey Visual Field Analyzer SITA Standard 24-2 Test grading scale (Table 4) at presentation and a worsening to moderate or greater visual function loss, defined as grades 3-5, after 1 month of treatment and/or medication intolerance', 'entities': [['6', '26', 'chronic_disease'], ['46', '47', 'lower_bound'], ['53', '54', 'upper_bound'], ['62', '130', 'clinical_variable'], ['236', '237', 'lower_bound'], ['238', '239', 'upper_bound'], ['247', '254', 'lower_bound'], ['258', '267', 'treatment'], ['275', '285', 'treatment']]}, 'NCT01407809'), ({'text': 'diagnosis of a lifetime psychotic disorder including schizophrenia or schizoaffective disorder', 'entities': [['25', '43', 'chronic_disease'], ['54', '67', 'chronic_disease'], ['71', '95', 'chronic_disease']]}, 'NCT02397889'), ({'text': 'cardiovascular, respiratory, bladder or renal disease unrelated to SCI', 'entities': [['1', '15', 'chronic_disease'], ['17', '28', 'chronic_disease'], ['30', '37', 'chronic_disease'], ['41', '54', 'chronic_disease']]}, 'NCT02339233'), ({'text': 'Age 21 years or older', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT02767518'), ({'text': 'Seizure disorder', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02792257'), ({'text': 'No episodes of fainting or significant chest pain for at least one month', 'entities': [['64', '73', 'lower_bound']]}, 'NCT02019641'), ({'text': 'Women with intermediate coronary stenoses (> 20% but < 50% luminal diameter stenosis assessed visually at the time of angiography) will undergo clinically indicated IVUS testing based on the judgement of the operator', 'entities': [['1', '6', 'gender'], ['25', '42', 'clinical_variable'], ['46', '49', 'lower_bound'], ['56', '59', 'upper_bound'], ['60', '85', 'clinical_variable']]}, 'NCT01568177'), ({'text': 'systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine)', 'entities': [['1', '34', 'treatment'], ['42', '63', 'treatment'], ['65', '78', 'treatment'], ['80', '93', 'treatment']]}, 'NCT02527421'), ({'text': 'Previous enrollment on another study involving the investigation of veliparib (ABT- 888), with the exception of receiving a single dose of study drug', 'entities': [['69', '89', 'treatment'], ['140', '150', 'treatment']]}, 'NCT01618357'), ({'text': 'Household members of the patient who are between the ages 3 months - 64 years', 'entities': [['54', '58', 'age'], ['59', '67', 'lower_bound'], ['70', '78', 'upper_bound']]}, 'NCT02127658'), ({'text': 'Subjects age 21 and older', 'entities': [['10', '13', 'age'], ['14', '16', 'lower_bound']]}, 'NCT02952365'), ({'text': 'Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective', 'entities': [['43', '54', 'cancer'], ['63', '73', 'cancer']]}, 'NCT02250157'), ({'text': 'Patients who have had radiotherapy within 14 days before registration', 'entities': [['23', '35', 'treatment'], ['43', '57', 'upper_bound']]}, 'NCT02481310'), ({'text': 'Physician determined the patient is healthy enough for chemotherapy and radiation therapy', 'entities': [['56', '68', 'treatment'], ['73', '90', 'treatment']]}, 'NCT02905591'), ({'text': 'Patients with Inflammatory Bowel Disease with a confirmed diagnosis of Hepatosplenic T-cell Lymphoma', 'entities': [['15', '41', 'chronic_disease'], ['72', '101', 'cancer']]}, 'NCT01804166'), ({'text': 'willingness to undergo fluoroscopy-guided SGB', 'entities': [['24', '35', 'treatment']]}, 'NCT02907983'), ({'text': 'Anticipated need for specific prescription medications', 'entities': [['44', '55', 'treatment']]}, 'NCT02159027'), ({'text': 'Male or female patients, 55 years of age', 'entities': [['1', '24', 'gender'], ['38', '41', 'age']]}, 'NCT02556606'), ({'text': 'to be undergoing surveillance or clinically indicated bronchoscopies with transbronchial biopsy as part of their routine care', 'entities': [['55', '96', 'treatment']]}, 'NCT02395393'), ({'text': 'Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab', 'entities': [['1', '33', 'clinical_variable'], ['45', '54', 'upper_bound']]}, 'NCT02488967'), ({'text': 'safety labs within 30 days of SGB intervention', 'entities': [['20', '27', 'upper_bound'], ['31', '34', 'treatment']]}, 'NCT02907983'), ({'text': 'No proximal large vessel atherosclerosis', 'entities': [['26', '41', 'chronic_disease']]}, 'NCT02169739'), ({'text': 'Singleton pregnancy', 'entities': [['11', '20', 'pregnancy']]}, 'NCT02469519'), ({'text': 'Cardiac disease', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02734888'), ({'text': 'Eating disorders, serious food allergies, consuming special diets, aversion to common foods', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02561754'), ({'text': 'Patient is not actively breastfeeding (or has agreed to discontinue breastfeeding before the initiation of protocol therapy)', 'entities': [['117', '124', 'treatment']]}, 'NCT02466971'), ({'text': 'surgical sterilization (such as a tubal ligation or hysterectomy)', 'entities': [['1', '23', 'treatment'], ['35', '49', 'treatment'], ['53', '65', 'treatment']]}, 'NCT02482376'), ({'text': 'Current use of antibiotics or antivirals', 'entities': [['16', '27', 'treatment'], ['31', '41', 'treatment']]}, 'NCT00186927'), ({'text': 'Men are not eligible for this study', 'entities': [['1', '4', 'gender']]}, 'NCT01245712'), ({'text': 'Infection with human immunodeficiency virus (HIV) and/or chronic/active infection with hepatitis B virus or hepatitis C virus', 'entities': [['16', '50', 'chronic_disease'], ['58', '82', 'chronic_disease'], ['88', '105', 'chronic_disease'], ['109', '126', 'chronic_disease']]}, 'NCT02760498'), ({'text': 'research participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections', 'entities': [['53', '69', 'chronic_disease'], ['71', '94', 'treatment'], ['123', '133', 'chronic_disease']]}, 'NCT02146924'), ({'text': 'All patients must have undergone complete hysterectomy and bilateral salpingo-oophorectomy at the time of original therapy for their uterine carcinoma', 'entities': [['34', '55', 'treatment'], ['60', '91', 'treatment'], ['116', '123', 'treatment'], ['134', '151', 'cancer']]}, 'NCT00492778'), ({'text': 'ability to walk on a treadmill for more than 20 minutes with partial body weight support as needed and short sitting/standing breaks', 'entities': [['46', '56', 'lower_bound'], ['70', '81', 'clinical_variable']]}, 'NCT02991248'), ({'text': 'The subject has not recovered to baseline or CTCAE d Grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant AEs', 'entities': [['46', '51', 'clinical_variable'], ['54', '61', 'upper_bound'], ['87', '102', 'treatment'], ['110', '118', 'chronic_disease'], ['156', '159', 'chronic_disease']]}, 'NCT01639508'), ({'text': 'Patients unable to speak English', 'entities': [['10', '33', 'language_fluency']]}, 'NCT03035799'), ({'text': 'At least 2 weeks from prior MF-directed treatment (till the start of study drug)', 'entities': [['10', '17', 'lower_bound'], ['23', '50', 'treatment'], ['70', '80', 'treatment']]}, 'NCT02098161'), ({'text': 'Patients who are not surgical candidates', 'entities': [['22', '30', 'treatment']]}, 'NCT01494324'), ({'text': 'Patients with inflammatory bowel disease', 'entities': [['15', '41', 'chronic_disease']]}, 'NCT02763033'), ({'text': 'traumatic segmental bone defect that warrants surgical reconstruction', 'entities': [['1', '32', 'chronic_disease'], ['47', '70', 'treatment']]}, 'NCT02015390'), ({'text': 'patients with sarcoma', 'entities': [['15', '22', 'cancer']]}, 'NCT02421380'), ({'text': 'First-degree family members with OCD or tic disorders', 'entities': [['34', '37', 'chronic_disease'], ['41', '54', 'chronic_disease']]}, 'NCT02437773'), ({'text': 'Age > or equal to 18 years old and < 80 years of age during the course of therapy', 'entities': [['1', '4', 'age'], ['19', '27', 'lower_bound'], ['38', '46', 'upper_bound'], ['50', '53', 'age']]}, 'NCT01750567'), ({'text': 'Evidence of progressive breast cancer within the last 30 days', 'entities': [['25', '38', 'cancer'], ['50', '62', 'upper_bound']]}, 'NCT02427581'), ({'text': 'Subjects who are receiving any other investigational agents', 'entities': [['32', '60', 'treatment']]}, 'NCT02427841'), ({'text': 'Nonverbal Intelligence Quotient (IQ) of 85 or higher on the Reynolds Intellectual Assessment Scale', 'entities': [['1', '37', 'clinical_variable'], ['41', '43', 'lower_bound']]}, 'NCT01829360'), ({'text': 'Patient has an IPSS score greater than or equal to 13', 'entities': [['16', '26', 'clinical_variable'], ['52', '54', 'lower_bound']]}, 'NCT02167009'), ({'text': 'Hemoglobin S <45%', 'entities': [['1', '13', 'clinical_variable'], ['15', '18', 'upper_bound']]}, 'NCT00920972'), ({'text': 'Patients must have normal pulmonary function testing for age based on pulse oximetry', 'entities': [['58', '61', 'age'], ['71', '85', 'treatment']]}, 'NCT01734512'), ({'text': 'Total bilirubin =< 1.5 x upper limit of normal (ULN) or direct bilirubin =< ULN', 'entities': [['1', '16', 'clinical_variable'], ['20', '53', 'upper_bound'], ['57', '73', 'clinical_variable']]}, 'NCT01737502'), ({'text': 'Patients of both genders must practice birth control for four months after receiving the preparative regimen. (Turnstile II - Chemotherapy/Cell Infusion- Inclusion Criteria)', 'entities': [['31', '53', 'contraception_consent'], ['58', '75', 'upper_bound'], ['127', '139', 'treatment'], ['140', '153', 'treatment']]}, 'NCT00338377'), ({'text': 'Self-identify as Latino or African American/Black', 'entities': [['18', '24', 'ethnicity'], ['28', '50', 'ethnicity']]}, 'NCT01643473'), ({'text': 'Life expectancy > 3 months', 'entities': [['1', '16', 'clinical_variable'], ['19', '27', 'lower_bound']]}, 'NCT02317991'), ({'text': '1 of the procedures is performed during the 6 weeks before study start (C1D1)', 'entities': [['45', '59', 'upper_bound']]}, 'NCT02561988'), ({'text': 'For obinutuzumab in combination with polatuzumab vedotin and lenalidomide (G + Pola + Len) treatment group: R/R FL after treatment with at least one prior chemoimmunotherapy regimen that included an anti-CD20 monoclonal antibody and for which no other more appropriate treatment option exists as determined by the investigator', 'entities': [['5', '17', 'treatment'], ['38', '57', 'treatment'], ['62', '101', 'treatment'], ['156', '174', 'treatment']]}, 'NCT02600897'), ({'text': 'Hostile mediastinum', 'entities': [['1', '20', 'treatment']]}, 'NCT02088554'), ({'text': 'individuals who are able to exercise (i.e. without orthopedic limitations or neuromuscular disorders)', 'entities': [['78', '101', 'chronic_disease']]}, 'NCT02435667'), ({'text': 'Participants with a known history of glucose-6-phosphate dehydrogenase deficiency', 'entities': [['38', '82', 'chronic_disease']]}, 'NCT02382549'), ({'text': 'scheduled for elective cardiac surgery (CABG, valve, or CABG/valve), including both first time and repeat procedures', 'entities': [['15', '39', 'treatment'], ['41', '45', 'treatment'], ['47', '52', 'treatment'], ['57', '67', 'treatment']]}, 'NCT02189889'), ({'text': 'Have e2 days/week of heavy drinking (>4 drinks/day)', 'entities': [['7', '18', 'lower_bound'], ['39', '51', 'lower_bound']]}, 'NCT02445339'), ({'text': 'Are currently receiving other medications or radiation intended for the treatment of their malignancy', 'entities': [['73', '82', 'treatment'], ['92', '102', 'cancer']]}, 'NCT02730481'), ({'text': 'Females must not be pregnant or lactating', 'entities': [['1', '8', 'gender'], ['9', '29', 'pregnancy']]}, 'NCT02424968'), ({'text': 'Subjects must have had at least 1 platinum based chemotherapy regimen for the treatment of metastatic or locally advanced unresectable disease', 'entities': [['33', '34', 'lower_bound'], ['35', '70', 'treatment'], ['79', '88', 'treatment'], ['92', '143', 'cancer']]}, 'NCT02553642'), ({'text': 'Subjects with any other serious disease that would require immunosuppressive or parenteral anti-microbial therapy outside the study protocol', 'entities': [['60', '77', 'treatment'], ['81', '114', 'treatment']]}, 'NCT02429934'), ({'text': 'spontaneous intestinal perforation', 'entities': [['1', '35', 'chronic_disease']]}, 'NCT02579265'), ({'text': 'Participation in a clinical trial within the last 3 months prior to screening for this trial', 'entities': [['46', '59', 'upper_bound']]}, 'NCT03038620'), ({'text': 'Life expectancy is not severely limited by concomitant illness', 'entities': [['1', '16', 'clinical_variable']]}, 'NCT02333162'), ({'text': '18 years of age or older', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT02796391'), ({'text': 'Serum biochemical values with the following limits unless considered due to leukemia', 'entities': [['77', '85', 'cancer']]}, 'NCT02257138'), ({'text': 'Weight e15 kg', 'entities': [['1', '7', 'clinical_variable'], ['9', '14', 'lower_bound']]}, 'NCT03153319'), ({'text': 'For the time frame of the past 7 days, C-SSRS score e 3', 'entities': [['27', '38', 'upper_bound'], ['40', '52', 'clinical_variable'], ['55', '56', 'lower_bound']]}, 'NCT02418195'), ({'text': 'may be permitted to enter the study with historical evidence of reversibility that was performed according to ATS/ERS guidelines within 2 years prior to Visit 1', 'entities': [['137', '150', 'upper_bound']]}, 'NCT02554786'), ({'text': 'AST (SGOT) and ALT (SGPT) > 3 X ULN (unless attributed to disease involvement)', 'entities': [['1', '11', 'clinical_variable'], ['16', '26', 'clinical_variable'], ['29', '36', 'lower_bound']]}, 'NCT02932280'), ({'text': 'received investigational therapy within a period of 5 half-lives of the investigational therapy in question prior to the day of dosing with the PEGylated AuroShell particles', 'entities': [['10', '33', 'treatment'], ['53', '65', 'upper_bound']]}, 'NCT02680535'), ({'text': 'current suicidal or homicidal ideation requiring hospitalization', 'entities': [['9', '17', 'chronic_disease'], ['21', '39', 'chronic_disease']]}, 'NCT02377089'), ({'text': "Patients with refractory B-cell or T-cell non-Hodgkin's lymphoma or Hodgkin's lymphoma who are eligible for allogeneic transplantation", 'entities': [['15', '32', 'chronic_disease'], ['36', '65', 'cancer'], ['47', '65', 'cancer'], ['109', '135', 'treatment']]}, 'NCT01701986'), ({'text': 'If the standard biopsy cores are positive, they must be from the same location in the prostate as MR lesion was biopsied and proven to be cancerous', 'entities': [['8', '23', 'treatment']]}, 'NCT02680535'), ({'text': 'A well-established genetic syndrome, such as Fragile X', 'entities': [['20', '36', 'chronic_disease'], ['46', '55', 'chronic_disease']]}, 'NCT03131635'), ({'text': 'Use of an investigational drug or device', 'entities': [['11', '41', 'treatment']]}, 'NCT02366611'), ({'text': 'Age at least 18', 'entities': [['1', '4', 'age'], ['14', '16', 'lower_bound']]}, 'NCT01059786'), ({'text': 'Use of hypno-sedative drugs for sleep or stimulants', 'entities': [['8', '28', 'treatment']]}, 'NCT01742182'), ({'text': 'failing to take the study medication daily for 10 or more days in the two-week period (i.e. one pill per day for > 10 days out of the 14 day run-in period)', 'entities': [['48', '50', 'lower_bound'], ['116', '123', 'lower_bound']]}, 'NCT02593110'), ({'text': 'Patients with active infection', 'entities': [['15', '31', 'chronic_disease']]}, 'NCT02031250'), ({'text': 'Normal creatinine for age', 'entities': [['23', '26', 'age']]}, 'NCT01864109'), ({'text': 'Tumor thrombus must be e level II', 'entities': [['1', '15', 'cancer'], ['26', '34', 'lower_bound']]}, 'NCT02473536'), ({'text': 'Toxicity from previous anti-cancer therapy that has not recovered to <=Grade 1 prior to enrollment (except for non-clinically significant toxicities, e.g., alopecia, vitiligo). Subjects with existing pneumonitis as a result of radiation are not excluded; however, subjects cannot be oxygen dependent', 'entities': [['15', '43', 'treatment'], ['72', '79', 'upper_bound'], ['157', '165', 'chronic_disease'], ['167', '175', 'chronic_disease'], ['201', '212', 'chronic_disease'], ['228', '237', 'treatment']]}, 'NCT02588612'), ({'text': "Diagnosed with Raynaud's syndrome", 'entities': [['16', '34', 'chronic_disease']]}, 'NCT01681264'), ({'text': 'History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within the past 12 months', 'entities': [['12', '33', 'chronic_disease'], ['35', '41', 'chronic_disease'], ['43', '65', 'chronic_disease'], ['70', '104', 'chronic_disease'], ['116', '130', 'upper_bound']]}, 'NCT02834403'), ({'text': 'The patient with a previous history of non-breast malignancy is eligible for this study only if the patient meets the following criteria for a cancer survivor', 'entities': [['51', '61', 'cancer'], ['144', '150', 'cancer']]}, 'NCT02427581'), ({'text': 'Topical treatments (except topical chemotherapy) and steroids are not considered as prior therapies', 'entities': [['1', '19', 'treatment'], ['28', '48', 'treatment'], ['54', '62', 'treatment'], ['85', '100', 'treatment']]}, 'NCT01871727'), ({'text': 'Prior monoclonal antibody within 4 weeks prior to study', 'entities': [['1', '26', 'treatment'], ['34', '47', 'upper_bound']]}, 'NCT02324582'), ({'text': 'breast cancer are not exclusionary', 'entities': [['1', '14', 'cancer']]}, 'NCT01591356'), ({'text': 'Known active infections', 'entities': [['7', '24', 'chronic_disease']]}, 'NCT02568267'), ({'text': 'immunosuppressive therapy', 'entities': [['1', '26', 'treatment']]}, 'NCT02266745'), ({'text': 'Presence or history of Diabetes Mellitus type I or II', 'entities': [['24', '54', 'chronic_disease']]}, 'NCT02252081'), ({'text': '18-60 years of age', 'entities': [['1', '3', 'lower_bound'], ['4', '12', 'upper_bound'], ['16', '19', 'age']]}, 'NCT02401074'), ({'text': 'Chemotherapy', 'entities': [['1', '13', 'treatment']]}, 'NCT02418195'), ({'text': 'Agree not to take any Pro-re-nata (PRN) medications on the mornings of drug sessions', 'entities': [['23', '52', 'treatment']]}, 'NCT02243813'), ({'text': 'Invasive cancer in the contralateral breast', 'entities': [['1', '44', 'cancer']]}, 'NCT02427581'), ({'text': 'females of childbearing potential must have a negative urine pregnancy test <7 days prior to registration', 'entities': [['1', '8', 'gender'], ['47', '71', 'pregnancy'], ['78', '90', 'upper_bound']]}, 'NCT03137121'), ({'text': 'Antidepressants: nefazodone', 'entities': [['1', '16', 'treatment'], ['18', '28', 'treatment']]}, 'NCT01989585'), ({'text': 'metoprolol', 'entities': [['1', '11', 'treatment']]}, 'NCT02971202'), ({'text': 'Non-melanoma skin cancer', 'entities': [['1', '25', 'cancer']]}, 'NCT01737502'), ({'text': 'Patients are at least 18 years of age, and under 75 years of age', 'entities': [['23', '31', 'lower_bound'], ['35', '38', 'age'], ['50', '58', 'upper_bound']]}, 'NCT02349958'), ({'text': 'Undiagnosed abnormal uterine bleeding', 'entities': [['13', '38', 'chronic_disease']]}, 'NCT03070899'), ({'text': 'Hepatitis C by history', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT02072148'), ({'text': 'Have any reported baseline lab values with a grade 3 or 4 toxicity as defined by the CTCAE Version 3.0', 'entities': [['46', '53', 'lower_bound'], ['57', '58', 'upper_bound'], ['86', '103', 'clinical_variable']]}, 'NCT02041936'), ({'text': 'Subject has physical ailments (other than COPD, PAH, HF, or hypertension) that would prevent them from study participation in the judgment of the investigator', 'entities': [['43', '47', 'chronic_disease'], ['49', '52', 'chronic_disease'], ['54', '56', 'chronic_disease'], ['61', '73', 'chronic_disease']]}, 'NCT02966665'), ({'text': 'Poor hematologic, renal, or hepatic function', 'entities': [['6', '17', 'chronic_disease'], ['19', '24', 'chronic_disease'], ['29', '45', 'chronic_disease']]}, 'NCT02600897'), ({'text': 'Surgical procedure: Tonsillectomy with monopolar cautery, hemostasis with monopolar cautery and/or suction cautery', 'entities': [['1', '19', 'treatment'], ['21', '57', 'treatment'], ['59', '115', 'treatment']]}, 'NCT02358850'), ({'text': 'variceal bleeding in the previous 1 month', 'entities': [['1', '18', 'chronic_disease'], ['26', '42', 'upper_bound']]}, 'NCT03106220'), ({'text': "Daily use of PPI's (Proton Pump Inhibitor) or H2 Blockers for GERD (it is permitted to take on an occasional basis- no more than 1x per week", 'entities': [['14', '43', 'treatment'], ['47', '58', 'treatment'], ['63', '67', 'chronic_disease'], ['130', '132', 'upper_bound']]}, 'NCT02433977'), ({'text': 'Must be diagnosed with treatment requiring PMF or post ET/PV MF with intermediate-1, intermediate -2 or high risk disease according to the International Working Group (IWG) prognostic scoring system, or if with low risk disease then with symptomatic splenomegaly that is >= 5 cm below left costal margin by physical exam', 'entities': [['24', '33', 'treatment'], ['44', '47', 'chronic_disease'], ['239', '263', 'clinical_variable'], ['275', '285', 'lower_bound']]}, 'NCT02098161'), ({'text': 'Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricle (LV) function', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02488967'), ({'text': 'Total abstinence from sexual intercourse (minimum one complete menstrual cycle prior to study drug administration)', 'entities': [['51', '54', 'lower_bound'], ['80', '99', 'treatment']]}, 'NCT02496663'), ({'text': 'BK nephropathy at 3 months post-transplant screening biopsy', 'entities': [['1', '15', 'chronic_disease'], ['19', '27', 'upper_bound'], ['28', '60', 'treatment']]}, 'NCT02213068'), ({'text': 'MagT1 mutation and active need to take anti-platelet agents and/or therapeutic anti-coagulation that cannot be interrupted during aplasia', 'entities': [['40', '60', 'treatment'], ['68', '96', 'treatment'], ['131', '138', 'chronic_disease']]}, 'NCT02579967'), ({'text': 'English speaking', 'entities': [['1', '17', 'language_fluency']]}, 'NCT03004170'), ({'text': 'Renal insufficiency', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT01184547'), ({'text': 'Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant', 'entities': [['28', '40', 'treatment'], ['42', '52', 'treatment'], ['80', '105', 'chronic_disease'], ['106', '133', 'treatment']]}, 'NCT02354547'), ({'text': 'Subject has had parenteral iron less than one month before screening visit', 'entities': [['17', '32', 'treatment'], ['43', '52', 'upper_bound']]}, 'NCT02404012'), ({'text': 'current pregnancy', 'entities': [['9', '18', 'pregnancy']]}, 'NCT02824276'), ({'text': 'who agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of study drug', 'entities': [['5', '59', 'contraception_consent'], ['81', '88', 'treatment'], ['97', '110', 'upper_bound'], ['128', '138', 'treatment']]}, 'NCT02553941'), ({'text': 'Diagnosis of progressive or additional neurologic disease', 'entities': [['14', '58', 'chronic_disease']]}, 'NCT01821690'), ({'text': 'active or suspected neoplasia', 'entities': [['21', '30', 'cancer']]}, 'NCT01525901'), ({'text': 'No co-existing medical condition which, in the opinion of the study team, could affect the immunomodulatory protocol, surgical procedure, or functional results (see Donor and Recipient Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of upper extremity transplantation.)', 'entities': [['119', '137', 'treatment'], ['244', '253', 'treatment'], ['356', '387', 'treatment']]}, 'NCT01459107'), ({'text': 'hemoglobin must be greater than or equal to 9 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['45', '51', 'lower_bound']]}, 'NCT02236000'), ({'text': 'Women of childbearing age who have the possibility of being pregnant must have a negative pregnancy test prior to participation', 'entities': [['1', '6', 'gender'], ['23', '26', 'age'], ['40', '69', 'pregnancy'], ['82', '100', 'pregnancy']]}, 'NCT02340650'), ({'text': 'Patients must be on standard of care PAH medications, allowing Endothelin Receptor Antagonists (ERA) and/or Prostacyclin Analogues (PCA), for at least 12 weeks prior to baseline visit', 'entities': [['38', '53', 'treatment'], ['64', '101', 'treatment'], ['109', '137', 'treatment'], ['152', '166', 'lower_bound']]}, 'NCT02562235'), ({'text': 'Severe concomitant illness limiting life expectancy (< 1 year)', 'entities': [['1', '27', 'chronic_disease'], ['37', '52', 'clinical_variable'], ['56', '62', 'upper_bound']]}, 'NCT02688647'), ({'text': 'Excess current alcohol use (more than 2 instances of intake of 5+ drinks (men) when or 4+ drinks (women) when drinking in the past two months, and/or on average drinking > 2 drinks per day (men)', 'entities': [['39', '40', 'lower_bound'], ['75', '78', 'gender'], ['99', '104', 'gender'], ['127', '142', 'upper_bound']]}, 'NCT02374918'), ({'text': 'Cognitive impairment or aphasia with inability to follow instructions', 'entities': [['1', '21', 'chronic_disease'], ['25', '32', 'chronic_disease']]}, 'NCT02369770'), ({'text': 'Be scheduled to undergo a standard-of-care resection of tumor tissue as part of treatment plan prior to beginning study therapy', 'entities': [['27', '53', 'treatment'], ['57', '69', 'cancer'], ['81', '90', 'treatment'], ['121', '128', 'treatment']]}, 'NCT02350764'), ({'text': 'Calculated Glomerular filtration rate (GFR) less than 50 mL/min/1.73m^2 at the time of enrollment', 'entities': [['1', '44', 'clinical_variable'], ['55', '72', 'upper_bound']]}, 'NCT02474199'), ({'text': 'C.difficile colitis or active diarrhea', 'entities': [['1', '20', 'chronic_disease'], ['31', '39', 'chronic_disease']]}, 'NCT02130388'), ({'text': 'Total Bilirubin < 1.5 X ULN', 'entities': [['7', '16', 'clinical_variable'], ['19', '28', 'upper_bound']]}, 'NCT02031250'), ({'text': 'Non-pregnant', 'entities': [['5', '13', 'pregnancy']]}, 'NCT02468024'), ({'text': 'Patients who do not undergo chemotherapy', 'entities': [['29', '41', 'treatment']]}, 'NCT02603757'), ({'text': 'Serum creatinine d 1.5 x ULN', 'entities': [['1', '17', 'clinical_variable'], ['20', '29', 'upper_bound']]}, 'NCT02132598'), ({'text': 'Pregnancy: positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization', 'entities': [['1', '10', 'pregnancy'], ['12', '30', 'pregnancy'], ['41', '46', 'gender'], ['111', '120', 'upper_bound'], ['136', '158', 'treatment']]}, 'NCT01823198'), ({'text': 'Left ventricular ejection fraction (LVEF) by either multigated acquisition (MUGA) or echocardiography (ECHO) less than lower limit of normal', 'entities': [['1', '42', 'clinical_variable'], ['53', '82', 'clinical_variable'], ['86', '109', 'clinical_variable']]}, 'NCT02503722'), ({'text': "Total bilirubin d 1.5 x institution's ULN", 'entities': [['1', '16', 'clinical_variable'], ['19', '42', 'upper_bound']]}, 'NCT02507232'), ({'text': 'Any history or evidence of opportunistic infection within 6 months of screening including tuberculosis, severe cytomegalovirus (CMV) or herpetic infections (such as disseminated herpes, herpes encephalitis, ophthalmic herpes)', 'entities': [['59', '67', 'upper_bound'], ['91', '103', 'chronic_disease'], ['112', '133', 'chronic_disease'], ['137', '156', 'chronic_disease'], ['166', '185', 'chronic_disease'], ['187', '206', 'chronic_disease'], ['208', '225', 'chronic_disease']]}, 'NCT02520791'), ({'text': 'Significant cardiovascular impairment', 'entities': [['13', '38', 'chronic_disease']]}, 'NCT01554371'), ({'text': 'Evidence of an acute myocardial infarction (defined as: ST Segment Elevation as evidenced on 12 Lead ECG) within 30 days prior to index procedure', 'entities': [['22', '43', 'chronic_disease'], ['114', '127', 'upper_bound']]}, 'NCT02000115'), ({'text': 'known allergy to lidocaine', 'entities': [['18', '27', 'allergy_name']]}, 'NCT02485639'), ({'text': 'planned administration during the study period Blood donation for human use (eg, American Red Cross or other similar blood drives) within the 56 days preceding study entry', 'entities': [['143', '150', 'upper_bound']]}, 'NCT02776761'), ({'text': 'pneumonia', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT01568177'), ({'text': 'Breast cancer non-candidate for hormone therapy alone', 'entities': [['1', '14', 'cancer'], ['33', '48', 'treatment']]}, 'NCT02533674'), ({'text': 'Patients must have histologically or cytologically confirmed cervical squamous cell carcinoma that is locally advanced or metastatic with no available therapy options that are known to provide clinical benefit per institutional standard of care', 'entities': [['62', '94', 'cancer'], ['123', '133', 'cancer'], ['152', '159', 'treatment']]}, 'NCT02587962'), ({'text': 'lactating female', 'entities': [['11', '17', 'gender']]}, 'NCT02574650'), ({'text': 'Age </= 65 years', 'entities': [['1', '4', 'age'], ['9', '17', 'upper_bound']]}, 'NCT02115295'), ({'text': 'History of serious neurologic disease', 'entities': [['20', '38', 'chronic_disease']]}, 'NCT02796209'), ({'text': 'within 14 days prior to the first dose of pazopanib', 'entities': [['8', '21', 'upper_bound'], ['43', '52', 'treatment']]}, 'NCT01532687'), ({'text': 'Subjects with (a history of) metabolic or gastrointestinal diseases including hepatic disorders', 'entities': [['30', '39', 'chronic_disease'], ['43', '68', 'chronic_disease'], ['79', '96', 'treatment']]}, 'NCT02366481'), ({'text': 'Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['47', '82', 'contraception_consent'], ['84', '92', 'contraception_consent'], ['96', '127', 'contraception_consent'], ['129', '139', 'contraception_consent'], ['212', '219', 'upper_bound'], ['244', '251', 'treatment']]}, 'NCT02473536'), ({'text': 'Pregnant at the time of evaluation', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01524536'), ({'text': 'Hemodynamic instability', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02973139'), ({'text': 'Willing to use effective contraception for at least 28-days post study drug administration', 'entities': [['1', '39', 'contraception_consent'], ['53', '60', 'lower_bound']]}, 'NCT02540330'), ({'text': 'Absolute neutrophil count >1,000 cells/mm3 (1.0 x 10^9/L)', 'entities': [['1', '26', 'clinical_variable'], ['28', '58', 'lower_bound']]}, 'NCT02309580'), ({'text': 'Osteoporosis or recent fracture of the hip or spinal joints', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT03101956'), ({'text': 'distinct lesion on the ADC map (Value <1000)', 'entities': [['24', '27', 'clinical_variable'], ['33', '38', 'clinical_variable'], ['40', '44', 'upper_bound']]}, 'NCT02307058'), ({'text': 'Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time', 'entities': [['15', '44', 'chronic_disease']]}, 'NCT01811368'), ({'text': 'Small bowel obstruction', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02770326'), ({'text': 'Severe uncontrolled cardiac disease within 6 months of screening, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA)', 'entities': [['21', '36', 'chronic_disease'], ['44', '52', 'upper_bound'], ['109', '121', 'chronic_disease'], ['123', '138', 'chronic_disease'], ['140', '166', 'chronic_disease'], ['170', '200', 'chronic_disease']]}, 'NCT03084640'), ({'text': 'infraspinatus', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT03032432'), ({'text': 'Must be e18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02013154'), ({'text': 'Congestive heart failure', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02700451'), ({'text': 'Patient suffers from paralysis or dysfunctional neuropathy at the elbow joint', 'entities': [['22', '31', 'chronic_disease'], ['35', '78', 'chronic_disease']]}, 'NCT02469662'), ({'text': 'Patients who do not have measurable disease on MRI', 'entities': [['48', '51', 'treatment']]}, 'NCT01734512'), ({'text': 'Ewing-like sarcoma', 'entities': [['1', '19', 'cancer']]}, 'NCT02520713'), ({'text': 'Pregnant women and women who are lactating', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT02192359'), ({'text': 'serum albumin greater than or equal to 2 g/dL', 'entities': [['1', '14', 'clinical_variable'], ['40', '46', 'lower_bound']]}, 'NCT02579044'), ({'text': 'Bilirubin =< 1.5 x normal', 'entities': [['1', '10', 'clinical_variable'], ['14', '26', 'upper_bound']]}, 'NCT01101451'), ({'text': 'Patients with significant co-morbid medical conditions that would prevent the patient from completing treatment on this protocol, per Investigator discretion', 'entities': [['27', '55', 'chronic_disease'], ['103', '112', 'treatment']]}, 'NCT02349958'), ({'text': 'Leukocytosis (> 13,000) with absolute monocytosis (> 1,000)', 'entities': [['1', '13', 'clinical_variable'], ['17', '23', 'lower_bound'], ['30', '50', 'clinical_variable'], ['54', '59', 'lower_bound']]}, 'NCT00167219'), ({'text': 'Rejection episode requiring the use of therapeutic plasma exchange immediately subsequent to rATG administration', 'entities': [['40', '67', 'treatment']]}, 'NCT02102854'), ({'text': 'Patients with complete fertilization failure with standard IVF or failure with one prior ICSI treatment cycle', 'entities': [['90', '104', 'treatment']]}, 'NCT01944332'), ({'text': 'female subjects', 'entities': [['1', '16', 'gender']]}, 'NCT02362308'), ({'text': 'Uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)', 'entities': [['14', '35', 'chronic_disease'], ['71', '90', 'treatment'], ['98', '110', 'chronic_disease'], ['112', '123', 'chronic_disease'], ['125', '139', 'chronic_disease']]}, 'NCT02101034'), ({'text': 'Provides an afternoon exhaled carbon monoxide reading of at least 10 ppm', 'entities': [['23', '54', 'clinical_variable'], ['67', '73', 'lower_bound']]}, 'NCT02266784'), ({'text': 'Subject who has alcohol or drug abuse within 12 months of screening', 'entities': [['46', '55', 'upper_bound']]}, 'NCT02656550'), ({'text': 'Exclusion criteria for individuals with SCI and Healthy Controls', 'entities': [['41', '44', 'chronic_disease']]}, 'NCT02446210'), ({'text': 'History of hypersensitivity reactions to other EGFR inhibitors', 'entities': [['48', '63', 'allergy_name']]}, 'NCT02438995'), ({'text': 'There is no evidence of the second malignancy at the time of study entry', 'entities': [['36', '46', 'cancer']]}, 'NCT02047474'), ({'text': 'History of clinically significant allergic reactions attributed to compounds of similar chemical or biologic composition to AT13387 or paclitaxel', 'entities': [['125', '132', 'allergy_name'], ['136', '146', 'allergy_name']]}, 'NCT02474173'), ({'text': 'Previous mediastinal or esophageal surgery', 'entities': [['1', '43', 'treatment']]}, 'NCT01399476'), ({'text': 'Recent (within 4 weeks of screening) or concomitant long term treatment with systemic steroids, immunosuppressive/immunomodulating drugs (e.g. cyclosporine, corticosteroids)', 'entities': [['63', '72', 'treatment'], ['78', '95', 'treatment'], ['97', '137', 'treatment'], ['144', '156', 'treatment'], ['158', '173', 'treatment']]}, 'NCT02382419'), ({'text': 'Absolute neutrophil count >= 1.5 (SqrRoot) 10^9/L', 'entities': [['1', '26', 'clinical_variable'], ['30', '50', 'lower_bound']]}, 'NCT02390752'), ({'text': 'History or evidence of cardiovascular risk', 'entities': [['24', '38', 'chronic_disease']]}, 'NCT02215096'), ({'text': 'Be between the ages of 3 and 6 and enrolled in a participating ASD preschool classroom', 'entities': [['16', '20', 'age'], ['24', '25', 'lower_bound'], ['30', '31', 'upper_bound'], ['64', '67', 'chronic_disease']]}, 'NCT01591707'), ({'text': 'For women of child-bearing potential, a negative serum pregnancy test is required within 72 hours prior to receiving study drug each cycle', 'entities': [['5', '10', 'gender'], ['41', '65', 'pregnancy'], ['90', '104', 'upper_bound'], ['118', '128', 'treatment']]}, 'NCT01553071'), ({'text': 'clinically stable type 2 diabetes', 'entities': [['19', '34', 'chronic_disease']]}, 'NCT02502253'), ({'text': 'Life expectancy of at least 2 months', 'entities': [['1', '16', 'clinical_variable'], ['29', '37', 'lower_bound']]}, 'NCT02267863'), ({'text': 'Congenital or acquired long QT syndrome', 'entities': [['24', '40', 'chronic_disease']]}, 'NCT02582827'), ({'text': 'No femoral pulses, very difficult endovascular access or extreme tortuosity of great vessels that is predicted to result in an inability to deliver timely endovascular therapy', 'entities': [['156', '176', 'treatment']]}, 'NCT02930018'), ({'text': 'Symptoms thought more likely to be caused by a non-UTI diagnosis (e.g., urinary calculus, sexually transmitted infection, etc.)', 'entities': [['52', '55', 'chronic_disease'], ['73', '89', 'chronic_disease'], ['91', '121', 'chronic_disease']]}, 'NCT01994538'), ({'text': 'if they have received prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician', 'entities': [['23', '48', 'treatment'], ['86', '95', 'treatment']]}, 'NCT02466971'), ({'text': 'Polycythemia (hematocrit > 65.0%)', 'entities': [['1', '13', 'clinical_variable'], ['15', '25', 'clinical_variable'], ['28', '33', 'lower_bound']]}, 'NCT02811263'), ({'text': 'limited English proficiency', 'entities': [['1', '28', 'language_fluency']]}, 'NCT03034863'), ({'text': 'Previously or currently treated with metreleptin under NIH study 02-DK-0022 and/or NIH study 13-DK-0057', 'entities': [['38', '49', 'treatment']]}, 'NCT02262806'), ({'text': 'Non-english speaking women', 'entities': [['1', '21', 'language_fluency'], ['22', '27', 'gender']]}, 'NCT03171480'), ({'text': 'Have evidence of uncontrolled disseminated intravascular coagulation', 'entities': [['31', '69', 'chronic_disease']]}, 'NCT02520011'), ({'text': 'wound less than 1cm in length and the bone not visualized through the skin', 'entities': [['17', '20', 'upper_bound']]}, 'NCT00870064'), ({'text': 'age < 21 years', 'entities': [['1', '4', 'age'], ['7', '15', 'upper_bound']]}, 'NCT02939755'), ({'text': '<21 years of age', 'entities': [['2', '10', 'upper_bound'], ['14', '17', 'age']]}, 'NCT02707471'), ({'text': 'Pregnant women or women who are breast-feeding', 'entities': [['1', '9', 'pregnancy'], ['10', '24', 'gender']]}, 'NCT01920737'), ({'text': 'Renal insufficiency (creatinine > 3.0 mg/dL) and/or end stage renal disease requiring chronic dialysis', 'entities': [['1', '20', 'chronic_disease'], ['22', '32', 'clinical_variable'], ['35', '44', 'lower_bound'], ['53', '76', 'chronic_disease'], ['95', '103', 'treatment']]}, 'NCT02000115'), ({'text': 'Platelet count >= 100,000/mm^3', 'entities': [['1', '15', 'clinical_variable'], ['19', '31', 'lower_bound']]}, 'NCT02524275'), ({'text': 'Age < 60 and amenorrhea > 12 consecutive months without another cause and documented follicle stimulating hormone (FSH) level of > 35 mIU/mL', 'entities': [['1', '4', 'age'], ['7', '9', 'upper_bound'], ['14', '24', 'clinical_variable'], ['27', '29', 'lower_bound'], ['86', '126', 'clinical_variable'], ['132', '141', 'lower_bound']]}, 'NCT02860000'), ({'text': 'Subjects with recurrent disease or histologically or cytologically confirmed Stage III/IV diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma who have previously progressed while receiving or within 6 months of completing a platinum-containing regimen', 'entities': [['104', '129', 'cancer'], ['131', '152', 'cancer'], ['157', '185', 'cancer'], ['243', '251', 'upper_bound'], ['268', '295', 'treatment']]}, 'NCT02091999'), ({'text': 'Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment', 'entities': [['20', '36', 'chronic_disease'], ['53', '77', 'treatment'], ['99', '124', 'treatment'], ['132', '144', 'upper_bound'], ['152', '181', 'treatment']]}, 'NCT02437370'), ({'text': 'scheduled by conventional criteria (symptomatic impairment of cardiac function with broadened QRS) for clinical CRT procedures at NYULMC', 'entities': [['37', '79', 'chronic_disease']]}, 'NCT02728336'), ({'text': 'ASA d 325 mg per day', 'entities': [['1', '4', 'clinical_variable'], ['7', '21', 'upper_bound']]}, 'NCT01976585'), ({'text': 'BRAF V600E melanoma patients who have failed BRAF inhibitors', 'entities': [['12', '20', 'cancer'], ['46', '61', 'treatment']]}, 'NCT02070549'), ({'text': 'age 18 years or above', 'entities': [['1', '4', 'age'], ['5', '13', 'lower_bound']]}, 'NCT02016430'), ({'text': 'Known or suspected active pelvic infection', 'entities': [['27', '43', 'chronic_disease']]}, 'NCT02441140'), ({'text': 'Member of a household that includes an immunocompromised individual or infants less than 4 months of age', 'entities': [['90', '98', 'upper_bound'], ['102', '105', 'age']]}, 'NCT01893554'), ({'text': "Major medical illness including renal disease requiring dialysis, lung disease requiring oxygen, Parkinson's disease", 'entities': [['33', '46', 'chronic_disease'], ['57', '65', 'treatment'], ['67', '79', 'chronic_disease'], ['98', '117', 'chronic_disease']]}, 'NCT02593110'), ({'text': 'Ability and willingness to provide written informed consent Mild to moderate cognitive impairment with global neuropsychological (NP) test (NPZglobal)', 'entities': [['78', '98', 'chronic_disease']]}, 'NCT02159027'), ({'text': 'Subject is currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzyme CYP3A', 'entities': [['32', '125', 'treatment']]}, 'NCT02393794'), ({'text': 'Subject is able to take prophylactic anticoagulation as detailed in section 9.1 (patients intolerant to aspirin may use warfarin or low molecular weight heparin)', 'entities': [['25', '53', 'chronic_disease'], ['105', '112', 'treatment'], ['121', '129', 'treatment'], ['133', '161', 'treatment']]}, 'NCT02516696'), ({'text': 'History of or signs/symptoms suggestive of protein-losing enteropathy', 'entities': [['44', '70', 'chronic_disease']]}, 'NCT02846532'), ({'text': 'Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['14', '35', 'chronic_disease'], ['78', '94', 'chronic_disease'], ['108', '132', 'chronic_disease'], ['134', '159', 'chronic_disease'], ['161', '185', 'chronic_disease'], ['200', '218', 'chronic_disease'], ['223', '260', 'chronic_disease']]}, 'NCT03042689'), ({'text': 'Current use of a medication likely to impair post-stroke recovery', 'entities': [['51', '57', 'chronic_disease']]}, 'NCT02737930'), ({'text': 'Asymptomatic congenital toxoplasmosis', 'entities': [['14', '38', 'chronic_disease']]}, 'NCT00004317'), ({'text': 'AST (SGOT) & ALT (SGPT) d 2.5 x ULN', 'entities': [['1', '11', 'clinical_variable'], ['14', '24', 'clinical_variable'], ['27', '36', 'upper_bound']]}, 'NCT02578732'), ({'text': 'The subject has less than 10 degrees of flexion contracture and greater than 90 degrees of flexion', 'entities': [['27', '37', 'upper_bound'], ['41', '60', 'clinical_variable'], ['41', '48', 'clinical_variable'], ['78', '88', 'lower_bound']]}, 'NCT00966979'), ({'text': 'Patient is on stable antiepileptic drug therapy for last 2 months and is willing to remain on same therapy for the duration of the study', 'entities': [['22', '48', 'treatment'], ['41', '48', 'treatment'], ['53', '66', 'upper_bound']]}, 'NCT02011971'), ({'text': 'Male pts must agree to never have unprotected sexual contact with a female who can become pregnant and must agree to either completely abstain from sexual contact with females who are pregnant or are able to become pregnant', 'entities': [['1', '5', 'gender'], ['69', '75', 'gender'], ['84', '99', 'pregnancy'], ['169', '176', 'gender'], ['181', '193', 'pregnancy'], ['201', '224', 'pregnancy']]}, 'NCT01464034'), ({'text': 'The patient and aneurysm are considered appropriate for either surgical or endovascular treatment by the treating team', 'entities': [['17', '25', 'chronic_disease'], ['64', '72', 'treatment'], ['76', '98', 'treatment']]}, 'NCT01668563'), ({'text': 'All patients who participate in this study must be willing and able to tolerate prophylactic anticoagulation with low-molecular weight heparin (LMWH) for the required dates in treatment protocol', 'entities': [['81', '150', 'treatment'], ['177', '195', 'treatment']]}, 'NCT01054196'), ({'text': 'Absolute neutrophil count (ANC) e 1,800 cells/mm3', 'entities': [['1', '32', 'clinical_variable'], ['35', '50', 'lower_bound']]}, 'NCT02040610'), ({'text': 'Men e 45 years', 'entities': [['1', '4', 'gender'], ['7', '15', 'lower_bound']]}, 'NCT02374021'), ({'text': 'using a dynamic imaging technique (arterial phase of triphasic computerized tomography [CT] scan, or dynamic contrast-enhanced magnetic resonance imaging [MRI]), and injectable under imaging-guidance (CT and/or ultrasound)', 'entities': [['36', '97', 'treatment'], ['89', '91', 'treatment'], ['102', '160', 'treatment'], ['212', '222', 'treatment']]}, 'NCT02562755'), ({'text': 'Prosthetic implants in the pelvic region that the investigator feels will impede treatment, planning, or delivery (e.g., an artificial hip)', 'entities': [['1', '41', 'treatment'], ['82', '91', 'treatment']]}, 'NCT02470897'), ({'text': 'Index diagnosis of noninflammatory arthritis', 'entities': [['20', '45', 'chronic_disease']]}, 'NCT02686528'), ({'text': 'Chronic active hepatitis', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02143726'), ({'text': 'Patients with high risk disease as defined in Appendix 1 who do not meet eligibility requirements/organ function requirements for myeloablative conditioning', 'entities': [['131', '144', 'chronic_disease']]}, 'NCT01804634'), ({'text': 'Adaptive functioning typical of autism as determined by the Vineland Adaptive Behavior Scales (VABS-II; survey interview form)', 'entities': [['33', '39', 'chronic_disease']]}, 'NCT03152383'), ({'text': 'Surgical implantation of LVAD within 90 days prior to Randomization', 'entities': [['26', '30', 'clinical_variable'], ['38', '51', 'upper_bound']]}, 'NCT02554903'), ({'text': 'must be willing to undergo pregnancy testing throughout the study', 'entities': [['20', '37', 'pregnancy']]}, 'NCT02911116'), ({'text': 'Breath CO > 80 ppm', 'entities': [['1', '10', 'clinical_variable'], ['13', '19', 'lower_bound']]}, 'NCT02250664'), ({'text': 'Known sensitivity to etidronate', 'entities': [['22', '32', 'treatment']]}, 'NCT01585402'), ({'text': 'DLCO <35% of predicted, or receiving continuous supplementary oxygen', 'entities': [['1', '5', 'clinical_variable'], ['7', '10', 'upper_bound'], ['49', '69', 'treatment']]}, 'NCT00472329'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02566395'), ({'text': 'Concurrent participation in another study with investigational drug or device treatment', 'entities': [['48', '68', 'chronic_disease'], ['72', '88', 'treatment']]}, 'NCT02169739'), ({'text': 'have completed primary surgery, chemotherapy, and/or radiation', 'entities': [['16', '31', 'treatment'], ['33', '45', 'treatment'], ['54', '63', 'treatment']]}, 'NCT02459769'), ({'text': 'Major psychiatric disorders that required hospitalization in the past 6 months such as: major depression, bipolar disorder, schizophrenia, anxiety disorder, or psychotic disorders', 'entities': [['1', '28', 'chronic_disease'], ['43', '58', 'treatment'], ['66', '79', 'upper_bound'], ['89', '105', 'chronic_disease'], ['107', '123', 'chronic_disease'], ['125', '138', 'chronic_disease'], ['140', '156', 'chronic_disease'], ['161', '180', 'chronic_disease']]}, 'NCT01681264'), ({'text': 'Creatinine =< upper limit of normal (ULN) or calculated creatinine clearance >= 60 mL/min', 'entities': [['1', '11', 'clinical_variable'], ['57', '77', 'clinical_variable'], ['81', '90', 'lower_bound']]}, 'NCT01101451'), ({'text': 'Clinical assessment by treating physician that the patient is responding to neoadjuvant therapy or umor Ki67 value is d 10% after 14 days', 'entities': [['77', '96', 'treatment'], ['100', '115', 'clinical_variable'], ['121', '124', 'upper_bound'], ['125', '138', 'upper_bound']]}, 'NCT02204098'), ({'text': 'Use of probiotics or antibiotics in the past 30 days', 'entities': [['8', '18', 'treatment'], ['22', '33', 'treatment'], ['41', '53', 'upper_bound']]}, 'NCT03042767'), ({'text': 'intend to reside in the geographic area for >8 months', 'entities': [['46', '54', 'lower_bound']]}, 'NCT02378714'), ({'text': 'Use of any over-the-counter medications (including herbal or dietary supplements and therapeutic doses of vitamins), except for required pre-op medications, is prohibited within 24 hours of dosing with study drug, with the exception of topical spermicide', 'entities': [['12', '40', 'treatment'], ['52', '81', 'treatment'], ['86', '115', 'treatment'], ['138', '156', 'treatment'], ['179', '187', 'upper_bound']]}, 'NCT01959204'), ({'text': 'Patients with seizure disorder requiring medication', 'entities': [['15', '31', 'chronic_disease'], ['42', '52', 'treatment']]}, 'NCT02459119'), ({'text': 'Complicating medical problems such as uncontrolled hypertension, diabetes with signs of neuropathy, and previous neurological illness such as head trauma, prior stroke, epilepsy or demyelinating disease, implanted neuromodulatory or electronic device, metal in head', 'entities': [['39', '64', 'chronic_disease'], ['66', '99', 'chronic_disease'], ['114', '134', 'chronic_disease'], ['143', '154', 'chronic_disease'], ['162', '168', 'chronic_disease'], ['170', '178', 'chronic_disease'], ['182', '203', 'chronic_disease']]}, 'NCT01681589'), ({'text': 'Current treatment with a separate ascorbic acid preparation', 'entities': [['9', '60', 'treatment']]}, 'NCT03116685'), ({'text': '> 5 years and < 7 years 11 months of age with a score > 40 on the CELF-4', 'entities': [['3', '10', 'lower_bound'], ['17', '34', 'upper_bound'], ['38', '41', 'age'], ['57', '59', 'lower_bound'], ['67', '73', 'clinical_variable']]}, 'NCT02483910'), ({'text': 'Twice-a-day controlled-release forms of theophylline: 24 hours', 'entities': [['41', '53', 'treatment']]}, 'NCT02495168'), ({'text': "History of Parkinson's disease, dementia or severe cognitive impairment", 'entities': [['12', '31', 'chronic_disease'], ['33', '41', 'chronic_disease'], ['45', '72', 'chronic_disease']]}, 'NCT01625923'), ({'text': 'Negative pregnancy test (if female of childbearing potential after reduced intensity conditioning)', 'entities': [['1', '19', 'pregnancy'], ['29', '35', 'gender'], ['62', '98', 'treatment']]}, 'NCT02510417'), ({'text': 'Children will be excluded from participating in the genetic analysis if they are treated oral glucocorticoids or antirejection or chemotherapy (e.g. tacrolimus, Lasparaginase', 'entities': [['90', '110', 'treatment'], ['114', '127', 'treatment'], ['131', '143', 'treatment'], ['150', '160', 'treatment'], ['162', '175', 'treatment']]}, 'NCT01967849'), ({'text': "Has histological confirmation of HER2 normal breast carcinoma with a clinical diagnosis of IBC based on presence of inflammatory changes in the involved breast, including diffuse erythema and edema (peau d'orange), with or without an underlying palpable mass involving the majority of the skin of the breast; pathological evidence of dermal lymphatic invasion should be noted but is not required for diagnosis of inflammatory breast cancer regardless estrogen receptor (ER)/progesterone receptor (PR) status; OR has histological confirmation of triple negative breast carcinoma (HER2 normal, ER/PR < 10%) without clinical diagnosis of IBC", 'entities': [['34', '62', 'cancer'], ['92', '95', 'cancer'], ['180', '188', 'chronic_disease'], ['193', '198', 'chronic_disease'], ['200', '213', 'chronic_disease'], ['335', '360', 'cancer'], ['414', '440', 'cancer'], ['546', '578', 'cancer'], ['593', '598', 'clinical_variable'], ['601', '604', 'upper_bound']]}, 'NCT02411656'), ({'text': 'HAMA score of over 7 (7 used as an outcome measure for remission)127', 'entities': [['1', '11', 'clinical_variable'], ['20', '21', 'lower_bound']]}, 'NCT02543983'), ({'text': 'Uncontrolled HIV disease', 'entities': [['14', '25', 'chronic_disease']]}, 'NCT01810588'), ({'text': 'Life time history of major Axis I disorders', 'entities': [['28', '44', 'chronic_disease']]}, 'NCT02665338'), ({'text': 'Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant', 'entities': [['27', '30', 'treatment']]}, 'NCT01366612'), ({'text': 'a cutaneous VAS score of >3 cm on a 10 cm VAS scale (MDAAT) will be required', 'entities': [['13', '22', 'clinical_variable'], ['27', '31', 'lower_bound']]}, 'NCT02347891'), ({'text': 'Intact hypoglycemia awareness indicated by a Clarke score of 3 or less', 'entities': [['8', '20', 'chronic_disease'], ['46', '58', 'clinical_variable'], ['62', '63', 'upper_bound']]}, 'NCT01474889'), ({'text': 'Meningioma', 'entities': [['1', '11', 'cancer']]}, 'NCT02451215'), ({'text': 'Major surgery, excluding skin biopsies and procedures for insertion of central venous access devices, within 28 days prior to the start of COTI-2', 'entities': [['1', '14', 'treatment'], ['26', '101', 'treatment'], ['110', '123', 'upper_bound'], ['140', '146', 'treatment']]}, 'NCT02433626'), ({'text': 'Unstable angina', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02494869'), ({'text': "Non-Hodgkin's lymphomas", 'entities': [['5', '24', 'cancer']]}, 'NCT00001337'), ({'text': 'Previous or current hormonal management of prostate cancer (unless terminated at least 12 months prior to trial)', 'entities': [['21', '40', 'treatment'], ['44', '59', 'cancer'], ['88', '103', 'lower_bound']]}, 'NCT02663908'), ({'text': 'Osteopenia or any other well documented Bone disease', 'entities': [['41', '53', 'chronic_disease']]}, 'NCT03008070'), ({'text': 'Age >18', 'entities': [['1', '4', 'age'], ['6', '8', 'lower_bound']]}, 'NCT01624090'), ({'text': 'Untreated Major Depression', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT02457832'), ({'text': 'History of inadequate response to 1 or 2 adequate antidepressant treatments', 'entities': [['51', '76', 'treatment']]}, 'NCT02741791'), ({'text': 'Use of finasteride within 30 days prior to registration', 'entities': [['8', '19', 'treatment'], ['27', '40', 'upper_bound']]}, 'NCT02064036'), ({'text': 'should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately', 'entities': [['10', '15', 'gender'], ['23', '31', 'pregnancy']]}, 'NCT02496663'), ({'text': 'Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control (CDC)', 'entities': [['1', '43', 'clinical_variable']]}, 'NCT02163317'), ({'text': 'Treatment of solid malignancy or non-melanoma skin cancer within the past 5 years', 'entities': [['1', '10', 'treatment'], ['14', '30', 'cancer'], ['34', '58', 'cancer'], ['70', '82', 'upper_bound']]}, 'NCT01793519'), ({'text': 'Men of reproductive potential and those who are surgically sterilized (i.e., postvasectomy) must agree to practice effective barrier contraception that has an expected failure rate of < 1% during and for 30 days after discontinuation of study treatment', 'entities': [['1', '4', 'gender'], ['49', '70', 'treatment'], ['78', '91', 'treatment'], ['98', '147', 'contraception_consent'], ['160', '181', 'clinical_variable'], ['187', '189', 'upper_bound'], ['205', '218', 'upper_bound'], ['238', '253', 'treatment']]}, 'NCT02516670'), ({'text': 'Control subjects: Will be matched for age and gender to iPD and parkinsonism groups', 'entities': [['39', '42', 'age'], ['57', '60', 'chronic_disease'], ['65', '77', 'chronic_disease']]}, 'NCT02231073'), ({'text': 'Known active hepatitis B virus', 'entities': [['14', '31', 'chronic_disease']]}, 'NCT02401347'), ({'text': 'Platelets >= 100,000/mcL', 'entities': [['1', '10', 'clinical_variable'], ['14', '25', 'lower_bound']]}, 'NCT02417701'), ({'text': 'History of vestibular dysfunction, balance problems or spontaneous falls', 'entities': [['12', '34', 'chronic_disease']]}, 'NCT01923662'), ({'text': 'Patients with acute MI (STEMI or NSTEMI) will be recruited from the PAC-CCU service and may have been admitted through the Duke Emergency Department or transferred from a referring hospital', 'entities': [['15', '23', 'chronic_disease'], ['25', '30', 'chronic_disease'], ['34', '40', 'chronic_disease']]}, 'NCT02276456'), ({'text': 'Serious intercurrent infections or non-malignant medical illnesses that are uncontrolled', 'entities': [['9', '32', 'chronic_disease'], ['36', '67', 'chronic_disease']]}, 'NCT02012296'), ({'text': 'Subjects with MRI or CT evidence of cerebrovascular disease but without clinical signs of stroke', 'entities': [['37', '60', 'chronic_disease']]}, 'NCT02862210'), ({'text': 'Express an unwillingness to receive human allograft tissue', 'entities': [['37', '59', 'treatment']]}, 'NCT02982226'), ({'text': 'Diabetes', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02905370'), ({'text': 'Arm 6: Suitable for front line maintenance treatment with pembrolizumab ± pemetrexed per the current approved package inserts', 'entities': [['21', '85', 'treatment']]}, 'NCT02439450'), ({'text': 'Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines', 'entities': [['1', '14', 'treatment'], ['25', '38', 'lower_bound'], ['69', '82', 'treatment'], ['89', '103', 'treatment']]}, 'NCT02323880'), ({'text': 'Patients with a known past medical history of chronic kidney disease', 'entities': [['47', '69', 'chronic_disease']]}, 'NCT02588027'), ({'text': 'The lower age limit was chosen based on the National Institutes of Health (NIH) definition of adults for participation in research', 'entities': [['11', '14', 'age']]}, 'NCT02945969'), ({'text': 'Patients with a history of carcinomatous meningitis are not eligible', 'entities': [['28', '52', 'cancer']]}, 'NCT01928576'), ({'text': 'Newly diagnosed MCL: Requires treatment with strong CYP3A4/5 inhibitors', 'entities': [['17', '20', 'chronic_disease'], ['31', '72', 'treatment']]}, 'NCT01880567'), ({'text': 'Any breast surgery or biopsy within the last 90 days', 'entities': [['5', '19', 'treatment'], ['23', '29', 'treatment'], ['41', '53', 'upper_bound']]}, 'NCT02511301'), ({'text': 'Two visual field tests of adequate quality with a maximum visual field index (VFI) variability of ± 10%', 'entities': [['51', '95', 'clinical_variable']]}, 'NCT02862938'), ({'text': 'ALT >1.5× upper limit of normal (ULN)', 'entities': [['1', '4', 'clinical_variable'], ['6', '38', 'lower_bound']]}, 'NCT02548351'), ({'text': 'Supine systolic blood pressure (SBP) >160 millimeters of mercury (mmHg)and/or supine diastolic blood pressure(DBP) >95mmHg', 'entities': [['1', '37', 'clinical_variable'], ['39', '72', 'lower_bound'], ['79', '115', 'clinical_variable'], ['117', '123', 'lower_bound']]}, 'NCT03058029'), ({'text': 'Patients with history of MDS transformed to AML are eligible regardless of their prior therapy for MDS provided', 'entities': [['26', '29', 'cancer'], ['45', '48', 'cancer'], ['82', '95', 'treatment']]}, 'NCT01515527'), ({'text': 'Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus (e.g., inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, malabsorption syndrome, and active peptic ulcer disease)', 'entities': [['21', '42', 'chronic_disease'], ['55', '65', 'chronic_disease'], ['118', '128', 'treatment'], ['159', '169', 'treatment'], ['191', '207', 'treatment'], ['228', '236', 'treatment'], ['270', '292', 'chronic_disease'], ['298', '325', 'chronic_disease']]}, 'NCT02397083'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02464878'), ({'text': 'Patients with any medical condition that is felt by the primary investigator to place the patient at unreasonable risk for adverse effects during treatment with H.P. Acthar', 'entities': [['147', '156', 'treatment'], ['162', '173', 'treatment']]}, 'NCT02245841'), ({'text': 'Liver function tests (ALT or AST) greater than 3 times normal', 'entities': [['1', '34', 'clinical_variable'], ['48', '62', 'lower_bound']]}, 'NCT03010917'), ({'text': "(Subjects not required to participate in HRT but it will be highly encouraged, and must be completed prior to start of this study's protocol", 'entities': [['42', '45', 'treatment']]}, 'NCT02056873'), ({'text': 'Female patients of childbearing potential', 'entities': [['1', '16', 'gender']]}, 'NCT01841333'), ({'text': 'Emergency surgery', 'entities': [['1', '18', 'treatment']]}, 'NCT02789111'), ({'text': 'Serum creatinine d 1.5 x ULN (upper normal limit) or calculated creatinine clearance (determined by MDRD) > 50 mL/min/1.73m2', 'entities': [['1', '17', 'clinical_variable'], ['20', '50', 'upper_bound'], ['54', '85', 'clinical_variable'], ['109', '125', 'lower_bound']]}, 'NCT02979366'), ({'text': 'Any human leukocyte antigen (HLA) type; (historic HLA typing is permitted)', 'entities': [['5', '34', 'clinical_variable'], ['30', '33', 'clinical_variable']]}, 'NCT02166905'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['67', '68', 'upper_bound']]}, 'NCT02807272'), ({'text': 'used other tobacco products (including e-cigarettes more than 9 days in the past month', 'entities': [['63', '69', 'lower_bound']]}, 'NCT02796391'), ({'text': 'Any chronic medical condition requiring a higher dose of corticosteroid than equivalent of 5 mg prednisone/prednisolone once daily', 'entities': [['58', '72', 'treatment'], ['92', '96', 'lower_bound'], ['97', '107', 'treatment'], ['108', '120', 'treatment']]}, 'NCT03009981'), ({'text': 'fever >38.5', 'entities': [['1', '6', 'clinical_variable'], ['8', '12', 'lower_bound']]}, 'NCT01072370'), ({'text': 'Participants who received more than one line of previous therapy (including HD-ASCT), and have achieved a duration of response (CR or PR) of at least 8 weeks (from the last day of the last cycle) after their last line of therapy', 'entities': [['58', '65', 'treatment'], ['77', '84', 'treatment'], ['129', '131', 'treatment'], ['135', '137', 'treatment'], ['151', '158', 'lower_bound']]}, 'NCT02564744'), ({'text': 'Negative pregnancy test', 'entities': [['1', '19', 'pregnancy']]}, 'NCT02035085'), ({'text': 'Female patients with infants must agree not to breastfeed their infants while on the study', 'entities': [['1', '16', 'gender']]}, 'NCT02512926'), ({'text': '20-30 or 70-85 years of age', 'entities': [['1', '3', 'lower_bound'], ['4', '6', 'upper_bound'], ['10', '12', 'lower_bound'], ['13', '21', 'upper_bound'], ['25', '28', 'age']]}, 'NCT02638454'), ({'text': 'Diagnosis of post-dural puncture headache based on the International Classification of Headache Disorders', 'entities': [['14', '42', 'chronic_disease']]}, 'NCT02962427'), ({'text': 'Life expectancy is severely limited by concomitant illness or uncontrolled infection', 'entities': [['1', '16', 'clinical_variable']]}, 'NCT01810588'), ({'text': 'presence of hypertension or risk for developing hypertension', 'entities': [['13', '25', 'chronic_disease']]}, 'NCT02214550'), ({'text': 'at the participating site of stage I-III malignant pleural mesothelioma', 'entities': [['30', '37', 'lower_bound'], ['38', '41', 'upper_bound'], ['42', '72', 'cancer']]}, 'NCT00715611'), ({'text': 'Change in medications treating hypertension within one (1) month prior to Screening Visit', 'entities': [['11', '22', 'treatment'], ['32', '44', 'chronic_disease'], ['52', '71', 'upper_bound']]}, 'NCT03058029'), ({'text': 'Patients with end-stage renal disease (ESRD) on hemodialysis or peritoneal dialysis', 'entities': [['15', '45', 'chronic_disease'], ['49', '61', 'treatment'], ['65', '84', 'treatment']]}, 'NCT02738749'), ({'text': 'Systemic or local infection', 'entities': [['1', '28', 'chronic_disease']]}, 'NCT02073292'), ({'text': 'chemotherapy', 'entities': [['1', '13', 'treatment']]}, 'NCT01676259'), ({'text': 'Concurrent or use within 14 days of drugs known to interact with DM or CYP2D6 or drugs known to increase the risk of adverse effects from DM', 'entities': [['26', '33', 'upper_bound'], ['66', '68', 'treatment'], ['72', '78', 'treatment']]}, 'NCT03076021'), ({'text': 'Subject has a hearing impairment', 'entities': [['15', '33', 'chronic_disease']]}, 'NCT01169155'), ({'text': 'Patients must be accessible for treatment and follow-up', 'entities': [['33', '42', 'treatment']]}, 'NCT02273375'), ({'text': 'Negative pregnancy test within 14 days of starting therapy', 'entities': [['1', '19', 'pregnancy'], ['32', '39', 'upper_bound'], ['52', '59', 'treatment']]}, 'NCT02314377'), ({'text': 'anaerobic bacterial growth after 14 days', 'entities': [['1', '20', 'chronic_disease'], ['34', '41', 'lower_bound']]}, 'NCT01883076'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['14', '34', 'chronic_disease'], ['77', '93', 'chronic_disease'], ['107', '131', 'chronic_disease'], ['133', '157', 'chronic_disease'], ['159', '177', 'chronic_disease'], ['182', '201', 'chronic_disease'], ['202', '219', 'chronic_disease']]}, 'NCT02873598'), ({'text': 'Subjects must have had a unilateral stroke', 'entities': [['26', '43', 'chronic_disease']]}, 'NCT01422005'), ({'text': 'lactating females', 'entities': [['11', '18', 'gender']]}, 'NCT01464034'), ({'text': 'Prescribed interferon regularly with stimulants, opioid drugs (Ritalin, Opioid, etc.) and steroids', 'entities': [['12', '22', 'treatment'], ['38', '48', 'treatment'], ['50', '62', 'treatment'], ['64', '71', 'treatment'], ['73', '79', 'treatment'], ['91', '99', 'treatment']]}, 'NCT03133013'), ({'text': 'Hematologic malignancy', 'entities': [['1', '23', 'cancer']]}, 'NCT02770326'), ({'text': 'Allergy desensitization injections', 'entities': [['1', '35', 'treatment']]}, 'NCT01130077'), ({'text': 'Active psychiatric disorder', 'entities': [['8', '28', 'chronic_disease']]}, 'NCT01187368'), ({'text': 'Pervasive developmental disorder', 'entities': [['1', '33', 'chronic_disease']]}, 'NCT03015805'), ({'text': 'with pre-existing cardiovascular disease requiring ongoing treatment. This includes: a) Congestive heart failure class III/IV CHF per new york heart association (NYHA) criteria. b) Cardiomyopathy, c) Uncontrolled cardiac arrhythmia, d) Unstable angina pectoris', 'entities': [['19', '41', 'chronic_disease'], ['60', '69', 'treatment'], ['89', '168', 'chronic_disease'], ['182', '196', 'chronic_disease'], ['214', '232', 'chronic_disease'], ['237', '261', 'chronic_disease']]}, 'NCT02106988'), ({'text': 'previously treated with radiation and off steroids', 'entities': [['25', '34', 'treatment'], ['43', '51', 'treatment']]}, 'NCT02459119'), ({'text': 'rheumatoid arthritis', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02442622'), ({'text': 'Obstructive lung disease: FEV1/ FVC ratio < 0.70', 'entities': [['1', '25', 'chronic_disease'], ['27', '42', 'clinical_variable'], ['45', '49', 'upper_bound']]}, 'NCT02688647'), ({'text': 'Using ICS/LABA (Advair HFA equivalent > 115/21 mcg bid) or Fluticasone (110 mcg bid or equivalent) for at least 1 month before Study Visit 1', 'entities': [['17', '38', 'clinical_variable'], ['41', '55', 'lower_bound'], ['60', '71', 'treatment'], ['113', '120', 'lower_bound']]}, 'NCT03089515'), ({'text': 'Presence of progressive neurological disease', 'entities': [['13', '45', 'chronic_disease']]}, 'NCT01072370'), ({'text': 'Untreated or clinically active melanoma brain metastases', 'entities': [['41', '57', 'cancer']]}, 'NCT02557321'), ({'text': 'Females who are pregnant or lactating or plan to become pregnant during the course of this study', 'entities': [['1', '8', 'gender'], ['17', '25', 'pregnancy'], ['42', '65', 'pregnancy']]}, 'NCT02340156'), ({'text': 'Life expectancy greater than or equal to (e) 12 weeks', 'entities': [['1', '16', 'clinical_variable'], ['46', '54', 'lower_bound']]}, 'NCT02091141'), ({'text': 'Men planning to conceive in the next 12 months', 'entities': [['1', '4', 'gender'], ['33', '47', 'upper_bound']]}, 'NCT02903446'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT03062111'), ({'text': 'Major surgical procedure or significant traumatic injury within 14 days of initiating study drug or anticipation of the need for major surgery during the study', 'entities': [['1', '25', 'treatment'], ['41', '57', 'chronic_disease'], ['65', '72', 'upper_bound'], ['130', '143', 'treatment']]}, 'NCT02584647'), ({'text': 'History or serologic evidence of prior infection with any hantavirus or prior participation in an HTNV or PUUV vaccine trial', 'entities': [['34', '69', 'chronic_disease'], ['99', '125', 'treatment']]}, 'NCT02776761'), ({'text': 'pathologically confirmed T1-T3 disease', 'entities': [['26', '28', 'cancer'], ['29', '39', 'cancer']]}, 'NCT02064673'), ({'text': 'Access to a computer and are able to enter information into the computer', 'entities': [['1', '21', 'technology_access']]}, 'NCT03112824'), ({'text': 'Coronary Angiography subjects: patients undergoing routine coronary angiography', 'entities': [['1', '21', 'treatment'], ['60', '80', 'treatment']]}, 'NCT02966665'), ({'text': "vitiligo, resolved childhood asthma/atopy, requirement of intermittent bronchodilators or local steroid injections, hypothyroidism stable on hormone replacement, psoriasis not requiring systemic treatment (within the past 2 years), Graves's disease and Sjogren's syndrome", 'entities': [['1', '9', 'chronic_disease'], ['30', '36', 'chronic_disease'], ['37', '42', 'chronic_disease'], ['59', '87', 'treatment'], ['91', '115', 'treatment'], ['117', '131', 'chronic_disease'], ['163', '172', 'chronic_disease'], ['218', '230', 'upper_bound'], ['233', '249', 'chronic_disease'], ['254', '272', 'chronic_disease']]}, 'NCT02639065'), ({'text': 'Exclusionary psychiatric conditions (schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, current post-traumatic stress disorder, current suicidality or history of medically serious suicide attempt)', 'entities': [['14', '36', 'chronic_disease'], ['38', '51', 'chronic_disease'], ['53', '77', 'chronic_disease'], ['79', '95', 'chronic_disease'], ['105', '129', 'chronic_disease'], ['139', '169', 'chronic_disease']]}, 'NCT02061293'), ({'text': 'Grade >= 2 peripheral neuropathy within 14 days prior to initiation of therapy', 'entities': [['1', '6', 'clinical_variable'], ['10', '11', 'lower_bound'], ['12', '33', 'chronic_disease'], ['41', '54', 'upper_bound'], ['72', '79', 'treatment']]}, 'NCT02120222'), ({'text': 'Patients who have had major surgery within 4 weeks prior to registration', 'entities': [['23', '36', 'treatment'], ['44', '57', 'upper_bound']]}, 'NCT02481310'), ({'text': 'HIV or Hepatitis C positive status', 'entities': [['1', '4', 'chronic_disease'], ['8', '19', 'chronic_disease']]}, 'NCT00467987'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of 0-2', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'lower_bound'], ['67', '68', 'upper_bound']]}, 'NCT02530034'), ({'text': 'Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period', 'entities': [['1', '24', 'chronic_disease'], ['36', '57', 'chronic_disease'], ['68', '103', 'treatment']]}, 'NCT01653080'), ({'text': 'Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy', 'entities': [['13', '33', 'chronic_disease'], ['85', '111', 'treatment'], ['115', '139', 'treatment']]}, 'NCT02956486'), ({'text': 'currently using anticoagulation or immunosuppressive therapy', 'entities': [['17', '61', 'treatment']]}, 'NCT03072381'), ({'text': 'warfarin (Coumadin)', 'entities': [['1', '20', 'treatment']]}, 'NCT02498301'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'lower_bound'], ['70', '71', 'upper_bound']]}, 'NCT02401347'), ({'text': '18 years or older', 'entities': [['1', '9', 'lower_bound']]}, 'NCT00001651'), ({'text': 'Chemotherapy allowed', 'entities': [['1', '13', 'treatment']]}, 'NCT00909909'), ({'text': 'current threat of harm to self or others, bipolar illness, psychosis, thought disorder, pervasive developmental disorder, mental retardation, neurological diseases that impair cognition, or significant head injuries (past 3 months)', 'entities': [['43', '58', 'chronic_disease'], ['60', '69', 'chronic_disease'], ['71', '87', 'chronic_disease'], ['89', '121', 'chronic_disease'], ['123', '141', 'chronic_disease'], ['143', '164', 'chronic_disease'], ['170', '186', 'chronic_disease'], ['203', '216', 'chronic_disease'], ['218', '231', 'upper_bound']]}, 'NCT03176004'), ({'text': 'pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT02308709'), ({'text': 'Childbearing potential, including any female who has had a negative serum pregnancy test', 'entities': [['39', '45', 'gender'], ['60', '84', 'pregnancy']]}, 'NCT01532687'), ({'text': 'Postmenopausal for a minimum of one year, OR surgically sterile, OR not pregnant, confirmed by a pregnancy test as per institutional standard of care, and willing to use adequate contraception (hormonal or barrier method of birth control~ abstinence) for the duration of study participation', 'entities': [['33', '41', 'lower_bound'], ['69', '81', 'pregnancy'], ['98', '107', 'pregnancy'], ['156', '193', 'contraception_consent'], ['195', '203', 'contraception_consent'], ['207', '238', 'contraception_consent'], ['240', '250', 'contraception_consent']]}, 'NCT02510456'), ({'text': 'Documented suppressed HIV-1 RNA (plasma HIV-1 RNA values <50 copies/ml)', 'entities': [['23', '28', 'chronic_disease'], ['29', '32', 'clinical_variable'], ['34', '57', 'clinical_variable'], ['59', '71', 'upper_bound']]}, 'NCT02471430'), ({'text': 'induction chemotherapy', 'entities': [['1', '23', 'treatment']]}, 'NCT02509546'), ({'text': 'sickle cell anemia', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02056470'), ({'text': '18 years of age or older with resectable pancreatic adenocarcinoma for whom surgery is planned (includes borderline resectable if deemed appropriate by surgical investigators) or has occurred within the past 3 years', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age'], ['31', '67', 'cancer'], ['77', '84', 'treatment'], ['204', '216', 'upper_bound']]}, 'NCT03187028'), ({'text': 'less than 6 months of age', 'entities': [['11', '19', 'upper_bound'], ['23', '26', 'age']]}, 'NCT02247193'), ({'text': 'no illicit drug use or excessive alcohol consumption (>10 drinks/week)', 'entities': [['56', '70', 'lower_bound']]}, 'NCT01438073'), ({'text': 'Patients must be either untreated or have not had more than one cycle of systemic MM therapy', 'entities': [['74', '93', 'treatment']]}, 'NCT02128230'), ({'text': 'Has a contradiction to TMS', 'entities': [['24', '27', 'allergy_name']]}, 'NCT02565199'), ({'text': 'Medication other than for asthma, allergies or contraception (e.g. monoamine oxidase inhibitors and beta-adrenergic antagonists in any form)', 'entities': [['1', '11', 'treatment'], ['27', '33', 'chronic_disease'], ['68', '96', 'treatment'], ['101', '128', 'treatment']]}, 'NCT01026532'), ({'text': 'Post-void residual urine volumes of > 350 cc', 'entities': [['1', '33', 'clinical_variable'], ['39', '45', 'lower_bound']]}, 'NCT02961114'), ({'text': 'A need for aspirin at a dose of >81 mg a day', 'entities': [['12', '19', 'treatment'], ['34', '39', 'lower_bound']]}, 'NCT03088072'), ({'text': 'Intolerance, refractory disease', 'entities': [['14', '32', 'chronic_disease']]}, 'NCT02394028'), ({'text': 'Patients with pre-existing cardiovascular disease requiring ongoing treatment', 'entities': [['28', '50', 'treatment'], ['69', '78', 'treatment']]}, 'NCT01473628'), ({'text': 'Be considered at risk for exposure to WEE virus and who have submitted a Request for IND Vaccines for the WEE vaccine', 'entities': [['39', '48', 'chronic_disease'], ['107', '118', 'treatment']]}, 'NCT02466750'), ({'text': 'Concurrent active malignancy of another type', 'entities': [['19', '29', 'cancer']]}, 'NCT02138214'), ({'text': 'Received any prophylactic vaccine within 14 days of first dose of study drug or received a live vaccine within 30 days of study treatment', 'entities': [['14', '34', 'treatment'], ['42', '49', 'upper_bound'], ['112', '119', 'upper_bound']]}, 'NCT03153410'), ({'text': 'Subjects with known epidermal growth factor receptor (EGFR) mutations or ALK or ROS1 gene rearrangements must have failed (disease progression [PD] or unacceptable toxicity) prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively (PD or unacceptable toxicity)', 'entities': [['74', '77', 'treatment'], ['175', '185', 'treatment'], ['196', '226', 'treatment']]}, 'NCT02588612'), ({'text': 'traumatic amnesia (1hour or greater) on the Post-traumatic Amnesia Questionnaire (PTAQ)', 'entities': [['1', '18', 'chronic_disease'], ['20', '25', 'lower_bound'], ['45', '67', 'chronic_disease']]}, 'NCT02377089'), ({'text': 'Age 18 or older', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT03105700'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01900093'), ({'text': 'Weight greater than 110 lbs', 'entities': [['1', '7', 'clinical_variable'], ['21', '28', 'lower_bound']]}, 'NCT02389465'), ({'text': 'Participant (where appropriate, depending on age) and their parent(s) or legal representative(s) have signed the Informed Consent Form (ICF)/Assent voluntarily', 'entities': [['46', '49', 'age']]}, 'NCT00980538'), ({'text': 'Scores moderate-severe on at least 3 out of 6 domains from the Kansas GWI Case Definition', 'entities': [['36', '37', 'lower_bound'], ['45', '46', 'upper_bound']]}, 'NCT02506192'), ({'text': 'Myopathic pain that cannot be attributed to other medical conditions', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT01568255'), ({'text': 'EXCEPTIONS: Non-melanoma skin cancer, ductal breast carcinoma in situ (DCIS) or carcinoma-in-situ of the cervix', 'entities': [['13', '37', 'cancer'], ['39', '77', 'cancer'], ['53', '62', 'cancer']]}, 'NCT02547662'), ({'text': 'Subject is determined by medical consultant to have medical contraindications to undergoing surgery', 'entities': [['93', '100', 'treatment']]}, 'NCT02361554'), ({'text': 'Patients with known human immunodeficiency virus (HIV) infection', 'entities': [['27', '55', 'chronic_disease']]}, 'NCT02101853'), ({'text': 'patients with indolent secondary malignancies', 'entities': [['24', '46', 'cancer']]}, 'NCT02152995'), ({'text': 'within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic immunosuppressive medications during the trial', 'entities': [['8', '21', 'upper_bound'], ['72', '110', 'treatment']]}, 'NCT02451423'), ({'text': 'Hemoglobin S greater than or equal to 50%, or B-thalassemia intermedia', 'entities': [['1', '13', 'clinical_variable'], ['39', '42', 'lower_bound'], ['47', '71', 'chronic_disease']]}, 'NCT02105766'), ({'text': 'Histologically confirmed malignant pleural mesothelioma that is not metastatic or unresectable', 'entities': [['36', '56', 'cancer'], ['69', '79', 'cancer']]}, 'NCT02004028'), ({'text': 'no secondary primary lung cancer diagnosed concurrently or within 2 year prior to registration', 'entities': [['14', '33', 'cancer'], ['67', '79', 'upper_bound']]}, 'NCT02194738'), ({'text': 'If female, currently pregnant', 'entities': [['4', '10', 'gender'], ['12', '30', 'pregnancy']]}, 'NCT03168971'), ({'text': 'Poorly controlled hypertension (systolic >170 mmHg, diastolic >105 mmHg)', 'entities': [['19', '31', 'chronic_disease'], ['33', '41', 'clinical_variable'], ['43', '51', 'lower_bound'], ['53', '62', 'clinical_variable'], ['64', '72', 'lower_bound']]}, 'NCT02570672'), ({'text': 'Karnofsky performance status 70-100', 'entities': [['1', '29', 'clinical_variable'], ['30', '32', 'lower_bound'], ['33', '36', 'upper_bound']]}, 'NCT02334579'), ({'text': 'Diabetes', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT01536522'), ({'text': 'Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female)', 'entities': [['1', '13', 'pregnancy'], ['30', '63', 'pregnancy'], ['76', '89', 'upper_bound']]}, 'NCT01807611'), ({'text': 'Diagnosis of B- or T-ALL or LLy', 'entities': [['20', '25', 'cancer'], ['29', '32', 'cancer']]}, 'NCT03117751'), ({'text': 'Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 × ULN', 'entities': [['1', '31', 'clinical_variable'], ['36', '68', 'clinical_variable'], ['72', '81', 'upper_bound']]}, 'NCT02542657'), ({'text': 'Patients ineligible for the treatment program', 'entities': [['29', '38', 'treatment']]}, 'NCT02305537'), ({'text': 'Undergo cardiac transplants or cardiac procedures performed using the percutaneous or thoracotomy approach', 'entities': [['9', '28', 'treatment'], ['32', '50', 'treatment'], ['71', '83', 'treatment'], ['87', '98', 'treatment']]}, 'NCT02216227'), ({'text': 'Severe liver dysfunction (Childs-Pugh Class C)', 'entities': [['8', '25', 'chronic_disease'], ['27', '38', 'clinical_variable']]}, 'NCT02816736'), ({'text': 'hormonal therapy', 'entities': [['1', '17', 'treatment']]}, 'NCT02176161'), ({'text': 'Retinoblastoma - disseminated at diagnosis and/or relapsed', 'entities': [['1', '15', 'cancer']]}, 'NCT01505569'), ({'text': 'Subjects who have received a cyclophosphamide (CYC) induction regimen may be included a minimum of 2 weeks after the last dose of daily oral CYC, or 3 weeks after the last dose of pulsed IV CYC prior to visit 1, if their total WBC is e4x109/L prior to visit 1', 'entities': [['30', '70', 'treatment'], ['48', '51', 'treatment'], ['100', '107', 'lower_bound'], ['188', '194', 'treatment'], ['228', '231', 'clinical_variable'], ['236', '243', 'lower_bound']]}, 'NCT02947945'), ({'text': 'Non-malignant diseases', 'entities': [['1', '23', 'cancer']]}, 'NCT02356653'), ({'text': 'Patients under the age of 18, or over the age of 85', 'entities': [['20', '23', 'age'], ['27', '29', 'upper_bound'], ['50', '52', 'lower_bound']]}, 'NCT03144206'), ({'text': 'Mechanically ventilated for longer than 6 hours', 'entities': [['41', '48', 'lower_bound']]}, 'NCT01504373'), ({'text': 'cured of a skin cancer', 'entities': [['12', '23', 'cancer']]}, 'NCT03007030'), ({'text': 'Life expectancy < 12 weeks', 'entities': [['1', '16', 'clinical_variable'], ['19', '27', 'upper_bound']]}, 'NCT01815359'), ({'text': 'Calculated creatinine clearance e 50 cc/min', 'entities': [['12', '32', 'clinical_variable'], ['35', '44', 'lower_bound']]}, 'NCT01660607'), ({'text': 'history of significant pyschiatric illness (for example, bipolar disorder, schizophrenia, or pyschosis) or a current diagnosis of Major Depressive Disorder, Schizophrenia, Epilepsy, Bipolar Disorder', 'entities': [['24', '43', 'chronic_disease'], ['58', '74', 'chronic_disease'], ['76', '89', 'chronic_disease'], ['94', '103', 'chronic_disease'], ['131', '156', 'chronic_disease'], ['158', '171', 'chronic_disease'], ['173', '181', 'chronic_disease'], ['183', '199', 'chronic_disease']]}, 'NCT02020564'), ({'text': 'History of heart disease, respiratory, renal, gastrointestinal or hepatic disease', 'entities': [['12', '25', 'chronic_disease'], ['27', '38', 'chronic_disease'], ['40', '45', 'chronic_disease'], ['47', '63', 'chronic_disease'], ['67', '82', 'chronic_disease']]}, 'NCT02695433'), ({'text': 'renal disease', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02139436'), ({'text': 'Non-WM must have at least one bi-dimensionally measurable lesion (which has not been previously irradiated) according to the Lugano Classification. For patients with splenic MZL (Marginal-zone lymphoma) this requirement may be restricted to splenomegaly alone since that is usually the only manifestation of measurable disease', 'entities': [['27', '30', 'lower_bound']]}, 'NCT02367040'), ({'text': 'Hematologic: ANC e 750/mm3, platelets e 75,000/mm3', 'entities': [['1', '12', 'chronic_disease'], ['14', '17', 'clinical_variable'], ['20', '27', 'lower_bound'], ['29', '38', 'clinical_variable'], ['41', '51', 'lower_bound']]}, 'NCT01505569'), ({'text': 'Diagnosis of chronic fatigue syndrome', 'entities': [['14', '38', 'chronic_disease']]}, 'NCT02660528'), ({'text': 'Fertile male subjects and female subjects of childbearing potential who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) must be using a highly effective method of contraception as outlined in this protocol throughout the study and for at least 28 days after the last dose of study medication', 'entities': [['9', '42', 'gender'], ['146', '155', 'pregnancy'], ['186', '234', 'contraception_consent'], ['302', '309', 'lower_bound']]}, 'NCT01500551'), ({'text': 'Treatment must be stable during the 6-week period immediately prior to NKA injection', 'entities': [['1', '10', 'treatment'], ['37', '43', 'upper_bound'], ['72', '85', 'treatment']]}, 'NCT02836574'), ({'text': 'Currently being prescribed psychotropic medication by another physician', 'entities': [['28', '51', 'treatment']]}, 'NCT01986075'), ({'text': 'Excluding the primary tumor leading to enrollment in this study, any other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the bladder or cervix) within the past 24 months', 'entities': [['15', '28', 'cancer'], ['83', '93', 'cancer'], ['127', '143', 'cancer'], ['145', '150', 'cancer'], ['154', '189', 'cancer'], ['194', '236', 'cancer'], ['249', '263', 'upper_bound']]}, 'NCT02501096'), ({'text': 'Germ cell tumors (GCTs)', 'entities': [['1', '24', 'cancer']]}, 'NCT02533674'), ({'text': 'Physicians Global Assessment score of 3 or 4 at baseline', 'entities': [['1', '35', 'clinical_variable'], ['39', '40', 'lower_bound'], ['44', '45', 'upper_bound']]}, 'NCT02340169'), ({'text': 'Willingness to undergo in-lab baseline polysomnography (PSG) and positive airway pressure (PAP) titration (if needed)', 'entities': [['40', '61', 'treatment'], ['66', '106', 'treatment']]}, 'NCT02544373'), ({'text': 'GERD-HRQL score e15 after discontinuing PPI therapy', 'entities': [['1', '16', 'clinical_variable'], ['18', '20', 'lower_bound'], ['41', '52', 'treatment']]}, 'NCT03090607'), ({'text': 'Patients with hematomas or biopsy site changes that limit response assessment of the primary tumor by diagnostic imaging', 'entities': [['15', '24', 'chronic_disease'], ['28', '34', 'chronic_disease'], ['86', '99', 'cancer']]}, 'NCT02276443'), ({'text': 'cerebral palsy', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02148796'), ({'text': 'patients can have tumor which is locally advanced or borderline resectable', 'entities': [['19', '24', 'cancer']]}, 'NCT02394535'), ({'text': 'Serous effusion (plural effusion or peritoneal ascites)', 'entities': [['1', '16', 'chronic_disease'], ['18', '33', 'chronic_disease'], ['37', '55', 'chronic_disease']]}, 'NCT01829958'), ({'text': 'Agreement to use one of the methods of contraception / follow the contraception scheme described in Section 4.5 from Screening and up to at least 30 days after study treatment discontinuation', 'entities': [['1', '53', 'contraception_consent'], ['147', '160', 'lower_bound'], ['161', '176', 'treatment']]}, 'NCT02554903'), ({'text': 'Intranasal, inhaled, and topical steroids', 'entities': [['1', '11', 'treatment'], ['13', '20', 'treatment'], ['26', '42', 'treatment']]}, 'NCT02311361'), ({'text': 'lifetime bipolar or psychotic disorder as determined by either self-report or clinical interview', 'entities': [['10', '17', 'chronic_disease'], ['21', '39', 'chronic_disease']]}, 'NCT02378714'), ({'text': 'Use of cognitive enhancing medications', 'entities': [['8', '39', 'treatment']]}, 'NCT02440815'), ({'text': 'Diagnosis of MS made at least 3 months prior based on McDonald criteria', 'entities': [['14', '16', 'chronic_disease'], ['31', '45', 'lower_bound']]}, 'NCT02490943'), ({'text': 'Grade V vesicoureteral reflux (Grade IV findings plus loss of the papillary impression and ureteral tortuosity)', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT01011777'), ({'text': 'Use of systemic steroids, NSAIDS (non-steroidal anti-inflammatory drugs), anti-VEGF agents within 7 days prior to surgery (through study exit). Daily doses of aspirin, up to 325 mg, will be permitted', 'entities': [['8', '25', 'treatment'], ['27', '33', 'treatment'], ['35', '72', 'treatment'], ['75', '91', 'treatment'], ['99', '111', 'upper_bound'], ['115', '122', 'treatment'], ['160', '167', 'treatment'], ['175', '181', 'upper_bound']]}, 'NCT01988246'), ({'text': 'Need for colonoscopy', 'entities': [['10', '21', 'treatment']]}, 'NCT02291523'), ({'text': 'not willing to go off steroids for 3 weeks prior to enrollment to end of study', 'entities': [['23', '31', 'treatment'], ['36', '49', 'upper_bound']]}, 'NCT03122912'), ({'text': 'Men', 'entities': [['1', '4', 'gender']]}, 'NCT02516332'), ({'text': 'Intended modification of antiretroviral therapy in the next 24 weeks', 'entities': [['26', '48', 'treatment'], ['56', '69', 'upper_bound']]}, 'NCT02191098'), ({'text': 'Age > 10 and < 13 years, 1.2 mg/dL (male) and 1.2 mg/dL (female)', 'entities': [['1', '4', 'age'], ['7', '9', 'lower_bound'], ['16', '24', 'upper_bound'], ['26', '35', 'upper_bound'], ['37', '41', 'gender'], ['58', '64', 'gender']]}, 'NCT02389309'), ({'text': 'For patients >= 1 but < 13 years old: glomerular filtration rate (GFR) estimated by updated Schwartz formula >= 90 mL/min/1.73 m^2', 'entities': [['17', '18', 'lower_bound'], ['25', '33', 'upper_bound'], ['39', '71', 'clinical_variable'], ['93', '109', 'clinical_variable'], ['113', '131', 'lower_bound']]}, 'NCT02833805'), ({'text': 'unwilling to use 2 or more acceptable methods of contraception when engaging in sexual activity throughout the study', 'entities': [['1', '63', 'contraception_consent']]}, 'NCT02496611'), ({'text': 'Patients with gross spinal instability on imaging', 'entities': [['15', '39', 'chronic_disease']]}, 'NCT02291978'), ({'text': 'Patients undergoing hysterectomy for endometrial hyperplasia or cervical dysplasia', 'entities': [['21', '33', 'treatment'], ['38', '61', 'chronic_disease'], ['65', '83', 'chronic_disease']]}, 'NCT02911831'), ({'text': 'Men and women with hyperprolactinemia', 'entities': [['1', '4', 'gender'], ['9', '14', 'gender'], ['20', '38', 'chronic_disease']]}, 'NCT00914823'), ({'text': 'In first or subsequent relapse or refractory status, with or without prior hematopoietic stem cell transplant (HSCT)', 'entities': [['70', '117', 'treatment']]}, 'NCT03150004'), ({'text': 'At least 3 half-lives must have elapsed after the last dose of GVHD meds', 'entities': [['10', '22', 'lower_bound'], ['64', '73', 'treatment']]}, 'NCT01614197'), ({'text': 'Age younger than 55 years', 'entities': [['1', '4', 'age'], ['18', '26', 'upper_bound']]}, 'NCT02614365'), ({'text': 'Each lesion must be >= 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray', 'entities': [['6', '12', 'clinical_variable'], ['24', '29', 'lower_bound'], ['102', '107', 'lower_bound']]}, 'NCT02912572'), ({'text': 'approved Receptor activator of nuclear factor kappa-B (RANK) ligand targeted agents <7 days prior to randomization', 'entities': [['32', '84', 'treatment'], ['86', '98', 'upper_bound']]}, 'NCT02107703'), ({'text': 'Patients may have received other non-targeted, immunotherapy or targeted treatment between the prior genetic testing at the outside lab and registration to Step 0', 'entities': [['34', '46', 'treatment'], ['48', '61', 'treatment'], ['65', '83', 'treatment']]}, 'NCT02465060'), ({'text': 'Fasting insulin >30 (Micro)U/ml', 'entities': [['1', '16', 'clinical_variable'], ['18', '32', 'lower_bound']]}, 'NCT00085982'), ({'text': 'Significant psychiatric history; a diagnosis of schizophrenia, bipolar disorder, or severe depression', 'entities': [['49', '62', 'chronic_disease'], ['64', '80', 'chronic_disease'], ['85', '102', 'chronic_disease']]}, 'NCT02341963'), ({'text': 'Patients must be willing to use contraception if they have childbearing potential', 'entities': [['18', '46', 'contraception_consent']]}, 'NCT02566304'), ({'text': 'lifetime history of psychotic disorders', 'entities': [['21', '40', 'chronic_disease']]}, 'NCT03079297'), ({'text': 'Any concurrent malignancy', 'entities': [['16', '26', 'cancer']]}, 'NCT02131597'), ({'text': 'Active and uncontrolled relapse of malignancy', 'entities': [['36', '46', 'cancer']]}, 'NCT02210078'), ({'text': 'patients may not have received prior ipilimumab', 'entities': [['32', '48', 'treatment']]}, 'NCT01896999'), ({'text': 'Hepatic metastases involving both branches of the portal vein or all three hepatic veins', 'entities': [['1', '19', 'cancer']]}, 'NCT01952730'), ({'text': 'e18yo with >1 yr of migraines and currently 4-20 days/month with migraines, although no migraine within 48 hrs of study visit', 'entities': [['2', '6', 'lower_bound'], ['13', '17', 'lower_bound'], ['45', '46', 'lower_bound'], ['47', '60', 'upper_bound'], ['105', '111', 'upper_bound']]}, 'NCT02748577'), ({'text': 'taken finasteride or dutasteride during the prior year', 'entities': [['7', '18', 'treatment'], ['22', '33', 'treatment'], ['45', '55', 'upper_bound']]}, 'NCT02176902'), ({'text': 'Clinical signs of unstable cardiovascular disease', 'entities': [['19', '50', 'chronic_disease']]}, 'NCT03003780'), ({'text': 'Measurable or evaluable disease by RECIST v1.1 (not required for ancillary cPoP part of the study)', 'entities': [['66', '80', 'treatment']]}, 'NCT02516813'), ({'text': 'Patient is a candidate for the surgery', 'entities': [['32', '39', 'treatment']]}, 'NCT03044054'), ({'text': 'A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or thinning of long bone cortex)', 'entities': [['28', '58', 'chronic_disease']]}, 'NCT02390752'), ({'text': 'ASA physical status classification > 3', 'entities': [['1', '35', 'clinical_variable'], ['38', '39', 'lower_bound']]}, 'NCT02341963'), ({'text': 'a greater than 100% increase or greater than 50% decrease in dose of GDMT', 'entities': [['16', '20', 'lower_bound'], ['46', '49', 'lower_bound'], ['70', '74', 'treatment']]}, 'NCT01626079'), ({'text': 'Platelets e 100 x 109/L', 'entities': [['1', '10', 'clinical_variable'], ['13', '24', 'lower_bound']]}, 'NCT02178709'), ({'text': 'The subject has a diagnosis of osteoarthritis (OA) or posttraumatic arthritis (TA)', 'entities': [['32', '51', 'chronic_disease'], ['55', '83', 'chronic_disease']]}, 'NCT00966979'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status d2', 'entities': [['1', '61', 'clinical_variable'], ['63', '64', 'upper_bound']]}, 'NCT02106650'), ({'text': 'Patients who have bone marrow disease must still have adequate bone marrow function to enter the study', 'entities': [['19', '38', 'chronic_disease']]}, 'NCT02035137'), ({'text': 'Significant scoliosis', 'entities': [['13', '22', 'chronic_disease']]}, 'NCT02271100'), ({'text': 'Adverse cytogenetics such as t(9;22), t(1;19), t(4;11), MLL rearrangements White blood cell counts >30,000/mcL Patients over 30 years of age Time to complete remission >4 weeks Presence of extramedullary disease', 'entities': [['57', '60', 'cancer'], ['76', '99', 'clinical_variable'], ['101', '111', 'lower_bound'], ['126', '134', 'lower_bound'], ['138', '141', 'age'], ['170', '177', 'lower_bound'], ['190', '212', 'chronic_disease']]}, 'NCT02167958'), ({'text': 'Previous randomization in a trial using 90Y RE', 'entities': [['41', '44', 'treatment']]}, 'NCT03059030'), ({'text': 'Psychiatric or other condition that may interfere with the study', 'entities': [['1', '12', 'chronic_disease']]}, 'NCT01726257'), ({'text': 'Contraindication to MRI scanning including claustrophobia and presence of a ferromagnetic object, including orthodontic braces', 'entities': [['21', '24', 'treatment'], ['44', '58', 'chronic_disease']]}, 'NCT02734602'), ({'text': 'Sentinel event and encephalopathy occurred only after birth', 'entities': [['20', '34', 'chronic_disease']]}, 'NCT02811263'), ({'text': 'Uncontrolled asthma with hospitalization for exacerbation within previous 30 days', 'entities': [['14', '20', 'chronic_disease'], ['26', '41', 'treatment'], ['66', '82', 'upper_bound']]}, 'NCT02449980'), ({'text': 'breast feeding women', 'entities': [['16', '21', 'gender']]}, 'NCT03150004'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT02547584'), ({'text': 'Patient is at low risk for metastasis with Gleason score at diagnosis < 8', 'entities': [['28', '38', 'cancer'], ['44', '57', 'clinical_variable'], ['73', '74', 'upper_bound']]}, 'NCT03085043'), ({'text': 'No active eczema within the past 12 months', 'entities': [['4', '17', 'chronic_disease'], ['29', '43', 'upper_bound']]}, 'NCT00788164'), ({'text': 'Female gender', 'entities': [['1', '7', 'gender']]}, 'NCT01568255'), ({'text': 'Has taken disallowed items (supplement containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) over the past 30 days', 'entities': [['29', '60', 'treatment'], ['64', '77', 'treatment'], ['79', '99', 'treatment'], ['104', '142', 'treatment'], ['153', '165', 'upper_bound']]}, 'NCT02402660'), ({'text': 'meets diagnostic criteria for full or subthreshold posttraumatic stress disorder', 'entities': [['39', '81', 'chronic_disease']]}, 'NCT02667119'), ({'text': 'Receipt of radiotherapy to >25 % of bone marrow', 'entities': [['12', '24', 'treatment'], ['29', '33', 'lower_bound']]}, 'NCT02266745'), ({'text': 'ALT and AST d 2.5x ULN (d 5x ULN in patients with liver metastases)', 'entities': [['1', '4', 'clinical_variable'], ['9', '12', 'clinical_variable'], ['15', '23', 'upper_bound'], ['17', '23', 'upper_bound'], ['51', '67', 'cancer']]}, 'NCT02531932'), ({'text': 'Patients with inflammatory arthritis', 'entities': [['15', '37', 'chronic_disease']]}, 'NCT02501733'), ({'text': "Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results", 'entities': [['18', '25', 'chronic_disease'], ['27', '40', 'chronic_disease'], ['44', '61', 'chronic_disease']]}, 'NCT01360606'), ({'text': 'Platelet count e 50 x 109/L', 'entities': [['1', '15', 'clinical_variable'], ['18', '28', 'lower_bound']]}, 'NCT01433965'), ({'text': 'clinically significant pulmonary hypertension', 'entities': [['24', '46', 'chronic_disease']]}, 'NCT02272634'), ({'text': 'cardiomegaly', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT01525901'), ({'text': 'A minimum ODI score of 10/50', 'entities': [['11', '20', 'clinical_variable'], ['24', '29', 'lower_bound']]}, 'NCT02373644'), ({'text': 'If lab results are available in the last 6 months, then a serum creatinine e1.3 mg/dL on 2 occasions during screening and/or follow-up, indicating potential impairment of renal functioning', 'entities': [['30', '50', 'upper_bound'], ['59', '75', 'clinical_variable'], ['77', '86', 'lower_bound']]}, 'NCT02515773'), ({'text': 'Treatment prior to surgery with any form of hormones, anti-androgens or androgen deprivation therapy', 'entities': [['1', '10', 'treatment'], ['20', '27', 'treatment'], ['45', '53', 'treatment'], ['55', '69', 'treatment'], ['73', '101', 'treatment']]}, 'NCT02957149'), ({'text': 'Patients must have a body surface area (BSA) >= 0.84 m^2', 'entities': [['22', '45', 'clinical_variable'], ['49', '57', 'lower_bound']]}, 'NCT02323880'), ({'text': 'Sexually active males unless they use a condom during intercourse', 'entities': [['17', '22', 'gender'], ['35', '66', 'contraception_consent']]}, 'NCT02414139'), ({'text': 'Patients with Body Mass Index (BMI) > 40kg/m2', 'entities': [['15', '36', 'bmi'], ['39', '46', 'lower_bound']]}, 'NCT02844751'), ({'text': 'Ability to be followed in BHP clinic for ART for up to 192 weeks after enrollment', 'entities': [['56', '71', 'upper_bound']]}, 'NCT02369406'), ({'text': 'Patients must demonstrate one or more of the following Sickle Cell Disease Complications (or patients in Cohort 2 can meet other high risk criteria instead)', 'entities': [['56', '75', 'chronic_disease']]}, 'NCT02675959'), ({'text': 'Regular use of analgesic medication for cancer-related bone pain (e level 1; WHO ladder for cancer pain)', 'entities': [['16', '36', 'treatment'], ['41', '65', 'cancer'], ['41', '47', 'cancer'], ['69', '76', 'lower_bound']]}, 'NCT02346526'), ({'text': 'Biopsy is also an acceptable method of confirming progression or recurrence', 'entities': [['1', '7', 'treatment']]}, 'NCT01817751'), ({'text': 'Children under the age of two', 'entities': [['20', '23', 'age'], ['27', '30', 'upper_bound']]}, 'NCT00630565'), ({'text': 'Patients should be immediately threatened for vision loss or other significant neurological impairment directly related to tumor mass effect. As such, all patients enrolled would likely benefit from tumor response (shrinkage)', 'entities': [['80', '103', 'chronic_disease'], ['124', '129', 'cancer']]}, 'NCT01444209'), ({'text': 'Subjects with any of the following MEDICATIONS within 4 weeks prior to IP treatment', 'entities': [['36', '47', 'treatment'], ['55', '68', 'upper_bound'], ['72', '84', 'treatment']]}, 'NCT02310464'), ({'text': 'evidence on HRCT of fibrosis or ground glass changes involving more than 30% of lung parenchyma', 'entities': [['13', '17', 'treatment'], ['21', '29', 'chronic_disease']]}, 'NCT02981082'), ({'text': 'Consumes grapefruit, grapefruit products, Seville oranges, or pomelo-containing products within 14 days of dosing', 'entities': [['97', '104', 'upper_bound']]}, 'NCT01959204'), ({'text': 'Prior treatment with bicalutamide (Casodex®) or nilutamide (Nilandron®) within 6 weeks of Cycle 1, Day 1', 'entities': [['1', '45', 'treatment'], ['49', '72', 'treatment'], ['80', '87', 'upper_bound']]}, 'NCT03072238'), ({'text': 'Episodic cluster headache with periods that are predictable', 'entities': [['10', '26', 'chronic_disease']]}, 'NCT02981173'), ({'text': 'Pregnancy (as confirmed by urine pregnancy test at study outset)', 'entities': [['1', '10', 'pregnancy'], ['28', '43', 'pregnancy']]}, 'NCT02463305'), ({'text': 'Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters', 'entities': [['8', '30', 'cancer'], ['32', '47', 'cancer'], ['51', '55', 'cancer'], ['70', '73', 'lower_bound'], ['99', '100', 'lower_bound']]}, 'NCT01245712'), ({'text': 'Bothersome idiopathic (non-neurologic) urgency urinary incontinence (UUI) who recall e 5 urgency predominant urinary incontinence episodes in the prior week (urgency urinary incontinence or mixed urinary incontinence-urgency predominant)', 'entities': [['40', '74', 'clinical_variable'], ['88', '89', 'lower_bound']]}, 'NCT02495389'), ({'text': 'Signs of dementia (score < 24 on the Montreal Cognitive Assessment)', 'entities': [['10', '18', 'chronic_disease'], ['28', '30', 'upper_bound']]}, 'NCT02465034'), ({'text': '2 hour plasma glucose <140 mg/dL (7.8 mmol/L)', 'entities': [['1', '22', 'clinical_variable'], ['25', '46', 'upper_bound']]}, 'NCT01773707'), ({'text': 'Patients who have received previous vaginal, pelvic, or abdominal irradiation', 'entities': [['28', '44', 'treatment'], ['46', '52', 'treatment'], ['57', '78', 'treatment']]}, 'NCT00492778'), ({'text': 'Patients with evidence of interstitial lung disease or active, non-infectious pneumonitis', 'entities': [['27', '52', 'chronic_disease'], ['64', '90', 'chronic_disease']]}, 'NCT03162731'), ({'text': 'The child has been diagnosed with leukemia or lymphoma, malignant solid tumor, or malignant brain tumor', 'entities': [['35', '43', 'cancer'], ['47', '55', 'cancer'], ['57', '78', 'cancer'], ['83', '104', 'cancer']]}, 'NCT02505165'), ({'text': 'Females who are pregnant', 'entities': [['1', '8', 'gender'], ['13', '25', 'pregnancy']]}, 'NCT03058783'), ({'text': 'Participants with known active collagen vascular disease', 'entities': [['32', '57', 'chronic_disease']]}, 'NCT02335671'), ({'text': 'Subject is currently on Benzodiazepine at a dose higher than 3 mg of Lorazepam or equivalent', 'entities': [['25', '39', 'treatment'], ['62', '66', 'lower_bound'], ['70', '79', 'clinical_variable']]}, 'NCT02479906'), ({'text': 'Participants with central nervous system (CNS) involvement by leukemia (CNS2 and CNS3) may be considered eligible after discussions with the study team', 'entities': [['63', '71', 'cancer']]}, 'NCT02146924'), ({'text': 'Must satisfy the 2010 ACR/EULAR classification criteria for rheumatoid arthritis plus a disease duration of at least 6 months', 'entities': [['61', '81', 'chronic_disease'], ['118', '126', 'lower_bound']]}, 'NCT01864265'), ({'text': 'Positive screen for sleep apnea via a portable sleep apnea screening device or a prior diagnosis of sleep apnea in medical records', 'entities': [['21', '32', 'chronic_disease'], ['39', '76', 'treatment']]}, 'NCT02535923'), ({'text': 'evidence of endocervical disease defined as CIN 2/3 diagnosed on endocervical curettage', 'entities': [['13', '33', 'cancer'], ['45', '48', 'chronic_disease'], ['66', '88', 'treatment']]}, 'NCT02864147'), ({'text': 'under 25', 'entities': [['7', '9', 'upper_bound']]}, 'NCT02477124'), ({'text': 'Patient has undergone stem cell transplant or gene therapy for the treatment of inherited EB', 'entities': [['23', '43', 'treatment'], ['47', '59', 'treatment'], ['82', '93', 'chronic_disease']]}, 'NCT03068780'), ({'text': 'Planned neoadjuvant treatment with anthracycline and taxane containing chemotherapy', 'entities': [['9', '30', 'treatment'], ['36', '49', 'treatment'], ['54', '60', 'treatment'], ['72', '84', 'treatment']]}, 'NCT02595372'), ({'text': 'HIV viral load should be well suppressed, defined as below the limit of detection of the local assay or below 75 copies/mL by Food and Drug Administration (FDA)-approved assays, within 4 weeks prior to registration', 'entities': [['1', '4', 'chronic_disease'], ['111', '123', 'upper_bound'], ['186', '199', 'upper_bound']]}, 'NCT02408861'), ({'text': 'Documented growth following prior surgery', 'entities': [['29', '42', 'treatment']]}, 'NCT00887146'), ({'text': 'Pathologically (histologically or cytologically) proven diagnosis of invasive breast cancer', 'entities': [['79', '92', 'cancer']]}, 'NCT01622868'), ({'text': 'Pneumonitis within the last 5 years', 'entities': [['1', '12', 'chronic_disease'], ['24', '36', 'upper_bound']]}, 'NCT03132636'), ({'text': 'Photosensitivity to flickering lights', 'entities': [['21', '38', 'allergy_name']]}, 'NCT03188042'), ({'text': 'New York Heart Association Class 3 or 4 congestive heart failure', 'entities': [['1', '33', 'clinical_variable'], ['34', '35', 'lower_bound'], ['39', '40', 'upper_bound'], ['41', '65', 'chronic_disease']]}, 'NCT02931110'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT01996436'), ({'text': 'At least 90 days must have elapsed if prior radiation to e50% of the pelvis, the spine, or other substantial bone marrow radiation including TBI', 'entities': [['10', '17', 'lower_bound'], ['39', '54', 'treatment'], ['59', '62', 'lower_bound'], ['70', '76', 'treatment'], ['82', '87', 'treatment'], ['98', '131', 'treatment'], ['142', '145', 'chronic_disease']]}, 'NCT02512926'), ({'text': 'Myeloma with < 5% plasma cells in the marrow', 'entities': [['1', '8', 'cancer'], ['16', '18', 'upper_bound']]}, 'NCT02566304'), ({'text': 'Males and females not willing to use effective contraception', 'entities': [['1', '18', 'gender'], ['19', '61', 'contraception_consent']]}, 'NCT02448381'), ({'text': 'Patients with a documented diagnosis of recurrent head and neck squamous cell cancer (squamous cell carcinoma, including nasopharyngeal cancer, or adenoid cystic carcinoma)', 'entities': [['51', '85', 'cancer'], ['87', '110', 'cancer'], ['122', '143', 'cancer'], ['148', '172', 'cancer']]}, 'NCT02438995'), ({'text': 'peripheral vascular disease and severe peripheral neuropathy', 'entities': [['1', '28', 'chronic_disease'], ['40', '61', 'chronic_disease']]}, 'NCT00065676'), ({'text': 'Evidence of traumatic brain injury', 'entities': [['13', '35', 'chronic_disease']]}, 'NCT02646787'), ({'text': 'Toxicity should be less than or equal to grade 1 or returned to baseline', 'entities': [['1', '9', 'clinical_variable'], ['42', '49', 'upper_bound']]}, 'NCT02311361'), ({'text': 'At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy', 'entities': [['10', '17', 'lower_bound'], ['81', '99', 'treatment'], ['103', '134', 'treatment']]}, 'NCT02568267'), ({'text': 'Subject meets DSM-5 criteria for major depression and/or bipolar disorder', 'entities': [['34', '50', 'chronic_disease'], ['58', '74', 'chronic_disease']]}, 'NCT03099590'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT01915095'), ({'text': 'Cyanotic congenital heart defect', 'entities': [['1', '33', 'chronic_disease']]}, 'NCT02579265'), ({'text': 'less than 16 weeks gestation', 'entities': [['11', '19', 'upper_bound']]}, 'NCT02267772'), ({'text': 'An aspartate transaminase (AST) or alanine transaminase (ALT) level more than 3 times the upper limit of normal', 'entities': [['4', '32', 'clinical_variable'], ['37', '68', 'clinical_variable'], ['79', '112', 'lower_bound']]}, 'NCT00713492'), ({'text': 'Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan performed within 90 days prior to randomization does not demonstrate metastatic disease', 'entities': [['15', '35', 'clinical_variable'], ['57', '66', 'upper_bound'], ['137', '146', 'treatment'], ['148', '159', 'treatment'], ['164', '172', 'treatment'], ['190', '203', 'upper_bound'], ['242', '260', 'cancer']]}, 'NCT02488967'), ({'text': 'Non-steroidal joint injection within the last 3 months', 'entities': [['1', '30', 'treatment'], ['42', '55', 'upper_bound']]}, 'NCT02657993'), ({'text': 'Serologic positivity for HIV, HCV, or HbsAg positivity', 'entities': [['26', '29', 'chronic_disease'], ['31', '34', 'chronic_disease'], ['39', '44', 'chronic_disease']]}, 'NCT01758042'), ({'text': 'History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies', 'entities': [['46', '55', 'allergy_name'], ['59', '87', 'allergy_name']]}, 'NCT02393157'), ({'text': 'Total serum bilirubin <1.5 X upper limit of normal (ULN)', 'entities': [['1', '22', 'clinical_variable'], ['24', '57', 'upper_bound']]}, 'NCT02863991'), ({'text': 'Adequate Renal function Creatinine <1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of e 50ml/min', 'entities': [['25', '35', 'clinical_variable'], ['37', '74', 'upper_bound'], ['89', '109', 'clinical_variable'], ['115', '123', 'lower_bound']]}, 'NCT01815359'), ({'text': 'severe bleeding phenotype', 'entities': [['8', '26', 'chronic_disease']]}, 'NCT03001830'), ({'text': 'ALT and AST d 3.0 x ULN', 'entities': [['1', '4', 'clinical_variable'], ['9', '12', 'clinical_variable'], ['15', '24', 'upper_bound']]}, 'NCT01925573'), ({'text': 'must be able to communicate effectively by telephone (no cognitive disability)', 'entities': [['17', '53', 'technology_access'], ['58', '78', 'chronic_disease']]}, 'NCT01983228'), ({'text': 'bilaterally intact tympanic membranes', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT01976429'), ({'text': 'extreme claustrophobia', 'entities': [['9', '23', 'chronic_disease']]}, 'NCT01591356'), ({'text': 'Biopsy proven HNSCC of the oropharynx, larynx, hypopharynx, or oral cavity Stage III-IVB as defined by American Joint Committee on Cancer (AJCC) T0-T4, N0 - N3, M0', 'entities': [['1', '7', 'treatment'], ['15', '38', 'cancer'], ['40', '46', 'cancer'], ['48', '59', 'cancer'], ['64', '75', 'cancer'], ['76', '85', 'lower_bound'], ['86', '89', 'upper_bound']]}, 'NCT02585973'), ({'text': 'Vasoactive infusion for at least 12 hours, including dopamine e5mcg/kg/min, dobutaminee5mcg/kg/min, or any dose of epinephrine, norepinephrine, milrinone, or vasopressin', 'entities': [['1', '20', 'treatment'], ['34', '42', 'lower_bound'], ['54', '62', 'treatment'], ['64', '75', 'lower_bound'], ['77', '87', 'treatment'], ['116', '127', 'treatment'], ['129', '143', 'treatment'], ['145', '154', 'treatment'], ['159', '170', 'treatment']]}, 'NCT02007239'), ({'text': 'Screening ANC should be independent of granulocyte-and granulocyte/macrophage colony stimulating factor (G-CSF and GM-CSF) support for at least 1 week and of pegylated G-CSF for at least 2 weeks', 'entities': [['11', '14', 'clinical_variable'], ['145', '151', 'lower_bound'], ['188', '195', 'lower_bound']]}, 'NCT01464034'), ({'text': 'History of organ allograft (including corneal transplant)', 'entities': [['12', '27', 'treatment'], ['39', '57', 'treatment']]}, 'NCT03042689'), ({'text': 'Fear of needles or unwilling to have needling performed due to fear or personal beliefs', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02532595'), ({'text': 'Known coronary artery disease', 'entities': [['7', '30', 'chronic_disease']]}, 'NCT01184547'), ({'text': 'Requirement for other reasons for another antibiotic potentially active against organisms commonly causing osteomyelitis in children', 'entities': [['108', '121', 'chronic_disease']]}, 'NCT02335905'), ({'text': "Have a negative serum or urine (investigator's discretion under local regulations) ²-hCG pregnancy test (sensitivity of at least 25 mIU/mL) within 72 hours prior to the start of study treatment in the Treatment Phase", 'entities': [['8', '99', 'pregnancy'], ['106', '117', 'clinical_variable'], ['130', '139', 'lower_bound'], ['148', '162', 'upper_bound'], ['179', '194', 'treatment'], ['202', '211', 'treatment']]}, 'NCT02577406'), ({'text': 'Have pain severity (arithmetic mean of four pain severity items) >/= 2 on BPI', 'entities': [['6', '65', 'clinical_variable'], ['70', '71', 'lower_bound']]}, 'NCT02754752'), ({'text': 'Patient must have performance status </=2 on the ECOG Performance Scale', 'entities': [['19', '37', 'clinical_variable'], ['41', '42', 'upper_bound'], ['50', '72', 'clinical_variable']]}, 'NCT02321501'), ({'text': 'Adult men', 'entities': [['7', '10', 'gender']]}, 'NCT02453113'), ({'text': 'Treatment with an investigational anti-cancer study drug within 3 weeks prior to study drug administration date', 'entities': [['1', '10', 'treatment'], ['35', '57', 'treatment'], ['47', '57', 'treatment'], ['65', '78', 'upper_bound']]}, 'NCT02419495'), ({'text': 'Myelodysplastic syndrome', 'entities': [['1', '25', 'cancer']]}, 'NCT02566395'), ({'text': 'ages 18-65', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '11', 'upper_bound']]}, 'NCT02563678'), ({'text': 'Patients on PDEV inhibition for pulmonary hypertension', 'entities': [['13', '28', 'treatment'], ['33', '55', 'chronic_disease']]}, 'NCT01970176'), ({'text': 'Must be willing to take effective antiretroviral therapy, if indicated', 'entities': [['35', '57', 'treatment']]}, 'NCT01415752'), ({'text': 'History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes)', 'entities': [['12', '15', 'chronic_disease'], ['19', '22', 'chronic_disease'], ['82', '90', 'chronic_disease'], ['94', '113', 'chronic_disease'], ['101', '113', 'chronic_disease'], ['128', '144', 'chronic_disease'], ['167', '184', 'chronic_disease'], ['200', '214', 'chronic_disease'], ['218', '236', 'chronic_disease']]}, 'NCT01989585'), ({'text': 'active participation in other stroke recovery trials testing experimental interventions', 'entities': [['31', '37', 'chronic_disease']]}, 'NCT00903266'), ({'text': 'a negative serum pregnancy test done d 7 days prior to registration', 'entities': [['3', '27', 'pregnancy'], ['40', '52', 'upper_bound']]}, 'NCT02143726'), ({'text': 'Pulmonary diseases', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT03154567'), ({'text': 'subjects receiving chemotherapy regimens not specified in the inclusion criteria', 'entities': [['20', '41', 'treatment']]}, 'NCT02122185'), ({'text': 'calculated creatinine clearance (Cockcroft-Gault formula)', 'entities': [['1', '32', 'clinical_variable']]}, 'NCT02272998'), ({'text': 'Has an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus infection, or active hepatitis B or C infection', 'entities': [['8', '30', 'chronic_disease'], ['41', '55', 'treatment'], ['57', '67', 'treatment'], ['72', '83', 'treatment'], ['91', '129', 'chronic_disease'], ['141', '167', 'chronic_disease']]}, 'NCT02319369'), ({'text': 'ages 18-90', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '11', 'upper_bound']]}, 'NCT01953575'), ({'text': 'Current evidence of GVHD > grade 2 for Arm A and B; Active GVHD of any grade is exclusion for arm C patients', 'entities': [['28', '35', 'lower_bound']]}, 'NCT02203903'), ({'text': 'No access to telephone', 'entities': [['1', '23', 'technology_access']]}, 'NCT03073811'), ({'text': 'History of Neck Surgery', 'entities': [['12', '24', 'treatment']]}, 'NCT02803359'), ({'text': 'FEV1, FVC and corrected DLCO >/= 40%', 'entities': [['1', '5', 'clinical_variable'], ['7', '10', 'clinical_variable'], ['25', '29', 'clinical_variable'], ['34', '37', 'lower_bound']]}, 'NCT02512497'), ({'text': 'Patients must have between 1 to 5 new or recurrent lesions suspicious for metastatic RCC on diagnostic imaging', 'entities': [['28', '29', 'lower_bound'], ['33', '34', 'upper_bound'], ['75', '89', 'cancer'], ['104', '111', 'treatment']]}, 'NCT02542202'), ({'text': 'Metal objects within the body that would contraindicate and MRI', 'entities': [['1', '14', 'allergy_name'], ['61', '64', 'treatment']]}, 'NCT01964404'), ({'text': 'Patients known to be human immunodeficiency virus (HIV) positive and currently receiving retroviral therapy', 'entities': [['22', '65', 'chronic_disease'], ['22', '56', 'chronic_disease'], ['90', '108', 'treatment']]}, 'NCT00887146'), ({'text': 'Category I drugs that are generally accepted to have a risk of causing torsades de pointes including: (patients must discontinue drug at least 7 days prior to starting dasatinib)', 'entities': [['10', '17', 'treatment'], ['144', '156', 'lower_bound'], ['169', '178', 'treatment']]}, 'NCT02389309'), ({'text': 'History of any neurological disease', 'entities': [['16', '36', 'chronic_disease']]}, 'NCT03023449'), ({'text': 'Diagnosis of cancer', 'entities': [['14', '20', 'cancer']]}, 'NCT03040726'), ({'text': 'History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening', 'entities': [['12', '36', 'chronic_disease'], ['48', '69', 'chronic_disease'], ['71', '86', 'chronic_disease'], ['88', '119', 'chronic_disease'], ['121', '141', 'chronic_disease'], ['171', '183', 'chronic_disease'], ['191', '205', 'upper_bound']]}, 'NCT03008408'), ({'text': 'Patients who did not enroll during their chemotherapy are still eligible to enroll during subsequent hormonal therapy or radiation as long as it is within 6 months of diagnosis', 'entities': [['42', '54', 'treatment'], ['91', '118', 'treatment'], ['122', '131', 'treatment'], ['156', '164', 'upper_bound']]}, 'NCT02639208'), ({'text': 'Platelet count (PLT) < 100,000/¼l', 'entities': [['1', '21', 'clinical_variable'], ['24', '34', 'upper_bound']]}, 'NCT02576444'), ({'text': "subjects with Crohn's disease or a partial or complete small bowel obstruction", 'entities': [['15', '30', 'chronic_disease'], ['56', '79', 'chronic_disease']]}, 'NCT01827384'), ({'text': 'Progression following both standard combined modality treatment with radiation and temozolomide chemotherapy, as well as anti-angiogenic therapy (ie, bevacizumab; patients not eligible for or refusing antiangiogenic therapy will also be allowed)', 'entities': [['37', '109', 'treatment'], ['122', '145', 'treatment'], ['151', '162', 'treatment'], ['202', '224', 'treatment']]}, 'NCT01906385'), ({'text': 'Intracardiac thrombus', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02513797'), ({'text': 'Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; patients who have had prior onalespib or AT7519M as a monotherapy will not be excluded', 'entities': [['23', '35', 'treatment'], ['39', '51', 'treatment'], ['59', '66', 'upper_bound'], ['68', '75', 'upper_bound'], ['80', '92', 'treatment'], ['96', '107', 'treatment'], ['160', '186', 'treatment'], ['192', '203', 'treatment']]}, 'NCT02503709'), ({'text': 'Pregnancy (including plan to become pregnant)', 'entities': [['1', '10', 'pregnancy'], ['22', '45', 'pregnancy']]}, 'NCT01789333'), ({'text': 'Protein C deficiency (increased risk of skin necrosis do those on injectable anticoagulation)', 'entities': [['1', '21', 'chronic_disease'], ['41', '54', 'chronic_disease'], ['67', '93', 'treatment']]}, 'NCT02366871'), ({'text': 'Patients with evidence of active central nervous system lymphoma', 'entities': [['34', '65', 'cancer']]}, 'NCT02227199'), ({'text': 'Prior sipuleucel-T treatment or investigational immunotherapy', 'entities': [['1', '29', 'treatment'], ['33', '62', 'treatment']]}, 'NCT01804465'), ({'text': 'Rapidly progressive brain lesions', 'entities': [['21', '34', 'cancer']]}, 'NCT02339376'), ({'text': 'Mini-Mental Status Examination (MMSE) score <23 or dementia', 'entities': [['1', '44', 'clinical_variable'], ['46', '48', 'upper_bound'], ['52', '60', 'chronic_disease']]}, 'NCT03054519'), ({'text': 'Currently or has participated in a clinical study in the last 3 months prior to signing informed consent', 'entities': [['36', '50', 'treatment'], ['58', '71', 'upper_bound']]}, 'NCT02393885'), ({'text': 'Concurrent anticonvulsant medications for psychiatric indications (e.g. bipolar disorder) will be allowed', 'entities': [['12', '38', 'treatment'], ['43', '66', 'chronic_disease'], ['73', '89', 'chronic_disease']]}, 'NCT03012815'), ({'text': 'Has had an allogeneic tissue/solid organ transplant', 'entities': [['12', '29', 'treatment'], ['30', '52', 'treatment']]}, 'NCT02501473'), ({'text': 'Prior therapy must have included a rituximab-based regimen', 'entities': [['1', '14', 'treatment'], ['36', '59', 'treatment']]}, 'NCT02594384'), ({'text': 'commit to using birth control during the study', 'entities': [['1', '30', 'contraception_consent']]}, 'NCT02905591'), ({'text': 'The subject is pregnant', 'entities': [['16', '24', 'pregnancy']]}, 'NCT03070899'), ({'text': 'Subjects e 16 years will be enrolled in Cohort A. Subjects 3 - 15 years will be enrolled in Cohort B', 'entities': [['12', '14', 'lower_bound'], ['60', '61', 'lower_bound'], ['64', '72', 'upper_bound']]}, 'NCT02101736'), ({'text': 'known additional malignancy that is progressing or requires active treatment', 'entities': [['18', '28', 'cancer'], ['61', '77', 'treatment']]}, 'NCT02407171'), ({'text': 'Active peptic ulcer disease', 'entities': [['8', '28', 'chronic_disease']]}, 'NCT02132598'), ({'text': 'Meningeal signs are present', 'entities': [['1', '10', 'chronic_disease']]}, 'NCT03185130'), ({'text': 'Narcotic or sedative within 4 hours of enrollment', 'entities': [['29', '36', 'upper_bound']]}, 'NCT02832115'), ({'text': 'Has a known additional malignancy that is progressing or requires active treatment', 'entities': [['24', '34', 'cancer'], ['67', '83', 'treatment']]}, 'NCT02541565'), ({'text': 'HLA identical or up to a 1 antigen mismatched unrelated BM donor', 'entities': [['26', '27', 'upper_bound']]}, 'NCT01652092'), ({'text': 'Participants must have evaluable or measurable disease in accordance with the International Working Group Guidelines for Lymphoma', 'entities': [['122', '130', 'cancer']]}, 'NCT02564744'), ({'text': "Ewing's sarcoma must have progressed following at least one standard prior chemotherapy regimen", 'entities': [['1', '16', 'cancer'], ['76', '96', 'treatment']]}, 'NCT01858168'), ({'text': 'men who are sexually active', 'entities': [['1', '4', 'gender']]}, 'NCT01993810'), ({'text': 'Patients with severe back pain, e 4 cm in visual analogue scale (0-10) [1] or radiating leg pain', 'entities': [['15', '31', 'chronic_disease'], ['35', '39', 'lower_bound'], ['43', '64', 'clinical_variable'], ['66', '67', 'lower_bound'], ['68', '70', 'upper_bound']]}, 'NCT03171168'), ({'text': 'history of severe systemic reaction(s)', 'entities': [['19', '39', 'chronic_disease']]}, 'NCT02836574'), ({'text': 'If serum IgM<normal for age', 'entities': [['4', '13', 'clinical_variable'], ['25', '28', 'age']]}, 'NCT01306019'), ({'text': 'Known human immunodeficiency virus (HIV) infection', 'entities': [['7', '51', 'chronic_disease']]}, 'NCT01389024'), ({'text': 'stroke', 'entities': [['1', '7', 'chronic_disease']]}, 'NCT02577406'), ({'text': 'men who have a pregnant partner must be willing to use a condom during sexual activity throughout protocol therapy and for 3 months after the last dose of protocol-specified therapy', 'entities': [['1', '4', 'gender'], ['16', '24', 'pregnancy'], ['41', '64', 'contraception_consent'], ['108', '115', 'treatment'], ['124', '138', 'upper_bound']]}, 'NCT02003222'), ({'text': 'Sickle cell disease', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02299414'), ({'text': 'All subjects must have recurrent or metastatic HER2-positive breast cancer', 'entities': [['24', '75', 'cancer']]}, 'NCT01976169'), ({'text': 'Patients who have untreated B-cell or T-cell ALL confirmed by conventional flow cytometry or immunohistochemical stain, but Ph status is unknown, may also enroll', 'entities': [['29', '35', 'cancer'], ['39', '49', 'cancer'], ['63', '90', 'treatment'], ['94', '119', 'treatment']]}, 'NCT01920737'), ({'text': 'Negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization', 'entities': [['1', '19', 'pregnancy'], ['28', '43', 'gender'], ['106', '115', 'upper_bound'], ['122', '153', 'treatment']]}, 'NCT02479698'), ({'text': "Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents; subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule; subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study; subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study", 'entities': [['15', '33', 'chronic_disease'], ['44', '62', 'treatment'], ['74', '87', 'upper_bound'], ['181', '198', 'treatment'], ['202', '226', 'treatment'], ['242', '250', 'chronic_disease'], ['273', '285', 'chronic_disease'], ['364', '379', 'treatment'], ['383', '407', 'treatment'], ['460', '474', 'chronic_disease'], ['485', '504', 'treatment'], ['508', '526', 'chronic_disease']]}, 'NCT02411656'), ({'text': 'Pinhole visual acuity worse than 20/200 in the unaffected eye', 'entities': [['1', '22', 'clinical_variable'], ['34', '40', 'lower_bound']]}, 'NCT02570321'), ({'text': 'patients with newly diagnosed or previously treated disease are eligible as long as prior therapy does not include hypomethylating agents', 'entities': [['85', '98', 'treatment'], ['116', '138', 'treatment']]}, 'NCT02257138'), ({'text': 'Any condition that would prohibit patient from initiating valproic acid', 'entities': [['59', '72', 'treatment']]}, 'NCT01817751'), ({'text': 'Patient has been previously diagnosed with multiple myeloma based on standard criteria', 'entities': [['44', '60', 'cancer']]}, 'NCT03143985'), ({'text': 'Leptomeningeal metastases', 'entities': [['1', '26', 'cancer']]}, 'NCT02531932'), ({'text': 'Chronic pain condition (e.g., fibromyalgia, migraines for healthy controls, etc.)', 'entities': [['1', '13', 'chronic_disease'], ['31', '43', 'chronic_disease'], ['45', '75', 'chronic_disease']]}, 'NCT02748577'), ({'text': 'Healthy women', 'entities': [['9', '14', 'gender']]}, 'NCT00914823'), ({'text': 'Patient has a prostate size larger than 90g as measured by transrectal ultrasound (TRUS)', 'entities': [['41', '44', 'lower_bound'], ['60', '89', 'treatment']]}, 'NCT02167009'), ({'text': 'A live vaccination fewer than 3 months before enrollment', 'entities': [['3', '19', 'treatment'], ['31', '46', 'upper_bound']]}, 'NCT02108860'), ({'text': 'must not be a candidate for radiation therapy or surgery', 'entities': [['29', '46', 'treatment'], ['50', '57', 'treatment']]}, 'NCT03132636'), ({'text': 'Asphyxia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02249039'), ({'text': 'Severe heart failure (NYHA association Class 3 or 4), high grade arrhythmias, severe valvular heart disease', 'entities': [['8', '21', 'chronic_disease'], ['23', '52', 'clinical_variable'], ['55', '77', 'chronic_disease'], ['86', '108', 'chronic_disease']]}, 'NCT02342808'), ({'text': 'Greater than moderate valvular disease or congenital heart disease', 'entities': [['14', '39', 'chronic_disease'], ['43', '67', 'chronic_disease']]}, 'NCT03111017'), ({'text': 'Meet both screening criteria on clinically-performed cardiopulmonary exercise testing within 12 months', 'entities': [['94', '103', 'upper_bound']]}, 'NCT02145351'), ({'text': 'Poor bone marrow reserve resulting in low blood cell counts', 'entities': [['43', '60', 'clinical_variable']]}, 'NCT02187848'), ({'text': 'Subjects must have persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix, with documented disease progression (disease not amenable to curative therapy)', 'entities': [['46', '80', 'cancer'], ['82', '105', 'cancer'], ['109', '137', 'cancer'], ['209', '216', 'treatment']]}, 'NCT03104699'), ({'text': 'Pain disorder of the jaw muscles or mandibular joint', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02442102'), ({'text': 'aspartate aminotransferase (AST) < 3 x upper limit of institutional normal', 'entities': [['1', '33', 'clinical_variable'], ['36', '75', 'upper_bound']]}, 'NCT01526603'), ({'text': 'unstable angina pectoris', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02227199'), ({'text': 'HIV infection', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT03078907'), ({'text': 'total bilirubin d 1.5 mg/dl', 'entities': [['7', '16', 'clinical_variable'], ['19', '28', 'upper_bound']]}, 'NCT03067051'), ({'text': 'Receiving immunosuppressive medications', 'entities': [['11', '40', 'treatment']]}, 'NCT02707692'), ({'text': 'Having a previous serious head injury or neurological disorder, or loss of consciousness for more than 2 minutes', 'entities': [['19', '38', 'chronic_disease'], ['42', '63', 'chronic_disease'], ['104', '113', 'lower_bound']]}, 'NCT03141164'), ({'text': 'Patients who received rituximab previously with CD20 count of zero at the time of enrollment', 'entities': [['23', '32', 'treatment'], ['49', '53', 'treatment']]}, 'NCT03095118'), ({'text': 'Anemia (Hgb less than 10g/dL)', 'entities': [['1', '7', 'chronic_disease'], ['9', '12', 'clinical_variable'], ['23', '29', 'upper_bound']]}, 'NCT01059786'), ({'text': 'long QT syndrome', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT01625923'), ({'text': 'Women who are pregnant', 'entities': [['1', '6', 'gender'], ['15', '23', 'pregnancy']]}, 'NCT02498951'), ({'text': 'Has a contralateral amputation', 'entities': [['7', '31', 'treatment']]}, 'NCT02131389'), ({'text': 'hypersensitivity to Afrin, Lidocaine or albuterol', 'entities': [['21', '26', 'allergy_name'], ['28', '37', 'allergy_name'], ['41', '50', 'allergy_name']]}, 'NCT02567448'), ({'text': "As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system", 'entities': [['136', '144', 'upper_bound']]}, 'NCT02562716'), ({'text': 'Traumatic brain injury', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02582957'), ({'text': 'Subjects who, in the opinion of the investigator, have a vascular disease prognosis that indicates they would require a major amputation in a time frame shortly after administration of the IMP (investigational drug or placebo)', 'entities': [['58', '74', 'chronic_disease'], ['121', '137', 'treatment'], ['195', '215', 'treatment']]}, 'NCT02551679'), ({'text': 'cardiac arrhythmia (past or present)', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02838797'), ({'text': 'Use of illicit drugs within the past 6 months prior to study start', 'entities': [['33', '52', 'upper_bound']]}, 'NCT02268448'), ({'text': 'Age >/= 18 years', 'entities': [['1', '4', 'age'], ['9', '17', 'lower_bound']]}, 'NCT02128100'), ({'text': 'at least one cutaneous lesion (each lesion e 10 mm longest diameteror up to 5 lesions in aggregate having a sum of longest diameters e 10 mm)', 'entities': [['10', '13', 'lower_bound'], ['14', '30', 'clinical_variable'], ['24', '30', 'clinical_variable'], ['46', '51', 'lower_bound'], ['77', '86', 'upper_bound'], ['116', '133', 'clinical_variable']]}, 'NCT02557321'), ({'text': 'Biopsy was performed or attempted but with complications requiring abortion of procedure', 'entities': [['1', '7', 'treatment']]}, 'NCT02950337'), ({'text': 'Presence of at least two vessel coronary artery disease not amenable to direct revascularization', 'entities': [['33', '56', 'chronic_disease']]}, 'NCT03043742'), ({'text': 'INR </=1.5', 'entities': [['1', '4', 'clinical_variable'], ['8', '11', 'upper_bound']]}, 'NCT03008408'), ({'text': 'Neuropathy with or without pain', 'entities': [['1', '11', 'chronic_disease']]}, 'NCT01419561'), ({'text': 'Female patients of childbearing age are excluded if they are pregnant as determined with a serum beta HCG no greater than 14 days prior to study registration, or breast-feeding', 'entities': [['1', '16', 'gender'], ['33', '36', 'age'], ['58', '70', 'pregnancy'], ['92', '106', 'clinical_variable'], ['123', '136', 'lower_bound']]}, 'NCT01644591'), ({'text': 'women who are breastfeeding', 'entities': [['1', '6', 'gender']]}, 'NCT02131467'), ({'text': 'intractable symptoms of ET or dystonia impacting at least 2 activities of daily living', 'entities': [['25', '27', 'cancer'], ['31', '39', 'chronic_disease'], ['59', '60', 'lower_bound']]}, 'NCT01581580'), ({'text': 'male', 'entities': [['1', '5', 'gender']]}, 'NCT02389465'), ({'text': 'eGFR retesting during the screening period is allowed (once)', 'entities': [['1', '5', 'clinical_variable']]}, 'NCT01895777'), ({'text': 'Respiratory failure requiring greater than 6 Lpm supplemental oxygen (O2) by nasal cannula or mechanical ventilation within the past six weeks', 'entities': [['1', '20', 'chronic_disease'], ['44', '49', 'lower_bound'], ['50', '74', 'treatment'], ['78', '91', 'treatment'], ['95', '117', 'treatment'], ['129', '143', 'upper_bound']]}, 'NCT02937402'), ({'text': 'Pediatric research participants must weigh > 50 kg', 'entities': [['38', '43', 'clinical_variable'], ['46', '51', 'lower_bound']]}, 'NCT02159495'), ({'text': "A decision by the subject's family and primary clinician to initiate hydroxyurea therapy, made independently of recruitment for the study (not applicable for the biological arm patients)", 'entities': [['70', '89', 'treatment']]}, 'NCT02042222'), ({'text': 'Male patients (even those post vasectomy) who are willing to use adequate contraceptive measures or abstain from heterosexual intercourse during the entire study treatment period and for 4 months after the last dose of study drug', 'entities': [['1', '14', 'gender'], ['32', '41', 'contraception_consent'], ['51', '97', 'contraception_consent'], ['163', '172', 'treatment'], ['188', '202', 'upper_bound']]}, 'NCT01990209'), ({'text': 'Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)', 'entities': [['1', '15', 'clinical_variable'], ['19', '31', 'lower_bound'], ['33', '44', 'treatment'], ['83', '104', 'treatment'], ['118', '130', 'lower_bound']]}, 'NCT02323880'), ({'text': 'Exposure to any immunomodulatory drug (including maraviroc) in the16 weeks prior to study', 'entities': [['17', '38', 'treatment'], ['50', '59', 'treatment'], ['67', '81', 'upper_bound']]}, 'NCT02531295'), ({'text': 'Have a history of drug or alcohol abuse within the past 24 months', 'entities': [['52', '66', 'upper_bound']]}, 'NCT03059355'), ({'text': 'Subjects with degenerative and toxic encephalopathies, especially after the use of methotrexate or treatment with ionizing radiation, should not receive cytarabine', 'entities': [['84', '96', 'treatment'], ['100', '133', 'treatment'], ['154', '164', 'treatment']]}, 'NCT02577406'), ({'text': 'Women of childbearing potential', 'entities': [['1', '6', 'gender']]}, 'NCT03114020'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT01878617'), ({'text': 'Hypersensitivity to perampanel', 'entities': [['21', '31', 'allergy_name']]}, 'NCT02131467'), ({'text': 'oral antibiotics </=4 weeks prior to screening', 'entities': [['1', '17', 'clinical_variable'], ['21', '34', 'upper_bound']]}, 'NCT02394028'), ({'text': 'Adequate anticoagulation cannot be achieved due to severe hemophilia, severe hemorrhage diathesis, severe gastrointestinal ulcers, or are recipients of vitamin K antagonist medications', 'entities': [['10', '25', 'treatment'], ['52', '69', 'chronic_disease'], ['78', '98', 'chronic_disease'], ['107', '130', 'chronic_disease'], ['153', '185', 'treatment']]}, 'NCT02235857'), ({'text': 'patients with hypercalcemia can be enrolled after the calcium is corrected with standard of care treatments', 'entities': [['15', '28', 'chronic_disease'], ['98', '108', 'treatment']]}, 'NCT01787409'), ({'text': 'High risk NSCLC with resection option for potential cure, as assessed by a faculty surgeon at SKCCC or MSKCC', 'entities': [['11', '16', 'cancer']]}, 'NCT02259621'), ({'text': 'Abnormal PC immunophenotype (greater than or equal to 95% of BMPCs are clonal)', 'entities': [['1', '28', 'clinical_variable'], ['55', '58', 'lower_bound']]}, 'NCT01572480'), ({'text': 'The subject has a planned cerclage placement for the current pregnancy', 'entities': [['27', '45', 'treatment'], ['54', '71', 'pregnancy']]}, 'NCT03151330'), ({'text': 'access to a telephone', 'entities': [['1', '22', 'technology_access']]}, 'NCT03108820'), ({'text': 'Stable, concurrent use of tamoxifen or aromatase inhibitors for hormone receptor positive breast cancer are allowed', 'entities': [['27', '36', 'treatment'], ['40', '60', 'treatment'], ['91', '104', 'cancer']]}, 'NCT01730118'), ({'text': 'Fasting plasma glucose < 110 mg/dL (6.1 mmol/L)', 'entities': [['1', '23', 'clinical_variable'], ['26', '48', 'upper_bound']]}, 'NCT01773707'), ({'text': 'Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting treatment on either arm', 'entities': [['9', '33', 'treatment'], ['35', '52', 'treatment'], ['57', '70', 'treatment'], ['72', '83', 'treatment'], ['145', '153', 'upper_bound'], ['167', '176', 'treatment']]}, 'NCT02520011'), ({'text': 'Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)', 'entities': [['1', '30', 'chronic_disease'], ['38', '49', 'chronic_disease'], ['51', '66', 'chronic_disease'], ['68', '79', 'chronic_disease']]}, 'NCT01626079'), ({'text': 'Creatinine =< 1.5 x upper limit of normal (ULN)', 'entities': [['1', '11', 'clinical_variable'], ['15', '48', 'upper_bound']]}, 'NCT02532231'), ({'text': 'Severe cognition or communication problems (such as coma, deafness without signing literacy, physician-documented dementia)', 'entities': [['8', '43', 'chronic_disease'], ['53', '57', 'chronic_disease'], ['59', '67', 'chronic_disease']]}, 'NCT02819141'), ({'text': 'for 90 days after the last dose of study drug', 'entities': [['5', '18', 'upper_bound']]}, 'NCT01877382'), ({'text': 'English speaking', 'entities': [['1', '17', 'language_fluency']]}, 'NCT02367092'), ({'text': 'Hypersensitivity to darbepoetin', 'entities': [['21', '32', 'allergy_name']]}, 'NCT02680574'), ({'text': 'Minimum life expectancy of six weeks as determined by consenting professional', 'entities': [['9', '24', 'clinical_variable'], ['28', '37', 'lower_bound']]}, 'NCT01099644'), ({'text': 'at least 1 systemic immunosuppressant other than corticosteroids', 'entities': [['10', '11', 'lower_bound'], ['12', '38', 'treatment'], ['50', '65', 'treatment']]}, 'NCT01280669'), ({'text': 'Hemoglobin e 9.0 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['14', '22', 'lower_bound']]}, 'NCT02507232'), ({'text': 'has a positive serum or urine pregnancy test at screening or at randomization', 'entities': [['31', '40', 'pregnancy']]}, 'NCT02402660'), ({'text': 'Availability of metreleptin to the patient either as an approved drug, or through local compassionate use or expanded access programs', 'entities': [['17', '28', 'treatment']]}, 'NCT02262806'), ({'text': 'patients who say they would be unavailable to participate in a 6 month study', 'entities': [['64', '71', 'upper_bound']]}, 'NCT01983228'), ({'text': 'Cockcroft calculated creatinine clearance of e 45 ml/min or 1.5 x the upper limit of normal (ULN)', 'entities': [['1', '42', 'clinical_variable'], ['48', '57', 'lower_bound'], ['61', '98', 'lower_bound']]}, 'NCT03128008'), ({'text': 'anticonvulsants', 'entities': [['1', '16', 'treatment']]}, 'NCT02233868'), ({'text': 'Has reliable access to a private computer or electronic tablet', 'entities': [['14', '63', 'technology_access']]}, 'NCT03096886'), ({'text': 'Presence of significant psychiatric or cognitive impairments as determined by oncologists and study teams', 'entities': [['25', '36', 'chronic_disease'], ['40', '61', 'chronic_disease']]}, 'NCT02543723'), ({'text': 'Diagnosis of allergic rhinitis and/or mild asthma', 'entities': [['14', '31', 'chronic_disease'], ['39', '50', 'chronic_disease']]}, 'NCT01026532'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01900301'), ({'text': 'Active serious infections not controlled by antibiotics', 'entities': [['8', '26', 'chronic_disease'], ['45', '56', 'treatment']]}, 'NCT01099644'), ({'text': 'Serum creatinine < 2mg/dl', 'entities': [['1', '17', 'clinical_variable'], ['20', '26', 'upper_bound']]}, 'NCT03131037'), ({'text': 'Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug', 'entities': [['1', '50', 'contraception_consent'], ['69', '84', 'treatment'], ['96', '111', 'upper_bound'], ['135', '145', 'treatment']]}, 'NCT02389517'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT02510456'), ({'text': 'Prior acetylcholinesterase inhibitor treatment', 'entities': [['1', '47', 'treatment']]}, 'NCT01584076'), ({'text': 'Granulomatous inflammation on biopsy, defined as histologic changes showing granulomatous inflammation within the wall of an artery or in the perivascular or extravascular area (artery or arteriole)', 'entities': [['31', '37', 'treatment']]}, 'NCT02108860'), ({'text': 'Patients with known renal failure and/or Cr > 5 within the last 6 months', 'entities': [['21', '34', 'chronic_disease'], ['42', '44', 'clinical_variable'], ['47', '48', 'lower_bound'], ['60', '73', 'upper_bound']]}, 'NCT02911831'), ({'text': 'Total bilirubin =<1.5 x the upper limit of the normal range (ULN)', 'entities': [['1', '16', 'clinical_variable'], ['19', '66', 'upper_bound']]}, 'NCT02339922'), ({'text': 'History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy', 'entities': [['20', '30', 'cancer'], ['38', '52', 'upper_bound'], ['102', '118', 'cancer']]}, 'NCT02091999'), ({'text': 'Prior treatment with fulvestrant in the metastatic setting is required, except for patients with a history of ER-negative metastatic breast cancer', 'entities': [['1', '59', 'treatment'], ['123', '147', 'cancer']]}, 'NCT02860000'), ({'text': 'and interocular difference in visual acuity of 3 lines or more', 'entities': [['31', '44', 'clinical_variable'], ['48', '55', 'lower_bound']]}, 'NCT02365090'), ({'text': 'Seronegative for active hepatitis B, and seronegative for hepatitis C antibody', 'entities': [['25', '36', 'chronic_disease'], ['59', '70', 'chronic_disease']]}, 'NCT02133196'), ({'text': 'bladder-neck obstruction', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03089515'), ({'text': 'emergent radiotherapy for treatment of eg. spinal cord compromise or threatened airway', 'entities': [['10', '22', 'treatment'], ['27', '36', 'treatment'], ['44', '66', 'chronic_disease'], ['70', '87', 'chronic_disease']]}, 'NCT01864109'), ({'text': 'The subject is e 18 years old on the day of consent', 'entities': [['18', '26', 'lower_bound']]}, 'NCT01639508'), ({'text': 'prior use of systemic methotrexate > 1 month prior to study entry is allowed', 'entities': [['1', '35', 'treatment'], ['38', '51', 'lower_bound']]}, 'NCT03175978'), ({'text': 'Liver mass (e 1 cm) that has suggestive imaging findings of a benign liver mass (adenoma, hemangioma, focal nodular hyperplasia)', 'entities': [['1', '11', 'clinical_variable'], ['15', '19', 'lower_bound'], ['63', '80', 'cancer'], ['82', '89', 'cancer'], ['91', '101', 'cancer'], ['103', '128', 'cancer']]}, 'NCT02379377'), ({'text': 'Evidence of glaucoma or an intraocular pressure greater than 22 mm Hg at baseline', 'entities': [['13', '21', 'chronic_disease'], ['28', '48', 'clinical_variable'], ['62', '82', 'lower_bound']]}, 'NCT02030990'), ({'text': 'A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2 years)', 'entities': [['76', '88', 'upper_bound']]}, 'NCT01993719'), ({'text': "Crohn's disease or ulcerative colitis", 'entities': [['1', '16', 'chronic_disease'], ['20', '38', 'chronic_disease']]}, 'NCT02346526'), ({'text': 'one of which must be a diuretic (with no changes for a minimum of two weeks prior to screening) that is expected to be maintained without changes for at least 6-9 months', 'entities': [['24', '32', 'treatment'], ['67', '82', 'lower_bound'], ['160', '161', 'lower_bound'], ['162', '170', 'upper_bound']]}, 'NCT02133885'), ({'text': 'The interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 70 days', 'entities': [['31', '38', 'treatment'], ['43', '56', 'cancer'], ['68', '90', 'treatment'], ['96', '109', 'treatment'], ['131', '138', 'lower_bound']]}, 'NCT01872975'), ({'text': 'Prescribed ICS as daily maintenance therapy', 'entities': [['12', '15', 'treatment']]}, 'NCT02995733'), ({'text': 'Patient with suspected intracranial neoplasm scheduled for routine MRI with GBCA (gadolinium naive patients)', 'entities': [['24', '45', 'cancer']]}, 'NCT03091803'), ({'text': 'Has a diagnosis of acute promyelocytic leukemia', 'entities': [['20', '48', 'cancer']]}, 'NCT02319369'), ({'text': 'Radiographic confirmation of at least moderate lumbar stenosis, which narrows the central spinal canal at one or two contiguous levels from L1-L5 that require surgical decompression', 'entities': [['48', '63', 'chronic_disease'], ['141', '143', 'lower_bound'], ['144', '146', 'upper_bound'], ['160', '182', 'treatment']]}, 'NCT02555280'), ({'text': 'Hepatic Function', 'entities': [['1', '17', 'treatment']]}, 'NCT01618357'), ({'text': 'Subjects with second malignancies that are indolent or definitively treated may be enrolled even if less than 5 years have elapsed since treatment', 'entities': [['22', '34', 'cancer'], ['111', '118', 'upper_bound'], ['138', '147', 'treatment']]}, 'NCT01943851'), ({'text': 'Less than 5 mm distance of the tumor margin from a major vessel >7mm in diameter)', 'entities': [['11', '15', 'upper_bound'], ['32', '44', 'clinical_variable'], ['52', '64', 'clinical_variable'], ['66', '81', 'lower_bound']]}, 'NCT01494324'), ({'text': 'Presence of diffuse leptomeningeal carcinomatosis (focal/localized involvement is acceptable), > 1 cm mid-line shift, uncal herniation or significant hemorrhage/hydrocephalous (small intra-lesional hemorrhage is acceptable); patients with seizure at presentation who have been started on levetiracetam and have been stable for 48 hours prior to study registration are eligible at the discretion of treating physician', 'entities': [['21', '50', 'cancer'], ['98', '102', 'lower_bound'], ['119', '135', 'chronic_disease'], ['151', '161', 'chronic_disease'], ['162', '176', 'chronic_disease'], ['184', '209', 'chronic_disease'], ['240', '247', 'chronic_disease'], ['289', '302', 'treatment'], ['328', '342', 'upper_bound']]}, 'NCT02589522'), ({'text': 'For Part F (LY2835219 + trastuzumab):The participant must have received at least 1 chemotherapy regimen for metastatic disease and may be receiving ongoing therapy with trastuzumab', 'entities': [['13', '22', 'treatment'], ['20', '21', 'lower_bound'], ['25', '36', 'treatment'], ['84', '104', 'treatment'], ['109', '127', 'cancer'], ['157', '181', 'treatment']]}, 'NCT02057133'), ({'text': 'Vasculitis', 'entities': [['1', '11', 'chronic_disease']]}, 'NCT02506192'), ({'text': 'congenital FIX deficiency', 'entities': [['12', '26', 'chronic_disease']]}, 'NCT02053792'), ({'text': 'stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a gonadotropin-releasing hormone [GnRH] agonist)', 'entities': [['20', '36', 'treatment'], ['46', '61', 'cancer'], ['68', '78', 'treatment'], ['82', '127', 'treatment']]}, 'NCT01591356'), ({'text': 'significant genetic/chromosomal syndrome', 'entities': [['21', '41', 'chronic_disease']]}, 'NCT02497690'), ({'text': 'Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval and cause torsades de pointes', 'entities': [['39', '55', 'clinical_variable'], ['93', '106', 'chronic_disease'], ['121', '148', 'chronic_disease'], ['132', '148', 'chronic_disease'], ['219', '227', 'upper_bound'], ['231', '234', 'age'], ['268', '290', 'treatment'], ['334', '353', 'chronic_disease']]}, 'NCT02496663'), ({'text': 'Stable medication regimen', 'entities': [['8', '18', 'treatment']]}, 'NCT02266004'), ({'text': 'Active infections', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02503722'), ({'text': 'Preoperative BCDVA worse than 0.2 LogMar (20/32) with or without glare', 'entities': [['14', '19', 'clinical_variable'], ['31', '41', 'lower_bound']]}, 'NCT03179397'), ({'text': 'Age 18 or older', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT02073292'), ({'text': 'Subjects on bisphosphonates for any cancer or on hormone therapy for prostate cancer may continue this therapy', 'entities': [['13', '28', 'treatment'], ['37', '43', 'cancer'], ['50', '65', 'treatment'], ['58', '65', 'treatment'], ['70', '85', 'cancer']]}, 'NCT02452268'), ({'text': "Total bilirubin < 2 times upper limit of normal (unless due to Gilbert's syndrome), performed within 28 days prior to registration", 'entities': [['1', '16', 'clinical_variable'], ['19', '48', 'upper_bound'], ['64', '82', 'chronic_disease'], ['102', '115', 'upper_bound']]}, 'NCT02227199'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02648282'), ({'text': 'Have any history or evidence suggestive of seizure disorder or brain injury', 'entities': [['44', '60', 'chronic_disease'], ['64', '76', 'chronic_disease']]}, 'NCT02308202'), ({'text': 'Patient is not now, and never has received adjuvant endocrine therapy OR patient is currently receiving or has received adjuvant endocrine therapy in the past', 'entities': [['44', '70', 'treatment']]}, 'NCT02398773'), ({'text': 'severe hepatic disease or ascites', 'entities': [['1', '23', 'chronic_disease'], ['27', '34', 'chronic_disease']]}, 'NCT02554253'), ({'text': 'malabsorption', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02541903'), ({'text': 'Males must agree to use a latex condom during any sexual contact with females of childbearing potential while participating in the study and for 112 days following the last dose of sotatercept', 'entities': [['1', '6', 'gender'], ['12', '65', 'contraception_consent'], ['71', '78', 'gender'], ['146', '154', 'upper_bound'], ['182', '193', 'treatment']]}, 'NCT01464164'), ({'text': 'Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment', 'entities': [['1', '6', 'gender'], ['45', '69', 'pregnancy'], ['82', '95', 'upper_bound'], ['113', '122', 'treatment']]}, 'NCT02099058'), ({'text': "As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system", 'entities': [['174', '182', 'upper_bound']]}, 'NCT02270450'), ({'text': 'Central nervous system involvement', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02389517'), ({'text': 'Hospitalization within 8 weeks before screening', 'entities': [['24', '31', 'upper_bound']]}, 'NCT02466685'), ({'text': 'Sensory peripheral neuropathy =< grade 1', 'entities': [['1', '30', 'clinical_variable'], ['34', '41', 'upper_bound']]}, 'NCT02020707'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT01978509'), ({'text': 'INR < 1.5 times institutional upper limit of normal', 'entities': [['1', '4', 'clinical_variable'], ['7', '52', 'upper_bound']]}, 'NCT03179995'), ({'text': 'Presence of a seizure disorder not attributable to hypoglycemia', 'entities': [['15', '31', 'chronic_disease'], ['52', '64', 'chronic_disease']]}, 'NCT01474889'), ({'text': 'Men', 'entities': [['1', '4', 'gender']]}, 'NCT02367196'), ({'text': 'co-existing elbow diagnosis (i.e. osteoarthritis or instability)', 'entities': [['35', '49', 'chronic_disease']]}, 'NCT01897259'), ({'text': 'Male subjects must agree to practice contraception', 'entities': [['1', '14', 'gender'], ['20', '51', 'contraception_consent']]}, 'NCT01959698'), ({'text': 'Diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder', 'entities': [['16', '36', 'chronic_disease'], ['45', '75', 'chronic_disease'], ['77', '90', 'chronic_disease'], ['94', '110', 'chronic_disease']]}, 'NCT02307565'), ({'text': 'Fat Pad Atrophy', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02982226'), ({'text': 'at risk of self harm or a suicide attempt within the past 12 months', 'entities': [['54', '68', 'upper_bound']]}, 'NCT02669030'), ({'text': 'Prior or simultaneous malignancy within the past 2 years (other than cutaneous squamous or basal cell carcinoma', 'entities': [['23', '33', 'cancer'], ['45', '57', 'upper_bound'], ['70', '88', 'cancer'], ['92', '112', 'cancer']]}, 'NCT02207465'), ({'text': 'Subjects who have a known hypersensitivity to E. coli derived proteins', 'entities': [['47', '71', 'allergy_name']]}, 'NCT02262806'), ({'text': 'Uncontrolled hypertension (systolic blood pressure e 160 mmHg or diastolic blood pressure e 95 mmHg)', 'entities': [['14', '26', 'chronic_disease'], ['28', '51', 'clinical_variable'], ['54', '62', 'lower_bound'], ['66', '90', 'clinical_variable'], ['93', '100', 'lower_bound']]}, 'NCT03072238'), ({'text': 'Subject has coronary artery disease with unstable angina and who has not received treatment', 'entities': [['13', '36', 'chronic_disease'], ['42', '57', 'chronic_disease'], ['83', '92', 'treatment']]}, 'NCT02365467'), ({'text': 'have known hypersensitivity to ondansetron or other selective serotonin 5HT3 receptor blockers', 'entities': [['32', '43', 'allergy_name'], ['63', '95', 'allergy_name']]}, 'NCT02933034'), ({'text': 'Patients at risk of being non-compliant with administration of the therapy and with record keeping', 'entities': [['68', '75', 'treatment']]}, 'NCT02216500'), ({'text': 'Creatinine <2.0 x ULN or Estimated Glomerular Filtration Rate GFR [Cockcroft-Gault] > 30 mL/min', 'entities': [['1', '11', 'clinical_variable'], ['13', '22', 'upper_bound'], ['26', '84', 'clinical_variable'], ['87', '96', 'lower_bound']]}, 'NCT02309580'), ({'text': 'Women of child-bearing potential', 'entities': [['1', '6', 'gender']]}, 'NCT03048448'), ({'text': 'Failure of treatment with methylphenidate in the past for apathy after convincing evidence of an adequate trial as judged by study physician', 'entities': [['12', '42', 'treatment']]}, 'NCT02346201'), ({'text': 'Rubber latex allergy', 'entities': [['1', '13', 'allergy_name']]}, 'NCT02986087'), ({'text': 'Platelets e 50,000 cells/mm^3', 'entities': [['1', '10', 'clinical_variable'], ['13', '30', 'lower_bound']]}, 'NCT03137771'), ({'text': 'who are known to have had accidental dural puncture with an epidural needle during placement of neuraxial labor analgesia, and have either an intrathecal catheter or epidural catheter in place', 'entities': [['84', '122', 'treatment'], ['143', '163', 'treatment'], ['167', '184', 'treatment']]}, 'NCT02473276'), ({'text': 'Other active malignancy', 'entities': [['14', '24', 'cancer']]}, 'NCT01737502'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, cognitive impairment, active substance abuse, or psychiatric illness/social situations that, in the view of the Investigator, would preclude safe treatment or the ability to give informed consent and limit compliance with study requirements', 'entities': [['77', '93', 'chronic_disease'], ['107', '131', 'chronic_disease'], ['133', '157', 'chronic_disease'], ['159', '177', 'chronic_disease'], ['179', '199', 'chronic_disease'], ['228', '247', 'chronic_disease'], ['325', '334', 'treatment']]}, 'NCT02452268'), ({'text': 'Tumor expression of NY-ESO-1 or LAGE-1 by immunohistochemistry (IHC) and/or reverse transcriptase polymerase chain reaction (RTPCR)', 'entities': [['1', '6', 'cancer'], ['43', '69', 'treatment']]}, 'NCT02166905'), ({'text': 'immunomodulatory drugs (IMiDs), proteasome inhibitors, monoclonal antibodies or steroids', 'entities': [['1', '31', 'treatment'], ['33', '54', 'treatment'], ['56', '89', 'treatment']]}, 'NCT02139280'), ({'text': 'Other concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational', 'entities': [['18', '30', 'treatment'], ['32', '44', 'treatment'], ['53', '70', 'treatment']]}, 'NCT02547662'), ({'text': 'Males who work as Kilimanjaro mountain porters', 'entities': [['1', '6', 'gender']]}, 'NCT02714140'), ({'text': '1 site of measurable disease greater than (>) 1 centimeter (cm) in the longest diameter', 'entities': [['47', '64', 'lower_bound']]}, 'NCT02703272'), ({'text': 'the planned dexamethasone during conditioning therapy', 'entities': [['13', '26', 'treatment'], ['34', '54', 'treatment']]}, 'NCT03097588'), ({'text': 'Previous chemotherapy', 'entities': [['10', '22', 'treatment']]}, 'NCT02309892'), ({'text': 'Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL prior to starting therapy and prior to beginning another cycle', 'entities': [['1', '8', 'gender'], ['54', '68', 'pregnancy'], ['72', '87', 'pregnancy'], ['124', '133', 'lower_bound'], ['134', '159', 'treatment']]}, 'NCT02101944'), ({'text': 'Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related disease', 'entities': [['18', '62', 'chronic_disease'], ['66', '107', 'chronic_disease']]}, 'NCT02932280'), ({'text': 'Apraxia', 'entities': [['1', '8', 'chronic_disease']]}, 'NCT02359253'), ({'text': 'Contraindication to NPWT applicable to women undergoing cesarean', 'entities': [['21', '25', 'allergy_name'], ['40', '45', 'gender'], ['57', '65', 'treatment']]}, 'NCT03009110'), ({'text': 'Willing to complete all scheduled visits and assessments at the institution administering therapy', 'entities': [['91', '98', 'treatment']]}, 'NCT03144245'), ({'text': '<37 weeks gestation', 'entities': [['2', '10', 'upper_bound']]}, 'NCT02573597'), ({'text': 'Patients must have recovered from the toxic effects of any prior chemotherapy to < Grade 2 (except for alopecia)', 'entities': [['60', '78', 'treatment'], ['84', '91', 'upper_bound'], ['104', '112', 'chronic_disease']]}, 'NCT01869114'), ({'text': 'COPD requiring home oxygen', 'entities': [['1', '5', 'chronic_disease']]}, 'NCT02992275'), ({'text': 'presence of at least one painful trigger point in the gluteals (gluteus maximus or medius) and infraspinatus on the same side', 'entities': [['22', '25', 'lower_bound']]}, 'NCT02838394'), ({'text': 'Birth weight <2.2 kg or >4kg', 'entities': [['1', '13', 'clinical_variable'], ['15', '18', 'upper_bound'], ['26', '29', 'lower_bound']]}, 'NCT02564796'), ({'text': 'All organ function testing should be done within 28 days of study registration', 'entities': [['50', '57', 'upper_bound']]}, 'NCT00959140'), ({'text': 'Adults over age 65 years', 'entities': [['13', '16', 'age'], ['17', '25', 'lower_bound']]}, 'NCT02990000'), ({'text': 'male subject agrees to use an acceptable method for contraception for the duration of the study', 'entities': [['1', '13', 'gender'], ['14', '66', 'contraception_consent']]}, 'NCT01701986'), ({'text': 'Subject has a history of Chronic Obstructive Pulmonary Disease (COPD)', 'entities': [['26', '70', 'chronic_disease']]}, 'NCT03059888'), ({'text': 'At least 4 weeks since last dose of chemotherapy, radiotherapy, immunotherapy, systemic glucocorticoid therapy or operation in order to receive vaccine', 'entities': [['10', '11', 'lower_bound'], ['37', '49', 'treatment'], ['51', '63', 'treatment'], ['65', '78', 'treatment'], ['89', '111', 'treatment']]}, 'NCT01952730'), ({'text': 'Documentation of HIV infection', 'entities': [['18', '31', 'chronic_disease']]}, 'NCT02256631'), ({'text': 'Lymphoma patients are permitted', 'entities': [['1', '9', 'cancer']]}, 'NCT02512926'), ({'text': 'There is no minimum duration of AI in the metastatic setting or neoadjuvant setting', 'entities': [['33', '84', 'treatment']]}, 'NCT02913430'), ({'text': 'Patients presenting with a CNS tumor presumed to be resectable and are at risk for local recurrence on pre-operative assessment', 'entities': [['28', '37', 'cancer']]}, 'NCT02710240'), ({'text': 'Allergy to lactose', 'entities': [['12', '19', 'allergy_name']]}, 'NCT02919436'), ({'text': 'Positive leukocytotoxic crossmatch', 'entities': [['10', '35', 'treatment']]}, 'NCT01804634'), ({'text': 'Cardiovascular conditions that are clinically non-significant for the purpose of this study, such as controlled hypertension, minor EKG abnormalities, mitral valve prolapse or benign murmurs are permissible', 'entities': [['1', '26', 'chronic_disease'], ['102', '125', 'chronic_disease'], ['127', '150', 'chronic_disease'], ['152', '173', 'chronic_disease'], ['177', '191', 'chronic_disease']]}, 'NCT02460783'), ({'text': 'intrauterine device', 'entities': [['1', '20', 'contraception_consent']]}, 'NCT02564978'), ({'text': 'Previously diagnosed with any major illness since birth (e.g. chronic birth asphyxia, cancer, etc.)', 'entities': [['31', '44', 'chronic_disease'], ['63', '85', 'chronic_disease'], ['87', '93', 'cancer']]}, 'NCT02668744'), ({'text': 'History of human immunodeficiency virus (HIV) infection; the human immunodeficiency virus (HIV) depletes CD4 T-cells and could also have a role in T-cell anergy; since MEDI-570 preferentially affects CD4 T-cell numbers and function, and the resultant immunosuppression by this agent can be prolonged, exposing HIV patients to MEDI-570 will place them in an unnecessary risk of developing infections due to an underlying acquired cellular immunity defect', 'entities': [['12', '46', 'chronic_disease'], ['42', '45', 'chronic_disease'], ['169', '177', 'treatment'], ['252', '269', 'treatment'], ['389', '399', 'chronic_disease']]}, 'NCT02520791'), ({'text': '6 weeks for mitomycin-C and nitrosoureas), and adequately recovered from adverse effects from prior therapy to meet all other eligibility criteria', 'entities': [['13', '24', 'treatment'], ['29', '41', 'treatment'], ['95', '108', 'treatment']]}, 'NCT01697293'), ({'text': 'History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABRAXANE or other agents used in the study', 'entities': [['102', '110', 'chronic_disease']]}, 'NCT02427841'), ({'text': 'Pregnancy testing must be performed within 2 weeks prior to randomization according to institutional standards for women of childbearing potential', 'entities': [['1', '10', 'pregnancy'], ['44', '57', 'upper_bound'], ['61', '74', 'treatment'], ['116', '121', 'gender']]}, 'NCT01872975'), ({'text': 'female patients', 'entities': [['1', '16', 'gender']]}, 'NCT03066648'), ({'text': 'Prior radiation therapy encompassing >25% of skeleton', 'entities': [['1', '24', 'treatment'], ['39', '42', 'lower_bound']]}, 'NCT00967577'), ({'text': 'Did not start radiation therapy and temozolomide within 7 weeks of surgery', 'entities': [['15', '32', 'treatment'], ['37', '49', 'treatment'], ['57', '64', 'upper_bound'], ['68', '75', 'treatment']]}, 'NCT02465268'), ({'text': 'Pregnant females', 'entities': [['1', '9', 'pregnancy'], ['10', '17', 'gender']]}, 'NCT02967315'), ({'text': 'Subject with a history of congenital QT prolongation', 'entities': [['27', '53', 'chronic_disease']]}, 'NCT02225548'), ({'text': 'Concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two years', 'entities': [['19', '38', 'cancer'], ['87', '90', 'lower_bound'], ['91', '111', 'clinical_variable'], ['124', '133', 'upper_bound']]}, 'NCT02122185'), ({'text': 'An 8/8 human leukocyte antigen (HLA) matched (high resolution typing at A, B, C, DRB1) sibling or unrelated donor', 'entities': [['8', '37', 'treatment'], ['82', '86', 'treatment']]}, 'NCT01701986'), ({'text': 'Prior pomalidomide exposure', 'entities': [['1', '19', 'treatment']]}, 'NCT02213913'), ({'text': 'Participants who are currently receiving a checkpoint molecule blockade therapy, or who have received this therapy within 3weeks prior to registration', 'entities': [['44', '80', 'treatment'], ['73', '80', 'treatment'], ['123', '135', 'upper_bound']]}, 'NCT02382549'), ({'text': 'Poorly controlled diabetes', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT01737502'), ({'text': 'Patients who have undergone surgery within 24 hours prior to the study sonographic examination', 'entities': [['29', '36', 'treatment'], ['44', '58', 'upper_bound']]}, 'NCT02489045'), ({'text': "has Rayanud's disease", 'entities': [['5', '22', 'chronic_disease']]}, 'NCT02473354'), ({'text': 'Tumor tissue for the confirmation of rare variant by the MATCH assay is to be submitted, preferably from the same time of collection as that evaluated by the designated outside laboratory', 'entities': [['1', '6', 'cancer']]}, 'NCT02465060'), ({'text': 'AST/ALT >2.5 x ULN', 'entities': [['1', '8', 'clinical_variable'], ['10', '19', 'lower_bound']]}, 'NCT01697930'), ({'text': 'Plan to treat with anastrozole for at least 12 months', 'entities': [['20', '31', 'treatment'], ['45', '54', 'lower_bound']]}, 'NCT01824836'), ({'text': 'Myocardial infarction', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT01822522'), ({'text': 'Men and women with hypogonadotropic hypogonadism', 'entities': [['1', '4', 'gender'], ['9', '14', 'gender'], ['20', '49', 'chronic_disease']]}, 'NCT01438073'), ({'text': 'Known active malignancy present and/or had chemotherapy 12 weeks prior to screening or planned chemotherapy within 12 weeks of treatment with exception of basal cell carcinoma, squamous cell carcinoma, or prostate cancer in situ', 'entities': [['7', '24', 'cancer'], ['44', '56', 'treatment'], ['57', '71', 'upper_bound'], ['57', '65', 'upper_bound'], ['156', '176', 'cancer'], ['178', '201', 'cancer'], ['206', '229', 'cancer']]}, 'NCT03034213'), ({'text': 'seasonal allergy medications and hormone replacement therapy', 'entities': [['18', '29', 'treatment'], ['34', '61', 'treatment']]}, 'NCT00914823'), ({'text': 'Intracranial bleed, including intraventricular hemorrhage, within 3 months prior to randomization', 'entities': [['1', '19', 'chronic_disease'], ['31', '58', 'chronic_disease'], ['67', '81', 'upper_bound']]}, 'NCT02464969'), ({'text': 'Received allograft, autograft or xenograft within 30 days of enrollment', 'entities': [['10', '19', 'treatment'], ['21', '30', 'treatment'], ['34', '43', 'treatment'], ['51', '58', 'upper_bound']]}, 'NCT02312570'), ({'text': 'Patients must be off of cannabis oil for 3 days prior to enrollment', 'entities': [['25', '37', 'treatment'], ['42', '54', 'upper_bound']]}, 'NCT02574728'), ({'text': "Has been diagnosed with Paget's disease or Congenital hip deformity (dysplasia and/or dislocation)", 'entities': [['25', '40', 'chronic_disease'], ['44', '68', 'chronic_disease'], ['70', '79', 'chronic_disease']]}, 'NCT02131389'), ({'text': 'Uncorrectable coagulopathy', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT02050113'), ({'text': 'More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). Patients must have progressive disease after prior treatment', 'entities': [['11', '21', 'lower_bound'], ['50', '72', 'treatment'], ['110', '129', 'treatment'], ['180', '187', 'upper_bound'], ['227', '235', 'chronic_disease'], ['239', '247', 'chronic_disease'], ['295', '310', 'treatment']]}, 'NCT01993719'), ({'text': "Known kidney or liver dysfunction or any condition which, in the investigator's opinion, place the patient at unjustifiable risk", 'entities': [['7', '13', 'chronic_disease'], ['17', '34', 'chronic_disease']]}, 'NCT02053792'), ({'text': 'Planned surgical intervention during the study period', 'entities': [['9', '30', 'treatment']]}, 'NCT02178566'), ({'text': 'Subject must be able to swallow and retain oral medication', 'entities': [['44', '59', 'treatment']]}, 'NCT02048371'), ({'text': 'pleural effusions related to liver insufficiency within 6 months of screening', 'entities': [['1', '18', 'chronic_disease'], ['30', '49', 'chronic_disease'], ['57', '65', 'upper_bound']]}, 'NCT02562755'), ({'text': 'Known hypersensitivity to ferumoxytol or any of its components', 'entities': [['27', '38', 'allergy_name']]}, 'NCT03179449'), ({'text': 'documented history of any gastrointestinal disorders, including bleeding ulcers', 'entities': [['27', '53', 'chronic_disease'], ['65', '80', 'chronic_disease']]}, 'NCT02502006'), ({'text': 'women with a history of any disorders that may potentially be complicated by hormonal treatment, such as DVT and breast, ovarian, or endometrial cancer', 'entities': [['1', '6', 'gender'], ['78', '96', 'clinical_variable'], ['106', '109', 'chronic_disease'], ['114', '120', 'cancer'], ['122', '129', 'cancer'], ['134', '152', 'cancer']]}, 'NCT00594217'), ({'text': 'PR interval >210 msec', 'entities': [['1', '12', 'clinical_variable'], ['14', '22', 'lower_bound']]}, 'NCT02145351'), ({'text': 'Metastatic disease; protocol does allow for bone-only disease', 'entities': [['1', '19', 'cancer'], ['45', '62', 'cancer']]}, 'NCT03092635'), ({'text': 'Treatment with other investigational drugs within 14 days prior to first study treatment administration', 'entities': [['1', '10', 'treatment'], ['22', '43', 'treatment'], ['51', '64', 'upper_bound'], ['80', '89', 'treatment']]}, 'NCT02267863'), ({'text': 'Serious non-healing wound, ulcer, or bone fracture', 'entities': [['9', '26', 'chronic_disease'], ['28', '33', 'chronic_disease']]}, 'NCT02349867'), ({'text': 'Adequate renal function, defined as estimated creatinine clearance >30 mL/min according to Cockcroft-Gault formula or measured 24-hour creatinine clearance (or local institutional standard method)', 'entities': [['47', '67', 'clinical_variable'], ['69', '78', 'lower_bound']]}, 'NCT03104699'), ({'text': 'Use of any standard chemotherapy or other investigational agent(s) within 1 week of study enrollment', 'entities': [['21', '33', 'treatment'], ['43', '67', 'treatment'], ['75', '81', 'upper_bound']]}, 'NCT01730118'), ({'text': 'aspirin', 'entities': [['1', '8', 'treatment']]}, 'NCT02594111'), ({'text': 'Central nervous system metastasis', 'entities': [['1', '34', 'cancer']]}, 'NCT02578641'), ({'text': 'Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months', 'entities': [['34', '59', 'chronic_disease'], ['71', '96', 'chronic_disease'], ['111', '130', 'chronic_disease'], ['144', '168', 'chronic_disease'], ['170', '185', 'chronic_disease'], ['190', '211', 'chronic_disease'], ['223', '236', 'upper_bound']]}, 'NCT02942095'), ({'text': 'aged 7-60', 'entities': [['1', '5', 'age'], ['6', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT03017937'), ({'text': 'pregnancy planned', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02719327'), ({'text': 'Hemodynamic instability as defined by a systolic blood pressure <90 mmHg', 'entities': [['1', '24', 'chronic_disease'], ['41', '64', 'clinical_variable'], ['66', '73', 'upper_bound']]}, 'NCT02836899'), ({'text': 'Receiving corticosteroids above physiological dosing (greater than 5mg per day of prednisone) within 28 days prior to anti-CD19-CAR-transduced T cell administration', 'entities': [['11', '26', 'treatment'], ['68', '71', 'lower_bound'], ['83', '93', 'treatment'], ['102', '115', 'upper_bound'], ['119', '150', 'treatment']]}, 'NCT01087294'), ({'text': 'Participants do not need to have measurable disease at the time of radiation. Age e 3 and d 25 years at the time of diagnosis because this study evaluates this disease entity in the pediatric population which may differ from the adult populatio', 'entities': [['68', '77', 'treatment'], ['79', '82', 'age'], ['85', '86', 'lower_bound'], ['93', '101', 'upper_bound']]}, 'NCT02112617'), ({'text': 'Absence of renal failure', 'entities': [['12', '25', 'chronic_disease']]}, 'NCT01572480'), ({'text': 'LVEF >/=40% or LVSF >/=26%', 'entities': [['1', '5', 'clinical_variable'], ['9', '12', 'lower_bound'], ['16', '20', 'clinical_variable'], ['24', '27', 'lower_bound']]}, 'NCT01821781'), ({'text': 'has current oral lesions, canker sores, or piercings', 'entities': [['13', '25', 'chronic_disease'], ['27', '39', 'chronic_disease'], ['44', '53', 'chronic_disease']]}, 'NCT02589353'), ({'text': 'Patients with uncontrolled diabetes; as defined by hemoglobin A1C e 7.1%', 'entities': [['15', '36', 'chronic_disease'], ['52', '66', 'clinical_variable'], ['69', '73', 'lower_bound']]}, 'NCT01925378'), ({'text': 'Thiazolidinedione use in the preceding 18 months', 'entities': [['1', '18', 'treatment'], ['30', '49', 'lower_bound']]}, 'NCT00904046'), ({'text': 'Subject has been diagnosed with mitochondrial dysfunction based on modified Walker criteria', 'entities': [['33', '58', 'chronic_disease']]}, 'NCT02053766'), ({'text': 'Refusal of Urine pregnancy test in post-menarchal females', 'entities': [['12', '27', 'pregnancy'], ['51', '58', 'gender']]}, 'NCT02484248'), ({'text': "Zubrod performance status of less than or equal to 2 (Zubrod performance status is a measure that attempts to quantify a cancer patients' general well-being. Scores run from 0 to 5 where 0 denotes normal activity and 5 denotes death)", 'entities': [['1', '26', 'clinical_variable'], ['52', '53', 'upper_bound'], ['122', '128', 'cancer'], ['175', '176', 'lower_bound'], ['180', '181', 'upper_bound']]}, 'NCT02460835'), ({'text': 'triglycerides > 150 mg/dL or on treatment for hypertriglyceridemia', 'entities': [['1', '14', 'clinical_variable'], ['17', '26', 'lower_bound'], ['47', '67', 'chronic_disease']]}, 'NCT03038620'), ({'text': 'mild-moderate erectile dysfunction based on International Index of Erectile Function (IIEF) erectile function score 13-25', 'entities': [['15', '35', 'chronic_disease'], ['45', '116', 'clinical_variable'], ['117', '119', 'lower_bound'], ['120', '122', 'upper_bound']]}, 'NCT01715571'), ({'text': 'a DSM-5 diagnosis of autism', 'entities': [['22', '28', 'chronic_disease']]}, 'NCT02553161'), ({'text': 'corticosteroid for at least one week prior to study registration', 'entities': [['1', '15', 'treatment'], ['29', '43', 'upper_bound']]}, 'NCT02358187'), ({'text': 'Age greater than or equal to18 Years', 'entities': [['1', '4', 'age'], ['29', '37', 'lower_bound']]}, 'NCT01419561'), ({'text': 'Meet criteria for PTSD of at least 3 months duration', 'entities': [['19', '23', 'chronic_disease'], ['36', '44', 'lower_bound']]}, 'NCT02856412'), ({'text': 'serious concurrent illness', 'entities': [['1', '27', 'chronic_disease']]}, 'NCT02924363'), ({'text': 'Open surgery in ipsilateral breast within 1 year', 'entities': [['6', '13', 'treatment'], ['17', '35', 'cancer'], ['43', '49', 'upper_bound']]}, 'NCT03113825'), ({'text': 'Willingness to allow stored samples to be used for future studies of HIV infection and/or immunological function, and willingness to have HLA typing performed. (For previously enrolled patients, patients would be requested, but not required, to provide permission to use stored samples in the future, and to permit HLA testing', 'entities': [['70', '83', 'chronic_disease']]}, 'NCT00001651'), ({'text': 'Current use of psychotropic medication (other than medications for attention deficit hyperactivity disorder, hypnotics, antihypertensives, hypoglycemic agents including insulin, anticonvulsants, anticoagulants, or growth hormone', 'entities': [['16', '39', 'treatment'], ['52', '63', 'treatment'], ['68', '108', 'chronic_disease'], ['110', '119', 'treatment'], ['121', '138', 'treatment'], ['140', '159', 'treatment'], ['170', '177', 'treatment'], ['179', '194', 'treatment'], ['196', '210', 'treatment'], ['215', '229', 'treatment']]}, 'NCT02562040'), ({'text': 'BMI e 30 kg/m2', 'entities': [['1', '4', 'bmi'], ['7', '15', 'lower_bound']]}, 'NCT02696980'), ({'text': 'The patient has a history of HIV or another known cause of immunosuppression', 'entities': [['30', '33', 'chronic_disease'], ['60', '77', 'treatment']]}, 'NCT02389959'), ({'text': '18 years or older', 'entities': [['1', '9', 'lower_bound']]}, 'NCT02520427'), ({'text': 'Planned continued use of glucocorticoids', 'entities': [['26', '41', 'treatment']]}, 'NCT01865162'), ({'text': 'Prior neurosurgical procedure', 'entities': [['7', '30', 'treatment']]}, 'NCT02355002'), ({'text': 'loop recorder explanted within the past 12 months', 'entities': [['36', '50', 'upper_bound']]}, 'NCT03001765'), ({'text': 'Patients with macular degeneration, uncontrolled glaucoma, or markedly decreased visual acuity', 'entities': [['15', '35', 'chronic_disease'], ['50', '58', 'chronic_disease']]}, 'NCT02269293'), ({'text': 'Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of trametinib and during the study; patients previously treated with v-raf murine sarcoma (RAF) and/or mitogen-activated protein kinase (MEK) inhibitors', 'entities': [['14', '35', 'treatment'], ['43', '50', 'upper_bound'], ['55', '70', 'upper_bound'], ['112', '119', 'lower_bound'], ['168', '178', 'treatment'], ['234', '260', 'treatment'], ['268', '317', 'treatment']]}, 'NCT02070549'), ({'text': 'Patients undergoing extrapleural pneumonectomy', 'entities': [['21', '47', 'treatment']]}, 'NCT00715611'), ({'text': 'with a cumulative illness rating scale (CIRS) score >= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator', 'entities': [['8', '52', 'clinical_variable'], ['56', '57', 'lower_bound'], ['83', '105', 'treatment']]}, 'NCT02232516'), ({'text': 'Concurrent anti-cancer therapy (chemotherapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib)', 'entities': [['12', '31', 'treatment'], ['33', '45', 'treatment'], ['47', '54', 'treatment'], ['56', '69', 'treatment'], ['71', '87', 'treatment'], ['92', '110', 'treatment'], ['140', '151', 'treatment']]}, 'NCT02048722'), ({'text': 'Any history of congenital long QT syndrome', 'entities': [['16', '43', 'chronic_disease']]}, 'NCT02496208'), ({'text': 'Biliary tract adenocarcinoma', 'entities': [['1', '29', 'cancer']]}, 'NCT02533674'), ({'text': 'Patients with severe aplastic anemia are eligible regardless of conditioning regimen', 'entities': [['22', '37', 'chronic_disease'], ['65', '85', 'treatment']]}, 'NCT02074631'), ({'text': 'Active malignancy at site of ulcer', 'entities': [['1', '35', 'cancer']]}, 'NCT02313428'), ({'text': 'An indication to be on statin therapy', 'entities': [['24', '38', 'treatment']]}, 'NCT01568255'), ({'text': 'Cervical Laminectomy', 'entities': [['1', '21', 'treatment']]}, 'NCT01568918'), ({'text': 'At least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1', 'entities': [['10', '16', 'lower_bound'], ['32', '48', 'treatment']]}, 'NCT02807272'), ({'text': 'Failed to achieve a cytogenetic remission to tyrosine kinase inhibitor treatment or has a cytogenetic relapse', 'entities': [['46', '71', 'treatment']]}, 'NCT01823198'), ({'text': 'Diamond Blackfan Anemia (DBA)', 'entities': [['1', '30', 'chronic_disease']]}, 'NCT01962415'), ({'text': 'Presence of a life-threatening disease such as cancer', 'entities': [['48', '54', 'cancer']]}, 'NCT02356861'), ({'text': 'patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection', 'entities': [['36', '68', 'cancer']]}, 'NCT01872975'), ({'text': 'History of (non-infectious) pneumonitis that required steroids or has current pneumonitis or interstitial lung disease', 'entities': [['29', '40', 'chronic_disease'], ['55', '63', 'treatment'], ['94', '119', 'chronic_disease']]}, 'NCT02501473'), ({'text': 'Any contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander)', 'entities': [['25', '28', 'treatment'], ['36', '45', 'treatment'], ['47', '60', 'treatment'], ['62', '77', 'treatment']]}, 'NCT01604512'), ({'text': 'Evidence of clinical MS relapse within the last 30 days prior to enrollment', 'entities': [['22', '24', 'chronic_disease'], ['44', '56', 'upper_bound']]}, 'NCT02544373'), ({'text': "patient's inability to provide consent for study participation due to his/her inability to demonstrate an understanding of study procedures as contained in the statement of informed consent, after no more than two explanations", 'entities': [['211', '214', 'lower_bound']]}, 'NCT02204956'), ({'text': 'having received cytotoxic doses of gemcitabine or any other chemotherapy in the adjuvant setting', 'entities': [['36', '47', 'treatment'], ['61', '73', 'treatment']]}, 'NCT02923921'), ({'text': 'Ongoing infection >Grade 2 NCI-CTCAE v4.0', 'entities': [['20', '27', 'lower_bound'], ['28', '37', 'clinical_variable']]}, 'NCT02459119'), ({'text': 'Had change of anti-TNF agent or DMARD in the last 6 months', 'entities': [['15', '29', 'treatment'], ['33', '38', 'treatment'], ['46', '59', 'upper_bound']]}, 'NCT01793519'), ({'text': 'Patients schedule to undergo an arterial revascularization procedure during the study or have undergone one within the past 6 months', 'entities': [['33', '59', 'treatment'], ['120', '133', 'upper_bound']]}, 'NCT02636283'), ({'text': 'At least 14 days passed since last brain surgery, or intracranial radiation therapy/radiosurgery', 'entities': [['10', '17', 'lower_bound'], ['36', '49', 'treatment'], ['54', '84', 'treatment'], ['85', '97', 'treatment']]}, 'NCT00147056'), ({'text': 'Participant has received intraocular (or periocular) steroi', 'entities': [['26', '60', 'treatment']]}, 'NCT02911116'), ({'text': 'Patients with a history of epilepsy, subjects currently prescribed treatments for epilepsy, or subjects with a history of seizure in the last 5 years', 'entities': [['28', '36', 'chronic_disease'], ['57', '78', 'treatment'], ['123', '130', 'chronic_disease'], ['138', '150', 'upper_bound']]}, 'NCT02560766'), ({'text': 'A1Ce6.5%', 'entities': [['1', '4', 'clinical_variable'], ['5', '9', 'lower_bound']]}, 'NCT02244814'), ({'text': "Because the composition, pharmacokinetics (PK), and metabolism of many herbal supplements are unknown, the concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John's wort, kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)", 'entities': [['72', '90', 'treatment'], ['212', '227', 'treatment'], ['229', '233', 'treatment'], ['235', '253', 'treatment'], ['255', '268', 'treatment'], ['270', '299', 'treatment'], ['301', '308', 'treatment'], ['310', '322', 'treatment'], ['327', '334', 'treatment']]}, 'NCT01989585'), ({'text': 'Prior treatment with any LAG-3 targeting biologic or small molecule', 'entities': [['1', '31', 'treatment']]}, 'NCT03005782'), ({'text': 'Moderate CDI not responding to standard therapy (vancomycin) for at least a week', 'entities': [['41', '48', 'treatment'], ['50', '60', 'treatment']]}, 'NCT01905709'), ({'text': 'with no known target organ damage (End organ damage includes the following: proliferative retinopathy, serum creatinine < 1.8 m/dl, ischemic heart disease, congestive heart failure, peripheral vascular disease and peripheral neuropathy)', 'entities': [['77', '102', 'chronic_disease'], ['104', '120', 'clinical_variable'], ['123', '131', 'upper_bound'], ['133', '155', 'chronic_disease'], ['157', '181', 'chronic_disease'], ['183', '210', 'chronic_disease'], ['215', '236', 'chronic_disease']]}, 'NCT00862433'), ({'text': 'Patients must have a serum creatinine d the institutional upper limit of normal OR a creatinine clearance e 60 cc/min, measured or calculated (Cockcroft-Gault formula), obtained within 14 days prior to registration', 'entities': [['22', '38', 'clinical_variable'], ['86', '106', 'clinical_variable'], ['109', '118', 'lower_bound'], ['144', '167', 'clinical_variable'], ['186', '193', 'upper_bound']]}, 'NCT01941316'), ({'text': 'Coronary angiographic lesion of e 60% stenosis in a major epicardial vessel or e 50% left main stenosis', 'entities': [['1', '29', 'clinical_variable'], ['35', '38', 'lower_bound'], ['53', '76', 'clinical_variable'], ['82', '85', 'lower_bound']]}, 'NCT03071692'), ({'text': 'GCS in emergency department of less than 13 (unless due to intubation, sedation or intoxication)', 'entities': [['1', '4', 'clinical_variable'], ['42', '44', 'upper_bound'], ['60', '70', 'treatment'], ['72', '80', 'treatment'], ['84', '96', 'treatment']]}, 'NCT02695043'), ({'text': 'Tuberculosis', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02937350'), ({'text': 'open biopsy', 'entities': [['1', '12', 'treatment']]}, 'NCT02317991'), ({'text': 'Women must not be pregnant or breastfeeding', 'entities': [['1', '6', 'gender'], ['7', '27', 'pregnancy']]}, 'NCT02237183'), ({'text': 'Renal insufficiency', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02389465'), ({'text': 'Positive human immunodeficiency virus (HIV) test, active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection or active tuberculosis', 'entities': [['10', '44', 'chronic_disease'], ['58', '81', 'chronic_disease'], ['93', '123', 'chronic_disease'], ['144', '156', 'chronic_disease']]}, 'NCT02091141'), ({'text': 'Uncontrolled intercurrent illness', 'entities': [['14', '34', 'chronic_disease']]}, 'NCT02552953'), ({'text': 'Age e 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02922023'), ({'text': 'Active acute or chronic infection requiring antimicrobial therapy or serious viral infection (HIV, hepatitis B or C, herpes simplex, varicella zoster virus, parvovirus)', 'entities': [['1', '34', 'chronic_disease'], ['45', '66', 'treatment'], ['78', '93', 'chronic_disease'], ['95', '98', 'chronic_disease'], ['100', '116', 'chronic_disease'], ['118', '132', 'chronic_disease'], ['134', '156', 'chronic_disease'], ['158', '168', 'chronic_disease']]}, 'NCT00977977'), ({'text': "Optimal therapy will be according to American Heart Association (AHA) /American College of Cardiology (ACC) and Heart Failure Society of America (HFSA) HF guidelines, including treatment with angiotensin-converting enzyme (ACE) and -blocker therapy (for at least 6 weeks), or have documented reason for variation, including medication intolerance, contraindication, patient preference, or personal physician's judgment", 'entities': [['1', '16', 'treatment'], ['193', '228', 'treatment'], ['234', '249', 'treatment'], ['264', '271', 'lower_bound']]}, 'NCT03136029'), ({'text': 'e20% blasts in bone marrow or peripheral blood', 'entities': [['2', '12', 'lower_bound']]}, 'NCT02649790'), ({'text': 'Less than 21 years of age', 'entities': [['11', '19', 'lower_bound'], ['23', '26', 'age']]}, 'NCT02058095'), ({'text': 'Severe stenotic valvular disease amendable to surgical treatment', 'entities': [['17', '33', 'chronic_disease'], ['47', '65', 'treatment']]}, 'NCT02476409'), ({'text': 'skin basal cell carcinoma', 'entities': [['1', '26', 'cancer']]}, 'NCT02913430'), ({'text': 'Unstable metabolic condition', 'entities': [['10', '29', 'chronic_disease']]}, 'NCT03008070'), ({'text': 'prior to evidence of vaccine clearance', 'entities': [['22', '29', 'treatment']]}, 'NCT00186927'), ({'text': "Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study", 'entities': [['1', '8', 'chronic_disease'], ['32', '56', 'chronic_disease']]}, 'NCT02608216'), ({'text': 'Tumor-associated deformity of the SMV (superior mesenteric vein) or PV (portal vein)', 'entities': [['1', '6', 'cancer']]}, 'NCT02427841'), ({'text': 'uncontrolled hypertension or clinically significant arrhythmias not controlled by medication)', 'entities': [['14', '26', 'chronic_disease'], ['53', '64', 'chronic_disease'], ['83', '93', 'treatment']]}, 'NCT02268253'), ({'text': 'lactating female', 'entities': [['11', '17', 'gender']]}, 'NCT03076333'), ({'text': 'evidence of developmental disability', 'entities': [['13', '37', 'chronic_disease']]}, 'NCT02481713'), ({'text': 'And/or trial of biofeedback for at least 4 sessions', 'entities': [['42', '43', 'lower_bound']]}, 'NCT02160288'), ({'text': 'ECOG 0-2', 'entities': [['1', '5', 'clinical_variable'], ['6', '7', 'lower_bound'], ['8', '9', 'upper_bound']]}, 'NCT01061515'), ({'text': 'Participants who enroll in a preoperative therapy trial or who have been treated with neoadjuvant chemotherapy', 'entities': [['30', '50', 'treatment'], ['87', '111', 'treatment']]}, 'NCT02335671'), ({'text': 'At least part of the tumor must be visible as observed in a diagnostic or planning CT', 'entities': [['22', '27', 'cancer'], ['84', '86', 'treatment']]}, 'NCT02434809'), ({'text': 'Women who are of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours of transplant and agree to use reliable contraception for one year following transplant', 'entities': [['1', '6', 'gender'], ['54', '72', 'pregnancy'], ['112', '120', 'upper_bound'], ['124', '134', 'treatment'], ['139', '174', 'contraception_consent']]}, 'NCT00711373'), ({'text': 'T2D', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT03164538'), ({'text': 'patients allergic to one or more components of the antibiotic solution', 'entities': [['52', '62', 'allergy_name']]}, 'NCT02395614'), ({'text': 'Serum aspartate transaminase (AST) and alanine transaminase (ALT) =< 3.0 x upper limit of normal (ULN)', 'entities': [['1', '66', 'clinical_variable'], ['70', '103', 'upper_bound']]}, 'NCT02553941'), ({'text': 'active Hepatitis B (e.g., HBs Ag reactive)', 'entities': [['1', '19', 'chronic_disease'], ['27', '33', 'chronic_disease']]}, 'NCT02324582'), ({'text': 'ECOG performance status of 0 or 1', 'entities': [['1', '24', 'clinical_variable'], ['28', '29', 'lower_bound'], ['33', '34', 'upper_bound']]}, 'NCT02072148'), ({'text': 'ANCe1500/mm3', 'entities': [['1', '4', 'clinical_variable'], ['5', '13', 'lower_bound']]}, 'NCT02585973'), ({'text': 'evidence of intolerance or toxicity associated with cyclosporine treatment of any duration including irreversible azotemia, liver dysfunction or hypertension', 'entities': [['53', '75', 'treatment'], ['115', '123', 'chronic_disease'], ['125', '142', 'chronic_disease'], ['146', '158', 'chronic_disease']]}, 'NCT00977977'), ({'text': 'provided there is no active graft-versus-host disease (GVHD) > grade 1', 'entities': [['29', '61', 'clinical_variable'], ['64', '71', 'lower_bound']]}, 'NCT03067571'), ({'text': 'participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone', 'entities': [['43', '50', 'treatment'], ['52', '67', 'treatment'], ['69', '81', 'treatment'], ['83', '95', 'treatment'], ['99', '108', 'treatment']]}, 'NCT02796391'), ({'text': 'No history of acquired immunodeficiency syndrome (AIDS)-defining conditions or other HIV related illness', 'entities': [['15', '56', 'chronic_disease'], ['86', '89', 'chronic_disease']]}, 'NCT02004275'), ({'text': 'history of arterial or venous thrombotic disease (including a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA)), pregnancy, breastfeeding', 'entities': [['12', '49', 'chronic_disease'], ['74', '100', 'chronic_disease'], ['102', '125', 'chronic_disease'], ['127', '157', 'chronic_disease'], ['159', '190', 'chronic_disease'], ['193', '202', 'pregnancy']]}, 'NCT02877381'), ({'text': 'Claustrophobia precluding MRI', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT01608438'), ({'text': 'Embedded metallic objects, prosthetics made of paramagnetic metals, aneurysmal clips and/or a history of claustrophobia', 'entities': [['1', '26', 'treatment'], ['28', '39', 'treatment'], ['48', '67', 'treatment'], ['69', '85', 'treatment'], ['106', '120', 'chronic_disease']]}, 'NCT02513485'), ({'text': 'Virilization', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT00594217'), ({'text': 'Females who are Pregnant or Nursing', 'entities': [['1', '8', 'gender'], ['13', '25', 'pregnancy']]}, 'NCT02506192'), ({'text': 'Have any history of malignancy, except fully resected cutaneous squamous cell cancer or cutaneous basal cell cancer, or cervical carcinoma in-situ with a minimum of 5 years period without recurrence', 'entities': [['21', '31', 'cancer'], ['55', '85', 'cancer'], ['89', '116', 'cancer'], ['121', '147', 'cancer'], ['166', '173', 'upper_bound']]}, 'NCT02725177'), ({'text': 'Non-viable newborns', 'entities': [['1', '20', 'clinical_variable']]}, 'NCT03115463'), ({'text': 'peripheral artery disease (aortic or lower extremity)', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT02680574'), ({'text': 'Subjects who respond to initial therapy for greater than one year must have had at least 2 prior lines of therapy including one line with chemoimmunotherapy including an anti-CD20 monoclonal antibody', 'entities': [['25', '40', 'treatment'], ['33', '40', 'treatment'], ['58', '66', 'lower_bound'], ['90', '91', 'lower_bound'], ['139', '200', 'treatment']]}, 'NCT02811679'), ({'text': 'Newly diagnosed MCL: Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure or myocardial infarction within 6 months at the time of consent or any class 3 (moderate) or 4 (severe) cardiac disease defined by the New York Heart Association Classification', 'entities': [['17', '20', 'cancer'], ['45', '67', 'chronic_disease'], ['104', '115', 'chronic_disease'], ['117', '141', 'chronic_disease'], ['145', '166', 'chronic_disease'], ['174', '182', 'upper_bound'], ['246', '261', 'chronic_disease'], ['277', '318', 'clinical_variable']]}, 'NCT01880567'), ({'text': 'White blood cell (WBC) count e3000 cells/mm3', 'entities': [['1', '29', 'clinical_variable'], ['31', '45', 'lower_bound']]}, 'NCT02414269'), ({'text': 'Male partner should use a condom', 'entities': [['1', '5', 'gender']]}, 'NCT02475707'), ({'text': 'Known allergy to iodine or intravenous contrast agent', 'entities': [['18', '24', 'allergy_name'], ['28', '54', 'allergy_name']]}, 'NCT02111824'), ({'text': 'Diagnosis of VOC necessitating IV opioids and admission to the hospital', 'entities': [['32', '42', 'treatment']]}, 'NCT02433158'), ({'text': 'Male patients with partners of childbearing potential', 'entities': [['1', '14', 'gender']]}, 'NCT03144245'), ({'text': 'tumor volume greater than 20 cc at enrollment', 'entities': [['1', '13', 'clinical_variable'], ['27', '32', 'lower_bound']]}, 'NCT01444209'), ({'text': 'use of Hormone Replacement Therapy (HRT) or oral contraceptives (OCP) or steroids', 'entities': [['8', '41', 'treatment'], ['45', '70', 'treatment'], ['74', '82', 'treatment']]}, 'NCT03070184'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02132598'), ({'text': 'The subject is pregnant', 'entities': [['16', '24', 'pregnancy']]}, 'NCT03157167'), ({'text': 'Sexually active women of child-bearing potential', 'entities': [['17', '22', 'gender']]}, 'NCT00293475'), ({'text': 'Enrollment preconception with an anticipated pregnancy within 18 months (preconception)', 'entities': [['46', '55', 'pregnancy'], ['63', '72', 'upper_bound']]}, 'NCT02333227'), ({'text': 'these potential risks may also apply to RAI and thyrogen', 'entities': [['41', '44', 'treatment'], ['49', '57', 'treatment']]}, 'NCT02152995'), ({'text': 'Vaginal estrogens are allowed if necessary for patient comfort', 'entities': [['1', '18', 'treatment']]}, 'NCT02953860'), ({'text': 'Significant laboratory abnormalities including: Haematocrit <20%; Absolute neutrophil count <0.5x10y/L; Platelet count < 50x10y/L; Alanine aminotransferase or aspartate aminotransferase >3 times the age-specific upper limit of normal', 'entities': [['49', '60', 'clinical_variable'], ['62', '65', 'upper_bound'], ['67', '92', 'clinical_variable'], ['94', '103', 'upper_bound'], ['105', '119', 'clinical_variable'], ['122', '130', 'upper_bound'], ['132', '156', 'clinical_variable'], ['160', '186', 'clinical_variable'], ['188', '234', 'lower_bound']]}, 'NCT02527681'), ({'text': 'Confirmed diagnosis of Pseudohypoparathyroidism type 1a and Pseudopseudohypoparathyroidism', 'entities': [['24', '56', 'chronic_disease'], ['61', '91', 'chronic_disease']]}, 'NCT00209235'), ({'text': 'glomerular filtration rate (GFR) <30', 'entities': [['1', '33', 'clinical_variable'], ['35', '37', 'upper_bound']]}, 'NCT02408120'), ({'text': 'no spontaneous menses e 1 year', 'entities': [['16', '22', 'clinical_variable'], ['25', '31', 'lower_bound']]}, 'NCT02204098'), ({'text': 'Subjects with CNS disease', 'entities': [['15', '26', 'chronic_disease']]}, 'NCT02315612'), ({'text': 'Has taken guanfacine (or other alpha-2AR agonists) in the last six (6) months', 'entities': [['11', '21', 'treatment'], ['32', '50', 'treatment'], ['59', '78', 'upper_bound']]}, 'NCT02192398'), ({'text': 'platelets e100,000/mcL', 'entities': [['1', '10', 'clinical_variable'], ['12', '23', 'lower_bound']]}, 'NCT02452268'), ({'text': 'Parkinsonism subjects: Gait characterized by slow short steps, shuffling gait and may be wide-based, with FoG, postural instability', 'entities': [['1', '13', 'chronic_disease'], ['112', '132', 'chronic_disease']]}, 'NCT02231073'), ({'text': 'Using narcotics, psychotropic or hypnotic medications', 'entities': [['7', '16', 'treatment'], ['18', '30', 'treatment'], ['34', '54', 'treatment']]}, 'NCT02341287'), ({'text': 'Prior therapy with decitabine or azacitidine', 'entities': [['1', '14', 'treatment'], ['20', '30', 'treatment'], ['34', '45', 'treatment']]}, 'NCT02269280'), ({'text': 'Severe Osteopetrosis (OP)', 'entities': [['8', '26', 'chronic_disease']]}, 'NCT02171104'), ({'text': 'Increased Troponin T (> 3X ULN) in patients with unstable angina at time of intervention', 'entities': [['11', '21', 'clinical_variable'], ['25', '31', 'lower_bound'], ['50', '65', 'chronic_disease']]}, 'NCT03043742'), ({'text': 'Greater than 18 and less than 80 years of age', 'entities': [['14', '16', 'lower_bound'], ['31', '39', 'upper_bound'], ['43', '46', 'age']]}, 'NCT02133872'), ({'text': 'Patients who previously received neoadjuvant, concurrent, or adjuvant chemotherapy for localized NSCLC and then recurred within 6 months of completing chemotherapy may be considered as having received one line of prior therapy', 'entities': [['34', '45', 'treatment'], ['47', '57', 'treatment'], ['62', '83', 'treatment'], ['71', '83', 'treatment'], ['98', '103', 'cancer'], ['129', '137', 'upper_bound'], ['214', '227', 'treatment']]}, 'NCT02350764'), ({'text': 'Age > = 18 years', 'entities': [['1', '4', 'age'], ['9', '17', 'lower_bound']]}, 'NCT01054196'), ({'text': 'Hemoglobin e 8 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['14', '20', 'lower_bound']]}, 'NCT02344355'), ({'text': 'Hepatitis B or C positive', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT01445821'), ({'text': 'Subjects with positive quantiferon Gold test in the absence of treatment for tuberculosis', 'entities': [['24', '45', 'treatment'], ['64', '73', 'treatment'], ['78', '90', 'chronic_disease']]}, 'NCT02429934'), ({'text': 'Participation to any clinical research study evaluating another investigational drug or therapy within 3 weeks of initiation of study regimen', 'entities': [['65', '85', 'treatment'], ['89', '96', 'treatment'], ['104', '111', 'upper_bound']]}, 'NCT02187848'), ({'text': 'No evidence of suicidal intentions or behaviors in the past 6 months', 'entities': [['16', '48', 'chronic_disease'], ['56', '69', 'upper_bound']]}, 'NCT02437773'), ({'text': 'Acute lymphocytic leukemia (ALL)', 'entities': [['1', '33', 'cancer']]}, 'NCT02593123'), ({'text': 'Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open biopsy or significant traumatic injury d 4 weeks prior to starting study drug, or patients who have had minor procedures, percutaneous biopsies or placement of vascular access device d 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury', 'entities': [['29', '42', 'treatment'], ['49', '63', 'treatment'], ['65', '80', 'treatment'], ['84', '96', 'treatment'], ['99', '110', 'treatment'], ['126', '142', 'chronic_disease'], ['145', '158', 'upper_bound'], ['171', '181', 'treatment'], ['239', '247', 'treatment'], ['264', '286', 'treatment'], ['289', '301', 'upper_bound']]}, 'NCT01925573'), ({'text': 'previous treatment with ketotifen', 'entities': [['1', '34', 'treatment']]}, 'NCT02484248'), ({'text': 'Greater than 30% reduction in wound size during the first two weeks of observation and treatment by the investigator', 'entities': [['14', '17', 'lower_bound'], ['18', '41', 'clinical_variable'], ['88', '97', 'treatment']]}, 'NCT02312596'), ({'text': 'Oral corticosteroid treatment within the last 4 weeks', 'entities': [['1', '30', 'treatment'], ['42', '54', 'upper_bound']]}, 'NCT02740543'), ({'text': "Medically diagnosed with Parkinson's Disease", 'entities': [['26', '45', 'chronic_disease']]}, 'NCT02107638'), ({'text': 'use of highly active anti-retroviral therapy (HAART) is allowed', 'entities': [['8', '53', 'treatment']]}, 'NCT02177838'), ({'text': 'History of variant angina', 'entities': [['12', '26', 'chronic_disease']]}, 'NCT02966665'), ({'text': 'Pregnant women are excluded from this study because TRC102 is agent with the potential for teratogenic or abortifacient effects', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender'], ['53', '59', 'treatment']]}, 'NCT02535312'), ({'text': 'Research participant does not require pressor support and/or does not have symptomatic cardiac arrhythmias', 'entities': [['39', '46', 'treatment'], ['88', '107', 'chronic_disease']]}, 'NCT02208362'), ({'text': 'Hemoglobin (Hgb) >= 8 g/dL', 'entities': [['1', '17', 'clinical_variable'], ['21', '27', 'lower_bound']]}, 'NCT02166905'), ({'text': 'No contraindications to A²-PET scan including hypersensitivity to PET ligand or radiation exposures in the past year that would exceed the acceptable safe annual exposure in combination with the A² PET', 'entities': [['25', '36', 'allergy_name'], ['67', '77', 'allergy_name'], ['81', '100', 'allergy_name'], ['108', '117', 'upper_bound'], ['196', '202', 'treatment']]}, 'NCT02849639'), ({'text': 'Bilirubin (total) < 2.0 ml/dl', 'entities': [['1', '18', 'clinical_variable'], ['21', '30', 'upper_bound']]}, 'NCT02479230'), ({'text': 'Use of dopaminergic CNS stimulants (prescription, over-the counter or recreational drugs) within 30 days of screening intake visit, as assessed by review of health history form and concomitant medication review at screening intake visit (from medical record and/or self-reported) that are deemed by a physician investigator to have a potential influence on the binding of [18F]FTP', 'entities': [['8', '35', 'treatment'], ['98', '105', 'upper_bound']]}, 'NCT02815917'), ({'text': 'Must be female', 'entities': [['9', '15', 'gender']]}, 'NCT01766297'), ({'text': 'patients must be reasonable medical candidates for ketamine or midazolam infusion, as determined by a board-certified physician co-investigator during study Screening', 'entities': [['52', '60', 'treatment'], ['64', '82', 'treatment']]}, 'NCT02556606'), ({'text': 'Female patients of childbearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test', 'entities': [['1', '16', 'gender'], ['55', '73', 'pregnancy'], ['91', '103', 'upper_bound']]}, 'NCT03168776'), ({'text': "Legally Authorized Representative(s) unwilling to comply with an exclusive human milk diet either in the form of mother's milk, human milk-based human milk fortifier, human milk based caloric fortifier or donor human milk during the initial hospitalization period and through the 30 day feeding period after surgical repair or hospital discharge, whichever comes first", 'entities': [['309', '324', 'treatment']]}, 'NCT02860702'), ({'text': 'Patient information available for each retrospective patient must, at minimum, include preoperative demographic information, preoperative physical exam information, the index surgery operative report, and details of the devices implanted', 'entities': [['176', '183', 'treatment']]}, 'NCT02469662'), ({'text': 'History of or active endocarditis (active treatment with antibiotics) within the past 180 days', 'entities': [['22', '34', 'chronic_disease'], ['36', '69', 'treatment'], ['82', '95', 'upper_bound']]}, 'NCT03130777'), ({'text': 'Female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion', 'entities': [['1', '7', 'gender'], ['65', '98', 'pregnancy'], ['121', '129', 'upper_bound']]}, 'NCT02374333'), ({'text': 'Owns a standard TV', 'entities': [['1', '19', 'technology_access']]}, 'NCT02839759'), ({'text': 'Be between 23 to 34 weeks pregnant with a singleton gestation', 'entities': [['12', '14', 'lower_bound'], ['18', '26', 'upper_bound'], ['27', '35', 'pregnancy']]}, 'NCT02983240'), ({'text': 'Patients with FA must have moderately severe aplastic anemia (AA), early myelodysplastic syndrome (MDS) with no excess blasts with or without chromosomal abnormalities', 'entities': [['15', '17', 'chronic_disease'], ['46', '66', 'chronic_disease'], ['74', '104', 'cancer'], ['143', '168', 'chronic_disease']]}, 'NCT00630253'), ({'text': 'portal hypertension with hepatofugal flow', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02724540'), ({'text': 'male', 'entities': [['1', '5', 'gender']]}, 'NCT02666638'), ({'text': 'Clinical evidence of cirrhosis or chronic active liver disease sufficiently severe to impair cyclosporine metabolism; this would include a prolonged prothrombin time', 'entities': [['22', '31', 'chronic_disease'], ['35', '63', 'chronic_disease'], ['94', '106', 'treatment']]}, 'NCT00977977'), ({'text': 'erum glutamic oxaloacetic transaminase (SGPT) < 5 x upper limit of normal', 'entities': [['1', '46', 'clinical_variable'], ['49', '74', 'upper_bound']]}, 'NCT02333162'), ({'text': 'Complicating medical conditions that may influence the outcome of neuropsychological assessment or functional imaging (e.g., HIV, brain tumor, etc.)', 'entities': [['126', '129', 'chronic_disease'], ['131', '142', 'cancer']]}, 'NCT02374918'), ({'text': 'e 20% (PC20) after inhalation of < 16 mg/ml of methacholine)', 'entities': [['3', '6', 'lower_bound'], ['36', '44', 'upper_bound'], ['48', '60', 'treatment']]}, 'NCT02740543'), ({'text': 'Serious intercurrent medical or psychiatric illness, including serious active infection', 'entities': [['22', '29', 'chronic_disease'], ['33', '52', 'chronic_disease'], ['72', '88', 'chronic_disease']]}, 'NCT01261728'), ({'text': "Women over 55 years old who haven't had a period for a year will be considered menopausal and do not need a FSH test", 'entities': [['1', '6', 'gender'], ['12', '24', 'lower_bound'], ['109', '112', 'treatment']]}, 'NCT01842399'), ({'text': 'Patients must have histologically confirmed persistent or recurrent triple-negative breast cancer (TNBC)', 'entities': [['69', '105', 'cancer']]}, 'NCT02484404'), ({'text': 'psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT02945800'), ({'text': 'Iodinated contrast allergy not controlled with 24-hour steroid preparation', 'entities': [['1', '19', 'allergy_name'], ['48', '55', 'upper_bound'], ['56', '63', 'treatment']]}, 'NCT02167009'), ({'text': 'Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered d28 days or limited field radiation for palliation d7 days prior to starting study drug or has not recovered from side effects of such therapy', 'entities': [['1', '24', 'treatment'], ['17', '24', 'treatment'], ['36', '61', 'treatment'], ['70', '82', 'treatment'], ['98', '105', 'upper_bound'], ['109', '132', 'treatment'], ['149', '161', 'upper_bound']]}, 'NCT01990209'), ({'text': 'Invasive breast cancer is estrogen receptor positive with an Allred score of 6, 7 or 8 by local institution standard protocol. If an Allred Score is not reported on the diagnostic pathology report, ER positivity in > 66% cells', 'entities': [['10', '23', 'cancer'], ['62', '74', 'clinical_variable'], ['78', '79', 'lower_bound'], ['86', '87', 'upper_bound'], ['134', '146', 'clinical_variable'], ['199', '212', 'clinical_variable'], ['218', '227', 'lower_bound']]}, 'NCT01953588'), ({'text': 'Use of systemic corticosteroids (>10 mg prednisone per day or equivalent) or other systemic immunosuppressive drugs', 'entities': [['8', '32', 'treatment'], ['35', '40', 'lower_bound'], ['41', '51', 'treatment'], ['84', '116', 'treatment']]}, 'NCT03131037'), ({'text': 'Per self-report/screening measures, has received cognitive-behavioral therapy since patients cancer diagnosis', 'entities': [['50', '78', 'treatment'], ['95', '101', 'cancer']]}, 'NCT03168971'), ({'text': 'Receiving ongoing treatment with immunosuppressive drugs', 'entities': [['19', '57', 'treatment']]}, 'NCT02549833'), ({'text': 'at least 2 of the 5 modified ACR classification criteria for GPA', 'entities': [['10', '11', 'lower_bound'], ['19', '20', 'upper_bound'], ['62', '65', 'clinical_variable']]}, 'NCT02108860'), ({'text': 'Radiation: Prior treatment with breast irradiation is not allowed due to the potential for cumulative toxicities', 'entities': [['1', '10', 'treatment'], ['12', '51', 'treatment']]}, 'NCT01618357'), ({'text': 'age 12 years, 0 mos. - 17 years, 11 mos', 'entities': [['1', '4', 'age'], ['5', '21', 'lower_bound'], ['24', '40', 'upper_bound']]}, 'NCT02553161'), ({'text': 'Major bleeding or clinically relevant non-major bleeding in the preceding 60 days', 'entities': [['75', '82', 'lower_bound']]}, 'NCT01999179'), ({'text': 'hemodynamic instability', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02240498'), ({'text': 'Renal: Serum creatinine less than 1.5 times the upper limit of normal for age', 'entities': [['8', '24', 'clinical_variable'], ['35', '70', 'upper_bound'], ['75', '78', 'age']]}, 'NCT01050855'), ({'text': 'Serum albumin <3.5 g/dL', 'entities': [['1', '14', 'clinical_variable'], ['16', '24', 'upper_bound']]}, 'NCT02579096'), ({'text': 'Evidence of complete or partial bowel obstruction', 'entities': [['33', '50', 'chronic_disease']]}, 'NCT02419495'), ({'text': 'Random blood glucose greater than 200mg/dL', 'entities': [['8', '21', 'clinical_variable'], ['35', '43', 'lower_bound']]}, 'NCT02587936'), ({'text': 'Age < 18 years of age', 'entities': [['1', '4', 'age'], ['7', '15', 'upper_bound'], ['19', '22', 'age']]}, 'NCT03001765'), ({'text': 'Patients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugs', 'entities': [['35', '47', 'treatment'], ['51', '58', 'lower_bound'], ['62', '74', 'treatment'], ['78', '91', 'lower_bound'], ['105', '116', 'treatment']]}, 'NCT02496663'), ({'text': 'females', 'entities': [['1', '8', 'gender']]}, 'NCT03057548'), ({'text': 'suspect she is pregnant while participating in this study, she should inform her treating physician immediately', 'entities': [['1', '24', 'pregnancy']]}, 'NCT01890590'), ({'text': 'Patients with B-lymphoblastic lymphoma (B-LL)', 'entities': [['15', '46', 'cancer']]}, 'NCT02101853'), ({'text': 'Bleeding disorders', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02558010'), ({'text': 'Histologically confirmed adenocarcinoma of the prostate', 'entities': [['26', '56', 'cancer']]}, 'NCT02290366'), ({'text': 'prior serum creatinine more than >1.5 mg/dlL', 'entities': [['7', '23', 'clinical_variable'], ['35', '45', 'lower_bound']]}, 'NCT03073070'), ({'text': 'alkaline phosphatase <= 3.0x the upper limit of normal', 'entities': [['1', '21', 'clinical_variable'], ['25', '29', 'upper_bound'], ['34', '55', 'clinical_variable']]}, 'NCT01562626'), ({'text': 'Patients must have prior bilateral orchiectomy', 'entities': [['36', '47', 'treatment']]}, 'NCT02911467'), ({'text': 'Suspected dissecting aneurysm', 'entities': [['11', '30', 'chronic_disease']]}, 'NCT02494869'), ({'text': 'Localized prostate cancer meeting the NCCN criteria of Intermediate Risk or patients having only one NCCN high-risk feature', 'entities': [['1', '26', 'cancer']]}, 'NCT01436968'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT02485418'), ({'text': 'prior history of SSI', 'entities': [['18', '21', 'chronic_disease']]}, 'NCT02490631'), ({'text': 'History of another cancer within 3 years before enrollment with the exception of nonmelanoma skin cancers, or American Joint Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of recurrence in the opinion of the investigator and the sponsor', 'entities': [['20', '26', 'cancer'], ['34', '41', 'upper_bound'], ['82', '106', 'cancer']]}, 'NCT03148795'), ({'text': 'women of childbearing age', 'entities': [['1', '6', 'gender'], ['23', '26', 'age']]}, 'NCT02046330'), ({'text': 'Prior MRI results dated within 120 days prior to ablation', 'entities': [['32', '46', 'upper_bound'], ['50', '58', 'treatment']]}, 'NCT02680535'), ({'text': '7-21 who have been diagnosed with ulcerative colitis', 'entities': [['1', '2', 'lower_bound'], ['3', '5', 'upper_bound'], ['35', '53', 'chronic_disease']]}, 'NCT02291523'), ({'text': 'Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment', 'entities': [['20', '36', 'chronic_disease'], ['53', '77', 'treatment'], ['99', '124', 'treatment'], ['132', '144', 'upper_bound']]}, 'NCT02977468'), ({'text': 'Contraindicated for medical treatment', 'entities': [['21', '38', 'treatment']]}, 'NCT02167009'), ({'text': 'Admission to the hospital (for > 24h) at the time of diagnosis', 'entities': [['34', '37', 'lower_bound']]}, 'NCT01994538'), ({'text': 'Measurable or non-measurable disease must be present outside the previous radiation field or a new lesion inside the radiation port must be present', 'entities': [['1', '11', 'chronic_disease'], ['15', '37', 'chronic_disease'], ['66', '90', 'treatment'], ['118', '132', 'treatment']]}, 'NCT01941316'), ({'text': 'Relapsed/refractory MCL: Patients with bone marrow or gastrointestinal (GI) only involvement', 'entities': [['21', '24', 'cancer']]}, 'NCT01880567'), ({'text': 'Age < 7 or > 18 y', 'entities': [['1', '4', 'age'], ['7', '8', 'upper_bound'], ['14', '18', 'lower_bound']]}, 'NCT01422746'), ({'text': 'Patients must have a histologically documented peritoneal carcinomatosis from either colorectal or appendiceal adenocarcinoma', 'entities': [['48', '73', 'cancer'], ['86', '96', 'cancer'], ['100', '126', 'cancer']]}, 'NCT01061515'), ({'text': 'Patients who have had prior WBRT and/or SRS and then whose prior treated lesions have progressed thereafter', 'entities': [['23', '33', 'treatment'], ['41', '44', 'treatment'], ['74', '81', 'cancer']]}, 'NCT01494662'), ({'text': 'Uncontrolled or poorly-controlled hypertension (>160 mmHg systolic or > 100 mmHg diastolic for >4 weeks) despite standard medical management', 'entities': [['35', '47', 'chronic_disease'], ['50', '58', 'lower_bound'], ['59', '67', 'clinical_variable'], ['73', '81', 'lower_bound'], ['82', '91', 'clinical_variable'], ['97', '104', 'lower_bound']]}, 'NCT02581215'), ({'text': 'total bilirubin d1.5 × ULN; AST d2.5 × ULN', 'entities': [['1', '16', 'clinical_variable'], ['18', '27', 'upper_bound'], ['29', '32', 'clinical_variable'], ['34', '43', 'upper_bound']]}, 'NCT03104699'), ({'text': 'Uncorrected hypokalemia, hypomagnesemia, hypocalcemia (can be due to diuretics, mineralocorticoid use, laxatives)', 'entities': [['13', '24', 'chronic_disease'], ['26', '40', 'chronic_disease'], ['42', '54', 'chronic_disease'], ['70', '79', 'treatment'], ['81', '98', 'treatment'], ['104', '113', 'treatment']]}, 'NCT02252432'), ({'text': 'Creatinine =< 2.0 mg/dl', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'upper_bound']]}, 'NCT02237183'), ({'text': 'Subjects (females) who are pregnant', 'entities': [['11', '18', 'gender'], ['28', '36', 'pregnancy']]}, 'NCT02151175'), ({'text': "History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. NOTE: patients with Grave's disease and/or psoriasis not requiring systemic therapy within the last two years from randomization and patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement are not excluded", 'entities': [['12', '30', 'chronic_disease'], ['61', '78', 'chronic_disease'], ['80', '88', 'chronic_disease'], ['90', '110', 'chronic_disease'], ['112', '140', 'chronic_disease'], ['142', '162', 'chronic_disease'], ['164', '190', 'chronic_disease'], ['192', '211', 'chronic_disease'], ['228', '253', 'chronic_disease'], ['255', '279', 'chronic_disease'], ['281', '299', 'chronic_disease'], ['301', '324', 'chronic_disease'], ['326', '344', 'chronic_disease'], ['346', '356', 'chronic_disease'], ['361', '379', 'chronic_disease'], ['401', '416', 'chronic_disease'], ['424', '433', 'chronic_disease'], ['448', '464', 'treatment'], ['476', '490', 'upper_bound'], ['528', '542', 'chronic_disease'], ['559', '577', 'chronic_disease'], ['589', '608', 'treatment']]}, 'NCT02273375'), ({'text': 'Active infection requiring systemic treatment within 28 days before the first dose of study treatment', 'entities': [['1', '17', 'chronic_disease'], ['28', '46', 'treatment'], ['37', '46', 'treatment'], ['54', '61', 'upper_bound']]}, 'NCT01822522'), ({'text': 'Allergy to iodine and/or soy', 'entities': [['12', '18', 'allergy_name'], ['26', '29', 'allergy_name']]}, 'NCT02647723'), ({'text': 'Women of child bearing potential must have a negative serum or urine pregnancy test within 7 days of registration', 'entities': [['1', '6', 'gender'], ['46', '79', 'pregnancy'], ['92', '98', 'upper_bound']]}, 'NCT02503722'), ({'text': 'Patients to be randomized to groups 1 and 2 must have tumor available for preparation of tumor lysate vaccine', 'entities': [['55', '60', 'cancer'], ['90', '110', 'treatment']]}, 'NCT00703105'), ({'text': 'Patients may have other metastases but only a maximum of 3 will be treated', 'entities': [['25', '35', 'cancer'], ['58', '59', 'upper_bound']]}, 'NCT02306954'), ({'text': 'Ability and willingness to come to Clinical Center for follow-up appointments and at the time of development of symptoms/signs suggestive of oral GVHD', 'entities': [['147', '151', 'chronic_disease']]}, 'NCT00391170'), ({'text': "multiple allergies that in the investigator's opinion would put the patient at an increased risk", 'entities': [['10', '19', 'allergy_name']]}, 'NCT02080221'), ({'text': 'Patients with other known malignancies within the past three years', 'entities': [['27', '39', 'cancer'], ['51', '67', 'upper_bound']]}, 'NCT01919619'), ({'text': 'Primary lymphedema', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02595996'), ({'text': 'For the renal cell carcinoma (RCC) cohort, participants must have progressed on treatment with an anti- programmed death receptor-1 /programmed death receptor-ligand 1 monoclonal antibody (anti-PD-1/PD-L1 mAb) administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies', 'entities': [['9', '35', 'cancer'], ['81', '210', 'treatment'], ['234', '245', 'treatment'], ['276', '297', 'treatment'], ['307', '316', 'treatment']]}, 'NCT02501096'), ({'text': 'Patient has an absolute neutrophil count of less 1000 within 14 days before enrollment', 'entities': [['16', '41', 'clinical_variable'], ['50', '54', 'upper_bound'], ['62', '76', 'upper_bound']]}, 'NCT02370693'), ({'text': 'Immunotherapy: anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)/anti-PD-1, other monoclonal antibody (mAb), or vaccine', 'entities': [['1', '14', 'treatment'], ['16', '73', 'treatment'], ['74', '83', 'treatment'], ['85', '116', 'treatment'], ['121', '128', 'treatment']]}, 'NCT02360579'), ({'text': 'The subject must have a baseline brain MRI scan or CT scan of the head (in patients unable to obtain an MRI) within 14 days prior to first dose of cabozantinib', 'entities': [['40', '43', 'treatment'], ['40', '48', 'treatment'], ['52', '71', 'treatment'], ['117', '130', 'upper_bound'], ['148', '160', 'treatment']]}, 'NCT02132598'), ({'text': 'cerebro-vascular attack within the prior year', 'entities': [['1', '17', 'chronic_disease'], ['36', '46', 'upper_bound']]}, 'NCT02807272'), ({'text': 'Have a recent history of myocardial infarction (within the past 2 months)', 'entities': [['26', '47', 'chronic_disease'], ['60', '73', 'upper_bound']]}, 'NCT02041936'), ({'text': 'Platelets greater than or equal to 100,000/mcL', 'entities': [['1', '10', 'clinical_variable'], ['36', '47', 'lower_bound']]}, 'NCT01851369'), ({'text': 'Patients must have evidence of biochemical (PSA) relapse after prostatectomy', 'entities': [['45', '48', 'clinical_variable'], ['64', '77', 'treatment']]}, 'NCT02203695'), ({'text': 'Stable dopaminergic medication regimen for 6 weeks prior to screening', 'entities': [['1', '39', 'treatment'], ['44', '57', 'upper_bound']]}, 'NCT03034564'), ({'text': 'Patients may have received other prior activating immunotherapies (i.e. checkpoint inhibitors), but must not have received them', 'entities': [['34', '66', 'treatment'], ['73', '94', 'treatment']]}, 'NCT01896999'), ({'text': 'adequate trials ( equal>4 weeks at the usually recommended or maximum tolerated dose) of augmentation/combination of a primary antidepressant using at least 2 different augmenting/combination agents (lithium, T3, stimulants, neuroleptics, anticonvulsants, buspirone, or a second primary antidepressant)', 'entities': [['25', '32', 'lower_bound'], ['128', '142', 'treatment'], ['158', '159', 'lower_bound'], ['201', '208', 'treatment'], ['210', '212', 'treatment'], ['214', '224', 'treatment'], ['226', '238', 'treatment'], ['240', '255', 'treatment'], ['257', '266', 'treatment'], ['273', '302', 'treatment']]}, 'NCT02046330'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT01974609'), ({'text': 'Leukemic phase (malignant cells e5 x 109/L)', 'entities': [['1', '15', 'cancer'], ['17', '32', 'clinical_variable'], ['34', '43', 'lower_bound']]}, 'NCT01829958'), ({'text': 'Spinal cord injury', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT01715571'), ({'text': 'Aneurysm with a history of growth e 0.5 cm per year', 'entities': [['1', '9', 'clinical_variable'], ['37', '52', 'lower_bound']]}, 'NCT02089607'), ({'text': 'Cefadroxil', 'entities': [['1', '11', 'treatment']]}, 'NCT03181516'), ({'text': 'Any platinum based chemotherapy (single agent platinum or any platinum doublet) administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen', 'entities': [['20', '32', 'treatment'], ['175', '196', 'treatment']]}, 'NCT02912572'), ({'text': 'lactating females', 'entities': [['11', '18', 'gender']]}, 'NCT02539160'), ({'text': 'Sickle cell disease (SCD)', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT01962415'), ({'text': 'Failure of antiviral therapy', 'entities': [['12', '29', 'treatment']]}, 'NCT02210078'), ({'text': 'Prior bevacizumab or tyrosine-kinase inhibitor', 'entities': [['1', '18', 'treatment'], ['22', '47', 'treatment']]}, 'NCT01817751'), ({'text': 'The dosage regimen of concomitant AED therapy must be kept constant for a period of >=2 weeks prior to Visit 1. A stable daily dosage regimen of a concomitant benzodiazepine (BZD) will be considered as a concomitant AED', 'entities': [['35', '46', 'treatment'], ['35', '38', 'treatment'], ['87', '100', 'upper_bound'], ['160', '180', 'treatment']]}, 'NCT02477839'), ({'text': 'Anticipated mortality rate with open repair estimated to be more than 20%', 'entities': [['71', '74', 'lower_bound']]}, 'NCT00488696'), ({'text': 'HCT-CI/Age Score d 5 points (Patients with greater than 5 points will be allowed for trial with approval of the PI and the Co-PI or his designee. This is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than HCT-CI 5 points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities', 'entities': [['1', '7', 'clinical_variable'], ['8', '17', 'clinical_variable'], ['332', '354', 'cancer'], ['344', '354', 'cancer'], ['421', '430', 'treatment']]}, 'NCT02566304'), ({'text': 'Patients must have tumor tissue available for submission that is sufficient to complete c-MET Fluorescence in Situ Hybridization (FISH) studies as well as routine molecular profiling at the UPMC', 'entities': [['20', '25', 'cancer'], ['95', '136', 'treatment']]}, 'NCT02132598'), ({'text': 'Presence of an Axis II disorder felt by the investigator to potentially interfere with study compliance', 'entities': [['16', '32', 'chronic_disease']]}, 'NCT02640950'), ({'text': 'History or evidence of current >= class II congestive heart failure as defined by the New York Heart Association (NYHA) functional classification system', 'entities': [['35', '43', 'lower_bound'], ['44', '68', 'chronic_disease'], ['87', '120', 'clinical_variable']]}, 'NCT01989585'), ({'text': 'AST & ALT > 2 X IULN', 'entities': [['1', '10', 'clinical_variable'], ['13', '21', 'lower_bound']]}, 'NCT02177695'), ({'text': 'Prior spinal surgery excluding laminectomy/discectomy', 'entities': [['7', '21', 'treatment'], ['32', '43', 'treatment'], ['44', '54', 'treatment']]}, 'NCT03033212'), ({'text': 'No active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs)', 'entities': [['11', '29', 'chronic_disease'], ['48', '66', 'treatment'], ['70', '82', 'upper_bound'], ['100', '124', 'treatment'], ['126', '141', 'treatment'], ['145', '168', 'treatment']]}, 'NCT02501096'), ({'text': 'patients with synchronous head and neck cancer primaries', 'entities': [['27', '47', 'cancer']]}, 'NCT02296684'), ({'text': 'Must have a negative serum pregnancy test prior to transplantation', 'entities': [['13', '37', 'pregnancy'], ['43', '67', 'treatment']]}, 'NCT02474667'), ({'text': 'patient is not receiving blocking adjuvant therapy (such as toremifene or tamoxifen) OR patient is receiving blocking adjuvant therapy, but will stop this therapy a minimum of 60 days prior to FES-PET/CT while still complying with the study timeline', 'entities': [['35', '51', 'treatment'], ['44', '51', 'treatment'], ['61', '71', 'treatment'], ['75', '84', 'treatment'], ['177', '190', 'lower_bound'], ['194', '204', 'treatment']]}, 'NCT02398773'), ({'text': 'The HBV DNA test will be performed only for patients who have a positive HBcAb test', 'entities': [['5', '8', 'chronic_disease'], ['74', '79', 'clinical_variable']]}, 'NCT03125902'), ({'text': 'Patients must not receive any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (i.e. megestrol acetate, bisphosphonates); in addition, men receiving treatment for prostate cancer will be maintained at castrate levels of testosterone by continuation of luteinizing-releasing hormone agonists; palliative radiation therapy (XRT) can be administered on study after documented discussion with the principal investigator; for patients in expansion cohorts, this must not involve target lesions', 'entities': [['37', '56', 'treatment'], ['58', '67', 'treatment'], ['69', '77', 'treatment'], ['79', '88', 'treatment'], ['93', '101', 'treatment'], ['124', '127', 'gender'], ['161', '172', 'treatment'], ['197', '212', 'treatment'], ['266', '283', 'treatment'], ['285', '300', 'treatment'], ['330', '339', 'treatment'], ['344', '359', 'cancer'], ['401', '413', 'clinical_variable'], ['433', '471', 'treatment'], ['473', '507', 'treatment']]}, 'NCT01434316'), ({'text': 'Total bilirubin within normal institutional limits', 'entities': [['1', '16', 'clinical_variable']]}, 'NCT02085941'), ({'text': 'Patients with prior therapy, other than therapy specified in the Inclusion Criteria', 'entities': [['15', '28', 'treatment'], ['21', '28', 'treatment']]}, 'NCT02553460'), ({'text': 'Uncontrolled infection', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02109627'), ({'text': 'True milk allergy (anaphylaxis or severe rash)', 'entities': [['6', '18', 'chronic_disease'], ['20', '31', 'allergy_name']]}, 'NCT02174016'), ({'text': 'Such patients are eligible for enrollment on this study providing that at least one residual (i.e. non-SRS-treated or non-resected) lesion is measurable (e10 mm)', 'entities': [['81', '84', 'lower_bound'], ['100', '107', 'treatment'], ['119', '131', 'treatment'], ['156', '161', 'lower_bound']]}, 'NCT01494662'), ({'text': 'between the ages of 20-50', 'entities': [['13', '17', 'age'], ['21', '23', 'lower_bound'], ['24', '26', 'upper_bound']]}, 'NCT02193373'), ({'text': 'males of childbearing potential must agree to practice 2 effective methods of contraception at the same time', 'entities': [['1', '6', 'gender'], ['38', '109', 'contraception_consent']]}, 'NCT02833805'), ({'text': 'Pericarditis', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02506192'), ({'text': "Parkinson's disease", 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02479906'), ({'text': 'Use of meropenem within 48 hours of administration of study drug or 12 hours after study drug administration', 'entities': [['8', '17', 'treatment'], ['25', '33', 'upper_bound'], ['69', '77', 'upper_bound']]}, 'NCT02687906'), ({'text': 'Prediction of Alcohol Withdrawal Severity Scale (PAWSS) score >4', 'entities': [['1', '62', 'clinical_variable'], ['64', '65', 'lower_bound']]}, 'NCT03012815'), ({'text': 'Active brain metastases or leptomeningeal metastases', 'entities': [['8', '24', 'cancer'], ['28', '53', 'cancer']]}, 'NCT02553642'), ({'text': 'Tumor volume less than 10 cm3 is mandatory for high grade tumors', 'entities': [['1', '13', 'clinical_variable'], ['24', '30', 'upper_bound'], ['59', '65', 'cancer']]}, 'NCT02451215'), ({'text': 'Patients must have left ventricular ejection fraction (LVEF) > 50% by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within 12 weeks prior to starting adriamycin', 'entities': [['20', '61', 'clinical_variable'], ['64', '67', 'lower_bound'], ['71', '106', 'treatment'], ['110', '131', 'treatment'], ['139', '153', 'upper_bound'], ['166', '176', 'treatment']]}, 'NCT02276443'), ({'text': 'uncontrolled angina, severe uncontrolled cardiac arrhythmias, or electrocardiographic evidence of acute ischemia', 'entities': [['1', '20', 'chronic_disease'], ['42', '61', 'chronic_disease'], ['105', '113', 'chronic_disease']]}, 'NCT02538198'), ({'text': 'History of bleeding disorder', 'entities': [['12', '29', 'chronic_disease']]}, 'NCT03028012'), ({'text': "Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator", 'entities': [['53', '60', 'treatment']]}, 'NCT02365766'), ({'text': 'Prednisone at Entry: It is also recommended that patients be on less than 1mg/kg/day of prednisone at study entry', 'entities': [['1', '11', 'treatment'], ['75', '85', 'upper_bound'], ['89', '99', 'treatment']]}, 'NCT02043548'), ({'text': 'ble to read and speak either English or Spanish', 'entities': [['1', '48', 'language_fluency']]}, 'NCT03035240'), ({'text': 'No available 10/10 or 9/10 HLA-matched related or unrelated donor, or haploidentical related donor', 'entities': [['14', '19', 'lower_bound'], ['23', '27', 'upper_bound'], ['28', '31', 'treatment']]}, 'NCT01861106'), ({'text': 'Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation', 'entities': [['61', '112', 'contraception_consent']]}, 'NCT02101853'), ({'text': 'History of seizure disorder or active use of anticonvulsants', 'entities': [['12', '28', 'chronic_disease'], ['46', '61', 'treatment']]}, 'NCT02012296'), ({'text': 'males', 'entities': [['1', '6', 'gender']]}, 'NCT02338999'), ({'text': 'History of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure', 'entities': [['12', '27', 'treatment']]}, 'NCT02734602'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03054870'), ({'text': 'The interval between the last surgery for breast cancer (including re-excision of margins) and randomization must be no more than 60 days', 'entities': [['31', '38', 'treatment'], ['43', '56', 'cancer'], ['131', '138', 'lower_bound']]}, 'NCT02488967'), ({'text': 'Any renal disease (eGFR < 90 ml/min) or acute nephritis', 'entities': [['5', '18', 'chronic_disease'], ['20', '24', 'clinical_variable'], ['27', '36', 'upper_bound'], ['41', '56', 'chronic_disease']]}, 'NCT02531295'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT03105362'), ({'text': 'CD4 cell percentage greater than or equal to 25 AND CD4 cell absolute count greater than or equal to the lower limit of normal for age (i.e., 1000 cells/mL if 2-3 years of age, greater than or equal to 750 cells/mL if 3-4 years of age)', 'entities': [['1', '20', 'clinical_variable'], ['17', '20', 'age'], ['46', '48', 'lower_bound'], ['46', '47', 'lower_bound'], ['53', '76', 'clinical_variable'], ['143', '156', 'lower_bound'], ['162', '163', 'lower_bound'], ['162', '169', 'upper_bound'], ['203', '215', 'lower_bound'], ['221', '228', 'upper_bound']]}, 'NCT02140255'), ({'text': 'Hepatitis C: boceprevir, telaprevir', 'entities': [['1', '12', 'chronic_disease'], ['14', '24', 'treatment'], ['26', '36', 'treatment']]}, 'NCT01822522'), ({'text': 'Be aged 18-80 years old', 'entities': [['4', '8', 'age'], ['9', '11', 'lower_bound'], ['12', '20', 'upper_bound']]}, 'NCT02565199'), ({'text': 'Patients may not be receiving any steroids or other anti-immune therapy at the time of registration', 'entities': [['35', '43', 'treatment'], ['53', '72', 'treatment']]}, 'NCT01720836'), ({'text': 'HgbA1C d7.0%', 'entities': [['1', '7', 'clinical_variable'], ['9', '13', 'upper_bound']]}, 'NCT02572323'), ({'text': 'organomegaly', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02931110'), ({'text': 'Myocardial infarction within the past 12 months, or stable or unstable angina', 'entities': [['1', '22', 'chronic_disease'], ['34', '48', 'upper_bound'], ['63', '78', 'chronic_disease']]}, 'NCT02584309'), ({'text': 'Patients must not be participating in any other clinical trial or taking any other experimental medications within 21 days prior to registration', 'entities': [['49', '63', 'treatment'], ['84', '108', 'treatment'], ['116', '129', 'upper_bound']]}, 'NCT01896999'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01970176'), ({'text': 'interfering comorbidities (e.g. fracture, cancer, peripheral neuropathy)', 'entities': [['43', '49', 'cancer'], ['51', '72', 'chronic_disease']]}, 'NCT02445768'), ({'text': 'Current use of prescription or non-prescription medication', 'entities': [['16', '59', 'treatment']]}, 'NCT01200940'), ({'text': 'Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with paclitaxel, breastfeeding should be discontinued if the mother is enrolled in the trial', 'entities': [['99', '108', 'treatment'], ['128', '138', 'treatment']]}, 'NCT03096418'), ({'text': 'hemodynamically significant valvular dysfunction', 'entities': [['29', '49', 'chronic_disease']]}, 'NCT02347995'), ({'text': 'unequivocal metastases and islet cell tumors are not eligible', 'entities': [['13', '23', 'cancer'], ['28', '45', 'cancer']]}, 'NCT02394535'), ({'text': 'Naive to treatment with TNF inhibitor therapy', 'entities': [['25', '46', 'treatment']]}, 'NCT02171429'), ({'text': 'History of autoimmune', 'entities': [['12', '22', 'chronic_disease']]}, 'NCT02665338'), ({'text': 'Patients with a known immunocompromised condition or a positive HIV test. Patients with a prior history of cervical cancer', 'entities': [['23', '40', 'chronic_disease'], ['65', '68', 'chronic_disease'], ['108', '123', 'cancer']]}, 'NCT01925378'), ({'text': 'platelet count > 50,000 cells/mL unless felt to be secondary to lymphoma at which any count is permissible', 'entities': [['1', '15', 'clinical_variable'], ['18', '33', 'lower_bound'], ['65', '73', 'cancer']]}, 'NCT02341209'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT00711373'), ({'text': 'Significant renal, hepatic, or bone marrow organ dysfunction', 'entities': [['13', '18', 'chronic_disease'], ['20', '27', 'chronic_disease'], ['32', '61', 'chronic_disease']]}, 'NCT03148795'), ({'text': 'Age 18 - 60 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['10', '18', 'upper_bound']]}, 'NCT01920737'), ({'text': 'Moderately severe anemia (Hgb < 8 mg/dL)', 'entities': [['19', '25', 'chronic_disease'], ['27', '30', 'clinical_variable'], ['33', '40', 'upper_bound']]}, 'NCT02226341'), ({'text': 'It is standard of care to post-pone routine dental procedures and radiographed until after pregnancy', 'entities': [['92', '101', 'pregnancy']]}, 'NCT03032705'), ({'text': 'History of more than 10 sessions of CBT and formal mindfulness/meditation training', 'entities': [['22', '24', 'lower_bound'], ['37', '40', 'treatment']]}, 'NCT02808702'), ({'text': 'NYHA class 4 CHF', 'entities': [['14', '17', 'chronic_disease']]}, 'NCT01333046'), ({'text': 'Cause of heart failure due to, or associated with, uncorrected thyroid disease, obstructive / restrictive cardiomyopathy, pericardial disease, amyloidosis, dermatomyositis, or active myocarditis', 'entities': [['10', '23', 'chronic_disease'], ['64', '79', 'chronic_disease'], ['81', '92', 'chronic_disease'], ['95', '121', 'chronic_disease'], ['123', '142', 'chronic_disease'], ['144', '155', 'chronic_disease'], ['157', '172', 'chronic_disease'], ['177', '195', 'chronic_disease']]}, 'NCT01627821'), ({'text': 'Existing diagnosis or history of leptomeningeal disease, spinal cord compression or brain metastases unless', 'entities': [['34', '56', 'chronic_disease'], ['58', '81', 'chronic_disease'], ['85', '101', 'cancer']]}, 'NCT02264236'), ({'text': 'Diagnosis of fructose malabsorption', 'entities': [['14', '36', 'chronic_disease']]}, 'NCT01185210'), ({'text': 'The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) >500 ms within 28 days before randomization', 'entities': [['29', '84', 'clinical_variable'], ['86', '92', 'lower_bound'], ['100', '114', 'upper_bound']]}, 'NCT02132598'), ({'text': "Patients with a history of inflammatory bowel disease such as Crohn's disease and ulcerative colitis", 'entities': [['28', '54', 'chronic_disease'], ['63', '78', 'chronic_disease'], ['83', '101', 'chronic_disease']]}, 'NCT02532231'), ({'text': 'Has taken NSAIDs or anti-secretory agents (proton pump inhibitors or H2 receptor antagonists) within 14 days prior to study drug administration', 'entities': [['11', '17', 'treatment'], ['21', '42', 'treatment'], ['44', '66', 'treatment'], ['70', '93', 'treatment'], ['102', '115', 'upper_bound']]}, 'NCT02502006'), ({'text': 'Known diagnosis of intracranial hypotension', 'entities': [['20', '44', 'chronic_disease']]}, 'NCT03041441'), ({'text': 'Presence of neutralising anti-hFVIII antibodies (inhibitor, determined by the Bethesda inhibitor assay) at the time of enrolment or a previous history of hFVIII inhibitor', 'entities': [['26', '48', 'treatment'], ['79', '103', 'clinical_variable'], ['155', '171', 'treatment']]}, 'NCT03001830'), ({'text': 'Current smoking or smoking history of greater than 10 pack-years', 'entities': [['52', '65', 'lower_bound']]}, 'NCT01536522'), ({'text': 'diabetes (1 point)', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT02169037'), ({'text': "Any current, serious, chronic medical or psychiatric disease that, in the Principal Investigator's judgment, may interfere with study participation or data integrity", 'entities': [['23', '38', 'chronic_disease'], ['42', '61', 'chronic_disease']]}, 'NCT03170856'), ({'text': 'History of hypertension that is not controlled by medication, stroke, or severe heart disease (donors with symptomatic angina will be excluded)', 'entities': [['12', '24', 'chronic_disease'], ['51', '61', 'treatment'], ['63', '69', 'chronic_disease'], ['81', '94', 'chronic_disease'], ['120', '126', 'chronic_disease']]}, 'NCT01087294'), ({'text': 'Diagnosis of significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study', 'entities': [['26', '46', 'chronic_disease']]}, 'NCT02371720'), ({'text': 'Completed radical prostatectomy for pathologically-verified adenocarcinoma of the prostate no more than 120 days prior to enrollment', 'entities': [['11', '32', 'treatment'], ['61', '91', 'cancer'], ['105', '119', 'upper_bound']]}, 'NCT02772562'), ({'text': 'Complete blood count (CBC)/differential obtained within 2 weeks (14 days) prior to registration on study, with adequate bone marrow function', 'entities': [['1', '27', 'clinical_variable'], ['57', '64', 'upper_bound'], ['66', '73', 'upper_bound']]}, 'NCT02064036'), ({'text': 'being insufficiently fluent in English', 'entities': [['22', '39', 'language_fluency']]}, 'NCT02386605'), ({'text': "Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study", 'entities': [['41', '62', 'chronic_disease']]}, 'NCT02245997'), ({'text': 'Anaplastic large cell lymphoma', 'entities': [['1', '31', 'cancer']]}, 'NCT01787409'), ({'text': 'Males must agree to adequate birth control', 'entities': [['1', '6', 'gender'], ['12', '43', 'contraception_consent']]}, 'NCT02301117'), ({'text': 'Patient has received other investigational drugs with 21 days before enrollment', 'entities': [['28', '49', 'treatment'], ['55', '69', 'upper_bound']]}, 'NCT02332850'), ({'text': 'participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial', 'entities': [['89', '101', 'lower_bound']]}, 'NCT03054519'), ({'text': 'Cephalexin', 'entities': [['1', '11', 'treatment']]}, 'NCT01595529'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02019940'), ({'text': 'Hemoglobin >= 8.0 g/dL, performed within 28 days of treatment initiation', 'entities': [['1', '11', 'clinical_variable'], ['15', '23', 'lower_bound'], ['42', '49', 'upper_bound'], ['53', '62', 'treatment']]}, 'NCT02446457'), ({'text': 'Unresolved post-surgical complications (eg, significant infection) with healing difficulties', 'entities': [['57', '66', 'chronic_disease']]}, 'NCT02515110'), ({'text': 'history of significant psychiatric illness (bipolar disorder, schizophrenia, or psychosis)', 'entities': [['24', '43', 'chronic_disease'], ['45', '61', 'chronic_disease'], ['63', '76', 'chronic_disease'], ['81', '90', 'chronic_disease']]}, 'NCT02301260'), ({'text': 'Mother with any detectable viral replication (HIV RNA above the limit of detection) at last measurement prior to delivery determined within 30 days of delivery', 'entities': [['47', '50', 'chronic_disease'], ['51', '54', 'clinical_variable'], ['141', '148', 'upper_bound']]}, 'NCT02256631'), ({'text': 'Tumor volume greater than 10 cm3 is acceptable in low grade tumors if the entire tumor can be ablated in more than one staged procedure', 'entities': [['1', '13', 'clinical_variable'], ['27', '33', 'lower_bound'], ['61', '66', 'cancer'], ['61', '67', 'cancer'], ['116', '119', 'lower_bound']]}, 'NCT02451215'), ({'text': 'Known hypersensitivity to albuterol or any of its components, or levalbuterol', 'entities': [['27', '36', 'allergy_name'], ['66', '78', 'allergy_name']]}, 'NCT02826343'), ({'text': 'Need to use acetaminophen on regular basis (since can interfere with CGM accuracy)', 'entities': [['13', '26', 'treatment']]}, 'NCT03078491'), ({'text': 'all females of childbearing potential must have a blood test or urine study within 24 hours prior to enrollment to rule out pregnancy', 'entities': [['1', '12', 'gender'], ['51', '61', 'treatment'], ['84', '98', 'upper_bound'], ['125', '134', 'pregnancy']]}, 'NCT01896999'), ({'text': 'Patients with a lesion < 2 mm', 'entities': [['17', '23', 'clinical_variable'], ['26', '30', 'upper_bound']]}, 'NCT01653080'), ({'text': 'Age greater than or equal to 18 years', 'entities': [['1', '4', 'age'], ['30', '38', 'lower_bound']]}, 'NCT02446236'), ({'text': 'Hepatitis B (HBV) or hepatitis C (HCV). Patients positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA, these patients should receive prophylactic antiviral therapy. Patients positive for anti- HCV antibody will be eligible if they are negative for HCV-RNA', 'entities': [['1', '18', 'chronic_disease'], ['14', '17', 'chronic_disease'], ['22', '39', 'chronic_disease'], ['35', '38', 'chronic_disease'], ['159', '189', 'treatment']]}, 'NCT02367040'), ({'text': 'Adequate hematologic, renal, and liver function as defined by laboratory values performed within 42 days prior to initiation of dosing', 'entities': [['98', '111', 'upper_bound']]}, 'NCT02143050'), ({'text': 'Prior hormonal therapy', 'entities': [['1', '23', 'treatment']]}, 'NCT02912572'), ({'text': 'MRI evidence', 'entities': [['1', '4', 'treatment']]}, 'NCT01505569'), ({'text': 'Subjects who are taking warfarin', 'entities': [['25', '33', 'treatment']]}, 'NCT02654236'), ({'text': 'Psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['1', '38', 'chronic_disease']]}, 'NCT02272998'), ({'text': 'Subjects e18 years of age with histological diagnosis of incurable cancer (solid tumor)', 'entities': [['11', '19', 'lower_bound'], ['23', '26', 'age'], ['68', '74', 'cancer'], ['76', '87', 'cancer']]}, 'NCT01614990'), ({'text': 'Adequate organ function within 14 days of study registration', 'entities': [['32', '39', 'upper_bound']]}, 'NCT02549833'), ({'text': 'No arrhythmia requiring treatment', 'entities': [['4', '14', 'chronic_disease'], ['25', '34', 'treatment']]}, 'NCT02199236'), ({'text': 'lesion at or below C2 and above T12 with non-progressive etiology', 'entities': [['20', '22', 'upper_bound'], ['33', '36', 'lower_bound']]}, 'NCT02323698'), ({'text': 'Preoperative prophylactic heparin is not an exclusion criterion', 'entities': [['1', '34', 'treatment']]}, 'NCT02908841'), ({'text': 'MRI/CT findings of neural compression (neural compression is defined as disc herniation or central or foraminal spinal stenosis)', 'entities': [['1', '4', 'treatment'], ['5', '7', 'treatment'], ['20', '38', 'chronic_disease'], ['103', '128', 'chronic_disease']]}, 'NCT02226159'), ({'text': 'class III-IV CHF, AIDS, severe COPD requiring use of home O2', 'entities': [['1', '10', 'lower_bound'], ['11', '13', 'upper_bound'], ['14', '17', 'chronic_disease'], ['19', '23', 'chronic_disease'], ['32', '36', 'chronic_disease'], ['54', '61', 'treatment']]}, 'NCT01614990'), ({'text': 'Symptomatic hypotension at randomization', 'entities': [['1', '24', 'chronic_disease']]}, 'NCT02816736'), ({'text': 'Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration', 'entities': [['22', '47', 'treatment'], ['51', '72', 'treatment'], ['77', '93', 'cancer'], ['153', '156', 'treatment'], ['201', '214', 'upper_bound']]}, 'NCT02860000'), ({'text': 'History of invasive breast cancer or contralateral DCIS', 'entities': [['21', '34', 'cancer'], ['52', '56', 'cancer']]}, 'NCT01953588'), ({'text': 'current GI bleed', 'entities': [['9', '17', 'chronic_disease']]}, 'NCT03100461'), ({'text': 'Score of 23 or below on the MMSE(Mini-Mental State Examination)', 'entities': [['10', '12', 'upper_bound'], ['29', '64', 'clinical_variable']]}, 'NCT03180905'), ({'text': '< 140 mmHg and diastolic < 90 mmHg', 'entities': [['3', '11', 'upper_bound'], ['16', '25', 'clinical_variable'], ['28', '35', 'upper_bound']]}, 'NCT02272998'), ({'text': 'Stage II or greater pelvic organ prolapse (POP)', 'entities': [['1', '48', 'chronic_disease']]}, 'NCT01886794'), ({'text': 'To any other site(s) within 28 days of the first dose of study treatment', 'entities': [['29', '36', 'upper_bound'], ['58', '73', 'treatment']]}, 'NCT02132598'), ({'text': 'Candidacy for surgical mitral valve repair or replacement determined by Heart Team evaluation', 'entities': [['15', '43', 'treatment']]}, 'NCT03170349'), ({'text': 'Age: 18-75 years at time of transplantation', 'entities': [['1', '4', 'age'], ['6', '8', 'lower_bound'], ['9', '17', 'upper_bound'], ['29', '44', 'treatment']]}, 'NCT01241708'), ({'text': 'unable to read or comprehend the informed consent in English', 'entities': [['1', '61', 'language_fluency']]}, 'NCT02214550'), ({'text': 'Active pathological bleeding', 'entities': [['8', '29', 'chronic_disease']]}, 'NCT02539160'), ({'text': 'Patients who have discontinued any of these medications must have a wash-out period of at least 5 days or at least 5 half-lives of the drug (whichever is longer) prior to the first dose of dinaciclib (Refer to Appendix 2 Drugs that interact strongly with CYP3A4)', 'entities': [['45', '56', 'treatment'], ['97', '103', 'lower_bound'], ['116', '128', 'lower_bound'], ['190', '200', 'treatment']]}, 'NCT01676753'), ({'text': 'FVC (Forced vital capacity) e 50% predicted', 'entities': [['1', '28', 'clinical_variable'], ['31', '34', 'lower_bound']]}, 'NCT00959140'), ({'text': 'The primary tumor must be measurable by an imaging modality prior to treatment', 'entities': [['13', '18', 'cancer'], ['70', '79', 'treatment']]}, 'NCT03096418'), ({'text': 'Subjects must be on a stable dose of the following medications/treatments for at least 4 weeks prior to the preliminary screening period, and must intend to continue the medication for the duration of the trial: psychoactive drugs, for example anticonvulsants, benzodiazepines, antidepressants, sedative/hypnotics; antihypertensive medications, including beta blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers; magnesium prescribed specifically for headache', 'entities': [['52', '62', 'treatment'], ['52', '63', 'treatment'], ['64', '74', 'treatment'], ['88', '101', 'lower_bound'], ['213', '231', 'treatment'], ['245', '260', 'treatment'], ['262', '277', 'treatment'], ['279', '294', 'treatment'], ['296', '304', 'treatment'], ['305', '314', 'treatment'], ['316', '332', 'treatment'], ['356', '369', 'treatment'], ['371', '395', 'treatment'], ['397', '437', 'treatment'], ['443', '472', 'treatment']]}, 'NCT02266329'), ({'text': 'Have a diagnosis of hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer for Parts A to E, G, and I', 'entities': [['21', '52', 'cancer'], ['54', '101', 'cancer'], ['111', '135', 'cancer']]}, 'NCT02057133'), ({'text': 'Platelets >= 100,000/mm^3', 'entities': [['1', '10', 'clinical_variable'], ['14', '26', 'lower_bound']]}, 'NCT01434316'), ({'text': 'History of allergy to IGF-1', 'entities': [['23', '28', 'allergy_name']]}, 'NCT01970345'), ({'text': 'Primary Sclerosing Cholangitis (PSC) or liver disease', 'entities': [['1', '37', 'chronic_disease'], ['41', '54', 'chronic_disease']]}, 'NCT02922881'), ({'text': 'Related donors will undergo the Donor Health History Screen by skilled staff in the Blood Services Section for adult donors and age-appropriate questioning when indicated for pediatric donors to determine donor eligibility using standard DTM criteria', 'entities': [['129', '132', 'age']]}, 'NCT02579967'), ({'text': '(international normalized ratio, or INR > 1.5; prothrombin time (PT)', 'entities': [['2', '32', 'clinical_variable'], ['37', '40', 'clinical_variable'], ['43', '46', 'lower_bound']]}, 'NCT02460783'), ({'text': 'severely uncontrolled diabetes', 'entities': [['1', '31', 'chronic_disease']]}, 'NCT03170375'), ({'text': 'Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support', 'entities': [['1', '18', 'chronic_disease'], ['37', '51', 'clinical_variable'], ['53', '64', 'treatment']]}, 'NCT02000115'), ({'text': 'Previous refractive surgery', 'entities': [['10', '28', 'treatment']]}, 'NCT03179397'), ({'text': 'active gastrointestinal bleeding or ulcers or major injuries or surgery', 'entities': [['1', '33', 'chronic_disease'], ['65', '72', 'treatment']]}, 'NCT02496585'), ({'text': 'American Spinal Injury Association Impairment Scale (AIS) grade A-D', 'entities': [['1', '58', 'clinical_variable'], ['59', '66', 'lower_bound'], ['67', '68', 'upper_bound']]}, 'NCT02632422'), ({'text': 'History of arterial or venous thromboembolic disease 6 months prior to screening', 'entities': [['12', '20', 'chronic_disease'], ['24', '45', 'chronic_disease']]}, 'NCT02074436'), ({'text': 'Age 21-60 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['8', '16', 'upper_bound']]}, 'NCT03099590'), ({'text': 'Hereditary Nonpolyposis Colorectal Cancer (HNPCC)/Lynch Syndrome: known genetic mutation, presumed HNPCC carrier, Amsterdam criteria', 'entities': [['1', '65', 'cancer'], ['44', '49', 'cancer']]}, 'NCT00539162'), ({'text': 'current or past history of clinically significant QT prolongation, including: QTcF > 450 ms (average of 3 12-lead measurements)', 'entities': [['79', '83', 'clinical_variable'], ['86', '92', 'lower_bound'], ['105', '106', 'lower_bound'], ['107', '127', 'clinical_variable']]}, 'NCT02354703'), ({'text': 'Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation', 'entities': [['1', '6', 'gender'], ['39', '74', 'contraception_consent'], ['76', '84', 'contraception_consent'], ['88', '119', 'contraception_consent'], ['121', '131', 'contraception_consent']]}, 'NCT00703105'), ({'text': 'Hgb <8 gm/dl', 'entities': [['1', '4', 'clinical_variable'], ['6', '13', 'upper_bound']]}, 'NCT02143830'), ({'text': 'Blasts plus progranulocytes e 30% in blood or bone marrow (BM)', 'entities': [['1', '28', 'clinical_variable'], ['31', '34', 'lower_bound']]}, 'NCT02353728'), ({'text': 'History of congestive heart failure (EF < 35%)', 'entities': [['12', '36', 'chronic_disease'], ['38', '40', 'clinical_variable'], ['43', '46', 'upper_bound']]}, 'NCT02209636'), ({'text': 'Postmenopausal women who have undergone a DEXA scan during the last year and have a T score better than -2.5 will be included without repeating the DEXA scan prior to enrollment', 'entities': [['16', '21', 'gender'], ['43', '52', 'treatment'], ['85', '92', 'clinical_variable'], ['105', '109', 'lower_bound']]}, 'NCT02338999'), ({'text': 'newly diagnosed invasive epithelial ovarian cancer FIGO stage IIIB-IV', 'entities': [['17', '51', 'cancer'], ['57', '67', 'lower_bound'], ['68', '70', 'upper_bound']]}, 'NCT02828618'), ({'text': 'Active acute or known chronic infections', 'entities': [['8', '41', 'chronic_disease']]}, 'NCT02826681'), ({'text': 'e moderate mitral stenosis', 'entities': [['3', '27', 'clinical_variable']]}, 'NCT03042104'), ({'text': 'Women of childbearing potential', 'entities': [['1', '6', 'gender']]}, 'NCT02438995'), ({'text': 'AST (SGOT) d 2.5 x institutional upper limit of normal (IULN) d 5 x IULN for patients with liver metastases', 'entities': [['1', '11', 'clinical_variable'], ['14', '55', 'upper_bound'], ['57', '61', 'clinical_variable'], ['65', '73', 'upper_bound'], ['92', '108', 'cancer']]}, 'NCT01553071'), ({'text': 'For women of childbearing potential, a serum or urine pregnancy test must be performed within 72 hours prior to registration', 'entities': [['5', '10', 'gender'], ['40', '64', 'pregnancy'], ['95', '109', 'upper_bound']]}, 'NCT01697371'), ({'text': 'following initiation of hormonal therapy', 'entities': [['25', '41', 'treatment']]}, 'NCT02064036'), ({'text': 'Subjects taking corticosteroids during the last 1 week prior treatment, unless administered at a dose equivalent to < 20 mg/day of prednisone', 'entities': [['17', '32', 'treatment'], ['44', '61', 'upper_bound'], ['62', '71', 'treatment'], ['119', '128', 'upper_bound'], ['132', '142', 'treatment']]}, 'NCT01996865'), ({'text': 'ganglioneuroblastoma', 'entities': [['1', '21', 'cancer']]}, 'NCT01804634'), ({'text': 'Currently taking any amphetamine product, an antipsychotic, bupropion, or any medication that would prohibit the safe concurrent use of methylphenidate, including but not limited to monoamine oxidase inhibitors and tricyclic antidepressants within the 30 days preceding randomization or a period of time equal to 5 half-lives of drug, whichever period of time is longer', 'entities': [['22', '41', 'treatment'], ['46', '59', 'treatment'], ['61', '70', 'treatment'], ['79', '89', 'treatment'], ['137', '152', 'treatment'], ['183', '211', 'treatment'], ['216', '241', 'treatment'], ['253', '270', 'upper_bound'], ['314', '326', 'upper_bound']]}, 'NCT02346201'), ({'text': 'Patients with HT must not have received an anthracycline-containing regimen in the past', 'entities': [['15', '17', 'chronic_disease'], ['44', '57', 'treatment']]}, 'NCT02734771'), ({'text': 'Have hypertension (blood pressure greater than or equal to 140 mmHg systolic pressure or greater than or equal to 90 mmHg diastolic pressure)', 'entities': [['6', '18', 'chronic_disease'], ['20', '34', 'clinical_variable'], ['60', '68', 'lower_bound'], ['69', '86', 'clinical_variable'], ['115', '122', 'lower_bound'], ['123', '141', 'clinical_variable']]}, 'NCT02263729'), ({'text': 'Hemoglobin > 10 g/dL serum creatinine < 1.5 times the upper limit of normal', 'entities': [['1', '11', 'clinical_variable'], ['14', '21', 'lower_bound'], ['22', '38', 'clinical_variable'], ['41', '76', 'upper_bound']]}, 'NCT02213497'), ({'text': 'Currently meets criteria for Major Depressive Episode, by Diagnostic Statistical Manual of Mental Disorder - IV (TR) criteria', 'entities': [['30', '54', 'chronic_disease']]}, 'NCT02346201'), ({'text': 'Willing to make quit attempt in next 30 days', 'entities': [['38', '45', 'upper_bound']]}, 'NCT02971137'), ({'text': 'Patients with life expectancy of < 6 months for reasons other than their underlying hematological/oncological disorder', 'entities': [['15', '30', 'clinical_variable'], ['36', '44', 'upper_bound'], ['85', '98', 'chronic_disease'], ['99', '119', 'chronic_disease']]}, 'NCT01349101'), ({'text': 'non-response to adequate trial of escitalopram (at least 4 weeks at dose of 20mg) during the current episode', 'entities': [['35', '47', 'treatment'], ['58', '65', 'upper_bound']]}, 'NCT01931202'), ({'text': 'Myeloma patients are required to have disease which has progressed following treatment with bortezomib', 'entities': [['1', '8', 'cancer'], ['78', '87', 'treatment'], ['93', '103', 'treatment']]}, 'NCT00720785'), ({'text': 'A trial of clozapine of at least12 weeks at a dose of at least 400 mg (or a clozapine level of at least 350 ng/mL)', 'entities': [['12', '21', 'treatment'], ['33', '41', 'lower_bound'], ['64', '70', 'lower_bound'], ['77', '92', 'clinical_variable'], ['105', '114', 'lower_bound']]}, 'NCT02361554'), ({'text': 'Patients must have a washout period e 28 days from prior anticancer therapy(ies) to the start of the planned NMA-LD preconditioning regimen', 'entities': [['22', '36', 'clinical_variable'], ['39', '46', 'lower_bound'], ['52', '81', 'treatment'], ['110', '140', 'treatment']]}, 'NCT02360579'), ({'text': 'Completed pre-operative chemo radiotherapy followed by surgery', 'entities': [['11', '43', 'treatment'], ['56', '63', 'treatment']]}, 'NCT02743494'), ({'text': 'Diagnosis with cancer, stage I-IV', 'entities': [['16', '34', 'cancer']]}, 'NCT02991677'), ({'text': 'Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4)', 'entities': [['1', '22', 'chronic_disease'], ['30', '44', 'upper_bound'], ['66', '99', 'clinical_variable'], ['100', '109', 'lower_bound'], ['113', '115', 'upper_bound'], ['116', '129', 'chronic_disease']]}, 'NCT01366612'), ({'text': 'Individuals receiving a single mood stabilizer (e.g., lithium. valproate, or lamictal) are allowed if a stable dose has been maintained for at least 2 months prior to screening', 'entities': [['25', '47', 'treatment'], ['55', '62', 'treatment'], ['64', '73', 'treatment'], ['78', '86', 'treatment'], ['150', '164', 'lower_bound']]}, 'NCT02466685'), ({'text': "Bilirubin equal or less than 1.5 mg/dl except for Gilbert's disease", 'entities': [['1', '10', 'clinical_variable'], ['30', '39', 'upper_bound'], ['51', '68', 'chronic_disease']]}, 'NCT01904136'), ({'text': 'Patients must be aware of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts', 'entities': [['188', '195', 'treatment']]}, 'NCT02553447'), ({'text': 'Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drugs including difficulty swallowing', 'entities': [['7', '36', 'chronic_disease'], ['40', '52', 'treatment'], ['83', '98', 'treatment'], ['115', '126', 'treatment']]}, 'NCT02542657'), ({'text': 'Any serious psychological condition or psychiatric illness that would prevent the subject from signing the informed consent document, in the investigator opinion', 'entities': [['5', '36', 'chronic_disease'], ['40', '59', 'chronic_disease']]}, 'NCT01787487'), ({'text': 'Active viral infection with HIV or hepatitis type B or C', 'entities': [['8', '23', 'chronic_disease'], ['29', '32', 'chronic_disease'], ['36', '52', 'chronic_disease'], ['56', '57', 'chronic_disease']]}, 'NCT01333046'), ({'text': 'Any other solid tumor and soft tissue sarcoma with an estimated <10% chance of survival will be considered on a case by case basis at the departmental tumor board and/or sarcoma meeting', 'entities': [['11', '22', 'cancer'], ['17', '22', 'cancer'], ['27', '46', 'cancer'], ['39', '46', 'cancer'], ['66', '69', 'upper_bound']]}, 'NCT01804634'), ({'text': 'Participating in another study involving an investigational medication', 'entities': [['45', '71', 'treatment']]}, 'NCT02542956'), ({'text': 'Renal insufficiency or serum creatinine >1.5 X ULN at screening', 'entities': [['1', '40', 'clinical_variable'], ['42', '51', 'lower_bound']]}, 'NCT02340156'), ({'text': 'the ablation injury with technical modifications such as hydro or air dissection', 'entities': [['58', '63', 'treatment'], ['67', '81', 'treatment']]}, 'NCT01494324'), ({'text': 'Any condition that prevents compliance with the protocol or adherence to therapy', 'entities': [['74', '81', 'treatment']]}, 'NCT02554903'), ({'text': 'Subject is pregnant (For a female subject of childbearing potential, a pregnancy test must be performed within 14 days (d14 days) prior to the index procedure per site standard test)', 'entities': [['12', '20', 'pregnancy'], ['28', '42', 'gender'], ['72', '81', 'pregnancy'], ['112', '119', 'upper_bound']]}, 'NCT02468778'), ({'text': 'Patients with diabetes', 'entities': [['15', '23', 'chronic_disease']]}, 'NCT02967315'), ({'text': 'Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in ¼mol/L', 'entities': [['1', '8', 'gender'], ['10', '13', 'clinical_variable'], ['28', '31', 'age'], ['35', '41', 'clinical_variable']]}, 'NCT02273375'), ({'text': 'Known hypersensitivity to fluoxetine or other selective serotonin reuptake inhibitors', 'entities': [['27', '37', 'allergy_name'], ['57', '86', 'allergy_name']]}, 'NCT02737930'), ({'text': 'Negative Tissue transglutaminase (TTG) for celiac disease', 'entities': [['10', '39', 'clinical_variable'], ['44', '58', 'chronic_disease']]}, 'NCT03078530'), ({'text': 'History of substance abuse in the past 6 months or positive urine drug screen', 'entities': [['35', '48', 'upper_bound']]}, 'NCT02460783'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02385110'), ({'text': 'Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) if no hepatic metastases are present', 'entities': [['1', '33', 'clinical_variable'], ['37', '67', 'clinical_variable'], ['70', '105', 'lower_bound'], ['112', '130', 'cancer']]}, 'NCT03037385'), ({'text': 'Initiating ADT for prostate cancer prior to the previous 3 months or are not on ADT holiday', 'entities': [['20', '35', 'cancer'], ['49', '66', 'upper_bound']]}, 'NCT02969577'), ({'text': 'Be aged between 18 and 55 years', 'entities': [['4', '8', 'age'], ['17', '19', 'lower_bound'], ['24', '32', 'upper_bound']]}, 'NCT02308202'), ({'text': 'Significant hypertension BP > 180 systolic or > 100 diastolic, at rest', 'entities': [['13', '25', 'chronic_disease'], ['26', '28', 'clinical_variable'], ['35', '43', 'clinical_variable'], ['49', '52', 'lower_bound'], ['53', '62', 'clinical_variable']]}, 'NCT03019510'), ({'text': 'Use of inhaled steroids or inhaled steroids plus long acting beta agonists for respiratory symptoms for greater than 4 months in the past year', 'entities': [['8', '24', 'treatment'], ['50', '75', 'treatment'], ['118', '126', 'lower_bound']]}, 'NCT02570984'), ({'text': 'Subjects who have a history of an adverse reaction to cosyntropin injection or similar test reagents', 'entities': [['55', '66', 'allergy_name']]}, 'NCT02527421'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, active liver disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['77', '93', 'chronic_disease'], ['95', '115', 'chronic_disease'], ['129', '153', 'chronic_disease'], ['155', '179', 'chronic_disease'], ['181', '199', 'chronic_disease'], ['204', '241', 'chronic_disease']]}, 'NCT02584647'), ({'text': 'Expected survival > 12 weeks', 'entities': [['1', '18', 'clinical_variable'], ['21', '29', 'lower_bound']]}, 'NCT02374333'), ({'text': 'uncontrolled arrhythmia', 'entities': [['14', '24', 'chronic_disease']]}, 'NCT02227199'), ({'text': 'The patient has a history of retinitis pigmentosa or severe vision loss', 'entities': [['30', '50', 'chronic_disease'], ['54', '72', 'chronic_disease']]}, 'NCT00737893'), ({'text': 'Patients must to have tumor tissue collected prior to enrolling on this trial', 'entities': [['23', '28', 'cancer']]}, 'NCT02178709'), ({'text': 'Absolute neutrophil count (ANC) >= 1.0 x 10^9/L', 'entities': [['1', '32', 'clinical_variable'], ['36', '48', 'lower_bound']]}, 'NCT01787487'), ({'text': 'Total bilirubin < 3.0 mg/dL', 'entities': [['1', '16', 'clinical_variable'], ['19', '28', 'upper_bound']]}, 'NCT01972919'), ({'text': 'autoimmune hepatitis', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02474199'), ({'text': 'severe cardiovascular and pulmonary disease', 'entities': [['1', '22', 'chronic_disease'], ['27', '44', 'chronic_disease']]}, 'NCT02991248'), ({'text': 'Patients with serious uncontrolled infections', 'entities': [['23', '46', 'chronic_disease']]}, 'NCT00432094'), ({'text': 'Platelets > 50,000/mm^3 (without support)', 'entities': [['1', '10', 'clinical_variable'], ['13', '24', 'lower_bound']]}, 'NCT01878617'), ({'text': 'confirmed diagnosis of type 2 diabetes as documented in the electronic health record', 'entities': [['24', '39', 'chronic_disease']]}, 'NCT02779556'), ({'text': 'Stroke (including transient ischemic attack [TIA], or other ischemic event)', 'entities': [['1', '7', 'chronic_disease'], ['19', '50', 'chronic_disease']]}, 'NCT01822522'), ({'text': 'Morbidly obese (body mass index > 40 kg/m2)', 'entities': [['1', '15', 'chronic_disease'], ['17', '32', 'bmi'], ['35', '43', 'lower_bound']]}, 'NCT02563678'), ({'text': 'Serum creatinine < 1.5 mg%', 'entities': [['1', '17', 'clinical_variable'], ['20', '27', 'upper_bound']]}, 'NCT01823198'), ({'text': 'Systemic treatment within 4 weeks before study entry with cyclosporine A or tacrolimus, everolimus, or sirolimus (calcineurin or mammalian target of rapamycin inhibitors)', 'entities': [['1', '19', 'treatment'], ['27', '34', 'upper_bound'], ['59', '73', 'treatment'], ['77', '87', 'treatment'], ['89', '99', 'treatment'], ['104', '113', 'treatment']]}, 'NCT02688647'), ({'text': 'No upper limit for the number of prior therapies', 'entities': [['34', '49', 'treatment']]}, 'NCT01947140'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status 0,1 (Appendix D)', 'entities': [['1', '61', 'clinical_variable'], ['62', '63', 'lower_bound'], ['64', '65', 'upper_bound']]}, 'NCT02301611'), ({'text': 'Transplantation-specific co-morbidity score of <5 at time of initiation of pre-transplant conditioning', 'entities': [['1', '44', 'clinical_variable'], ['49', '50', 'upper_bound']]}, 'NCT02338232'), ({'text': 'Any pregnant woman', 'entities': [['5', '13', 'pregnancy'], ['14', '19', 'gender']]}, 'NCT01856049'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02404155'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT00896493'), ({'text': 'GEP risk score of e 0.66', 'entities': [['1', '15', 'clinical_variable'], ['21', '25', 'lower_bound']]}, 'NCT00734877'), ({'text': 'Patients with Gynecologic Oncology Group (GOG) performance status > 2', 'entities': [['15', '66', 'clinical_variable'], ['69', '70', 'lower_bound']]}, 'NCT02324439'), ({'text': 'BCC/SCC in region adjacent to or overlapping with region of prior radiotherapy', 'entities': [['67', '79', 'treatment']]}, 'NCT02131805'), ({'text': 'Patients must have untreated cervical biopsy-proven, CIN 2/3 ectocervical lesion(s)', 'entities': [['30', '45', 'treatment'], ['54', '61', 'chronic_disease']]}, 'NCT02864147'), ({'text': 'Absolute granulocyte count >= 1.2 x 10^3/mm^3', 'entities': [['1', '27', 'clinical_variable'], ['31', '46', 'lower_bound']]}, 'NCT00075387'), ({'text': 'Patients previously treated with an mammalian TOR (mTOR) or PI3K inhibitor', 'entities': [['37', '57', 'treatment'], ['61', '75', 'treatment']]}, 'NCT02417701'), ({'text': 'Documented history of serious neurological disorder', 'entities': [['31', '52', 'chronic_disease']]}, 'NCT02469389'), ({'text': 'aged 18-55', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '11', 'upper_bound']]}, 'NCT02613936'), ({'text': 'Participants whose insurance does not cover Occupational Therapy costs or who have no insurance', 'entities': [['45', '65', 'treatment']]}, 'NCT03049033'), ({'text': 'Performance status (Eastern Cooperative Oncology Group [ECOG]) must be less than or equal to 2 (Karnofsky greater than or equal to 50)', 'entities': [['1', '63', 'clinical_variable'], ['94', '95', 'upper_bound'], ['97', '106', 'clinical_variable'], ['132', '134', 'lower_bound']]}, 'NCT00075387'), ({'text': 'Clinically significant peripheral vascular disease or vascular disease, including rapidly growing aortic aneurysm or abdominal aortic aneurysm', 'entities': [['24', '51', 'chronic_disease'], ['35', '51', 'chronic_disease'], ['99', '114', 'chronic_disease'], ['118', '143', 'chronic_disease']]}, 'NCT02484404'), ({'text': 'Patients who have received prior immunotherapy', 'entities': [['28', '47', 'treatment']]}, 'NCT02358187'), ({'text': 'who has not recovered (i.e., d Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier', 'entities': [['32', '39', 'upper_bound'], ['113', '120', 'lower_bound']]}, 'NCT02324582'), ({'text': 'Documented case of liver disease other than Parenteral Nutrition Associated Cholestasis', 'entities': [['20', '33', 'chronic_disease']]}, 'NCT00969332'), ({'text': 'inhaled/topical steroids', 'entities': [['1', '8', 'treatment'], ['9', '25', 'treatment']]}, 'NCT01804465'), ({'text': 'subjects who have received autologous bone marrow stem cell transplant will be eligible', 'entities': [['28', '71', 'treatment']]}, 'NCT02464436'), ({'text': 'Subject has a diagnosis of ulcerative colitis (UC) or indeterminate colitis', 'entities': [['28', '51', 'chronic_disease'], ['55', '76', 'chronic_disease']]}, 'NCT03169894'), ({'text': 'Critical illness', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT03174834'), ({'text': 'thrombocytopenia', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT02366871'), ({'text': 'Participants who have previously been treated with endocrine therapy only, and later develop triple negative disease are eligible as long as they have had one line of chemotherapy in either the advanced or adjuvant setting', 'entities': [['52', '69', 'treatment'], ['94', '117', 'cancer'], ['168', '180', 'treatment'], ['207', '223', 'treatment']]}, 'NCT02393794'), ({'text': 'Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)', 'entities': [['1', '35', 'clinical_variable'], ['84', '105', 'treatment']]}, 'NCT01989585'), ({'text': 'Female', 'entities': [['1', '7', 'gender']]}, 'NCT01356290'), ({'text': 'Able to complete Topical Oxygen Therapy 4 day/week for 16 weeks (must be able to remove existing wound dressing and apply TO2 Boot/treatment, and then re-dress wound)', 'entities': [['18', '40', 'treatment']]}, 'NCT02313428'), ({'text': 'abnormal PET scans will not constitute evaluable disease unless verified by a diagnostic quality CT scan', 'entities': [['10', '19', 'treatment'], ['98', '105', 'treatment']]}, 'NCT01896999'), ({'text': 'planning on becoming pregnant within 60 months', 'entities': [['13', '30', 'pregnancy'], ['38', '47', 'upper_bound']]}, 'NCT02266719'), ({'text': 'Severe COPD', 'entities': [['8', '12', 'chronic_disease']]}, 'NCT03043742'), ({'text': 'ubject requiring an aortic conduit or direct aortic access', 'entities': [['21', '35', 'treatment'], ['39', '59', 'treatment']]}, 'NCT02365467'), ({'text': 'Transmural myocardial infarction within the last 6 months', 'entities': [['1', '33', 'chronic_disease'], ['45', '58', 'upper_bound']]}, 'NCT01622868'), ({'text': 'serum glutamate pyruvate transaminase (SGPT) (ALT) < 3 x upper limit of normal (ULN) for age', 'entities': [['1', '51', 'clinical_variable'], ['54', '85', 'upper_bound'], ['90', '93', 'age']]}, 'NCT02774421'), ({'text': 'MD global VAS with a minimum value of 2.0cm on a 10cm scale', 'entities': [['1', '14', 'clinical_variable'], ['39', '44', 'lower_bound'], ['50', '54', 'upper_bound']]}, 'NCT02043548'), ({'text': 'inhaled corticosteroids', 'entities': [['1', '24', 'treatment']]}, 'NCT02203695'), ({'text': 'ECOG performance status of 0, 1, or 2', 'entities': [['1', '24', 'clinical_variable'], ['28', '29', 'lower_bound'], ['37', '38', 'upper_bound']]}, 'NCT00924027'), ({'text': 'Presence of coagulopathy (PT or PTT> 1.2 x upper limit of normal)', 'entities': [['13', '25', 'chronic_disease'], ['27', '29', 'clinical_variable'], ['33', '36', 'clinical_variable'], ['38', '65', 'lower_bound']]}, 'NCT02706249'), ({'text': 'Women', 'entities': [['1', '6', 'gender']]}, 'NCT01896921'), ({'text': 'Metastatic cancer or any active primary cancer, at time of enrollment', 'entities': [['1', '18', 'cancer'], ['26', '47', 'cancer']]}, 'NCT03085784'), ({'text': 'History of allergy to study drug component or history of severe hypersensitivity reaction to any monoclonal antibody', 'entities': [['98', '117', 'allergy_name']]}, 'NCT02553642'), ({'text': 'ECOG performance status 0-2', 'entities': [['1', '24', 'clinical_variable'], ['25', '26', 'lower_bound'], ['27', '28', 'upper_bound']]}, 'NCT02003222'), ({'text': 'Patients with abnormal urologic conditions, including post-void residual, urethral stricture and bladder neck contracture, spastic bladder, vesicoureteral reflux, bladder stones, bladder tumors, hydronephrosis, other renal impairment', 'entities': [['24', '43', 'chronic_disease'], ['55', '73', 'chronic_disease'], ['75', '93', 'chronic_disease'], ['98', '122', 'chronic_disease'], ['124', '139', 'chronic_disease'], ['141', '162', 'chronic_disease'], ['164', '178', 'chronic_disease'], ['180', '194', 'cancer'], ['196', '210', 'chronic_disease'], ['218', '234', 'chronic_disease']]}, 'NCT01953263'), ({'text': 'prior chemotherapy for a different cancer', 'entities': [['1', '19', 'treatment'], ['36', '42', 'cancer']]}, 'NCT02567422'), ({'text': 'Individuals with history of ventricular arrhythmia or new onset ventricular arrhythmia after enrollment that requires medical management', 'entities': [['29', '51', 'chronic_disease']]}, 'NCT02914171'), ({'text': 'Hepatic encephalopathy', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02905188'), ({'text': 'Body mass index > 50', 'entities': [['1', '16', 'bmi'], ['19', '21', 'lower_bound']]}, 'NCT01730794'), ({'text': 'ECOG >2 performance status (Appendix D)', 'entities': [['1', '5', 'clinical_variable'], ['7', '8', 'lower_bound']]}, 'NCT02301611'), ({'text': 'Previous therapy with anthracyclines or taxanes for any malignancy', 'entities': [['10', '17', 'treatment'], ['23', '37', 'treatment'], ['41', '48', 'treatment'], ['57', '67', 'cancer']]}, 'NCT02488967'), ({'text': 'who are mechanically ventilated', 'entities': [['9', '32', 'treatment']]}, 'NCT01705119'), ({'text': "Diagnosis of Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV major depression and currently off antidepressant medication, unless otherwise approved by the PI or PI's designee", 'entities': [['14', '93', 'chronic_disease'], ['112', '137', 'treatment']]}, 'NCT02513485'), ({'text': "Waldenstrom's macroglobulinemia", 'entities': [['1', '32', 'cancer']]}, 'NCT02939183'), ({'text': 'No proven multicentric carcinoma (tumors in different quadrants of the breast or tumor separated by e 4 cm) with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy', 'entities': [['24', '33', 'cancer'], ['35', '41', 'cancer'], ['35', '40', 'cancer'], ['103', '107', 'lower_bound'], ['175', '193', 'cancer'], ['230', '240', 'cancer'], ['244', '250', 'treatment']]}, 'NCT00909909'), ({'text': 'Colloidal (mucinous) carcinoma', 'entities': [['1', '31', 'cancer']]}, 'NCT00909909'), ({'text': 'refractory to or intolerant of steroids', 'entities': [['32', '40', 'allergy_name']]}, 'NCT00044304'), ({'text': 'Second or third degree heart block or bradycardia (heart rate < 50 beats/min)', 'entities': [['1', '35', 'chronic_disease'], ['39', '50', 'chronic_disease'], ['52', '62', 'clinical_variable'], ['65', '77', 'upper_bound']]}, 'NCT02819141'), ({'text': "History of xerostomia, Sjogren's disease or other illness known to affect salivation prior to head/neck radiation", 'entities': [['12', '22', 'chronic_disease'], ['24', '41', 'chronic_disease'], ['95', '114', 'treatment']]}, 'NCT02589938'), ({'text': 'Left ventricular ejection fraction >/= 50%', 'entities': [['1', '35', 'clinical_variable'], ['40', '43', 'lower_bound']]}, 'NCT02861417'), ({'text': 'Administration of an investigational medication for sarcoidosis within 3 months, or 5 half-lives, whichever is longer', 'entities': [['53', '64', 'chronic_disease'], ['72', '80', 'upper_bound']]}, 'NCT02725177'), ({'text': 'Maternal use of progesterone within 30 days of enrollment', 'entities': [['17', '29', 'treatment'], ['37', '44', 'upper_bound']]}, 'NCT02133573'), ({'text': "administration of heparin to keep subject's infusion lines patent", 'entities': [['19', '26', 'treatment']]}, 'NCT02520778'), ({'text': 'recurrent malignancies of the lung or metastatic malignancies to the lung', 'entities': [['11', '35', 'cancer'], ['39', '74', 'cancer']]}, 'NCT02434809'), ({'text': 'Short-segment venous occlusion resulting from either tumor thrombus or encasement with suitable proximal and distal vessel for reconstruction/grafting', 'entities': [['15', '31', 'chronic_disease'], ['54', '68', 'cancer'], ['128', '142', 'treatment'], ['143', '151', 'treatment']]}, 'NCT02207465'), ({'text': 'History of osteomalacia', 'entities': [['12', '24', 'chronic_disease']]}, 'NCT02903446'), ({'text': 'Participation in another non-observational clinical trial that contradicts or interferes with the therapies or measured outcomes in this trial', 'entities': [['18', '58', 'treatment'], ['99', '108', 'treatment']]}, 'NCT02593526'), ({'text': 'Exacerbation requiring treatment with systemic corticosteroids within the last 3 months', 'entities': [['39', '63', 'treatment'], ['75', '88', 'upper_bound']]}, 'NCT03114020'), ({'text': "Healthy male or female according to the investigator's or appointed staff's judgment", 'entities': [['9', '23', 'gender']]}, 'NCT01787682'), ({'text': 'Suspected high risk GVHD', 'entities': [['21', '25', 'chronic_disease']]}, 'NCT02525029'), ({'text': 'Subjects must have a life expectancy of at least 4 weeks', 'entities': [['22', '37', 'clinical_variable'], ['50', '57', 'lower_bound']]}, 'NCT02583893'), ({'text': 'Investigator deems cyst does not meet safety or need for cyst ablation', 'entities': [['20', '24', 'chronic_disease'], ['58', '71', 'treatment']]}, 'NCT01643460'), ({'text': 'No concurrent erythroid-stimulating agents (e.g., Procrit, Aranesp)', 'entities': [['15', '43', 'treatment'], ['51', '58', 'treatment'], ['60', '67', 'treatment']]}, 'NCT00670358'), ({'text': 'Previous use of an anti-Vascular Endothelial Growth Factor (VEGF) drug within 1 month of study entry', 'entities': [['20', '66', 'treatment'], ['79', '86', 'upper_bound']]}, 'NCT02688309'), ({'text': 'legally blind', 'entities': [['9', '14', 'chronic_disease']]}, 'NCT02943109'), ({'text': 'Patients must report at least minimal suicidal ideation, depressive or anxiety symptoms to be eligible for this phase', 'entities': [['39', '56', 'chronic_disease'], ['58', '68', 'chronic_disease'], ['72', '79', 'chronic_disease']]}, 'NCT02543983'), ({'text': 'Hgb A1C e6.5%', 'entities': [['1', '8', 'clinical_variable'], ['10', '14', 'lower_bound']]}, 'NCT02130687'), ({'text': 'Have completed effective antibiotic therapy to treat syphilis', 'entities': [['26', '44', 'treatment'], ['54', '62', 'chronic_disease']]}, 'NCT01660607'), ({'text': 'use of montelukast-type of allergy medications', 'entities': [['8', '19', 'treatment']]}, 'NCT02962128'), ({'text': 'Total bilirubin within normal institutional limits 12', 'entities': [['1', '54', 'clinical_variable']]}, 'NCT01985087'), ({'text': 'Presence of at least one measurable lesion', 'entities': [['22', '25', 'lower_bound']]}, 'NCT03153410'), ({'text': 'Stage at least T2 or greater', 'entities': [['1', '6', 'clinical_variable'], ['16', '18', 'lower_bound']]}, 'NCT02955394'), ({'text': 'History of primary immunodeficiency disease', 'entities': [['12', '44', 'chronic_disease']]}, 'NCT02536794'), ({'text': 'Subject anatomy with significant stenosis, calcification, thrombus or tortuosity', 'entities': [['34', '42', 'chronic_disease'], ['44', '57', 'chronic_disease'], ['59', '67', 'chronic_disease'], ['71', '81', 'chronic_disease']]}, 'NCT02818972'), ({'text': 'Well delineated focal hyperintensity <2.0 cm in size at largest dimension (including rostro-caudal extent) on FLAIR or T2 and clearly corresponding to the clinical syndrome', 'entities': [['17', '37', 'clinical_variable'], ['39', '45', 'upper_bound'], ['111', '116', 'treatment'], ['120', '122', 'treatment']]}, 'NCT02169739'), ({'text': 'Patients with cirrhosis, or active viral or nonviral hepatitis', 'entities': [['15', '24', 'chronic_disease'], ['45', '63', 'chronic_disease']]}, 'NCT01894061'), ({'text': 'Requiring renal dialysis', 'entities': [['11', '25', 'treatment']]}, 'NCT02340156'), ({'text': 'Persistent CMV infection despite optimum anti-viral therapy', 'entities': [['12', '25', 'chronic_disease'], ['42', '60', 'treatment']]}, 'NCT02210078'), ({'text': 'Planned cataract removal by phacoemulsification', 'entities': [['1', '25', 'treatment'], ['29', '48', 'treatment']]}, 'NCT03179397'), ({'text': 'substance dependence in the past 6 months or abuse in the past month', 'entities': [['29', '42', 'upper_bound']]}, 'NCT02386605'), ({'text': "Diagnosis of asthma: based on previous physician diagnosis and either baseline pre-bronchodilator FEV1 50% or greater predicted with a 12% or greater bronchodilator response to 4 puffs of albuterol or PC20 methacholine (16 mg) if no BD response.If the subject is not currently on an ICS/ ICS LABA, PC20 should be < 8 mg, if no BD response. Spirometry results within the prior 24 months located in the subject's medical records can be used to determine eligibility, if available", 'entities': [['14', '20', 'chronic_disease'], ['99', '103', 'clinical_variable'], ['104', '107', 'lower_bound'], ['136', '139', 'lower_bound'], ['189', '198', 'treatment'], ['202', '206', 'clinical_variable'], ['202', '219', 'treatment'], ['284', '287', 'treatment'], ['289', '297', 'treatment'], ['316', '320', 'upper_bound'], ['371', '386', 'upper_bound']]}, 'NCT02433977'), ({'text': 'For both sexes, an unwillingness to use contraception during the study period', 'entities': [['20', '54', 'contraception_consent']]}, 'NCT02573376'), ({'text': 'history of psychosis', 'entities': [['12', '21', 'chronic_disease']]}, 'NCT02613936'), ({'text': 'Patients with a history of head and neck cancer or oral premalignant disease but without any clinical evidence of disease', 'entities': [['28', '48', 'cancer'], ['52', '77', 'cancer']]}, 'NCT00542373'), ({'text': 'Animal reproductive studies have not been conducted with trametinib', 'entities': [['58', '68', 'treatment']]}, 'NCT02152995'), ({'text': 'prothrombin time (PT) >6 seconds above control', 'entities': [['1', '22', 'clinical_variable'], ['24', '33', 'lower_bound']]}, 'NCT02508467'), ({'text': 'Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN', 'entities': [['1', '33', 'clinical_variable'], ['38', '68', 'clinical_variable'], ['72', '81', 'upper_bound']]}, 'NCT02532231'), ({'text': 'Prior chemotherapy (docetaxel, cabazitaxel) for castrate resistant prostate cancer', 'entities': [['1', '19', 'treatment'], ['21', '30', 'treatment'], ['32', '43', 'treatment'], ['49', '83', 'cancer']]}, 'NCT02995330'), ({'text': 'Anticoagulant therapy', 'entities': [['1', '22', 'treatment']]}, 'NCT00969332'), ({'text': 'The effects of nivolumab and ipilimumab on the developing human fetus are unknown; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of childbearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of investigational drug', 'entities': [['16', '25', 'treatment'], ['30', '40', 'treatment'], ['118', '136', 'treatment'], ['172', '183', 'treatment'], ['185', '190', 'gender'], ['187', '190', 'gender'], ['238', '273', 'contraception_consent'], ['275', '318', 'contraception_consent'], ['320', '330', 'contraception_consent'], ['443', '452', 'pregnancy'], ['457', '471', 'upper_bound'], ['489', '509', 'treatment']]}, 'NCT02408861'), ({'text': 'Allergy or intolerance to spironolactone or amiloride', 'entities': [['27', '41', 'allergy_name'], ['45', '54', 'allergy_name']]}, 'NCT02497300'), ({'text': '21-60 years of age', 'entities': [['1', '3', 'lower_bound'], ['4', '12', 'upper_bound'], ['16', '19', 'age']]}, 'NCT03046017'), ({'text': 'speak English or Spanish', 'entities': [['1', '25', 'language_fluency']]}, 'NCT03046121'), ({'text': 'Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy', 'entities': [['1', '14', 'gender'], ['22', '70', 'contraception_consent'], ['109', '116', 'treatment'], ['125', '139', 'upper_bound']]}, 'NCT02437370'), ({'text': 'Receipt of blood products within the past 6 months', 'entities': [['38', '51', 'upper_bound']]}, 'NCT01940757'), ({'text': 'Patients with sinonasal SCCAs', 'entities': [['15', '24', 'cancer']]}, 'NCT02296684'), ({'text': 'Adolescents with a reported history of intellectual disability or for whom there is substantial evidence (e.g., multiple learning disorders, extensive school-based accommodations for learning) that the cognitive level of the UP-A would make it inappropriate as an individual therapy modality, as determined via Family Background Questionnaire and/or based on PI judgement', 'entities': [['40', '63', 'chronic_disease'], ['113', '140', 'chronic_disease'], ['276', '283', 'treatment']]}, 'NCT02567266'), ({'text': 'The use of a stable dose of oral steroid post-HSCT and/or topical steroids for ongoing skin GVHD', 'entities': [['29', '51', 'treatment'], ['59', '75', 'treatment'], ['93', '97', 'chronic_disease']]}, 'NCT02577406'), ({'text': 'Desires to undergo ovarian stimulation and oocyte retrieval prior to cancer treatment', 'entities': [['20', '39', 'treatment'], ['44', '60', 'treatment'], ['70', '86', 'treatment']]}, 'NCT03011684'), ({'text': 'Anemia on complete blood count', 'entities': [['1', '7', 'chronic_disease'], ['20', '31', 'clinical_variable']]}, 'NCT02134392'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT03143153'), ({'text': 'who developed autoimmune disorders of Grade <=3 may enroll if the disorder has resolved to Grade <=1 and the participant has been off systemic steroids at doses greater than (>) 10 milligrams per day (mg/day) for at least 2 weeks', 'entities': [['15', '35', 'chronic_disease'], ['47', '48', 'upper_bound'], ['100', '101', 'upper_bound'], ['135', '152', 'treatment'], ['179', '209', 'lower_bound'], ['223', '230', 'lower_bound']]}, 'NCT03084640'), ({'text': 'Congenital long QT syndrome or a known family history of long QT syndrome', 'entities': [['12', '28', 'chronic_disease']]}, 'NCT02353728'), ({'text': 'Maternal depression as assessed by a Beck Depression Inventory score equal to or greater than 17', 'entities': [['1', '20', 'chronic_disease'], ['38', '69', 'clinical_variable'], ['95', '97', 'lower_bound']]}, 'NCT02710968'), ({'text': 'Treatment related acute myeloid leukemia (AML)', 'entities': [['19', '47', 'cancer']]}, 'NCT01823198'), ({'text': "Relapsed/refractory MCL: The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patient's health and survival, than of the MCL, within the subsequent 6 months at the time of consent", 'entities': [['21', '24', 'cancer'], ['64', '74', 'cancer'], ['217', '225', 'upper_bound']]}, 'NCT01880567'), ({'text': 'less than 18 years of age', 'entities': [['11', '19', 'upper_bound'], ['23', '26', 'age']]}, 'NCT02267772'), ({'text': 'Significant persistent bradycardia (resting heart rate < 60 bpm) without a permanent pacemaker', 'entities': [['24', '35', 'chronic_disease'], ['37', '55', 'clinical_variable'], ['58', '64', 'upper_bound'], ['86', '95', 'treatment']]}, 'NCT02507011'), ({'text': 'Interval between the last surgery for breast cancer (including re-excision of margins) or the completion of adjuvant chemotherapy and study enrollment must be =< 56 days (ie, a maximum of 8 weeks)', 'entities': [['22', '34', 'treatment'], ['39', '52', 'cancer'], ['109', '130', 'treatment'], ['163', '170', 'upper_bound'], ['189', '196', 'upper_bound']]}, 'NCT02515110'), ({'text': 'Unilateral onset, response to levodopa', 'entities': [['31', '39', 'treatment']]}, 'NCT02231073'), ({'text': 'the individual must be 40 years of age or older', 'entities': [['24', '32', 'lower_bound'], ['36', '39', 'age']]}, 'NCT02266823'), ({'text': 'Able (i.e., sufficiently fluent) and willing to effectively communicate with the physical activity consultant affiliated with the originating cancer center', 'entities': [['143', '149', 'cancer']]}, 'NCT00819208'), ({'text': 'Subjects must be able to step on a treadmill with no more than 40% body weight support', 'entities': [['64', '67', 'upper_bound']]}, 'NCT02115685'), ({'text': 'Veterans who fulfill the AHA/ACC level I recommendation criteria for perioperative beta blocker therapy (e.g., metoprolol, atenolol) and should not be randomized to placebo group', 'entities': [['70', '104', 'treatment'], ['112', '122', 'treatment'], ['124', '132', 'treatment']]}, 'NCT01555554'), ({'text': 'Female patients who are lactating or have a positive serum pregnancy test suggestive of pregnancy and not as a tumor marker during the screening period', 'entities': [['1', '16', 'gender'], ['45', '69', 'pregnancy'], ['60', '69', 'pregnancy'], ['112', '117', 'cancer']]}, 'NCT02942095'), ({'text': 'Drug or toxin induced PAH', 'entities': [['23', '26', 'chronic_disease']]}, 'NCT02932410'), ({'text': 'Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the subject properly providing informed consent or any condition which would jeopardize compliance with the protocol', 'entities': [['23', '30', 'chronic_disease'], ['34', '55', 'chronic_disease']]}, 'NCT02493530'), ({'text': 'No prolonged QT syndrome as indicated by baseline EKG', 'entities': [['14', '25', 'chronic_disease']]}, 'NCT00872950'), ({'text': 'Tumor sample must be available for HPV p16 and PD-L1 testing', 'entities': [['1', '6', 'cancer'], ['36', '43', 'cancer'], ['48', '61', 'treatment']]}, 'NCT03162731'), ({'text': 'Rupture of membranes due to likelihood of pregnancy loss and preterm delivery as well as the risk of ascending infection which could be increased with pessary placement', 'entities': [['43', '52', 'pregnancy'], ['112', '121', 'chronic_disease']]}, 'NCT02518594'), ({'text': 'subject must be allowed to attempt prosthetic use prior to hand transplantation', 'entities': [['60', '80', 'treatment']]}, 'NCT00711373'), ({'text': 'Have taken an investigational agent within 30 days of visit 1', 'entities': [['15', '36', 'treatment'], ['44', '51', 'upper_bound']]}, 'NCT02041936'), ({'text': 'Serum triglyceride level d300 mg/dL', 'entities': [['1', '25', 'clinical_variable'], ['27', '36', 'upper_bound']]}, 'NCT02574728'), ({'text': 'Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study', 'entities': [['39', '54', 'gender'], ['64', '86', 'contraception_consent'], ['88', '107', 'contraception_consent'], ['109', '134', 'contraception_consent'], ['136', '158', 'contraception_consent']]}, 'NCT03056339'), ({'text': 'Any history of Stevens-Johnson syndrome', 'entities': [['16', '40', 'chronic_disease']]}, 'NCT02281409'), ({'text': 'The subject is receiving concomitant treatment with warfarin, warfarin-related agents, or low molecular weight heparin (LMWH) at the time of study entry at therapeutic doses. Low-dose warfarin (d 1 mg/day) or LMWH at prophylactic doses', 'entities': [['38', '61', 'treatment'], ['63', '86', 'treatment'], ['91', '126', 'treatment'], ['121', '125', 'treatment'], ['176', '193', 'treatment'], ['197', '205', 'upper_bound']]}, 'NCT02132598'), ({'text': 'Known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability', 'entities': [['14', '53', 'cancer'], ['61', '85', 'cancer'], ['120', '136', 'cancer'], ['235', '251', 'lower_bound'], ['273', '288', 'treatment'], ['418', '426', 'treatment'], ['440', '452', 'lower_bound']]}, 'NCT02581982'), ({'text': 'Allergy to lidocaine or oxymetazoline hydroclhoride', 'entities': [['12', '21', 'allergy_name'], ['25', '52', 'allergy_name']]}, 'NCT01738009'), ({'text': 'Subject has Long corrected QT interval (QTc) Syndrome at Screening', 'entities': [['28', '54', 'chronic_disease']]}, 'NCT02236013'), ({'text': 'Ability to become pregnant', 'entities': [['19', '27', 'pregnancy']]}, 'NCT03144245'), ({'text': 'Subjects with a pacemaker or who have received cardiac transplant', 'entities': [['17', '26', 'treatment'], ['48', '66', 'treatment']]}, 'NCT03019133'), ({'text': 'A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice)', 'entities': [['3', '9', 'gender'], ['44', '49', 'gender'], ['104', '118', 'treatment']]}, 'NCT02950337'), ({'text': 'A documented clinical assessment including a physical assessment and Complete Blood Count (CBC) with White Blood Cell Count (WBC) within two weeks prior to enrollment', 'entities': [['70', '96', 'clinical_variable'], ['102', '130', 'clinical_variable'], ['138', '153', 'upper_bound']]}, 'NCT02181257'), ({'text': 'Alpha-blockers', 'entities': [['1', '15', 'treatment']]}, 'NCT02335242'), ({'text': "The child's parent/guardian must have a working direct contact telephone", 'entities': [['34', '73', 'technology_access']]}, 'NCT02148796'), ({'text': 'Current/recent (within 3 months of donation/screening consent) IV drug abuse', 'entities': [['24', '32', 'upper_bound']]}, 'NCT01459107'), ({'text': 'Any NSAIDs aspirin or omega-3 free fatty acid supplementation within the last 14 days', 'entities': [['5', '19', 'treatment'], ['23', '62', 'treatment'], ['74', '86', 'upper_bound']]}, 'NCT02538484'), ({'text': 'American Society of Anesthesiologists (ASA) IV and above', 'entities': [['1', '44', 'clinical_variable'], ['45', '47', 'lower_bound']]}, 'NCT02252432'), ({'text': 'Major anticipated illness or organ failure incompatible with survival from PBSC transplant', 'entities': [['1', '26', 'chronic_disease'], ['30', '43', 'chronic_disease'], ['76', '91', 'treatment']]}, 'NCT01174108'), ({'text': 'Chronic opioid use', 'entities': [['1', '15', 'treatment']]}, 'NCT03094663'), ({'text': 'Intra-articular injection within the 4 weeks prior to baseline FDG PET/CT', 'entities': [['1', '26', 'treatment'], ['38', '63', 'upper_bound']]}, 'NCT02374021'), ({'text': 'Immunotherapy [Interferons, Cytokines] (except PD-1/PD-L1 antagonists)', 'entities': [['1', '14', 'treatment'], ['16', '27', 'treatment'], ['29', '38', 'treatment'], ['48', '70', 'treatment']]}, 'NCT02310464'), ({'text': 'Prior allergic reaction to paclitaxel or carboplatin', 'entities': [['28', '38', 'allergy_name'], ['42', '53', 'allergy_name']]}, 'NCT01684904'), ({'text': 'Patients who have been previously treated in the adjuvant setting for melanoma will be eligible for treatment after a 28 day wash-out period', 'entities': [['50', '66', 'treatment'], ['71', '79', 'cancer'], ['101', '110', 'treatment']]}, 'NCT02519322'), ({'text': 'Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional ULN', 'entities': [['1', '33', 'clinical_variable'], ['35', '81', 'clinical_variable'], ['83', '113', 'clinical_variable'], ['115', '159', 'clinical_variable'], ['163', '186', 'upper_bound']]}, 'NCT02315196'), ({'text': 'History of craniotomy, cerebral metastases, cerebrovascular accident, current diagnosis of seizure disorder, bipolar disorder, schizophrenia, schizo-affective disorder, dementia, mental retardation, or major depression with psychotic features, or use of depot neuroleptics in the last 12 months', 'entities': [['12', '22', 'treatment'], ['24', '43', 'cancer'], ['45', '69', 'chronic_disease'], ['92', '108', 'chronic_disease'], ['110', '126', 'chronic_disease'], ['128', '141', 'chronic_disease'], ['143', '168', 'chronic_disease'], ['170', '178', 'chronic_disease'], ['180', '198', 'chronic_disease'], ['203', '243', 'chronic_disease'], ['255', '273', 'treatment'], ['281', '295', 'upper_bound']]}, 'NCT01794559'), ({'text': 'Administration or planned administration of any other concomitant chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy which would be considered a treatment of multiple myeloma until Day +28 post-transplant through discontinuation from study', 'entities': [['67', '79', 'treatment'], ['81', '94', 'treatment'], ['96', '108', 'treatment'], ['117', '134', 'treatment'], ['163', '172', 'treatment'], ['176', '192', 'cancer'], ['207', '222', 'treatment']]}, 'NCT02253316'), ({'text': 'status-post surgical sterilization', 'entities': [['13', '35', 'treatment']]}, 'NCT02362308'), ({'text': 'Unable to follow directions in English as standardized scales are not all validated in other languages', 'entities': [['1', '39', 'language_fluency']]}, 'NCT03161028'), ({'text': 'Patients may have received no more than one Donor Lymphocyte Infusion (DLI), DLI must have been administered > 6 weeks prior to enrollment on study, and no plans for a DLI in the upcoming 30 days', 'entities': [['41', '44', 'lower_bound'], ['45', '76', 'treatment'], ['72', '75', 'treatment'], ['112', '125', 'lower_bound'], ['189', '196', 'upper_bound']]}, 'NCT02611063'), ({'text': 'Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day methylprednisolone equivalent (excluding inhaled steroids)', 'entities': [['1', '45', 'treatment'], ['64', '73', 'lower_bound'], ['74', '92', 'treatment'], ['115', '131', 'treatment']]}, 'NCT02488967'), ({'text': 'Active pressure ulcers', 'entities': [['8', '23', 'chronic_disease']]}, 'NCT02533882'), ({'text': 'For procedures with moderate or significant risk of bleeding, long-acting agents such as aspirin or clopidogrel should be discussed with the Medical Monitor and may need to be discontinued before G100 therapy', 'entities': [['53', '61', 'chronic_disease'], ['63', '81', 'treatment'], ['90', '97', 'treatment'], ['101', '112', 'treatment'], ['197', '209', 'treatment']]}, 'NCT02501473'), ({'text': 'Patient e18 years old', 'entities': [['10', '18', 'lower_bound']]}, 'NCT02664168'), ({'text': 'Patients must begin treatment as outlined in the protocol within 36 days of definitive surgery (day of surgery is day 0; definitive surgery includes second surgeries to resect residual tumor)', 'entities': [['21', '30', 'treatment'], ['66', '73', 'upper_bound'], ['77', '95', 'treatment'], ['88', '95', 'treatment'], ['157', '166', 'treatment'], ['186', '191', 'cancer']]}, 'NCT01878617'), ({'text': 'Known active concurrent malignancy, as determined by treating physicians', 'entities': [['25', '35', 'cancer']]}, 'NCT02344355'), ({'text': 'Subjects have experienced a concussion or mTBI within the preceding 18 months, but no sooner that 4 weeks prior to their screening', 'entities': [['29', '39', 'chronic_disease'], ['43', '47', 'chronic_disease'], ['69', '78', 'upper_bound'], ['99', '112', 'upper_bound']]}, 'NCT02374918'), ({'text': 'Women', 'entities': [['1', '6', 'gender']]}, 'NCT02908841'), ({'text': 'Lung cancer', 'entities': [['1', '12', 'cancer']]}, 'NCT03135522'), ({'text': 'Creatinine =< 1.5 x ULN', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'upper_bound']]}, 'NCT02498613'), ({'text': 'suprapubic', 'entities': [['1', '11', 'treatment']]}, 'NCT01595529'), ({'text': 'Only one failed one prior antidepressant in the current episode', 'entities': [['27', '41', 'treatment']]}, 'NCT02562430'), ({'text': 'Have metastatic melanoma or NSCLC, or locally advanced NSCLC not suitable for curative-intent local therapy', 'entities': [['6', '25', 'cancer'], ['29', '34', 'cancer'], ['79', '108', 'treatment']]}, 'NCT02407171'), ({'text': "Adhere to the following requirements for concomitant medication for the treatment of Crohn's disease, which are permitted provided that doses meeting these requirements are stable, or have been discontinued, for at least 3 weeks before baseline (Week 0), unless otherwise specified", 'entities': [['86', '101', 'chronic_disease'], ['222', '229', 'lower_bound']]}, 'NCT02877134'), ({'text': 'an IIEF-5 tadalafil-alone baseline score that is d 18', 'entities': [['4', '10', 'clinical_variable'], ['11', '20', 'treatment'], ['52', '54', 'upper_bound']]}, 'NCT02225548'), ({'text': 'SAF Fibrosis score < 4', 'entities': [['1', '19', 'clinical_variable'], ['22', '23', 'upper_bound']]}, 'NCT03008070'), ({'text': 'LDH <360 U/L Rule out hemolysis, infection, and contact PI for Clarification', 'entities': [['1', '4', 'clinical_variable'], ['6', '13', 'upper_bound'], ['23', '32', 'chronic_disease']]}, 'NCT00734877'), ({'text': 'Contra-indicated for treatment with MEDI4736', 'entities': [['22', '31', 'treatment'], ['37', '45', 'allergy_name']]}, 'NCT02264678'), ({'text': 'No prior malignancy is allowed', 'entities': [['10', '20', 'cancer']]}, 'NCT00734877'), ({'text': 'history of seizures or taking medications that may lower the seizure threshold', 'entities': [['12', '19', 'chronic_disease'], ['12', '20', 'chronic_disease'], ['31', '42', 'treatment']]}, 'NCT02608840'), ({'text': 'known active hepatitis A, B, or C infection', 'entities': [['7', '44', 'chronic_disease']]}, 'NCT02493530'), ({'text': 'Non-Hodgkin lymphoma', 'entities': [['1', '21', 'cancer']]}, 'NCT02566395'), ({'text': 'Able to speak and understand English and/or Spanish', 'entities': [['1', '52', 'language_fluency']]}, 'NCT03037346'), ({'text': 'Patients receiving glucocorticoids must be on a stable dose of glucocorticoids during the 5 days prior to the baseline brain imaging', 'entities': [['20', '35', 'treatment'], ['91', '103', 'upper_bound'], ['120', '133', 'treatment']]}, 'NCT02132598'), ({'text': 'Patients who require medications that are strong inhibitors/inducers CYP3A4 enzyme activity, including anticonvulsants, (Appendix II) to control concurrent medical conditions', 'entities': [['22', '33', 'treatment'], ['70', '83', 'treatment'], ['104', '119', 'treatment']]}, 'NCT02110069'), ({'text': 'Head trauma/central nervous system injury', 'entities': [['1', '12', 'chronic_disease'], ['13', '42', 'chronic_disease']]}, 'NCT02901067'), ({'text': 'Subjects must have at least one measurable lesion as defined by RECIST v1.1', 'entities': [['29', '32', 'lower_bound']]}, 'NCT02576431'), ({'text': 'Uncontrolled hypertension defined as a systolic BP greater than 150 mmHg or diastolic BP greater than 90 mmHg, with or without anti-hypertensive medications', 'entities': [['14', '26', 'chronic_disease'], ['40', '51', 'clinical_variable'], ['65', '73', 'lower_bound'], ['77', '89', 'clinical_variable'], ['103', '110', 'lower_bound'], ['128', '157', 'treatment']]}, 'NCT02236000'), ({'text': 'Arterial thromboembolic or embolic events such as myocardial infarction, cerebrovascular accident, including transient ischemic attacks 6 months prior to first study treatment', 'entities': [['1', '24', 'chronic_disease'], ['51', '72', 'chronic_disease'], ['74', '98', 'chronic_disease'], ['110', '136', 'chronic_disease'], ['137', '151', 'upper_bound'], ['161', '176', 'treatment']]}, 'NCT01817751'), ({'text': 'Patients whose dystonia is not severe enough to interfere with musical performance in the opinion of a skilled examiner', 'entities': [['16', '24', 'chronic_disease']]}, 'NCT02107261'), ({'text': 'HIV, cardiac, pulmonary, hepatic or renal dysfunction', 'entities': [['1', '4', 'chronic_disease'], ['6', '13', 'chronic_disease'], ['15', '24', 'chronic_disease'], ['26', '33', 'chronic_disease'], ['37', '54', 'chronic_disease']]}, 'NCT03078530'), ({'text': 'Renal insufficiency: serum creatinine > 2 mg/dL', 'entities': [['1', '20', 'chronic_disease'], ['22', '38', 'clinical_variable'], ['41', '48', 'lower_bound']]}, 'NCT02101944'), ({'text': 'Newly diagnosed breast cancer patients', 'entities': [['17', '30', 'cancer']]}, 'NCT00948285'), ({'text': 'AST and ALT d 3 x ULN', 'entities': [['1', '12', 'clinical_variable'], ['15', '22', 'upper_bound']]}, 'NCT02553642'), ({'text': 'hormone ablation for 2 months prior to treatment or during treatment', 'entities': [['1', '17', 'treatment'], ['22', '36', 'upper_bound']]}, 'NCT01581749'), ({'text': 'those who report that they are unwilling to refrain from self-injurious behaviors during the waitlist and treatment periods', 'entities': [['107', '116', 'treatment']]}, 'NCT02305537'), ({'text': 'First relapse within 12 months after date of first CR or CRi', 'entities': [['22', '37', 'upper_bound'], ['52', '61', 'clinical_variable']]}, 'NCT02109627'), ({'text': 'Uncontrolled hypertension (systolic BP >160, diastolic BP >100)', 'entities': [['14', '26', 'chronic_disease'], ['28', '39', 'clinical_variable'], ['41', '44', 'lower_bound'], ['46', '58', 'clinical_variable'], ['60', '63', 'lower_bound']]}, 'NCT01553214'), ({'text': 'Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment', 'entities': [['13', '48', 'treatment'], ['59', '79', 'treatment'], ['115', '129', 'upper_bound'], ['153', '162', 'treatment']]}, 'NCT02215096'), ({'text': '21-65 years of age', 'entities': [['1', '3', 'lower_bound'], ['4', '12', 'upper_bound'], ['16', '19', 'age']]}, 'NCT02676193'), ({'text': 'Diagnostic and Statistical Manual-5 (DSM-5) substance use disorder', 'entities': [['1', '44', 'clinical_variable']]}, 'NCT03015805'), ({'text': 'becoming pregnant during the study (pregnancy test)', 'entities': [['1', '18', 'pregnancy'], ['37', '46', 'pregnancy']]}, 'NCT02460900'), ({'text': 'Age e 40 years-old', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT01742338'), ({'text': 'Evidence of of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)', 'entities': [['22', '25', 'lower_bound'], ['43', '66', 'clinical_variable'], ['77', '80', 'upper_bound'], ['99', '108', 'chronic_disease']]}, 'NCT01189786'), ({'text': 'Has gastrointestinal conditions that could affect the absorption of DS-3032b in the opinion of the Investigator', 'entities': [['5', '32', 'chronic_disease'], ['69', '77', 'treatment']]}, 'NCT01877382'), ({'text': 'pN1 lymph node disease', 'entities': [['1', '23', 'cancer']]}, 'NCT02772562'), ({'text': 'allowable histologies for cervical cancer include squamous cell carcinoma, adenocarcinoma, and mixed/adenosquamous carcinoma', 'entities': [['27', '42', 'cancer'], ['51', '74', 'cancer'], ['76', '90', 'cancer'], ['102', '125', 'cancer']]}, 'NCT02020707'), ({'text': 'severe emotional distress', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT03187028'), ({'text': 'Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the investigator?s opinion, may interfere with protocol adherence or a subject?s ability to give informed consent', 'entities': [['89', '108', 'cancer']]}, 'NCT02553447'), ({'text': 'History of positive human immunodeficiency virus test', 'entities': [['21', '49', 'chronic_disease']]}, 'NCT02474667'), ({'text': 'chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration', 'entities': [['1', '38', 'chronic_disease'], ['61', '80', 'chronic_disease'], ['121', '134', 'treatment']]}, 'NCT01950351'), ({'text': 'Ages 7-18', 'entities': [['1', '5', 'age'], ['6', '7', 'lower_bound'], ['8', '10', 'upper_bound']]}, 'NCT02926677'), ({'text': 'Treatment with NSAIDs within the previous 1 week', 'entities': [['1', '10', 'treatment'], ['16', '22', 'treatment'], ['34', '49', 'upper_bound']]}, 'NCT03081390'), ({'text': 'Prior or concurrent invasive malignancy (except non-melanomatous skin cancer or lymphomatous/hematogenous malignancy) unless continually disease free for a minimum of 5 years', 'entities': [['21', '40', 'cancer'], ['49', '77', 'cancer'], ['81', '117', 'cancer'], ['168', '175', 'lower_bound']]}, 'NCT01950351'), ({'text': 'Neuromuscular or neurologic disease', 'entities': [['1', '14', 'chronic_disease'], ['18', '36', 'chronic_disease']]}, 'NCT01730794'), ({'text': 'clinical stage 1-3 early stage breast cancer with primary tumor is at least 1cm measured by clinical exam or by radiologic breast imaging tests', 'entities': [['1', '15', 'clinical_variable'], ['16', '17', 'lower_bound'], ['18', '19', 'upper_bound'], ['32', '45', 'cancer'], ['51', '64', 'cancer'], ['77', '80', 'lower_bound']]}, 'NCT03112590'), ({'text': 'Have an unresectable, locally advanced pancreatic cancer (AJCC stage III)', 'entities': [['40', '57', 'cancer'], ['59', '73', 'cancer']]}, 'NCT01676259'), ({'text': 'Has had restaging imaging after initiation of immunotherapy, at least 4 weeks after pre-immunotherapy baseline imaging; computed tomography (CT) or positron emission tomography (PET)/CT of at least chest/upper abdomen must be performed within 4 weeks prior to registration; for patients with history of brain metastases, brain magnetic resonance imaging (MRI) or CT is required within 4 weeks of registration; for other patients brain MRI or CT is required within 12 weeks of registration', 'entities': [['47', '60', 'treatment'], ['85', '102', 'treatment'], ['121', '145', 'treatment'], ['142', '144', 'treatment'], ['149', '183', 'treatment'], ['244', '257', 'upper_bound'], ['304', '320', 'cancer'], ['322', '360', 'treatment'], ['356', '359', 'treatment'], ['465', '473', 'upper_bound']]}, 'NCT03176173'), ({'text': 'Previously received GnRH analog or other form of androgen deprivation therapy (estrogen or antiandrogen) for > 18 months total duration', 'entities': [['50', '78', 'treatment'], ['112', '121', 'lower_bound']]}, 'NCT03085095'), ({'text': 'Known, existing uncontrolled coagulopathy, international normalized ratio (INR) > 1.5', 'entities': [['30', '42', 'chronic_disease'], ['44', '80', 'clinical_variable'], ['83', '86', 'lower_bound']]}, 'NCT02394535'), ({'text': 'Patients with known severe allergy to antithymocyte globulin or rabbits', 'entities': [['39', '61', 'allergy_name'], ['65', '72', 'allergy_name']]}, 'NCT02102854'), ({'text': 'Tanner stage II-V', 'entities': [['1', '13', 'clinical_variable'], ['14', '16', 'lower_bound'], ['17', '18', 'upper_bound']]}, 'NCT02535169'), ({'text': 'Patient must not be receiving protease inhibitors or once daily formulations containing cobicistat, stavudine, or on regimens containing stavudine or zidovudine', 'entities': [['31', '50', 'treatment'], ['89', '99', 'treatment'], ['101', '110', 'treatment'], ['118', '126', 'treatment']]}, 'NCT02003222'), ({'text': 'Patients with active duodenal ulcer or bleeding or history of a gastrointestinal fistula or perforation or other significant bowel problems (severe nausea, vomiting, inflammatory bowel disease and significant bowel resection)', 'entities': [['22', '36', 'chronic_disease'], ['65', '89', 'chronic_disease'], ['149', '155', 'chronic_disease'], ['167', '193', 'chronic_disease'], ['210', '225', 'treatment']]}, 'NCT03073785'), ({'text': 'Life expectancy of more than 3 months', 'entities': [['1', '16', 'clinical_variable'], ['30', '38', 'lower_bound']]}, 'NCT01464034'), ({'text': 'Women with TAAA larger than 4.5 cm in diameter and enlarging at a rate of more than 10mm/year or', 'entities': [['1', '6', 'gender'], ['12', '16', 'clinical_variable'], ['29', '47', 'lower_bound'], ['85', '94', 'lower_bound']]}, 'NCT02323581'), ({'text': 'Traumatic hemorrhagic pleural effusion', 'entities': [['1', '39', 'chronic_disease']]}, 'NCT02135588'), ({'text': 'Evidence of prostate cancer progression by any of the following criteria: radiographic or PSA criteria, or symptomatic progression related to prostate cancer', 'entities': [['13', '28', 'cancer']]}, 'NCT02522715'), ({'text': 'neuroprosthesis implantation delayed until no longer pregnant', 'entities': [['1', '29', 'treatment'], ['54', '62', 'pregnancy']]}, 'NCT02329652'), ({'text': 'Only subjects who are not appropriate candidates for autologous or HLA-matched sibling hematopoietic cell transplants (HCT) may be enrolled', 'entities': [['54', '64', 'treatment'], ['68', '124', 'treatment']]}, 'NCT02100891'), ({'text': 'Androgen or estrogen therapy or other hormone replacement therapy', 'entities': [['1', '29', 'treatment'], ['39', '66', 'treatment']]}, 'NCT02638454'), ({'text': 'Meets criteria for mild TBI', 'entities': [['20', '28', 'chronic_disease']]}, 'NCT02404402'), ({'text': 'Only negative pregnancy test result would allow the drug administration to proceed', 'entities': [['6', '24', 'pregnancy']]}, 'NCT02414178'), ({'text': 'Receiving central nervous system (CNS) stimulants that cannot be safely discontinued via titration', 'entities': [['11', '50', 'treatment'], ['90', '99', 'treatment']]}, 'NCT02366754'), ({'text': 'Absolute neutrophil count (ANC) /=> 1000/mm^3 *Platelets >/= 80,000/mm^3, *Hemoglobin >/= 8g/dL. These values must be obtained within four weeks before protocol entry', 'entities': [['1', '32', 'clinical_variable'], ['37', '46', 'lower_bound'], ['48', '57', 'clinical_variable'], ['62', '73', 'lower_bound'], ['76', '86', 'clinical_variable'], ['91', '96', 'lower_bound'], ['135', '145', 'upper_bound']]}, 'NCT01473628'), ({'text': 'Allergy to either of the study medications or 5-fluorouracil', 'entities': [['26', '43', 'allergy_name'], ['47', '61', 'allergy_name']]}, 'NCT02524275'), ({'text': 'Must not have received bevacizumab or other monoclonal antibody therapy within 4 weeks of study the entry', 'entities': [['24', '35', 'treatment'], ['45', '72', 'treatment'], ['80', '87', 'upper_bound']]}, 'NCT02389309'), ({'text': 'participants must agree to use barrier contraceptives from the time of study enrollment until 6 months after the last MDC injection', 'entities': [['19', '54', 'contraception_consent'], ['95', '103', 'upper_bound'], ['119', '132', 'treatment']]}, 'NCT01011777'), ({'text': 'Visual acuity of e20/200 in both eyes at the time of the screening visit', 'entities': [['1', '14', 'clinical_variable'], ['19', '25', 'lower_bound']]}, 'NCT01367444'), ({'text': 'A prolonged history of cigarette smoking (greater than or equal to 20 pack-year smoking history, with cessation within the past two years', 'entities': [['68', '70', 'lower_bound'], ['124', '138', 'upper_bound']]}, 'NCT01967823'), ({'text': 'All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v 4.0) grade =< 1', 'entities': [['11', '20', 'treatment'], ['48', '126', 'clinical_variable'], ['130', '131', 'upper_bound']]}, 'NCT02152995'), ({'text': 'History of organ transplant', 'entities': [['12', '28', 'treatment']]}, 'NCT02496208'), ({'text': 'Plan for therapeutic anticoagulation post-partum', 'entities': [['10', '37', 'treatment'], ['38', '49', 'chronic_disease']]}, 'NCT02962427'), ({'text': 'FEV1 percent predicted less than 25%', 'entities': [['1', '5', 'clinical_variable'], ['34', '37', 'upper_bound']]}, 'NCT02826343'), ({'text': 'Recent (within the past 30 days) diagnosis of moderate to severe chronic periodontitis in at least two quadrants according to the Armitage Classification', 'entities': [['20', '32', 'upper_bound'], ['66', '87', 'chronic_disease'], ['100', '113', 'lower_bound']]}, 'NCT03003689'), ({'text': 'On standard immunosuppression with tacrolimus and prednisone', 'entities': [['4', '61', 'treatment']]}, 'NCT02974686'), ({'text': 'Adults 18 to 75 years old', 'entities': [['8', '10', 'lower_bound'], ['14', '22', 'upper_bound']]}, 'NCT02845245'), ({'text': 'all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy', 'entities': [['5', '12', 'gender'], ['84', '97', 'upper_bound'], ['126', '135', 'pregnancy']]}, 'NCT02003222'), ({'text': 'they must have recovered from ASCT toxicities at the time of first study treatment', 'entities': [['31', '35', 'treatment'], ['68', '83', 'treatment']]}, 'NCT02362997'), ({'text': 'Recent infection', 'entities': [['8', '17', 'chronic_disease']]}, 'NCT02532595'), ({'text': 'Patients who have had prior anti EGFR antibody therapy inhibitors and who have not responded to this treatment will be excluded', 'entities': [['23', '38', 'treatment'], ['39', '55', 'treatment'], ['102', '111', 'treatment']]}, 'NCT01312857'), ({'text': 'Chronic use of opioids', 'entities': [['16', '23', 'treatment']]}, 'NCT02159560'), ({'text': 'History of allergic reactions attributed to IRX4204 or erlotinib or to compounds of similar chemical or biologic composition', 'entities': [['45', '52', 'allergy_name'], ['56', '65', 'allergy_name'], ['93', '101', 'allergy_name'], ['105', '125', 'allergy_name']]}, 'NCT02991651'), ({'text': 'AST or ALT <3xULN, or <5x ULN if known liver metastases', 'entities': [['1', '4', 'clinical_variable'], ['8', '11', 'clinical_variable'], ['13', '18', 'upper_bound'], ['24', '30', 'upper_bound'], ['40', '56', 'cancer']]}, 'NCT02199236'), ({'text': 'Primary study eye must have clear ocular media and adequate pupillary dilation, including no allergy to dilating eyedrops, to permit good quality retinal imaging', 'entities': [['105', '122', 'allergy_name'], ['147', '162', 'treatment']]}, 'NCT02402660'), ({'text': 'Diagnosis of a hormone responsive malignancy', 'entities': [['16', '45', 'cancer']]}, 'NCT02525029'), ({'text': 'BMI greater than or equal to 27', 'entities': [['1', '4', 'bmi'], ['30', '32', 'lower_bound']]}, 'NCT02460783'), ({'text': 'Patients with confined liver disease or stable limited extrahepatic disease', 'entities': [['24', '37', 'chronic_disease'], ['48', '76', 'chronic_disease']]}, 'NCT01494324'), ({'text': 'planning to become pregnant during the study period', 'entities': [['1', '28', 'pregnancy']]}, 'NCT02266329'), ({'text': 'Previous prostatectomy, cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer', 'entities': [['1', '23', 'treatment'], ['25', '36', 'treatment'], ['41', '81', 'treatment'], ['86', '101', 'cancer']]}, 'NCT01950351'), ({'text': 'Age > 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02468024'), ({'text': 'Chronically taking an oral medication known to be a P-gp substrate within 7 days of starting treatment with Oratecan', 'entities': [['23', '38', 'treatment'], ['75', '81', 'upper_bound'], ['94', '117', 'treatment']]}, 'NCT02250157'), ({'text': 'patients taking cimetidine must have this drug discontinued', 'entities': [['17', '27', 'treatment']]}, 'NCT02394535'), ({'text': 'HLA Match', 'entities': [['1', '4', 'clinical_variable']]}, 'NCT02181478'), ({'text': 'Patients who are receiving monoamine oxidase (MAO) inhibitors', 'entities': [['28', '62', 'treatment']]}, 'NCT01696734'), ({'text': 'Palliative radiation therapy is permitted so long as it does not involve lesions being selected for TIL, or as target or non-target lesions. Washout is not required if all related toxicities have resolved to d Grade 1 as per CTCAE v4.03', 'entities': [['1', '29', 'treatment'], ['74', '81', 'cancer'], ['101', '104', 'cancer'], ['112', '140', 'cancer'], ['181', '191', 'clinical_variable'], ['211', '218', 'upper_bound']]}, 'NCT02360579'), ({'text': 'Indications: Suspected malignancy', 'entities': [['24', '34', 'cancer']]}, 'NCT02358850'), ({'text': 'Major head trauma', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02428205'), ({'text': 'Uncontrolled seizure disorder', 'entities': [['14', '30', 'chronic_disease']]}, 'NCT02404155'), ({'text': 'Age <2 years at the time of enrollment', 'entities': [['1', '4', 'age'], ['6', '13', 'upper_bound']]}, 'NCT01512888'), ({'text': 'Estimated glomerular filtration rate (eGFR) <20 ml/min', 'entities': [['1', '44', 'clinical_variable'], ['46', '55', 'upper_bound']]}, 'NCT03023059'), ({'text': 'Other neurologic disorders unrelated to stroke', 'entities': [['7', '27', 'chronic_disease'], ['41', '47', 'chronic_disease']]}, 'NCT02743728'), ({'text': 'Use of NSAID or aspirin within 7days of each study visit', 'entities': [['8', '13', 'treatment'], ['17', '24', 'treatment'], ['32', '37', 'upper_bound']]}, 'NCT02857283'), ({'text': 'Healthy children at least 12 but less than 60 months of age', 'entities': [['27', '29', 'lower_bound'], ['44', '53', 'upper_bound'], ['57', '60', 'age']]}, 'NCT01893554'), ({'text': 'DLBCL including ABC, GCB or PMBCL subtypes', 'entities': [['1', '6', 'cancer'], ['29', '34', 'cancer']]}, 'NCT02471911'), ({'text': 'Clinically manifested by no attempt at securing aneurysm', 'entities': [['49', '57', 'chronic_disease']]}, 'NCT02872857'), ({'text': 'Normotensive (screening blood pressure <140/90 mmHg)', 'entities': [['25', '39', 'clinical_variable'], ['41', '52', 'upper_bound']]}, 'NCT03029806'), ({'text': 'Adequate hematological function defined by white blood cell (WBC) count e3 × 10^9/L', 'entities': [['44', '72', 'clinical_variable'], ['74', '84', 'lower_bound']]}, 'NCT03104699'), ({'text': 'Have no contraindication to MRI examinations such as metal implants, etc', 'entities': [['29', '32', 'treatment']]}, 'NCT02335242'), ({'text': 'Nursing women', 'entities': [['9', '14', 'gender']]}, 'NCT02020707'), ({'text': 'Any history of nasal surgery or known clinically relevant abnormalities, such as rhinitis medicamentosa, polyposis, septum deviation with clinical symptoms, recent nasal trauma, or nasal structural abnormalities', 'entities': [['16', '29', 'treatment'], ['82', '104', 'chronic_disease'], ['106', '115', 'chronic_disease'], ['117', '133', 'chronic_disease'], ['165', '177', 'chronic_disease']]}, 'NCT02588326'), ({'text': 'Meets DSM-5 criteria for bipolar disorder or disruptive mood dysregulation disorder or DSM IV criteria for mood disorder NOS', 'entities': [['26', '42', 'chronic_disease'], ['46', '84', 'chronic_disease'], ['108', '125', 'chronic_disease']]}, 'NCT02845453'), ({'text': 'females', 'entities': [['1', '8', 'gender']]}, 'NCT03112720'), ({'text': 'Participants 18 years and older', 'entities': [['14', '22', 'lower_bound']]}, 'NCT02724540'), ({'text': 'Cognitive impairment as determined by the Mini-Mental State Examination (MMSE) score of d 26', 'entities': [['1', '21', 'chronic_disease'], ['43', '85', 'clinical_variable'], ['91', '93', 'upper_bound']]}, 'NCT01742182'), ({'text': 'Major congenital or surgical malformations', 'entities': [['7', '43', 'chronic_disease']]}, 'NCT02851472'), ({'text': 'within the last 5 years', 'entities': [['12', '24', 'upper_bound']]}, 'NCT01599559'), ({'text': 'Diabetes mellitus with end organ damage', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02950337'), ({'text': 'Part C: Patients with recurrent or refractory high grade glioma (WHO grade III/IV) and requiring surgical resection (excluding DIPG and disseminated tumors), who in the opinion of treating physicians, are medically stable to receive 3-4 doses of selinexor (8-10 days of treatment) before undergoing surgery without compromising the success of the procedure', 'entities': [['58', '64', 'cancer'], ['98', '116', 'treatment'], ['128', '132', 'cancer'], ['137', '156', 'cancer'], ['234', '235', 'lower_bound'], ['236', '237', 'upper_bound'], ['258', '259', 'lower_bound'], ['260', '267', 'upper_bound'], ['271', '280', 'treatment'], ['300', '307', 'treatment']]}, 'NCT02323880'), ({'text': '< 18 years of age', 'entities': [['3', '11', 'upper_bound'], ['15', '18', 'age']]}, 'NCT02950649'), ({'text': 'myocardial infarction', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT03007745'), ({'text': 'Severe cardiovascular disorders that interfere with ability to perform moderate movement exercises', 'entities': [['1', '32', 'chronic_disease']]}, 'NCT02369770'), ({'text': 'Clinically significant cardiac dysfunction defined as a history of >= NYHA Class II symptoms, angina, congestive heart failure, myocardial infarction, arrhythmias or cardiac dysfunction requiring treatment or discontinuation of chemotherapy', 'entities': [['24', '43', 'chronic_disease'], ['71', '84', 'clinical_variable'], ['95', '101', 'chronic_disease'], ['103', '127', 'chronic_disease'], ['129', '150', 'chronic_disease'], ['152', '163', 'chronic_disease'], ['197', '206', 'treatment'], ['229', '241', 'treatment']]}, 'NCT01730118'), ({'text': 'planning a pregnancy', 'entities': [['1', '21', 'pregnancy']]}, 'NCT02640950'), ({'text': 'Pregnant with a singleton gestation that is equal to or greater than 36 weeks', 'entities': [['1', '9', 'pregnancy'], ['27', '36', 'clinical_variable'], ['70', '78', 'lower_bound']]}, 'NCT02487797'), ({'text': 'Prior anthracycline, platinum salt, or taxane for any malignancy', 'entities': [['7', '20', 'treatment'], ['40', '46', 'treatment'], ['55', '65', 'cancer']]}, 'NCT02315196'), ({'text': 'Individuals who weigh more than 90 kg', 'entities': [['17', '22', 'clinical_variable'], ['33', '38', 'lower_bound']]}, 'NCT02914171'), ({'text': 'behavioral disorders that would prevent ability to follow the protocol', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02663934'), ({'text': 'Patients with malabsorption syndrome', 'entities': [['15', '37', 'chronic_disease']]}, 'NCT02187848'), ({'text': 'Women who are pregnant', 'entities': [['1', '6', 'gender'], ['15', '23', 'pregnancy']]}, 'NCT02438995'), ({'text': 'Absolute neutrophil count (ANC) > 1500/mm3', 'entities': [['1', '32', 'clinical_variable'], ['35', '43', 'lower_bound']]}, 'NCT02128906'), ({'text': 'Post-primary androgen-deprivation therapy', 'entities': [['1', '42', 'treatment']]}, 'NCT02217709'), ({'text': 'Life expectancy of >3 months', 'entities': [['1', '16', 'clinical_variable'], ['21', '29', 'lower_bound']]}, 'NCT02770326'), ({'text': 'counselors who have received training online or in person in conducting the NYUCI and provided the intervention to at least one caregiver in person', 'entities': [['125', '128', 'lower_bound']]}, 'NCT02347202'), ({'text': 'albumin greater than or equal to 3.0 g/dL (30 g/L)', 'entities': [['1', '8', 'clinical_variable'], ['34', '51', 'lower_bound']]}, 'NCT01871727'), ({'text': 'Participant is currently taking minocycline or another tetracycline medication', 'entities': [['33', '44', 'treatment'], ['56', '79', 'treatment']]}, 'NCT02564978'), ({'text': 'Comorbid condition that has moderate likelihood of requiring a course of prednisone within one year of enrollment (e.g. chronic obstructive pulmonary disease (COPD), asthma, adrenal insufficiency)', 'entities': [['74', '84', 'treatment'], ['92', '100', 'upper_bound'], ['121', '165', 'chronic_disease'], ['167', '173', 'chronic_disease'], ['175', '196', 'chronic_disease']]}, 'NCT01940094'), ({'text': 'Participants with active, known or suspected autoimmune disease', 'entities': [['46', '64', 'chronic_disease']]}, 'NCT03001882'), ({'text': 'body mass index (BMI) > 40', 'entities': [['1', '22', 'bmi'], ['25', '27', 'lower_bound']]}, 'NCT02501733'), ({'text': 'ubjects who have taken an investigational drug within 30 days of enrollment', 'entities': [['27', '47', 'treatment'], ['55', '62', 'upper_bound']]}, 'NCT02584244'), ({'text': 'Wrist range of motion of at least 10 degrees', 'entities': [['1', '12', 'clinical_variable'], ['35', '45', 'lower_bound']]}, 'NCT02840643'), ({'text': '(mild elevations may be seen in polycystic ovary syndrome (PCOS) and adolescent hyperandrogenemia (HA), and elevations < 1.5 times the age-appropriate upper limit of normal will be accepted in these groups)', 'entities': [['7', '17', 'clinical_variable'], ['33', '65', 'chronic_disease'], ['81', '103', 'chronic_disease'], ['122', '173', 'upper_bound']]}, 'NCT01422746'), ({'text': 'appropriate fixation procedure', 'entities': [['13', '31', 'treatment']]}, 'NCT02507505'), ({'text': 'Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) d2', 'entities': [['9', '74', 'clinical_variable'], ['76', '77', 'upper_bound']]}, 'NCT02520011'), ({'text': 'Active hepatitis, known HIV, or other condition that requires immunosuppressive therapy, including current use of high dose systemic corticosteroids', 'entities': [['1', '17', 'chronic_disease'], ['25', '28', 'chronic_disease'], ['63', '88', 'treatment'], ['134', '149', 'treatment']]}, 'NCT02865135'), ({'text': 'Myocardial infarction more than 6 months prior to study entry', 'entities': [['1', '22', 'chronic_disease'], ['33', '47', 'lower_bound']]}, 'NCT01360606'), ({'text': 'Use of biologics for asthma/allergies unless there is a 4 month washout prior to enrollment (the washout for biologics is done for clinical reasons and not specifically for inclusion for the study)', 'entities': [['8', '17', 'treatment'], ['22', '38', 'chronic_disease'], ['57', '78', 'upper_bound']]}, 'NCT02433977'), ({'text': 'Completely resected histologically confirmed adenocarcinoma of the colon', 'entities': [['46', '73', 'cancer']]}, 'NCT00819208'), ({'text': 'Any major surgery within the last 3 weeks', 'entities': [['5', '18', 'treatment'], ['30', '42', 'upper_bound']]}, 'NCT02519322'), ({'text': 'Distant metastatic disease', 'entities': [['1', '27', 'cancer']]}, 'NCT02207465'), ({'text': 'Evidence of moderate/ severe chronic white matter disease or cerebellar stroke on MRI', 'entities': [['13', '58', 'chronic_disease'], ['62', '79', 'chronic_disease']]}, 'NCT01668602'), ({'text': 'History of allergic reactions attributed to compounds of similar chemical or biologic composition to tranexamic acid', 'entities': [['102', '117', 'allergy_name']]}, 'NCT02911831'), ({'text': 'nonallergic bronchospasm', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT02620579'), ({'text': '30-50', 'entities': [['1', '3', 'lower_bound'], ['4', '6', 'upper_bound']]}, 'NCT03082157'), ({'text': 'For the past 12 months, has smoked 5 or more cigarettes a day', 'entities': [['9', '23', 'upper_bound'], ['36', '37', 'lower_bound']]}, 'NCT02905656'), ({'text': 'Corrected QT interval (QTc) of < 480 milliseconds', 'entities': [['1', '28', 'clinical_variable'], ['34', '50', 'upper_bound']]}, 'NCT02474173'), ({'text': 'Subjects with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary. Topical or inhaled steroids are allowed', 'entities': [['15', '37', 'chronic_disease'], ['92', '100', 'treatment'], ['115', '122', 'treatment'], ['126', '142', 'treatment']]}, 'NCT02579044'), ({'text': 'imaging must have been performed no greater than 30 days prior to initiation of chemotherapy', 'entities': [['50', '63', 'upper_bound'], ['81', '93', 'treatment']]}, 'NCT02315196'), ({'text': 'have an unstable medical condition or stable medical condition that would interact with study medications or participation, including a current chronic pain or other medical condition that requires ongoing opioid agonist treatment (determined by physician assessment)', 'entities': [['207', '231', 'treatment']]}, 'NCT02543944'), ({'text': 'Active malignancy other than basal or squamous skin cancer', 'entities': [['8', '18', 'cancer'], ['30', '35', 'cancer'], ['39', '59', 'cancer']]}, 'NCT02572323'), ({'text': 'Concomitant prolapse surgery other than anterior colporrhaphy', 'entities': [['1', '29', 'treatment'], ['41', '62', 'treatment']]}, 'NCT02316275'), ({'text': 'Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 X institutional ULN', 'entities': [['1', '33', 'clinical_variable'], ['34', '82', 'clinical_variable'], ['83', '113', 'clinical_variable'], ['114', '160', 'clinical_variable'], ['164', '185', 'upper_bound']]}, 'NCT02177838'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02439450'), ({'text': 'History of malignancy of any organ system within the past 5 years', 'entities': [['12', '22', 'cancer'], ['54', '66', 'upper_bound']]}, 'NCT02471430'), ({'text': 'Greater than 3, 30-min bouts of planned exercise/week', 'entities': [['14', '15', 'lower_bound']]}, 'NCT02932748'), ({'text': 'AAT deficiency (defined as < 1.0ng/mg AAT)', 'entities': [['1', '15', 'chronic_disease'], ['30', '42', 'upper_bound']]}, 'NCT02464878'), ({'text': 'Prior stroke with functional impairment or other severe, uncontrolled medical problems that may impair ability to participate in the study exams, based on medical history and review of medical records', 'entities': [['7', '13', 'chronic_disease']]}, 'NCT01807897'), ({'text': 'End-stage organ disease or medical condition with subsequent vision loss (e.g., diabetes, stroke)', 'entities': [['1', '24', 'chronic_disease'], ['81', '89', 'chronic_disease'], ['91', '97', 'chronic_disease']]}, 'NCT03188042'), ({'text': 'axial length of >26.5mm', 'entities': [['1', '13', 'clinical_variable'], ['18', '24', 'lower_bound']]}, 'NCT02988895'), ({'text': 'Smoking within the previous 30 days', 'entities': [['20', '36', 'upper_bound']]}, 'NCT03010852'), ({'text': 'lifetime diagnosis of any psychotic or bipolar disorder as sleep restriction for insomnia may precipitate hallucinations and mania', 'entities': [['27', '56', 'chronic_disease'], ['60', '77', 'treatment'], ['82', '90', 'chronic_disease'], ['126', '131', 'chronic_disease']]}, 'NCT03109210'), ({'text': 'Patients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, and biologics)', 'entities': [['30', '50', 'treatment'], ['100', '107', 'upper_bound'], ['115', '134', 'treatment'], ['146', '158', 'treatment'], ['160', '177', 'treatment'], ['183', '192', 'treatment']]}, 'NCT02531932'), ({'text': 'Autologous bone marrow transplant', 'entities': [['1', '34', 'treatment']]}, 'NCT02457845'), ({'text': 'Serum creatinine =< 1.8 mg/dL', 'entities': [['1', '17', 'clinical_variable'], ['21', '30', 'upper_bound']]}, 'NCT02208362'), ({'text': 'within 72 hours prior to receiving the first dose of study medication', 'entities': [['8', '22', 'upper_bound'], ['60', '70', 'treatment']]}, 'NCT02332668'), ({'text': 'Evidence of hindbrain herniation (confirmed on MRI to have an Arnold-Chiari type II malformation)', 'entities': [['13', '33', 'chronic_disease'], ['48', '51', 'treatment'], ['63', '97', 'chronic_disease']]}, 'NCT03044821'), ({'text': 'Platelet count e 100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions within 7 days prior to laboratory sample)', 'entities': [['1', '15', 'clinical_variable'], ['18', '29', 'lower_bound'], ['31', '42', 'treatment'], ['81', '102', 'treatment'], ['110', '122', 'upper_bound']]}, 'NCT02578732'), ({'text': 'Subject has fresh and/or archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue confirmed available for analyses', 'entities': [['86', '91', 'cancer']]}, 'NCT02099058'), ({'text': 'ALT and either alkaline phosphatase or GGT remain within normal limits or <\\\\= 1.5 x baseline after darTregs infusion', 'entities': [['1', '4', 'clinical_variable'], ['16', '36', 'clinical_variable'], ['40', '43', 'clinical_variable'], ['79', '82', 'upper_bound'], ['94', '117', 'treatment']]}, 'NCT02474199'), ({'text': 'Late MDS with greater than 5% blasts in bone marrow', 'entities': [['6', '9', 'clinical_variable'], ['28', '30', 'lower_bound']]}, 'NCT00630253'), ({'text': 'Patients with a cardiac ejection fraction (as measured by either multigated acquisition scan [MUGA] or echocardiogram)', 'entities': [['17', '42', 'clinical_variable'], ['66', '100', 'treatment'], ['104', '118', 'treatment']]}, 'NCT01371630'), ({'text': 'Subject has had or is scheduled to have a chest X-ray within 24 hours prior to the investigational imaging study', 'entities': [['62', '76', 'upper_bound']]}, 'NCT03054870'), ({'text': 'at suicidal risk assessed by SCID interview', 'entities': [['4', '12', 'chronic_disease']]}, 'NCT03056287'), ({'text': 'Major surgery other than diagnostic surgery =< 4 weeks prior to registration', 'entities': [['1', '14', 'treatment'], ['26', '44', 'treatment'], ['48', '61', 'upper_bound']]}, 'NCT02320292'), ({'text': 'Prior treatment with an FTase inhibitor', 'entities': [['7', '16', 'treatment'], ['25', '40', 'treatment']]}, 'NCT02383927'), ({'text': 'Patient must be able to tolerate a major surgical procedure based on clinical evaluation, status of their cancer, and any other underlying medical problems', 'entities': [['36', '60', 'treatment'], ['107', '113', 'cancer']]}, 'NCT02270450'), ({'text': 'Speaks and reads English fluently', 'entities': [['1', '34', 'language_fluency']]}, 'NCT02839759'), ({'text': 'Zubrod performance status d 2 (Karnofsky or ECOG performance status may be used to estimate Zubrod)', 'entities': [['1', '26', 'clinical_variable'], ['1', '7', 'clinical_variable'], ['29', '30', 'upper_bound'], ['32', '41', 'clinical_variable'], ['45', '68', 'clinical_variable']]}, 'NCT02997709'), ({'text': 'completed local definitive treatment (i.e., surgery, chemotherapy, radiation)', 'entities': [['28', '37', 'treatment'], ['45', '52', 'treatment'], ['54', '66', 'treatment'], ['68', '77', 'treatment']]}, 'NCT02707471'), ({'text': 'excisional biopsy procedure', 'entities': [['1', '28', 'treatment']]}, 'NCT00625417'), ({'text': 'Life expectancy >= 90 days (3 months)', 'entities': [['1', '16', 'clinical_variable'], ['20', '38', 'lower_bound']]}, 'NCT02020707'), ({'text': '18 years or older', 'entities': [['1', '9', 'lower_bound']]}, 'NCT03153969'), ({'text': '- Persons having colorectal disease (e.g., ulcerative colitis or colectomy), personal history of colorectal cancer or colorectal disease,', 'entities': [['19', '37', 'chronic_disease'], ['45', '63', 'chronic_disease'], ['67', '76', 'chronic_disease'], ['99', '116', 'cancer']]}, 'NCT03167125'), ({'text': 'prior history of LVEF below 50%', 'entities': [['18', '22', 'clinical_variable'], ['29', '32', 'lower_bound']]}, 'NCT02589977'), ({'text': 'life expectancy of 3 years', 'entities': [['1', '16', 'clinical_variable'], ['20', '27', 'upper_bound']]}, 'NCT02064673'), ({'text': 'Renal function < 30% of normal for age and size as determined by the Schwartz formula', 'entities': [['1', '15', 'clinical_variable'], ['18', '21', 'upper_bound']]}, 'NCT02369653'), ({'text': 'Requires concomitant anticoagulation with Coumadin (warfarin) or other vitamin K antagonists', 'entities': [['22', '37', 'treatment'], ['43', '62', 'treatment'], ['72', '93', 'treatment']]}, 'NCT02514083'), ({'text': 'MV > 24, < 96 hours', 'entities': [['1', '3', 'clinical_variable'], ['6', '8', 'lower_bound'], ['12', '20', 'upper_bound']]}, 'NCT01777035'), ({'text': "Patient's will have no evidence of gross vascular invasion", 'entities': [['36', '59', 'chronic_disease']]}, 'NCT01360606'), ({'text': "serious infections, hepatic, renal or other organ dysfunction, which in the judgment of the Principal or Associate Investigator would compromise the patient's ability to tolerate the general anesthetic required for the procedure", 'entities': [['1', '19', 'chronic_disease'], ['21', '28', 'chronic_disease'], ['30', '35', 'chronic_disease'], ['45', '62', 'chronic_disease']]}, 'NCT02076906'), ({'text': 'Evidence of any complication of diabetes (proliferative retinopathy, autonomic neuropathy, nephropathy, etc), or likelihood of requiring laser photocoagulation, vitrectomy, or other specific treatment for diabetic retinopathy in the coming year', 'entities': [['33', '41', 'chronic_disease'], ['43', '68', 'chronic_disease'], ['70', '90', 'chronic_disease'], ['92', '103', 'chronic_disease'], ['138', '160', 'treatment'], ['162', '172', 'treatment'], ['183', '201', 'treatment'], ['206', '226', 'chronic_disease']]}, 'NCT02527265'), ({'text': 'Subjects on chronic steroid therapy for treatment of MS or other systematic disease', 'entities': [['13', '36', 'treatment'], ['41', '50', 'treatment'], ['54', '56', 'chronic_disease'], ['66', '84', 'chronic_disease']]}, 'NCT02446886'), ({'text': 'kidney disease', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT02682147'), ({'text': 'Individuals with evidence of proliferative diabetic retinopathy, plasma creatinine >1.4 females or >1.5 males, or 24-hour urine albumin excretion > 300 mg will be excluded', 'entities': [['30', '64', 'chronic_disease'], ['66', '83', 'clinical_variable'], ['85', '88', 'lower_bound'], ['89', '96', 'gender'], ['91', '96', 'gender'], ['101', '104', 'lower_bound'], ['115', '146', 'clinical_variable'], ['149', '155', 'lower_bound']]}, 'NCT02981069'), ({'text': 'A serum creatinine based on age', 'entities': [['3', '19', 'clinical_variable'], ['29', '32', 'age']]}, 'NCT02110069'), ({'text': 'Patients with active brain metastases or carcinomatous meningitis', 'entities': [['22', '38', 'cancer'], ['42', '66', 'cancer']]}, 'NCT01827384'), ({'text': 'Males', 'entities': [['1', '6', 'gender']]}, 'NCT01589263'), ({'text': 'Cardiac surgery that requires intraoperative circulatory arrest, such as aortic arch replacement', 'entities': [['1', '16', 'treatment']]}, 'NCT02361944'), ({'text': 'with the last menstrual period being over two years prior to enrolment', 'entities': [['43', '58', 'upper_bound']]}, 'NCT01505062'), ({'text': 'Serum creatinine d 1.5 X ULN (OR creatinine clearance e 60 mL/min/1.73 m2)', 'entities': [['1', '17', 'clinical_variable'], ['20', '29', 'upper_bound'], ['34', '54', 'clinical_variable'], ['57', '74', 'lower_bound']]}, 'NCT02863991'), ({'text': 'current participation in other therapeutic investigational procedures', 'entities': [['32', '59', 'treatment']]}, 'NCT01877382'), ({'text': 'Diagnosis of recurrent and/or metastatic thyroid cancer', 'entities': [['14', '23', 'cancer'], ['31', '56', 'cancer']]}, 'NCT02393690'), ({'text': 'Previous systemic anti-cancer therapy must have been discontinued at least 3 weeks prior to treatment in this study', 'entities': [['1', '38', 'treatment'], ['76', '89', 'lower_bound'], ['93', '102', 'treatment']]}, 'NCT02309580'), ({'text': 'Recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, prior to study entry and for at least 3 months after the last dose of study drug', 'entities': [['23', '27', 'gender'], ['56', '57', 'lower_bound'], ['149', '163', 'lower_bound'], ['181', '191', 'treatment']]}, 'NCT02385110'), ({'text': 'ANC>= 1500/mm^3', 'entities': [['1', '4', 'clinical_variable'], ['7', '16', 'lower_bound']]}, 'NCT02706353'), ({'text': 'Women diagnosed with Absolute Uterine Infertility (AUI) and intact native ovaries', 'entities': [['1', '6', 'gender'], ['22', '56', 'chronic_disease']]}, 'NCT02656550'), ({'text': 'History of cervical spine surgery', 'entities': [['12', '34', 'treatment']]}, 'NCT02415660'), ({'text': 'Liver disease with history of positive serology', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02004275'), ({'text': 'Pulmonary hypertension', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02950337'), ({'text': 'Receiving a bi-ventricular ICD device', 'entities': [['13', '38', 'treatment']]}, 'NCT02121158'), ({'text': 'Platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and treatment to achieve a target plt >= 75,000/uL and hemoglobin of >= 8.5 g/dl, provided that patients have not received growth factors for at least 14 days prior to entering trial', 'entities': [['1', '21', 'treatment'], ['33', '59', 'treatment'], ['100', '109', 'treatment'], ['144', '147', 'clinical_variable'], ['151', '160', 'lower_bound'], ['165', '175', 'clinical_variable'], ['182', '190', 'lower_bound'], ['261', '274', 'lower_bound']]}, 'NCT03016871'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT02567448'), ({'text': 'Hemophagocytic Lymphohistiocytosis (HLH) syndromes', 'entities': [['1', '41', 'chronic_disease']]}, 'NCT01962415'), ({'text': 'Cohort 3b will have had prior lapatinib therapy', 'entities': [['25', '48', 'treatment']]}, 'NCT01494662'), ({'text': 'Any other hemorrhage/bleeding event >= grade 3 (NCI CTCAE v4.0) within 4 weeks or less prior to first dose of study treatment', 'entities': [['40', '47', 'lower_bound'], ['49', '58', 'clinical_variable'], ['72', '79', 'upper_bound'], ['117', '126', 'treatment']]}, 'NCT01817751'), ({'text': 'Greater than 6 months post-spinal cord injury', 'entities': [['14', '22', 'lower_bound'], ['23', '46', 'chronic_disease']]}, 'NCT03071393'), ({'text': 'Systolic blood pressure greater than 140 mmHg on two different occasions at least one week apart', 'entities': [['1', '24', 'clinical_variable'], ['38', '46', 'lower_bound'], ['83', '91', 'lower_bound']]}, 'NCT02587936'), ({'text': 'Presence of an acute illness at time of study', 'entities': [['16', '29', 'chronic_disease']]}, 'NCT01555905'), ({'text': 'Lansoprazole (Prevacid)', 'entities': [['1', '13', 'treatment'], ['15', '23', 'treatment']]}, 'NCT02595372'), ({'text': 'A reasonable suspicion of ovarian cancer by the treating oncologist', 'entities': [['27', '41', 'cancer']]}, 'NCT02122185'), ({'text': 'History of malignancy', 'entities': [['12', '22', 'cancer']]}, 'NCT02134392'), ({'text': 'Serum creatinine > 1.4 mg/dl', 'entities': [['1', '17', 'clinical_variable'], ['20', '29', 'lower_bound']]}, 'NCT01445821'), ({'text': 'Unable to obtain liver iron concentration within 12 months prior or 6 months after study entry', 'entities': [['18', '42', 'clinical_variable'], ['50', '65', 'upper_bound']]}, 'NCT02308904'), ({'text': '18+ years old', 'entities': [['1', '10', 'lower_bound']]}, 'NCT02688569'), ({'text': 'Tandem autologous transplantation', 'entities': [['1', '34', 'treatment']]}, 'NCT02253316'), ({'text': 'chemotherapy or biological cancer therapy within 2 weeks prior to the first dose of study drug', 'entities': [['1', '13', 'treatment'], ['17', '42', 'treatment'], ['50', '63', 'upper_bound'], ['85', '95', 'treatment']]}, 'NCT01876511'), ({'text': 'recent surgery or hospitalization', 'entities': [['8', '15', 'treatment'], ['19', '34', 'treatment']]}, 'NCT02830074'), ({'text': 'Branch or central retinal vein or artery occlusion', 'entities': [['11', '31', 'chronic_disease'], ['35', '51', 'chronic_disease']]}, 'NCT02564978'), ({'text': 'Ulcerative colitis patients have a Ulcerative Colitis Clinical Score > 5', 'entities': [['1', '19', 'chronic_disease'], ['36', '69', 'clinical_variable'], ['72', '73', 'lower_bound']]}, 'NCT02413047'), ({'text': 'The effects of TRC102 on the developing human fetus are unknown; for this reason and because TRC102 as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 4 months after completion of the study drugs', 'entities': [['16', '22', 'treatment'], ['118', '136', 'treatment'], ['185', '190', 'gender'], ['187', '190', 'gender'], ['231', '266', 'contraception_consent'], ['268', '311', 'contraception_consent'], ['313', '323', 'contraception_consent'], ['392', '406', 'upper_bound'], ['425', '436', 'treatment']]}, 'NCT02535312'), ({'text': 'either ritonavir-boosted atazanavir or ritonavir-boosted darunavir once or twice daily as per product label for a minimum of 3 months prior to the screening visit', 'entities': [['8', '17', 'treatment'], ['26', '36', 'treatment'], ['58', '67', 'treatment'], ['126', '134', 'upper_bound']]}, 'NCT02016924'), ({'text': 'Prior invasive malignancy unless disease free for a minimum of 3 years', 'entities': [['16', '26', 'cancer'], ['64', '71', 'upper_bound']]}, 'NCT02353819'), ({'text': 'high-risk MDS (i.e. refractory anemia with excess blasts [RAEB-1 or RAEB-2] by World Health Organization [WHO] classification, or any WHO subset with International Prognostic Scoring System [IPSS] intermediate-2 or high, or any patients that has failed prior therapy with hypomethylating agents)', 'entities': [['1', '14', 'cancer'], ['21', '57', 'chronic_disease'], ['59', '65', 'chronic_disease'], ['69', '75', 'chronic_disease'], ['151', '197', 'clinical_variable'], ['254', '295', 'treatment']]}, 'NCT02530034'), ({'text': 'Reversible causes of atrial arrhythmia such as hyperthyroidism, sarcoidosis, pulmonary embolism etc', 'entities': [['22', '39', 'chronic_disease'], ['48', '63', 'chronic_disease'], ['65', '76', 'chronic_disease'], ['78', '96', 'chronic_disease']]}, 'NCT01672138'), ({'text': 'Active hepatitis B', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02624258'), ({'text': 'Subject is pregnant', 'entities': [['12', '20', 'pregnancy']]}, 'NCT02053766'), ({'text': 'A malignancy diagnosed e2 years ago if the subject has had no evidence of disease for 2 years prior to screening', 'entities': [['3', '13', 'clinical_variable'], ['25', '32', 'lower_bound']]}, 'NCT02302235'), ({'text': 'History of New York Heart Association class 3-4 congestive heart failure or history myocardial infarction within 6 months of starting study treatment', 'entities': [['12', '44', 'clinical_variable'], ['45', '46', 'lower_bound'], ['47', '48', 'upper_bound'], ['49', '73', 'chronic_disease'], ['85', '106', 'chronic_disease'], ['114', '122', 'upper_bound']]}, 'NCT02706353'), ({'text': 'AST (SGOT)/ALT (SGPT) greater than 4 times upper limit of normal', 'entities': [['1', '11', 'clinical_variable'], ['12', '22', 'clinical_variable'], ['36', '65', 'lower_bound']]}, 'NCT00720785'), ({'text': 'fluency in English', 'entities': [['1', '19', 'language_fluency']]}, 'NCT03106740'), ({'text': 'Neurologic disease', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02703090'), ({'text': 'Prior transplant with stem cell infusion 90 days or active graft-versus-host treatment within 8 weeks of Day 1', 'entities': [['1', '41', 'treatment'], ['42', '49', 'upper_bound'], ['53', '87', 'treatment'], ['95', '102', 'upper_bound']]}, 'NCT01994382'), ({'text': 'The patient on behalf of whom the individual acted as surrogate is deceased for less than two months', 'entities': [['91', '101', 'upper_bound']]}, 'NCT02898194'), ({'text': 'Life-limiting comorbid medical condition such as cancer', 'entities': [['1', '41', 'chronic_disease'], ['50', '56', 'cancer']]}, 'NCT02342808'), ({'text': 'Patients must have previously received prior first line standard therapy (or effective salvage chemotherapy regimens) for their disease, if known to be effective for that disease, and have been either non-responders (progressive disease) or have recurred', 'entities': [['40', '73', 'treatment'], ['88', '117', 'treatment']]}, 'NCT02111850'), ({'text': 'Subject must have discontinued osimertinib due to disease progression', 'entities': [['32', '43', 'treatment']]}, 'NCT02099058'), ({'text': 'Concomitant treatment with any of the following drugs: azathioprine, cyclophosphamide, cyclosporine, pirfenidone, full dose anticoagulation (vitamin K antagonists, dabigatran, heparin, etc.), fibrinolysis and high dose anti-platelet therapy (ex. Plavix 150mg)^2 Myocardial infarction or unstable angina within 6 or 1 month of starting nintedanib treatment, respectively', 'entities': [['56', '68', 'treatment'], ['70', '86', 'treatment'], ['88', '100', 'treatment'], ['102', '113', 'treatment'], ['115', '140', 'treatment'], ['142', '163', 'treatment'], ['165', '175', 'treatment'], ['177', '184', 'treatment'], ['193', '205', 'treatment'], ['210', '241', 'treatment'], ['263', '284', 'chronic_disease'], ['288', '303', 'chronic_disease'], ['311', '312', 'upper_bound'], ['316', '323', 'lower_bound'], ['336', '346', 'treatment']]}, 'NCT02496585'), ({'text': 'Known skin allergy to adhesives (hydrocolloid, silicone, acrylic)', 'entities': [['23', '32', 'allergy_name'], ['34', '46', 'allergy_name'], ['48', '56', 'allergy_name'], ['58', '65', 'allergy_name']]}, 'NCT02391987'), ({'text': 'Age less than 18', 'entities': [['1', '4', 'age'], ['15', '17', 'upper_bound']]}, 'NCT02744430'), ({'text': 'Has Internet access at home', 'entities': [['5', '20', 'technology_access']]}, 'NCT02839759'), ({'text': 'Any conditions contraindicated for MRI (e.g., pacemaker, metal in body, significant claustrophobia)', 'entities': [['36', '39', 'treatment'], ['47', '56', 'treatment'], ['85', '99', 'chronic_disease']]}, 'NCT00739362'), ({'text': 'DLCO > 50%', 'entities': [['1', '5', 'clinical_variable'], ['8', '11', 'lower_bound']]}, 'NCT00914628'), ({'text': 'Inability to cooperate with NIPPV', 'entities': [['29', '34', 'treatment']]}, 'NCT02464696'), ({'text': 'patients with prior surgery cannot have received prior radiation, chemotherapy or targeted therapy', 'entities': [['21', '28', 'treatment'], ['50', '65', 'treatment'], ['67', '79', 'treatment'], ['72', '79', 'treatment']]}, 'NCT00887146'), ({'text': 'Active genital ulcers', 'entities': [['8', '22', 'chronic_disease']]}, 'NCT02382419'), ({'text': 'Primary hypertrophic or infiltrative cardiomyopathy', 'entities': [['1', '21', 'chronic_disease'], ['25', '52', 'chronic_disease']]}, 'NCT02816736'), ({'text': 'Significant malabsorption syndrome or inability to tolerate oral medications', 'entities': [['13', '35', 'chronic_disease'], ['66', '77', 'treatment']]}, 'NCT01494662'), ({'text': 'expected to require parenteral nutrition (PN) for 28 days', 'entities': [['51', '58', 'upper_bound']]}, 'NCT02579265'), ({'text': 'Patients with previously untreated ALL of pre-B, Philadelphia chromosome (Ph-) negative ALL', 'entities': [['36', '39', 'cancer']]}, 'NCT01371630'), ({'text': 'Measurable disease within the past 4 weeks', 'entities': [['31', '43', 'upper_bound']]}, 'NCT01572480'), ({'text': 'Prisoners or subjects who are involuntarily incarcerated or compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness', 'entities': [['87', '96', 'treatment'], ['109', '120', 'chronic_disease'], ['124', '132', 'chronic_disease'], ['139', '157', 'chronic_disease']]}, 'NCT02259621'), ({'text': 'Chronic renal disease', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT00904046'), ({'text': 'WOCBP must follow instructions for birth control when the half-life of the study drug is > 24 hours', 'entities': [['12', '49', 'contraception_consent'], ['76', '86', 'treatment'], ['92', '100', 'lower_bound']]}, 'NCT02519322'), ({'text': 'For Parts A, B, C, D, E, F, H: Have received prior therapy with a CDK4/6 inhibitor', 'entities': [['46', '83', 'treatment']]}, 'NCT02057133'), ({'text': 'Pregnant or lactating women', 'entities': [['1', '9', 'pregnancy'], ['23', '28', 'gender']]}, 'NCT02986815'), ({'text': 'Philadelphia Chromosome (Ph)+ ALL subjects on TKIs at Screening may enroll and remain on Tyrosine Kinase Inhibitor (TKI) therapy to control disease', 'entities': [['1', '34', 'cancer'], ['47', '51', 'treatment'], ['90', '129', 'treatment']]}, 'NCT03181126'), ({'text': 'Pregnant and lactating women are excluded from the study because the risks to an unborn fetus or potential risks in nursing infants are unknown', 'entities': [['1', '9', 'pregnancy'], ['24', '29', 'gender']]}, 'NCT01054196'), ({'text': 'Osteoporotic by DXA of either spine or total hip', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02440581'), ({'text': 'PID as defined by monogenetic mutation or, in the absence of a PID-associated genetic mutation, patients with an immune defect potentially amenable to allo BMT who meet the clinical history criteria below may be eligible upon discussion with the PI', 'entities': [['1', '4', 'chronic_disease'], ['157', '160', 'treatment']]}, 'NCT02579967'), ({'text': 'Previous thoracotomy on the operative side', 'entities': [['10', '21', 'treatment']]}, 'NCT02063438'), ({'text': 'Smokers (quit e 1 year ago acceptable)', 'entities': [['17', '23', 'lower_bound']]}, 'NCT02484300'), ({'text': 'No known histologic transformation from iNHL to DLBCL', 'entities': [['41', '45', 'cancer'], ['49', '54', 'cancer']]}, 'NCT02384954'), ({'text': 'Massive nodes or clusters or progressive lymphadenopathy', 'entities': [['42', '57', 'chronic_disease']]}, 'NCT02514083'), ({'text': 'Creatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels about institutional normal', 'entities': [['1', '11', 'clinical_variable'], ['50', '70', 'clinical_variable'], ['73', '90', 'lower_bound'], ['109', '126', 'clinical_variable']]}, 'NCT01985087'), ({'text': 'Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy', 'entities': [['44', '50', 'cancer'], ['67', '89', 'cancer'], ['105', '109', 'cancer'], ['123', '140', 'treatment']]}, 'NCT01872975'), ({'text': 'Previous pelvic radiation or prostate brachytherapy', 'entities': [['1', '26', 'treatment'], ['30', '52', 'treatment']]}, 'NCT01950351'), ({'text': "Other co-morbidity which would interfere with patient's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease", 'entities': [['95', '117', 'chronic_disease'], ['119', '138', 'chronic_disease'], ['142', '154', 'chronic_disease']]}, 'NCT02547662'), ({'text': 'HIV positive mothers', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT02766998'), ({'text': 'An unchanged antipsychotic medication regimen for at least eight (8) weeks prior to screening into the study and expected to remain unchanged during the study (longer for depot or long-acting antipsychotics: ten (10) months for Aripiprazole and Paliperidone', 'entities': [['14', '46', 'treatment'], ['60', '81', 'lower_bound'], ['193', '207', 'treatment'], ['229', '241', 'treatment'], ['246', '258', 'treatment']]}, 'NCT02261519'), ({'text': 'Severe co-existing cardiac disease', 'entities': [['20', '35', 'chronic_disease']]}, 'NCT01474889'), ({'text': 'Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer', 'entities': [['24', '34', 'cancer'], ['67', '83', 'treatment'], ['104', '136', 'cancer'], ['138', '173', 'cancer'], ['205', '221', 'treatment'], ['225', '248', 'cancer']]}, 'NCT02286687'), ({'text': 'Weight >100kg', 'entities': [['1', '7', 'clinical_variable'], ['9', '14', 'lower_bound']]}, 'NCT02764359'), ({'text': 'T3b or T4 or node positive disease', 'entities': [['1', '4', 'cancer'], ['8', '10', 'cancer'], ['14', '35', 'cancer']]}, 'NCT02064673'), ({'text': 'Active or relapsing autoimmune disorder that may require immunotherapy during this treatment trial', 'entities': [['21', '40', 'chronic_disease'], ['58', '71', 'treatment'], ['84', '93', 'treatment']]}, 'NCT02572323'), ({'text': '18-80 years', 'entities': [['1', '3', 'lower_bound'], ['4', '12', 'upper_bound']]}, 'NCT02789111'), ({'text': 'received at least one dose of a monoamine oxidase inhibitor (MAOI) four weeks or less prior', 'entities': [['19', '27', 'lower_bound'], ['33', '67', 'treatment'], ['68', '78', 'upper_bound']]}, 'NCT02977299'), ({'text': 'clinically-significant cardiac arrhythmias', 'entities': [['24', '43', 'chronic_disease']]}, 'NCT02101736'), ({'text': 'coronary heart disease or stroke within previous 3 months', 'entities': [['1', '23', 'chronic_disease'], ['27', '33', 'chronic_disease'], ['41', '58', 'upper_bound']]}, 'NCT02891850'), ({'text': 'Pupil size greater or equal to 6.0mm after dilation', 'entities': [['1', '11', 'clinical_variable'], ['32', '37', 'lower_bound']]}, 'NCT03179397'), ({'text': 'The patient has a history of acute or chronic depression', 'entities': [['30', '57', 'chronic_disease']]}, 'NCT00737893'), ({'text': 'Estimated life expectancy of at least 3 months', 'entities': [['11', '26', 'clinical_variable'], ['39', '47', 'lower_bound']]}, 'NCT02480036'), ({'text': 'Known or presumed intolerance of gemcitabine, vorinostat or sorafenib', 'entities': [['34', '45', 'treatment'], ['47', '57', 'treatment'], ['61', '70', 'treatment']]}, 'NCT02349867'), ({'text': 'Planned radiation dose of 24 Gy', 'entities': [['9', '18', 'treatment']]}, 'NCT02387905'), ({'text': 'Known pre-existing interstitial lung disease', 'entities': [['20', '45', 'chronic_disease']]}, 'NCT02423525'), ({'text': 'Breaks in BCL-2 via cytogenetic studies', 'entities': [['11', '16', 'cancer'], ['21', '40', 'treatment']]}, 'NCT02213913'), ({'text': 'Patients at least 18 years of age', 'entities': [['19', '27', 'lower_bound'], ['31', '34', 'age']]}, 'NCT01668563'), ({'text': 'Metachromatic leukodystrophy', 'entities': [['1', '29', 'chronic_disease']]}, 'NCT02171104'), ({'text': 'History of clinical deterioration when any of the medications that the patient is taking at presentation have been discontinued in the past with the exception of any medications that will be continued during the research protocol', 'entities': [['51', '62', 'treatment']]}, 'NCT02473250'), ({'text': 'Participation in a prior gene transfer therapy study', 'entities': [['20', '47', 'treatment']]}, 'NCT01505062'), ({'text': 'Deemed too psychiatrically unstable to safely enroll in randomized trial of psychotherapy. Requiring psychiatric hospitalization at baseline for safety', 'entities': [['77', '90', 'treatment']]}, 'NCT03043573'), ({'text': 'Uncontrolled hypertension, i.e., blood pressure (BP) of >/= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose and meet all other inclusion criteria', 'entities': [['1', '26', 'chronic_disease'], ['14', '26', 'chronic_disease'], ['34', '53', 'clinical_variable'], ['61', '67', 'lower_bound'], ['127', '137', 'treatment']]}, 'NCT02512497'), ({'text': 'age e18', 'entities': [['1', '4', 'age'], ['6', '8', 'lower_bound']]}, 'NCT02577731'), ({'text': 'para-aortic lymph node sampling', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02501954'), ({'text': 'Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG) changes and biomarkers of myocardial necrosis (e.g. troponin) in an appropriate clinical setting (chest discomfort or anginal equivalent)', 'entities': [['1', '24', 'chronic_disease'], ['32', '39', 'upper_bound'], ['54', '80', 'treatment'], ['107', '126', 'chronic_disease']]}, 'NCT02816736'), ({'text': 'Multiple Myeloma patients specified in the protocol', 'entities': [['1', '17', 'cancer']]}, 'NCT01947140'), ({'text': 'Willing to undergo in-vitro fertilization', 'entities': [['20', '42', 'treatment']]}, 'NCT02656550'), ({'text': 'Strong inducers of CYP3A or CYP2C8', 'entities': [['1', '25', 'treatment'], ['29', '35', 'treatment']]}, 'NCT01989585'), ({'text': 'Hb > 10 g/dL', 'entities': [['1', '3', 'clinical_variable'], ['6', '13', 'lower_bound']]}, 'NCT01757418'), ({'text': 'Life expectancy e 6 weeks', 'entities': [['1', '16', 'clinical_variable'], ['19', '26', 'lower_bound']]}, 'NCT02379520'), ({'text': 'The study eye must have at least (Omega) disc area (approximately 1 mm(2)) of GA compatible with dry AMD', 'entities': [['67', '74', 'lower_bound'], ['98', '105', 'chronic_disease']]}, 'NCT02564978'), ({'text': 'Clinically significant gastrointestinal impairment that could interfere with drug absorption', 'entities': [['24', '51', 'chronic_disease']]}, 'NCT02130687'), ({'text': 'Brain Injury at least 6 months prior', 'entities': [['1', '13', 'chronic_disease'], ['23', '37', 'lower_bound']]}, 'NCT01681589'), ({'text': 'any history of syndromal bipolar I or II disorder (i.e., history of mania, mixed episode, or major depression with hypomania)', 'entities': [['26', '50', 'chronic_disease'], ['69', '74', 'chronic_disease'], ['76', '89', 'chronic_disease'], ['94', '110', 'chronic_disease'], ['116', '125', 'chronic_disease']]}, 'NCT02553161'), ({'text': 'Self reports being 100% adherent to PrEP', 'entities': [['37', '41', 'treatment']]}, 'NCT03175159'), ({'text': 'At least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT02573493'), ({'text': 'Renal dysfunction', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT02739035'), ({'text': 'Creatinine =< 1.5 x ULN', 'entities': [['1', '11', 'clinical_variable'], ['15', '24', 'upper_bound']]}, 'NCT02217709'), ({'text': 'Patients who have had prior radiotherapy at the spine site and level to be treated', 'entities': [['23', '41', 'treatment']]}, 'NCT02387905'), ({'text': 'Abnormal cardiac valve morphology (egrade 2) documented by echocardiogram', 'entities': [['10', '34', 'clinical_variable'], ['37', '44', 'lower_bound'], ['60', '74', 'treatment']]}, 'NCT02257424'), ({'text': 'history of congenital long QT syndrome', 'entities': [['12', '39', 'chronic_disease']]}, 'NCT02417701'), ({'text': 'Lack of recovery of prior adverse events due to prior cancer therapy to Grade less than or equal to 1 (NCI CTCAE; except alopecia)', 'entities': [['49', '69', 'treatment'], ['73', '78', 'clinical_variable'], ['101', '102', 'upper_bound'], ['122', '130', 'chronic_disease']]}, 'NCT02203513'), ({'text': 'minor surgical procedures', 'entities': [['1', '26', 'treatment']]}, 'NCT03038620'), ({'text': 'Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met', 'entities': [['67', '80', 'treatment']]}, 'NCT01430390'), ({'text': 'women of childbearing potential will undergo a blood or urine pregnancy test under Protocol 95-H-0186', 'entities': [['1', '6', 'gender'], ['57', '72', 'pregnancy']]}, 'NCT01799538'), ({'text': 'Platelets > 100,000 cells/ul', 'entities': [['1', '10', 'clinical_variable'], ['13', '29', 'lower_bound']]}, 'NCT02192359'), ({'text': 'should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately', 'entities': [['10', '15', 'gender'], ['16', '31', 'pregnancy'], ['47', '58', 'pregnancy']]}, 'NCT02122172'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance score of =< 2', 'entities': [['1', '60', 'clinical_variable'], ['67', '68', 'upper_bound']]}, 'NCT01918644'), ({'text': "Patients (18 years or older) with Stargardt's Macular Degeneration", 'entities': [['11', '19', 'lower_bound'], ['35', '67', 'chronic_disease']]}, 'NCT01367444'), ({'text': 'Patient must have a Type A thoracic aortic dissection, retrograde Type A thoracic aortic dissection, intramural hematoma, penetrating ulcer or pseudoaneurysm of the ascending thoracic aorta affecting the area between the Sinus of Valsalva and the innominate artery orifice (with no involvement of the aortic valve) and be considered candidates for endovascular repair;', 'entities': [['21', '54', 'treatment'], ['56', '100', 'treatment'], ['102', '121', 'treatment'], ['123', '140', 'chronic_disease'], ['144', '158', 'chronic_disease']]}, 'NCT02201589'), ({'text': 'cardiac index [CI] d 2.2 L/min/m2', 'entities': [['1', '19', 'clinical_variable'], ['22', '34', 'upper_bound']]}, 'NCT02369900'), ({'text': 'Patients must have untreated AML, or high-risk myelodysplastic syndromes (MDS) (refractory anemia with excess blasts, [RAEB], or RAEB in transformation [RAEB-t]) characterized by t(8;21), inv(16), or t(16;16); the presence of additional abnormalities is irrelevant', 'entities': [['30', '33', 'cancer'], ['38', '79', 'cancer'], ['81', '98', 'chronic_disease'], ['120', '124', 'chronic_disease']]}, 'NCT00801489'), ({'text': 'Subjects with disease recurrence within 1 year of a platinum based neoadjuvant or adjuvant therapy for bladder cancer', 'entities': [['41', '47', 'upper_bound'], ['68', '79', 'treatment'], ['83', '99', 'treatment'], ['104', '118', 'cancer']]}, 'NCT02553642'), ({'text': 'Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE v4', 'entities': [['32', '59', 'treatment'], ['95', '103', 'chronic_disease']]}, 'NCT01877382'), ({'text': 'Congenital or acquired immune deficiency, chronic hepatitis B or C infection, HIV positive', 'entities': [['1', '41', 'chronic_disease'], ['43', '77', 'chronic_disease'], ['79', '91', 'chronic_disease']]}, 'NCT02171429'), ({'text': 'Other malignancy treated within the last 3 years', 'entities': [['7', '17', 'cancer'], ['37', '49', 'upper_bound']]}, 'NCT02346526'), ({'text': 'Requires any other form of systemic or localized antineoplastic therapy while on study', 'entities': [['28', '72', 'treatment']]}, 'NCT01876511'), ({'text': 'Not currently using narcotics, psychotropic or hypnotic medications and willing to refrain from using these medications during the course of the study', 'entities': [['21', '30', 'treatment'], ['32', '44', 'treatment'], ['48', '68', 'treatment']]}, 'NCT02341287'), ({'text': 'Hypothyroidism on stable doses of thyroid replacement therapy', 'entities': [['1', '15', 'chronic_disease'], ['35', '62', 'treatment']]}, 'NCT02536794'), ({'text': 'creatinine clearance (CrCl) e40 mL/min', 'entities': [['1', '28', 'clinical_variable'], ['30', '39', 'lower_bound']]}, 'NCT02985554'), ({'text': 'ECOG performance status <3', 'entities': [['1', '24', 'clinical_variable'], ['26', '27', 'upper_bound']]}, 'NCT02332928'), ({'text': 'pregnant or lactating', 'entities': [['1', '9', 'pregnancy']]}, 'NCT03117751'), ({'text': 'Able to read, speak, and understand English', 'entities': [['1', '44', 'language_fluency']]}, 'NCT03175159'), ({'text': 'Prior adverse reaction to tetanus toxoid-containing vaccines', 'entities': [['27', '61', 'allergy_name']]}, 'NCT02737475'), ({'text': 'Age: 17 years or less at time of enrollment', 'entities': [['1', '4', 'age'], ['6', '14', 'upper_bound']]}, 'NCT02030015'), ({'text': 'Significant hemoptysis within 30 days prior to screening (e5 mL of blood in one coughing episode or >30 mL of blood in a 24 hour period)', 'entities': [['13', '23', 'chronic_disease'], ['31', '44', 'upper_bound'], ['60', '64', 'lower_bound'], ['102', '107', 'lower_bound'], ['122', '129', 'upper_bound']]}, 'NCT02498535'), ({'text': 'Prior navitoclax, BRAF inhibitor, and MEK inhibitor is prohibited; (exceptions for Phase I are described above)', 'entities': [['1', '17', 'treatment'], ['19', '33', 'treatment'], ['39', '52', 'treatment']]}, 'NCT01989585'), ({'text': 'Legally blind', 'entities': [['9', '14', 'chronic_disease']]}, 'NCT02698722'), ({'text': 'Age < 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'upper_bound']]}, 'NCT02249520'), ({'text': 'All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (surgical sterilization or the use or barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose', 'entities': [['1', '10', 'gender'], ['49', '73', 'pregnancy'], ['83', '107', 'gender'], ['113', '158', 'contraception_consent'], ['160', '182', 'contraception_consent'], ['197', '218', 'contraception_consent'], ['233', '239', 'contraception_consent'], ['243', '288', 'contraception_consent'], ['295', '298', 'contraception_consent'], ['353', '367', 'upper_bound']]}, 'NCT01906385'), ({'text': 'Serum CK/CPK d2.5 x ULN', 'entities': [['1', '13', 'clinical_variable'], ['15', '24', 'upper_bound']]}, 'NCT02979366'), ({'text': "brain MRI (or CT if MRI contraindicated) is required for PDAC if clinically suspected by patient's symptoms or neurological exam; should patient found to have brain metastasis, treatment of brain metastasis must precede the participation in this study", 'entities': [['1', '10', 'treatment'], ['7', '10', 'treatment'], ['15', '17', 'treatment'], ['160', '176', 'cancer'], ['178', '187', 'treatment']]}, 'NCT02498613'), ({'text': 'ROS1 infustion', 'entities': [['1', '15', 'treatment']]}, 'NCT01639508'), ({'text': 'Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal', 'entities': [['1', '33', 'clinical_variable'], ['34', '80', 'clinical_variable'], ['82', '112', 'clinical_variable'], ['113', '157', 'clinical_variable'], ['162', '167', 'upper_bound'], ['168', '203', 'clinical_variable']]}, 'NCT02013492'), ({'text': 'For Part G: Have a baseline electrocardiogram (obtained from Day -14 to Day -1) with any of the following abnormal findings: ventricular arrhythmia, evidence of acute myocardial ischemia, heart block (of any degree), or QTc prolongation (defined as QTcB e450 milliseconds)', 'entities': [['29', '46', 'treatment'], ['126', '148', 'chronic_disease'], ['168', '187', 'chronic_disease'], ['189', '200', 'chronic_disease'], ['250', '254', 'clinical_variable'], ['256', '272', 'lower_bound']]}, 'NCT02057133'), ({'text': 'for women, at time of screening negative hCG pregnancy test', 'entities': [['5', '10', 'gender'], ['33', '55', 'pregnancy']]}, 'NCT00914823'), ({'text': 'Patients must not have received these therapies for 21 days or five half-lives of the drug (whichever is less) prior to the initiation of study treatment and must have full recovery from any acute clinically significant effects of these therapies', 'entities': [['39', '48', 'treatment'], ['53', '60', 'upper_bound'], ['139', '154', 'treatment']]}, 'NCT02576444'), ({'text': 'Active non-ovarian malignancy', 'entities': [['8', '30', 'cancer']]}, 'NCT00539162'), ({'text': 'Uncontrolled hypertension', 'entities': [['14', '26', 'chronic_disease']]}, 'NCT01306045'), ({'text': 'known acute stroke, intracerebral hemorrhage, intracranial mass effect, or elevated intracranial pressure within the last 30 days', 'entities': [['7', '19', 'chronic_disease'], ['21', '45', 'chronic_disease'], ['47', '71', 'chronic_disease'], ['76', '106', 'chronic_disease'], ['118', '130', 'upper_bound']]}, 'NCT03078504'), ({'text': 'Currently abstaining from consuming alcoholic beverages longer than 10 days', 'entities': [['69', '76', 'upper_bound']]}, 'NCT03099590'), ({'text': "Approximately between 5'0 and 6'4 tall", 'entities': [['23', '26', 'lower_bound'], ['31', '39', 'upper_bound']]}, 'NCT02943915'), ({'text': 'history of complicated solid organ transplant', 'entities': [['24', '46', 'treatment']]}, 'NCT03120728'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02376205'), ({'text': 'Conditions which may be negatively affected by bezafibrate treatment, such as hepatobiliary disease', 'entities': [['48', '69', 'treatment'], ['79', '100', 'chronic_disease']]}, 'NCT02481245'), ({'text': 'Prior vincristine therapy', 'entities': [['1', '26', 'treatment']]}, 'NCT02110069'), ({'text': 'Recipient of frontline multi-agent chemotherapy (for example, RCHOP, dose adjusted-REPOCH, RCHOP/RICE, RCHOP+investigational agent, etc)', 'entities': [['24', '48', 'treatment'], ['63', '68', 'treatment'], ['84', '90', 'treatment'], ['92', '102', 'treatment']]}, 'NCT02633111'), ({'text': 'for this reason and because DNA-damage response (DDR) inhibitors as well as other therapeutic agents used in this trial may have teratogenic potential', 'entities': [['83', '101', 'treatment']]}, 'NCT02567422'), ({'text': 'At least 2 weeks from prior chemotherapy or radiation therapy to time of start of treatment', 'entities': [['10', '17', 'lower_bound'], ['29', '41', 'treatment'], ['45', '62', 'treatment']]}, 'NCT02509546'), ({'text': 'Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent', 'entities': [['29', '47', 'treatment'], ['53', '68', 'treatment'], ['80', '103', 'treatment']]}, 'NCT03008408'), ({'text': 'Patients must have experienced documented, confirmed radiographic progression of disease by iRECIST, or by RECIST v1.1 (various solid tumors cohort head and neck squamous cell carcinoma, Check point inhibitor experienced group only)', 'entities': [['129', '141', 'cancer'], ['149', '186', 'cancer']]}, 'NCT02587962'), ({'text': 'breast-feeding women', 'entities': [['16', '21', 'gender']]}, 'NCT02389309'), ({'text': 'Life expectancy of e 3 months (Phase Ia, Arm A) or e 6 months (Phase Ia, Arm B and Phase Ib)', 'entities': [['1', '16', 'clinical_variable'], ['22', '30', 'lower_bound'], ['32', '47', 'clinical_variable'], ['54', '62', 'lower_bound'], ['64', '92', 'clinical_variable']]}, 'NCT02516813'), ({'text': 'Use of serotonergic antiemetics (i.e. ondansetron) in the past 2 weeks', 'entities': [['8', '32', 'treatment'], ['39', '50', 'treatment'], ['59', '71', 'upper_bound']]}, 'NCT02981173'), ({'text': 'Prior thoracic radiation therapy preventing hemithoracic pleural IMRT', 'entities': [['1', '33', 'treatment'], ['45', '70', 'treatment']]}, 'NCT00715611'), ({'text': 'Use of more than 2 g/day of acetaminophen', 'entities': [['18', '25', 'lower_bound'], ['29', '42', 'treatment']]}, 'NCT03006302'), ({'text': 'Platelets >= 75 x 10^9/L', 'entities': [['1', '10', 'clinical_variable'], ['14', '25', 'lower_bound']]}, 'NCT02070549'), ({'text': 'Administration of immunosuppressive drugs less than 2 weeks prior to first dose of ERC1671', 'entities': [['19', '42', 'treatment'], ['53', '66', 'upper_bound'], ['84', '91', 'treatment']]}, 'NCT01903330'), ({'text': 'Patients must have < grade 2 pre-existing peripheral neuropathy (per Common Terminology Criteria for Adverse Events [CTCAE])', 'entities': [['22', '29', 'upper_bound'], ['43', '64', 'chronic_disease'], ['70', '123', 'clinical_variable']]}, 'NCT02394535'), ({'text': 'No prior treatment with an aurora Kinase inhibitor (either an aurora A or pan-aurora kinase inhibitor)', 'entities': [['4', '19', 'treatment'], ['28', '51', 'treatment'], ['63', '71', 'treatment'], ['75', '102', 'treatment']]}, 'NCT02860000'), ({'text': 'Allergy to topical steroid', 'entities': [['12', '27', 'allergy_name']]}, 'NCT02573883'), ({'text': 'Other neurological diagnosis', 'entities': [['7', '19', 'chronic_disease']]}, 'NCT02428205'), ({'text': 'situ cervical cancer that has undergone potentially curative therapy', 'entities': [['1', '21', 'cancer'], ['53', '69', 'treatment']]}, 'NCT02710396'), ({'text': 'Inability to comply with study protocol due to a chronic disease, psychiatric illness, alcoholism, drug abuse, or geographic distance (as determined by investigator)', 'entities': [['50', '65', 'chronic_disease'], ['67', '86', 'chronic_disease']]}, 'NCT03090607'), ({'text': 'Participants must have either sputum cytologic atypia of mild dysplasia or greater or a history of bronchial biopsy with mild or greater dysplasia within the past 12 months', 'entities': [['100', '116', 'treatment'], ['122', '147', 'cancer'], ['159', '173', 'upper_bound']]}, 'NCT02237183'), ({'text': 'unable to carry out physical activity, including walking,due to a chronic disability or documented medical condition', 'entities': [['67', '85', 'chronic_disease']]}, 'NCT02901314'), ({'text': 'Provide an intake breath CO sample > 8 ppm', 'entities': [['19', '35', 'clinical_variable'], ['38', '43', 'lower_bound']]}, 'NCT02250534'), ({'text': 'ages 18-65', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['9', '11', 'upper_bound']]}, 'NCT03071393'), ({'text': 'Availability of archived tumor tissue for carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 or CEA) testing', 'entities': [['26', '31', 'cancer'], ['43', '117', 'treatment']]}, 'NCT02187848'), ({'text': 'participants with known hepatitis C infection must not be actively receiving treatment for the infectio', 'entities': [['25', '36', 'chronic_disease'], ['78', '87', 'treatment']]}, 'NCT01822522'), ({'text': 'documentation that the patient has evidence of measurable metastatic breast cancer that is accessible to biopsy at study entry', 'entities': [['59', '83', 'cancer'], ['106', '112', 'treatment']]}, 'NCT02236000'), ({'text': 'Karnofsky Performance Status e 50% for patients > 16 years of age', 'entities': [['1', '29', 'clinical_variable'], ['32', '35', 'lower_bound'], ['51', '59', 'lower_bound'], ['63', '66', 'age']]}, 'NCT01505569'), ({'text': 'Diagnosis of type 2 diabetes mellitus', 'entities': [['14', '38', 'chronic_disease']]}, 'NCT02522494'), ({'text': '18 year of age or older', 'entities': [['1', '8', 'lower_bound'], ['12', '15', 'age']]}, 'NCT02665962'), ({'text': 'Presence of tremors, spasm and other significant involuntary movements', 'entities': [['13', '20', 'chronic_disease'], ['22', '27', 'chronic_disease']]}, 'NCT01608438'), ({'text': 'male', 'entities': [['1', '5', 'gender']]}, 'NCT02132130'), ({'text': 'Current presence of a clinically significant major psychiatric disorder (e.g. major depressive disorder, bipolar disorder, schizophrenia, etc., according to the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV', 'entities': [['52', '72', 'chronic_disease'], ['79', '104', 'chronic_disease'], ['106', '122', 'chronic_disease'], ['124', '137', 'chronic_disease']]}, 'NCT02359864'), ({'text': 'Active and/or untreated CNS disease or non-stable brain metastases', 'entities': [['25', '36', 'chronic_disease'], ['51', '67', 'cancer']]}, 'NCT02771626'), ({'text': 'Pathologically confirmed advanced solid tumor for which standard therapy proven to provide clinical benefit does not exist or is no longer effective', 'entities': [['35', '46', 'cancer'], ['57', '73', 'treatment']]}, 'NCT02266745'), ({'text': 'Patients with thyroid disease', 'entities': [['15', '30', 'chronic_disease']]}, 'NCT03153410'), ({'text': 'Apple shaped adiposity', 'entities': [['14', '23', 'chronic_disease']]}, 'NCT03059355'), ({'text': 'Subjects requiring bone augmentation or socket grafting prior to surgery', 'entities': [['20', '56', 'treatment'], ['66', '73', 'treatment']]}, 'NCT02953392'), ({'text': 'Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia', 'entities': [['18', '42', 'chronic_disease'], ['53', '76', 'chronic_disease'], ['80', '94', 'chronic_disease'], ['107', '122', 'chronic_disease'], ['173', '184', 'chronic_disease']]}, 'NCT03008408'), ({'text': 'Estimated glomerular filtration rate (eGFR) less than 30 mL/min', 'entities': [['1', '44', 'clinical_variable'], ['55', '64', 'upper_bound']]}, 'NCT02479620'), ({'text': 'Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack within 1 year prior to randomization, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)', 'entities': [['1', '8', 'chronic_disease'], ['52', '59', 'chronic_disease'], ['96', '102', 'chronic_disease'], ['104', '129', 'chronic_disease'], ['137', '149', 'upper_bound'], ['168', '200', 'chronic_disease'], ['205', '224', 'cancer'], ['233', '244', 'cancer'], ['249', '260', 'cancer'], ['278', '283', 'chronic_disease']]}, 'NCT03093272'), ({'text': 'Presence or planned permanent (or semi-permanent) metallic structures attached to their body. (e.g., braces on teeth), which their physicians believe will interfere with the MRI of the brain', 'entities': [['175', '191', 'treatment']]}, 'NCT01389024'), ({'text': 'Age between birth and 70 years', 'entities': [['1', '4', 'age'], ['23', '31', 'upper_bound']]}, 'NCT01189786'), ({'text': 'psychiatric disorder', 'entities': [['1', '21', 'chronic_disease']]}, 'NCT02942095'), ({'text': 'all pre-natal diagnoses of any single ventricle circulation physiology (SVP)', 'entities': [['32', '77', 'chronic_disease']]}, 'NCT02766998'), ({'text': 'Prior VEGF targeted therapies for renal cell carcinoma (RCC) including adjuvant or neoadjuvant treatments', 'entities': [['1', '30', 'treatment'], ['35', '61', 'cancer'], ['72', '80', 'treatment'], ['84', '106', 'treatment']]}, 'NCT01684397'), ({'text': 'patients beyond CR1 or with primary induction failure may be without minimal residual disease', 'entities': [['17', '20', 'cancer'], ['70', '94', 'cancer']]}, 'NCT02807883'), ({'text': 'Systemic corticosteroid therapy must be at a dose of d 4 mg of dexamethasone or equivalent per day during the week prior to Day 1', 'entities': [['1', '32', 'treatment'], ['56', '60', 'upper_bound'], ['64', '77', 'treatment']]}, 'NCT01903330'), ({'text': 'Unstable angina that is not due to frequent or incessant VT', 'entities': [['1', '16', 'chronic_disease'], ['48', '60', 'treatment']]}, 'NCT01791543'), ({'text': 'cisatracurium', 'entities': [['1', '14', 'treatment']]}, 'NCT02041936'), ({'text': 'Over-expression by immunohistochemistry (IHC) with score of 3+ (in > 30% of invasive tumor cells)', 'entities': [['20', '46', 'clinical_variable'], ['70', '73', 'lower_bound'], ['86', '91', 'cancer']]}, 'NCT01494662'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02401074'), ({'text': 'Mothers must have anti-Ro and/or anti-La Ab documented in the NYU immunology laboratory (CLIA-approved), which utilizes an ELISA as well as reactivity on ELISA to at least one of three recombinant antigens (48La, 52Ro, 60Ro, JB laboratory)', 'entities': [['173', '176', 'lower_bound'], ['180', '185', 'upper_bound']]}, 'NCT01379573'), ({'text': 'COPD exacerbation within the previous 12 months defined as taking antibiotics and/or prednisone for respiratory symptoms, hospitalization or emergency department visit for respiratory illness', 'entities': [['1', '5', 'chronic_disease'], ['30', '48', 'upper_bound'], ['67', '78', 'treatment'], ['86', '96', 'treatment'], ['173', '192', 'chronic_disease']]}, 'NCT02252588'), ({'text': 'Life expectancy e 3 months', 'entities': [['1', '16', 'clinical_variable'], ['19', '27', 'lower_bound']]}, 'NCT02533674'), ({'text': 'No signs of clinically significant hearing loss', 'entities': [['36', '48', 'chronic_disease']]}, 'NCT01042522'), ({'text': 'hepatitis C ab', 'entities': [['1', '15', 'chronic_disease']]}, 'NCT01660607'), ({'text': 'History of allergic reactions to Pralatrexate or Romidepsin', 'entities': [['34', '46', 'allergy_name'], ['50', '60', 'allergy_name']]}, 'NCT01947140'), ({'text': 'Male and females', 'entities': [['1', '17', 'gender']]}, 'NCT02446210'), ({'text': 'Pathologically confirmed MCL, with documentation of a chromosome translocation t(11;14)(q13;q32) and/or overexpression of cyclin D1 in association with other relevant markers (eg, CD5, CD19, CD20, PAX5)', 'entities': [['26', '29', 'cancer']]}, 'NCT02972840'), ({'text': 'Females of childbearing potential (FCBP)', 'entities': [['1', '8', 'gender']]}, 'NCT02332850'), ({'text': 'History of malabsorption or other gastrointestinal (GI) disease that may significantly alter the absorption of LAM-002A', 'entities': [['35', '64', 'chronic_disease'], ['112', '120', 'treatment']]}, 'NCT02594384'), ({'text': 'At least 4 weeks must have elapsed since any changes to hormonal therapy', 'entities': [['10', '17', 'lower_bound'], ['57', '73', 'treatment']]}, 'NCT02217709'), ({'text': 'ECOG performance status of 3 or more', 'entities': [['1', '24', 'clinical_variable'], ['28', '29', 'lower_bound']]}, 'NCT02105766'), ({'text': 'Acute leukemia not in remission', 'entities': [['1', '15', 'cancer']]}, 'NCT02424968'), ({'text': "The patient's Endocrinologist has determined that the patient cannot be safely managed with standard medical therapy (failed) and surgery is recommended to prevent future episodes of severe hypoglycemia and preserve brain function", 'entities': [['93', '117', 'treatment'], ['131', '138', 'treatment'], ['184', '203', 'chronic_disease']]}, 'NCT02021604'), ({'text': 'unstable medical problems which may include but are not limited to immune system disorders, severe respiratory diseases, kidney or liver diseases, thyroid problems, substance abuse or dependence that would limit patients ability to follow experimental protocol (based on history and drug and alcohol questionaires) or other heart conditions', 'entities': [['10', '26', 'chronic_disease'], ['68', '91', 'chronic_disease'], ['100', '120', 'chronic_disease'], ['122', '128', 'chronic_disease'], ['132', '146', 'chronic_disease'], ['148', '164', 'chronic_disease'], ['325', '341', 'chronic_disease']]}, 'NCT02048852'), ({'text': 'Patients with breast tumors that are AR+ (e10% staining by immunohisto-chemistry)', 'entities': [['15', '28', 'cancer'], ['38', '41', 'clinical_variable'], ['44', '56', 'lower_bound'], ['60', '81', 'treatment']]}, 'NCT01990209'), ({'text': 'All patients must agree to use effective contraception while on study', 'entities': [['19', '55', 'contraception_consent']]}, 'NCT02232516'), ({'text': 'History of liver disease', 'entities': [['12', '25', 'chronic_disease']]}, 'NCT02358850'), ({'text': 'History of severe hypersensitivity reaction to any monoclonal antibody', 'entities': [['52', '71', 'allergy_name']]}, 'NCT02519322'), ({'text': 'positive serum or urine pregnancy test(s) in females of childbearing potential', 'entities': [['1', '34', 'pregnancy'], ['46', '53', 'gender']]}, 'NCT03058029'), ({'text': 'clinical axillary nodal involvement can be assessed by palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, or PET/CT scan', 'entities': [['19', '36', 'cancer'], ['56', '65', 'treatment'], ['67', '77', 'treatment'], ['79', '86', 'treatment'], ['88', '120', 'treatment'], ['122', '161', 'treatment'], ['166', '177', 'treatment']]}, 'NCT01872975'), ({'text': 'Prior therapy with any proteasome inhibitor other than bortezomib or carfilzomib', 'entities': [['1', '14', 'treatment'], ['24', '44', 'treatment'], ['56', '66', 'treatment'], ['70', '81', 'treatment']]}, 'NCT01415882'), ({'text': 'History of seizures', 'entities': [['12', '20', 'chronic_disease']]}, 'NCT02939287'), ({'text': 'above L5 with at least motor function preserved below the neurologic level', 'entities': [['7', '9', 'lower_bound']]}, 'NCT02632422'), ({'text': 'Mean arterial pressure less than 55 mmHg despite appropriate fluid resuscitation and vasopressor support', 'entities': [['1', '23', 'clinical_variable'], ['34', '41', 'upper_bound'], ['62', '81', 'treatment'], ['86', '97', 'treatment']]}, 'NCT02203019'), ({'text': 'Any other invasive cancer in the past 5 years', 'entities': [['11', '26', 'cancer'], ['34', '46', 'upper_bound']]}, 'NCT03109041'), ({'text': 'between the age of 55-64', 'entities': [['13', '16', 'age'], ['20', '22', 'lower_bound'], ['23', '25', 'upper_bound']]}, 'NCT02938130'), ({'text': 'Stage IV breast cancer', 'entities': [['1', '23', 'cancer']]}, 'NCT02763228'), ({'text': 'Eastern Cooperative Oncology Group performance status d3', 'entities': [['1', '54', 'clinical_variable'], ['56', '57', 'upper_bound']]}, 'NCT03089554'), ({'text': 'Platelets (PLT) >= 100,000 uL', 'entities': [['1', '16', 'clinical_variable'], ['20', '30', 'lower_bound']]}, 'NCT01737502'), ({'text': 'Heart transplant', 'entities': [['1', '17', 'treatment']]}, 'NCT03133793'), ({'text': 'Adolescent women/young women of childbearing potential must have a negative highly sensitive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at Screening before enrollment/randomization', 'entities': [['12', '17', 'gender'], ['68', '163', 'pregnancy']]}, 'NCT02703272'), ({'text': "Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise the patient's safety or compliance with the protocol", 'entities': [['5', '21', 'chronic_disease'], ['25', '39', 'chronic_disease']]}, 'NCT02141074'), ({'text': 'Prior history of diagnosis or treatment for serious mental illness (obsessive-compulsive disorder, schizophrenia, other psychotic disorders, bipolar disorder)', 'entities': [['31', '40', 'treatment'], ['53', '67', 'chronic_disease'], ['69', '98', 'chronic_disease'], ['100', '113', 'chronic_disease'], ['121', '140', 'chronic_disease'], ['142', '158', 'chronic_disease']]}, 'NCT02106052'), ({'text': 'ANC<2500 cells/mm3 in past 24 months', 'entities': [['1', '4', 'clinical_variable'], ['5', '19', 'upper_bound'], ['23', '37', 'upper_bound']]}, 'NCT02404155'), ({'text': 'Use of a quad tendon graft or BTB graft', 'entities': [['10', '27', 'treatment'], ['31', '40', 'treatment']]}, 'NCT02913404'), ({'text': 'No contraindications to MRI scanning with intravenous contrast', 'entities': [['25', '28', 'treatment']]}, 'NCT02514915'), ({'text': "cyclic Cushing's syndrome", 'entities': [['1', '26', 'chronic_disease']]}, 'NCT03053271'), ({'text': 'Thoracotomy', 'entities': [['1', '12', 'treatment']]}, 'NCT02020018'), ({'text': 'History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis)', 'entities': [['12', '38', 'chronic_disease'], ['46', '59', 'chronic_disease'], ['64', '82', 'chronic_disease']]}, 'NCT03072238'), ({'text': 'peripheral neuropathy', 'entities': [['1', '22', 'chronic_disease']]}, 'NCT02057133'), ({'text': 'any time within 6 months of study entry', 'entities': [['17', '25', 'upper_bound']]}, 'NCT02159027'), ({'text': 'Effective contraception is required while receiving obinutuzumab', 'entities': [['11', '24', 'contraception_consent'], ['53', '65', 'treatment']]}, 'NCT02498951'), ({'text': 'Women with pathologically demonstrated breast cancer', 'entities': [['1', '6', 'gender'], ['40', '53', 'cancer']]}, 'NCT03096418'), ({'text': 'Patients may have CNS intracranial tumor', 'entities': [['19', '41', 'cancer']]}, 'NCT02311621'), ({'text': 'Current or past non-affective psychotic disorder, Bipolar Disorder, Schizophrenia, or Schizoaffective disorder', 'entities': [['31', '49', 'chronic_disease'], ['51', '67', 'chronic_disease'], ['69', '82', 'chronic_disease'], ['87', '111', 'chronic_disease']]}, 'NCT02046330'), ({'text': 'Pediatric patients <18 years old', 'entities': [['21', '29', 'upper_bound']]}, 'NCT02679560'), ({'text': 'Serum bilirubin =< 1.5 x upper limit of normal (ULN)', 'entities': [['1', '16', 'clinical_variable'], ['20', '53', 'upper_bound']]}, 'NCT02131597'), ({'text': 'Stage IV metastatic Non Small Cell Lung Cancer', 'entities': [['1', '47', 'cancer']]}, 'NCT03035890'), ({'text': 'Alcohol use of at least 28 drinks a week if male or an average of 21 drinks per week if female and 3 drinking days a week in the 28 days prior to intake', 'entities': [['25', '27', 'lower_bound'], ['45', '49', 'gender'], ['89', '95', 'gender'], ['130', '143', 'upper_bound']]}, 'NCT02582905'), ({'text': 'History of left ventricular ejection fraction (LVEF) below institutional normal unless repeated and within institutional normal range within 90 days of study entry', 'entities': [['12', '53', 'clinical_variable'], ['142', '149', 'upper_bound']]}, 'NCT01622868'), ({'text': 'Obese BMI group: BMI 30-35 as calculated based on height and weight', 'entities': [['1', '6', 'chronic_disease'], ['7', '10', 'bmi'], ['22', '24', 'lower_bound'], ['25', '27', 'upper_bound']]}, 'NCT02402088'), ({'text': 'serum AST,ALT and alkaline phosphatase should be d5 x upper limit of normal (ULN)', 'entities': [['1', '10', 'clinical_variable'], ['11', '14', 'clinical_variable'], ['19', '39', 'clinical_variable'], ['51', '82', 'upper_bound']]}, 'NCT01099644'), ({'text': 'ongoing or active infection', 'entities': [['12', '28', 'chronic_disease']]}, 'NCT02843568'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, gastrointestinal disease limiting absorption of AZD9291 such as a malabsorption syndrome or inflammatory bowel disease or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['77', '93', 'chronic_disease'], ['107', '131', 'chronic_disease'], ['133', '148', 'chronic_disease'], ['159', '177', 'chronic_disease'], ['179', '203', 'chronic_disease'], ['227', '234', 'treatment'], ['245', '267', 'chronic_disease'], ['271', '297', 'chronic_disease'], ['301', '320', 'chronic_disease']]}, 'NCT02496663'), ({'text': 'Posterior lumbar, cervical, or thoracic (up to and including 6 vertebral levels) spine fusion with instrumentation', 'entities': [['1', '17', 'treatment'], ['19', '27', 'treatment'], ['32', '40', 'treatment'], ['82', '94', 'treatment']]}, 'NCT02376153'), ({'text': 'Myocardial infarction within the last 6 months', 'entities': [['1', '22', 'chronic_disease'], ['34', '47', 'upper_bound']]}, 'NCT02567422'), ({'text': 'More than 2 episodes of chest pain within 24 hours prior to IP administration', 'entities': [['11', '12', 'lower_bound'], ['43', '57', 'upper_bound']]}, 'NCT02832115'), ({'text': 'Symptomatic MM, based on IMWG guidelines', 'entities': [['13', '15', 'cancer']]}, 'NCT02343042'), ({'text': 'ability to ambulate without orthotics or with orthotics that do not cross the knee for more than 10 meters', 'entities': [['98', '107', 'lower_bound']]}, 'NCT02991248'), ({'text': 'Patients must have a peripheral blast count < 25,000/uL within 2 days prior to registration; (treatment with hydroxyurea and steroids is permitted to bring the countdown)', 'entities': [['22', '44', 'clinical_variable'], ['47', '56', 'upper_bound'], ['64', '76', 'upper_bound'], ['95', '134', 'treatment']]}, 'NCT01925131'), ({'text': 'Platelets > 100,000/mm^3', 'entities': [['1', '10', 'clinical_variable'], ['13', '25', 'lower_bound']]}, 'NCT03007030'), ({'text': 'Previous diagnosis of bleeding disorder(s) or current use of blood thinners/anticoagulants', 'entities': [['23', '43', 'chronic_disease'], ['62', '91', 'treatment']]}, 'NCT01785719'), ({'text': 'Spirometry in the past 6 months or on day of evaluation with a bronchodilator* response of e 12% and 200 ml improvement in FEV', 'entities': [['1', '11', 'treatment'], ['19', '32', 'lower_bound'], ['64', '88', 'clinical_variable'], ['94', '97', 'lower_bound'], ['102', '108', 'lower_bound'], ['124', '127', 'clinical_variable']]}, 'NCT02740543'), ({'text': 'postmenopausal women', 'entities': [['16', '21', 'gender']]}, 'NCT02927392'), ({'text': 'Patients must have bilirubin < 1.5 × normal', 'entities': [['20', '29', 'clinical_variable'], ['32', '44', 'upper_bound']]}, 'NCT02213497'), ({'text': 'Patients with known lupus anticoagulant or positive antiphospholipid antibody', 'entities': [['21', '40', 'chronic_disease'], ['44', '78', 'chronic_disease']]}, 'NCT02074436'), ({'text': 'Significant liver disease', 'entities': [['13', '26', 'chronic_disease']]}, 'NCT02827526'), ({'text': 'Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)', 'entities': [['24', '58', 'chronic_disease'], ['54', '57', 'chronic_disease']]}, 'NCT02446457'), ({'text': 'Conservative therapy is defined as systemic pain medications and anti-inflammatory medications, as well as physical therapy, such as massage, heating, hydrotherapy, and strengthening exercises', 'entities': [['1', '21', 'treatment'], ['36', '61', 'treatment'], ['66', '95', 'treatment'], ['108', '124', 'treatment'], ['134', '141', 'treatment'], ['143', '150', 'treatment'], ['152', '164', 'treatment'], ['170', '193', 'treatment']]}, 'NCT02291978'), ({'text': 'Failed 6 weeks of conservative treatment (conservative treatment is defined as relative rest, home exercise, physical therapy, and use of anti-inflammatory and/or analgesic medications)', 'entities': [['19', '41', 'treatment'], ['110', '126', 'treatment'], ['139', '156', 'treatment'], ['164', '185', 'treatment']]}, 'NCT02226159'), ({'text': 'Have confirmed metastatic disease to the central nervous system', 'entities': [['16', '34', 'cancer']]}, 'NCT01238120'), ({'text': '(DLCO > 50% of predicted)', 'entities': [['2', '6', 'clinical_variable'], ['9', '12', 'lower_bound']]}, 'NCT00630565'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01760655'), ({'text': 'Radiation to >= 25% of bone marrow', 'entities': [['1', '10', 'treatment'], ['17', '35', 'lower_bound']]}, 'NCT01737502'), ({'text': 'pelvic or total body irradiation', 'entities': [['1', '33', 'treatment']]}, 'NCT01421095'), ({'text': 'Must be fluent in speaking the English language', 'entities': [['9', '48', 'language_fluency']]}, 'NCT02252588'), ({'text': 'Patient Health Questionnaire-9 (PHQ-9) score of 10 or higher', 'entities': [['1', '45', 'clinical_variable'], ['49', '51', 'lower_bound']]}, 'NCT02960763'), ({'text': 'Left ventricular ejection fraction (LVEF) e55% (or the institutional lower limit of normal [LLN]) as evidenced on ECHO', 'entities': [['1', '42', 'clinical_variable'], ['44', '47', 'lower_bound'], ['115', '119', 'treatment']]}, 'NCT02433626'), ({'text': 'Patients with AML must be unlikely to benefit from recommended standard of care', 'entities': [['15', '18', 'cancer']]}, 'NCT02152956'), ({'text': 'Has a primary diagnosis of any other Axis I Disorder (determined by the Structured Diagnostic Interview for DSM; SCID) that is significantly impairing and would contraindicate participation in the present study', 'entities': [['38', '53', 'chronic_disease']]}, 'NCT02266784'), ({'text': 'organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed', 'entities': [['16', '31', 'cancer'], ['169', '185', 'treatment'], ['210', '231', 'treatment']]}, 'NCT02131597'), ({'text': 'History and Physical done within 4 weeks of enrollment', 'entities': [['34', '41', 'upper_bound']]}, 'NCT02424955'), ({'text': 'Taking more than 3 AEDs', 'entities': [['18', '19', 'lower_bound'], ['20', '24', 'treatment']]}, 'NCT02011971'), ({'text': 'Age 18 to 70 years', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound'], ['11', '19', 'upper_bound']]}, 'NCT03112824'), ({'text': '18 years or older', 'entities': [['1', '9', 'lower_bound']]}, 'NCT02905656'), ({'text': 'radiculopathy', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT03033212'), ({'text': 'are e 14 days from treatment of brain metastasis are eligible', 'entities': [['7', '14', 'lower_bound'], ['20', '29', 'treatment'], ['33', '49', 'cancer']]}, 'NCT02393794'), ({'text': 'esophageal spasm', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT01568177'), ({'text': 'willing and able to return to follow-up visits as described in treatment plan', 'entities': [['64', '73', 'treatment']]}, 'NCT02158793'), ({'text': 'Presence of CNS disease', 'entities': [['13', '24', 'chronic_disease']]}, 'NCT01059786'), ({'text': 'no serious cardiac arrhythmia requiring medication', 'entities': [['12', '30', 'chronic_disease'], ['41', '51', 'treatment']]}, 'NCT02128906'), ({'text': 'bladder carcinoma in situ', 'entities': [['1', '25', 'cancer']]}, 'NCT02237183'), ({'text': 'Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication', 'entities': [['1', '16', 'gender'], ['51', '101', 'contraception_consent'], ['138', '146', 'upper_bound'], ['176', '186', 'treatment']]}, 'NCT02977468'), ({'text': 'Subject has known history of testing positive for HIV or AIDS', 'entities': [['51', '54', 'chronic_disease'], ['58', '62', 'chronic_disease']]}, 'NCT02393794'), ({'text': 'Serum total 25(OH)D 10-50 ng/mL', 'entities': [['1', '20', 'clinical_variable'], ['21', '23', 'lower_bound'], ['24', '32', 'upper_bound']]}, 'NCT02937350'), ({'text': 'Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the participant at high risk from treatment complications', 'entities': [['139', '159', 'allergy_name'], ['255', '264', 'treatment']]}, 'NCT02091141'), ({'text': 'greater than or equal to 50,000 blasts/ L', 'entities': [['26', '42', 'lower_bound']]}, 'NCT02315612'), ({'text': "Individuals with Idiopathic Parkinson's disease (IPD)", 'entities': [['18', '54', 'chronic_disease']]}, 'NCT02265315'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02166905'), ({'text': 'Estimated creatinine clearance < 50 mL/min', 'entities': [['11', '31', 'clinical_variable'], ['34', '43', 'upper_bound']]}, 'NCT02924402'), ({'text': 'First untreated relapse after a first CR lasting less than 12 months or first relapse refractory to salvage therapy regardless of length of first CR', 'entities': [['60', '69', 'upper_bound'], ['101', '116', 'treatment']]}, 'NCT03144245'), ({'text': 'Subjects with cotinine levels greater than 500ng/mL are considered as smokers and will not be enrolled', 'entities': [['15', '30', 'clinical_variable'], ['44', '52', 'lower_bound']]}, 'NCT01429337'), ({'text': 'cardiac disease', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT02990481'), ({'text': 'Pathologic lymphadenopathy (at least five discrete nodes each >1cm in their longest dimension)', 'entities': [['12', '27', 'chronic_disease'], ['38', '42', 'lower_bound'], ['64', '67', 'lower_bound']]}, 'NCT01419561'), ({'text': 'For use of Zenith Flex: diameter >32 mm or <18 mm', 'entities': [['12', '23', 'treatment'], ['25', '33', 'clinical_variable'], ['35', '40', 'lower_bound'], ['45', '50', 'upper_bound']]}, 'NCT02050113'), ({'text': 'HIV-positive status', 'entities': [['1', '4', 'chronic_disease']]}, 'NCT02929069'), ({'text': 'diabetic neuropathy', 'entities': [['1', '20', 'chronic_disease']]}, 'NCT02864160'), ({'text': 'Pregnant or may be pregnant', 'entities': [['1', '9', 'pregnancy'], ['13', '28', 'pregnancy']]}, 'NCT02532595'), ({'text': 'Diagnosed with chronic pancreatitis', 'entities': [['16', '36', 'chronic_disease']]}, 'NCT03112759'), ({'text': 'fungal infections of nail beds', 'entities': [['1', '31', 'chronic_disease']]}, 'NCT03113695'), ({'text': 'Low Risk Myelodysplastic Syndromes (MDS)', 'entities': [['1', '35', 'chronic_disease'], ['37', '40', 'chronic_disease']]}, 'NCT02958462'), ({'text': 'Severe renal impairment (calculated creatinine clearance =< 29 cc/min)', 'entities': [['1', '24', 'chronic_disease'], ['37', '57', 'clinical_variable'], ['61', '70', 'upper_bound']]}, 'NCT03040726'), ({'text': 'Systemic infection requiring intravenous (IV) antibiotic therapy =< 14 days prior to registration', 'entities': [['1', '65', 'treatment'], ['69', '82', 'upper_bound']]}, 'NCT02860000'), ({'text': 'BMI>30', 'entities': [['1', '4', 'clinical_variable'], ['5', '7', 'lower_bound']]}, 'NCT02823379'), ({'text': 'Total bilirubin d upper limit of normal', 'entities': [['7', '16', 'clinical_variable']]}, 'NCT03093272'), ({'text': 'Systolic blood pressure > 150', 'entities': [['1', '24', 'clinical_variable'], ['27', '30', 'lower_bound']]}, 'NCT02418195'), ({'text': 'History of GI bleed', 'entities': [['12', '20', 'chronic_disease']]}, 'NCT03152409'), ({'text': 'Greater than or equal to 1 week since receipt of standard or investigational HER2- directed therapy for metastatic or recurrent disease', 'entities': [['26', '32', 'lower_bound'], ['50', '58', 'treatment'], ['62', '100', 'treatment'], ['105', '115', 'cancer']]}, 'NCT01730118'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01140087'), ({'text': 'Patients unable to tolerate venipuncture procedures for blood sampling', 'entities': [['29', '41', 'treatment']]}, 'NCT02918864'), ({'text': 'Has a diagnosis of immunodeficiency', 'entities': [['20', '36', 'chronic_disease']]}, 'NCT02446457'), ({'text': 'having an acute MI', 'entities': [['11', '19', 'chronic_disease']]}, 'NCT02750319'), ({'text': 'abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication', 'entities': [['72', '86', 'upper_bound'], ['110', '120', 'treatment']]}, 'NCT02332668'), ({'text': 'A donor who will undergo marrow harvest with general anesthesia will have a pre-anesthesia consultation prior to the collection', 'entities': [['46', '64', 'treatment']]}, 'NCT01861106'), ({'text': 'congestive heart failure', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT00065676'), ({'text': 'Duration of injury < 6-months', 'entities': [['22', '30', 'upper_bound']]}, 'NCT03029442'), ({'text': 'Current anticoagulant or anti-platelet treatment other than aspirin', 'entities': [['1', '22', 'treatment'], ['26', '49', 'treatment'], ['61', '68', 'treatment']]}, 'NCT02473250'), ({'text': 'Acute medical complication: cardiac abnormalities, skin breakdowns, uncontrolled seizures, or immunological, pulmonary/ renal/ circulatory compromise, auto-immune deficiencies, sepsis, active infection, dental caries', 'entities': [['29', '50', 'chronic_disease'], ['52', '67', 'chronic_disease'], ['69', '90', 'chronic_disease'], ['95', '108', 'chronic_disease'], ['110', '150', 'chronic_disease'], ['152', '176', 'chronic_disease'], ['178', '184', 'chronic_disease'], ['186', '202', 'chronic_disease'], ['204', '217', 'chronic_disease']]}, 'NCT01923662'), ({'text': 'Unable to tolerate apheresis procedure including placement of temporary apheresis catheter', 'entities': [['20', '29', 'treatment'], ['73', '91', 'treatment']]}, 'NCT02311621'), ({'text': 'More than 5% blasts in bone marrow', 'entities': [['11', '20', 'lower_bound']]}, 'NCT02520427'), ({'text': 'History of bariatric surgery', 'entities': [['12', '29', 'treatment']]}, 'NCT03104205'), ({'text': 'Patients with high risk factors, such as T3, Gleason 8-10 or PSA > 20ng/mL who are not considered candidates for pelvic lymph node radiation treatment', 'entities': [['42', '44', 'clinical_variable'], ['46', '53', 'clinical_variable'], ['54', '55', 'lower_bound'], ['56', '58', 'upper_bound'], ['62', '65', 'clinical_variable'], ['68', '75', 'lower_bound'], ['114', '151', 'treatment']]}, 'NCT02040610'), ({'text': 'Lactating females', 'entities': [['11', '18', 'gender']]}, 'NCT02508038'), ({'text': 'Subjects with known or clinically manifest, symptomatic CNS metastases in Dose Escalation Phase', 'entities': [['57', '71', 'cancer']]}, 'NCT02310464'), ({'text': 'Pulmonary embolism', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02503722'), ({'text': 'Meet DSM-IV criteria for alcohol abuse or dependence in the last six months', 'entities': [['61', '76', 'upper_bound']]}, 'NCT01970293'), ({'text': 'History of head injuries resulting in loss of consciousness > 10 minutes', 'entities': [['39', '60', 'clinical_variable'], ['63', '73', 'lower_bound']]}, 'NCT01614990'), ({'text': '>10 mg prednisone per day or equivalent', 'entities': [['2', '7', 'lower_bound'], ['8', '18', 'treatment']]}, 'NCT02446093'), ({'text': 'Pregnant women', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT02408406'), ({'text': 'Normal to moderate hearing loss in the low frequencies with severe to profound mid to high frequency hearing loss in the ear to be implanted', 'entities': [['20', '32', 'chronic_disease']]}, 'NCT02379819'), ({'text': 'antibiotics within 14 days of enrollment', 'entities': [['20', '27', 'upper_bound']]}, 'NCT03174834'), ({'text': 'Diagnosis of any disease for which a second or greater hematopoietic stem cell transplant is needed due to insufficient donor chimerism following hematopoietic recovery after previous HSCT', 'entities': [['56', '90', 'treatment'], ['176', '189', 'treatment']]}, 'NCT01666080'), ({'text': 'Hepatic insufficiency, bilirubin > 2.0 or transaminases > 3.0 x normal', 'entities': [['1', '22', 'chronic_disease'], ['24', '33', 'clinical_variable'], ['36', '39', 'lower_bound'], ['43', '56', 'clinical_variable'], ['59', '71', 'lower_bound']]}, 'NCT02287558'), ({'text': 'Severe hepatic impairment', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT03074240'), ({'text': 'if only one (1)value is within this range, the other value should not be e126mg/dL (e7.0mmol/L) and HbA1c should be e5.7% (e39 mmol/mol) and d6.4%(d46 mmol/mol)', 'entities': [['75', '83', 'lower_bound'], ['86', '95', 'lower_bound'], ['101', '106', 'clinical_variable'], ['118', '122', 'lower_bound'], ['125', '136', 'lower_bound'], ['143', '147', 'upper_bound'], ['149', '160', 'upper_bound']]}, 'NCT03058029'), ({'text': 'Sensitized recipients with high levels (50%) of panel-reactive human leukocyte antigen (HLA) antibodies', 'entities': [['64', '93', 'clinical_variable']]}, 'NCT01459107'), ({'text': 'Severe hypertension (diastolic BP > 100 on medication)', 'entities': [['1', '20', 'chronic_disease'], ['22', '34', 'clinical_variable'], ['37', '40', 'lower_bound']]}, 'NCT02923011'), ({'text': 'previous GI surgery resulting in disturbed gut function due to of loss of bowel or altered anatomy', 'entities': [['1', '20', 'treatment']]}, 'NCT03028831'), ({'text': 'Participants with self-reported history of nicotine use but who report no use within at least 3 months prior to study enrollment will be eligible for the study if they have a negative urine dipcard test for nicotine/cotinine at screening', 'entities': [['95', '109', 'lower_bound']]}, 'NCT02815917'), ({'text': 'Serum creatinine in normal range for age', 'entities': [['1', '17', 'clinical_variable'], ['38', '41', 'age']]}, 'NCT01011777'), ({'text': 'Subjects must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the investigator, would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy', 'entities': [['29', '51', 'treatment'], ['74', '79', 'cancer'], ['233', '257', 'treatment']]}, 'NCT02576431'), ({'text': 'Elevated depressive symptoms based on screening with the Edinburgh Postnatal Depression Scale (EPDS) with score > 9', 'entities': [['58', '101', 'clinical_variable'], ['115', '116', 'lower_bound']]}, 'NCT03011801'), ({'text': '<400 mg/dL without laboratory evidence of diabetic ketoacidosis', 'entities': [['2', '11', 'upper_bound'], ['43', '64', 'chronic_disease']]}, 'NCT02408120'), ({'text': 'Any contraindication that would prevent the patient from being treated with the standard multimodal postoperative pain management regimen History of infection of surgical knee', 'entities': [['90', '130', 'treatment']]}, 'NCT02219581'), ({'text': 'subjects with a history of completely resected non-melanomatous skin carcinoma, successfully treated in situ carcinoma, or successfully treated bladder cancer are eligible', 'entities': [['48', '79', 'cancer'], ['102', '119', 'cancer'], ['145', '159', 'cancer']]}, 'NCT01532687'), ({'text': 'Uncontrolled infection', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02162420'), ({'text': 'Any confirmed evidence of hepatitis B or C infection', 'entities': [['27', '53', 'chronic_disease']]}, 'NCT02776761'), ({'text': 'Tumor with known or expected RAS/RAF/MEK/ERK pathway involvement', 'entities': [['1', '6', 'cancer']]}, 'NCT02639546'), ({'text': 'Patients unable to or unwilling to reliably participate in telephone followup', 'entities': [['60', '78', 'technology_access']]}, 'NCT01275716'), ({'text': 'within normal institutional limits OR creatinine clearance: > 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal', 'entities': [['39', '59', 'clinical_variable'], ['63', '80', 'lower_bound'], ['99', '116', 'clinical_variable']]}, 'NCT01835626'), ({'text': 'Patients can receive chemoradiotherapy preoperatively prior to surgical resection or as definitive/primary chemoradiotherapy', 'entities': [['22', '82', 'treatment'], ['89', '125', 'treatment']]}, 'NCT02027948'), ({'text': 'Calculated GFR e 55 mL/min', 'entities': [['1', '15', 'clinical_variable'], ['18', '27', 'lower_bound']]}, 'NCT02592707'), ({'text': 'Creatinine - < 2X institution upper limit of normal', 'entities': [['1', '11', 'clinical_variable'], ['16', '52', 'upper_bound']]}, 'NCT02311361'), ({'text': 'International normalized ratio (INR) =< 1.5 x institutional ULN', 'entities': [['1', '37', 'clinical_variable'], ['41', '64', 'upper_bound']]}, 'NCT02070549'), ({'text': 'must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugs', 'entities': [['26', '38', 'treatment'], ['42', '49', 'lower_bound'], ['53', '65', 'treatment'], ['69', '82', 'lower_bound']]}, 'NCT02520778'), ({'text': 'Untreated clinically significant coronary artery disease requiring revascularization', 'entities': [['34', '57', 'chronic_disease'], ['68', '85', 'treatment']]}, 'NCT02000115'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'upper_bound'], ['68', '77', 'clinical_variable'], ['81', '84', 'lower_bound']]}, 'NCT02387905'), ({'text': 'The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment', 'entities': [['26', '41', 'treatment'], ['32', '41', 'treatment'], ['49', '80', 'treatment'], ['86', '102', 'treatment'], ['114', '159', 'treatment'], ['168', '175', 'upper_bound']]}, 'NCT02132598'), ({'text': 'Active sinusitis', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT03014687'), ({'text': 'Lean (not overweight or obese) will be defined as a body mass index (BMI) (kg/m2) less than the 85th percentile specific for age and gender, overweight will be defined as a BMI between the 85th and 95th percentiles, and obesity will be defined as a BMI greater than the 95th percentile', 'entities': [['53', '68', 'clinical_variable'], ['70', '73', 'clinical_variable'], ['97', '101', 'lower_bound'], ['97', '112', 'upper_bound'], ['126', '129', 'age'], ['199', '214', 'lower_bound'], ['199', '215', 'upper_bound'], ['221', '228', 'chronic_disease']]}, 'NCT01967849'), ({'text': 'Molecular evidence of KSHV in whole blood, confirmed by testing at Focus Laboratories, CA (HHV-8 Quantitative PCR, Focus Unit Code 45700)', 'entities': [['23', '27', 'chronic_disease']]}, 'NCT01419561'), ({'text': 'over 90 years of age', 'entities': [['6', '14', 'upper_bound'], ['18', '21', 'age']]}, 'NCT03080142'), ({'text': 'Have Wi-Fi high speed internet', 'entities': [['6', '31', 'technology_access']]}, 'NCT03104205'), ({'text': 'Clinical status at enrollment to allow tapering of steroids equal to or less than 0.5 mg/kg/day of prednisone', 'entities': [['52', '60', 'treatment'], ['83', '96', 'upper_bound'], ['100', '110', 'treatment']]}, 'NCT02210078'), ({'text': 'Women of childbearing potential', 'entities': [['1', '6', 'gender']]}, 'NCT02436408'), ({'text': 'Patients 18 years or older', 'entities': [['10', '18', 'lower_bound']]}, 'NCT02588027'), ({'text': 'female', 'entities': [['1', '7', 'gender']]}, 'NCT02551679'), ({'text': 'Prostate-specific antigen < or = 20 ng/ml', 'entities': [['1', '26', 'clinical_variable'], ['34', '42', 'upper_bound']]}, 'NCT01045148'), ({'text': 'serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal', 'entities': [['1', '46', 'clinical_variable'], ['50', '91', 'upper_bound']]}, 'NCT02272998'), ({'text': 'Any movement disorders with a total score higher than 6 on SAS scale, or more than 2 on any items of the AIMS scale', 'entities': [['5', '23', 'chronic_disease'], ['55', '56', 'lower_bound'], ['60', '69', 'clinical_variable'], ['84', '85', 'lower_bound'], ['106', '116', 'clinical_variable']]}, 'NCT02261519'), ({'text': 'Patients with an identified familial hyperlipidemia disorder', 'entities': [['29', '61', 'chronic_disease']]}, 'NCT01553071'), ({'text': 'History of major surgery', 'entities': [['18', '25', 'treatment']]}, 'NCT01822522'), ({'text': 'liver transplant', 'entities': [['1', '17', 'treatment']]}, 'NCT03114020'), ({'text': 'Previous unknown bypass grafts', 'entities': [['18', '31', 'treatment']]}, 'NCT02832115'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT01631318'), ({'text': 'Clinically significant, unstable physical illness (e.g., hematologic, hepatic or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance)', 'entities': [['34', '50', 'chronic_disease'], ['58', '69', 'chronic_disease'], ['71', '78', 'chronic_disease'], ['82', '101', 'chronic_disease'], ['108', '122', 'chronic_disease'], ['124', '133', 'chronic_disease'], ['135', '151', 'chronic_disease'], ['153', '162', 'chronic_disease'], ['164', '176', 'chronic_disease'], ['178', '188', 'chronic_disease'], ['190', '200', 'chronic_disease'], ['205', '226', 'chronic_disease']]}, 'NCT02354703'), ({'text': 'adenocarcinoma at either MSKCC or a participating site (biopsy may be performed at other institutions but slides must be confirmed at MSKCC or a participating site, as is routine care at our institution)', 'entities': [['1', '15', 'cancer']]}, 'NCT01970306'), ({'text': 'tumors of the GC are defined as originating within 5 cm of the GEJ', 'entities': [['1', '17', 'cancer'], ['52', '56', 'upper_bound']]}, 'NCT02037048'), ({'text': 'Cohort 1: HIV-1 infected adolescents (12 to < 18 years of age and screening weight e 35 kg) who are virologically suppressed for e 6 months prior to screening', 'entities': [['11', '16', 'chronic_disease'], ['39', '41', 'lower_bound'], ['47', '55', 'upper_bound'], ['59', '62', 'age'], ['67', '83', 'clinical_variable'], ['86', '91', 'lower_bound'], ['132', '146', 'lower_bound']]}, 'NCT02881320'), ({'text': 'Terminal medical condition', 'entities': [['10', '27', 'chronic_disease']]}, 'NCT02522494'), ({'text': "Total bilirubin =< 1.5 x the upper limit of normal unless considered due to Gilbert's syndrome", 'entities': [['1', '16', 'clinical_variable'], ['20', '51', 'upper_bound'], ['77', '95', 'chronic_disease']]}, 'NCT02530034'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active major infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['77', '99', 'chronic_disease'], ['101', '125', 'chronic_disease'], ['130', '167', 'chronic_disease']]}, 'NCT02122185'), ({'text': 'The last dose of bevacizumab must have been administered at least 6 weeks prior to liver resection', 'entities': [['18', '29', 'treatment'], ['67', '80', 'lower_bound'], ['84', '99', 'treatment']]}, 'NCT02172651'), ({'text': 'Iliac artery distal fixation site <10 mm in length', 'entities': [['36', '41', 'upper_bound'], ['45', '51', 'lower_bound']]}, 'NCT02050113'), ({'text': 'Age 18 years old', 'entities': [['1', '4', 'age'], ['5', '13', 'upper_bound']]}, 'NCT02013778'), ({'text': 'Part 1 (Dose Escalation): Diagnosis of B-cell DLBCL, FL, MCL, HL, CLL/SLL or MM as documented by medical records', 'entities': [['40', '52', 'chronic_disease'], ['54', '56', 'chronic_disease'], ['58', '61', 'chronic_disease'], ['63', '65', 'chronic_disease'], ['67', '74', 'chronic_disease'], ['78', '80', 'chronic_disease']]}, 'NCT02931110'), ({'text': 'Female patients', 'entities': [['1', '16', 'gender']]}, 'NCT02339922'), ({'text': 'If it again shows 1+ protein, the patient is excluded until a 24-hr urine <300mg/24hr or p/c ratio is <0.3', 'entities': [['63', '68', 'upper_bound'], ['69', '74', 'clinical_variable'], ['76', '86', 'upper_bound'], ['90', '99', 'clinical_variable'], ['104', '107', 'upper_bound']]}, 'NCT02299414'), ({'text': '(GFR can also be used in place of creatinine or CrCl) e60 mL/min for subject with creatinine levels > 1.5 X institutional ULN Hepatic', 'entities': [['2', '5', 'clinical_variable'], ['35', '45', 'clinical_variable'], ['49', '53', 'clinical_variable'], ['56', '65', 'lower_bound'], ['83', '100', 'clinical_variable'], ['103', '126', 'lower_bound']]}, 'NCT02407171'), ({'text': 'History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization', 'entities': [['12', '36', 'chronic_disease'], ['48', '69', 'chronic_disease'], ['74', '89', 'chronic_disease'], ['92', '112', 'treatment'], ['117', '125', 'treatment'], ['133', '147', 'upper_bound']]}, 'NCT02070549'), ({'text': 'received a live vaccine within 4 weeks prior to or after any dose of MK-3475 (exception: inactivated flu vaccines)', 'entities': [['12', '24', 'treatment'], ['32', '45', 'upper_bound'], ['70', '77', 'treatment'], ['90', '114', 'treatment']]}, 'NCT01876511'), ({'text': 'Clinically significant cerebrovascular disease including cortical infarct, strategically located subcortical gray matter or extensive white matter abnormalities', 'entities': [['24', '47', 'chronic_disease']]}, 'NCT02614365'), ({'text': '22 years of age or older', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT03026816'), ({'text': 'Uncontrolled illness including ongoing or active infection', 'entities': [['14', '21', 'chronic_disease'], ['50', '59', 'chronic_disease']]}, 'NCT02094794'), ({'text': 'Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', 'entities': [['77', '93', 'chronic_disease'], ['107', '131', 'chronic_disease'], ['133', '157', 'chronic_disease'], ['159', '177', 'chronic_disease'], ['182', '219', 'chronic_disease']]}, 'NCT01905046'), ({'text': 'ECOG 0-1', 'entities': [['1', '5', 'clinical_variable'], ['6', '7', 'lower_bound'], ['8', '9', 'upper_bound']]}, 'NCT02873598'), ({'text': 'be treatment naive for 3rd generation EGFR-TKI (CO-1686 and osimertinib [AZD9291]) and mTOR inhibitors', 'entities': [['4', '13', 'treatment'], ['39', '47', 'treatment'], ['49', '56', 'treatment'], ['61', '82', 'treatment'], ['88', '103', 'treatment']]}, 'NCT02503722'), ({'text': 'Children who attend facilities that separate children by age and minimize opportunities for transmission of virus through direct physical or aerosol contact are acceptable', 'entities': [['58', '61', 'age']]}, 'NCT01893554'), ({'text': '>0.1% residual cells in the blast gate with immune phenotype of original leukemic clone', 'entities': [['2', '6', 'lower_bound'], ['7', '21', 'clinical_variable']]}, 'NCT00357565'), ({'text': 'tumors that encase any major blood vessel (carotid, jugular, vertebral)', 'entities': [['1', '7', 'cancer']]}, 'NCT02085941'), ({'text': 'A family history of schizophrenia or schizoaffective disorder (first or second degree relatives), or bipolar disorder type 1 (first degree relatives)', 'entities': [['21', '34', 'chronic_disease'], ['38', '62', 'chronic_disease'], ['102', '125', 'chronic_disease']]}, 'NCT02061293'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02990481'), ({'text': 'Have completed previous WEE vaccine study as a nonresponder (PRNT80 < 1:40)', 'entities': [['25', '42', 'treatment'], ['62', '68', 'clinical_variable'], ['71', '75', 'upper_bound']]}, 'NCT02466750'), ({'text': 'their families/caregivers that are scheduled for outpatient surgical intervention in the division of pediatric surgery', 'entities': [['102', '119', 'treatment']]}, 'NCT03075059'), ({'text': 'Contraindications for MR exam, i.e., no claustrophobia, no paramagnetic metal implants, able to fit in the MRI machine comfortably', 'entities': [['41', '55', 'chronic_disease'], ['60', '87', 'treatment']]}, 'NCT02440815'), ({'text': 'hypertriglyceridemia or hypofibrinogenemia', 'entities': [['1', '21', 'chronic_disease'], ['25', '43', 'chronic_disease']]}, 'NCT02400463'), ({'text': 'Able to follow verbal and written instructions in English', 'entities': [['1', '58', 'language_fluency']]}, 'NCT02964182'), ({'text': 'Patient with history of focal neurological deficits (with the exception of vibratory peripheral neuropathy', 'entities': [['25', '52', 'chronic_disease'], ['76', '107', 'chronic_disease']]}, 'NCT02359864'), ({'text': 'vasculitis', 'entities': [['1', '11', 'chronic_disease']]}, 'NCT02312596'), ({'text': 'creatinine (more than 3 times normal values)', 'entities': [['1', '11', 'clinical_variable'], ['23', '44', 'lower_bound']]}, 'NCT01269034'), ({'text': 'Any hemorrhage or bleeding event e NCI CTCAE Grade 3 within 4 weeks prior to start of study medication', 'entities': [['5', '15', 'clinical_variable'], ['19', '33', 'clinical_variable'], ['46', '53', 'lower_bound'], ['61', '74', 'upper_bound'], ['87', '103', 'treatment']]}, 'NCT02459119'), ({'text': 'Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (or =< 5 x ULN if liver metastases [mets])', 'entities': [['1', '33', 'clinical_variable'], ['35', '81', 'clinical_variable'], ['87', '117', 'treatment'], ['119', '163', 'treatment'], ['168', '177', 'upper_bound'], ['170', '177', 'upper_bound'], ['196', '220', 'cancer']]}, 'NCT02286687'), ({'text': 'Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) starting 28 days prior to starting the study until at least 90 days following discontinuation of the trial therapy', 'entities': [['1', '6', 'gender'], ['3', '6', 'gender'], ['47', '82', 'contraception_consent'], ['84', '92', 'contraception_consent'], ['96', '127', 'contraception_consent'], ['129', '139', 'contraception_consent'], ['150', '163', 'lower_bound'], ['201', '208', 'lower_bound'], ['248', '255', 'treatment']]}, 'NCT02101944'), ({'text': 'Sexually active males not committing to birth control during the course of the study (except if their partner is not of childbearing potential)', 'entities': [['17', '22', 'gender']]}, 'NCT02496585'), ({'text': "Subjects with known Dementia, Parkinson's disease, or other neurodegenerative disorder", 'entities': [['21', '29', 'chronic_disease'], ['31', '50', 'chronic_disease'], ['61', '87', 'chronic_disease']]}, 'NCT03019133'), ({'text': 'Willing to comply with extensive post-transplant rehabilitation for a minimum of two years', 'entities': [['24', '64', 'treatment'], ['82', '91', 'lower_bound']]}, 'NCT01293214'), ({'text': 'Agree to pre and post-treatment tumor biopsies', 'entities': [['10', '47', 'treatment']]}, 'NCT02584647'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02106650'), ({'text': 'Patients with acutely active or chronic infections', 'entities': [['41', '51', 'chronic_disease']]}, 'NCT02245841'), ({'text': 'Have not recovered to d Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs)', 'entities': [['25', '32', 'upper_bound'], ['56', '77', 'treatment']]}, 'NCT02730481'), ({'text': 'Positive pregnancy test', 'entities': [['1', '24', 'pregnancy']]}, 'NCT01422746'), ({'text': 'Percutaneous contraceptive patches', 'entities': [['1', '35', 'contraception_consent']]}, 'NCT01532687'), ({'text': 'Age >=50 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT03149783'), ({'text': 'Previous (within 6 months) or current use of medication(s) prescribed primarily for weight loss (refer to appendix material for comprehensive list)', 'entities': [['18', '26', 'upper_bound']]}, 'NCT02496611'), ({'text': 'Concomitant use of CYP3A4 inhibitors', 'entities': [['20', '37', 'treatment']]}, 'NCT01908777'), ({'text': 'high dose of any beta-blockers (greater than 100 mg daily of metoprolol, or equivalent)', 'entities': [['18', '31', 'treatment'], ['46', '52', 'lower_bound'], ['62', '72', 'treatment']]}, 'NCT02053246'), ({'text': 'Patient has signed the informed consent document agreeing to the use of the study drug, domperidone', 'entities': [['90', '100', 'treatment']]}, 'NCT01696734'), ({'text': 'Has received prior therapy with PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways) within 3 months', 'entities': [['14', '37', 'treatment'], ['39', '49', 'treatment'], ['51', '61', 'treatment'], ['63', '73', 'treatment'], ['78', '144', 'treatment'], ['136', '144', 'treatment'], ['156', '166', 'treatment'], ['273', '281', 'treatment']]}, 'NCT02411656'), ({'text': 'If cytokine levels are unknown at the time of study enrollment', 'entities': [['4', '19', 'clinical_variable']]}, 'NCT02007239'), ({'text': 'Subjects on full dose anticoagulants must be on a stable regimen of warfarin or low molecular weight heparin (LMWH) for at least two weeks', 'entities': [['23', '37', 'treatment'], ['69', '77', 'treatment'], ['81', '116', 'treatment'], ['130', '139', 'lower_bound']]}, 'NCT02365766'), ({'text': 'ECOG performance status of 0 or 1', 'entities': [['1', '24', 'clinical_variable'], ['28', '29', 'lower_bound'], ['33', '34', 'upper_bound']]}, 'NCT02584309'), ({'text': 'Pregnant or nursing women or unwillingness for subject with childbearing potential to use contraception during the first year of the study', 'entities': [['1', '9', 'pregnancy'], ['21', '26', 'gender'], ['30', '104', 'contraception_consent']]}, 'NCT02161380'), ({'text': 'High risk for poor compliance with therapy or follow-up as assessed by investigator', 'entities': [['36', '43', 'treatment']]}, 'NCT00975520'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01690468'), ({'text': 'Currently have severe renal impairment', 'entities': [['16', '39', 'chronic_disease']]}, 'NCT02589340'), ({'text': 'Uncontrolled, symptomatic, intercurrent illness including but not limited to infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the subject', 'entities': [['28', '48', 'chronic_disease'], ['78', '87', 'chronic_disease'], ['89', '113', 'chronic_disease'], ['115', '139', 'chronic_disease'], ['141', '159', 'chronic_disease'], ['161', '180', 'chronic_disease'], ['185', '202', 'chronic_disease']]}, 'NCT02315612'), ({'text': 'New pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within 2 months of study enrollment', 'entities': [['5', '23', 'chronic_disease'], ['35', '62', 'chronic_disease'], ['67', '89', 'chronic_disease'], ['97', '105', 'upper_bound']]}, 'NCT03006302'), ({'text': 'Hemoglobin >= 9 g/dL (within 1 week of study entry)', 'entities': [['1', '11', 'clinical_variable'], ['15', '21', 'lower_bound'], ['30', '36', 'upper_bound']]}, 'NCT01822522'), ({'text': 'more than 6 months prior to enrollment may be considered for protocol participation', 'entities': [['11', '25', 'lower_bound']]}, 'NCT02008656'), ({'text': 'INR < 1.5 times ULN, or if on warfarin, can safely transition off for biopsy', 'entities': [['1', '4', 'clinical_variable'], ['7', '20', 'upper_bound'], ['31', '39', 'treatment'], ['71', '77', 'treatment']]}, 'NCT02955394'), ({'text': 'Receipt of > 6 units of blood', 'entities': [['14', '21', 'lower_bound'], ['25', '30', 'clinical_variable']]}, 'NCT02582957'), ({'text': 'Confirmed germline BRCA1 or BRCA2 mutation, regardless of subtype of breast cancer', 'entities': [['70', '83', 'cancer']]}, 'NCT02393794'), ({'text': 'abnormal serum free light chain ratio (<0.26 or >1.65)', 'entities': [['1', '38', 'clinical_variable'], ['41', '45', 'upper_bound'], ['50', '54', 'lower_bound']]}, 'NCT02332850'), ({'text': 'Allogeneic stem cell transplant within 6 months', 'entities': [['1', '32', 'treatment'], ['40', '48', 'upper_bound']]}, 'NCT02493530'), ({'text': 'Received IPs within 14 days or 5 half-lives of the first study dosing day, whichever is longer', 'entities': [['10', '13', 'treatment'], ['21', '28', 'upper_bound'], ['32', '44', 'upper_bound']]}, 'NCT02730481'), ({'text': 'Any live vaccinations within 30 days prior to study drug administration except for the influenza vaccine', 'entities': [['5', '22', 'treatment'], ['30', '43', 'upper_bound'], ['88', '105', 'treatment']]}, 'NCT02413047'), ({'text': 'Normal WBC (> 3000/mm3)', 'entities': [['1', '11', 'clinical_variable'], ['15', '23', 'lower_bound']]}, 'NCT02133196'), ({'text': 'quantiferon testing done within three months prior to enrollment or had latent tuberculosis (TB) but has completed prophylactic anti-TB treatment', 'entities': [['33', '51', 'upper_bound'], ['80', '97', 'chronic_disease'], ['129', '146', 'treatment']]}, 'NCT02911116'), ({'text': 'Patients who are concurrently receiving or requiring any of the following agents, which may increase the risk for mithramycin related toxicities, such as hemorrhage', 'entities': [['115', '126', 'treatment'], ['155', '165', 'chronic_disease']]}, 'NCT01624090'), ({'text': 'Subjects <18 or >80 years of age', 'entities': [['11', '13', 'upper_bound'], ['18', '26', 'lower_bound'], ['30', '33', 'age']]}, 'NCT01585402'), ({'text': 'Previous radioimmunotherapy', 'entities': [['10', '28', 'treatment']]}, 'NCT02454010'), ({'text': 'have a diagnosis of ASD', 'entities': [['21', '24', 'chronic_disease']]}, 'NCT03015272'), ({'text': 'Adequate hemostatic function as determined by PT, INR and aPTT < 1.5X ULN (unless on therapeutic coagulation, in which case the adequate level of anticoagulation will be determined by the investigator)', 'entities': [['47', '49', 'clinical_variable'], ['51', '54', 'clinical_variable'], ['59', '63', 'clinical_variable'], ['66', '74', 'upper_bound']]}, 'NCT02913430'), ({'text': 'Meets DSM-V criteria for current Alcohol Use Disorder', 'entities': [['34', '54', 'chronic_disease']]}, 'NCT02316574'), ({'text': 'Proteinuria >1 g/day or > 0.5 g/day if diabetic', 'entities': [['1', '12', 'clinical_variable'], ['14', '21', 'lower_bound'], ['27', '36', 'lower_bound'], ['40', '48', 'chronic_disease']]}, 'NCT02213068'), ({'text': 'Singleton pregnant women', 'entities': [['1', '19', 'pregnancy'], ['20', '25', 'gender']]}, 'NCT03052270'), ({'text': 'Negative serum pregnancy test and using medically acceptable form of contraception if of child bearing potential', 'entities': [['1', '25', 'pregnancy'], ['35', '83', 'contraception_consent']]}, 'NCT03113825'), ({'text': 'Subjects must not have any history of Bipolar Disease', 'entities': [['39', '54', 'chronic_disease']]}, 'NCT00926237'), ({'text': '<= 17.85 years at the time of enrollment', 'entities': [['4', '15', 'upper_bound']]}, 'NCT01666769'), ({'text': 'History of prior pelvic radiation therapy', 'entities': [['12', '42', 'treatment']]}, 'NCT02177292'), ({'text': 'The washout period must have been completed prior to the start of neratinib if the patient was taking any of these agents', 'entities': [['67', '76', 'treatment']]}, 'NCT01670877'), ({'text': 'Receiving Chemotherapy', 'entities': [['11', '23', 'treatment']]}, 'NCT02442635'), ({'text': 'chronic obstructive lung disease', 'entities': [['1', '33', 'chronic_disease']]}, 'NCT02473250'), ({'text': 'Have a Karnofsky Performance Status Score of 60 or above', 'entities': [['8', '42', 'clinical_variable'], ['46', '48', 'lower_bound']]}, 'NCT02442635'), ({'text': 'Aplastic anemia', 'entities': [['1', '16', 'chronic_disease']]}, 'NCT01810588'), ({'text': 'Concurrent participation in other experimental trials for motor dysfunction treatment', 'entities': [['59', '86', 'treatment']]}, 'NCT02631850'), ({'text': "Participant's medical screening clears s/he for allogeneic transplantation as per current institutional SOP based on standards of foundation for accreditation of cellular therapy and stem cell transplantation (FACT)", 'entities': [['49', '75', 'treatment'], ['163', '179', 'treatment'], ['184', '209', 'treatment']]}, 'NCT02162511'), ({'text': 'Performance status >70', 'entities': [['1', '19', 'clinical_variable'], ['21', '23', 'lower_bound']]}, 'NCT02566395'), ({'text': 'brain metastases', 'entities': [['1', '17', 'cancer']]}, 'NCT02921022'), ({'text': 'Distinguished Spanish language fluency by Oral Proficiency testing Received professional training for a health-related profession in a Spanish-speaking country', 'entities': [['15', '39', 'language_fluency'], ['136', '152', 'language_fluency']]}, 'NCT02864160'), ({'text': 'Severe underlying chronic illness or disease (other than breast cancer)', 'entities': [['1', '45', 'chronic_disease'], ['58', '71', 'cancer']]}, 'NCT02949726'), ({'text': 'but the adolescent must be on a stable dosage for 2 months for SSRI or 1 month for benzodiazepine prior to consenting to the study. The type, dosage and frequency of medication will be monitored at all major study assessment points, but subsequent changes will not incur exclusion from the investigation', 'entities': [['51', '59', 'upper_bound'], ['64', '68', 'treatment'], ['72', '79', 'upper_bound'], ['84', '98', 'treatment'], ['167', '177', 'treatment']]}, 'NCT02567266'), ({'text': 'neuromuscular or neurosensory deficit', 'entities': [['1', '14', 'chronic_disease'], ['18', '38', 'chronic_disease']]}, 'NCT02056470'), ({'text': 'Colon cancer stages I-II and IV or Rectal cancer stage I or IV', 'entities': [['1', '32', 'cancer'], ['36', '63', 'cancer']]}, 'NCT02603757'), ({'text': 'Absolute Neutrophil Count > 1,000/mcL', 'entities': [['1', '26', 'clinical_variable'], ['29', '38', 'lower_bound']]}, 'NCT03179995'), ({'text': 'Currently receiving any investigational agents or registration on another therapy based trial', 'entities': [['25', '47', 'treatment'], ['75', '82', 'treatment']]}, 'NCT02549833'), ({'text': 'Chronic use of NSAIDs (nonsteroidal anti-inflammatory drugs) aspirin or omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)', 'entities': [['16', '69', 'treatment'], ['73', '112', 'treatment'], ['124', '136', 'upper_bound'], ['174', '192', 'lower_bound']]}, 'NCT02538484'), ({'text': "not a certified or Master's level social worker or nurse with an RN and at least two years' experience working with older adults and their family members, or other professional with at last two years' experience working with older adults and their family members (to be decided by the PIs)", 'entities': [['82', '92', 'lower_bound'], ['186', '201', 'upper_bound']]}, 'NCT02347202'), ({'text': 'Chemotherapy', 'entities': [['1', '13', 'treatment']]}, 'NCT02176161'), ({'text': "Neuro-muscular disorder (ie: Parkinson's)", 'entities': [['1', '24', 'chronic_disease'], ['30', '41', 'chronic_disease']]}, 'NCT01697865'), ({'text': 'DLCO (Diffusing Capacity of the Lung for Carbon Monoxide ) e45% of predicted corrected for hemoglobin, FEV-1 (forced expiratory volume at 1 second e50% of predicted', 'entities': [['1', '59', 'clinical_variable'], ['61', '64', 'lower_bound'], ['104', '147', 'clinical_variable'], ['149', '152', 'lower_bound']]}, 'NCT02566304'), ({'text': 'Children less than 36 months (3 years) of age at time of definitive surgery (for histopathologic diagnosis) who have high risk Medulloblastoma', 'entities': [['20', '39', 'upper_bound'], ['43', '46', 'age'], ['69', '76', 'treatment'], ['128', '143', 'cancer']]}, 'NCT01505569'), ({'text': 'This value must be obtained within two weeks before protocol entry', 'entities': [['36', '45', 'upper_bound']]}, 'NCT02106988'), ({'text': 'Prior diagnosis of intrinsic renal diseases including renal artery stenosis of > 50%', 'entities': [['20', '44', 'chronic_disease'], ['55', '76', 'clinical_variable'], ['82', '85', 'lower_bound']]}, 'NCT01970176'), ({'text': 'Based on screening computed tomography angiography performed within 90 days prior to study intervention as confirmed by the core lab', 'entities': [['20', '51', 'treatment'], ['69', '82', 'upper_bound']]}, 'NCT02513797'), ({'text': 'Treatment-related leukemia', 'entities': [['1', '10', 'treatment'], ['19', '27', 'cancer']]}, 'NCT02181478'), ({'text': 'Patient may not be pregnant or breastfeeding', 'entities': [['13', '28', 'pregnancy']]}, 'NCT01886105'), ({'text': 'scheduled for a primary or repeat cesarean section', 'entities': [['17', '51', 'treatment']]}, 'NCT02402907'), ({'text': 'The FDA recommends avoiding LPV/r in infants less than 14 days of age or less than 42 weeks postmenstrual age', 'entities': [['56', '63', 'upper_bound'], ['67', '70', 'age'], ['84', '92', 'upper_bound']]}, 'NCT02140255'), ({'text': 'Cardiac: ejection fraction > 45%', 'entities': [['1', '27', 'clinical_variable'], ['30', '33', 'lower_bound']]}, 'NCT00167219'), ({'text': 'are pregnant', 'entities': [['1', '13', 'pregnancy']]}, 'NCT02342327'), ({'text': 'Confirmed cutaneous KS/oral lesions with or without edema and suspected non-cutaneous KS due to clinical symptomology or confirmed non-cutaneous KS lesion(s)', 'entities': [['11', '23', 'cancer']]}, 'NCT03157167'), ({'text': 'At least 4 weeks must have lapsed since major surgery (e.g., laparotomy, laparoscopy, thoracotomy, video assisted thoracoscopy) prior to study treatment initiation', 'entities': [['10', '17', 'lower_bound'], ['41', '54', 'treatment'], ['62', '72', 'treatment'], ['74', '85', 'treatment'], ['87', '98', 'treatment'], ['100', '127', 'treatment'], ['138', '153', 'treatment']]}, 'NCT02269293'), ({'text': 'Medical contraindications for MRI (e.g., any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects or body piercings that are not MRI-safe or that cannot be removed)', 'entities': [['31', '34', 'treatment'], ['46', '65', 'treatment'], ['92', '109', 'treatment'], ['113', '126', 'treatment'], ['136', '153', 'treatment']]}, 'NCT01326715'), ({'text': 'Healthy women', 'entities': [['9', '14', 'gender']]}, 'NCT02607917'), ({'text': 'has > Stage II pelvic organ prolapse', 'entities': [['7', '37', 'chronic_disease']]}, 'NCT02357784'), ({'text': 'Complete resection of plexiform neurofibroma is not feasible or if subject refuses surgery', 'entities': [['23', '45', 'cancer'], ['84', '91', 'treatment']]}, 'NCT02101736'), ({'text': 'patients will be euthyroid on thyroid replacement if needed', 'entities': [['18', '27', 'chronic_disease'], ['31', '50', 'treatment']]}, 'NCT00383656'), ({'text': 'Women of childbearing potential', 'entities': [['1', '6', 'gender']]}, 'NCT02133872'), ({'text': 'History of malignancy', 'entities': [['12', '22', 'cancer']]}, 'NCT01996449'), ({'text': 'ages 18 to 75 years', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['12', '20', 'upper_bound']]}, 'NCT02914561'), ({'text': 'Prothrombin time (PT)/international normalized ration (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN', 'entities': [['1', '22', 'clinical_variable'], ['23', '60', 'clinical_variable'], ['63', '72', 'upper_bound'], ['77', '110', 'clinical_variable'], ['112', '128', 'clinical_variable']]}, 'NCT03016871'), ({'text': 'The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding', 'entities': [['27', '45', 'chronic_disease'], ['49', '87', 'chronic_disease']]}, 'NCT01906385'), ({'text': 'clinical practice for patients normally not seen in primary care behavioral health, i.e., patients greater than mild risk for self-harm, patients with current alcohol dependence, psychotic disorder, significant dissociative disorder, or moderate or severe brain injury', 'entities': [['180', '198', 'chronic_disease'], ['212', '233', 'chronic_disease'], ['238', '269', 'chronic_disease']]}, 'NCT02571478'), ({'text': 'At least 18 years of age', 'entities': [['10', '18', 'lower_bound'], ['22', '25', 'age']]}, 'NCT01670877'), ({'text': 'Systemic disease including AIDS, HIV, Hepatitis C', 'entities': [['28', '32', 'chronic_disease'], ['34', '37', 'chronic_disease'], ['39', '50', 'chronic_disease']]}, 'NCT02184520'), ({'text': 'Confirmed diagnosis of PCOS', 'entities': [['24', '28', 'chronic_disease']]}, 'NCT00914823'), ({'text': 'Prior monoclonal antibody, radioimmunoconjugate, antibody drug conjugate, phototherapy, radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any test agent within 3 weeks or for alemtuzumab 8 weeks of Day 1', 'entities': [['28', '48', 'treatment'], ['50', '73', 'treatment'], ['75', '87', 'treatment'], ['89', '101', 'treatment'], ['103', '115', 'treatment'], ['117', '130', 'treatment'], ['132', '157', 'treatment'], ['184', '191', 'upper_bound'], ['199', '210', 'treatment']]}, 'NCT01994382'), ({'text': 'Stable medication regimen for at least 4 weeks prior to study', 'entities': [['1', '26', 'treatment'], ['40', '53', 'lower_bound']]}, 'NCT02589340'), ({'text': 'Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix', 'entities': [['47', '52', 'cancer'], ['56', '91', 'cancer'], ['95', '126', 'cancer']]}, 'NCT02498951'), ({'text': "Any severe, acute, or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or NEV801 administration; that may interfere with the informed consent process or with compliance with the requirements of the study; or that may interfere with the interpretation of study results and, in the Investigator's opinion, would make the subject inappropriate for entry into this study", 'entities': [['42', '63', 'chronic_disease'], ['157', '163', 'treatment']]}, 'NCT02797795'), ({'text': 'Subjects with prior history at any time of any in situ cancer, including lobular carcinoma of the breast in situ, cervical cancer in situ, atypical melanocytic hyperplasia or Clark I melanoma in situ or basal or squamous skin cancer are eligible, provided they are disease-free at the time of registration', 'entities': [['48', '62', 'cancer'], ['74', '113', 'cancer'], ['140', '172', 'cancer'], ['176', '200', 'cancer'], ['204', '233', 'cancer']]}, 'NCT02264236'), ({'text': 'Absolute neutrophil count (ANC) >= 1,500/mcL', 'entities': [['1', '32', 'clinical_variable'], ['36', '45', 'lower_bound']]}, 'NCT01591356'), ({'text': 'A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice)', 'entities': [['3', '9', 'gender'], ['44', '49', 'gender']]}, 'NCT02893982'), ({'text': 'Age > 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT01407809'), ({'text': 'Agree not to take sildenafil (Viagra®), tadalafil, or similar medications within 72 hours of each drug administration', 'entities': [['19', '39', 'treatment'], ['41', '50', 'treatment'], ['63', '74', 'treatment'], ['82', '90', 'upper_bound']]}, 'NCT02243813'), ({'text': 'recurrent hypoglycemia post gastric bypass', 'entities': [['11', '23', 'chronic_disease'], ['24', '43', 'treatment']]}, 'NCT01803451'), ({'text': 'A 4/6, 5/6 or 6/6 HLA matched related or unrelated UCB unit available that will deliver a pre-cryopreservation total nucleated cell dose of e 3 x 10e7 cells/kg, or double unit grafts, each cord blood unit delivering at least 2 x 10e7 cells/kg OR an 8 of 8 or 7 of 8 HLA allele level matched unrelated donor bone marrow or peripheral blood progenitor graft', 'entities': [['118', '137', 'clinical_variable'], ['143', '160', 'lower_bound'], ['226', '243', 'lower_bound'], ['250', '256', 'upper_bound'], ['260', '266', 'lower_bound'], ['267', '283', 'clinical_variable'], ['323', '356', 'treatment']]}, 'NCT01962415'), ({'text': 'squamous cell carcinoma of the skin', 'entities': [['1', '36', 'cancer']]}, 'NCT02710396'), ({'text': 'Pregnancy', 'entities': [['1', '10', 'pregnancy']]}, 'NCT01777035'), ({'text': 'Active suicidal ideation', 'entities': [['8', '25', 'chronic_disease']]}, 'NCT02421315'), ({'text': 'Pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT01631318'), ({'text': 'Men who partner with a woman of childbearing potential, unless they agree to use 2 effective contraceptive methods (i.e., a condom, female partner using oral, injectable, or barrier method) while on study drug and for 3 months afterward', 'entities': [['1', '4', 'gender'], ['24', '29', 'gender'], ['78', '115', 'contraception_consent'], ['125', '131', 'contraception_consent'], ['133', '147', 'gender'], ['160', '170', 'contraception_consent'], ['175', '189', 'contraception_consent']]}, 'NCT02797795'), ({'text': 'Subjects with a history of seizure disorder', 'entities': [['28', '44', 'chronic_disease']]}, 'NCT02924194'), ({'text': 'No prior therapy with neratinib', 'entities': [['4', '32', 'treatment']]}, 'NCT01494662'), ({'text': 'Active urinary sediment, defined as microscopic hematuria (>5 red blood cells per high power field) or red blood cell casts', 'entities': [['1', '24', 'clinical_variable'], ['61', '99', 'lower_bound']]}, 'NCT02108860'), ({'text': 'Absolute neutrophil count (ANC) >= 1500/mm^3', 'entities': [['1', '32', 'clinical_variable'], ['36', '45', 'lower_bound']]}, 'NCT01905046'), ({'text': 'Myocardial infarction within 6 months of transplantation', 'entities': [['1', '22', 'chronic_disease'], ['30', '38', 'upper_bound'], ['42', '57', 'treatment']]}, 'NCT01908777'), ({'text': 'Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator', 'entities': [['37', '52', 'clinical_variable'], ['66', '75', 'upper_bound']]}, 'NCT03170349'), ({'text': 'Anemia', 'entities': [['1', '7', 'chronic_disease']]}, 'NCT00904046'), ({'text': 'Hematologic function: ANC e 1.5 x 109/L, platelets e 75 x109/L, INR d1.3', 'entities': [['23', '26', 'clinical_variable'], ['29', '40', 'lower_bound'], ['42', '51', 'clinical_variable'], ['54', '63', 'lower_bound'], ['65', '68', 'clinical_variable'], ['70', '73', 'upper_bound']]}, 'NCT01648023'), ({'text': "Patients with sickle cell anemia, multiple myeloma, leukemia or penile deformities placing them at risk for priapism (angulation, cavernosal fibrosis or Peyronie's disease)", 'entities': [['15', '33', 'chronic_disease'], ['35', '51', 'cancer'], ['53', '61', 'cancer'], ['65', '83', 'chronic_disease'], ['109', '117', 'chronic_disease'], ['131', '150', 'chronic_disease'], ['154', '172', 'chronic_disease']]}, 'NCT02058095'), ({'text': 'Prior major surgery or trauma', 'entities': [['1', '20', 'treatment'], ['24', '30', 'chronic_disease']]}, 'NCT01532687'), ({'text': 'congestive heart failure', 'entities': [['1', '25', 'chronic_disease']]}, 'NCT03007745'), ({'text': 'Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant', 'entities': [['27', '30', 'treatment']]}, 'NCT02585973'), ({'text': 'For variegate porphyria (VP): Substantial increases in fecal porphyrins (mostly coproporphyrin III and protoporphyrin), increased plasma total porphyrins and a fluorescence emission maximum of diluted plasma at neutral pH near 626 nm. Almost all (~95 percent) will have a demonstrable disease-causing protoporphyrinogen oxidase (PPO) mutation', 'entities': [['5', '29', 'chronic_disease'], ['302', '334', 'treatment']]}, 'NCT02180412'), ({'text': 'Hb level e9 g/dL', 'entities': [['1', '9', 'clinical_variable'], ['11', '17', 'lower_bound']]}, 'NCT02290951'), ({'text': 'women', 'entities': [['1', '6', 'gender']]}, 'NCT02570672'), ({'text': 'oligoasthenoteratospermia or azoospermia on semen analysis', 'entities': [['1', '26', 'chronic_disease'], ['30', '41', 'chronic_disease'], ['45', '59', 'treatment']]}, 'NCT03038867'), ({'text': 'Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease', 'entities': [['20', '48', 'cancer'], ['52', '67', 'cancer']]}, 'NCT01312857'), ({'text': 'Currently participating in an interventional research study related to HPV', 'entities': [['31', '60', 'treatment'], ['72', '75', 'chronic_disease']]}, 'NCT03051516'), ({'text': 'History of documented congestive heart failure (CHF)', 'entities': [['23', '53', 'chronic_disease']]}, 'NCT02488967'), ({'text': 'Life expectancy > 3 months', 'entities': [['1', '16', 'clinical_variable'], ['19', '27', 'lower_bound']]}, 'NCT01827384'), ({'text': 'Heavy alcohol drinking is defined as > 40 grams per day on average in women and > 60 grams per day on average in men for a minimum of 6 months', 'entities': [['40', '48', 'lower_bound'], ['71', '76', 'gender'], ['73', '76', 'gender'], ['83', '91', 'lower_bound'], ['135', '143', 'lower_bound']]}, 'NCT02654236'), ({'text': 'Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender'], ['44', '58', 'clinical_variable'], ['66', '74', 'upper_bound']]}, 'NCT02602119'), ({'text': 'At least 3 of the following persistent symptoms from the injury: headaches, dizziness or balance problems, blurred vision, tiredness/fatigue or sleep problems, seizures, remembering things or solving problems, managing stress or emotional upsets, controlling temper/irritability, depression, anxiety, post-traumatic stress, or ringing in the ears', 'entities': [['10', '11', 'lower_bound'], ['161', '169', 'chronic_disease'], ['281', '291', 'chronic_disease'], ['293', '300', 'chronic_disease'], ['302', '323', 'chronic_disease']]}, 'NCT01986205'), ({'text': 'Performance status >/= 40', 'entities': [['1', '19', 'clinical_variable'], ['24', '26', 'lower_bound']]}, 'NCT01821781'), ({'text': 'In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy', 'entities': [['14', '19', 'gender'], ['57', '70', 'chronic_disease'], ['123', '132', 'pregnancy']]}, 'NCT02306954'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) 0-1', 'entities': [['1', '42', 'clinical_variable'], ['43', '44', 'lower_bound'], ['45', '46', 'upper_bound']]}, 'NCT02754141'), ({'text': 'Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy', 'entities': [['1', '14', 'gender'], ['22', '70', 'contraception_consent'], ['109', '116', 'treatment'], ['125', '139', 'upper_bound']]}, 'NCT02581982'), ({'text': 'under 18 years of age', 'entities': [['7', '15', 'upper_bound'], ['19', '22', 'age']]}, 'NCT02324387'), ({'text': 'develop a stroke as a new event during the course of hospitalization', 'entities': [['11', '17', 'chronic_disease'], ['54', '69', 'treatment']]}, 'NCT03108820'), ({'text': 'Choroid plexus carcinoma (CPC)', 'entities': [['1', '31', 'clinical_variable']]}, 'NCT02451215'), ({'text': 'Electrocardiogram findings suggestive of significant current or previous ischemic heart disease, or left bundle branch block', 'entities': [['1', '18', 'treatment'], ['74', '96', 'chronic_disease'], ['101', '125', 'chronic_disease']]}, 'NCT02582827'), ({'text': 'Unstable medical illness', 'entities': [['10', '25', 'chronic_disease']]}, 'NCT02069925'), ({'text': 'Restorations must have a buccal to lingual/palatal width equal to or greater than 1/3 the distance from buccal to lingual/palatal cusp tips', 'entities': [['83', '86', 'lower_bound']]}, 'NCT03032705'), ({'text': 'must have recovered from the toxic effects of prior therapy and be at least 3 weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy, at least one week from the last dose of non-myelosuppressive biological therapy and at least 4 weeks from the completion of radiation therapy', 'entities': [['47', '60', 'treatment'], ['77', '84', 'lower_bound'], ['107', '138', 'treatment'], ['142', '177', 'treatment'], ['188', '196', 'lower_bound'], ['219', '258', 'treatment'], ['272', '279', 'lower_bound'], ['303', '320', 'treatment']]}, 'NCT01795313'), ({'text': 'Pulmonary fibrotic changes on chest radiograph consistent with prior healed tuberculosis', 'entities': [['31', '47', 'treatment'], ['77', '89', 'chronic_disease']]}, 'NCT02226341'), ({'text': 'Age e 18', 'entities': [['1', '4', 'age'], ['7', '9', 'lower_bound']]}, 'NCT01972919'), ({'text': 'Subjects will be over 18 years of age', 'entities': [['23', '31', 'lower_bound'], ['35', '38', 'age']]}, 'NCT02585791'), ({'text': 'If currently taking either of these medications, patient must discontinue for one week before receiving treatment with nab-paclitaxel', 'entities': [['120', '134', 'treatment']]}, 'NCT02573493'), ({'text': 'History of Brain Surgery', 'entities': [['12', '25', 'treatment']]}, 'NCT02803359'), ({'text': 'Requirement for intravenous bacterial treatment', 'entities': [['17', '48', 'treatment']]}, 'NCT03137173'), ({'text': 'Hypertension', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02587936'), ({'text': 'Total daily insulin dose d1.5 units/kg/day with a minimum of 3 units of RAA at every meal', 'entities': [['13', '25', 'clinical_variable'], ['27', '43', 'upper_bound'], ['62', '69', 'lower_bound'], ['73', '76', 'clinical_variable']]}, 'NCT02527265'), ({'text': 'In the Control group (N=10), we will include volunteers with no history of stone disease matched for age (within 5 years)', 'entities': [['76', '89', 'chronic_disease'], ['102', '105', 'age'], ['114', '121', 'upper_bound']]}, 'NCT02975986'), ({'text': 'Oxygen therapy within the previous 30 days', 'entities': [['1', '15', 'treatment'], ['27', '43', 'upper_bound']]}, 'NCT03010852'), ({'text': 'Calculated creatinine clearance >50 mL/min', 'entities': [['1', '32', 'clinical_variable'], ['34', '43', 'lower_bound']]}, 'NCT02433626'), ({'text': 'Subjects receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent', 'entities': [['20', '27', 'treatment'], ['29', '47', 'treatment'], ['53', '68', 'treatment'], ['80', '103', 'treatment']]}, 'NCT02579044'), ({'text': 'Subjects already consuming more than 1.5 g per day of EPA/DHA in any form', 'entities': [['38', '51', 'lower_bound'], ['55', '62', 'clinical_variable']]}, 'NCT02514070'), ({'text': 'Ascending aortic aneurysm or dissection repair requiring circulatory arrest', 'entities': [['11', '26', 'chronic_disease'], ['30', '47', 'treatment']]}, 'NCT02088554'), ({'text': 'Major mental illness (e.g., schizophrenia, major depressive disorder)', 'entities': [['1', '21', 'chronic_disease'], ['29', '42', 'chronic_disease'], ['44', '69', 'chronic_disease']]}, 'NCT02465541'), ({'text': 'Full-tolerated doses of 3 or more antihypertensive medications of different classes, one of which must be a diuretic (with no changes for a minimum of two weeks prior to screening) that is expected to be maintained without changes for at least 3 months', 'entities': [['25', '26', 'lower_bound'], ['35', '63', 'treatment'], ['109', '117', 'treatment'], ['152', '167', 'lower_bound'], ['245', '253', 'lower_bound']]}, 'NCT02133872'), ({'text': 'Recent steroid use (injected, inhaled, oral)', 'entities': [['8', '15', 'treatment']]}, 'NCT03029806'), ({'text': '>18 years of age', 'entities': [['2', '10', 'lower_bound'], ['14', '17', 'age']]}, 'NCT03116074'), ({'text': 'Chronic heart failure, New York Heart Association (NYHA) class II-IV, with ongoing treatment with medications for heart failure for at least 1 month prior to enrollment', 'entities': [['1', '22', 'chronic_disease'], ['9', '22', 'chronic_disease'], ['24', '57', 'clinical_variable'], ['58', '66', 'lower_bound'], ['67', '69', 'upper_bound'], ['84', '93', 'treatment'], ['99', '110', 'treatment'], ['142', '155', 'lower_bound']]}, 'NCT02918175'), ({'text': 'History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization', 'entities': [['12', '36', 'chronic_disease'], ['48', '69', 'chronic_disease'], ['74', '89', 'chronic_disease'], ['92', '112', 'treatment'], ['117', '125', 'treatment'], ['133', '147', 'upper_bound']]}, 'NCT02257424'), ({'text': 'Age range 18-70 years old', 'entities': [['1', '4', 'age'], ['11', '13', 'lower_bound'], ['14', '22', 'upper_bound']]}, 'NCT02268448'), ({'text': 'ANC < 500/ml', 'entities': [['1', '4', 'clinical_variable'], ['7', '13', 'upper_bound']]}, 'NCT02893982'), ({'text': 'Metabolic bone disease or sick physis syndrome, that may cause bone to grow in an unpredictable manne', 'entities': [['1', '23', 'chronic_disease'], ['27', '47', 'chronic_disease']]}, 'NCT02260856'), ({'text': 'Weight < 70kg for cord blood transplantation', 'entities': [['1', '7', 'clinical_variable'], ['10', '14', 'upper_bound'], ['19', '45', 'treatment']]}, 'NCT01364363'), ({'text': 'Patients with pre-existing medical conditions or other factors that renders them at high risk for regimen related toxicity or ineligible for conventional myeloablative HCT and who do not have HLA-matched related or unrelated donors', 'entities': [['15', '46', 'chronic_disease'], ['155', '172', 'treatment']]}, 'NCT00358657'), ({'text': 'AST(SGOT)/ALT(SGPT) d 2.5 x IULN', 'entities': [['1', '20', 'clinical_variable'], ['23', '33', 'upper_bound']]}, 'NCT02907918'), ({'text': 'Subjects who report active untreated major depression, psychosis, or mania, or who present with those symptoms at the baseline visit', 'entities': [['38', '54', 'chronic_disease'], ['56', '65', 'chronic_disease'], ['70', '75', 'chronic_disease']]}, 'NCT03070535'), ({'text': 'Documented hypersensitivity to fludarabine or melphalan or to bortezomib, boron or mannitol or any components of the formulation', 'entities': [['32', '43', 'allergy_name'], ['47', '56', 'allergy_name'], ['63', '73', 'allergy_name'], ['75', '80', 'allergy_name'], ['84', '92', 'allergy_name']]}, 'NCT01366612'), ({'text': 'Abnormal vital signs and/or ECG that suggest potential contraindication for planned study anesthesia', 'entities': [['77', '101', 'treatment']]}, 'NCT02132130'), ({'text': 'pervasive developmental disorder', 'entities': [['1', '33', 'chronic_disease']]}, 'NCT02553161'), ({'text': 'Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP', 'entities': [['29', '33', 'chronic_disease'], ['46', '50', 'treatment'], ['62', '65', 'chronic_disease'], ['69', '72', 'chronic_disease']]}, 'NCT02222545'), ({'text': "Patients with a diagnosis of/problems with von Willebrand's disease or other bleeding disorders (as flaxseed may slow blood clotting; the risk of bruising or bleeding in people on anticoagulants or with bleeding disorders may be a concern)", 'entities': [['44', '68', 'chronic_disease'], ['78', '96', 'chronic_disease'], ['181', '195', 'treatment']]}, 'NCT02324439'), ({'text': 'History or presence of an abnormal electrocardiogram (ECG)', 'entities': [['36', '59', 'clinical_variable']]}, 'NCT03162250'), ({'text': 'All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)', 'entities': [['5', '12', 'gender'], ['121', '142', 'lower_bound'], ['163', '166', 'age'], ['357', '364', 'lower_bound']]}, 'NCT02501096'), ({'text': 'Hemoglobin >= 8.5 g/dL (within 28 days of first study treatment)', 'entities': [['1', '11', 'clinical_variable'], ['15', '23', 'lower_bound'], ['32', '39', 'upper_bound'], ['55', '64', 'treatment']]}, 'NCT02519322'), ({'text': 'Use of herbal medications', 'entities': [['15', '26', 'treatment']]}, 'NCT02192359'), ({'text': 'Pathologically (histologically or cytologically) proven diagnosis of HCC,(biopsies are recommended, and are to be submitted for research evaluation if patients consent)', 'entities': [['70', '73', 'cancer'], ['75', '83', 'treatment']]}, 'NCT01730937'), ({'text': 'Subjects with a history of herpes zoster who have had an outbreak within the last year', 'entities': [['28', '41', 'chronic_disease']]}, 'NCT02281409'), ({'text': 'Hemoglobin e 9 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['14', '20', 'lower_bound']]}, 'NCT02259621'), ({'text': 'previous diagnosis of asthma', 'entities': [['23', '29', 'chronic_disease']]}, 'NCT03002389'), ({'text': 'd 26 years at time of delivery who deliver at YNHH YSC or SRC', 'entities': [['3', '11', 'upper_bound']]}, 'NCT02994290'), ({'text': 'for the duration of study participation, and for number (#) days following completion of therapy', 'entities': [['90', '97', 'treatment']]}, 'NCT02536794'), ({'text': 'Have a history of hepatic impairment', 'entities': [['19', '37', 'chronic_disease']]}, 'NCT02589340'), ({'text': 'Unable to tolerate anesthesia or sedation', 'entities': [['20', '30', 'treatment'], ['34', '42', 'treatment']]}, 'NCT02434809'), ({'text': 'Major surgical procedure or significant traumatic injury within 28 days prior to Day 1, Cycle 1, or anticipation of the need for major surgery during study treatment', 'entities': [['41', '57', 'chronic_disease'], ['65', '78', 'upper_bound'], ['157', '166', 'treatment']]}, 'NCT03072238'), ({'text': 'Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >10 mm with CT scan, as >20 mm by chest x-ray, or >10 mm with calipers by clinical exam by RECIST 1.1', 'entities': [['83', '86', 'lower_bound'], ['135', '140', 'lower_bound'], ['146', '153', 'treatment'], ['159', '164', 'lower_bound'], ['168', '179', 'treatment'], ['196', '204', 'treatment']]}, 'NCT02296684'), ({'text': 'ECOG performance status of 0-1', 'entities': [['1', '24', 'clinical_variable'], ['28', '29', 'lower_bound'], ['30', '31', 'upper_bound']]}, 'NCT02350764'), ({'text': 'AJCC stage III or IV completely resectable melanoma identified before surgery', 'entities': [['1', '5', 'clinical_variable'], ['6', '15', 'lower_bound'], ['19', '21', 'upper_bound'], ['44', '52', 'cancer'], ['71', '78', 'treatment']]}, 'NCT02301611'), ({'text': 'Any patient with a malignant diagnosis at the time of diagnosis or relapse', 'entities': [['20', '29', 'cancer']]}, 'NCT02105545'), ({'text': 'The benefits/risks of the induction chemotherapy regimen will be reviewed', 'entities': [['27', '57', 'treatment']]}, 'NCT01807091'), ({'text': 'Patients who are pregnant', 'entities': [['18', '26', 'pregnancy']]}, 'NCT01473628'), ({'text': 'small bowel bacterial overgrowth (SBBO) regimen', 'entities': [['1', '40', 'chronic_disease']]}, 'NCT03105362'), ({'text': 'Patients of childbearing potential must have a negative serum pregnancy test prior to study entry and be practicing an effective form of contraception', 'entities': [['48', '72', 'pregnancy']]}, 'NCT02349958'), ({'text': 'Internet access at home', 'entities': [['1', '16', 'technology_access']]}, 'NCT02408406'), ({'text': 'Patients currently receiving concurrent investigational chemotherapeutic agents', 'entities': [['41', '80', 'treatment']]}, 'NCT00924027'), ({'text': 'Platelets > 10 x 10^9/L', 'entities': [['1', '10', 'clinical_variable'], ['13', '24', 'lower_bound']]}, 'NCT03175978'), ({'text': 'women', 'entities': [['1', '6', 'gender']]}, 'NCT02169830'), ({'text': 'Patients may not be receiving any other investigational agents', 'entities': [['41', '63', 'treatment']]}, 'NCT02122172'), ({'text': 'The subject has received any other type of investigational agent within 28 days before the first dose of study treatment', 'entities': [['44', '65', 'treatment'], ['73', '87', 'upper_bound'], ['112', '121', 'treatment']]}, 'NCT02496208'), ({'text': 'Histologically and clinically confirmed diagnosis of well-differentiated neuro-endocrine tumour of non-functional gastroenteric origin (GE-NET) or both functional or non-functional pancreatic origin (P-NET)', 'entities': [['74', '96', 'cancer'], ['100', '144', 'chronic_disease'], ['153', '207', 'chronic_disease']]}, 'NCT03049189'), ({'text': 'A trial of withdrawal of immunosuppressive therapy', 'entities': [['26', '51', 'treatment']]}, 'NCT01087294'), ({'text': 'The ulcer is greater than 4 weeks duration', 'entities': [['5', '10', 'chronic_disease'], ['27', '34', 'lower_bound']]}, 'NCT02312596'), ({'text': 'Albumin e 2.5 g/dl', 'entities': [['1', '8', 'clinical_variable'], ['11', '19', 'lower_bound']]}, 'NCT02533674'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02427997'), ({'text': 'Presence of gait disorder diagnosed by clinician (e.g. neuropathy)', 'entities': [['13', '26', 'chronic_disease']]}, 'NCT02762604'), ({'text': 'A child hospitalized with a UTI that has the following: concomitant bacteremia associated with the UTI, urosepsis, or is in intensive care', 'entities': [['29', '32', 'chronic_disease'], ['69', '79', 'chronic_disease'], ['105', '114', 'chronic_disease']]}, 'NCT01595529'), ({'text': 'pregnant', 'entities': [['1', '9', 'pregnancy']]}, 'NCT02857270'), ({'text': 'Adult patients (18 and over)', 'entities': [['17', '19', 'lower_bound']]}, 'NCT02862158'), ({'text': 'Histological or cytological diagnosis of advanced/metastatic solid tumor', 'entities': [['42', '73', 'cancer']]}, 'NCT02554812'), ({'text': 'Use of other prohibited medications within 7 days prior to cycle 1 day 1 on study (Arms B and C only)', 'entities': [['44', '56', 'upper_bound']]}, 'NCT03009981'), ({'text': 'Age between 18-70 years', 'entities': [['1', '4', 'age'], ['13', '15', 'lower_bound'], ['16', '24', 'upper_bound']]}, 'NCT01185210'), ({'text': 'Subjects actively progressing within that window who have recovered from toxicities of prior therapy are also eligible', 'entities': [['94', '101', 'treatment']]}, 'NCT02811679'), ({'text': 'Hypersensitivity or intolerance to OCA or any components of its formulation', 'entities': [['36', '39', 'allergy_name']]}, 'NCT02430077'), ({'text': 'Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS (central nervous system) metastatic disease and are without evidence of clinical progression for at least 12 weeks after therapy', 'entities': [['15', '45', 'chronic_disease'], ['96', '114', 'treatment'], ['107', '114', 'treatment'], ['118', '125', 'treatment'], ['138', '185', 'cancer'], ['248', '262', 'lower_bound']]}, 'NCT02048371'), ({'text': 'Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal', 'entities': [['1', '33', 'clinical_variable'], ['35', '82', 'clinical_variable'], ['83', '113', 'clinical_variable'], ['115', '159', 'clinical_variable'], ['164', '205', 'upper_bound']]}, 'NCT02012296'), ({'text': 'Acute unilateral pulmonary infiltrate/s on chest radiograph with no clinical evidence of left-sided heart failure', 'entities': [['1', '27', 'chronic_disease'], ['44', '60', 'treatment'], ['90', '114', 'chronic_disease']]}, 'NCT02370095'), ({'text': 'Applicable disorders include but are not limited to dystonia, hemifacial spasm, blepharospasm, tremor, spasmodic dysphonia, tics, vocal fold tremor, oral lingual dyskinesia, tardive dyskinesia, spasticity, and spasmodic dysphonia', 'entities': [['53', '61', 'chronic_disease'], ['63', '79', 'chronic_disease'], ['81', '94', 'chronic_disease'], ['96', '102', 'chronic_disease'], ['104', '123', 'chronic_disease'], ['125', '129', 'chronic_disease'], ['131', '148', 'chronic_disease'], ['150', '173', 'chronic_disease'], ['175', '193', 'chronic_disease'], ['195', '205', 'chronic_disease']]}, 'NCT00001208'), ({'text': 'Sedentary or minimally physically active for at least the prior 1 year', 'entities': [['59', '71', 'lower_bound']]}, 'NCT01883258'), ({'text': 'Must have one or more tumors measurable on radiographic imaging as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Patients with evaluable but not measurable disease per RECIST criteria may be enrolled with the approval of the medical monitor', 'entities': [['11', '14', 'lower_bound'], ['23', '29', 'cancer'], ['115', '127', 'cancer']]}, 'NCT02013154'), ({'text': 'The subject has evidence of tumor invading the Gastro Intestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib', 'entities': [['29', '34', 'cancer'], ['156', '168', 'cancer'], ['172', '191', 'cancer'], ['199', '213', 'upper_bound'], ['232', '244', 'treatment']]}, 'NCT02132598'), ({'text': 'Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (except for patients with liver metastases in whom AST/ALT can be < 5 x institutional upper limit of normal)', 'entities': [['1', '33', 'clinical_variable'], ['29', '32', 'clinical_variable'], ['34', '82', 'clinical_variable'], ['83', '113', 'clinical_variable'], ['109', '112', 'clinical_variable'], ['115', '159', 'clinical_variable'], ['164', '205', 'upper_bound'], ['166', '205', 'upper_bound'], ['232', '248', 'cancer']]}, 'NCT02474173'), ({'text': 'Hypertension included in problem list', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT02587936'), ({'text': 'Ability to understand and provide signed informed consent', 'entities': [['1', '58', 'contraception_consent']]}, 'NCT01672138'), ({'text': 'all decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitor', 'entities': [['40', '55', 'treatment']]}, 'NCT02520778'), ({'text': 'Requirement for CD34+ stem cell selection for a second infusion of stem cells following an allogeneic stem cell transplant from a related or unrelated adult donor', 'entities': [['92', '123', 'treatment']]}, 'NCT01966367'), ({'text': 'Second active cancer', 'entities': [['1', '21', 'cancer']]}, 'NCT01913106'), ({'text': 'If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative', 'entities': [['4', '24', 'treatment'], ['116', '123', 'treatment']]}, 'NCT02111850'), ({'text': 'Patients with peripheral neuropathy of > grade 1', 'entities': [['15', '36', 'clinical_variable'], ['42', '49', 'lower_bound']]}, 'NCT02227199'), ({'text': 'English speaking', 'entities': [['1', '17', 'language_fluency']]}, 'NCT02480114'), ({'text': 'Age 18 or older', 'entities': [['1', '4', 'age'], ['5', '7', 'lower_bound']]}, 'NCT01770587'), ({'text': 'ECOG performance status d 3', 'entities': [['1', '24', 'clinical_variable'], ['27', '28', 'upper_bound']]}, 'NCT02476786'), ({'text': 'with only simple partial seizures', 'entities': [['18', '34', 'chronic_disease']]}, 'NCT02804230'), ({'text': 'Recurrent or previously resected tumors', 'entities': [['34', '40', 'cancer']]}, 'NCT03109041'), ({'text': 'Women who are pregnant', 'entities': [['1', '6', 'gender'], ['15', '23', 'pregnancy']]}, 'NCT03138733'), ({'text': 'Women who are pregnant', 'entities': [['1', '6', 'gender'], ['15', '23', 'pregnancy']]}, 'NCT02250157'), ({'text': 'Serum/urine pregnancy test (for females of childbearing potential) that is negative within 72 hours prior to initiation of first dose of treatment', 'entities': [['1', '22', 'pregnancy'], ['33', '40', 'gender'], ['92', '106', 'upper_bound'], ['138', '147', 'treatment']]}, 'NCT01841333'), ({'text': 'Required steroid increase within 1 week prior to injection', 'entities': [['10', '17', 'treatment'], ['34', '46', 'upper_bound'], ['50', '59', 'treatment']]}, 'NCT02457845'), ({'text': 'Patients with diagnosis of neuromuscular disease', 'entities': [['28', '49', 'chronic_disease']]}, 'NCT03171168'), ({'text': 'Obesity induced by other endocrinologic disorders (e.g. Cushing Syndrome)', 'entities': [['1', '8', 'chronic_disease'], ['26', '50', 'chronic_disease'], ['57', '73', 'chronic_disease']]}, 'NCT03038620'), ({'text': 'Subjects must be in complete remission from prior malignancy in order to be eligible to enter the study', 'entities': [['51', '61', 'cancer']]}, 'NCT02588612'), ({'text': '5-FU', 'entities': [['1', '5', 'treatment']]}, 'NCT01562626'), ({'text': 'Subject has an active or chronic systemic infection including any gynecologic infection, urinary tract infection (UTI), or tissue necrosis', 'entities': [['16', '22', 'chronic_disease'], ['26', '52', 'chronic_disease'], ['67', '88', 'chronic_disease'], ['90', '119', 'chronic_disease'], ['124', '139', 'chronic_disease']]}, 'NCT02021279'), ({'text': 'Gestational age: 16 weeks, 0 days to 26 weeks, 0 days', 'entities': [['1', '16', 'age'], ['28', '34', 'lower_bound'], ['38', '46', 'upper_bound']]}, 'NCT02122328'), ({'text': 'Use of any other experimental drug or therapy within 21 days prior to first dose', 'entities': [['18', '35', 'treatment'], ['39', '46', 'treatment'], ['54', '67', 'upper_bound']]}, 'NCT01464034'), ({'text': 'Symptomatic coronary artery disease (CAD)', 'entities': [['13', '42', 'chronic_disease']]}, 'NCT02393794'), ({'text': 'The older adult must speak English and be able to be contacted by telephone (to obtain pre-study information and to remind the participant about the study appointment and confirm that he/she is in a normal state of health on the day of the study)', 'entities': [['22', '35', 'language_fluency'], ['43', '76', 'technology_access']]}, 'NCT01169155'), ({'text': 'Past or present history of a medical disorder or medication known to affect body composition', 'entities': [['30', '46', 'chronic_disease']]}, 'NCT02500147'), ({'text': 'Women of childbearing potential must not be pregnant or breast-feeding', 'entities': [['1', '6', 'gender'], ['33', '53', 'pregnancy']]}, 'NCT02355535'), ({'text': 'no family history of hypertension, diabetes, stroke or cardiac disease in first-degree relatives', 'entities': [['22', '34', 'chronic_disease'], ['36', '44', 'chronic_disease'], ['46', '52', 'chronic_disease'], ['56', '71', 'chronic_disease']]}, 'NCT02871648'), ({'text': 'Age at screening e 18 years for male and permanently sterilized', 'entities': [['1', '4', 'age'], ['20', '28', 'lower_bound'], ['33', '37', 'gender']]}, 'NCT03165227'), ({'text': 'Subjects who have contraindications to carboplatin, cyclophosphamide, etoposide phosphate, or sodium thiosulfate', 'entities': [['40', '51', 'treatment'], ['53', '69', 'treatment'], ['71', '90', 'treatment'], ['95', '113', 'treatment']]}, 'NCT00075387'), ({'text': '30-365 days after birth if HIV-infection diagnosed within 96 hours after birth', 'entities': [['1', '3', 'lower_bound'], ['4', '18', 'upper_bound'], ['28', '41', 'chronic_disease'], ['59', '73', 'upper_bound']]}, 'NCT02369406'), ({'text': 'localized radiation', 'entities': [['11', '20', 'treatment']]}, 'NCT02128230'), ({'text': 'Epithelioid sarcoma', 'entities': [['1', '20', 'cancer']]}, 'NCT02584309'), ({'text': 'Stone size greater than 1.5 cm on preoperative imaging', 'entities': [['1', '11', 'clinical_variable'], ['25', '31', 'lower_bound']]}, 'NCT03130907'), ({'text': 'Exposure to at least one traumatic event and endorsement of any trauma symptoms on the UCLA PTSD Reaction Index for DSM-V', 'entities': [['22', '25', 'lower_bound']]}, 'NCT02926677'), ({'text': 'ulcerative colitis', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02541903'), ({'text': 'Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration', 'entities': [['1', '27', 'treatment'], ['28', '62', 'treatment'], ['63', '92', 'treatment'], ['112', '125', 'upper_bound']]}, 'NCT01993810'), ({'text': 'Age 2 to < 6 years: 0.8 for males and females', 'entities': [['1', '4', 'age'], ['5', '6', 'lower_bound'], ['12', '19', 'upper_bound'], ['21', '24', 'upper_bound'], ['29', '34', 'gender'], ['39', '46', 'gender']]}, 'NCT02304458'), ({'text': 'Severe renal function impairment (estimated glomerular filtration rate [eGFR] < 45 mL/min/1.73 m^2) would make the patient inappropriate for enrollment due to the increased risk of nephrogenic systemic fibrosis (NSF) with higher dose of IV gadolinium-based contrast agents (GBCA) administration', 'entities': [['1', '33', 'chronic_disease'], ['35', '78', 'clinical_variable'], ['81', '99', 'upper_bound'], ['182', '217', 'chronic_disease'], ['238', '280', 'treatment']]}, 'NCT02526511'), ({'text': 'Anatomic eligibility for the Nellix System per the instructions', 'entities': [['30', '43', 'treatment']]}, 'NCT01726257'), ({'text': 'Hemoglobin >= 9.0 g/dL', 'entities': [['1', '11', 'clinical_variable'], ['15', '23', 'lower_bound']]}, 'NCT02860000'), ({'text': 'HDRS > 20', 'entities': [['1', '5', 'clinical_variable'], ['8', '10', 'lower_bound']]}, 'NCT02440815'), ({'text': 'non-melanomatous skin cancer, or T1-2, N0, M0 resected differentiated thyroid carcinoma', 'entities': [['1', '29', 'cancer'], ['34', '36', 'lower_bound'], ['37', '38', 'upper_bound'], ['71', '88', 'cancer']]}, 'NCT02128906'), ({'text': 'unstable cardiovascular condition', 'entities': [['10', '34', 'chronic_disease']]}, 'NCT02421380'), ({'text': 'smoking >20 tobacco cigarettes per day', 'entities': [['10', '12', 'lower_bound']]}, 'NCT02983773'), ({'text': 'Symptoms indicative of irritable bowel syndrome', 'entities': [['24', '48', 'chronic_disease']]}, 'NCT02134392'), ({'text': 'Established use of oral, injected or implanted hormonal methods of contraception', 'entities': [['20', '81', 'contraception_consent']]}, 'NCT02236013'), ({'text': 'Altomare Obstructed Defecation Syndrome score of 15 points or above', 'entities': [['1', '46', 'clinical_variable'], ['50', '59', 'lower_bound']]}, 'NCT02160288'), ({'text': 'requires continuous intravenous vasopressor infusion for blood pressure support', 'entities': [['21', '53', 'treatment']]}, 'NCT03065465'), ({'text': 'Concomitant use of any anticancer therapy or use of any investigational agent(s)', 'entities': [['24', '42', 'treatment']]}, 'NCT02915744'), ({'text': 'Adequate renal function as defined by a serum creatinine clearance of > 30 mL/min calculated by Cockcroft-Gault equation', 'entities': [['41', '67', 'clinical_variable'], ['73', '82', 'lower_bound']]}, 'NCT03159702'), ({'text': 'Any major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 2 weeks prior to the first dose of the study drugs', 'entities': [['5', '18', 'treatment'], ['20', '32', 'treatment'], ['34', '46', 'treatment'], ['48', '64', 'treatment'], ['66', '79', 'treatment'], ['81', '101', 'treatment'], ['109', '122', 'upper_bound'], ['148', '159', 'treatment']]}, 'NCT02532231'), ({'text': 'Radiographic evidence of sinus inflammation during chronic bacterial rhinosinusitis indicating sinus disease at the ostiomeatal complex', 'entities': [['52', '84', 'chronic_disease'], ['96', '109', 'chronic_disease']]}, 'NCT02900794'), ({'text': 'Karnofsky Performance Status of 70-100%', 'entities': [['1', '29', 'clinical_variable'], ['33', '35', 'lower_bound'], ['36', '40', 'upper_bound']]}, 'NCT02593123'), ({'text': 'Major medical problems that can permanently impact brain function (e.g., CNS, cardiovascular, metabolic, autoimmune, endocrine) as determined by history and clinical exam', 'entities': [['7', '23', 'chronic_disease']]}, 'NCT02233868'), ({'text': 'Polyhydramnios: maximum vertical pocket e 8 cm in the recipient twin, prior to amniodrainage', 'entities': [['1', '15', 'chronic_disease'], ['17', '40', 'clinical_variable'], ['43', '47', 'lower_bound'], ['80', '93', 'treatment']]}, 'NCT02122328'), ({'text': 'Negative pregnancy test required for females <61 years of age or without prior hysterectomy', 'entities': [['1', '19', 'pregnancy'], ['38', '45', 'gender'], ['47', '55', 'upper_bound'], ['59', '62', 'age'], ['74', '92', 'treatment']]}, 'NCT02667418'), ({'text': 'Patient has stage 3B or 4 NSLC or extensive stage SCLC and is within one month of treatment initiation', 'entities': [['19', '31', 'cancer'], ['51', '55', 'cancer'], ['70', '79', 'upper_bound'], ['83', '92', 'treatment']]}, 'NCT02414672'), ({'text': 'Patients with elevated alkaline phosphatase, total bilirubin, AST and ALT, who have subsequently undergone biliary stenting and their liver tests are improving, do not need to wait for their alkaline phosphatase to become < 2.5x ULN if their total bilirubin, AST and ALT have improved to within required study levels and the alkaline phosphatase is decreasing.)', 'entities': [['24', '44', 'clinical_variable'], ['225', '233', 'upper_bound']]}, 'NCT02578732'), ({'text': 'surgery or other ablative therapy is allowed for lesions appearing after enrollment to this protocol as per section 4.4.2 and 4.4.3 is allowed', 'entities': [['1', '8', 'treatment'], ['18', '34', 'treatment']]}, 'NCT02893982'), ({'text': 'BMI < 25 or > 37.9 kgm-2', 'entities': [['1', '4', 'bmi'], ['7', '9', 'upper_bound'], ['15', '25', 'lower_bound']]}, 'NCT02298790'), ({'text': 'Patient has received other investigational drugs within 4 weeks before enrollment', 'entities': [['28', '49', 'treatment'], ['57', '71', 'upper_bound']]}, 'NCT01959698'), ({'text': 'interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity', 'entities': [['1', '26', 'chronic_disease']]}, 'NCT02323126'), ({'text': 'malignancy', 'entities': [['1', '11', 'cancer']]}, 'NCT03001830'), ({'text': 'Telomere Length Testing', 'entities': [['1', '24', 'treatment']]}, 'NCT01174108'), ({'text': 'Contraindications to lumbar puncture', 'entities': [['22', '37', 'allergy_name']]}, 'NCT03070535'), ({'text': 'Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment', 'entities': [['24', '49', 'chronic_disease'], ['57', '72', 'upper_bound'], ['97', '106', 'treatment']]}, 'NCT01822522'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT02414269'), ({'text': 'Age: 0 - 70 years', 'entities': [['1', '4', 'age'], ['6', '7', 'lower_bound'], ['10', '18', 'upper_bound']]}, 'NCT01505569'), ({'text': 'an FVC between 50% and 85% of the predicted value', 'entities': [['4', '7', 'clinical_variable'], ['16', '19', 'lower_bound'], ['24', '27', 'upper_bound']]}, 'NCT02265874'), ({'text': 'the subject has histological or cytological evidence of a solid tumor', 'entities': [['59', '70', 'cancer']]}, 'NCT02799095'), ({'text': 'Presence of any known or suspected obstructive disease of the gastrointestinal tract', 'entities': [['48', '85', 'chronic_disease']]}, 'NCT03053908'), ({'text': 'Pulmonary embolism within 30 days prior to study entry', 'entities': [['1', '19', 'chronic_disease'], ['27', '40', 'upper_bound']]}, 'NCT02091141'), ({'text': 'submit a urine sample negative for benzodiazepines or barbiturates prior to starting the study', 'entities': [['36', '51', 'treatment'], ['55', '67', 'treatment']]}, 'NCT02543944'), ({'text': 'Patients requiring emergency radiation therapy are eligible for enrollment on this study', 'entities': [['30', '47', 'treatment']]}, 'NCT01871766'), ({'text': 'ability to read and speak English or Spanish', 'entities': [['1', '45', 'language_fluency']]}, 'NCT02452645'), ({'text': 'Hemoglobin (Hgb) > 8.5 g/dL', 'entities': [['1', '17', 'clinical_variable'], ['20', '28', 'lower_bound']]}, 'NCT03007030'), ({'text': "Adequate liver function as defined by total bilirubin d 2.0 mg/dL (d 3.0 mg/dL for patients with known Gilbert's syndrome) and AST/ALT d 3 times upper limit of normal, unless these are thought to be due to AML", 'entities': [['39', '54', 'clinical_variable'], ['57', '66', 'upper_bound'], ['70', '79', 'upper_bound'], ['104', '122', 'chronic_disease'], ['128', '131', 'clinical_variable'], ['132', '135', 'clinical_variable'], ['138', '167', 'upper_bound'], ['207', '210', 'cancer']]}, 'NCT02109627'), ({'text': 'Skin grafts in which all bleeding points must be readily distinguished', 'entities': [['1', '12', 'treatment']]}, 'NCT02746458'), ({'text': 'have a community diagnosis of Autism Spectrum Disorder (as reported by parent)', 'entities': [['31', '55', 'chronic_disease']]}, 'NCT03020927'), ({'text': 'Consumption of >14 units of alcohol (e.g., glass of wine or bottle of beer) per week', 'entities': [['17', '25', 'lower_bound'], ['29', '36', 'clinical_variable']]}, 'NCT02786251'), ({'text': 'Chemotherapy within 3 weeks prior to the first dose of trial treatment', 'entities': [['1', '13', 'treatment'], ['21', '34', 'upper_bound'], ['56', '71', 'treatment']]}, 'NCT02865135'), ({'text': 'Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to index procedure', 'entities': [['5', '65', 'treatment'], ['83', '96', 'upper_bound'], ['100', '115', 'treatment']]}, 'NCT02000115'), ({'text': 'history of cardiac event or distress within the past 3 months', 'entities': [['12', '37', 'chronic_disease'], ['49', '62', 'upper_bound']]}, 'NCT03113136'), ({'text': 'Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment', 'entities': [['1', '4', 'gender'], ['9', '14', 'gender'], ['46', '96', 'contraception_consent'], ['104', '113', 'treatment'], ['122', '138', 'upper_bound']]}, 'NCT02200445'), ({'text': 'Previous history of failure to reach target uric acid levels despite therapy with allopurinol at dose > 300 mg/day', 'entities': [['70', '94', 'treatment'], ['105', '115', 'lower_bound']]}, 'NCT02579096'), ({'text': 'Recovered to d grade 1 NCI CTCAE version 4.0 from toxicity of prior chemotherapy or biologic therapy administered more than 4 weeks earlier', 'entities': [['16', '23', 'upper_bound'], ['24', '33', 'clinical_variable'], ['63', '81', 'treatment'], ['85', '101', 'treatment'], ['125', '132', 'lower_bound']]}, 'NCT02452268'), ({'text': 'Has a condition that may interfere with the ability to accurately report symptoms, (Severe Psychiatric Problems, Schizophrenia, Bipolar Disorder, Alcohol or Drug Dependence requiring hospitalization, or regular illegal drug use)', 'entities': [['85', '112', 'chronic_disease'], ['114', '127', 'chronic_disease'], ['129', '145', 'chronic_disease']]}, 'NCT02506192'), ({'text': 'Serum albumin e 3.5 g/dL', 'entities': [['1', '14', 'clinical_variable'], ['17', '25', 'lower_bound']]}, 'NCT02383927'), ({'text': 'Multicentric cancer in the same breast as diagnosed by clinical examination', 'entities': [['1', '20', 'cancer']]}, 'NCT01570998'), ({'text': 'Uncontrolled tumor-related pain', 'entities': [['14', '19', 'cancer']]}, 'NCT03125902'), ({'text': 'Uncontrolled hypertension (>150/100 mmHg despite optimal medical therapy)', 'entities': [['14', '26', 'chronic_disease'], ['29', '41', 'lower_bound'], ['50', '73', 'treatment']]}, 'NCT01261728'), ({'text': 'Patient at least 18 years of age', 'entities': [['18', '26', 'lower_bound'], ['30', '33', 'age']]}, 'NCT01643460'), ({'text': 'Child-Pugh A or B (up to 2 lesions < 5cm in size)', 'entities': [['1', '18', 'clinical_variable'], ['26', '27', 'lower_bound'], ['38', '41', 'upper_bound']]}, 'NCT02556619'), ({'text': 'Incidence of or uncontrolled medical illness (e.g. active cardiac symptoms, active systemic infection, etc.)', 'entities': [['77', '102', 'chronic_disease']]}, 'NCT02177695'), ({'text': 'Increase of an elevated LDH alone does not constitute progressive disease', 'entities': [['25', '28', 'treatment'], ['55', '74', 'chronic_disease']]}, 'NCT01505569'), ({'text': 'Duration of injury <12 weeks', 'entities': [['21', '29', 'upper_bound']]}, 'NCT01983475'), ({'text': 'mediastinal gray zone lymphoma', 'entities': [['1', '31', 'cancer']]}, 'NCT00001337'), ({'text': 'History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization', 'entities': [['12', '36', 'chronic_disease'], ['48', '69', 'chronic_disease'], ['74', '89', 'chronic_disease'], ['92', '112', 'treatment'], ['117', '125', 'treatment'], ['133', '147', 'upper_bound'], ['151', '164', 'treatment']]}, 'NCT01989585'), ({'text': 'Non corrected coagulopathy', 'entities': [['15', '27', 'chronic_disease']]}, 'NCT02973139'), ({'text': 'DONOR: Unrelated Umbilical Cord Blood: The UCB unit with the least HLA disparity (with the patient) will be selected first (i.e., selection priority is 6/6 match > 5/6 match> 4/6 match); additional UCB units then may be selected to achieve the required cell dose; if a second unit is required, this unit will be the unit that most closely HLA matches the patient and meets minimum size criteria outlined below of at least 1.5 x 10^7 TNC/kg (i.e. a smaller more closely matched unit will be selected over a larger less well matched unit as long as minimum criteria are met)', 'entities': [['165', '168', 'lower_bound'], ['176', '179', 'lower_bound'], ['423', '440', 'lower_bound']]}, 'NCT00919503'), ({'text': 'Patients with single or multiple (2-4 nodules) HCC who are unsuitable or unwilling for surgical resection or RFA. The largest tumor nodule should be less than 10 cm in the largest diameter. The total volume of tumor cannot exceed 50% of liver; or patients with liver metastatic gastrointestinal cancer, including neuroendocrine tumor', 'entities': [['48', '51', 'cancer'], ['88', '106', 'treatment'], ['110', '113', 'treatment'], ['127', '132', 'cancer'], ['160', '165', 'upper_bound'], ['231', '234', 'upper_bound'], ['262', '302', 'cancer'], ['314', '334', 'cancer']]}, 'NCT02174549'), ({'text': 'Macroscopic complete salvage surgery with curative intent (surgery was not performed only for biopsy or palliation)', 'entities': [['1', '37', 'treatment'], ['30', '37', 'treatment'], ['95', '101', 'treatment'], ['105', '115', 'treatment']]}, 'NCT02516969'), ({'text': 'definite or probable dermatomyositis (DM)', 'entities': [['22', '42', 'chronic_disease']]}, 'NCT02347891'), ({'text': 'TBI (open or closed), sustained at least 6 months prior, of at least complicated-mild injury severity as evidenced by loss or alteration of consciousness not due to intoxication/ sedation and/ or positive neuroimaging findings consistent with TBI', 'entities': [['1', '4', 'chronic_disease'], ['42', '56', 'lower_bound'], ['119', '154', 'chronic_disease']]}, 'NCT02061553'), ({'text': 'Poor nutrition: Requires G-tube or intravenous feeding supplement to maintain weight or nutrition', 'entities': [['26', '32', 'treatment'], ['36', '66', 'treatment']]}, 'NCT01306019'), ({'text': 'diabetes mellitus', 'entities': [['1', '18', 'chronic_disease']]}, 'NCT01037790'), ({'text': 'Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease)', 'entities': [['13', '37', 'chronic_disease'], ['47', '87', 'chronic_disease']]}, 'NCT01993719'), ({'text': 'Patients with a history of prior rotator cuff repair', 'entities': [['28', '53', 'treatment']]}, 'NCT02588027'), ({'text': 'Colchicine use within 1 month', 'entities': [['1', '11', 'treatment'], ['23', '30', 'upper_bound']]}, 'NCT02594111'), ({'text': 'Life expectancy of < 6 months', 'entities': [['1', '16', 'clinical_variable'], ['22', '30', 'upper_bound']]}, 'NCT02352467'), ({'text': 'Willing to return to enrolling institution for follow-up 2-4 weeks after treatment discontinuation', 'entities': [['58', '59', 'lower_bound'], ['60', '67', 'upper_bound'], ['74', '83', 'treatment']]}, 'NCT02020707'), ({'text': 'Hypertension', 'entities': [['1', '13', 'chronic_disease']]}, 'NCT00862433'), ({'text': 'Patients with clinical or radiographic evidence of spinal cord or cauda equine compression or effacement', 'entities': [['52', '105', 'treatment']]}, 'NCT02480036'), ({'text': 'Patients on oral anticoagulation including Coumadin, Warfarin', 'entities': [['13', '33', 'treatment'], ['44', '52', 'treatment'], ['54', '62', 'treatment']]}, 'NCT02560623'), ({'text': 'Patients are not of childbearing potential or they must agree to use a physical method of contraception', 'entities': [['57', '104', 'contraception_consent']]}, 'NCT03146663'), ({'text': 'intracranial clips', 'entities': [['1', '19', 'treatment']]}, 'NCT02249520'), ({'text': 'for spiral CT, measurable is defined as 10 mm in at least one dimension', 'entities': [['5', '14', 'treatment'], ['59', '62', 'lower_bound']]}, 'NCT02495415'), ({'text': 'These patients would ordinarily choose to have 12 cycles of Taxol given after standard first-line surgery and chemotherapy, and instead choose one course of IPHC as their CC', 'entities': [['48', '57', 'upper_bound'], ['61', '66', 'treatment'], ['73', '106', 'treatment'], ['111', '123', 'treatment'], ['158', '162', 'treatment']]}, 'NCT02349958'), ({'text': 'patients with margins positive for lobular carcinoma in situ (LCIS) are eligible without additional resection', 'entities': [['36', '68', 'cancer']]}, 'NCT02515110'), ({'text': 'Patients with DUs must have a documented history of diabetes mellitus of at least six months', 'entities': [['53', '70', 'chronic_disease'], ['83', '93', 'lower_bound']]}, 'NCT03041844'), ({'text': 'gastric emptying (e.g. metoclopramide)', 'entities': [['1', '17', 'treatment'], ['24', '38', 'treatment']]}, 'NCT01200940'), ({'text': 'Sum of aortic and mitral valve z-scores (standard deviation based on gestational age) less than -4.5', 'entities': [['1', '40', 'clinical_variable'], ['97', '101', 'upper_bound']]}, 'NCT02965638'), ({'text': 'Vasopressors', 'entities': [['1', '13', 'treatment']]}, 'NCT02920086'), ({'text': 'Lenalidomide-refractory disease is defined as disease progression on or progression within 60 days of the last dose of a lenalidomide-based treatment', 'entities': [['1', '13', 'treatment'], ['14', '32', 'cancer'], ['92', '99', 'upper_bound'], ['122', '150', 'treatment']]}, 'NCT02004275'), ({'text': 'Patients with brain metastases are eligible if these lesions have been previously treated and the patients have no clinical or radiographic evidence of progression prior to enrollment', 'entities': [['15', '31', 'cancer']]}, 'NCT03137771'), ({'text': 'Any chronic or active neurologic disorder, including seizures and epilepsy', 'entities': [['5', '42', 'chronic_disease'], ['54', '62', 'chronic_disease'], ['67', '75', 'chronic_disease']]}, 'NCT02776761'), ({'text': 'Duration of psychosis > 2 years', 'entities': [['13', '22', 'chronic_disease'], ['25', '32', 'lower_bound']]}, 'NCT02841956'), ({'text': 'INR > 1.3', 'entities': [['1', '4', 'clinical_variable'], ['7', '10', 'lower_bound']]}, 'NCT02278315'), ({'text': 'Patients will be defined to have chronic pain if they are using regular daily doses of systemic narcotics for the past 6 months prior to the surgery', 'entities': [['88', '106', 'treatment'], ['115', '134', 'upper_bound'], ['142', '149', 'treatment']]}, 'NCT02744352'), ({'text': 'within 4 weeks following notification of treatment assignment', 'entities': [['8', '15', 'upper_bound'], ['42', '51', 'treatment']]}, 'NCT02465060'), ({'text': 'Aphasia', 'entities': [['1', '8', 'chronic_disease']]}, 'NCT02011971'), ({'text': 'Subjects must have a performance status of d 2 on the ECOG (Eastern Cooperative Oncology Group)Performance scale', 'entities': [['46', '47', 'upper_bound'], ['55', '113', 'clinical_variable']]}, 'NCT01976169'), ({'text': '3 of 5 criteria: (i) Elevated erythrocyte sedimentation rate (ESR) (>30mm/jr) and c-reactive protein (CRP) (>10mg/L) (ii) Elevated synovial leukocyte count (>3000 cells/µL) or change of ++ on leukocyte esterase strip (iii) Elevated synovial neutrophil percentage (>80%) (iv) One positive culture (v) Positive histological analysis of periprosthetic tissue (>5 neutrophils per high power field in 5 high power fields x400)', 'entities': [['22', '67', 'clinical_variable'], ['70', '77', 'lower_bound'], ['83', '107', 'clinical_variable'], ['110', '116', 'lower_bound'], ['123', '156', 'clinical_variable'], ['159', '172', 'lower_bound'], ['193', '217', 'treatment'], ['224', '263', 'clinical_variable'], ['266', '269', 'lower_bound'], ['335', '356', 'clinical_variable'], ['359', '372', 'lower_bound']]}, 'NCT02734134'), ({'text': 'Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)', 'entities': [['1', '34', 'contraception_consent'], ['24', '34', 'contraception_consent'], ['138', '146', 'contraception_consent'], ['148', '157', 'contraception_consent'], ['159', '172', 'contraception_consent'], ['174', '196', 'contraception_consent']]}, 'NCT02542657'), ({'text': 'For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment', 'entities': [['5', '22', 'chronic_disease'], ['12', '21', 'chronic_disease'], ['70', '89', 'treatment'], ['137', '149', 'treatment']]}, 'NCT02479698'), ({'text': 'Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein), and skin changes (POEMS) syndrome', 'entities': [['1', '22', 'chronic_disease'], ['28', '42', 'chronic_disease'], ['44', '56', 'chronic_disease'], ['58', '72', 'chronic_disease'], ['74', '104', 'chronic_disease'], ['110', '139', 'chronic_disease']]}, 'NCT02101944'), ({'text': 'Negative hantavirus PsVNA test result at screening', 'entities': [['10', '20', 'chronic_disease'], ['10', '26', 'treatment'], ['21', '26', 'treatment']]}, 'NCT02776761'), ({'text': 'Aniridia', 'entities': [['1', '9', 'chronic_disease']]}, 'NCT03179397'), ({'text': 'Adequate cardiac function left ventricular ejection fraction (LVEF) > 50% as assessed by echocardiogram or MUGA (Multi Gated Acquisition Scan)', 'entities': [['27', '68', 'clinical_variable'], ['71', '74', 'lower_bound'], ['90', '104', 'treatment'], ['108', '143', 'treatment']]}, 'NCT02073097'), ({'text': 'History of intracranial hypertension', 'entities': [['12', '37', 'chronic_disease']]}, 'NCT03185130'), ({'text': 'there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy', 'entities': [['37', '48', 'chronic_disease'], ['52', '65', 'treatment'], ['75', '88', 'lower_bound'], ['89', '111', 'treatment'], ['119', '136', 'treatment']]}, 'NCT02557321'), ({'text': 'History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or lenalidomide agents used in study, such as bortezomib or thalidomide, in addition to patients with known allergy to sulfobutyl ether <=- cyclodextrin (Captisol )', 'entities': [['102', '113', 'treatment'], ['117', '129', 'treatment'], ['160', '170', 'treatment'], ['174', '185', 'treatment'], ['233', '243', 'allergy_name'], ['254', '266', 'allergy_name']]}, 'NCT01572480'), ({'text': 'History of myocardial infarction', 'entities': [['12', '33', 'chronic_disease']]}, 'NCT02966665'), ({'text': 'Glomerulonephritis (haematuria, red cell casts, proteinuria)', 'entities': [['1', '19', 'chronic_disease']]}, 'NCT02947945'), ({'text': 'Surgically treated patients have an undetectable prostate specific antigen (PSA)', 'entities': [['50', '81', 'clinical_variable']]}, 'NCT02037048'), ({'text': 'Eastern Cooperative Oncology Group (ECOG) performance status of 0 (fully active, able to carry on all pre-disease performance without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, such as light housework or office work) or 2 (Ambulatory and capable of all self-care but unable to carry out any work activities', 'entities': [['1', '61', 'clinical_variable'], ['65', '66', 'lower_bound'], ['151', '152', 'upper_bound']]}, 'NCT02535533'), ({'text': 'Pathologic or clinical diagnosis of a new pancreatic adenocarcinoma', 'entities': [['43', '68', 'cancer']]}, 'NCT02128100'), ({'text': 'Have a negative serum ²-subunit of human chorionic gonadotropin (²-hCG) pregnancy test (sensitivity of at least 25 mIU/mL) at screening', 'entities': [['8', '82', 'pregnancy'], ['89', '100', 'clinical_variable'], ['113', '122', 'lower_bound']]}, 'NCT02577406'), ({'text': 'Evidence of active infection with HIV-1, hepatitis B, Hepatitis C, CMV, adenovirus, parvovirus B19 or toxoplasmosis by DNA PCR within 8 weeks prior to mobilization/pheresis or bone marrow harvest', 'entities': [['20', '40', 'chronic_disease'], ['42', '53', 'chronic_disease'], ['55', '66', 'chronic_disease'], ['68', '71', 'chronic_disease'], ['73', '83', 'chronic_disease'], ['85', '99', 'chronic_disease'], ['103', '116', 'chronic_disease'], ['120', '127', 'clinical_variable'], ['135', '148', 'upper_bound'], ['165', '173', 'treatment']]}, 'NCT02234934'), ({'text': 'Patient must have been treated with an anti-estrogen at any time in their disease history', 'entities': [['40', '53', 'treatment']]}, 'NCT02188745'), ({'text': 'Psychiatric hospitalization within 1 year of screening date', 'entities': [['36', '42', 'upper_bound']]}, 'NCT02271919'), ({'text': 'Ulcer not of PU pathophysiology (e.g., pure diabetic, vasculitic, radiation, rheumatoid, collagen vascular disease, venous, or arterial etiology)', 'entities': [['1', '6', 'chronic_disease'], ['14', '16', 'chronic_disease'], ['45', '53', 'chronic_disease'], ['55', '65', 'chronic_disease'], ['78', '88', 'chronic_disease'], ['90', '115', 'chronic_disease'], ['117', '123', 'chronic_disease'], ['128', '136', 'chronic_disease']]}, 'NCT02352467'), ({'text': 'Endoscopic and surgical treatment to be provided by same team', 'entities': [['1', '11', 'treatment'], ['16', '34', 'treatment']]}, 'NCT01774019'), ({'text': 'Currently receiving or having used a CCR5 antagonist as part of an antiretroviral regimen', 'entities': [['38', '53', 'treatment'], ['68', '90', 'treatment']]}, 'NCT02159027'), ({'text': 'Patients with evidence of metastatic spinal disease by MRI', 'entities': [['27', '52', 'chronic_disease'], ['56', '59', 'treatment']]}, 'NCT02774421'), ({'text': 'acute myeloid leukemia (AML) by WHO classification', 'entities': [['1', '29', 'cancer']]}, 'NCT02530034'), ({'text': 'AHI >20 or SaO2 Nadir <87%', 'entities': [['1', '4', 'clinical_variable'], ['6', '8', 'lower_bound'], ['12', '22', 'clinical_variable'], ['24', '27', 'upper_bound']]}, 'NCT02981082'), ({'text': "Treatment with strong inducers of cytochrome P450 isozyme 3A4 (CYP3A4) within 28 days prior to study treatment initiation (e.g., carbamazepine, rifampicin, rifabutin, phenytoin and St. John's Wort)", 'entities': [['1', '71', 'treatment'], ['79', '92', 'upper_bound'], ['102', '111', 'treatment'], ['130', '143', 'treatment'], ['145', '155', 'treatment'], ['157', '166', 'treatment'], ['168', '177', 'treatment'], ['182', '197', 'treatment']]}, 'NCT02554903'), ({'text': 'Absolute neutrophil count (ANC) e 1.0 x 10^9/L', 'entities': [['1', '32', 'clinical_variable'], ['35', '47', 'lower_bound']]}, 'NCT02091999'), ({'text': 'Require therapeutic use of anticoagulation medications', 'entities': [['28', '55', 'treatment']]}, 'NCT02250157'), ({'text': 'Presence of any intracranial mass', 'entities': [['17', '34', 'cancer']]}, 'NCT02135588'), ({'text': 'Liver disease or elevation of liver enzymes', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT02484248'), ({'text': 'Known human immunodeficiency virus (HIV) infection', 'entities': [['7', '51', 'chronic_disease']]}, 'NCT02533674'), ({'text': 'K<3.1 meq/L (or K<3.5 meq/L if on digoxin) in the past 90 days', 'entities': [['3', '12', 'upper_bound'], ['19', '28', 'upper_bound'], ['35', '42', 'treatment'], ['51', '63', 'upper_bound']]}, 'NCT02185417'), ({'text': 'oral anticoagulants', 'entities': [['1', '20', 'treatment']]}, 'NCT02931110'), ({'text': 'Patients taking carbamazepine or nitroglycerin', 'entities': [['17', '30', 'treatment'], ['34', '47', 'treatment']]}, 'NCT03167281'), ({'text': 'antiarrhythmics', 'entities': [['1', '16', 'treatment']]}, 'NCT02233868'), ({'text': 'Invasively mechanically ventilated >72 hours at the time of screening', 'entities': [['1', '35', 'clinical_variable'], ['37', '45', 'lower_bound']]}, 'NCT02462590'), ({'text': 'The brain metastases are stable on pre-registration imaging', 'entities': [['5', '21', 'cancer'], ['53', '60', 'treatment']]}, 'NCT02503722'), ({'text': 'Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program', 'entities': [['25', '40', 'treatment'], ['130', '170', 'treatment']]}, 'NCT01666080'), ({'text': 'Serum creatinine > 2x ULN', 'entities': [['1', '17', 'clinical_variable'], ['20', '26', 'lower_bound']]}, 'NCT00967577'), ({'text': 'Age e 35 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT03038620'), ({'text': 'Less than 300 CD3+ T-cells by flow cytometry or higher if evidence of maternal engraftment as supported by peripheral blood FISH analysis for XY and XX', 'entities': [['11', '14', 'upper_bound'], ['15', '27', 'clinical_variable'], ['36', '45', 'treatment'], ['71', '91', 'treatment'], ['108', '138', 'treatment']]}, 'NCT01512888'), ({'text': 'Palliative steroids for disease related symptoms < 7 days prior to C1D1', 'entities': [['1', '20', 'treatment'], ['52', '64', 'upper_bound']]}, 'NCT02702492'), ({'text': 'Patients must agree to continue contraception for 3 months from the date of the last study drug administration', 'entities': [['15', '46', 'contraception_consent'], ['51', '59', 'upper_bound'], ['86', '96', 'treatment']]}, 'NCT02303977'), ({'text': 'BMI between 18-35 Kg/m2', 'entities': [['1', '4', 'bmi'], ['13', '15', 'lower_bound'], ['16', '24', 'upper_bound']]}, 'NCT03028831'), ({'text': 'Age > 18 years', 'entities': [['1', '4', 'age'], ['7', '15', 'lower_bound']]}, 'NCT02843945'), ({'text': 'Women of childbearing potential', 'entities': [['1', '6', 'gender']]}, 'NCT03023059'), ({'text': 'adenocarcinoma of the prostate', 'entities': [['1', '15', 'cancer']]}, 'NCT02177292'), ({'text': 'availability of cohabitating study partner without cognitive impairment', 'entities': [['52', '72', 'chronic_disease']]}, 'NCT02521818'), ({'text': 'prothrombin time (PT) =< 1.2 x upper limit of normal (ULN)', 'entities': [['1', '22', 'clinical_variable'], ['26', '49', 'upper_bound']]}, 'NCT02520778'), ({'text': 'Have had a prior catheter ablation procedure for VT', 'entities': [['12', '45', 'treatment'], ['50', '52', 'chronic_disease']]}, 'NCT02830360'), ({'text': 'bipolar disorder I, II, or NOS', 'entities': [['1', '23', 'chronic_disease']]}, 'NCT02214667'), ({'text': 'Presence of a comorbid disease or medical condition that would impair the ability of the patient to receive or comply with the study protocol', 'entities': [['15', '31', 'chronic_disease']]}, 'NCT02881242'), ({'text': 'Patients must be 18 years of age or older', 'entities': [['18', '26', 'lower_bound'], ['30', '33', 'age']]}, 'NCT01941316'), ({'text': 'Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment', 'entities': [['18', '57', 'cancer'], ['65', '89', 'cancer'], ['124', '140', 'cancer'], ['218', '225', 'treatment'], ['239', '255', 'lower_bound'], ['277', '292', 'treatment'], ['422', '430', 'treatment'], ['444', '456', 'lower_bound']]}, 'NCT02437370'), ({'text': 'Overweight or obese (BMI e 85th%ile on CDC growth charts, or waist circumference to height ratio > 0.5', 'entities': [['22', '25', 'bmi'], ['28', '36', 'lower_bound'], ['62', '97', 'clinical_variable'], ['100', '103', 'lower_bound']]}, 'NCT02561754'), ({'text': 'Any other acute or chronic medical or psychiatric condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of data, in the opinion of the investigator or sponsor, including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study', 'entities': [['11', '35', 'chronic_disease'], ['39', '60', 'chronic_disease'], ['82', '91', 'chronic_disease'], ['326', '343', 'chronic_disease']]}, 'NCT03148795'), ({'text': 'Qualifying TTE must be obtained after the subject has been stabilized on optimal therapy including Guideline Directed Medical Therapy (GDMT) and at least 30 days after', 'entities': [['100', '141', 'treatment'], ['155', '162', 'lower_bound']]}, 'NCT01626079'), ({'text': '16 years of age or older', 'entities': [['1', '9', 'lower_bound'], ['13', '16', 'age']]}, 'NCT01789333'), ({'text': "Subject who has a known hypersensitivity to risankizumab or the excipients of any of the study drugs or the ingredients of CHO, or had an AE during Studies M16-006, M15-991 or M15-989 that in the Investigator's judgment makes the subject unsuitable for this study", 'entities': [['45', '57', 'allergy_name'], ['124', '127', 'allergy_name']]}, 'NCT03105102'), ({'text': 'Tumors that are not clearly seen by MRI but showing on PET/CT will be ablated with PET/CT guidance', 'entities': [['1', '7', 'cancer'], ['37', '40', 'treatment'], ['56', '59', 'treatment'], ['60', '62', 'treatment']]}, 'NCT02085941'), ({'text': 'patients may have de novo DLBCL', 'entities': [['19', '32', 'cancer']]}, 'NCT02541565'), ({'text': 'females of childbearing potential not willing to practice an effective method of contraception', 'entities': [['1', '8', 'treatment'], ['35', '95', 'contraception_consent']]}, 'NCT02664168'), ({'text': 'A parent or legal guardian of a patient <18 years of age will provide informed consent and patients 11 to 18 years of age will provide written assent or as per participating institutional policy', 'entities': [['42', '50', 'upper_bound'], ['54', '57', 'age'], ['101', '103', 'lower_bound']]}, 'NCT02013336'), ({'text': 'Resection may include major vascular resection with reconstruction as needed', 'entities': [['1', '10', 'treatment'], ['23', '47', 'treatment']]}, 'NCT02446093'), ({'text': 'Head and neck cancer patients with tumor invading major blood vessels for whom there may be a risk of blockage or bleeding if inflammation or edema is transiently increased by Hiltonol injections', 'entities': [['1', '21', 'cancer'], ['36', '41', 'cancer'], ['143', '148', 'chronic_disease'], ['177', '196', 'treatment']]}, 'NCT02423863'), ({'text': 'MS - mild to moderate disability (Patient Determined Disease Steps Score 0-6)', 'entities': [['35', '73', 'clinical_variable'], ['74', '75', 'lower_bound'], ['76', '77', 'upper_bound']]}, 'NCT02533882'), ({'text': 'only cases where a complete surgical resection with tumor-free margins can safely be achieved are defined as resectable', 'entities': [['29', '47', 'treatment'], ['53', '58', 'cancer']]}, 'NCT02519322'), ({'text': 'lactating women', 'entities': [['11', '16', 'gender']]}, 'NCT02323191'), ({'text': 'Creatinine <1.5 mg/dL', 'entities': [['1', '11', 'clinical_variable'], ['13', '22', 'upper_bound']]}, 'NCT01312857'), ({'text': 'bisphosphonates or denosumab should not be initiated after registration and during active treatment', 'entities': [['1', '16', 'treatment'], ['20', '29', 'treatment'], ['91', '100', 'treatment']]}, 'NCT02565901'), ({'text': 'Absolute neutrophil count (ANC) e1.5 x 10^9/L', 'entities': [['1', '32', 'clinical_variable'], ['34', '46', 'lower_bound']]}, 'NCT01894061'), ({'text': 'Patients who relapse after either single or tandem autologous BMT are eligible', 'entities': [['52', '66', 'treatment']]}, 'NCT01804634'), ({'text': 'mutations, fusions or amplifications [> 6 copies', 'entities': [['1', '37', 'clinical_variable'], ['41', '49', 'lower_bound']]}, 'NCT02272998'), ({'text': 'BMI is between 18 to 36 kg/m2', 'entities': [['1', '4', 'bmi'], ['16', '18', 'lower_bound'], ['22', '30', 'upper_bound']]}, 'NCT03122912'), ({'text': 'Filgrastim may be secreted in human milk, although its bioavailability from this source is not known', 'entities': [['1', '11', 'treatment']]}, 'NCT01861106'), ({'text': 'Treatment with ERT for e1 year', 'entities': [['16', '19', 'treatment'], ['25', '31', 'lower_bound']]}, 'NCT03153319'), ({'text': 'Evidence of active, uncontrolled, viral, bacterial, or systemic fungal infection', 'entities': [['42', '51', 'chronic_disease'], ['65', '81', 'chronic_disease']]}, 'NCT03144245'), ({'text': 'Synchronous or previous contralateral invasive breast cancer', 'entities': [['25', '61', 'cancer']]}, 'NCT02488967'), ({'text': 'e 18 years old', 'entities': [['3', '11', 'lower_bound']]}, 'NCT02350764'), ({'text': 'individuals currently taking Coumadin, Plavix, or medications that increase bleeding', 'entities': [['30', '38', 'treatment'], ['40', '46', 'treatment'], ['51', '62', 'treatment']]}, 'NCT01974609'), ({'text': 'other immunosuppressive medications within 14 days of study drug administration', 'entities': [['7', '36', 'treatment'], ['44', '51', 'upper_bound']]}, 'NCT02259621'), ({'text': 'Hydrocephalus', 'entities': [['1', '14', 'chronic_disease']]}, 'NCT03017937'), ({'text': 'with symptomatic angina or angina equivalent', 'entities': [['6', '24', 'chronic_disease'], ['28', '45', 'chronic_disease']]}, 'NCT01568177'), ({'text': 'Glucocorticoid use in the 2 weeks prior to enrollment', 'entities': [['1', '15', 'treatment'], ['27', '40', 'upper_bound']]}, 'NCT02317523'), ({'text': 'As of Screen Visit, the subject is sharing a household with a subject randomized to any investigational trial of ondansetron', 'entities': [['114', '125', 'treatment']]}, 'NCT02354703'), ({'text': 'History of psychosis, psychotic disorder, mania, or bipolar disorder', 'entities': [['12', '21', 'chronic_disease'], ['23', '41', 'chronic_disease'], ['43', '48', 'chronic_disease'], ['53', '69', 'chronic_disease']]}, 'NCT01931202'), ({'text': 'Hemoglobin (Hgb) >= 9 g/dL', 'entities': [['1', '17', 'clinical_variable'], ['21', '27', 'lower_bound']]}, 'NCT02411656'), ({'text': 'Female subjects', 'entities': [['1', '16', 'gender']]}, 'NCT02914171'), ({'text': 'Patients with metastatic disease are eligible for enrollment', 'entities': [['15', '33', 'cancer']]}, 'NCT02502708'), ({'text': 'MR-guided biopsy confirmation of one or more radiographically visible prostate lesion(s) with Gleason score of 7 (3+4 or 4+3) or less', 'entities': [['1', '17', 'treatment'], ['95', '108', 'clinical_variable'], ['112', '126', 'upper_bound']]}, 'NCT02600156'), ({'text': 'Eligible patients in the dose escalation phases of the trial must agree to biopsies of normal skin, unless they undergo optional tumor biopsies; the mandatory biopsy requirement can be waived at the discretion of principal investigator in the event of any medical contraindication (e.g. lidocaine allergy); patients enrolled to the expanded cohorts must agree to tumor sampling; patients on anticoagulation must be able to hold warfarin or low molecular weight heparin for a sufficient amount of time to make skin and tumor biopsies safe to perform; PT/INR and PTT should be =< 1.5 times the institutional upper limit of normal prior to performance of skin or tumor biopsies, with values re-checked after the eligibility screen as medically indicated', 'entities': [['76', '84', 'treatment'], ['130', '144', 'treatment'], ['130', '135', 'cancer'], ['160', '166', 'treatment'], ['288', '297', 'allergy_name'], ['392', '407', 'treatment'], ['429', '437', 'treatment'], ['441', '469', 'treatment'], ['510', '533', 'treatment'], ['551', '553', 'clinical_variable'], ['554', '557', 'clinical_variable'], ['562', '565', 'clinical_variable'], ['579', '628', 'upper_bound'], ['653', '675', 'treatment']]}, 'NCT01434316'), ({'text': 'Tumor verified by a thoracic surgeon to be in a location that will permit sublobar resection', 'entities': [['1', '6', 'cancer'], ['75', '93', 'treatment']]}, 'NCT02468024'), ({'text': 'A positive Hepatitis B surface antigen test result', 'entities': [['12', '23', 'chronic_disease']]}, 'NCT02570854'), ({'text': 'History of interstitial lung disease, idiopathic pulmonary fibrosis, silicosis, sarcoidosis or connective tissue disorders (including rheumatoid arthritis and systemic lupus erythematosus)', 'entities': [['12', '37', 'chronic_disease'], ['39', '68', 'chronic_disease'], ['70', '79', 'chronic_disease'], ['81', '92', 'chronic_disease'], ['96', '123', 'chronic_disease'], ['135', '155', 'chronic_disease'], ['160', '188', 'chronic_disease']]}, 'NCT02427841'), ({'text': 'Minimum of 10 years of education', 'entities': [['12', '20', 'lower_bound']]}, 'NCT02924194'), ({'text': 'Allergies to shell fish, seafood, eggs or iodine', 'entities': [['14', '24', 'allergy_name'], ['26', '33', 'allergy_name'], ['35', '39', 'allergy_name'], ['43', '49', 'allergy_name']]}, 'NCT02682147'), ({'text': 'Pregnancy, present (positive pregnancy test), suspected or planned, breast feeding', 'entities': [['1', '10', 'pregnancy'], ['30', '39', 'pregnancy']]}, 'NCT02594501'), ({'text': 'Known hypersensitivity to GM-CSF', 'entities': [['27', '33', 'allergy_name']]}, 'NCT02033616'), ({'text': 'History of stroke', 'entities': [['12', '18', 'chronic_disease']]}, 'NCT02471833'), ({'text': 'Confirmed diagnosis of FD (genetic testing)', 'entities': [['24', '26', 'chronic_disease']]}, 'NCT02553265'), ({'text': 'Patients with previously untreated brain metastases (including parenchymal, meningeal or dural-based CNS lesions)', 'entities': [['36', '52', 'cancer'], ['64', '75', 'chronic_disease'], ['77', '86', 'chronic_disease'], ['90', '113', 'chronic_disease']]}, 'NCT01553071'), ({'text': 'Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy following radiation as part of their cervical cancer treatment', 'entities': [['25', '37', 'treatment'], ['65', '86', 'treatment'], ['97', '106', 'treatment'], ['124', '149', 'treatment']]}, 'NCT02466971'), ({'text': 'Patients who have had treatment with docetaxel for the treatment of metastatic castrate-sensitive prostate cancer', 'entities': [['23', '32', 'treatment'], ['23', '47', 'treatment'], ['69', '114', 'cancer']]}, 'NCT02484404'), ({'text': 'Known allergy or sensitivity to sodium hypochlorite (NaOCl)', 'entities': [['33', '60', 'allergy_name']]}, 'NCT01631617'), ({'text': 'Male', 'entities': [['1', '5', 'gender']]}, 'NCT02141074'), ({'text': 'Unlimited prior endocrine therapy regimens in the metastatic setting are allowed', 'entities': [['11', '34', 'treatment'], ['51', '61', 'cancer']]}, 'NCT02860000'), ({'text': 'Stable on PAH-specific therapy as defined by no change in PAH-specific treatment and functional class in the past 3 months', 'entities': [['11', '31', 'treatment'], ['59', '81', 'treatment'], ['86', '102', 'clinical_variable'], ['110', '123', 'upper_bound']]}, 'NCT02507011'), ({'text': 'patients with confirmed Gilberts syndrome, the TBil should be less than or equal to 1.5 (SqrRoot) ULN', 'entities': [['25', '42', 'chronic_disease'], ['48', '52', 'clinical_variable'], ['85', '102', 'upper_bound']]}, 'NCT02390752'), ({'text': 'Congenital cyanotic heart defects', 'entities': [['1', '34', 'chronic_disease']]}, 'NCT01504373'), ({'text': 'Seizure disorder requiring medication', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT03042689'), ({'text': 'Patient has received other investigational drugs with 14 days before enrollment', 'entities': [['28', '49', 'treatment'], ['55', '62', 'upper_bound']]}, 'NCT01366612'), ({'text': 'History of severe acne or hirsutism', 'entities': [['12', '23', 'chronic_disease'], ['27', '36', 'chronic_disease']]}, 'NCT01662466'), ({'text': 'Platelet count less than (<)50*10^9/Liters (L)', 'entities': [['1', '15', 'clinical_variable'], ['29', '47', 'upper_bound']]}, 'NCT02846532'), ({'text': 'History of or active autoimmune disorders (including but not limited to: myasthenia gravis, thyroiditis, pneumonitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, scleroderma) and other conditions that disorganize or alter the immune system', 'entities': [['22', '42', 'chronic_disease'], ['74', '91', 'chronic_disease'], ['93', '104', 'chronic_disease'], ['106', '117', 'chronic_disease'], ['119', '139', 'chronic_disease'], ['141', '159', 'chronic_disease'], ['161', '189', 'chronic_disease'], ['191', '202', 'chronic_disease']]}, 'NCT02616185'), ({'text': 'Absolute neutrophil count (ANC) >= 750/mcl', 'entities': [['1', '32', 'clinical_variable'], ['36', '43', 'lower_bound']]}, 'NCT02232516'), ({'text': '>6 months after completion of adjuvant therapy (including chemotherapy and/or radiotherapy)', 'entities': [['2', '10', 'lower_bound'], ['31', '47', 'treatment'], ['59', '71', 'treatment'], ['79', '91', 'treatment']]}, 'NCT02213289'), ({'text': 'Be aged 55-80 years old', 'entities': [['4', '8', 'age'], ['9', '11', 'lower_bound'], ['12', '20', 'upper_bound']]}, 'NCT02565199'), ({'text': 'radiation treatment for breast cancer, identified by Drs. Mittendorf and Shaitelman of the Nellie B. Connally Breast Cancer Center at MD Anderson)', 'entities': [['1', '20', 'treatment'], ['25', '38', 'cancer']]}, 'NCT02949726'), ({'text': 'Diagnosis of active or recurrent cancer, or less than 3 months at the time of initial evaluation from the completion of chemotherapy, radiation therapy or primary surgery for the treatment of cancer', 'entities': [['34', '40', 'cancer'], ['55', '63', 'upper_bound'], ['121', '133', 'treatment'], ['135', '152', 'treatment'], ['164', '171', 'treatment']]}, 'NCT01239160'), ({'text': 'Bipolar disorder', 'entities': [['1', '17', 'chronic_disease']]}, 'NCT00875342'), ({'text': 'Ages 18 to 49', 'entities': [['1', '5', 'age'], ['6', '8', 'lower_bound'], ['12', '14', 'upper_bound']]}, 'NCT02513225'), ({'text': 'Pregnant women (status determined by self-reporting)', 'entities': [['1', '9', 'pregnancy'], ['10', '15', 'gender']]}, 'NCT02355912'), ({'text': 'Myocardial ischemia or infarction (group 1)', 'entities': [['1', '34', 'chronic_disease']]}, 'NCT02855554'), ({'text': 'Patients must have at least one measurable lesion that can be accurately measured with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or physical exam (by calipers only); (PTCL, AITL and follicular lymphoma patients will be assessed on this study using the Lugano criteria for the evaluation of lymphomas; CTCL and MF patients will be assessed using International Society for Cutaneous Lymphomas [ISCL] and European Organization for Research and Treatment of Cancer [EORTC criteria])', 'entities': [['29', '32', 'lower_bound'], ['88', '124', 'treatment'], ['126', '163', 'treatment'], ['203', '207', 'cancer'], ['209', '213', 'cancer'], ['218', '237', 'cancer'], ['326', '335', 'cancer'], ['337', '341', 'cancer'], ['346', '348', 'cancer']]}, 'NCT02520791')]